PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Peters, R; Sikorski, R				Peters, R; Sikorski, R			Mass spectroscopic genomics	SCIENCE			English	Article									Medsite Commun, Boston, MA USA		Peters, R (corresponding author), Medsite Commun, Boston, MA USA.							Griffin TJ, 1997, NAT BIOTECHNOL, V15, P1368, DOI 10.1038/nbt1297-1368; TANG K, 1995, NUCLEIC ACIDS RES, V23, P3126, DOI 10.1093/nar/23.16.3126	2	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	1998	279	5354					1230	1230						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9508694				2022-12-28	WOS:000072115200050
J	Peters, R; Sikorski, R				Peters, R; Sikorski, R			Molecular plumbing	SCIENCE			English	Article									Medsite Commun, Boston, MA USA		Peters, R (corresponding author), Medsite Commun, Boston, MA USA.							L'Heureux N, 1998, FASEB J, V12, P47, DOI 10.1096/fasebj.12.1.47; Lantz G C, 1990, J Invest Surg, V3, P217, DOI 10.3109/08941939009140351; WEINBERG CB, 1986, SCIENCE, V231, P397, DOI 10.1126/science.2934816	3	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	1998	279	5354					1230	1231						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9508694				2022-12-28	WOS:000072115200051
J	Lawrence, S; Giles, CL				Lawrence, S; Giles, CL			Searching the World Wide Web	SCIENCE			English	Article								The coverage and recency of the major World Wide Web search engines was analyzed, yielding some surprising results. The coverage of any one engine is significantly limited: No single engine indexes more than about one-third of the "indexable Web," the coverage of the six engines investigated varies by an order of magnitude, and combining the results of the six engines yields about 3.5 times as many documents on average as compared with the results from only one engine. Analysis of the overlap between pairs of engines gives an estimated lower bound on the size of the indexable Web of 320 million pages.	NEC Res Inst, Comp Sci, Princeton, NJ 08540 USA; Univ Maryland, Inst Adv Comp Studies, College Pk, MD 20742 USA	NEC Corporation; University System of Maryland; University of Maryland College Park	Giles, CL (corresponding author), NEC Res Inst, Comp Sci, 4 Independence Way, Princeton, NJ 08540 USA.		Albion, Peter R/B-5980-2008; Albion, Peter/R-6122-2019	Albion, Peter R/0000-0001-7911-5537; Albion, Peter/0000-0001-7911-5537; Giles, C Lee/0000-0002-1931-585X				Barrie JM, 1996, SCIENCE, V274, P371, DOI 10.1126/science.274.5286.371; Brake D, 1997, NEW SCI, V154, P12; CUNNINGHAM M, 1997, BREWSTERS MILLIONS; EISENBERG M, 1986, P AM SOC INFORM SCI, P80; ETZIONI O, 1994, COMMUN ACM, V37, P72, DOI 10.1145/176789.176797; FOX PT, 1994, SCIENCE, V266, P994, DOI 10.1126/science.7973682; GRAY M, 1996, MEASURING GROWTH WEB; GUGIELMO C, 1997, UPSIDE           NOV, P48; HOWE W, 1997, NETWORK WIZARDS INTE; HOWE W, 1996, WHEN DID INTERNET ST; MITCHELL TE, COMMUNICATION; NEWSWIRE PR, 1997, WIRED DIGITALS HOTBO; RUTKOWSKI AM, 1997, INTERNET TRENDS; SALTON G, 1983, INTRO MODERN INFORMA; Schatz BR, 1997, SCIENCE, V275, P327, DOI 10.1126/science.275.5298.327; Selberg E., 1995, P 4 INT WORLD WID WE, P195; Shakes J., 1997, P 6 INT WORLD WID WE; Taubes G, 1996, SCIENCE, V271, P764, DOI 10.1126/science.271.5250.764; [No title captured]	19	509	542	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 3	1998	280	5360					98	100		10.1126/science.280.5360.98	http://dx.doi.org/10.1126/science.280.5360.98			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF314	9525866	Green Submitted			2022-12-28	WOS:000072885100043
J	Inzucchi, SE; Maggs, DG; Spollett, GR; Page, SL; Rife, FS; Walton, V; Shulman, GI				Inzucchi, SE; Maggs, DG; Spollett, GR; Page, SL; Rife, FS; Walton, V; Shulman, GI			Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	Annual Scientific Sessions of the American-Diabetes-Association	JUN 21-24, 1997	BOSTON, MASSACHUSETTS	Amer Diabetes Assoc			SULFONYLUREA THERAPY; COMBINATION THERAPY; NIDDM SUBJECTS; INSULIN; RESISTANCE; MUSCLE; CS-045; AGENT	Background Combination therapy is logical for patients with non-insulin-dependent (type II) diabetes mellitus, because they often have poor responses to single-drug therapy. We studied the efficacy and physiologic effects of metformin and troglitazone alone and in combination in patients with type II diabetes. Methods We randomly assigned 29 patients to receive either metformin or troglitazone for three months, after which they were given both drugs for another three months. Plasma glucose concentrations during fasting and postprandially and glycosylated hemoglobin values were measured periodically during both treatments. Endogenous glucose production and peripheral glucose disposal were measured at base line and after three and six months. Results During metformin therapy, fasting and postprandial plasma glucose concentrations decreased by 20 percent (58 mg per deciliter [3.2 mmol per liter], P<0.001) and 25 percent (87 mg per deciliter [4.8 mmol per liter], P<0.001), respectively. The corresponding decreases during troglitazone therapy were 20 percent (54 mg per deciliter [2.9 mmol per liter], P=0.01) and 25 percent (83 mg per deciliter [4.6 mmol per liter], P<0.001). Endogenous glucose production decreased during metformin therapy by a mean of 19 percent (P=0.001), whereas it was unchanged by troglitazone therapy (P=0.04 for the comparison between groups). The mean rate of glucose disposal increased by 54 percent during troglitazone therapy (P=0.006) and 13 percent during metformin therapy (P=0.03 for the com pa risen within the group and between groups). In combination, metformin and troglitazone further lowered fasting and postprandial plasma glucose concentrations by 18 percent (41 mg per deciliter [2.3 mmol per liter], P=0.001) and 21 percent (54 mg per deciliter [3.0 mmol per liter], P<0.001), respectively, and the mean glycosylated hemoglobin value decreased 1.2 percentage points. Conclusions Metformin and troglitazone have equal and additive beneficial effects on glycemic control in patients with type II diabetes. Metformin acts primarily by decreasing endogenous glucose production, and troglitazone by increasing the rate of peripheral glucose disposal. (C) 1998, Massachusetts Medical Society.	Yale Univ, Sch Med, Endocrinol Sect, New Haven, CT 06520 USA; Howard Hughes Med Inst, New Haven, CT 06510 USA	Yale University; Howard Hughes Medical Institute	Inzucchi, SE (corresponding author), Yale Univ, Sch Med, Endocrinol Sect, TMP 5,Box 208020, New Haven, CT 06520 USA.		Shulman, Gerald I./P-7176-2019; Inzucchi, Silvio/ABF-4121-2021	Shulman, Gerald I./0000-0003-1529-5668; 	NCRR NIH HHS [MO1-RR00125] Funding Source: Medline; NIDDK NIH HHS [R01-DK49230] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000125] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049230] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ashcroft FM, 1996, HORM METAB RES, V28, P456, DOI 10.1055/s-2007-979837; CHEN YDI, 1988, J CLIN ENDOCR METAB, V67, P1084, DOI 10.1210/jcem-67-5-1084; CIARALDI TP, 1990, METABOLISM, V39, P1056, DOI 10.1016/0026-0495(90)90166-A; DEFRONZO RA, 1995, NEW ENGL J MED, V333, P541, DOI 10.1056/NEJM199508313330902; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; DORNAN TL, 1991, DIABETES CARE, V14, P342, DOI 10.2337/diacare.14.4.342; Fery F, 1997, METABOLISM, V46, P227, DOI 10.1016/S0026-0495(97)90307-3; GHAZZI M, 1997, DIABETES S1, V46, pA44; HARRIS M, 1979, DIABETES, V28, P1039; HAUPT E, 1991, DIABETES METAB, V17, P224; HERMANN LS, 1994, DIABETES CARE, V17, P1100, DOI 10.2337/diacare.17.10.1100; Iwamoto Y, 1996, DIABETIC MED, V13, P365, DOI 10.1002/(SICI)1096-9136(199604)13:4<365::AID-DIA19>3.0.CO;2-M; Iwamoto Y, 1996, DIABETES CARE, V19, P151, DOI 10.2337/diacare.19.2.151; Kumar S, 1996, DIABETOLOGIA, V39, P701; LEE MK, 1994, DIABETES, V43, P1435, DOI 10.2337/diabetes.43.12.1435; MAGNUSSON I, 1992, J CLIN INVEST, V90, P1323, DOI 10.1172/JCI115997; ORourke CM, 1997, METABOLISM, V46, P192, DOI 10.1016/S0026-0495(97)90301-2; RASKIN P, 1997, DIABETES S1, V46, pA44; ROSSETTI L, 1987, J CLIN INVEST, V79, P1510, DOI 10.1172/JCI112981; Saltiel AR, 1996, DIABETES, V45, P1661, DOI 10.2337/diabetes.45.12.1661; SHEU WHH, 1995, DIABETES CARE, V18, P1582, DOI 10.2337/diacare.18.12.1582; STUMVOLL M, 1995, NEW ENGL J MED, V333, P550, DOI 10.1056/NEJM199508313330903; SUTER SL, 1992, DIABETES CARE, V15, P193, DOI 10.2337/diacare.15.2.193; TOELLER M, 1994, EUR J CLIN INVEST, V24, P31; *TROGL STUD GROUP, 1997, DIABETES S1, V46, pA149; VALIQUETT T, 1997, DIABETES S1, V46, pA43; VESTERGAARD H, 1995, J CLIN ENDOCR METAB, V80, P270, DOI 10.1210/jc.80.1.270; WOLFE RR, 1992, PRINCIPLES PRACTICE, P283	29	610	641	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 26	1998	338	13					867	872		10.1056/NEJM199803263381303	http://dx.doi.org/10.1056/NEJM199803263381303			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD284	9516221				2022-12-28	WOS:000072669800003
J	Treiber, DK; Rook, MS; Zarrinkar, PP; Williamson, JR				Treiber, DK; Rook, MS; Zarrinkar, PP; Williamson, JR			Kinetic intermediates trapped by native interactions in RNA folding	SCIENCE			English	Article							GROUP-I RIBOZYME; TETRAHYMENA RIBOZYME; TERTIARY STRUCTURE; DOMAIN; BARRIERS; LYSOZYME; PATHWAY	In the magnesium ion-dependent folding of the Tetrahymena ribozyme, a kinetic intermediate accumulates in which the P4-P6 domain is formed, but the P3-P7 domain is not. The kinetic barriers to P3-P7 formation were investigated with the use of in vitro selection to identify mutant RNA molecules in which the folding rate of the P3-P7 domain was increased. The critical mutations disrupt native tertiary interactions within the P4-P6 domain and increase the rate of P3-P7 formation by destabilizing a kinetically trapped intermediate. Hence, kinetic traps stabilized by native interactions, and not simply by mispaired nonnative structures, can present a substantial barrier to RNA folding.	Scripps Res Inst, Dept Biol Mol, La Jolla, CA 92037 USA; MIT, Dept Chem, Cambridge, MA 02139 USA	Scripps Research Institute; Massachusetts Institute of Technology (MIT)	Williamson, JR (corresponding author), Scripps Res Inst, Dept Biol Mol, MB33,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Williamson, James/AAL-2104-2021; Williamson, James R/B-2891-2009	Williamson, James/0000-0002-8772-468X; Williamson, James R/0000-0002-8772-468X				BANERJEE AR, 1995, BIOCHEMISTRY-US, V34, P6504, DOI 10.1021/bi00019a031; BEAUDRY AA, 1992, SCIENCE, V257, P635, DOI 10.1126/science.1496376; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; Cate JH, 1997, NAT STRUCT BIOL, V4, P553, DOI 10.1038/nsb0797-553; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; COLE PE, 1972, BIOCHEMISTRY-US, V11, P4358, DOI 10.1021/bi00773a024; DILL KA, 1994, NAT STRUCT BIOL, V4, P10; Downs WD, 1996, RNA, V2, P718; Draper DE, 1996, TRENDS BIOCHEM SCI, V21, P145; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; LAGGERBAUER B, 1994, EMBO J, V13, P2669, DOI 10.1002/j.1460-2075.1994.tb06557.x; Lehnert V, 1996, CHEM BIOL, V3, P993, DOI 10.1016/S1074-5521(96)90166-0; MIRANKER A, 1993, SCIENCE, V262, P896, DOI 10.1126/science.8235611; Munson M, 1997, FOLD DES, V2, P77, DOI 10.1016/S1359-0278(97)00008-4; MURPHY FL, 1993, BIOCHEMISTRY-US, V32, P5291, DOI 10.1021/bi00071a003; MURPHY FL, 1994, J MOL BIOL, V236, P49, DOI 10.1006/jmbi.1994.1117; Pan J, 1997, J MOL BIOL, V273, P7, DOI 10.1006/jmbi.1997.1311; Pan T, 1997, NAT STRUCT BIOL, V4, P931, DOI 10.1038/nsb1197-931; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0; ROOK MS, UNPUB; Rothwarf DM, 1996, BIOCHEMISTRY-US, V35, P13797, DOI 10.1021/bi9608119; SCIAVI B, 1998, SCIENCE, V279, P1940; SCIAVI B, 1997, J MOL BIOL, V266, P144; SOSNICK TR, 1994, NAT STRUCT BIOL, V1, P149, DOI 10.1038/nsb0394-149; Thirumalai D, 1996, ACCOUNTS CHEM RES, V29, P433, DOI 10.1021/ar9500933; TREIBER DK, UNPUB; Waldburger CD, 1996, P NATL ACAD SCI USA, V93, P2629, DOI 10.1073/pnas.93.7.2629; Weeks KM, 1996, SCIENCE, V271, P345, DOI 10.1126/science.271.5247.345; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; Wildegger G, 1997, J MOL BIOL, V270, P294, DOI 10.1006/jmbi.1997.1030; WOODSON SA, 1991, BIOCHEMISTRY-US, V30, P2042, DOI 10.1021/bi00222a006; Zarrinkar PP, 1996, RNA, V2, P564; Zarrinkar PP, 1996, NAT STRUCT BIOL, V3, P432, DOI 10.1038/nsb0596-432; ZARRINKAR PP, 1994, SCIENCE, V265, P918, DOI 10.1126/science.8052848	34	191	195	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 20	1998	279	5358					1943	1946		10.1126/science.279.5358.1943	http://dx.doi.org/10.1126/science.279.5358.1943			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506945				2022-12-28	WOS:000072613300048
J	Blendon, RJ; Young, JT				Blendon, RJ; Young, JT			The public and the war on illicit drugs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								This article presents what Americans think about the policies subsumed under the label of the "War on Drugs." It is based on an analysis of 47 national surveys conducted between 1978 and 1997. The major results are that most Americans rely on the mass media for information about the scope of the drug abuse problem; Americans do not think that the Wars on Drugs have succeeded, but they do not want to quit on these efforts; weak support exists for increasing funding for drug treatment; support for preventive education has increased during the 1990s; criminal justice responses remain very popular; for many, illicit drug use is a moral rather than a public health issue; the public supports allowing physicians to prescribe marijuana for severe illness, but opposes the general legalization of marijuana and other illicit drugs; and needle exchange programs are supported by a bare majority, but only when they are told that the American Medical Association supports these programs.	Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02215 USA; Harvard Univ, John F Kennedy Sch Govt, Cambridge, MA 02138 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University	Blendon, RJ (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave, Boston, MA 02215 USA.							[Anonymous], 1996, NY TIMES; [Anonymous], 1996, WASHINGTON POST; [Anonymous], 1995, US TODAY; [Anonymous], 1988, WASHINGTON POST; [Anonymous], 1996, CBS NEWS POLL; BUCKLEY W, 1996, NATL REV        0212; Canadian Institute of Public Opinion (CIPO), 1990, GALLUP POLL; Danielian LH, 1989, COMMUNICATION CAMPAI, P29; Davis James A., GEN SOCIAL SURVEYS 1; *FED AM SCI, 1997, PRINC PRACT DRUG POL; FRIEDMAN M, 1998, NY TIMES        0111, V149, P19; HART PD, 1994, DRUG STRATEGIES; *LINDSM FDN, 1997, LAK RES POLL; Lundberg GD, 1997, JAMA-J AM MED ASSOC, V278, P946, DOI 10.1001/jama.278.11.946; MacCoun R, 1996, J POLICY ANAL MANAG, V15, P330, DOI 10.1002/(SICI)1520-6688(199622)15:3<330::AID-PAM1>3.0.CO;2-J; MAGINNIS RL, 1997, AM ASSESS MED MARIJU; MERRIAM JE, 1989, COMMUNICATION CAMPAI, P21; Newsweek, 1995, NEWSWEEK; *OFF APP STUD, 1997, 17 DAWN OFF APPL STU; *PRINC SURV RES AS, 1995, HJ KAIS FAM FDN POLL; Reese S.D., 1989, COMMUNICATION CAMPAI, P29; *ROP CTR PUBL OP R, 1990, PARTN DRUG FREE AM G; *ROP CTR PUBL OP R, 1996, ABC NEWS POLL; SOROS G, 1997, WASHINGTON POST 0202; Specter M, 1990, WASHINGTON POST; *SUBST AB MENT HLT, 1997, NAT ADM SUBST AB TRE; *SUBST AB MENT HLT, 1997, PREL FIL 1996 NAT HO; *SUBST AB MENT HLT, 1996, 18 SUBST AB MENT HLT; U. S. Bureau of the Census, 1996, STAT ABSTR US; *U VIRG, 1997, POST MOD PROJ; YANKELOVICH, 1997, TIME             JUN; YANKELOVICH, 1993, TIME; 1996, CBS NEWS POLL    OCT; 1997, CBS NEWS POLL; 1996, NEWSWEEK POLL; 1996, WASHINGTON POST 0703; 1997, ABC WASHINGTON POST; 1986, CBS NEWS NY TIMES; 1995, CNN US TODAY     AUG	39	71	71	0	26	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 18	1998	279	11					827	832		10.1001/jama.279.11.827	http://dx.doi.org/10.1001/jama.279.11.827			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA943	9515986				2022-12-28	WOS:000072417600012
J	Epstein, RM; Morse, DS; Frankel, RM; Frarey, L; Anderson, K; Beckman, HB				Epstein, RM; Morse, DS; Frankel, RM; Frarey, L; Anderson, K; Beckman, HB			Awkward moments in patient-physician communication about HIV risk	ANNALS OF INTERNAL MEDICINE			English	Article						communication; physician-patient relations; human immunodeficiency virus infections; physician's role; risk	PRIMARY-CARE PHYSICIANS; AIDS; PREVENTION; SKILLS; ATTITUDES; KNOWLEDGE; INFECTION	Background: Physicians frequently encounter patients who are at risk for HIV infection, but they often evaluate risk behaviors ineffectively. Objective: To describe the barriers to and facilitators of comprehensive HIV risk evaluation in primary care office visits. Design: Qualitative thematic and sequential analysis of videotaped patient-physician discussions about HIV risk. Tapes were reviewed independently by physician and patient and were coded by the research team. Setting: Physicians' offices. Participants: Convenience sample of 17 family physicians and general internists. Twenty-six consenting patients 18 to 45 years of age who indicated concern about or risks for HIV infection on a 10-item questionnaire administered before the physician visit were included. Measurements: A thematic coding scheme and a five-level description of the depth of HIV-related discussion. Results: In 73% of the encounters, physicians did not elicit enough information to characterize patients' HIV risk status. The outcome of HIV-related discussions was substantially influenced by the manner in which the physician introduced the topic, handled awkward moments, and dealt with problematic language and the extent to which the physician sought the patient's perspective. Feelings of ineffectiveness and strong emotions interfered with some physicians' ability to assess HIV risk. Physicians easily recognized problematic communication during reviews of their own videotapes. Conclusions: Comprehensive HIV risk discussions included providing a rationale for discussion, effectively negotiating awkward moments, repairing problematic language, persevering with the topic, eliciting the patient's perspective, responding to fears and expectations, and being empathic. Educational programs should use videotape review and should concentrate on physicians' personal reactions to discussing emotionally charged topics.	Univ Rochester, Highland Hosp, Sch Med & Dent, Primary Care Inst,Dept Family Med, Rochester, NY 14620 USA; Rochester Gen Hosp, Gen Med Unit, Rochester, NY 14621 USA; Univ Rochester, Highland Hosp, Sch Med & Dent, Primary Care Inst,Dept Internal Med, Rochester, NY 14620 USA	University of Rochester; Rochester General Hospital; University of Rochester	Epstein, RM (corresponding author), Univ Rochester, Highland Hosp, Sch Med & Dent, Primary Care Inst,Dept Family Med, 885 South Ave, Rochester, NY 14620 USA.			Morse, Diane/0000-0001-9603-0324				Altheide D. L., 1987, QUAL SOCIOL, V10, P65, DOI [10.1007/BF00988269, DOI 10.1007/BF00988269]; BECKMAN HB, 1984, ANN INTERN MED, V101, P692, DOI 10.7326/0003-4819-101-5-692; BOWMAN MA, 1992, ARCH INTERN MED, V152, P1823, DOI 10.1001/archinte.152.9.1823; BROWN JB, 1989, CAN FAM PHYSICIAN, V35, P153; CAMASSO MJ, 1994, SOC SCI MED, V38, P733, DOI 10.1016/0277-9536(94)90464-2; Deci E. L., 1985, INTRINSIC MOTIVATION; DRUMMOND K, 1991, MISCOMMUNICATION PRO, P301; ENDE J, 1984, ARCH INTERN MED, V144, P558, DOI 10.1001/archinte.144.3.558; EPSTEIN R, 1991, J FAM PRACTICE, V32, P373; Epstein R M, 1993, Fam Med, V25, P264; Epstein R M, 1993, Arch Fam Med, V2, P159, DOI 10.1001/archfami.2.2.159; EPSTEIN RM, 1997, PSYCHOSOM MED, P623; Frankel R.M., 1982, STRAIGHT TALK EXPLOR, P71; FREDMAN L, 1989, AM J PREV MED, V5, P188, DOI 10.1016/S0749-3797(18)31079-1; GEMSON DH, 1991, ARCH INTERN MED, V151, P1102, DOI 10.1001/archinte.151.6.1102; GERBERT B, 1988, JAMA-J AM MED ASSOC, V260, P3481, DOI 10.1001/jama.260.23.3481; GERBERT B, 1992, J GEN INTERN MED, V7, P657, DOI 10.1007/BF02599211; Gerbert B, 1993, Arch Fam Med, V2, P45, DOI 10.1001/archfami.2.1.45; GERBERT B, 1990, AM J PUBLIC HEALTH, V80, P467, DOI 10.2105/AJPH.80.4.467; GREEN L W, 1988, American Journal of Preventive Medicine, V4, P101; Heath C., 1986, BODY MOVEMENT SPEECH, DOI [10.1017/CBO9780511628221, DOI 10.1017/CBO9780511628221]; KAPLAN SH, 1989, MED CARE, V27, pS110, DOI 10.1097/00005650-198903001-00010; KELLY JA, 1987, AM J PUBLIC HEALTH, V77, P789, DOI 10.2105/AJPH.77.7.789; KORSCH BM, 1968, PEDIATRICS, V42, P855; KUZEL AJ, 1992, RES METH PR, V3, P31; LEVINSON W, 1993, J GEN INTERN MED, V8, P318, DOI 10.1007/BF02600146; LEWIS CE, 1987, AM J PUBLIC HEALTH, V77, P795, DOI 10.2105/AJPH.77.7.795; LEWIS CE, 1986, J GEN INTERN MED, V1, P287, DOI 10.1007/BF02596205; LEWIS CE, 1994, W J MED, V169, P651; MAGUIRE P, 1986, BRIT MED J, V292, P1573, DOI 10.1136/bmj.292.6535.1573; MATHEWS WC, 1989, J GEN INTERN MED, V4, P34, DOI 10.1007/BF02596487; MCPHEE SJ, 1984, ARCH INTERN MED, V144, P1265, DOI 10.1001/archinte.144.6.1265; Novack DH, 1997, JAMA-J AM MED ASSOC, V278, P502, DOI 10.1001/jama.278.6.502; Patton M. Q., 1980, QUALITATIVE EVALUATI; PLATT FW, 1995, CONVERSATION REPAIR; PRITCHARD JG, 1988, J FAM PRACTICE, V27, P639; PRITCHARD JG, 1988, J FAM PRACTICE, V27, P637; PROCHASKA JO, 1982, PSYCHOTHER-THEOR RES, V19, P276, DOI 10.1037/h0088437; RABIN DL, 1994, ANN INTERN MED, V121, P513, DOI 10.7326/0003-4819-121-7-199410010-00007; ROTER DL, 1995, ARCH INTERN MED, V155, P1877, DOI 10.1001/archinte.155.17.1877; Samet JH, 1997, PEDIATRICS, V100, P371, DOI 10.1542/peds.100.3.371; SCHLEGOFF EA, 1977, LANGUAGE, V53, P361; SIMPSON M, 1991, BRIT MED J, V303, P1385, DOI 10.1136/bmj.303.6814.1385; STANGE KC, 1994, J GEN INTERN MED, V9, P278, DOI 10.1007/BF02599656; STARFIELD B, 1981, AM J PUBLIC HEALTH, V71, P127, DOI 10.2105/AJPH.71.2.127; STEWART M, 1989, CAN FAM PHYSICIAN, V35, P159; STREET RL, 1992, MED CARE, V30, P976, DOI 10.1097/00005650-199211000-00002; WAITZKIN H, 1990, MED CARE, V28, P473, DOI 10.1097/00005650-199006000-00001; Wenrich MD, 1997, J GEN INTERN MED, V12, P107, DOI 10.1046/j.1525-1497.1997.00015.x; WEST C, 1991, MISCOMMUNICATION PRO, P166; [No title captured]	51	106	107	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1998	128	6					435	+		10.7326/0003-4819-128-6-199803150-00003	http://dx.doi.org/10.7326/0003-4819-128-6-199803150-00003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA914	9499326				2022-12-28	WOS:000072414700003
J	Albee, AL; Palluconi, FD; Arvidson, RE				Albee, AL; Palluconi, FD; Arvidson, RE			Mars global surveyor mission: Overview and status	SCIENCE			English	Article								The Mars Global Surveyor (MGS) spacecraft achieved a 45-hour elliptical orbit at Mars on 11 September 1997 after an 11-month cruise from Earth, The mission is acquiring high-quality global observations of the martian surface and atmosphere and of its magnetic and gravitational fields. These observations will continue for one martian year.	CALTECH, Pasadena, CA 91125 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Washington Univ, St Louis, MO 63130 USA	California Institute of Technology; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Washington University (WUSTL)	Albee, AL (corresponding author), CALTECH, Pasadena, CA 91125 USA.							Smith DE, 1998, SCIENCE, V279, P1686, DOI 10.1126/science.279.5357.1686; 1992, J GEOPHYS RES, V97, P7663	2	114	117	2	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 13	1998	279	5357					1671	1672		10.1126/science.279.5357.1671	http://dx.doi.org/10.1126/science.279.5357.1671			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9497277				2022-12-28	WOS:000072490000042
J	de Vos, RM; Verweij, H				de Vos, RM; Verweij, H			High-selectivity, high-flux silica membranes for gas separation	SCIENCE			English	Article							CERAMIC MEMBRANES	Process improvements in silica membrane fabrication, especially the use of clean-room techniques, resulted in silica membranes without detectable mesoscopic defects, resulting in significantly improved transport properties. Supported membranes calcined at 400 degrees C were 30 nanometers in thickness, showed a H-2 permeance at 200 degrees C of 2 x 10(-6) moles per square meter per second per Pascal (mol m(-2) s(-1) Pa-1), and had a CH4 permeance more than 500 times smaller. Molecules larger than CH4 were completely blocked. Silica membranes calcined at 600 degrees C showed no detectable CH4 flux, with a H-2 permeance of 5 x 10(-7) (mol m(-2) s(-1) Pa-1) at 200 degrees C. These results signify an important step toward the industrial application of these membranes such as purification of H-2 and natural gas as well as the selective removal of CO2.	Univ Twente, Fac Chem Technol, Lab Inorgan Mat Sci, NL-7500 AE Enschede, Netherlands	University of Twente	de Vos, RM (corresponding author), Univ Twente, Fac Chem Technol, Lab Inorgan Mat Sci, POB 217, NL-7500 AE Enschede, Netherlands.		Verweij, Henk Verweij/F-6948-2015; Way, James Douglas/A-9408-2010	Way, James Douglas/0000-0001-9612-8508				Breck D.W., 1973, ZEOLITES MOL SIEVES, P626; BURGGRAAF AJ, 1996, MEMBRANE SCI TECHNOL, V4, pCH1; de Lange RSA, 1995, J POROUS MAT, V2, P141, DOI 10.1007/BF00489722; DELANGE RSA, 1995, MICROPOROUS MATER, V4, P169, DOI 10.1016/0927-6513(95)00004-S; DELANGE RSA, 1995, J MEMBRANE SCI, V99, P57, DOI 10.1016/0376-7388(94)00206-E; FAIN DE, 1995, P 3 INT C IN MEMBR 1, P365; HASSAN MH, 1995, J MEMBRANE SCI, V104, P27, DOI 10.1016/0376-7388(95)00009-2; Iler K.R., 1979, CHEM SILICA SOLUBILI; Koros WJ, 1996, PURE APPL CHEM, V68, P1479, DOI 10.1351/pac199668071479; UHLHORN RJR, 1992, J MATER SCI, V27, P527, DOI 10.1007/BF00543947; 1996, MEASUREMENTS MEDIA P	11	510	532	9	244	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 13	1998	279	5357					1710	1711		10.1126/science.279.5357.1710	http://dx.doi.org/10.1126/science.279.5357.1710			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9497287				2022-12-28	WOS:000072490000052
J	Hard, RJ; Roney, JR				Hard, RJ; Roney, JR			A massive terraced village complex in Chihuahua, Mexico, 3000 years before present	SCIENCE			English	Article							AMERICAN SOUTHWEST; CALIBRATION	Cerro Juanaquena is a residential complex with 8 kilometers of terrace walls in northwestern Mexico that was occupied at similar to 3000 calendar years before present based on radiocarbon dates on maize (Zea mays L.), Most other similar sized terrace complex sites that have been found date to similar to 1000 years before present, Cerro Juanaquena was contemporaneous with 10 other sites in the southwestern United States that have yielded 18 of the earliest maize or squash radiocarbon dates yet, and it is by far the largest and most complex site, The archaeological evidence from this site, combined with other recent data, implies that highly variable combinations of population aggregation, agricultural dependence, and degrees of sedentism were present during the time maize was being introduced into the American Southwest.	Univ Texas, Ctr Archaeol Res, San Antonio, TX 78249 USA; Bur Land Management, Albuquerque, NM 87107 USA	University of Texas System	Hard, RJ (corresponding author), Univ Texas, Ctr Archaeol Res, 6900 N Loop 1604 W, San Antonio, TX 78249 USA.	rhrd@lonestar.utsa.edu; jroney@ix.netcom.com	Hard, Robert/ABC-5966-2021	Hard, Robert/0000-0001-5920-2836				ADAMS KR, CORN CULTURE PREHIST, P273; [Anonymous], 1996, J ARCHAEOL METHOD TH, DOI [10.1007/BF02229401, DOI 10.1007/BF02229401]; BERRY CE, 1987, THESIS U UTAH; Bohrer Vorsila L., 1977, CONTRIBUTIONS ANTHR, V8; DEAN JS, 1993, CULTURE CONTACT CC D, P96; DOWNUM CE, 1993, ANTHR PAP U ARIZ, V57, P91; Downum Christian E, 1994, KIVA, V59, P271; Downum Christian E., 1986, KIVA, V51, P219; FERG A, 1997, ARCHAEOL TUCSON, V11, P8; FISH PR, 1986, AM ANTIQUITY, V51, P564; FORD RI, 1981, J ETHNOBIOL, V1, P13; GERALD RE, 1990, ARTIFACT, V28, P59; Gilpin Dennis., 1994, KIVA, V60, P203; Glover TJ, 1989, POCKET REFERENCE; GREGORY DA, 1997, ARCHAEOL TUCSON, V11, P2; HARD RJ, 1997, PUBL CTR INVESTIGACI, V12; Hard Robert J., 1990, PERSPECTIVES SW PREH, P135; Haury E., 1962, COURSES URBAN LIFE, P106; HORSFALL A, 1987, LITHIC STUDIES CONT, P342; HUCKELL B, 1990, THESIS U ARIZONA; HUCKELL BB, 1995, 59 U AR; HUCKELL BB, 1995, 945 CTR DES ARCH; HUCKELL BB, 1996, J WORLD PREHISTORY, V10, P336; JOHNSON AE, 1963, AM ANTIQUITY, V29, P174, DOI 10.2307/278488; MABRY JB, 1994, ARCHAEOL TUCSON, V8; MABRY JB, 1997, ARCHAEOL TUCSON, V11, P1; MABRY JB, 1997, ARCHAEOL TUCSON, V11, P6; Mabry Jonathan, 1997, ANTHR PAPERS, V18; MacNeish R.S., 1992, ORIGINS AGR SETTLED; MACNEISH RS, 1993, 9 CULT RES MAN BRANC, P167; MARTIN PS, 1952, FIELDIANA ANTHR, V40, P148; MATSON RG, 1991, ORIGINS SW AGR, P90; MCGUIRE RH, 1993, CERROS TRINCHERAS MA; MCGUIRE RH, 1990, 14 ANN M SOC AM ARCH; Minnis PaulE., 1992, ORIGINS AGR INT PERS, P121; MINNIS PE, 1985, ANTHR PAPERS U MICHI, V75, P309; NORDT L, COMMUNICATION; PEARSON GW, 1993, RADIOCARBON, V35, P25, DOI 10.1017/S0033822200013795; ROTH B, 1989, THESIS U ARIZONA; Roth BJ, 1992, KIVA, V57, P353; SANCHEZ G, 1996, C ARCH PREH N AM SW; Sauer Carl O., 1931, U CALIFORNIA PUBLICA, P67; Schmidt K. P., COMMUNICATION; SILVA RJ, 1997, ARCHAEOL TUCSON, V11, P11; SIMMONS AH, 1986, AM ANTIQUITY, V51, P73, DOI 10.2307/280395; Smiley FrancisE., 1994, KIVA, V60, P165; STUIVER M, 1993, RADIOCARBON, V35, P215, DOI 10.1017/S0033822200013904; Stuiver M, 1993, RADIOCARBON, V35; Tagg MD, 1996, AM ANTIQUITY, V61, P311, DOI 10.2307/282428; Turner E. S., 1993, FIELD GUIDE STONE AR; Turpin S. A., 1991, STUDIES ARCHAEOLOGY, V8, P1; UPHAM S, 1987, AM ANTHROPOL, V89, P410, DOI 10.1525/aa.1987.89.2.02a00090; WARD GK, 1978, ARCHAEOMETRY, V20, P19, DOI 10.1111/j.1475-4754.1978.tb00208.x; WHALEN ME, 1994, AM ANTIQUITY, V59, P622, DOI 10.2307/282337; Whittlesey Stephanie M., 1996, EARLY FORMATIVE ADAP, P49; Wills W. H., 1988, EARLY PREHISTORIC AG; WILLS WH, 1988, J WORLD PREHIST, V2, P445, DOI 10.1007/BF00976198; WILLS WH, 1990, PERSPECTIVES SW PREH, P319; Wilshusen RH, 1988, DOLORES ARCHAEOLOGIC, P599	59	40	40	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 13	1998	279	5357					1661	1664		10.1126/science.279.5357.1661	http://dx.doi.org/10.1126/science.279.5357.1661			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	ZB612	9497275				2022-12-28	WOS:000072490000040
J	Bottomley, PA; Weiss, RG				Bottomley, PA; Weiss, RG			Non-invasive magnetic-resonance detection of creatine depletion in non-viable infarcted myocardium	LANCET			English	Article							CORONARY-ARTERY DISEASE; HUMAN SKELETAL-MUSCLE; SPECTROSCOPY; TOMOGRAPHY; METABOLISM; EXERCISE; INVIVO	Background Presented energy metabolism is essential for myocardial viability and the creatine kinase reaction is central to energy production and reserve. Although the appearance of myocardial creatine kinase enzyme in the blood is widely used to diagnose cardiac necrosis, there are no non-invasive ways to measure local creatine concentrations in the healthy and diseased human heart. Methods We measured total myocardial creatine by spatially-localised, water-suppressed hydrogen magnetic-resonance spectroscopy (H-1-MRS) on a clinical (1.5 T) magnetic-resonance-imaging systemin ten healthy volunteers (controls) and ten patients with a history of myocardial infarction. We validated this technique by comparison of H-1-MRS Values of creatine with biopsy assays in an animal model of infarction. Findings Total creatine was measured in the posterior and anterior left ventricle and septum, and was significantly lower in regions of infarction (10 [9] SD mu mol/g wet weight) than in non-infarcted regions (26 [11] mu mol/g, p=0.001) of myocardium in patients or in the myocardium of healthy controls (28 [6] mu mol/g, p<0.0001). Interpretation Spatially localised H-1-MRS can be used to measure total creatine non-invasively throughout the human heart. The detection of regional creatine depletion may provide a metabolic means to distinguish healthy from infarcted non-viable myocardium.	Johns Hopkins Univ, Sch Med, Dept Radiol, Div Magnet Resonance Res, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Weiss, RG (corresponding author), Johns Hopkins Hosp, Carnegie 584,600 N Wolfe St, Baltimore, MD 21205 USA.	rgweiss@rad.jhu.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL052315, R01HL056882] Funding Source: NIH RePORTER; NHLBI NIH HHS [1RO1-HL56882, SCOR-HL-52315-02] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAER FM, 1995, CIRCULATION, V91, P1006, DOI 10.1161/01.CIR.91.4.1006; BONGERS H, 1992, MAGN RESON IMAGING, V10, P957, DOI 10.1016/0730-725X(92)90450-E; Bottomley PA, 1997, RADIOLOGY, V204, P403, DOI 10.1148/radiology.204.2.9240527; BOTTOMLEY PA, 1994, RADIOLOGY, V191, P593, DOI 10.1148/radiology.191.3.8184033; Bottomley PA, 1996, MAGNET RESON MED, V35, P664, DOI 10.1002/mrm.1910350507; BOTTOMLEY PA, 1995, P SMR, V1, P90; BRUHN H, 1991, MAGN RESON MED, V17, P82, DOI 10.1002/mrm.1910170113; DELANGHE J, 1988, ANN CLIN BIOCHEM, V25, P383, DOI 10.1177/000456328802500410; DENHOLLANDER JA, 1994, MAGN RESON MED, V32, P175, DOI 10.1002/mrm.1910320205; DILSIZIAN V, 1990, NEW ENGL J MED, V323, P141, DOI 10.1056/NEJM199007193230301; INGWALL JS, 1993, CIRCULATION, V87, P58; INGWALL JS, 1985, NEW ENGL J MED, V313, P1050, DOI 10.1056/NEJM198510243131704; JENNINGS RB, 1981, AM J PATHOL, V102, P241; LEE TH, 1986, ANN INTERN MED, V105, P221, DOI 10.7326/0003-4819-105-2-221; MANNING WJ, 1991, J AM COLL CARDIOL, V18, P959, DOI 10.1016/0735-1097(91)90754-W; SNYDER WS, 1984, REPORT TASK GROUP RE, P34; SWAIN JL, 1982, P NATL ACAD SCI-BIOL, V79, P655, DOI 10.1073/pnas.79.2.655; TILLISCH J, 1986, NEW ENGL J MED, V314, P884, DOI 10.1056/NEJM198604033141405; WEISS RG, 1990, NEW ENGL J MED, V323, P1593, DOI 10.1056/NEJM199012063232304; YABE T, 1994, CIRCULATION, V89, P1709, DOI 10.1161/01.CIR.89.4.1709; YABE T, 1995, CIRCULATION, V92, P15, DOI 10.1161/01.CIR.92.1.15	21	113	115	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 7	1998	351	9104					714	718		10.1016/S0140-6736(97)06402-7	http://dx.doi.org/10.1016/S0140-6736(97)06402-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB359	9504516	hybrid			2022-12-28	WOS:000072463800009
J	White, RL				White, RL			Tumor suppressing pathways	CELL			English	Review							COLORECTAL CANCERS; GENE; IDENTIFICATION; MUTATIONS; APC; CHROMOSOME-5Q21; ASSOCIATION; PROTEIN		Univ Utah, Howard Hughes Med Inst, Eccles Inst Human Genet, Salt Lake City, UT 84112 USA	Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah	White, RL (corresponding author), Univ Utah, Howard Hughes Med Inst, Eccles Inst Human Genet, Salt Lake City, UT 84112 USA.							CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0	20	53	58	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 6	1998	92	5					591	592		10.1016/S0092-8674(00)81124-1	http://dx.doi.org/10.1016/S0092-8674(00)81124-1			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZA827	9506511	Bronze			2022-12-28	WOS:000072406000002
J	Gerasimova, TI; Corces, VG				Gerasimova, TI; Corces, VG			Polycomb and trithorax group proteins mediate the function of a chromatin insulator	CELL			English	Article							POSITION-EFFECT VARIEGATION; DROSOPHILA-MELANOGASTER; CHROMOSOMAL DOMAINS; GENES; ENHANCER; EXPRESSION; PROMOTER; SITES; GYPSY	Chromatin boundaries or insulator elements affect the interaction between enhancers and promoters. The gypsy insulator contains two proteins, Su(Hw) and Mod(mdg4). Both proteins colocalize on several hundred sites on polytene chromosomes and are distributed in a punctated pattern in the nuclear matrix. Mutations in mod(mdg4) have properties characteristic of a trxG gene. In addition, mutations in trxG genes enhance insulator effects on adjacent enhancers, whereas mutations in Pc have the opposite result. These alterations correlate with changes in the pattern of nuclear localization of insulator components. The results suggest a model in which PcG and TrxG proteins regulate insulator function by establishing higher order domains of chromatin organization required for the assembly of functional insulators at the nuclear matrix.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	Johns Hopkins University	Corces, VG (corresponding author), Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA.			Corces, Victor/0000-0001-5140-4337	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035463] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35463] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CAI H, 1995, NATURE, V376, P533, DOI 10.1038/376533a0; Cai HN, 1997, EMBO J, V16, P1732, DOI 10.1093/emboj/16.7.1732; CHANG YL, 1995, MOL CELL BIOL, V15, P6601; CHINWALLA V, 1995, EMBO J, V14, P2056, DOI 10.1002/j.1460-2075.1995.tb07197.x; Chung JH, 1997, P NATL ACAD SCI USA, V94, P575, DOI 10.1073/pnas.94.2.575; DORN R, 1993, P NATL ACAD SCI USA, V90, P11376, DOI 10.1073/pnas.90.23.11376; Gdula DA, 1996, P NATL ACAD SCI USA, V93, P9378, DOI 10.1073/pnas.93.18.9378; GEORGIEV PG, 1989, MOL GEN GENET, V220, P121, DOI 10.1007/BF00260865; GERASIMOVA TI, 1995, CELL, V82, P587, DOI 10.1016/0092-8674(95)90031-4; Hagstrom K, 1996, GENE DEV, V10, P3202, DOI 10.1101/gad.10.24.3202; HARRISON DA, 1993, GENE DEV, V7, P1966, DOI 10.1101/gad.7.10.1966; KALOS M, 1995, MOL CELL BIOL, V15, P198, DOI 10.1128/MCB.15.1.198; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KUZIN B, 1994, GENE DEV, V8, P2478, DOI 10.1101/gad.8.20.2478; Laemmli UK, 1992, CURR OPIN GENET DEV, V2, P275, DOI 10.1016/S0959-437X(05)80285-0; LAJEUNESSE D, 1995, MECH DEVELOP, V53, P123, DOI 10.1016/0925-4773(95)00430-0; MESSMER S, 1992, GENE DEV, V6, P1241, DOI 10.1101/gad.6.7.1241; PalBhadra M, 1997, CELL, V90, P479, DOI 10.1016/S0092-8674(00)80508-5; Paro R., 1996, EPIGENETIC MECH GENE, P507; PIRROTTA V, 1997, TRENDS GENET, V13, P3314; Scott KS, 1995, EMBO J, V14, P6258, DOI 10.1002/j.1460-2075.1995.tb00316.x; SHEARN A, 1989, GENETICS, V121, P517; Tripoulas N, 1996, GENETICS, V143, P913; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; ZHAO K, 1995, CELL, V81, P879, DOI 10.1016/0092-8674(95)90008-X	25	184	190	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 20	1998	92	4					511	521		10.1016/S0092-8674(00)80944-7	http://dx.doi.org/10.1016/S0092-8674(00)80944-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YZ409	9491892	hybrid			2022-12-28	WOS:000072251500011
J	Carlisle, R; Groom, LM; Avery, AJ; Boot, D; Earwicker, S				Carlisle, R; Groom, LM; Avery, AJ; Boot, D; Earwicker, S			Relation of out of hours activity by general practice and accident and emergency services with deprivation in Nottingham: longitudinal survey	BRITISH MEDICAL JOURNAL			English	Article							HOURS WORKLOAD; RATES; CARE; IDENTIFICATION; HEALTH	Objectives: To investigate the relation between out of hours activity of general practice and accident and emergency services with deprivation and distance from accident and emergency department. Design: Six month longitudinal study. Setting: Six general practices and the sole accident and emergency department in Nottingham. Subjects: 4745 out of hours contacts generated by 45 182 patients from 23 electoral wards registered with six practices. Main outcome measures: Rates of out of hours contacts for general practice and accident and emergency services calculated by electoral ward; Jarman and Townsend deprivation scores and distance from accident and emergency department of electoral wards. Results: Distances of wards from accident and emergency department ranged from 0.8 to 9 km, and Jarman deprivation scores ranged from -23.4 to 51.8. Out of hours contacts varied by ward from 110 to 350 events/1000 patients/year, and 58% of this variation was explained by the Jarman score. General practice and accident and emergency rates were positively correlated (Pearson coefficient 0.50, P = 0.015). Proximity to accident and emergency department was not significantly associated with increased activity when deprivation was included in regression analysis. One practice had substantially higher out of hours activity (B coefficient 124 (95% confidence interval 67 to 181)) even when deprivation was included in regression analysis. Conclusions: A disproportionate amount of out of hours workload fell on deprived inner city practices. High general practice and high accident and emergency activity occurred in the same areas rather than one service substituting for the other.	Univ Nottingham Hosp, Div Gen Practice, Nottingham NG7 2UH, England; Stapleford Hlth Ctr, Nottingham NG9 7AT, England	University of Nottingham	Carlisle, R (corresponding author), Roundwood Surg, Wood St, Mansfield NG18 1QQ, Notts, England.			Avery, Anthony/0000-0001-7591-4438				BENSHLOMO Y, 1992, J EPIDEMIOL COMMUN H, V46, P532, DOI 10.1136/jech.46.5.532; CALMAN K, 1996, DEV EMERGENCY SERVIC; CARLISLE RD, 1993, BRIT MED J, V306, P1383, DOI 10.1136/bmj.306.6889.1383; CarrHill RA, 1996, BRIT MED J, V312, P1008; DALE J, 1995, BRIT MED J, V311, P423, DOI 10.1136/bmj.311.7002.423; HALLAM L, 1994, BRIT MED J, V308, P249, DOI 10.1136/bmj.308.6923.249; Hallam L, 1997, BMJ-BRIT MED J, V314, P157, DOI 10.1136/bmj.314.7075.157; ILIFFE S, 1991, BRIT MED J, V302, P1584, DOI 10.1136/bmj.302.6792.1584; JANKOWSKI RF, 1993, BRIT MED J, V306, P121; JARMAN B, 1983, BRIT MED J, V286, P1705, DOI 10.1136/bmj.286.6379.1705; LIVINGSTONE AE, 1989, BRIT MED J, V299, P368, DOI 10.1136/bmj.299.6695.368; MACRAE K, 1994, BRIT MED J, V309, P1478, DOI 10.1136/bmj.309.6967.1478; MAJEED FA, 1995, BRIT J GEN PRACT, V45, P531; MAJEED FA, 1995, BRIT MED J, V310, P1373, DOI 10.1136/bmj.310.6991.1373; MCKEE CM, 1990, BRIT J GEN PRACT, V40, P150; MILNER PC, 1988, J EPIDEMIOL COMMUN H, V42, P274, DOI 10.1136/jech.42.3.274; MOORE AT, 1989, BRIT MED J, V298, P500, DOI 10.1136/bmj.298.6672.500; PITTS J, 1990, BRIT MED J, V300, P1113, DOI 10.1136/bmj.300.6732.1113; Tomlinson B., 1992, REPORT INQUIRY LONDO; Townsend P., 1988, HLTH DEPRIVATION; USHERWOOD TP, 1985, J ROY COLL GEN PRACT, V35, P395; Whynes DK, 1996, FAM PRACT, V13, P174, DOI 10.1093/fampra/13.2.174; Wills DS, 1996, IEEE J SEL TOP QUANT, V2, P24, DOI 10.1109/2944.541872; WITKIN D, 1992, HOSP REFERRALS, P76	24	46	46	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 14	1998	316	7130					520	523		10.1136/bmj.316.7130.520	http://dx.doi.org/10.1136/bmj.316.7130.520			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX955	9501715	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000072097400023
J	Sprang, SR				Sprang, SR			Gap into the breach	SCIENCE			English	Editorial Material							GTP HYDROLYSIS; CRYSTAL-STRUCTURE; MECHANISM; PROTEINS; RAS; BINDING		UNIV TEXAS,SW MED SCH,HOWARD HUGHES MED INST,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sprang, SR (corresponding author), UNIV TEXAS,SW MED SCH,DEPT BIOCHEM,DALLAS,TX 75235, USA.							Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CANNON WR, 1996, NAT STRUCT BIOL, V3, P822; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; SCHWEINS T, 1995, NAT STRUCT BIOL, V2, P36, DOI 10.1038/nsb0195-36; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4	16	16	16	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 18	1997	277	5324					329	330		10.1126/science.277.5324.329	http://dx.doi.org/10.1126/science.277.5324.329			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL358	9518363				2022-12-28	WOS:A1997XL35800033
J	Colwell, JE; Horanyi, M; Grun, E				Colwell, JE; Horanyi, M; Grun, E			Capture of interplanetary and interstellar dust by the Jovian magnetosphere	SCIENCE			English	Article							EJECTA; DYNAMICS; GALILEO	Interplanetary and interstellar dust grains entering Jupiter's magnetosphere form a detectable diffuse faint ring of exogenic material, This ring is composed of particles in the size range of 0.5 to 1.5 micrometers on retrograde and prograde orbits in a 4:1 ratio, with semimajor axes 3 < a < 20 jovian radii, eccentricities 0.1 < e < 0.3, and inclinations i less than or similar to 20 degrees or i greater than or similar to 160 degrees, The size range and the orbital characteristics are consistent with in situ detections of micrometer-sized grains by the Galileo dust detector, and the measured rates match the number densities predicted from numerical trajectory integrations.	Univ Colorado, Atmospher & Space Phys Lab, Boulder, CO 80309 USA; Max Planck Inst Kernphys, D-69117 Heidelberg, Germany	University of Colorado System; University of Colorado Boulder; Max Planck Society	Colwell, JE (corresponding author), Univ Colorado, Atmospher & Space Phys Lab, Campus Box 392, Boulder, CO 80309 USA.	colwell@casper.colorado.edu	Colwell, Joshua/AAP-2692-2020	Colwell, Joshua/0000-0001-8269-6408; Horanyi, Mihaly/0000-0002-5920-9226				ASADA N, 1985, J GEOPHYS RES-SOLID, V90, P2445, DOI 10.1029/JB090iB14p12445; BAGENAL F, 1989, NASA SPEC PUBL SP, V494; BAGUHL M, 1995, SPACE SCI REV, V72, P471, DOI 10.1007/BF00768822; Burns J.A., 1984, IAU COLLO Q 75 PLANE, P200; COLWELL JE, 1993, ICARUS, V106, P536, DOI 10.1006/icar.1993.1191; Colwell JE, 1996, J GEOPHYS RES-PLANET, V101, P2169, DOI 10.1029/95JE03103; CONNERNEY JEP, 1993, J GEOPHYS RES-PLANET, V98, P18659, DOI 10.1029/93JE00980; DIVINE N, 1993, J GEOPHYS RES-PLANET, V98, P17029, DOI 10.1029/93JE01203; DIVINE N, 1983, J GEOPHYS RES-SPACE, V88, P6889, DOI 10.1029/JA088iA09p06889; Gault D. E., 1973, Moon, V6, P32, DOI 10.1007/BF02630651; GRUN E, 1985, ICARUS, V62, P244, DOI 10.1016/0019-1035(85)90121-6; GRUN E, 1992, SPACE SCI REV, V60, P317, DOI 10.1007/BF00216860; GRUN E, IN PRESS GEOPHYS RES; Horanyi M, 1996, ANNU REV ASTRON ASTR, V34, P383, DOI 10.1146/annurev.astro.34.1.383; HORANYI M, 1991, J GEOPHYS RES-SPACE, V96, P19283, DOI 10.1029/91JA01982; HORANYI M, 1994, GEOPHYS RES LETT, V21, P1039, DOI 10.1029/94GL01326; HOUSEN KR, 1983, J GEOPHYS RES, V88, P2485, DOI 10.1029/JB088iB03p02485; Opik E.J., 1951, P R IRISH ACAD A, V54, P165; SITTLER EC, 1987, J GEOPHYS RES, V92, P5741, DOI 10.1029/JA092iA06p05741; STOFFLER D, 1975, J GEOPHYS RES, V80, P4062, DOI 10.1029/JB080i029p04062; Zook H. A., 1982, LUNAR PLANETARY SCI, V13, P893; ZOOK HA, 1985, LUNAR PLANET SCI, V16, P946	22	38	39	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 3	1998	280	5360					88	91		10.1126/science.280.5360.88	http://dx.doi.org/10.1126/science.280.5360.88			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF314	9525863				2022-12-28	WOS:000072885100040
J	Ogino, H; Yasuda, K				Ogino, H; Yasuda, K			Induction of lens differentiation by activation of a bZIP transcription factor, L-maf	SCIENCE			English	Article							A-CRYSTALLIN GENE; DEVELOPMENTAL REGULATION; ENHANCER ELEMENT; EYELESS GENE; V-MAF; EXPRESSION; BINDING; ONCOGENE; PROTEIN; ENCODES	After the vertebrate lens is induced from head ectoderm, lens-specific genes are expressed. Transcriptional regulation of the lens-specific alpha A-crystallin gene is controlled by an enhancer element, alpha CE2. A gene encoding an alpha CE2-binding protein, L-maf (lens-specific maf), was isolated. L-maf expression is initiated in the lens placode and is restricted to lens cells. The gene product L-Maf regulates the expression of multiple genes expressed in the lens, and ectopic expression of this transcription factor converts chick embryonic ectodermal cells and cultured cells into lens fibers. Thus, vertebrate lens induction and differentiation can be triggered by the activation of L-Maf.	Nara Inst Sci & Technol, Grad Sch Biol Sci, Ikoma 6300101, Japan	Nara Institute of Science & Technology	Yasuda, K (corresponding author), Nara Inst Sci & Technol, Grad Sch Biol Sci, 8916-5 Takayama, Ikoma 6300101, Japan.	kyasuda@bs.aist-nara.ac.jp	Ogino, Hajime/G-5279-2019	Ogino, Hajime/0000-0003-2707-2330				ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; AYA T, UNPUB; CEPKO CL, 1992, CURRENT PROTOCOLS MO; CORDES SP, 1994, CELL, V79, P1025, DOI 10.1016/0092-8674(94)90033-7; Cvekl A, 1996, BIOESSAYS, V18, P621, DOI 10.1002/bies.950180805; Duncan MK, 1996, MECH DEVELOP, V57, P79, DOI 10.1016/0925-4773(96)00533-3; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; GORING DR, 1993, DEV DYNAM, V196, P143, DOI 10.1002/aja.1001960208; GRAINGER RM, 1992, TRENDS GENET, V8, P349, DOI 10.1016/0168-9525(92)90280-H; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; HAYASHI S, 1987, GENE DEV, V1, P818, DOI 10.1101/gad.1.8.818; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; ISHIBASHI S, UNPUB; JACOBSON AG, 1966, SCIENCE, V152, P25, DOI 10.1126/science.152.3718.25; KAMACHI Y, 1995, EMBO J, V14, P3510, DOI 10.1002/j.1460-2075.1995.tb07357.x; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; LEE YM, 1995, DEVELOPMENT, V121, P825; Manzanares M, 1997, NATURE, V387, P191, DOI 10.1038/387191a0; Mathers PH, 1997, NATURE, V387, P603, DOI 10.1038/42475; MATSUO I, 1992, NUCLEIC ACIDS RES, V20, P3701, DOI 10.1093/nar/20.14.3701; MATSUO I, 1991, DEVELOPMENT, V113, P539; Muramatsu Tatsuo, 1996, Animal Science and Technology, V67, P906; NAKAMURA T, 1990, MOL CELL BIOL, V10, P3700, DOI 10.1128/MCB.10.7.3700; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; Oliver G, 1995, DEVELOPMENT, V121, P4045; Oliver G, 1996, MECH DEVELOP, V60, P233, DOI 10.1016/S0925-4773(96)00632-6; PIATIGORSKY J, 1981, DIFFERENTIATION, V19, P134, DOI 10.1111/j.1432-0436.1981.tb01141.x; Porter FD, 1997, DEVELOPMENT, V124, P2935; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; SAKAL M, 1997, ONCOGENE, V14; SAWADA K, 1993, JPN J OPHTHALMOL, V37, P355; SHINOHARA T, 1976, P NATL ACAD SCI USA, V73, P2808, DOI 10.1073/pnas.73.8.2808; Spemann H, 1901, VERH ANAT GESELLSCH, V15, P61; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; TINI M, 1993, GENE DEV, V7, P295, DOI 10.1101/gad.7.2.295; Tokui M, 1997, BIOCHEM BIOPH RES CO, V233, P527, DOI 10.1006/bbrc.1997.6485; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; Wilkinson D.G., 1993, ESSENTIAL DEV BIOL P, P257; Yasuda K, 1986, Oxf Surv Eukaryot Genes, V3, P183; Yoshida K, 1997, INVEST OPHTH VIS SCI, V38, P2679	41	236	242	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 3	1998	280	5360					115	118		10.1126/science.280.5360.115	http://dx.doi.org/10.1126/science.280.5360.115			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF314	9525857				2022-12-28	WOS:000072885100049
J							Diabet Control Complications Trial Res Grp	Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article						diabetes mellitus, insulin-dependent; insulin; dose-response relationship, drug; diabetic retinopathy; hypoglycemia	C-PEPTIDE; INSULIN; RETINOPATHY	Background: Although insulin secretion is severely decreased in most patients with type 1 diabetes, levels of residual insulin secretion often vary early in the disease. The significance of residual insulin secretion with regard to metabolic control and to long-term complications and ways to preserve such secretion are not well understood. objective: To compare the effect of intensive and conventional therapy on residual insulin secretion in Diabetes Control and Complications Trial (DCCT) participants. Design: Multicenter, randomized, controlled clinical trial. Setting: 29 DCCT clinical centers. Patients: 855 of the 1441 DCCT participants had had type 1 diabetes for 1 to 5 years at baseline. Of these 855 patients, 303 were C-peptide responders (C-peptide level, 0.20 to 0.50 pmol/mL after ingestion of a standardized, mixed meal); 138 of these patients were randomly assigned to intensive therapy, and 165 were assigned to conventional therapy. Five hundred fifty-two patients were nonresponders (stimulated C-peptide level < 0.2 pmol/mL); 274 of these patients were assigned to intensive therapy, and 278 were assigned to conventional therapy. Interventions: 1) Intensive therapy with 3 or more insulin injections daily or continuous subcutaneous infusion of insulin, guided by 4 or more glucose tests per day or 2) conventional therapy with 1 or 2 insulin injections daily. Measurements: Stimulated C-peptide level was measured annually in responders. Development of retinopathy and microalbuminuria was assessed annually, hemoglobin A,, levels were measured quarterly, and episodes of hypoglycemia were ascertained quarterly. Results: Responders receiving intensive therapy maintained a higher stimulated C-peptide level and a lower likelihood of becoming nonresponders than did responders receiving conventional therapy (risk reduction, 57% [95% CI, 39% to 71%]; P < 0.001). As in the entire DCCT cohort, intensively treated responders had a reduced risk for retinopathy progression and development of microalbuminuria and a higher risk far severe hypoglycemia compared with conventionally treated responders. Among intensively treated patients, responders had a lower hemoglobin A(1c) value (P < 0.01), a 50% (95% CI, 12% to 72%) reduced risk for retinopathy progression, and a lower risk for severe hypoglycemia (risk reduction, 65% [CI, 53% to 74%]; P < 0.001) compared with nonresponders. Conclusions: Intensive therapy for type 1 diabetes helps sustain endogenous insulin secretion, which, in turn, is associated with better metabolic control and lower risk for hypoglycemia and chronic complications. These observations underscore the importance of initiating intensive diabetic management as early as safely possible after type 1 diabetes is diagnosed.	DCCT Res Grp, Bethesda, MD 20892 USA		Diabet Control Complications Trial Res Grp (corresponding author), DCCT Res Grp, Box NDIC-DCCT, Bethesda, MD 20892 USA.		Zinman, Bernard/E-7266-2013; Hramiak, Irene/G-3305-2011					[Anonymous], 1996, DIABETES, V45, P1289; [Anonymous], 1995, DIABETES, V44, P968; BERGENSTAL RM, 1985, DIABETES, V34, P31, DOI 10.2337/diab.34.3.S31; DCCT Res Grp, 1986, DIABETES, V35, P530; DCCT Res Grp, 1987, J CLIN ENDOCR METAB, V65, P30; de Beaufort C E, 1985, Neth J Med, V28 Suppl 1, P53; Diabet Control Complications DCCT Res Grp, 1995, KIDNEY INT, V47, P1703; GOLDSTEIN DE, 1987, CLIN CHEM, V33, P2267; KERNELL A, 1990, ACTA OPHTHALMOL, V68, P415; KRARUP T, 1986, DIABETES METAB, V12, P256; LEAHY JL, 1990, DIABETES CARE, V13, P992, DOI 10.2337/diacare.13.9.992; LEE ET, 1980, STATISTICAL METHODS, P88; LUDVIGSSON J, 1978, DIABETES, V27, P230, DOI 10.2337/diab.27.1.S230; MADSBAD S, 1986, DIABETIC MED, V3, P42, DOI 10.1111/j.1464-5491.1986.tb00704.x; MADSBAD S, 1981, DIABETOLOGIA, V20, P530; MCCULLAGH P, 1989, GENERALIZED LINEAR M, P194; PERLMAN K, 1984, DIABETES, V33, P995, DOI 10.2337/diabetes.33.10.995; SHAMOON H, 1995, DIABETES CARE, V18, P361; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; STEFFES M, 1996, DIABETES S2, V46, pA18; Wahren J, 1996, J INTERN MED, V240, P115, DOI 10.1046/j.1365-2796.1996.19841000.x; WAHREN J, 1994, DIABETOLOGIA, V37, pS99, DOI 10.1007/BF00400832; WEI LJ, 1984, J AM STAT ASSOC, V79, P653, DOI 10.2307/2288413	23	456	466	0	22	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1998	128	7					517	+		10.7326/0003-4819-128-7-199804010-00001	http://dx.doi.org/10.7326/0003-4819-128-7-199804010-00001			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE539	9518395				2022-12-28	WOS:000072803500001
J	Clary, DC				Clary, DC			Quantum theory of chemical reaction dynamics	SCIENCE			English	Article							POTENTIAL-ENERGY SURFACES; REACTION PROBABILITIES; TRANSITION-STATE; RATE CONSTANTS; OH+CO->CO2+H REACTION; CROSS-SECTIONS; SCATTERING; H-2+OH->H2O+H; CHEMISTRY; FEMTOCHEMISTRY	It is now possible to use rigorous quantum scattering theory to perform accurate calculations on the detailed state-to-state dynamics of chemical reactions in the gas phase. Calculations on simple reactions, such as H + D(2) --> HD + D and F + H(2) --> HF + H, compete with experiment in their accuracy. Recent advances in theory promise to extend such accurate predictions to more complicated reactions, such as OH + H(2) --> H(2)O + H, and even to reactions of molecules on solid surfaces. New experimental techniques for probing reaction transition states, such as negative-ion photodetachment spectroscopy and pump-probe femtosecond spectroscopy, are stimulating the development of new theories.	UCL, Dept Chem, London WC1H 0AJ, England	University of London; University College London	Clary, DC (corresponding author), UCL, Dept Chem, London WC1H 0AJ, England.		Clary, David C/AAC-3903-2019	Clary, David C/0000-0003-4439-741X				Alagia M, 1996, CHEM PHYS, V207, P389, DOI 10.1016/0301-0104(95)00422-X; Aoiz FJ, 1996, CHEM PHYS LETT, V262, P175, DOI 10.1016/0009-2614(96)01074-3; Aoiz FJ, 1997, J PHYS CHEM A, V101, P6403, DOI 10.1021/jp970695z; ARNOLD DW, 1995, J CHEM PHYS, V102, P6088, DOI 10.1063/1.469343; BRONIKOWSKI MJ, 1993, J PHYS CHEM-US, V97, P2194, DOI 10.1021/j100112a021; BROOKS AN, 1990, J CHEM PHYS, V92, P4178, DOI 10.1063/1.457776; Brouard M, 1997, CHEM PHYS LETT, V281, P97, DOI 10.1016/S0009-2614(97)01158-5; Clary DC, 1997, J CHEM SOC FARADAY T, V93, P747, DOI 10.1039/a605739j; CLARY DC, 1993, J CHEM PHYS, V99, P4578, DOI 10.1063/1.466057; CLARY DC, 1994, J PHYS CHEM-US, V98, P10678, DOI 10.1021/j100093a004; CLARY DC, 1991, J CHEM PHYS, V95, P7298, DOI 10.1063/1.461407; Dai JQ, 1997, J CHEM PHYS, V107, P1676, DOI 10.1063/1.474520; Darling GR, 1995, REP PROG PHYS, V58, P1595, DOI 10.1088/0034-4885/58/12/001; de Miranda MP, 1998, J CHEM PHYS, V108, P3142, DOI 10.1063/1.476369; DEBEER E, 1995, J PHYS CHEM-US, V99, P13627, DOI 10.1021/j100037a009; DOUHAL A, 1995, NATURE, V378, P260, DOI 10.1038/378260a0; Duley W. W., 1984, INTERSTELLAR CHEM; GOLDFIELD EM, 1995, J CHEM PHYS, V102, P8807, DOI 10.1063/1.468934; Hartke B, 1997, CHEM PHYS LETT, V280, P430, DOI 10.1016/S0009-2614(97)01209-8; HeadGordon M, 1996, J PHYS CHEM-US, V100, P13213, DOI 10.1021/jp953665+; HERNANDEZ MI, 1994, J CHEM PHYS, V101, P2779, DOI 10.1063/1.467593; IONOV SI, 1993, J CHEM PHYS, V99, P6553, DOI 10.1063/1.465847; JACOBS A, 1994, J CHEM PHYS, V100, P1936, DOI 10.1063/1.466546; KIM SK, 1995, CHEM PHYS LETT, V233, P500; Korolkov MV, 1996, J CHEM PHYS, V105, P10874, DOI 10.1063/1.472894; Kroes GJ, 1997, J CHEM PHYS, V107, P3309, DOI 10.1063/1.474682; KUPPERMANN A, 1975, CHEM PHYS LETT, V32, P374, DOI 10.1016/0009-2614(75)85148-7; LEVINE RD, 1987, MOL REACTION DYNAMIC; LIGHT GC, 1978, CHEM PHYS LETT, V58, P578, DOI 10.1016/0009-2614(78)80023-2; Manolopoulos DE, 1997, J CHEM SOC FARADAY T, V93, P673, DOI 10.1039/a606090k; MANOLOPOULOS DE, 1993, SCIENCE, V262, P1852, DOI 10.1126/science.262.5141.1852; MANTHE U, 1993, J CHEM PHYS, V99, P10078, DOI 10.1063/1.465514; McRae RP, 1997, J CHEM SOC FARADAY T, V93, P997, DOI 10.1039/a605914g; MILLER JA, 1990, ANNU REV PHYS CHEM, V41, P345, DOI 10.1146/annurev.physchem.41.1.345; PARK TJ, 1992, J CHEM PHYS, V96, P8853, DOI 10.1063/1.462242; PARKER GA, 1993, J CHEM PHYS, V98, P6883, DOI 10.1063/1.464778; Pogrebnya SK, 1997, J CHEM PHYS, V107, P8975, DOI 10.1063/1.475189; Schatz GC, 1996, J PHYS CHEM-US, V100, P12839, DOI 10.1021/jp953344y; SCHATZ GC, 1992, CHEM PHYS LETT, V188, P11, DOI 10.1016/0009-2614(92)85080-T; SCHATZ GC, 1997, J CHEM SOC FARADAY T, V93; SCHERER NF, 1987, J CHEM PHYS, V87, P1451, DOI 10.1063/1.453280; Schwartz RL, 1997, CHEM PHYS LETT, V273, P18, DOI 10.1016/S0009-2614(97)00597-6; SINHA A, 1990, J CHEM PHYS, V92, P6333, DOI 10.1063/1.458312; SUN QY, 1990, J CHEM PHYS, V92, P5201, DOI 10.1063/1.458555; SZICHMAN H, 1994, J CHEM PHYS, V101, P2081, DOI 10.1063/1.467715; TRAINOR DW, 1975, P 15 INT S COMB COMB; WAYNE RP, 1992, CHEM ATMOSPHERES; Wrede E, 1997, J CHEM PHYS, V107, P786, DOI 10.1063/1.474378; ZELLNER R, 1981, CHEM PHYS LETT, V81, P568, DOI 10.1016/0009-2614(81)80465-4; Zewail AH, 1996, J PHYS CHEM-US, V100, P12701, DOI 10.1021/jp960658s; Zhang DH, 1997, J CHEM SOC FARADAY T, V93, P691, DOI 10.1039/a605888d; ZHANG DH, 1994, J CHEM PHYS, V100, P2697, DOI 10.1063/1.466464; ZHANG DH, 1993, J CHEM PHYS, V99, P5615, DOI 10.1063/1.465954; ZHANG DH, 1995, J CHEM PHYS, V103, P6512, DOI 10.1063/1.470377; Zhong D, 1997, J AM CHEM SOC, V119, P2305, DOI 10.1021/ja963879k	55	117	126	4	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 20	1998	279	5358					1879	1882		10.1126/science.279.5358.1879	http://dx.doi.org/10.1126/science.279.5358.1879			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506929				2022-12-28	WOS:000072613300032
J	Cook, D; Guyatt, G; Marshall, J; Leasa, D; Fuller, H; Hall, R; Peters, S; Rutledge, F; Griffith, L; McLellan, A; Wood, G; Kirby, A				Cook, D; Guyatt, G; Marshall, J; Leasa, D; Fuller, H; Hall, R; Peters, S; Rutledge, F; Griffith, L; McLellan, A; Wood, G; Kirby, A		Canadian Critical Care Trials Grp	A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							STRESS-ULCER PROPHYLAXIS; INTENSIVE-CARE UNIT; CRITICALLY ILL PATIENTS; NOSOCOMIAL PNEUMONIA; GASTRIC COLONIZATION; SECONDARY PNEUMONIA; RISK-FACTORS; FREQUENCY; ANTACIDS; CIMETIDINE	Background Critically ill patients who require mechanical ventilation are at increased risk for gastrointestinal bleeding from stress ulcers. There are conflicting data on the effect of histamine H-2-receptor antagonists and the cytoprotective agent sucralfate on rates of gastrointestinal bleeding, ventilator-associated pneumonia, and mortality. Methods In a multicenter, randomized, blinded, placebo-controlled trial, we compared sucralfate with the H-2-receptor antagonist ranitidine for the prevention of upper gastrointestinal bleeding in 1200 patients who required mechanical ventilation. Patients received either nasogastric sucralfate suspension (1 g every six hours) and an intravenous placebo or intravenous ranitidine (50 mg every eight hours) and a nasogastric placebo. Results The patients in the two groups had similar base-line characteristics. Clinically important gastrointestinal bleeding developed in 10 of 596 (1.7 percent) of the patients receiving ranitidine, as compared with 23 of 604 (3.8 percent) of those receiving sucralfate (relative risk, 0.44; 95 percent confidence interval, 0.21 to 0.92; P = 0.02). In the ranitidine group, 114 of 596 patients (19.1 percent) had ventilator-associated pneumonia, as compared with 98 of 604 (16.2 percent) in the sucralfate group (relative risk, 1.18; 95 percent confidence interval, 0.92 to 1.51; P = 0.19). There was no significant difference between the groups in mortality in the intensive care unit (ICU) (23.5 percent in the ranitidine group and 22.8 percent in the sucralfate group) or the duration of the stay in the ICU (median, nine days in both groups). Conclusions Among critically ill patients requiring mechanical ventilation, those receiving ranitidine had a significantly lower rate of clinically important gastrointestinal bleeding than those treated with sucralfate. There were no significant differences in the rates of ventilator-associated pneumonia, the duration of the stay in the ICU, or mortality. (C) 1998, Massachusetts Medical Society.	McMaster Univ, Hamilton, ON, Canada; Univ Toronto, Toronto, ON, Canada; Univ Western Ontario, London, ON, Canada; Dalhousie Univ, Halifax, NS, Canada; Mem Univ Newfoundland, St John, NF, Canada; Queens Univ, Kingston, ON, Canada	McMaster University; University of Toronto; Western University (University of Western Ontario); Dalhousie University; Memorial University Newfoundland; Queens University - Canada	Cook, D (corresponding author), St Josephs Hosp, Dept Med, 50 Charlton Ave, Hamilton, ON L8N 4A6, Canada.							Aitkin M., 1989, STAT MODELLING GLIM; [Anonymous], 1989, AM REV RESPIR DIS, V139, P1058; ATHERTON ST, 1978, LANCET, V2, P968; BenMenachem T, 1996, CRIT CARE MED, V24, P338, DOI 10.1097/00003246-199602000-00026; BENMENACHEM T, 1994, ANN INTERN MED, V121, P568, DOI 10.7326/0003-4819-121-8-199410150-00003; BORRERO E, 1985, AM J MED, V79, P62, DOI 10.1016/0002-9343(85)90575-3; CANNON LA, 1987, ARCH INTERN MED, V147, P2101, DOI 10.1001/archinte.147.12.2101; COOK DJ, 1994, NEW ENGL J MED, V330, P377, DOI 10.1056/NEJM199402103300601; Cook DJ, 1996, JAMA-J AM MED ASSOC, V275, P308, DOI 10.1001/jama.275.4.308; Cook DJ, 1991, J INTENSIVE CARE MED, V6, P167; CRAVEN DE, 1986, AM REV RESPIR DIS, V133, P792; DRIKS MR, 1987, NEW ENGL J MED, V317, P1376, DOI 10.1056/NEJM198711263172204; DUMOULIN GC, 1982, LANCET, V1, P242; EDDLESTON JM, 1991, CRIT CARE MED, V19, P1491, DOI 10.1097/00003246-199112000-00009; EDDLESTON JM, 1994, CRIT CARE MED, V22, P1949; Erstad BL, 1997, CRIT CARE MED, V25, P1678, DOI 10.1097/00003246-199710000-00017; FABIAN TC, 1993, ARCH SURG-CHICAGO, V128, P185; FAGON JY, 1993, AM J MED, V94, P281, DOI 10.1016/0002-9343(93)90060-3; Fleiss J. L., 1981, STAT METHODS RATES P, V2; GARCIALABATTUT A, 1990, INTENSIVE CARE ME S1, V16, pS19; KAMADA T, 1977, J TRAUMA, V17, P44, DOI 10.1097/00005373-197701000-00006; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LABATTUT AG, 1992, CLIN INTENSIVE CARE, V3, pS19; LACROIX J, 1992, CRIT CARE MED, V20, P35, DOI 10.1097/00003246-199201000-00013; LAGGNER AN, 1988, ANAESTHESIST, V37, P704; LEVY MM, 1993, CRIT CARE MED S, V21, pS181; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; MEDURI GU, 1992, CHEST, V102, pS557, DOI 10.1378/chest.102.5_Supplement_1.557S; MUSTAFA NA, 1995, INTENS CARE MED, V21, P287, DOI 10.1007/BF01701491; NAVAB F, 1995, AM J GASTROENTEROL, V90, P708; NOSEWORTHY TW, 1987, CRIT CARE MED, V15, P817, DOI 10.1097/00003246-198709000-00003; Papazian L, 1996, AM J RESP CRIT CARE, V154, P91, DOI 10.1164/ajrccm.154.1.8680705; PETERSON WL, 1994, NEW ENGL J MED, V330, P428, DOI 10.1056/NEJM199402103300610; PICKWORTH KK, 1992, CRIT CARE MED, V20, pS95; PINGLETON SK, 1992, CHEST, V102, pS553, DOI 10.1378/chest.102.5_Supplement_1.553S; PRODHOM G, 1991, 31 INT C ANT AG CHEM; PUGIN J, 1991, AM REV RESPIR DIS, V143, P1121, DOI 10.1164/ajrccm/143.5_Pt_1.1121; RUIZSANTANA S, 1991, CRIT CARE MED, V19, P887, DOI 10.1097/00003246-199107000-00011; RYAN P, 1993, ARCH SURG-CHICAGO, V128, P1353; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Schumock GT, 1996, PHARMACOECONOMICS, V9, P455, DOI 10.2165/00019053-199609050-00008; SCHUSTER DP, 1984, AM J MED, V76, P623, DOI 10.1016/0002-9343(84)90286-9; SCHUSTER DP, 1993, CRIT CARE MED, V21, P4, DOI 10.1097/00003246-199301000-00003; SHUMAN RB, 1987, ANN INTERN MED, V106, P562, DOI 10.7326/0003-4819-106-4-562; SIMMS HH, 1991, J TRAUMA, V31, P531, DOI 10.1097/00005373-199104000-00013; THOMASON M, 1995, CRIT CARE MED, V23, pA93; TRYBA M, 1994, INTENS CARE MED, V20, P311, DOI 10.1007/BF01720900; WIMBERLEY N, 1979, AM REV RESPIR DIS, V119, P337; ZANDSTRA DF, 1994, INTENS CARE MED, V20, P335, DOI 10.1007/BF01720905; [No title captured]	50	478	509	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 19	1998	338	12					791	797		10.1056/NEJM199803193381203	http://dx.doi.org/10.1056/NEJM199803193381203			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC163	9504939	Bronze			2022-12-28	WOS:000072546800003
J	Zhang, JK; Cado, D; Chen, A; Kabra, NH; Winoto, A				Zhang, JK; Cado, D; Chen, A; Kabra, NH; Winoto, A			Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; DOMAIN-CONTAINING RECEPTOR; DEATH-DOMAIN; SIGNALING COMPLEX; CD95 FAS/APO-1; LYMPHOCYTES-T; PROTEIN; INTERACTS; THYMOCYTES; FADD	Programmed cell death, or apoptosis, is important in homeostasis of the immune system: for example, non-functional or autoreactive lymphocytes are eliminated through apoptosis, One member of the tumour necrosis factor receptor (TNFR) family; Fas (also known as CD95 or Apo-1), can trigger cell death and is essential for lymphocyte homeostasis(1,2). FADD/Mort1 (refs 3-6) is a Pas-associated protein that is thought to mediate apoptosis by recruiting the protease caspase-8 (refs 7, 8), A dominant-negative mutant of FADD inhibits apoptosis initiated by Fas and other TNFR family members(6,9-14). Other proteins, notably Daax, also bind Fas and presumably mediate a FADD-independent apoptotic pathway(15). Here we investigate the role of FADD in vivo by generating FADD-deficient mice. As homozygous mice die in utero, we generated FADD(-/-) embryonic stem cells and FADD(-/-) chimaeras in a background devoid of the recombination activating gene RAG-1, which activates rearrangement of the immunoglobulin and T-cell receptor genes, We found that thymocyte subpopulations were apparently normal in newborn chimaeras. Fas-induced apoptosis was completely blocked, indicating that there are no redundant Fas apoptotic pathways, As these mice age, their thymocytes decrease to an undetectable level, although peripheral T cells are present in all older FADD(-/-) chimaeras, Unexpectedly, activation-induced proliferation is impaired in these FADD(-/-) T cells, despite production of the cytokine interleukin (IL)-2, These results and the similarities between FADD(-/-) mice and mice lacking the P-subunit of the IL-2 receptor suggest that there is an unexpected connection between cell proliferation and apoptosis.	Univ Calif Berkeley, Dept Mol & Cell Biol, Div Immunol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Canc Res Lab, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Winoto, A (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Immunol, 469 LSA, Berkeley, CA 94720 USA.			Zhang, Jianke/0000-0002-5822-2226; Shi, Yufang/0000-0001-8964-319X				Bodmer JL, 1997, IMMUNITY, V6, P79, DOI 10.1016/S1074-7613(00)80244-7; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CHU KT, 1995, P NATL ACAD SCI USA, V92, P11894, DOI 10.1073/pnas.92.25.11894; Fournel S, 1996, J IMMUNOL, V157, P4309; HERNANDEZCASELLES T, 1993, J IMMUNOL, V151, P3999; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; Lenardo M J, 1997, Semin Immunol, V9, P1, DOI 10.1006/smim.1996.0050; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; Matiba B, 1997, Semin Immunol, V9, P59, DOI 10.1006/smim.1996.0054; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OGASAWARA J, 1995, J EXP MED, V181, P485, DOI 10.1084/jem.181.2.485; Parijs LV, 1997, J IMMUNOL, V158, P3738; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SCHMID I, 1994, J IMMUNOL METHODS, V170, P145, DOI 10.1016/0022-1759(94)90390-5; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; SUZUKI H, 1995, SCIENCE, V268, P1472, DOI 10.1126/science.7770771; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zhang J, 1996, MOL CELL BIOL, V16, P2756	30	623	638	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1998	392	6673					296	300		10.1038/32681	http://dx.doi.org/10.1038/32681			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC739	9521326				2022-12-28	WOS:000072612300051
J	Wen, LX; Helmberger, DV				Wen, LX; Helmberger, DV			Ultra-low velocity zones near the core-mantle boundary from broadband PKP precursors	SCIENCE			English	Article							INNER-CORE; PACIFIC; LAYER	Short- and long-period precursors of the PKP phase were used to study an ultra-low velocity zone (ULVZ) near the core-mantle boundary beneath the Western Pacific. Synthetic seismograms were computed from a hybrid method, which handles seismic wave propagation through two-dimensional complex structures, Long-period precursors were explained by Gaussian-shaped ULVZs of 60 to 80 kilometers height with P velocity drops of at least 7 percent over 100 to 300 kilometers, Short-period precursors suggest the presence of smaller scale anomalies accompanying these larger Gaussian-shaped structures. These fine structures may be areas of partial melt caused by vigorous small-scale convection or the instability of a thermal boundary layer at the mantle's base, or both.	CALTECH, Seismol Lab, Pasadena, CA 91125 USA	California Institute of Technology	Wen, LX (corresponding author), CALTECH, Seismol Lab, Pasadena, CA 91125 USA.			Wen, Lianxing/0000-0002-5344-6212				BATAILLE K, 1990, PURE APPL GEOPHYS, V132, P151, DOI 10.1007/BF00874361; BUCHBINDER GG, 1974, B SEISMOL SOC AM, V64, P33; CLEARY JR, 1972, NATURE, V240, P549, DOI 10.1038/240549a0; CORMIER VF, 1995, GEOPHYS J INT, V121, P725, DOI 10.1111/j.1365-246X.1995.tb06434.x; CORMIER VF, 1977, J GEOPHYS-Z GEOPHYS, V43, P3; DOOMBOS DJ, 1978, GEOPHYS J ROY ASTRON, V53, P643; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; GARNERO EJ, 1995, PHYS EARTH PLANET IN, V91, P161, DOI 10.1016/0031-9201(95)03039-Y; Haddon R. A. W., 1974, Physics of the Earth and Planetary Interiors, V8, P211, DOI 10.1016/0031-9201(74)90088-0; Hedlin MAH, 1997, NATURE, V387, P145, DOI 10.1038/387145a0; Helmberger DV, 1996, J GEOPHYS RES-SOL EA, V101, P13963, DOI 10.1029/96JB00534; HELMBERGER DV, 1997, EOS SF, V78, pF1; Holland KG, 1997, SCIENCE, V275, P1623, DOI 10.1126/science.275.5306.1623; KIND R, 1975, J GEOPHYS-Z GEOPHYS, V41, P149; LIU XF, 1994, EOS T AGU S, V75, P663; MORI J, 1995, J GEOPHYS RES-SOL EA, V100, P20359, DOI 10.1029/95JB02243; OLSEN P, 1987, NATURE, V327, P409; SONG XD, 1995, J GEOPHYS RES-SOL EA, V100, P9805, DOI 10.1029/95JB00244; SU WJ, 1994, J GEOPHYS RES-SOL EA, V99, P6945, DOI 10.1029/93JB03408; Vidale JE, 1998, NATURE, V391, P682, DOI 10.1038/35601; WEN L, IN PRESS J GEOPHYS R; Williams Q, 1996, SCIENCE, V273, P1528, DOI 10.1126/science.273.5281.1528	22	165	172	1	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 13	1998	279	5357					1701	1703		10.1126/science.279.5357.1701	http://dx.doi.org/10.1126/science.279.5357.1701			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9497284				2022-12-28	WOS:000072490000049
J	Eastell, R				Eastell, R			Treatment of postmenopausal osteoporosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							BONE-MINERAL DENSITY; VITAMIN-D SUPPLEMENTATION; SALMON-CALCITONIN; HIP-FRACTURES; CALCIUM SUPPLEMENTATION; REPLACEMENT THERAPY; CONTROLLED TRIAL; TRABECULAR BONE; SODIUM-FLUORIDE; BREAST-CANCER		Univ Sheffield, Div Clin Sci, Sheffield, S Yorkshire, England	University of Sheffield	Eastell, R (corresponding author), No Gen Hosp, Ctr Clin Sci, Div Clin Sci, Med Sect, Herries Rd, Sheffield S5 7AU, S Yorkshire, England.		Eastell, Richard/G-5851-2011	Eastell, Richard/0000-0002-0323-3366				[Anonymous], 1994, JAMA, V272, P1942; ARMAMENTOVILLAREAL R, 1995, J CLIN ENDOCR METAB, V80, P776, DOI 10.1210/jc.80.3.776; Arnala I, 1996, BONE, V18, P629, DOI 10.1016/8756-3282(96)00084-1; Beresford SAA, 1997, LANCET, V349, P458, DOI 10.1016/S0140-6736(96)07365-5; Bergkvist L, 1996, DRUG SAFETY, V15, P360, DOI 10.2165/00002018-199615050-00006; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; BLUMSOHN A, 1994, J CLIN ENDOCR METAB, V79, P730, DOI 10.1210/jc.79.3.730; BYRNE PM, 1995, CALCIFIED TISSUE INT, V56, P518, DOI 10.1007/BF00298580; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; CHAPUY MC, 1994, BRIT MED J, V308, P1081, DOI 10.1136/bmj.308.6936.1081; CHRISTIANSEN C, 1981, LANCET, V1, P459; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; Compston JE, 1997, LANCET, V350, P676, DOI 10.1016/S0140-6736(97)22036-2; COMPSTON JE, 1995, CALCIFIED TISSUE INT, V57, P247, DOI 10.1007/BF00298877; CUMMINGS SR, 1995, J BONE MINER RES, V10, P518; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003; DAWSONHUGHES B, 1990, NEW ENGL J MED, V323, P878, DOI 10.1056/NEJM199009273231305; deGroen PC, 1996, NEW ENGL J MED, V335, P1016, DOI 10.1056/NEJM199610033351403; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; Draper MW, 1996, J BONE MINER RES, V11, P835; EASTELL R, 1995, J INTERN MED, V237, P439, DOI 10.1111/j.1365-2796.1995.tb00868.x; EASTELL R, 1996, OSTEOPOROS INT S2, V6, pS3; EDDY DM, IN PRESS OSTEOPOOSIS; ERIKSEN EF, 1986, ENDOCR REV, V7, P379, DOI 10.1210/edrv-7-4-379; FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601; FISHER B, 1994, J NATL CANCER I, V86, P527, DOI 10.1093/jnci/86.7.527; FOGELMAN I, 1986, CLIN ENDOCRINOL, V24, P57, DOI 10.1111/j.1365-2265.1986.tb03254.x; GALLAGHER JC, 1990, ANN INTERN MED, V113, P649, DOI 10.7326/0003-4819-113-9-649; GALLAGHER JC, 1989, P SOC EXP BIOL MED, V191, P287; GARNERO P, 1994, J CLIN ENDOCR METAB, V79, P1693, DOI 10.1210/jc.79.6.1693; Garnero P, 1996, J BONE MINER RES, V11, P337, DOI 10.1002/jbmr.5650110307; GENNARI C, 1991, CALCIFIED TISSUE INT, V49, pS9, DOI 10.1007/BF02561370; GREY AB, 1995, AM J MED, V99, P636, DOI 10.1016/S0002-9343(99)80251-4; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; Guo CY, 1996, J CLIN ENDOCR METAB, V81, P3487, DOI 10.1210/jc.81.10.3487; HANSEN MA, 1991, BMJ-BRIT MED J, V303, P961, DOI 10.1136/bmj.303.6808.961; HARRIS ST, 1993, AM J MED, V95, P557, DOI 10.1016/0002-9343(93)90350-X; HEIKINHEIMO RJ, 1992, CALCIFIED TISSUE INT, V51, P105, DOI 10.1007/BF00298497; Hodsman AB, 1997, J CLIN ENDOCR METAB, V82, P620, DOI 10.1210/jc.82.2.620; Hosking D, 1998, NEW ENGL J MED, V338, P485, DOI 10.1056/NEJM199802193380801; HUGHES DE, 1995, J BONE MINER RES, V10, P1478; JOHNSTON CC, 1989, J BONE MINER RES S2, V4, P1; KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; Kleerekoper M, 1991, Osteoporos Int, V1, P155, DOI 10.1007/BF01625446; KOLLERUP G, 1994, CALCIFIED TISSUE INT, V54, P12, DOI 10.1007/BF00316282; KOVACS AB, 1994, AGENTS ACTIONS, V41, P86, DOI 10.1007/BF01986400; LANDMAN JO, 1995, J CLIN ENDOCR METAB, V80, P3465, DOI 10.1210/jc.80.12.3465; LAURITZEN JB, 1993, LANCET, V341, P11, DOI 10.1016/0140-6736(93)92480-H; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; Lindsay R, 1997, OSTEOPOROSIS INT, V7, P1; LINDSAY R, 1980, LANCET, V2, P1151; Lindsay R, 1997, LANCET, V350, P550, DOI 10.1016/S0140-6736(97)02342-8; LINDSAY R, 1981, LANCET, V1, P729; Lips P, 1996, ANN INTERN MED, V124, P400, DOI 10.7326/0003-4819-124-4-199602150-00003; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; MAMELLE N, 1988, LANCET, V2, P361, DOI 10.1016/S0140-6736(88)92834-6; Marcus R, 1996, J CLIN ENDOCR METAB, V81, P1, DOI 10.1210/jc.81.1.1; MARIE PJ, 1993, J BONE MINER RES, V8, P607; MARX CW, 1992, J BONE MINER RES, V7, P1275; MAXIM P, 1995, OSTEOPOROSIS INT, V5, P23, DOI 10.1007/BF01623654; MELTON LJ, 1993, J BONE MINER RES, V8, P1227; MEUNIER PJ, IN PRESS OSTEOPOROSI; Muff R, 1991, Osteoporos Int, V1, P72, DOI 10.1007/BF01880446; NIELSEN SP, 1994, BRIT J OBSTET GYNAEC, V101, P319, DOI 10.1111/j.1471-0528.1994.tb13618.x; ORIMO H, 1994, CALCIFIED TISSUE INT, V54, P370, DOI 10.1007/BF00305521; ORIMO H, 1987, BONE MINER, V3, P47; OTT SM, 1994, J CLIN ENDOCR METAB, V78, P968, DOI 10.1210/jc.78.4.968; OVERGAARD K, 1989, BRIT MED J, V299, P477, DOI 10.1136/bmj.299.6697.477; OVERGAARD K, 1992, BRIT MED J, V305, P556, DOI 10.1136/bmj.305.6853.556; OVERGAARD K, 1994, CALCIFIED TISSUE INT, V55, P82, DOI 10.1007/BF00297179; PAGANINIHILL A, 1981, ANN INTERN MED, V95, P28, DOI 10.7326/0003-4819-95-1-28; PAK CYC, 1995, ANN INTERN MED, V123, P401, DOI 10.7326/0003-4819-123-6-199509150-00001; PARFITT AM, 1987, AM J MED, V82, P68, DOI 10.1016/0002-9343(87)90274-9; Parfitt AM, 1996, J BONE MINER RES, V11, P150; PARFITT AM, 1980, MINER ELECTROL METAB, V4, P273; PARFITT AM, 1993, OSTEOPOROSIS, P164; Recker RR, 1996, J BONE MINER RES, V11, P1961; REGINSTER JY, 1995, AM J MED, V98, P452, DOI 10.1016/S0002-9343(99)80344-1; REID IR, 1995, AM J MED, V98, P331, DOI 10.1016/S0002-9343(99)80310-6; RICO H, 1995, CALCIFIED TISSUE INT, V56, P181, DOI 10.1007/BF00298606; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; Riggs BL, 1996, BONE, V18, pS197, DOI 10.1016/8756-3282(95)00502-1; ROSSINI M, 1994, J BONE MINER RES, V9, P1833; ROUX C, 1995, OSTEOPOROSIS INT, V5, P185, DOI 10.1007/BF02106098; SOGAARD CH, 1994, BONE, V15, P393, DOI 10.1016/8756-3282(94)90815-X; STEVENSON JC, 1992, LANCET, V339, P370; STORM T, 1990, NEW ENGL J MED, V322, P1265, DOI 10.1056/NEJM199005033221803; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; TILYARD MW, 1992, NEW ENGL J MED, V326, P357, DOI 10.1056/NEJM199202063260601; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201; *WRIT GROUP PEPI, 1906, JAMA-J AM MED ASSOC, V276, P1389	95	472	518	0	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 12	1998	338	11					736	746		10.1056/NEJM199803123381107	http://dx.doi.org/10.1056/NEJM199803123381107			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB546	9494151				2022-12-28	WOS:000072483400007
J	Passalacqua, G; Albano, M; Fregonese, L; Riccio, A; Pronzato, C; Mela, GS; Canonica, GW				Passalacqua, G; Albano, M; Fregonese, L; Riccio, A; Pronzato, C; Mela, GS; Canonica, GW			Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis	LANCET			English	Article							DOUBLE-BLIND; SUBLINGUAL IMMUNOTHERAPY; ORAL IMMUNOTHERAPY; EPITHELIAL-CELLS; RHINITIS; ASTHMA; PARIETARIA; CHALLENGE; EFFICACY; ICAM-1	Background Non-injective routes of immunotherapy are thought to be valuable therapeutic options for respiratory allergy. We investigated the clinical efficacy and the effects of sublingual/oral immunotherapy on conjunctival allergic inflammation in patients with mite-induced respiratory allergy. Methods We used a double-blind placebo-controlled design. 20 patients with mite-induced rhinoconjunctivitis (six of whom also had mild asthma) were randomly assigned sublingual/oral immunotherapy (n=10) or placebo (n=10) for 2 years. We assessed symptom score by diary cards and inflammatory-cell infiltrate, and expression of intercellular adhesion molecule 1 (ICAM-1) in the conjunctiva after specific allergen challenge at enrolment and after 12 and 24 months of treatment. Findings We found significantly lower symptom scores in the immunotherapy group than in the placebo group in most of the winter months (p=0.05). Compared with the placebo group, inflammatory-cell infiltration after conjunctival challenge, and ICAM-1 expression on conjunctival epithelium decreased significantly in the first year of treatment in the immunotherapy group (p=0.04 and p=0.02, respectively). These effects were also seen for the minimum persistent inflammation, in symptom-free patients exposed constantly to allergens (p=0.02). Serum concentrations of eosinophil cationic protein decreased significantly (p=0.04). Immunotherapy was well tolerated and compliance was good. Interpretation Our results suggest that this immunotherapy is clinically effective in rhinoconjunctivitis and that it decreases the immune-mediated inflammatory responses to the allergen.	Univ Genoa, Dept Internal Med, DIMI, Allergy & Clin Immunol Serv, I-16132 Genoa, Italy; Univ Genoa, Dept Internal Med, DIMI, Lab Clin Informat, I-16132 Genoa, Italy	University of Genoa; University of Genoa	Canonica, GW (corresponding author), Univ Genoa, Dept Internal Med, DIMI, Allergy & Clin Immunol Serv, V Benedetto XV 6, I-16132 Genoa, Italy.		Mela, Giuseppe S/F-6072-2010; canonica, giorgio walter/ABF-2037-2020	canonica, giorgio walter/0000-0001-8467-2557; RICCIO, ANNA MARIA/0000-0001-8392-533X				BAGNASCO M, 1997, J ALLERGY CLIN IMMUN, V100, P121; CIPRANDI G, 1994, AM J RESP CRIT CARE, V150, P1653, DOI 10.1164/ajrccm.150.6.7524984; CIPRANDI G, 1993, J ALLERGY CLIN IMMUN, V91, P783, DOI 10.1016/0091-6749(93)90198-O; Ciprandi G, 1995, J ALLERGY CLIN IMMUN, V96, P971, DOI 10.1016/S0091-6749(95)70235-0; COOPER PJ, 1984, CLIN ALLERGY, V14, P541, DOI 10.1111/j.1365-2222.1984.tb02242.x; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; FELIZIANI V, 1995, ALLERGOL IMMUNOPATH, V23, P173; GIOVANE AL, 1994, CLIN EXP ALLERGY, V24, P53, DOI 10.1111/j.1365-2222.1994.tb00917.x; Hamid QA, 1997, J ALLERGY CLIN IMMUN, V99, P254, DOI 10.1016/S0091-6749(97)70106-4; HOLT PG, 1994, LANCET, V344, P456, DOI 10.1016/S0140-6736(94)91776-0; MALLING HJ, 1993, ALLERGY          S14, V48, P1; Mistrello G, 1996, ALLERGY, V51, P8, DOI 10.1111/j.1398-9995.1996.tb04543.x; Passalacqua G, 1996, J INVEST ALLERG CLIN, V6, P81; PASSALACQUA G, 1995, AM J RESP CRIT CARE, V152, P461, DOI 10.1164/ajrccm.152.2.7633693; RAK S, 1990, J ALLERGY CLIN IMMUN, V86, P706, DOI 10.1016/S0091-6749(05)80174-5; SABBAH A, 1994, ALLERGY, V49, P309, DOI 10.1111/j.1398-9995.1994.tb02273.x; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; TARI MG, 1990, ALLERGOL IMMUNOPATH, V18, P277; TAUDORF E, 1989, J ALLERGY CLIN IMMUN, V83, P589, DOI 10.1016/0091-6749(89)90070-5; TROISE C, 1995, J INVEST ALLERG CLIN, V5, P25	20	222	230	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 28	1998	351	9103					629	632		10.1016/S0140-6736(97)07055-4	http://dx.doi.org/10.1016/S0140-6736(97)07055-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA447	9500318				2022-12-28	WOS:000072364200008
J	Rusznak, C; Davies, RJ				Rusznak, C; Davies, RJ			ABC of allergies - Diagnosing allergy	BRITISH MEDICAL JOURNAL			English	Review									London Chest Hosp, Dept Asthma & Allergy, London, England	University of London; Queen Mary University London	Rusznak, C (corresponding author), London Chest Hosp, Dept Asthma & Allergy, London, England.								0	26	28	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 28	1998	316	7132					686	689		10.1136/bmj.316.7132.686	http://dx.doi.org/10.1136/bmj.316.7132.686			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA282	9522798	Green Published			2022-12-28	WOS:000072347900038
J	Suarez-Lopez, P; Coupland, G				Suarez-Lopez, P; Coupland, G			Botany - Plants see the blue light	SCIENCE			English	Article							ARABIDOPSIS; GENE; MUTANTS; ENCODES; PROTEIN		John Innes Ctr Plant Sci Res, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Suarez-Lopez, P (corresponding author), John Innes Ctr Plant Sci Res, Colney Lane, Norwich NR4 7UH, Norfolk, England.	george.coupland@bbsrc.ac.uk	Coupland, George/AAP-8609-2020; Suárez-López, Paula/D-4894-2012	Coupland, George/0000-0001-6988-4172; Suárez-López, Paula/0000-0001-5748-9263				AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; Bagnall DJ, 1996, PLANTA, V200, P278, DOI 10.1007/BF00208319; ESKINS K, 1992, PHYSIOL PLANTARUM, V86, P439, DOI 10.1111/j.1399-3054.1992.tb01341.x; Garner WW, 1919, J AGRIC RES, V18, P0553; Guo HW, 1998, SCIENCE, V279, P1360, DOI 10.1126/science.279.5355.1360; Hicks KA, 1996, SCIENCE, V274, P790, DOI 10.1126/science.274.5288.790; JOHNSON E, 1994, PLANT PHYSIOL, V105, P141, DOI 10.1104/pp.105.1.141; Koornneef M, 1998, GENETICS, V148, P885; Lin CT, 1998, P NATL ACAD SCI USA, V95, P2686, DOI 10.1073/pnas.95.5.2686; MILLAR AJ, 1995, SCIENCE, V267, P1163, DOI 10.1126/science.7855596; PUTTERILL J, 1995, CELL, V80, P847, DOI 10.1016/0092-8674(95)90288-0; Simon R, 1996, NATURE, V384, P59, DOI 10.1038/384059a0; SOMERS DE, 1991, PLANT CELL, V3, P1263, DOI 10.1105/tpc.3.12.1263; Thomas B., 1997, PHOTOPERIODISM PLANT; Weller JL, 1997, PLANT PHYSIOL, V114, P1225, DOI 10.1104/pp.114.4.1225; Zagotta MT, 1996, PLANT J, V10, P691, DOI 10.1046/j.1365-313X.1996.10040691.x	16	11	11	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 27	1998	279	5355					1323	1324		10.1126/science.279.5355.1323	http://dx.doi.org/10.1126/science.279.5355.1323			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ412	9508709				2022-12-28	WOS:000072251800040
J	Levenstein, S				Levenstein, S			Stress and peptic ulcer: life beyond Helicobacter	BRITISH MEDICAL JOURNAL			English	Article							GASTRIC-ACID SECRETION; DUODENAL-ULCER; UNITED-STATES; RISK-FACTORS; PYLORI INFECTION; SERUM GASTRIN; EVENT STRESS; DISEASE; MEN; PERSONALITY		Nuovo Regina Margherita Hosp, Gastroenterol Serv, Rome, Italy	Poliambulatorio Nuovo Regina Margherita	Levenstein, S (corresponding author), Via Tempio 1A, I-00186 Rome, Italy.							ANDA RF, 1992, ARCH INTERN MED, V152, P829, DOI 10.1001/archinte.152.4.829; ANDERSSON SI, 1994, J PSYCHOSOM RES, V38, P241, DOI 10.1016/0022-3999(94)90119-8; Bennett JC, 1996, CECIL TXB MED; BRESNICK WH, 1993, J CLIN GASTROENTEROL, V17, P117, DOI 10.1097/00004836-199309000-00006; CHANDRAKUMARAN K, 1994, GUT, V35, P1022; Drossman DA, 1996, J CLIN GASTROENTEROL, V22, P252, DOI 10.1097/00004836-199606000-00002; ELOMAR EM, 1995, GASTROENTEROLOGY, V109, P681, DOI 10.1016/0016-5085(95)90374-7; FELDMAN M, 1992, GASTROENTEROLOGY, V102, P175, DOI 10.1016/0016-5085(92)91798-9; GILLIGAN I, 1987, J PSYCHOSOM RES, V31, P117, DOI 10.1016/0022-3999(87)90106-1; GOGGIN PM, 1992, GASTROENTEROLOGY, V103, P1486, DOI 10.1016/0016-5085(92)91168-4; GRAHAM DY, 1991, GASTROENTEROLOGY, V100, P1495, DOI 10.1016/0016-5085(91)90644-Z; Han SW, 1996, AM J GASTROENTEROL, V91, P1135; Hogan DL, 1996, GASTROENTEROLOGY, V110, P705, DOI 10.1053/gast.1996.v110.pm8608879; HOLTMANN G, 1992, SCAND J GASTROENTERO, V27, P917, DOI 10.3109/00365529209000163; HUNTER FM, 1993, DIGEST DIS SCI, V38, P2081, DOI 10.1007/BF01297088; JESS P, 1994, J INTERN MED, V236, P271, DOI 10.1111/j.1365-2796.1994.tb00795.x; LEE A, 1995, EUR J GASTROEN HEPAT, V7, P461; LEVENSTEIN S, 1995, J CLIN GASTROENTEROL, V21, P110, DOI 10.1097/00004836-199509000-00010; LEVENSTEIN S, 1995, J CLIN GASTROENTEROL, V21, P185, DOI 10.1097/00004836-199510000-00004; Levenstein S, 1996, J CLIN GASTROENTEROL, V22, P84, DOI 10.1097/00004836-199603000-00002; Levenstein S, 1996, J PSYCHOSOM RES, V41, P465, DOI 10.1016/S0022-3999(96)00196-1; Levenstein S, 1997, J CLIN GASTROENTEROL, V24, P140, DOI 10.1097/00004836-199704000-00004; LOFFELD RJLF, 1991, J CLIN PATHOL, V44, P516, DOI 10.1136/jcp.44.6.516; MARSHALL BJ, 1995, ANN MED, V27, P565, DOI 10.3109/07853899509002470; MARTIN DF, 1989, AM J GASTROENTEROL, V84, P1268; MCCOLL KEL, 1993, GUT, V34, P762, DOI 10.1136/gut.34.6.762; MCINTOSH JH, 1985, SCAND J GASTROENTERO, V20, P563, DOI 10.3109/00365528509089697; MEDALIE JH, 1992, AM J EPIDEMIOL, V136, P1280, DOI 10.1093/oxfordjournals.aje.a116436; Melmed RN, 1996, ISRAEL J MED SCI, V32, P211; MIRSKY IA, 1958, AM J DIG DIS, V3, P285, DOI 10.1007/BF02232411; Oektedalen O., 1984, SCAND J GASTROENTERO, V19, P770; PETERS MN, 1983, GASTROENTEROLOGY, V84, P114; PETERSON WL, 1993, AM J GASTROENTEROL, V88, P2038; POMAKOV P, 1993, J RADIOL, V74, P265; SONNENBERG A, 1993, AM J PUBLIC HEALTH, V83, P1006, DOI 10.2105/AJPH.83.7.1006; Spicer CC, 1944, LANCET, V1, P14; *US DEP HHS, 1986, CURR EST NAT HLTH IN; WALKER P, 1988, GASTROENTEROLOGY, V94, P323, DOI 10.1016/0016-5085(88)90419-2	38	75	79	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 14	1998	316	7130					538	541		10.1136/bmj.316.7130.538	http://dx.doi.org/10.1136/bmj.316.7130.538			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YX955	9501720	Green Published			2022-12-28	WOS:000072097400030
J	Schauber, C; Chen, L; Tongaonkar, P; Vega, I; Lambertson, D; Potts, W; Madura, K				Schauber, C; Chen, L; Tongaonkar, P; Vega, I; Lambertson, D; Potts, W; Madura, K			Rad23 links DNA repair to the ubiquitin/proteasome pathway	NATURE			English	Article							NUCLEOTIDE EXCISION-REPAIR; TRANSCRIPTION FACTOR TFIIH; SACCHAROMYCES-CEREVISIAE; PYRIMIDINE DIMERS; IN-VIVO; PROTEIN; MUTANTS; PURIFICATION; HOMOLOG; XPC	Rad23 is an evolutionarily conserved protein that is important for nucleotide excision repair(1-3). A regulatory role has been proposed for Rad23 because rad23 mutants are sensitive to ultraviolet light but are still capable of incising damaged DNA(4,5). Here we show that Rad23 interacts with the 26S proteasome through an aminoterminal ubiquitin-like domain (UbL(R23)). The carboxy terminus of Rad23 binds to the Rad4 DNA repair protein and creates a link between the DNA repair and proteasome pathways. The ultraviolet sensitivity caused by deletion of the UbL(R23) domain may therefore arise from its inability to interact with the proteasome. The fusion proteins glutathione S-transferase (GST)-Rad23 and Rad4-haemagglutinin (HA), and the proteasome subunits Cim3 and Cim5, cofractionate through consecutive chromatography steps. The ubiquitin-like domain of human Rad23 (UbL(HRB)) also interacts with the human proteasome. These results demonstrate that ubiquitin-like domains (UbLs) represent a new class of proteasome-interacting motifs.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Madura, K (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Lane, Piscataway, NJ 08854 USA.	maduraki@umdnj.edu						BANIAHMAD C, 1994, BIOTECHNIQUES, V16, P194; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; GARRETT KP, 1995, P NATL ACAD SCI USA, V92, P7172, DOI 10.1073/pnas.92.16.7172; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GUZDER SN, 1995, J BIOL CHEM, V270, P12973, DOI 10.1074/jbc.270.22.12973; GUZDER SN, 1995, J BIOL CHEM, V270, P8385, DOI 10.1074/jbc.270.15.8385; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; MADURA K, 1994, SCIENCE, V265, P1454, DOI 10.1126/science.8073290; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MCCREADY S, 1994, MUTAT RES-DNA REPAIR, V315, P261, DOI 10.1016/0921-8777(94)90037-X; Merrick W C, 1979, Methods Enzymol, V60, P108, DOI 10.1016/S0076-6879(79)60011-3; MILLER RD, 1982, MOL GEN GENET, V188, P235, DOI 10.1007/BF00332681; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; Mueller JP, 1996, MOL CELL BIOL, V16, P2361; Reardon JT, 1996, J BIOL CHEM, V271, P19451, DOI 10.1074/jbc.271.32.19451; Rubin DM, 1996, NATURE, V379, P655, DOI 10.1038/379655a0; Sugasawa K, 1996, MOL CELL BIOL, V16, P4852; vanderSpek PJ, 1996, NUCLEIC ACIDS RES, V24, P2551, DOI 10.1093/nar/24.13.2551; Verhage RA, 1996, MUTAT RES-DNA REPAIR, V362, P155, DOI 10.1016/0921-8777(95)00045-3; Wang ZG, 1997, MOL CELL BIOL, V17, P635, DOI 10.1128/MCB.17.2.635; WATKINS JF, 1993, MOL CELL BIOL, V13, P7757, DOI 10.1128/MCB.13.12.7757	23	396	406	1	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 12	1998	391	6668					715	718		10.1038/35661	http://dx.doi.org/10.1038/35661			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW872	9490418				2022-12-28	WOS:000071982500058
J	Matson, PA; Naylor, R; Ortiz-Monasterio, I				Matson, PA; Naylor, R; Ortiz-Monasterio, I			Integration of environmental, agronomic, and economic aspects of fertilizer management	SCIENCE			English	Article							OXIDE EMISSIONS; TROPICAL FOREST; NITROUS-OXIDE; SOIL	Nitrogen fertilization is a substantial source of nitrogen-containing trace gases that have both regional and global consequences, In the intensive wheat systems of Mexico, typical fertilization practices lead to extremely high fluxes of nitrous oxide (N2O) and nitric oxide (NO). In experiments, lower rates of nitrogen fertilizer, applied later in the crop cycle, reduced the loss of nitrogen without affecting yield and grain quality. Economic analyses projected this alternative practice to save 12 to 17 percent of after-tax profits, A knowledge-intensive approach to fertilizer management can substitute for higher levels of inputs, saving farmers money and reducing environmental costs.	Stanford Univ, Inst Int Studies, Stanford, CA 94305 USA; Int Maize & Wheat Improvement Ctr, El Batan, Mexico	Stanford University; CGIAR; International Maize & Wheat Improvement Center (CIMMYT)	Matson, PA (corresponding author), Stanford Univ, Inst Int Studies, Stanford, CA 94305 USA.			, Ivan/0000-0002-2572-3219				AVALOS B, 1997, THESIS STANFORD U ST; BOUWMAN AF, 1994, 773004004 NAT I PUBL; Bumb B. L., 1996, ROLE FERTILIZER SUST; Cassman K. G., 1995, Geojournal, V35, P299, DOI 10.1007/BF00989137; Davidson EA, 1997, NUTR CYCL AGROECOSYS, V48, P37, DOI 10.1023/A:1009738715891; DAVIDSON EA, 1991, J GEOPHYS RES-ATMOS, V96, P15439, DOI 10.1029/91JD01476; EICHNER MJ, 1990, J ENVIRON QUAL, V19, P272, DOI 10.2134/jeq1990.00472425001900020013x; *EPA, 1990, GREENH GAS EM AGR EC; FAO,, 1990, FERT YB; GALLOWAY JN, 1995, GLOBAL BIOGEOCHEM CY, V9, P235, DOI 10.1029/95GB00158; Hall SJ, 1996, ANNU REV ENERG ENV, V21, P311, DOI 10.1146/annurev.energy.21.1.311; HOBBS PR, 1997, INCREASING WHEAT YIE; Howarth RW, 1996, BIOGEOCHEMISTRY, V35, P75, DOI 10.1007/BF02179825; *IFA FAO IFDC, 1992, FERT US CROP; MATSON PA, 1987, ECOLOGY, V68, P491, DOI 10.2307/1938454; Matson PA, 1997, SCIENCE, V277, P504, DOI 10.1126/science.277.5325.504; Matson PA, 1996, J GEOPHYS RES-ATMOS, V101, P18533, DOI 10.1029/96JD01536; Meisner C., 1992, 6 CIMMYT; MOSIER AR, 1980, SOIL SCI SOC AM J, V44, P1121, DOI 10.2136/sssaj1980.03615995004400050048x; MOSLER AR, 1994, FERT RES, V37, P191; Naylor RL, 1996, ANNU REV ENERG ENV, V21, P99, DOI 10.1146/annurev.energy.21.1.99; ORTIZMONASTERIO I, UNPUB; PANEK J, UNPUB; SMIL V, 1991, POPUL DEV REV, V17, P569, DOI 10.2307/1973598; *UN, 1992, STAT YB; Veldkamp E, 1997, NUTR CYCL AGROECOSYS, V48, P69, DOI 10.1023/A:1009725319290; Vitousek PM, 1997, ECOL APPL, V7, P737, DOI 10.2307/2269431; Watson R, 1992, CLIMATIC CHANGE, P25; Williams EJ, 1992, GLOBAL BIOGEOCHEM CY, V6, P351, DOI 10.1029/92GB02124	29	327	352	5	157	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 3	1998	280	5360					112	115		10.1126/science.280.5360.112	http://dx.doi.org/10.1126/science.280.5360.112			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF314	9525856				2022-12-28	WOS:000072885100048
J	Bodenheimer, T; Sullivan, K				Bodenheimer, T; Sullivan, K			How large employers are shaping the health care marketplace - First of two parts	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							COSTS		Univ Calif San Francisco, Sch Med, Dept Family & Community Med, San Francisco, CA 94143 USA; Minnesota Citizens Organized Acting Together, St Paul, MN USA	University of California System; University of California San Francisco	Bodenheimer, T (corresponding author), 1580 Valencia St,Suite 201, San Francisco, CA 94110 USA.							Baumgarten A, 1996, Bus Health, V14, P23; BERGTHOLD L, 1990, PURCHASING POWER HLT; BLEAKLEY FR, 1997, WALL STREET J   0718; Buchmueller TC, 1997, J HEALTH ECON, V16, P231, DOI 10.1016/S0167-6296(96)00531-0; *BUS HLTH, 1996, STAT HLTH CARE AM 19; CANTOR JC, 1991, HEALTH AFFAIR, V10, P98, DOI 10.1377/hlthaff.10.1.98; CHRISTIANSON J, 1995, HEALTH AFFAIR, V14, P114, DOI 10.1377/hlthaff.14.2.114; CRENSHAW AB, 1989, WASHINGTON POST 0116, P18; Findlay S, 1996, Bus Health, V14, P16; Gabel JR, 1997, HEALTH AFFAIR, V16, P103, DOI 10.1377/hlthaff.16.5.103; *GEN ACCT OFF, 1997, PRIV HLTH INS CONT E; IGLEHART JK, 1982, NEW ENGL J MED, V306, P120, DOI 10.1056/NEJM198201143060235; KRAMON G, 1989, NY TIMES        0418, pC2; KUTTNER R, 1980, REVOLT HAVES TAX REB; LEIGHTY J, 1995, CALIFORNIA MED   SEP, P23; LEVIT KR, 1994, HEALTH AFFAIR, V13, P14, DOI 10.1377/hlthaff.13.5.14; MARTIN CJ, 1994, HLTH CARE REFORM 90S, P183; *OFF TECHN ASS, 1994, MAN CAR COMP HLTH CA; *PAC BUS GROUP HLT, 1997, MEMB INF PAC BUS GRO; Polzer K, 1997, HEALTH AFFAIR, V16, P93, DOI 10.1377/hlthaff.16.5.93; Robinson JC, 1995, HEALTH AFFAIR, V14, P117, DOI 10.1377/hlthaff.14.4.117; SAPOLSKY HM, 1981, MILBANK FUND Q, V59, P561, DOI 10.2307/3349741; Scanlon DP, 1997, ANNU REV PUBL HEALTH, V18, P507, DOI 10.1146/annurev.publhealth.18.1.507; Schauffler HH, 1996, HEALTH AFFAIR, V15, P73, DOI 10.1377/hlthaff.15.1.73; SCHAUFFLER HH, 1998, STATE HLTH INSURANCE; Slomski A J, 1997, Med Econ, V74, P200; Smith N S, 1994, Manag Care Q, V2, P21; SULLIVAN CB, 1992, HEALTH AFFAIR, V11, P172, DOI 10.1377/hlthaff.11.4.172; SULLIVAN K, 1995, STRANGLED COMPETITIO; THORPE KE, 1992, HEALTH AFFAIR, V11, P41, DOI 10.1377/hlthaff.11.2.41; Tweed V, 1994, Bus Health, V12, P27; Zelman W. A., 1996, CHANGING HLTH CARE M; 1997, PHYSICIAN PRACTI JUL	33	63	64	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 2	1998	338	14					1003	1007		10.1056/NEJM199804023381422	http://dx.doi.org/10.1056/NEJM199804023381422			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZE776	9521990				2022-12-28	WOS:000072829800029
J	Shiraki, H; Yoshikawa, T; Anzai, T; Negishi, K; Takahashi, T; Asakura, Y; Akaishi, M; Mitamura, H; Ogawa, S				Shiraki, H; Yoshikawa, T; Anzai, T; Negishi, K; Takahashi, T; Asakura, Y; Akaishi, M; Mitamura, H; Ogawa, S			Association between preinfarction angina and a lower risk of right ventricular infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	69th Annual Meeting of the American-Heart-Association	NOV 09-18, 1996	NEW ORLEANS, LA	Amer Heart Assoc, Natl Inst Alcohol Abuse & Alcoholism			ACUTE MYOCARDIAL-INFARCTION; CORONARY-ARTERY OCCLUSION; SHORT-TERM PROGNOSIS; COLLATERAL CIRCULATION; HEART-DISEASE; ISCHEMIA; ANGIOPLASTY; PECTORIS; SIZE; PROTECTION	Background Right ventricular infarction occurs in conjunction with inferior myocardial infarction caused by proximal occlusion of the right coronary artery. However, right ventricular infarction occurs infrequently, and the reasons for this are uncertain. Methods We retrospectively assessed the association between preinfarction angina and right ventricular infarction, as well as the short-term outcome, in 113 patients with a first acute inferior myocardial infarction caused by right-coronary-artery occlusion. The association between the timing of angina during the week before infarction and the clinical outcome was also assessed. Results The absence of preinfarction angina predicted the development of right ventricular infarction (odds ratio, 6.3; 95 percent confidence interval, 2.7 to 15.1; P<0.001), complete atrioventricular block (odds ratio, 3.6; 95 percent confidence interval, 1.4 to 10.3; P=0.01), and combined hypotension and shock (odds ratio, 12.4; 95 percent confidence interval, 4.5 to 40.6; P<0.001). Angina 24 to 72 hours before infarction was most strongly associated with reductions in the rates of right ventricular infarction (adjusted odds ratio, 0.2; 95 percent confidence interval, 0 to 0.8; P=0.02) and combined hypotension and shock (adjusted odds ratio, 0.1; 95 percent confidence interval, 0 to 0.5; P=0.02). Conclusions Preinfarction angina was an independent predictor of the absence of right ventricular infarction in patients with acute inferior myocardial infarction. The patients with preinfarction angina also had better short-term outcomes than those without preinfarction angina. (C) 1998, Massachusetts Medical Society.	Yokohama Municipal Hosp, Dept Cardiol, Hodogaya Ku, Yokohama, Kanagawa 2400062, Japan; Keio Univ, Sch Med, Dept Internal Med, Tokyo, Japan	Keio University	Shiraki, H (corresponding author), Yokohama Municipal Hosp, Dept Cardiol, Hodogaya Ku, 56 Okazawa Cho, Yokohama, Kanagawa 2400062, Japan.		Anzai, Toshihisa/J-2179-2015	Anzai, Toshihisa/0000-0003-3319-4967				ANDERSEN HR, 1987, J AM COLL CARDIOL, V10, P1223, DOI 10.1016/S0735-1097(87)80122-5; ANDERSEN HR, 1989, INT J CARDIOL, V23, P349, DOI 10.1016/0167-5273(89)90195-2; Andreotti F, 1996, NEW ENGL J MED, V334, P7, DOI 10.1056/NEJM199601043340102; ANZAI T, 1995, J AM COLL CARDIOL, V26, P319, DOI 10.1016/0735-1097(95)80002-X; ANZAI T, 1994, AM J CARDIOL, V74, P755, DOI 10.1016/0002-9149(94)90428-6; BRAAT SH, 1983, BRIT HEART J, V49, P368; CABIN HS, 1987, AM HEART J, V113, P16, DOI 10.1016/0002-8703(87)90004-4; CORTINA A, 1985, J AM COLL CARDIOL, V5, P619, DOI 10.1016/S0735-1097(85)80386-7; CRIBIER A, 1992, J AM COLL CARDIOL, V20, P578, DOI 10.1016/0735-1097(92)90011-B; CROFT CH, 1982, AM J CARDIOL, V50, P421, DOI 10.1016/0002-9149(82)90305-8; DEUTSCH E, 1990, CIRCULATION, V82, P2044, DOI 10.1161/01.CIR.82.6.2044; FUJITA M, 1987, BRIT HEART J, V57, P139; GEFT IL, 1984, AM J CARDIOL, V53, P991, DOI 10.1016/0002-9149(84)90623-4; GENSINI GG, 1969, AM J CARDIOL, V24, P393, DOI 10.1016/0002-9149(69)90434-2; GOLDSTEIN JA, 1992, J AM COLL CARDIOL, V19, P704, DOI 10.1016/S0735-1097(10)80296-7; HAUPT HM, 1983, CIRCULATION, V67, P1268, DOI 10.1161/01.CIR.67.6.1268; HIRAI T, 1992, AM HEART J, V124, P19, DOI 10.1016/0002-8703(92)90915-I; ISNER JM, 1978, AM J CARDIOL, V42, P885, DOI 10.1016/0002-9149(78)90672-0; KINCH JW, 1994, NEW ENGL J MED, V330, P1211, DOI 10.1056/NEJM199404283301707; KLONER RA, 1995, CIRCULATION, V91, P37, DOI 10.1161/01.CIR.91.1.37; KUZUYA T, 1993, CIRC RES, V72, P1293, DOI 10.1161/01.RES.72.6.1293; LEW AS, 1985, AM J CARDIOL, V55, P883, DOI 10.1016/0002-9149(85)90711-8; LOVE JC, 1984, AM HEART J, V108, P5, DOI 10.1016/0002-8703(84)90537-4; MARBER MS, 1993, CIRCULATION, V88, P1264, DOI 10.1161/01.CIR.88.3.1264; MATSUDA Y, 1984, AM HEART J, V108, P955, DOI 10.1016/0002-8703(84)90460-5; MULLER DWM, 1990, AM HEART J, V119, P224, DOI 10.1016/S0002-8703(05)80008-0; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; NAKAGAWA Y, 1995, J AM COLL CARDIOL, V25, P1076, DOI 10.1016/0735-1097(94)00542-X; NICOD P, 1988, J AM COLL CARDIOL, V12, P589, DOI 10.1016/S0735-1097(88)80042-1; OPOLSKI G, 1986, INT J CARDIOL, V10, P141, DOI 10.1016/0167-5273(86)90222-6; OTTANI F, 1995, CIRCULATION, V91, P291, DOI 10.1161/01.CIR.91.2.291; RACKLEY CE, 1981, AM HEART J, V101, P215, DOI 10.1016/0002-8703(81)90668-2; RATLIFF NB, 1980, AM J CARDIOL, V45, P217, DOI 10.1016/0002-9149(80)90638-4; RENTROP KP, 1985, J AM COLL CARDIOL, V5, P587; RENTROP KP, 1988, AM J CARDIOL, V61, P677, DOI 10.1016/0002-9149(88)91048-X; SETARO J F, 1992, Cardiology Clinics, V10, P69; Yang XM, 1996, CARDIOVASC RES, V31, P777, DOI 10.1016/0008-6363(96)00026-0; Yoshida N, 1993, J AM COLL CARDIOL, V22, P426, DOI 10.1016/0735-1097(93)90046-4; YOSHIKAWA T, 1993, CARDIOLOGY, V82, P42, DOI 10.1159/000175852; ZEHENDER M, 1993, NEW ENGL J MED, V328, P981, DOI 10.1056/NEJM199304083281401	40	70	72	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 2	1998	338	14					941	947		10.1056/NEJM199804023381402	http://dx.doi.org/10.1056/NEJM199804023381402			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	ZE776	9521981	Bronze			2022-12-28	WOS:000072829800002
J	Suda, N; Nawa, K; Fukao, Y				Suda, N; Nawa, K; Fukao, Y			Earth's background free oscillations	SCIENCE			English	Article							NOISE	Earth's free oscillations were considered to be transient phenomena occurring after large earthquakes. An analysis of records of the IDA (International Deployment of Accelerometers) gravimeter network shows that Earth is freely oscillating at an observable level even in seismically inactive periods. The observed oscillations are the fundamental spheroidal modes at frequencies between 2 and 7 millihertz. Numerical modeling indicates that these incessant excitations cannot be explained by stacked effects of a large number of small earthquakes. The observed "background" free oscillations represent some unknown dynamic process of Earth.	Nagoya Univ, Dept Earth & Planetary Sci, Nagoya, Aichi, Japan; Univ Tokyo, Earthquake Res Inst, Tokyo 113, Japan	Nagoya University; University of Tokyo	Suda, N (corresponding author), Nagoya Univ, Dept Earth & Planetary Sci, Nagoya, Aichi, Japan.		Nawa, Kazunari/K-6291-2016	Nawa, Kazunari/0000-0002-6237-2876				AGNEW D, 1976, EOS T AM GEOPHYS UN, V57, P180, DOI 10.1029/EO057i004p00180; Agnew D. C., 1986, EOS Transactions of the American Geophysical Union, V67, P203, DOI 10.1029/EO067i016p00203; AGNEW DC, 1978, J GEOPHYS RES, V83, P5420, DOI 10.1029/JB083iB11p05420; BEROZA GC, 1990, J GEOPHYS RES-SOLID, V95, P2485, DOI 10.1029/JB095iB03p02485; BULAND R, 1979, NATURE, V277, P358, DOI 10.1038/277358a0; Bulsara AR, 1996, PHYS TODAY, V49, P39, DOI 10.1063/1.881491; DZIEWONSKI AM, 1995, PHYS EARTH PLANET IN, V91, P187, DOI 10.1016/0031-9201(95)03081-7; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; GILBERT F, 1975, PHILOS T R SOC A, V278, P187, DOI 10.1098/rsta.1975.0025; *INC RES I SEISM, 1994, FED DIG SEISM NETW S; KOBAYASHI N, 1996, FALL M JAP SOC PLAN; LAY T, 1985, J GEOPHYS RES-SOLID, V90, P605, DOI 10.1029/JB090iB01p00605; Nawa K, 1998, EARTH PLANETS SPACE, V50, P3, DOI 10.1186/BF03352080; SORRELLS GG, 1971, GEOPHYS J ROY ASTR S, V26, P71, DOI 10.1111/j.1365-246X.1971.tb03383.x; Thomson D. J, 1991, ADV SPECTRUM ANAL AR, VI, P58; WARBURTON RJ, 1977, GEOPHYS J ROY ASTR S, V48, P281, DOI 10.1111/j.1365-246X.1977.tb03672.x	16	138	146	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 27	1998	279	5359					2089	2091		10.1126/science.279.5359.2089	http://dx.doi.org/10.1126/science.279.5359.2089			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZE274	9516105				2022-12-28	WOS:000072775600041
J	Williams, A; Cusack, M; Buckman, JO; Stachel, T				Williams, A; Cusack, M; Buckman, JO; Stachel, T			Siliceous tablets in the larval shells of apatitic discinid brachiopods	SCIENCE			English	Article								The marine bivalved Brachiopoda are abundant throughout the geological record and have apatitic (CaPO4-rich) or calcitic (CaCO3-rich) shells. Vesicles covering the larval valves of living apatitic-shelled discinids contain tablets of silica. The tablets are cemented into close-packed mosaics by spherular apatite in glycosaminoglycans. They are usually lost as vesicles degrade but leave imprints on the underlying apatitic shell. Similar imprints ornament larval surfaces of some of the earliest Paleozoic apatitic-shelled brachiopods and may also be indicators of siliceous biomineralization.	Univ Glasgow, Palaeobiol Unit, Glasgow G12 8QQ, Lanark, Scotland; Univ Glasgow, Dept Geol & Appl Geol, Glasgow G12 8QQ, Lanark, Scotland; Univ Frankfurt, Inst Mineral, D-60054 Frankfurt, Germany	University of Glasgow; University of Glasgow; Goethe University Frankfurt	Williams, A (corresponding author), Univ Glasgow, Palaeobiol Unit, Glasgow G12 8QQ, Lanark, Scotland.		Cusack, Maggie/A-2532-2009; Buckman, Jim/H-9797-2019; Stachel, Thomas/G-3198-2010	Cusack, Maggie/0000-0003-0145-1180; Stachel, Thomas/0000-0002-0189-4224; Buckman, Jim/0000-0003-1396-7539				BLERNAT G, 1970, PALAEONTOLOGY, V13, P98; Holmer L.E., 1989, FOSSILS STRATA, V26, P1; Holmer Lars E., 1996, Palaeontologia Polonica, V55, P37; LANDIS WJ, 1986, CALCIFIED TISSUE INT, V38, P52, DOI 10.1007/BF02556595; LI PJ, 1992, J AM CERAM SOC, V75, P2094, DOI 10.1111/j.1151-2916.1992.tb04470.x; Lowenstam H. A., 1989, BIOMINERALISATION, P324; Ludvigsen R., 1974, NEUES JB GEOLOGIE PA, V3, P133; MANN S, 1986, SILICON BIOCH, P40; OHIURA K, 1991, J BIOMED MATER RES, V25, P357; POPOV L, 1994, PALAEONTOLOGY, V37, P627; WILLIAMS A, 1978, PROC R SOC SER B-BIO, V202, P191, DOI 10.1098/rspb.1978.0063; WILLIAMS A, 1991, BRACHIOPODS THROUGH TIME, P133; WILLIAMS A, 1992, PALAEONTOLOGY, V35, P657; Williams A, 1997, TREATISE INVERTEBR H, V1; WILLIAMS A, IN PRESS PHILOS T B	15	36	37	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 27	1998	279	5359					2094	2096		10.1126/science.279.5359.2094	http://dx.doi.org/10.1126/science.279.5359.2094			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZE274	9516107				2022-12-28	WOS:000072775600043
J	Weber, T; Zemelman, BV; McNew, JA; Westermann, B; Gmachl, M; Parlati, F; Sollner, TH; Rothman, JE				Weber, T; Zemelman, BV; McNew, JA; Westermann, B; Gmachl, M; Parlati, F; Sollner, TH; Rothman, JE			SNAREpins: Minimal machinery for membrane fusion	CELL			English	Article							SYNAPTIC VESICLE DOCKING; VESICULAR TRANSPORT; RAT-BRAIN; IN-VITRO; PROTEIN; SYNTAXIN; COMPLEX; SYNAPTOBREVIN; EXOCYTOSIS; SNAP-25	Recombinant v- and t-SNARE proteins reconstituted into separate lipid bilayer vesicles assemble into SNARE-pins-SNARE complexes linking two membranes. This leads to spontaneous fusion of the docked membranes at physiological temperature. Docked unfused intermediates can accumulate at lower temperatures and can fuse when brought to physiological temperature. A supply of unassembled v-and t-SNAREs is needed for these intermediates to form, but not for the fusion that follows. These data imply that SNARE-pins are the minimal machinery for cellular membrane fusion.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Rothman, JE (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave, New York, NY 10021 USA.		McNew, James/AAV-4911-2020; Weber, Thomas/A-2363-2008; Westermann, Benedikt/H-7766-2013; Wunder, Stephanie L/B-5066-2012; McNew, James/ABD-8081-2020; Zdilla, Michael J/B-4145-2011; Weber, Thomas/GLS-9125-2022	McNew, James/0000-0001-8459-3664; Weber, Thomas/0000-0002-0494-0484; Westermann, Benedikt/0000-0002-2991-1604; Weber, Thomas/0000-0002-0494-0484; Zemelman, Boris/0000-0003-2463-4887				AALTO MK, 1992, CELL, V68, P181, DOI 10.1016/0092-8674(92)90462-L; Bagai S, 1996, J CELL BIOL, V135, P73, DOI 10.1083/jcb.135.1.73; Banerjee A, 1996, J BIOL CHEM, V271, P20227, DOI 10.1074/jbc.271.34.20227; Banerjee A, 1996, J BIOL CHEM, V271, P20223, DOI 10.1074/jbc.271.34.20223; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BENNETT MK, 1995, CURR OPIN CELL BIOL, V7, P581, DOI 10.1016/0955-0674(95)80016-6; Binley J, 1997, NATURE, V387, P346, DOI 10.1038/387346a0; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BRENNWALD P, 1993, NATURE, V362, P560, DOI 10.1038/362560a0; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BRUNS D, 1995, NATURE, V377, P62, DOI 10.1038/377062a0; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; CHAPMAN CF, 1995, PHOTOCHEM PHOTOBIOL, V62, P416, DOI 10.1111/j.1751-1097.1995.tb02362.x; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; Davanger S, 1997, MOL BIOL CELL, V8, P1261, DOI 10.1091/mbc.8.7.1261; Dimitrov DS, 1997, CELL, V91, P721, DOI 10.1016/S0092-8674(00)80460-2; DUNN B, 1993, NATURE, V362, P53; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; Giovane C, 1997, BIOTECHNIQUES, V22, P796, DOI 10.2144/97225bm01; Glenn DE, 1996, FEBS LETT, V386, P137, DOI 10.1016/0014-5793(96)00432-2; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; Kee Y, 1997, P NATL ACAD SCI USA, V94, P14438, DOI 10.1073/pnas.94.26.14438; KEMBLE GW, 1994, CELL, V76, P383, DOI 10.1016/0092-8674(94)90344-1; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; LANGNER M, 1993, CHEM PHYS LIPIDS, V65, P23, DOI 10.1016/0009-3084(93)90078-H; Lentz BR, 1997, BIOCHEMISTRY-US, V36, P2076, DOI 10.1021/bi9623340; Lewis MJ, 1997, EMBO J, V16, P3017, DOI 10.1093/emboj/16.11.3017; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; LINDAU M, 1995, CURR OPIN CELL BIOL, V7, P509, DOI 10.1016/0955-0674(95)80007-7; Linial M, 1997, J NEUROCHEM, V69, P1781; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; MCINTYRE JC, 1991, BIOCHEMISTRY-US, V30, P11819, DOI 10.1021/bi00115a012; Monck JR, 1996, CURR OPIN CELL BIOL, V8, P524, DOI 10.1016/S0955-0674(96)80031-7; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; Orci L, 1998, P NATL ACAD SCI USA, V95, P2279, DOI 10.1073/pnas.95.5.2279; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PARSONS TD, 1995, NEURON, V15, P1085, DOI 10.1016/0896-6273(95)90097-7; Patel SK, 1998, CELL, V92, P611, DOI 10.1016/S0092-8674(00)81129-0; Pelham HRB, 1995, COLD SPRING HARB SYM, V60, P105, DOI 10.1101/SQB.1995.060.01.013; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; Pfeffer SR, 1996, ANNU REV CELL DEV BI, V12, P441, DOI 10.1146/annurev.cellbio.12.1.441; PROTOPOPOV V, 1993, CELL, V74, P855, DOI 10.1016/0092-8674(93)90465-3; Rabenstein MD, 1996, BIOCHEMISTRY-US, V35, P13922, DOI 10.1021/bi961743t; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; Rabouille C, 1998, CELL, V92, P603, DOI 10.1016/S0092-8674(00)81128-9; Rothman JE, 1997, SCIENCE, V276, P1212, DOI 10.1126/science.276.5316.1212; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Schiavo G, 1997, P NATL ACAD SCI USA, V94, P997, DOI 10.1073/pnas.94.3.997; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STEGMANN T, 1991, J BIOL CHEM, V266, P18404; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; TSURUDOME M, 1992, J BIOL CHEM, V267, P20225; Ungermann C, 1998, J CELL BIOL, V140, P61, DOI 10.1083/jcb.140.1.61; VAN MEER G, 1986, EMBO J, V5, P1455, DOI 10.1002/j.1460-2075.1986.tb04382.x; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0	81	1964	1999	4	190	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 20	1998	92	6					759	772		10.1016/S0092-8674(00)81404-X	http://dx.doi.org/10.1016/S0092-8674(00)81404-X			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZD198	9529252	Bronze			2022-12-28	WOS:000072661200009
J	Leitzmann, MF; Giovannucci, EL; Rimm, EB; Stampfer, MJ; Spiegelman, D; Wing, AL; Willett, WC				Leitzmann, MF; Giovannucci, EL; Rimm, EB; Stampfer, MJ; Spiegelman, D; Wing, AL; Willett, WC			The relation of physical activity to risk for symptomatic gallstone disease in men	ANNALS OF INTERNAL MEDICINE			English	Article						cholelithiasis; exercise; obesity; weight loss	DENSITY-LIPOPROTEIN CHOLESTEROL; MALE HEALTH-PROFESSIONALS; GASTROINTESTINAL TRANSIT; HISPANIC POPULATIONS; GALLBLADDER-DISEASE; LOGISTIC-REGRESSION; GLUCOSE-UTILIZATION; INTESTINAL TRANSIT; DANISH POPULATION; DEOXYCHOLIC-ACID	Background: Gallstone disease is a major source of morbidity in the United States. Gallstones are twice as common in women as in men, but severe biliary events leading to surgery occur with equal frequency in the two sexes. Objective: To determine whether physical activity decreases risk for symptomatic gallstone disease in men. Design: Prospective cohort study. Setting: U.S. male health professionals. Patients: 45813 men 40 to 75 years of age were followed from 1986 to 1994. Measurements: Questionnaires mailed in 1986, 1988, 1990, 1992, and 1994 asked about physical activity, incidence of gallstone disease, age, body weight, dietary and alcohol intake, smoking habits, use of medications, and occurrence of diagnosed medical conditions other than gallstone disease. Results: 828 men reported having newly symptomatic gallstones (diagnosed by ultrasonography or radiography) or undergoing cholecystectomy for recent symptoms. After adjustment for multiple confounders, increased physical activity was inversely related to risk for symptomatic gallstone disease. When extreme quintiles were compared, men younger than 65 years of age had a stronger inverse association (multivariate relative risk, 0.58 [95% CI, 0.44 to 0.78]) with risk than did men 65 years of age or older (relative risk, 0.75 [CI, 0.52 to 1.09]). In contrast, sedentary behavior was positively related to risk for symptomatic gallstone disease. Men who watched television more than 40 hours per week had a higher risk for symptomatic gallstones than men who watched less than 6 hours per week (relative risk for older men, 3.32 [CI, 1.51 to 7.27]; relative risk for younger men, 1.58 [CI, 0.38 to 6.48]). Conclusions: Physical activity may play an important role in the prevention of symptomatic gallstone disease in men even beyond its benefit for control of body weight. The results of this study indicate that 34% of cases of symptomatic gallstone disease in men could be prevented by increasing exercise to 30 minutes of endurance-type training five times per week.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Channing Lab, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health	Leitzmann, MF (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.							AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; ALDOORI WH, 1995, GUT, V36, P276, DOI 10.1136/gut.36.2.276; ANGELICO M, 1988, HEPATOLOGY, V8, P907; ATTILI AF, 1987, DIGEST DIS SCI, V32, P349, DOI 10.1007/BF01296286; BAKER TT, 1986, METABOLISM, V35, P1037, DOI 10.1016/0026-0495(86)90040-5; BASSO L, 1992, EUR J EPIDEMIOL, V8, P629, DOI 10.1007/BF00145375; BOUCHARD G, 1994, P SOC EXP BIOL MED, V206, P409; CHAIT A, 1979, J CLIN INVEST, V64, P1309, DOI 10.1172/JCI109587; ChasanTaber S, 1996, EPIDEMIOLOGY, V7, P81, DOI 10.1097/00001648-199601000-00014; CUPPLES LA, 1988, STAT MED, V7, P205, DOI 10.1002/sim.4780070122; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; DURRLEMAN S, 1989, STAT MED, V8, P551, DOI 10.1002/sim.4780080504; EVERHART JE, 1993, ANN INTERN MED, V119, P1029, DOI 10.7326/0003-4819-119-10-199311150-00010; FRIEDMAN GD, 1989, J CLIN EPIDEMIOL, V42, P127, DOI 10.1016/0895-4356(89)90086-3; FRIEDMAN GD, 1966, J CHRON DIS, V19, P273, DOI 10.1016/0021-9681(66)90132-9; HALLORAN LG, 1978, SURGERY, V84, P1; HEATON KW, 1993, LANCET, V341, P8, DOI 10.1016/0140-6736(93)92479-D; Hussaini SH, 1995, HEPATOLOGY, V22, P1735, DOI 10.1016/0270-9139(95)90199-X; JANOWITZ P, 1992, CLIN INVESTIGATOR, V70, P430, DOI 10.1007/BF00235527; JENNINGS G, 1986, CIRCULATION, V73, P30, DOI 10.1161/01.CIR.73.1.30; JORGENSEN T, 1990, SCAND J GASTROENTERO, V25, P335, DOI 10.3109/00365529009095495; JORGENSEN T, 1989, GUT, V30, P528, DOI 10.1136/gut.30.4.528; Kang J, 1996, DIABETES CARE, V19, P341, DOI 10.2337/diacare.19.4.341; KATO I, 1992, DIGEST DIS SCI, V37, P784, DOI 10.1007/BF01296440; KEELING WF, 1987, J APPL PHYSIOL, V63, P978, DOI 10.1152/jappl.1987.63.3.978; KOFFLER KH, 1992, MED SCI SPORT EXER, V24, P415; KONO S, 1995, SCAND J GASTROENTERO, V30, P372, DOI 10.3109/00365529509093293; LEE SP, 1981, J CLIN INVEST, V67, P1712, DOI 10.1172/JCI110209; Linos A D, 1989, HPB Surg, V1, P221, DOI 10.1155/1989/56539; MARCUS SN, 1986, GUT, V27, P550, DOI 10.1136/gut.27.5.550; MAURER KR, 1990, AM J EPIDEMIOL, V131, P836, DOI 10.1093/oxfordjournals.aje.a115574; MAURER KR, 1989, GASTROENTEROLOGY, V96, P487, DOI 10.1016/0016-5085(89)91575-8; MIETTINE.OS, 1974, AM J EPIDEMIOL, V99, P325, DOI 10.1093/oxfordjournals.aje.a121617; MINGRONE G, 1988, BIOCHIM BIOPHYS ACTA, V958, P52, DOI 10.1016/0005-2760(88)90245-7; *NAT CTR HLTH STAT, 1994, ADV DAT VIT HLTH STA, V278; NEPOKROEFF CM, 1974, ARCH BIOCHEM BIOPHYS, V160, P387, DOI 10.1016/0003-9861(74)90412-3; Ortega RM, 1997, J AM COLL NUTR, V16, P88, DOI 10.1080/07315724.1997.10718655; Ostrowska Lucyna, 1996, Medycyna Pracy, V47, P461; OZEKI K, 1992, GASTROENTEROLOGY, V103, P759, DOI 10.1016/0016-5085(92)90003-H; PERSSON GE, 1991, ACTA CHIR-EUR J SURG, V157, P473; PETITTI DB, 1981, NEW ENGL J MED, V304, P1396, DOI 10.1056/NEJM198106043042305; PHILLIPP E, 1992, PEPTIDES, V13, P125, DOI 10.1016/0196-9781(92)90150-2; RIMM E, 1995, AM J EPIDEMIOL, V141, pS17; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; ROSENTHAL M, 1983, DIABETES, V32, P408, DOI 10.2337/diabetes.32.5.408; ROSNER B, 1990, AM J EPIDEMIOL, V132, P734, DOI 10.1093/oxfordjournals.aje.a115715; ROTHMAN KJ, 1986, EPIDEMIOLOGY, P87; SARIN SK, 1986, DIGEST DIS SCI, V31, P1041, DOI 10.1007/BF01300256; SARLES H, 1969, AM J DIG DIS, V14, P531, DOI 10.1007/BF02232927; SCHWARTZ RS, 1992, METABOLISM, V41, P649, DOI 10.1016/0026-0495(92)90058-I; SCRAGG RKR, 1984, BMJ-BRIT MED J, V289, P521, DOI 10.1136/bmj.289.6444.521; SUBBIAH MTR, 1984, BIOCHEM BIOPH RES CO, V124, P896, DOI 10.1016/0006-291X(84)91042-8; THORNTON JR, 1981, BRIT MED J, V283, P1352, DOI 10.1136/bmj.283.6303.1352; TRAN ZV, 1983, MED SCI SPORT EXER, V15, P393; *US DEP HHS CDCP N, 1996, PHYS ACT HLTH REP SU; *US DEP HHS NAT I, 1995, NIH PUBL; *USDA AGR RES SERV, 1995, USDA NUTR DAT STAND; Utter A. C., 1995, Medicine and Science in Sports and Exercise, V27, pS57; WATKINS JB, 1994, DRUG METAB DISPOS, V22, P537; WHEELER M, 1970, GUT, V11, P430, DOI 10.1136/gut.11.5.430; WILLETT WC, 1990, NUTR EPIDEMIOLOGY, P262; WILLIAMS CN, 1980, CAN MED ASSOC J, V122, P664	62	129	132	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1998	128	6					417	+		10.7326/0003-4819-128-6-199803150-00001	http://dx.doi.org/10.7326/0003-4819-128-6-199803150-00001			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA914	9499324				2022-12-28	WOS:000072414700001
J	Morton, CC				Morton, CC			US dialysis survival strategy	ANNALS OF INTERNAL MEDICINE			English	Article																			0	5	5	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1998	128	6					514	516		10.7326/0003-4819-128-6-199803150-00039	http://dx.doi.org/10.7326/0003-4819-128-6-199803150-00039			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA914	9499351				2022-12-28	WOS:000072414700036
J	Saks, ME; Sampson, JR; Abelson, J				Saks, ME; Sampson, JR; Abelson, J			Evolution of a transfer RNA gene through a point mutation in the anticodon	SCIENCE			English	Article							ESCHERICHIA-COLI; PROTEIN-SYNTHESIS; AMINO-ACIDS; DISCRIMINATOR BASE; ACCEPTOR STEM; HAIRPIN RNA; IDENTITY; CODE; SYNTHETASE; RECOGNITION	The transfer RNA (tRNA) multigene family comprises 20 amino acid-accepting groups, many of which contain isoacceptors, The addition of isoacceptors to the tRNA repertoire was critical to establishing the genetic code, yet the origin of isoacceptors remains largely unexplored, A model of tRNA evolution, termed "tRNA gene recruitment," was formulated. It proposes that a tRNA gene can be recruited from one isoaccepting group to another by a point mutation that concurrently changes tRNA amino acid identity and messenger RNA coupling capacity, A test of the model showed that an Escherichia coli strain, in which the essential tRNA(UGU)(Thr), gene was inactivated, was rendered viable when a tRNA(Arg) with a point mutation that changed its anticodon from UCU to UGU (threonine) was expressed, Insertion of threonine at threonine codons by the "recruited" tRNA(Arg) was corroborated by in vitro aminoacylation assays showing that its specificity had been changed from arginine to threonine, Therefore, the recruitment model may account for the evolution of some tRNA genes.	CALTECH, Div Biol 147 75, Pasadena, CA 91125 USA	California Institute of Technology	Saks, ME (corresponding author), Univ Oregon, Dept Biol, Eugene, OR 97403 USA.				NIGMS NIH HHS [GM 48560] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048560] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNER SA, 1993, RNA WORLD, P27; BLATTNER FR, 1993, NUCLEIC ACIDS RES, V21, P5408; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BLOCH DP, 1985, BIOSYSTEMS, V17, P209, DOI 10.1016/0303-2647(85)90075-9; CEDERGREN RJ, 1980, P NATL ACAD SCI-BIOL, V77, P2791, DOI 10.1073/pnas.77.5.2791; CHANDA VB, 1990, CURRENT PROTOCOLS MO; CHATTAPADHYAY R, 1990, BIOCHEMISTRY-US, V29, P4263, DOI 10.1021/bi00470a001; Cusack S, 1996, EMBO J, V15, P6321, DOI 10.1002/j.1460-2075.1996.tb01022.x; DICK TP, 1995, J MOL EVOL, V41, P1; DIGIULIO M, 1994, J THEOR BIOL, V171, P303, DOI 10.1006/jtbi.1994.1233; DIGIULIO M, 1995, J THEOR BIOL, V177, P95, DOI 10.1016/S0022-5193(05)80007-4; EIGEN M, 1989, SCIENCE, V244, P673, DOI 10.1126/science.2497522; Felsenstein J., PHYLOGENY INFERENCE; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; FITCH WM, 1987, COLD SPRING HARB SYM, V52, P759, DOI 10.1101/SQB.1987.052.01.085; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Gabriel K, 1996, SCIENCE, V271, P195, DOI 10.1126/science.271.5246.195; GAUSS DH, 1979, TRANSFER RNA STRUCTU, P518; Genetic Computer Group, 1994, PROGR MAN WISC PACK; GIEGE R, 1993, PROG NUCLEIC ACID RE, V45, P129, DOI 10.1016/S0079-6603(08)60869-7; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HASEGAWA T, 1992, BIOCHEM BIOPH RES CO, V184, P478, DOI 10.1016/0006-291X(92)91219-G; IKEMURA T, 1981, J MOL BIOL, V146, P1, DOI 10.1016/0022-2836(81)90363-6; JUKES TH, 1987, NATURE, V325, P668, DOI 10.1038/325668b0; JUKES TH, 1987, COLD SPRING HARB SYM, V52, P769, DOI 10.1101/SQB.1987.052.01.086; KOMINE Y, 1990, J MOL BIOL, V212, P579, DOI 10.1016/0022-2836(90)90224-A; LACEY JC, 1990, ORIGINS LIFE EVOL B, V20, P303, DOI 10.1007/BF01808112; LI SH, 1993, J BIOL CHEM, V268, P18335; LOFTFIELD RB, 1963, BIOCHEM J, V89, P82, DOI 10.1042/bj0890082; MAIZELS N, 1994, P NATL ACAD SCI USA, V91, P6729, DOI 10.1073/pnas.91.15.6729; Martinis Susan A., 1995, P349; MCCLAIN WH, 1987, J MOL BIOL, V194, P635, DOI 10.1016/0022-2836(87)90240-3; MCCLAIN WH, 1990, P NATL ACAD SCI USA, V87, P9260, DOI 10.1073/pnas.87.23.9260; MCCLAIN WH, 1993, J MOL BIOL, V234, P257, DOI 10.1006/jmbi.1993.1582; MOLLER W, 1992, J MOL EVOL, V34, P471, DOI 10.1007/BF00160461; MOLLER W, 1990, BIOCHIMIE, V72, P361, DOI 10.1016/0300-9084(90)90033-D; MUENCH KH, 1966, PROCEDURES NUCLEIC A, P375; Nakamura Y, 1997, NUCLEIC ACIDS RES, V25, P244, DOI 10.1093/nar/25.1.244; Noller H.F., 1993, RNA WORLD, P137; NORMANLY J, 1986, NATURE, V321, P213, DOI 10.1038/321213a0; NORMANLY J, 1990, J MOL BIOL, V213, P719, DOI 10.1016/S0022-2836(05)80258-X; NORMANLY J, 1986, P NATL ACAD SCI USA, V83, P6548, DOI 10.1073/pnas.83.17.6548; OCHMAN H, 1987, J MOL EVOL, V26, P74, DOI 10.1007/BF02111283; OLSEN GJ, 1994, J BACTERIOL, V176, P1, DOI 10.1128/JB.176.1.1-6.1994; OSAWA S, 1992, MICROBIOL REV, V56, P229, DOI 10.1128/MMBR.56.1.229-264.1992; PAK M, 1992, BIOCHEMISTRY-US, V31, P3303, DOI 10.1021/bi00128a001; PALLANCK L, 1992, J BIOL CHEM, V267, P7221; PALLANCK L, 1991, P NATL ACAD SCI USA, V88, P3872, DOI 10.1073/pnas.88.9.3872; Pallanck Leo, 1995, P371; Rodin S, 1996, P NATL ACAD SCI USA, V93, P4537, DOI 10.1073/pnas.93.10.4537; RODIN S, 1993, P NATL ACAD SCI USA, V90, P4723, DOI 10.1073/pnas.90.10.4723; Rodin SN, 1997, P NATL ACAD SCI USA, V94, P5183, DOI 10.1073/pnas.94.10.5183; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SAKS ME, 1994, SCIENCE, V263, P191, DOI 10.1126/science.7506844; SAKS ME, 1995, J MOL EVOL, V40, P509; SAMPSON JR, 1993, NUCLEIC ACIDS RES, V21, P4467, DOI 10.1093/nar/21.19.4467; SCHIMMEL P, 1994, P NATL ACAD SCI USA, V91, P11283, DOI 10.1073/pnas.91.24.11283; SCHIMMEL P, 1993, P NATL ACAD SCI USA, V90, P8763, DOI 10.1073/pnas.90.19.8763; SCHIMMEL P, 1995, CELL, V81, P983, DOI 10.1016/S0092-8674(05)80002-9; SCHULMAN LH, 1989, SCIENCE, V246, P1595, DOI 10.1126/science.2688091; SCHULMAN LH, 1988, SCIENCE, V242, P765, DOI 10.1126/science.3055296; SCHULMAN LH, 1990, NUCLEIC ACIDS RES, V18, P285, DOI 10.1093/nar/18.2.285; Sprinzl M, 1996, NUCLEIC ACIDS RES, V24, P68, DOI 10.1093/nar/24.1.68; SQUIRES C, 1971, NATURE-NEW BIOL, V233, P274, DOI 10.1038/newbio233274a0; STAVES MP, 1988, ORIGINS LIFE EVOL B, V18, P97, DOI 10.1007/BF01808784; STAVES MP, 1987, Z NATURFORSCH C, V42, P129; TAMURA K, 1992, NUCLEIC ACIDS RES, V20, P2335, DOI 10.1093/nar/20.9.2335; WEINER AM, 1987, P NATL ACAD SCI USA, V84, P7383, DOI 10.1073/pnas.84.21.7383; YOUNG RA, 1979, J BIOL CHEM, V254, P2725	70	68	69	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 13	1998	279	5357					1665	1670		10.1126/science.279.5357.1665	http://dx.doi.org/10.1126/science.279.5357.1665			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9497276				2022-12-28	WOS:000072490000041
J	Nakamura, TM; Cech, TR				Nakamura, TM; Cech, TR			Reversing time: Origin of telomerase	CELL			English	Review							RETROTRANSPOSON		Univ Colorado, Howard Hughes Med Inst, Dept Chem & Biochem, Boulder, CO 80309 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder	Nakamura, TM (corresponding author), Univ Colorado, Howard Hughes Med Inst, Dept Chem & Biochem, Boulder, CO 80309 USA.		Nakamura, Toru M/B-2055-2008	Nakamura, Toru M/0000-0001-5752-0814				Biessmann H, 1997, CHROMOSOMA, V106, P63, DOI 10.1007/s004120050225; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; Eickbush TH, 1997, SCIENCE, V277, P911, DOI 10.1126/science.277.5328.911; Eickbush Thomas H., 1994, P121; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Gupta RS, 1996, TRENDS BIOCHEM SCI, V21, P166, DOI 10.1016/0968-0004(96)20013-1; Hansen JL, 1997, STRUCTURE, V5, P1109, DOI 10.1016/S0969-2126(97)00261-X; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; Knoop V, 1996, GENETICS, V142, P579; Lendvay TS, 1996, GENETICS, V144, P1399; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Pardue ML, 1996, TRENDS GENET, V12, P48, DOI 10.1016/0168-9525(96)81399-0; Roger AJ, 1998, P NATL ACAD SCI USA, V95, P229, DOI 10.1073/pnas.95.1.229; Takahashi H, 1997, NUCLEIC ACIDS RES, V25, P1578, DOI 10.1093/nar/25.8.1578; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Zou S, 1996, GENE DEV, V10, P634, DOI 10.1101/gad.10.5.634	20	261	278	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 6	1998	92	5					587	590		10.1016/S0092-8674(00)81123-X	http://dx.doi.org/10.1016/S0092-8674(00)81123-X			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZA827	9506510	Bronze			2022-12-28	WOS:000072406000001
J	Renault, L; Nassar, N; Vetter, I; Becker, J; Klebe, C; Roth, M; Wittinghofer, A				Renault, L; Nassar, N; Vetter, I; Becker, J; Klebe, C; Roth, M; Wittinghofer, A			The 1.7 angstrom crystal structure of the regulator of chromosome condensation (RCC1) reveals a seven-bladed propeller	NATURE			English	Article							GUANINE-NUCLEOTIDE-EXCHANGE; GENE RCC1; G-PROTEIN; RAN; HOMOLOGY; PATHWAY; MITOSIS; PROGRAM	The gene encoding the regulator of chromosome condensation (RCC1) was cloned by virtue of its ability to complement the temperature-sensitive phenotype of the hamster cell line tsBN2, which undergoes premature chromosome condensation or arrest in the G1 phase of the cell cycle at non-permissive temperatures(1-2). RCC1 homologues have been identified in many eukaryotes, including budding and fission yeast. Mutations in the gene affect pre-messenger RNA processing and transport(3,4), mating(5), initiation of mitosis(6) and chromatin decondensation(7), suggesting that RCC1 is important in the control of nucleo-cytoplasmic transport and the cell cycle. Biochemically, RCC1 is a guanine-nucleotide-exchange factor for the nuclear Ras homologue Ran(8); it increases the dissociation of Ran-bound GDP by 10(5)-fold (ref. 9). It may also bind to DNA via a protein-protein complex(2). Here we show that the structure of human RCC1, solved to 1.7-Angstrom resolution by X-ray crystallography, consists of a seven-bladed propeller formed from internal repeats of 51-68 residues per blade. The sequence and structure of the repeats differ from those of WD40-domain proteins, which also form seven-bladed propellers and include the beta-subunits of G proteins. The nature of the structure explains the consequences of a wide range of known mutations. The region of the protein that is involved in guanine-nucleotide exchange is located opposite the region that is thought to be involved in chromosome binding.	Max Planck Inst Mol Physiol, Abt Strukturelle Biol, D-44139 Dortmund, Germany; Inst Biol Struct Jean Pierre Ebel, Lab Cristallog & Cristallogenese Prot, F-38027 Grenoble 1, France	Max Planck Society; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Wittinghofer, A (corresponding author), Max Planck Inst Mol Physiol, Abt Strukturelle Biol, Rheinlanddamm 201, D-44139 Dortmund, Germany.	alfred.wittinghofer@mpi-dortmund.mpg.de		RENAULT, Louis/0000-0003-1722-074X				AEBI M, 1990, MOL GEN GENET, V224, P72, DOI 10.1007/BF00259453; Azuma Y, 1996, J BIOCHEM-TOKYO, V120, P82; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BRUNGER AT, 1996, XPLOR VERSION 3 8; CLARK KL, 1989, MOL CELL BIOL, V9, P2682, DOI 10.1128/MCB.9.6.2682; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KADOWAKI T, 1993, EMBO J, V12, P2929, DOI 10.1002/j.1460-2075.1993.tb05955.x; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P12543, DOI 10.1021/bi00039a008; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; MATSUMOTO T, 1991, CELL, V66, P347, DOI 10.1016/0092-8674(91)90624-8; MATYNIA A, IN PRESS GENETICS; Meindl A, 1996, NAT GENET, V13, P35, DOI 10.1038/ng0596-35; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; OHTSUBO M, 1987, GENE DEV, V1, P585, DOI 10.1101/gad.1.6.585; Otwinowski Z., 1993, DATA COLLECTION PROC, P556; Roepman R, 1996, HUM MOL GENET, V5, P1035, DOI 10.1093/hmg/5.7.1035; Rosa JL, 1996, EMBO J, V15, P4262, DOI 10.1002/j.1460-2075.1996.tb00801.x; SAZER S, 1994, EMBO J, V13, P606, DOI 10.1002/j.1460-2075.1994.tb06298.x; SEABRA MC, 1993, SCIENCE, V259, P377, DOI 10.1126/science.8380507; Seki T, 1996, J BIOCHEM, V120, P207; VELLIEUX FMDAP, 1995, J APPL CRYSTALLOGR, V28, P347, DOI 10.1107/S0021889894012355; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wang Y, 1997, NAT STRUCT BIOL, V4, P650, DOI 10.1038/nsb0897-650	29	240	247	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 5	1998	392	6671					97	101		10.1038/32204	http://dx.doi.org/10.1038/32204			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA528	9510255				2022-12-28	WOS:000072373000058
J	Nightingale, SL				Nightingale, SL			Generic substitution	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.							U.S. Food and Drug Administration, APPROVED DRUG PRODUC	1	22	25	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1998	279	9					645	645		10.1001/jama.279.9.645-b	http://dx.doi.org/10.1001/jama.279.9.645-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY849	9496968				2022-12-28	WOS:000072192800006
J	Yaffe, K; Sawaya, G; Lieberburg, I; Grady, D				Yaffe, K; Sawaya, G; Lieberburg, I; Grady, D			Estrogen therapy in postmenopausal women - Effects on cognitive function and dementia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HORMONE REPLACEMENT THERAPY; ALZHEIMERS-DISEASE; OLDER WOMEN; BASAL FOREBRAIN; VENOUS THROMBOEMBOLISM; MYOCARDIAL-INFARCTION; ESTRADIOL PROTECTS; MONOAMINE-OXIDASE; GONADAL-STEROIDS; CAROTID-ARTERY	Context.-Several studies have suggested that estrogen replacement therapy in postmenopausal women improves cognition, prevents development of dementia, and improves the severity of dementia, while other studies have not found a benefit of estrogen use, Objective.-To determine whether postmenopausal estrogen therapy improves cognition, prevents development of dementia, or improves dementia severity. Data Sources.-We performed a literature search of studies published from January 1966 through June 1997, using MEDLINE, manually searched bibliographies of articles identified, and consulted experts. Study Selection.-Studies that evaluated biological mechanisms of estrogen's effect on the central nervous system and studies that addressed the effect of estrogen on cognitive function or on dementia. Data Extraction.-We reviewed studies for methods, sources of bias, and outcomes and performed a meta-analysis of the 10 studies of postmenopausal estrogen use and risk of dementia using standard meta-analytic methods. Data Synthesis.-Biochemical and neurophysiologic studies suggest several mechanisms by which estrogen may affect cognition: promotion of cholinergic and serotonergic activity in specific brain regions, maintenance of neural circuitry, favorable lipoprotein alterations, and prevention of cerebral ischemia. Five observational studies and 8 trials have addressed the effect of estrogen on cognitive function in nondemented postmenopausal women, Cognition seems to improve in perimenopausal women, possibly because menopausal symptoms improve, but there is no clear benefit in asymptomatic women. Ten observational studies have measured the effect of postmenopausal estrogen use on risk of developing dementia. Meta-analysis of these studies suggests a 29% decreased risk of developing dementia among estrogen users, but the findings of the studies are heterogeneous. Four trials of estrogen therapy in women with Alzheimer disease have been conducted and have had primarily positive results, but most have been small, of short duration, nonrandomized, and uncontrolled. Conclusions.-There are plausible biological mechanisms by which estrogen might lead to improved cognition, reduced risk for dementia, or improvement in the severity of dementia. Studies conducted in women, however, have substantial methodologic problems and have produced conflicting results. Large placebo-controlled trials are required to address estrogen's role in prevention and treatment of Alzheimer disease and other dementias. Given the known risks of estrogen therapy, we do not recommend estrogen for the prevention or treatment of Alzheimer disease or other dementias until adequate trials have been completed.	Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Obstet & Gynecol, San Francisco, CA 94143 USA; Athena Neurosci Inc, San Francisco, CA 94080 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Yaffe, K (corresponding author), Univ Calif San Francisco, Vet Adm Med Ctr, 111G,4150 Clement St, San Francisco, CA 94121 USA.	kyaffe@itsa.ucsf.edu						AMADUCCI LA, 1986, NEUROLOGY, V36, P922, DOI 10.1212/WNL.36.7.922; APPLEBAUMBOWDEN D, 1989, J LIPID RES, V30, P1895; ARONSON MK, 1990, NEUROLOGY, V40, P1102, DOI 10.1212/WNL.40.7.1102; AYLWARD M, 1973, INT RESEARCH COMMUNI, V1, P30; BARRETTCONNOR E, 1993, JAMA-J AM MED ASSOC, V269, P2637, DOI 10.1001/jama.269.20.2637; BARRETTCONNOR E, 1991, ANN INTERN MED, V115, P455, DOI 10.7326/0003-4819-115-6-455; BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051; BEHL C, 1995, BIOCHEM BIOPH RES CO, V216, P473, DOI 10.1006/bbrc.1995.2647; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; BRENNER DE, 1994, AM J EPIDEMIOL, V140, P262, DOI 10.1093/oxfordjournals.aje.a117245; BROE GA, 1990, NEUROLOGY, V40, P1698, DOI 10.1212/WNL.40.11.1698; CALDWELL BM, 1952, J GERONTOL, V7, P228; CAMPBELL S, 1977, CLIN OBSTET GYNAECOL, V4, P31; CAULEY JA, 1990, AM J OBSTET GYNECOL, V163, P1438, DOI 10.1016/0002-9378(90)90602-4; COBB JL, 1995, NEUROLOGY, V45, P1707, DOI 10.1212/WNL.45.9.1707; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; Coronary Drug Project Research Group, 1981, N ENGL J MED, V304, P612; COYLE JT, 1983, SCIENCE, V219, P1184, DOI 10.1126/science.6338589; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DITKOFF EC, 1991, OBSTET GYNECOL, V78, P991; DOHANICH GP, 1994, BEHAV NEUROSCI, V108, P988, DOI 10.1037/0735-7044.108.5.988; Drachman DA, 1997, NEW ENGL J MED, V336, P1245, DOI 10.1056/NEJM199704243361710; EGELAND GM, 1991, PREV MED, V20, P343, DOI 10.1016/0091-7435(91)90033-Z; ERNST RL, 1994, AM J PUBLIC HEALTH, V84, P1261, DOI 10.2105/AJPH.84.8.1261; EVANS DA, 1990, MILBANK Q, V68, P267, DOI 10.2307/3350099; Fedor-Freybergh P, 1977, Acta Obstet Gynecol Scand Suppl, V64, P1; FILLIT H, 1986, PSYCHONEUROENDOCRINO, V11, P337, DOI 10.1016/0306-4530(86)90019-3; GANGAR KF, 1991, LANCET, V338, P839; Gibbs RB, 1997, BRAIN RES, V749, P143, DOI 10.1016/S0006-8993(96)01375-3; Goodman YD, 1996, J NEUROCHEM, V66, P1836; GOULD E, 1990, J NEUROSCI, V10, P1286; GRADY D, 1991, AM J EPIDEMIOL, V134, P1396, DOI 10.1093/oxfordjournals.aje.a116043; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GRAVES AB, 1990, ANN NEUROL, V28, P766, DOI 10.1002/ana.410280607; Green PS, 1996, NEUROSCI LETT, V218, P165, DOI 10.1016/S0304-3940(96)13148-7; GREENLAND S, 1987, EPIDEMIOL REV, V9, P1; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; Gutthann SP, 1997, BMJ-BRIT MED J, V314, P796, DOI 10.1136/bmj.314.7083.796; Hackman B W, 1976, Curr Med Res Opin, V4, P303, DOI 10.1185/03007997609109322; HENDERSON VW, 1994, ARCH NEUROL-CHICAGO, V51, P896, DOI 10.1001/archneur.1994.00540210068014; HEYMAN A, 1984, ANN NEUROL, V15, P335, DOI 10.1002/ana.410150406; HONJO H, 1992, J STEROID BIOCHEM, V41, P633, DOI 10.1016/0960-0760(92)90395-Y; HONJO H, 1989, J STEROID BIOCHEM, V34, P521; HONJO H, 1995, HORM METAB RES, V27, P204, DOI 10.1055/s-2007-979941; Honjo H., 1993, J JPN MENOPAUSE SOC, V1, P167; HORWITZ RI, 1990, LANCET, V336, P542, DOI 10.1016/0140-6736(90)92095-Y; JAFFE AB, 1994, J BIOL CHEM, V269, P13065; Jick H, 1996, LANCET, V348, P981, DOI 10.1016/S0140-6736(96)07114-0; KAMPEN DL, 1994, OBSTET GYNECOL, V83, P979, DOI 10.1097/00006250-199406000-00017; KATZMAN R, 1986, NEW ENGL J MED, V314, P964, DOI 10.1056/NEJM198604103141506; Kawas C, 1997, NEUROLOGY, V48, P1517, DOI 10.1212/WNL.48.6.1517; KIMURA D, 1995, HORM BEHAV, V29, P312, DOI 10.1006/hbeh.1995.1022; KITTNER SJ, 1986, J CHRON DIS, V39, P163, DOI 10.1016/0021-9681(86)90019-6; KLAIBER EL, 1979, ARCH GEN PSYCHIAT, V36, P550; LUINE VN, 1985, EXP NEUROL, V89, P484, DOI 10.1016/0014-4886(85)90108-6; LUINE VN, 1975, BRAIN RES, V86, P293, DOI 10.1016/0006-8993(75)90704-0; MATSUMOTO A, 1991, PSYCHONEUROENDOCRINO, V16, P25, DOI 10.1016/0306-4530(91)90069-6; MCEWEN BS, 1994, EXP GERONTOL, V29, P431, DOI 10.1016/0531-5565(94)90022-1; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MORTEL KF, 1995, J NEUROPSYCH CLIN N, V7, P334; MORTIMER JA, 1998, NEUROLOGY S4, V43, pS39; OHKURA T, 1994, ENDOCR J, V41, P361, DOI 10.1507/endocrj.41.361; OMALLEY CA, 1987, BRAIN RES, V403, P389, DOI 10.1016/0006-8993(87)90082-5; OXMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367, DOI 10.1001/jama.272.17.1367; PaganiniHill A, 1996, J AM GERIATR SOC, V44, P818, DOI 10.1111/j.1532-5415.1996.tb03740.x; PAGANINIHILL A, 1988, BMJ-BRIT MED J, V297, P519, DOI 10.1136/bmj.297.6647.519; PAGANINIHILL A, 1994, AM J EPIDEMIOL, V140, P256, DOI 10.1093/oxfordjournals.aje.a117244; PALMER AM, 1993, J NEURAL TRANSM-GEN, V91, P135, DOI 10.1007/BF01245229; PETITTI DB, 1988, GASTROENTEROLOGY, V94, P91, DOI 10.1016/0016-5085(88)90614-2; Petitti Diana B., 1994, Annals of Epidemiology, V4, P115; PHILLIPS SM, 1992, PSYCHONEUROENDOCRINO, V17, P485, DOI 10.1016/0306-4530(92)90007-T; PIZZO PA, 1983, J PEDIATR-US, V102, P125, DOI 10.1016/S0022-3476(83)80310-2; POIRIER MF, 1985, NEUROPSYCHOBIOLOGY, V14, P165, DOI 10.1159/000118222; POSTHUMA WFM, 1994, BRIT MED J, V308, P1268; Rauramo L, 1975, Front Horm Res, V3, P94; ROBINSON D, 1994, J AM GERIATR SOC, V42, P919, DOI 10.1111/j.1532-5415.1994.tb06580.x; ROSES AD, 1995, ANN NEUROL, V38, P6, DOI 10.1002/ana.410380105; Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704; SASS KJ, 1990, NEUROLOGY, V40, P1694, DOI 10.1212/WNL.40.11.1694; SHERWIN BB, 1988, PSYCHONEUROENDOCRINO, V13, P345, DOI 10.1016/0306-4530(88)90060-1; SIMPKINS JW, 1994, NEUROBIOL AGING, V15, pS195; Srivastava RAK, 1996, BIOCHEM MOL BIOL INT, V38, P91; SULLIVAN TR, 1995, J CLIN INVEST, V96, P2482, DOI 10.1172/JCI118307; SUMNER BEH, 1995, J STEROID BIOCHEM, V54, P15, DOI 10.1016/0960-0760(95)00075-B; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; THOMSON J, 1977, J ENDOCRINOL, V72, P395, DOI 10.1677/joe.0.0720395; TORANALLERAND CD, 1992, P NATL ACAD SCI USA, V89, P4668, DOI 10.1073/pnas.89.10.4668; Yaffe K, 1997, ARCH NEUROL-CHICAGO, V54, P1110, DOI 10.1001/archneur.1997.00550210044011	89	713	733	0	27	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1998	279	9					688	695		10.1001/jama.279.9.688	http://dx.doi.org/10.1001/jama.279.9.688			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY849	9496988				2022-12-28	WOS:000072192800034
J	Buse, K; Gwin, C				Buse, K; Gwin, C			The World Bank and global cooperation in health: The case of Bangladesh	LANCET			English	Article							ORGANIZATION	The final quarter of the 20th century saw a profound change in international health cooperation. The World Bank emerged and consolidated its position as the reading external financier of health-sector activities in countries of row and middle income. As a result of its resources, philosophy, and legitimacy, the World Bank leveraged fundamental reform of the health-sector agenda as well as institutional relations at global and national levels. The scope of the Bank's involvement, and the nature of its policy thrusts and investment strategy in the sector, are outlined in this paper and illustrated with specific reference to Bangladesh. This backdrop serves to raise four issues and enables us to explore their relevance to global health cooperation in the first quarter of the 21st century.	Univ London London Sch Hyg & Trop Med, Hlth Policy Unit, London WC1E 7HT, England; Overseas Dev Council, Washington, DC 20036 USA	University of London; London School of Hygiene & Tropical Medicine	Buse, K (corresponding author), Univ London London Sch Hyg & Trop Med, Hlth Policy Unit, Keppel St, London WC1E 7HT, England.		Buse, Kent/AAK-6688-2020	Buse, Kent/0000-0002-5485-0110				Anand S, 1997, J HEALTH ECON, V16, P685, DOI 10.1016/S0167-6296(97)00005-2; Brown P, 1997, NEW SCI, V153, P12; BUSE K, 1998, IN PRESS SOC SCI MED; BUSE K, 1997, UN INT TASK FORC BAS; DEBEYER JA, 1998, IN PRESS SOC SCI MED; Gilson L., 1995, J INT DEVEL, V7, P369, DOI 10.1002/jid.3380070305; GODLEE F, 1994, BRIT MED J, V309, P1636, DOI 10.1136/bmj.309.6969.1636; GODLEE F, 1994, BRIT MED J, V309, P1566, DOI 10.1136/bmj.309.6968.1566; GODLEE F, 1994, BRIT MED J, V309, P1424, DOI 10.1136/bmj.309.6966.1424; GODLEE F, 1994, BRIT MED J, V309, P1491, DOI 10.1136/bmj.309.6967.1491; GODLEE F, 1994, BRIT MED J, V310, P389; GODLEE F, 1994, BRIT MED J, V310, P583; GODLEE F, 1994, BRIT MED J, V310, P110; GODLEE F, 1994, BRIT MED J, V310, P178; *MIN HLTH FAM WELF, 1997, GOV BANGL HLTH POP S; *MIN PLANN, 1975, GOV BANGL BAS AN ANN; STOUT S, 1997, EVALUATING HLTH PROJ; Vaughan JP, 1996, HEALTH POLICY, V35, P229, DOI 10.1016/0168-8510(95)00786-5; WAPENHANS A, 1992, EFFECTIVE IMPLEMENTA; *WHO, 1997, WORK WHO; World Bank, 1997, HLTH NUTR POP SECT S; World Bank, 1992, POP WORLD BANK IMPL; *WORLD BANK, 1987, FIN HLTH SERV DEV CO; World Bank, 1980, ED SECT POL PAP; Zwi A B, 1995, J Int Dev, V7, P299, DOI 10.1002/jid.3380070302	25	37	37	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 28	1998	351	9103					665	669		10.1016/S0140-6736(97)11453-2	http://dx.doi.org/10.1016/S0140-6736(97)11453-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA447	9500349				2022-12-28	WOS:000072364200042
J	Siersted, HC; Boldsen, J; Hansen, HS; Mostgaard, G; Hyldebrandt, N				Siersted, HC; Boldsen, J; Hansen, HS; Mostgaard, G; Hyldebrandt, N			Population based study of risk factors for underdiagnosis of asthma in adolescence: Odense schoolchild study	BRITISH MEDICAL JOURNAL			English	Article							PEAK EXPIRATORY FLOW; BRONCHIAL RESPONSIVENESS; LUNG-FUNCTION; YOUNG-ADULTS; CHILDREN; CHILDHOOD; SYMPTOMS; DIAGNOSIS; ATOPY; UNDERTREATMENT	Objective: To describe factors related to underdiagnosis of asthma in adolescence. Design: Subgroup analysis in a population based cohort study. Setting: Odense municipality, Denmark. Subjects: 495 schoolchildren aged 12 to 15 years were selected from a cohort of 1369 children investigated 3 years earlier. Selection was done by randomisation (n = 292) and by a history indicating allergy or asthma-like symptoms in subject or family (n = 203). Main outcome measures: Undiagnosed asthma defined as coexistence of asthma-like symptoms and one or more obstructive airway abnormalities (low ratio of forced expiratory volume in 1 second to forced vital capacity, hyperresponsiveness to methacholine or exercise, or peak now hypervariability) in the absence of physician diagnosed asthma. Risk factors (odds ratios) for underdiagnosis. Results: Undiagnosed asthma comprised about one third of all asthma identified. Underdiagnosis was independently associated with low physical activity, high body mass, serious family problems, passive smoking, and the absence of rhinitis. Girls were overrepresented among undiagnosed patients with asthma (69%) and underrepresented among diagnosed patients (33%). Among the risk factors identified, low physical activity and problems in the family were independently associated with female sex. The major symptom among those undiagnosed was cough (58%), whereas wheezing (35%) or breathing trouble (50%) was reported less frequently than among those diagnosed. Less than one third of those undiagnosed had reported their symptoms to a doctor. Conclusions: Asthma, as defined by combined symptoms and test criteria, was seriously underdiagnosed among adolescents. Underdiagnosis was most prevalent among girls and was associated with a low tendency to report symptoms and with several independent risk factors that may help identification of previously undiagnosed asthmatic patients.	Odense Univ Hosp, Dept Med C, Sect Resp Dis, DK-5000 Odense C, Denmark; Odense Univ Hosp, Dept Cardiol, DK-5000 Odense, Denmark; Odense Univ, Ctr Hlth & Social Policy, DK-5230 Odense M, Denmark; Private Specialist Clin, DK-5000 Odense C, Denmark	University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Odense University Hospital; University of Southern Denmark	Siersted, HC (corresponding author), Odense Univ Hosp, Dept Med C, Sect Resp Dis, DK-5000 Odense C, Denmark.							BAUMAN A, 1992, AUST NZ J MED, V22, P36, DOI 10.1111/j.1445-5994.1992.tb01706.x; CLOUGH JB, 1991, AM REV RESPIR DIS, V143, P755, DOI 10.1164/ajrccm/143.4_Pt_1.755; CUIJPERS CEJ, 1994, J ASTHMA, V31, P301, DOI 10.3109/02770909409089477; Cunningham J, 1996, AM J RESP CRIT CARE, V153, P218, DOI 10.1164/ajrccm.153.1.8542119; DuranTauleria E, 1996, BRIT MED J, V313, P148, DOI 10.1136/bmj.313.7050.148; HANNAWAY PJ, 1982, JAMA-J AM MED ASSOC, V247, P206, DOI 10.1001/jama.247.2.206; HANSEN HS, 1990, J HYPERTENS, V8, P641, DOI 10.1097/00004872-199007000-00007; Husman T, 1996, SCAND J WORK ENV HEA, V22, P5, DOI 10.5271/sjweh.103; Joyce DP, 1996, CHEST, V109, P697, DOI 10.1378/chest.109.3.697; KOLNAAR BGM, 1994, FAM PRACT, V11, P133, DOI 10.1093/fampra/11.2.133; KUHN CE, 1995, PEDIATR PULM, V19, P156, DOI 10.1002/ppul.1950190303; Mostgaard G, 1997, RESP MED, V91, P443, DOI 10.1016/S0954-6111(97)90108-6; NISH WA, 1992, ANN ALLERGY, V69, P239; NORUSIS MJ, 1990, SPSS PC PLUS ADV STA; OCONNOR G, 1987, AM REV RESPIR DIS, V136, P1412, DOI 10.1164/ajrccm/136.6.1412; PEAT JK, 1987, CLIN ALLERGY, V17, P283, DOI 10.1111/j.1365-2222.1987.tb02016.x; QUANJER PH, 1983, B EUR PHYSIOPATH RES, V19, P1; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P941, DOI 10.1111/j.1365-2222.1993.tb00279.x; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P957, DOI 10.1111/j.1365-2222.1993.tb00281.x; SEARS MR, 1991, ASTHMA ITS PATHOLOGY; SIERSTED HC, 1994, AM J RESP CRIT CARE, V149, P598, DOI 10.1164/ajrccm.149.3.8118624; Siersted HC, 1996, THORAX, V51, P503, DOI 10.1136/thx.51.5.503; SPEIGHT AN, 1978, BRIT MED J, V29, P331; SPEIGHT ANP, 1983, BRIT MED J, V286, P1253, DOI 10.1136/bmj.286.6373.1253; TANNER JM, 1976, ARCH DIS CHILD, V51, P170, DOI 10.1136/adc.51.3.170; TOELLE BG, 1992, AM REV RESPIR DIS, V146, P633, DOI 10.1164/ajrccm/146.3.633; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	27	142	143	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 28	1998	316	7132					651	655		10.1136/bmj.316.7132.651	http://dx.doi.org/10.1136/bmj.316.7132.651			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA282	9522784	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000072347900021
J	Granzin, J; Wilden, U; Choe, HW; Labahn, J; Krafft, B; Buldt, G				Granzin, J; Wilden, U; Choe, HW; Labahn, J; Krafft, B; Buldt, G			X-ray crystal structure of arrestin from bovine rod outer segments	NATURE			English	Article							CYCLIC-NUCLEOTIDE CASCADE; PHOSPHORYLATED RHODOPSIN; PHOSPHODIESTERASE ACTIVATION; 48-KDA PROTEIN; BINDING; TRANSDUCIN; VISION; GTP	Retinal arrestin is the essential protein for the termination of the light response in vertebrate rod outer segments. It plays an important role in quenching the light-induced enzyme cascade by its ability to bind to phosphorylated light-activated rhodopsin (P-Rh*). Arrestins are found in various G-protein-coupled amplification cascades. Here we report on the three-dimensional structure of bovine arrestin (relative molecular mass, 45,300) at 3.3 Angstrom resolution. The crystal structure comprises two domains of antiparallel beta-sheets connected through a hinge region and one short alpha-helix on the back of the amino-terminal fold. The binding region for phosphorylated light-activated rhodopsin is located at the N-terminal domain, as indicated by the docking of the photoreceptor to the three-dimensional structure of arrestin. This ag rees with the interpretation of binding studies on partially digested and mutated arrestin.	Forschungszentrum Julich, Inst Biol Informationsverarbeitung, D-52425 Julich, Germany; Chonbuk Natl Univ, Coll Nat Sci, Dept Chem, Chongju 560756, South Korea	Helmholtz Association; Research Center Julich; Jeonbuk National University	Granzin, J (corresponding author), Forschungszentrum Julich, Inst Biol Informationsverarbeitung, Postfach 1913, D-52425 Julich, Germany.	J.Granzin@fz-juelich.de	Granzin, Joachim/G-8937-2013; Buldt, Georg/K-5345-2013; Labahn, Jörg/G-9593-2013; Büldt, Georg/H-9509-2014	Granzin, Joachim/0000-0001-6604-950X; Labahn, Jörg/0000-0002-0648-8145; 				Attwood TK, 1997, NUCLEIC ACIDS RES, V25, P212, DOI 10.1093/nar/25.1.212; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1992, X PLOR VERSION 3 1 3; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FUNG BKK, 1980, P NATL ACAD SCI-BIOL, V77, P2500, DOI 10.1073/pnas.77.5.2500; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; Gurevich VV, 1997, MOL PHARMACOL, V51, P161, DOI 10.1124/mol.51.1.161; HOLM L, 1994, NUCLEIC ACIDS RES, V22, P3600; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KLEYWEGT GJ, 1996, CCP4 ESF EACBM NEWSL, V32, P32; KUHN H, 1978, BIOCHEMISTRY-US, V17, P4389; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MILLER JL, 1986, BIOCHEMISTRY-US, V25, P4983, DOI 10.1021/bi00366a002; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P18649; Pogozheva ID, 1997, BIOPHYS J, V72, P1963, DOI 10.1016/S0006-3495(97)78842-8; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; SHINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6975, DOI 10.1073/pnas.84.20.6975; UCHIDA S, 1981, J CYCLIC NUCL PROT, V7, P95; VUONG TM, 1984, NATURE, V311, P659, DOI 10.1038/311659a0; WILDEN U, 1995, BIOCHEMISTRY-US, V34, P1446, DOI 10.1021/bi00004a040; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1986, FEBS LETT, V207, P292, DOI 10.1016/0014-5793(86)81507-1; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; Wilden U, 1997, FEBS LETT, V415, P268, DOI 10.1016/S0014-5793(97)01137-X; XINYU Z, 1995, BIOPHYS CHEM, V56, P183	28	188	194	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 26	1998	391	6670					918	921		10.1038/36147	http://dx.doi.org/10.1038/36147			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ206	9495348				2022-12-28	WOS:000072230900059
J	Godfrey-Faussett, P; Mwinga, A; Hosp, M; Baggaley, R; Quigley, M; Porter, J				Godfrey-Faussett, P; Mwinga, A; Hosp, M; Baggaley, R; Quigley, M; Porter, J			Ethics and international research - Obtaining informed consent for trials in Africa is possible	BRITISH MEDICAL JOURNAL			English	Letter									Univ Teaching Hosp, Dept Med, Lusaka, Zambia; Kara Counselling & Training Trust, Lusaka, Zambia; Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England	University of Zambia; University of London; London School of Hygiene & Tropical Medicine	Godfrey-Faussett, P (corresponding author), Univ Teaching Hosp, Dept Med, POB 50110, Lusaka, Zambia.		Kitchen, Maria/AAN-4964-2020	Kitchen, Maria/0000-0003-1391-0532; Quigley, Maria/0000-0002-8058-6181				GODFREYFAUSSETT P, 1995, T ROY SOC TROP MED H, V89, P354, DOI 10.1016/0035-9203(95)90005-5; Mhlongo SWP, 1997, BRIT MED J, V315, P252	2	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 21	1998	316	7131					627	628						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ031	9518929				2022-12-28	WOS:000072213200050
J	McNamee, D				McNamee, D			Fast-track publication at The Lancet	LANCET			English	Editorial Material									Lancet, London WC1B 3SL, England		McNamee, D (corresponding author), Lancet, London WC1B 3SL, England.							Cooper DA, 1997, LANCET, V349, P1413, DOI 10.1016/S0140-6736(97)04441-3; Davis DL, 1997, LANCET, V350, P1341, DOI 10.1016/S0140-6736(97)10209-4; Gurfinkel E, 1997, LANCET, V350, P404, DOI 10.1016/S0140-6736(97)07201-2; Hall AS, 1997, LANCET, V349, P1493, DOI 10.1016/S0140-6736(97)04442-5; McNamee D, 1997, LANCET, V349, P970, DOI 10.1016/S0140-6736(05)62891-7; Nashan B, 1997, LANCET, V350, P1193, DOI 10.1016/S0140-6736(97)09278-7; Saunders M, 1997, LANCET, V350, P161, DOI 10.1016/S0140-6736(97)06305-8; Wilson RD, 1998, LANCET, V351, P242	8	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 21	1998	351	9102					542	542		10.1016/S0140-6736(05)78553-6	http://dx.doi.org/10.1016/S0140-6736(05)78553-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ216	9492771				2022-12-28	WOS:000072231900007
J	Ramos, PC; Hockendorff, J; Johnson, ES; Varshavsky, A; Dohmen, RJ				Ramos, PC; Hockendorff, J; Johnson, ES; Varshavsky, A; Dohmen, RJ			Ump1p is required for proper maturation of the 20S proteasome and becomes its substrate upon completion of the assembly	CELL			English	Article							N-END RULE; YEAST SACCHAROMYCES-CEREVISIAE; PROTEIN-DEGRADATION; SHUTTLE VECTORS; UBIQUITIN; PATHWAY; SUBUNIT; ENZYME; GENE; CONSTRUCTION	We report the discovery of a short-lived chaperone that is required for the correct maturation of the eukaryotic 20S proteasome and is destroyed at a specific stage of the assembly process. The S. cerevisiae Ump1p protein is a component of proteasome precursor complexes containing unprocessed beta subunits but is not detected in the mature 20S proteasome. Upon the association of two precursor complexes, Ump1p is encased and is rapidly degraded after the proteolytic sites in the interior of the nascent proteasome are activated. Cells lacking Ump1p exhibit a lack of coordination between the processing of beta subunits and proteasome assembly, resulting in functionally impaired proteasomes. We also show that the propeptide of the PreSp/Doa3p beta subunit is required for Ump1p's function in proteasome maturation.	Univ Dusseldorf, Biotechnol Zentrallabor Inst Mikrobiol, D-40225 Dusseldorf, Germany; CALTECH, Div Biol, Pasadena, CA 91125 USA; Rockefeller Univ, Cell Biol Lab, New York, NY 10021 USA	Heinrich Heine University Dusseldorf; California Institute of Technology; Rockefeller University	Dohmen, RJ (corresponding author), Univ Dusseldorf, Biotechnol Zentrallabor Inst Mikrobiol, Univ Str 1,Geb 25-02, D-40225 Dusseldorf, Germany.		Dohmen, R. Jürgen/AAD-6649-2022	Dohmen, R. Jürgen/0000-0002-5756-6780	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031530] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31530] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; Arendt CS, 1997, P NATL ACAD SCI USA, V94, P7156, DOI 10.1073/pnas.94.14.7156; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BAKER RT, 1995, J BIOL CHEM, V270, P12065, DOI 10.1074/jbc.270.20.12065; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; Chen P, 1996, CELL, V86, P961, DOI 10.1016/S0092-8674(00)80171-3; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; DOHMEN RJ, 1995, J BIOL CHEM, V270, P18099, DOI 10.1074/jbc.270.30.18099; DOHMEN RJ, 1994, SCIENCE, V263, P1273, DOI 10.1126/science.8122109; FISCHER M, 1994, FEBS LETT, V355, P69, DOI 10.1016/0014-5793(94)01177-X; FRENTZEL S, 1994, J MOL BIOL, V236, P975, DOI 10.1016/0022-2836(94)90003-5; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; Hochstrasser M, 1995, COLD SPRING HARB SYM, V60, P503, DOI 10.1101/SQB.1995.060.01.054; HOCHSTRASSER M, 1990, CELL, V61, P697, DOI 10.1016/0092-8674(90)90481-S; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOUGH R, 1987, J BIOL CHEM, V262, P8303; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; LIU HP, 1992, GENETICS, V132, P665; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Lupas A, 1997, TRENDS BIOCHEM SCI, V22, P399, DOI 10.1016/S0968-0004(97)01117-1; Nandi D, 1997, EMBO J, V16, P5363, DOI 10.1093/emboj/16.17.5363; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; Ramos PCR, 1995, AUST J PLANT PHYSIOL, V22, P893, DOI 10.1071/PP9950893; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Schmidtke G, 1997, J MOL BIOL, V268, P95, DOI 10.1006/jmbi.1997.0947; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; Seemuller E, 1996, NATURE, V382, P468, DOI 10.1038/382468a0; SIKORSKI RS, 1989, GENETICS, V122, P19; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; YANG Y, 1995, J BIOL CHEM, V270, P27687, DOI 10.1074/jbc.270.46.27687	40	241	252	0	6	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 20	1998	92	4					489	499		10.1016/S0092-8674(00)80942-3	http://dx.doi.org/10.1016/S0092-8674(00)80942-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YZ409	9491890	Bronze			2022-12-28	WOS:000072251500009
J	Webber, AL; Ingram, RS; Levorse, JM; Tilghman, SM				Webber, AL; Ingram, RS; Levorse, JM; Tilghman, SM			Location of enhancers is essential for the imprinting of H19 and Igf2 genes	NATURE			English	Article							BETA-GLOBIN; MOUSE; METHYLATION; MICE; EXPRESSION; BOUNDARIES; DELETION; DOMAINS; ALLELE; ASSAY	Genomic imprinting is the process in mammals by which gamete-specific epigenetic modifications establish the differential expression of the two alleles of a gene, The tightly linked H19 and Igf2 genes are expressed in tissues of endodermal and mesodermal origin, with H19 expressed from the maternal chromosome and Igf2 expressed from the paternal chromosome, A model has been proposed to explain the reciprocal imprinting of these genes(1); in this model, expression of the genes is governed by competition between their promoters for a common set of enhancers. An extra set of enhancers might be predicted to relieve the competition, thereby eliminating imprinting, Here we tested this prediction by generating mice with a duplication of the endoderm-specific enhancers, The normally silent Igf2 gene on the maternal chromosome was expressed in liver, consistent with relief from competition. We then generated a maternal chromosome containing a single set of enhancers located equidistant from Igf2 and H19; the direction of the imprint was reversed, Thus, the location of the enhancers determines the outcome of competition in liver, and the strength of the H19 promoter is not sufficient to silence Igf2.	Princeton Univ, Howard Hughes Med Inst, Princeton, NJ 08544 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Howard Hughes Medical Institute; Princeton University; Princeton University	Tilghman, SM (corresponding author), Princeton Univ, Howard Hughes Med Inst, Princeton, NJ 08544 USA.							AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; Bartolomei M.S., 1992, SEMIN DEV BIOL, V3, P107; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; BRANDEIS M, 1993, EMBO J, V12, P3669, DOI 10.1002/j.1460-2075.1993.tb06041.x; BRUNKOW ME, 1991, GENE DEV, V5, P1092, DOI 10.1101/gad.5.6.1092; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; FEIL R, 1994, DEVELOPMENT, V120, P2933; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FERGUSONSMITH AC, 1993, NATURE, V362, P751, DOI 10.1038/362751a0; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; JOHNSON KA, 1995, NUCLEIC ACIDS RES, V23, P1273, DOI 10.1093/nar/23.7.1273; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KELLUM R, 1992, MOL CELL BIOL, V12, P2424, DOI 10.1128/MCB.12.5.2424; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LEIGHTON PA, 1995, GENE DEV, V9, P2079, DOI 10.1101/gad.9.17.2079; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Lyko F, 1997, NAT GENET, V16, P171, DOI 10.1038/ng0697-171; MCCARRICK JW, 1993, TRANSGENIC RES, V2, P183, DOI 10.1007/BF01977348; NICKOL JM, 1988, P NATL ACAD SCI USA, V85, P2548, DOI 10.1073/pnas.85.8.2548; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; Ripoche MA, 1997, GENE DEV, V11, P1596, DOI 10.1101/gad.11.12.1596; SASAKI H, 1992, GENE DEV, V6, P1843, DOI 10.1101/gad.6.10.1843; SAUER B, 1990, New Biologist, V2, P441; Walter J., 1996, Epigenetic mechanisms of gene regulation., P195; YOOWARREN H, 1988, MOL CELL BIOL, V8, P4707, DOI 10.1128/MCB.8.11.4707	28	110	116	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 12	1998	391	6668					711	715		10.1038/35655	http://dx.doi.org/10.1038/35655			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW872	9490417				2022-12-28	WOS:000071982500057
J	Caldicott, CV				Caldicott, CV			What's wrong with this medical student today? - Dysfluency on inpatient rounds	ANNALS OF INTERNAL MEDICINE			English	Article							DIAGNOSIS; LANGUAGE		SUNY Hlth Sci Ctr, Dept Med, Syracuse, NY 13202 USA; Univ Michigan, Ann Arbor, MI 48109 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; University of Michigan System; University of Michigan	Caldicott, CV (corresponding author), SUNY Hlth Sci Ctr, Dept Med, 90 Presidential Plaza, Syracuse, NY 13202 USA.							ANSPACH RR, 1988, J HEALTH SOC BEHAV, V29, P357, DOI 10.2307/2136869; Bateson G., 1972, STEPS ECOLOGY MIND C; BURNUM JF, 1993, ANN INTERN MED, V119, P939, DOI 10.7326/0003-4819-119-9-199311010-00012; CASSELL EJ, 1985, TALKING PATIENTS, V1; DONNELLY WJ, 1986, PERSPECT BIOL MED, V30, P81; DuBois John W., 1992, SANTA BARBARA PAPERS; DUFFY TP, 1992, NEW ENGL J MED, V326, P394, DOI 10.1056/NEJM199202063260607; Hill JH, 1996, DIALOGIC EMERGENCE C, P97; Lipkin MJ, 1995, MED INTERVIEW CLIN C; Mishler EG, 1984, DISCOURSE MED DIALEC; Nizami Khaliq Ahmad, 1992, TALK WORK INTERACTIO, P3, DOI DOI 10.2277/0521376335; SACKS H, 1974, LANGUAGE, V50, P696, DOI 10.2307/412243; Todd A. D., 1993, SOCIAL ORG DOCTOR PA; West C., 1984, ROUTINE COMPLICATION	14	5	5	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1998	128	7					607	610		10.7326/0003-4819-128-7-199804010-00037	http://dx.doi.org/10.7326/0003-4819-128-7-199804010-00037			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZE539	9518424				2022-12-28	WOS:000072803500036
J	Canac, Y; Bourissou, D; Baceiredo, A; Gornitzka, H; Schoeller, WW; Bertrand, G				Canac, Y; Bourissou, D; Baceiredo, A; Gornitzka, H; Schoeller, WW; Bertrand, G			Isolation of a benzene valence isomer with one-electron phosphorus-phosphorus bonds	SCIENCE			English	Article							3-MEMBERED RINGS; C6H6 ISOMERS; 1,3,5-TRIPHOSPHABENZENE; HETEROCYCLES; CHEMISTRY; ELEMENTS	A tetraphosphabenzene analog of the postulated anti-tricyclohexylene, a singlet biradical valence isomer of benzene, has been isolated. The tricyclic derivative features one-electron phosphorus-phosphorus bonds, which result from the pi*-pi* interaction between two diphosphirenyl radicals. Such one-electron bonds may play a wider role in phosphorus chemistry.	CNRS, Chim Coordinat Lab, F-31077 Toulouse, France; Univ Bielefeld, Fak Chem, D-33615 Bielefeld, Germany	Centre National de la Recherche Scientifique (CNRS); University of Bielefeld	Schoeller, WW (corresponding author), CNRS, Chim Coordinat Lab, 205 Route Narbonne, F-31077 Toulouse, France.	gbertran@lcctoul.lcc-toulouse.fr	Schoeller, Wolfgang W/A-5755-2011; Bourissou, Didier/F-7761-2014					Ando W, 1997, J AM CHEM SOC, V119, P3629, DOI 10.1021/ja9637412; ASHE AJ, 1995, ANGEW CHEM INT EDIT, V34, P1357, DOI 10.1002/anie.199513571; ASHE AJ, 1971, J AM CHEM SOC, V93, P3293, DOI 10.1021/ja00742a038; Avarvari N, 1996, J AM CHEM SOC, V118, P11978, DOI 10.1021/ja962736v; BALABAN AT, 1966, REV ROUM CHIM, V11, P1097; BARRON AR, 1987, ANGEW CHEM INT EDIT, V26, P907, DOI 10.1002/anie.198709071; Beck J, 1997, COORDIN CHEM REV, V163, P55, DOI 10.1016/S0010-8545(97)00009-X; BILLUPS WE, 1989, ANGEW CHEM INT EDIT, V28, P1711, DOI 10.1002/anie.198917111; BINGER P, 1995, ANGEW CHEM INT EDIT, V34, P2227, DOI 10.1002/anie.199522271; BOCK H, 1989, ANGEW CHEM INT EDIT, V28, P1627, DOI 10.1002/anie.198916271; BOHM D, 1995, ANGEW CHEM INT EDIT, V34, P198, DOI 10.1002/anie.199501981; BOURISSOU D, 1997, J CHEM SOC CHEM COMM, P2399; BRESLOW R, 1959, J AM CHEM SOC, V81, P4747, DOI 10.1021/ja01526a077; BRESLOW R, 1965, J AM CHEM SOC, V87, P5139, DOI 10.1021/ja00950a028; BYUN YG, 1991, J AM CHEM SOC, V113, P3689, DOI 10.1021/ja00010a009; CHIPMAN DM, 1984, J AM CHEM SOC, V106, P6236, DOI 10.1021/ja00333a020; CHRISTL M, 1992, ANGEW CHEM INT EDIT, V31, P473, DOI 10.1002/anie.199204731; COWLEY AH, 1965, CHEM REV, V65, P617, DOI 10.1021/cr60238a001; DUBAUASSIBAT N, 1996, J AM CHEM SOC, V118, P516; DULMAGE WJ, 1953, ACTA CRYSTALLOGR, V6, P760, DOI 10.1107/S0365110X53002179; DURIG JR, 1974, J AM CHEM SOC, V96, P2688, DOI 10.1021/ja00816a004; FRANCL MM, 1982, J CHEM PHYS, V77, P3654, DOI 10.1063/1.444267; GLEITER R, 1980, Z NATURFORSCH B, V35, P1166; GUTMAN I, 1994, J CHEM EDUC, V71, P222, DOI 10.1021/ed071p222; HARIHARAN PC, 1972, CHEM PHYS LETT, V16, P217, DOI 10.1016/0009-2614(72)80259-8; HOIC DA, 1995, J AM CHEM SOC, V117, P8480, DOI 10.1021/ja00137a030; Johnson RP, 1996, J AM CHEM SOC, V118, P7381, DOI 10.1021/ja961066q; Katritzky A. R., 1996, COMPREHENSIVE HETERO, V1st; KATZ TJ, 1973, J AM CHEM SOC, V95, P2738, DOI 10.1021/ja00789a084; KLAPOTKE T, 1989, ACCOUNTS CHEM RES, V22, P234, DOI 10.1021/ar00163a002; KOBAYASHI Y, 1976, TETRAHEDRON LETT, P3715; KOBAYASHI Y, 1980, J AM CHEM SOC, V102, P252, DOI 10.1021/ja00521a039; KUKOLICH SG, 1982, J AM CHEM SOC, V104, P4715, DOI 10.1021/ja00381a052; LEUNG YC, 1956, J PHYS CHEM-US, V60, P539, DOI 10.1021/j150539a007; LIDE DR, 1992, CRC HDB CHEM PHYSICS; LIPSCOMB WN, 1961, ACTA CRYSTALLOGR, V14, P1100, DOI 10.1107/S0365110X61003259; MAEDA Y, 1979, J AM CHEM SOC, V101, P837, DOI 10.1021/ja00498a010; MARKL G, 1966, ANGEW CHEM INT EDIT, V5, P846, DOI 10.1002/anie.196608463; MARKL G, 1990, MULTIPLE BONDS LOW C, P220; MATHEY F, 1990, CHEM REV, V90, P997, DOI 10.1021/cr00104a004; NORMAN NC, 1993, POLYHEDRON, V12, P2431, DOI 10.1016/S0277-5387(00)83067-3; PASSMORE J, 1980, J CHEM SOC CHEM COMM, P289, DOI 10.1039/c39800000289; Qiao S, 1996, J AM CHEM SOC, V118, P6329, DOI 10.1021/ja960938l; REGITZ M, 1990, MULTIPLE BONDS LOW C; SCHERER OJ, 1985, ANGEW CHEM INT EDIT, V24, P351, DOI 10.1002/anie.198503511; SCHLEGEL HB, 1986, J CHEM PHYS, V84, P4530, DOI 10.1063/1.450026; Schlegel HB., 2009, GAUSSIAN 09 REVISION; Schoeller WW, 1997, J CHEM SOC FARADAY T, V93, P2957, DOI 10.1039/a701636k; SHAKESPEARE WC, 1990, J AM CHEM SOC, V112, P8578, DOI 10.1021/ja00179a050; Tokitoh N, 1997, J AM CHEM SOC, V119, P6951, DOI 10.1021/ja9710924; VANTAMELEN EE, 1963, J AM CHEM SOC, V85, P3297, DOI 10.1021/ja00903a056; WARREN DS, 1992, J AM CHEM SOC, V114, P5378, DOI 10.1021/ja00039a058; WEISS R, 1975, J AM CHEM SOC, V97, P3224, DOI 10.1021/ja00844a054; WILZBACH KE, 1967, J AM CHEM SOC, V89, P1031, DOI 10.1021/ja00980a053	54	63	63	1	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 27	1998	279	5359					2080	2082		10.1126/science.279.5359.2080	http://dx.doi.org/10.1126/science.279.5359.2080			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZE274	9516102				2022-12-28	WOS:000072775600038
J	Gilman, S				Gilman, S			Medical progress - Imaging the brain - Second of two parts	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							POSITRON EMISSION TOMOGRAPHY; MULTIPLE SYSTEM ATROPHY; ALZHEIMERS-DISEASE; PARKINSONS-DISEASE; SUPRANUCLEAR PALSY; FRIEDREICHS ATAXIA; HEAD-INJURY; MR FINDINGS; CT; MENINGITIS		Univ Michigan, Dept Neurol, Ann Arbor, MI USA	University of Michigan System; University of Michigan	Gilman, S (corresponding author), Univ Michigan, Med Ctr, 1500 E Med Ctr Dr,TC 1914, Ann Arbor, MI 48109 USA.				NIAAA NIH HHS [AA07378] Funding Source: Medline; NIA NIH HHS [AG08671] Funding Source: Medline; NINDS NIH HHS [NS07222] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P50AG008671] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA007378] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ADELMAN JU, 1995, NEUROIMAGING COMPANI, P83; Albin RL, 1996, NEUROLOGY, V47, P462, DOI 10.1212/WNL.47.2.462; Antinori A, 1997, NEUROLOGY, V48, P687, DOI 10.1212/WNL.48.3.687; Arnder L, 1996, J COMPUT ASSIST TOMO, V20, P1023, DOI 10.1097/00004728-199611000-00031; ASHWAL S, 1992, NEUROLOGY, V42, P739, DOI 10.1212/WNL.42.4.739; Aylward EH, 1997, NEUROLOGY, V48, P394, DOI 10.1212/WNL.48.2.394; Barone R, 1996, AM J MED GENET, V63, P209; BERENGUER J, 1992, NEW ENGL J MED, V326, P668, DOI 10.1056/NEJM199203053261004; BONTE FJ, 1990, SEMIN NUCL MED, V20, P342, DOI 10.1016/S0001-2998(05)80238-7; BROOKS DJ, 1992, ANN NEUROL, V31, P184, DOI 10.1002/ana.410310209; BYRNE TN, 1994, SEMIN ONCOL, V21, P162; Cooney BS, 1996, HEADACHE, V36, P616, DOI 10.1046/j.1526-4610.1996.3610616.x; Deresiewicz RL, 1997, NEW ENGL J MED, V336, P1867, DOI 10.1056/NEJM199706263362604; DUARA R, 1992, CLIN BRAIN IMAGING P, P294; EIDELBERG D, 1991, J NEUROL NEUROSUR PS, V54, P856, DOI 10.1136/jnnp.54.10.856; Eldevik OP, 1996, AM J NEURORADIOL, V17, P1427; Evans AC, 1997, ANN NEUROL, V41, P125, DOI 10.1002/ana.410410123; Filippi M, 1996, ANN NEUROL, V40, P901, DOI 10.1002/ana.410400612; FOSTER NL, 1988, ANN NEUROL, V24, P399, DOI 10.1002/ana.410240308; GILMAN S, 1994, ANN NEUROL, V36, P166, DOI 10.1002/ana.410360208; GILMAN S, 1990, ANN NEUROL, V28, P750, DOI 10.1002/ana.410280605; GIMENEZROLDAN S, 1994, J NEURAL TRANSM-SUPP, P79; Ginsberg LE, 1996, J NEURO-ONCOL, V29, P229, DOI 10.1007/BF00165653; JINKINS JR, 1995, RADIOL CLIN N AM, V33, P771; KERMODE AG, 1990, NEUROLOGY, V40, P229, DOI 10.1212/WNL.40.2.229; KUHN MJ, 1994, COMPUT MED IMAG GRAP, V18, P391, DOI 10.1016/0895-6111(94)90011-6; Laakso MP, 1996, NEUROLOGY, V46, P678, DOI 10.1212/WNL.46.3.678; MacNamara AF, 1995, INJURY, V26, P667, DOI 10.1016/0020-1383(95)00147-6; MASCALCHI M, 1994, AM J ROENTGENOL, V163, P187, DOI 10.2214/ajr.163.1.8010211; MAYR NA, 1994, AM J NEURORADIOL, V15, P1053; MAZZIOTTA JC, 1992, SEMIN NUCL MED, V22, P233, DOI 10.1016/S0001-2998(05)80118-7; MAZZIOTTA JC, 1989, SEMIN NEUROL, V9, P360, DOI 10.1055/s-2008-1041346; Mazziotta JC, 1992, CLIN BRAIN IMAGING P, P244; MinamikawaTachino R, 1996, BRAIN DEV-JPN, V18, P394, DOI 10.1016/0387-7604(96)00040-X; MINOSHIMA S, 1995, J NUCL MED, V36, P1238; Minoshima S, 1997, ANN NEUROL, V42, P85, DOI 10.1002/ana.410420114; MORAN SG, 1994, AM SURGEON, V60, P533; ORMEROD IEC, 1994, J NEUROL NEUROSUR PS, V57, P51, DOI 10.1136/jnnp.57.1.51; SALCMAN M, 1992, NEUROCHIRURGIE, V38, P329; SAWLE GV, 1991, BRAIN, V114, P541, DOI 10.1093/brain/114.1.541; Schatz IJ, 1996, NEUROLOGY, V46, P1470, DOI 10.1212/wnl.46.5.1470; SCHULZ JB, 1994, J NEUROL NEUROSUR PS, V57, P1047, DOI 10.1136/jnnp.57.9.1047; Stout JC, 1996, ARCH NEUROL-CHICAGO, V53, P742, DOI 10.1001/archneur.1996.00550080056013; UCHINO A, 1991, NEURORADIOLOGY, V33, P364, DOI 10.1007/BF00587828; VanderBorght T, 1997, J NUCL MED, V38, P797; WEINGARTEN S, 1992, ARCH INTERN MED, V152, P2457, DOI 10.1001/archinte.152.12.2457; WERNER MH, 1995, CANCER, V76, P1634, DOI 10.1002/1097-0142(19951101)76:9<1634::AID-CNCR2820760921>3.0.CO;2-0; WOHL TA, 1991, AM J OPHTHALMOL, V112, P689, DOI 10.1016/S0002-9394(14)77276-9; WROBEL CJ, 1992, AM J NEURORADIOL, V13, P1241; WU W, 1995, ACTA RADIOL, V36, P529; Yagishita Y, 1996, NEURORADIOLOGY, V38, pS60; ZIMMERMAN RA, 1991, CANCER, V67, P1278, DOI 10.1002/1097-0142(19910215)67:4+<1278::AID-CNCR2820671526>3.0.CO;2-U	52	39	40	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 26	1998	338	13					889	896		10.1056/NEJM199803263381307	http://dx.doi.org/10.1056/NEJM199803263381307			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD284	9516225				2022-12-28	WOS:000072669800007
J	Alvarez, ME; Pennell, RI; Meijer, PJ; Ishikawa, A; Dixon, RA; Lamb, C				Alvarez, ME; Pennell, RI; Meijer, PJ; Ishikawa, A; Dixon, RA; Lamb, C			Reactive oxygen intermediates mediate a systemic signal network in the establishment of plant immunity	CELL			English	Article							DISEASE RESISTANCE RESPONSE; ACQUIRED-RESISTANCE; SALICYLIC-ACID; CELL-DEATH; ARABIDOPSIS-THALIANA; GENE; APOPTOSIS; TRANSDUCTION; EXPRESSION; INFECTION	Recognition of an avirulent pathogen stimulates an oxidative burst generating O-2(-) and H2O2, and these reactive oxygen intermediates (ROIs) cue the induction of defense genes and cell death in the development of a restricted lesion. This localized hypersensitive response (HR) is accompanied by the development of systemic acquired resistance to virulent pathogens. Here we show that inoculation of Arabidopsis leaves with avirulent Pseudomonas syringae induces secondary oxidative bursts in discrete cells in distant tissues, leading to low-frequency systemic micro-HRs. The primary oxidative burst induces these systemic responses, and both the primary burst and the secondary microbursts are required for systemic immunity. Hence, ROIs mediate a reiterative signal network underlying systemic as well as local resistance responses.	Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA; Samuel Roberts Noble Fdn Inc, Div Plant Biol, Ardmore, OK 73402 USA	Salk Institute; Noble Research Institute	Lamb, C (corresponding author), Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA.			Alvarez, Maria Elena/0000-0001-7001-5898				Bauerle PA, 1996, CELL, V87, P13; BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; Bent AF, 1996, PLANT CELL, V8, P1757, DOI 10.1105/tpc.8.10.1757; Bestwick CS, 1997, PLANT CELL, V9, P209, DOI 10.1105/tpc.9.2.209; Breda C, 1996, MOL PLANT MICROBE IN, V9, P713, DOI 10.1094/MPMI-9-0713; Buschges R, 1997, CELL, V88, P695, DOI 10.1016/S0092-8674(00)81912-1; CAMERON RK, 1994, PLANT J, V5, P715, DOI 10.1111/j.1365-313X.1994.00715.x; Cao H, 1997, CELL, V88, P57, DOI 10.1016/S0092-8674(00)81858-9; Creelman RA, 1997, ANNU REV PLANT PHYS, V48, P355, DOI 10.1146/annurev.arplant.48.1.355; Dangl JL, 1996, PLANT CELL, V8, P1793, DOI 10.1105/tpc.8.10.1793; Dietrich RA, 1997, CELL, V88, P685, DOI 10.1016/S0092-8674(00)81911-X; DOARES SH, 1995, P NATL ACAD SCI USA, V92, P4095, DOI 10.1073/pnas.92.10.4095; Glazener JA, 1996, PLANT PHYSIOL, V110, P759, DOI 10.1104/pp.110.3.759; Gray J, 1997, CELL, V89, P25, DOI 10.1016/S0092-8674(00)80179-8; HammondKosack KE, 1996, PLANT CELL, V8, P1773, DOI 10.1105/tpc.8.10.1773; HammondKosack KE, 1996, PLANT PHYSIOL, V110, P1381, DOI 10.1104/pp.110.4.1381; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Jabs T, 1996, SCIENCE, V273, P1853, DOI 10.1126/science.273.5283.1853; KOCH E, 1990, PLANT CELL, V2, P437, DOI 10.1105/tpc.2.5.437; Lamb C, 1997, ANNU REV PLANT PHYS, V48, P251, DOI 10.1146/annurev.arplant.48.1.251; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; Levine A, 1996, CURR BIOL, V6, P427, DOI 10.1016/S0960-9822(02)00510-9; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; MINDRINOS M, 1994, CELL, V78, P1089, DOI 10.1016/0092-8674(94)90282-8; NEUENSCHWANDER U, 1995, PLANT J, V8, P227, DOI 10.1046/j.1365-313X.1995.08020227.x; Pallas JA, 1996, PLANT J, V10, P281, DOI 10.1046/j.1365-313X.1996.10020281.x; Pennell RI, 1997, PLANT CELL, V9, P1157, DOI 10.1105/tpc.9.7.1157; RASMUSSEN JB, 1991, PLANT PHYSIOL, V97, P1342, DOI 10.1104/pp.97.4.1342; Ryals J, 1997, PLANT CELL, V9, P425, DOI 10.1105/tpc.9.3.425; Ryals JA, 1996, PLANT CELL, V8, P1809, DOI 10.1105/tpc.8.10.1809; Shirasu K, 1997, PLANT CELL, V9, P261, DOI 10.1105/tpc.9.2.261; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; ThordalChristensen H, 1997, PLANT J, V11, P1187, DOI 10.1046/j.1365-313X.1997.11061187.x; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; VERNOOIJ B, 1994, PLANT CELL, V6, P959, DOI 10.1105/tpc.6.7.959; WU G, 1995, PLANT CELL, V7, P619; Wu GS, 1997, PLANT PHYSIOL, V115, P427, DOI 10.1104/pp.115.2.427	38	874	956	2	103	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 20	1998	92	6					773	784		10.1016/S0092-8674(00)81405-1	http://dx.doi.org/10.1016/S0092-8674(00)81405-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZD198	9529253	Bronze			2022-12-28	WOS:000072661200010
J	Stefanadis, C; Vlachopoulos, C; Tsiamis, E; Diamantopoulos, L; Toutouzas, K; Giatrakos, N; Vaina, S; Tsekoura, D; Toutouzas, P				Stefanadis, C; Vlachopoulos, C; Tsiamis, E; Diamantopoulos, L; Toutouzas, K; Giatrakos, N; Vaina, S; Tsekoura, D; Toutouzas, P			Unfavorable effects of passive smoking on aortic function in men	ANNALS OF INTERNAL MEDICINE			English	Article						tobacco smoke pollution; aorta; elasticity; ventricular function, left; coronary circulation	CORONARY-ARTERY DISEASE; HEALTHY-YOUNG ADULTS; CIGARETTE-SMOKING; ASCENDING AORTA; DISTENSIBILITY ABNORMALITIES; HABITUAL SMOKERS; BLOOD-FLOW; VASOCONSTRICTION; TERM; CIRCULATION	Background: The aorta acts as both a conduit and an elastic buffering chamber that modulates left ventricular function and coronary blood flow. Previous studies have shown that active smoking has unfavorable effects on aortic elasticity. Objective: To study the association between passive smoking and the elastic properties of the human aorta. Design: Comparison of nonsmokers during passive smoking studies and smokers during active smoking or sham smoking studies. Setting: Academic medical center. Participants: 16 male nonsmokers were assigned to passive smoking studies, and 32 current, long-term, male smokers were randomly assigned to either active smoking (16 patients) or sham smoking (16 patients) studies. Intervention: All participants underwent diagnostic catheterization. In the passive smoking group, environmental tobacco smoke was vented into an exposure cham-ber for 5 minutes (mean carbon monoxide level, 30 parts per million). Each participant in the active smoking group smoked one filtered cigarette (1.0 mg of nicotine) under standardized conditions within 5 minutes; each participant in the sham smoking group performed a similar pattern of inhalation with one unlit cigarette. Measurements: Aortic elastic properties were studied by measuring the aortic pressure-diameter relation before and for 20 minutes after passive, active, or sham smoking. Instantaneous diameter of the thoracic aorta was measured with a high-fidelity ultrasonic dimension catheter. Instantaneous aortic pressure and diameter were measured at the same site. Results: Both passive and active smoking were associated with changes in the aortic pressure-diameter relation (change in mean distensibility in the passive smoking group, from 2.02 to 1.59 x 10(-6) cm(2) dyne(-1) [for comparisons of time course between passive and sham smoking groups. P < 0.001]; change in mean distensibility in the active smoking group, from 2.08 to 1.51 x 10(-6) cm(2) dyne(-1) [for comparisons of time course between active and sham smoking groups. P < 0.001]). These changes represent decreases of 21% and 27%, respectively. No changes in aortic elasticity were seen in the sham smoking group. Conclusions: Both passive and active smoking are associated with an acute deterioration in the elastic properties of the aorta. This association between exposure to tobacco smoke and aortic elasticity indicates that aortic function deteriorates during passive or active smoking.	Univ Athens, Hippokrat Hosp, Sch Med, Dept Cardiol, Athens 11527, Greece	Athens Medical School; Hippokration General Hospital; National & Kapodistrian University of Athens	Stefanadis, C (corresponding author), 9 Tepeleniou Str, Athens 15452, Greece.		TSEKOURA, Dorothea/AFP-6835-2022; Tsekoura, Dorothea/AAJ-9815-2020; Stefanadis, Christodoulos/ABH-2232-2020; TSEKOURA, Dorothea/AAD-7275-2019	Stefanadis, Christodoulos/0000-0001-5974-6454; TSEKOURA, DOROTHEA/0000-0002-9896-964X				ARONOW WS, 1978, NEW ENGL J MED, V299, P21, DOI 10.1056/NEJM197807062990105; BELZ GG, 1995, CARDIOVASC DRUG THER, V9, P73, DOI 10.1007/BF00877747; BENOWITZ NL, 1988, NEW ENGL J MED, V319, P1318; BERLIN I, 1990, EUR J CLIN PHARMACOL, V38, P57, DOI 10.1007/BF00314804; BINKLEY PF, 1991, CARDIOTONIC DRUGS CL, P37; BOGREN HG, 1989, AM HEART J, V118, P234, DOI 10.1016/0002-8703(89)90181-6; Boudoulas H., 1996, FUNCTIONAL ABNORMALI, P3; BROWN RE, 1993, CIRCULATION, V88, P260; CARO CG, 1987, LANCET, V2, P11; CELERMAJER DS, 1993, CIRCULATION, V88, P2149, DOI 10.1161/01.CIR.88.5.2149; Celermajer DS, 1996, NEW ENGL J MED, V334, P150, DOI 10.1056/NEJM199601183340303; CRYER PE, 1976, NEW ENGL J MED, V295, P573, DOI 10.1056/NEJM197609092951101; CZERNIN J, 1995, CIRCULATION, V91, P2891, DOI 10.1161/01.CIR.91.12.2891; DART AM, 1991, LANCET, V338, P270, DOI 10.1016/0140-6736(91)90415-L; DAVIS JW, 1985, J LAB CLIN MED, V105, P479; DEANFIELD JE, 1986, AM J CARDIOL, V57, P1005, DOI 10.1016/0002-9149(86)90665-X; EVERITT B, 1992, TALKING STAT, P85; GIANNATTASIO C, 1994, J HYPERTENS, V12, P691; ISNARD RN, 1989, J AM COLL CARDIOL, V13, P399, DOI 10.1016/0735-1097(89)90518-4; KELLY RP, 1992, CIRC RES, V71, P490, DOI 10.1161/01.RES.71.3.490; KIOWSKI W, 1994, CIRCULATION, V90, P27, DOI 10.1161/01.CIR.90.1.27; KOOL MJF, 1993, J AM COLL CARDIOL, V22, P1881, DOI 10.1016/0735-1097(93)90773-T; Lekakis J, 1997, AM J CARDIOL, V79, P529, DOI 10.1016/S0002-9149(96)00805-3; MAOUAD J, 1986, CATHETER CARDIO DIAG, V12, P366, DOI 10.1002/ccd.1810120603; Milnor W.R., 1989, HEMODYNAMICS, V2nd, P58; MOLITERNO DJ, 1994, NEW ENGL J MED, V330, P454, DOI 10.1056/NEJM199402173300702; MOREYRA AE, 1992, AM HEART J, V124, P392, DOI 10.1016/0002-8703(92)90603-S; MURGO JP, 1980, CIRCULATION, V62, P105, DOI 10.1161/01.CIR.62.1.105; NADLER JL, 1983, LANCET, V1, P1248; NICHOLS WW, 1990, MCDONALDS BLOOD FLOW, P77; NICHOLS WW, 1990, MCDONALDS BLOOD FLOW, P251; NICOD P, 1984, J AM COLL CARDIOL, V4, P964, DOI 10.1016/S0735-1097(84)80058-3; OHTSUKA S, 1994, J AM COLL CARDIOL, V24, P1406, DOI 10.1016/0735-1097(94)90127-9; QUILLEN JE, 1993, J AM COLL CARDIOL, V22, P642, DOI 10.1016/0735-1097(93)90170-6; STEFANADIS C, 1995, CIRCULATION, V92, P2210, DOI 10.1161/01.CIR.92.8.2210; STEFANADIS C, 1990, EUR HEART J, V11, P990, DOI 10.1093/oxfordjournals.eurheartj.a059639; STEFANADIS C, 1987, AM J CARDIOL, V59, P1300, DOI 10.1016/0002-9149(87)90908-8; Stefanadis C, 1997, CIRCULATION, V96, P1853, DOI 10.1161/01.CIR.96.6.1853; STEFANADIS C, 1994, CHEST, V105, P1017, DOI 10.1378/chest.105.4.1017; Stefanadis C, 1997, CIRCULATION, V95, P31, DOI 10.1161/01.CIR.95.1.31; STEFANADIS C, 1995, CIRCULATION, V91, P2669, DOI 10.1161/01.CIR.91.10.2669; STRATOS C, 1992, AM J MED, V93, P505, DOI 10.1016/0002-9343(92)90577-X; URSCHEL CW, 1968, AM J PHYSIOL, V214, P298, DOI 10.1152/ajplegacy.1968.214.2.298; WATANABE H, 1993, J AM COLL CARDIOL, V21, P1497, DOI 10.1016/0735-1097(93)90330-4; WINNIFORD MD, 1986, CIRCULATION, V73, P662, DOI 10.1161/01.CIR.73.4.662	45	107	111	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1998	128	6					426	+		10.7326/0003-4819-128-6-199803150-00002	http://dx.doi.org/10.7326/0003-4819-128-6-199803150-00002			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA914	9499325				2022-12-28	WOS:000072414700002
J	Barnes, NC				Barnes, NC			Inhaled steroids in COPD	LANCET			English	Editorial Material							ASTHMA		London Chest Hosp, Dept Resp Med, London E2 9JX, England	University of London; Queen Mary University London	Barnes, NC (corresponding author), London Chest Hosp, Dept Resp Med, London E2 9JX, England.							Barnes PJ, 1998, THORAX, V53, P137, DOI 10.1136/thx.53.2.137; *BRIT THOR SOC, 1997, THORAX S5, V52; BURGE PS, 1996, AM J RESP CRIT CARE, V153, pA126; Campbell MJ, 1997, BRIT MED J, V314, P1439, DOI 10.1136/bmj.314.7092.1439; Chanez P, 1997, AM J RESP CRIT CARE, V155, P1529, DOI 10.1164/ajrccm.155.5.9154853; DJUKANOVIC R, 1995, ASTHMA RHINITIS, P118; ERNST P, 1992, JAMA-J AM MED ASSOC, V268, P3462, DOI 10.1001/jama.268.24.3462; JEFFREY PK, 1997, THORAX, V53, P129; Keatings VM, 1997, AM J RESP CRIT CARE, V155, P542, DOI 10.1164/ajrccm.155.2.9032192; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; LlewellynJones CG, 1996, AM J RESP CRIT CARE, V153, P616, DOI 10.1164/ajrccm.153.2.8564107; PAUWELS RA, 1992, EUR RESPIR J, V5, P1254; 1997, THORAX S1, V52; 961 LUNG ASTHM INF A	14	11	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 14	1998	351	9105					766	767		10.1016/S0140-6736(98)22011-3	http://dx.doi.org/10.1016/S0140-6736(98)22011-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB916	9519941				2022-12-28	WOS:000072521200002
J	Block, JA				Block, JA			Hydroxychloroquine and retinal safety	LANCET			English	Editorial Material									Rush Presbyterian St Lukes Med Ctr, Dept Internal Med, Rheumatol Sect, Chicago, IL 60612 USA	Rush University	Block, JA (corresponding author), Rush Presbyterian St Lukes Med Ctr, Dept Internal Med, Rheumatol Sect, Chicago, IL 60612 USA.			Block, Joel/0000-0002-0330-7353				BERNSTEIN HN, 1992, SOUTHERN MED J, V85, P274, DOI 10.1097/00007611-199203000-00010; Easterbrook M, 1997, J RHEUMATOL, V24, P1390; HOBBS HE, 1959, LANCET, V2, P478; Levy GD, 1997, ARTHRITIS RHEUM, V40, P1482, DOI 10.1002/art.1780400817; SCHERBEL AL, 1965, NEW ENGL J MED, V273, P360, DOI 10.1056/NEJM196508122730704; Silman A, 1997, BRIT J RHEUMATOL, V36, P599; WEISE EE, 1974, AM J OPHTHALMOL, V78, P204, DOI 10.1016/0002-9394(74)90077-4	7	38	41	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 14	1998	351	9105					771	771		10.1016/S0140-6736(05)78925-X	http://dx.doi.org/10.1016/S0140-6736(05)78925-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB916	9519945				2022-12-28	WOS:000072521200006
J	Horton, R				Horton, R			The unmasked carnival of science	LANCET			English	Editorial Material									Lancet, London WC1B 3SL, England		Horton, R (corresponding author), Lancet, London WC1B 3SL, England.							Biagioli M, 1998, FASEB J, V12, P3, DOI 10.1096/fasebj.12.1.3; BOYLE J, 1996, SHARMANS SOFTWARE SP; Clever LH, 1997, ANN INTERN MED, V126, P36, DOI 10.7326/0003-4819-126-1-199701010-00006; FYE WB, 1990, ANN INTERN MED, V113, P317, DOI 10.7326/0003-4819-113-4-317; Greenfield B, 1998, JAMA-J AM MED ASSOC, V279, P356, DOI 10.1001/jama.279.5.356; Horton R, 1997, LANCET, V350, P234, DOI 10.1016/S0140-6736(05)62223-4; Horton R, 1997, LANCET, V350, P5, DOI 10.1016/S0140-6736(05)66236-8; JONES AH, 1997, 3 INT C PEER REV BIO; McLellan F, 1997, LIT MED, V16, P88, DOI 10.1353/lm.1997.0007; Parmley WW, 1997, J AM COLL CARDIOL, V29, P702; Rennie D, 1997, JAMA-J AM MED ASSOC, V278, P579, DOI 10.1001/jama.278.7.579; Scott T, 1997, BRIT MED J, V315, P744; Slone RM, 1996, AM J ROENTGENOL, V167, P571, DOI 10.2214/ajr.167.3.8751654; Smith R, 1997, BRIT MED J, V315, P696, DOI 10.1136/bmj.315.7110.696; 1998, NY TIMES        0221, pA24	15	28	29	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 7	1998	351	9104					688	689		10.1016/S0140-6736(98)22010-1	http://dx.doi.org/10.1016/S0140-6736(98)22010-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB359	9504509				2022-12-28	WOS:000072463800002
J	Marahrens, Y; Loring, J; Jaenisch, R				Marahrens, Y; Loring, J; Jaenisch, R			Role of the Xist gene in X chromosome choosing	CELL			English	Article							PARTHENOGENETIC MOUSE EMBRYOS; INACTIVATION CENTER; LINKED GENES; TRANSLOCATION; EXPRESSION; MEMBRANES	In female mammals a "random choice" mechanism decides which of the two X chromosomes will be inactivated. It has been postulated that Xist is crucial for heterochromatinization and thus functions downstream of the choice mechanism. Here we report that females heterozygous for an internal deletion in the Xist gene, which includes part of exon 1 and extends to exon 5, undergo primary nonrandom inactivation of the wild-type X chromosome. The Xist gene, therefore, not only has a role in chromatin remodeling, but also includes an element required for X chromosome choosing. In conflict with the prevailing view of how choosing occurs, the element identified by the deletion plays a positive role in the choice mechanism and forces a reassessment of how X chromosome choosing is thought to occur.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Jaenisch, R (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.		Loring, Jeanne F/A-1620-2011	Loring, Jeanne F/0000-0001-6226-9767	NATIONAL CANCER INSTITUTE [R35CA044339] Funding Source: NIH RePORTER; NCI NIH HHS [R35-CA44339] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER ID, 1989, GENET RES, V53, P77, DOI 10.1017/S0016672300027944; BEARD C, 1995, GENE DEV, V9, P2325, DOI 10.1101/gad.9.19.2325; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BROCKDORFF N, 1991, NATURE, V351, P329, DOI 10.1038/351329a0; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; CATTANACH BM, 1981, GENET RES, V38, P57, DOI 10.1017/S0016672300020401; Clemson CM, 1996, J CELL BIOL, V132, P259, DOI 10.1083/jcb.132.3.259; ENDO F, 1981, HUM GENET, V56, P349, DOI 10.1007/BF00274691; GRUMBACH MM, 1963, P NATL ACAD SCI USA, V49, P581, DOI 10.1073/pnas.49.5.581; Herzing LBK, 1997, NATURE, V386, P272, DOI 10.1038/386272a0; Hogan B, 1994, MANIPULATING MOUSE E; KAUFMAN MH, 1978, NATURE, V271, P547, DOI 10.1038/271547a0; Lee JT, 1997, CURR OPIN GENET DEV, V7, P274, DOI 10.1016/S0959-437X(97)80138-4; Lee JT, 1997, NATURE, V386, P275, DOI 10.1038/386275a0; Lee JT, 1996, CELL, V86, P83, DOI 10.1016/S0092-8674(00)80079-3; LYON MF, 1964, CYTOGENETICS, V3, P306, DOI 10.1159/000129820; Marahrens Y, 1997, GENE DEV, V11, P156, DOI 10.1101/gad.11.2.156; MCMAHON A, 1983, GENET RES, V41, P69, DOI 10.1017/S0016672300021078; Panning B, 1996, GENE DEV, V10, P1991, DOI 10.1101/gad.10.16.1991; Panning B, 1997, CELL, V90, P907, DOI 10.1016/S0092-8674(00)80355-4; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; Plenge RM, 1997, NAT GENET, V17, P353, DOI 10.1038/ng1197-353; RASTAN S, 1983, J EMBRYOL EXP MORPH, V78, P1; RASTAN S, 1985, J EMBRYOL EXP MORPH, V90, P379; RASTAN S, 1990, GENET RES, V56, P99, DOI 10.1017/S0016672300035163; RASTAN S, 1980, NATURE, V288, P172, DOI 10.1038/288172a0; RUSSELL LB, 1963, SCIENCE, V140, P976, DOI 10.1126/science.140.3570.976; RUSSELL LB, 1965, GENETICS, V52, P470; Sheardown SA, 1997, CELL, V91, P99, DOI 10.1016/S0092-8674(01)80012-X; SIMMLER MC, 1993, MAMM GENOME, V4, P523, DOI 10.1007/BF00364788; TADA T, 1993, GENET RES, V62, P139, DOI 10.1017/S0016672300031736; TADA T, 1992, MOL REPROD DEV, V31, P20, DOI 10.1002/mrd.1080310105; TAKAGI N, 1975, NATURE, V256, P640, DOI 10.1038/256640a0	33	131	135	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 6	1998	92	5					657	664		10.1016/S0092-8674(00)81133-2	http://dx.doi.org/10.1016/S0092-8674(00)81133-2			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZA827	9506520	Bronze			2022-12-28	WOS:000072406000011
J	Gunn, RA; Rolfs, RT; Greenspan, JR; Seidman, RL; Wasserheit, JN				Gunn, RA; Rolfs, RT; Greenspan, JR; Seidman, RL; Wasserheit, JN			The changing paradigm of sexually transmitted disease control in the era of managed health care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PARTNER NOTIFICATION; REPRODUCTIVE HEALTH; CHAIN-REACTION; HIV-INFECTION; CRACK COCAINE; SYPHILIS; INTERVENTION; PREVENTION; DIAGNOSIS	Several trends in sexually transmitted diseases (STDs) have laid the foundation for a new paradigm for STD treatment and prevention that: encompasses a community-wide, population-oriented approach, Public health STD programs, in partnership with a wide variety of community collaborators, will need to carry out the essential functions of public health-assessment, policy development, and assurance-by developing resources for community organizing and planning, enhanced information systems, and comprehensive training programs for professional staff and community partners, Community providers (particularly practicing clinicians and community and hospital clinics) will need to deliver primary prevention (community health promotion and clinical preventive services) and secondary prevention (screening and treatment) services while categorical STD clinics focus on providing care for high-risk, high-frequency STD transmitters who serve as the reservoir for much of a community's bacterial STDs, Managed care organizations and public health STD programs will need to formalize collaborative arrangements and capitalize on the strengths of each organization in order to have a population-level impact on STD transmission.	Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV STD TB Prevent, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Atlanta, GA 30333 USA; Hlth & Human Serv Agcy, San Diego, CA USA; Utah Dept Hlth, Salt Lake City, UT 84116 USA; San Diego State Univ, Grad Sch Publ Hlth, San Diego, CA 92182 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); California State University System; San Diego State University	Gunn, RA (corresponding author), Ctr Dis Control & Prevent, Off Commun, Natl Ctr HIV STD TB Prevent, 1600 Clifton Rd, Atlanta, GA 30333 USA.	rag5@cdc.gov						*AM MED ASS DEP AD, 1992, GUID AD PREV SERV; *AM SOC HLTH ASS, 1996, STD NEWS, V3, P5; *AM SOC HLTH ASS, 1996, STD NEWS, V3, P1; ANDRUS JK, 1990, ANN INTERN MED, V112, P539, DOI 10.7326/0003-4819-112-7-539; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; BAKER EL, 1994, JAMA-J AM MED ASSOC, V272, P1276, DOI 10.1001/jama.272.16.1276; BRUNHAM RC, 1990, MED CLIN N AM, V74, P1339, DOI 10.1016/S0025-7125(16)30484-9; Cates W, 1996, SEX TRANSM DIS, V23, P68, DOI 10.1097/00007435-199601000-00013; *CDCP, 1994, MMWR-MORBID MORTAL W, V43, P366; *CDCP, 1996, SEX TRANSM DIS PREV; Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V42, P988; CHERNESKY MA, 1994, J CLIN MICROBIOL, V32, P2682, DOI 10.1128/JCM.32.11.2682-2685.1994; Childs James E., 1993, Morbidity and Mortality Weekly Report, V42, P1; COOPER ML, 1994, HEALTH PSYCHOL, V13, P251, DOI 10.1037/0278-6133.13.3.251; DONOVAN P, 1993, TESTING POSITIVE SEX; EDLIN BR, 1994, NEW ENGL J MED, V331, P1422, DOI 10.1056/NEJM199411243312106; ENGELGAU MM, 1995, SEX TRANSM DIS, V22, P203, DOI 10.1097/00007435-199507000-00001; Gindler J. S., 1995, Morbidity and Mortality Weekly Report, V44, P1; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; GUNN RA, 1995, SEX TRANSM DIS, V22, P60, DOI 10.1097/00007435-199501000-00010; Gunn RA, 1997, SEX TRANSM DIS, V24, P90, DOI 10.1097/00007435-199702000-00006; Hessol NA, 1996, SEX TRANSM DIS, V23, P157, DOI 10.1097/00007435-199603000-00012; HIBBS JR, 1991, AM J PUBLIC HEALTH, V81, P1259, DOI 10.2105/AJPH.81.10.1259; *I MED, 1997, IMPR HLTH COMM ROL P; *I MED, 1996, HIDD EP CONFR SEX TR; Institute of Medicine, 1996, HLTH COMM NEW PARTN; Institute of Medicine Committee for the Study of the Future of Public Health, 1988, FUT PUBL HLTH; JAFFE HW, 1979, AM J PUBLIC HEALTH, V69, P1181, DOI 10.2105/AJPH.69.11.1181; Jensen GA, 1997, HEALTH AFFAIR, V16, P125, DOI 10.1377/hlthaff.16.1.125; Kann Laura, 1996, Morbidity and Mortality Weekly Report, V45, P1; MAJER LS, 1992, J SCHOOL HEALTH, V62, P294, DOI 10.1111/j.1746-1561.1992.tb01246.x; Marrazzo JM, 1997, SEX TRANSM DIS, V24, P131, DOI 10.1097/00007435-199703000-00003; RAWITSCHER LA, 1995, PEDIATRICS, V96, P52; StLouis ME, 1997, AM J PUBLIC HEALTH, V87, P10, DOI 10.2105/AJPH.87.1.10; *US DEP HHS, 1993, PLANN APPR COMM HLTH; *US DEP HHS, 1991, ASS PROT EXC PUBL HL; *US PREV SERV TASK, 1996, GUID CLIN PREV SERV, P269; VALDISERRI RO, 1995, J COMMUN HEALTH, V20, P87, DOI 10.1007/BF02260331; Wasserheit JN, 1996, J INFECT DIS, V174, pS201, DOI 10.1093/infdis/174.Supplement_2.S201; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001; WIESENFELD HC, 1994, SEX TRANSM DIS, V21, P268, DOI 10.1097/00007435-199409000-00004	41	40	41	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1998	279	9					680	684		10.1001/jama.279.9.680	http://dx.doi.org/10.1001/jama.279.9.680			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YY849	9496986				2022-12-28	WOS:000072192800032
J	Andrews, C; Pinner, G				Andrews, C; Pinner, G			Postural hypotension induced by paroxetine	BRITISH MEDICAL JOURNAL			English	Letter							ANTIDEPRESSANTS		Queens Med Ctr, Dept Hlth Care Elderly, Nottingham NG7 2UH, England	University of Nottingham	Andrews, C (corresponding author), Queens Med Ctr, Dept Hlth Care Elderly, Nottingham NG7 2UH, England.							Dewan M J, 1992, J Geriatr Psychiatry Neurol, V5, P40; KATONA C, 1995, INT CLIN PSYCHOPHARM, V10, P37, DOI 10.1097/00004850-199503001-00007; LEINONEN E, 1995, HUM PSYCHOPHARM CLIN, V10, P345, DOI 10.1002/hup.470100415; Tandan T, 1997, LANCET, V349, P1145, DOI 10.1016/S0140-6736(05)63021-8; Warrington SJ, 1989, PSYCHOL MED S, V16, pi	5	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 21	1998	316	7131					595	595		10.1136/bmj.316.7131.595	http://dx.doi.org/10.1136/bmj.316.7131.595			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ031	9518913	Green Published, Green Submitted			2022-12-28	WOS:000072213200031
J	Birchall, M				Birchall, M			Human laryngeal allograft: shift of emphasis in transplantation	LANCET			English	Editorial Material									Univ Bristol, Dept Otorhinolaryngol & Head & Neck Surg, Bristol BS10 5ND, Avon, England	University of Bristol	Birchall, M (corresponding author), Univ Bristol, Dept Otorhinolaryngol & Head & Neck Surg, Bristol BS10 5ND, Avon, England.							AFFLECK J, 1998, PHILADELPHIA DA 0110; Birchall MA, 1997, BRIT J SURG, V84, P739, DOI 10.1002/bjs.1800840603; DICK D, 1987, LIVER TRANSPLANTATIO, P145; LEOPOLD DA, 1983, ARCH OTOLARYNGOL, V109, P106; SINGER MI, 1980, ANN OTO RHINOL LARYN, V89, P529, DOI 10.1177/000348948008900608; STROME S, 1992, ANN OTO RHINOL LARYN, V101, P156, DOI 10.1177/000348949210100209; VanLithBijl JT, 1997, ARCH OTOLARYNGOL, V123, P406	7	28	30	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 21	1998	351	9102					539	540		10.1016/S0140-6736(05)78550-0	http://dx.doi.org/10.1016/S0140-6736(05)78550-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ216	9492768				2022-12-28	WOS:000072231900004
J	Cooper, RS; Rotimi, CN; Kaufman, JS; Muna, WFT; Mensah, GA				Cooper, RS; Rotimi, CN; Kaufman, JS; Muna, WFT; Mensah, GA			Hypertension treatment and control in sub-Saharan Africa: the epidemiological basis for policy	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BLOOD-PRESSURE; MORTALITY; DISEASE		Loyola Univ, Stritch Sch Med, Dept Epidemiol & Prevent Med, Maywood, IL 60153 USA; Univ Hlth Sci, Yaounde, Cameroon; Med Coll Georgia, Augusta, GA 30912 USA	Loyola University Chicago; University System of Georgia; Augusta University	Cooper, RS (corresponding author), Loyola Univ, Stritch Sch Med, Dept Epidemiol & Prevent Med, 2160 S 1st Ave, Maywood, IL 60153 USA.	rcooper@orion.it.luc.edu		Mensah, George/0000-0002-0387-5326; Kaufman, Jay/0000-0003-1606-401X	NHLBI NIH HHS [HL 45508, R37 HL045508, HL 47910] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL045508, R01HL045508, R01HL047910] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADETUNJI JA, 1996, POP ASS AM ANN M NEW; Akinkugbe OO, 1997, FINAL REPORT NATL SU; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1995, B WORLD HEALTH ORGAN, V73, P417; Asuzu M C, 1996, World Health Forum, V17, P373; BENNETT S, 1993, J TROP MED HYG, V96, P267; BUNKER CH, 1992, PREV MED, V21, P710, DOI 10.1016/0091-7435(92)90078-V; Chalmers J, 1996, J HYPERTENS, V14, pS3, DOI 10.1097/00004872-199606234-00002; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; Cooper, 1997, Blood Press Monit, V2, P35; Cooper R, 1997, AM J PUBLIC HEALTH, V87, P160, DOI 10.2105/AJPH.87.2.160; Cooper RS, 1998, LANCET, V351, P208, DOI 10.1016/S0140-6736(97)06512-4; Donnison CP, 1929, LANCET, V1, P6; Effects of treatment on morbidity in hypertension, 1970, JAMA-J AM MED ASSOC, V213, P1143, DOI DOI 10.1001/JAMA.213.7.1143; Feachem R.G., 1991, CHANGING PATTERNS DI, P3; FEACHEM RG, 1991, DIS MORTALITY SUBSAH, P3; FEACHEM RGA, 1992, HLTH ADULTS DEV WORL, P273; FREIS ED, 1975, EPIDEMIOLOGY CONTROL, P449; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; *HYP DET FOLL UP P, 1979, JAMA-J AM MED ASSOC, V242, P2562; Jamison D.T., 1993, DIS CONTROL PRIORITI; Kaufman Jay, 1993, Ethnicity and Disease, V3, pS83; Kaufman JS, 1997, B WORLD HEALTH ORGAN, V75, P389; Kaufman JS, 1996, EPIDEMIOLOGY, V7, P398, DOI 10.1097/00001648-199607000-00010; Kaufman JS, 1996, AM J EPIDEMIOL, V143, P1203, DOI 10.1093/oxfordjournals.aje.a008708; Kaufman JS, 1996, J HUM HYPERTENS, V10, P461; MBUYAMBAKABANGU JR, 1986, AM J EPIDEMIOL, V124, P957, DOI 10.1093/oxfordjournals.aje.a114485; *MRC WORK PART, 1996, BMJ-BRIT MED J, V14, pS3; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Murray CJL, 1996, SCIENCE, V274, P740, DOI 10.1126/science.274.5288.740; PEARCE KA, 1998, IN PRESS AM J HYPERT; POULTER N, 1984, HYPERTENSION, V6, P810, DOI 10.1161/01.HYP.6.6.810; STAMLER R, 1992, CORONARY HEART DIS E, P415; Sytkowski PA, 1996, CIRCULATION, V93, P697, DOI 10.1161/01.CIR.93.4.697; *VET ADM COOP STUD, 1970, JAMA-J AM MED ASSOC, V202, P1028; Whelton P, 1995, HIGH BLOOD PRESSURE, V4, P36; *WORLD BANK, 1991, SOC IND DEV 1990	37	95	98	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 21	1998	316	7131					614	617		10.1136/bmj.316.7131.614	http://dx.doi.org/10.1136/bmj.316.7131.614			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ031	9518920	Green Published			2022-12-28	WOS:000072213200038
J	Crimlisk, HL; Bhatia, K; Cope, H; David, A; Marsden, CD; Ron, MA				Crimlisk, HL; Bhatia, K; Cope, H; David, A; Marsden, CD; Ron, MA			Slater revisited: 6 year follow up study of patients with medically unexplained motor symptoms	BRITISH MEDICAL JOURNAL			English	Article							CONVERSION DISORDER; FREQUENCY; HYSTERIA	Objective: To investigate psychiatric and neurological morbidity diagnostic stability and indicators of prognosis in patients previously identified as having London medically unexplained motor symptoms. Design: Follow up study. Setting: National Hospital for Neurology and Neurosurgery; London-a secondary and tertiary referral hospital for neurological disorders. Subjects: 73 patients with medically unexplained motel symptoms admitted consecutively in 1989-91. 35 (48%) patients had absence of motor function (for example, hemiplegia) and 35 (52%,) had abnormal motor activity (for example, tremour dystonia, or ataxia). Main outcome measures: Neurological clinical diagnosis at face to face reassessment by a neurologist and a psychiatric diagnosis after a standardised assessment interview-the schedule for affective disorders and schizophrenia-conducted by a psychiatrist. Results: Good follow up data were available for 64 subjects (88%). Only three subjects had new organic neurological disorders at follow up that fully or partly explained their previous symptoms. 44/59 (75%) subjects had had psychiatric disorders; in 33 (75%) patients, the psychiatric diagnosis coincided with their unexplained motor symptoms. 31/59 (45%) patients had a personality disorder: Three subjects had developed new psychiatric illnesses at follow up, but in only one did the diagnosis account for the previous motor symptoms. Resolution of physical symptoms was associated with shaft length of symptoms, comorbid psychiatric disorder, and a cl-range in marital status during follow up. Conclusions: Unlike Slater's study of 1965, a low incidence of physical or psychiatric diagnoses which explained these patients' symptoms or disability was found. However, a high level of psychiatric comorbidity existed.	Inst Neurol, London WC1N 3BG, England; Inst Psychiat, London SE5 8AF, England	University of London; University College London; University of London; King's College London	Ron, MA (corresponding author), Inst Neurol, Queen Sq, London WC1N 3BG, England.		David, Anthony/O-1750-2019; David, Anthony S/C-1315-2011	David, Anthony/0000-0003-0967-774X; David, Anthony S/0000-0003-0967-774X; Crimlisk, Helen/0000-0003-0448-4850				BAKER JHE, 1987, J NEUROL NEUROSUR PS, V50, P375, DOI 10.1136/jnnp.50.4.375; COUPRIE W, 1995, J NEUROL NEUROSUR PS, V58, P750, DOI 10.1136/jnnp.58.6.750; DEMIRKIRAN M, 1995, ANN NEUROL, V38, P571, DOI 10.1002/ana.410380405; ENDICOTT J, 1978, ARCH GEN PSYCHIAT, V35, P837; EWALD H, 1994, ACTA PSYCHIAT SCAND, V89, P174, DOI 10.1111/j.1600-0447.1994.tb08088.x; FACTOR SA, 1995, J NEUROL NEUROSUR PS, V59, P406, DOI 10.1136/jnnp.59.4.406; GATFIELD PD, 1962, DIS NERV SYST, V23, P623; LEMPERT T, 1990, ACTA NEUROL SCAND, V82, P335; Mace CJ, 1996, BRIT J PSYCHIAT, V169, P282, DOI 10.1192/bjp.169.3.282; MACE CJ, 1991, J ROY SOC MED, V84, P471, DOI 10.1177/014107689108400808; MARSDEN CD, 1986, PSYCHOL MED, V16, P277, DOI 10.1017/S0033291700009090; RASKIN M, 1966, J AMER MED ASSOC, V197, P530, DOI 10.1001/jama.197.7.530; ROY A, 1980, J PSYCHOSOM RES, V24, P53, DOI 10.1016/0022-3999(80)90053-7; SLATER E, 1965, BRIT MED J, V1, P1395, DOI 10.1136/bmj.1.5447.1395; SLATER ETO, 1965, J PSYCHOSOM RES, V9, P9, DOI 10.1016/0022-3999(65)90004-8; STEPHANSSON JG, 1976, ACTA PSYCHIAT SCAND, V53, P119; WATSON CG, 1979, J NERV MENT DIS, V167, P243, DOI 10.1097/00005053-197904000-00008; WILSONBARNETT J, 1985, BRIT J PSYCHIAT, V146, P601, DOI 10.1192/bjp.146.6.601; World Health Organization, 1992, CLIN DESCR DIAGN GUI, V10th	19	223	226	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 21	1998	316	7131					582	586		10.1136/bmj.316.7131.582	http://dx.doi.org/10.1136/bmj.316.7131.582			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YZ031	9518908	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000072213200024
J	Yin, YX; Terauchi, Y; Solomon, GG; Aizawa, S; Rangarajan, PN; Yazaki, Y; Kadowaki, T; Barrett, JC				Yin, YX; Terauchi, Y; Solomon, GG; Aizawa, S; Rangarajan, PN; Yazaki, Y; Kadowaki, T; Barrett, JC			Involvement of p85 in p53-dependent apoptotic response to oxidative stress	NATURE			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; GROWTH-FACTOR; KINASE; P53; PROTEIN; REQUIREMENT; SUPPRESSION; ASSOCIATION; GENERATION; ACTIVATION	Reactive oxygen species have damaging effects on cellular components and so trigger defensive responses by the cell(1,2) and even programmed cell death(3,4), although the mechanisms by which mammalian cells transmit signals in response to oxidative damage are unknown. We report here that the protein p85, a regulator of the signalling protein phosphatidyl-3-OH kinase (PI(3)K), participates in the cell death process that is induced in response to oxidative stress and that this role of p85 in apoptosis does not involve PI(S)K. We show that disruption of p85 by homologous recombination impairs the cellular apoptotic response to oxidative stress. Because the protein p53 is required for cell death induced by oxidative damage, we examined the relation between p85 and p53. Using a chimaeric p53 fusion protein with the oestrogen receptor (p53ER) to supply p53 (p53 is induced upon binding of p53ER to oestradiol) in a p53-deficient cell line, we found that p85 is upregulated by p53 and that its involvement in p53-mediated apoptosis is independent of PI(3)K. We propose that p85 acts as a signal transducer in the cellular response to oxidative stress, mediating cell death regulated by p53.	NIEHS, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA; Univ N Carolina, Sch Med, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ Tokyo, Dept Internal Med 3, Tokyo 113, Japan; Kumamoto Univ, Sch Med, Lab Morphogenesis, Kumamoto 860, Japan; Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Tokyo; Kumamoto University; Indian Institute of Science (IISC) - Bangalore	Barrett, JC (corresponding author), NIEHS, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA.		Terauchi, Yasuo/AAO-4347-2020; Rangarajan, Pundi/A-7365-2009	Rangarajan, Pundi/0000-0002-6536-9891				ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Bagchi D, 1995, TOXICOLOGY, V104, P129, DOI 10.1016/0300-483X(95)03156-A; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CARPENTER CL, 1996, BIOCH BIOPHYS ACTA R, V1288, P11; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ferby IM, 1996, J BIOL CHEM, V271, P11684, DOI 10.1074/jbc.271.20.11684; HARTLEY D, 1995, J BIOL CHEM, V270, P18260, DOI 10.1074/jbc.270.31.18260; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KORSMEYER SJ, 1995, BBA-MOL BASIS DIS, V1271, P63, DOI 10.1016/0925-4439(95)00011-R; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V208, P985, DOI 10.1006/bbrc.1995.1431; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Preston GA, 1996, MOL CELL BIOL, V16, P211; Sambrook J., 2002, MOL CLONING LAB MANU; STORZ G, 1990, TRENDS GENET, V6, P363, DOI 10.1016/0168-9525(90)90278-E; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	27	149	157	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 12	1998	391	6668					707	710		10.1038/35648	http://dx.doi.org/10.1038/35648			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW872	9490416				2022-12-28	WOS:000071982500056
J	Huberman, BA; Pirolli, PLT; Pitkow, JE; Lukose, RM				Huberman, BA; Pirolli, PLT; Pitkow, JE; Lukose, RM			Strong regularities in World Wide Web surfing	SCIENCE			English	Article							ACTIVATION	One of the most common modes of accessing information in the World Wide Web is surfing from one document to another along hyperlinks. Several large empirical studies have revealed common patterns of surfing behavior, A model that assumes that users make a sequence of decisions to proceed to another page, continuing as long as the value of the current page exceeds some threshold, yields the probability distribution for the number of pages that a user visits within a given Web site. This model was verified by comparing its predictions with detailed measurements of surfing patterns, The model also explains the observed Zipf-like distributions in page hits observed at Web sites.	Xerox Corp, Palo Alto Res Ctr, Palo Alto, CA 94304 USA	Xerox	Huberman, BA (corresponding author), Xerox Corp, Palo Alto Res Ctr, 3333 Coyote Hill Rd, Palo Alto, CA 94304 USA.							ANDERSON JR, 1984, J EXP PSYCHOL LEARN, V10, P791, DOI 10.1037/0278-7393.10.4.791; CATLEDGE LD, 1995, COMPUT NETWORKS ISDN, V27, P1065, DOI 10.1016/0169-7552(95)00043-7; Dixit A.K., 1994, INVESTMENT UNCERTAIN, DOI DOI 10.1515/9781400830176; GLASSMAN S, 1994, COMPUT NETWORKS ISDN, V27, P165, DOI 10.1016/0169-7552(94)90130-9; Huberman BA, 1997, SCIENCE, V277, P535, DOI 10.1126/science.277.5325.535; LUKOSE RM, 1998, 4 INT C COMP EC CAMB; PIROLLI P, 1996, C HUM FACT COMP SYST; PITKOW J, 1997, GVUS WWW USER SURVEY; Quillan MR, 1966, SEMANTIC MEMORY; SESHARDRI V, 1993, INVERSE GAUSSIAN DIS; SHRAGER J, 1987, SCIENCE, V236, P1092, DOI 10.1126/science.236.4805.1092; VanAlstyne M, 1996, SCIENCE, V274, P1479, DOI 10.1126/science.274.5292.1479; Zipf G. K., 1949, HUMAN BEHAV PRINCIPL; [No title captured]	14	368	389	2	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 3	1998	280	5360					95	97		10.1126/science.280.5360.95	http://dx.doi.org/10.1126/science.280.5360.95			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF314	9525865	Green Submitted			2022-12-28	WOS:000072885100042
J	Miller, FG; Meier, DE				Miller, FG; Meier, DE			Voluntary death: A comparison of terminal dehydration and physician-assisted suicide	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							EUTHANASIA; HYDRATION; NUTRITION	The controversial issue of legalizing physician-assisted suicide should be considered in light of legally available alternative methods of voluntary death. The increasingly polarized debate over this issue has failed to give due attention to an alternative: terminal dehydration. By voluntarily forgoing food and water, competent patients with terminal or incurable illness can escape intolerable, irremediable conditions without requiring transformation of the law and medical ethics. Terminal dehydration offers substantial advantages over physician-assisted suicide with respect to self-determination, access, professional integrity, and social implications but also has distinctive drawbacks as a humane means of voluntary death. This article analyzes clinical, ethical, and policy issues related to terminal dehydration compared with physician-assisted suicide.	Univ Virginia, Charlottesville, VA USA; Mt Sinai Sch Med, New York, NY USA	University of Virginia; Icahn School of Medicine at Mount Sinai	Meier, DE (corresponding author), Mt Sinai Med Ctr, POB 1070, New York, NY 10029 USA.							Angell M, 1997, NEW ENGL J MED, V336, P50, DOI 10.1056/NEJM199701023360108; Baron CH, 1996, HARVARD J LEGIS, V33, P1; BERNAT JL, 1993, ARCH INTERN MED, V153, P2723, DOI 10.1001/archinte.153.24.2723; Breitbart W, 1996, AM J PSYCHIAT, V153, P238; Cherny N I, 1994, J Palliat Care, V10, P31; CHOCHINOV HM, 1995, AM J PSYCHIAT, V152, P1185; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; Donelan K, 1996, JAMA-J AM MED ASSOC, V276, P1346, DOI 10.1001/jama.276.16.1346; EDDY DM, 1994, JAMA-J AM MED ASSOC, V272, P179, DOI 10.1001/jama.272.3.179; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; IGLEHART JK, 1994, NEW ENGL J MED, V331, P1167, DOI 10.1056/NEJM199410273311719; KASS LR, 1989, PUBLIC INTEREST, P25; LANGRETH R, 1996, WALL STREET J    OCT, V7, pA2; Meisel Alan, 1992, Kennedy Institute of Ethics Journal, V2, P309; MILLER FG, 1994, NEW ENGL J MED, V331, P119, DOI 10.1056/NEJM199407143310211; MILLER FG, 1995, HASTINGS CENT REP, V25, P8, DOI 10.2307/3562107; Miller FG, 1997, CAMB Q HEALTHC ETHIC, V6, P78, DOI 10.1017/S0963180100007635; MILLER FG, 1996, BIOLAW LEGAL ETHICAL, pS136; *NEW YORK STAT TAS, 1994, DEATH IS SOUGHT ASS; Pellegrino E D, 1992, J Clin Ethics, V3, P95; Powell T, 1996, J LAW MED ETHICS, V24, P54, DOI 10.1111/j.1748-720X.1996.tb01833.x; PRINTZ LA, 1992, ARCH INTERN MED, V152, P697, DOI 10.1001/archinte.152.4.697; Quill T, 1996, MIDWIFE DYING PROCES; QUILL TE, 1995, ARCH INTERN MED, V155, P1250, DOI 10.1001/archinte.155.12.1250; SHAVELSON L, 1995, CHOSEN DEATH DYING C; Starr P, 1982, SOCIAL TRANSFORMATIO; SULLIVAN RJ, 1993, J GEN INTERN MED, V8, P220, DOI 10.1007/BF02599271	27	51	52	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1998	128	7					559	562		10.7326/0003-4819-128-7-199804010-00007	http://dx.doi.org/10.7326/0003-4819-128-7-199804010-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZE539	9518401				2022-12-28	WOS:000072803500007
J	Banatvala, JE				Banatvala, JE			Rubella - could do better	LANCET			English	Editorial Material							CONGENITAL-RUBELLA; DIAGNOSIS		United Med & Dent Sch Guys & St Thomas Hosp, Dept Virol, London SE1 7EH, England	University of London; King's College London	Banatvala, JE (corresponding author), United Med & Dent Sch Guys & St Thomas Hosp, Dept Virol, London SE1 7EH, England.							BANATVALA JE, 1997, TOPLEY WILSONS MICRO, P551; BOSMA TJ, 1995, J CLIN MICROBIOL, V33, P2881, DOI 10.1128/JCM.33.11.2881-2887.1995; Cutts FT, 1997, B WORLD HEALTH ORGAN, V75, P55; Cutts FT, 1998, BMJ-BRIT MED J, V316, P765, DOI 10.1136/bmj.316.7133.765; DOWDLE WR, 1970, B WORLD HEALTH ORGAN, V42, P314; Eckstein MB, 1996, BRIT MED J, V312, P161; MENSER MA, 1967, LANCET, V2, P387; PECKHAM C, 1985, REV INFECT DIS, V7, pS11; PHIROMSAWAT S, 1988, Journal of the Medical Association of Thailand, V71, P26; PRUKSANANONDA P, 1983, Southeast Asian Journal of Tropical Medicine and Public Health, V14, P380; Robertson SE, 1997, B WORLD HEALTH ORGAN, V75, P69; SALISBURY DM, 1991, EPI GLOB ADV GROUP M	12	9	11	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 21	1998	351	9106					849	850		10.1016/S0140-6736(05)70283-X	http://dx.doi.org/10.1016/S0140-6736(05)70283-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD047	9525357				2022-12-28	WOS:000072645500005
J	Perman, B; Srajer, V; Ren, Z; Teng, TY; Pradervand, C; Ursby, T; Bourgeois, D; Schotte, F; Wulff, M; Kort, R; Hellingwerf, K; Moffat, K				Perman, B; Srajer, V; Ren, Z; Teng, TY; Pradervand, C; Ursby, T; Bourgeois, D; Schotte, F; Wulff, M; Kort, R; Hellingwerf, K; Moffat, K			Energy transduction on the nanosecond time scale: Early structural events in a xanthopsin photocycle	SCIENCE			English	Article							PHOTOACTIVE YELLOW PROTEIN; GREEN FLUORESCENT PROTEIN; P-COUMARIC ACID; LINKED 4-HYDROXYCINNAMYL CHROMOPHORE; ECTOTHIORHODOSPIRA-HALOPHILA; LAUE DIFFRACTION; PHOTOTROPHIC BACTERIUM; PHOTORECEPTOR; REFINEMENT; CRYSTALLOGRAPHY	Photoactive yellow protein (PYP) is a member of the xanthopsin family of eubacterial blue-light photoreceptors. On absorption of light, PYP enters a photocycle that ultimately transduces the energy contained in a light signal into an altered biological response, Nanosecond time-resolved x-ray crystallography was used to determine the structure of the short-lived, red-shifted, intermediate state denoted [pR], which develops within 1 nanosecond after photoelectronic excitation of the chromophore of PYP by absorption of light. The resulting structural model demonstrates that the [pR] state possesses the cis conformation of the 4-hydroxyl cinnamic thioester chromophore, and that the process of trans to cis isomerization is accompanied by the specific formation of new hydrogen bonds that replace those broken upon excitation of the chromophore. Regions of flexibility that compose the chromophore-binding pocket serve to lower the activation energy barrier between the dark state, denoted pG, and [pR], and help initiate entrance into the photocycle. Direct structural evidence is provided for the initial processes of transduction of light energy, which ultimately translate into a physiological signal.	Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; Univ Chicago, Consortium Adv Radiat Sources, Chicago, IL 60637 USA; Univ Lund, Ctr Chem, S-22100 Lund, Sweden; European Synchrotron Radiat Facil, F-38043 Grenoble, France; Univ Amsterdam, EC Slater Inst Biochem Res, Microbiol Lab, NL-1018 WS Amsterdam, Netherlands	University of Chicago; University of Chicago; Lund University; European Synchrotron Radiation Facility (ESRF); University of Amsterdam	Moffat, K (corresponding author), Univ Chicago, Dept Biochem & Mol Biol, 920 E 58th St, Chicago, IL 60637 USA.		Kort, Remco/ABH-1915-2021; Pradervand, Claude/GPF-4155-2022; , Bourgeois/AAI-2337-2020; Pradervand, Claude P/I-8114-2013	Kort, Remco/0000-0003-3674-598X; Pradervand, Claude/0000-0001-5251-3930; 				BACA M, 1994, BIOCHEMISTRY-US, V33, P14369, DOI 10.1021/bi00252a001; Baltuska A, 1997, CHEM PHYS LETT, V270, P263, DOI 10.1016/S0009-2614(97)00376-X; BORGSTAHL GEO, 1995, BIOCHEMISTRY-US, V34, P6278, DOI 10.1021/bi00019a004; Bourgeois D, 1996, J SYNCHROTRON RADIAT, V3, P65, DOI 10.1107/S090904959501661X; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Chosrowjan H, 1997, CHEM PHYS LETT, V270, P267, DOI 10.1016/S0009-2614(97)00365-5; CHOU PY, 1977, J MOL BIOL, V115, P135, DOI 10.1016/0022-2836(77)90094-8; Genick UK, 1997, BIOCHEMISTRY-US, V36, P8, DOI 10.1021/bi9622884; Genick UK, 1997, SCIENCE, V275, P1471, DOI 10.1126/science.275.5305.1471; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; HOFF WD, 1992, PHOTOCHEM PHOTOBIOL, V56, P529, DOI 10.1111/j.1751-1097.1992.tb02197.x; HOFF WD, 1994, BIOCHEMISTRY-US, V33, P13959, DOI 10.1021/bi00251a001; HOFF WD, 1994, BIOPHYS J, V67, P1691, DOI 10.1016/S0006-3495(94)80643-5; IMAMOTO Y, 1995, FEBS LETT, V374, P157, DOI 10.1016/0014-5793(95)01096-W; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KIM M, 1995, BIOCHEMISTRY-US, V34, P12669, DOI 10.1021/bi00039a024; Kort R, 1996, FEBS LETT, V382, P73, DOI 10.1016/0014-5793(96)00149-4; KORT R, 1996, EMBO J, V15, P101; Kroon AR, 1996, J BIOL CHEM, V271, P31949, DOI 10.1074/jbc.271.50.31949; MEYER TE, 1991, BIOPHYS J, V59, P988, DOI 10.1016/S0006-3495(91)82313-X; MEYER TE, 1985, BIOCHIM BIOPHYS ACTA, V806, P175, DOI 10.1016/0005-2728(85)90094-5; NG K, 1995, BIOCHEMISTRY-US, V34, P879, DOI 10.1021/bi00003a022; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; PALCZEWSKI K, 1994, PROTEIN SCI, V3, P1355, DOI 10.1002/pro.5560030901; REN Z, 1995, J APPL CRYSTALLOGR, V28, P461, DOI 10.1107/S0021889895003207; REN Z, 1995, J APPL CRYSTALLOGR, V28, P482, DOI 10.1107/S0021889895003219; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SPRENGER WW, 1993, J BACTERIOL, V175, P3096, DOI 10.1128/JB.175.10.3096-3104.1993; Srajer V, 1996, SCIENCE, V274, P1726, DOI 10.1126/science.274.5293.1726; TERWILLIGER TC, 1995, ACTA CRYSTALLOGR D, V51, P609, DOI 10.1107/S0907444994013247; VANBREDERODE ME, 1995, BIOPHYS J, V68, P1101, DOI 10.1016/S0006-3495(95)80284-5; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; Xie AH, 1996, BIOCHEMISTRY-US, V35, P14671, DOI 10.1021/bi9623035; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246; YARFITZ S, 1994, J BIOL CHEM, V269, P14329; ZHOU F, COMMUNICATION	38	273	280	0	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 20	1998	279	5358					1946	1950		10.1126/science.279.5358.1946	http://dx.doi.org/10.1126/science.279.5358.1946			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506946				2022-12-28	WOS:000072613300049
J	Debregeas, G; de Gennes, PG; Brochard-Wyart, F				Debregeas, G; de Gennes, PG; Brochard-Wyart, F			The life and death of "bare" viscous bubbles	SCIENCE			English	Article							FOAM	Air bubbles collect and explode at the surface of many viscous liquids, as observed with polymer foams, in glass furnaces, and during volcanic eruptions, The liquid film separating the bubble from bulk air can have a long lifetime (if it is viscous) even if it is not protected by a surfactant, These "bare" films display unusual dynamic behaviors in drainage and rupture, Two different model systems were studied: a polymer melt (silicone oil) and a molten (borosilicate) glass of comparable viscosity, Although the two systems differ greatly in their relaxation time, they are described by the same set of laws, which can be understood from a relatively simple hydrodynamic model.	Univ Chicago, James Franck Inst, Chicago, IL 60637 USA; Ecole Super Phys & Chim Ind, F-75231 Paris 05, France; Inst Curie, F-75248 Paris 05, France	University of Chicago; UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Debregeas, G (corresponding author), Univ Chicago, James Franck Inst, 5640 S Ellis Ave, Chicago, IL 60637 USA.							BHAKTA A, 1995, LANGMUIR, V11, P1486, DOI 10.1021/la00005a014; DEBREGEAS G, 1995, PHYS REV LETT, V75, P3886, DOI 10.1103/PhysRevLett.75.3886; deGennes PG, 1996, FARADAY DISCUSS, V104, P1, DOI 10.1039/fd9960400001; DEGENNES PG, 1987, CR ACAD SCI II, V305, P9; DORAMUS RH, 1995, GLASS SCI, pCH11; LANDAU LD, 1959, THEORY ELASTICITY, P110; Lindemann M, 1997, PROG COLL POL SCI S, V105, P209, DOI 10.1007/BF01188952; LUCASSEN J, 1981, ANIONIC SURFACTANTS; Mangan MT, 1996, J VOLCANOL GEOTH RES, V73, P1, DOI 10.1016/0377-0273(96)00018-2; Mysels K.J., 1959, SOAP FILMS; WEAIRE D, 1993, PHYS REV LETT, V71, P2670, DOI 10.1103/PhysRevLett.71.2670	11	214	215	3	88	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 13	1998	279	5357					1704	1707		10.1126/science.279.5357.1704	http://dx.doi.org/10.1126/science.279.5357.1704			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9497285				2022-12-28	WOS:000072490000050
J	Kilgard, MP; Merzenich, MM				Kilgard, MP; Merzenich, MM			Cortical map reorganization enabled by nucleus basalis activity	SCIENCE			English	Article							AUDITORY-CORTEX RESPONSIVENESS; PRIMARY SOMATOSENSORY CORTEX; RECEPTIVE-FIELD ALTERATIONS; TONE-EVOKED RESPONSES; ADULT OWL MONKEYS; CHOLINERGIC MODULATION; RAT; STIMULATION; FOREBRAIN; FREQUENCY	Little is known about the mechanisms that allow the cortex to selectively improve the neural representations of behaviorally important stimuli while ignoring irrelevant stimuli. Diffuse neuromodulatory systems may facilitate cortical plasticity by acting as teachers to mark important stimuli. This study demonstrates that episodic electrical stimulation of the nucleus basalis, paired with an auditory stimulus, results in a massive progressive reorganization of the primary auditory cortex in the adult rat. Receptive field sizes can be narrowed, broadened, or left unaltered depending on specific parameters of the acoustic stimulus paired with nucleus basalis activation. This differential plasticity parallels the receptive field remodeling that results from different types of behavioral training. This result suggests that input characteristics may be able to drive appropriate alterations of receptive fields independently of explicit knowledge of the task. These findings also suggest that the basal forebrain plays an active instructional role in representational plasticity.	Univ Calif San Francisco, WM Keck Fdn, Ctr Integrat Neurosci, Dept Otolaryngol, San Francisco, CA 94143 USA; Univ Calif San Francisco, WM Keck Fdn, Ctr Integrat Neurosci, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Kilgard, MP (corresponding author), Univ Calif San Francisco, WM Keck Fdn, Ctr Integrat Neurosci, Dept Otolaryngol, 513 Parnassus Ave,Box 0732, San Francisco, CA 94143 USA.			Kilgard, Michael/0000-0002-6699-1818	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS110414] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-10414] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHISSAR E, 1992, SCIENCE, V257, P1412, DOI 10.1126/science.1529342; Ahissar Ehud, 1994, Current Opinion in Neurobiology, V4, P580, DOI 10.1016/0959-4388(94)90060-4; Bakin JS, 1996, P NATL ACAD SCI USA, V93, P11219, DOI 10.1073/pnas.93.20.11219; Baskerville KA, 1997, NEUROSCIENCE, V80, P1159, DOI 10.1016/S0306-4522(97)00064-X; Butt AE, 1997, PSYCHOBIOLOGY, V25, P18; BUTT AE, 1995, BEHAV NEUROSCI, V109, P699, DOI 10.1037/0735-7044.109.4.699; CASAMENTI F, 1986, BRAIN RES BULL, V16, P689, DOI 10.1016/0361-9230(86)90140-1; CONDON CD, 1991, BEHAV NEUROSCI, V105, P416, DOI 10.1037/0735-7044.105.3.416; Dykes RW, 1997, CAN J PHYSIOL PHARM, V75, P535, DOI 10.1139/cjpp-75-5-535; EDELINE JM, 1994, EXP BRAIN RES, V97, P373; EDELINE JM, 1994, BRAIN RES, V636, P333, DOI 10.1016/0006-8993(94)91033-2; Gritti I, 1997, J COMP NEUROL, V383, P163; HARS B, 1993, NEUROSCIENCE, V56, P61, DOI 10.1016/0306-4522(93)90562-T; HASSELMO ME, 1993, TRENDS NEUROSCI, V16, P218, DOI 10.1016/0166-2236(93)90159-J; HECKERS S, 1994, J NEUROSCI, V14, P1271, DOI 10.1523/JNEUROSCI.14-03-01271.1994; JENKINS WM, 1990, J NEUROPHYSIOL, V63, P82, DOI 10.1152/jn.1990.63.1.82; JimenezCapdeville ME, 1997, J COMP NEUROL, V381, P53, DOI 10.1002/(SICI)1096-9861(19970428)381:1<53::AID-CNE5>3.0.CO;2-J; KILGARD MP, UNPUB; Leanza G, 1996, EUR J NEUROSCI, V8, P1535, DOI 10.1111/j.1460-9568.1996.tb01616.x; MCKENNA TM, 1989, SYNAPSE, V4, P30, DOI 10.1002/syn.890040105; MERZENICH MM, 1990, COLD SPRING HARB SYM, V55, P873; MESULAM MM, 1983, NEUROSCIENCE, V10, P1185, DOI 10.1016/0306-4522(83)90108-2; METHERATE R, 1989, BRAIN RES, V480, P372, DOI 10.1016/0006-8993(89)90210-2; METHERATE R, 1990, SYNAPSE, V6, P133, DOI 10.1002/syn.890060204; METHERATE R, 1988, J NEUROPHYSIOL, V59, P1231, DOI 10.1152/jn.1988.59.4.1231; METHERATE R, 1991, BRAIN RES, V559, P163, DOI 10.1016/0006-8993(91)90301-B; METHERATE R, 1993, SYNAPSE, V14, P132, DOI 10.1002/syn.890140206; PETERSEN RC, 1977, PSYCHOPHARMACOLOGY, V52, P283, DOI 10.1007/BF00426713; RASMUSSON DD, 1992, BRAIN RES, V594, P150, DOI 10.1016/0006-8993(92)91041-C; RECANZONE GH, 1993, J NEUROSCI, V13, P87; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1031, DOI 10.1152/jn.1992.67.5.1031; Richardson R T, 1991, Adv Exp Med Biol, V295, P233; RICHARDSON RT, 1991, ACTIVATION ACQUISITI, P135; RYE DB, 1984, NEUROSCIENCE, V13, P627, DOI 10.1016/0306-4522(84)90083-6; SALLY SL, 1988, J NEUROPHYSIOL, V59, P1627, DOI 10.1152/jn.1988.59.5.1627; Sarter M, 1997, BRAIN RES REV, V23, P28, DOI 10.1016/S0165-0173(96)00009-4; SINGER W, 1986, EUR ARCH PSY CLIN N, V236, P4, DOI 10.1007/BF00641050; STERIADE M, 1990, BRAIN CHOLINERGIC SY; Thorndike EL., 1911, ANIMAL INTELLIGENCE, DOI DOI 10.4324/9781351321044; WEBSTER HH, 1991, SOMATOSENS MOT RES, V8, P327, DOI 10.3109/08990229109144756; Weinberger N M, 1993, Curr Opin Neurobiol, V3, P570, DOI 10.1016/0959-4388(93)90058-7	41	898	932	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 13	1998	279	5357					1714	1718		10.1126/science.279.5357.1714	http://dx.doi.org/10.1126/science.279.5357.1714			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9497289				2022-12-28	WOS:000072490000054
J	Kubo, Y; Miyashita, T; Murata, Y				Kubo, Y; Miyashita, T; Murata, Y			Structural basis for a Ca2+-sensing function of the metabotropic glutamate receptors	SCIENCE			English	Article							LONG-TERM DEPRESSION; MGLUR1 MUTANT MICE; MOLECULAR CHARACTERIZATION; SIGNAL-TRANSDUCTION; EXTRACELLULAR CALCIUM; SENSING RECEPTOR; EXPRESSION; CLONING; RAT; CHANNEL	The metabotropic glutamate receptors (mGluRs) are widely distributed in the brain and play important roles in synaptic plasticity. Here it is shown that some types of mGluRs are activated not only by glutamate but also by extracellular Ca2+(Ca-o(2+)). A single amino acid residue was found to determine the sensitivity of mGluRs to Ca-o(2+). One of the receptors, mGluR1 alpha, but not its point mutant with reduced sensitivity to Ca-o(2+), caused morphological changes when transfected into mammalian cells, Thus, the sensing of Ca-o(2+) by mGluRs may be important in cells under physiological condition.	Tokyo Metropolitan Inst Neurosci, Dept Neurophysiol, Tokyo 1838526, Japan; Meiji Coll Pharm, Dept Med Physiol, Tokyo 154003, Japan	Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science; Meiji Pharmaceutical University	Kubo, Y (corresponding author), Tokyo Metropolitan Inst Neurosci, Dept Neurophysiol, Musashidai 2-6, Tokyo 1838526, Japan.		Oka, Yoshitaka/C-9670-2010	Oka, Yoshitaka/0000-0002-3482-3051; Kubo, Yoshihiro/0000-0001-6707-0837; Murata, Yoshimichi/0000-0002-2070-7949				ABE T, 1992, J BIOL CHEM, V267, P13361; AIBA A, 1994, CELL, V79, P365, DOI 10.1016/0092-8674(94)90204-6; AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; ARAMORI I, 1992, NEURON, V8, P757, DOI 10.1016/0896-6273(92)90096-V; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; DUVOISIN RM, 1995, J NEUROSCI, V15, P3075; GARRETT JE, 1995, J BIOL CHEM, V270, P12919, DOI 10.1074/jbc.270.21.12919; Kano M, 1997, NEURON, V18, P71, DOI 10.1016/S0896-6273(01)80047-7; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KUBO Y, UNPUB; Kubokawa K, 1996, FEBS LETT, V392, P71, DOI 10.1016/0014-5793(96)00786-7; LESAGE F, 1995, J BIOL CHEM, V270, P28660, DOI 10.1074/jbc.270.48.28660; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; NAKAJIMA Y, 1993, J BIOL CHEM, V268, P11868; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; OKAMOTO N, 1994, J BIOL CHEM, V269, P1231; RICCARDI D, 1995, P NATL ACAD SCI USA, V92, P131, DOI 10.1073/pnas.92.1.131; RUAT M, 1995, P NATL ACAD SCI USA, V92, P3161, DOI 10.1073/pnas.92.8.3161; Shigemoto R, 1997, J NEUROSCI, V17, P7503, DOI 10.1523/jneurosci.17-19-07503.1997; SHIGEMOTO R, 1994, NEURON, V12, P1245, DOI 10.1016/0896-6273(94)90441-3; SUGIYAMA H, 1987, NATURE, V325, P531, DOI 10.1038/325531a0; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; Vassilev PM, 1997, BIOPHYS J, V72, P2103, DOI 10.1016/S0006-3495(97)78853-2	26	188	209	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 13	1998	279	5357					1722	1725		10.1126/science.279.5357.1722	http://dx.doi.org/10.1126/science.279.5357.1722			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9497291				2022-12-28	WOS:000072490000056
J	de la Pompa, JL; Timmerman, LA; Takimoto, H; Yoshida, H; Elia, AJ; Samper, E; Potter, J; Wakeham, A; Marengere, L; Langille, BL; Crabtree, GR; Mak, TW				de la Pompa, JL; Timmerman, LA; Takimoto, H; Yoshida, H; Elia, AJ; Samper, E; Potter, J; Wakeham, A; Marengere, L; Langille, BL; Crabtree, GR; Mak, TW			Role of the NF-ATc transcription factor in morphogenesis of cardiac valves and septum	NATURE			English	Article							T-CELL ACTIVATION; CYCLOSPORINE-A; GENE; CALCINEURIN; FAMILY; IDENTIFICATION; CONTAINS; PROTEINS; MEMBER	In lymphocytes, the expression of early immune response genes is regulated by NF-AT transcription factors(1,2) which translocate to the nucleus after dephosphorylation by the Ca2+-dependent phosphatase, calcineurin(3). We report here that mice bearing a disruption in the NF-ATc gene fail to develop normal cardiac valves and septa and die of circulatory failure before day 14.5 of development. NF-ATc is first expressed in the heart at day 7.5, and is restricted to the endocardium, a specialized endothelium that gives rise to the valves and septum. Within the endocardium, specific inductive events appear to activate NF-ATc: it is localized to the nucleus only in endocardial cells that are adjacent to the interface with the cardiac jelly and myocardium, which are thought to give the inductive stimulus to the valve primordia(4). Treatment of wild-type embryos with FK506, a specific calcineurin inhibitor(5), prevents nuclear localization of NF-ATc. These data indicate that the Ca2+/calcineurin/NF-ATc signalling pathway is essential for normal cardiac valve and septum morphogenesis; hence, NF-ATc and its regulatory pathways are candidates for genetic defects underlying congenital human heart disease.	Univ Toronto, Ontario Canc Inst, Amgen Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 2C1, Canada; Stanford Univ, Sch Med, Howard Hughes Med Inst, Dept Dev Biol, Stanford, CA 94305 USA; Univ Toronto, Dept Pathol, Toronto, ON M5S 1A8, Canada; Toronto Gen Div, Max Bell Res Ctr, Toronto, ON M5G 2C4, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; Howard Hughes Medical Institute; Stanford University; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Mak, TW (corresponding author), Univ Toronto, Ontario Canc Inst, Amgen Inst, 620 Univ Ave, Toronto, ON M5G 2C1, Canada.	t.mak@oci.utoronto.ca	De La Pompa, José Luis/F-9719-2014	De La Pompa, José Luis/0000-0001-6761-7265				Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; Bennett PC, 1996, BRAIN RES, V730, P107; Buck Clayton A., 1993, Comptes Rendus de l'Academie des Sciences Serie III Sciences de la Vie, V316, P838; CHANG HY, 1995, NATURE, V376, P686, DOI 10.1038/376686a0; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; EISENBERG LM, 1995, CIRC RES, V77, P1, DOI 10.1161/01.RES.77.1.1; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; HOFFMAN JIE, 1995, PEDIATR CARDIOL, V16, P155; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; KIRBY ML, 1983, SCIENCE, V220, P1059, DOI 10.1126/science.6844926; Koop KE, 1996, MECH DEVELOP, V59, P73, DOI 10.1016/0925-4773(96)00582-5; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; RUNYAN RB, 1990, CELL REGUL, V1, P301, DOI 10.1091/mbc.1.3.301; SASSOON DA, 1988, DEVELOPMENT, V104, P155; Schilham MW, 1996, NATURE, V380, P711, DOI 10.1038/380711a0; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; TRUMPP A, 1992, GENE DEV, V6, P14, DOI 10.1101/gad.6.1.14	24	507	511	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 12	1998	392	6672					182	186		10.1038/32419	http://dx.doi.org/10.1038/32419			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB349	9515963				2022-12-28	WOS:000072462700063
J	Summitt, RL; Herrick, RR; Martins, M				Summitt, RL; Herrick, RR; Martins, M			Addressing a state's physician workforce priorities through the funding of graduate medical education - The TennCare model	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TENNESSEE	TennCare is Tennessee's innovative program that replaces the state's Medicaid program with a health care system based on managed care and designed to cover the vast majority of the state's poor and uninsured. The program provides health care benefits not only to those eligible for Medicaid, but also to the uninsured poor who do not qualify for Medicaid and those who are uninsurable because of existing medical conditions, This article describes the allocation of TennCare graduate medical education funding, which is designed to address the state's physician workforce priorities regarding specialty mix and practice location. Under the new TennCare graduate medical education funding design, funds flow to the state's 4 medical schools and then to the sites of the residents' training. Allocation to the medical schools is based primarily on the number of primary care residents in residency programs under sponsorship of each.	Univ Tennessee, Ctr Hlth Sci, Coll Med, Memphis, TN 38163 USA; Robert Herrick Associates Inc, Nashville, TN USA	University of Tennessee System; University of Tennessee Health Science Center	Summitt, RL (corresponding author), Univ Tennessee, Ctr Hlth Sci, Coll Med, Memphis, TN 38163 USA.							*GOV TENNC ROUNDT, 1995, INT REP GOV TENNC RO; MEYER G, 1996, INITIAL EFFECTS TENN; Meyer GS, 1996, JAMA-J AM MED ASSOC, V276, P672, DOI 10.1001/jama.276.9.672; MIRVIS DM, 1995, JAMA-J AM MED ASSOC, V274, P1235, DOI 10.1001/jama.274.15.1235; PLUMB DH, 1995, MEDICAID FUNDING GRA; *TN DEP FIN ADM, 1996, MEM UND TENN DEP FIN	6	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 11	1998	279	10					767	771		10.1001/jama.279.10.767	http://dx.doi.org/10.1001/jama.279.10.767			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA474	9508153				2022-12-28	WOS:000072366900034
J	Gray, RA; Pertsov, AM; Jalife, J				Gray, RA; Pertsov, AM; Jalife, J			Spatial and temporal organization during cardiac fibrillation	NATURE			English	Article							VENTRICULAR-FIBRILLATION; REENTRANT ACTIVITY; SPIRAL WAVES; TERMINATION; MECHANISM; HEART; MUSCLE	Cardiac fibrillation (spontaneous, asynchronous contractions of cardiac muscle fibres) is the leading cause of death in the industrialized world(1), yet it is not dear how it occurs. It has been debated whether or not fibrillation is a random phenomenon. There is some determinism during fibrillation(2,3), perhaps resulting from rotating waves of electrical activity(4-6). Here we present a new algorithm that markedly reduces the amount of data required to depict the complex spatiotemporal patterns of fibrillation. We use a potentiometric dye(7) and video imaging(8,9) to record the dynamics of transmembrane potentials at many sites during fibrillation. Transmembrane signals at each site exhibit a strong periodic component centred near 8 Hz. This periodicity is seen as an attractor in two-dimensional-phase space and each site can be represented by its phase around the attractor, Spatial phase maps at each instant reveal the 'sources' of fibrillation in the form of topological defects, or phase singularities(10), at a few sites. Using our method of identifying phase singularities, we can elucidate the mechanisms for the formation and termination of these singularities, and represent an episode of fibrillation by locating singularities. Our results indicate an unprecedented amount of temporal and spatial organization during cardiac fibrillation.	SUNY Hlth Sci Ctr, Dept Pharmacol, Syracuse, NY 13210 USA; Univ Alabama Birmingham, Dept Biomed Engn, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Pertsov, AM (corresponding author), SUNY Hlth Sci Ctr, Dept Pharmacol, 766 Irving Ave, Syracuse, NY 13210 USA.	rag@crml.uab.edu	Jalife, Jose/L-4833-2015; Jalife, Jose/AAJ-9156-2021; Gray, Richard/F-3916-2015	Jalife, Jose/0000-0003-0080-3500; Jalife, Jose/0000-0003-0080-3500; Gray, Richard/0000-0003-2798-6378				AGLADZE KI, 1982, NATURE, V296, P424, DOI 10.1038/296424a0; Allessie M, 1985, CARDIAC ELECTROPHYSI, P265, DOI DOI 10.1016/J.HRTHM.2012.03.008; BAYLY PV, 1993, J CARDIOVASC ELECTR, V4, P533, DOI 10.1111/j.1540-8167.1993.tb01242.x; BOVE RT, 1996, CIRCULATION, V94, P1; CHA YM, 1994, CIRC RES, V74, P495, DOI 10.1161/01.RES.74.3.495; DAVIDENKO JM, 1992, NATURE, V355, P349, DOI 10.1038/355349a0; FAST V G, 1990, Biophysics (English Translation of Biofizika), V35, P489; FITZHUGH R, 1961, BIOPHYS J, V1, P445, DOI 10.1016/S0006-3495(61)86902-6; Garfinkel A, 1997, J CLIN INVEST, V99, P305, DOI 10.1172/JCI119159; Glass L., 1988, CLOCKS CHAOS RHYTHMS; GOLDBETER A, 1975, NATURE, V253, P540, DOI 10.1038/253540a0; Gotoh M, 1997, CIRCULATION, V95, P2141, DOI 10.1161/01.CIR.95.8.2141; Gray RA, 1996, INT J BIFURCAT CHAOS, V6, P415, DOI 10.1142/S0218127496000163; GRAY RA, 1995, CIRCULATION, V91, P2454, DOI 10.1161/01.CIR.91.9.2454; GRAY RA, 1995, SCIENCE, V270, P1222, DOI 10.1126/science.270.5239.1222; Gray RA, 1997, CIRCULATION, V95, P1038; Ikeda T, 1996, CIRCULATION, V94, P1962, DOI 10.1161/01.CIR.94.8.1962; KRINSKY VI, 1978, PHARMACOL THER PT B, V3, P539, DOI 10.1016/S0306-039X(78)90020-X; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; Lee JJ, 1996, CIRC RES, V78, P660, DOI 10.1161/01.RES.78.4.660; MOE GK, 1959, AM HEART J, V58, P59, DOI 10.1016/0002-8703(59)90274-1; MYERBURG RJ, 1990, CARDIAC ELECTROPHYSI; PERTSOV AM, 1993, CIRC RES, V72, P631, DOI 10.1161/01.RES.72.3.631; SALZBERG BM, 1973, NATURE, V246, P508, DOI 10.1038/246508a0; Takens F., 1981, DYNAMICAL SYSTEMS TU, V898, P366, DOI [10.1007/bfb0091924, DOI 10.1007/BFB0091924, 10.1007/BFb0091924]; WINFREE AT, 1973, SCIENCE, V181, P937, DOI 10.1126/science.181.4103.937; WINFREE AT, 1994, SCIENCE, V266, P1003, DOI 10.1126/science.7973648; WINFREE AT, 1987, TIME BREAKS DOWN; WITKOWSKI FX, 1995, PHYS REV LETT, V75, P1230, DOI 10.1103/PhysRevLett.75.1230; Zykov V S, 1987, SIMULATION WAVE PROC	30	722	740	2	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 5	1998	392	6671					75	78		10.1038/32164	http://dx.doi.org/10.1038/32164			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA528	9510249				2022-12-28	WOS:000072373000052
J	Greenberg, DS				Greenberg, DS			Chance and grants	LANCET			English	Editorial Material																			0	15	15	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 28	1998	351	9103					686	686		10.1016/S0140-6736(05)78485-3	http://dx.doi.org/10.1016/S0140-6736(05)78485-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA447	9500372				2022-12-28	WOS:000072364200070
J	Corcoran, AE; Riddell, A; Krooshoop, D; Venkitaraman, AR				Corcoran, AE; Riddell, A; Krooshoop, D; Venkitaraman, AR			Impaired immunoglobulin gene rearrangement in mice lacking the IL-7 receptor	NATURE			English	Article							B-CELL DEVELOPMENT; LYMPHOCYTES-B; FETAL LIVER; BONE-MARROW; EXPRESSION; HEAVY; DIFFERENTIATION; TRANSCRIPTION; SEGMENTS; REGION	To generate the full diversity of antibody heavy-chain genes, hundreds of dispersed germline V segments must undergo recombination following D-J segment joining. Here we report that this process is regulated by the alpha-chain of the receptor for interleukin-7, a cytokine that stimulates B-cell lymphopoiesis(1). D-J joining occurs normally in immature B lymphocytes from mice lacking the alpha-chain of the interleukin-7 receptor (IL-7R alpha). But recombination of V segments is progressively impaired as their distance increases upstream of D/J, causing infrequent rearrangement of most V segments, which markedly reduces diversity. This is not simply due to defective cell proliferation or impaired recombinase expression. Rather, germline transcripts from distal, unrearranged V segments, a marker of chromatin changes that precede recombination, are specifically silenced. So too is expression of Pax-5, which binds to heavy-chain locus control elements and normally stimulates recombination, suggesting a mechanism for these effects. Thus ligands of the interleukin-7 receptor deliver an extrinsic signal that targets. V segment recombination in the heavy-chain locus by altering the accessibility of DNA substrates to the recombinase. This mechanism augments the recombinational diversity of the primary antibody repertoire.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Venkitaraman, AR (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	arv@mrc-lmb.cam.ac.uk						ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; CHANG Y, 1992, EMBO J, V11, P1891, DOI 10.1002/j.1460-2075.1992.tb05241.x; Corcoran AE, 1996, EMBO J, V15, P1924, DOI 10.1002/j.1460-2075.1996.tb00543.x; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; EHLICH A, 1994, CURR BIOL, V4, P127; GRAWUNDER U, 1995, IMMUNITY, V3, P601, DOI 10.1016/1074-7613(95)90131-0; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HONJO T, 1995, IMMUNOGLOBULIN GENES, P145; Kabat EA, 1991, SEQUENCES PROTEINS I; KITAMURA D, 1992, NATURE, V356, P154, DOI 10.1038/356154a0; LI YS, 1993, J EXP MED, V178, P951, DOI 10.1084/jem.178.3.951; LIN HH, 1995, NATURE, V376, P263, DOI 10.1038/376263a0; MADISEN L, 1994, GENE DEV, V8, P2212, DOI 10.1101/gad.8.18.2212; Marshall AJ, 1996, J IMMUNOL, V156, P2077; Michaelson JS, 1996, J IMMUNOL, V156, P2349; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Nutt SL, 1997, GENE DEV, V11, P476, DOI 10.1101/gad.11.4.476; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; RATHBUN GA, 1987, EMBO J, V6, P2931, DOI 10.1002/j.1460-2075.1987.tb02597.x; SCHLISSEL M, 1991, GENE DEV, V5, P1367, DOI 10.1101/gad.5.8.1367; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; tenBoekel E, 1997, IMMUNITY, V7, P357; TENBOEKEL E, 1995, INT IMMUNOL, V7, P1013; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; WU GE, 1986, EMBO J, V5, P3475, DOI 10.1002/j.1460-2075.1986.tb04672.x; YANCOPOULOS GD, 1986, ANNU REV IMMUNOL, V4, P339, DOI 10.1146/annurev.iy.04.040186.002011; YANCOPOULOS GD, 1985, CELL, V40, P271, DOI 10.1016/0092-8674(85)90141-2; YANCOPOULOS GD, 1984, NATURE, V311, P727, DOI 10.1038/311727a0	30	271	275	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 26	1998	391	6670					904	907		10.1038/36122	http://dx.doi.org/10.1038/36122			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ206	9495344				2022-12-28	WOS:000072230900055
J	Callen, JP				Callen, JP			Pyoderma gangrenosum	LANCET			English	Article							SUPERFICIAL GRANULOMATOUS PYODERMA; INFLAMMATORY BOWEL-DISEASE; ULCERATIVE-COLITIS; PYOSTOMATITIS VEGETANS; SODIUM CROMOGLYCATE; ASSOCIATION; CYCLOSPORINE; ARTHRITIS; ERUPTION; CHILDREN		Univ Louisville, Dept Dermatol, Louisville, KY 40292 USA	University of Louisville	Callen, JP (corresponding author), Univ Louisville, Dept Dermatol, Louisville, KY 40292 USA.							Adam DJ, 1996, J HAND SURG-BRIT EUR, V21B, P792, DOI 10.1016/S0266-7681(96)80193-8; AMELIO PX, 1994, EUR J DERMATOL, V4, P514; ASUGA I, 1997, RESP MED, V91, P493; BALLO FS, 1989, J AM ACAD DERMATOL, V21, P381, DOI 10.1016/S0190-9622(89)80040-4; BARNES L, 1986, J AM ACAD DERMATOL, V15, P608, DOI 10.1016/S0190-9622(86)70212-0; BROWN TS, 1997, SO MED J, V90, pA27; Brunsting LA, 1930, ARCH DERMATOL SYPH, V22, P655, DOI 10.1001/archderm.1930.01440160053009; Burruss JB, 1996, J AM ACAD DERMATOL, V35, P720, DOI 10.1016/S0190-9622(96)90727-6; CALLEN JP, 1989, J AM ACAD DERMATOL, V21, P515, DOI 10.1016/S0190-9622(89)70218-8; CALLEN JP, 1985, ARCH DERMATOL, V121, P339; CALLEN JP, 1976, ARCH DERMATOL, V113, P1585; Callen JP, 1990, DERMATOL CLIN, V7, P1249; Chow RKP, 1996, J AM ACAD DERMATOL, V34, P1047, DOI 10.1016/S0190-9622(96)90285-6; CLUGSTON PA, 1991, CAN J SURG, V34, P157; COX NH, 1987, CLIN EXP DERMATOL, V12, P375, DOI 10.1111/j.1365-2230.1987.tb02515.x; DAGAN O, 1995, PEDIATR DERMATOL, V12, P39, DOI 10.1111/j.1525-1470.1995.tb00122.x; DECOCK KM, 1980, BRIT J DERMATOL, V102, P231; DUFILL MB, 1994, AUSTRALAS J DERMATOL, V35, P15; Duguid C M, 1993, Australas J Dermatol, V34, P17, DOI 10.1111/j.1440-0960.1993.tb00841.x; DUGUID CM, 1993, CLIN DERMATOL, V11, P129, DOI 10.1016/0738-081X(93)90109-P; ELGART G, 1991, J AM ACAD DERMATOL, V24, P83, DOI 10.1016/0190-9622(91)70016-U; ESNAULT P, 1995, INT J DERMATOL, V34, P647, DOI 10.1111/j.1365-4362.1995.tb01101.x; FENSKE NA, 1983, ARCH DERMATOL, V119, P664, DOI 10.1001/archderm.119.8.664; FRIDUSS SR, 1992, J AM ACAD DERMATOL, V27, P356, DOI 10.1016/0190-9622(92)70199-P; Gibson LE, 1997, MAYO CLIN PROC, V72, P734; GRAHAM JA, 1994, PEDIATR DERMATOL, V11, P10, DOI 10.1111/j.1525-1470.1994.tb00065.x; GREEN LK, 1985, J AM ACAD DERMATOL, V13, P892, DOI 10.1016/S0190-9622(85)70236-8; GUPTA AK, 1995, J AM ACAD DERMATOL, V32, P140, DOI 10.1016/0190-9622(95)90218-X; HAY CRM, 1987, J CLIN PATHOL, V40, P387, DOI 10.1136/jcp.40.4.387; Hohenleutner U, 1997, LANCET, V350, P1748, DOI 10.1016/S0140-6736(05)63571-4; HOLT PJA, 1980, MEDICINE, V59, P114, DOI 10.1097/00005792-198003000-00003; JACKSON JM, 1997, J CUTAN MED SURG, V2, P1; JOHNSON RB, 1982, ARCH DERMATOL, V118, P76, DOI 10.1001/archderm.118.2.76; JORIZZO JL, 1988, INFLAMMATION BASIC P, P785; KANEL KT, 1987, AM J MED, V82, P1031, DOI 10.1016/0002-9343(87)90170-7; KAPLAN RP, 1987, J DERMATOL SURG ONC, V13, P1029, DOI 10.1111/j.1524-4725.1987.tb00581.x; KELTZ M, 1993, J AM ACAD DERMATOL, V37, P360; KO CB, 1992, INT J DERMATOL, V31, P574, DOI 10.1111/j.1365-4362.1992.tb02723.x; KOESTER G, 1993, J AM ACAD DERMATOL, V29, P875, DOI 10.1016/0190-9622(93)70261-Q; Lear JT, 1997, POSTGRAD MED J, V73, P65, DOI 10.1136/pgmj.73.856.65; LEBBE C, 1992, J AM ACAD DERMATOL, V27, P623, DOI 10.1016/S0190-9622(08)80200-9; LEVITT MD, 1991, BRIT J SURG, V78, P676, DOI 10.1002/bjs.1800780613; LEWIS SJ, 1978, JAMA-J AM MED ASSOC, V239, P935, DOI 10.1001/jama.239.10.935; Liu JW, 1997, LANCET, V350, P860, DOI 10.1016/S0140-6736(97)04454-1; LU ML, 1994, EUR J DERMATOL, V4, P540; MATIS WL, 1992, ARCH DERMATOL, V128, P1060, DOI 10.1001/archderm.128.8.1060; MCCALMONT CS, 1991, INT J GYNECOL OBSTET, V35, P175, DOI 10.1016/0020-7292(91)90823-N; MIRMADJLESSI SH, 1985, AM J GASTROENTEROL, V80, P615; MURRAY JC, 1983, CUTIS, V32, P503; NEWELL LM, 1982, ARCH DERMATOL, V118, P769, DOI 10.1001/archderm.1982.01650220073008; NEWELL LM, 1983, ARCH DERMATOL, V119, P477; NEWMAN WD, 1993, EYE, V7, P89, DOI 10.1038/eye.1993.19; Olivieri I, 1996, ARTHRITIS RHEUM, V39, P1062, DOI 10.1002/art.1780390627; OLOUGHLIN S, 1978, ARCH DERMATOL, V114, P1061, DOI 10.1001/archderm.114.7.1061; PALLER AS, 1990, J PEDIATR-US, V117, P63, DOI 10.1016/S0022-3476(05)82444-8; PERRY HO, 1969, SOUTHERN MED J, V62, P899, DOI 10.1097/00007611-196908000-00001; PERRY HO, 1972, ARCH DERMATOL, V106, P901, DOI 10.1001/archderm.106.6.901; PERRY HO, 1968, ARCH DERMATOL, V98, P561, DOI 10.1001/archderm.98.6.561; POWELL FC, 1983, BRIT J DERMATOL, V108, P287, DOI 10.1111/j.1365-2133.1983.tb03966.x; POWELL FC, 1983, ARCH DERMATOL, V119, P468, DOI 10.1001/archderm.119.6.468; Powell FC, 1996, J AM ACAD DERMATOL, V34, P395, DOI 10.1016/S0190-9622(96)90428-4; POWELL FC, 1985, Q J MED, V55, P173; PRYSTOWSKY JH, 1989, ARCH DERMATOL, V125, P57, DOI 10.1001/archderm.125.1.57; PYE RJ, 1977, CLIN EXP DERMATOL, V2, P33, DOI 10.1111/j.1365-2230.1977.tb01534.x; QUIMBY SR, 1989, MAYO CLIN PROC, V64, P37, DOI 10.1016/S0025-6196(12)65301-4; RAND RP, 1993, ANN THORAC SURG, V55, P1016, DOI 10.1016/0003-4975(93)90142-5; RICHARDSON JB, 1993, J AM ACAD DERMATOL, V28, P1005, DOI 10.1016/S0190-9622(08)80654-8; ROMANO J, 1979, ARCH INTERN MED, V139, P932, DOI 10.1001/archinte.139.8.932; ROSS HJ, 1991, CANCER, V68, P441, DOI 10.1002/1097-0142(19910715)68:2<441::AID-CNCR2820680239>3.0.CO;2-4; SANUSI ID, 1982, J UROLOGY, V127, P547, DOI 10.1016/S0022-5347(17)53905-1; SARKAR C, 1994, EUR J DERMATOL, V4, P532; SMITH DL, 1994, ARTHRITIS RHEUM, V37, P1258, DOI 10.1002/art.1780370823; SNYDER RA, 1986, ARCH DERMATOL, V122, P295, DOI 10.1001/archderm.122.3.295; SOTO L D, 1970, International Journal of Dermatology, V9, P293, DOI 10.1111/j.1365-4362.1970.tb04745.x; Stone MS, 1996, AM J MED, V100, P663; STONE N, 1997, BR J DERMATOL, V46; STORWICK GS, 1994, J AM ACAD DERMATOL, V31, P336, DOI 10.1016/S0190-9622(94)70167-9; STRUTTON G, 1995, J AM ACAD DERMATOL, V32, P192, DOI 10.1016/0190-9622(95)90125-6; SU WPD, 1986, J CUTAN PATHOL, V13, P323, DOI 10.1111/j.1600-0560.1986.tb00466.x; TALANSKY AL, 1993, J CLIN GASTROENTEROL, V108, P580; Tamir A, 1996, DERMATOLOGY, V192, P252, DOI 10.1159/000246377; Teitel AD, 1996, CUTIS, V57, P326; TSELE E, 1992, CLIN EXP DERMATOL, V17, P437, DOI 10.1111/j.1365-2230.1992.tb00254.x; VANHALE HM, 1985, ARCH DERMATOL, V121, P94, DOI 10.1001/archderm.121.1.94; VESTEY JP, 1988, INT J DERMATOL, V27, P654, DOI 10.1111/j.1365-4362.1988.tb02428.x; VIGNONPENNAMEN MD, 1995, EUR J DERMATOL, V5, P449; WERNIKOFF S, 1987, ARCH DERMATOL, V123, P371, DOI 10.1001/archderm.123.3.371; WILSONJONES E, 1988, J AM ACAD DERMATOL, V18, P511, DOI 10.1016/S0190-9622(88)70074-2; WOLFSEN HC, 1990, J CLIN GASTROENTEROL, V12, P651, DOI 10.1097/00004836-199012000-00011; ZONANANACACH A, 1994, J RHEUMATOL, V21, P1352	90	275	285	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 21	1998	351	9102					581	585		10.1016/S0140-6736(97)10187-8	http://dx.doi.org/10.1016/S0140-6736(97)10187-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ216	9492798				2022-12-28	WOS:000072231900043
J	Zhang, HB; Tombline, G; Weber, BL				Zhang, HB; Tombline, G; Weber, BL			BRCA1, BRCA2, and DNA damage response: Collision or collusion?	CELL			English	Review									Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Thomas Jefferson Univ, Dept Microbiol & Immunol Genet, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Program Mol Biol, Philadelphia, PA 19107 USA	University of Pennsylvania; University of Pennsylvania; Jefferson University; Jefferson University	Weber, BL (corresponding author), Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA.							Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Crook T, 1997, LANCET, V350, P638, DOI 10.1016/S0140-6736(05)63327-2; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; FREIDBERG EC, 1995, DNA REPAIR MUTAGENES; FRIEDMAN LS, 1998, IN PRESS CANC RES; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Rajan JV, 1997, DEV BIOL, V184, P385, DOI 10.1006/dbio.1997.8526; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941	20	119	126	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 20	1998	92	4					433	436		10.1016/S0092-8674(00)80936-8	http://dx.doi.org/10.1016/S0092-8674(00)80936-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YZ409	9491884	hybrid			2022-12-28	WOS:000072251500003
J	Witte, W				Witte, W			Medical consequences of antibiotic use in agriculture	SCIENCE			English	Article							RESISTANCE		Robert Koch Inst, Wernigerode Branch, D-38855 Wernigerode, Germany	Robert Koch Institute	Witte, W (corresponding author), Robert Koch Inst, Wernigerode Branch, D-38855 Wernigerode, Germany.		Ha, Dat Thinh/D-4995-2015	Ha, Dat Thinh/0000-0003-4260-4876				Arthur M, 1996, TRENDS MICROBIOL, V4, P401, DOI 10.1016/0966-842X(96)10063-9; DAVIES J, 1994, SCIENCE, V264, P375, DOI 10.1126/science.8153624; Gaunt PN, 1996, J ANTIMICROB CHEMOTH, V37, P747, DOI 10.1093/jac/37.4.747; Levy S B, 1994, Trends Microbiol, V2, P341, DOI 10.1016/0966-842X(94)90607-6; LEVY SB, 1976, NEW ENGL J MED, V295, P583, DOI 10.1056/NEJM197609092951103; Tenover FC, 1996, AM J MED SCI, V311, P9, DOI 10.1097/00000441-199601000-00003; THOMKE S, 1997, REPORT COMMISSION AN; TRELFALL J, 1996, LANCET, V347, P1053; TSCHAPE H, 1994, FEMS MICROBIOL ECOL, V15, P23, DOI 10.1016/0168-6496(94)90022-1; *WHO SCI WORK GROU, 1994, WHOCDSBVI957; Witte W, 1995, MICROB DRUG RESIST, V1, P259, DOI 10.1089/mdr.1995.1.259; 1997, WHO M MED IMP US ANT; 1969, REPORT JOINT COMMITT	13	628	657	1	196	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 13	1998	279	5353					996	997		10.1126/science.279.5353.996	http://dx.doi.org/10.1126/science.279.5353.996			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX100	9490487				2022-12-28	WOS:000072006400032
J	Kitchens, LW; Brennan, TA; Caroll, RJ; Clagett, CL; Dunn, LJ; Eden, KV; Lynn, J; Miles, SH; Povar, GJ; Schiedermayer, DL; Thompson, SH; Tulsky, JA				Kitchens, LW; Brennan, TA; Caroll, RJ; Clagett, CL; Dunn, LJ; Eden, KV; Lynn, J; Miles, SH; Povar, GJ; Schiedermayer, DL; Thompson, SH; Tulsky, JA		Amer Coll Phys	Ethics manual - Fourth edition	ANNALS OF INTERNAL MEDICINE			English	Article							HEALTH-CARE; PHYSICIANS; DISCRIMINATION; MEDICINE	Medicine, law, and social values are not static. Reexamining the ethical tenets of medical practice and their application in new circumstances is a necessary exercise. The fourth edition of the American College of Physicians Ethics Manual covers emerging issues in medical ethics and revisits old ones. It reflects on many of the ethical tensions faced by internists and their patients and attempts to shed light on how existing principles extend to emerging concerns. In addition, by reiterating ethical principles that have provided guidance in resolving past ethical problems, it may help physicians to avert future problems. The Manual is not a substitute for the experience and integrity of individual physicians, but it may serve as a reminder of the shared obligations and duties of the medical profession.			Kitchens, LW (corresponding author), Care of Snyder L, Amer Coll Phys, Independence Mall W,6th St & Race, Philadelphia, PA 19106 USA.							*AM AC NEUR EX BOA, 1989, POS AM AC NEUR CERT, V39, P125; American College of Physicians Ethics Manual, 1989, ANN INTERN MED, V111, P327; American College of Physicians Ethics Manual, 1989, ANN INTERN MED, V111, P245; ANNAS GJ, 1991, NEW ENGL J MED, V324, P1210, DOI 10.1056/NEJM199104253241711; [Anonymous], 1989, PEDIATRICS, V83, P135; [Anonymous], 1990, NEW MED OLD ETHICS; BATTIN MP, 1995, ACAD MED, V70, P583; Beauchamp TL, 2009, PRINCIPLES BIOMEDICA; BUCHAN ML, 1995, J CLIN ETHIC, V6, P53; BURNUM JF, 1991, NEW ENGL J MED, V324, P1130, DOI 10.1056/NEJM199104183241611; Cassel CK, 1996, NEW ENGL J MED, V335, P1232, DOI 10.1056/NEJM199610173351612; Clever L, 1997, NEW ENGL J MED, V336, P309; *COMM RES INT, 1995, INT MISC RES; CONLEY FK, 1993, NEW ENGL J MED, V328, P351, DOI 10.1056/NEJM199302043280513; Dunn P M, 1994, Ann Intern Med, V121, P627; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Fletcher JC, 1996, J CLIN ETHIC, V7, P122; Geller G, 1997, JAMA-J AM MED ASSOC, V277, P1467, DOI 10.1001/jama.277.18.1467; *HAST CTR, 1987, GUID TERM LIF SUST T; HENDEE WR, 1990, JAMA-J AM MED ASSOC, V263, P426; *I MED, 1997, APPR DEATH IMPR CAR; *JOINT COMM ACCR H, 1992, ACCR MAN HOSP, P106; KATZ J, 1997, SILENT WORLD DOCTOR; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; LaPuma J, 1995, Trends Health Care Law Ethics, V10, P73; Levine RJ, 1986, ETHICS REGULATION CL, V2nd; LIND SE, 1988, CLIN RES, V36, P546; LIND SE, 1990, NEW ENGL J MED, V323, P192, DOI 10.1056/NEJM199007193230310; MCMURRAY RJ, 1991, JAMA-J AM MED ASSOC, V266, P2741, DOI 10.1001/jama.1991.03470190089035; Mechanic D, 1996, JAMA-J AM MED ASSOC, V275, P1693, DOI 10.1001/jama.275.21.1693; MURRAY RH, 1992, NEW ENGL J MED, V326, P61, DOI 10.1056/NEJM199201023260113; *NEW YORK STAT TAS, 1994, DEATH IS SOUGHT ASS; ORENTLICHER D, 1992, JAMA-J AM MED ASSOC, V267, P2366; Peabody FW, 1927, J AMER MED ASSOC, V88, P0877, DOI 10.1001/jama.1927.02680380001001; POVAR G, 1988, ANN INTERN MED, V109, P419, DOI 10.7326/0003-4819-109-5-419; *PRES COMM STUD ET, 1983, SEC ACC HLTH CAR REP; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1982, SPLICING LIFE REPORT; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, SCREEN COUNS GEN CON; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DEC FORG LIF SUST TR; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1982, MAK HLTH CAR DEC REP; QUILL TE, 1991, ARCH INTERN MED, V151, P463; Reiser S. J., 1977, ETHICS MED HIST PERS; Roter DL, 1997, JAMA-J AM MED ASSOC, V277, P350, DOI 10.1001/jama.277.4.350; Rothman D., 1991, STRANGERS BEDSIDE HI, DOI DOI 10.4324/9781315130286; Rozovsky F.A., 1990, CONSENT TREATMENT PR; SNYDER L, 1989, ANN INTERN MED, V110, P930; SNYDER L, 1990, ANN INTERN MED, V112, P802, DOI 10.7326/0003-4819-112-11-802; SNYDER L, 1990, ANN INTERN MED, V113, P789, DOI 10.7326/0003-4819-113-10-789; Snyder L, 1996, ETHICAL CHOICES CASE, P105; SNYDER L, 1996, ETHICAL CHOICES CASE, P63; SNYDER L, 1996, ETHICAL CHOICES CASE, P35; TOLLE SW, 1987, ANN INTERN MED, V106, P740, DOI 10.7326/0003-4819-106-5-740; TOLLE SW, 1996, ETHICAL CHOICES CASE, P17; United Nations, 1955, 1 C PREV CRIM TREATM; VARKI A, 1992, ANN INTERN MED, V116, P762, DOI 10.7326/0003-4819-116-9-762; Veatch Robert M, 1981, THEORY MED ETHICS, V1; WEINER J, 1996, ETHICAL CHOICES CASE, P79; WEINER J, 1996, THICAL CHOICES CASE, P71; WEINER J, 1996, ETHICAL CHOICES CASE, P53; WHITE LJ, 1990, ANN INTERN MED, V112, P624, DOI 10.7326/0003-4819-112-8-624; WHITE LJ, 1988, ANN INTERN MED, V108, P460, DOI 10.7326/0003-4819-108-3-460; WHITE LJ, 1989, ANN INTERN MED, V111, P843, DOI 10.7326/0003-4819-111-10-843; Zinn W, 1996, J GEN INTERN MED, V11, P525, DOI 10.1007/BF02599599; 1991, AM REV RESP DIS 1, V144, P726; 1986, J R COLL PHYSICIANS, V20, P235; 1997, ACP OBSERVER, V17, P30	66	168	171	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1998	128	7					576	594		10.7326/0003-4819-128-7-199804010-00012	http://dx.doi.org/10.7326/0003-4819-128-7-199804010-00012			19	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE539	9518406				2022-12-28	WOS:000072803500012
J	Pomerantz, J; Schreiber-Agus, N; Liegeois, NJ; Silverman, A; Alland, L; Chin, L; Potes, J; Chen, K; Orlow, I; Lee, HW; Cordon-Cardo, C; DePinho, RA				Pomerantz, J; Schreiber-Agus, N; Liegeois, NJ; Silverman, A; Alland, L; Chin, L; Potes, J; Chen, K; Orlow, I; Lee, HW; Cordon-Cardo, C; DePinho, RA			The Ink4a tumor suppressor gene product, p19(Arf), interacts with MDM2 and neutralizes MDM2's inhibition of p53	CELL			English	Article							CELL-CYCLE CONTROL; WILD-TYPE P53; RETINOBLASTOMA-PROTEIN; TRANSCRIPTIONAL ACTIVATION; GROWTH SUPPRESSION; GERMLINE MUTATIONS; ONCOPROTEIN MDM2; TRANSGENIC MICE; T-ANTIGEN; TRANSFORMATION	The INK4a gene encodes two distinct growth inhibitors-the cyclin-dependent kinase inhibitor p16(Ink4a), which is a component of the Rb pathway, and the tumor suppressor p19(Arf), which has been functionally linked to p53. Here we show that p19(Arf) potently suppresses oncogenic transformation in primary cells and that this function is abrogated when p53 is neutralized by viral oncoproteins and dominant-negative mutants but not by the p53 antagonist MDM2. This finding, coupled with the observations that p19(Arf) and MDM2 physically interact and that p19(Arf) blocks MDM2-induced p53 degradation and transactivational silencing, suggests that p19(Arf) functions mechanistically to prevent MDM2's neutralization of p53. Together, our findings ascribe INK4a's potent tumor suppressor activity to the cooperative actions of its two protein products and their relation to the two central growth control pathways, Rb and p53.	Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Pediat, Div Pediat Hematol Oncol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Div Dermatol, Bronx, NY 10461 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Memorial Sloan Kettering Cancer Center	DePinho, RA (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.			DePinho, Ronald/0000-0002-5625-577X	NCI NIH HHS [CADK97650, CA47538, CA47179] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA047179, U01CA047538, R01CA047538] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; Bartkova J, 1996, CANCER RES, V56, P5475; Brenner AJ, 1996, CLIN CANCER RES, V2, P1993; BROWN DR, 1993, MOL CELL BIOL, V13, P6849, DOI 10.1128/MCB.13.11.6849; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN JD, 1995, MOL MED, V1, P141; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; CORDONCARDO C, 1995, AM J PATHOL, V147, P545; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; Elledge SJ, 1996, TRENDS CELL BIOL, V6, P388, DOI 10.1016/0962-8924(96)10030-1; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FANNING E, 1992, J VIROL, V66, P1289, DOI 10.1128/JVI.66.3.1289-1293.1992; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GRUIS NA, 1995, AM J PATHOL, V146, P1199; Hangaishi A, 1996, BLOOD, V87, P4949, DOI 10.1182/blood.V87.12.4949.bloodjournal87124949; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Heinzel PA, 1996, INT J CANCER, V68, P420, DOI 10.1002/(SICI)1097-0215(19961115)68:4<420::AID-IJC3>3.0.CO;2-2; Henning W, 1997, J VIROL, V71, P7609, DOI 10.1128/JVI.71.10.7609-7618.1997; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kinoshita I, 1996, CANCER RES, V56, P5557; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MAHON KA, 1987, SCIENCE, V235, P1622, DOI 10.1126/science.3029873; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MUNGER K, 1989, J VIROL, V63, P4417; NEWCOMB EW, 1995, MOL CARCINOGEN, V14, P141, DOI 10.1002/mc.2940140302; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; QUELLE DE, 1995, ONCOGENE, V11, P635; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SCHREIBERAGUS N, 1994, ONCOGENE, V9, P3167; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; VANDYKE TA, 1994, SEMIN CANCER BIOL, V5, P47; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	66	1287	1323	1	47	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 20	1998	92	6					713	723		10.1016/S0092-8674(00)81400-2	http://dx.doi.org/10.1016/S0092-8674(00)81400-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZD198	9529248	Bronze			2022-12-28	WOS:000072661200005
J	Gilman, S				Gilman, S			Imaging the brain part 1	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							POSITRON EMISSION TOMOGRAPHY; SUBARACHNOID HEMORRHAGE; INTRACRANIAL ANEURYSMS; ARTERY DISSECTION; MR-ANGIOGRAPHY; STROKE; MANAGEMENT; LANGUAGE; INFARCT; ISSUES		Univ Michigan, Med Ctr, Dept Neurol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Gilman, S (corresponding author), Univ Michigan, Med Ctr, Dept Neurol, 1500 E Med Ctr Dr,TC 1914, Ann Arbor, MI 48109 USA.							Adams HP, 1996, NEUROLOGY, V47, P835; Altrocchi PH, 1996, NEUROLOGY, V46, P278; ATLAS SW, 1991, MAGNETIC RESONANCE I; Bakke SJ, 1996, ACTA RADIOL, V37, P529; BOTTINI G, 1994, BRAIN, V117, P1241, DOI 10.1093/brain/117.6.1241; Desmond JE, 1995, BRAIN, V118, P1411, DOI 10.1093/brain/118.6.1411; Fazekas F, 1996, STROKE, V27, P607, DOI 10.1161/01.STR.27.4.607; Frey KA, 1996, ANN NEUROL, V40, P873, DOI 10.1002/ana.410400609; GILMAN S, 1995, ANN NEUROL, V38, P176, DOI 10.1002/ana.410380209; Gilman S, 1996, ANN NEUROL, V40, P885, DOI 10.1002/ana.410400610; GREENBERG JO, 1995, NEUROIMAGING COMPANI; GROSSMAN RI, 1994, NEURORADIOLOGY REQUI; Harrison MJ, 1997, NEUROSURGERY, V40, P947, DOI 10.1097/00006123-199705000-00014; HUSTON J, 1994, AM J NEURORADIOL, V15, P1607; Kanal E, 1996, RADIOLOGY, V200, P576, DOI 10.1148/radiology.200.2.8685361; Khurana DS, 1996, PEDIATR NEUROL, V14, P255, DOI 10.1016/0887-8994(96)00015-X; KLUCZNIK RP, 1993, RADIOLOGY, V187, P855, DOI 10.1148/radiology.187.3.8497645; Lutsep HL, 1997, ANN NEUROL, V41, P574, DOI 10.1002/ana.410410505; Madar I, 1997, ANN NEUROL, V41, P358, DOI 10.1002/ana.410410311; Marks MP, 1996, RADIOLOGY, V199, P403, DOI 10.1148/radiology.199.2.8668785; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Mattay VS, 1996, RADIOLOGY, V201, P399, DOI 10.1148/radiology.201.2.8888231; MAYBERG MR, 1994, STROKE, V25, P2315, DOI 10.1161/01.STR.25.11.2315; MAZZIOTTA JC, 1992, CLIN BRAIN IMAGING P; Meltzer CC, 1996, NEUROLOGY, V47, P454, DOI 10.1212/WNL.47.2.454; Morris P, 1997, PRACTICAL NEUROANGIO; Moulin T, 1996, NEUROLOGY, V47, P366, DOI 10.1212/WNL.47.2.366; Mullan S, 1996, J NEUROSURG, V85, P9, DOI 10.3171/jns.1996.85.1.0009; Newton T.H., 1981, RADIOLOGY SKULL BRAI, V5; Osborn, 1980, INTRO CEREBRAL ANGIO; Osborn AG, 1994, DIAGNOSTIC NEURORADI; ROTHMAN DL, 1993, P NATL ACAD SCI USA, V90, P5662, DOI 10.1073/pnas.90.12.5662; SASIADEK M, 1990, COMPUT MED IMAG GRAP, V14, P89, DOI 10.1016/0895-6111(90)90145-2; Schievink WI, 1997, NEW ENGL J MED, V336, P28, DOI 10.1056/NEJM199701023360106; Schneider LB, 1996, AM J NEURORADIOL, V17, P1259; SHELLOCK F, 1997, POCKET GUIDE MR PROC; Sorensen AG, 1996, RADIOLOGY, V199, P391, DOI 10.1148/radiology.199.2.8668784; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; Toni D, 1996, NEUROLOGY, V46, P341, DOI 10.1212/WNL.46.2.341; WAIDHAUSER E, 1990, NEUROSURG REV, V13, P211, DOI 10.1007/BF00313021; Wang ZY, 1996, AM J ROENTGENOL, V167, P191, DOI 10.2214/ajr.167.1.8659371; WARACH S, 1995, ANN NEUROL, V37, P231, DOI 10.1002/ana.410370214; Wieshmann UC, 1996, J NEUROL NEUROSUR PS, V61, P357, DOI 10.1136/jnnp.61.4.357; Wilcock D, 1996, CLIN RADIOL, V51, P330, DOI 10.1016/S0009-9260(96)80109-7; WILLIAMS AL, 1995, CRANIAL COMPUTED TOM; WOODRUFF WW, 1993, FUNDAMENTALS NEUROIM	46	62	63	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 19	1998	338	12					812	820		10.1056/NEJM199803193381207	http://dx.doi.org/10.1056/NEJM199803193381207			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC163	9504943				2022-12-28	WOS:000072546800007
J	Conrad, DA; Maynard, C; Cheadle, A; Ramsey, S; Marcus-Smith, M; Kirz, H; Madden, CA; Martin, D; Perrin, EB; Wickizer, T; Zierler, B; Ross, A; Noren, J; Liang, SY				Conrad, DA; Maynard, C; Cheadle, A; Ramsey, S; Marcus-Smith, M; Kirz, H; Madden, CA; Martin, D; Perrin, EB; Wickizer, T; Zierler, B; Ross, A; Noren, J; Liang, SY			Primary care physician compensation method in medical groups - Does it influence the use and cost of health services for enrollees in managed care organizations?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DISEASE PREVENTION; PARTNERSHIPS; INCENTIVES; EFFICIENCY; CAPITATION; ISSUES	Context.-Growth of at-risk managed care contracts between health plans and medical groups has been well documented, but less is known about the nature of financial incentives within those medical groups or their effects on health care utilization. Objective.-To test whether utilization and cost of health services per enrollee were influenced independently by the compensation method of the enrollee's primary care physician. Design.-Survey of medical groups contracting with selected managed care health plans, linked to 1994 plan enrollment and utilization data for adult enrollees. Setting.-Medical groups, major managed care hearth plans, and their patients/enrollees in the state of Washington. Study Participants.-Sixty medical groups in Washington, 865 primary care physicians (internal medicine, pediatrics, family practice, or general practice) from those groups and affiliated with 1 or more of 4 managed care health plans, and 200 931 adult plan enrollees. Intervention.-The effect of method of primary care physician's compensation on the utilization and cost of health services was analyzed by weighted least squares and random effects regression. Main Outcome Measures.-Total visits, hospital days, and per member per year estimated costs. Results.-Compensation method was not significantly (P>.30) related to utilization and cost in any multivariate analyses. Patient age (P<.001), female gender (P<.001), and plan benefit level (P<.001) were significantly positively related to visits, hospital days, and per member per year costs. The primary care physician's age was significantly negatively related (P<.001) to all 3 dependent measures. Conclusions.-Compensation method was not significantly related to use and cost of health services per person. Enrollee, physician, and health plan benefit factors were the prime determinants of utilization and cost of health services.	Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Conrad, DA (corresponding author), Univ Washington, Dept Hlth Serv, POB 357660, Seattle, WA 98195 USA.		Maynard, Charles/N-3906-2015	Maynard, Charles/0000-0002-1644-7814				Conrad D, 1996, HEALTH SERV RES, V31, P235; Gaynor M, 1995, RAND J ECON, V26, P591, DOI 10.2307/2556008; GAYNOR M, 1990, J POLIT ECON, V98, P544, DOI 10.1086/261694; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; HILLMAN AL, 1989, NEW ENGL J MED, V321, P86, DOI 10.1056/NEJM198907133210205; HILLMAN AL, 1992, MED CARE, V30, P136, DOI 10.1097/00005650-199202000-00005; KOEPSELL TD, 1991, J CLIN EPIDEMIOL, V44, P701, DOI 10.1016/0895-4356(91)90030-D; MANNING W, 1988, HLTH INSURGANCE EXPT, P1; MANNING WG, 1984, NEW ENGL J MED, V310, P1505, DOI 10.1056/NEJM198406073102305; ROBINSON JC, 1995, NEW ENGL J MED, V333, P1684, DOI 10.1056/NEJM199512213332506; SALONEN JT, 1986, INT J EPIDEMIOL, V15, P176, DOI 10.1093/ije/15.2.176; Simon CJ, 1997, HEALTH AFFAIR, V16, P120, DOI 10.1377/hlthaff.16.3.120; STEARNS SC, 1992, INQUIRY-J HEALTH CAR, V29, P416; *US DEP HHS, 1994, VITAL HLTH STAT PUBL; WEINER JP, 1991, MED CARE, V29, P452, DOI 10.1097/00005650-199105000-00006; WHITINGOKEEFE QE, 1984, MED CARE, V22, P1101, DOI 10.1097/00005650-198412000-00005; WILLIAMS PT, 1981, J CHRON DIS, V34, P565, DOI 10.1016/0021-9681(81)90019-9; World Health Organisation, 1977, INT CLASS DIS 9 REV; Zierler BK, 1998, AM J MANAG CARE, V4, P209	19	87	87	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 18	1998	279	11					853	858		10.1001/jama.279.11.853	http://dx.doi.org/10.1001/jama.279.11.853			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZA943	9516000	Bronze			2022-12-28	WOS:000072417600032
J	Chang, HJ; Miller, HL; Watkins, N; Arduino, MJ; Ashford, DA; Midgley, G; Aguero, SM; Pinto-Powell, R; von Reyn, F; Edwards, W; McNeil, MM; Jarvis, WR				Chang, HJ; Miller, HL; Watkins, N; Arduino, MJ; Ashford, DA; Midgley, G; Aguero, SM; Pinto-Powell, R; von Reyn, F; Edwards, W; McNeil, MM; Jarvis, WR			An epidemic of Malassezia pachydermatis in an intensive care nursery associated with colonization of health care workers pet dogs	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INFANTS; INFECTIONS; SEVERITY; FURFUR; UNIT; DNA	Background Malassezia species are lipophilic yeasts that are emerging as nosocomial pathogens, particularly in low-birth-weight neonates who receive lipid emulsions. When a cluster of patients with Malassezia pachydermatis infection was identified in an intensive care nursery, we initiated an investigation. Methods A case patient was defined as any infant in the intensive care nursery who had a positive culture for M. pachydermatis between October 17, 1993, and January 18, 1995. We conducted a cohort study to identify risk factors for colonization and infection with M. pachydermatis. We collected cultures from the infants and the health care workers and from the health care workers' pets, since this organism has been associated with otitis externa in dogs. Results Fifteen infants met the case definition: eight with bloodstream infections, two with urinary tract infections, one with meningitis, and four with asymptomatic colonization. The case patients were significantly more likely than the other infants to weigh 1300 g or less (15 of 65 vs. 0 of 419, P<0.001). In a multivariate analysis of infants weighing 1300 g or less, the independent risk factors for colonization or infection with M. pachydermatis were a greater severity of concomitant illness (odds ratio, 19.7; P=0.001), arterial catheterization for nine or more days (odds ratio, 29.5; P=0.02), and exposure to Nurse A (odds ratio, 74.7; P=0.01). In a point-prevalence survey, 9 additional infants, 1 health care worker, and 12 of the health care workers' pet dogs had positive cultures for M. pachydermatis. The isolates from all 15 case patients, the 9 additional colonized infants, 1 health care worker, and 3 of the 12 dogs had identical patterns of restriction-fragment-length polymorphisms. Conclusions In this outbreak, it is likely that M. pachydermatis was introduced into the intensive care nursery on health care workers' hands after being colonized from pet dogs at home. The organism persisted in the nursery through patient-to-patient transmission. (C)1998, Massachusetts Medical Society.	Ctr Dis Control, Hosp Infect Program, Atlanta, GA 30333 USA; Ctr Dis Control, Div Bacterial & Mycot Dis, Atlanta, GA 30333 USA; Ctr Dis Control, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Univ Chicago, Robert Wood Johnson Clin Scholars Program, Chicago, IL 60637 USA; Univ Illinois, Chicago, IL USA; Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA; St Thomas Hosp, London, England	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; University of Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Dartmouth College; Guy's & St Thomas' NHS Foundation Trust	Jarvis, WR (corresponding author), Ctr Dis Control, Hosp Infect Program, Mailstop E-69, Atlanta, GA 30333 USA.		Arduino, Matthew/C-1461-2012	Arduino, Matthew/0000-0001-7072-538X; McNeil, Michael/0000-0003-0713-8312				ABOUGABAL M, 1979, MYKOSEN, V22, P192; Bandhaya Mayouree, 1993, Southeast Asian Journal of Tropical Medicine and Public Health, V24, P343; DANKNER WM, 1987, REV INFECT DIS, V9, P743; Dean AG, 1994, EPI INFO VERSION 6 0; GRAY JE, 1995, PEDIATRICS, V95, P225; GUEHO E, 1987, J CLIN MICROBIOL, V25, P1789, DOI 10.1128/JCM.25.9.1789-1790.1987; Gueho E, 1996, ANTON LEEUW INT J G, V69, P337, DOI 10.1007/BF00399623; LAROCCO M, 1988, PEDIATR INFECT DIS J, V7, P398, DOI 10.1097/00006454-198806000-00006; LEEMING JP, 1995, PEDIATR INFECT DIS J, V14, P719, DOI 10.1097/00006454-199508000-00018; LONG JG, 1985, PEDIATRICS, V76, P896; PETERSEN NJ, 1973, HEALTH LAB SCI, V10, P18; RICHARDSON DK, 1993, PEDIATRICS, V91, P617; RICHET HM, 1989, J CLIN MICROBIOL, V27, P1197, DOI 10.1128/JCM.27.6.1197-1200.1989; *SAS I, 1990, SAS PROC GUID PC SAS; SCHERER S, 1987, J CLIN MICROBIOL, V25, P675, DOI 10.1128/JCM.25.4.675-679.1987; VARMA A, 1989, J GEN MICROBIOL, V135, P3353; WEIDMAN FD, 1925, REP LAB MUS COMP PAT, V53, P36; WELBEL SF, 1994, PEDIATR INFECT DIS J, V13, P104, DOI 10.1097/00006454-199402000-00005	18	177	189	1	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 12	1998	338	11					706	711		10.1056/NEJM199803123381102	http://dx.doi.org/10.1056/NEJM199803123381102			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB546	9494146	Bronze			2022-12-28	WOS:000072483400002
J	Chen, L; Glover, JNM; Hogan, PG; Rao, A; Harrison, SC				Chen, L; Glover, JNM; Hogan, PG; Rao, A; Harrison, SC			Structure of the DNA binding domains from NFAT, Fos and Jun bound specifically to DNA	NATURE			English	Article							ACTIVATED T-CELLS; TRANSCRIPTION FACTOR NFAT1; NUCLEAR FACTOR; CRYSTAL-STRUCTURE; CYCLOSPORINE-A; CALCINEURIN; FAMILY; COMPLEX; GENE; AP-1	The nuclear factor of activated T cells (NFAT) and the AP-1 heterodimer, Fos-Jun, cooperatively bind a composite DNA site and synergistically activate the expression of many immune-response genes. A 2.7-Angstrom-resolution crystal structure of the DNA-binding domains of NFAT, Fos and Jun, in a quaternary complex with a DNA fragment containing the distal antigen-receptor response element from the interleukin-2 gene promoter, shows an extended interface between NFAT and AP-1, facilitated by the bending of Fos and DNA, The tight association of the three proteins on DNA creates a continuous groove for the recognition of 15 base pairs.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Harvard Univ, Howard Hughes Med Inst, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA	Harvard University; Harvard University; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Harrison, SC (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.	schadmin@crystal.harvard.edu	chen, Lin/A-3392-2008	chen, Lin/0000-0003-4798-6199				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; BRUNGER A, 1992, XPLOR VERSION 3 0 SY; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHEN L, 1995, CURR BIOL, V5, P882, DOI 10.1016/S0960-9822(95)00178-3; CHEN L, 1994, THESIS HARVARD U; Chytil M, 1996, CURR OPIN STRUC BIOL, V6, P91, DOI 10.1016/S0959-440X(96)80100-X; COCKERILL PN, 1995, MOL CELL BIOL, V15, P2071; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; GARRITY PA, 1994, MOL CELL BIOL, V14, P2159, DOI 10.1128/MCB.14.3.2159; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JAIN JN, 1995, J BIOL CHEM, V270, P4138, DOI 10.1074/jbc.270.8.4138; JAIN JN, 1993, J IMMUNOL, V151, P837; Johnson A. A, 1992, TRANSCRIPTIONAL REGU, P975; JONES TA, 1989, CRYSTALLOGRAPHIC COM; KLEYWEGT GJ, 1994, 1 MAP FINAL MODEL; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Luo C, 1996, P NATL ACAD SCI USA, V93, P8907, DOI 10.1073/pnas.93.17.8907; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; Peterson BR, 1996, P NATL ACAD SCI USA, V93, P13671, DOI 10.1073/pnas.93.24.13671; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SERFLING E, 1995, BBA-GENE STRUCT EXPR, V1263, P181, DOI 10.1016/0167-4781(95)00112-T; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Sun LJ, 1997, P NATL ACAD SCI USA, V94, P4919, DOI 10.1073/pnas.94.10.4919; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Wolfe SA, 1997, NATURE, V385, P172, DOI 10.1038/385172a0; YAMAMOTO KR, 1992, TRANSCRIPTIONAL REGU, P1169	50	408	427	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 5	1998	392	6671					42	48		10.1038/32100	http://dx.doi.org/10.1038/32100			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA528	9510247				2022-12-28	WOS:000072373000042
J	Davis, GW; Goodman, CS				Davis, GW; Goodman, CS			Synapse-specific control of synaptic efficacy at the terminals of a single neuron	NATURE			English	Article							GROWTH CONE GUIDANCE; FUNCTIONAL COMPONENTS; GENETIC DISSECTION; PLASTICITY; DROSOPHILA; EXPRESSION; MEMORY	The regulation of synaptic efficacy is essential for the proper functioning of neural circuits, If synaptic gain is set too high or too low cells are either activated inappropriately or remain silent. There is extra complexity because synapses are not static, but form, retract, expand, strengthen, and weaken throughout life, Homeostatic regulatory mechanisms that control synaptic efficacy presumably exist to ensure that neurons remain functional within a meaningful physiological range(1-5). One of the best defined systems for analysis of the mechanisms that regulate synaptic efficacy is the neuromuscular junction. It has been shown, in organisms ranging from insects to humans, that changes in synaptic efficacy are tightly coupled to changes in muscle size during development(1,6-8). It has been proposed that a signal from muscle to motor neuron maintains this coupling(9). Here we show, by genetically manipulating muscle innervation, that there are two independent mechanisms by which muscle regulates synaptic efficacy at the terminals of single motor neurons. Increased muscle innervation results in a compensatory, target-specific decrease in presynaptic transmitter release, implying a retrograde regulation of presynaptic release, Decreased muscle innervation results in a compensatory increase in quantal size.	Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Div Neurobiol, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley	Davis, GW (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Div Neurobiol, LSA Room 519, Berkeley, CA 94720 USA.	gdavis@coreys.berkeley.edu						Abraham WC, 1996, TRENDS NEUROSCI, V19, P126, DOI 10.1016/S0166-2236(96)80018-X; [Anonymous], [No title captured]; Bear MF, 1996, P NATL ACAD SCI USA, V93, P13453, DOI 10.1073/pnas.93.24.13453; BRAND AH, 1993, DEVELOPMENT, V118, P401; Davis GW, 1997, NEURON, V19, P561, DOI 10.1016/S0896-6273(00)80372-4; FRANK E, 1973, J PHYSIOL-LONDON, V233, P635, DOI 10.1113/jphysiol.1973.sp010327; GOVIND CK, 1981, SCIENCE, V212, P1522, DOI 10.1126/science.7233240; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; JAN LY, 1976, J PHYSIOL-LONDON, V262, P189, DOI 10.1113/jphysiol.1976.sp011592; KESHISHIAN H, 1995, J NEUROBIOL, V24, P575; LICHTMAN JW, 1987, J NEUROSCI, V7, P1215; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; Marder E, 1996, P NATL ACAD SCI USA, V93, P13481, DOI 10.1073/pnas.93.24.13481; Miller KD, 1996, NEURON, V17, P371, DOI 10.1016/S0896-6273(00)80169-5; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; Schuster CM, 1996, NEURON, V17, P655, DOI 10.1016/S0896-6273(00)80198-1; Schuster CM, 1996, NEURON, V17, P641, DOI 10.1016/S0896-6273(00)80197-X; Stewart BA, 1996, J NEUROSCI, V16, P3877; STEWART BA, 1994, J COMP PHYSL, V175, P175	19	188	189	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 5	1998	392	6671					82	86		10.1038/32176	http://dx.doi.org/10.1038/32176			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA528	9510251				2022-12-28	WOS:000072373000054
J	Gharib, H; Mazzaferri, EL				Gharib, H; Mazzaferri, EL			Thyroxine suppressive therapy in patients with nodular thyroid disease	ANNALS OF INTERNAL MEDICINE			English	Review							BONE-MINERAL DENSITY; NEEDLE ASPIRATION CYTOLOGY; SPORADIC NONTOXIC GOITER; TERM FOLLOW-UP; SUBCLINICAL HYPERTHYROIDISM; BENIGN SOLITARY; PREMENOPAUSAL WOMEN; RANDOMIZED TRIAL; COLD NODULES; RISK FACTOR	Purpose: To review evidence about thyroxine suppressive therapy in patients with thyroid nodules, including the clinical importance and natural history of nodules and the effects and potential side effects of thyroxine therapy. Data Sources: English-language articles published from 1986 to December 1996 were identified through searches of the MEDLINE database, selected bibliographies, and personal files. Data Extraction: Randomized, controlled trials and nonrandomized trials of thyroxine suppressive therapy for solitary and predominantly solid thyroid nodules were reviewed. In most studies, nodule cytology was evaluated by fine-needle aspiration biopsy. Therapy was considered suppressive if suppression was documented by thyroid-stimulating hormone-releasing hormone tests or sensitive thyroid-stimulating hormone assays. Response was defined as a decrease of 50% or more in nodule size or volume; most recent studies measured nodule size by ultrasonography. Data Synthesis: The evidence suggests that thyroxine suppressive therapy fails to shrink most nodules: Only 10% to 20% of nodules responded to this treatment. Fine-needle aspiration biopsy is more reliable in distinguishing benign from malignant nodules. Recent studies suggest that spontaneous decrease in size with complete disappearance of thyroid nodules is not uncommon. No data show that thyroxine therapy arrests further growth in most existing nodules or prevents the emergence of new nodules. Postoperative thyroxine therapy does not seem to prevent recurrence of thyroid nodules except in patients with a history of radiation therapy. Potential adverse effects of long-term suppressive therapy include osteoporosis and heart disease. Conclusions: Patients with cytologically benign nodules are best followed without thyroxine treatment. Most benign nodules remain stable in size and remain benign when monitored for a long time. For nodules that increase in size, biopsy should be done again or surgery should be performed.	Mayo Clin & Mayo Fdn, Div Endocrinol Metab Nutr & Internal Med, Rochester, MN 55905 USA; Ohio State Univ, Coll Med, Dept Internal Med, Div Endocrinol, Columbus, OH 43210 USA; Ohio State Univ, Hlth Sci Ctr, Columbus, OH 43210 USA	Mayo Clinic; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Gharib, H (corresponding author), Mayo Clin & Mayo Fdn, Div Endocrinol Metab Nutr & Internal Med, 200 1st St SW, Rochester, MN 55905 USA.							BELFIORE A, 1992, AM J MED, V93, P363, DOI 10.1016/0002-9343(92)90164-7; BERGHOUT A, 1990, LANCET, V336, P193, DOI 10.1016/0140-6736(90)91730-X; BERGLUND J, 1990, ACTA CHIR SCAND, V156, P433; BIONDI B, 1994, J CLIN ENDOCR METAB, V78, P1028, DOI 10.1210/jc.78.5.1028; BIONDI B, 1993, J CLIN ENDOCR METAB, V77, P334, DOI 10.1210/jc.77.2.334; BISTRUP C, 1994, CLIN ENDOCRINOL, V40, P323; BLUM M, 1995, ANN INTERN MED, V122, P63, DOI 10.7326/0003-4819-122-1-199501010-00011; BOEY J, 1986, WORLD J SURG, V10, P623, DOI 10.1007/BF01655540; BURCH HB, 1995, ENDOCRIN METAB CLIN, V24, P663, DOI 10.1016/S0889-8529(18)30019-7; BURMEISTER LA, 1992, J CLIN ENDOCR METAB, V75, P344, DOI 10.1210/jc.75.2.344; Caruso D, 1991, ENDOCRINOLOGIST, V1, P194, DOI 10.1097/00019616-199106000-00009; CELANI MF, 1993, EXP CLIN ENDOCRINOL, V101, P326, DOI 10.1055/s-0029-1211253; CELANI MF, 1990, ACTA ENDOCRINOL-COP, V123, P603, DOI 10.1530/acta.0.1230603; CHEUNG PSY, 1989, WORLD J SURG, V13, P818, DOI 10.1007/BF01658447; COOPER DS, 1995, J CLIN ENDOCR METAB, V80, P331, DOI 10.1210/jc.80.2.331; Daniels Gilbert H., 1996, Comprehensive Therapy, V22, P239; DEGROOT LJ, 1989, J CLIN ENDOCR METAB, V69, P925, DOI 10.1210/jcem-69-5-925; Diacinti D, 1992, Minerva Med, V83, P745; DUNCAN WE, 1994, THYROID, V4, P183, DOI 10.1089/thy.1994.4.183; EZZAT S, 1994, ARCH INTERN MED, V154, P1838; FABER J, 1994, EUR J ENDOCRINOL, V130, P350, DOI 10.1530/eje.0.1300350; FOGELFELD L, 1989, NEW ENGL J MED, V320, P835, DOI 10.1056/NEJM198903303201304; FOLDES J, 1993, CLIN ENDOCRINOL, V39, P521, DOI 10.1111/j.1365-2265.1993.tb02403.x; GEERDSEN JP, 1986, ACTA MED SCAND, V220, P341; GEERDSEN JP, 1984, CLIN ENDOCRINOL, V21, P529, DOI 10.1111/j.1365-2265.1984.tb01391.x; GHARIB H, 1987, NEW ENGL J MED, V317, P70, DOI 10.1056/NEJM198707093170202; GHARIB H, 1993, CLIN LAB MED, V13, P699, DOI 10.1016/S0272-2712(18)30434-7; GHARIB H, 1993, ANN INTERN MED, V118, P282, DOI 10.7326/0003-4819-118-4-199302150-00007; GHARIB H, 1994, MAYO CLIN PROC, V69, P44, DOI 10.1016/S0025-6196(12)61611-5; GIUFFRIDA D, 1995, AM J MED, V99, P642, DOI 10.1016/S0002-9343(99)80252-6; GRANT CS, 1989, SURGERY, V106, P980; HEGEDUS L, 1987, BRIT MED J, V294, P801, DOI 10.1136/bmj.294.6575.801; ITO M, 1995, THYROID, V5, P365, DOI 10.1089/thy.1995.5.365; KLEIN I, 1990, AM J MED, V88, P631, DOI 10.1016/0002-9343(90)90531-H; KLEIN I, 1986, J CLIN INVEST, V77, P1694, DOI 10.1172/JCI112488; KUMA K, 1994, WORLD J SURG, V18, P495, DOI 10.1007/BF00353745; KUMA K, 1992, WORLD J SURG, V16, P583, DOI 10.1007/BF02067327; KUNG AWC, 1991, JAMA-J AM MED ASSOC, V265, P2688, DOI 10.1001/jama.265.20.2688; Kuo Shi-Wen, 1993, Journal of the Formosan Medical Association, V92, P55; LaRosa GL, 1996, J CLIN ENDOCR METAB, V81, P4385, DOI 10.1210/jc.81.12.4385; LAROSA GL, 1995, ANN INTERN MED, V122, P1, DOI 10.7326/0003-4819-122-1-199501010-00001; LEESE GP, 1992, CLIN ENDOCRINOL, V37, P500, DOI 10.1111/j.1365-2265.1992.tb01480.x; LEHMKE J, 1992, CLIN ENDOCRINOL, V36, P511, DOI 10.1111/j.1365-2265.1992.tb02254.x; Mainini E, 1995, J ENDOCRINOL INVEST, V18, P796, DOI 10.1007/BF03349813; MAZZAFERRI EL, 1988, MED CLIN N AM, V72, P1177, DOI 10.1016/S0025-7125(16)30736-2; MAZZAFERRI EL, 1992, AM J MED, V93, P359, DOI 10.1016/0002-9343(92)90163-6; MAZZAFERRI EL, 1993, NEW ENGL J MED, V328, P553; MCCALL A, 1986, SURGERY, V100, P1128; MICCOLI P, 1993, SURGERY, V114, P1097; MORITA T, 1989, J CLIN ENDOCR METAB, V69, P227, DOI 10.1210/jcem-69-2-227; PAPINI E, 1993, CLIN ENDOCRINOL, V38, P507, DOI 10.1111/j.1365-2265.1993.tb00347.x; PAUL TL, 1988, JAMA-J AM MED ASSOC, V259, P3137, DOI 10.1001/jama.259.21.3137; PERSSON CPA, 1982, WORLD J SURG, V6, P391, DOI 10.1007/BF01657664; POLIKAR R, 1993, CIRCULATION, V87, P1435, DOI 10.1161/01.CIR.87.5.1435; REVERTER JL, 1992, CLIN ENDOCRINOL, V36, P25, DOI 10.1111/j.1365-2265.1992.tb02898.x; ROJESKI MT, 1985, NEW ENGL J MED, V313, P428, DOI 10.1056/NEJM198508153130707; ROLLA AR, 1995, CLIN GERIATR MED, V11, P259, DOI 10.1016/S0749-0690(18)30296-9; ROSS DS, 1992, THYROID, V2, P263, DOI 10.1089/thy.1992.2.263; SAWIN CT, 1994, NEW ENGL J MED, V331, P1249, DOI 10.1056/NEJM199411103311901; SCHNEIDER AB, 1986, ANN INTERN MED, V105, P405, DOI 10.7326/0003-4819-105-3-405; SCHNEIDER DL, 1994, JAMA-J AM MED ASSOC, V271, P1245, DOI 10.1001/jama.271.16.1245; SMITH SA, 1991, ADV ENDOCRINOLOGY ME, V2, P107; STALL GM, 1990, ANN INTERN MED, V113, P265, DOI 10.7326/0003-4819-113-4-265; STOCKWELL RM, 1984, J CLIN ENDOCR METAB, V58, P804, DOI 10.1210/jcem-58-5-804; TAN GH, 1995, ARCH INTERN MED, V155, P2418, DOI 10.1001/archinte.155.22.2418; Tan GH, 1997, ANN INTERN MED, V126, P226, DOI 10.7326/0003-4819-126-3-199702010-00009; WARTOFSKY L, 1995, ARCH INTERN MED, V155, P1130, DOI 10.1001/archinte.155.11.1130; WARTOFSKY L, 1993, ADV ENDOCRINOL METAB, V4, P157	68	89	95	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1998	128	5					386	394		10.7326/0003-4819-128-5-199803010-00008	http://dx.doi.org/10.7326/0003-4819-128-5-199803010-00008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY519	9490600				2022-12-28	WOS:000072155600008
J	Sangha, O; Phillips, CB; Fleischmann, KE; Wang, TJ; Fossel, AH; Lew, R; Liang, MH; Shadick, NA				Sangha, O; Phillips, CB; Fleischmann, KE; Wang, TJ; Fossel, AH; Lew, R; Liang, MH; Shadick, NA			Lack of cardiac manifestations among patients with previously treated Lyme disease	ANNALS OF INTERNAL MEDICINE			English	Article						Lyme disease; heart disease; electrocardiography; antibiotics; heart block	BORRELIA-BURGDORFERI INFECTION; NEUROLOGIC MANIFESTATIONS; MYOCARDITIS; CARDIOMYOPATHY; ARTHRITIS	Background: Cardiac involvement is common in acute Lyme disease, and case reports suggest that cardiac abnormalities might also occur years after the primary infection. Objective: To determine the prevalence of cardiac abnormalities in persons with previously treated Lyme disease. Design: Population-based, retrospective cohort study with controls. Setting: Nantucket Island, Massachusetts. Participants: From among 3703 adult respondents to a total-population (n = 6046) mail survey, 336 (176 case-patients and 160 controls) were randomly selected for clinical evaluation. Measurements: Current cardiac symptoms and major or minor abnormal electrocardiographic features, including heart rate; rhythm; axis; PR, QRS, and QT intervals; QRS structure; atrioventricular blocks; and ST-segment and T-wave changes. Results: Persons with Lyme disease (case-patients, n = 176) (mean duration from disease onset to study evaluation, 5.2 years) and persons without evidence of previous Lyme disease (controls, n = 160) did not differ significantly in their patterns of current cardiac symptoms and electrocardiographic findings, including heart rate (P > 0.2), PR interval (P = 0.15), QRS interval (P > 0.2), QT interval (P > 0.2), axis (P > 0.2), presence of arrhythmias (P > O.Z), first-degree heart block (P = 0.12), bundle-branch block (P > 0.2), and ST-segment abnormalities (P > 0.2). In multivariate analyses that adjusted for age, sex, and previous heart disease, a history of previously treated Lyme disease was not associated with either major (odds ratio, 0.78; P > O.Z) or minor (odds ratio, 1.09; P > O.Z) electrocardiographic abnormalities. Conclusion: Persons with a history of previously treated Lyme disease do not have a higher prevalence of cardiac abnormalities than persons without a history of Lyme disease.	Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Cardiovasc Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	Shadick, NA (corresponding author), Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, 75 Francis St, Boston, MA 02115 USA.				NIAMS NIH HHS [AR02033, AR36308] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR002033, P60AR036308] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALPERT LI, 1985, CLIN NUCL MED, V10, P617, DOI 10.1097/00003072-198509000-00002; [Anonymous], 1978, MAIL TELEPHONE SURVE; ASBRINK E, 1988, ANN NY ACAD SCI, V539, P4, DOI 10.1111/j.1749-6632.1988.tb31833.x; ASCH ES, 1994, J RHEUMATOL, V21, P454; BERARDI VP, 1988, J INFECT DIS, V158, P754, DOI 10.1093/infdis/158.4.754; Breslow NE, 1980, IARC SCI PUBL, P5; CASANS I, 1989, EUR J NUCL MED, V15, P330, DOI 10.1007/BF00435476; CIESIELSKI CA, 1989, REV INFECT DIS, V11, pS1435; COX J, 1991, AM HEART J, V122, P1449, DOI 10.1016/0002-8703(91)90589-A; CRAFT JE, 1986, J CLIN INVEST, V78, P934, DOI 10.1172/JCI112683; DEKONING J, 1989, J INFECT DIS, V160, P150, DOI 10.1093/infdis/160.1.150; GASSER R, 1992, LANCET, V339, P1174, DOI 10.1016/0140-6736(92)90777-Z; GOLDINGS EA, 1986, CLIN RHEUM DIS, V12, P343; GOODMAN JL, 1991, J CLIN MICROBIOL, V29, P894, DOI 10.1128/JCM.29.5.894-896.1991; Heinisch O., 1963, PREIS S BIOM J, V1965, P203, DOI [10.1002/bimj.19650070312, DOI 10.1002/BIMJ.19650070312]; JACOBS JC, 1984, J PEDIATR-US, V105, P950, DOI 10.1016/S0022-3476(84)80086-4; KLEIN J, 1991, EUR HEART J, V12, P73, DOI 10.1093/eurheartj/12.suppl_D.73; LOGIGIAN EL, 1990, NEW ENGL J MED, V323, P1438, DOI 10.1056/NEJM199011223232102; MARCUS LC, 1985, ANN INTERN MED, V103, P374, DOI 10.7326/0003-4819-103-3-374; MCALISTER HF, 1989, ANN INTERN MED, V110, P339, DOI 10.7326/0003-4819-110-5-339; MCNEMAR Q, 1969, PSYCHOL STAT, P322; NOKOA K, 1990, GEN SOCIAL SURVEY ME, V70, P1; PACHNER AR, 1985, NEUROLOGY, V35, P47, DOI 10.1212/WNL.35.1.47; PEETERS AJ, 1990, P 5 INT C LYM BORR S; RIENZO RJ, 1987, CLIN NUCL MED, V12, P475, DOI 10.1097/00003072-198706000-00017; SAS/STAT, 1990, US GUID; SHADICK NA, 1994, ANN INTERN MED, V121, P560, DOI 10.7326/0003-4819-121-8-199410150-00002; SONNESYN SW, 1995, AM J CARDIOL, V76, P97, DOI 10.1016/S0002-9149(99)80814-5; STANEK G, 1991, SCAND J INFECT DIS, P85; STANEK G, 1990, NEW ENGL J MED, V322, P249, DOI 10.1056/NEJM199001253220407; *STAT CONN DEP HLT, 1990, CONNECTICUT EPIDEMIO, V10, P9; STEERE AC, 1983, ANN INTERN MED, V99, P76, DOI 10.7326/0003-4819-99-1-76; STEERE AC, 1980, ANN INTERN MED, V93, P8, DOI 10.7326/0003-4819-93-1-8; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1987, ANN INTERN MED, V107, P725, DOI 10.7326/0003-4819-107-5-725; SZER IS, 1991, NEW ENGL J MED, V325, P159, DOI 10.1056/NEJM199107183250304; VANDERLINDE MR, 1990, BRIT HEART J, V63, P162, DOI 10.1136/hrt.63.3.162; VANDERLINDE MR, 1991, SCAND J INFECT DIS, P81; VEGSUNDVAG J, 1993, BRIT MED J, V307, P173, DOI 10.1136/bmj.307.6897.173; VIDAILLET HJ, 1993, AM J CARDIOL, V71, P1249, DOI 10.1016/0002-9149(93)90663-W; VLAY SC, 1986, NEW ENGL J MED, V315, P1418; VLAY SC, 1991, AM HEART J, V121, P1558, DOI 10.1016/0002-8703(91)90173-F; 1996, MMWR MORB MORTAL WKL, V45, P481	43	22	23	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1998	128	5					346	+		10.7326/0003-4819-128-5-199803010-00002	http://dx.doi.org/10.7326/0003-4819-128-5-199803010-00002			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY519	9490594				2022-12-28	WOS:000072155600002
J	Brenner, H; Rothenbacher, D; Bode, G; Adler, G				Brenner, H; Rothenbacher, D; Bode, G; Adler, G			Parental history of gastric or duodenal ulcer and prevalence of Helicobacter pylori infection in preschool children: population based study	BRITISH MEDICAL JOURNAL			English	Article									Univ Ulm, Dept Epidemiol, D-89069 Ulm, Germany; Univ Ulm, Dept Internal Med 1, D-7900 Ulm, Germany	Ulm University; Ulm University	Brenner, H (corresponding author), Univ Ulm, Dept Epidemiol, D-89069 Ulm, Germany.		Brenner, Hermann/B-4627-2017; Brenner, Hermann/ABE-6383-2020	Brenner, Hermann/0000-0002-6129-1572; Brenner, Hermann/0000-0002-6129-1572; Rothenbacher, Dietrich/0000-0002-3563-2791				GOODMAN KJ, 1995, INT J EPIDEMIOL, V24, P875, DOI 10.1093/ije/24.5.875; MALATY HM, 1994, ANN INTERN MED, V120, P982, DOI 10.7326/0003-4819-120-12-199406150-00002; ROTHENBACHER D, IN PRESS INT J EPIDE; WEBB PM, 1994, BRIT MED J, V308, P750, DOI 10.1136/bmj.308.6931.750; YAMADA T, 1994, JAMA-J AM MED ASSOC, V272, P65, DOI 10.1001/jama.272.1.65	5	36	36	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 28	1998	316	7132					665	665		10.1136/bmj.316.7132.665	http://dx.doi.org/10.1136/bmj.316.7132.665			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA282	9522790	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000072347900029
J	Gupta, AK; Scher, RK				Gupta, AK; Scher, RK			Oral antifungal agents for onychomycosis	LANCET			English	Editorial Material							STRATUM-CORNEUM; ITRACONAZOLE; KINETICS		Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Med, Div Dermatol, Toronto, ON, Canada; Columbia Univ Coll Phys & Surg, Dept Dermatol, New York, NY 10032 USA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Columbia University	Scher, RK (corresponding author), Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Med, Div Dermatol, 2075 Bayview Ave, Toronto, ON, Canada.		Gupta, Aditya/AAE-5797-2020	Gupta, Aditya K./0000-0002-8664-7723				CAUWENBERGH G, 1988, J AM ACAD DERMATOL, V18, P263, DOI 10.1016/S0190-9622(88)70037-7; De Doncker P, 1997, J AM ACAD DERMATOL, V37, P969, DOI 10.1016/S0190-9622(97)70074-4; DeDoncker P, 1996, ARCH DERMATOL, V132, P34, DOI 10.1001/archderm.132.1.34; EPSTEIN WL, 1972, ARCH DERMATOL, V106, P344, DOI 10.1001/archderm.106.3.344; Gupta A. K., 1997, Dermatologic Therapy, V3, P58; Gupta AK, 1997, INT J DERMATOL, V36, P783, DOI 10.1046/j.1365-4362.1997.00349.x; Gupta AK, 1998, PHARMACOECONOMICS, V13, P243, DOI 10.2165/00019053-199813020-00007; Gupta AK, 1997, J AM ACAD DERMATOL, V37, P979, DOI 10.1016/S0190-9622(97)70076-8; GUPTA AK, 1994, J AM ACAD DERMATOL, V30, P677, DOI 10.1016/S0190-9622(08)81495-8; HARRIS R, 1983, ANTIMICROB AGENTS CH, V24, P876, DOI 10.1128/AAC.24.6.876; Havu V, 1997, BRIT J DERMATOL, V136, P230, DOI 10.1111/j.1365-2133.1997.tb14902.x; MEINHOF W, 1993, J AM ACAD DERMATOL, V29, pS37, DOI 10.1016/S0190-9622(08)81835-X; Schatz F, 1995, CLIN EXP DERMATOL, V20, P377, DOI 10.1111/j.1365-2230.1995.tb01353.x; SCHER RK, 1994, BRIT J DERMATOL, V130, P15, DOI 10.1111/j.1365-2133.1994.tb06087.x; SCHER RK, 1997, 37 INT C ANT AG CHEM; Tausch I, 1997, BRIT J DERMATOL, V136, P737, DOI 10.1111/j.1365-2133.1997.tb03662.x	16	26	27	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 21	1998	351	9102					541	542		10.1016/S0140-6736(05)78552-4	http://dx.doi.org/10.1016/S0140-6736(05)78552-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ216	9492770	hybrid			2022-12-28	WOS:000072231900006
J	Pozniak, A				Pozniak, A			Surrogacy in HIV-1 clinical trials	LANCET			English	Editorial Material							PLASMA; AIDS; RNA		Univ London Kings Coll Hosp, Dept HIV & Genitourinary Med, London SE5 9RS, England	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	Pozniak, A (corresponding author), Univ London Kings Coll Hosp, Dept HIV & Genitourinary Med, Denmark Hill, London SE5 9RS, England.							BABIKER A, 1997, 6 EUR C CLIN ASP TRE, P6; DeGruttola V, 1997, J INFECT DIS, V175, P237, DOI 10.1093/infdis/175.2.237; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; Fleming TR, 1996, ANN INTERN MED, V125, P605, DOI 10.7326/0003-4819-125-7-199610010-00011; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Katzenstein DA, 1996, NEW ENGL J MED, V335, P1091, DOI 10.1056/NEJM199610103351502; KEMPF D, 1997, 4 C RETR OPP INF WAS, P176; Lange JMA, 1997, SCIENCE, V276, P548, DOI 10.1126/science.276.5312.548; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; Mildvan D, 1997, CLIN INFECT DIS, V24, P764, DOI 10.1093/clinids/24.5.764; OBrien TR, 1996, JAMA-J AM MED ASSOC, V276, P105, DOI 10.1001/jama.276.2.105; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; YERLY S, IN PRESS ARCH INT ME	14	15	15	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 21	1998	351	9102					536	537		10.1016/S0140-6736(98)22008-3	http://dx.doi.org/10.1016/S0140-6736(98)22008-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ216	9492766				2022-12-28	WOS:000072231900002
J	Nibu, Y; Zhang, HL; Levine, M				Nibu, Y; Zhang, HL; Levine, M			Interaction of short-range repressors with Drosophila CtBP in the embryo	SCIENCE			English	Article							LOOP-HELIX REPRESSOR; TRANSCRIPTIONAL REPRESSION; CELLULAR PHOSPHOPROTEIN; NEGATIVE MODULATION; PROTEIN-INTERACTION; E1A PROTEIN; HAIRY; DOMAIN; TRANSFORMATION; SEGMENTATION	Human CtBP attenuates transcriptional activation and tumorigenesis mediated by the adenovirus E1A protein. The E1A sequence motif that interacts with CtBP, Pro-X-Asp-Leu-Ser-X-Lys (P-DLS-K), is present in the repression domains of two unrelated short-range repressors in Drosophila, Knirps and Snail, and is essential for the interaction of these proteins with Drosophila CtBP (dCtBP). A P-element-induced mutation in dCtBP exhibits gene-dosage interactions with a null mutation in knirps, which is consistent with the occurrence of Knirps-dCtBP interactions in vivo, These observations suggest that CtBP and dCtBP are engaged in an evolutionarily conserved mechanism of transcriptional repression, which is used in both Drosophila and mammals.	Univ Calif Berkeley, Dept Mol & Cellular Biol, Div Genet, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Levine, M (corresponding author), Univ Calif Berkeley, Dept Mol & Cellular Biol, Div Genet, 401 Barker Hall, Berkeley, CA 94720 USA.		Nibu, Yutaka/J-4136-2019	Nibu, Yutaka/0000-0002-4696-7503; Levine, Michael/0000-0001-7629-0081	NIGMS NIH HHS [GM46638] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046638, R37GM046638] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arnosti DN, 1996, EMBO J, V15, P3659, DOI 10.1002/j.1460-2075.1996.tb00735.x; Barolo S, 1997, EMBO J, V16, P2883, DOI 10.1093/emboj/16.10.2883; BOULAY JL, 1987, NATURE, V330, P395, DOI 10.1038/330395a0; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; CAL HN, 1996, P NATL ACAD SCI USA, V93, P9309; Dubnicoff T, 1997, GENE DEV, V11, P2952, DOI 10.1101/gad.11.22.2952; Fisher AL, 1996, MOL CELL BIOL, V16, P2670; Gray S, 1996, CURR OPIN CELL BIOL, V8, P358; Gray S, 1996, GENE DEV, V10, P700, DOI 10.1101/gad.10.6.700; HannaRose W, 1997, MOL CELL BIOL, V17, P4820, DOI 10.1128/MCB.17.8.4820; HERSCHBACH BM, 1994, NATURE, V370, P309, DOI 10.1038/370309a0; HOCH M, 1992, SCIENCE, V256, P94, DOI 10.1126/science.1348871; Ip YT, 1997, CURR BIOL, V7, pR216, DOI 10.1016/S0960-9822(06)00104-7; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; Jimenez G, 1997, GENE DEV, V11, P3072, DOI 10.1101/gad.11.22.3072; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; KOSMAN D, 1991, SCIENCE, V254, P188; LEPTIN M, 1991, GENE DEV, V5, P1568, DOI 10.1101/gad.5.9.1568; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; NAUBER U, 1988, NATURE, V336, P489, DOI 10.1038/336489a0; NIBU Y, UNPUB; OHSAKO S, 1994, GENE DEV, V8, P2743, DOI 10.1101/gad.8.22.2743; PANKRATZ MJ, 1990, CELL, V61, P30; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Perrimon N, 1996, GENETICS, V144, P1681; POORTINGA G, IN PRESS EMBO J; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; SMALL S, 1992, EMBO J, V11, P4047, DOI 10.1002/j.1460-2075.1992.tb05498.x; Small S, 1996, DEV BIOL, V175, P314, DOI 10.1006/dbio.1996.0117; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sollerbrant K, 1996, NUCLEIC ACIDS RES, V24, P2578, DOI 10.1093/nar/24.13.2578; Sourdive DJD, 1997, NUCLEIC ACIDS RES, V25, P1476, DOI 10.1093/nar/25.8.1476; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; Tearle R., 1987, DROSOPHILA INFORMATI, V66, P209; VANDOREN M, 1994, GENE DEV, V8, P2729, DOI 10.1101/gad.8.22.2729; Yu Y, 1997, NATURE, V385, P552, DOI 10.1038/385552a0; Zhang HL, 1996, P NATL ACAD SCI USA, V93, P1764, DOI 10.1073/pnas.93.5.1764	38	212	214	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 3	1998	280	5360					101	104		10.1126/science.280.5360.101	http://dx.doi.org/10.1126/science.280.5360.101			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF314	9525852				2022-12-28	WOS:000072885100044
J	Hansen, JA; Gooley, TA; Martin, PJ; Appelbaum, F; Chauncey, TR; Clift, RA; Petersdorf, EW; Radich, J; Sanders, JE; Storb, RF; Sullivan, KM; Anasetti, C				Hansen, JA; Gooley, TA; Martin, PJ; Appelbaum, F; Chauncey, TR; Clift, RA; Petersdorf, EW; Radich, J; Sanders, JE; Storb, RF; Sullivan, KM; Anasetti, C			Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; VERSUS-HOST DISEASE; CYTOMEGALOVIRUS DISEASE; INTERFERON-ALPHA; ACUTE GRAFT; PROPHYLAXIS; COMPLICATIONS; METHOTREXATE; CYCLOSPORINE; EXPERIENCE	Background Chronic myeloid leukemia can be cured by marrow transplantation from an HLA-identical sibling donor. The use of transplants from unrelated donors is an option for the 70 percent of patients without an HLA-identical sibling, but the morbidity and mortality associated with such transplants have been cause for concern. We analyzed the safety and efficacy of transplants from unrelated donors for the treatment of chronic myeloid leukemia and identified variables that predict a favorable outcome. Methods Between May 1985 and December 1994, 196 patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase received marrow transplants from unrelated donors. Results The median follow-up was 5 years (range, 1.2 to 10.1). Graft failure occurred in 5 percent of patients wile could be evaluated. Acute graft-versus-host disease of grade III or IV severity was observed in 35 percent of patients who received HLA-matched transplants, and the estimated cumulative incidence of relapse at five years was 10 percent. The Kaplan-Meier estimate of survival at five years was 57 percent. Survival was adversely affected by an interval from diagnosis to transplantation of one year or more, an HLA-DRB1 mismatch, a high body-weight index, and an age of more than 50 years. Survival was improved by the prophylactic use of fluconazole and ganciclovir. The Kaplan-Meier estimate of survival at five years was 74 percent (95 percent confidence interval, 62 to 86 percent) for patients who were 50 years of age or younger who received a transplant from an HLA-matched donor within one year after diagnosis. Conclusions Transplantation of marrow from an HLA-matched, unrelated donor is safe and effective therapy for selected patients with chronic myeloid leukemia. (C)1998, Massachusetts Medical Society.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Vet Affairs Med Ctr, Seattle, WA 98108 USA; Univ Washington, Sch Med, Seattle, WA USA	Fred Hutchinson Cancer Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle	Hansen, JA (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N, Seattle, WA 98109 USA.		Chauncey, Thomas/AAK-1331-2021	Chauncey, Thomas/0000-0003-2815-7301	NCI NIH HHS [CA18029, CA15704] Funding Source: Medline; NIAID NIH HHS [AI33484] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA015704, P01CA018029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI033484] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLAN NC, 1995, LANCET, V345, P1392, DOI 10.1016/S0140-6736(95)92596-1; Anasetti C, 1995, Cancer Treat Res, V76, P137; ANASETTI C, 1994, TRANSFUS SCI, V15, P221, DOI 10.1016/0955-3886(94)90134-1; BEATTY PG, 1985, NEW ENGL J MED, V313, P765, DOI 10.1056/NEJM198509263131301; BEATTY PG, 1991, TRANSPLANTATION, V51, P443, DOI 10.1097/00007890-199102000-00034; BEATTY PG, 1989, BONE MARROW TRANSPL, V4, P287; BLAZAR BR, 1985, BLOOD, V66, P1436; Buckner C. Dean, 1995, Bone Marrow Transplantation, V15, pS203; CLIFT RA, 1994, BLOOD, V84, P2036, DOI 10.1182/blood.V84.6.2036.2036; DURNAM DM, 1989, BLOOD, V74, P2220; GOLDMAN JM, 1993, BLOOD, V82, P2235; GOLDMAN JM, 1986, NEW ENGL J MED, V314, P202, DOI 10.1056/NEJM198601233140403; GOODRICH JM, 1993, ANN INTERN MED, V118, P173, DOI 10.7326/0003-4819-118-3-199302010-00003; GOODRICH JM, 1994, CLIN INFECT DIS, V19, P287, DOI 10.1093/clinids/19.2.287; HANSEN JA, 1992, MANUAL CLIN LAB IMMU, P850; HATHAWAY ML, 1960, 10 USDA, P111; HEHLMANN R, 1994, BLOOD, V84, P4064, DOI 10.1182/blood.V84.12.4064.bloodjournal84124064; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Lee SJ, 1997, ANN INTERN MED, V127, P1080, DOI 10.7326/0003-4819-127-12-199712150-00005; MACKINNON S, 1990, EXP HEMATOL, V18, P421; MARKS DI, 1993, ANN INTERN MED, V119, P207, DOI 10.7326/0003-4819-119-3-199308010-00005; McCullough J, 1989, Oncology (Williston Park), V3, P63; MCGLAVE, 1990, BLOOD, V76, P654; MCGLAVE P, 1993, BLOOD, V81, P543; MCGLAVE PB, 1990, BLOOD, V75, P1728; Mickelson EM, 1996, TISSUE ANTIGENS, V47, P27, DOI 10.1111/j.1399-0039.1996.tb02511.x; MICKELSON EM, 1994, TISSUE ANTIGENS, V44, P83, DOI 10.1111/j.1399-0039.1994.tb02363.x; NASH RA, 1992, BLOOD, V80, P1838; PEPE MS, 1993, BRIT J HAEMATOL, V83, P602, DOI 10.1111/j.1365-2141.1993.tb04697.x; Petersdorf EW, 1997, BLOOD, V89, P1818, DOI 10.1182/blood.V89.5.1818.1818_1818_1823; PETERSDORF EW, 1995, BLOOD, V86, P1606, DOI 10.1182/blood.V86.4.1606.bloodjournal8641606; PRZEPIORKA D, 1995, BONE MARROW TRANSPL, V15, P825; SLAVIN MA, 1995, J INFECT DIS, V171, P1545, DOI 10.1093/infdis/171.6.1545; SPENCER A, 1995, BLOOD, V86, P3590, DOI 10.1182/blood.V86.9.3590.bloodjournal8693590; STORB R, 1986, NEW ENGL J MED, V314, P729, DOI 10.1056/NEJM198603203141201; SULLIVAN KM, 1991, SEMIN HEMATOL, V28, P250; TALPAZ M, 1986, NEW ENGL J MED, V314, P1065, DOI 10.1056/NEJM198604243141701; THOMAS ED, 1986, ANN INTERN MED, V104, P155, DOI 10.7326/0003-4819-104-2-155; TURA S, 1994, NEW ENGL J MED, V330, P820	39	470	487	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 2	1998	338	14					962	968		10.1056/NEJM199804023381405	http://dx.doi.org/10.1056/NEJM199804023381405			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE776	9521984				2022-12-28	WOS:000072829800005
J	Bernstein, M				Bernstein, M			The genie in the bottle	ANNALS OF INTERNAL MEDICINE			English	Article											Bernstein, M (corresponding author), 19 Warren Pl, Murray Hill, NJ 07974 USA.								0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1998	128	7					595	596		10.7326/0003-4819-128-7-199804010-00013	http://dx.doi.org/10.7326/0003-4819-128-7-199804010-00013			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE539	9518407				2022-12-28	WOS:000072803500013
J	Cohen, JJ				Cohen, JJ			Remembering the real questions	ANNALS OF INTERNAL MEDICINE			English	Article									Assoc Amer Med Coll, Washington, DC 20036 USA	Association of American Medical Colleges	Cohen, JJ (corresponding author), Assoc Amer Med Coll, 2450 N St NW, Washington, DC 20036 USA.							Cohen JJ, 1997, ACAD MED, V72, P103, DOI 10.1097/00001888-199702000-00010; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; REINERTSEN JL, 1996, BULLETIN, V40, P61	3	3	4	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1998	128	7					563	566		10.7326/0003-4819-128-7-199804010-00008	http://dx.doi.org/10.7326/0003-4819-128-7-199804010-00008			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE539	9518402				2022-12-28	WOS:000072803500008
J	Cotell, SL; Roholt, NS				Cotell, SL; Roholt, NS			Molluscum contagiosum in a patient with the acquired immunodeficiency syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Northwestern Univ, Chicago, IL 60611 USA; MeritCare Clin, Bemidji, MN 56601 USA	Northwestern University	Cotell, SL (corresponding author), Northwestern Univ, Chicago, IL 60611 USA.								0	3	4	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 26	1998	338	13					888	888		10.1056/NEJM199803263381306	http://dx.doi.org/10.1056/NEJM199803263381306			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD284	9516224				2022-12-28	WOS:000072669800006
J	Schwartz, S; Raskin, P; Fonseca, V; Graveline, JF				Schwartz, S; Raskin, P; Fonseca, V; Graveline, JF		Troglitazone Exogenous Insulin Study Grp	Effect of troglitazone in insulin-treated patients with type II diabetes mellitus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTIDIABETIC AGENT ENGLITAZONE; ORAL HYPOGLYCEMIC AGENT; RESISTANCE; CS-045; RATS; THIAZOLIDINEDIONES; DYSFUNCTION; SECRETION; TRIAL; OBESE	Background Troglitazone is a new oral antidiabetic drug that increases the sensitivity of peripheral tissues to insulin. It may therefore increase the efficacy of exogenous insulin in patients with insulin-resistant diabetes mellitus. Methods We studied the effect of troglitazone or placebo in 350 patients with poorly controlled noninsulin-dependent (type II) diabetes mellitus (glycosylated hemoglobin values, 8 to 12 percent; normal, 4.3 to 6.1 percent) despite therapy with at least 30 U of insulin daily. The patients were randomly assigned to receive 200 mg of troglitazone (116 patients), 600 mg of troglitazone (116 patients), or placebo (118 patients) daily for 26 weeks. Insulin doses were not increased and were reduced only to prevent hypoglycemia. Glycosylated hemoglobin, serum glucose while fasting, serum total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and triglycerides were measured 5 times during an 8-week base-line period and 10 times during the 26-week treatment period. Daily insulin doses were recorded during both periods. Results Ninety percent of the patients completed the study. The adjusted mean glycosylated hemoglobin values decreased by 0.8 and 1.4 percentage points, respectively, in the group given 200 mg of troglitazone and the group given 600 mg of troglitazone, and fasting serum glucose concentrations decreased by 35 and 49 mg per deciliter (1.9 and 2.7 mmol per liter), respectively, despite decreases in the insulin dose of 11 percent and 29 percent (P<0.001 for all comparisons with the placebo group). Serum total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol concentrations increased slightly and serum triglyceride concentrations decreased slightly in the troglitazone-treated patients. Conclusions When given in conjunction with insulin, troglitazone improves glycemic control in patients with type II diabetes mellitus. (C) 1998, Massachusetts Medical Society.	Univ Texas, SW Med Sch, Dallas, TX USA; Diabet & Glandular Dis Clin, San Antonio, TX USA; Univ Arkansas Med Sci, Little Rock, AR 72205 USA; John L McClellan Mem Vet Hosp, Little Rock, AR USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Arkansas System; University of Arkansas Medical Sciences	Graveline, JF (corresponding author), Sankyo USA, 780 3rd Ave,Suite 4700, New York, NY 10017 USA.							American Diabetes Association, 1997, DIABETES CARE S1, V20, pS5; Antonucci T, 1997, DIABETES CARE, V20, P188, DOI 10.2337/diacare.20.2.188; ERIKSSON J, 1989, NEW ENGL J MED, V321, P337, DOI 10.1056/NEJM198908103210601; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; FUJITA T, 1983, DIABETES, V32, P804, DOI 10.2337/diabetes.32.9.804; FUJIWARA T, 1988, DIABETES, V37, P1549, DOI 10.2337/diabetes.37.11.1549; HENRY RR, 1993, DIABETES CARE, V16, P21, DOI 10.2337/diacare.16.1.21; HOWARD LJ, 1991, HARRISONS PRINCIPLES, V1, P427; IWAMOTO Y, 1991, DIABETES CARE, V14, P1083, DOI 10.2337/diacare.14.11.1083; KHOURSHEED M, 1995, METABOLISM, V44, P1489, DOI 10.1016/0026-0495(95)90151-5; Klein R, 1996, DIABETES CARE, V19, P744, DOI 10.2337/diacare.19.7.744; KUZUYA T, 1991, DIABETES RES CLIN PR, V11, P147, DOI 10.1016/S0168-8227(05)80027-0; LEE MK, 1994, DIABETES, V43, P1435, DOI 10.2337/diabetes.43.12.1435; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; ORAHILLY S, 1988, NEW ENGL J MED, V318, P1225, DOI 10.1056/NEJM198805123181902; PIMENTA W, 1995, JAMA-J AM MED ASSOC, V273, P1855, DOI 10.1001/jama.273.23.1855; Saltiel AR, 1996, DIABETES, V45, P1661, DOI 10.2337/diabetes.45.12.1661; STEVENSON RW, 1991, METABOLISM, V40, P1268, DOI 10.1016/0026-0495(91)90027-T; STEVENSON RW, 1990, DIABETES, V39, P1218, DOI 10.2337/diabetes.39.10.1218; SUTER SL, 1992, DIABETES CARE, V15, P193, DOI 10.2337/diacare.15.2.193; TOMINAGA M, 1993, ENDOCR J, V40, P343, DOI 10.1507/endocrj.40.343; TUKEY JW, 1985, BIOMETRICS, V41, P295, DOI 10.2307/2530666; VAAG A, 1995, J CLIN INVEST, V95, P690, DOI 10.1172/JCI117715; WARRAM JH, 1990, ANN INTERN MED, V113, P909, DOI 10.7326/0003-4819-113-12-909; 1996, DIABETES, V45, P1289; 1991, DIABETES CARE S2, V14, P20	27	280	290	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 26	1998	338	13					861	866		10.1056/NEJM199803263381302	http://dx.doi.org/10.1056/NEJM199803263381302			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD284	9516220	Bronze			2022-12-28	WOS:000072669800002
J	Farrell, L				Farrell, L			No cure for the 'flu	LANCET			English	Editorial Material																			0	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 21	1998	351	9106					920	920		10.1016/S0140-6736(05)70350-0	http://dx.doi.org/10.1016/S0140-6736(05)70350-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD047	9525412				2022-12-28	WOS:000072645500078
J	McConnell, J				McConnell, J			WHO's tuberculosis research initiative	LANCET			English	Editorial Material									Lancet, London WC1B 3SL, England		McConnell, J (corresponding author), Lancet, London WC1B 3SL, England.			McConnell, John/0000-0002-9928-6568					0	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 21	1998	351	9106					852	852						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD047	9525360				2022-12-28	WOS:000072645500008
J	Yuh, CH; Bolouri, H; Davidson, EH				Yuh, CH; Bolouri, H; Davidson, EH			Genomic cis-regulatory logic: Experimental and computational analysis of a sea urchin gene	SCIENCE			English	Article							STRONGYLOCENTROTUS-PURPURATUS; PROTEIN; ORGANIZATION; EMBRYO; ENDO16; GASTRULATION; MARKER; DNA	The genomic regulatory network that controls gene expression ultimately determines form and function in each species. The operational nature of the regulatory programming specified in cis-regulatory DNA sequence was determined from a detailed functional analysis of a sea urchin control element that directs the expression of a gene in the endoderm during development. Spatial expression and repression, and the changing rate of transcription of this gene, are mediated by a complex and extended cis-regulatory system. The system may be typical of developmental cis-regulatory apparatus. All of its activities are integrated in the proximal element, which contains seven target sites for DNA binding proteins. A quantitative computational model of this regulatory element was constructed that explicitly reveals the logical Interrelations hard-wired into the DNA.	CALTECH, Div Biol, Pasadena, CA 91125 USA; Univ Hertfordshire, Ctr Res Dev & Engn, Hatfield AL10 9AB, Herts, England	California Institute of Technology; University of Hertfordshire	Davidson, EH (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.	davidson@mirsky.caltech.edu	Yuh, Chiou-Hwa/AAL-3531-2020; Yuh, Chiou-Hwa/AAL-2938-2020; Yuh, Chiou-Hwa/E-3972-2010	Yuh, Chiou-Hwa/0000-0002-2356-1551				AKASAKA K, 1994, J BIOL CHEM, V269, P20592; Arnone MI, 1997, DEVELOPMENT, V124, P1851; Cameron RA, 1997, DEV BIOL, V187, P236, DOI 10.1006/dbio.1997.8615; Coffman JA, 1997, DEVELOPMENT, V124, P4717; GAN L, 1995, DEV BIOL, V167, P517, DOI 10.1006/dbio.1995.1046; HORSTADIUS S, 1973, EXPT EMBRYOLOGY ECHI, pCH6; Kirchhamer CV, 1996, DEVELOPMENT, V122, P333; Kirchhamer CV, 1996, P NATL ACAD SCI USA, V93, P9322, DOI 10.1073/pnas.93.18.9322; Kirchhamer CV, 1996, P NATL ACAD SCI USA, V93, P13849, DOI 10.1073/pnas.93.24.13849; Li XT, 1997, DEV BIOL, V187, P253, DOI 10.1006/dbio.1997.8610; Michael LF, 1996, MOL ENDOCRINOL, V10, P159, DOI 10.1210/me.10.2.159; NOCENTEMCGRATH C, 1989, DEV BIOL, V136, P264, DOI 10.1016/0012-1606(89)90147-4; RANSICK A, 1993, MECH DEVELOP, V42, P117, DOI 10.1016/0925-4773(93)90001-E; RANSICK A, IN PRESS DEV BIOL; SOLTYSIKESPANOLA M, 1994, DEV BIOL, V165, P73, DOI 10.1006/dbio.1994.1235; Yuh CH, 1996, DEVELOPMENT, V122, P1069; YUH CH, 1994, MECH DEVELOP, V47, P165, DOI 10.1016/0925-4773(94)90088-4; Yuh CH, 1996, DEVELOPMENT, V122, P4045; YUH CH, UNPUB; ZELLER RW, 1995, P NATL ACAD SCI USA, V92, P2989, DOI 10.1073/pnas.92.7.2989	20	529	550	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 20	1998	279	5358					1896	1902		10.1126/science.279.5358.1896	http://dx.doi.org/10.1126/science.279.5358.1896			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506933	Green Submitted			2022-12-28	WOS:000072613300036
J	Marwick, TH				Marwick, TH			The viable myocardium: epidemiology, detection, and clinical implications	LANCET			English	Review							POSITRON EMISSION TOMOGRAPHY; LEFT-VENTRICULAR DYSFUNCTION; HEART-FAILURE; WALL-MOTION; REVASCULARIZATION; INFARCTION; DOBUTAMINE; PERFUSION; PROGNOSIS; DISEASE	The success of fibrinolytic and other therapies has reduced the mortality of myocardial infarction. However, many survivors develop congestive heart failure. Medical treatment of this disorder has limited efficacy, and cardiac transplantation has limited availability. Contrary to previous teaching about ischaemic injury, roughly 40% of segments involved in myocardial infarction may subsequently recover, either spontaneously or after revascularisation. The persistence of such viable myocardium means that previous approaches to treatment of myocardial infarction must be reappraised. This review examines the pathogenesis of this response, the techniques that may be used to identify the salvageable tissue, and the clinical implications. Myocardial revascularisation may improve symptom status, exercise capacity, and prognosis in selected patients with viable myocardium.	Cleveland Clin Fdn, Dept Cardiol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Marwick, TH (corresponding author), Cleveland Clin Fdn, Dept Cardiol, F15,9500 Euclid Ave, Cleveland, OH 44195 USA.		Marwick, Thomas H/C-7261-2013	Marwick, Thomas H/0000-0001-9065-0899				ALDERMAN EL, 1983, CIRCULATION, V68, P785, DOI 10.1161/01.CIR.68.4.785; Bonow RO, 1996, CIRCULATION, V94, P2674, DOI 10.1161/01.CIR.94.11.2674; BRAUNWALD E, 1982, CIRCULATION, V66, P1146, DOI 10.1161/01.CIR.66.6.1146; BRUNKEN R, 1986, CIRCULATION, V73, P951, DOI 10.1161/01.CIR.73.5.951; CANDELLRIERA J, 1991, J AM COLL CARDIOL, V18, P1207, DOI 10.1016/0735-1097(91)90537-J; COSTANZO MR, 1995, CIRCULATION, V92, P3593, DOI 10.1161/01.CIR.92.12.3593; DICARLI MF, 1994, AM J CARDIOL, V73, P527, DOI 10.1016/0002-9149(94)90327-1; Hendel R C, 1996, Curr Probl Cardiol, V21, P145; HO KKL, 1993, J AM COLL CARDIOL, V22, pA6, DOI 10.1016/0735-1097(93)90455-A; HOCHBERG MS, 1983, J THORAC CARDIOV SUR, V86, P519; Kaul S, 1996, J AM COLL CARDIOL, V27, P1608, DOI 10.1016/0735-1097(96)00132-5; KAUL S, 1995, CIRCULATION, V92, P2790, DOI 10.1161/01.CIR.92.10.2790; LEE KS, 1994, CIRCULATION, V90, P2687, DOI 10.1161/01.CIR.90.6.2687; MARWICK TH, 1992, AM J CARDIOL, V69, P854, DOI 10.1016/0002-9149(92)90782-T; Pagley PR, 1997, CIRCULATION, V96, P793; RAHIMTOOLA SH, 1989, AM HEART J, V117, P2113; ROSS J, 1991, CIRCULATION, V83, P1076, DOI 10.1161/01.CIR.83.3.1076; Schelbert Heinrich R., 1994, Cardiology Clinics, V12, P303; SCHULZ R, 1995, EUR HEART J, V16, pJ19; TILLISCH J, 1986, NEW ENGL J MED, V314, P884, DOI 10.1056/NEJM198604033141405; VANOVERSCHELDE JL, 1996, CARDIAC STRESS TESTI, P475; VANOVERSCHELDE JLJ, 1993, CIRCULATION, V87, P1513, DOI 10.1161/01.CIR.87.5.1513; Williams MJ, 1996, J AM COLL CARDIOL, V27, P132, DOI 10.1016/0735-1097(95)00393-2; Yellon DM, 1996, LANCET, V347, P1159, DOI 10.1016/S0140-6736(96)90613-3	24	53	58	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 14	1998	351	9105					815	819		10.1016/S0140-6736(97)08080-X	http://dx.doi.org/10.1016/S0140-6736(97)08080-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB916	9519973				2022-12-28	WOS:000072521200042
J	Glaser, DA; Riordan, AT				Glaser, DA; Riordan, AT			Tinea Barbae: Man and beast	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									St Louis Univ, St Louis, MO 63103 USA	Saint Louis University	Glaser, DA (corresponding author), St Louis Univ, St Louis, MO 63103 USA.								0	5	5	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 12	1998	338	11					735	735		10.1056/NEJM199803123381106	http://dx.doi.org/10.1056/NEJM199803123381106			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB546	9494150				2022-12-28	WOS:000072483400006
J	Nightingale, SL				Nightingale, SL			Promotional practices of pharmacy benefits management companies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg, Rockville, MD 20857 USA.								0	22	25	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1998	279	9					645	645		10.1001/jama.279.9.645-b	http://dx.doi.org/10.1001/jama.279.9.645-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY849	9496968				2022-12-28	WOS:000072192800004
J	Yoon, SS; Macdonald, SC; Parrish, RG				Yoon, SS; Macdonald, SC; Parrish, RG			Deaths from unintentional carbon monoxide poisoning and potential for prevention with carbon monoxide detectors	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-Unintentional carbon monoxide (CO) poisoning causes approximately 2100 deaths in the United States per year, but the use of CO detectors could potentially prevent many of these deaths. Objective.-To describe the epidemiology of potentially preventable unintentional CO poisoning deaths in New Mexico. Design.-Descriptive analysis. Population Studied.-A total of 136 deaths from CO poisoning investigated by the New Mexico Office of the Medical Investigator, 1980 through 1995. Main Outcome Measures.-Characteristics of deaths from CO poisoning; estimates of the number of deaths potentially preventable with CO detectors. Results.-Of 136 people whose deaths were classified as "unintentional carbon monoxide poisoning, not fire related," 49 (36%) most likely were asleep when poisoned. Thirty-nine (49%) of 80 people whose deaths were identified as "residential fatalities" most likely were asleep vs 10 (18%) of 56 of those whose deaths were identified as occurring in or around motor vehicles. A blood-alcohol level greater than 0.01% was present in 56 (42%) of the decedents. Among decedents who had a negative blood-alcohol level (52 in residences and 26 in vehicles), an electronic audible CO detector may have prevented CO poisoning; whereas, among those who had a negative blood-alcohol level and most likely were awake at the time of CO exposure (28 in residences and 23 in vehicles), an electronic detector or a nonaudible, chemical reagent type detector may have prevented CO poisoning. Conclusion.-Differences exist between deaths due to unintentional CO poisoning that occur in residences and those that occur in or around motor vehicles. Carbon monoxide detectors, whether the electronic or chemical reagent types, may have prevented approximately half of these deaths, The high proportion of decedents with alcohol in their blood indicates that effective public health campaigns must address the role of alcohol in CO poisoning deaths.	Ctr Dis Control & Prevent, Epidem Intelligence Serv, Epidemiol Program Off, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Surveillance & Programs Branch, Div Environm Hazzards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Yoon, SS (corresponding author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, Epidemiol Program Off, Mail Stop F47,4770 Buford Hwy NE, Atlanta, GA 30341 USA.							BALL LB, 1997, EP INT SERV C CTR DI; BARON RC, 1979, AM J PUBLIC HEALTH, V9, P1656; BARRET L, 1985, CLIN TOXICOL, V23, P309; CAPLAN YH, 1986, J FORENSIC SCI, V31, P117; COOK M, 1995, AM J PUBLIC HEALTH, V85, P988, DOI 10.2105/AJPH.85.7.988; FAWCETT TA, 1992, J OCCUP ENVIRON MED, V34, P12; GAJODS P, 1992, ARCH ENVIRON HEALTH, V46, P373; KLEINMAN MT, 1989, ARCH ENVIRON HEALTH, V44, P361, DOI 10.1080/00039896.1989.9935908; Krenzelok EP, 1996, AM J EMERG MED, V14, P484, DOI 10.1016/S0735-6757(96)90159-X; Leikin JB, 1996, AM J EMERG MED, V14, P90, DOI 10.1016/S0735-6757(96)90025-X; Rao R, 1997, ANN EMERG MED, V29, P290, DOI 10.1016/S0196-0644(97)70284-1; SILVERS SM, 1995, JAMA-J AM MED ASSOC, V274, P1614; WOOLF A, 1994, VET HUM TOXICOL, V6, P344; 1984, DRUG THER B, V22, P81	14	65	65	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1998	279	9					685	687		10.1001/jama.279.9.685	http://dx.doi.org/10.1001/jama.279.9.685			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY849	9496987				2022-12-28	WOS:000072192800033
J	Oliveira, DBG				Oliveira, DBG			Membranous nephropathy: an IgG4-mediated disease	LANCET			English	Article							IMMUNE-COMPLEXES; ANTIBODY-RESPONSE; IGG4 SUBCLASS; CELLS; RAT; INTERLEUKIN-4; AUTOIMMUNITY; PATHOGENESIS; COMPLEMENT; KIDNEY	Membranous nephropathy is characterised by the deposition of immunoglobulin, predominantly of the IgG4 subclass, along the epithelial surface of the glomerular-basement membrane. Current models of pathogenesis usually assume in-situ immune-complex formation involving an as yet uncharacterised fixed glomerular antigen. I argue that the properties of IgG4 (inability to fix complement and therefore impaired clearance of IgG4-containing complexes; low affinity and therefore ability for IgG4-containing complexes to dissociate and traverse the glomerular-basement membrane) are compatible with a pathogenic mechanism that involves the deposition of circulating IgG4 immune complexes containing diverse antigens.	Univ London St Georges Hosp, Sch Med, Div Renal Med, London SW17 0RE, England	St Georges University London	Oliveira, DBG (corresponding author), Univ London St Georges Hosp, Sch Med, Div Renal Med, London SW17 0RE, England.			Oliveira, David/0000-0002-7507-5651				ADLER SG, 1983, J CLIN INVEST, V71, P487, DOI 10.1172/JCI110793; BAKER PJ, 1989, AM J PATHOL, V135, P185; COGGINS CH, 1993, DISEASES KIDNEY, P1785; COUSER WG, 1978, J CLIN INVEST, V62, P1275, DOI 10.1172/JCI109248; DAVIS P, 1973, BRIT MED J, V3, P676, DOI 10.1136/bmj.3.5882.676; DEVEY ME, 1985, IMMUNOLOGY, V55, P565; DIXON FJ, 1968, AM J MED, V44, P493, DOI 10.1016/0002-9343(68)90050-8; DOI T, 1991, NEPHRON, V57, P131, DOI 10.1159/000186239; FARQUHAR MG, 1995, J AM SOC NEPHROL, V6, P35; FLEUREN G, 1980, KIDNEY INT, V17, P631, DOI 10.1038/ki.1980.74; FRENCH MAH, 1984, CLIN EXP IMMUNOL, V56, P473; GOLDMAN M, 1991, IMMUNOL TODAY, V12, P223, DOI 10.1016/0167-5699(91)90034-Q; GOODYER PR, 1986, BIOCHEM CELL BIOL, V64, P441, DOI 10.1139/o86-062; Imai H, 1997, KIDNEY INT, V51, P270, DOI 10.1038/ki.1997.32; KERJASCHKI D, 1989, KIDNEY INT, V35, P1418; Kermarrec N, 1995, NEPHROL DIAL TRANSPL, V10, P2187, DOI 10.1093/ndt/10.12.2187; LUNDGREN M, 1989, EUR J IMMUNOL, V19, P1311, DOI 10.1002/eji.1830190724; NGU JL, 1985, CLIN NEPHROL, V24, P128; OLIVEIRA DBG, 1995, EUR J IMMUNOL, V25, P2259, DOI 10.1002/eji.1830250822; OTTESEN EA, 1985, J IMMUNOL, V134, P2707; PRIGENT P, 1995, J CLIN INVEST, V96, P1484, DOI 10.1172/JCI118185; SCHIFFERLI JA, 1986, NEW ENGL J MED, V315, P488; VANDERZEE JS, 1986, CLIN EXP IMMUNOL, V64, P415	23	65	70	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 28	1998	351	9103					670	671		10.1016/S0140-6736(97)04122-6	http://dx.doi.org/10.1016/S0140-6736(97)04122-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA447	9500350				2022-12-28	WOS:000072364200043
J	Cameron, DW; Heath-Chiozzi, M; Danner, S; Cohen, C; Kravcik, S; Maurath, C; Sun, E; Henry, D; Rode, R; Potthoff, A; Leonard, J				Cameron, DW; Heath-Chiozzi, M; Danner, S; Cohen, C; Kravcik, S; Maurath, C; Sun, E; Henry, D; Rode, R; Potthoff, A; Leonard, J		Adv HIV Dis Ritonavir Study Grp	Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease	LANCET			English	Article							CUBIC MILLIMETER; INFECTED PATIENTS; DOUBLE-BLIND; CD4 CELLS; INHIBITOR; PROTEASE; ZIDOVUDINE; THERAPY; COMBINATION; DIDANOSINE	Background Ritonavir is a potent, orally bioavailable inhibitor of HIV-1 protease. We undertook an international, multicentre, randomised, double-blind, placebo-controlled trial of ritonavir in patients with HIV-1 infection and CD4-lymphocyte counts of 100 cells/mu L or less, who had previously been treated with antiretroviral drugs. Methods 1090 patients were randomly assigned twice-daily liquid oral ritonavir 600 mg (n=543) or placebo (n=547) while continuing treatment with up to two licensed nucleoside agents. The primary study outcome was any first new, or specified recurrent, AIDS-defining event or death. Open-label ritonavir was provided after 16 weeks in the study to any patient who had an AIDS-defining event. Findings The baseline median CD4-lymphocyte count was 18 (IQR 10-43)/mu L in the ritonavir group and 22 (10-47)/mu L in the placebo group. Study medication was discontinued in 114 (21.1%) ritonavir-group patients and 45 (8.3%) placebo-group patients mainly because of initial adverse symptoms. Outcomes of AIDS-defining illness or death occurred in 119 (21.9%) ritonavir-group patients and 205 (37.5%) placebo-group patients (hazard ratio 0.53 [95% CI 0.42-0.66]; log-rank p<0.0001) during median follow-up of 28.9 weeks, with loss to follow-up of 15 (1.4%) patients. Ritonavir was then offered to all patients; at median follow-up of 51 weeks, 87 (16%) ritonavir-group patients had died of any cause versus 126 (23%) placebo-group patients (hazard ratio 0.69 [95% CI 0.52-0.91], log-rank p=0.0072). Interpretation Although earlier intervention with combination therapy may provide much more effective treatment, ritonavir in patients with advanced disease and extensive previous antiretroviral use is safe and effective, lowers the risk of AIDS complications, and prolongs survival.	Univ Ottawa, Ottawa Gen Hosp, Dept Med, Div Infect Dis, Ottawa, ON K1H 8L6, Canada; Abbott Labs, Abbott Pk, IL 60064 USA; Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; Community Res Initiat New England, Brookline, MA 02146 USA	University of Ottawa; Ottawa Hospital Research Institute; Abbott Laboratories; University of Amsterdam; Academic Medical Center Amsterdam	Cameron, DW (corresponding author), Univ Ottawa, Ottawa Gen Hosp, Dept Med, Div Infect Dis, 501 Smyth, Ottawa, ON K1H 8L6, Canada.		Cameron, Bill/E-9180-2010	Cameron, Bill/0000-0002-0090-3539				Aber V, 1996, LANCET, V348, P283, DOI 10.1016/S0140-6736(96)05387-1; AUTRAN G, 1997, SCIENCE, V277, P112; CAMERON DW, 3 INT C DRUG THER HI; Carr A, 1996, J ACQ IMMUN DEF SYND, V13, P320, DOI 10.1097/00042560-199612010-00004; *CDCP, 1992, MMWR-MORBID MORTAL W, V41, pRR17; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; COOPER DA, 1993, NEW ENGL J MED, V329, P297, DOI 10.1056/NEJM199307293290501; DANNER SA, 1995, NEW ENGL J MED, V333, P1528, DOI 10.1056/NEJM199512073332303; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; HAMMER JM, 1997, NEW ENGL J MED, V337, P725; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; Katzenstein DA, 1996, NEW ENGL J MED, V335, P1091, DOI 10.1056/NEJM199610103351502; Kelleher AD, 1996, J INFECT DIS, V173, P321, DOI 10.1093/infdis/173.2.321; KEMPF DJ, 1995, P NATL ACAD SCI USA, V92, P2484, DOI 10.1073/pnas.92.7.2484; KINLOCHDELOES S, 1995, NEW ENGL J MED, V333, P408, DOI 10.1056/NEJM199508173330702; LALAZAMI J, 1996, 11 INT C AIDS VANC C, P29; MARKOWITZ M, 1995, NEW ENGL J MED, V333, P1534, DOI 10.1056/NEJM199512073332304; MARKOWITZ M, 1996, 11 INT C AIDS VANC C; MATHEZ D, 1996, 11 INT C AIDS VANC C; MONTANER JSG, 1995, ANN INTERN MED, V123, P561, DOI 10.7326/0003-4819-123-8-199510150-00001; NOTERMANS DW, 1996, 3 INT C DRUG THER HI; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; Saravolatz LD, 1996, NEW ENGL J MED, V335, P1099, DOI 10.1056/NEJM199610103351503; SUN E, 1996, 11 INT C AIDS VANC C; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484	26	433	439	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 21	1998	351	9102					543	549		10.1016/S0140-6736(97)04161-5	http://dx.doi.org/10.1016/S0140-6736(97)04161-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ216	9492772				2022-12-28	WOS:000072231900008
J	Sakurai, T; Amemiya, A; Ishii, M; Matsuzaki, I; Chemelli, RM; Tanaka, H; Williams, SC; Richardson, JA; Kozlowski, GP; Wilson, S; Arch, JRS; Buckingham, RE; Haynes, AC; Carr, SA; Annan, RS; McNulty, DE; Liu, WS; Terrett, JA; Elshourbagy, NA; Bergsma, DJ; Yanagisawa, M				Sakurai, T; Amemiya, A; Ishii, M; Matsuzaki, I; Chemelli, RM; Tanaka, H; Williams, SC; Richardson, JA; Kozlowski, GP; Wilson, S; Arch, JRS; Buckingham, RE; Haynes, AC; Carr, SA; Annan, RS; McNulty, DE; Liu, WS; Terrett, JA; Elshourbagy, NA; Bergsma, DJ; Yanagisawa, M			Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior	CELL			English	Article							GLUCAGON-LIKE PEPTIDE-1; RAT-BRAIN; LEPTIN RECEPTOR; HUMAN GENOME; FOOD-INTAKE; OBESE GENE; IDENTIFICATION; LOCALIZATION; MICE; NEUROENDOCRINE	The hypothalamus plays a central role in the integrated control of feeding and energy homeostasis. We have identified two novel neuropeptides, both derived from the same precursor by proteolytic processing, that bind and activate two closely related (previously) orphan G protein-coupled receptors. These peptides, termed orexin-A and -B, have no significant structural similarities to known families of regulatory peptides. prepro-orexin mRNA and immunoreactive orexin-A are localized in neurons within and around the lateral and posterior hypothalamus in the adult rat brain. When administered centrally to rats, these peptides stimulate food consumption. prepro-orexin mRNA level is up-regulated upon fasting, suggesting a physiological role for the peptides as mediators in the central feedback mechanism that regulates feeding behavior.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Mol Genet, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA; SmithKline Beecham Pharmaceut, Harlow CM19 5AD, Essex, England; SmithKline Beecham Pharmaceut, King Of Prussia, PA 19406 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; GlaxoSmithKline; GlaxoSmithKline	Yanagisawa, M (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Mol Genet, Dallas, TX 75235 USA.		sheng, jian/E-9474-2012; Carr, Steven A./AAH-8366-2019	Ishii, Makoto/0000-0003-3397-9908				AIYAR N, 1994, MOL CELL BIOCHEM, V131, P75, DOI 10.1007/BF01075727; [Anonymous], [No title captured]; ARASE K, 1988, AM J PHYSIOL, V255, pE255, DOI 10.1152/ajpendo.1988.255.3.E255; BATEMAN A, 1990, J BIOL CHEM, V265, P22130; Benjamin IJ, 1997, DEV DYNAM, V208, P75; Bernardis LL, 1996, NEUROSCI BIOBEHAV R, V20, P189, DOI 10.1016/0149-7634(95)00015-1; BERNARDIS LL, 1993, NEUROSCI BIOBEHAV R, V17, P141, DOI 10.1016/S0149-7634(05)80149-6; Bing C, 1996, BIOCHEM SOC T, V24, P559, DOI 10.1042/bst0240559; BITTENCOURT JC, 1992, J COMP NEUROL, V319, P218, DOI 10.1002/cne.903190204; BRADBURY AF, 1991, TRENDS BIOCHEM SCI, V16, P112, DOI 10.1016/0968-0004(91)90044-V; Bray George A., 1995, P1591; BUSBY WH, 1987, J BIOL CHEM, V262, P8532; CARR S, 1996, CURRENT PROTOCOLS PR; Carr SA, 1996, ANAL BIOCHEM, V239, P180, DOI 10.1006/abio.1996.0313; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; EIPPER BA, 1993, PROTEIN SCI, V2, P489; Erickson JC, 1996, SCIENCE, V274, P1704, DOI 10.1126/science.274.5293.1704; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; Friedman JM, 1997, NATURE, V385, P119, DOI 10.1038/385119a0; Gerald C, 1996, NATURE, V382, P168, DOI 10.1038/382168a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gyapay G, 1996, HUM MOL GENET, V5, P339, DOI 10.1093/hmg/5.3.339; HEPLER JR, 1994, METHOD ENZYMOL, V237, P191; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; IKEDA M, 1980, J NEUROSCI METH, V2, P9, DOI 10.1016/0165-0270(80)90041-2; JACOBOWITZ DM, 1978, P NATL ACAD SCI USA, V75, P6300, DOI 10.1073/pnas.75.12.6300; MOUNTJOY KG, 1994, MOL ENDOCRINOL, V8, P1298, DOI 10.1210/me.8.10.1298; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OhkiHamazaki H, 1997, NATURE, V390, P165, DOI 10.1038/36568; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; OOMURA Y, 1974, NATURE, V247, P284, DOI 10.1038/247284a0; Paxinos G., 1986, RAT BRAIN STEREOTAXI, V2nd; Qu DQ, 1996, NATURE, V380, P243, DOI 10.1038/380243a0; Roden D.M., 1996, GOODMAN GILMANS PHAR, V9th, P869; Rosenbaum M, 1997, NEW ENGL J MED, V337, P396, DOI 10.1056/NEJM199708073370606; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; Shughrue PJ, 1996, ENDOCRINOLOGY, V137, P5159, DOI 10.1210/en.137.11.5159; Shutter JR, 1997, GENE DEV, V11, P593, DOI 10.1101/gad.11.5.593; Stadel JM, 1997, TRENDS PHARMACOL SCI, V18, P430, DOI 10.1016/S0165-6147(97)01117-6; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; TAKIGAWA M, 1995, EUR J BIOCHEM, V228, P102, DOI 10.1111/j.1432-1033.1995.0102o.x; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Turton MD, 1996, NATURE, V379, P69, DOI 10.1038/379069a0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WAREMBOURG M, 1993, J NEUROENDOCRINOL, V5, P487, DOI 10.1111/j.1365-2826.1993.tb00512.x; Wijker M, 1996, HUM MOL GENET, V5, P151, DOI 10.1093/hmg/5.1.151; Wilhelmsen KC, 1997, ANN NEUROL, V41, P139, DOI 10.1002/ana.410410202; WILHELMSEN KC, 1994, AM J HUM GENET, V55, P1159; WILHELMSEN KC, 1997, AM J HUM GENET, V55, P85; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; Wolf G, 1997, NUTR REV, V55, P85, DOI 10.1111/j.1753-4887.1997.tb01602.x; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; YEN TT, 1994, FASEB J, V8, P479, DOI 10.1096/fasebj.8.8.8181666; ZARJEVSKI N, 1993, ENDOCRINOLOGY, V133, P1753, DOI 10.1210/en.133.4.1753; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	57	4004	4267	7	222	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 20	1998	92	4					573	585		10.1016/S0092-8674(00)80949-6	http://dx.doi.org/10.1016/S0092-8674(00)80949-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YZ409	9491897	Bronze			2022-12-28	WOS:000072251500016
J	Welte, MA; Gross, SP; Postner, M; Block, SM; Wieschaus, EF				Welte, MA; Gross, SP; Postner, M; Block, SM; Wieschaus, EF			Developmental regulation of vesicle transport in Drosophila embryos: Forces and kinetics	CELL			English	Article							FAST AXONAL-TRANSPORT; ORGANELLE TRANSPORT; NUCLEAR MIGRATION; KINESIN; MELANOGASTER; CELLS; PHOSPHORYLATION; GASTRULATION; MICROSCOPY; POLARITY	In Drosophila embryos, microtubules oriented along apical-basal directions support saltatory vesicle movement. Vesicle traffic includes lipid droplets whose distribution shifts twice during early embryogenesis. Using microscopy, optical tweezers, and a novel squashed-mount embryo preparation, we tracked single droplets and measured the forces these generated. Droplet stalling forces change developmentally, in a roughly quantized fashion, consistent with variation in the number of active motors. We characterized a mutation, klarsicht, that affects droplet transport. Klar(+) facilitates changes in force, possibly by coordinating the activity of multiple motors. Alterations in transport affected motion in both apical and basal directions, indicating tight coupling between motors of opposite polarity. Mutations in klar also affect nuclear migration during eye development, suggesting multiple roles for klar-based transport.	Princeton Univ, Howard Hughes Med Inst, Dept Mol Biol, Princeton, NJ 08544 USA; Princeton Univ, Howard Hughes Med Inst, Princeton Mat Inst, Princeton, NJ 08544 USA	Howard Hughes Medical Institute; Princeton University; Howard Hughes Medical Institute; Princeton University	Wieschaus, EF (corresponding author), Princeton Univ, Howard Hughes Med Inst, Dept Mol Biol, Princeton, NJ 08544 USA.		Welte, Michael/AAH-5589-2019	Welte, Michael/0000-0001-5741-4720	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD015587] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM018329] Funding Source: NIH RePORTER; NICHD NIH HHS [5R37HD15587] Funding Source: Medline; NIGMS NIH HHS [5F32GM18329, 5R01GM5143] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSO LAG, 1988, ROUX ARCH DEV BIOL, V197, P328, DOI 10.1007/BF00375952; ASHKIN A, 1990, NATURE, V348, P346, DOI 10.1038/348346a0; BEREITERHAHN J, 1979, J CELL BIOL, V82, P767, DOI 10.1083/jcb.82.3.767; Bevington P. R, 1969, DATA REDUCTION ERROR; BRADY ST, 1985, CELL MOTIL CYTOSKEL, V5, P81, DOI 10.1002/cm.970050203; EDGAR BA, 1987, GENE DEV, V1, P1226, DOI 10.1101/gad.1.10.1226; Fan SS, 1997, DEVELOPMENT, V124, P1497; FISCHERVIZE JA, 1994, DEVELOPMENT, V120, P2609; FOE VE, 1983, J CELL SCI, V61, P31; FULLILOVE SL, 1971, DEV BIOL, V26, P560, DOI 10.1016/0012-1606(71)90141-2; GELLES J, 1988, NATURE, V331, P450, DOI 10.1038/331450a0; Gepner J, 1996, GENETICS, V142, P865; GINIGER E, 1993, ROUX ARCH DEV BIOL, V202, P112, DOI 10.1007/BF00636536; GRAFSTEIN B, 1980, PHYSIOL REV, V60, P1167, DOI 10.1152/physrev.1980.60.4.1167; GREENSPAN P, 1985, J CELL BIOL, V100, P965, DOI 10.1083/jcb.100.3.965; HAMMALVAREZ SF, 1993, J CELL SCI, V106, P955; Hurd DD, 1996, GENETICS, V144, P1075; HYMAN AA, 1991, NATURE, V351, P206, DOI 10.1038/351206a0; LEE KD, 1995, J BIOL CHEM, V270, P5600, DOI 10.1074/jbc.270.10.5600; MERRILL PT, 1988, DEVELOPMENT, V104, P495; MORRIS NR, 1995, TRENDS CELL BIOL, V5, P278; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; Parsons SF, 1997, CELL MOTIL CYTOSKEL, V36, P1; Preece A., 1972, MANUAL HISTOLOGIC TE; RAY S, 1993, J CELL BIOL, V121, P1083, DOI 10.1083/jcb.121.5.1083; RICKOLL WL, 1976, DEV BIOL, V49, P304, DOI 10.1016/0012-1606(76)90278-5; SATOYOSHITAKE R, 1992, J BIOL CHEM, V267, P23930; SAXTON WM, 1991, CELL, V64, P1093, DOI 10.1016/0092-8674(91)90264-Y; SCHLIWA M, 1991, J CELL BIOL, V112, P1199, DOI 10.1083/jcb.112.6.1199; SVOBODA K, 1994, ANNU REV BIOPH BIOM, V23, P247, DOI 10.1146/annurev.bb.23.060194.001335; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; Thaler C D, 1996, Int Rev Cytol, V164, P269; THALER CD, 1992, CELL MOTIL CYTOSKEL, V22, P175, DOI 10.1002/cm.970220305; TIFFANY JM, 1986, CURR EYE RES, V5, P887, DOI 10.3109/02713688609029242; TOMLINSON A, 1985, J EMBRYOL EXP MORPH, V89, P313; VALE RD, 1992, J CELL BIOL, V119, P1589, DOI 10.1083/jcb.119.6.1589; VALKENBURG JAC, 1984, J BACTERIOL, V160, P1151, DOI 10.1128/JB.160.3.1151-1157.1984; Visscher K, 1996, IEEE J SEL TOP QUANT, V2, P1066, DOI 10.1109/2944.577338; WANG SX, 1994, NATURE, V369, P400, DOI 10.1038/369400a0; Wang ZH, 1995, BIOPHYS J, V69, P2011, DOI 10.1016/S0006-3495(95)80071-8; WEAST R, 1986, CRC HDB CHEM PHYSICS, pE374; White G, 1996, BIOPHYS J, V71, P2701, DOI 10.1016/S0006-3495(96)79461-4; Wieschaus E., 1986, P199	44	306	311	3	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 20	1998	92	4					547	557		10.1016/S0092-8674(00)80947-2	http://dx.doi.org/10.1016/S0092-8674(00)80947-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YZ409	9491895	Bronze			2022-12-28	WOS:000072251500014
J	Fox, RD; Bennett, NL				Fox, RD; Bennett, NL			Continuing medical education - Learning and change: implications for continuing medical education	BRITISH MEDICAL JOURNAL			English	Article									Univ Oklahoma, Res Ctr Continuing Profess & Higher Educ, Norman, OK 73037 USA; Harvard Univ, Sch Med, Dept Continuing Educ, Boston, MA 02115 USA	University of Oklahoma System; University of Oklahoma - Norman; Harvard University; Harvard Medical School	Fox, RD (corresponding author), Univ Oklahoma, Res Ctr Continuing Profess & Higher Educ, Norman, OK 73037 USA.							BENNETT NL, 1995, J CONT ED HLTH PROF, V15, P70; BENNETT NL, 1993, ED PROFESSIONALS RES; CONFESSORE SJ, 1997, J CONTIN EDUC HEALTH, V17, P5; FOX RD, 1994, PHYSICIANS LEARNERS; FOX RD, 1989, CHANGE LEARNING LIVE; RANKIN R, 1997, J CONTINUING ED HLTH, V17, P173; Rogers E., 2003, DIFFUSION INNOVATION, VFifth; Senge P., 1990, 5 DISCIPLINE; Watkins K.E., 1993, SCULPTING LEARNING O	9	133	139	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 7	1998	316	7129					466	468		10.1136/bmj.316.7129.466	http://dx.doi.org/10.1136/bmj.316.7129.466			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW874	9492684	Green Published			2022-12-28	WOS:000071982700050
J	Hermon-Taylor, J; Barnes, N; Clarke, C; Finlayson, C				Hermon-Taylor, J; Barnes, N; Clarke, C; Finlayson, C			Grand round - Mycobacterium paratuberculosis cervical lymphadenitis, followed five years later by terminal ileitis similar to Crohn's disease	BRITISH MEDICAL JOURNAL			English	Review							JOHNES-DISEASE; COWS MILK; IS900; HYBRIDIZATION; CATTLE; PASTEURIZATION; PATHOLOGY; ENGLAND; OVINE; AVIUM		St George Hosp, Sch Med, Dept Surg, London SW17 0RE, England; Addenbrookes Hosp, Childrens Serv, Cambridge CB2 2QQ, England; Univ Edinburgh, Dept Vet Pathol, Vet Field Stn, Roslin EH25 9RG, Midlothian, Scotland; St George Hosp, Sch Med, Dept Histopathol, London SW17 0RE, England	St Georges University London; Addenbrooke's Hospital; University of Cambridge; University of Edinburgh; St Georges University London	Hermon-Taylor, J (corresponding author), St George Hosp, Sch Med, Dept Surg, London SW17 0RE, England.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bauerfeind R, 1996, J CLIN MICROBIOL, V34, P1617, DOI 10.1128/JCM.34.7.1617-1621.1996; BODDINGHAUS B, 1990, FEMS MICROBIOL LETT, V70, P197, DOI 10.1016/S0378-1097(05)80039-4; Cetinkaya B, 1996, EPIDEMIOL INFECT, V116, P373, DOI 10.1017/S0950268800052705; CHIODINI RJ, 1984, CORNELL VET, V74, P218; CHIODINI RJ, 1993, J VET DIAGN INVEST, V5, P629, DOI 10.1177/104063879300500424; CHIODINI RJ, 1984, J CLIN MICROBIOL, V20, P966, DOI 10.1128/JCM.20.5.966-971.1984; CHOREMIS CB, 1955, AM REV TUBERC PULM, V72, P527; Clarke CJ, 1996, J COMP PATHOL, V114, P419, DOI 10.1016/S0021-9975(96)80017-X; COHEN S, 1991, PSYCHOL BULL, V109, P5, DOI 10.1037/0033-2909.109.1.5; COLLINS CH, 1984, J APPL BACTERIOL, V57, P193, DOI 10.1111/j.1365-2672.1984.tb01384.x; COLOE P, 1986, AUST MICROBIOL, V7, pA188; DALZEIL TK, 1913, BRIT MED J, V2, P1068; Forcione DG, 1996, P NATL ACAD SCI USA, V93, P5094, DOI 10.1073/pnas.93.10.5094; GITNICK G, 1989, DIGEST DIS SCI, V34, P925, DOI 10.1007/BF01540280; Grant IR, 1996, APPL ENVIRON MICROB, V62, P631, DOI 10.1128/AEM.62.2.631-636.1996; GREEN EP, 1989, NUCLEIC ACIDS RES, V17, P9063, DOI 10.1093/nar/17.22.9063; GRIEG A, 1997, VET REC, V140, P141; Gui GPH, 1997, J ANTIMICROB CHEMOTH, V39, P393, DOI 10.1093/jac/39.3.393; HAAGSMA J, 1991, ACTA ENDOSC, P255; HERMONTAYLOR J, 1990, BAILLIERE CLIN GASTR, V4, P23, DOI 10.1016/0950-3528(90)90037-H; HINES ME, 1995, LAB ANIM SCI, V45, P334; Hugot JP, 1996, NATURE, V379, P821, DOI 10.1038/379821a0; Humphriss E, 1937, LANCET, V2, P151; JOHNE HA, 1895, DTSCH Z TIERMED PATH, V21, P438; MCCLURE HM, 1987, J INFECT DIS, V155, P1011, DOI 10.1093/infdis/155.5.1011; MCFADDEN JJ, 1987, J CLIN MICROBIOL, V25, P796, DOI 10.1128/JCM.25.5.796-801.1987; Millar D, 1996, APPL ENVIRON MICROB, V62, P3446, DOI 10.1128/AEM.62.9.3446-3452.1996; MILLAR DS, 1995, ANAL BIOCHEM, V226, P325, DOI 10.1006/abio.1995.1232; NAAFS B, 1989, BIOL MYCOBACTERIA, V3, P359; PAVLIK I, 1995, VET MICROBIOL, V45, P311, DOI 10.1016/0378-1135(94)00130-O; Plevy SE, 1996, GASTROENTEROLOGY, V110, P1053, DOI 10.1053/gast.1996.v110.pm8612993; ROTH MP, 1989, GASTROENTEROLOGY, V97, P900, DOI 10.1016/0016-5085(89)91495-9; Sachar DB, 1996, GASTROENTEROLOGY, V111, P813, DOI 10.1053/gast.1996.v111.agast961110813; SWEENEY RW, 1992, J CLIN MICROBIOL, V30, P166, DOI 10.1128/JCM.30.1.166-171.1992; SWEENEY RW, 1992, AM J VET RES, V53, P1312; THOREL MF, 1989, ANN RECH VET, V20, P417	36	71	71	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 7	1998	316	7129					449	453		10.1136/bmj.316.7129.449	http://dx.doi.org/10.1136/bmj.316.7129.449			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW874	9492675	Green Published			2022-12-28	WOS:000071982700039
J	Marshall, MN				Marshall, MN			Qualitative study of educational interaction between general practitioners and specialists	BRITISH MEDICAL JOURNAL			English	Article							COMMUNICATION; CONSULTANTS	Objectives: To identify the main barriers to effective educational interaction between general practitioners and specialists and to suggest ways of overcoming these barriers. Design: Qualitative study using semistructured interviews and focus groups. A content analysis of the data was performed Setting: South and West Regional Health Authority. Subjects: 12 general practitioner principals and 12 hospital consultants were sampled purposefully and underwent a semistructured interview; a further 16 general practitioners and 16 hospital consultants similarly sampled made up four focus groups representing the two branches of the medical profession. Results: There was a mismatch between what the general practitioners wanted from specialists in educational terms, and what the specialists were providing. General practitioners wanted to learn information that was directly applicable to their clinical work and to use referrals as two way learning opportunities. They were not sufficiently explicit about their learning needs. Specialists preferred to concentrate on new developments in their subject and would benefit from learning different ways of teaching. The participants were willing to learn from each other. Three models of educational interaction were identified: traditional didactic lectures given by specialists to general practitioners, interactive clinically based teaching, and informal interaction based on referrals. Conclusions: The two main branches of the medical profession have to address several significant problems before the full potential of teaching and learning together can be realised.	Univ Exeter, Postgrad Med Sch, Inst Gen Practice, Exeter EX2 5DW, Devon, England	University of Exeter	Marshall, MN (corresponding author), Univ Exeter, Postgrad Med Sch, Inst Gen Practice, Exeter EX2 5DW, Devon, England.							BAILEY JJ, 1994, BRIT MED J, V308, P1083, DOI 10.1136/bmj.308.6936.1083; Drury M, 1976, Med Educ, V10, P309; LONG A, 1974, BRIT MED J, V4, P456, DOI 10.1136/bmj.4.5942.456; Marshall MN, 1996, FAM PRACT, V13, P522, DOI 10.1093/fampra/13.6.522; Marshall MN, 1996, FAM PRACT, V13, P92, DOI 10.1093/fampra/13.1.92; McCracken G., 1988, LONG INTERVIEW, V13; MECHANIC D, 1968, NEW ENGL J MED, V297, P680; Miles M., 2013, QUALITATIVE DATA ANA; MORGAN DL, 1988, FOCUS GROUPS QUALITA; NEWTON J, 1992, BRIT MED J, V304, P821, DOI 10.1136/bmj.304.6830.821; NEWTON J, 1994, FAM PRACT, V11, P15, DOI 10.1093/fampra/11.1.15; POP P, 1989, J ROY COLL GEN PRACT, V39, P507; Riley J, 1990, GETTING MOST YOUR DA; WESTERMAN RF, 1990, BRIT J GEN PRACT, V40, P445	14	44	45	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 7	1998	316	7129					442	445		10.1136/bmj.316.7129.442	http://dx.doi.org/10.1136/bmj.316.7129.442			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW874	9492673	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000071982700035
J	Seaman, SR; Brettle, RP; Gore, SM				Seaman, SR; Brettle, RP; Gore, SM			Mortality from overdose among injecting drug users recently released from prison: database linkage study	BRITISH MEDICAL JOURNAL			English	Article							COHORT	Objective: To assess whether injecting drug users have a higher than usual risk of death from overdose in the 2 weeks after release from prison. Design: Sounder coding of surnames and information on date of birth were used to link entry and release dates from the local prison between 1983 and 1994 with clinical data from Edinburgh City Hospital's cohort of male injecting drug users who are infected with HIV. Setting: Edinburgh City Hospital and Edinburgh Prison. Subjects: 316/332 male injecting drug users infected with HIV in the City Hospital HIV cohort; 16 were excluded because they were enrolled after developing AIDS or because their precise date of death was not available. Main outcome measure: Relative risk of dying from overdose before developing AIDS and relative risk of dying of all causes before developing AIDS during the 2 weeks after release from prison; this was compared with relative risks of death during other time at liberty. Results: 238/316 (75%) injecting drug users served time in the prison between 1983 and 1994. 33 out of 316 injecting drug users who were infected with HIV died before developing AIDS during 517 177 days at risk 20 of these men died of an overdose; 6 of these deaths occurred within 2 weeks of release during 5903 days at risk Death rates from overdose before the development of AIDS were 1.02/1000 days during the 2 weeks after release (recently released) and 0.029/1000 days during other times of liberty. The relative risk of death from overdose became 7.7 (1.5 to 39.1) after temporal matching (when the comparison was limited to the first 2 weeks after release v the next 10 weeks). The crude relative risk in an analysis combining stratified prison term and the 2 weeks after release was 4.5 (1.7 to 11.7) for death from overdose. After temporal matching these risks became 1.8 (0.4 to 9.2). Conclusion: Prisons should evaluate interventions to reduce the risk of death from overdose after release.	Inst Publ Hlth, MRC, Biostat Unit, Cambridge CB2 2SR, England; City Hosp Edinburgh, Reg Infect Dis Unit, Edinburgh EH11 3XA, Midlothian, Scotland	MRC Biostatistics Unit; University of Cambridge	Gore, SM (corresponding author), Inst Publ Hlth, MRC, Biostat Unit, Cambridge CB2 2SR, England.			Seaman, Shaun/0000-0003-3726-5937				BIRD AG, 1995, AIDS, V9, P801, DOI 10.1097/00002030-199507000-00019; Bird AG, 1997, BRIT MED J, V315, P21, DOI 10.1136/bmj.315.7099.21; BRETTLE RP, 1995, QJM-INT J MED, V88, P479; FAIRWEATHER C, 1997, HER MAJESTYS CHIEF I; GORE SM, 1995, ANSWER, V39, P1; Strang J, 1996, BRIT MED J, V312, P1435, DOI 10.1136/bmj.312.7044.1435; vanHaastrecht HJA, 1996, AM J EPIDEMIOL, V143, P380	7	183	185	1	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 7	1998	316	7129					426	428		10.1136/bmj.316.7129.426	http://dx.doi.org/10.1136/bmj.316.7129.426			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW874	9492665	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000071982700023
J	Al-Kaff, NS; Covey, SN; Kreike, MM; Page, AM; Pinder, R; Dale, PJ				Al-Kaff, NS; Covey, SN; Kreike, MM; Page, AM; Pinder, R; Dale, PJ			Transcriptional and posttranscriptional plant gene silencing in response to a pathogen	SCIENCE			English	Article							CAULIFLOWER MOSAIC-VIRUS; TRANSGENIC PLANTS; EXPRESSION; RESISTANCE; DNA	Plants are able to respond to pathogen attack to restrain development of a systemic infection. The response of Brassica napus (oilseed rape) to systemic infection with the DNA virus cauliflower mosaic virus was shown to result in enhancement and subsequent suppression of viral gene expression in parallel with changes in symptom expression, Transgenes with homology to viral sequences were also affected, This phenomenon, which was shown to be mediated by both transcriptional and posttranscriptional mechanisms, might be related to regulation of highly expressed genetic elements.	John Innes Ctr Plant Sci Res, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Al-Kaff, NS (corresponding author), John Innes Ctr Plant Sci Res, Norwich Res Pk, Norwich NR4 7UH, Norfolk, England.	alkaff@bbsrc.ac.uk						AlKaff NS, 1996, MOL PLANT MICROBE IN, V9, P357, DOI 10.1094/MPMI-9-0357; Aranda MA, 1996, P NATL ACAD SCI USA, V93, P15289, DOI 10.1073/pnas.93.26.15289; Baulcombe DC, 1996, PLANT CELL, V8, P1833, DOI 10.1105/tpc.8.10.1833; Baulcombe DC, 1996, CURR OPIN BIOTECH, V7, P173, DOI 10.1016/S0958-1669(96)80009-7; COVEY SN, 1990, P NATL ACAD SCI USA, V87, P1633, DOI 10.1073/pnas.87.5.1633; Covey SN, 1997, NATURE, V385, P781, DOI 10.1038/385781a0; COX KH, 1988, PLANT MOL BIOL PRACT, P1; FLAVELL RB, 1994, P NATL ACAD SCI USA, V91, P3490, DOI 10.1073/pnas.91.9.3490; GODIARD L, 1994, CURR OPIN GENET DEV, V4, P662, DOI 10.1016/0959-437X(94)90132-M; HULL R, 1983, NUCLEIC ACIDS RES, V11, P1881, DOI 10.1093/nar/11.6.1881; JEFFERSON RA, 1987, EMBO J, V6, P3901; Jones Jonathan D. G., 1992, Transgenic Research, V1, P285, DOI 10.1007/BF02525170; MATZKE MA, 1995, PLANT PHYSIOL, V107, P679, DOI 10.1104/pp.107.3.679; Meyer P, 1996, ANNU REV PLANT PHYS, V47, P23, DOI 10.1146/annurev.arplant.47.1.23; Ratcliff F, 1997, SCIENCE, V276, P1558, DOI 10.1126/science.276.5318.1558; SAUNDERS K, 1991, J GEN VIROL, V71, P2603; Taylor CB, 1997, PLANT CELL, V9, P1245; Turner DS, 1996, J VIROL, V70, P5414, DOI 10.1128/JVI.70.8.5414-5421.1996; WANG DW, 1995, SCIENCE, V267, P229, DOI 10.1126/science.267.5195.229	19	165	175	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 27	1998	279	5359					2113	2115		10.1126/science.279.5359.2113	http://dx.doi.org/10.1126/science.279.5359.2113			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZE274	9516113				2022-12-28	WOS:000072775600049
J	Jochimsen, EM; Carmichael, WW; An, JS; Cardo, DM; Cookson, ST; Holmes, CEM; Antunes, MBD; de Melo, DA; Lyra, TM; Barreto, VST; Azevedo, SMFO; Jarvis, WR				Jochimsen, EM; Carmichael, WW; An, JS; Cardo, DM; Cookson, ST; Holmes, CEM; Antunes, MBD; de Melo, DA; Lyra, TM; Barreto, VST; Azevedo, SMFO; Jarvis, WR			Liver failure and death after exposure to microcystins at a hemodialysis center in Brazil	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DIALYSIS CENTER; HEMOLYSIS; ANEMIA	Background Hemodialysis is a common but potentially hazardous procedure. From February 17 to 20, 1996, 116 of 130 patients (89 percent) at a dialysis center (dialysis center A) in Caruaru, Brazil, had visual disturbances, nausea, and vomiting associated with hemodialysis. By March 24, 26 of the patients had died of acute liver failure. Methods A case patient was defined as any patient undergoing dialysis at dialysis center A or Caruaru's other dialysis center (dialysis center B) during February 1996 who had acute liver failure. To determine the risk factors for and the source of the outbreak, we conducted a cohort study of the 130 patients at dialysis center A and the 47 patients at dialysis center B, reviewed the centers' water supplies, and collected water, patients' serum, and postmortem liver tissue for microcystin assays. Results One hundred one patients (all at dialysis center A) met the case definition, and 50 died. Affected patients who died were older than those who survived (median age, 47 vs. 35 years; P<0.001). Furthermore, all 17 patients undergoing dialysis on the Tuesday-, Thursday-, and Saturday-night schedule became ill, and 13 of them (76 percent) died. Both centers received water from a nearby reservoir. However, the water supplied to dialysis center B was treated, filtered, and chlorinated, whereas the water supplied to dialysis center A was not. Microcystins produced by cyanobacteria were detected in water from the reservoir and from dialysis center A and in serum and liver tissue of case patients. Conclusions Water used for hemodialysis can contain toxic materials, and its quality should therefore be carefully monitored. (C) 1998, Massachusetts Medical Society.	Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Hosp Infect Program, Atlanta, GA 30333 USA; Wright State Univ, Dept Biol Sci, Dayton, OH 45435 USA; Secretaria Saude Pernambuco, Recife, PE, Brazil; Hosp Barao Lucena, Recife, PE, Brazil; Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil	Centers for Disease Control & Prevention - USA; University System of Ohio; Wright State University Dayton; Universidade Federal do Rio de Janeiro	Jochimsen, EM (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Hosp Infect Program, Mailstop E-69,1600 Clifton Rd, Atlanta, GA 30333 USA.		de oliveira e azevedo, sandra maria feliciano/G-8362-2015	de oliveira e azevedo, sandra maria feliciano/0000-0002-3046-0652				ALFREY AC, 1972, T AM SOC ART INT ORG, V18, P257; AN JS, 1994, TOXICON, V32, P1495, DOI 10.1016/0041-0101(94)90308-5; ARNOW PM, 1994, ANN INTERN MED, V121, P339, DOI 10.7326/0003-4819-121-5-199409010-00005; *ASS ADV MED INSTR, 1996, AAMI STAND REC PRACT, V3; AZEVEDO SMFO, 1994, J APPL PHYCOL, V6, P261, DOI 10.1007/BF02181936; BURWEN DR, 1995, KIDNEY INT, V48, P469, DOI 10.1038/ki.1995.315; CARMICHAEL WW, 1992, J APPL BACTERIOL, V72, P445, DOI 10.1111/j.1365-2672.1992.tb01858.x; Carmichael WW, 1997, ADV BOT RES, V27, P211; Dean A.G., 1994, EPI INFO VERSION 6 W; EATON JW, 1973, SCIENCE, V181, P463, DOI 10.1126/science.181.4098.463; *FOOD DRUG ADM, 1989, FDA SAF AL SOD AZ CO; FREEMAN RM, 1967, NEW ENGL J MED, V276, P1113, DOI 10.1056/NEJM196705182762003; GORDON SM, 1990, AM J NEPHROL, V10, P123, DOI 10.1159/000168066; GORDON SM, 1990, KIDNEY INT, V37, P110, DOI 10.1038/ki.1990.15; HOY RH, 1981, AM J HOSP PHARM, V38, P1512, DOI 10.1093/ajhp/38.10.1512; LEVIN NW, 1990, CLIN DIALYSIS, P172; MANZLER AD, 1970, ANN INTERN MED, V73, P409, DOI 10.7326/0003-4819-73-3-409; NICKEY WA, 1970, J AMER MED ASSOC, V214, P915, DOI 10.1001/jama.1970.03180050069020; ORRINGER EP, 1976, NEW ENGL J MED, V294, P1416, DOI 10.1056/NEJM197606242942602; PETRIE JJB, 1977, LANCET, V1, P1178; Rao PVL, 1996, TOXICOLOGY, V114, P29, DOI 10.1016/S0300-483X(96)03413-0; SCHREEDER MT, 1983, J CHRON DIS, V36, P581, DOI 10.1016/0021-9681(83)90146-7; Stotts RR, 1997, TOXICON, V35, P455, DOI 10.1016/S0041-0101(96)00120-1; Teixeira M da G, 1993, Bull Pan Am Health Organ, V27, P244; Tipple M A, 1991, ASAIO Trans, V37, P588; VELANDIA M, 1995, LANCET, V345, P1417, DOI 10.1016/S0140-6736(95)92603-8	26	833	890	3	179	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 26	1998	338	13					873	878		10.1056/NEJM199803263381304	http://dx.doi.org/10.1056/NEJM199803263381304			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD284	9516222				2022-12-28	WOS:000072669800004
J	Hartman, G; Wise, R				Hartman, G; Wise, R			Quorum sensing: potential means of treating gram-negative infections?	LANCET			English	Editorial Material							PSEUDOMONAS-AERUGINOSA; VIBRIO-FISCHERI; BACTERIA		City Hosp NHS Trust, Dept Med Microbiol, Birmingham B18 7QH, W Midlands, England		Hartman, G (corresponding author), City Hosp NHS Trust, Dept Med Microbiol, Birmingham B18 7QH, W Midlands, England.							FUQUA WC, 1994, J BACTERIOL, V176, P269, DOI 10.1128/JB.176.2.269-275.1994; Givskov M, 1996, J BACTERIOL, V178, P6618, DOI 10.1128/jb.178.22.6618-6622.1996; KAPLAN HB, 1985, J BACTERIOL, V163, P1210, DOI 10.1128/JB.163.3.1210-1214.1985; MCKENNEY D, 1995, J BACTERIOL, V177, P6989, DOI 10.1128/jb.177.23.6989-6992.1995; SITNIKOV DM, 1995, MOL MICROBIOL, V17, P801, DOI 10.1111/j.1365-2958.1995.mmi_17050801.x; SWIFT S, 1993, MOL MICROBIOL, V10, P511, DOI 10.1111/j.1365-2958.1993.tb00923.x; Tang HB, 1996, INFECT IMMUN, V64, P37, DOI 10.1128/IAI.64.1.37-43.1996; WINSON MK, 1995, P NATL ACAD SCI USA, V92, P9427, DOI 10.1073/pnas.92.20.9427	8	32	39	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 21	1998	351	9106					848	849		10.1016/S0140-6736(05)70282-8	http://dx.doi.org/10.1016/S0140-6736(05)70282-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD047	9525356				2022-12-28	WOS:000072645500004
J	Perl, AK; Wilgenbus, P; Dahl, U; Semb, H; Christofori, G				Perl, AK; Wilgenbus, P; Dahl, U; Semb, H; Christofori, G			A causal role for E-cadherin in the transition from adenoma to carcinoma	NATURE			English	Article							TRANSCRIPTION FACTOR LEF-1; BETA-CATENIN; PANCREATIC-ISLETS; GROWTH-FACTOR; EXPRESSION; TUMORIGENESIS; CELLS; PROGRESSION; GENE	Development of malignant tumours is in part characterized by the ability of a tumour cell to overcome cell-cell adhesion and to invade surrounding tissue. E-cadherin is the main adhesion molecule of epithelia(1-3), and it has been implicated in carcinogenesis because it is frequently lost in human epithelial cancers(4-6). Re-establishing the functional cadherin complex in tumour cell lines results in a reversion from an invasive to a benign epithelial phenotype(7), However, it remained unresolved whether the loss of E-cadherin-mediated cell adhesion was a cause or a consequence of tumour progression in vivo, Here we report that the loss of E-cadherin expression coincides with the transition from well differentiated adenoma to invasive carcinoma in a transgenic mouse model of pancreatic beta-cell carcinogenesis (Rip1Tag2)(8). Intercrossing Rip1Tag2 mice with transgenic mice that maintain E-cadherin expression in beta-tumour cells results in arrest of tumour development at the adenoma stage, whereas expression of a dominant-negative form of E-cadherin induces early invasion and metastasis. The results demonstrate that loss of E-cadherin-mediated cell adhesion is one rate-limiting step in the progression from adenoma to carcinoma.	Res Inst Mol Pathol, A-1030 Vienna, Austria; Umea Univ, Dept Microbiol, S-90187 Umea, Sweden	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Umea University	Christofori, G (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.		Perl, Anne-Karina T/M-7174-2013	Perl, Anne-Karina T/0000-0002-8445-4565; Semb, Henrik/0000-0002-6747-787X				Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BIRCHMEIER W, 1993, SEMIN CANCER BIOL, V4, P231; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; CHRISTOFORI G, 1995, MOL ENDOCRINOL, V9, P1760, DOI 10.1210/me.9.12.1760; Dahl U, 1996, DEVELOPMENT, V122, P2895; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; GRAFF JR, 1995, CANCER RES, V55, P5195; GUMBINER BM, 1997, CURR BIOL, V7, P443; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Hennig G, 1996, J BIOL CHEM, V271, P595, DOI 10.1074/jbc.271.1.595; HOGAN B, 1986, MANIPULATING MOUSE E; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Huber O, 1996, CURR OPIN CELL BIOL, V8, P685, DOI 10.1016/S0955-0674(96)80110-4; HUTTON JC, 1993, MOL ENDOCRINOL, V7, P1151, DOI 10.1210/me.7.9.1151; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; RBINFELD B, 1997, SCIENCE, V275, P1790; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; TEITELMAN G, 1988, CELL, V52, P97, DOI 10.1016/0092-8674(88)90534-X; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416	28	1157	1209	1	67	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 12	1998	392	6672					190	193		10.1038/32433	http://dx.doi.org/10.1038/32433			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB349	9515965				2022-12-28	WOS:000072462700065
J	Stern, K; McClintock, MK				Stern, K; McClintock, MK			Regulation of ovulation by human pheromones	NATURE			English	Article							WOMENS MENSTRUAL CYCLES; OVARIAN-CYCLE; ESTROUS SYNCHRONY; FEMALE RATS; NORWAY RATS; MICE	Pheromones are airborne chemical signals that are released by an individual into the environment and which affect the physiology or behaviour of other members of the same species(1). The idea that humans produce pheromones has excited the imagination of scientists and the public, leading to widespread claims for their existence, which, however, has remained unproven. Here we investigate whether humans produce compounds that regulate a specific neuroendocrine mechanism in other people without being consciously detected as odours (thereby fulfilling the classic definition of a pheromone). We found that odourless compounds from the armpits of women in the late follicular phase of their menstrual cycles accelerated the preovulatory surge of luteinizing hormone of recipient women and shortened their menstrual cycles. Axillary (underarm) compounds from the same donors which were collected later in the menstrual cycle (at ovulation) had the opposite effect: they delayed the luteinizing-hormone surge of the recipients and lengthened their menstrual cycles. By showing in a fully controlled experiment that the timing of ovulation can be manipulated, this study provides definitive evidence of human pheromones.	Univ Chicago, Dept Psychol, Chicago, IL 60637 USA	University of Chicago	McClintock, MK (corresponding author), Univ Chicago, Dept Psychol, 5730 Woodlawn Ave, Chicago, IL 60637 USA.	mkml@midway.uchicago.edu						Beauchamp G.K., 1976, MAMMALIAN OLFACTION, P144; CHRISTIAN MS, 1983, ADV MODERN ENV TOXIC, V3; COHN BA, 1994, ARCH DERMATOL, V130, P1048, DOI 10.1001/archderm.130.8.1048; CUTLER WB, 1979, HORM BEHAV, V13, P214, DOI 10.1016/0018-506X(79)90039-4; DOTY RL, 1981, J COMP PHYSIOL PSYCH, V95, P45, DOI 10.1037/h0077755; DOTY RL, 1981, CHEM SENSES, V6, P351, DOI 10.1093/chemse/6.4.351; GALEF BG, 1986, J COMP PSYCHOL, V100, P331, DOI 10.1037/0735-7036.100.4.331; Graham C A, 1991, Hum Nat, V2, P293, DOI 10.1007/BF02692195; JOHNSON E, IN PRESS ANN NY ACAD; LEFEVRE J, 1991, HORM BEHAV, V25, P258, DOI 10.1016/0018-506X(91)90055-M; LEON M, 1972, PHYSIOL BEHAV, V8, P683, DOI 10.1016/0031-9384(72)90095-9; McClintock M.K., 1983, P113; MCCLINTOCK MK, 1984, PHYSIOL BEHAV, V32, P701, DOI 10.1016/0031-9384(84)90181-1; MCCLINTOCK MK, 1971, NATURE, V229, P244, DOI 10.1038/229244a0; MCCLINTOCK MK, 1981, AM ZOOL, V21, P243; MENNELLA JA, 1990, BEHAV ECOL SOCIOBIOL, V27, P183; NIXON A, 1988, J STEROID BIOCHEM, V29, P505, DOI 10.1016/0022-4731(88)90185-9; PRETI G, 1986, HORM BEHAV, V20, P474, DOI 10.1016/0018-506X(86)90009-7; Rasmussen L. E. L., 1994, Chemical Senses, V19, P540; ROTTMAN SJ, 1972, J COMP PHYSIOL PSYCH, V81, P483, DOI 10.1037/h0033703; RUSSELL MJ, 1980, PHARMACOL BIOCHEM BE, V13, P737, DOI 10.1016/0091-3057(80)90020-9; RYAN KD, 1977, BIOL REPROD, V17, P578, DOI 10.1095/biolreprod17.4.578; SCHANK JC, 1992, J THEOR BIOL, V157, P317, DOI 10.1016/S0022-5193(05)80614-9; SPIELMAN AI, 1995, EXPERIENTIA, V51, P40; STERN K, 1996, PSYCHOPHARMACOLOGY W, P393; TREOLAR AE, 1967, INT J FERTIL, V12, P77; Weller A, 1997, J COMP PSYCHOL, V111, P143; WELLER L, 1993, NEUROSCI BIOBEHAV R, V17, P427, DOI 10.1016/S0149-7634(05)80118-6; WILSON HC, 1987, HORM BEHAV, V21, P536, DOI 10.1016/0018-506X(87)90012-2; [No title captured]	30	386	403	1	132	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 12	1998	392	6672					177	179		10.1038/32408	http://dx.doi.org/10.1038/32408			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB349	9515961				2022-12-28	WOS:000072462700061
J	Lantz, CS; Boesiger, J; Song, CH; Mach, N; Kobayashi, T; Mulligan, RC; Nawa, Y; Dranoff, G; Galli, SJ				Lantz, CS; Boesiger, J; Song, CH; Mach, N; Kobayashi, T; Mulligan, RC; Nawa, Y; Dranoff, G; Galli, SJ			Role for interleukin-3 in mast-cell and basophil development and in immunity to parasites	NATURE			English	Article							C-KIT LIGAND; STRONGYLOIDES-VENEZUELENSIS; MICE; IL-3; INFECTION; INVIVO; DIFFERENTIATION; HEMATOPOIESIS; PROLIFERATION; ANTIBODIES	The cytokine interleukin-3 (IL-3), which can be derived from T cells and other sources, is a potentially important link between the immune and haematopoietic systems(1). IL-3 may be particularly critical for the development, survival and function of tissue mast cells(1-6) and blood basophils(7,8), which are thought to be important effector cells in immunity to parasites and other immunological responses, such as allergic reactions(9). Here we show using IL-3-deficient mice(10), that IL-3 is not essential for the generation of mast cells or basophils under physiological conditions, but that it does contribute to increased numbers of tissue mast cells, enhanced basophil production, and immunity in mice infected with the nematode Stronglyoides venezuelensis, Parasite expulsion and mast-cell development are impaired even more severely in IL-3-deficient mice that also show a marked reduction in signalling by c-kit, These findings establish a role for IL-3 in immunity to parasites and indicate that one of the functions of IL-3 in host defence against infection is to expand populations of haematopoietic effector cells.	Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02215 USA; Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA; Miyazaki Med Coll, Dept Parasitol, Miyazaki 88916, Japan; Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; University of Miyazaki; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute	Galli, SJ (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA.	sgalli@bidmc.harvard.edu	Nawa, Yukifumi/I-1147-2019					Donaldson LE, 1996, INT IMMUNOL, V8, P559, DOI 10.1093/intimm/8.4.559; FINKELMAN FD, 1993, J IMMUNOL, V151, P1235; GALLI SJ, 1987, AM J PATHOL, V127, P191; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; HAYASHI SI, 1991, NUCLEIC ACIDS RES, V19, P1267, DOI 10.1093/nar/19.6.1267; ICHIHARA M, 1995, EMBO J, V14, P939, DOI 10.1002/j.1460-2075.1995.tb07075.x; IHLE JN, 1983, J IMMUNOL, V131, P282; IHLE JN, 1992, CHEM IMMUNOL, V51, P65; JACOBY W, 1984, J INVEST DERMATOL, V83, P302, DOI 10.1111/1523-1747.ep12340431; Khalil RMA, 1996, INFECT IMMUN, V64, P4960, DOI 10.1128/IAI.64.12.4960-4966.1996; KHAN AI, 1993, INT J PARASITOL, V23, P551, DOI 10.1016/0020-7519(93)90159-V; KITAMURA Y, 1978, BLOOD, V52, P447; Lantz CS, 1997, J IMMUNOL, V158, P2517; MACH N, IN PRESS BLOOD; MADDEN KB, 1991, J IMMUNOL, V147, P1387; MAEDA H, 1992, DEVELOPMENT, V116, P369; MAYER P, 1989, BLOOD, V74, P613; NAWA Y, 1994, PARASITE IMMUNOL, V16, P333, DOI 10.1111/j.1365-3024.1994.tb00358.x; Nishinakamura R, 1996, BLOOD, V88, P2458, DOI 10.1182/blood.V88.7.2458.bloodjournal8872458; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; ODY C, 1990, J EXP MED, V172, P403, DOI 10.1084/jem.172.1.403; PAUL WE, 1993, ADV IMMUNOL, V53, P1, DOI 10.1016/S0065-2776(08)60496-4; PUDDINGTON L, 1994, IMMUNITY, V1, P733, DOI 10.1016/S1074-7613(94)80015-4; Rodewald HR, 1996, SCIENCE, V271, P818, DOI 10.1126/science.271.5250.818; SAITO H, 1988, P NATL ACAD SCI USA, V85, P2288, DOI 10.1073/pnas.85.7.2288; SATO Y, 1990, INT J PARASITOL, V20, P63, DOI 10.1016/0020-7519(90)90174-L; SVETIC A, 1993, J IMMUNOL, V150, P3434; TSAI M, 1991, P NATL ACAD SCI USA, V88, P6382, DOI 10.1073/pnas.88.14.6382; TSAI M, 1991, J EXP MED, V174, P125, DOI 10.1084/jem.174.1.125; TSUJI K, 1991, J CELL PHYSIOL, V148, P362, DOI 10.1002/jcp.1041480306	30	426	439	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 5	1998	392	6671					90	93		10.1038/32190	http://dx.doi.org/10.1038/32190			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA528	9510253				2022-12-28	WOS:000072373000056
J	Baril, L; Caumes, E; Bricaire, F				Baril, L; Caumes, E; Bricaire, F			Pubic pain after a marathon	LANCET			English	Article									Hop La Pitie Salpetriere, Serv Malad Infect & Med Trop, F-75013 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Baril, L (corresponding author), Hop La Pitie Salpetriere, Serv Malad Infect & Med Trop, 47 Bld Hop, F-75013 Paris, France.			Baril, Laurence/0000-0003-2346-883X				BATT ME, 1995, MED SCI SPORT EXER, V27, P629; SCHLECH WF, 1981, AM J MED, V71, P900, DOI 10.1016/0002-9343(81)90395-8; SHEPHERD JJ, 1983, LANCET, V2, P1240; UKWU HN, 1992, CLIN INFECT DIS, V15, P636, DOI 10.1093/clind/15.4.636	4	5	5	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 28	1998	351	9103					642	642		10.1016/S0140-6736(97)10470-6	http://dx.doi.org/10.1016/S0140-6736(97)10470-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA447	9500321				2022-12-28	WOS:000072364200011
J	Smeeth, L; Iliffe, S				Smeeth, L; Iliffe, S			Effectiveness of screening older people for impaired vision in community setting: systematic review of evidence from randomised controlled trials	BRITISH MEDICAL JOURNAL			English	Article							QUALITY-OF-LIFE; VISUAL-ACUITY; ELDERLY POPULATION; HIP FRACTURE; EYE TESTS; DISABILITY	Objective: To assess whether population screening for impaired vision among older people in the community leads to improvements in vision. Design: Systematic review of randomised controlled trials of population screening in the community that included any assessment of vision or visual function with at least 6 months' follow up. Subjects: Adults aged 65 or over. Main outcome measure: Proportions with visual impairment in intervention and control groups with any method of assessing visual impairment. Results: There were no trials that primarily assessed visual screening. Outcome data on vision were available for 3494 people in five trials of multiphasic assessment All the trials used self reported measures for vision impairment, both as screening tools and as outcome measures. The inclusion of a visual screening component in the assessments did not result in improvements in self reported visual problems (pooled odds ratio 1.04: 95% confidence interval 0.89 to 1.22). A small reduction (11%) in the number of older people with self reported visual problems cannot be excluded. Conclusions: Screening of asymptomatic older people in the community is not justified on present evidence. Visual impairment in this age group can usually be reduced with treatment. It is unclear why no benefit was seen. Further work is needed to clarify what interventions are appropriate for older people with unreported impairment of vision.	Royal Free Hosp, Sch Med, Dept Primary Care & Populat Sci, London NW3 2PF, England; UCL, Sch Med, London NW3 2PF, England	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; UCL Medical School	Smeeth, L (corresponding author), Royal Free Hosp, Sch Med, Dept Primary Care & Populat Sci, London NW3 2PF, England.	l.smeeth@ucl.ac.uk	Iliffe, Steve/L-8379-2019; Smeeth, Liam/X-5862-2018	Iliffe, Stephen/0000-0003-2806-3997; Smeeth, Liam/0000-0002-9168-6022				BROCKLEHURST J C, 1978, Age and Ageing, V7, P7, DOI 10.1093/ageing/7.1.7; CARABELLESE C, 1993, J AM GERIATR SOC, V41, P401, DOI 10.1111/j.1532-5415.1993.tb06948.x; *COCHR COLL, 1997, COCHR LIB DAT DISK C; CULLINAN TR, 1977, 28 U KENT HLTH SERV; CULLINAN TR, 1986, VISUAL DISABILITY EL; *DEP HLTH, 1996, NAT HLTH SERV SERV A; *DEP HLTH WELSH OF, 1989, GEN PRACT NAT HLTH S; DICKERSIN K, 1994, BMJ-BRIT MED J, V309, P1286, DOI 10.1136/bmj.309.6964.1286; *DRIV MED GROUP, 1996, GLANC GUID CURR MED; FELSON DT, 1989, J AM GERIATR SOC, V37, P495, DOI 10.1111/j.1532-5415.1989.tb05678.x; GRINDEY S, 1997, LOSING SIGHT BLINDNE; GRISSO JA, 1991, NEW ENGL J MED, V324, P1326, DOI 10.1056/NEJM199105093241905; HITCHINGS RA, 1989, BRIT MED J, V298, P1126, DOI 10.1136/bmj.298.6681.1126; ILIFFE S, 1997, EVALUATION 75 CHECKS; Jones D A, 1987, Health Visit, V60, P256; KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310; Landes R, 1993, HLTH SOCIAL CARE COM, V1, P325; LAVERY JR, 1988, OPHTHAL PHYSL OPT, V8, P390, DOI 10.1111/j.1475-1313.1988.tb01174.x; Leibowitz H M, 1980, Surv Ophthalmol, V24, P335; LONG CA, 1991, AGE AGEING, V20, P392, DOI 10.1093/ageing/20.6.392; MULROW CD, 1997, COCHRANE COLLABORATI; *NHS CTR REV DISS, 1996, EFFECTIVE HLTH CARE, V2; REINSTEIN DZ, 1993, BRIT J OPHTHALMOL, V77, P293, DOI 10.1136/bjo.77.5.293; ROSENTHAL AR, 1990, BRIT MED J, V300, P695, DOI 10.1136/bmj.300.6726.695; Rovner BW, 1996, J AM GERIATR SOC, V44, P181, DOI 10.1111/j.1532-5415.1996.tb02436.x; Sackett DL, 1996, EVIDENCE BASED MED, V1, P164, DOI DOI 10.1136/EBM.1996.1.164; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SCOTT IU, 1994, ARCH OPHTHALMOL-CHIC, V112, P329, DOI 10.1001/archopht.1994.01090150059023; South-East London Screening Group, 1977, INT J EPIDEMIOL, V6, P357; STONE DH, 1978, BRIT MED J, V2, P859, DOI 10.1136/bmj.2.6141.859; STUCK AE, 1993, LANCET, V342, P1032, DOI 10.1016/0140-6736(93)92884-V; TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048; *UPD SOFTW, 1996, VERS 3 0 WIND; WEBSTER E, 1992, J ROY SOC MED, V85, P614; WILLIAMS EI, 1993, HLTH CHECKS PEOPLE A; WORMALD RPL, 1992, BRIT MED J, V304, P1226, DOI 10.1136/bmj.304.6836.1226	36	34	34	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 28	1998	316	7132					660	663		10.1136/bmj.316.7132.660	http://dx.doi.org/10.1136/bmj.316.7132.660			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA282	9522788	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000072347900027
J	Bell, J				Bell, J			The new genetics - The new genetics in clinical practice	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MYOCARDIAL-INFARCTION; MUTATIONS; CANCER; IDENTIFICATION; POLYMORPHISM; GENOME; BREAST		Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England	University of Oxford	Bell, J (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England.	john.bell@ndm.ox.ac.uk			Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; LUDWORTH AG, 1974, LANCET, V2, P1153; Marshall E, 1996, SCIENCE, V272, P477; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Nebert DW, 1997, AM J HUM GENET, V60, P265; RIDKER PM, 1995, CIRCULATION, V92, P2800, DOI 10.1161/01.CIR.92.10.2800; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROSES AD, 1995, ANN NEUROL, V38, P6, DOI 10.1002/ana.410380105; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SCHMIDT S, 1995, KIDNEY INT, V47, P1176, DOI 10.1038/ki.1995.167; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; WARD CJ, 1994, CELL, V77, P881; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0; 1996, NATURE GENET, V14, P367	19	142	145	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 21	1998	316	7131					618	620		10.1136/bmj.316.7131.618	http://dx.doi.org/10.1136/bmj.316.7131.618			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ031	9518921	Green Published			2022-12-28	WOS:000072213200040
J	Otto, M; Wiltfang, J; Schutz, E; Zerr, I; Otto, A; Pfahlberg, A; Gefeller, O; Uhr, M; Giese, A; Weber, T; Kretzschmar, HA; Poser, S				Otto, M; Wiltfang, J; Schutz, E; Zerr, I; Otto, A; Pfahlberg, A; Gefeller, O; Uhr, M; Giese, A; Weber, T; Kretzschmar, HA; Poser, S			Diagnosis of Creutzfeldt-Jakob disease by measurement of S100 protein in serum: prospective case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NEURON-SPECIFIC ENOLASE; CEREBROSPINAL-FLUID; NERVOUS-SYSTEM; S-100 PROTEIN; HUMAN-BRAIN; MARKER	Objective: To analyse serum concentrations of brain specific S100 protein in patients with Creutzfeldt-Jakob disease and in controls. Design: Prospective case-control study. Setting: National Creutzfeldt-Jakob disease surveillance unit. Subjects: 224 patients referred to the surveillance unit with suspected Creutzfeldt-Jakob disease and 35 control patients without dementia. Main outcome measure: Serum concentration of S100 protein in patients with Creutzfeldt-Jakob disease, in patients with other diseases causing dementia, and in the control group. Results: Of the 224 patients with suspected Creutzfeldt-Jakob disease, 65 were classed as definitely having the disease after neuropathological verification, an additional 6 were classed as definitely having the disease as a result of a genetic mutation, 43 as probably having the disease, 36 as possibly having the disease, and 74 patients were classed as having other disease. In the 108 patients classed as definitely or probably having Creutzfeldt-Jakob disease the median serum concentration of S100 was 395 pg/ml (SD 387 pg/ml). This was significantly higher than concentrations found in the 74 patients classed as having other diseases (median 109 pg/ml; SD 177 pg/ml; P = 0.0001). At a cut off point of 213 pg/ml sensitivity for the diagnosis of the disease was 77.8% (95% confidence interval 68.8% to 85.2%) and specificity was 81.1% (70.3% to 89.3%). There was a significant difference in survival at different concentrations of S100 in Kaplan-Meier curves (P = 0.023). Conclusion: Measurement of serum concentrations of S100 is a valuable tool which can be used more easily than tests on cerebrospinal fluid in the differential diagnosis of Creutzfeldt-Jakob disease. More studies are needed to determine whether serial testing of serum S100 improves diagnostic accuracy.	Univ Gottingen, Neurol Klin & Poliklin, D-37075 Gottingen, Germany; Univ Gottingen, Psychiat Klin & Poliklin, D-37075 Gottingen, Germany; Univ Gottingen, Klin Chem Abt, D-37075 Gottingen, Germany; Univ Gottingen, Abt Med Stat, D-37075 Gottingen, Germany; Max Planck Inst Psychiat, D-80804 Munich, Germany; Univ Gottingen, Inst Neuropathol, D-37075 Gottingen, Germany; Marien Hosp, Neurol Abt, Dept Neurol, D-22087 Hamburg, Germany	University of Gottingen; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Gottingen; University of Gottingen; University of Gottingen; Max Planck Society; University of Gottingen; St. Marien Hospital	Otto, M (corresponding author), Univ Gottingen, Neurol Klin & Poliklin, Robert Koch Str 40, D-37075 Gottingen, Germany.	100634.133@compuserve.com	Cruz e Silva, Odete/AAH-5595-2020; Gefeller, Olaf/W-9604-2019; Giese, Armin/F-3271-2010; Schuetz, Ekkehard/H-3929-2013; Otto, Markus/F-4304-2015	Gefeller, Olaf/0000-0002-8985-7582; Giese, Armin/0000-0002-8238-4102; Otto, Markus/0000-0003-4273-4267; Wiltfang, Jens/0000-0003-1492-5330; Pfahlberg, Annette/0000-0002-2234-1215				ALPEROVITCH A, 1994, LANCET, V343, P918, DOI 10.1016/S0140-6736(94)90037-X; Astudillo R, 1996, Eur J Cardiothorac Surg, V10, P1107, DOI 10.1016/S1010-7940(96)80358-7; BROWN P, 1994, ANN NEUROL, V35, P513, DOI 10.1002/ana.410350504; Hill AF, 1997, LANCET, V349, P99, DOI 10.1016/S0140-6736(97)24002-X; Hsich G, 1996, NEW ENGL J MED, V335, P924, DOI 10.1056/NEJM199609263351303; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; ISOBE T, 1984, J NEUROCHEM, V43, P1494, DOI 10.1111/j.1471-4159.1984.tb05415.x; JENSEN R, 1985, J NEUROCHEM, V45, P700, DOI 10.1111/j.1471-4159.1985.tb04048.x; JIMI T, 1992, CLIN CHIM ACTA, V211, P37, DOI 10.1016/0009-8981(92)90103-W; KINDBLOM LG, 1984, ACTA PATH MICRO IM A, V92, P219; Kretzschmar HA, 1996, ARCH NEUROL-CHICAGO, V53, P913, DOI 10.1001/archneur.1996.00550090125018; Lee KH, 1996, LANCET, V348, P887, DOI 10.1016/S0140-6736(96)24039-5; MASTERS CL, 1979, ANN NEUROL, V5, P177, DOI 10.1002/ana.410050212; METZ CE, 1978, SEMIN NUCL MED, V8, P283, DOI 10.1016/S0001-2998(78)80014-2; Moussavian M, 1997, NEW ENGL J MED, V336, P873, DOI 10.1056/NEJM199703203361212; Otto M, 1997, J NEUROL, V244, P566, DOI 10.1007/s004150050145; Otto M, 1997, NEUROSCI LETT, V225, P210, DOI 10.1016/S0304-3940(97)00215-2; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; Steinhoff BJ, 1996, ARCH NEUROL-CHICAGO, V53, P162, DOI 10.1001/archneur.1996.00550020074017; USUI A, 1989, CLIN CHEM, V35, P1942; VOLLSET SE, 1993, STAT MED, V12, P809, DOI 10.1002/sim.4780120902; WEBER T, 1995, J NEUROL, V242, P257; Will RG, 1996, LANCET, V348, P955, DOI 10.1016/S0140-6736(96)24040-1; WILL RG, 1993, BRIT MED BULL, V49, P960, DOI 10.1093/oxfordjournals.bmb.a072655; Windl O, 1996, HUM GENET, V98, P259, DOI 10.1007/s004390050204; YOUDEN WJ, 1950, CANCER-AM CANCER SOC, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3; Zerr I, 1996, LANCET, V348, P846, DOI 10.1016/S0140-6736(96)08077-4; ZERR I, 1995, LANCET, V345, P1609, DOI 10.1016/S0140-6736(95)90118-3	28	101	106	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 21	1998	316	7131					577	582		10.1136/bmj.316.7131.577	http://dx.doi.org/10.1136/bmj.316.7131.577			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ031	9518907	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000072213200023
J	Wang, SY; Miura, M; Jung, YK; Zhu, H; Li, E; Yuan, JY				Wang, SY; Miura, M; Jung, YK; Zhu, H; Li, E; Yuan, JY			Murine caspase-11, an ICE-interacting protease, is essential for the activation of ICE	CELL			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; DEATH GENE CED-3; CELL-DEATH; IL-1-BETA-CONVERTING ENZYME; MAMMALIAN HOMOLOG; CYSTEINE PROTEASE; MOLECULAR-CLONING; MICE DEFICIENT; APOPTOSIS; INDUCTION	We report here the inactivation of a member of the Ice/Ced-3 (caspase) family of cell death genes, casp-11, by gene targeting. Like Ice-deficient mice, casp-11 mutant mice are resistant to endotoxic shock induced by lipopolysaccharide. Production of both IL-1 alpha and IL-1 beta after lipopolysaccharide stimulation, a crucial event during septic shock and an indication of ICE activation, is blocked in casp-11 mutant mice. casp-11 mutant embryonic fibroblast cells are resistant to apoptosis induced by overexpression of ICE. Furthermore, we found that pro-caspase-11 physically interacts with pro-ICE in cells, and the expression of casp-11 is essential for activation of ICE. Our data suggest that caspase-11 is a component of ICE complex and is required for the activation of ICE.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA 02129 USA; Osaka Univ, Sch Med, Biomed Res Ctr, Dept Neuroanat, Osaka 5650871, Japan	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Osaka University	Yuan, JY (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.			Jung, Yong-Keun/0000-0002-9686-3120; Zhu, Hong/0000-0002-2575-4031				AREND WP, 1986, CLIN EXP IMMUNOL, V64, P656; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; DINARELLO CA, 1993, JAMA-J AM MED ASSOC, V269, P1829, DOI 10.1001/jama.269.14.1829; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Friedlander RM, 1997, NATURE, V388, P31, DOI 10.1038/40299; Friedlander RM, 1997, J EXP MED, V185, P933, DOI 10.1084/jem.185.5.933; Ghayur T, 1997, NATURE, V386, P619, DOI 10.1038/386619a0; GU Y, 1995, EMBO J, V14, P1923, DOI 10.1002/j.1460-2075.1995.tb07184.x; Gu Y, 1997, SCIENCE, V275, P206, DOI 10.1126/science.275.5297.206; Hugunin M, 1996, J BIOL CHEM, V271, P3517, DOI 10.1074/jbc.271.7.3517; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NEWTON RC, 1986, J LEUKOCYTE BIOL, V39, P299, DOI 10.1002/jlb.39.3.299; RAMAGE P, 1995, J BIOL CHEM, V270, P9378, DOI 10.1074/jbc.270.16.9378; Shi LF, 1996, P NATL ACAD SCI USA, V93, P11002, DOI 10.1073/pnas.93.20.11002; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Van de Craen M, 1997, FEBS LETT, V403, P61, DOI 10.1016/S0014-5793(97)00026-4; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wang SY, 1996, J BIOL CHEM, V271, P20580, DOI 10.1074/jbc.271.34.20580; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; Yamin TT, 1996, J BIOL CHEM, V271, P13273, DOI 10.1074/jbc.271.22.13273	36	554	571	0	21	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 20	1998	92	4					501	509		10.1016/S0092-8674(00)80943-5	http://dx.doi.org/10.1016/S0092-8674(00)80943-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YZ409	9491891	Bronze			2022-12-28	WOS:000072251500010
J	Rogerson, L; Bancroft, K				Rogerson, L; Bancroft, K			Outcome of pregnancy in women with insulin dependent diabetes - Management of impaired glucose tolerance in pregnancy needs study	BRITISH MEDICAL JOURNAL			English	Letter									Bradford Royal Infirm, Bradford BD9 6RJ, W Yorkshire, England	Bradford Royal Infirmary	Rogerson, L (corresponding author), Bradford Royal Infirm, Bradford BD9 6RJ, W Yorkshire, England.							Casson IF, 1997, BRIT MED J, V315, P275, DOI 10.1136/bmj.315.7103.275; Hawthorne G, 1997, BRIT MED J, V315, P279, DOI 10.1136/bmj.315.7103.279; HOD M, 1991, DIABETES, V40, P74, DOI 10.2337/diab.40.2.S74; LI DFH, 1987, BRIT J OBSTET GYNAEC, V94, P851, DOI 10.1111/j.1471-0528.1987.tb03753.x	4	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 14	1998	316	7130					551	551						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX955	9501727				2022-12-28	WOS:000072097400038
J	Warwick, JA; Corrall, RJ				Warwick, JA; Corrall, RJ			Serious interaction between warfarin and oral terbinafine	BRITISH MEDICAL JOURNAL			English	Letter									Univ Bristol, Bristol Royal Infirm, Dept Pharm, Anticoagulant Clin, Bristol BS2 8HW, Avon, England; Univ Bristol, Bristol Royal Infirm, Directorate Med, Bristol BS2 8HW, Avon, England	Bristol Royal Infirmary; University of Bristol; Bristol Royal Infirmary; University of Bristol	Warwick, JA (corresponding author), Univ Bristol, Bristol Royal Infirm, Dept Pharm, Anticoagulant Clin, Bristol BS2 8HW, Avon, England.							BACK DJ, 1991, BRIT J CLIN PHARMACO, V32, P624, DOI 10.1111/j.1365-2125.1991.tb03963.x; BALFOUR JA, 1992, DRUGS, V43, P259, DOI 10.2165/00003495-199243020-00010; Long C. C., 1992, Skin Pharmacology, V5, P200; OKINO K, 1986, DRUG INTEL CLIN PHAR, V20, P291, DOI 10.1177/106002808602000417; YOUNG LY, 1995, APPL THERAPEUTICS CL	5	20	20	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 7	1998	316	7129					440	440		10.1136/bmj.316.7129.440	http://dx.doi.org/10.1136/bmj.316.7129.440			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW874	9492670	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000071982700030
J	Jollis, JG; Romano, PS				Jollis, JG; Romano, PS			Sounding board - Pennsylvania's Focus on Heart Attack - Grading the scorecard	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ADMISSION SEVERITY; DISCHARGE DATA; MORTALITY; OUTCOMES; COMORBIDITIES; MEDISGROUPS; INFARCTION; VOLUME; CARE		Univ Calif Davis, Sch Med, Sacramento, CA 95817 USA; Duke Clin Res Inst, Durham, NC 27710 USA	University of California System; University of California Davis; Duke University	Jollis, JG (corresponding author), Duke Univ, Med Ctr, Box 3254, Durham, NC 27710 USA.		Romano, Patrick S/N-4225-2014	Romano, Patrick S/0000-0001-6749-3979	AHRQ HHS [HS08574] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Berwick DM, 1996, JAMA-J AM MED ASSOC, V275, P877, DOI 10.1001/jama.275.11.877; BLUMBERG MS, 1991, JAMA-J AM MED ASSOC, V265, P2965; Chassin MR, 1996, NEW ENGL J MED, V334, P394, DOI 10.1056/NEJM199602083340611; Ellis SG, 1996, CIRCULATION, V93, P431, DOI 10.1161/01.CIR.93.3.431; FISHER ES, 1992, AM J PUBLIC HEALTH, V82, P243, DOI 10.2105/AJPH.82.2.243; Ghali WA, 1997, JAMA-J AM MED ASSOC, V277, P379, DOI 10.1001/jama.277.5.379; GREEN J, 1993, MED CARE, V31, P719, DOI 10.1097/00005650-199308000-00005; GREEN J, 1995, NEW ENGL J MED, V332, P1229, DOI 10.1056/NEJM199505043321812; IEZZONI LI, 1995, ANN INTERN MED, V123, P763, DOI 10.7326/0003-4819-123-10-199511150-00004; IEZZONI LI, 1992, JAMA-J AM MED ASSOC, V267, P2197, DOI 10.1001/jama.267.16.2197; IEZZONI LI, 1988, JAMA-J AM MED ASSOC, V260, P3159, DOI 10.1001/jama.260.21.3159; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P2240, DOI 10.1001/jama.260.15.2240; Jencks SF, 1997, JAMA-J AM MED ASSOC, V277, P419; Jollis JG, 1996, NEW ENGL J MED, V335, P1880, DOI 10.1056/NEJM199612193352505; JOLLIS JG, 1994, NEW ENGL J MED, V331, P1625, DOI 10.1056/NEJM199412153312406; Jollis JG, 1996, MAYO CLIN PROC, V71, P1016, DOI 10.1016/S0025-6196(11)63780-4; KRAKAUER H, 1992, HEALTH SERV RES, V27, P317; LEGNINI MW, 1996, 2 OFF STAT HLTH PLAN, V2; MCMAHON LF, 1986, ANN INTERN MED, V104, P562, DOI 10.7326/0003-4819-104-4-562; *PA HLTH CAR COST, 1996, RES PLAN 1993 HEART; Pennsylvania Health Care Cost Containment Council, 1996, FOC HEART ATT PENNS; *PRACT MAN INF, 1991, INT CLASS DIS; RUBIN DB, 1991, STAT MED, V10, P585, DOI 10.1002/sim.4780100410; SHOWSTACK JA, 1987, JAMA-J AM MED ASSOC, V257, P785, DOI 10.1001/jama.257.6.785; SHOWSTACK JA, 1987, JAMA-J AM MED ASSOC, V257, P2438; STEEN PM, 1993, INQUIRY-J HEALTH CAR, V30, P128; TOPOL EJ, 1994, ANN INTERN MED, V120, P65, DOI 10.7326/0003-4819-120-1-199401010-00011	27	48	48	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 2	1998	338	14					983	987		10.1056/NEJM199804023381410	http://dx.doi.org/10.1056/NEJM199804023381410			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE776	9521989				2022-12-28	WOS:000072829800010
J	Lowenstein, DH; Alldredge, BK				Lowenstein, DH; Alldredge, BK			Current concepts - Status epilepticus	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							GENERALIZED STATUS-EPILEPTICUS; REFRACTORY STATUS EPILEPTICUS; INTRAVENOUS PHENYTOIN; BRAIN-DAMAGE; DOMOIC ACID; DIAZEPAM; SEIZURES; MIDAZOLAM; LORAZEPAM; FEATURES		Univ Calif San Francisco, Sch Med, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Pharm, Div Clin Pharm, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Lowenstein, DH (corresponding author), Univ Calif San Francisco, Sch Med, Dept Neurol, Box 0114,505 Parnassus Ave, San Francisco, CA 94143 USA.				PHS HHS [R01 31403] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLDREDGE B K, 1992, Neurology, V42, P400; ALLDREDGE BK, 1995, PEDIATR NEUROL, V12, P213, DOI 10.1016/0887-8994(95)00044-G; AMINOFF MJ, 1980, AM J MED, V69, P657, DOI 10.1016/0002-9343(80)90415-5; ARENDT RM, 1983, J PHARMACOL EXP THER, V227, P98; BANCAUD J, 1981, EPILEPSIA, V22, P489, DOI 10.1111/j.1528-1157.1981.tb06159.x; BELL DM, 1991, EPILEPSY RES, V10, P183, DOI 10.1016/0920-1211(91)90011-4; BLECK TP, 1991, CLIN NEUROPHARMACOL, V14, P191, DOI 10.1097/00002826-199106000-00001; BLECK TP, 1993, CRIT CARE MED, V21, P955, DOI 10.1097/00003246-199307000-00004; Browne T R, 1983, Adv Neurol, V34, P509; CELESIA GG, 1988, ARCH NEUROL-CHICAGO, V45, P781, DOI 10.1001/archneur.1988.00520310099023; Corsellis J A, 1983, Adv Neurol, V34, P129; CRANFORD RE, 1978, NEUROLOGY, V28, P874, DOI 10.1212/WNL.28.9.874; DELORENZO RJ, 1995, J CLIN NEUROPHYSIOL, V12, P316; DODSON WE, 1993, JAMA-J AM MED ASSOC, V270, P854; EGLI M, 1981, 12 WORLD C NEUR KYOT, P44; GEORGE KA, 1977, BRIT J CLIN PHARMACO, V4, P45, DOI 10.1111/j.1365-2125.1977.tb00665.x; GIROUD M, 1993, DRUG INVEST, V5, P154, DOI 10.1007/BF03258440; Goldberg M A, 1983, Adv Neurol, V34, P499; HAUSER WA, 1990, NEUROLOGY, V40, P9; HOPPU K, 1981, ACTA PAEDIATR SCAND, V70, P369, DOI 10.1111/j.1651-2227.1981.tb16565.x; JORDAN KG, 1993, J CLIN NEUROPHYSIOL, V10, P445, DOI 10.1097/00004691-199310000-00006; Kapur J, 1997, J NEUROSCI, V17, P7532, DOI 10.1523/jneurosci.17-19-07532.1997; Kugler Alan R., 1996, Neurology, V46, pA176; KUMAR A, 1992, CRIT CARE MED, V20, P483, DOI 10.1097/00003246-199204000-00009; LAHAT E, 1992, PEDIATR NEUROL, V8, P215, DOI 10.1016/0887-8994(92)90071-6; LEPPIK IE, 1983, JAMA-J AM MED ASSOC, V249, P1452, DOI 10.1001/jama.249.11.1452; LOTHMAN E, 1990, NEUROLOGY, V40, P13; LOTHMAN EW, 1991, PROG NEUROBIOL, V37, P1, DOI 10.1016/0301-0082(91)90011-O; LOWENSTEIN DH, 1992, NEUROLOGY, V42, P100, DOI 10.1212/WNL.42.1.100; LOWENSTEIN DH, 1993, NEUROLOGY, V43, P483, DOI 10.1212/WNL.43.3_Part_1.483; Macdonald R L, 1986, Adv Neurol, V44, P713; MELDRUM BS, 1973, ARCH NEUROL-CHICAGO, V29, P82, DOI 10.1001/archneur.1973.00490260026003; MELDRUM BS, 1973, ARCH NEUROL-CHICAGO, V28, P10, DOI 10.1001/archneur.1973.00490190028002; Mitchell Wendy G., 1996, Epilepsia, V37, P154; NICOL CF, 1969, NEUROLOGY, V19, P332, DOI 10.1212/WNL.19.4.332; OSORIO I, 1989, EPILEPSIA, V30, P464, DOI 10.1111/j.1528-1157.1989.tb05327.x; PARENT JM, 1994, NEUROLOGY, V44, P1837, DOI 10.1212/WNL.44.10.1837; PELLOCK JM, 1994, J CHILD NEUROL S2, V9, pS27; PERL TM, 1990, NEW ENGL J MED, V322, P1775, DOI 10.1056/NEJM199006213222504; SHANER DM, 1988, NEUROLOGY, V38, P202, DOI 10.1212/WNL.38.2.202; Shorvon S., 1994, STATUS EPILEPTICUS I, P218; SIMON RP, 1985, EPILEPSIA, V26, pS58, DOI 10.1111/j.1528-1157.1985.tb05725.x; SIMON RP, 1986, ANN NEUROL, V20, P351, DOI 10.1002/ana.410200313; SLOVITER RS, 1983, BRAIN RES BULL, V10, P675, DOI 10.1016/0361-9230(83)90037-0; Stecker MM, 1998, EPILEPSIA, V39, P18, DOI 10.1111/j.1528-1157.1998.tb01269.x; SUNG CY, 1989, ACTA NEUROL SCAND, V80, P51, DOI 10.1111/j.1600-0404.1989.tb03842.x; TEITELBAUM JS, 1990, NEW ENGL J MED, V322, P1781, DOI 10.1056/NEJM199006213222505; THEODORE WH, 1994, NEUROLOGY, V44, P1403, DOI 10.1212/WNL.44.8.1403; TOWNE AR, 1994, EPILEPSIA, V35, P27, DOI 10.1111/j.1528-1157.1994.tb02908.x; TREIMAN D M, 1987, Neurology, V37, P244; TREIMAN DM, 1996, NEUROLOGY S, V46, pA219; WALTON NY, 1988, EXP NEUROL, V101, P267, DOI 10.1016/0014-4886(88)90010-6; WALTON NY, 1990, NEUROLOGY, V40, P990, DOI 10.1212/WNL.40.6.990; Wilder B J, 1983, Adv Neurol, V34, P441; WILDER BJ, 1977, ANN NEUROL, V1, P511, DOI 10.1002/ana.410010602; YAFFE K, 1993, NEUROLOGY, V43, P895, DOI 10.1212/WNL.43.5.895; [No title captured]	57	487	502	1	20	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 2	1998	338	14					970	976		10.1056/NEJM199804023381407	http://dx.doi.org/10.1056/NEJM199804023381407			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE776	9521986				2022-12-28	WOS:000072829800007
J	Porter, WG				Porter, WG			Venus on the right	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Carolinas Med Ctr, Dept Med, Charlotte, NC 28232 USA	Carolinas Medical Center	Porter, WG (corresponding author), Carolinas Med Ctr, Dept Med, POB 32861, Charlotte, NC 28232 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1998	128	6					500	501		10.7326/0003-4819-128-6-199803150-00013	http://dx.doi.org/10.7326/0003-4819-128-6-199803150-00013			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA914	9499336				2022-12-28	WOS:000072414700013
J	Dolk, H				Dolk, H			Rise in prevalence of hypospadias	LANCET			English	Editorial Material									Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Environm Epidemiol Unit, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Dolk, H (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Environm Epidemiol Unit, London WC1E 7HT, England.							CALZOLARI E, 1986, J MED GENET, V23, P333, DOI 10.1136/jmg.23.4.333; *EUROCAT WORK GROU, 1997, 7 EUROCAT SCI I PUBL; *INT CTR BIRTH DEF, 1982, INT CLEAR BIRTH DEF; KALLEN B, 1986, ACTA PAEDIATR SCAND, P1; KALLEN B, 1986, J MED GENET, V23, P333; MATLAI P, 1985, LANCET, V1, P108; Paulozzi LJ, 1997, PEDIATRICS, V100, P831, DOI 10.1542/peds.100.5.831; RAMANWILMS L, 1995, OBSTET GYNECOL, V85, P141, DOI 10.1016/0029-7844(94)00341-A; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; Toppari J, 1996, ENVIRON HEALTH PERSP, V104, P741, DOI 10.2307/3432709	10	65	69	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 14	1998	351	9105					770	770		10.1016/S0140-6736(05)78924-8	http://dx.doi.org/10.1016/S0140-6736(05)78924-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB916	9519944				2022-12-28	WOS:000072521200005
J	Nattinger, AB; Hoffmann, RG; Howel-Pelz, A; Goodwin, JS				Nattinger, AB; Hoffmann, RG; Howel-Pelz, A; Goodwin, JS			Effect of Nancy Reagan's mastectomy on choice of surgery for breast cancer by US women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONSERVING SURGERY; MEDIA COVERAGE; AIDS; REAGAN,RONALD; REQUIREMENTS; HEALTH; ISSUES	Context.-While the actions of popular figures are believed to influence the behavior of the general public, including health care decisions, little research has examined such an effect, Objective.-To determine whether a temporal association exists between use of breast-conserving surgery (BCS) for treatment of breast cancer and Nancy Reagan's mastectomy in October 1987. Design/Setting.-Population-based observational cohort study, Patients.-Two sources of data: (1) 82 230 women aged 30 years and older who were included in the Surveillance, Epidemiology, and End Results tumor registry because of a diagnosis of local or regional breast cancer from 1983 to 1990; and (2) 80 057 female Medicare beneficiaries aged 65 to 79 years who received inpatient surgery for local or regional breast cancer in 1987 or 1988. Main Outcome Measure.-Percentage of use of BCS vs mastectomy over time, Results.-Compared with women undergoing surgery for breast cancer in the third quarter of 1987 (just prior to Mrs Reagan's mastectomy), women were 25% less likely to undergo BCS in the fourth quarter of 1987 (odds ratio [OR], 0.75; 95% confidence interval [CI], 0.66-0.85) and in the first quarter of 1988 (OR, 0.76; 95% CI, 0.67-0.86), In subsequent quarters, the rate returned to the baseline, In multivariate analyses, the decline was significant among white but not nonwhite women, It was most prominent among women aged 50 to 79 years in the central and southern regions of the country, and most sustained among women living in areas with lower levels of income and education, Conclusions.-Celebrity role models can influence decisions about medical care, The influence appears strongest among persons who demographically resemble the celebrity, and those of lower income and educational status.	Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Biostat, Milwaukee, WI 53226 USA; Univ Texas, Med Branch, Dept Med, Galveston, TX 77550 USA; Univ Texas, Med Branch, Ctr Aging, Galveston, TX 77550 USA	Medical College of Wisconsin; Medical College of Wisconsin; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Nattinger, AB (corresponding author), Div Gen Internal Med FMLH E, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.	anatting@mcw.edu		Nattinger, Ann/0000-0002-8189-3300	NATIONAL CANCER INSTITUTE [R01CA054676] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA54676] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEAHRS OH, 1994, J AM COLL SURGEONS, V178, P86; BLACK MM, 1977, JAMA-J AM MED ASSOC, V237, P970, DOI 10.1001/jama.237.10.970; BROWN ML, 1990, PUBLIC OPIN QUART, V54, P317, DOI 10.1086/269209; *BUR HLTH PROF, 1992, AR RES FIL 1992; *CDC, 1989, MMWR-MORBID MORTAL W, V38, P137; FINK R, 1978, PUBLIC HEALTH REP, V93, P318; GANZ PA, 1992, NEW ENGL J MED, V326, P1147, DOI 10.1056/NEJM199204233261708; GREENBERG ER, 1986, BRIT MED J, V292, P1487, DOI 10.1136/bmj.292.6534.1487; HALL WH, 1991, JAMA-J AM MED ASSOC, V265, P391; Helfenstein U, 1996, Stat Methods Med Res, V5, P3, DOI 10.1177/096228029600500102; *HLTH CAR FIN ADM, 1990, HCFA PUBL; KLEINBAUM DG, 1994, LOGISTIC REGRESSION, P73; KOLATA G, 1987, NY TIMES, V137, P19; KREIGER N, 1992, AM J PUBLIC HEALTH, V82, P703; LANE DS, 1989, AM J PUBLIC HEALTH, V79, P1551, DOI 10.2105/AJPH.79.11.1551; LANGER LM, 1992, AIDS EDUC PREV, V4, P295; LEWIN T, 1988, NY TIMES, V137, P6; Michalski TA, 1997, CANCER-AM CANCER SOC, V79, P314; *NAT CANC I, 1993, SURV EP END RES SEER; Nattinger AB, 1996, NEW ENGL J MED, V335, P1035, DOI 10.1056/NEJM199610033351407; Nattinger AB, 1996, MED CARE, V34, P479, DOI 10.1097/00005650-199605000-00009; Nattinger AB, 1997, J CLIN EPIDEMIOL, V50, P939, DOI 10.1016/S0895-4356(97)00099-1; NATTINGER AB, 1992, NEW ENGL J MED, V326, P1102, DOI 10.1056/NEJM199204233261702; NAYFIELD SG, 1994, J NATL CANCER I, V86, P1202, DOI 10.1093/jnci/86.16.1202; POLLOCK PH, 1994, AM J POLIT SCI, V38, P426; SUMSER J, 1992, SOCIOL SOC RES, V76, P182; *US DEP HHS, 1988, INT CLASS DIS 9 REV; WALLIS C, 1987, TIME, V130, P8; WHALEN CK, 1994, J PEDIATR PSYCHOL, V19, P3, DOI 10.1093/jpepsy/19.1.3; WILDE GJS, 1993, ADDICTION, V88, P983, DOI 10.1111/j.1360-0443.1993.tb02116.x; 1998, AM CONSERVATIVE UNIO; 1996, POLITICS US     1108	32	96	98	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 11	1998	279	10					762	766						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZA474	9508152				2022-12-28	WOS:000072366900033
J	Tang, MX; Stern, Y; Marder, K; Bell, K; Gurland, B; Lantigua, R; Andrews, H; Feng, L; Tycko, B; Mayeux, R				Tang, MX; Stern, Y; Marder, K; Bell, K; Gurland, B; Lantigua, R; Andrews, H; Feng, L; Tycko, B; Mayeux, R			The APOE-epsilon 4 allele and the risk of Alzheimer disease among African Americans, Whites, and Hispanics	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PARADIGM-BASED DIAGNOSIS; APOLIPOPROTEIN-E; HETEROGENEOUS POPULATION; DEMENTIA; EPSILON-4; ASSOCIATION; EDUCATION; COMMUNITY; SURVIVAL	Context.-Although the association between Alzheimer disease (AD) and the apolipoprotein E epsilon 4 (APOE-epsilon 4) allele has been confirmed worldwide, it appears to be inconsistent among African Americans, Hispanics, and Nigerians. Objective.-To investigate the association between the APOE-epsilon 4 allele and AD in elderly African Americans, Hispanics, and whites. Design.-Prospective, population-based, longitudinal study over a 5-year period (1991-1996). Setting.-The Washington Heights-Inwood community of New York City. Participants.-A total of 1079 Medicare recipients without AD or a related disorder at baseline. Main Outcome Measures.-Risk of clinically diagnosed AD in the 3 ethnic groups and among individuals with and without an APOE-epsilon 4 allele. Results.-Compared with individuals with the APOE-epsilon 3/epsilon 3 genotype, the relative risk (RR) of AD associated with 1 or more copies of the APOE-epsilon 4 allele was significantly increased among whites (RR, 2.5; 95% confidence interval [CI], 1.1-6.4), but not among African Americans (RR, 1.0; 95% CI, 0.6-1.6) or Hispanics (RR, 1.1; 95% CI, 0.7-1.6). In the absence of the APOE-epsilon 4 allele, the cumulative risks of AD to age 90 years, adjusted for education and sex, were 4 times higher for African Americans (RR, 4.4; 95% CI, 2.3-8.6) and 2 times higher for Hispanics (RR, 2.3; 95% CI, 1.2-4.3) than for whites. In the presence of an APOE-epsilon 4 allele, the cumulative risk of AD to age 90 years was similar for individuals in all 3 ethnic groups. Conclusion.-The presence of an APOE-epsilon 4 allele is a determinant of AD risk in whites, but African Americans and Hispanics have an increased frequency of AD regardless of their APOE genotype. These results suggest that other genes or risk factors may contribute to the increased risk of AD in African Americans and Hispanics.	Columbia Univ, Coll Phys & Surg, Gertrude H Sergievsky Ctr, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Taub Ctr Alzheimers Dis Res, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Sch Publ Hlth, Div Biostat, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Sch Publ Hlth, Div Epidemiol, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Morris W Stroud III Ctr Study Qual Life, New York, NY 10032 USA; Columbia Presbyterian Med Ctr, New York, NY 10032 USA; New York State Psychiat Inst & Hosp, Dept Stat, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; NewYork-Presbyterian Hospital; New York State Psychiatry Institute	Mayeux, R (corresponding author), Columbia Univ, Coll Phys & Surg, Gertrude H Sergievsky Ctr, 630 W 168th St, New York, NY 10032 USA.	rpm2@columbia.edu		Stern, Yaakov/0000-0001-7542-3241	NATIONAL INSTITUTE ON AGING [R35AG010963, P01AG007232, P50AG008702] Funding Source: NIH RePORTER; NIA NIH HHS [AG07232, AG10963, AG08702] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		American Psychiatric Association, 1987, DIAGN STAT MAN MENT; BOHNSTEDT M, 1994, J CLIN EPIDEMIOL, V47, P1381, DOI 10.1016/0895-4356(94)90082-5; Bureau of the Census, 1991, 1990 CENS POP HOUS S; Collett D, 1994, MODELLING SURVIVAL D, P149; CORDER EH, 1995, NEUROLOGY, V45, P1323, DOI 10.1212/WNL.45.7.1323; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Cox D. R., 1984, ANAL SURVIVAL DATA; DELAMONTE SM, 1989, J NATL MED ASSOC, V81, P644; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.1997.03550160069041; FLEISS JL, 1981, STATISTICAL METHODS, P160; GURLAND B, 1995, AM J GERIAT PSYCHIAT, V3, P6, DOI 10.1097/00019442-199524310-00002; Gurland B, 1997, RACIAL AND ETHNIC DIFFERENCES IN THE HEALTH OF OLDER AMERICANS, P233; HENDERSON AS, 1995, LANCET, V346, P1387, DOI 10.1016/S0140-6736(95)92405-1; HENDRIE HC, 1995, ANN NEUROL, V37, P118, DOI 10.1002/ana.410370123; HIXSON JE, 1990, J LIPID RES, V31, P545; HOBBS FB, 1996, PUBLICATION BUR CENS; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; Korn EL, 1997, AM J EPIDEMIOL, V145, P72; MAESTRE G, 1995, ANN NEUROL, V37, P254, DOI 10.1002/ana.410370217; MAYEUX R, 1993, ANN NEUROL, V34, P752, DOI 10.1002/ana.410340527; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; OSUNTOKUN BO, 1995, ANN NEUROL, V38, P463, DOI 10.1002/ana.410380319; PITTMAN J, 1992, ARCH NEUROL-CHICAGO, V49, P461, DOI 10.1001/archneur.1992.00530290043010; POLVIKOSKI T, 1995, NEW ENGL J MED, V333, P1242, DOI 10.1056/NEJM199511093331902; ROSES AD, 1994, LANCET, V343, P1564, DOI 10.1016/S0140-6736(94)92960-2; Sahota A, 1997, ANN NEUROL, V42, P659, DOI 10.1002/ana.410420418; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Saunders AM, 1996, LANCET, V348, P90, DOI 10.1016/S0140-6736(96)01251-2; Scott WK, 1997, ANN NEUROL, V42, P376, DOI 10.1002/ana.410420317; STERN Y, 1994, JAMA-J AM MED ASSOC, V271, P1004, DOI 10.1001/jama.271.13.1004; Stern Y, 1997, ANN NEUROL, V41, P615, DOI 10.1002/ana.410410510; STERN Y, 1992, ARCH NEUROL-CHICAGO, V49, P453, DOI 10.1001/archneur.1992.00530290035009; Tang MX, 1996, AM J HUM GENET, V58, P574; VANDUIJN CM, 1995, ANN NEUROL, V37, P605, DOI 10.1002/ana.410370510; VANDUIJN CM, 1994, NAT GENET, V7, P74, DOI 10.1038/ng0594-74	36	550	558	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 11	1998	279	10					751	755		10.1001/jama.279.10.751	http://dx.doi.org/10.1001/jama.279.10.751			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA474	9508150	Bronze			2022-12-28	WOS:000072366900031
J	Keirse, MJNC				Keirse, MJNC			What does prevent postpartum haemorrhage?	LANCET			English	Editorial Material							3RD STAGE; ACTIVE MANAGEMENT; LABOR; TRIAL; 3RD-STAGE; OXYTOCIN		Flinders Univ S Australia, Flinders Med Ctr, Dept Obstet & Gynaecol, Bedford Pk, SA 5042, Australia	Flinders Medical Centre; Flinders University South Australia	Keirse, MJNC (corresponding author), Flinders Univ S Australia, Flinders Med Ctr, Dept Obstet & Gynaecol, Bedford Pk, SA 5042, Australia.							Begley C M, 1990, Midwifery, V6, P3, DOI 10.1016/S0266-6138(05)80091-9; ElRefaey H, 1997, BRIT J OBSTET GYNAEC, V104, P336, DOI 10.1111/j.1471-0528.1997.tb11464.x; KHAN GQ, 1995, EUR J OBSTET GYN R B, V58, P147, DOI 10.1016/0028-2243(94)02004-3; MCDONALD S, 1997, PREGNANCY CHILDBIRTH; MCDONALD SJ, 1993, BMJ-BRIT MED J, V307, P1167, DOI 10.1136/bmj.307.6913.1167; PRENDIVILLE W, 1989, EFFECTIVE CARE PREGN, P1145; PRENDIVILLE WJ, 1988, BMJ-BRIT MED J, V297, P1295, DOI 10.1136/bmj.297.6659.1295; PRENDIVILLE WJ, 1997, PREGNANCY CHILDBIRTH; THILAGANATHAN B, 1993, EUR J OBSTET GYN R B, V48, P19, DOI 10.1016/0028-2243(93)90048-H; YUEN PM, 1995, BRIT J OBSTET GYNAEC, V102, P377, DOI 10.1111/j.1471-0528.1995.tb11288.x	10	12	12	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 7	1998	351	9104					690	692		10.1016/S0140-6736(05)78490-7	http://dx.doi.org/10.1016/S0140-6736(05)78490-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB359	9504511				2022-12-28	WOS:000072463800004
J	Siersted, HC				Siersted, HC			Commentary: Improving the diagnostic rate in asthma: a community issue	BRITISH MEDICAL JOURNAL			English	Editorial Material									Odense Univ Hosp, Dept Med C, Sect Resp Dis, DK-5000 Odense C, Denmark	University of Southern Denmark; Odense University Hospital	Siersted, HC (corresponding author), Odense Univ Hosp, Dept Med C, Sect Resp Dis, DK-5000 Odense C, Denmark.								0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 28	1998	316	7132					657	657						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA282	9522786				2022-12-28	WOS:000072347900025
J	Flier, JS; Maratos-Flier, E				Flier, JS; Maratos-Flier, E			Obesity and the hypothalamus: Novel peptides for new pathways	CELL			English	Review							GENE; NEUROENDOCRINE; RECEPTOR; HORMONE; LEPTIN		Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Endocrinol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	Flier, JS (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Endocrinol, Boston, MA 02215 USA.		Flier, jeffrey/AAG-6223-2019					Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Boston BA, 1997, SCIENCE, V278, P1641, DOI 10.1126/science.278.5343.1641; Caro JF, 1996, DIABETES, V45, P1455, DOI 10.2337/diab.45.11.1455; De Lecea L, 1998, P NATL ACAD SCI USA, V95, P322, DOI 10.1073/pnas.95.1.322; Elmquist JK, 1998, P NATL ACAD SCI USA, V95, P741, DOI 10.1073/pnas.95.2.741; Erickson JC, 1996, SCIENCE, V274, P1704, DOI 10.1126/science.274.5293.1704; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; Halaas JL, 1997, P NATL ACAD SCI USA, V94, P8878, DOI 10.1073/pnas.94.16.8878; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; MOUNTJOY KG, 1994, MOL ENDOCRINOL, V8, P1298, DOI 10.1210/me.8.10.1298; NAHON JL, 1994, CRIT REV NEUROBIOL, V8, P221; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; Qu DQ, 1996, NATURE, V380, P243, DOI 10.1038/380243a0; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Seeley RJ, 1997, NATURE, V390, P349, DOI 10.1038/37016; Thornton JE, 1997, ENDOCRINOLOGY, V138, P5063, DOI 10.1210/en.138.11.5063; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	20	341	370	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 20	1998	92	4					437	440		10.1016/S0092-8674(00)80937-X	http://dx.doi.org/10.1016/S0092-8674(00)80937-X			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YZ409	9491885	Bronze			2022-12-28	WOS:000072251500004
J	Kerry, SM; Bland, JM				Kerry, SM; Bland, JM			Statistics notes - Sample size in cluster randomisation	BRITISH MEDICAL JOURNAL			English	Article									St George Hosp, Sch Med, Div Gen Practice & Primary Care, London SW17 0RE, England; Dept Publ Hlth Sci, Surrey, England	St Georges University London	Kerry, SM (corresponding author), St George Hosp, Sch Med, Div Gen Practice & Primary Care, Cranmer Terrace, London SW17 0RE, England.							Bland JM, 1997, BRIT MED J, V315, P600; CHOSIDOW O, 1994, LANCET, V344, P1724, DOI 10.1016/S0140-6736(94)92884-3; DUFLOREY C, 1993, BRIT MED J, V306, P1181; Kerry SM, 1998, BMJ-BRIT MED J, V316, P54, DOI 10.1136/bmj.316.7124.54; Machin D., 1987, STAT TABLES DESIGN C; MEADE TW, 1992, THROMB HAEMOSTASIS, V68, P1	6	106	106	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 14	1998	316	7130					549	549		10.1136/bmj.316.7130.549	http://dx.doi.org/10.1136/bmj.316.7130.549			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX955	9501723	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000072097400034
J	Graves, BJ				Graves, BJ			Transcription - Inner workings of a transcription factor partnership	SCIENCE			English	Article							ETS-DOMAIN; DNA-BINDING; MURINE ETS-1; COMPLEX; HELIX; GABP; SEQUENCES; REVEALS; ALPHA		Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, Salt Lake City, UT 84132 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Graves, BJ (corresponding author), Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, Salt Lake City, UT 84132 USA.	graves@bioscience.utah.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038663] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM038663] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; DELABROUSSE FC, 1994, GENE DEV, V8, P1853, DOI 10.1101/gad.8.15.1853; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; Luh FY, 1997, NATURE, V389, P999, DOI 10.1038/40202; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; SHARROCKS A, 1998, ADV CANC RES, V75; Skalicky JJ, 1996, PROTEIN SCI, V5, P296; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; WERNER MH, 1996, CELL, V87, P355	19	29	29	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 13	1998	279	5353					1000	1002		10.1126/science.279.5353.1000	http://dx.doi.org/10.1126/science.279.5353.1000			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX100	9490475				2022-12-28	WOS:000072006400035
J	Entwistle, VA; Renfrew, MJ; Yearley, S; Forrester, J; Lamont, T				Entwistle, VA; Renfrew, MJ; Yearley, S; Forrester, J; Lamont, T			Lay perspectives: advantages for health research	BRITISH MEDICAL JOURNAL			English	Article							PREFERENCES; PATIENT; TRIALS		Univ York, NHS Ctr Reviews & Disseminat, York YO1 5DD, N Yorkshire, England; Univ Leeds, Ctr Reprod Growth & Dev, Leeds LS2 9JT, W Yorkshire, England; Univ York, Dept Sociol, York YO1 5DD, N Yorkshire, England; Audit Commiss, London SW1P 2PN, England	University of York - UK; University of Leeds; University of York - UK	Entwistle, VA (corresponding author), Univ York, NHS Ctr Reviews & Disseminat, York YO1 5DD, N Yorkshire, England.		Renfrew, Mary/A-2440-2010; Entwistle, Vikki Ann/I-9266-2019	Entwistle, Vikki Ann/0000-0002-0856-4025; Renfrew, Mary/0000-0003-2905-403X				Alderson P, 1996, J MED ETHICS, V22, P135, DOI 10.1136/jme.22.3.135; Barnes B, 1985, SCIENCE; BASTIAN H, 1995, POWER SHARING KNOWLE; Bell R W, 1994, Rehabil Nurs, V19, P198; CHALMERS I, 1995, BRIT MED J, V310, P1315, DOI 10.1136/bmj.310.6990.1315; CHALMERS I, 1991, BIRTH-ISS PERINAT C, V18, P137, DOI 10.1111/j.1523-536X.1991.tb00083.x; Cornwall A, 1995, SOC SCI MED, V41, P1667, DOI 10.1016/0277-9536(95)00127-S; COULTER A, 1994, FAM PRACT, V11, P67, DOI 10.1093/fampra/11.1.67; DOLAN JG, 1993, J GEN INTERN MED, V8, P525, DOI 10.1007/BF02599632; FLYNN BC, 1994, HEALTH EDUC QUART, V21, P395, DOI 10.1177/109019819402100310; GOODARE H, 1995, BMJ-BRIT MED J, V310, P1277, DOI 10.1136/bmj.310.6990.1277; Goodare H, 1996, FIGHTING SPIRIT STOR; GROOME PA, 1994, MED DECIS MAKING, V14, P91, DOI 10.1177/0272989X9401400111; Hamilton-Gurney B, 1994, PUBLIC PARTICIPATION; Hares T, 1992, Qual Health Care, V1, P219, DOI 10.1136/qshc.1.4.219; IRWIN A, 1995, CITIZEN SCI STUDY PE, P111; *LOC MAN GOV BOARD, 1994, COMM PART LOC AG 21; Lumley J, 1996, INT J TECHNOL ASSESS, V12, P247, DOI 10.1017/S0266462300009600; MACILWAIN C, 1993, NATURE, V363, P388; MARSHALL E, 1993, SCIENCE, V259, P616, DOI 10.1126/science.8430307; NOWAK R, 1995, SCIENCE, V269, P1666, DOI 10.1126/science.7569888; OLIVER SR, 1995, BRIT MED J, V310, P1318, DOI 10.1136/bmj.310.6990.1318; Ong BN, 1996, INT J TECHNOL ASSESS, V12, P511; RENFREW MJ, 1992, WOMENS HLTH MATTERS, P81; TIGHE R, 1993, CAN J REHABIL, V7, P127; YEARLEY S, 1994, PUBLIC UNDERST SCI, V3, P245	26	226	226	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 7	1998	316	7129					463	466		10.1136/bmj.316.7129.463	http://dx.doi.org/10.1136/bmj.316.7129.463			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW874	9492683	Green Published			2022-12-28	WOS:000071982700049
J	MacKinnon, R; Cohen, SL; Kuo, AL; Lee, A; Chait, BT				MacKinnon, R; Cohen, SL; Kuo, AL; Lee, A; Chait, BT			Structural conservation in prokaryotic and eukaryotic potassium channels	SCIENCE			English	Article							SHAKER K+ CHANNEL; PEPTIDE INHIBITOR; CHARYBDOTOXIN; PORE; CONDUCTANCE; MECHANISM; RECEPTOR; GEOMETRY; RESIDUES; BLOCK	Toxins from scorpion venom interact with potassium channels. Resin-attached, mutant K+ channels from Streptomyces lividans were used to screen venom from Leiurus quinquestriatus hebraeus, and the toxins that interacted with the channel were rapidly identified by mass spectrometry. One of the toxins, agitoxin2, was further studied by mutagenesis and radioligand binding. The results show that a prokaryotic K+ channel has the same pore structure as eukaryotic K+ channels. This structural conservation, through application of techniques presented here, offers a new approach for K+ channel pharmacology.	Rockefeller Univ, Lab Mol Neurobiol & Biophys, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; Rockefeller Univ, Lab Mass Spectrometry & Gaseous Ion Chem, New York, NY 10021 USA	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; Rockefeller University	MacKinnon, R (corresponding author), Rockefeller Univ, Lab Mol Neurobiol & Biophys, 1230 York Ave, New York, NY 10021 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043949] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43949] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aggarwal SK, 1996, NEURON, V16, P1169, DOI 10.1016/S0896-6273(00)80143-9; Cohen SL, 1996, ANAL CHEM, V68, P31, DOI 10.1021/ac9507956; DEBIN JA, 1993, AM J PHYSL SOC, V264, pC369; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; GARCIA ML, 1994, BIOCHEMISTRY-US, V33, P6834, DOI 10.1021/bi00188a012; GARCIA ML, 1991, J BIOENERG BIOMEMBR, V23, P615, DOI 10.1007/BF00785814; GIANGIACOMO KM, 1992, BIOCHEMISTRY-US, V31, P6719, DOI 10.1021/bi00144a011; GOLDSTEIN SAN, 1994, NEURON, V12, P1377, DOI 10.1016/0896-6273(94)90452-9; Gross A, 1996, NEURON, V16, P399, DOI 10.1016/S0896-6273(00)80057-4; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KREZEL AM, 1995, PROTEIN SCI, V4, P1478, DOI 10.1002/pro.5560040805; LIPPENS G, 1995, BIOCHEMISTRY-US, V34, P13, DOI 10.1021/bi00001a003; MACKINNON R, 1988, J GEN PHYSIOL, V91, P335, DOI 10.1085/jgp.91.3.335; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MACKINNON R, 1990, NEURON, V5, P767, DOI 10.1016/0896-6273(90)90335-D; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MILLER C, 1995, NEURON, V15, P5, DOI 10.1016/0896-6273(95)90057-8; Naranjo D, 1996, NEURON, V16, P123, DOI 10.1016/S0896-6273(00)80029-X; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PARK CS, 1992, NEURON, V9, P307, DOI 10.1016/0896-6273(92)90169-E; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; STOCKER M, 1994, P NATL ACAD SCI USA, V91, P9509, DOI 10.1073/pnas.91.20.9509	23	357	366	3	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 3	1998	280	5360					106	109		10.1126/science.280.5360.106	http://dx.doi.org/10.1126/science.280.5360.106			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF314	9525854				2022-12-28	WOS:000072885100046
J	Goodnight, SH; Feinstein, DI				Goodnight, SH; Feinstein, DI			Update in hematology	ANNALS OF INTERNAL MEDICINE			English	Article							VENOUS THROMBOEMBOLISM; BONE METASTASES; BREAST-CANCER; RISK; PAMIDRONATE; THROMBOSIS		Oregon Hlth & Sci Univ, Portland, OR 97201 USA; Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90033 USA	Oregon Health & Science University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Goodnight, SH (corresponding author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd,L-471, Portland, OR 97201 USA.							Conte PF, 1996, J CLIN ONCOL, V14, P2552, DOI 10.1200/JCO.1996.14.9.2552; Grisso JA, 1997, ANN INTERN MED, V127, P1006, DOI 10.7326/0003-4819-127-11-199712010-00011; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; Hall WJ, 1997, ANN INTERN MED, V127, P557, DOI 10.7326/0003-4819-127-7-199710010-00007; Hortobagyi GN, 1996, NEW ENGL J MED, V335, P1785, DOI 10.1056/NEJM199612123352401; Hull RD, 1997, ARCH INTERN MED, V157, P289; Jick H, 1996, LANCET, V348, P981, DOI 10.1016/S0140-6736(96)07114-0; Koopman MMW, 1996, NEW ENGL J MED, V334, P682, DOI 10.1056/NEJM199603143341102; MACIK BG, 1995, CLIN CHEST MED, V16, P375; Mannuci PM, 1996, HAEMOSTASIS, V26, P1; Price DT, 1997, ANN INTERN MED, V127, P895, DOI 10.7326/0003-4819-127-10-199711150-00007; Schulman S, 1997, NEW ENGL J MED, V336, P393, DOI 10.1056/NEJM199702063360601; Simonneau G, 1997, NEW ENGL J MED, V337, P663, DOI 10.1056/NEJM199709043371002; tenCate JW, 1997, NEW ENGL J MED, V337, P657; Vandenbroucke JP, 1996, LANCET, V348, P972, DOI 10.1016/S0140-6736(05)64918-5; VESSEY M, 1986, BRIT MED J, V292, P526, DOI 10.1136/bmj.292.6519.526	16	2	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1998	128	7					545	551		10.7326/0003-4819-128-7-199804010-00005	http://dx.doi.org/10.7326/0003-4819-128-7-199804010-00005			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE539	9518399				2022-12-28	WOS:000072803500005
J	Kahn, J; Walcheck, B; Migaki, GI; Jutila, MA; Kishimoto, TK				Kahn, J; Walcheck, B; Migaki, GI; Jutila, MA; Kishimoto, TK			Calmodulin regulates L-selectin adhesion molecule expression and function through a protease-dependent mechanism	CELL			English	Article							MEMBRANE-PROXIMAL CLEAVAGE; CROSS-LINKING; GLYCOPROTEIN LIGAND-1; HUMAN NEUTROPHILS; KINASE-C; HYDRODYNAMIC SHEAR; CYTOPLASMIC DOMAIN; LEUKOCYTE ADHESION; HOMING RECEPTOR; CELL-SURFACE	Expression of the L-selectin adhesion molecule is rapidly down-regulated upon cell activation through proteolysis at a membrane-proximal site. Here we demonstrate that calmodulin, an intracellular calcium regulatory protein, specifically coprecipitates with L-selectin through a direct association with the cytoplasmic domain of L-selectin. Furthermore, calmodulin inhibitors disrupt L-selectin-dependent adhesion by inducing proteolytic release of L-selectin from the cell surface. The effects of the calmodulin inhibitors on L-selectin expression and function can be prevented by cotreatment with a hydroxamic acid-based metalloprotease inhibitor. Our results suggest a novel role for calmodulin in regulating the expression and function of an integral membrane protein through a protease-dependent mechanism. These findings may have broader implications for other cell surface proteins that also undergo regulated proteolysis.	Boehringer Ingelheim Pharmaceut Inc, Dept Immunol Dis, Ridgefield, CT 06877 USA; Montana State Univ, Vet Mol Biol Lab, Bozeman, MT 59717 USA	Boehringer Ingelheim; Montana State University System; Montana State University Bozeman	Kishimoto, TK (corresponding author), Boehringer Ingelheim Pharmaceut Inc, Dept Immunol Dis, 90 E Ridge POB 368, Ridgefield, CT 06877 USA.							ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; Allport JR, 1997, J IMMUNOL, V158, P4365; ALOBAIDI T, 1981, BIOCHIM BIOPHYS ACTA, V675, P316, DOI 10.1016/0304-4165(81)90020-9; Alon R, 1996, J CELL BIOL, V135, P849, DOI 10.1083/jcb.135.3.849; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; BARGATZE RF, 1994, J EXP MED, V180, P1785, DOI 10.1084/jem.180.5.1785; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; Bennett TA, 1996, J IMMUNOL, V156, P3093; BERGER M, 1985, J IMMUNOL, V135, P1342; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; BRENNER B, 1996, P NATL ACAD SCI USA, V93, P15736; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CHEN AJ, 1995, J EXP MED, V182, P519, DOI 10.1084/jem.182.2.519; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; CROCKETTTORABI E, 1995, J IMMUNOL, V154, P2291; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; ELFERINK JGR, 1982, RES COMMUN CHEM PATH, V38, P77; Feehan C, 1996, J BIOL CHEM, V271, P7019, DOI 10.1074/jbc.271.12.7019; Finger EB, 1996, NATURE, V379, P266, DOI 10.1038/379266a0; Gnegy M E, 1995, Prog Drug Res, V45, P33; Guyer DA, 1996, FASEB J, V10, P3536; Haribabu B, 1997, J BIOL CHEM, V272, P13961, DOI 10.1074/jbc.272.21.13961; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4820, DOI 10.1021/bi00182a010; HUANG KP, 1993, ARCH BIOCHEM BIOPHYS, V305, P570, DOI 10.1006/abbi.1993.1463; Hwang ST, 1996, J EXP MED, V184, P1343, DOI 10.1084/jem.184.4.1343; JONES HP, 1984, METHOD ENZYMOL, V105, P389; KAHN J, 1994, J CELL BIOL, V125, P461, DOI 10.1083/jcb.125.2.461; KANSAS GS, 1993, J EXP MED, V177, P833, DOI 10.1084/jem.177.3.833; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KISHIMOTO TK, 1990, P NATL ACAD SCI USA, V87, P2244, DOI 10.1073/pnas.87.6.2244; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LAUDANNA C, 1994, J BIOL CHEM, V269, P4021; LAWRENCE MB, 1995, EUR J IMMUNOL, V25, P1025, DOI 10.1002/eji.1830250425; MCDONALD JR, 1989, J BIOL CHEM, V264, P9611; MIGAKI GI, 1995, J EXP MED, V182, P549, DOI 10.1084/jem.182.2.549; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Mullberg J, 1997, FEBS LETT, V401, P235, DOI 10.1016/S0014-5793(96)01480-9; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PALECANDA A, 1992, EUR J IMMUNOL, V22, P1279, DOI 10.1002/eji.1830220524; PAVALKO FM, 1995, J CELL BIOL, V129, P1155, DOI 10.1083/jcb.129.4.1155; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; Preece G, 1996, J BIOL CHEM, V271, P11634, DOI 10.1074/jbc.271.20.11634; SIMON SI, 1995, J IMMUNOL, V155, P1502; SMITH RJ, 1981, IMMUNOLOGY, V44, P677; SOBUE K, 1983, P NATL ACAD SCI-BIOL, V80, P6868, DOI 10.1073/pnas.80.22.6868; SPERTINI O, 1991, NATURE, V349, P691, DOI 10.1038/349691a0; Spertini O, 1996, J CELL BIOL, V135, P523, DOI 10.1083/jcb.135.2.523; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Steeber DA, 1997, J IMMUNOL, V159, P952; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; SWANLJUNGCOLLINS H, 1991, J BIOL CHEM, V266, P1312; Tu LL, 1996, J IMMUNOL, V157, P3995; VANELDIK LJ, 1984, BIOCHEM BIOPH RES CO, V124, P752, DOI 10.1016/0006-291X(84)91022-2; VONANDRIAN UH, 1995, CELL, V82, P989, DOI 10.1016/0092-8674(95)90278-3; WADDELL TK, 1994, J BIOL CHEM, V269, P18485; WADDELL TK, 1995, J BIOL CHEM, V270, P15403, DOI 10.1074/jbc.270.25.15403; Walcheck B, 1996, NATURE, V380, P720, DOI 10.1038/380720a0; Walcheck B, 1996, J CLIN INVEST, V98, P1081, DOI 10.1172/JCI118888; WELSH MJ, 1982, SCIENCE, V216, P642, DOI 10.1126/science.6280283; WRIGHT CD, 1987, BIOCHEM BIOPH RES CO, V142, P53, DOI 10.1016/0006-291X(87)90450-5; Zouki C, 1997, J CLIN INVEST, V100, P522, DOI 10.1172/JCI119561	65	172	178	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 20	1998	92	6					809	818		10.1016/S0092-8674(00)81408-7	http://dx.doi.org/10.1016/S0092-8674(00)81408-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZD198	9529256	Bronze			2022-12-28	WOS:000072661200013
J	Vahava, O; Morell, R; Lynch, ED; Weiss, S; Kagan, ME; Ahituv, N; Morrow, JE; Lee, MK; Skvorak, AB; Morton, CC; Blumenfeld, A; Frydman, M; Friedman, TB; King, MC; Avraham, KB				Vahava, O; Morell, R; Lynch, ED; Weiss, S; Kagan, ME; Ahituv, N; Morrow, JE; Lee, MK; Skvorak, AB; Morton, CC; Blumenfeld, A; Frydman, M; Friedman, TB; King, MC; Avraham, KB			Mutation in transcription factor POU4F3 associated with inherited progressive hearing loss in humans	SCIENCE			English	Article							DNA-BINDING; DOMAIN FACTORS; BRN-3 FAMILY; DEAFNESS; MOUSE; CELLS; SPECIFICITY; RECOGNITION; SUBSETS; NEURONS	The molecular basis for autosomal dominant progressive nonsyndromic hearing loss in an Israeli Jewish family, Family H, has been determined. Linkage analysis placed this deafness locus, DFNA15, on chromosome 5q31, The human homolog of mouse Pou4f3, a member of the POU-domain family of transcription factors whose targeted inactivation causes profound deafness in mice, was physically mapped to the 25-centimorgan DFNA15-linked region. An 8-base pair deletion in the POU homeodomain of human POU4F3 was identified in Family H. A truncated protein presumably impairs high-affinity binding of this transcription factor in a dominant negative fashion, leading to progressive hearing loss.	Tel Aviv Univ, Sackler Sch Med, Dept Human Genet, IL-69978 Tel Aviv, Israel; NIDCD, NIH, Bethesda, MD 20850 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Genet, Seattle, WA 98195 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA; Hadassah Univ Hosp, Unit Dev Mol Biol & Genet Engn, IL-91240 Jerusalem, Israel; Chaim Sheba Med Ctr, Genet Inst, IL-52621 Tel Hashomer, Israel; Harvard Univ, Sch Med, Boston, MA 02115 USA	Tel Aviv University; Sackler Faculty of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Hebrew University of Jerusalem; Chaim Sheba Medical Center; Harvard University; Harvard Medical School	Avraham, KB (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Human Genet, IL-69978 Tel Aviv, Israel.	karena@post.tau.ac.il	Morell, Robert James/Q-2042-2019	Ahituv, Nadav/0000-0002-7434-8144; Avraham, Karen B/0000-0002-4913-251X; Morell, Robert/0000-0003-1537-7356; King, Mary-Claire/0000-0001-9426-1743	NIDCD NIH HHS [Z01 DC 00039, R01 DC01076] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC001076] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		AVRAHAM KB, 1995, NAT GENET, V11, P369, DOI 10.1038/ng1295-369; BOTFIELD MC, 1992, BIOCHEMISTRY-US, V31, P5841, DOI 10.1021/bi00140a020; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; DEKOK YJM, 1995, SCIENCE, V267, P685, DOI 10.1126/science.7839145; Denoyelle F, 1997, HUM MOL GENET, V6, P2173, DOI 10.1093/hmg/6.12.2173; Erkman L, 1996, NATURE, V381, P603, DOI 10.1038/381603a0; GERRERO MR, 1993, P NATL ACAD SCI USA, V90, P10841, DOI 10.1073/pnas.90.22.10841; GIBSON F, 1995, NATURE, V374, P62, DOI 10.1038/374062a0; Gruber CA, 1997, MOL CELL BIOL, V17, P2391, DOI 10.1128/MCB.17.5.2391; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; Liu XZ, 1997, NAT GENET, V16, P188, DOI 10.1038/ng0697-188; Liu XZ, 1997, NAT GENET, V17, P268, DOI 10.1038/ng1197-268; Lynch ED, 1997, SCIENCE, V278, P1315, DOI 10.1126/science.278.5341.1315; Maquat LE, 1996, AM J HUM GENET, V59, P279; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Morris PJ, 1997, NEUROREPORT, V8, P2041, DOI 10.1097/00001756-199705260-00047; MORTON NE, 1991, ANN NY ACAD SCI, V630, P16, DOI 10.1111/j.1749-6632.1991.tb19572.x; NEITZEL H, 1986, HUM GENET, V73, P320, DOI 10.1007/BF00279094; NINKINA NN, 1993, NUCLEIC ACIDS RES, V21, P3175, DOI 10.1093/nar/21.14.3175; RYAN A, COMMUNICATION; Schuknecht H.F., 1974, PATHOLOGY EAR; Scott DA, 1998, NATURE, V391, P32, DOI 10.1038/34079; STEEL KP, 1994, TRENDS GENET, V10, P428, DOI 10.1016/0168-9525(94)90113-9; Theil T, 1995, J BIOL CHEM, V270, P30958, DOI 10.1074/jbc.270.52.30958; THEIL T, 1994, CYTOGENET CELL GENET, V66, P267, DOI 10.1159/000133709; VERRIJZER CP, 1992, EMBO J, V11, P4993, DOI 10.1002/j.1460-2075.1992.tb05606.x; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; XIA YR, 1993, GENOMICS, V18, P126, DOI 10.1006/geno.1993.1435; Xiang MQ, 1997, P NATL ACAD SCI USA, V94, P9445, DOI 10.1073/pnas.94.17.9445; XIANG MQ, 1995, J NEUROSCI, V15, P4762	36	238	260	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 20	1998	279	5358					1950	1954		10.1126/science.279.5358.1950	http://dx.doi.org/10.1126/science.279.5358.1950			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506947				2022-12-28	WOS:000072613300050
J	Malin, MC; Carr, MH; Danielson, GE; Davies, ME; Hartmann, WK; Ingersoll, AP; James, PB; Masursky, H; McEwen, AS; Soderblom, LA; Thomas, P; Veverka, J; Caplinger, MA; Ravine, MA; Soulanille, TA				Malin, MC; Carr, MH; Danielson, GE; Davies, ME; Hartmann, WK; Ingersoll, AP; James, PB; Masursky, H; McEwen, AS; Soderblom, LA; Thomas, P; Veverka, J; Caplinger, MA; Ravine, MA; Soulanille, TA			Early views of the Martian surface from the Mars orbiter camera of Mars global surveyor	SCIENCE			English	Article							SOUTH POLAR-CAP; VALLES-MARINERIS; LAYERED DEPOSITS; RESOLUTION; VOLCANISM; REGIONS; ORIGIN; VIKING; WATER; DUNES	High-resolution images of the martian surface at scales of a few meters show ubiquitous erosional and depositional eolian landforms. Dunes, sandsheets, and drifts are prevalent and exhibit a range of morphology, composition (inferred from albedo), and age (as seen in occurrences of different dune orientations at the same location). Steep walls of topographic depressions such as canyons, valleys, and impact craters show the martian crust to be stratified at scales of a few tens of meters. The south polar layered terrain and superposed permanent ice cap display diverse surface textures that may reflect the complex interplay of volatile and non-volatile components, Low resolution regional views of the planet provide synoptic observations of polar cap retreat, condensate clouds, and the lifecycle of local and regional dust storms.	Malin Space Sci Syst, San Diego, CA 92191 USA; US Geol Survey, Menlo Park, CA 94025 USA; CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA; Rand Corp, Santa Monica, CA 90406 USA; Planetary Sci Inst, Tucson, AZ 85719 USA; Univ Toledo, Dept Phys & Astron, Toledo, OH 43606 USA; US Geol Survey, Flagstaff, AZ 86001 USA; Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA; Cornell Univ, Ctr Radiophys & Space Res, Ithaca, NY 14853 USA; Prama Corp, Pasadena, CA 91116 USA	United States Department of the Interior; United States Geological Survey; California Institute of Technology; RAND Corporation; University System of Ohio; University of Toledo; United States Department of the Interior; United States Geological Survey; University of Arizona; Cornell University	Malin, MC (corresponding author), Malin Space Sci Syst, POB 910148, San Diego, CA 92191 USA.							BELL JF, 1997, LUNAR PLANET SCI, V28, P87; BLASIUS RK, 1982, ICARUS, V50, P140; BRIGGS GA, 1979, J GEOPHYS RES, V84, P2795, DOI 10.1029/JB084iB06p02795; Carr M., 1981, SURFACE MARS; Carr M.H, 1996, WATER MARS; CUTTS JA, 1973, J GEOPHYS RES, V78, P4231, DOI 10.1029/JB078i020p04231; EDGETT KS, 1994, ICARUS, V112, P448, DOI 10.1006/icar.1994.1197; EDGETT KS, IN PRESS ICARUS; ERARD S, 1991, P LUNAR PLANET SCI, V21, P437; GEISSLER PE, 1990, J GEOPHYS RES-SOLID, V95, P14399, DOI 10.1029/JB095iB09p14399; GREELEY R, 1987, SCIENCE, V236, P1653, DOI 10.1126/science.236.4809.1653; GREELEY R, 1993, J GEOPHYS RES-PLANET, V98, P3183, DOI 10.1029/92JE02580; Greeley R., 1992, MARS, P730; HERKENHOFF KE, 1990, J GEOPHYS RES-SOLID, V95, P14511, DOI 10.1029/JB095iB09p14511; HUNT GE, 1981, NATURE, V293, P1; JAMES PB, 1979, J GEOPHYS RES, V84, P2889, DOI 10.1029/JB084iB06p02889; JAMES PB, 1982, ICARUS, V50, P368, DOI 10.1016/0019-1035(82)90130-0; Kahn R. A., 1992, MARS, P1017; Keating GM, 1998, SCIENCE, V279, P1672, DOI 10.1126/science.279.5357.1672; Kieffer H. H., 1992, MARS, P1180; KIEFFER HH, 1976, SCIENCE, V194, P1341, DOI 10.1126/science.194.4271.1341; LEE P, 1995, J GEOPHYS RES-PLANET, V100, P5381, DOI 10.1029/95JE00225; Lucchitta B. K., 1992, MARS, P453; MAHONEY JJ, 1997, GEOPHYS MONOGR SER, V100; Malin M. C., 1991, International Journal of Imaging Systems and Technology, V3, P76, DOI 10.1002/ima.1850030205; MALIN MC, 1992, J GEOPHYS RES-PLANET, V97, P7699, DOI 10.1029/92JE00340; MALIN MC, 1979, NASA C PUBL, V2072, P54; MCCAULEY JF, 1972, ICARUS, V17, P289, DOI 10.1016/0019-1035(72)90003-6; MUHLEMAN DO, 1991, SCIENCE, V253, P1508, DOI 10.1126/science.253.5027.1508; MURRAY BC, 1972, ICARUS, V17, P328, DOI 10.1016/0019-1035(72)90004-8; NEDELL SS, 1987, ICARUS, V70, P409, DOI 10.1016/0019-1035(87)90086-8; Nummedal D., 1978, CHANNELED SCABLAND; PAIGE DA, 1992, ICARUS, V99, P15, DOI 10.1016/0019-1035(92)90167-6; PLAUT JJ, 1988, ICARUS, V75, P357; Schubert G., 1992, MARS, P147, DOI [10.2307/j.ctt207g59v.9, DOI 10.2307/J.CTT207G59V.9]; SCHULTZ PH, 1988, ICARUS, V73, P91, DOI 10.1016/0019-1035(88)90087-5; SCOTT DH, 1982, J GEOPHYS RES, V87, P1179, DOI 10.1029/JB087iB02p01179; SHARP RP, 1973, J GEOPHYS RES, V78, P4063, DOI 10.1029/JB078i020p04063; SODERBLOM LA, 1973, J GEOPHYS RES, V78, P4197, DOI 10.1029/JB078i020p04197; Squyres S. W., 1992, MARS, P523; Tanaka K. L., 1992, MARS, P345; Tanaka K L., 1989, P LUN PLAN SCI C, P383, DOI DOI 10.1017/CB09781107415324.004; TANAKA KL, 1986, J GEOPHYS RES-SOLID, V91, pE139, DOI 10.1029/JB091iB13p0E139; Thomas P., 1992, MARS, P767; WARD AW, 1985, J GEOPHYS RES-SOLID, V90, P2038, DOI 10.1029/JB090iB02p02038; ZIMBELMAN JR, 1987, ICARUS, V71, P257, DOI 10.1016/0019-1035(87)90151-5; Zurek R.W., 1992, MARS, P835	47	193	193	3	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 13	1998	279	5357					1681	1685		10.1126/science.279.5357.1681	http://dx.doi.org/10.1126/science.279.5357.1681			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9497280				2022-12-28	WOS:000072490000045
J	Deisseroth, K; Heist, EK; Tsien, RW				Deisseroth, K; Heist, EK; Tsien, RW			Translocation of calmodulin to the nucleus supports CREB phosphorylation in hippocampal neurons	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; CAMP-RESPONSIVE ELEMENT; CENTRAL-NERVOUS-SYSTEM; LONG-TERM-MEMORY; C-FOS EXPRESSION; BINDING PROTEIN; PYRAMIDAL NEURONS; TRANSCRIPTION; CHANNELS; CALCIUM	Activation of the transcription factor CREB is thought to be important in the formation of long-term memory in several animal species(1-3). The phosphorylation of a serine residue at position 133 of CREB is critical for activation of CREB4. This phosphorylation is rapid when driven by brief synaptic activity in hippocampal neurons(5), It is initiated by a highly local, rise in calcium ion concentration(5) near the cell membrane, but culminates in the activation of a specific calmodulin-dependent kinase known as CaMK IV (ref. 7), which is constitutively present in the neuronal nucleus(7,8). It is unclear how the signal is conveyed from the synapse to the nucleus, We show here that brief bursts of activity cause a swift (similar to 1 min) translocation of calmodulin from the cytoplasm to the nucleus, and that this translocation is important for the rapid phosphorylation of CREB, Certain Ca2+ entry systems (L-type Ca2+ channels and NMDA receptors) are able to cause mobilization of calmodulin, whereas others (N- and P/Q-type Ca2+ channels) are not. This translocation of calmodulin provides a form of cellular communication that combines the specificity of local Ca2+ signalling with the ability to produce action at a distance.	Stanford Univ, Sch Med, Beckman Ctr Mol & Genet Med, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA	Stanford University; Stanford University	Tsien, RW (corresponding author), Stanford Univ, Sch Med, Beckman Ctr Mol & Genet Med, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA.							Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Bito H, 1997, CURR OPIN NEUROBIOL, V7, P419, DOI 10.1016/S0959-4388(97)80072-4; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HAHN KM, 1990, J BIOL CHEM, V265, P20335; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; HAROOTUNIAN AT, 1993, MOL BIOL CELL, V4, P993, DOI 10.1091/mbc.4.10.993; HULEN D, 1991, CELL MOTIL CYTOSKEL, V18, P113, DOI 10.1002/cm.970180206; Kavalali ET, 1997, NEURON, V18, P651, DOI 10.1016/S0896-6273(00)80305-0; LUBYPHELPS K, 1995, J BIOL CHEM, V270, P21532, DOI 10.1074/jbc.270.37.21532; MAGEE JC, 1995, J PHYSIOL-LONDON, V487, P67, DOI 10.1113/jphysiol.1995.sp020862; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; MITSUI K, 1993, J BIOL CHEM, V268, P13422; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; MURPHY TH, 1991, NEURON, V7, P625, DOI 10.1016/0896-6273(91)90375-A; NAKAMURA Y, 1995, NEUROSCIENCE, V68, P181, DOI 10.1016/0306-4522(95)00092-W; PRUSCHY M, 1994, J CELL BIOL, V127, P1527, DOI 10.1083/jcb.127.6.1527; SACKS DB, 1991, ANAL BIOCHEM, V194, P369, DOI 10.1016/0003-2697(91)90243-M; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; Tokumitsu H, 1996, J BIOL CHEM, V271, P5617, DOI 10.1074/jbc.271.10.5617; VENDRELL M, 1992, MOL BRAIN RES, V14, P285, DOI 10.1016/0169-328X(92)90095-S; Wang JH, 1995, J BIOL CHEM, V270, P30245, DOI 10.1074/jbc.270.51.30245; WESTENBROEK RE, 1990, NATURE, V347, P281, DOI 10.1038/347281a0; Xia ZG, 1996, J NEUROSCI, V16, P5425; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9	30	518	564	1	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 12	1998	392	6672					198	202		10.1038/32448	http://dx.doi.org/10.1038/32448			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB349	9515967				2022-12-28	WOS:000072462700067
J	Robinson, H; Gao, YG; McCrary, BS; Edmondson, SP; Shriver, JW; Wang, AHJ				Robinson, H; Gao, YG; McCrary, BS; Edmondson, SP; Shriver, JW; Wang, AHJ			The hyperthermophile chromosomal protein Sac7d sharply kinks DNA	NATURE			English	Article							COLD-SHOCK PROTEIN; CRYSTAL-STRUCTURE; SULFOLOBUS-ACIDOCALDARIUS; BINDING PROPERTIES; MINOR-GROOVE; ARCHAEA; SOLFATARICUS; COMPLEX; HISTONE; SYSTEM	The proteins Sac7d and Sso7d belong to a class of small chromosomal proteins from the hyperthermophilic archaeon Sulfolobus acidocaldarius and S. solfactaricus, respectively(1,2). These proteins are extremely stable to heat, acid and chemical agents', Sac7d binds to DNA without any particular sequence preference and thereby increases its melting temperature by similar to 40 degrees C (ref. 4). We have now solved and refined the crystal structure of Sac7d in complex with two DNA sequences to high resolution, The structures are examples of a nonspecific DNA-binding protein bound to DNA, and reveal that Sac7d binds in the minor groove, causing a sharp kinking of the DNA helix that is more marked than that induced by an): sequence-specific DNA-binding proteins, The kink results from the intercalation of specific hydrophobic side chains of Sac7d into the DNA structure, but without causing any significant distortion of the protein structure relative to the uncomplexed protein in solution.	Univ Illinois, Dept Cell & Struct Biol, Urbana, IL 61801 USA; So Illinois Univ, Sch Med, Dept Med Biochem, Carbondale, IL 62901 USA	University of Illinois System; University of Illinois Urbana-Champaign; Southern Illinois University System; Southern Illinois University	Wang, AHJ (corresponding author), Univ Illinois, Dept Cell & Struct Biol, Urbana, IL 61801 USA.							BAUMANN H, 1994, NAT STRUCT BIOL, V1, P808, DOI 10.1038/nsb1194-808; BAUMANN H, 1995, J MOL BIOL, V247, P840, DOI 10.1006/jmbi.1995.0184; Brunger A. T, 1992, XPLOR 3 1 SYSTEM XRA; CHOLI T, 1988, J BIOL CHEM, V263, P7087; DEHASETH PL, 1977, BIOCHEMISTRY-US, V16, P4783, DOI 10.1021/bi00641a004; Dijk J., 1986, BACTERIAL CHROMATIN, P185; EDMONDSON SP, 1995, BIOCHEMISTRY-US, V34, P13289, DOI 10.1021/bi00041a004; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; Grayling RA, 1996, FEMS MICROBIOL REV, V18, P203; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MCAFEE JG, 1995, BIOCHEMISTRY-US, V34, P10063, DOI 10.1021/bi00031a031; McAfee JG, 1996, BIOCHEMISTRY-US, V35, P4034, DOI 10.1021/bi952555q; McCrary BS, 1996, J MOL BIOL, V264, P784, DOI 10.1006/jmbi.1996.0677; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; Parkinson G, 1996, ACTA CRYSTALLOGR D, V52, P57, DOI 10.1107/S0907444995011115; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; RONIMUS RS, 1995, FEMS MICROBIOL LETT, V134, P79; SCHINDELIN H, 1994, P NATL ACAD SCI USA, V91, P5119, DOI 10.1073/pnas.91.11.5119; SCHINDELIN H, 1993, NATURE, V364, P164, DOI 10.1038/364164a0; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; Starich MR, 1996, J MOL BIOL, V255, P187, DOI 10.1006/jmbi.1996.0016; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407	27	157	169	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 12	1998	392	6672					202	205		10.1038/32455	http://dx.doi.org/10.1038/32455			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB349	9515968				2022-12-28	WOS:000072462700068
J	Holt, PG; Sly, PD; Smith, W				Holt, PG; Sly, PD; Smith, W			Sublingual immunotherapy for allergic respiratory disease	LANCET			English	Editorial Material									TVWT Inst Child Hlth Res, W Perth, WA 6872, Australia		Holt, PG (corresponding author), TVWT Inst Child Hlth Res, W Perth, WA 6872, Australia.		Sly, Peter D/F-1486-2010; Holt, Patrick G/H-1548-2011	Sly, Peter D/0000-0001-6305-2201; Holt, Patrick G/0000-0003-1193-0935				Barnes PJ, 1996, AM J RESP CRIT CARE, V154, P1227, DOI 10.1164/ajrccm.154.5.8912730; *BRIT SOC ALL CLIN, 1993, CLIN EXP ALLERGY  S3, V23, P1; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; Hamid QA, 1997, J ALLERGY CLIN IMMUN, V99, P254, DOI 10.1016/S0091-6749(97)70106-4; HOLT PG, 1994, IMMUNOL TODAY, V15, P484, DOI 10.1016/0167-5699(94)90194-5; HOLT PG, 1988, CLIN ALLERGY, V18, P229, DOI 10.1111/j.1365-2222.1988.tb02864.x; MOSBECH H, 1988, ALLERGY, V43, P523, DOI 10.1111/j.1398-9995.1988.tb01631.x; Weiner HL, 1997, IMMUNOL TODAY, V18, P335, DOI 10.1016/S0167-5699(97)01053-0	9	10	10	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 28	1998	351	9103					613	614		10.1016/S0140-6736(05)78425-7	http://dx.doi.org/10.1016/S0140-6736(05)78425-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA447	9500315				2022-12-28	WOS:000072364200005
J	Lee, JO; Russo, AA; Pavletich, NP				Lee, JO; Russo, AA; Pavletich, NP			Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7	NATURE			English	Article							ONCOGENIC POINT MUTATIONS; LARGE T-ANTIGEN; GENE-PRODUCT; CELL-CYCLE; INCOMPLETE PENETRANCE; SUSCEPTIBILITY GENE; COMPLEX-FORMATION; ADENOVIRUS E1A; RB GENE; PROTEIN	The pocket domain of the retinoblastoma (Rb) tumour suppressor is central to Rb function, and is frequently inactivated by the binding of the human papilloma virus E7 oncoprotein in cervical cancer. The crystal structure of the Rb pocket bound to a nine-residue E7 peptide containing the LxCxE motif, shared by other Rb-binding viral and cellular proteins, shows that the LxCxE peptide binds a highly conserved groove on the B-box portion of the pocket; the A-box portion appears to be required for the stable folding of the B box. Also highly consented is the extensive A-B interface, suggesting that it may be an additional protein-binding site. The A and B boxes each contain the cyclin-fold structural motif, with the LxCxE-binding site on the B-box cyclin fold being similar to a Cdk2-binding site of cyclin A and to a TBP-binding site of TFIIB.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Pavletich, NP (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave, New York, NY 10021 USA.	Nikola@xray2.mskcc.org	Lee, Jie-Oh/AAG-4302-2020; Lee, Jie-Oh/C-1581-2011	Lee, Jie-Oh/0000-0001-6519-6049				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BRUNGER AT, 1991, XPLOR SYSTEM CRYSTAL; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; Chow KNB, 1996, MOL CELL BIOL, V16, P4862; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; FATTAEY AR, 1993, MOL CELL BIOL, V13, P7267, DOI 10.1128/MCB.13.12.7267; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GIBSON TJ, 1994, NUCLEIC ACIDS RES, V22, P946, DOI 10.1093/nar/22.6.946; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; Grafi G, 1996, P NATL ACAD SCI USA, V93, P8962, DOI 10.1073/pnas.93.17.8962; Gulliver GA, 1997, J VIROL, V71, P5905, DOI 10.1128/JVI.71.8.5905-5914.1997; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Herber R, 1996, J VIROL, V70, P1873, DOI 10.1128/JVI.70.3.1873-1881.1996; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; JONES RE, 1990, J BIOL CHEM, V265, P12782; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; Kim HY, 1997, NAT STRUCT BIOL, V4, P390, DOI 10.1038/nsb0597-390; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; KRATZKE RA, 1994, ONCOGENE, V9, P1321; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; OCONNOR RJ, 1994, J VIROL, V68, P6848, DOI 10.1128/JVI.68.11.6848-6862.1994; ONADIM Z, 1992, P NATL ACAD SCI USA, V89, P6177, DOI 10.1073/pnas.89.13.6177; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Shan B, 1996, P NATL ACAD SCI USA, V93, P679, DOI 10.1073/pnas.93.2.679; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WU EW, 1993, J VIROL, V67, P2402, DOI 10.1128/JVI.67.4.2402-2407.1993; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	48	351	364	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 26	1998	391	6670					859	865		10.1038/36038	http://dx.doi.org/10.1038/36038			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ206	9495340				2022-12-28	WOS:000072230900042
J	Martin, JN; Ganem, DE; Osmond, DH; Page-Shafer, KA; Macrae, D; Kedes, DH				Martin, JN; Ganem, DE; Osmond, DH; Page-Shafer, KA; Macrae, D; Kedes, DH			Sexual transmission and the natural history of human herpesvirus 8 infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SARCOMA-ASSOCIATED HERPESVIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; FRANCISCO MENS HEALTH; KAPOSIS-SARCOMA; DNA-SEQUENCES; REGRESSION MODELS; ANTIBODIES; AIDS; RISK; SEROCONVERSION	Background Although human herpesvirus 8 (HHV-8) has been suspected to be the etiologic agent of Kaposi's sarcoma, little is known about its seroprevalence in the population, its modes of transmission, and its natural history. Methods The San Francisco Men's Wealth Study, begun in 1984, is a study of a population-based sample of men in an area with a high incidence of human immunodeficiency virus (HIV) infection. We studied all 400 men infected at base line with HIV and a sample of 400 uninfected men, Base-line serum samples were assayed for antibodies to HHV-8 latency-associated nuclear antigen (anti-LANA). In addition to the seroprevalence and risk factors for anti-LANA seropositivity, we analyzed the time to the development of Kaposi's sarcoma. Results Anti-LANA antibodies were: found in 223 of 593 men (37.6 percent) who reported any homosexual activity in the previous five years and in none of 195 exclusively heterosexual men, Anti-LANA seropositivity correlated with a history of sexually transmitted diseases and had a linear association with the number of male sexual-intercourse partners. Among the men who were infected with both HIV and HHV-8 at base line, the 10-year probability of Kaposi's sarcoma was 49.6 percent, Base-line anti-LANA seropositivity preceded and was independently associated with subsequent Kaposi's sarcoma, even after adjustment; for CD4 cell counts and the number of homosexual partners. Conclusions The prevalence of HHV-8 infection is high among homosexual men, correlates with the number of homosexual partners, and is temporally and independently associated with Kaposi's sarcoma, These observations are further evidence that HHV-8 has an etiologic Pole in Kaposi's sarcoma and is sexually transmitted among men. (C) 1998 Massachusetts Medical Society.	Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; San Francisco Gen Hosp, Ctr Aids Prevent Studies, San Francisco, CA 94110 USA; San Francisco Gen Hosp, Dept Epidemiol & Biostat, San Francisco, CA 94110 USA; San Francisco Gen Hosp, Dept Med, AIDS Program, San Francisco, CA 94110 USA; San Francisco Gen Hosp, Dept Med, Div Infect Dis, San Francisco, CA 94110 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; San Francisco General Hospital Medical Center; San Francisco General Hospital Medical Center; San Francisco General Hospital Medical Center; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Kedes, DH (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, Box 0414, San Francisco, CA 94143 USA.			Page, Kimberly/0000-0002-7120-1673	NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH019105] Funding Source: NIH RePORTER; NIMH NIH HHS [T32 MH-19105] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AMBROZIAK JA, 1995, SCIENCE, V268, P582, DOI 10.1126/science.7725108; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, ARCH INTERN MED, V156, P202, DOI 10.1001/archinte.156.2.202; Chuck S, 1996, J INFECT DIS, V173, P248, DOI 10.1093/infdis/173.1.248; COX DR, 1972, J R STAT SOC B, V34, P187; Davis DA, 1997, J INFECT DIS, V175, P1071, DOI 10.1086/516444; DREW WL, 1982, LANCET, V2, P125; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; Gao SJ, 1996, NEW ENGL J MED, V335, P233, DOI 10.1056/NEJM199607253350403; HUANG YQ, 1992, LANCET, V339, P515, DOI 10.1016/0140-6736(92)90338-4; HUANG YQ, 1995, LANCET, V345, P759, DOI 10.1016/S0140-6736(95)90641-X; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kedes DH, 1997, JAMA-J AM MED ASSOC, V277, P478, DOI 10.1001/jama.277.6.478; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; Kleinbaum DG, 1996, SURVIVAL ANAL; LANG W, 1987, JAMA-J AM MED ASSOC, V257, P326, DOI 10.1001/jama.257.3.326; Lefrere JJ, 1996, J INFECT DIS, V174, P283, DOI 10.1093/infdis/174.2.283; LEMESHOW S, 1982, AM J EPIDEMIOL, V115, P92, DOI 10.1093/oxfordjournals.aje.a113284; Lennette ET, 1996, LANCET, V348, P858, DOI 10.1016/S0140-6736(96)03240-0; Lin SF, 1997, J VIROL, V71, P3069, DOI 10.1128/JVI.71.4.3069-3076.1997; Martin JN, 1996, NEW ENGL J MED, V335, P819, DOI 10.1056/NEJM199609123351112; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; PIAZZA T, 1986, TECHNICAL REPORT NAT; *SAS I, 1996, SAS VERS 6 11; Simpson GR, 1996, LANCET, V348, P1133, DOI 10.1016/S0140-6736(96)07560-5; Smith MS, 1997, J INFECT DIS, V176, P84, DOI 10.1086/514043; *STAT CORP, 1997, STAT VERS 5 0; *STAT CORP, 1997, SURV EST REF MAN VER, P400; WANG RYH, 1993, CLIN INFECT DIS, V17, P724, DOI 10.1093/clinids/17.4.724; WHITBY D, 1995, LANCET, V346, P799, DOI 10.1016/S0140-6736(95)91619-9; WINKELSTEIN W, 1987, JAMA-J AM MED ASSOC, V257, P321, DOI 10.1001/jama.257.3.321; Wolter K. M., 1985, INTRO VARIANCE ESTIM	33	519	543	0	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 2	1998	338	14					948	954		10.1056/NEJM199804023381403	http://dx.doi.org/10.1056/NEJM199804023381403			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE776	9521982				2022-12-28	WOS:000072829800003
J	Meigs, JB; Nathan, DM; Wilson, PWF; Cupples, LA; Singer, DE				Meigs, JB; Nathan, DM; Wilson, PWF; Cupples, LA; Singer, DE			Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance - The Framingham Offspring Study	ANNALS OF INTERNAL MEDICINE			English	Article						glucose intolerance; diabetes mellitus, non-insulin-dependent; cardiovascular diseases; risk factors; insulin resistance	CORONARY HEART-DISEASE; UNITED-STATES POPULATION; DENSITY-LIPOPROTEIN CHOLESTEROL; CARDIOVASCULAR-DISEASE; INSULIN-RESISTANCE; PIMA-INDIANS; ASYMPTOMATIC HYPERGLYCEMIA; PRECIPITATION PROCEDURE; DIAGNOSTIC-CRITERIA; ORIGINAL COHORT	Background: Categorical definitions for glucose intolerance imply that risk thresholds exist, but metabolic risk for type 2 diabetes mellitus or cardiovascular disease may increase continuously as glucose intolerance increases. Objective: To examine the distributions of the following meta belie risk factors across the spectrum of glucose tolerance: overall and central obesity, hypertension, low levels of high-density lipoprotein cholesterol, and increased triglyceride and insulin levels. Design: Cross-sectional analysis. Setting: The community-based Framingham Offspring Study. Participants: 2583 adults without previously diagnosed diabetes. Measurements: Clinical data; fasting glucose, insulin, and lipid levels; and glucose and insulin levels taken 2 hours after oral challenge were collected from 1991 to 1993. Glucose tolerance was determined by 1980 World Health Organization criteria. Patients with normal glucose tolerance were categorized into quintiles of fasting glucose. The distributions of each metabolic risk factor and the metabolic sum of the six risk factors were assessed across seven categories from the lowest quintile of normal fasting glucose level through impaired glucose tolerance and previously undiagnosed diabetes. Results: The mean age of patients was 54 years (range, 26 to 82 years); 52.7% of patients were women. Glucose tolerance testing found that 12.7% of patients had impaired glucose tolerance and 4.8% had previously undiagnosed diabetes. Multivariable-adjusted mean measures of risk factors and odds ratios for obesity, elevated waist-to-hip ratio, hypertension, low levels of high-density lipoprotein cholesterol, elevated triglyceride levels, and hyperinsulinemia showed continuous increases across the spectrum of nondiabetic glucose tolerance. Although a threshold effect near the upper range of nondiabetic glucose tolerance could not be ruled out for triglyceride levels in men and for insulin levels Z hours after oral challenge in men and women, no other metabolic risk factors showed clear evidence of thresholds for increased risk. Conclusions: Metabolic risk factors for type 2 diabetes mellitus and for cardiovascular disease worsen continuously across the spectrum of glucose tolerance categories, beginning in the lowest quintiles of normal fasting glucose level.	Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA; Boston Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Boston, MA 02118 USA; Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA; Boston Univ, Sch Med, Boston, MA 02118 USA; NHLBI, Framingham, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Boston University; Harvard University; Massachusetts General Hospital; Boston University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Meigs, JB (corresponding author), Massachusetts Gen Hosp, Div Gen Med, Staniford 50-9, Boston, MA 02114 USA.	jmeigs@sol.mgh.harvard.edu	Meigs, James/P-3927-2019	Meigs, James/0000-0002-2439-2657; Cupples, L. Adrienne/0000-0003-0273-7965	NHLBI NIH HHS [N01-HC-38083] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON RL, 1995, AM J EPIDEMIOL, V142, P724, DOI 10.1093/aje/142.7.724; BARRETTCONNOR E, 1984, J CHRON DIS, V37, P773, DOI 10.1016/0021-9681(84)90046-8; BURCHFIEL CM, 1990, AM J EPIDEMIOL, V131, P57, DOI 10.1093/oxfordjournals.aje.a115485; Curb JD, 1996, JAMA-J AM MED ASSOC, V276, P1886, DOI 10.1001/jama.276.23.1886; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; DONAHUE RP, 1987, DIABETES, V36, P689, DOI 10.2337/diabetes.36.6.689; Eastman RC, 1997, DIABETES CARE, V20, P127, DOI 10.2337/diacare.20.2.127; Eastman RC, 1997, DIABETES CARE, V20, P735, DOI 10.2337/diacare.20.5.735; Edelstein SL, 1997, DIABETES, V46, P701, DOI 10.2337/diabetes.46.4.701; EVERHART JE, 1985, NIH PUBLICATION; FESKENS EJM, 1992, J CLIN EPIDEMIOL, V45, P1327, DOI 10.1016/0895-4356(92)90173-K; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; FUJIMOTO WY, 1987, DIABETES, V36, P730, DOI 10.2337/diabetes.36.6.730; FULLER JH, 1980, LANCET, V1, P1373; Gavin JR, 1997, DIABETES CARE, V20, P1183; Gerstein HC, 1996, LANCET, V347, P949, DOI 10.1016/S0140-6736(96)91420-8; GIDEZ LI, 1982, J LIPID RES, V23, P1206; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; HAFFNER SM, 1992, DIABETES, V41, P715, DOI 10.2337/diabetes.41.6.715; HARRIS M, 1979, DIABETES, V28, P1039; HARRIS MI, 1989, DIABETES CARE, V12, P464, DOI 10.2337/diacare.12.7.464; HARRIS MI, 1987, DIABETES, V36, P523, DOI 10.2337/diabetes.36.4.523; HOSMER DW, 1989, APPL LOGISTIC REGRES; Jarrett R J, 1984, Diabet Med, V1, P279; JARRETT RJ, 1982, DIABETOLOGIA, V22, P79, DOI 10.1007/BF00254833; JARRETT RJ, 1987, DIABETIC MED, V4, P544, DOI 10.1111/j.1464-5491.1987.tb00927.x; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; KANNEL WB, 1979, ARCH INTERN MED, V139, P857, DOI 10.1001/archinte.139.8.857; KEEN H, 1982, DIABETOLOGIA, V22, P73, DOI 10.1007/BF00254832; KNOWLER WC, 1981, AM J EPIDEMIOL, V113, P144, DOI 10.1093/oxfordjournals.aje.a113079; LAAKSO M, 1993, AM J EPIDEMIOL, V137, P959, DOI 10.1093/oxfordjournals.aje.a116768; LAAKSO M, 1989, ARTERIOSCLEROSIS, V9, P665, DOI 10.1161/01.ATV.9.5.665; MCNAMARA JR, 1987, CLIN CHIM ACTA, V166, P1, DOI 10.1016/0009-8981(87)90188-4; Meigs JB, 1996, J CLIN EPIDEMIOL, V49, P411, DOI 10.1016/0895-4356(95)00513-7; MITCHELL BD, 1990, AM J EPIDEMIOL, V131, P423, DOI 10.1093/oxfordjournals.aje.a115517; MITRAKOU A, 1992, NEW ENGL J MED, V326, P22, DOI 10.1056/NEJM199201023260104; Mooy JM, 1996, DIABETOLOGIA, V39, P298, DOI 10.1007/BF00418345; MYKKANEN L, 1992, DIABETES CARE, V15, P1020, DOI 10.2337/diacare.15.8.1020; NATHAN DM, 1981, CLIN CHEM, V27, P1261; NATHAN DM, 1984, NEW ENGL J MED, V310, P341, DOI 10.1056/NEJM198402093100602; Nathan DM, 1997, LANCET S1, V350, pSI4, DOI DOI 10.1016/S0140-6736(97)90021-0; OLEFSKY JM, 1974, DIABETES, V23, P449, DOI 10.2337/diab.23.5.449; OSULLIVAN JB, 1964, DIABETES, V13, P278; Pyorala K, 1997, DIABETES CARE, V20, P614, DOI 10.2337/diacare.20.4.614; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; REWERS M, 1992, AM J EPIDEMIOL, V135, P1321, DOI 10.1093/oxfordjournals.aje.a116243; RICCARDI G, 1985, AM J EPIDEMIOL, V121, P422, DOI 10.1093/oxfordjournals.aje.a114014; Rodriguez BL, 1996, DIABETES CARE, V19, P587, DOI 10.2337/diacare.19.6.587; SAAD MF, 1988, BRIT MED J, V297, P1438, DOI 10.1136/bmj.297.6661.1438; SAAD MF, 1991, NEW ENGL J MED, V324, P733, DOI 10.1056/NEJM199103143241105; SAAD MF, 1988, NEW ENGL J MED, V319, P1500, DOI 10.1056/NEJM198812083192302; *SAS I, 1989, SAS STAT US GUID VER; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SINGER DE, 1992, DIABETES, V41, P202, DOI 10.2337/diabetes.41.2.202; STAMLER J, 1993, ARCH INTERN MED, V153, P598, DOI 10.1001/archinte.153.5.598; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; STERN MP, 1993, DIABETES CARE, V16, P978, DOI 10.2337/diacare.16.7.978; STERN MP, 1985, ARTERIOSCLEROSIS, V5, P311, DOI 10.1161/01.ATV.5.4.311; Stokes 3rd J, 1989, HYPERTENSION S1, V13, pI13; United Kingdom Prospective Diabetes Study (UKPDS), 1995, BMJ-BRIT MED J, V310, P83, DOI DOI 10.1136/BMJ.310.6972.83; *US PREV SERV TASK, 1996, GUID LIN PREV SERV; WARNICK GR, 1982, CLIN CHEM, V28, P1379; WILLETT WC, 1995, JAMA-J AM MED ASSOC, V273, P461, DOI 10.1001/jama.273.6.461; WILSON PW, 1981, AM J EPIDEMIOL, V114, P697, DOI 10.1093/oxfordjournals.aje.a113240; WINGARD DL, 1987, AM J EPIDEMIOL, V125, P948, DOI 10.1093/oxfordjournals.aje.a114633; World Health Organisation, 1980, WHO EXP COMM DIAB ME; YUDKIN JS, 1990, BRIT MED J, V301, P397, DOI 10.1136/bmj.301.6749.397; 1985, ANN INTERN MED 2, V103, P1073	68	149	154	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1998	128	7					524	+		10.7326/0003-4819-128-7-199804010-00002	http://dx.doi.org/10.7326/0003-4819-128-7-199804010-00002			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE539	9518396				2022-12-28	WOS:000072803500002
J	Ciufolini, I; Pavlis, E; Chieppa, F; Fernandes-Vieira, E; Perez-Mercader, J				Ciufolini, I; Pavlis, E; Chieppa, F; Fernandes-Vieira, E; Perez-Mercader, J			Test of general relativity and measurement of the lense-thirring effect with two Earth satellites	SCIENCE			English	Article							LAGEOS; DRAG	The Lense-Thirring effect, a tiny perturbation of the orbit of a particle caused by the spin of the attracting body, was accurately measured with the use of the data of two laser-ranged satellites, LAGEOS and LAGEOS II, and the Earth gravitational model EGM-96. The parameter mu, which measures the strength of the Lense-Thirring effect, was found to be 1.1 +/- 0.2; general relativity predicts mu = 1. This result represents an accurate test and measurement of one of the fundamental predictions of general relativity, that the spin of a body changes the geometry of the universe by generating space-time curvature.	Univ Rome La Sapienza, CNR, Ist Fis Spazio Interplanetario, I-00184 Rome, Italy; Univ Rome La Sapienza, Dipartimento Aerosp, I-00184 Rome, Italy; Univ Maryland Baltimore Cty, Joint Ctr Earth Syst Technol, Baltimore, MD 21250 USA; Univ Rome La Sapienza, Scuola Ingn Aerosp, Rome, Italy; CSIC, INTA, Lab Astrofis Espacial & Fis Fundamental, Madrid, Spain	Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale Astrofisica (INAF); Sapienza University Rome; Sapienza University Rome; University System of Maryland; University of Maryland Baltimore County; Sapienza University Rome; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Astrobiologia (INTA)	Ciufolini, I (corresponding author), Univ Rome La Sapienza, CNR, Ist Fis Spazio Interplanetario, Via Eudossiana 16, I-00184 Rome, Italy.		Ciufolini, Ignazio/AAX-6592-2021; Pavlis, Erricos C./AAF-4151-2019	Pavlis, Erricos C./0000-0002-9726-7064; ciufolini, ignazio/0000-0001-9166-7916				BENDER P, 1979, P 2 INT S US ART SAT, P145; CIUFOLINI I, 1986, PHYS REV LETT, V56, P278, DOI 10.1103/PhysRevLett.56.278; Ciufolini I, 1996, NUOVO CIMENTO A, V109, P1709, DOI 10.1007/BF02773551; CIUFOLINI I, 1989, INT J MOD PHYS A, V4, P3083, DOI 10.1142/S0217751X89001266; Ciufolini I, 1997, CLASSICAL QUANT GRAV, V14, P2701, DOI 10.1088/0264-9381/14/10/003; CLUFOLINI I, 1995, GRAVITATION INERTIA; CLUFOLINI I, 1996, NUOVO CIMENTO A, V109, P579; COHEN SC, 1985, J GEOPHYS RES-SOLID, V90, P9215, DOI 10.1029/JB090iB11p09215; Cui W, 1998, ASTROPHYS J, V492, pL53, DOI 10.1086/311092; DEGNAN JJ, 1994, GPS WORLD, V5, P62; Farinella P, 1996, J GEOPHYS RES-SOL EA, V101, P17861, DOI 10.1029/96JB00108; Gross RS, 1996, J GEOPHYS RES-SOL EA, V101, P8729, DOI 10.1029/96JB00113; LEMOINE FG, 1997, 1997 I ASTR GEOPH SC; Lense J., 1918, PHYZ, V19, P156; Martin CF, 1996, J GEOPHYS RES-SOL EA, V101, P3215, DOI 10.1029/95JB02810; MASHHOON B, 1984, GEN RELAT GRAVIT, V16, P711, DOI 10.1007/BF00762913; MCCARTHY D, 1996, 1996 IERS CONV OBS P; Misner C. W., 1973, GRAVITATION; NORDTVEDT K, 1988, INT J THEOR PHYS, V27, P1395, DOI 10.1007/BF00671317; Nordtvedt K, 1996, PHYS TODAY, V49, P26, DOI 10.1063/1.881496; *OBS PAR, 1997, INT EARTH ROT SERV A; PAVLIS DE, 1997, GEODYN 2 OPERATIONS, V3; RUBINCAM DP, 1995, J GEOPHYS RES-SOL EA, V100, P20285, DOI 10.1029/95JB02278; RUBINCAM DP, 1990, J GEOPHYS RES-SOLID, V95, P4881, DOI 10.1029/JB095iB04p04881; RUBINCAM DP, 1988, J GEOPHYS RES, V93, P13803; TAPLEY B, 1989, NASA ASI STUDY LAG B, V3; TAPLEY B, 1989, NASA ASI STUDY LAG A, V3; Thorne K.S., 1986, BLACK HOLES MEMBRANE	28	176	177	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 27	1998	279	5359					2100	2103		10.1126/science.279.5359.2100	http://dx.doi.org/10.1126/science.279.5359.2100			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZE274	9516109				2022-12-28	WOS:000072775600045
J	Agid, Y; Chase, T; Marsden, D				Agid, Y; Chase, T; Marsden, D			Adverse reactions to levodopa: drug toxicity or progression of disease?	LANCET			English	Editorial Material							DOPA		Hop La Pitie Salpetriere, INSERM, U289, F-75013 Paris, France; Hop La Pitie Salpetriere, Federat Neurol, F-75013 Paris, France; UCL Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England; NINDS, Bethesda, MD 20892 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Agid, Y (corresponding author), Hop La Pitie Salpetriere, INSERM, U289, F-75013 Paris, France.							BONNET AM, 1987, NEUROLOGY, V37, P1539, DOI 10.1212/WNL.37.9.1539; DIAMOND SG, 1987, ANN NEUROL, V22, P8, DOI 10.1002/ana.410220105; Dziewczapolski G, 1997, NEUROREPORT, V8, P975, DOI 10.1097/00001756-199703030-00031; Fahn S, 1996, NEUROLOGY, V47, pS184, DOI 10.1212/WNL.47.6_Suppl_3.184S; Han SK, 1996, J NEUROCHEM, V66, P501; MARSDEN CD, 1980, CURRENT PROGR PROBLE, P241; Mena MA, 1996, NEUROREPORT, V7, P441, DOI 10.1097/00001756-199601310-00016; MOURADIAN MM, 1994, MOVEMENT DISORD, V3, P181; YAHR MD, 1972, NEUROLOGY, V22, P56, DOI 10.1212/WNL.22.5_Part_2.56	9	32	33	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 21	1998	351	9106					851	852		10.1016/S0140-6736(05)70285-3	http://dx.doi.org/10.1016/S0140-6736(05)70285-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD047	9525359				2022-12-28	WOS:000072645500007
J	Moller, JT; Cluitmans, P; Rasmussen, LS; Houx, P; Rasmussen, H; Canet, J; Rabbitt, P; Jolles, J; Larsen, K; Hanning, CD; Langeron, O; Johnson, T; Lauven, PM; Kristensen, PA; Biedler, A; van Beem, H; Fraidakis, O; Silverstein, JH; Beneken, JEW; Gravenstein, JS				Moller, JT; Cluitmans, P; Rasmussen, LS; Houx, P; Rasmussen, H; Canet, J; Rabbitt, P; Jolles, J; Larsen, K; Hanning, CD; Langeron, O; Johnson, T; Lauven, PM; Kristensen, PA; Biedler, A; van Beem, H; Fraidakis, O; Silverstein, JH; Beneken, JEW; Gravenstein, JS		ISPOCD Investigators	Long-term postoperative cognitive dysfunction in the elderly: ISPOCD1 study	LANCET			English	Article							PULSE OXIMETRY; RANDOMIZED EVALUATION; REGIONAL ANESTHESIA; PERFORMANCE; HYPOXEMIA; SURGERY; HEALTH; AGE	Background Long-term postoperative cognitive dysfunction may occur in the elderly. Age may be a risk factor and hypoxaemia and arterial hypotension causative factors. We investigated these hypotheses in an international multicentre study. Methods 1218 patients aged at least 60 years completed neuropsychological tests before and 1 week and 3 months after major non-cardiac surgery. We measured oxygen saturation by continuous pulse oximetry before surgery and throughout the day of and the first 3 nights after surgery. We recorded blood pressure every 3 min by oscillometry during the operation and every 15-30 min for the rest of that day and night. We identified postoperative cognitive dysfunction with neuropsychological tests compared with controls recruited from the UK (n=176) and the same countries as study centres (n=145). Findings Postoperative cognitive dysfunction was present in 266 (25.8% [95% CI 23.1-28.5]) of patients 1 week after surgery and in 94 (9.9% [8.1-12.0]) 3 months after surgery, compared with 3.4% and 2.8%, respectively, of UK controls (p<0.0001 and p=0.0037, respectively). Increasing age and duration of anaesthesia, little education, a second operation, postoperative infections, and respiratory complications were risk factors for early postoperative cognitive dysfunction, but only age was a risk factor for tale postoperative cognitive dysfunction. Hypoxaemia and hypotension were not significant risk factors at any time. Interpretation Our findings have implications for studies of the causes of cognitive decline and, in clinical practice, for the information given to patients before surgery.	Univ Copenhagen Hosp, Dept Anaesthesia & Intens Care, Rigshosp, Sect 4132, DK-2100 Copenhagen, Denmark; Eindhoven Univ Technol, Eindhoven, Netherlands; Rijks Univ Limburg, Maastricht, Netherlands; Univ Copenhagen, Herlev Hosp, DK-2730 Herlev, Denmark; Hosp Univ Germans Trias & PUjol, Barcelona, Spain; Univ Manchester, Age & Cognit Performance Res Ctr, Manchester M13 9PL, Lancs, England; Univ Copenhagen, Copenhagen, Denmark; Leicester Gen Hosp, Leicester LE5 4PW, Leics, England; Grp Hosp Pitie Salpetriere, F-75634 Paris, France; Hope Hosp, Salford M6 8HD, Lancs, England; Stadt Kliniken Mitte, Bielefeld, Germany; Cent Hosp Hillerod, Hillerod, Denmark; Univ Kliniken Saarlandes, Homburg, Germany; Univ Nijmegen Hosp, NL-6500 HB Nijmegen, Netherlands; Univ Hosp, Iraklion, Greece; Bronx VAMC, Mt Sinai Sch Med, New York, NY USA; Univ Florida, Gainesville, FL USA	Rigshospitalet; University of Copenhagen; Eindhoven University of Technology; Maastricht University; University of Copenhagen; Herlev & Gentofte Hospital; Hospital Germans Trias i Pujol; University of Manchester; University of Copenhagen; University Hospitals of Leicester NHS Trust; Leicester General Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Universitatsklinikum des Saarlandes; Radboud University Nijmegen; University of Patras; Icahn School of Medicine at Mount Sinai; State University System of Florida; University of Florida	Moller, JT (corresponding author), Univ Copenhagen Hosp, Dept Anaesthesia & Intens Care, Rigshosp, Sect 4132, DK-2100 Copenhagen, Denmark.		Sneyd, John/AFV-7886-2022; Sneyd, John Robert/B-2957-2012; Sneyd, John/AFV-7887-2022	Sneyd, John/0000-0003-3546-9856; Sneyd, John Robert/0000-0003-3546-9856; Sneyd, John/0000-0003-3546-9856; Rasmussen, Lars/0000-0002-7480-3004				BEDFORD PD, 1955, LANCET, V2, P259; BOHNEN N, 1992, ACTA NEUROL SCAND, V85, P116, DOI 10.1111/j.1600-0404.1992.tb04009.x; BRAND N, 1985, J GEN PSYCHOL, V112, P201, DOI 10.1080/00221309.1985.9711004; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; CAMPBELL DNC, 1993, ANAESTHESIA, V48, P422, DOI 10.1111/j.1365-2044.1993.tb07019.x; Cattell R.B., 1960, INDIVIDUAL GROUP CUL; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GHONEIM MM, 1988, ANESTHESIOLOGY, V69, P507, DOI 10.1097/00000542-198810000-00010; GUSTAFSON Y, 1988, J AM GERIATR SOC, V36, P525, DOI 10.1111/j.1532-5415.1988.tb04023.x; HOUX PJ, 1991, BRAIN COGNITION, V15, P246, DOI 10.1016/0278-2626(91)90029-8; HOUX PJ, 1993, PERCEPT MOTOR SKILL, V76, P195, DOI 10.2466/pms.1993.76.1.195; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; McKhann GM, 1997, LANCET, V349, P1282, DOI 10.1016/S0140-6736(96)09466-4; MOLLER JT, 1993, BRIT J ANAESTH, V71, P340, DOI 10.1093/bja/71.3.340; MOLLER JT, 1993, ANESTHESIOLOGY, V78, P445, DOI 10.1097/00000542-199303000-00007; MOLLER JT, 1993, ANESTHESIOLOGY, V78, P436, DOI 10.1097/00000542-199303000-00006; MOLLER JT, 1992, BRIT J ANAESTH, V68, P146, DOI 10.1093/bja/68.2.146; NEWMAN S, 1989, J PSYCHOSOM RES, V33, P227, DOI 10.1016/0022-3999(89)90050-0; NIELSON WR, 1990, ANESTHESIOLOGY, V73, P1103, DOI 10.1097/00000542-199012000-00006; OKEEFE ST, 1994, BRIT J ANAESTH, V73, P673, DOI 10.1093/bja/73.5.673; RABBITT P, 1990, BRIT J PSYCHOL, V81, P1, DOI 10.1111/j.2044-8295.1990.tb02342.x; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; ROSENBERG J, 1994, EUR J SURG, V160, P137; SAVAGEAU JA, 1982, J THORAC CARDIOV SUR, V84, P595; SHAW PJ, 1987, Q J MED, V62, P259; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008; 1992, LANCET, V340, P580	27	1526	1747	6	136	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 21	1998	351	9106					857	861		10.1016/S0140-6736(97)07382-0	http://dx.doi.org/10.1016/S0140-6736(97)07382-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZD047	9525362	Green Submitted			2022-12-28	WOS:000072645500011
J	Tributsch, H; Pohlmann, L				Tributsch, H; Pohlmann, L			Electron transfer: Classical approaches and new frontiers	SCIENCE			English	Article							ENERGY-CONVERSION; ELECTROCATALYSTS; REDUCTION	Electron transfer, under conditions of weak interaction and a medium acting as a passive thermal bath, is very well understood. When electron transfer is accompanied by transient chemical bonding, such as in interfacial coordination electrochemical mechanisms, strong interaction and molecular selectivity are involved. These mechanisms, which take advantage of "passive self-organization," cannot yet be properly described theoretically, but they show substantial experimental promise for energy conversion and catalysis. The biggest challenge for the future, however, may be dynamic, self-organized electron transfer. As with other energy fluxes, a suitable positive feedback mechanism, through an active molecular environment, can lead to a (transient) decrease of entropy equivalent to an increase of molecular electronic order for the activated complex. A resulting substantial increase in the rate of electron transfer and the possibility of cooperative transfer of several electrons (without intermediates) can be deduced from phenomenological theory. The need to extend our present knowledge may be derived from the observation that chemical syntheses and fuel utilization in industry typically require high temperatures (where catalysis is less relevant), whereas corresponding processes in biological systems are catalyzed at environmental conditions. This article therefore focuses on interfacial or membrane-bound electron transfer and investigates an aspect that nature has developed to a high degree of perfection: self-organization.	Hahn Meitner Inst Kernforsch Berlin GmbH, Dept Solare Energet, D-14109 Berlin, Germany	Helmholtz Association; Helmholtz-Zentrum fuer Materialien und Energie GmbH (HZB)	Tributsch, H (corresponding author), Hahn Meitner Inst Kernforsch Berlin GmbH, Dept Solare Energet, Glienicker Str 100, D-14109 Berlin, Germany.							ALONSOVANTE N, 1991, J ELECTROCHEM SOC, V138, P639, DOI 10.1149/1.2085650; ALONSOVANTE N, 1994, FRONTIERS ELECTROCHE, P1; ALONSOVANTE N, 1986, NATURE, V323, P431; [Anonymous], 1967, PROG INORG CHEM, DOI DOI 10.1002/9780470166093.CH7; BIXON M, 1992, PHOTOSYNTHETIC BACTE, V2, P292; CREUTZ C, 1969, J AM CHEM SOC, V91, P3988, DOI 10.1021/ja01042a072; DOGONADZE RR, 1972, PHYS STATUS SOLIDI B, V54, P425, DOI 10.1002/pssb.2220540206; Gerischer H., 1961, ADVANCES ELECTROCHEM, V1, P139; Gerischer H, 1960, Z PHYS CHEM, V26, P223; Gladstone S., 1941, THEORY RATE PROCESSE; GLANSDORF P, 1971, THERMODYNAMICS STRUC; Hannappel T, 1997, J PHYS CHEM B, V101, P6799, DOI 10.1021/jp971581q; HUSH NS, 1958, J CHEM PHYS, V28, P962, DOI 10.1063/1.1744305; JAEGERMANN W, 1988, PROG SURF SCI, V29, P1, DOI 10.1016/0079-6816(88)90015-9; JORTNER J, 1980, BIOCHIM BIOPHYS ACTA, V594, P193, DOI 10.1016/0304-4173(80)90001-4; Kramers HA, 1940, PHYSICA, V7, P284, DOI 10.1016/S0031-8914(40)90098-2; KUEHNE HM, 1984, CHEM PHYS LETT, V112, P160; LEVICH VG, 1959, DOKL AKAD NAUK SSSR+, V124, P123; MARCUS HBG, 1997, J ELECTROANAL CHEM, V438, P1; MARCUS RA, 1956, J CHEM PHYS, V24, P966, DOI 10.1063/1.1742723; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MARCUS RA, 1956, J CHEM PHYS, V24, P979, DOI 10.1063/1.1742724; MARCUS RA, 1959, CAN J CHEM, V37, P155, DOI 10.1139/v59-022; MARCUS RA, 1963, J PHYS CHEM-US, V67, P853, DOI 10.1021/j100798a033; MARCUS RA, 1965, J CHEM PHYS, V43, P679, DOI 10.1063/1.1696792; NAEH T, 1990, SIAM J APPL MATH, V50, P595, DOI 10.1137/0150036; NEWTON MD, 1991, CHEM REV, V91, P767, DOI 10.1021/cr00005a007; Niki K, 1977, J ELECTROCHEM SOC, V124, P1889, DOI 10.1149/1.2133181; POHLMANN L, 1992, J THEOR BIOL, V155, P443, DOI 10.1016/S0022-5193(05)80629-0; POHLMANN L, 1992, J THEOR BIOL, V156, P63, DOI 10.1016/S0022-5193(05)80656-3; POHLMANN L, 1997, ELECTROCHIM ACTA, V42, P211; POLLAK E, 1989, J CHEM PHYS, V91, P4073, DOI 10.1063/1.456837; PROSERPIO DM, 1992, J AM CHEM SOC, V114, P4374, DOI 10.1021/ja00037a052; SEELIGER W, 1995, J ELECTROCHEM SOC, V142, P166; STEIGER B, 1994, INORG CHEM, V33, P5767, DOI 10.1021/ic00103a026; SUMI H, 1985, J PHYS CHEM-US, V84, P4894; TAUBE H, 1955, J AM CHEM SOC, V77, P4481, DOI 10.1021/ja01622a010; TAUBE H, 1954, J AM CHEM SOC, V76, P4035; TRIBUTSCH H, 1985, J PHOTOCHEM, V29, P89, DOI 10.1016/0047-2670(85)87063-5; TRIBUTSCH H, 1995, J ELECTROANAL CHEM, V396, P53, DOI 10.1016/0022-0728(95)04057-U; TRIBUTSCH H, 1994, SOL ENERG MAT SOL C, V31, P548, DOI 10.1016/0927-0248(94)90197-X; Ulstrup J., 1979, CHARGE TRANSFER PROC, DOI 10.1007/978-3-642-93116-1; ZUSMAN LD, 1980, CHEM PHYS, V49, P295, DOI 10.1016/0301-0104(80)85267-0	43	94	94	1	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 20	1998	279	5358					1891	1895		10.1126/science.279.5358.1891	http://dx.doi.org/10.1126/science.279.5358.1891			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506932				2022-12-28	WOS:000072613300035
J	Nicolaou, KC; Yang, Z; Shi, GQ; Gunzner, JL; Agrios, KA; Gartner, P				Nicolaou, KC; Yang, Z; Shi, GQ; Gunzner, JL; Agrios, KA; Gartner, P			Total synthesis of brevetoxin A	NATURE			English	Article							ORGANIC-SYNTHESIS; STEREOCONTROLLED SYNTHESIS; GENERATION STRATEGIES; CONSTRUCTION; SYSTEMS; ETHERS; BINDING; OXIDANT; TOXINS; CHAIN	Brevetoxin A is the most potent neurotoxin secreted by Gymnodinium breve Davis, a marine organism often associated with harmful algal blooms known as 'red tides'(1-3). The compound, whose mechanism of action involves binding to and opening of sodium channels(4-7), is sufficiently toxic to kill fish at concentrations of nanogams per mi (refs 3, 4) and, after accumulation in filter-feeding shellfish, to poison human consumers. The precise pathway by which nature constructs brevetoxin A is at present unknown(8,9), but strategies for its total synthesis have been contemplated for some time. The synthetic challenge posed by brevetoxin A reflects the high complexity of its molecular structure: 10 oxygen atoms and a chain of 44 carbon atoms are woven into a polycyclic macromolecule that includes 10 rings (containing between 5 and 9 atoms) and 22 stereogenic centres. Particularly challenging are the 7-, 8- and 9-membered rings which allow the molecule to undergo slow conformational changes and force a 90 degrees twist at one of its rings(1-6). Here we describe the successful incorporation of methods that were specifically developed for the construction of these rings(10,11) into an overall strategy for the total synthesis of brevetoxin A in its naturally occurring form. The convergent synthesis reported here renders this scarce neurotoxin synthetically available and, more importantly, allows the design and synthesis of analogues for further biochemical studies.	Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	Scripps Research Institute; Scripps Research Institute; University of California System; University of California San Diego	Nicolaou, KC (corresponding author), Scripps Res Inst, Dept Chem, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Yang, Zhen/GWQ-4960-2022; Yang, Zhen/J-6306-2015; Zanardi, Franca/L-6551-2017	Yang, Zhen/0000-0001-8036-934X; Gaertner, Peter/0000-0003-1569-5020; Zanardi, Franca/0000-0001-7451-781X				Anderson DM, 1997, NATURE, V388, P513, DOI 10.1038/41415; ANDERSON DM, 1992, OCEANUS, V35, P55; ANDERSON DM, 1994, SCI AM, V271, P62, DOI 10.1038/scientificamerican0894-62; ARHART RJ, 1972, J AM CHEM SOC, V94, P4997, DOI 10.1021/ja00769a035; Barker R, 1997, WATERS TURNED BLOOD; CHOU HN, 1987, J AM CHEM SOC, V109, P2184, DOI 10.1021/ja00241a048; Clayden J, 1996, ANGEW CHEM INT EDIT, V35, P241, DOI 10.1002/anie.199602411; COREY EJ, 1972, J AM CHEM SOC, V94, P7210, DOI 10.1021/ja00775a089; DESS DB, 1983, J ORG CHEM, V48, P4155, DOI 10.1021/jo00170a070; FEIXAS J, 1994, TETRAHEDRON, V50, P8539, DOI 10.1016/S0040-4020(01)85572-1; FREEMAN JP, 1990, ORG SYNTH COLLECT, V7, P139; GAWLEY RE, 1995, CHEM BIOL, V2, P533, DOI 10.1016/1074-5521(95)90187-6; HOMAKA Y, 1993, FOOD ADDIT CONTAM, V10, P71; HOVEYDA AH, 1993, CHEM REV, V93, P1307, DOI 10.1021/cr00020a002; INANAGA J, 1979, B CHEM SOC JPN, V52, P1989, DOI 10.1246/bcsj.52.1989; KLINDGREN BO, 1973, ACTA CHEM SCAND, V27, P888; LEE MS, 1987, NEW J CHEM, V11, P753; LEE MS, 1989, J AM CHEM SOC, V111, P6234, DOI 10.1021/ja00198a039; LEY SV, 1994, SYNTHESIS-STUTTGART, P639; MAHONEY WS, 1997, J AM CHEM SOC, V119, P8105; MUKAIYAMA T, 1974, J AM CHEM SOC, V96, P7503, DOI 10.1021/ja00831a019; Nicolaou KC, 1997, J AM CHEM SOC, V119, P8105, DOI 10.1021/ja971219p; NICOLAOU KC, 1991, ANGEW CHEM INT EDIT, V30, P299, DOI 10.1002/anie.199102991; NICOLAOU KC, 1995, J AM CHEM SOC, V117, P10239, DOI 10.1021/ja00146a009; NICOLAOU KC, 1990, J AM CHEM SOC, V112, P3696, DOI 10.1021/ja00165a085; Nicolaou KC, 1997, J AM CHEM SOC, V119, P5467, DOI 10.1021/ja970619+; Nicolaou KC, 1996, ANGEW CHEM INT EDIT, V35, P589; NICOLAOU KC, 1989, J AM CHEM SOC, V111, P5330, DOI 10.1021/ja00196a043; NICOLAOU KC, 1995, J AM CHEM SOC, V117, P10252, DOI 10.1021/ja00146a010; NICOLAOU KC, 1989, J AM CHEM SOC, V111, P5321, DOI 10.1021/ja00196a042; NICOLAOU KC, 1995, J AM CHEM SOC, V117, P10227, DOI 10.1021/ja00146a008; Okaichi T., 1989, RED TIDES BIOL ENV S; PARIKH JR, 1967, J AM CHEM SOC, V89, P5505, DOI 10.1021/ja00997a067; PAWLAK J, 1987, J AM CHEM SOC, V109, P1144, DOI 10.1021/ja00238a025; REIN KS, 1994, J ORG CHEM, V59, P2101, DOI 10.1021/jo00087a027; REIN KS, 1994, J ORG CHEM, V59, P2107, DOI 10.1021/jo00087a028; Rodenheaver G.T., 1971, CHEM COMMUN, P818; SCHREIBER J, 1971, ANGEW CHEM INT EDIT, V10, P330, DOI 10.1002/anie.197103301; SHIMIZU Y, 1986, J CHEM SOC CHEM COMM, P1656, DOI 10.1039/c39860001656; SHIMIZU Y, 1986, J AM CHEM SOC, V108, P314; TAMURA Y, 1986, TETRAHEDRON LETT, V27, P955; Xie MQ, 1996, J ORG CHEM, V61, P5178, DOI 10.1021/jo960355u; YASUMOTO T, 1993, CHEM REV, V93, P1897, DOI 10.1021/cr00021a011; ZAGORSKI MG, 1988, J ORG CHEM, V53, P4156, DOI 10.1021/jo00252a068	44	144	147	3	54	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1998	392	6673					264	269		10.1038/32623	http://dx.doi.org/10.1038/32623			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	ZC739	9521320				2022-12-28	WOS:000072612300042
J	Ytterstad, B; Norton, R				Ytterstad, B; Norton, R			Does CPAP prevent injuries?	LANCET			English	Editorial Material									Injury Prevent Res Ctr, Auckland 1, New Zealand		Ytterstad, B (corresponding author), Injury Prevent Res Ctr, Private Bag 92019, Auckland 1, New Zealand.							Krieger J, 1997, CHEST, V112, P1561, DOI 10.1378/chest.112.6.1561; LANGLEY JD, 1988, ACCIDENT ANAL PREV, V20, P1, DOI 10.1016/0001-4575(88)90009-7; Lindqvist KS, 1996, ACCIDENT ANAL PREV, V28, P209, DOI 10.1016/0001-4575(95)00065-8; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Norton R, 1997, ACCIDENT ANAL PREV, V29, P699, DOI 10.1016/S0001-4575(97)00018-3; Wright J, 1997, BRIT MED J, V314, P851; YTTERSTAD B, 1995, ACCIDENT ANAL PREV, V27, P111, DOI 10.1016/0001-4575(94)00036-L	7	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 7	1998	351	9104					692	692		10.1016/S0140-6736(05)78491-9	http://dx.doi.org/10.1016/S0140-6736(05)78491-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZB359	9504512				2022-12-28	WOS:000072463800005
J	Lin, DCH; Grossman, AD				Lin, DCH; Grossman, AD			Identification and characterization of a bacterial chromosome partitioning site	CELL			English	Article							BACILLUS-SUBTILIS; SMC FAMILY; SPORULATION; PLASMIDS; CONDENSATION; SEGREGATION; INITIATION; GENES	We have identified a DNA site involved in chromosome partitioning in B. subtilis. This site was identified in vivo as the binding site for the chromosome partitioning protein Spo0J, a member of the ParB family of partitioning proteins. Spo0J is a site-specific DNA-binding protein that recognizes a 16 bp sequence found in spo0J. Allowing two mismatches, this sequence occurs ten times in the entire B. subtilis chromosome, all in the origin-proximal similar to 20%. Eight of the ten sequences are bound to Spo0J in vivo. The presence of a site on an otherwise unstable plasmid stabilized the plasmid in a Spo0J-dependent manner, demonstrating that this site, called parS, can function as a partitioning site. This site and Spo0J are conserved in a wide range of bacterial species.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Grossman, AD (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.				NIGMS NIH HHS [GM41934] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041934] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSTIN S, 1990, CELL, V60, P351, DOI 10.1016/0092-8674(90)90584-2; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; Bickel SE, 1996, BIOESSAYS, V18, P293, DOI 10.1002/bies.950180407; Glaser P, 1997, GENE DEV, V11, P1160, DOI 10.1101/gad.11.9.1160; Gordon GS, 1997, CELL, V90, P1113, DOI 10.1016/S0092-8674(00)80377-3; Grossman AD, 1995, ANNU REV GENET, V29, P477, DOI 10.1146/annurev.ge.29.120195.002401; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Harwood C.R., 1990, MOL BIOL METHODS BAC; Hassan AKM, 1997, J BACTERIOL, V179, P2494, DOI 10.1128/jb.179.8.2494-2502.1997; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; Heck MMS, 1997, CELL, V91, P5, DOI 10.1016/S0092-8674(01)80002-7; HIRAGA S, 1992, ANNU REV BIOCHEM, V61, P283; HIRANO T, 1995, CURR OPIN CELL BIOL, V7, P329, DOI 10.1016/0955-0674(95)80087-5; IRETON K, 1994, J BACTERIOL, V176, P5320, DOI 10.1128/JB.176.17.5320-5329.1994; JAACKS KJ, 1989, J BACTERIOL, V171, P4121, DOI 10.1128/JB.171.8.4121-4129.1989; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Lewis PJ, 1997, MOL MICROBIOL, V25, P945, DOI 10.1111/j.1365-2958.1997.mmi530.x; Lin DCH, 1997, P NATL ACAD SCI USA, V94, P4721, DOI 10.1073/pnas.94.9.4721; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; Mohl DA, 1997, CELL, V88, P675, DOI 10.1016/S0092-8674(00)81910-8; Niki H, 1997, CELL, V90, P951, DOI 10.1016/S0092-8674(00)80359-1; NORDSTROM K, 1989, ANNU REV GENET, V23, P37, DOI 10.1146/annurev.genet.23.1.37; OGASAWARA N, 1992, MOL MICROBIOL, V6, P629, DOI 10.1111/j.1365-2958.1992.tb01510.x; Oguro A, 1996, GENE, V172, P17, DOI 10.1016/0378-1119(96)00181-3; PETERSON CL, 1994, CELL, V79, P389, DOI 10.1016/0092-8674(94)90247-X; SOLOMON MJ, 1985, P NATL ACAD SCI USA, V82, P6470, DOI 10.1073/pnas.82.19.6470; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; VASANTHA N, 1980, J BACTERIOL, V144, P1119, DOI 10.1128/JB.144.3.1119-1125.1980; Wake RG, 1995, ANNU REV GENET, V29, P41; Webb CD, 1997, CELL, V88, P667, DOI 10.1016/S0092-8674(00)81909-1; WILLIAMS DR, 1992, J GEN MICROBIOL, V138, P1	33	337	343	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 6	1998	92	5					675	685		10.1016/S0092-8674(00)81135-6	http://dx.doi.org/10.1016/S0092-8674(00)81135-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZA827	9506522	Green Published, Bronze			2022-12-28	WOS:000072406000013
J	Fitchet, A; Fitzpatrick, AP				Fitchet, A; Fitzpatrick, AP			Lesson of the week - Central venous air embolism causing pulmonary oedema mimicking left ventricular failure	BRITISH MEDICAL JOURNAL			English	Review							VASCULAR-PERMEABILITY; ECHOCARDIOGRAPHY; SHEEP		Univ Manchester, Manchester Royal Infirm, Dept Cardiol, Manchester Heart Ctr, Manchester M13 9WL, Lancs, England	University of Manchester	Fitchet, A (corresponding author), Univ Manchester, Manchester Royal Infirm, Dept Cardiol, Manchester Heart Ctr, Manchester M13 9WL, Lancs, England.							CLARK MC, 1984, AM REV RESPIR DIS, V129, P633; FLICK MR, 1981, CIRC RES, V48, P344, DOI 10.1161/01.RES.48.3.344; FLICK MR, 1983, J APPL PHYSIOL, V55, P1284, DOI 10.1152/jappl.1983.55.4.1284; KASHUK JL, 1984, SURG GYNECOL OBSTET, V159, P249; KIMURA BJ, 1994, CRIT CARE MED, V22, P1884; KUHN M, 1987, CHEST, V92, P364, DOI 10.1378/chest.92.2.364; MARCUS RH, 1991, CHEST, V99, P784, DOI 10.1378/chest.99.3.784; MURPHY PG, 1991, FREE RADICAL RES COM, V15, P167, DOI 10.3109/10715769109049137; MURPHY PG, 1991, BR J INTENSIVE CARE, V1, P110; OKHUDA K, 1981, J APPL PHYSIOL, V51, P887	10	16	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 21	1998	316	7131					604	606		10.1136/bmj.316.7131.604	http://dx.doi.org/10.1136/bmj.316.7131.604			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ031	9518916	Green Published			2022-12-28	WOS:000072213200034
J	Flanagan, JG; Van Vactor, D				Flanagan, JG; Van Vactor, D			Through the looking glass: Axon guidance at the midline choice point	CELL			English	Review							GROWTH CONE GUIDANCE; DROSOPHILA		Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Flanagan, JG (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.		Flanagan, John/AAM-2995-2020	Van Vactor, Jr., David L./0000-0001-8156-9482				COHEN NR, 1997, CURR BIOL, V8, P26; COLAMARINO SA, 1995, ANNU REV NEUROSCI, V18, P497, DOI 10.1146/annurev.ne.18.030195.002433; Kang JS, 1997, J CELL BIOL, V138, P203, DOI 10.1083/jcb.138.1.203; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; Kidd T, 1998, NEURON, V20, P25, DOI 10.1016/S0896-6273(00)80431-6; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; Shirasaki R, 1998, SCIENCE, V279, P105, DOI 10.1126/science.279.5347.105; Stoeckli ET, 1997, NEURON, V18, P209, DOI 10.1016/S0896-6273(00)80262-7; Tear G, 1996, NEURON, V16, P501, DOI 10.1016/S0896-6273(00)80070-7; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Zallen JA, 1998, CELL, V92, P217, DOI 10.1016/S0092-8674(00)80916-2	11	29	29	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 20	1998	92	4					429	432		10.1016/S0092-8674(00)80935-6	http://dx.doi.org/10.1016/S0092-8674(00)80935-6			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YZ409	9491883	Bronze			2022-12-28	WOS:000072251500002
J	Brogan, C; Pickard, D; Gray, A; Fairman, S; Hill, A				Brogan, C; Pickard, D; Gray, A; Fairman, S; Hill, A			The use of out of hours health services: a cross sectional survey	BRITISH MEDICAL JOURNAL			English	Article							NORMAL WORKING HOURS; CARE; NIGHT	Objectives: To determine the use and costs of the principal out of hours health services in Buckinghamshire. Design: Prospective cross sectional survey and cost description of patient contacts with out of hours services. Setting: Buckinghamshire during March and April 1995. Subjects: General practices, accident and emergency departments, ambulance services, and community nursing services. Main outcome measure: Contacts with patients and cost of out of hours services. Results: 438 patient contacts/1000 population/year were recorded at an annual incremental cost of between pound 4.6m and pound 7.2m (depending on the costing of general practitioner services), for a population of 660 000. Of these contacts, 21 649 (45%) were with general practitioners. Night time contacts with all services diminished sharply after 10 pm. General practitioners considered that 40% of contacts were unnecessary or could have waited until morning. Over 70% of contacts were for upper respiratory tract infections, carache, gastroenteritis, and other minor ailments. Nursing care was predominantly for elderly people, and 33% of nursing contacts were to supervise medication. Accident and emergency care was predominately for young adults, especially men, and 41% of attendances were for medical conditions. Conclusions: New models such as multidisciplinary primary care centres with telephone advice lines and triaging are required to ensure high quality, cost effective care that is responsive to the needs of both consumers and professionals.	Anglia & Oxford Reg Off NHS Execut, Milton Keynes MK14 6QP, Bucks, England; Buckinghamshire Hlth Author, Aylesbury HP19 3ET, Bucks, England; Univ Oxford, Inst Hlth Sci, Hlth Econ Res Ctr, Oxford OX3 7LF, England	University of Oxford	Brogan, C (corresponding author), Anglia & Oxford Reg Off NHS Execut, Linford Wood, Milton Keynes MK14 6QP, Bucks, England.							HALLAM L, 1994, BRIT MED J, V308, P249, DOI 10.1136/bmj.308.6923.249; HALLAM L, 1994, BRIT MED J, V309, P1621, DOI 10.1136/bmj.309.6969.1621; Hallam L, 1996, BRIT MED J, V312, P1402; Jessopp L, 1997, BRIT MED J, V314, P199, DOI 10.1136/bmj.314.7075.199; Lattimer V, 1997, BRIT MED J, V314, P198; MCKEE M, 1991, ANN ROY COLL SURG, V73, P295; MCKEE M, 1991, ANN R COLL SURG ENGL, V73, P301; PITTS J, 1988, J ROY COLL GEN PRACT, V38, P2; SALISBURY C, 1993, BRIT MED J, V306, P762, DOI 10.1136/bmj.306.6880.762; Salisbury C, 1997, BRIT MED J, V314, P182, DOI 10.1136/bmj.314.7075.182; SOLER M, 1991, Health Bulletin (Edinburgh), V49, P40; YEATMAN M, 1994, ANN ROY COLL SURG, V76, P90	12	45	45	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 14	1998	316	7130					524	527		10.1136/bmj.316.7130.524	http://dx.doi.org/10.1136/bmj.316.7130.524			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX955	9501716	Green Published			2022-12-28	WOS:000072097400024
J	Donaldson, GC; Tchernjavskii, VE; Ermakov, SP; Bucher, K; Keatinge, WR				Donaldson, GC; Tchernjavskii, VE; Ermakov, SP; Bucher, K; Keatinge, WR			Winter mortality and cold stress in Yekaterinburg, Russia: interview survey	BRITISH MEDICAL JOURNAL			English	Article							PLASMA-FIBRINOGEN; DISEASE; TEMPERATURE; INCREASES; DEATH	Objectives: To evaluate how mortality and protective measures against exposure to cold change as temperatures fall between October and March in a region of Russia with a mean winter temperature below -6 degrees C. Design: Interview to assess factors associated with cold stress both indoors and outdoors, to measure temperatures in living room, and to survey unheated rooms. Setting: Sverdlovsk Oblast (district), Yekaterinburg, Russia. Subjects: Residents aged 50-59 and 65-74 living within approximately 140 km of Yekaterinburg in Sverdlovsk Oblast. Survey of sample of 1000 residents equally distributed by sex and age groups. Main outcome measures: Regression analysis was used to relate data on indoor heating and temperatures, the amount of clothing worn, the amount of physical activity, and shivering while outside, to outdoor temperature; results were compared with mortality patterns for ischaemic heart disease, cerebrovascular disease, respiratory disease, and mortality from all causes. Results: As mean daily temperatures fell to 0 degrees C the amount of clothing worn outdoors increased, physical activity while outdoors became more continuous, and only 11 (6.6%) of the 167 people surveyed who went outdoors at temperatures above 0 degrees C reported shivering. The mean temperature in living rooms in the evening remained above 21.9 degrees C. Mortality from ischaemic heart disease, cerebrovascular disease, respiratory disease, and all causes did not change. As the temperature fell below 0 degrees C the number of items of clothing worn plateaued at 16.0 and the number of layers at 3.7. With regression analysis, shivering outdoors was found to increase progressively to 34.6% (P < 0.001) of excursions at -25 degrees C, and mortality (after declining slightly) rose progressively (all cause mortality rose by 1.15% for each 1 degrees C drop in temperature from 0 degrees C to -29.6 degrees C, 95% confidence interval 0.97% to 1.32%). 94.2% of bedrooms were directly heated, and evening temperatures in the living room averaged 19.8 degrees C even when outside temperatures reached -25 degrees C. Conclusions: Outdoor cold stress and mortality in Yekaterinburg increased only when the mean daily temperature dropped below 0 degrees C. At temperatures down to 0 degrees C cold stress and excess mortality were prevented by increasing the number of items of clothing worn and the amount of physical activity outdoors in combination with maintaining warmth in houses.	Univ London Queen Mary & Westfield Coll, Dept Physiol, London E1 4NS, England; Russian Minist Hlth, Moscow 127254, Russia; Forschungsstelle Deutschen Wetterdienstes, Dezemat Biosynopt Zentralen Med Meteorol, D-7800 Freiburg, Germany	University of London; Queen Mary University London; Ministry of Health of the Russian Federation	Keatinge, WR (corresponding author), Univ London Queen Mary & Westfield Coll, Dept Physiol, London E1 4NS, England.	wr.keatinge@qmw.ac.uk	Donaldson, Gavin/M-7992-2017; Ermakov, Sergey/G-1709-2016	Ermakov, Sergey/0000-0003-1072-1162; Donaldson, Gavin/0000-0002-5538-4190				BAINTON D, 1978, INT J EPIDEMIOL, V7, P231, DOI 10.1093/ije/7.3.231; BULL G M, 1978, Age and Ageing, V7, P210, DOI 10.1093/ageing/7.4.210; Donaldson GC, 1997, J EPIDEMIOL COMMUN H, V51, P643, DOI 10.1136/jech.51.6.643; FROST DB, 1992, INT J BIOMETEOROL, V36, P14, DOI 10.1007/BF01208729; GRAY PG, 1950, J ROY STAT SOC A STA, V113, P150, DOI 10.2307/2981039; HAYWARD MG, 1981, J PHYSIOL-LONDON, V320, P229, DOI 10.1113/jphysiol.1981.sp013946; HEUNIS JC, 1995, S AFR MED J, V85, P1016; Keatinge WR, 1997, LANCET, V349, P1341, DOI 10.1016/S0140-6736(96)12338-2; KEATINGE WR, 1984, BMJ-BRIT MED J, V289, P1405, DOI 10.1136/bmj.289.6456.1405; LOVETT AA, 1986, SOC SCI MED, V23, P935, DOI 10.1016/0277-9536(86)90251-0; NEILD PJ, 1994, CLIN SCI, V86, P43, DOI 10.1042/cs0860043; WOODHOUSE PR, 1994, LANCET, V343, P435, DOI 10.1016/S0140-6736(94)92689-1	12	58	61	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 14	1998	316	7130					514	518		10.1136/bmj.316.7130.514	http://dx.doi.org/10.1136/bmj.316.7130.514			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX955	9501713	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000072097400020
J	Tincello, DG; Richmond, DH				Tincello, DG; Richmond, DH			Evaluation of reagent strips in detecting asymptomatic bacteriuria in early pregnancy: prospective case series	BRITISH MEDICAL JOURNAL			English	Article							URINE; NITRITE; WOMEN	Objective: To evaluate the performance of reagent test strips in screening pregnant women for asymptomatic bacteriuria at their first visit to an antenatal clinic. Design: Prospective case series. Setting: Antenatal clinic of a large inner city maternity hospital. Subjects: All women attending for their first antenatal clinic. Patients taking antibiotics for any reason and those with urinary tract symptoms were excluded. Intervention: A midstream urine specimen was divided; half was sent for microscopy and formal bacteriological culture and the other half was tested with a commercial reagent strip test for the presence of blood, protein, nitrite, and leucocyte esterase, Main outcome measures: Sensitivity, specificity, and positive and negative predictive values of the reagent strips in diagnosing asymptomatic bacteriuria (defined as 10(5) colony forming units/ml urine). Results: Sensitivity was low, with a maximum of 33% when all four tests were used in combination, Specificity was high, with typical values of 99% or more. Positive predictive value reached a maximum of 69% and negative predictive value was typically 95% or more. Conclusion: Urine reagent strips are not sufficiently sensitive to be of use in the screening for asymptomatic bacteriuria and therefore many patients would be missed. In view of the potentially serious sequelae of this condition in pregnant women we recommend that formal bacteriological investigation remain the investigation of choice in this group of patients.	Liverpool Womens Hosp, Dept Urogynaecol, Liverpool L8 7SS, Merseyside, England	University of Liverpool	Tincello, DG (corresponding author), Liverpool Womens Hosp, Dept Urogynaecol, Liverpool L8 7SS, Merseyside, England.							ETHERINGTON IJ, 1993, BRIT J OBSTET GYNAEC, V100, P806, DOI 10.1111/j.1471-0528.1993.tb14303.x; KASS EH, 1955, AM J MED, V18, P764, DOI 10.1016/0002-9343(55)90190-X; LENKE RR, 1981, AM J OBSTET GYNECOL, V140, P427, DOI 10.1016/0002-9378(81)90039-9; MARQUETTE GP, 1988, AM J OBSTET GYNECOL, V153, P888; MCFADYEN IR, 1973, J OBSTET GYN BR COMM, V80, P385; MCFADYEN IR, 1986, KIDNEY PREGNANCY, P205; MCNEELY SG, 1987, OBSTET GYNECOL, V69, P50; MOLLER M, 1984, LANCET, V2, P69; NUNNS D, 1995, BRIT J UROL, V76, P87, DOI 10.1111/j.1464-410X.1995.tb07838.x; ROBERTSON AW, 1988, OBSTET GYNECOL, V71, P878; VANDORSTEN JP, 1986, AM J OBSTET GYNECOL, V155, P777, DOI 10.1016/S0002-9378(86)80019-9	11	32	33	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 7	1998	316	7129					435	437		10.1136/bmj.316.7129.435	http://dx.doi.org/10.1136/bmj.316.7129.435			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW874	9492667	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000071982700026
J	Eichenbaum, H				Eichenbaum, H			How does the brain organize memories?	SCIENCE			English	Editorial Material							HIPPOCAMPAL-NEURONS; TERM-MEMORY; PLACE; AMNESIA; LESIONS; RATS; DISSOCIATION; MONKEY; TASK				Eichenbaum, H (corresponding author), BOSTON UNIV,DEPT PSYCHOL,LAB COGNIT NEUROBIOL,64 CUMMINGTON ST,BOSTON,MA 02215, USA.							Bunsey M, 1996, NATURE, V379, P255, DOI 10.1038/379255a0; Cohen N. J., 1993, MEMORY AMNESIA HIPPO; COHEN NJ, 1980, SCIENCE, V210, P207, DOI 10.1126/science.7414331; Corkin S, 1997, J NEUROSCI, V17, P3964; Deadwyler SA, 1996, J NEUROSCI, V16, P354; Dusek JA, 1997, P NATL ACAD SCI USA, V94, P7109, DOI 10.1073/pnas.94.13.7109; EICHENBAUM H, 1994, BEHAV BRAIN SCI, V17, P449, DOI 10.1017/S0140525X00035391; Eichenbaum H, 1996, CURR OPIN NEUROBIOL, V6, P187, DOI 10.1016/S0959-4388(96)80072-9; EICHENBAUM H, 1990, J NEUROSCI, V10, P3531; Eichenbaum H, 1997, ANNU REV PSYCHOL, V48, P547, DOI 10.1146/annurev.psych.48.1.547; Fried I, 1997, NEURON, V18, P753, DOI 10.1016/S0896-6273(00)80315-3; Gabrieli JDE, 1997, SCIENCE, V276, P264, DOI 10.1126/science.276.5310.264; Gluck MA, 1996, HIPPOCAMPUS, V6, P643, DOI 10.1002/(SICI)1098-1063(1996)6:6<643::AID-HIPO7>3.0.CO;2-H; Gothard KM, 1996, J NEUROSCI, V16, P823; Hamann SB, 1995, BEHAV NEUROSCI, V109, P1027, DOI 10.1037/0735-7044.109.6.1027; MARKUS EJ, 1995, J NEUROSCI, V15, P7079; MILLER EK, 1994, SCIENCE, V263, P520, DOI 10.1126/science.8290960; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Murray EA, 1996, SEMIN NEUROSCI, V8, P13, DOI 10.1006/smns.1996.0003; OKEEFE J, 1976, EXP NEUROL, V51, P78, DOI 10.1016/0014-4886(76)90055-8; ONO T, 1993, J NEUROPHYSIOL, V70, P1516, DOI 10.1152/jn.1993.70.4.1516; OSTERGAARD A, 1990, BRAIN COGNITION, V14, P127, DOI 10.1016/0278-2626(90)90024-I; PHILLIPS RG, 1994, LEARN MEMORY, V1, P34; Reber PJ, 1996, BEHAV NEUROSCI, V110, P861, DOI 10.1037/0735-7044.110.5.861; RICHES IP, 1991, J NEUROSCI, V11, P1763; ROLLS ET, 1989, J NEUROSCI, V9, P1835; SACHACTER DL, 1994, MEMORY SYSTEMS; SAKAI K, 1991, NATURE, V354, P152, DOI 10.1038/354152a0; SCHACTER DL, 1985, MEMORY SYSTEMS BRAIN, P351; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; Shapiro Matthew L., 1994, P87; SQUIRE LR, 1993, ANNU REV PSYCHOL, V44, P453, DOI 10.1146/annurev.ps.44.020193.002321; Tanila H, 1997, J NEUROSCI, V17, P5167; TULVING E, 1991, J EXP PSYCHOL LEARN, V17, P595, DOI 10.1037/0278-7393.17.4.595; VARGHAKHADEM F, 1997, SCIENCE, V277, P377; WHISHAW IQ, 1995, J NEUROSCI, V15, P5779; WIENER SI, 1989, J NEUROSCI, V9, P2737; WOOD FB, 1989, BRAIN COGNITION, V10, P76, DOI 10.1016/0278-2626(89)90076-6; Young BJ, 1997, J NEUROSCI, V17, P5183; YOUNG BJ, 1994, J NEUROSCI, V14, P6553	40	113	116	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 18	1997	277	5324					330	332		10.1126/science.277.5324.330	http://dx.doi.org/10.1126/science.277.5324.330			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XL358	9518364				2022-12-28	WOS:A1997XL35800034
J	Haddow, JE; Palomaki, GE; Knight, GJ; Williams, J; Miller, WA; Johnson, A				Haddow, JE; Palomaki, GE; Knight, GJ; Williams, J; Miller, WA; Johnson, A			Screening of maternal serum for fetal Down's syndrome in the first trimester	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN CHORIONIC-GONADOTROPIN; PLASMA PROTEIN-A; NEURAL-TUBE DEFECTS; ALPHA-FETOPROTEIN; CHROMOSOME-ABNORMALITIES; NUCHAL TRANSLUCENCY; 1ST TRIMESTER; UNCONJUGATED ESTRIOL; 2ND TRIMESTERS; PREGNANCY	Background Screening of maternal serum to identify fetuses with Down's syndrome is now routinely offered during the second trimester of pregnancy. Prenatal screening by means of serum assays or ultrasonographic measurements, either alone or in combination, may also be possible in the first trimester. Methods We measured serum alpha-fetoprotein, unconjugated estriol, human chorionic gonadotropin (hCG), the free beta subunit of hCG, and pregnancy-associated protein A in 4412 women (82 percent of whom were 35 years of age or older) who came to 16 prenatal diagnostic centers for chorionic-villus sampling or early amniocentesis at 9 to 15 weeks of gestation, Ultrasound measurements of fetal nuchal translucency were also reported. Fetal chromosomal analysis was performed in all pregnancies, Altogether, there were 61 fetuses with Down's syndrome. Results A total of 48 pregnancies affected by Down's syndrome and 3169 unaffected pregnancies were identified before 14 weeks of gestation; the rates of detection of Down's syndrome for the five serum markers were as follows: 17 percent for alpha-fetoprotein, 4 percent for unconjugated estriol, 29 percent for hCG, 25 percent for the free beta subunit of hCG, and 42 percent for pregnancy-associated protein A, at false positive rates of 5 percent. The results of the measurements of serum hCG and its free beta subunit were highly correlated. When used in combination with the serum concentration of pregnancy-associated protein A and maternal age, the detection rate was 63 percent for hCG (95 percent confidence interval, 47 to 76 percent) and 60 percent for its free beta subunit (95 percent confidence interval, 45 to 74 percent). Measurements of nuchal translucency varied considerably between centers and could not be reliably incorporated into our calculations. Conclusions Screening for Down's syndrome in the first trimester is feasible, with use of measurements of pregnancy-associated protein A and either hCG or its free beta subunit in maternal serum. (C)1998, Massachusetts Medical Society.	Fdn Blood Res, Scarborough, ME 04074 USA; Prenatal Diagnost Ctr, Lexington, MA USA	Foundation for Blood Research (FBR)	Haddow, JE (corresponding author), POB 190, Scarborough, ME 04070 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD031183] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD31183] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AITKEN DA, 1993, PRENATAL DIAG, V13, P681, DOI 10.1002/pd.1970130804; Aitken DA, 1996, NEW ENGL J MED, V334, P1231, DOI 10.1056/NEJM199605093341904; BOGART MH, 1989, PRENATAL DIAG, V9, P379, DOI 10.1002/pd.1970090602; BOGART MH, 1987, PRENATAL DIAG, V7, P623, DOI 10.1002/pd.1970070904; BRAMBATI B, 1986, LANCET, V2, P165; BRIZOT ML, 1995, BRIT J OBSTET GYNAEC, V102, P127, DOI 10.1111/j.1471-0528.1995.tb09065.x; BROCK DJH, 1990, PRENATAL DIAG, V10, P245, DOI 10.1002/pd.1970100406; CANICK JA, 1988, BRIT J OBSTET GYNAEC, V95, P330, DOI 10.1111/j.1471-0528.1988.tb06601.x; CRANDALL BF, 1993, AM J OBSTET GYNECOL, V168, P1864, DOI 10.1016/0002-9378(93)90703-L; CUCKLE H, 1992, BRIT MED J, V305, P425, DOI 10.1136/bmj.305.6850.425-a; CUCKLE HS, 1984, LANCET, V1, P926; CUCKLE HS, 1987, BRIT J OBSTET GYNAEC, V94, P387, DOI 10.1111/j.1471-0528.1987.tb03115.x; CUCKLE HS, 1988, LANCET, V2, P851; FOREST JC, 1995, CLIN BIOCHEM, V28, P443, DOI 10.1016/0009-9120(95)00021-Z; HADDOW JE, 1983, OBSTET GYNECOL, V62, P556; HADDOW JE, 1992, NEW ENGL J MED, V327, P588, DOI 10.1056/NEJM199208273270902; HOGDALL CK, 1992, PRENATAL DIAG, V12, P223, DOI 10.1002/pd.1970120312; ILES RK, 1993, 4 C END MET HUM REPR; Jauniaux E, 1996, J ENDOCRINOL, V148, P27, DOI 10.1677/joe.0.1480027; JOHNSON A, 1991, PRENATAL DIAG, V11, P443, DOI 10.1002/pd.1970110706; KNIGHT GJ, 1993, PRENATAL DIAG, V13, P222, DOI 10.1002/pd.1970130312; KONYNE LM, 1993, MMWR-MORBID MORTAL W, V41, P1; KRATZER PG, 1991, PRENATAL DIAG, V11, P751, DOI 10.1002/pd.1970111003; MACINTOSH MC, 1994, BRIT J OBSTET GYNAEC, V102, P798; MACINTOSH MCM, 1994, PRENATAL DIAG, V14, P203, DOI 10.1002/pd.1970140311; MERKATZ IR, 1984, AM J OBSTET GYNECOL, V148, P886, DOI 10.1016/0002-9378(84)90530-1; Neveux LM, 1996, PRENATAL DIAG, V16, P1115, DOI 10.1002/(SICI)1097-0223(199612)16:12<1115::AID-PD3>3.0.CO;2-6; NICOLAIDES KH, 1992, BRIT MED J, V304, P867, DOI 10.1136/bmj.304.6831.867; OZTURK M, 1990, AM J MED GENET, V36, P480, DOI 10.1002/ajmg.1320360422; Palomaki GE, 1997, AM J OBSTET GYNECOL, V176, P1046, DOI 10.1016/S0002-9378(97)70400-9; Scott F, 1996, PRENATAL DIAG, V16, P629, DOI 10.1002/(SICI)1097-0223(199607)16:7<629::AID-PD922>3.0.CO;2-X; Snijders RJM, 1996, ULTRASOUND OBST GYN, V7, P216, DOI 10.1046/j.1469-0705.1996.07030216.x; SZABO J, 1995, ULTRASOUND OBST GYN, V5, P161, DOI 10.1046/j.1469-0705.1995.05030161.x; VANLITH JMM, 1992, PRENATAL DIAG, V12, P495, DOI 10.1002/pd.1970120604; WALD N, 1992, BRIT MED J, V305, P28, DOI 10.1136/bmj.305.6844.28; Wald NJ, 1995, PRENATAL DIAG, V15, P1227, DOI 10.1002/pd.1970151305; WALD NJ, 1988, BRIT MED J, V297, P1029; Wald NJ, 1996, BRIT J OBSTET GYNAEC, V103, P407, DOI 10.1111/j.1471-0528.1996.tb09765.x; WALD NJ, 1992, BRIT J OBSTET GYNAEC, V99, P144, DOI 10.1111/j.1471-0528.1992.tb14474.x; Wald NJ, 1996, PRENATAL DIAG, V16, P387; WALD NJ, 1993, PRENATAL DIAG, V13, P1047, DOI 10.1002/pd.1970131108	41	172	188	1	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 2	1998	338	14					955	961		10.1056/NEJM199804023381404	http://dx.doi.org/10.1056/NEJM199804023381404			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE776	9521983				2022-12-28	WOS:000072829800004
J	Harrison, CN; Linch, DC; Machin, SJ				Harrison, CN; Linch, DC; Machin, SJ			Desirability and problems of early diagnosis of essential thrombocythaemia	LANCET			English	Editorial Material							RISK		UCL, Sch Med, Dept Haematol, London WC1E 6HX, England	University of London; University College London; UCL Medical School	Harrison, CN (corresponding author), UCL, Sch Med, Dept Haematol, London WC1E 6HX, England.							CORTELAZZO S, 1995, NEW ENGL J MED, V332, P1132, DOI 10.1056/NEJM199504273321704; CORTELAZZO S, 1990, J CLIN ONCOL, V8, P556, DOI 10.1200/JCO.1990.8.3.556; ElKassar N, 1997, BLOOD, V89, P128, DOI 10.1182/blood.V89.1.128.128_128_134; Gale RE, 1997, BRIT J HAEMATOL, V98, P512, DOI 10.1046/j.1365-2141.1997.2573078.x; GILES FJ, 1988, LANCET, V2, P70; Harrison Claire N., 1997, Blood, V90, p347A; Harrison CN, 1997, AM J MED, V102, P317; Horikawa Y, 1997, BLOOD, V90, P4031, DOI 10.1182/blood.V90.10.4031; Lengfelder E, 1998, BRIT J HAEMATOL, V100, P15, DOI 10.1046/j.1365-2141.1998.00529.x; MURPHY S, 1986, SEMIN HEMATOL, V23, P177; Petitt RM, 1997, SEMIN HEMATOL, V34, P51; Sterkers Y, 1998, BLOOD, V91, P616, DOI 10.1182/blood.V91.2.616.616_616_622; Tahara T, 1996, BRIT J HAEMATOL, V93, P783, DOI 10.1046/j.1365-2141.1996.d01-1741.x	13	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 21	1998	351	9106					846	847		10.1016/S0140-6736(98)22012-5	http://dx.doi.org/10.1016/S0140-6736(98)22012-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD047	9525354				2022-12-28	WOS:000072645500002
J	Lo, JC; Mulligan, K; Tai, VW; Algren, H; Schambelan, M				Lo, JC; Mulligan, K; Tai, VW; Algren, H; Schambelan, M			"Buffalo hump" in men with HIV-1 infection	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; CUSHINGS-SYNDROME; OBESITY; METABOLISM	Background: Enlargement of the dorsocervical fat pad ("buffalo hump") has been reported in numerous HIV-1-infected patients. Some investigators have speculated that this finding is associated with protease-inhibitor treatment. Methods: Between June, 1995, and October, 1997, we studied eight HIV-1-infected men who had developed a buffalo hump while otherwise stable on antiretroviral therapy. Measurement of 24 h urinary free cortisol excretion and an overnight low-dose dexamethasone suppression test were done to screen for Cushing's syndrome. In one patient, plasma cortisol concentrations were measured every 4 h for 24 h to assess the circadian rhythm of cortisol. Results of total and regional body-composition analysis by dual-energy X-ray absorptiometry, and glucose, cholesterol, triglyceride, and cortisol concentrations were compared with those obtained in a control population of 15 HIV-1-positive men whose age, body-mass index (BMI), and CD4-lymphocyte count were within the range of values in the eight study patients. Findings: The eight patients with a buffalo hump were clinically stable on various antiretroviral regimens, four of which included a protease inhibitor. No other signs of Cushing's syndrome were observed, and plasma cortisol values did not differ significantly from those of controls, 24 h urinary free cortisol excretion was normal in seven patients and slightly raised in one (248 nmoles). In this patient, a repeat 24 h urinary free cortisol was 175 nmoles and plasma cortisol concentrations over 24 h showed a normal circadian pattern (nadir 83 nmol/L at 2400 h). All eight patients had normal suppression of cortisol values after dexamethasone 1 mg (plasma cortisol less than 83 nmol/L). When compared with HIV-1-positive controls, men with a buffalo hump had a significantly greater proportion of fat in the trunk region, suggesting central fat accumulation. Triglyceride but not cholesterol values were higher in the patients than in controls but this difference was not significant. Fasting glucose values did not differ significantly. Interpretation: The development of a buffalo hump cannot be attributed to hypercortisolism in these eight men. Furthermore, its occurrence is not unique to patients on protease inhibitors. Although the mechanism for dorsocervical fat accumulation is unclear, we speculate that regional abnormalities in lipogenesis and lipolysis occur, possibly influenced by the hormonal and metabolic changes seen with HIV-1 infection and its treatment.	San Francisco Gen Hosp, Div Endocrinol, San Francisco, CA 94110 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Lo, JC (corresponding author), San Francisco Gen Hosp, Div Endocrinol, Bldg 100,Room 321, San Francisco, CA 94110 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045833] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45833] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bjorntorp P, 1996, INT J OBESITY, V20, P291; Bujalska IJ, 1997, LANCET, V349, P1210, DOI 10.1016/S0140-6736(96)11222-8; CRAPO L, 1979, METABOLISM, V28, P955, DOI 10.1016/0026-0495(79)90097-0; FINDLING JW, 1994, ENDOCRIN METAB CLIN, V23, P511, DOI 10.1016/S0889-8529(18)30081-1; FOK ACK, 1991, STEROIDS, V56, P549, DOI 10.1016/0039-128X(91)90011-J; FUJIOKA S, 1987, METABOLISM, V36, P54, DOI 10.1016/0026-0495(87)90063-1; GRUNFELD C, 1992, J CLIN ENDOCR METAB, V74, P1045, DOI 10.1210/jc.74.5.1045; HELLERSTEIN MK, 1993, J CLIN ENDOCR METAB, V76, P559, DOI 10.1210/jc.76.3.559; Hengel RL, 1997, LANCET, V350, P1596, DOI 10.1016/S0140-6736(05)64011-1; MATSUZAWA Y, 1995, ANN NY ACAD SCI, V748, P399; MAZESS RB, 1990, AM J CLIN NUTR, V51, P1106, DOI 10.1093/ajcn/51.6.1106; MENGDEN T, 1992, CLIN INVESTIGATOR, V70, P545; Mulligan K, 1997, J ACQ IMMUN DEF SYND, V15, P43, DOI 10.1097/00042560-199705010-00007; MURPHY BEP, 1967, J CLIN ENDOCR METAB, V27, P973, DOI 10.1210/jcem-27-7-973; NUGENT CA, 1965, ARCH INTERN MED, V116, P172, DOI 10.1001/archinte.1965.03870020012006; PAVLATOS FC, 1965, JAMA-J AM MED ASSOC, V193, P96; Peeke PM, 1995, ANN NY ACAD SCI, V771, P665, DOI 10.1111/j.1749-6632.1995.tb44719.x; Ramsay TG, 1996, ENDOCRIN METAB CLIN, V25, P847, DOI 10.1016/S0889-8529(05)70358-3; REBUFFESCRIVE M, 1988, J CLIN ENDOCR METAB, V67, P1122, DOI 10.1210/jcem-67-6-1122; REBUFFESCRIVE M, 1990, J CLIN ENDOCR METAB, V71, P1215, DOI 10.1210/jcem-71-5-1215; RUANE PJ, 1997, 37 INT C ANT AG CHEM, pI185; SCHAMBELAN M, 1995, MED MANAGEMENT AIDS, P345; YANOVSKI JA, 1994, ENDOCRIN METAB CLIN, V23, P487, DOI 10.1016/S0889-8529(18)30080-X	23	439	444	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 21	1998	351	9106					867	870		10.1016/S0140-6736(97)11443-X	http://dx.doi.org/10.1016/S0140-6736(97)11443-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD047	9525364				2022-12-28	WOS:000072645500013
J	Bassotti, G; Fiorella, S				Bassotti, G; Fiorella, S			Oesophageal pressure during an earthquake	LANCET			English	Article							DEATH		Univ Perugia, Sch Med, Dept Clin & Expt Med, GI Sect,Gastrointestinal Motil Lab, Perugia, Italy	University of Perugia	Bassotti, G (corresponding author), Univ Perugia, Sch Med, Dept Clin & Expt Med, GI Sect,Gastrointestinal Motil Lab, Perugia, Italy.							BASS C, 1986, GUT, V27, P123, DOI 10.1136/gut.27.2.123; DIAMANT NE, 1993, GASTROINTESTINAL DIS, P319; Holtmann G, 1991, J GASTROINTEST MOTIL, V3, P245, DOI DOI 10.1111/j.1365-2982.1991.tb00068.x; Leor J, 1996, NEW ENGL J MED, V334, P413, DOI 10.1056/NEJM199602153340701; Muller JE, 1996, NEW ENGL J MED, V334, P460, DOI 10.1056/NEJM199602153340709	5	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 14	1998	351	9105					806	806		10.1016/S0140-6736(05)78934-0	http://dx.doi.org/10.1016/S0140-6736(05)78934-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB916	9519961				2022-12-28	WOS:000072521200022
J	Genick, UK; Soltis, SM; Kuhn, P; Canestrelli, IL; Getzoff, ED				Genick, UK; Soltis, SM; Kuhn, P; Canestrelli, IL; Getzoff, ED			Structure at 0.85 angstrom resolution of an early protein photocycle intermediate	NATURE			English	Article							PHOTOACTIVE YELLOW PROTEIN; LINKED 4-HYDROXYCINNAMYL CHROMOPHORE; ECTOTHIORHODOSPIRA-HALOPHILA; PHOTOTROPHIC BACTERIUM; CRYSTALLOGRAPHY; SPECTROSCOPY; TEMPERATURE; CRYSTALS	Protein photosensors from all kingdoms of life(1,2) use bound organic molecules, known as chromophores, to detect light, A specific double bond within each chromophore is isomerized by light, triggering slower changes in the protein as a whole, The initial movements of the chromophore, which can occur in femtoseconds, are tightly constrained by the surrounding protein, making it difficult to see how isomerization can occur, be recognized, and be appropriately converted into a protein-wide structural change and biological signal, Here we report how this dilemma is resolved in the photoactive yellow protein (PYP). We trapped a key early intermediate in the light cycle of PYP at temperatures below -100 degrees C, and determined its structure at better than 1 Angstrom resolution, The 4-hydroxycinnamoyl chromophore(3,4) isomerizes by flipping its thioester linkage with the protein, thus avoiding collisions resulting from large-scale movement of its aromatic ring during the initial light reaction, A protein-to-chromophore hydrogen bond that is present in both the preceding dark state(5) and the subsequent signalling state(6) of the photosensor breaks, forcing one of the hydrogen-bonding partners into a hydrophobic pocket. The isomerized bond is distorted into a conformation resembling that in the transition state. The resultant stored energy is used to drive the PYP light cycle. These results suggest a model for phototransduction, with implications for bacteriorhodopsin(7,8), photoactive proteins(1,2), PAS domains(9), and signalling proteins.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Stanford Synchrotron Radiat Lab, Stanford, CA 94309 USA	Scripps Research Institute; Scripps Research Institute; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory	Getzoff, ED (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Genick, Ulrich/0000-0002-6526-3552				BACA M, 1994, BIOCHEMISTRY-US, V33, P14369, DOI 10.1021/bi00252a001; BORGSTAHL GEO, 1995, BIOCHEMISTRY-US, V34, P6278, DOI 10.1021/bi00019a004; Bourgeois D, 1996, J SYNCHROTRON RADIAT, V3, P65, DOI 10.1107/S090904959501661X; Genick UK, 1997, BIOCHEMISTRY-US, V36, P8, DOI 10.1021/bi9622884; Genick UK, 1997, SCIENCE, V275, P1471, DOI 10.1126/science.275.5305.1471; HADFIELD A, 1993, J APPL CRYSTALLOGR, V26, P839, DOI 10.1107/S0021889893005552; HAJDU J, 1993, ANNU REV BIOPH BIOM, V22, P467, DOI 10.1146/annurev.bb.22.060193.002343; HOFF WD, 1994, BIOCHEMISTRY-US, V33, P13959, DOI 10.1021/bi00251a001; HOFF WD, 1994, BIOPHYS J, V67, P1691, DOI 10.1016/S0006-3495(94)80643-5; Imamoto Y, 1996, BIOCHEMISTRY-US, V35, P14047, DOI 10.1021/bi961342d; Kay SA, 1997, SCIENCE, V276, P753, DOI 10.1126/science.276.5313.753; KIM M, 1995, BIOCHEMISTRY-US, V34, P12669, DOI 10.1021/bi00039a024; Kimura Y, 1997, NATURE, V389, P206, DOI 10.1038/38323; MEYER TE, 1989, BIOPHYS J, V56, P559, DOI 10.1016/S0006-3495(89)82703-1; MEYER TE, 1985, BIOCHIM BIOPHYS ACTA, V806, P175, DOI 10.1016/0005-2728(85)90094-5; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PebayPeyroula E, 1997, SCIENCE, V277, P1676, DOI 10.1126/science.277.5332.1676; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; SCHERTLER GFX, 1991, EMBO J, V10, P2353, DOI 10.1002/j.1460-2075.1991.tb07774.x; SCHLICHTING I, 1994, NATURE, V371, P808, DOI 10.1038/371808a0; SHELDRICK GM, IN PRESS CRYSTALLOGR, V7; SPRENGER WW, 1993, J BACTERIOL, V175, P3096, DOI 10.1128/JB.175.10.3096-3104.1993; Stowell MHB, 1997, SCIENCE, V276, P812, DOI 10.1126/science.276.5313.812; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; VANBREDERODE ME, 1995, BIOPHYS J, V68, P1101, DOI 10.1016/S0006-3495(95)80284-5; Williams PA, 1997, NATURE, V389, P406, DOI 10.1038/38775; Xie AH, 1996, BIOCHEMISTRY-US, V35, P14671, DOI 10.1021/bi9623035	27	311	317	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 12	1998	392	6672					206	209		10.1038/32462	http://dx.doi.org/10.1038/32462			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB349	9515969				2022-12-28	WOS:000072462700069
J	Ranger, AM; Grusby, MJ; Hodge, MR; Gravallese, EM; de la Brousse, FC; Hoey, T; Mickanin, C; Baldwin, HS; Glimcher, LH				Ranger, AM; Grusby, MJ; Hodge, MR; Gravallese, EM; de la Brousse, FC; Hoey, T; Mickanin, C; Baldwin, HS; Glimcher, LH			The transcription factor NF-ATc is essential for cardiac valve formation	NATURE			English	Article							T-CELL ACTIVATION; NEUREGULIN RECEPTOR; MICE LACKING; HEART; PROTEINS; DEFECTS; FAMILY; RAT	Nuclear factor of activated T cells (NF-AT) is the name of a family of four related transcription factors that may be needed for cytokine gene expression in activated lymphocytes(1-4). Here we report that mice with a targeted disruption of the NF-ATc gene show an unexpected and dramatic defect in cardiac morphogenesis, with selective absence of the aortic and pulmonary valves, leading to death in utero from congestive heart failure at days 13.5-17.5 of gestation, In contrast, tricuspid and mitral valve morphogenesis is normal, NF-ATc is the first transcription factor known to be expressed only in the endothelial cells of the heart, As in T cells, nuclear translocation of NF-ATc in cardiac endothelial cells is controlled by the calcium-regulated phosphatase calcineurin(5,6): NF-ATc remains cytoplasmic in normal embryos cultured with cyclosporin A, an inhibitor of calcineurin. Abnormal development of the cardiac valves and septae is the most frequent form of birth defect, yet few molecular regulators of valve formation are known, Our results indicate that NF-ATc may play a critical role in signal-transduction processes required for normal cardiac valve formation.	Harvard Univ, Sch Publ Hlth, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Tularik Inc, S San Francisco, CA 94080 USA; Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Glimcher, LH (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Biol, 665 Huntington Ave, Boston, MA 02115 USA.	lglimche@hsph.harvard.edu						BALDWIN HS, 1991, DIFFERENTIATION, V47, P163, DOI 10.1111/j.1432-0436.1991.tb00234.x; BROWN PAJ, 1985, BIOL NEONATE, V48, P172; CLARK EB, 1987, GENETICS CARDIOVASCU, P3; COOP AJ, 1995, TRENDS GENET, V11, P87; EISENBURG LM, 1995, CIRC RES, V77, P106; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FERENCZ C, 1985, AM J EPIDEMIOL, V121, P31, DOI 10.1093/oxfordjournals.aje.a113979; Fishman MC, 1997, DEVELOPMENT, V124, P2099; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; HURLE JM, 1980, ANAT EMBRYOL, V160, P83, DOI 10.1007/BF00315651; KWEE L, 1995, DEVELOPMENT, V121, P489; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; LYONS KM, 1995, MECH DEVELOP, V50, P71, DOI 10.1016/0925-4773(94)00326-I; MARKWALD RR, 1994, ROLE EXTRACELLULAR M, P323; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; MIYABARA S, 1994, HEART VESSELS, V9, P49, DOI 10.1007/BF01744495; MOENS CB, 1993, DEVELOPMENT, V119, P485; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Olson EN, 1996, SCIENCE, V272, P671, DOI 10.1126/science.272.5262.671; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rossant J, 1996, CIRC RES, V78, P349, DOI 10.1161/01.RES.78.3.349; RUNYAN RB, 1990, CELL REGUL, V1, P301, DOI 10.1091/mbc.1.3.301; Schilham MW, 1996, NATURE, V380, P711, DOI 10.1038/380711a0; STURM K, 1993, METHOD ENZYMOL, V225, P164; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; Yamamura H, 1997, DEV BIOL, V186, P58, DOI 10.1006/dbio.1997.8559; YANG JT, 1995, DEVELOPMENT, V121, P549	30	478	487	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 12	1998	392	6672					186	190		10.1038/32426	http://dx.doi.org/10.1038/32426			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB349	9515964				2022-12-28	WOS:000072462700064
J	Palumbo, PE; Raskino, C; Fiscus, S; Pahwa, S; Fowler, MG; Spector, SA; Englund, JA; Baker, CJ				Palumbo, PE; Raskino, C; Fiscus, S; Pahwa, S; Fowler, MG; Spector, SA; Englund, JA; Baker, CJ			Predictive value of quantitative plasma HIV RNA and CD4(+) lymphocyte count in HIV-infected infants and children	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MARKERS; VIRUS; THERAPY	Context.-Pediatric human immunodeficiency virus (HIV) infection has unique viral pathogenetic features that preclude routine extrapolation from adult studies and require specific analysis. Objectives.-To evaluate the prognostic value of 2 key laboratory markers-plasma RNA and CD4(+) lymphocyte count-for HIV disease progression in infants and children and to establish targeted values for optimal outcome. Design.-Data from a cohort of 566 infants and children who participated in a randomized, placebo-controlled trial of nucleoside reverse transcriptase inhibitors (ACTG 152) were analyzed. The trial was conducted between 1991 and 1995 and enrolled a heterogenous cohort of antiretroviral therapy-naive children (age, 3 months to 18 years); patients had a median follow-up of 32 months. Main Outcome Measures.-The trial clinical end points consisted of time to first HIV disease progression (growth failure, decline in neurologic or neurodevelopmental function, opportunistic infections) or death. Results.-Baseline plasma RNA levels were high (age group medians, 5x10(4) to >10(6) copies/mL), and both baseline RNA and CD4(+) lymphocyte count were independently predictive of subsequent clinical course. Risk reduction for disease progression between 49% and 64% was observed for each log(10) reduction in baseline RNA and was linear without suggestion of a threshold or age effect. Disease progression predictive power was enhanced by the combined use of plasma RNA and CD4(+) cell count, Marker values of less than 10 000 copies/mL for plasma RNA and greater than 500 x 10(6)/L (<6.5 years of age) or greater than 200 x 10(6)/L (>6.5 years) for CD4(+) cell count were associated with a 2-year disease progression rate of less than 5%. Conclusions.-Two key laboratory markers-plasma RNA and CD4(+) lymphocyte count-are independent predictors of clinical course among HIV-infected infants and children. The linear, age-independent relationship between log(10) plasma RNA and relative risk of disease progression strongly supports therapeutic efforts to achieve plasma virus levels as low as possible.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pediat, Newark, NJ 07103 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC USA; NYU, Sch Med, N Shore Univ Hosp, Dept Pediat, Manhasset, NY USA; NIAID, Bethesda, MD 20892 USA; Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Harvard University; Harvard T.H. Chan School of Public Health; University of North Carolina; University of North Carolina Chapel Hill; New York University; Northwell Health; North Shore University Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of California System; University of California San Diego; Baylor College of Medicine; Baylor College of Medicine	Palumbo, PE (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pediat, 185 S Orange Ave, Newark, NJ 07103 USA.		Pahwa, Savita/AAA-4900-2019	Pahwa, Savita/0000-0002-4470-4216				Altman D.G., 1991, PRACTICAL STAT MED R; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; Englund JA, 1997, NEW ENGL J MED, V336, P1704, DOI 10.1056/NEJM199706123362403; Englund JA, 1996, PEDIATR INFECT DIS J, V15, P1025, DOI 10.1097/00006454-199611000-00018; Hughes MD, 1997, ANN INTERN MED, V126, P929, DOI 10.7326/0003-4819-126-12-199706150-00001; Kalbfleisch M, 1980, STAT ANAL FAILURE TI; Katzenstein DA, 1996, NEW ENGL J MED, V335, P1091, DOI 10.1056/NEJM199610103351502; KIEVITS T, 1991, J VIROL METHODS, V35, P273, DOI 10.1016/0166-0934(91)90069-C; KROGSTAD P, 1997, 4 C RETR OPP INF JAN; Luzuriaga K, 1997, NEW ENGL J MED, V336, P1343, DOI 10.1056/NEJM199705083361902; MCKINNEY R, 1997, 35 ANN M INF DIS SOC; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Melvin AJ, 1997, PEDIATR INFECT DIS J, V16, P968, DOI 10.1097/00006454-199710000-00013; Mofenson LM, 1997, J INFECT DIS, V175, P1029, DOI 10.1086/516441; MUELLER BU, 1997, 4 C RETR OPP INF JAN; OBrien WA, 1997, ANN INTERN MED, V126, P939, DOI 10.7326/0003-4819-126-12-199706150-00002; PALUMBO PE, 1995, J PEDIATR-US, V126, P592, DOI 10.1016/S0022-3476(95)70357-8; PALUMBO PE, 1997, 4 C RETR OPP INF JAN; Rich KC, 1997, CLIN DIAGN LAB IMMUN, V4, P358, DOI 10.1128/CDLI.4.3.358-361.1997; Saag MS, 1996, NAT MED, V2, P625, DOI 10.1038/nm0696-625; SCHLESINGER M, 1995, PEDIATR RES, V38, P390, DOI 10.1203/00006450-199509000-00020; Shearer WT, 1997, NEW ENGL J MED, V336, P1337, DOI 10.1056/NEJM199705083361901	24	170	175	1	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 11	1998	279	10					756	761		10.1001/jama.279.10.756	http://dx.doi.org/10.1001/jama.279.10.756			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA474	9508151	Bronze			2022-12-28	WOS:000072366900032
J	Hochschild, A; Dove, SL				Hochschild, A; Dove, SL			Protein-protein contacts that activate and repress prokaryotic transcription	CELL			English	Review							COLI RNA-POLYMERASE; ALPHA-SUBUNIT; RECOGNITION; DOMAIN; DNA		Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Hochschild, A (corresponding author), Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, 200 Longwood Ave D-1, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044025] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Artsimovitch I, 1996, J BIOL CHEM, V271, P32343, DOI 10.1074/jbc.271.50.32343; BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; CHOY HE, 1995, EMBO J, V14, P4523, DOI 10.1002/j.1460-2075.1995.tb00131.x; Dove SL, 1997, NATURE, V386, P627, DOI 10.1038/386627a0; DOVE SL, 1998, IN PRESS GENES DEV; Gaal T, 1996, GENE DEV, V10, P16, DOI 10.1101/gad.10.1.16; JEON YH, 1995, SCIENCE, V270, P1495, DOI 10.1126/science.270.5241.1495; LEE JH, 1995, P NATL ACAD SCI USA, V92, P9702, DOI 10.1073/pnas.92.21.9702; Li M, 1997, P NATL ACAD SCI USA, V94, P3691, DOI 10.1073/pnas.94.8.3691; Malhotra A, 1996, CELL, V87, P127, DOI 10.1016/S0092-8674(00)81329-X; Miller A, 1997, SCIENCE, V275, P1655, DOI 10.1126/science.275.5306.1655; Monsalve M, 1997, MOL CELL, V1, P99, DOI 10.1016/S1097-2765(00)80011-8; Murakami K, 1997, P NATL ACAD SCI USA, V94, P11274, DOI 10.1073/pnas.94.21.11274; Niu W, 1996, CELL, V87, P1123, DOI 10.1016/S0092-8674(00)81806-1; North AK, 1997, J MOL BIOL, V267, P17, DOI 10.1006/jmbi.1996.0838; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Rhodius VA, 1997, NUCLEIC ACIDS RES, V25, P326, DOI 10.1093/nar/25.2.326; Roberts CW, 1996, CELL, V86, P495; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; Sanders GM, 1997, EMBO J, V16, P3124, DOI 10.1093/emboj/16.11.3124	20	120	123	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 6	1998	92	5					597	600		10.1016/S0092-8674(00)81126-5	http://dx.doi.org/10.1016/S0092-8674(00)81126-5			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZA827	9506513	Bronze			2022-12-28	WOS:000072406000004
J	Kahn, BB				Kahn, BB			Type 2 diabetes: When insulin secretion fails to compensate for insulin resistance	CELL			English	Review							TRANSGENIC MICE; MELLITUS; EXPRESSION		Beth Israel Deaconess Med Ctr, Dept Med, Diabet Unit, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Kahn, BB (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Diabet Unit, Boston, MA 02215 USA.				NIDDK NIH HHS [R01 DK043051] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Accili D, 1997, TRENDS ENDOCRIN MET, V8, P101, DOI 10.1016/S1043-2760(97)00031-3; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BERNAL D, 1998, IN PRESS DIABETES; Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; DeFronzo RA, 1997, DIABETES REV, V5, P177; Holman GD, 1997, DIABETOLOGIA, V40, P991, DOI 10.1007/s001250050780; Houseknecht KL, 1996, J BIOL CHEM, V271, P11347, DOI 10.1074/jbc.271.19.11347; Kahn CR, 1996, ANNU REV MED, V47, P509; Katz EB, 1996, J MOL MED, V74, P639, DOI 10.1007/s001090050068; KLOPPEL G, 1985, SURV SYN PATHOL RES, V4, P110; McClain DA, 1996, DIABETES, V45, P1003, DOI 10.2337/diabetes.45.8.1003; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; Patti ME, 1996, TRENDS ENDOCRIN MET, V7, P311, DOI 10.1016/S1043-2760(96)00154-3; Stenbit AE, 1997, NAT MED, V3, P1096, DOI 10.1038/nm1097-1096; SURWIT RS, 1991, DIABETES, V40, P82, DOI 10.2337/diabetes.40.1.82; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Terauchi Y, 1997, J CLIN INVEST, V99, P861, DOI 10.1172/JCI119250; VALERA A, 1994, P NATL ACAD SCI USA, V91, P9151, DOI 10.1073/pnas.91.19.9151; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116	20	336	358	2	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 6	1998	92	5					593	596		10.1016/S0092-8674(00)81125-3	http://dx.doi.org/10.1016/S0092-8674(00)81125-3			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZA827	9506512	Bronze			2022-12-28	WOS:000072406000003
J	Evans, SJW				Evans, SJW			Commentary: Identifying the correct risks in diagnosis	BRITISH MEDICAL JOURNAL			English	Editorial Material									London Sch Hyg & Trop Med, London WC1, England	University of London; London School of Hygiene & Tropical Medicine	Evans, SJW (corresponding author), London Sch Hyg & Trop Med, London WC1, England.			Evans, Stephen/0000-0002-1474-2596					0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 28	1998	316	7132					656	656						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA282	9522785				2022-12-28	WOS:000072347900023
J	Guyatt, GH; Juniper, EF; Walter, SD; Griffith, LE; Goldstein, RS				Guyatt, GH; Juniper, EF; Walter, SD; Griffith, LE; Goldstein, RS			Interpreting treatment effects in randomised trials	BRITISH MEDICAL JOURNAL			English	Article							QUALITY-OF-LIFE; CLINICAL-TRIALS; IMPORTANT DIFFERENCE; QUESTIONNAIRE; ASTHMA; DISEASE		McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada; Univ Toronto, Div Resp Med, Toronto, ON, Canada	McMaster University; University of Toronto	Guyatt, GH (corresponding author), McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada.	guyatt@fhs.csu.mcmaster.ca	Walter, Stephen/AAB-5548-2022	Walter, Stephen/0000-0003-4157-8928				DUFFY JC, 1991, J R STAT SOC A, V156, P225; GOLDSTEIN RS, 1994, LANCET, V344, P1394, DOI 10.1016/S0140-6736(94)90568-1; GUYATT GH, 1987, THORAX, V42, P773, DOI 10.1136/thx.42.10.773; JAESCHKE R, 1995, CAN MED ASSOC J, V152, P351; JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6; Juniper EF, 1996, J ALLERGY CLIN IMMUN, V98, P843, DOI 10.1016/S0091-6749(96)70135-5; JUNIPER EF, 1995, AM J RESP CRIT CARE, V151, P66, DOI 10.1164/ajrccm.151.1.7812574; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; Juniper EF, 1996, QUAL LIFE RES, V5, P27, DOI 10.1007/BF00435966; JUNIPER EF, 1996, QUAL LIFE RES, V5, P36; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Redelmeier DA, 1996, J CLIN EPIDEMIOL, V49, P1215, DOI 10.1016/S0895-4356(96)00206-5	14	389	399	0	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 28	1998	316	7132					690	693		10.1136/bmj.316.7132.690	http://dx.doi.org/10.1136/bmj.316.7132.690			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA282	9522799	Green Published			2022-12-28	WOS:000072347900040
J	Hopes, E; McDougall, C; Christie, G; Dewar, J; Wheatley, A; Hall, IP; Helms, PJ				Hopes, E; McDougall, C; Christie, G; Dewar, J; Wheatley, A; Hall, IP; Helms, PJ			Association of glutamine 27 polymorphism of beta(2) adrenoceptor with reported childhood asthma: population based study	BRITISH MEDICAL JOURNAL			English	Article							ABERDEEN SCHOOLCHILDREN; RESPIRATORY SYMPTOMS; ATOPY		Univ Aberdeen, Sch Med, Dept Child Hlth, Aberdeen AB25 2ZD, Scotland; Univ Nottingham Hosp, Queens Med Ctr, Dept Med, Nottingham NG7 2UH, England	University of Aberdeen; University of Nottingham	Helms, PJ (corresponding author), Univ Aberdeen, Sch Med, Dept Child Hlth, Aberdeen AB25 2ZD, Scotland.			Henry, Amanda/0000-0001-6299-7676				Dewar JC, 1997, J ALLERGY CLIN IMMUN, V100, P261, DOI 10.1016/S0091-6749(97)70234-3; GREEN SA, 1995, AM J RESP CELL MOL, V13, P25, DOI 10.1165/ajrcmb.13.1.7598936; HALL IP, 1995, LANCET, V345, P1213, DOI 10.1016/S0140-6736(95)91994-5; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; Omran M, 1996, BRIT MED J, V312, P34, DOI 10.1136/bmj.312.7022.34	5	71	76	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 28	1998	316	7132					664	664		10.1136/bmj.316.7132.664	http://dx.doi.org/10.1136/bmj.316.7132.664			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA282	9522789	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000072347900028
J	Lancaster, T; Swart, AM; Jick, H				Lancaster, T; Swart, AM; Jick, H			Risk of serious haematological toxicity with use of chloramphenicol eye drops in a British general practice database	BRITISH MEDICAL JOURNAL			English	Article									Univ Oxford, Imperial Canc Res Fund, Gen Practice Res Grp, Div Publ Hlth & Primary Care,Inst Hlth Sci, Oxford OX3 7LF, England; Boston Univ, Med Ctr, Boston Collaborat Drug Surveillance Program, Lexington, MA 02173 USA	University of Oxford; Boston University	Lancaster, T (corresponding author), Univ Oxford, Imperial Canc Res Fund, Gen Practice Res Grp, Div Publ Hlth & Primary Care,Inst Hlth Sci, Oxford OX3 7LF, England.			Jick, Hershel/0000-0003-4270-5992	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		DOONA M, 1995, BRIT MED J, V310, P1217, DOI 10.1136/bmj.310.6989.1217; JICK H, 1995, PHARMACOTHERAPY, V15, P176; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Rayner SA, 1996, DRUG SAFETY, V14, P273, DOI 10.2165/00002018-199614050-00001	4	31	31	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 28	1998	316	7132					667	667		10.1136/bmj.316.7132.667	http://dx.doi.org/10.1136/bmj.316.7132.667			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA282	9522792	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000072347900031
J	Morris, K				Morris, K			Short course of AZT halves HIV-1 perinatal transmission	LANCET			English	News Item																			0	8	9	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 28	1998	351	9103					651	651		10.1016/S0140-6736(05)78436-1	http://dx.doi.org/10.1016/S0140-6736(05)78436-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA447	9500334				2022-12-28	WOS:000072364200024
J	Stewart, JH; Andrews, J; Cartlidge, PHT				Stewart, JH; Andrews, J; Cartlidge, PHT			Numbers of deaths related to intrapartum asphyxia and timing of birth in all Wales perinatal survey, 1993-5	BRITISH MEDICAL JOURNAL			English	Article							OBSTETRIC CARE; ACCIDENTS	Objectives: To investigate the relation between the timing of birth and the occurrence of death related to an intrapartum event Design: Analysis of 107 206 births to Welsh residents in 1993-5, including 608 cases of stillbirth and 407 of neonatal death identified in the all Wales perinatal survey, the cause of death classified with the clinicopathological system. Subjects: 79 normally formed babies stillborn or who died in the neonatal period, birth weight > 1499 g, for whom cause of death was related to an intrapartum event. Main outcome measures: Relative risk of death due to an intrapartum event according to the hour, day, and month of birth. Results: Mortality was higher in babies born between 9 00 pm and 8 59 am than in those born between 9 00 am and 8 59 pm; relative risk (95% confidence interval) 2.18 (1.37 to 3.47). July and August births also had a higher death rate than births in other months; relative risk 1.99 (1.23 to 3.23). Weekend births had a higher death rate but it was not significant. Conclusions: The excess of deaths at night and during months when annual leave is popular may indicate an overreliance on inexperienced staff at these times. Errors of judgment may also be related to physical and mental fatigue, demanding a more disciplined systematic approach at night. Mistakes may be ameliorated by increasing shiftwork, but shifts should be carefully designed to avoid undue disruption of circadian rhythms. In addition, greater supervision by senior staff may be required at night and during summer months.	Univ Wales Coll Med, Dept Child Hlth, Cardiff CF4 4XN, S Glam, Wales	Cardiff University	Cartlidge, PHT (corresponding author), Univ Wales Coll Med, Dept Child Hlth, Cardiff CF4 4XN, S Glam, Wales.							ANDREWS J, 1996, REP MAT DAT INF ASP; *BRIT POSTGR MED F, 1991, PATT HOSP MED STAFF; *CEPOD, 1997, NAT CONF ENQ PER DEA; *DEP HLTH, 1993, CONF ENQ STILLB DEAT; DRISCOLL P, 1995, RISK MANAGEMENT ACCI; Field D J, 1988, Paediatr Perinat Epidemiol, V2, P213, DOI 10.1111/j.1365-3016.1988.tb00209.x; GAFFNEY G, 1994, BRIT MED J, V308, P743, DOI 10.1136/bmj.308.6931.743; GOLD DR, 1992, AM J PUBLIC HEALTH, V82, P1011, DOI 10.2105/AJPH.82.7.1011; Kapur N, 1997, J ROY COLL PHYS LOND, V31, P162; KEELING JW, 1989, ARCH DIS CHILD, V64, P1345, DOI 10.1136/adc.64.10_Spec_No.1345; KIELY JL, 1985, AM J OBSTET GYNECOL, V153, P721, DOI 10.1016/0002-9378(85)90331-X; MACFARLANE A, 1984, BIRTH COUNTS STAT PR; *MAT CHILD HLTH RE, 1997, 4 MAT CHILD HLTH RES; MEER L, 1990, BRIT MED J, V301, P118; NISWANDER K, 1984, LANCET, V2, P827; *PER SURV OFF, 1997, WAL PER SURV CONF EN; WIGGLESWORTH JS, 1980, LANCET, V2, P684	17	85	87	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 28	1998	316	7132					657	660		10.1136/bmj.316.7132.657	http://dx.doi.org/10.1136/bmj.316.7132.657			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA282	9522787	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000072347900026
J	Logmans, A; Verhoeff, A; Raap, RB; Creighton, F; van Lent, M				Logmans, A; Verhoeff, A; Raap, RB; Creighton, F; van Lent, M			Who wants the procedure and why	BRITISH MEDICAL JOURNAL			English	Article							MUTILATION FEMALE CIRCUMCISION		Dr Daniel den Hoed Klin, Dept Gynaecol, NL-3075 EA Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute	Logmans, A (corresponding author), Zuiderziekenhuis, Gr Hilledijik 315, NL-3075 EA Rotterdam, Netherlands.							BAKER CA, 1993, AM J OBSTET GYNECOL, V169, P1616, DOI 10.1016/0002-9378(93)90448-R; BOLANDE RP, 1969, NEW ENGL J MED, V280, P591, DOI 10.1056/NEJM196903132801105; DESANTIS L, 1995, ARCH PSYCHIAT NURS, V9, P354, DOI 10.1016/S0883-9417(95)80059-X; DESILVA S, 1989, EUR J OBSTET GYN R B, V32, P233, DOI 10.1016/0028-2243(89)90041-5; JORDAN JA, 1994, BRIT J OBSTET GYNAEC, V101, P94, DOI 10.1111/j.1471-0528.1994.tb13070.x; KLUGE EH, 1993, CAN MED ASSOC J, V148, P288; Lipson J G, 1995, Health Care Women Int, V16, P279; MENIRU GI, 1994, BRIT J OBSTET GYNAEC, V101, P832, DOI 10.1111/j.1471-0528.1994.tb11967.x; Wall LL, 1996, OBSTET GYNECOL, V88, P633, DOI 10.1016/0029-7844(96)00177-9	9	34	34	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 7	1998	316	7129					459	460		10.1136/bmj.316.7129.459	http://dx.doi.org/10.1136/bmj.316.7129.459			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW874	9492678	Green Published, Green Submitted			2022-12-28	WOS:000071982700042
J	Fatemi, M; Greenleaf, JF				Fatemi, M; Greenleaf, JF			Ultrasound-stimulated vibro-acoustic spectrography	SCIENCE			English	Article							RADIATION PRESSURE; FORCE	An ultrasound method based on radiation force is presented for imaging the acoustic response of a material to mechanical excitation, Acoustic energy was emitted from solids and tissues in response to an oscillatory radiation force produced by interfering focused beams of ultrasound. Frequency spec tra of ultrasound-stimulated acoustic emission exhibited object resonances. Raster-scanning the radiation force over the object and recording the amplitude and phase of the emitted sound resulted in data from which images related to the elastic compositions of the acoustically emitting objects could be computed. Acoustic emission signals distinguished tuning-fork resonances, submillimeter glass spheres, and calcification in excised arteries and detected object motions on the order of nanometers.	Mayo Clin & Mayo Fdn, Dept Physiol & Biophys, Rochester, MN 55905 USA	Mayo Clinic	Fatemi, M (corresponding author), Mayo Clin & Mayo Fdn, Dept Physiol & Biophys, Rochester, MN 55905 USA.							BEYER RT, 1978, J ACOUST SOC AM, V63, P1025, DOI 10.1121/1.381833; CHU BT, 1982, J ACOUST SOC AM, V72, P1673, DOI 10.1121/1.388660; FISCH MR, 1976, J ACOUST SOC AM, V60, P623, DOI 10.1121/1.381124; Gao L, 1996, ULTRASOUND MED BIOL, V22, P959, DOI 10.1016/S0301-5629(96)00120-2; Jiang ZY, 1996, J ACOUST SOC AM, V100, P741, DOI 10.1121/1.416236; LIDE DR, 1991, CRC HDB CHEM PHYSICS, V72, P6; Maynard J, 1996, PHYS TODAY, V49, P26, DOI 10.1063/1.881483; Morse P.M., 1968, THEORETICAL ACOUSTIC; MUTHUPILLAI R, 1995, SCIENCE, V269, P1854, DOI 10.1126/science.7569924; Rayleigh, 1902, PHILOS MAG, V3, P338, DOI 10.1080/14786440209462769; RAYLEIGH, 1905, PHIL MAG, V10, P364; Rudenko OV, 1996, J ACOUST SOC AM, V99, P2791, DOI 10.1121/1.414805; SUGIMOTO T, 1990, 1990 IEEE ULTR S P, V3, P1377; TORR GR, 1984, AM J PHYS, V52, P402, DOI 10.1119/1.13625; WESTERVELT PJ, 1951, J ACOUST SOC AM, V23, P312, DOI 10.1121/1.1906764	15	521	571	1	86	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 3	1998	280	5360					82	85		10.1126/science.280.5360.82	http://dx.doi.org/10.1126/science.280.5360.82			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF314	9525861				2022-12-28	WOS:000072885100038
J	Grebenev, S; Toennies, JP; Vilesov, AF				Grebenev, S; Toennies, JP; Vilesov, AF			Superfluidity within a small helium-4 cluster: The microscopic Andronikashvili experiment	SCIENCE			English	Article							RESOLUTION INFRARED-SPECTROSCOPY; INTEGRAL MONTE-CARLO; LIQUID-HELIUM; EVAPORATION RATE; HE-4; TEMPERATURE; DYNAMICS; DROPLETS; SF6	The infrared spectrum of single oxygen carbon sulfide (OCS) molecules was measured inside large superfluid pure helium-4 droplets and nonsuperfluid pure helium-3 droplets, both consisting of about 10(4) atoms. In the helium-4 droplets, sharp rotational lines were observed, whereas in helium-3 only a broad peak was found. This difference is interpreted as evidence that the narrow rotational lines, which imply free rotations, are a microscopic manifestation of superfluidity. Upon addition of 60 helium-4 atoms to the pure helium-3 droplets, the same sharp rotational lines were found; it appears that 60 is the minimum number needed for superfluidity.	Max Planck Inst Stromungsforsch, D-37073 Gottingen, Germany	Max Planck Society	Toennies, JP (corresponding author), Max Planck Inst Stromungsforsch, Bunsenstr 10, D-37073 Gottingen, Germany.	jtoenni@gwdg.de						Allen JF, 1938, NATURE, V141, P75, DOI 10.1038/141075a0; Andronikashvili E.L., 1946, J PHYS USSR, V10, P201; Barranco M, 1997, PHYS REV B, V56, P8997, DOI 10.1103/PhysRevB.56.8997; BERKHOUT PJ, 1977, COMMUN PHYS, V2, P109; BETTS DS, 1963, PHILOS MAG, V8, P977, DOI 10.1080/14786436308214457; BRINK DM, 1990, Z PHYS D ATOM MOL CL, V15, P257, DOI 10.1007/BF01437187; CHESTER M, 1973, PHYS REV LETT, V31, P1377, DOI 10.1103/PhysRevLett.31.1377; CLARKE JHR, 1978, ADV INFRARED RAMAN S, V4, P109; EDWARDS DO, 1992, J LOW TEMP PHYS, V89, P831, DOI 10.1007/BF00683889; FROCHTENICHT R, 1994, CHEM PHYS LETT, V229, P1, DOI 10.1016/0009-2614(94)01026-9; GORDON RG, 1966, J CHEM PHYS, V44, P1830, DOI 10.1063/1.1726949; GOYAL S, 1992, PHYS REV LETT, V69, P933, DOI 10.1103/PhysRevLett.69.933; GREBENEV S, UNPUB; GUIRAO A, 1991, Z PHYS D ATOM MOL CL, V21, P185, DOI 10.1007/BF01425597; GUO HM, 1971, PHYS REV LETT, V27, P1259, DOI 10.1103/PhysRevLett.27.1259; Harms J, 1997, J MOL SPECTROSC, V185, P204, DOI 10.1006/jmsp.1997.7343; HARMS J, UNPUB; Hartmann M, 1996, PHYS REV LETT, V76, P4560, DOI 10.1103/PhysRevLett.76.4560; Hartmann M, 1996, SCIENCE, V272, P1631, DOI 10.1126/science.272.5268.1631; HARTMANN M, 1995, PHYS REV LETT, V75, P1566, DOI 10.1103/PhysRevLett.75.1566; HARTMANN M, 1997, THESIS U GOTTINGEN G; Higgins J, 1996, SCIENCE, V273, P629, DOI 10.1126/science.273.5275.629; Kapitza P, 1938, NATURE, V141, P74, DOI 10.1038/141074a0; Kwon YK, 1996, J CHEM PHYS, V104, P2341, DOI 10.1063/1.470929; LAMB H, 1945, HYDRODYNAMICS, P154; Landau L, 1941, J PHYS-USSR, V5, P71; Landau L. D., 1947, J PHYS USSR, V11, P91; LEWERENZ M, 1993, CHEM PHYS LETT, V206, P381, DOI 10.1016/0009-2614(93)85569-A; LEWERENZ M, 1995, J CHEM PHYS, V102, P8191, DOI 10.1063/1.469231; OKUMURA M, 1989, PHYS REV LETT, V62, P32, DOI 10.1103/PhysRevLett.62.32; PITAEVSKII L, 1990, Z PHYS D ATOM MOL CL, V16, P299, DOI 10.1007/BF01437534; SINDZINGRE P, 1989, PHYS REV LETT, V63, P1601, DOI 10.1103/PhysRevLett.63.1601; Tisza L, 1938, CR HEBD ACAD SCI, V207, P1186; Tisza L, 1938, CR HEBD ACAD SCI, V207, P1035; Tisza L, 1938, NATURE, V141, P913, DOI 10.1038/141913a0; WHALEY KB, 1994, INT REV PHYS CHEM, V13, P41, DOI 10.1080/01442359409353290; WOODS ADB, 1963, CAN J PHYS, V41, P596, DOI 10.1139/p63-062	37	570	573	1	76	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 27	1998	279	5359					2083	2086		10.1126/science.279.5359.2083	http://dx.doi.org/10.1126/science.279.5359.2083			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZE274	9516103				2022-12-28	WOS:000072775600039
J	Raad, I				Raad, I			Intravascular-catheter-related infections	LANCET			English	Article							CENTRAL VENOUS CATHETERS; PROSPECTIVE RANDOMIZED MULTICENTER; STAPHYLOCOCCUS-AUREUS BACTEREMIA; IMMUNOCOMPROMISED PATIENTS; BARRIER PRECAUTIONS; ENDOLUMINAL BRUSH; CONTROLLED TRIAL; CRITICALLY ILL; SEPSIS; PREVENTION		Univ Texas, MD Anderson Cancer Ctr, Dept Med Specialties, Sect Infect Control, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Raad, I (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Med Specialties, Sect Infect Control, Box 47,1515 Holcombe Blvd, Houston, TX 77030 USA.	iraad@notes.mdacc.tmc.edu						ANAISSIE E, 1995, EUR J CLIN MICROBIOL, V14, P134, DOI 10.1007/BF02111873; ANDRIVET P, 1994, CLIN INFECT DIS, V18, P199, DOI 10.1093/clinids/18.2.199; BENEZRA D, 1988, AM J MED, V85, P495; CALWELL DE, 1992, J MICROBIOL METH, V15, P249; Christensen Gordon D., 1994, P45; COSTERTON JW, 1995, ANNU REV MICROBIOL, V49, P711, DOI 10.1146/annurev.mi.49.100195.003431; COSTERTON JW, 1986, BACTERIA NATURE, V2, P49; DAROUICHE R, 1997, 37 INT C ANT AG CHEM; DERETIC V, 1994, J BACTERIOL, V176, P2773, DOI 10.1128/JB.176.10.2773-2780.1994; DUGDALE DC, 1990, AM J MED, V89, P137, DOI 10.1016/0002-9343(90)90290-T; ELTING LS, 1990, MEDICINE, V69, P296, DOI 10.1097/00005792-199009000-00003; FAUBION WC, 1986, JPEN-PARENTER ENTER, V10, P642, DOI 10.1177/0148607186010006642; GRISTINA AG, 1988, JAMA-J AM MED ASSOC, V259, P870, DOI 10.1001/jama.259.6.870; GROEGER JS, 1993, ANN SURG, V218, P206, DOI 10.1097/00000658-199308000-00014; HEISELMAN D, 1994, JAMA-J AM MED ASSOC, V272, P1819, DOI 10.1001/jama.272.23.1819; HERRMANN M, 1988, J INFECT DIS, V158, P693, DOI 10.1093/infdis/158.4.693; HILL RLR, 1990, J HOSP INFECT, V15, P311, DOI 10.1016/0195-6701(90)90088-6; KIEHN TE, 1990, EUR J CLIN MICROBIOL, V9, P869, DOI 10.1007/BF01967501; Kite P, 1997, J CLIN PATHOL, V50, P278, DOI 10.1136/jcp.50.4.278; LINARES J, 1985, J CLIN MICROBIOL, V21, P357; MAKI DG, 1991, LANCET, V338, P339, DOI 10.1016/0140-6736(91)90479-9; MAKI DG, 1994, INFECT CONT HOSP EP, V15, P227; MAKI DG, 1981, AM J MED, V70, P739, DOI 10.1016/0002-9343(81)90605-7; MAKI DG, 1988, AM J MED, V85, P307, DOI 10.1016/0002-9343(88)90579-7; Maki DG, 1997, ANN INTERN MED, V127, P257, DOI 10.7326/0003-4819-127-4-199708150-00001; MAKI DG, 1977, NEW ENGL J MED, V296, P1305, DOI 10.1056/NEJM197706092962301; MAKI DG, 1991, INFECT CAUSED INTRAV; MALANOSKI GJ, 1995, ARCH INTERN MED, V155, P1161, DOI 10.1001/archinte.155.11.1161; MERMEL LA, 1991, AM J MED, V91, pS197, DOI 10.1016/0002-9343(91)90369-9; NGUYEN MH, 1995, ARCH INTERN MED, V155, P2429, DOI 10.1001/archinte.155.22.2429; Quilici N, 1997, CLIN INFECT DIS, V25, P1066, DOI 10.1086/516090; RAAD I, 1992, INFECT CONT HOSP EP, V13, P215; Raad I, 1996, J INFECT DIS, V173, P418, DOI 10.1093/infdis/173.2.418; Raad I, 1997, ANN INTERN MED, V127, P267, DOI 10.7326/0003-4819-127-4-199708150-00002; Raad I, 1997, CLIN INFECT DIS, V25, P149, DOI 10.1086/514518; Raad I, 1995, CLINIGUIDE FUNGAL IN, V6, P5; RAAD II, 1992, CLIN INFECT DIS, V14, P75, DOI 10.1093/clinids/14.1.75; RAAD II, 1994, INFECT CONT HOSP EP, V15, P231; RAAD II, 1996, INFECT MED, V13, P807; RACKOFF WR, 1995, J PEDIATR-US, V127, P147, DOI 10.1016/S0022-3476(95)70276-8; RADD I, 1993, J INFECT DIS, V168, P400, DOI 10.1093/infdis/168.2.400; REIFSTECK F, 1987, J MED MICROBIOL, V24, P65, DOI 10.1099/00222615-24-1-65; REX JH, 1994, NEW ENGL J MED, V331, P1325, DOI 10.1056/NEJM199411173312001; RIEBEL W, 1986, REV INFECT DIS, V8, P42; ROSE HD, 1978, AM J MED SCI, V275, P265, DOI 10.1097/00000441-197805000-00004; SCHWARTZ C, 1990, J CLIN ONCOL, V8, P1591, DOI 10.1200/JCO.1990.8.9.1591; Segura M, 1996, ANN SURG, V223, P363, DOI 10.1097/00000658-199604000-00004; SHERERTZ RJ, 1995, J BIOMED MATER RES, V29, P635, DOI 10.1002/jbm.820290511; SHERERTZ RJ, 1990, J CLIN MICROBIOL, V28, P76, DOI 10.1128/JCM.28.1.76-82.1990; SHETH NK, 1983, J CLIN MICROBIOL, V18, P1061, DOI 10.1128/JCM.18.5.1061-1063.1983; Tighe MJ, 1996, BRIT MED J, V313, P1528, DOI 10.1136/bmj.313.7071.1528; Tighe MJ, 1996, JPEN-PARENTER ENTER, V20, P215, DOI 10.1177/0148607196020003215; Timsit JF, 1996, JAMA-J AM MED ASSOC, V276, P1416, DOI 10.1001/jama.276.17.1416	53	422	452	1	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 21	1998	351	9106					893	898		10.1016/S0140-6736(97)10006-X	http://dx.doi.org/10.1016/S0140-6736(97)10006-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD047	9525387				2022-12-28	WOS:000072645500045
J	Chabinyc, ML; Craig, SL; Regan, CK; Brauman, JI				Chabinyc, ML; Craig, SL; Regan, CK; Brauman, JI			Gas-phase ionic reactions: Dynamics and mechanism of nucleophilic displacements	SCIENCE			English	Article							SN2 TRANSITION-STATES; S(N)2 REACTIONS; CHLORIDE-ION; TEMPERATURE-DEPENDENCE; VIBRATIONAL-EXCITATION; CYCLOTRON RESONANCE; INTRINSIC BARRIERS; IDENTITY EXCHANGE; METHYL-CHLORIDE; KINETIC-ENERGY	Nucleophilic displacement reactions (the S(N)2 reaction) of ions in the gas phase are a prototypical reaction system that allows a study of dynamics, mechanisms, and structure-energy relations. This article reviews aspects of the kinetics (especially the applicability of statistical reaction rate theory), the relation of structure and reactivity, and the effects of small numbers of solvent molecules on the reaction and compares the behavior of the ionic reaction in the gas phase with that in solution.	Stanford Univ, Dept Chem, Stanford, CA 94305 USA; Dupont Co, Dept Cent Res & Dev, Wilmington, DE 19880 USA	Stanford University; DuPont	Brauman, JI (corresponding author), Stanford Univ, Dept Chem, Stanford, CA 94305 USA.	brauman@stanford.edu	Chabinyc, Michael/E-2387-2011; Craig, Stephen/AAP-6717-2020; Craig, Stephen L/D-3484-2011	Craig, Stephen/0000-0002-8810-0369; Craig, Stephen L/0000-0002-8810-0369				ARMENTROUT PB, 1995, ACCOUNTS CHEM RES, V28, P430, DOI 10.1021/ar00058a005; ARSHADI M, 1970, J PHYS CHEM-US, V74, P1475, DOI 10.1021/j100702a014; BAER S, 1989, J AM CHEM SOC, V111, P4097, DOI 10.1021/ja00193a049; BARLOW SE, 1988, J AM CHEM SOC, V110, P7240, DOI 10.1021/ja00229a064; BERGSMA JP, 1987, J CHEM PHYS, V86, P1356, DOI 10.1063/1.452224; BOERING KA, 1992, J CHEM PHYS, V97, P5439, DOI 10.1063/1.463803; BOHME DK, 1984, J AM CHEM SOC, V106, P3447, DOI 10.1021/ja00324a011; BOHME DK, 1984, IONIC PROCESSES GAS; CALDWELL G, 1984, J AM CHEM SOC, V106, P959, DOI 10.1021/ja00316a023; CHANDRASEKHAR J, 1985, J AM CHEM SOC, V107, P154, DOI 10.1021/ja00287a028; Craig SL, 1996, J AM CHEM SOC, V118, P6786, DOI 10.1021/ja953586b; Craig SL, 1997, BER BUNSEN PHYS CHEM, V101, P510, DOI 10.1002/bbpc.19971010325; Craig SL, 1997, SCIENCE, V276, P1536, DOI 10.1126/science.276.5318.1536; CRAIG SP, UNPUB; CYR DM, 1991, J AM CHEM SOC, V113, P9697, DOI 10.1021/ja00025a059; DEPUY CH, 1990, J AM CHEM SOC, V112, P8650, DOI 10.1021/ja00180a003; Dessent CEH, 1997, J AM CHEM SOC, V119, P5067, DOI 10.1021/ja970583l; DeTuri VF, 1997, J PHYS CHEM A, V101, P5969, DOI 10.1021/jp971452+; DODD JA, 1984, J AM CHEM SOC, V106, P5356, DOI 10.1021/ja00330a056; Dunbar RC, 1995, J AM CHEM SOC, V117, P12819, DOI 10.1021/ja00156a020; Gilbert RG., 1990, THEORY UNIMOLECULAR; GOLDBERG N, 1994, ACCOUNTS CHEM RES, V27, P347, DOI 10.1021/ar00047a005; Gonzalez-Lafont A., 1996, CHEM REACTIONS CLUST, P3; GRAUL ST, 1994, J AM CHEM SOC, V116, P3875, DOI 10.1021/ja00088a024; GRAUL ST, 1991, J AM CHEM SOC, V113, P9696, DOI 10.1021/ja00025a058; GRAUL ST, UNPUB; HASE WL, 1994, SCIENCE, V266, P998, DOI 10.1126/science.266.5187.998; HIERL PM, 1988, FARADAY DISCUSS, V85, P37; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; HU WP, 1994, J AM CHEM SOC, V116, P7797, DOI 10.1021/ja00096a041; JENSEN F, 1992, CHEM PHYS LETT, V196, P368, DOI 10.1016/0009-2614(92)85984-I; KNIGHTON WB, 1993, J AM CHEM SOC, V115, P12079, DOI 10.1021/ja00078a053; LARSON JW, 1987, J AM CHEM SOC, V109, P6230, DOI 10.1021/ja00255a002; LEE J, 1992, CHEM REV, V92, P1611, DOI 10.1021/cr00015a007; Li C, 1996, J AM CHEM SOC, V118, P9360, DOI 10.1021/ja960565o; March J., 1992, ADV ORG CHEM, V4th; Marcus RA, 1997, J PHYS CHEM A, V101, P4072, DOI 10.1021/jp963722e; MARCUS RA, 1964, ANNU REV PHYS CHEM, V15, P155, DOI 10.1146/annurev.pc.15.100164.001103; MOROKUMA K, 1982, J AM CHEM SOC, V104, P3733; Moylan C. R., 1994, ADV CLAS TR, P95; MURDOCH JR, 1972, J AM CHEM SOC, V94, P4410, DOI 10.1021/ja00768a002; NIBBERING NMM, 1996, STRUCTURE ENERGETICS; OHAIR RAJ, 1994, J AM CHEM SOC, V116, P3609, DOI 10.1021/ja00087a061; OLMSTEAD WN, 1977, J AM CHEM SOC, V99, P4219, DOI 10.1021/ja00455a002; PELLERITE MJ, 1980, J AM CHEM SOC, V102, P5993, DOI 10.1021/ja00539a003; PELLERITE MJ, 1983, J AM CHEM SOC, V105, P2672, DOI 10.1021/ja00347a026; RIVEROS JM, 1973, J AM CHEM SOC, V95, P4066, DOI 10.1021/ja00793a050; RIVEROS JM, 1985, ADV PHYS ORG CHEM, V21, P197, DOI 10.1016/S0065-3160(08)60100-8; Sahlstrom KE, 1997, J PHYS CHEM A, V101, P5543, DOI 10.1021/jp9712718; Seeley JV, 1997, J AM CHEM SOC, V119, P577, DOI 10.1021/ja960872u; Shaik S. S., 1992, THEORETICAL ASPECTS; SQUIRES RR, 1992, ACCOUNTS CHEM RES, V25, P461, DOI 10.1021/ar00022a005; StreitwieserJr, 1962, SOLVOLYTIC DISPLACEM; SU T, 1994, J CHEM PHYS, V100, P4703, DOI 10.1063/1.466255; TORBORG CJ, 1995, TETRAHEDRON LETT, V38, P6025; TUCKER SC, 1990, J AM CHEM SOC, V112, P3347, DOI 10.1021/ja00165a014; TUCKER SC, 1989, CHEM PHYS LETT, V157, P164, DOI 10.1016/0009-2614(89)87227-6; VANDELINDE SR, 1990, J CHEM PHYS, V93, P7962, DOI 10.1063/1.459326; VANDERWEL H, 1987, J AM CHEM SOC, V109, P5823, DOI 10.1021/ja00253a039; VIGGIANO AA, 1992, J AM CHEM SOC, V114, P10477, DOI 10.1021/ja00052a050; VIGGIANO AA, 1994, J AM CHEM SOC, V116, P2213, DOI 10.1021/ja00084a099; WANG HB, 1995, J AM CHEM SOC, V117, P9347, DOI 10.1021/ja00141a029; Wang HB, 1997, J AM CHEM SOC, V119, P3093, DOI 10.1021/ja962622j; WILBUR JL, 1991, J AM CHEM SOC, V113, P9699, DOI 10.1021/ja00025a060; WLADKOWSKI BD, 1992, J AM CHEM SOC, V114, P9136, DOI 10.1021/ja00049a055; WLADKOWSKI BD, 1993, J PHYS CHEM-US, V97, P13158, DOI 10.1021/j100152a021; WLADKOWSKI BD, 1994, J AM CHEM SOC, V116, P2471, DOI 10.1021/ja00085a030; WOLFE S, 1981, J AM CHEM SOC, V103, P7692, DOI 10.1021/ja00415a068; WOLFE S, 1981, J AM CHEM SOC, V103, P7694, DOI 10.1021/ja00415a069; ZHAO XG, 1992, J CHEM PHYS, V97, P6369, DOI 10.1063/1.463698	70	256	257	2	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 20	1998	279	5358					1882	1886		10.1126/science.279.5358.1882	http://dx.doi.org/10.1126/science.279.5358.1882			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506930				2022-12-28	WOS:000072613300033
J	McCall, BJ; Geballe, TR; Hinkle, KH; Oka, T				McCall, BJ; Geballe, TR; Hinkle, KH; Oka, T			Detection of H-3(+) in the diffuse interstellar medium toward Cygnus OB2 No. 12	SCIENCE			English	Article							ION-MOLECULE REACTIONS; PHYSICAL CONDITIONS; ABSORPTION-LINES; CLOUDS; STARS; H-3+; ABUNDANCES; ASSOCIATION	The molecular ion H-3(+) is considered the cornerstone of interstellar chemistry because it initiates the reactions responsible for the production of many larger molecules, Recently discovered in dense molecular clouds. H-3(+) has now been observed in the diffuse interstellar medium toward Cygnus OB2 No. 12, Analysis of H-3(+) chemistry suggests that the high H-3(+) column density (3.8 x 10(14) per square centimeter) is due not to a high H-3(+) concentration but to a long absorption path. This and other work demonstrate the ubiquity of H-3(+) and its potential as a probe of the physical and chemical conditions in the interstellar medium.	Univ Chicago, Dept Astron & Astrophys, Chicago, IL 60637 USA; Univ Chicago, Dept Chem, Chicago, IL 60637 USA; Univ Chicago, Enrico Fermi Inst, Chicago, IL 60637 USA; Joint Astron Ctr, Hilo, HI 96720 USA; Natl Opt Astron Observ, Tucson, AZ 85726 USA	University of Chicago; University of Chicago; University of Chicago; National Optical Astronomy Observatory	McCall, BJ (corresponding author), Univ Chicago, Dept Astron & Astrophys, 5640 S Ellis Ave, Chicago, IL 60637 USA.		McCall, Benjamin J/A-3136-2008	McCall, Benjamin/0000-0003-1022-7295				ADAMSON AJ, 1990, MON NOT R ASTRON SOC, V243, P400; AMANO T, 1988, ASTROPHYS J, V329, pL121, DOI 10.1086/185190; ANICICH VG, 1986, ASTROPHYS J SUPPL S, V62, P553, DOI 10.1086/191151; BIEGING JH, 1989, ASTROPHYS J, V340, P518, DOI 10.1086/167414; BLACK JH, 1990, ASTROPHYS J, V358, P459, DOI 10.1086/168999; BOHLIN RC, 1978, ASTROPHYS J, V224, P132, DOI 10.1086/156357; CHAFFEE FH, 1982, ASTROPHYS J SUPPL S, V50, P169, DOI 10.1086/190824; GEBALLE TH, UNPUB; Geballe TR, 1996, NATURE, V384, P334, DOI 10.1038/384334a0; GLASSGOLD AE, 1974, ASTROPHYS J, V193, P73, DOI 10.1086/153130; GREDEL R, 1994, ASTRON ASTROPHYS, V285, P640; HERBST E, 1973, ASTROPHYS J, V185, P505, DOI 10.1086/152436; HINKLE KH, IN PRESS P SOC PHOTO; Lee HH, 1996, ASTRON ASTROPHYS SUP, V119, P111, DOI 10.1051/aas:1996232; LEPP S, 1987, ASTROPHYS J, V321, P383, DOI 10.1086/165636; MASSEY P, 1991, ASTRON J, V101, P1408, DOI 10.1086/115774; MCCALL BJ, UNPUB; Morgan W. W., 1954, PUBL ASTRON SOC PAC, V66, P85; MOUNTAIN CM, 1990, P SOC PHOTO-OPT INS, V1235, P25, DOI 10.1117/12.19068; OKA T, 1981, PHILOS T R SOC A, V303, P543, DOI 10.1098/rsta.1981.0223; PERSI P, 1982, ASTRON ASTROPHYS, V111, pL7; RIEKE GH, 1985, ASTROPHYS J, V288, P618, DOI 10.1086/162827; RIEKE GH, 1974, ASTROPHYS J, V193, pL81, DOI 10.1086/181637; SHARPLESS S, 1957, PUBL ASTRON SOC PAC, V69, P239, DOI 10.1086/127056; TORRESDODGEN AV, 1991, MON NOT R ASTRON SOC, V249, P1; Uy D, 1997, PHYS REV LETT, V78, P3844, DOI 10.1103/PhysRevLett.78.3844; VANDISHOECK EF, 1986, ASTROPHYS J SUPPL S, V62, P109, DOI 10.1086/191135; WATSON WD, 1973, ASTROPHYS J, V183, pL17, DOI 10.1086/181242; WATSON WD, 1974, ASTROPHYS J, V188, P35, DOI 10.1086/152681; Whittet DCB, 1997, ASTROPHYS J, V490, P729, DOI 10.1086/304914	31	188	189	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 20	1998	279	5358					1910	1913		10.1126/science.279.5358.1910	http://dx.doi.org/10.1126/science.279.5358.1910			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506936				2022-12-28	WOS:000072613300039
J	Zare, RN				Zare, RN			Laser control of chemical reactions	SCIENCE			English	Article							CONTROLLING BIMOLECULAR REACTIONS; ORBITAL ALIGNMENT DEPENDENCE; MOLECULAR REACTION DYNAMICS; BOND SELECTED REACTION; O PRODUCT FORMATION; CROSS-SECTIONS; VIBRATIONAL-EXCITATION; MULTIPHOTON IONIZATION; COHERENT CONTROL; HYDROGEN-ATOMS	Experiments show how product pathways can be controlled by irradiation with one or more laser beams during individual bimolecular collisions or during unimolecular decompositions. For bimolecular collisions, control has been achieved by selective excitation of reagent vibrational modes, by control of reagent approach geometry, and by control of orbital alignment. For unimolecular reactions, control has been achieved by quantum interference between different reaction pathways connecting the same initial and final states and by adjusting the temporal shape and spectral content of ultrashort, chirped pulses of radiation. These collision-control experiments deeply enrich the understanding of how chemical reactions occur.	Stanford Univ, Dept Chem, Stanford, CA 94305 USA	Stanford University	Zare, RN (corresponding author), Stanford Univ, Dept Chem, Stanford, CA 94305 USA.	zare@stanford.edu	Zare, Richard N./A-8410-2009	Zare, Richard/0000-0001-5266-4253				BEUHLER RJ, 1966, J AM CHEM SOC, V88, P5331, DOI 10.1021/ja00974a059; BRONIKOWSKI MJ, 1991, J CHEM PHYS, V95, P8647, DOI 10.1063/1.461243; BRONIKOWSKI MJ, 1993, J PHYS CHEM-US, V97, P2204, DOI 10.1021/j100112a022; BRONIKOWSKI MJ, 1993, J PHYS CHEM-US, V97, P2194, DOI 10.1021/j100112a021; BROOKS PR, 1966, J CHEM PHYS, V45, P3449, DOI 10.1063/1.1728128; BRUMER P, 1986, CHEM PHYS LETT, V126, P541, DOI 10.1016/S0009-2614(86)80171-3; BUTLER LJ, 1986, J CHEM PHYS, V84, P4104, DOI 10.1063/1.450075; BUTLER LJ, 1987, J CHEM PHYS, V86, P2051, DOI 10.1063/1.452155; CHEN C, 1990, PHYS REV LETT, V64, P507, DOI 10.1103/PhysRevLett.64.507; CHIU YH, 1994, J CHEM PHYS, V101, P5410, DOI 10.1063/1.467394; CHIU YH, 1995, J CHEM PHYS, V102, P1199, DOI 10.1063/1.468907; CRIM FF, 1984, ANNU REV PHYS CHEM, V35, P657; DAHLEH M, 1990, PHYS REV A, V42, P1065, DOI 10.1103/PhysRevA.42.1065; Ding GW, 1997, CHEM PHYS LETT, V265, P392, DOI 10.1016/S0009-2614(96)01439-X; EBATA T, 1986, CHEM PHYS LETT, V130, P467, DOI 10.1016/0009-2614(86)80241-X; FRIEDRICH B, 1991, NATURE, V353, P412, DOI 10.1038/353412a0; Gordon RJ, 1997, ANNU REV PHYS CHEM, V48, P601, DOI 10.1146/annurev.physchem.48.1.601; GREELEY JN, 1995, J CHEM PHYS, V102, P4996, DOI 10.1063/1.469550; GUETTLER RD, 1994, SCIENCE, V266, P259, DOI 10.1126/science.266.5183.259; Holmes D, 1996, J CHEM PHYS, V105, P9162, DOI 10.1063/1.472749; JUDSON RS, 1992, PHYS REV LETT, V68, P1500, DOI 10.1103/PhysRevLett.68.1500; Keller A, 1996, J CHEM PHYS, V105, P4556, DOI 10.1063/1.472301; KELLER JS, 1992, J CHEM PHYS, V96, P4324, DOI 10.1063/1.462825; KHUNDKAR LR, 1990, ANNU REV PHYS CHEM, V41, P15; Klippenstein SJ, 1996, J CHEM PHYS, V104, P5437, DOI 10.1063/1.471783; KOSLOFF R, 1989, CHEM PHYS, V139, P201, DOI 10.1016/0301-0104(89)90012-8; Kreher C, 1996, J CHEM PHYS, V104, P4481, DOI 10.1063/1.471713; LIN KC, 1988, J CHEM PHYS, V89, P4771, DOI 10.1063/1.455671; LOESCH HJ, 1990, J CHEM PHYS, V93, P4779, DOI 10.1063/1.458668; LOESCH HJ, 1994, J CHEM PHYS, V100, P4308, DOI 10.1063/1.466312; LOESCH HJ, 1994, J CHEM PHYS, V100, P740, DOI 10.1063/1.466942; MARCELIN G, 1975, J AM CHEM SOC, V97, P1710, DOI 10.1021/ja00840a015; MARTIN JS, 1994, J CHEM PHYS, V100, P6791, DOI 10.1063/1.467039; METZ RB, 1993, J CHEM PHYS, V99, P1744, DOI 10.1063/1.465291; MOORE CB, 1979, FARADAY DISCUSS, V67, P146, DOI 10.1039/dc9796700146; ODIORNE TJ, 1971, J CHEM PHYS, V55, P1980, DOI 10.1063/1.1676338; OrrEwing AJ, 1996, J CHEM SOC FARADAY T, V92, P881, DOI 10.1039/ft9969200881; ORREWING AJ, 1997, J PHYS CHEM, V101; PARK SM, 1991, J CHEM PHYS, V94, P8622, DOI 10.1063/1.460047; PARKER DH, 1989, ANNU REV PHYS CHEM, V40, P561, DOI 10.1146/annurev.pc.40.100189.003021; PEIRCE AP, 1988, PHYS REV A, V37, P4950, DOI 10.1103/PhysRevA.37.4950; Pfeiffer JM, 1996, J CHEM PHYS, V104, P4490, DOI 10.1063/1.471200; POLANYI JC, 1987, FARADAY DISCUSS, V84, P1, DOI 10.1039/dc9878400001; POLANYI JC, 1972, ACCOUNTS CHEM RES, V5, P161, DOI 10.1021/ar50053a001; PRUETT JG, 1976, J CHEM PHYS, V64, P1774, DOI 10.1063/1.432355; RETTNER CT, 1982, J CHEM PHYS, V77, P2416, DOI 10.1063/1.444110; Schatz G. C., 1980, CHEM PHYS LETT, V21, P73; SCHATZ GC, 1984, J PHYS CHEM-US, V88, P2971, DOI 10.1021/j150658a011; Shapiro M, 1996, PHYS REV LETT, V77, P2574, DOI 10.1103/PhysRevLett.77.2574; Shapiro M, 1997, J CHEM SOC FARADAY T, V93, P1263, DOI 10.1039/a605920a; SHI SH, 1988, J CHEM PHYS, V88, P6870, DOI 10.1063/1.454384; SHIN SK, 1991, ADV PHOTOCHEM, V16, P249; SINHA A, 1991, J CHEM PHYS, V94, P4928, DOI 10.1063/1.460578; SINHA A, 1990, J CHEM PHYS, V92, P6333, DOI 10.1063/1.458312; SINHA A, 1992, J CHEM PHYS, V96, P372, DOI 10.1063/1.462473; SMITH CJ, 1993, J CHEM SOC FARADAY T, V89, P1401, DOI 10.1039/ft9938901401; SMITH CJ, 1992, J CHEM PHYS, V96, P8212, DOI 10.1063/1.462326; SPAIN EM, 1995, J CHEM PHYS, V102, P9532, DOI 10.1063/1.468768; SUITS AG, 1991, J CHEM PHYS, V95, P8178, DOI 10.1063/1.461297; SUITS AG, 1992, J CHEM PHYS, V96, P2777, DOI 10.1063/1.462026; TACHIKAWA H, 1994, CHEM PHYS, V182, P185, DOI 10.1016/0301-0104(94)00040-9; Tachikawa H, 1996, CHEM PHYS, V211, P305, DOI 10.1016/0301-0104(96)00205-4; TANNOR DJ, 1985, J CHEM PHYS, V83, P5013, DOI 10.1063/1.449767; Wang XB, 1996, J CHEM PHYS, V105, P2992, DOI 10.1063/1.472172; Xing GQ, 1996, J CHEM PHYS, V104, P826, DOI 10.1063/1.470808; Yakovlev VV, 1998, J CHEM PHYS, V108, P2309, DOI 10.1063/1.475615; ZARE RN, 1982, BER BUNSEN PHYS CHEM, V86, P422, DOI 10.1002/bbpc.19820860516; Zhu L, 1997, PHYS REV LETT, V79, P4108, DOI 10.1103/PhysRevLett.79.4108; ZHU LC, 1995, SCIENCE, V270, P77, DOI 10.1126/science.270.5233.77	69	461	473	3	134	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 20	1998	279	5358					1875	1879		10.1126/science.279.5358.1875	http://dx.doi.org/10.1126/science.279.5358.1875			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506928	Green Submitted			2022-12-28	WOS:000072613300031
J	Wylie, DRW; Bischof, WF; Frost, BJ				Wylie, DRW; Bischof, WF; Frost, BJ			Common reference frame for neural coding of translational and rotational optic flow	NATURE			English	Article							PIGEON VESTIBULOCEREBELLAR NEURONS; OPTOKINETIC STIMULATION; SPATIAL-ORGANIZATION; SELF-MOTION; VISUAL FLOW; RESPONSES; PERCEPTION; FLOCCULUS	Self-movement of an organism through the environment is guided jointly by information provided by the vestibular system and by visual pathways that are specialized for detecting 'optic flow'(1,2). Motion of any object through space, including the self-motion of organisms, can be described with reference to six degrees of freedom: rotation about three orthogonal axes, and translation along these axes, Here we describe neurons in the pigeon brain that respond best to optic flow resulting from translation along one of the three orthogonal axes, We show that these translational optic flow neurons, like rotational optic flow neuron(3-5), share a common spatial frame of reference with the semicircular canals of the vestibular system. The three axes to which these neurons respond best are the vertical axis and two horizontal axes orientated at 45 degrees to either side of the body midline.	Univ Alberta, Dept Psychol, Edmonton, AB T6G 2E9, Canada; Queens Univ, Dept Psychol, Kingston, ON K7L 3N6, Canada	University of Alberta; Queens University - Canada	Wylie, DRW (corresponding author), Univ Alberta, Dept Psychol, Edmonton, AB T6G 2E9, Canada.		Bischof, Walter/AAB-9343-2020	Bischof, Walter/0000-0001-5508-0421				ANDERSEN GJ, 1986, PSYCHOL BULL, V99, P52, DOI 10.1037/0033-2909.99.1.52; Bradley DC, 1996, SCIENCE, V273, P1544, DOI 10.1126/science.273.5281.1544; DUFFY CJ, 1991, J NEUROPHYSIOL, V65, P1329, DOI 10.1152/jn.1991.65.6.1329; GIBSON JJ, 1954, PSYCHOL REV, V61, P304, DOI 10.1037/h0061885; GRAF W, 1988, J NEUROPHYSIOL, V60, P2091, DOI 10.1152/jn.1988.60.6.2091; HESS BJM, 1991, J NEUROPHYSIOL, V66, P1805, DOI 10.1152/jn.1991.66.6.1805; JAY MF, 1984, NATURE, V309, P345, DOI 10.1038/309345a0; KNUDSEN EI, 1987, ANNU REV NEUROSCI, V10, P41, DOI 10.1146/annurev.ne.10.030187.000353; Krapp HG, 1996, NATURE, V384, P463, DOI 10.1038/384463a0; LEE DN, 1974, PERCEPT PSYCHOPHYS, V15, P529, DOI 10.3758/BF03199297; MACPHERSON JM, 1988, J NEUROPHYSIOL, V60, P204, DOI 10.1152/jn.1988.60.1.204; MASINO T, 1990, NATURE, V345, P434, DOI 10.1038/345434a0; Owen D. H., 1990, PERCEPTION CONTROL S, P289; Simpson J.I., 1981, PROGR OCULOMOTOR RES, P475; SIMPSON JI, 1984, ANNU REV NEUROSCI, V7, P13, DOI 10.1146/annurev.ne.07.030184.000305; SIMPSON JI, 1985, ADAPTIVE MECHANISMS, P3; SOECHTING JF, 1992, ANNU REV NEUROSCI, V15, P167, DOI 10.1146/annurev.ne.15.030192.001123; WYLIE DR, 1993, J NEUROPHYSIOL, V70, P2647, DOI 10.1152/jn.1993.70.6.2647; WYLIE DR, 1990, VISUAL NEUROSCI, V5, P489, DOI 10.1017/S0952523800000614; WYLIE DR, 1993, J NEUROPHYSIOL, V70, P2632, DOI 10.1152/jn.1993.70.6.2632; [No title captured]	21	91	91	1	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1998	392	6673					278	282		10.1038/32648	http://dx.doi.org/10.1038/32648			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC739	9521321				2022-12-28	WOS:000072612300046
J	Mallick-Wood, CA; Lewis, JM; Richie, LI; Owen, MJ; Tigelaar, RE; Hayday, AC				Mallick-Wood, CA; Lewis, JM; Richie, LI; Owen, MJ; Tigelaar, RE; Hayday, AC			Conservation of T cell receptor conformation in epidermal gamma delta cells with disrupted primary V-gamma gene usage	SCIENCE			English	Article							ALPHA-BETA; INTESTINAL EPITHELIUM; JUNCTIONAL SEQUENCES; LIMITED DIVERSITY; ANTIGEN RECEPTORS; DEFICIENT MICE; LYMPHOCYTES; THYMOCYTES; INFECTION; DISTINCT	A feature that distinguishes gamma delta T cell subsets from most alpha beta T cells and B cells is the association of expression of single T cell receptor (TCR) gamma and delta variable (V) region gene segments with specific anatomic sites. Mice lacking the TCR V(gamma)5 chain normally expressed by most dendritic epidermal T cells were shown to retain a conformational determined (idiotype) ordinarily expressed exclusively by such V(gamma)5(+) cells, Conservation by shuffled gamma delta TCR chains of an idiotype associated with a specific anatomic site indicates that for TCR gamma delta, as for immunoglobulin, conformation is associated to a greater extent with the function or development of lymphocyte repertoires than is the use of particular gene segments.	Yale Univ, Dept Mol Cell & Dev Biol, New Haven, CT 06520 USA; Yale Univ, Immunobiol Sect, New Haven, CT 06520 USA; Yale Univ, Dept Dermatol, New Haven, CT 06511 USA; Yale Univ, Immunobiol Sect, New Haven, CT 06511 USA; Imperial Canc Res Fund, London WC2A 3PX, England	Yale University; Yale University; Yale University; Yale University; Cancer Research UK	Mallick-Wood, CA (corresponding author), Yale Univ, Dept Mol Cell & Dev Biol, New Haven, CT 06520 USA.			Ehrlich, Lauren/0000-0002-1697-1755	NIAID NIH HHS [AI27855, AI27404] Funding Source: Medline; NIGMS NIH HHS [GM37759] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027404, R01AI027855] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037759] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASARNOW DM, 1993, NATURE, V362, P158, DOI 10.1038/362158a0; ASARNOW DM, 1988, CELL, V55, P837, DOI 10.1016/0092-8674(88)90139-0; CARDING S, 1989, GENE DEV, V4, P1304; DELFAU MH, 1992, EUR J IMMUNOL, V22, P2437, DOI 10.1002/eji.1830220937; EZQUERRA A, 1992, EUR J IMMUNOL, V22, P491, DOI 10.1002/eji.1830220230; HAVRAN WL, 1989, P NATL ACAD SCI USA, V86, P4185, DOI 10.1073/pnas.86.11.4185; HAVRAN WL, 1991, SCIENCE, V252, P1430, DOI 10.1126/science.1828619; HAVRAN WL, 1988, NATURE, V335, P443, DOI 10.1038/335443a0; HAYDAY AC, IN PRESS ENCY IMMUNO; HEYBORNE K, 1993, J IMMUNOL, V151, P4523; HEYBORNE KD, 1992, J IMMUNOL, V149, P2872; Hong SC, 1996, J EXP MED, V183, P1437, DOI 10.1084/jem.183.4.1437; Housset D, 1997, EMBO J, V16, P4205, DOI 10.1093/emboj/16.14.4205; ITO K, 1989, P NATL ACAD SCI USA, V86, P631, DOI 10.1073/pnas.86.2.631; ITOHARA S, 1993, CELL, V72, P337, DOI 10.1016/0092-8674(93)90112-4; ITOHARA S, 1990, NATURE, V343, P754, DOI 10.1038/343754a0; KYES S, 1989, P NATL ACAD SCI USA, V86, P5527, DOI 10.1073/pnas.86.14.5527; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; MALLICK CA, 1993, CELL, V73, P513, DOI 10.1016/0092-8674(93)90138-G; MallickWood CA, 1996, P NATL ACAD SCI USA, V93, P9704, DOI 10.1073/pnas.93.18.9704; MALLICKWOOD CA, UNPUB; MCCONNELL TJ, 1989, J IMMUNOL, V142, P2924; MUKASA A, 1995, J IMMUNOL, V155, P2047; NIXONFULTON JL, 1988, J IMMUNOL, V141, P1897; Pao W, 1996, CURR BIOL, V6, P1317, DOI 10.1016/S0960-9822(02)70718-5; PEREIRA P, 1995, J EXP MED, V182, P1921, DOI 10.1084/jem.182.6.1921; RAULET DH, 1991, IMMUNOL REV, V120, P185, DOI 10.1111/j.1600-065X.1991.tb00592.x; Roberts SJ, 1996, P NATL ACAD SCI USA, V93, P11774, DOI 10.1073/pnas.93.21.11774; SANGER F, 1977, P NATL ACAD SCI USA, V74, P513; Sciammas R, 1997, J EXP MED, V185, P1969, DOI 10.1084/jem.185.11.1969; STINGL G, 1987, P NATL ACAD SCI USA, V84, P2430, DOI 10.1073/pnas.84.8.2430; TAKAGAKI Y, 1989, NATURE, V339, P712, DOI 10.1038/339712a0; TAKASHIMA A, 1988, J INVEST DERMATOL, V90, P671, DOI 10.1111/1523-1747.ep12560835; TIGELAAR R, 1995, J INVEST DERMATOL, V105, P435; TONEGUZZO F, 1988, BIOTECHNIQUES, V6, P460; Tsuji M, 1996, INT IMMUNOL, V8, P359, DOI 10.1093/intimm/8.3.359; VANDERHEYDE HC, 1995, J IMMUNOL, V154, P3985	37	104	104	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 13	1998	279	5357					1729	1733		10.1126/science.279.5357.1729	http://dx.doi.org/10.1126/science.279.5357.1729			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9497293				2022-12-28	WOS:000072490000058
J	Goldman, LK; Glantz, SA				Goldman, LK; Glantz, SA			Evaluation of antismoking advertising campaigns	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MASS-MEDIA; CIGARETTE-SMOKING; TOBACCO CONTROL; CALIFORNIA; CONSUMPTION; PREVENTION; DIVERSION; ILLEGAL; MONEY	Context.-Active and passive smoking are the first and third leading preventable causes of death. Many states are running or initiating antitobacco media campaigns. Objective.-To review research on the effectiveness of different antismoking messages and published evidence of the effectiveness of paid antismoking advertising, Data Sources.-Focus group studies conducted by professional advertising agencies that contract with California, Massachusetts, and Michigan to run their antismoking advertising campaigns, the Centers for Disease Control and Prevention's Media Campaign Resource Book, and copies of the advertisements. In total, we reviewed the results of 186 focus groups involving more than 1500 children and adults dealing with 118 advertisements that had actually been aired and additional concept advertisements that were not produced, Published literature was located using MEDLINE and standard bibliographic sources on the effectiveness of large, paid antitobacco media campaigns, We also reviewed reports and studies conducted by, or for, the California and Massachusetts health departments on program effectiveness, and conducted our own comparison of California vs Massachusetts using cigarette consumption data from the Tobacco institute. Study Selection.-All available studies, Data Synthesis.-Eight advertising strategies to prevent people from starting to smoke and persuading them to stop were reviewed: industry manipulation, secondhand smoke, addiction, cessation, youth access, short-term effects, long-term health effects, and romantic rejection. These focus groups identified strategies that would be expected to be effective and ineffective. Regression analysis was used to compare the cost-effectiveness of the California and Massachusetts programs. Conclusions.-Focus group participants indicated that industry manipulation and secondhand smoke are the most effective strategies for denormalizing smoking and reducing cigarette consumption. Addiction and cessation can be effective when used in conjunction with the industry manipulation and secondhand smoke strategies, Youth access, short-term effects, long-term health effects, and romantic rejection are not effective strategies. More aggressive advertising strategies appear to be more effective at reducing tobacco consumption.	Univ Calif San Francisco, Inst Hlth Policy Studies, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Glantz, SA (corresponding author), Univ Calif San Francisco, Inst Hlth Policy Studies, Dept Med, Box 0124, San Francisco, CA 94143 USA.	glantz@cardio.ucsf.edu			NCI NIH HHS [CA-61021] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061021] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*AR DEP HLTH SERV, 1996, AR TOB ED PREV PROGR; BAL DG, 1990, JAMA-J AM MED ASSOC, V264, P1570, DOI 10.1001/jama.264.12.1570; BALBACH ED, 1997, HOLDING GOVT ACCOUNT; Begay M E, 1997, Tob Control, V6, P213; BEGAY ME, 1995, QUESTION 1 TOBACCO E; BLUM A, 1994, AM J PREV MED, V10, P8, DOI 10.1016/S0749-3797(18)30543-9; *FED TRAD COMM, 1981, STAFF REP CIG ADV IN; Flynn BS, 1997, PREV MED, V26, P389, DOI 10.1006/pmed.1997.0159; FLYNN BS, 1994, AM J PUBLIC HEALTH, V84, P1148, DOI 10.2105/AJPH.84.7.1148; FLYNN BS, 1992, AM J PUBLIC HEALTH, V82, P827, DOI 10.2105/AJPH.82.6.827; FRIEDMAN M, 1996, TEEN ANTISMOKING STR; Glantz S., 1993, TOB CONTROL, V2, P311, DOI DOI 10.1136/TC.2.4.311; Glantz SA, 1996, AM J PUBLIC HEALTH, V86, P156, DOI 10.2105/AJPH.86.2.156; Glantz SA, 1997, AM J PUBLIC HEALTH, V87, P870, DOI 10.2105/AJPH.87.5.870; HARRIS JE, 1996, MMWR-MORBID MORTAL W, V45, P966; Harty KC, 1993, TOB CONTROL, V2, P271, DOI DOI 10.1136/TC.2.4.271; Haskins Jack, 1993, SUCCESSFUL ADVERTISI; Heiser PF, 1997, AM J PUBLIC HEALTH, V87, P968, DOI 10.2105/AJPH.87.6.968; HONIG B, 1990, TOBACCO FREE CALIFOR; HONIG B, 1992, TOBACCO FREE CALIFOR; *HOUST HERST FAV, EX TOB IND MAN POS Y; *HOUST HERST FAV, ASS MASS TOB CONTR P; *HOUST HERST FAV, EXPL RES AD SMOK AG; *HOUST HERST FAV, 1996, YOUTH EXPL 1996 MASS; HU TW, 1995, AM ECON REV, V85, P85; HU TW, 1995, AM J PUBLIC HEALTH, V85, P1218, DOI 10.2105/AJPH.85.9.1218; *I MED, 1994, GROW TOB FREE PREV N; JOHNSON CA, 1994, EVALUATION TOBACCO I; KEYE P, 1993, WHAT DONT WE KNOW HA; Koh H K, 1996, Tob Control, V5, P220, DOI 10.1136/tc.5.3.220; *LACHM RES MARK SE, 1995, CAL DEP HLTH SERV AN; *LACHM RES MARK SE, 1993, REACT SMOK REL ISS C; MCKENNA JW, 1994, AM J PREV MED, V10, P378, DOI 10.1016/S0749-3797(18)30569-5; MCKENNA JW, 1993, PUBLIC HEALTH REP, V108, P85; *MI DEP COMM HLTH, 1996, MICH DEP COMM HLTH P; MONARDI F, 1996, SHIFTING ALLEGIANCES; MURRAY DM, 1994, PREV MED, V23, P54, DOI 10.1006/pmed.1994.1008; *NORDH RES I, 1995, SMOK CESS FOC GROUPS; PECHMANN C, 1994, J CONSUM RES, V21, P236, DOI 10.1086/209395; Pechmann C, 1997, ADVERT CONS, P189; PECHMANN C, 1996, SMOKING MOVIES ANTIS; Pierce J.P, 1993, TOBACCO USE CALIFORN; Pierce JP, 1994, TOBACCO USE CALIFORN; POPHAM WJ, 1994, AM J PREV MED, V10, P319, DOI 10.1016/S0749-3797(18)30559-2; POPHAM WJ, 1993, PUBLIC HEALTH REP, V108, P510; *QUAL RES CTR, 1992, ANT STUD CREAT DEV R; *QUAL RES CTR, 1990, TOB ED RES PRES DRAF; ROSS M, 1996, TOBACCO TAX CAMPAIGN; RUSSELL S, 1996, SAN FRANCISCO C 0627, pA16; Schwartz J, 1998, WASHINGTON POST 0708, pA3; SCOTT S, 1997, CALIF J, P14; SKOLNICK AA, 1994, JAMA-J AM MED ASSOC, V271, P1387, DOI 10.1001/jama.271.18.1387; SKOLNICK AA, 1995, JAMA-J AM MED ASSOC, V273, P610, DOI 10.1001/jama.273.8.610; SKOLNICK AA, 1992, JAMA-J AM MED ASSOC, V267, P2721, DOI 10.1001/jama.267.20.2721; STEELE C, 1996, COMMUNICATION   1204; *TOB ED RES OV COM, 1997, TOB FREE CAL REN COM; *TOB I, 1995, TAX BURD TOB, P33; Traynor MP, 1996, J HEALTH POLIT POLIC, V21, P543, DOI 10.1215/03616878-21-3-543; *TROTT ASS, 1993, QUAL RES CLIFF ANT C; *US DEP HHS, 1995, MED CAMP RES BOOK; *US DEP HHS, 1994, PREV TOB US YOUNG PE; WARREN J, 1998, LOS ANGELES TIM 0121, pA1; Worden JK, 1996, HEALTH EDUC QUART, V23, P453, DOI 10.1177/109019819602300406	63	245	248	0	40	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 11	1998	279	10					772	777		10.1001/jama.279.10.772	http://dx.doi.org/10.1001/jama.279.10.772			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZA474	9508154				2022-12-28	WOS:000072366900035
J	Wellbery, C				Wellbery, C			Of moles and men	LANCET			English	Editorial Material																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 7	1998	351	9104					764	764		10.1016/S0140-6736(05)78548-2	http://dx.doi.org/10.1016/S0140-6736(05)78548-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB359	9504558				2022-12-28	WOS:000072463800073
J	Nash, HA				Nash, HA			Protein structure - Topological nuts and bolts	SCIENCE			English	Article							DNA TOPOISOMERASES		NIMH, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Nash, HA (corresponding author), NIMH, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.							BURGIN AB, 1995, NUCLEIC ACIDS RES, V23, P2973, DOI 10.1093/nar/23.15.2973; Kunkel TA, 1996, NATURE, V384, P25, DOI 10.1038/384025a0; LIU LF, 1994, ADV PHARM, V29; Maxwell A, 1996, NAT STRUCT BIOL, V3, P109, DOI 10.1038/nsb0296-109; Nash HA, 1996, CELLULAR MOL BIOL, V2, P2363; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; SHARMA A, 1995, CURR OPIN STRUC BIOL, V5, P39, DOI 10.1016/0959-440X(95)80007-N; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Stivers JT, 1997, BIOCHEMISTRY-US, V36, P5212, DOI 10.1021/bi962880t; WANG JC, 1971, J MOL BIOL, V55, P523, DOI 10.1016/0022-2836(71)90334-2; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223	11	4	4	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 6	1998	279	5356					1490	1491		10.1126/science.279.5356.1490	http://dx.doi.org/10.1126/science.279.5356.1490			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA527	9508726				2022-12-28	WOS:000072372900054
J	Nightingale, SL				Nightingale, SL			Tobramycin inhalation product approved for use in cystic fibrosis therapy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	22	25	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1998	279	9					645	645		10.1001/jama.279.9.645-b	http://dx.doi.org/10.1001/jama.279.9.645-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY849	9496968				2022-12-28	WOS:000072192800005
J	Southgate, L; Dauphinee, D				Southgate, L; Dauphinee, D			Continuing medical education - Maintaining standards in British and Canadian medicine: the developing role of the regulatory body	BMJ-BRITISH MEDICAL JOURNAL			English	Article									UCL, Sch Med, Ctr Hlth Informat & Multiprofess Educ, London N19 5NF, England; Med Council Canada, Ottawa, ON, Canada	University of London; University College London; UCL Medical School	Southgate, L (corresponding author), UCL, Sch Med, Ctr Hlth Informat & Multiprofess Educ, Whittington Hosp Campus, London N19 5NF, England.	l.southgate@chime.ucl.ac.uk						Brook RH, 1996, JAMA-J AM MED ASSOC, V276, P476, DOI 10.1001/jama.276.6.476; CAULFORD PG, 1994, ACAD MED, V69, pS16, DOI 10.1097/00001888-199410000-00028; Cunnington JPW, 1997, ACAD MED, V72, P9; DAUPHINEE WD, 1995, JAMA-J AM MED ASSOC, V274, P741, DOI 10.1001/jama.274.9.741; *FED MED LIC AUTH, 1996, POS PAP CAN MOD MON; *GEN MED COUNC, 1997, NEW PERF PROC CONS D; *GEN MED COUNC, 1997, NEW DOCT REC GEN CLI; *GEN MED COUNC, 1995, DUT DOCT GOOD MED PR; General Medical Council, 1993, TOM DOCT REC UND MED; GREEN J, 1995, NEW ENGL J MED, V332, P1229, DOI 10.1056/NEJM199505043321812; Irvine D, 1997, BRIT MED J, V314, P1540, DOI 10.1136/bmj.314.7093.1540; Irvine D, 1997, BRIT MED J, V314, P1613, DOI 10.1136/bmj.314.7094.1613; JACQUES A, 1997, ANN M FED MED LIC AU; LESCOP J, 1995, P AYLM 2 WORKSH MON; LESCOP J, 1996, P ALYM 3 WORKSH MON; LESCOP J, 1994, P WORKSH MAINT COMP; Norman GR, 1993, JAMA-J AM MED ASSOC, V270, P1046, DOI DOI 10.1001/JAMA.270.9.1046; Page GG, 1995, CAN MED ASSOC J, V153, P1723; *SECR STAT HLTH, 1996, PRIM CAR FUT; SOUTHGATE L, PERFORMANCE PROCEDUR, P97; TOPOL EJ, 1994, ANN INTERN MED, V120, P65, DOI 10.7326/0003-4819-120-1-199401010-00011; WARD B, 1997, ANN M FED MED LIC AU	22	25	25	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 28	1998	316	7132					697	700		10.1136/bmj.316.7132.697	http://dx.doi.org/10.1136/bmj.316.7132.697			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA282	9522801	Green Published			2022-12-28	WOS:000072347900042
J	Wakefield, AJ; Murch, SH; Anthony, A; Linnell, J; Casson, DM; Malik, M; Berelowitz, M; Dhillon, AP; Thomson, MA; Harvey, P; Valentine, A; Davies, SE; Walker-Smith, JA				Wakefield, AJ; Murch, SH; Anthony, A; Linnell, J; Casson, DM; Malik, M; Berelowitz, M; Dhillon, AP; Thomson, MA; Harvey, P; Valentine, A; Davies, SE; Walker-Smith, JA			RETRACTED: Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children (Retracted article. See vol 375, pg 445, 2010)	LANCET			English	Article; Retracted Publication							CROHNS-DISEASE; MEASLES VACCINATION; AUTISM	Background We investigated a consecutive series of children with chronic enterocolitis and regressive developmental disorder. Methods 12 children (mean age 6 years [range 3-10], 11 boys) were referred to a paediatric gastroenterology unit with a history of normal development followed by loss of acquired skills, including language, together with diarrhoea and abdominal pain. Children underwent gastroenterological, neurological, and developmental assessment and review of developmental records. Ileocolonoscopy and biopsy sampling, magnetic-resonance imaging (MRI), electroencephalography (EEG), and lumbar puncture were done under sedation. Barium follow-through radiography was done where possible. Biochemical, haematological, and immunological profiles were examined. Findings Onset of behavioural symptoms was associated, by the parents, with measles, mumps, and rubella vaccination in eight of the 12 children, with measles infection in one child, and otitis media in another. All 12 children had intestinal abnormalities, ranging from lymphoid nodular hyperplasia to aphthoid ulceration. Histology showed patchy chronic inflammation in the colon in 11 children and reactive ileal lymphoid hyperplasia in seven, but no granulomas. Behavioural disorders included autism (nine), disintegrative psychosis (one), and possible postviral or vaccinal encephalitis (two). There were no focal neurological abnormalities and MRI and EEG tests were normal. Abnormal laboratory results were significantly raised urinary methylmalonic acid compared with age-matched controls (p=0.003), low haemoglobin in four children, and a low serum IgA in four children. Interpretation We identified associated gastrointestinal disease and developmental regression in a group of previously normal children, which was generally associated in time with possible environmental triggers.	Univ London Royal Free Hosp, Sch Med, Dept Med, Inflammatory Bowel Dis Study Grp, London NW3 2QG, England; Univ London Royal Free Hosp, Sch Med, Dept Histopathol, London NW3 2QG, England; Univ London Royal Free Hosp, Sch Med, Dept Paediat Gastroenterol, London NW3 2QG, England; Univ London Royal Free Hosp, Sch Med, Dept Child & Adolescent Psychiat, London NW3 2QG, England; Univ London Royal Free Hosp, Sch Med, Dept Neurol, London NW3 2QG, England; Univ London Royal Free Hosp, Sch Med, Dept Radiol, London NW3 2QG, England	University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School	Wakefield, AJ (corresponding author), Univ London Royal Free Hosp, Sch Med, Dept Med, Inflammatory Bowel Dis Study Grp, London NW3 2QG, England.		Dhillon, Amar P/C-5619-2009					American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Asperger Hans, 1961, ANN PAEDIAT, V197, P146; BHATT HR, 1982, CLIN CHIM ACTA, V118, P311, DOI 10.1016/0009-8981(82)90018-3; DEufemia P, 1996, ACTA PAEDIATR, V85, P1076, DOI 10.1111/j.1651-2227.1996.tb14220.x; DILLON MJ, 1974, CLIN SCI MOL MED, V47, P43, DOI 10.1042/cs0470043; EKBOM A, 1994, LANCET, V344, P508, DOI 10.1016/S0140-6736(94)91898-8; ENGLAND JM, 1980, LANCET, V2, P1072; FUDENBERG HH, 1996, BIOTHERAPY, V9, P13; Fujimura Y, 1996, GUT, V38, P724, DOI 10.1136/gut.38.5.724; Gupta S, 1996, P NATL AUTISM ASS CH, P455; Kawashima H, 1996, ARCH VIROL, V141, P877, DOI 10.1007/BF01718162; Lucarelli S, 1995, PANMINERVA MED, V37, P137; Miller D, 1997, LANCET, V349, P730, DOI 10.1016/S0140-6736(05)60171-7; MIYAMOTO H, 1995, J GASTROENTEROL, V30, P28, DOI 10.1007/BF01211371; MURCH SH, 1993, LANCET, V341, P711, DOI 10.1016/0140-6736(93)90485-Y; PANKSEPP J, 1979, TRENDS NEUROSCI, V2, P174, DOI 10.1016/0166-2236(79)90071-7; Reichelt K L, 1981, Adv Biochem Psychopharmacol, V28, P627; RUTTER M, CHILD ADOLESCENT PSY, P581; SHATTOCK P, 1990, Brain Dysfunction, V3, P328; THOMPSON NP, 1995, LANCET, V345, P1071, DOI 10.1016/S0140-6736(95)90816-1; WALKERSMITH J, 1972, LANCET, V2, P883; WARING RH, C P BIOL PERSP AUT U, pNAS35; Warren RP, 1996, NEUROPSYCHOBIOLOGY, V34, P72, DOI 10.1159/000119295; WARREN RP, 1991, CLIN EXP IMMUNOL, V83, P438; Wing L, 1996, BRIT MED J, V312, P327; WING L, 1996, AUTISTIC SPECTRUM, P68	26	1592	1678	19	821	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	FEB 28	1998	351	9103					637	641		10.1016/S0140-6736(97)11096-0	http://dx.doi.org/10.1016/S0140-6736(97)11096-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA447	9500320				2022-12-28	WOS:000072364200010
J	Shen, H; Miller, JF; Fan, X; Kolwyck, D; Ahmed, R; Harty, JT				Shen, H; Miller, JF; Fan, X; Kolwyck, D; Ahmed, R; Harty, JT			Compartmentalization of bacterial antigens: Differential effects on priming of CD8 T cells and protective immunity	CELL			English	Article							RECOMBINANT LISTERIA-MONOCYTOGENES; TOXIC LYMPHOCYTE-T; I MHC PRESENTATION; EXOGENOUS ANTIGENS; CHORIOMENINGITIS VIRUS; INTRACELLULAR BACTERIA; MEDIATED-IMMUNITY; EPITOPE; INFECTION; PROTEIN	Bacterial pathogens synthesize numerous proteins that are either secreted or localized within bacterial cells. To address the impact of antigen compartmentalization on T cell immunity, we constructed recombinant Listeria monocytogenes that express a model CD8 T cell epitope as a secreted or nonsecreted fusion protein. Both forms of the antigen, either secreted into the host cell cytoplasm or retained within bacterial cells, efficiently prime CD8 T cell responses. However, epitope-specific CD8 T cells confer protection only against bacteria secreting the antigen but not against the bacteria expressing the nonsecreted form of the same antigen. This dichotomy as a result of antigen compartmentalization suggests that bacterial antigens are presented by multiple MHC class I pathways to prime CD8 T cells, but only the endogenous pathway provides target antigens for CD8 T cell-mediated protective immunity.	Emory Univ, Sch Med, Dept Microbiol & Immunol, Emory Vaccine Ctr, Atlanta, GA 30322 USA; Univ Calif Los Angeles, Sch Med, Inst Mol Biol, Dept Microbiol & Immunol, Los Angeles, CA 90095 USA; Univ Iowa, Interdisciplinary Grad Program Immunol, Dept Microbiol, Iowa City, IA 52242 USA	Emory University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Iowa	Ahmed, R (corresponding author), Emory Univ, Sch Med, Dept Microbiol & Immunol, Emory Vaccine Ctr, Atlanta, GA 30322 USA.			Harty, John/0000-0001-7266-2802	NIAID NIH HHS [AI38955, AI30048, AI36864] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI038955, R01AI030048, R29AI036864, R37AI030048] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; AHMED R, 1984, J EXP MED, V160, P521, DOI 10.1084/jem.160.2.521; BARRY RA, 1992, INFECT IMMUN, V60, P1625, DOI 10.1128/IAI.60.4.1625-1632.1992; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; BIELECKI J, 1990, NATURE, V345, P175, DOI 10.1038/345175a0; BRUNT LM, 1990, J IMMUNOL, V145, P3540; COSSART P, 1989, MOL BIOL MED, V6, P463; DECHASTELLIER C, 1994, INFECT IMMUN, V62, P543, DOI 10.1128/IAI.62.2.543-553.1994; DEVRIES JE, 1989, IMMUNOL REV, V109, P119; FRANKEL FR, 1995, J IMMUNOL, V155, P4775; Harding CV, 1996, J CLIN IMMUNOL, V16, P90, DOI 10.1007/BF01540955; HARTY JT, 1992, J EXP MED, V175, P1531, DOI 10.1084/jem.175.6.1531; HARTY JT, 1995, IMMUNITY, V3, P109, DOI 10.1016/1074-7613(95)90163-9; HARTY JT, 1995, J IMMUNOL, V154, P4642; Hess J, 1996, P NATL ACAD SCI USA, V93, P1458, DOI 10.1073/pnas.93.4.1458; HURT EC, 1984, EMBO J, V3, P3149, DOI 10.1002/j.1460-2075.1984.tb02272.x; IKONOMIDIS G, 1994, J EXP MED, V180, P2209, DOI 10.1084/jem.180.6.2209; Jensen ER, 1997, IMMUNOL REV, V158, P147, DOI 10.1111/j.1600-065X.1997.tb01001.x; Jondal M, 1996, IMMUNITY, V5, P295, DOI 10.1016/S1074-7613(00)80255-1; KAUFMANN SHE, 1993, ANNU REV IMMUNOL, V11, P129, DOI 10.1146/annurev.immunol.11.1.129; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KOVACSOVICSBANKOWSKI M, 1995, SCIENCE, V267, P243, DOI 10.1126/science.7809629; Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859; LAU LL, 1994, NATURE, V369, P648, DOI 10.1038/369648a0; LOESSNER MJ, 1995, APPL ENVIRON MICROB, V61, P1150, DOI 10.1128/AEM.61.3.1150-1152.1995; MATLOUBIAN M, 1994, J VIROL, V68, P8056, DOI 10.1128/JVI.68.12.8056-8063.1994; MURALIKRISHNA K, 1998, IN PRES IMMUNITY; NORTH RJ, 1970, J EXP MED, V132, P521, DOI 10.1084/jem.132.3.521; PAMER EG, 1991, NATURE, V353, P852, DOI 10.1038/353852a0; PAN ZK, 1995, NAT MED, V1, P471, DOI 10.1038/nm0595-471; PFEIFER JD, 1993, NATURE, V361, P359, DOI 10.1038/361359a0; PORTNOY DA, 1994, ANN NY ACAD SCI, V730, P15, DOI 10.1111/j.1749-6632.1994.tb44235.x; PORTNOY DA, 1989, J EXP MED, V170, P2141, DOI 10.1084/jem.170.6.2141; Rock KL, 1996, IMMUNOL TODAY, V17, P131, DOI 10.1016/0167-5699(96)80605-0; ROGERS HW, 1993, INFECT IMMUN, V61, P5090, DOI 10.1128/IAI.61.12.5090-5096.1993; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHAFER R, 1992, J IMMUNOL, V149, P53; SHEN H, 1995, P NATL ACAD SCI USA, V92, P3987, DOI 10.1073/pnas.92.9.3987; SIMONEN M, 1993, MICROBIOL REV, V57, P109, DOI 10.1128/MMBR.57.1.109-137.1993; Slifka MK, 1996, J VIROL, V70, P2902, DOI 10.1128/JVI.70.5.2902-2910.1996; SMITH GA, 1995, INFECT IMMUN, V63, P4231, DOI 10.1128/IAI.63.11.4231-4237.1995; Smith GA, 1996, J CELL BIOL, V135, P647, DOI 10.1083/jcb.135.3.647; SOLDATI T, 1991, CELL, V66, P277, DOI 10.1016/0092-8674(91)90618-9; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; vanderMost RG, 1996, J IMMUNOL, V157, P5543; Vijh S, 1997, J IMMUNOL, V158, P3366; VILLANUEVA MS, 1995, J IMMUNOL, V155, P5227; WHITTON JL, 1989, J VIROL, V63, P4303, DOI 10.1128/JVI.63.10.4303-4310.1989; WICK MJ, 1995, MOL MICROBIOL, V16, P465, DOI 10.1111/j.1365-2958.1995.tb02411.x; York IA, 1996, ANNU REV IMMUNOL, V14, P369, DOI 10.1146/annurev.immunol.14.1.369	51	180	207	0	8	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 20	1998	92	4					535	545		10.1016/S0092-8674(00)80946-0	http://dx.doi.org/10.1016/S0092-8674(00)80946-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YZ409	9491894	hybrid			2022-12-28	WOS:000072251500013
J	Wei, P; Garber, ME; Fang, SM; Fischer, WH; Jones, KA				Wei, P; Garber, ME; Fang, SM; Fischer, WH; Jones, KA			A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA	CELL			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CARBOXYL-TERMINAL DOMAIN; CELLULAR PROTEIN-KINASE; POLYMERASE-II; ACTIVATING KINASE; TRANSCRIPTION; ELONGATION; TRANSACTIVATION; RECOGNITION; INITIATION	The HIV-1 Tat protein regulates transcription elongation through binding to the viral TAR RNA stem-loop structure. We have isolated a novel 87 kDa cyclin C-related protein (cyclin T) that interacts specifically with the transactivation domain of Tat. Cyclin T is a partner for CDK9, an RNAPII transcription elongation factor. Remarkably, the interaction of Tat with cyclin T strongly enhances the affinity and specificity of the Tat:TAR RNA interaction, and confers a requirement for sequences in the loop of TAR that are not recognized by Tat alone. Moreover, overexpression of human cyclin T rescues Tat activity in nonpermissive rodent cells. We propose that Tat directs cyclin T-CDK9 to RNAPII through cooperative binding to TAR RNA.	Salk Inst Biol Studies, Regulat Biol Lab, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Peptide Biol Lab, La Jolla, CA 92037 USA; Univ Calif San Diego, Grad Program Biomed Sci, La Jolla, CA 92093 USA	Salk Institute; Salk Institute; University of California System; University of California San Diego	Jones, KA (corresponding author), Salk Inst Biol Studies, Regulat Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033824] Funding Source: NIH RePORTER; NIAID NIH HHS [AI33824] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALONSO A, 1994, J VIROL, V68, P6505, DOI 10.1128/JVI.68.10.6505-6513.1994; Bellier S, 1997, EMBO J, V16, P6250, DOI 10.1093/emboj/16.20.6250; BOELENS W, 1991, NUCLEIC ACIDS RES, V19, P455, DOI 10.1093/nar/19.3.455; CHURCHER MJ, 1993, J MOL BIOL, V230, P90, DOI 10.1006/jmbi.1993.1128; Cooper KF, 1997, EMBO J, V16, P4665, DOI 10.1093/emboj/16.15.4665; Cujec TP, 1997, MOL CELL BIOL, V17, P1817, DOI 10.1128/MCB.17.4.1817; CULLEN BR, 1993, CELL, V73, P417, DOI 10.1016/0092-8674(93)90126-B; DUBOIS MF, 1994, EMBO J, V13, P4787, DOI 10.1002/j.1460-2075.1994.tb06804.x; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; Furnari BA, 1997, J BIOL CHEM, V272, P12100, DOI 10.1074/jbc.272.18.12100; GAIT MJ, 1993, TRENDS BIOCHEM SCI, V18, P255, DOI 10.1016/0968-0004(93)90176-N; GarciaMartinez LF, 1997, J BIOL CHEM, V272, P6951, DOI 10.1074/jbc.272.11.6951; GHOSH S, 1993, J MOL BIOL, V234, P610, DOI 10.1006/jmbi.1993.1615; HART CE, 1993, J VIROL, V67, P5020, DOI 10.1128/JVI.67.8.5020-5024.1993; HERRMANN CH, 1993, VIROLOGY, V197, P601, DOI 10.1006/viro.1993.1634; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; Keen NJ, 1997, EMBO J, V16, P5260, DOI 10.1093/emboj/16.17.5260; Keen NJ, 1996, P NATL ACAD SCI USA, V93, P2505, DOI 10.1073/pnas.93.6.2505; Lee JM, 1997, J BIOL CHEM, V272, P10990; Li HM, 1996, ONCOGENE, V13, P705; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; LUO Y, 1993, J VIROL, V67, P3441, DOI 10.1128/JVI.67.6.3441-3445.1993; LUO Y, 1993, J VIROL, V67, P5617, DOI 10.1128/JVI.67.9.5617-5622.1993; MADORE SJ, 1993, J VIROL, V67, P3703, DOI 10.1128/JVI.67.7.3703-3711.1993; MALDONADO E, 1995, CURR OPIN CELL BIOL, V7, P352, DOI 10.1016/0955-0674(95)80090-5; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; MORAS D, 1995, CURR BIOL, V5, P249, DOI 10.1016/S0960-9822(95)00051-0; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; SCHERLY D, 1990, EMBO J, V9, P3675, DOI 10.1002/j.1460-2075.1990.tb07579.x; SHELINE CT, 1991, GENE DEV, V5, P2508, DOI 10.1101/gad.5.12b.2508; Shilatifard A, 1997, CURR OPIN GENET DEV, V7, P199, DOI 10.1016/S0959-437X(97)80129-3; STEMER D, 1995, MOL CELL BIOL, V15, P5716; TILEY LS, 1992, GENE DEV, V6, P2077, DOI 10.1101/gad.6.11.2077; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656; Yang XZ, 1997, P NATL ACAD SCI USA, V94, P12331, DOI 10.1073/pnas.94.23.12331; Yang XZ, 1996, J VIROL, V70, P4576, DOI 10.1128/JVI.70.7.4576-4584.1996; ZHOU QA, 1995, EMBO J, V14, P321, DOI 10.1002/j.1460-2075.1995.tb07006.x; Zhou QA, 1996, SCIENCE, V274, P605, DOI 10.1126/science.274.5287.605; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	48	1020	1045	2	50	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 20	1998	92	4					451	462		10.1016/S0092-8674(00)80939-3	http://dx.doi.org/10.1016/S0092-8674(00)80939-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YZ409	9491887	Bronze			2022-12-28	WOS:000072251500006
J	Davis, CH; Kluever, CA; Haines, BJ				Davis, CH; Kluever, CA; Haines, BJ			Elevation change of the southern Greenland ice sheet	SCIENCE			English	Article							SEA-LEVEL CHANGE; SATELLITE ALTIMETRY; GROWTH; RETRACKING	Seasat and Geosat satellite altimeter measurements for the Greenland ice sheet (south of 72 degrees N latitude) show that surface elevations above 2000 meters increased at an average rate of only 1.5 +/- 0.5 centimeters per year from 1978 to 1988. In contrast, elevation changes varied regionally from -15 to +18 centimeters per year, seasonally by +/-15 centimeters, and interannually by +/-8 centimeters. The average growth rate is too small to determine if the Greenland ice sheet is undergoing a long-term change due to a warmer polar climate.	Univ Missouri, Dept Elect Engn, Kansas City, MO 64110 USA; Univ Missouri, Dept Mech & Aerosp Engn, Kansas City, MO 64110 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA	University of Missouri System; University of Missouri Kansas City; University of Missouri System; University of Missouri Kansas City; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Davis, CH (corresponding author), Univ Missouri, Dept Elect Engn, 5605 Troost Ave, Kansas City, MO 64110 USA.							BARRON E, 1995, 9502 USGCRP; BOLZAN JF, 1992, EOS S, V73, P203; BORN GH, 1982, J GEOPHYS RES-OCEANS, V87, P3221, DOI 10.1029/JC087iC05p03221; CHELTON DB, 1993, J GEOPHYS RES-OCEANS, V98, P12579, DOI 10.1029/93JC00721; Davis CH, 1997, IEEE T GEOSCI REMOTE, V35, P974, DOI 10.1109/36.602540; DAVIS CH, 1995, IEEE T GEOSCI REMOTE, V33, P1108, DOI 10.1109/36.469474; DOUGLAS BC, 1995, REV GEOPHYS, V33, P1425, DOI 10.1029/95RG00355; DOUGLAS BC, 1990, SCIENCE, V248, P288, DOI 10.1126/science.248.4953.288; HAINES B.J., 1991, THESIS U COLORADO BO, P175; KLUEVER CA, 1997, EOS S, V78, P103; KRABILL W, 1995, GEOPHYS RES LETT, V22, P2341, DOI 10.1029/95GL02069; Kruizinga G. J., 1997, THESIS U TEXAS AUSTI; LAMOINE FG, 1997, EOS S, V78, P103; Lichten S. M., 1990, Manuscripta Geodaetica, V15, P159; LINGLE CS, 1994, ANN GLACIOL, V20, P26, DOI 10.3189/172756494794586907; MARSH JG, 1982, J ASTRONAUT SCI, V87, P3207; MARTIN TV, 1983, J GEOPHYS RES-OCEANS, V88, P1608, DOI 10.1029/JC088iC03p01608; SMITH S, 1987, J HOPKINS APL TECH D, V8, P198; TAPLEY BD, 1996, J GEOPHYS RES, V101, P28209; VANDERVEEN CJ, 1993, CLIMATIC CHANGE, V23, P383, DOI 10.1007/BF01091624; WAGNER CA, 1992, J GEOPHYS RES-OCEANS, V97, P15607, DOI 10.1029/92JC01641; ZWALLY HJ, 1990, SCIENCE, V248, P288, DOI 10.1126/science.248.4953.288-a; ZWALLY HJ, 1989, SCIENCE, V246, P1587, DOI 10.1126/science.246.4937.1587; ZWALLY HJ, 1989, SCIENCE, V246, P1589, DOI 10.1126/science.246.4937.1589; ZWALLY HJ, 1994, ESA, P159; ZWALLY HJ, 1990, NASA REF PUBL, V1233	26	67	67	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 27	1998	279	5359					2086	2088		10.1126/science.279.5359.2086	http://dx.doi.org/10.1126/science.279.5359.2086			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZE274	9516104				2022-12-28	WOS:000072775600040
J	McConnell, J; Horton, R				McConnell, J; Horton, R			The Lancet and the Internet, mark II	LANCET			English	Editorial Material									Lancet, London WC1B 3SL, England		McConnell, J (corresponding author), Lancet, London WC1B 3SL, England.			McConnell, John/0000-0002-9928-6568					0	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 21	1998	351	9106					852	852						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD047	9525360				2022-12-28	WOS:000072645500009
J	Lin, L; DeMartino, GN; Greene, WC				Lin, L; DeMartino, GN; Greene, WC			Cotranslational biogenesis of NF-kappa B p50 by the 26S proteasome	CELL			English	Article							NASCENT POLYPEPTIDE-CHAINS; DNA-BINDING SUBUNIT; MOLECULAR CHAPERONES; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; PRECURSOR P105; BETA-LACTONE; IN-VIVO; PROTEIN	The NFKB1 gene encodes two functionally distinct proteins termed p50 and p105. p50 corresponds to the N terminus of p105 and with p65 (RelA) forms the prototypical NF-kappa B transcription factor complex. In contrast, p105 functions as a Rel-specific inhibitor (I kappa B) and has been proposed to be the precursor of p50. Our studies now demonstrate that p50 is generated by a unique cotranslational processing event involving the 26S proteasome, whereas cotranslational folding of sequences near the C terminus of p50 abrogates proteasome processing acid leads to p105 production. These results indicate that p105 is not the precursor of p50 and reveal a novel mechanism of gene regulation that ensures the balanced production and independent function of the p50 and p105 proteins.	Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Immunol & Microbiol, San Francisco, CA 94141 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Lin, L (corresponding author), Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94141 USA.				NIAID NIH HHS [P30AI27763] Funding Source: Medline; NIDDK NIH HHS [R01 DK46181] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027763] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046181] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; Betts JC, 1996, MOL CELL BIOL, V16, P6363; BLOBEL G, 1971, P NATL ACAD SCI USA, V68, P390, DOI 10.1073/pnas.68.2.390; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; Dick LR, 1997, J BIOL CHEM, V272, P182; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; DONALD R, 1995, J BIOL CHEM, V270, P9, DOI 10.1074/jbc.270.1.9; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FENTEANY G, 1994, P NATL ACAD SCI USA, V91, P3358, DOI 10.1073/pnas.91.8.3358; Frydman J, 1996, SCIENCE, V272, P1497, DOI 10.1126/science.272.5267.1497; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GEGNER JA, 1995, J BIOL CHEM, V270, P5320, DOI 10.1074/jbc.270.10.5320; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GOLDBERG AL, 1995, SCIENCE, V268, P522, DOI 10.1126/science.7725095; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; HANSEN WJ, 1994, J BIOL CHEM, V269, P26610; Harhaj EW, 1996, ONCOGENE, V12, P2385; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; INOUE JI, 1992, CELL, V66, P1109; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; Komar AA, 1997, J BIOL CHEM, V272, P10646; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; Lin L, 1996, MOL CELL BIOL, V16, P2248; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MA CP, 1994, J BIOL CHEM, V269, P3539; MacKichan ML, 1996, J BIOL CHEM, V271, P6084, DOI 10.1074/jbc.271.11.6084; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Netzer WJ, 1997, NATURE, V388, P343, DOI 10.1038/41024; NEUMANN M, 1993, EMBO J, V12, P213; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Rousset R, 1996, NATURE, V381, P328, DOI 10.1038/381328a0; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; STEWART ML, 1971, P NATL ACAD SCI USA, V68, P97, DOI 10.1073/pnas.68.1.97; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; Suzuki CK, 1997, TRENDS BIOCHEM SCI, V22, P118, DOI 10.1016/S0968-0004(97)01020-7; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WAGNER I, 1994, EMBO J, V13, P5135, DOI 10.1002/j.1460-2075.1994.tb06843.x; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Watanabe N, 1997, EMBO J, V16, P3609, DOI 10.1093/emboj/16.12.3609; WEISSMAN JS, 1995, SCIENCE, V268, P523, DOI 10.1126/science.7725096	63	241	248	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 20	1998	92	6					819	828		10.1016/S0092-8674(00)81409-9	http://dx.doi.org/10.1016/S0092-8674(00)81409-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZD198	9529257	Bronze			2022-12-28	WOS:000072661200014
J	Waldrip, WR; Bikoff, EK; Hoodless, PA; Wrana, JL; Robertson, EJ				Waldrip, WR; Bikoff, EK; Hoodless, PA; Wrana, JL; Robertson, EJ			Smad2 signaling in extraembryonic tissues determines anterior-posterior polarity of the early mouse embryo	CELL			English	Article							BONE-MORPHOGENETIC PROTEIN-4; GERM LAYER FORMATION; STEM-CELLS; MAD PROTEINS; TRANSCRIPTION FACTOR; MESODERM FORMATION; NEURAL PLATE; VG1 PROTEIN; GENE; ENDODERM	Smad proteins transmit TGF beta signals from the cell surface to the nucleus. Here we analyze Smad2 mutant embryos created using ES cell technology. Smad2 function is not required for mesoderm production per se, but, rather unexpectedly, in the absence of Smad2 the entire epiblast adopts a mesodermal fate giving rise to a normal yolk sac and fetal blood cells. In contrast, Smad2 mutants entirely lack tissues of the embryonic germ layers. Smad2 signals serve to restrict the site of primitive streak formation and establish anterior-posterior identity within the epiblast. Chimera experiments demonstrate these essential activities are contributed by the extraembryonic tissues. Thus, the extraembryonic tissues play critical roles in establishing the body plan during early mouse development.	Harvard Univ, Dept Mol & Cell Biol, Cambridge, MA 02138 USA; Hosp Sick Children, Div Gastroenterol, Program Dev Biol, Toronto, ON M5G 1X8, Canada	Harvard University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Robertson, EJ (corresponding author), Harvard Univ, Dept Mol & Cell Biol, Cambridge, MA 02138 USA.		Wrana, Jeffrey/F-8857-2013	Hoodless, Pamela/0000-0003-1371-0725	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025208] Funding Source: NIH RePORTER; NICHD NIH HHS [HD25208] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANG SL, 1993, DEVELOPMENT, V119, P1301; ANG SL, 1994, DEVELOPMENT, V120, P2979; Baker JC, 1997, CURR OPIN GENET DEV, V7, P467, DOI 10.1016/S0959-437X(97)80072-X; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; BARNES JD, 1994, DEV BIOL, V161, P168, DOI 10.1006/dbio.1994.1018; BARON MH, 1994, MOL CELL BIOL, V14, P3108, DOI 10.1128/MCB.14.5.3108; BEDDINGTON RSP, 1989, DEVELOPMENT, V105, P733; Belo JA, 1997, MECH DEVELOP, V68, P45, DOI 10.1016/S0925-4773(97)00125-1; Bouwmeester T, 1996, NATURE, V382, P595, DOI 10.1038/382595a0; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P131; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; CONLON FL, 1991, DEVELOPMENT, V111, P969; CONLON FL, 1994, DEVELOPMENT, V120, P1919; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; DZIADEK M, 1978, J EMBRYOL EXP MORPH, V46, P135; Graff JM, 1997, CELL, V89, P171, DOI 10.1016/S0092-8674(00)80196-8; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; GURDON JB, 1992, CELL, V68, P185, DOI 10.1016/0092-8674(92)90465-O; HARLAND RM, 1994, P NATL ACAD SCI USA, V91, P10243, DOI 10.1073/pnas.91.22.10243; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heasman J, 1997, DEVELOPMENT, V124, P4179; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hermesz E, 1996, DEVELOPMENT, V122, P41; Hogan B, 1994, MANIPULATING MOUSE E; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; JONES CM, 1991, DEVELOPMENT, V111, P531; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; KESSLER DS, 1995, DEVELOPMENT, V121, P2155; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; LAWSON KA, 1987, DEVELOPMENT, V101, P627; LAWSON KA, 1991, DEVELOPMENT, V113, P891; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; MARCIASSILVA M, 1996, CELL, V87, P1215; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; MATZUK MM, 1995, NATURE, V374, P354, DOI 10.1038/374354a0; MATZUK MM, 1995, NATURE, V374, P356, DOI 10.1038/374356a0; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Popperl H, 1997, DEVELOPMENT, V124, P2997; PROETZEL G, 1995, NAT GENET, V11, P409, DOI 10.1038/ng1295-409; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; ROSENQUIST TA, 1995, MECH DEVELOP, V49, P117, DOI 10.1016/0925-4773(94)00308-A; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; Rossant Janet, 1995, Seminars in Developmental Biology, V6, P237, DOI 10.1016/S1044-5781(06)80049-6; Sanford LP, 1997, DEVELOPMENT, V124, P2659; SASAKI H, 1994, CELL, V76, P103, DOI 10.1016/0092-8674(94)90176-7; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Suzuki A, 1997, DEV BIOL, V184, P402, DOI 10.1006/dbio.1997.8548; Tam PPL, 1997, MECH DEVELOP, V68, P3, DOI 10.1016/S0925-4773(97)00123-8; Thomas P, 1996, CURR BIOL, V6, P1487, DOI 10.1016/S0960-9822(96)00753-1; THOMAS P, 1997, IN PRESS COLD SPRING, V62; Thomas PQ, 1998, DEVELOPMENT, V125, P85; Thomsen GH, 1996, DEVELOPMENT, V122, P2359; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; VARIET I, 1997, DEVELOPMENT, V122, P1033; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; WILKINSON DG, 1992, HYBRIDIZATION PRACTI, P75; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489; Zhang HB, 1996, DEVELOPMENT, V122, P2977; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	69	387	402	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 20	1998	92	6					797	808		10.1016/S0092-8674(00)81407-5	http://dx.doi.org/10.1016/S0092-8674(00)81407-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZD198	9529255	Bronze			2022-12-28	WOS:000072661200012
J	Vaughan, JI; Manning, M; Warwick, RM; Letsky, EA; Murray, NA; Roberts, IAG				Vaughan, JI; Manning, M; Warwick, RM; Letsky, EA; Murray, NA; Roberts, IAG			Inhibition of erythroid progenitor cells by anti-Kell antibodies in fetal alloimmune anemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BLOOD-GROUP PROTEIN; MOLECULAR-CLONING; EXPRESSION; FAMILY	Background In alloimmune anemia of the newborn, the level of hemolysis caused by the presence of antibodies to antigens of the Kell blood-group system is less than that caused by antibodies to the D antigen of the Rh blood-group system, and the numbers of reticulocytes and normoblasts in the baby's circulation are inappropriately low for the degree of anemia. These findings suggest that sensitization to Kell antigens results in suppression of fetal erythropoiesis as well as hemolysis. Methods We compared the growth in vitro of Kell-positive and Kell-negative hematopoietic progenitor cells from cord blood in the presence of human monoclonal anti-Kelt antibodies and anti-D antibodies and serum from women with anti-Kell antibodies. Results The growth of Kell-positive erythroid progenitor cells (erythroid burst-forming units and colony-forming units) from cord blood was markedly inhibited by monoclonal IgG and IgM anti-Kell antibodies in a dose-dependent fashion (range of concentrations, 0.2 to 20 percent), but monoclonal anti-D antibodies had no effect, The growth of these types of cells from Kell-negative cord blood was not affected by either type of antibody. Neither monoclonal anti-Kelt antibodies nor monoclonal anti-D antibodies inhibited the growth of granulocyte or megakaryocyte progenitor cells from cord blood, Serum from 22 women with anti-Kell antibodies inhibited the growth of Kelt-positive erythroid burst-forming units and colony-forming units but not of Kell-negative erythroid burst-forming units and colony-forming units (P<0.001 for the difference between groups). The maternal anti-Kell antibodies had no inhibitory effects on granulocyte-macrophage or megakaryocyte progenitor cells from cord blood. Conclusions Anti-Kell antibodies specifically inhibit the growth of Kell-positive erythroid burst-forming units and colony-forming units, a finding that supports the hypothesis that these antibodies cause fetal anemia by suppressing erythropoiesis at the progenitor-cell level. (C) 1998, Massachusetts Medical Society.	Royal Postgrad Med Sch, Imperial Coll, Sch Med, Dept Haematol, London W12 0NN, England; Queen Charlottes Hosp, Inst Obstet & Gynaecol, Dept Obstet, London, England; Queen Charlottes Hosp, Inst Obstet & Gynaecol, Dept Haematol, London, England	Imperial College London; Imperial College London; Imperial College London	Roberts, IAG (corresponding author), Royal Postgrad Med Sch, Imperial Coll, Sch Med, Dept Haematol, Du Cane Rd, London W12 0NN, England.							Avent ND, 1996, BRIT J HAEMATOL, V93, P728, DOI 10.1046/j.1365-2141.1996.d01-1695.x; BOWMAN JM, 1992, OBSTET GYNECOL, V79, P239; CONTRERAS M, 1987, LAB HAEMATOLOGY ACCO, P403; FARR V, 1988, SCOT MED J, V33, P300, DOI 10.1177/003693308803300407; GREER IA, 1994, OBSTET GYNECOL, V84, P937; JABER A, 1991, BRIT J HAEMATOL, V79, P311, DOI 10.1111/j.1365-2141.1991.tb04539.x; JONGENEEL CV, 1989, FEBS LETT, V242, P211, DOI 10.1016/0014-5793(89)80471-5; KENNY AJ, 1989, LANCET, V2, P785; LEE S, 1995, BLOOD, V85, P1364, DOI 10.1182/blood.V85.5.1364.bloodjournal8551364; LEE S, 1993, BLOOD, V81, P2804; LEE S, 1991, P NATL ACAD SCI USA, V88, P6353, DOI 10.1073/pnas.88.14.6353; LEE SH, 1995, BLOOD, V85, P912, DOI 10.1182/blood.V85.4.912.bloodjournal854912; LEGGAT HM, 1991, BRIT J OBSTET GYNAEC, V98, P162, DOI 10.1111/j.1471-0528.1991.tb13362.x; MARSH WL, 1990, TRANSFUSION, V30, P158, DOI 10.1046/j.1537-2995.1990.30290162904.x; MCGINNISS MH, 1985, TRANSFUSION, V25, P105, DOI 10.1046/j.1537-2995.1985.25285169197.x; MOLLISON PL, 1993, BLOOD TRANSFUSION CL, P581; MURRAY NA, 1995, BRIT J HAEMATOL, V89, P41, DOI 10.1111/j.1365-2141.1995.tb08913.x; NICOLAIDES KH, 1986, AM J OBSTET GYNECOL, V155, P90, DOI 10.1016/0002-9378(86)90085-2; REDMAN CM, 1996, BLOOD CELL BIOCH, V6, P227; SHIPP MA, 1989, P NATL ACAD SCI USA, V86, P297, DOI 10.1073/pnas.86.1.297; VAUGHAN JI, 1994, AM J OBSTET GYNECOL, V171, P247, DOI 10.1016/0002-9378(94)90477-4; VAUGHAN JI, 1991, BRIT J OBSTET GYNAEC, V98, P944, DOI 10.1111/j.1471-0528.1991.tb13522.x; Weiner CP, 1996, AM J OBSTET GYNECOL, V174, P547, DOI 10.1016/S0002-9378(96)70425-8; WU Q, 1990, P NATL ACAD SCI USA, V87, P993, DOI 10.1073/pnas.87.3.993	24	165	174	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 19	1998	338	12					798	803		10.1056/NEJM199803193381204	http://dx.doi.org/10.1056/NEJM199803193381204			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC163	9504940				2022-12-28	WOS:000072546800004
J	Chang, CF; Kiser, LJ; Bailey, JE; Martins, M; Gibson, WC; Schaberg, KA; Mirvis, DM; Applegate, WB				Chang, CF; Kiser, LJ; Bailey, JE; Martins, M; Gibson, WC; Schaberg, KA; Mirvis, DM; Applegate, WB			Tennessee's failed managed care program for mental health and substance abuse services	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								In July 1996, Tennessee initiated a managed mental health and substance abuse program called TennCare Partners. This publicly funded "carve-out" experiment started chaotically and soon deteriorated into a crisis, Many patients did not receive care or lost continuity of care, and the traditional "safety net" mental health system nearly disintegrated. This qualitative case study sought to ascertain the impact of the TennCare Partners program. It points out that the program's difficulties stemmed directly from a flawed design that spread funds previously earmarked for severely mentally ill patients across the entire Medicaid population. States contemplating similar reforms should strive to protect vulnerable patients by risk-adjusting capitation payments and by focusing resources on care for severely mentally ill persons, States should also minimize program complexity and ensure the accountability of managed care networks for their patients' behavioral health care needs.	Univ Memphis, Fogelman Coll Business & Econ, Memphis, TN 38152 USA; Univ Tennessee, Dept Med, Memphis, TN 38104 USA; Univ Tennessee, Dept Prevent Med, Memphis, TN 38104 USA; Univ Tennessee, Dept Psychiat, Memphis, TN 38104 USA; Univ Tennessee, Off Chancellor, Memphis, TN 38104 USA	University of Memphis; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Chang, CF (corresponding author), Univ Memphis, Fogelman Coll Business & Econ, Memphis, TN 38152 USA.	cchang@cc.memphis.edu						Anderson A. J. B., 1971, MEMPHIS HLTH CA 0221, V3, P1; BONNYMAN G, 1997, STATUS TENNCARE; DOWNING S, 1997, COMMERCIAL APPE 0324; DOWNING S, 1997, COMMERCIAL APPE 0525; FRANK RG, 1995, HEALTH AFFAIR, V14, P50, DOI 10.1377/hlthaff.14.3.50; FREEMAN MA, 1995, POLICY PERSPECTIVE, P1; *G WASH U POL RES, 1996, 1 G WASH U POL RES C; Garrigan L M, 1996, Tenn Med, V89, P239; GOLD M, 1995, MANAGED CARE LOW INC; LUDDEN JM, 1994, BEHAV HEALTHC TOM, V3, P40; Meyer GS, 1996, JAMA-J AM MED ASSOC, V276, P672, DOI 10.1001/jama.276.9.672; MIRVIS DM, 1995, JAMA-J AM MED ASSOC, V274, P1177, DOI DOI 10.1001/JAMA.274.15.1235; *TENN DEP HLTH, 1997, TENNC PARTN PROGR AC; *TENN DEP MENT HLT, 1995, TARG POP GROUPS CHIL; *TENN DEP MENT HLT, 1996, TENNC PARTN PROGR Q; *TENN DEP MENT HLT, 1995, TENNC PARTN PROGR PR; *TENN DEP MENT HLT, 1995, MAN TENN CLIN REL GR; *TENN JUST CTR, 1997, MED MAN BEH HLTH CAR; WADE P, 1997, COMMERICAL APPE 0722	19	80	80	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 18	1998	279	11					864	869		10.1001/jama.279.11.864	http://dx.doi.org/10.1001/jama.279.11.864			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA943	9516002				2022-12-28	WOS:000072417600034
J	Chasan-Taber, L; Stampfer, MJ				Chasan-Taber, L; Stampfer, MJ			Epidemiology of oral contraceptives and cardiovascular disease	ANNALS OF INTERNAL MEDICINE			English	Review							ACUTE MYOCARDIAL-INFARCTION; OF-GENERAL-PRACTITIONERS; CORONARY-ARTERY ATHEROSCLEROSIS; INTERNATIONAL CASE-CONTROL; MU-G ETHINYLESTRADIOL; DEEP-VEIN THROMBOSIS; YOUNG-WOMEN; VENOUS THROMBOEMBOLISM; RISK-FACTORS; VASCULAR-DISEASE	Purpose: To review the association between combined oral contraceptives and cardiovascular disease, with emphasis on oral contraceptives containing low doses of estrogen (low-dose oral contraceptives). Data Sources: A systematic search of the MEDLINE database was done for all relevant articles published between 1967 (when low-dose oral contraceptives were introduced in the United States) and June 1997. Textbooks, meeting proceedings, and reference lists were also searched. Study Selection: All English-language human epidemiology studies of oral contraceptives that used cardiovascular disease as an end point were reviewed. Animal and metabolic studies were reviewed only if they were especially relevant to the mechanism of action of oral contraceptives. Data Extraction: Descriptive and analytic data from each study were collected. Data Synthesis: Data were organized by cardiovascular end point, study design, estrogen dose, and type of progestogen. Data on relative and absolute risk are presented to address current prescription guidelines. Conclusions: The risk for cardiovascular disease is lower with current preparations of oral contraceptives, including those that contain the new progestogens, than with older oral contraceptives containing high doses of estrogen. Among users of low-dose oral contraceptives, cardiovascular diseases occur mainly in smokers and women with predisposing factors. Every effort should be made to encourage smoking cessation among potential users of oral contraceptives.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Chasan-Taber, L (corresponding author), Univ Massachusetts, Sch Publ Hlth & Hlth Sci, Dept Biostat & Epidemiol, 420 Arnold House, Amherst, MA 01003 USA.							ADAM SA, 1981, BRIT J OBSTET GYNAEC, V88, P838, DOI 10.1111/j.1471-0528.1981.tb01311.x; ADAMS MR, 1987, FERTIL STERIL, V47, P1010; [Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P718; [Anonymous], 1973, NEW ENGL J MED, V288, P871; BEAUMONT V, 1992, ATHEROSCLEROSIS, V94, P147, DOI 10.1016/0021-9150(92)90239-D; BERNSTEIN MJ, 1986, JAMA-J AM MED ASSOC, V256, P744; BLOEMENKAMP KWM, 1995, LANCET, V346, P1593, DOI 10.1016/S0140-6736(95)91929-5; BOTTIGER LE, 1989, LANCET, V8178, P1097; Child TJ, 1996, LANCET, V347, P1260, DOI 10.1016/S0140-6736(96)90775-8; CLARKSON TB, 1990, OBSTET GYNECOL, V75, P217; CONARD J, 1990, THROMB HAEMOSTASIS, V63, P319; CROFT P, 1989, BRIT MED J, V298, P165, DOI 10.1136/bmj.298.6667.165; DAVANZO B, 1994, J EPIDEMIOL COMMUN H, V48, P324, DOI 10.1136/jech.48.3.324; Dillner L, 1996, BRIT MED J, V312, P996; ENGEL HJ, 1983, EUR HEART J, V4, P1; ENGEL HJ, 1977, BRIT HEART J, V39, P477; FARLEY TMM, 1995, LANCET, V346, P1582; Farmer RDT, 1997, LANCET, V349, P83, DOI 10.1016/S0140-6736(96)07496-X; FUERTESDELAHABA A, 1971, OBSTET GYNECOL, V38, P259; GERSTMAN BB, 1991, AM J EPIDEMIOL, V133, P32, DOI 10.1093/oxfordjournals.aje.a115799; GERSTMAN BB, 1990, INT J EPIDEMIOL, V19, P931, DOI 10.1093/ije/19.4.931; GERSTMAN BB, 1991, AM J PUBLIC HEALTH, V81, P90, DOI 10.2105/AJPH.81.1.90; HANNAFORD PC, 1994, STROKE, V25, P935, DOI 10.1161/01.STR.25.5.935; HELMRICH SP, 1987, OBSTET GYNECOL, V69, P91; HIRVONEN E, 1990, AM J OBSTET GYNECOL, V163, P281, DOI 10.1016/0002-9378(90)90568-R; HOLCK S, 1989, B WORLD HEALTH ORGAN, V67, P417; HUISMAN MV, 1986, NEW ENGL J MED, V314, P823, DOI 10.1056/NEJM198603273141305; HUMPEL M, 1990, HORM RES, V33, P35, DOI 10.1159/000181445; INMAN WHW, 1979, BRIT MED J, V2, P1468, DOI 10.1136/bmj.2.6203.1468; JENSEN G, 1991, EUR HEART J, V12, P298, DOI 10.1093/oxfordjournals.eurheartj.a059894; Jick H, 1996, LANCET, V347, P627, DOI 10.1016/S0140-6736(96)91334-3; JICK H, 1995, LANCET, V346, P1589, DOI 10.1016/S0140-6736(95)91928-7; JICK H, 1978, JAMA-J AM MED ASSOC, V239, P1403, DOI 10.1001/jama.239.14.1403; JUGDUTT BI, 1983, AM HEART J, V106, P757, DOI 10.1016/0002-8703(83)90100-X; KAY CR, 1982, AM J OBSTET GYNECOL, V142, P762; KAY CR, 1981, LANCET, V1, P541; KRUEGER DE, 1981, AM J EPIDEMIOL, V113, P357, DOI 10.1093/oxfordjournals.aje.a113104; KUHL H, 1988, CONTRACEPTION, V38, P381, DOI 10.1016/0010-7824(88)90110-2; KUHL H, 1988, CONTRACEPTION, V38, P477, DOI 10.1016/0010-7824(88)90088-1; KUHNZ W, 1990, AM J OBSTET GYNECOL, V163, P2120, DOI 10.1016/0002-9378(90)90551-H; LAVECCHIA C, 1987, AM J EPIDEMIOL, V125, P832, DOI 10.1093/oxfordjournals.aje.a114599; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; Lewis MA, 1996, CONTRACEPTION, V54, P5, DOI 10.1016/0010-7824(96)00112-6; Lewis MA, 1996, BRIT MED J, V312, P88; LIDEGAARD O, 1993, BRIT MED J, V306, P956, DOI 10.1136/bmj.306.6883.956; Lidegaard O, 1996, CONTRACEPTION, V53, P135, DOI 10.1016/0010-7824(96)00035-2; LONGSTRETH WT, 1994, ANN INTERN MED, V121, P168, DOI 10.7326/0003-4819-121-3-199408010-00002; MANN JI, 1975, BMJ-BRIT MED J, V2, P241, DOI 10.1136/bmj.2.5965.241; MANN JI, 1975, BRIT MED J, V2, P245, DOI 10.1136/bmj.2.5965.245; MANN JI, 1976, BRIT MED J, V2, P445, DOI 10.1136/bmj.2.6033.445; MEADE TW, 1980, BRIT MED J, V280, P1157, DOI 10.1136/bmj.280.6224.1157; MISHELL DR, 1989, AM J OBSTET GYNECOL, V161, P1385; PETITTI DB, 1979, JAMA-J AM MED ASSOC, V242, P1150, DOI 10.1001/jama.242.11.1150; PETITTI DB, 1978, LANCET, V2, P234; Petitti DB, 1996, NEW ENGL J MED, V335, P8, DOI 10.1056/NEJM199607043350102; PORTER JB, 1985, OBSTET GYNECOL, V66, P1; PORTER JB, 1987, OBSTET GYNECOL, V70, P29; Poulter NR, 1996, LANCET, V348, P505; POULTER NR, 1995, LANCET, V346, P1575; Poulter NR, 1996, LANCET, V348, P498; Poulter NR, 1997, LANCET, V349, P1202, DOI 10.1016/S0140-6736(97)02358-1; REALINI JP, 1985, AM J OBSTET GYNECOL, V152, P729, DOI 10.1016/S0002-9378(85)80001-6; ROBINSON GE, 1994, BRIT J OBSTET GYNAEC, V101, P1036, DOI 10.1111/j.1471-0528.1994.tb13578.x; ROSENBERG L, 1990, AM J EPIDEMIOL, V131, P1009, DOI 10.1093/oxfordjournals.aje.a115592; ROSENBERG L, 1985, JAMA-J AM MED ASSOC, V253, P2965, DOI 10.1001/jama.253.20.2965; ROSENBERG L, 1980, AM J EPIDEMIOL, V111, P59, DOI 10.1093/oxfordjournals.aje.a112874; ROSENBERG L, 1988, CVD EPIDEMIOL NEWSLE, V43, P29; ROSENDAAL FR, 1995, BLOOD, V85, P1504, DOI 10.1182/blood.V85.6.1504.bloodjournal8561504; Rosing J, 1997, BRIT J HAEMATOL, V97, P233, DOI 10.1046/j.1365-2141.1997.192707.x; SALONEN JT, 1982, ACTA MED SCAND, V212, P141; SARTWELL PE, 1982, EPIDEMIOL REV, V4, P95, DOI 10.1093/oxfordjournals.epirev.a036253; SHAPIRO S, 1979, LANCET, V1, P743; Sidney S, 1996, OBSTET GYNECOL, V88, P939, DOI 10.1016/S0029-7844(96)00351-1; SLONE D, 1981, NEW ENGL J MED, V305, P420, DOI 10.1056/NEJM198108203050802; SPEROFF L, 1993, OBSTET GYNECOL, V81, P1034; Spitzer WO, 1996, BRIT MED J, V312, P83; STADEL BV, 1981, NEW ENGL J MED, V305, P672, DOI 10.1056/NEJM198109173051205; STAMPFER MJ, 1990, AM J OBSTET GYNECOL, V163, P285, DOI 10.1016/0002-9378(90)90569-S; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P1313, DOI 10.1056/NEJM198811173192004; STOLLEY PD, 1989, EPIDEMIOL REV, V11, P241, DOI 10.1093/oxfordjournals.epirev.a036041; STUBBLEFIELD PG, 1990, INT J FERTIL S, V34, P40; THOROGOOD M, 1991, BRIT J OBSTET GYNAEC, V98, P1245, DOI 10.1111/j.1471-0528.1991.tb15397.x; THOROGOOD M, 1992, INT J EPIDEMIOL, V21, P48, DOI 10.1093/ije/21.1.48; THOROGOOD M, 1992, AM J EPIDEMIOL, V136, P35, DOI 10.1093/oxfordjournals.aje.a116418; TZOURIO C, 1995, BMJ-BRIT MED J, V310, P830, DOI 10.1136/bmj.310.6983.830; *US DEP HHS CDCP N, 1996, VIT STAT US, V1, P24; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0; Vandenbroucke JP, 1997, LANCET, V349, P1113, DOI 10.1016/S0140-6736(05)63015-2; VESSEY M, 1986, BRIT MED J, V292, P526, DOI 10.1136/bmj.292.6519.526; Vessey M P, 1989, Int J Fertil, V34 Suppl, P64; VESSEY MP, 1984, BRIT MED J, V289, P530, DOI 10.1136/bmj.289.6444.530-a	91	74	77	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1998	128	6					467	477		10.7326/0003-4819-128-6-199803150-00008	http://dx.doi.org/10.7326/0003-4819-128-6-199803150-00008			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA914	9499331				2022-12-28	WOS:000072414700008
J	Paggiaro, PL; Dahle, R; Bakran, I; Frith, L; Hollingworth, K; Efthimiou, J				Paggiaro, PL; Dahle, R; Bakran, I; Frith, L; Hollingworth, K; Efthimiou, J		Int COPD Study Grp	Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease	LANCET			English	Article							AIR-FLOW OBSTRUCTION; BECLOMETHASONE DIPROPIONATE; CHRONIC-BRONCHITIS; SEVERE ASTHMA; BRONCHODILATOR THERAPY; CORTICOSTEROIDS; COPD; BUDESONIDE; EMPHYSEMA; SMOKERS	Background The efficacy of inhaled corticosteroids in the treatment of chronic obstructive pulmonary disease (COPD) remains controversial because of a lack of placebo-controlled studies, We compared the effect of inhaled fluticasone propionate with placebo in the treatment of patients with COPD. Methods We used a randomised, double-blind, placebo-controlled design. We enrolled from 13 European countries, New Zealand, and South Africa, 281 outpatient current or ex-smokers, aged between 50 and 75 years. They had a forced expiratory volume in 1 s (FEV1) of between 35% and 90% of predicted normal values, a ratio of FEV1 to forced vital capacity of 70% or less and bronchodilator reversibility of less than 15%, as well as a history of chronic bronchitis. Patients were randomly assigned fluticasone propionate 500 mu g (n=142) or placebo (n=139) twice daily via a metered-dose inhaler for 6 months. The main outcome measures were the number of patients who had at least one exacerbation by the end of treatment, the number and severity of exacerbations, clinic lung function, diary card symptoms and peak expiratory flow and 6 min walking distance. Findings 51 (37%) patients in the placebo group compared with 45 (32%) in the fluticasone propionate group had had at least one exacerbation by the end of treatment (p=0.449). Significantly more patients had moderate or severe exacerbations in the placebo group than in the fluticasone propionate group (86% vs 60%, p<0.001). Diary-card and clinic morning peak expiratory flows improved significantly in the fluticasone propionate group (p<0.001, p=0.048, respectively), as did clinic FEV, (p<0.001), forced vital capacity (p<0.001), and mid-expiratory flow (p=0.01). Symptom scores for median daily cough and sputum volume were significantly lower with fluticasone propionate treatment than with placebo (p=0.004 and p=0.016, respectively). At the end of treatment, patients on fluticasone propionate had increased their 6 min walking distance significantly more than those on placebo (p=0.032). Fluticasone propionate was tolerated as well as placebo, with few adverse effects and without a clinically important effect on mean serum cortisol concentration. Interpretation Fluticasone propionate may be of clinical benefit in patients with COPD over at least 6 months, Inhaled corticosteroids may have an important role in the long-term treatment of COPD.	Glaxo Wellcome Res & Dev Ltd, Res & Dev, Dept Resp Clin Res, Greenford UB6 0HE, Middx, England; Glaxo Wellcome Res & Dev Ltd, Res & Dev, Dept European Med Stat, Greenford UB6 0HE, Middx, England; Clin Hosp Ctr, Dept Med, Zagreb, Croatia; Ostfold Cent Hosp, Lung Dept, Fredrikstad, Norway; Univ Pisa, Pisa, Italy	GlaxoSmithKline; GlaxoSmithKline; University of Pisa	Efthimiou, J (corresponding author), Glaxo Wellcome Res & Dev Ltd, Res & Dev, Dept Resp Clin Res, Greenford UB6 0HE, Middx, England.							AUFFARTH B, 1991, THORAX, V46, P327; AYRES JG, 1995, EUR RESPIR J, V8, P579; BARNES NC, 1993, EUR RESPIR J, V6, P877; Barnes NC, 1998, RESP MED, V92, P95, DOI 10.1016/S0954-6111(98)90039-7; Boyd G, 1997, EUR RESPIR J, V10, P815; BURGE PS, 1996, AM J RESP CRIT CARE, V153, P126; CALLAHAN C, 1993, ANN INTERN MED, V118, P770; Chanez P, 1997, AM J RESP CRIT CARE, V155, P1529, DOI 10.1164/ajrccm.155.5.9154853; DOMPELING E, 1993, ANN INTERN MED, V118, P770, DOI 10.7326/0003-4819-118-10-199305150-00003; ENGEL T, 1989, EUR RESPIR J, V2, P935; FABBRI L, 1993, THORAX, V48, P817, DOI 10.1136/thx.48.8.817; FLETCHER CM, 1984, THORAX, V39, P81, DOI 10.1136/thx.39.2.81; FLETCHER CM, 1978, BRIT MED J, V1, P1645; Humbert M, 1996, CLIN EXP ALLERGY, V26, P735; Keatings VM, 1997, AM J RESP CRIT CARE, V155, P542, DOI 10.1164/ajrccm.155.2.9032192; KERSTJENS HAM, 1992, NEW ENGL J MED, V327, P1413, DOI 10.1056/NEJM199211123272003; LEBLANC P, 1994, ALLERGY, V49, P380, DOI 10.1111/j.1398-9995.1994.tb02286.x; LlewellynJones CG, 1996, AM J RESP CRIT CARE, V153, P616, DOI 10.1164/ajrccm.153.2.8564107; NOONAN M, 1995, AM J RESP CRIT CARE, V152, P1467, DOI 10.1164/ajrccm.152.5.7582278; PAUWELS RA, 1992, EUR RESPIR J, V5, P1254; PEACE KE, 1988, BIOPHARMACEUTICAL ST, P403; PRIDE NB, 1987, B EUR PHYSIOPATH RES, V23, P369; Renkema TEJ, 1996, CHEST, V109, P1156, DOI 10.1378/chest.109.5.1156; RUTTENVANMOLKEN MPMH, 1995, AM J RESP CRIT CARE, V151, P975; SIAFAKAS NM, 1995, EUR RESPIR J, V8, P1398, DOI 10.1183/09031936.95.08081398; THOM TJ, 1989, AM REV RESPIR DIS, V140, P27; THOMPSON AB, 1992, AM REV RESPIR DIS, V146, P389, DOI 10.1164/ajrccm/146.2.389; VANELTEREN P, 1960, B INT STATIST INST, V37, P351; vanSchayck CP, 1996, EUR RESPIR J, V9, P1969, DOI 10.1183/09031936.96.09101969; WEINER P, 1995, CHEST, V108, P1568, DOI 10.1378/chest.108.6.1568; WEIR DC, 1990, THORAX, V45, P112, DOI 10.1136/thx.45.2.112; WILSON RC, 1991, CLIN SCI, V80, P309, DOI 10.1042/cs0800309	32	338	349	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 14	1998	351	9105					773	780		10.1016/S0140-6736(97)03471-5	http://dx.doi.org/10.1016/S0140-6736(97)03471-5			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB916	9519948				2022-12-28	WOS:000072521200009
J	McCluskey, DR; Buckley, MRE; McCluggage, WG				McCluskey, DR; Buckley, MRE; McCluggage, WG			Night sweats and swollen glands	LANCET			English	Article							CASTLEMANS-DISEASE		Royal Victoria Hosp, Belfast BT12 6BA, Antrim, North Ireland		McCluskey, DR (corresponding author), Royal Victoria Hosp, Grosvenor Rd, Belfast BT12 6BA, Antrim, North Ireland.							Barbounis V, 1996, ANTICANCER RES, V16, P545; Corbellino M, 1996, CLIN INFECT DIS, V22, P1120, DOI 10.1093/clinids/22.6.1120; DeHeerGroen TA, 1996, EUR J PEDIATR, V155, P1015, DOI 10.1007/BF02532521; ISCHLYAMA T, 1996, ANN HAEMATOL, V73, P179; SHAHIDI H, 1995, MAYO CLIN PROC, V70, P969, DOI 10.4065/70.10.969	5	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 7	1998	351	9104					722	722		10.1016/S0140-6736(97)11083-2	http://dx.doi.org/10.1016/S0140-6736(97)11083-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB359	9504518				2022-12-28	WOS:000072463800011
J	Marteau, TM; Croyle, RT				Marteau, TM; Croyle, RT			The new genetics - Psychological responses to genetic testing	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BREAST-OVARIAN-CANCER; CYSTIC-FIBROSIS; HUNTINGTONS-DISEASE; HEREDITARY BREAST; DECISION-MAKING; PHYSICIANS; PRESCRIBE; FAMILIES; IMPACT; CARE		United Med & Dent Sch Guys & St Thomas Hosp, Psychol & Genet Res Grp, London SE1 9RT, England; Univ Utah, Dept Psychol, Salt Lake City, UT 84112 USA	University of London; King's College London; Utah System of Higher Education; University of Utah	Marteau, TM (corresponding author), United Med & Dent Sch Guys & St Thomas Hosp, Psychol & Genet Res Grp, London SE1 9RT, England.	t.marteau@umds.ac.uk		Marteau, Theresa/0000-0003-3025-1129	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Allanson A, 1997, J Med Screen, V4, P21; BEKKER H, 1993, BRIT MED J, V306, P1584, DOI 10.1136/bmj.306.6892.1584; Bell J, 1998, BMJ-BRIT MED J, V316, P618, DOI 10.1136/bmj.316.7131.618; BILLINGS PR, 1991, AM J HUM GENET, V49, P1109; BOBBIO M, 1994, LANCET, V343, P1209, DOI 10.1016/S0140-6736(94)92407-4; BUCHER HC, 1994, BRIT MED J, V309, P761, DOI 10.1136/bmj.309.6957.761; CRAUFURD D, 1989, LANCET, V2, P603; Croyle RT, 1997, HEALTH PSYCHOL, V16, P63, DOI 10.1037/0278-6133.16.1.63; CROYLE RT, 1995, PSYCHOSOCIAL EFFECTS; Decruyenaere M, 1996, J MED GENET, V33, P737, DOI 10.1136/jmg.33.9.737; Evans DGR, 1997, J MED GENET, V34, P746, DOI 10.1136/jmg.34.9.746; Hallowell N, 1997, J Genet Couns, V6, P269, DOI 10.1023/A:1025624221369; HOLTZMAN NA, IN PRESS BMJ; Klein WM, 1997, J PERS SOC PSYCHOL, V72, P763, DOI 10.1037/0022-3514.72.4.763; Lazarus RS., 1984, STRESS APPRAISAL COP; Lerman C, 1997, HEALTH PSYCHOL, V16, P87, DOI 10.1037/0278-6133.16.1.87; Lerman C, 1996, JAMA-J AM MED ASSOC, V275, P1885, DOI 10.1001/jama.275.24.1885; LYNCH HT, 1993, ARCH INTERN MED, V153, P1979; Marteau TM, 1997, HEALTH PSYCHOL, V16, P51; MARTEAU TM, 1988, BRIT MED J, V297, P1469, DOI 10.1136/bmj.297.6661.1469-b; MARTEAU TM, 1995, SOC SCI MED, V40, P1127, DOI 10.1016/0277-9536(94)00180-2; MARTEAU TM, 1991, BRIT J OBSTET GYNAEC, V98, P282, DOI 10.1111/j.1471-0528.1991.tb13394.x; Marteau TM, 1993, J REPROD INFANT PSYC, V11, P3; Marteau TM, 1996, TROUBLED HELIX SOCIA, P123; Marteau TM, 1997, PERCEPTIONS HLTH ILL, P241; QUAID KA, 1993, AM J MED GENET, V45, P41, DOI 10.1002/ajmg.1320450112; Skinner EA, 1996, J PERS SOC PSYCHOL, V71, P549, DOI 10.1037/0022-3514.71.3.549; STRUEWING JP, 1995, CANCER EPIDEM BIOMAR, V4, P169; TAMBOR ES, 1994, AM J HUM GENET, V55, P626; TIBBEN A, 1993, AM J MED GENET, V48, P103, DOI 10.1002/ajmg.1320480209; Tibben A, 1997, HEALTH PSYCHOL, V16, P20, DOI 10.1037/0278-6133.16.1.20; TIBBEN A, 1990, LANCET, V335, P553, DOI 10.1016/0140-6736(90)90796-8; WATSON EK, 1991, BRIT MED J, V303, P504, DOI 10.1136/bmj.303.6801.504; WIGGINS S, 1992, NEW ENGL J MED, V327, P1401, DOI 10.1056/NEJM199211123272001	34	142	142	1	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 28	1998	316	7132					693	696		10.1136/bmj.316.7132.693	http://dx.doi.org/10.1136/bmj.316.7132.693			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZA282	9522800	Green Published			2022-12-28	WOS:000072347900041
J	Pokorski, RJ				Pokorski, RJ			A test for the insurance industry	NATURE			English	Editorial Material							LONG-TERM-CARE		Cologne Life Reinsurance Co, Stamford, CT 06905 USA		Pokorski, RJ (corresponding author), Cologne Life Reinsurance Co, 30 Oak St, Stamford, CT 06905 USA.							HARPER PS, 1993, LANCET, V341, P224, DOI 10.1016/0140-6736(93)90080-Z; MOES SA, 1996, NATL UNDERWRITE 0805; MOSELEY R, 1995, REPORT HUMAN GENOME; MURTAUGH CM, 1995, INQUIRY-J HEALTH CAR, V32, P271; National Institutes of Health, 1993, NIH PUBL; NORTON EC, 1994, JAMA-J AM MED ASSOC, V271, P1520, DOI 10.1001/jama.271.19.1520; Pokorski RJ, 1997, AM J HUM GENET, V60, P205; POKORSKI RJ, 1995, NATURE, V376, P13, DOI 10.1038/376013a0; Post SG, 1997, JAMA-J AM MED ASSOC, V277, P832, DOI 10.1001/jama.277.10.832; WEINER J, 1994, JAMA-J AM MED ASSOC, V271, P1525, DOI 10.1001/jama.271.19.1525	10	10	10	1	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 26	1998	391	6670					835	836		10.1038/35971	http://dx.doi.org/10.1038/35971			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ206	9495331				2022-12-28	WOS:000072230900019
J	Shaham, S; Shuman, MA; Herskowitz, I				Shaham, S; Shuman, MA; Herskowitz, I			Death-defying yeast identify novel apoptosis genes	CELL			English	Review							CELL-DEATH; CAENORHABDITIS-ELEGANS		Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Shaham, S (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, 513 Parnassus Ave, San Francisco, CA 94143 USA.							HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; Ink B, 1997, MOL CELL BIOL, V17, P2468, DOI 10.1128/MCB.17.5.2468; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Longo VD, 1997, J CELL BIOL, V137, P1581, DOI 10.1083/jcb.137.7.1581; Madeo F, 1997, J CELL BIOL, V139, P729, DOI 10.1083/jcb.139.3.729; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; Matsuyama S, 1998, MOL CELL, V1, P327, DOI 10.1016/S1097-2765(00)80033-7; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; Zha HB, 1996, MOL CELL BIOL, V16, P6494; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	17	36	38	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 20	1998	92	4					425	427		10.1016/S0092-8674(00)80934-4	http://dx.doi.org/10.1016/S0092-8674(00)80934-4			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YZ409	9491882	Bronze			2022-12-28	WOS:000072251500001
J	Muldoon, MF; Barger, SD; Flory, JD; Manuck, SB				Muldoon, MF; Barger, SD; Flory, JD; Manuck, SB			What are quality of life measurements measuring?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SICKNESS IMPACT PROFILE; OF-LIFE; HEALTH-STATUS; CANCER-PATIENTS; MENTAL-HEALTH; VALIDITY; DISTRESS; INDEX		Univ Pittsburgh, Ctr Clin Pharmacol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA; Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Muldoon, MF (corresponding author), Univ Pittsburgh, Ctr Clin Pharmacol, Pittsburgh, PA 15260 USA.	mfm10+@pitt.edu	Barger, Steven/I-3724-2012	Barger, Steven/0000-0002-8296-0974	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040962, R01HL046328] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07560, HL40962, HL46328] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARSKY AJ, 1992, SOC SCI MED, V34, P1147, DOI 10.1016/0277-9536(92)90288-2; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BREETVELT IS, 1991, SOC SCI MED, V32, P981, DOI 10.1016/0277-9536(91)90156-7; BROOKS WB, 1990, MED CARE, V28, P793, DOI 10.1097/00005650-199009000-00009; BUCQUET D, 1990, SOC SCI MED, V30, P829, DOI 10.1016/0277-9536(90)90207-9; CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016; CASSILETH BR, 1984, NEW ENGL J MED, V311, P506, DOI 10.1056/NEJM198408233110805; Centers for Disease Control and Prevention (CDC), 1994, MMWR-MORBID MORTAL W, V43, P375; DANOFF B, 1983, AM J CLIN ONCOL-CANC, V6, P339, DOI 10.1097/00000421-198306000-00015; Duits AA, 1997, PSYCHOSOM MED, V59, P257, DOI 10.1097/00006842-199705000-00009; Fromm K, 1996, J BEHAV MED, V19, P221, DOI 10.1007/BF01857767; GILL TM, 1994, JAMA-J AM MED ASSOC, V272, P619, DOI 10.1001/jama.272.8.619; GUYATT GH, 1993, ANN INTERN MED, V118, P622, DOI 10.7326/0003-4819-118-8-199304150-00009; Hays R. D., 1990, PSYCHOL ASSESSMENT J, V2, P22, DOI DOI 10.1037/1040-3590.2.1.22; Hemingway H, 1997, BMJ-BRIT MED J, V315, P1273, DOI 10.1136/bmj.315.7118.1273; HLATKY MA, 1989, AM J CARDIOL, V64, P651, DOI 10.1016/0002-9149(89)90496-7; HURNY C, 1992, EUR J CANCER, V28A, P118, DOI 10.1016/0959-8049(92)90399-M; KAPLAN RM, 1995, PSYCHOSOM MED, V57, P138, DOI 10.1097/00006842-199503000-00006; KATZ S, 1970, GERONTOLOGIST, V10, P20, DOI 10.1093/geront/10.1_Part_1.20; Kempen GIJM, 1997, HEALTH PSYCHOL, V16, P539, DOI 10.1037/0278-6133.16.6.539; Kempen GIJM, 1996, J GERONTOL B-PSYCHOL, V51, pP254, DOI 10.1093/geronb/51B.5.P254; Leplege A, 1997, JAMA-J AM MED ASSOC, V278, P47, DOI 10.1001/jama.278.1.47; LOPEZ OL, 1994, EUR NEUROL, V34, P277, DOI 10.1159/000117056; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; *QUAL LIF CLIN TRI, 1995, LANCET, V346, P1; SHEDLER J, 1993, AM PSYCHOL, V48, P1117, DOI 10.1037/0003-066X.48.11.1117; SPITZER RL, 1995, JAMA-J AM MED ASSOC, V274, P1511, DOI 10.1001/jama.274.19.1511; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; TAYLOR SE, 1984, J PERS SOC PSYCHOL, V46, P489, DOI 10.1037/0022-3514.46.3.489; TEMPELAAR R, 1989, SOC SCI MED, V29, P635, DOI 10.1016/0277-9536(89)90183-4; van der Zee KI, 1996, INT J BEHAV MED, V3, P104, DOI 10.1207/s15327558ijbm0302_2; VEIT CT, 1983, J CONSULT CLIN PSYCH, V51, P730, DOI 10.1037/0022-006X.51.5.730; WATSON D, 1989, PSYCHOL REV, V96, P234, DOI 10.1037/0033-295X.96.2.234	33	274	291	0	26	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 14	1998	316	7130					542	545		10.1136/bmj.316.7130.542	http://dx.doi.org/10.1136/bmj.316.7130.542			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YX955	9501721	Green Published			2022-12-28	WOS:000072097400032
J	Losos, JB; Jackman, TR; Larson, A; de Queiroz, K; Rodriguez-Schettino, L				Losos, JB; Jackman, TR; Larson, A; de Queiroz, K; Rodriguez-Schettino, L			Contingency and determinism in replicated adaptive radiations of island lizards	SCIENCE			English	Article							ANOLIS LIZARDS; EVOLUTION	The vagaries of history lead to the prediction that repeated instances of evolutionary diversification will lead to disparate outcomes even if starting conditions are similar. We tested this proposition by examining the evolutionary radiation of Anolis lizards on the four islands of the Greater Antilles. Morphometric analyses indicate that the same set of habitat specialists, termed ecomorphs, occurs on all four islands. Although these similar assemblages could result from a single evolutionary origin of each ecomorph, followed by dispersal or vicariance, phylogenetic analysis indicates that the ecomorphs originated independently on each island. Thus, adaptive radiation in similar environments can overcome historical contingencies to produce strikingly similar evolutionary outcomes.	Washington Univ, Dept Biol, St Louis, MO 63130 USA; Smithsonian Inst, Natl Museum Nat Hist, Div Amphibians & Reptiles, Washington, DC 20560 USA; CITMA, Inst Ecol & Sistemat, La Habana 10800, Cuba	Washington University (WUSTL); Smithsonian Institution; Smithsonian National Museum of Natural History	Losos, JB (corresponding author), Washington Univ, Dept Biol, Campus Box 1137, St Louis, MO 63130 USA.			Jackman, Todd/0000-0002-5391-8136				BOCK WJ, 1977, MAJOR PATTERNS VERTE, P57; BURNELL K L, 1990, Caribbean Journal of Science, V26, P7; Cadle John E., 1993, P281; deQueiroz K, 1997, Q REV BIOL, V72, P3, DOI 10.1086/419656; Gould S. J., 1989, WONDERFUL LIFE BURGE; GOULD SJ, 1985, PALEOBIOLOGY, V1, P2; Harman H. H., 1976, MODERN FACTOR ANAL; Harvey P.H., 1991, COMP METHOD EVOLUTIO; Hotelling H, 1933, J EDUC PSYCHOL, V24, P417, DOI 10.1037/h0071325; Irschick DJ, 1997, ECOLOGY, V78, P2191, DOI 10.2307/2265955; KISHINO H, 1989, J MOL EVOL, V29, P170, DOI 10.1007/BF02100115; KUMAZAWA Y, 1993, J MOL EVOL, V37, P380, DOI 10.1007/BF00178868; Larson A., 1994, P371; LOSOS JB, 1990, ECOL MONOGR, V60, P369, DOI 10.2307/1943062; LOSOS JB, 1994, ANNU REV ECOL SYST, V25, P467, DOI 10.1146/annurev.es.25.110194.002343; Macey JR, 1997, J MOL EVOL, V44, P660, DOI 10.1007/PL00006190; Macey JR, 1997, MOL PHYLOGENET EVOL, V7, P272, DOI 10.1006/mpev.1997.0379; Macey JR, 1997, MOL BIOL EVOL, V14, P91, DOI 10.1093/oxfordjournals.molbev.a025706; MADDISON WP, 1992, MACCLADE ANAL PHYLOG; MOERMOND TC, 1979, ECOLOGY, V60, P152, DOI 10.2307/1936477; MOERMOND TC, 1979, BEHAVIOUR, V70, P147, DOI 10.1163/156853979X00034; Orians G.H., 1983, P431; Ricklefs R.E., 1993, J EVOLUTION BIOL, DOI DOI 10.1046/J.1420-9101.1993.6020171.X; SOKAL ROBERT R., 1958, UNIV KANSAS SCI BULL, V38, P1409; Swofford DL, 1997, PHYLOGENETIC ANAL US; TEMPLETON AR, 1983, EVOLUTION, V37, P221, DOI 10.1111/j.1558-5646.1983.tb05533.x; TRAVISANO M, 1995, SCIENCE, V267, P87, DOI 10.1126/science.7809610; Wiens J.A., 1992, ECOLOGY BIRD COMMUNI; Williams E.E., 1983, P326; Williams EE., 1972, EVOL BIOL, V6, P47, DOI [DOI 10.1007/978-1-4684-9063-3_3, 10. 1007/978-1-4684-9063-3]; Zar JH., 1999, BIOSTAT ANAL	31	842	856	4	237	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 27	1998	279	5359					2115	2118		10.1126/science.279.5359.2115	http://dx.doi.org/10.1126/science.279.5359.2115			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZE274	9516114				2022-12-28	WOS:000072775600050
J	Lipsky, JJ				Lipsky, JJ			Abnormal fat accumulation in patients with HIV-1 infection	LANCET			English	Editorial Material									Mayo Clin & Mayo Fdn, Clin Pharmacol Unit, Rochester, MN 55905 USA	Mayo Clinic	Lipsky, JJ (corresponding author), Mayo Clin & Mayo Fdn, Clin Pharmacol Unit, 200 1st St SW, Rochester, MN 55905 USA.							Hengel RL, 1997, LANCET, V350, P1596, DOI 10.1016/S0140-6736(05)64011-1; HENGEL RL, 1998, 5 C RETR OPP INF CHI; ROTH VR, 1998, 5 C RETR OPP INF CHI	3	43	43	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 21	1998	351	9106					847	848		10.1016/S0140-6736(05)70281-6	http://dx.doi.org/10.1016/S0140-6736(05)70281-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD047	9525355				2022-12-28	WOS:000072645500003
J	Phanuphak, P				Phanuphak, P			Ethical issues in studies in Thailand of the vertical transmission of HIV	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Thai Red Cross Soc, Program AIDS, Bangkok 10330, Thailand	Thai Red Cross Society	Phanuphak, P (corresponding author), Thai Red Cross Soc, Program AIDS, 1871 Rama IV Rd, Bangkok 10330, Thailand.							CHAISILWATTANA P, 1997, C GLOB STRAT PREV HI; CONOR EM, 1994, NEW ENGL J MED, V331, P1173; Lurie P, 1997, NEW ENGL J MED, V337, P853, DOI 10.1056/NEJM199709183371212; SRIPLIENCHAN S, 1997, C GLOB STRAT PREV HI; *WHO, 1994, REC M MOTH INF TRANS	5	25	26	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 19	1998	338	12					834	835		10.1056/NEJM199803193381212	http://dx.doi.org/10.1056/NEJM199803193381212			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC163	9504948				2022-12-28	WOS:000072546800012
J	Whelton, PK; Appel, LJ; Espeland, MA; Applegate, WB; Ettinger, WH; Kostis, JB; Kumanyika, S; Lacy, CR; Johnson, KC; Folmar, S; Cutler, JA				Whelton, PK; Appel, LJ; Espeland, MA; Applegate, WB; Ettinger, WH; Kostis, JB; Kumanyika, S; Lacy, CR; Johnson, KC; Folmar, S; Cutler, JA		TONE Collaborative Res Grp	Sodium reduction and weight loss in the treatment of hypertension in older persons - A randomized controlled trial of nonpharmacologic interventions in the elderly (TONE)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; BLOOD-PRESSURE; MILD HYPERTENSION; RISK; THERAPY; WOMEN; MASS	Context.-Nonpharmacologic interventions are frequently recommended for treatment of hypertension in the elderly, but there is a paucity of evidence from randomized controlled trials in support of this recommendation. Objective.-To determine whether weight loss or reduced sodium intake is effective in the treatment of older persons with hypertension. Design.-Randomized controlled trial. Participants.-A total of 875 men and women aged 60 to 80 years with systolic blood pressure lower than 145 mm Hg and diastolic blood pressure lower than 85 mm Hg while receiving treatment with a single antihypertensive medication. Setting.-Four academic health centers. Intervention.-The 585 obese participants were randomized to reduced sodium intake, weight loss, both, or usual care, and the 390 nonobese participants were randomized to reduced sodium intake or usual care, Withdrawal of antihypertensive medication was attempted after 3 months of intervention. Main Outcome Measure.-Diagnosis of high blood pressure at 1 or more follow-up visits, or treatment with antihypertensive medication, or a cardiovascular event during follow-up (range, 15-36 months; median, 29 months). Results.-The combined outcome measure was less frequent among those assigned vs not assigned to reduced sodium intake (relative hazard ratio, 0.69; 95% confidence interval [CI], 0.59-0.81; P<.001) and, in obese participants, among those assigned vs not assigned to weight loss (relative hazard ratio, 0.70; 95% CI, 0.57-0.87; P<.001). Relative to usual care, hazard ratios among the obese participants were 0.60 (95% CI, 0.45-0.80; P<.001) for reduced sodium intake alone, 0.64 (95% CI, 0.49-0.85; P=.002) for weight loss alone, and 0.47 (95% CI, 0.35-0.64; P<.001) for reduced sodium intake and weight loss combined. The frequency of cardiovascular events during follow-up was similar in each of the 6 treatment groups. Conclusion.-Reduced sodium intake and weight loss constitute a feasible, effective, and safe nonpharmacologic therapy of hypertension in older persons.	Tulane Univ, Sch Publ Hlth & Trop Med, Off Dean, Dept Biostat & Epidemiol, New Orleans, LA 70112 USA; Johns Hopkins Univ, Sch Med, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD USA; Wake Forest Univ, Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27109 USA; Wake Forest Univ, Sch Med, Dept Internal Med, Winston Salem, NC 27109 USA; Univ Tennessee, Dept Prevent Med, Memphis, TN USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Div Cardiovasc Dis & Hypertens, New Brunswick, NJ USA; Penn State Univ, Coll Med, Ctr Biostat & Epidemiol, Hershey, PA 17033 USA; NHLBI, Clin Applicat & Prevent Program, NIH, Bethesda, MD 20892 USA	Tulane University; Johns Hopkins University; Wake Forest University; Wake Forest University; University of Tennessee System; University of Tennessee Health Science Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Whelton, PK (corresponding author), Tulane Univ, Sch Publ Hlth & Trop Med, Off Dean, Dept Biostat & Epidemiol, 17th Floor,1501 Canal St, New Orleans, LA 70112 USA.	PWHELTON@TULANE.EDU	Appel, Larry/GLT-2608-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048642] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009771, R01AG009799] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-48642] Funding Source: Medline; NIA NIH HHS [R01 AG-09799, R01 AG-09771] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALDERMAN MH, 1995, HYPERTENSION, V25, P1144, DOI 10.1161/01.HYP.25.6.1144; *AM ASS CLIN CHEM, 1961, STAND METH CLIN CHEM, V3, P81; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1990, Arch Intern Med, V150, P153, DOI 10.1001/archinte.150.1.153; [Anonymous], 1997, ARCH INTERN MED, V157, P2413; APPEL LA, 1997, J AM GERIATR SOC, V45, P185; Appel Lawrence J., 1995, Annals of Epidemiology, V5, P119, DOI 10.1016/1047-2797(94)00056-Y; Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; APPLEGATE WB, 1992, ARCH INTERN MED, V152, P1162, DOI 10.1001/archinte.152.6.1162; BLACK HR, 1994, HYPERTENSION, V23, P275; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COOK NR, 1995, HYPERTENSION, V25, P1153, DOI 10.1161/01.HYP.25.6.1153; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; DEVINE A, 1995, AM J CLIN NUTR, V62, P740, DOI 10.1093/ajcn/62.4.740; Elliott P, 1996, BMJ-BRIT MED J, V312, P1249, DOI 10.1136/bmj.312.7041.1249; EWART CK, 1991, AM PSYCHOL, V46, P931, DOI 10.1037/0003-066X.46.9.931; FESKANICH D, 1989, COMPUT METH PROG BIO, V30, P47, DOI 10.1016/0169-2607(89)90122-3; HE J, 1994, AM J EPIDEMIOL, V139, P380, DOI 10.1093/oxfordjournals.aje.a117010; HEBERT PR, 1993, ARCH INTERN MED, V153, P578, DOI 10.1001/archinte.153.5.578; KLAG MJ, 1995, AM J EPIDEMIOL, V142, P295, DOI 10.1093/oxfordjournals.aje.a117635; Kumanyika S K, 1989, Clin Geriatr Med, V5, P769; MACMAHON S, 1987, EUR HEART J, V8, P57, DOI 10.1093/eurheartj/8.suppl_B.57; MACMAHON S, 1993, CLIN EXP HYPERTENS, V15, P967, DOI 10.3109/10641969309037085; MACMAHON SW, 1986, NEW ENGL J MED, V314, P334, DOI 10.1056/NEJM198602063140602; MANOLIO TA, 1995, ARCH INTERN MED, V155, P829, DOI 10.1001/archinte.155.8.829; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; Puddey IB, 1995, J HYPERTENS, V13, P1229, DOI 10.1097/00004872-199511000-00002; ROSE GA, 1965, MILBANK FUND Q, V43, P32, DOI 10.2307/3348873; STAMLER J, 1997, CAN J CARDIOL SB, V13, pB272; STAMLER R, 1987, JAMA-J AM MED ASSOC, V257, P1484, DOI 10.1001/jama.257.11.1484; WHELTON PK, 1993, ARCH INTERN MED, V153, P186, DOI 10.1001/archinte.153.2.186; WHELTON PK, 1992, JAMA-J AM MED ASSOC, V267, P1213, DOI 10.1001/jama.1992.03480090061028; Whelton PK, 1997, ARCH INTERN MED, V157, P657, DOI 10.1001/archinte.157.6.657; Whelton PK, 1997, JAMA-J AM MED ASSOC, V277, P1624, DOI 10.1001/jama.277.20.1624; WRIGHT BM, 1970, LANCET, V1, P337	37	794	811	1	41	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 18	1998	279	11					839	846		10.1001/jama.279.11.839	http://dx.doi.org/10.1001/jama.279.11.839			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA943	9515998	Bronze			2022-12-28	WOS:000072417600030
J	Christensen, PR; Anderson, DL; Chase, SC; Clancy, RT; Clark, RN; Conrath, BJ; Kieffer, HH; Kuzmin, RO; Malin, MC; Pearl, JC; Roush, TL				Christensen, PR; Anderson, DL; Chase, SC; Clancy, RT; Clark, RN; Conrath, BJ; Kieffer, HH; Kuzmin, RO; Malin, MC; Pearl, JC; Roush, TL			Results from the Mars global surveyor thermal emission spectrometer	SCIENCE			English	Article							GREAT DUST STORMS; SOUTH POLAR-CAP; SNC METEORITES; ATMOSPHERE; VIKING; CLOUDS	The Thermal Emission Spectrometer spectra of low albedo surface materials suggests that a four to one mixture of pyroxene to plagioclase, together with about a 35 percent dust component provides the best fit to the spectrum. Qualitative upper limits can be placed on the concentration of carbonates (<10 percent), olivine (<10 percent), clay minerals (<20 percent), and quartz (<5 percent) in the limited regions observed. Limb observations in the northern hemisphere reveal low-lying dust hazes and detached water-ice clouds at altitudes up to 55 kilometers. At an aerocentric longitude of 224 degrees a major dust storm developed in the Noachis Terra region, The south polar cap retreat was similar to that observed by Viking.	Arizona State Univ, Tempe, AZ 85287 USA; Univ Colorado, Goleta, CA 93017 USA; US Geol Survey, Denver, CO 80225 USA; Cornell Univ, Ithaca, NY 14850 USA; US Geol Survey, Flagstaff, AZ 86001 USA; VI Vernadskii Inst Geochem & Analyt Chem, Moscow 117975, Russia; Malin Space Sci Syst, San Diego, CA USA; NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; NASA, Ames Res Ctr, Moffett Field, CA 94035 USA; Santa Barbara Remote Sensing, Goleta, CA 93017 USA	Arizona State University; Arizona State University-Tempe; University of Colorado System; United States Department of the Interior; United States Geological Survey; Cornell University; United States Department of the Interior; United States Geological Survey; Russian Academy of Sciences; Vernadsky Institute of Geochemistry & Analytical Chemistry; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; National Aeronautics & Space Administration (NASA); NASA Ames Research Center	Christensen, PR (corresponding author), Arizona State Univ, Tempe, AZ 85287 USA.	phil.christensen@asu.edu						ADAMS JB, 1969, J GEOPHYS RES, V74, P4851, DOI 10.1029/JB074i020p04851; Albee AL, 1998, SCIENCE, V279, P1671, DOI 10.1126/science.279.5357.1671; CHASE SC, 1978, APPL OPTICS, V17, P1243, DOI 10.1364/AO.17.001243; CHRISTENSEN PR, 1992, J GEOPHYS RES-PLANET, V97, P7719, DOI 10.1029/92JE00453; Christensen PR, 1998, J GEOPHYS RES-PLANET, V103, P1733, DOI 10.1029/97JE02114; CLANCY RT, 1991, ICARUS, V93, P135, DOI 10.1016/0019-1035(91)90169-T; CONRATH B, 1973, J GEOPHYS RES, V78, P4267, DOI 10.1029/JB078i020p04267; CURRAN RJ, 1973, SCIENCE, V182, P381, DOI 10.1126/science.182.4110.381; FISCHBACHER GE, 1969, 951547 JET PROP LAB; Hamilton VE, 1997, J GEOPHYS RES-PLANET, V102, P25593, DOI 10.1029/97JE01874; HANEL RA, 1972, SCIENCE, V175, P305, DOI 10.1126/science.175.4019.305; Hanel RA, 1992, EXPLORATION SOLAR SY; JAMES PB, 1979, J GEOPHYS RES, V84, P2889, DOI 10.1029/JB084iB06p02889; JAMES PB, 1982, ICARUS, V50, P368, DOI 10.1016/0019-1035(82)90130-0; JAMES PB, 1994, MARS; Kieffer H. H., 1977, Journal of Geophysical Research, V82, P4249, DOI 10.1029/JS082i028p04249; KIEFFER HH, 1976, SCIENCE, V193, P780, DOI 10.1126/science.193.4255.780; MARTIN TZ, 1986, ICARUS, V66, P2, DOI 10.1016/0019-1035(86)90003-5; MCSWEEN HY, 1994, METEORITICS, V29, P757, DOI 10.1111/j.1945-5100.1994.tb01092.x; MUSTARD JF, 1993, J GEOPHYS RES-PLANET, V98, P3387, DOI 10.1029/92JE02682; MUSTARD JF, 1995, SCIENCE, V267, P1623, DOI 10.1126/science.7886449; POLLACK JB, 1990, J GEOPHYS RES-SOLID, V95, P1447, DOI 10.1029/JB095iB02p01447; Ramsey MS, 1998, J GEOPHYS RES-SOL EA, V103, P577, DOI 10.1029/97JB02784; Ruff SW, 1997, J GEOPHYS RES-SOL EA, V102, P14899, DOI 10.1029/97JB00593; SINGER RB, 1990, RESOURCES NEAR EARTH; SINGER RB, 1985, B AM ASTRON SOC, V17, P737; SINGER RB, 1980, LUNAR PLANET SCI C, V11, P1045; Smith PH, 1997, SCIENCE, V278, P1758, DOI 10.1126/science.278.5344.1758; TILLMAN JE, 1993, J GEOPHYS RES-PLANET, V98, P10963, DOI 10.1029/93JE01084; ZUREK RW, 1982, ICARUS, V50, P288, DOI 10.1016/0019-1035(82)90127-0	30	165	167	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 13	1998	279	5357					1692	1698		10.1126/science.279.5357.1692	http://dx.doi.org/10.1126/science.279.5357.1692			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9497282				2022-12-28	WOS:000072490000047
J	Groh, V; Steinle, A; Bauer, S; Spies, T				Groh, V; Steinle, A; Bauer, S; Spies, T			Recognition of stress-induced MHC molecules by intestinal epithelial gamma delta T cells	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-I MOLECULES; HUMAN INTRAEPITHELIAL LYMPHOCYTES; MONOCLONAL-ANTIBODY; NONPEPTIDE ANTIGENS; PERIPHERAL-BLOOD; RECEPTOR; GENE; EXPRESSION; DIVERSITY	T cells with variable region V(delta)1 gamma delta T cell receptors (TCRs) are distributed throughout the human intestinal epithelium and may function as sentinels that respond to self antigens. The expression of a major histocompatibility complex (MHC) class I-related molecule, MICA, matches this localization. MICA and the closely related MICE were recognized by intestinal epithelial T cells expressing diverse V(delta)1 gamma delta TCRs, These interactions involved the alpha 1 beta 2 domains of MICA and MICE but were independent of antigen processing. With intestinal epithelial cell lines, the expression and recognition of MICA and MICE could be stress-induced. Thus, these molecules may broadly regulate protective responses by the V(delta)1 gamma delta T cells in the epithelium of the intestinal tract.	Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Groh, V (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N, Seattle, WA 98109 USA.		Steinle, Alexander/E-6131-2012	Steinle, Alexander/0000-0001-5081-8503; Bauer, Stefan/0000-0002-8462-1845	NATIONAL CANCER INSTITUTE [P01CA018221] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030581] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA18221] Funding Source: Medline; NIAID NIH HHS [R01 AI30581] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARCEGOMEZ B, 1978, TISSUE ANTIGENS, V11, P96, DOI 10.1111/j.1399-0039.1978.tb01233.x; Arden Bernhard, 1995, Immunogenetics, V42, P455; ARNOLD D, 1992, NATURE, V360, P171, DOI 10.1038/360171a0; ASARNOW DM, 1988, CELL, V55, P837, DOI 10.1016/0092-8674(88)90139-0; Bahram S, 1996, IMMUNOGENETICS, V43, P230, DOI 10.1007/BF00587305; BAHRAM S, 1994, P NATL ACAD SCI USA, V91, P6259, DOI 10.1073/pnas.91.14.6259; BOISMENU R, 1994, SCIENCE, V266, P1253, DOI 10.1126/science.7973709; BORST J, 1988, J EXP MED, V167, P1625, DOI 10.1084/jem.167.5.1625; BUKOWSKI JF, 1995, J IMMUNOL, V154, P998; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; CERFBENSUSSAN N, 1987, EUR J IMMUNOL, V17, P1279, DOI 10.1002/eji.1830170910; CHOWERS Y, 1994, J EXP MED, V180, P183, DOI 10.1084/jem.180.1.183; DELIBERO G, 1991, J EXP MED, V173, P1311, DOI 10.1084/jem.173.6.1311; DEUSCH K, 1991, EUR J IMMUNOL, V21, P1053, DOI 10.1002/eji.1830210429; EBERT EC, 1989, GASTROENTEROLOGY, V97, P1372, DOI 10.1016/0016-5085(89)90379-X; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Fodil N, 1996, IMMUNOGENETICS, V44, P351, DOI 10.1007/s002510050136; GRANDEA AG, 1995, SCIENCE, V270, P105, DOI 10.1126/science.270.5233.105; Groh V, 1996, P NATL ACAD SCI USA, V93, P12445, DOI 10.1073/pnas.93.22.12445; HATA S, 1988, SCIENCE, V240, P1541, DOI 10.1126/science.3259726; HAVRAN WL, 1991, SCIENCE, V252, P1430, DOI 10.1126/science.1828619; HOLOSHITZ J, 1993, INT IMMUNOL, V5, P1437, DOI 10.1093/intimm/5.11.1437; Holtmeier W, 1997, J IMMUNOL, V158, P5632; JANEWAY CA, 1988, IMMUNOL TODAY, V9, P73, DOI 10.1016/0167-5699(88)91267-4; KABELITZ D, 1990, J EXP MED, V171, P667, DOI 10.1084/jem.171.3.667; KaneiIshii C, 1997, SCIENCE, V277, P246, DOI 10.1126/science.277.5323.246; KONING F, 1989, EUR J IMMUNOL, V19, P2099, DOI 10.1002/eji.1830191120; Koopmann JO, 1997, CURR OPIN IMMUNOL, V9, P80, DOI 10.1016/S0952-7915(97)80163-X; LOH EY, 1988, P NATL ACAD SCI USA, V85, P9714, DOI 10.1073/pnas.85.24.9714; LUNDQVIST C, 1995, INT IMMUNOL, V7, P1473, DOI 10.1093/intimm/7.9.1473; Maeurer MJ, 1996, J EXP MED, V183, P1681, DOI 10.1084/jem.183.4.1681; MELLINS E, 1991, J EXP MED, V174, P1607, DOI 10.1084/jem.174.6.1607; MILARSKI KL, 1986, P NATL ACAD SCI USA, V83, P9517, DOI 10.1073/pnas.83.24.9517; MODLIN RL, 1989, NATURE, V339, P544, DOI 10.1038/339544a0; MORITA CT, 1995, IMMUNITY, V3, P495, DOI 10.1016/1074-7613(95)90178-7; PARHAM P, 1979, J IMMUNOL, V123, P342; PORCELLI S, 1991, IMMUNOL REV, V120, P137, DOI 10.1111/j.1600-065X.1991.tb00591.x; ROCK EP, 1994, J EXP MED, V179, P323, DOI 10.1084/jem.179.1.323; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; SCHILD H, 1994, CELL, V76, P29, DOI 10.1016/0092-8674(94)90170-8; SPENCER J, 1989, EUR J IMMUNOL, V19, P1335, DOI 10.1002/eji.1830190728; TANAKA Y, 1995, NATURE, V375, P155, DOI 10.1038/375155a0; TAX WJM, 1983, NATURE, V304, P445, DOI 10.1038/304445a0; WATANABE M, 1995, J CLIN INVEST, V95, P2945, DOI 10.1172/JCI118002; WEINTRAUB BC, 1994, J IMMUNOL, V153, P3051; WHITESIDE TL, 1986, INT J CANCER, V37, P803, DOI 10.1002/ijc.2910370602; WU YJ, 1988, J IMMUNOL, V141, P1476; York IA, 1996, ANNU REV IMMUNOL, V14, P369, DOI 10.1146/annurev.immunol.14.1.369	48	974	1014	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 13	1998	279	5357					1737	1740		10.1126/science.279.5357.1737	http://dx.doi.org/10.1126/science.279.5357.1737			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9497295				2022-12-28	WOS:000072490000060
J	Caritis, S; Sibai, B; Hauth, J; Lindheimer, MD; Klebanoff, M; Thom, E; VanDorsten, P; Landon, M; Paul, R; Miodovnik, M; Meis, P; Thurnau, G				Caritis, S; Sibai, B; Hauth, J; Lindheimer, MD; Klebanoff, M; Thom, E; VanDorsten, P; Landon, M; Paul, R; Miodovnik, M; Meis, P; Thurnau, G		Natl Inst Child Hlth Human Dev Network Materna	Low-dose aspirin to prevent preeclampsia in women at high risk	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PREGNANCY-INDUCED HYPERTENSION; PRE-ECLAMPSIA; FETAL GROWTH; PROSTACYCLIN; THERAPY	Background Whether low-dose aspirin prevents preeclampsia is unclear. It is not recommended as prophylaxis in women at low risk for preeclampsia but may reduce the incidence of the disease in women at high risk. Methods We conducted a double-blind, randomized, placebo-controlled trial in four groups of pregnant women at high risk for preeclampsia, including 471 women with pregestational insulin-treated diabetes mellitus, 774 women with chronic hypertension, 688 women with multifetal gestations, and 606 women who had had preeclampsia during a previous pregnancy. The women were enrolled between gestational weeks 13 and 26 and received either 60 mg of aspirin or placebo daily. Results Outcome data were obtained on all but 36 of the 2539 women who entered the study. The incidence of preeclampsia was similar in the 1254 women in the aspirin group and the 1249 women in the placebo group (aspirin, 18 percent; placebo, 20 percent; P=0.23). The incidences in the aspirin and placebo groups for each of the four high-risk categories were also similar: for women with pregestational diabetes mellitus, the incidence was 18 percent in the aspirin group and 22 percent in the placebo group (P=0.38); for women with chronic hypertension, 26 percent and 25 percent (P=0.66); for those with multifetal gestations, 12 percent and 16 percent (P=0.10); and for those with preeclampsia during a previous pregnancy, 17 percent and 19 percent (P=0.47). In addition, the incidences of perinatal death, preterm birth, and infants small for gestational age were similar in the aspirin and placebo groups. Conclusions In our study, low-dose aspirin did not reduce the incidence of preeclampsia significantly or improve perinatal outcomes in pregnant women at high risk for preeclampsia. (C) 1998, Massachusetts Medical Society.	Univ Pittsburgh, Dept Obstet & Gynecol, Pittsburgh, PA 15260 USA; Univ Tennessee, Dept Obstet & Gynecol, Memphis, TN 38103 USA; Univ Alabama, Dept Obstet & Gynecol, Birmingham, AL 35294 USA; Univ Chicago, Dept Obstet & Gynecol, Chicago, IL 60637 USA; Med Univ S Carolina, Dept Obstet & Gynecol, Charleston, SC 29425 USA; Ohio State Univ, Dept Obstet & Gynecol, Columbus, OH 43210 USA; Univ So Calif, Dept Obstet & Gynecol, Los Angeles, CA 90089 USA; Univ Cincinnati, Dept Obstet & Gynecol, Cincinnati, OH 45221 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Obstet & Gynecol, Winston Salem, NC USA; Univ Oklahoma, Dept Obstet & Gynecol, Oklahoma City, OK USA; NICHHD, Bethesda, MD 20892 USA; George Washington Univ, Ctr Biostat, Washington, DC USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Tennessee System; University of Tennessee Health Science Center; University of Alabama System; University of Alabama Birmingham; University of Chicago; Medical University of South Carolina; University System of Ohio; Ohio State University; University of Southern California; University System of Ohio; University of Cincinnati; Wake Forest University; Wake Forest Baptist Medical Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); George Washington University	Caritis, S (corresponding author), Magee Womens Hosp, Dept Obstet Gynecol & Reprod Sci, 300 Halket St,Rm 2229, Pittsburgh, PA 15213 USA.			caritis, steve/0000-0002-2169-0712	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U10HD021410] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U10HD021414, U01HD019897, U01HD021414, U01HD021410] Funding Source: NIH RePORTER; NICHD NIH HHS [HD19897, HD21414, HD21410] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Atallah AN, 1996, BRIT J OBSTET GYNAEC, V103, P39; BEAUFILS M, 1985, LANCET, V1, P840, DOI 10.1016/S0140-6736(85)92207-X; BEROYZ G, 1994, LANCET, V343, P619; BRENNER WE, 1976, AM J OBSTET GYNECOL, V126, P555, DOI 10.1016/0002-9378(76)90748-1; COLLINS R, 1995, COCHRANE PREGNANCY C; GOLDIN J, IN PRESS BR J OBSTET; Grant JM, 1996, BRIT J OBSTET GYNAEC, V103, P599, DOI 10.1111/j.1471-0528.1996.tb09823.x; HAUTH JC, 1993, AM J OBSTET GYNECOL, V168, P1083, DOI 10.1016/0002-9378(93)90351-I; NAEYE RL, 1966, PEDIATRICS, V37, P409; PARAZZINI F, 1993, LANCET, V341, P396; PIPKIN B, 1993, BRIT J OBSTET GYNAEC, V103, P603; ROTCHELL YE, IN PRESS BR J OBSTET; SCHIFF E, 1989, NEW ENGL J MED, V321, P351, DOI 10.1056/NEJM198908103210603; SIBAI BM, 1993, NEW ENGL J MED, V329, P1213, DOI 10.1056/NEJM199310213291701; UZAN S, 1991, LANCET, V337, P1427, DOI 10.1016/0140-6736(91)93124-R; VIINIKKA L, 1993, BRIT J OBSTET GYNAEC, V100, P809, DOI 10.1111/j.1471-0528.1993.tb14304.x; Volpe JJ, 1995, NEUROLOGY NEWBORN, P403; WALLENBURG HCS, 1986, LANCET, V1, P1	18	451	469	0	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 12	1998	338	11					701	705		10.1056/NEJM199803123381101	http://dx.doi.org/10.1056/NEJM199803123381101			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB546	9494145	Bronze			2022-12-28	WOS:000072483400001
J	Murray, JB; Terwey, DP; Maloney, L; Karpeisky, A; Usman, N; Beigelman, L; Scott, WG				Murray, JB; Terwey, DP; Maloney, L; Karpeisky, A; Usman, N; Beigelman, L; Scott, WG			The structural basis of hammerhead ribozyme self-cleavage	CELL			English	Article							CATALYTIC RNA; MECHANISM; ENZYME; PHOSPHOROTHIOATE; CONFORMATION	We have captured an 8.7 Angstrom conformational change that takes place in the cleavage site of the hammerhead ribozyme during self-cleavage, using X-ray crystallography combined with physical and chemical trapping techniques. This rearrangement brings the hammerhead ribozyme from the ground state into a conformation that is poised to form the transition state geometry required for hammerhead RNA self-cleavage. Use of a 5'-C-methylated ribose adjacent to the cleavage site permits this ordinarily transient conformational change to be kinetically trapped and observed crystallographically after initiating the hammerhead ribozyme reaction in the crystal. Cleavage of the corresponding unmodified hammerhead ribozyme in the crystal under otherwise identical conditions is faster than in solution, indicating that we have indeed trapped a catalytically relevant intermediate form of this RNA enzyme.	Indiana Univ, Dept Chem, Bloomington, IN 47405 USA; Ribosyme Pharmaceut Inc, Boulder, CO 80301 USA	Indiana University System; Indiana University Bloomington	Scott, WG (corresponding author), Indiana Univ, Dept Chem, Bloomington, IN 47405 USA.			Karpeisky, Alexander/0000-0002-9226-8789; Scott, William/0000-0002-9273-3564	NIGMS NIH HHS [R01 GM087721] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amiri KMA, 1996, J MOL BIOL, V261, P125, DOI 10.1006/jmbi.1996.0446; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bassi GS, 1996, RNA, V2, P756; Bassi GS, 1997, EMBO J, V16, P7481, DOI 10.1093/emboj/16.24.7481; BEIGELMAN L, 1995, NUCLEOS NUCLEOT, V14, P901, DOI 10.1080/15257779508012498; BOLDUC JM, 1995, SCIENCE, V268, P1312, DOI 10.1126/science.7761851; BROWN RS, 1985, BIOCHEMISTRY-US, V24, P4785, DOI 10.1021/bi00339a012; BRUNGER AT, 1993, XPLOR 3 1 SYSTEM CRY; ClouetDOrval B, 1996, RNA, V2, P483; DAHM SC, 1993, BIOCHEMISTRY-US, V32, P13040, DOI 10.1021/bi00211a013; DAHM SC, 1991, BIOCHEMISTRY-US, V30, P9464, DOI 10.1021/bi00103a011; Feig AL, 1998, SCIENCE, V279, P81, DOI 10.1126/science.279.5347.81; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HERMAN T, 1998, IN PRESS EUR J BIOPH; Hermann T, 1997, NUCLEIC ACIDS RES, V25, P3421, DOI 10.1093/nar/25.17.3421; HERTEL KJ, 1994, BIOCHEMISTRY-US, V33, P3374, DOI 10.1021/bi00177a031; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; JONES TA, 1997, O VERSION 6 1 0 DEP; KOIZUMI M, 1991, BIOCHEMISTRY-US, V30, P5145, DOI 10.1021/bi00235a005; McKay DB, 1996, RNA, V2, P395; MOFFAT K, 1995, CURR OPIN STRUC BIOL, V5, P656, DOI 10.1016/0959-440X(95)80059-X; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parkinson G, 1996, ACTA CRYSTALLOGR D, V52, P57, DOI 10.1107/S0907444995011115; PEARSON RG, 1963, J AM CHEM SOC, V85, P3533, DOI 10.1021/ja00905a001; Peracchi A, 1997, J BIOL CHEM, V272, P26822, DOI 10.1074/jbc.272.43.26822; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Scott WG, 1996, SCIENCE, V274, P2065, DOI 10.1126/science.274.5295.2065; Scott WG, 1996, TRENDS BIOCHEM SCI, V21, P220; SCOTT WG, 1995, CELL, V81, P991, DOI 10.1016/S0092-8674(05)80004-2; SIGURDSSON ST, 1995, RNA, V1, P575; Simorre JP, 1997, BIOCHEMISTRY-US, V36, P518, DOI 10.1021/bi9620520; SLIM G, 1991, NUCLEIC ACIDS RES, V19, P1183, DOI 10.1093/nar/19.6.1183; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; SYMONS RH, 1992, ANNU REV BIOCHEM, V61, P641; THOMSON JB, 1996, NUCL ACIDS MOL BIOL, V10, P173; UCHIMARU T, 1993, NUCL ACIDS S SER, V29, P179; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; VANTOL H, 1990, NUCLEIC ACIDS RES, V18, P1971, DOI 10.1093/nar/18.8.1971; WINCOTT F, 1995, NUCLEIC ACIDS RES, V23, P2677, DOI 10.1093/nar/23.14.2677; ZAUG AJ, 1986, SCIENCE, V231, P470, DOI 10.1126/science.3941911	41	201	205	1	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 6	1998	92	5					665	673		10.1016/S0092-8674(00)81134-4	http://dx.doi.org/10.1016/S0092-8674(00)81134-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZA827	9506521	Green Published, Bronze			2022-12-28	WOS:000072406000012
J	Rabouille, C; Kondo, H; Newman, R; Hui, N; Freemont, P; Warren, G				Rabouille, C; Kondo, H; Newman, R; Hui, N; Freemont, P; Warren, G			Syntaxin 5 is a common component of the NSF- and p97-mediated reassembly pathways of Golgi cisternae from mitotic Golgi fragments in vitro	CELL			English	Article							INTEGRAL MEMBRANE-PROTEIN; SENSITIVE FUSION PROTEIN; CELL-FREE SYSTEM; VESICULAR TRANSPORT; ENDOPLASMIC-RETICULUM; VESICLE FUSION; ALPHA-SNAP; PEROXISOME BIOGENESIS; SYNAPTIC VESICLES; YEAST	A cell-free system that mimics the reassembly of Golgi stacks at the end of mitosis requires two ATPases, NSF and p97, to rebuild Golgi cisternae. Morphological studies now show that alpha-SNAP, a component of the NSF pathway, can inhibit the p97 pathway, whereas p47, a component of the p97 pathway, can inhibit the NSF pathway. Anti-syntaxin 5 antibodies and a soluble, recombinant syntaxin 5 inhibited both pathways, suggesting that this t-SNARE is a common component. Biochemical studies confirmed this, showing that p47 binds directly to syntaxin 5 and competes for binding with alpha-SNAP. p47 also mediates the binding of p97 to syntaxin 5 and so plays an analogous role to alpha-SNAP, which mediates the binding of NSF.	Imperial Canc Res Fund, Cell Biol Lab, London WC2A 3PX, England; Imperial Canc Res Fund, Mol Struct & Funct Lab, London WC2A 3PX, England	Cancer Research UK; Cancer Research UK	Warren, G (corresponding author), Imperial Canc Res Fund, Cell Biol Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.			Freemont, Paul/0000-0002-5658-8486				ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; Banerjee A, 1996, J BIOL CHEM, V271, P20223, DOI 10.1074/jbc.271.34.20223; BANFIELD DK, 1995, NATURE, V375, P806, DOI 10.1038/375806a0; BANFIELD DK, 1994, J CELL BIOL, V127, P357, DOI 10.1083/jcb.127.2.357; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; Bock JB, 1996, J BIOL CHEM, V271, P17961, DOI 10.1074/jbc.271.30.17961; Bock JB, 1997, NATURE, V387, P133, DOI 10.1038/387133a0; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; DASCHER C, 1994, J BIOL CHEM, V269, P29363; Davanger S, 1997, MOL BIOL CELL, V8, P1261, DOI 10.1091/mbc.8.7.1261; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; ELAZAR Z, 1994, J BIOL CHEM, V269, P794; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; Haas A, 1996, EMBO J, V15, P3296, DOI 10.1002/j.1460-2075.1996.tb00694.x; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; Hay JC, 1997, CELL, V89, P149, DOI 10.1016/S0092-8674(00)80191-9; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Hui N, 1997, MOL BIOL CELL, V8, P1777, DOI 10.1091/mbc.8.9.1777; HUI N, 1997, CELL BIOL LAB HDB, P46; INOUE A, 1992, J BIOL CHEM, V267, P10613; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; LATTERICH M, 1994, CELL, V78, P87, DOI 10.1016/0092-8674(94)90575-4; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; Levine TP, 1996, J BIOL CHEM, V271, P17304, DOI 10.1074/jbc.271.29.17304; Lewis MJ, 1997, EMBO J, V16, P3017, DOI 10.1093/emboj/16.11.3017; Lowe SL, 1997, NATURE, V389, P881, DOI 10.1038/39923; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; McNew JA, 1997, J BIOL CHEM, V272, P17776, DOI 10.1074/jbc.272.28.17776; MELLMAN I, 1995, CELL, V82, P869, DOI 10.1016/0092-8674(95)90018-7; MISTELI T, 1995, J CELL BIOL, V130, P1027, DOI 10.1083/jcb.130.5.1027; MORGAN A, 1995, EMBO J, V14, P232, DOI 10.1002/j.1460-2075.1995.tb06996.x; Nagahama M, 1996, J CELL BIOL, V133, P507, DOI 10.1083/jcb.133.3.507; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; Patel SK, 1998, CELL, V92, P611, DOI 10.1016/S0092-8674(00)81129-0; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PETERS JM, 1992, J MOL BIOL, V223, P557, DOI 10.1016/0022-2836(92)90670-F; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; RABOUILLE C, 1995, J CELL BIOL, V129, P605, DOI 10.1083/jcb.129.3.605; Rothman JE, 1997, SCIENCE, V276, P1212, DOI 10.1126/science.276.5316.1212; SAPPERSTEIN SK, 1995, P NATL ACAD SCI USA, V92, P522, DOI 10.1073/pnas.92.2.522; Saxton WO, 1996, J STRUCT BIOL, V116, P230, DOI 10.1006/jsbi.1996.0035; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLIMENA CW, 1995, J CELL BIOL, V128, P637; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SPONG AP, 1993, J CELL BIOL, V123, P535, DOI 10.1083/jcb.123.3.535; Subramaniam VN, 1997, J BIOL CHEM, V272, P25441, DOI 10.1074/jbc.272.41.25441; Subramaniam VN, 1996, SCIENCE, V272, P1161, DOI 10.1126/science.272.5265.1161; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; WEIDMAN P, 1993, CELL, V75, P123, DOI 10.1016/S0092-8674(05)80089-3; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0	62	219	226	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 6	1998	92	5					603	610		10.1016/S0092-8674(00)81128-9	http://dx.doi.org/10.1016/S0092-8674(00)81128-9			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZA827	9506515	Bronze			2022-12-28	WOS:000072406000006
J	Newstead, CG				Newstead, CG			Assessment of risk of cancer after renal transplantation	LANCET			English	Editorial Material							SKIN-CANCER; RECIPIENTS		St James Univ Hosp, Renal Unit, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital	Newstead, CG (corresponding author), St James Univ Hosp, Renal Unit, Leeds LS9 7TF, W Yorkshire, England.							al-Sulaiman M H, 1994, Transplant Sci, V4, P46; ALLEN RDM, 1994, MANUAL RENAL TRANSPL, P241; Bavinck JNB, 1996, TRANSPLANTATION, V61, P715, DOI 10.1097/00007890-199603150-00008; BAVINCK JNB, 1995, J CLIN ONCOL, V13, P1933, DOI 10.1200/JCO.1995.13.8.1933; BIRKELAND SA, 1995, INT J CANCER, V60, P183, DOI 10.1002/ijc.2910600209; BOYLE J, 1984, LANCET, V1, P702; HARTEVELT MM, 1990, TRANSPLANTATION, V49, P506, DOI 10.1097/00007890-199003000-00006; Hiesse C, 1997, TRANSPL P, V29, P831, DOI 10.1016/S0041-1345(96)00153-4; Holley JL, 1996, KIDNEY INT, V49, P494, DOI 10.1038/ki.1996.70; Hoshida Y, 1997, INT J CANCER, V71, P517, DOI 10.1002/(SICI)1097-0215(19970516)71:4<517::AID-IJC3>3.0.CO;2-X; KO CB, 1994, BRIT J DERMATOL, V130, P269, DOI 10.1111/j.1365-2133.1994.tb02920.x; Laupacis A, 1996, KIDNEY INT, V50, P235, DOI 10.1038/ki.1996.307; LONDON NJ, 1995, LANCET, V346, P403, DOI 10.1016/S0140-6736(95)92780-8; Montagnino G, 1996, CLIN TRANSPLANT, V10, P461; OPELZ G, 1996, CANC TRANSPLANTATION, P17; SEUKERAN DC, IN PRESS BR J DERMAT; VINCEK V, 1993, CANCER RES, V53, P728	17	46	46	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 28	1998	351	9103					610	611		10.1016/S0140-6736(98)22009-5	http://dx.doi.org/10.1016/S0140-6736(98)22009-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA447	9500312				2022-12-28	WOS:000072364200002
J	Shim, JK; Johnson, S; Samore, MH; Bliss, DZ; Gerding, DN				Shim, JK; Johnson, S; Samore, MH; Bliss, DZ; Gerding, DN			Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea	LANCET			English	Article							NOSOCOMIAL ACQUISITION; CROSS-INFECTION; COLITIS; COLONIZATION; ENVIRONMENT	Background Little is known about whether patients who develop Clostridium-difficile-associated diarrhoea (CDAD) are culture-positive or culture-negative before illness. The most important risk factor is antibiotic exposure. We aimed to find out whether patients identified as primary symptom-free C difficile carriers are at higher risk of developing CDAD than patients who are culture-negative. Method We reviewed four longitudinal studies in which 810 patients admitted to hospital were followed up by prospective rectal-swab culture. At least two consecutive weekly cultures were obtained. We calculated the difference in risk of CDAD between colonised and non-colonised patients in each study and combined the results of the four studies in a random-effects model. Findings Of 618 non-colonised patients (mean follow-up 1.7 weeks [SD 1.3]), 22 (3.6%) developed CDAD, whereas only two (1.0%) of 192 primary symptom-free carriers (1.5 [1.5]) developed CDAD (pooled risk difference -2.3% [95% CI 0.3-4.3], p=0.021). Of patients who received antibiotics, the risk difference was increased: 22 (4.5%) of 491 non-colonised patients compared with two (1.1%) of 176 colonised patients developed CDAD (-3.2% [0.4-6.0], p=0.024). Of the primary symptom-free C difficile carriers, 95 were colonised with toxigenic strains, 76 with nontoxigenic strains, 12 with both toxigenic and non-toxigenic strains (non-concurrently), and nine with strains of undetermined toxigenicity. Nine of the 12 toxogenic strains of C difficile isolates that cause CDAD were also recovered from stools of symptom-free patients. Interpretation Primary symptomless C difficile colonisation is associated with a decreased risk of CDAD. Although the mechanism is unknown, risk reduction is found in colonisation with non-toxigenic and toxigenic strains.	Vet Affairs Healthcare Syst, Lakeside Div, Dept Med, Infect Dis Sect, Chicago, IL USA; Northwestern Univ, Sch Med, Chicago, IL USA; Univ Minnesota, Sch Nursing, Minneapolis, MN 55455 USA; Beth Israel Deaconess Med Ctr, Dept Med, Infect Dis Sect, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA	Northwestern University; University of Minnesota System; University of Minnesota Twin Cities; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Gerding, DN (corresponding author), VACHS Lakeside, Med Serv, 333 E Huron, Chicago, IL 60611 USA.			Johnson, Stuart/0000-0001-9548-229X	NATIONAL INSTITUTE OF NURSING RESEARCH [F32NR006746] Funding Source: NIH RePORTER; NINR NIH HHS [IF 32-NR06746] Funding Source: Medline	NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		BLISS D, 1994, 34 INT C ANT AG CHEM; BORRIELLO SP, 1985, J MED MICROBIOL, V19, P339, DOI 10.1099/00222615-19-3-339; CLABOTS CR, 1993, J CLIN MICROBIOL, V31, P1870, DOI 10.1128/JCM.31.7.1870-1875.1993; CLABOTS CR, 1992, J INFECT DIS, V166, P561, DOI 10.1093/infdis/166.3.561; CUMMING AD, 1986, BRIT MED J, V292, P238, DOI 10.1136/bmj.292.6515.238; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; GERDING DN, 1986, ARCH INTERN MED, V146, P95, DOI 10.1001/archinte.146.1.95; HASSELBLAD V, 1995, MED CARE, V33, P202; HEARD SR, 1986, J INFECT DIS, V153, P159, DOI 10.1093/infdis/153.1.159; JOHNSON S, 1990, LANCET, V336, P97, DOI 10.1016/0140-6736(90)91605-A; KELLY CP, 1994, NEW ENGL J MED, V330, P257, DOI 10.1056/NEJM199401273300406; KIM KH, 1981, J INFECT DIS, V143, P42, DOI 10.1093/infdis/143.1.42; MCFARLAND LV, 1989, NEW ENGL J MED, V320, P204, DOI 10.1056/NEJM198901263200402; MULLIGAN ME, 1979, CURR MICROBIOL, V3, P173, DOI 10.1007/BF02601862; Petitti D, 1994, METAANALYSIS DECISIO; SAMORE MH, 1994, CLIN INFECT DIS, V18, P181, DOI 10.1093/clinids/18.2.181; SEAL D, 1987, EUR J CLIN MICROBIOL, V6, P51, DOI 10.1007/BF02097191; SHANHOLTZER CJ, 1983, J CLIN MICROBIOL, V17, P906, DOI 10.1128/JCM.17.5.906-908.1983; WILSON KH, 1983, J INFECT DIS, V147, P733, DOI 10.1093/infdis/147.4.733; WILSON KH, 1993, CLIN INFECT DIS S4, V16, P214	20	268	288	0	20	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 28	1998	351	9103					633	636		10.1016/S0140-6736(97)08062-8	http://dx.doi.org/10.1016/S0140-6736(97)08062-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA447	9500319				2022-12-28	WOS:000072364200009
J	Stephenson, J; Imrie, J				Stephenson, J; Imrie, J			Why do we need randomised controlled trials to assess behavioural interventions?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PREVENTION; HEALTH		UCL, Sch Med, Dept Sexually Transmitted Dis, London WC1 6AU, England	University of London; University College London; UCL Medical School	Stephenson, J (corresponding author), UCL, Sch Med, Dept Sexually Transmitted Dis, London WC1 6AU, England.	jstephen@gum.ucl.ac.uk						Black N, 1996, BRIT MED J, V312, P1215; CHOI KH, 1994, AIDS, V8, P1371, DOI 10.1097/00002030-199410000-00003; Coates TJ, 1996, LANCET, V348, P1143, DOI 10.1016/S0140-6736(96)02307-0; DEVINCENZI I, 1994, NEW ENGL J MED, V331, P341, DOI 10.1056/NEJM199408113310601; GUTHRIE E, 1993, BRIT J PSYCHOL, V163, P321; KELLY J, 1992, AM J PUBLIC HEALTH, V80, P1483; LAW M, 1995, ARCH INTERN MED, V155, P1933, DOI 10.1001/archinte.155.18.1933; OAKLEY A, 1995, AIDS, V9, P479, DOI 10.1097/00002030-199509050-00010; OAKLEY A, 1996, EVALUATING SOCIAL IN; OAKLEY A, 1990, WOMENS HLTH COUNTS; OLeary A, 1997, AIDS EDUC PREV, V9, P1; Pocock SJ, 1983, CLIN TRIALS PRACTICA, P50; POPE C, 1995, BRIT MED J, V311, P42, DOI 10.1136/bmj.311.6996.42; Power R, 1996, SOCIOL HEALTH ILL, V18, P86, DOI 10.1111/1467-9566.ep10934419; POWERS E, 1951, EXPT PREVENTION DELI; Rojanapithayakorn W, 1996, AIDS, V10, P1, DOI 10.1097/00002030-199601000-00001; SMITH PG, 1987, INT J EPIDEMIOL, V16, P159, DOI 10.1093/ije/16.2.159; STEPHENSON JM, 1995, RES METHODOLOGIES 2; SUSSER M, 1995, AM J PUBLIC HEALTH, V85, P156, DOI 10.2105/AJPH.85.2.156; ZENILMAN JM, 1992, JAMA-J AM MED ASSOC, V267, P843, DOI 10.1001/jama.267.6.843	20	106	106	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 21	1998	316	7131					611	613		10.1136/bmj.316.7131.611	http://dx.doi.org/10.1136/bmj.316.7131.611			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YZ031	9518919	Green Submitted, Green Published			2022-12-28	WOS:000072213200037
J	Williams, RJ; Heymann, DL				Williams, RJ; Heymann, DL			Containment of antibiotic resistance	SCIENCE			English	Article							ANTIMICROBIAL DRUGS		WHO, Div Emerging & Other Communicable Dis Surveillanc, CH-1211 Geneva, Switzerland	World Health Organization	Williams, RJ (corresponding author), WHO, Div Emerging & Other Communicable Dis Surveillanc, CH-1211 Geneva, Switzerland.							Acar JF, 1997, CLIN INFECT DIS, V24, pS17, DOI 10.1093/clinids/24.Supplement_1.S17; BAGER F, 1997, CONSUMPTION ANTIMICR; DUA V, 1994, SOC SCI MED, V38, P717, DOI 10.1016/0277-9536(94)90462-6; FORDER AA, 1993, J HOSP INFECT, V24, P87, DOI 10.1016/0195-6701(93)90070-G; Goldmann DA, 1997, CLIN INFECT DIS, V24, pS139, DOI 10.1093/clinids/24.Supplement_1.S139; Gonzales R, 1997, JAMA-J AM MED ASSOC, V278, P901, DOI 10.1001/jama.278.11.901; *GROUP DEP ET PREV, 1994, ACTA CLIN BELG, P108; KLUGMAN KP, 1994, J ANTIMICROB CHEMOTH, V34, P191, DOI 10.1093/jac/34.2.191; Kondro W, 1997, LANCET, V349, P1156, DOI 10.1016/S0140-6736(05)63043-7; KUNIN CM, 1993, ANN INTERN MED, V118, P557, DOI 10.7326/0003-4819-118-7-199304010-00011; Management Science for Health & World Health Organization, 1997, MAN DRUG SUPPL SEL P; OBrien TF, 1997, CLIN INFECT DIS, V24, pS2, DOI 10.1093/clinids/24.Supplement_1.S2; Qazi SA, 1996, B WORLD HEALTH ORGAN, V74, P501; Schwartz B, 1997, JAMA-J AM MED ASSOC, V278, P944, DOI 10.1001/jama.278.11.944; Seto WH, 1996, BRIT J CLIN PHARMACO, V41, P229, DOI 10.1111/j.1365-2125.1996.tb00187.x; TOUWOTTEN FWMM, 1992, FAM PRACT, V9, P255, DOI 10.1093/fampra/9.3.255; *WHO, 1992, TECHN REP SER WHO, V823; *WHO, 1997, US ESS DRUGS; WHO, 1988, ETH CRIT MED DRUG PR; Witte W, 1998, SCIENCE, V279, P996, DOI 10.1126/science.279.5353.996; 1992, MORB MORTAL WKLY REP, V41, P783	21	141	147	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	1998	279	5354					1153	1154		10.1126/science.279.5354.1153	http://dx.doi.org/10.1126/science.279.5354.1153			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9508688				2022-12-28	WOS:000072115200025
J	Ogasawara, K; Hida, S; Azimi, N; Tagaya, Y; Sato, T; Yokochi-Fukuda, T; Waldmann, TA; Taniguchi, T; Taki, S				Ogasawara, K; Hida, S; Azimi, N; Tagaya, Y; Sato, T; Yokochi-Fukuda, T; Waldmann, TA; Taniguchi, T; Taki, S			Requirement for IRF-1 in the microenvironment supporting development of natural killer cells	NATURE			English	Article							RECEPTOR-GAMMA CHAIN; REGULATORY FACTOR-I; INTERLEUKIN-2 RECEPTOR; BETA-CHAIN; TRANSCRIPTION FACTOR; IL-2 RECEPTOR; MICE; MARROW; DIFFERENTIATION; SUPPRESSION	Natural killer (NK) cells are critical for both innate and adaptive immunity(1,2). The development of NK cells requires interactions between their progenitors and the bone-marrow microenvironment(3-6); however, little is known about the molecular nature of such interactions, Mice that do not express the transcription factor interferon-regulatory factor-1 (IRF-1; such mice are IRF-1(-/-) mice) have been shown to exhibit a severe NK-cell deficiency(7,8). Here we demonstrate that the lack of IRF-1 affects the radiation-resistant cells that constitute the microenvironment required for NK-cell development, but not the NK-cell progenitors themselves. We also show that IRF-1(-/-) bone-marrow cells can generate functional NK cells when cultured with the cytokine interleukin-15 (refs 9-12) and that the interleukin-15 gene is transcriptionally regulated by IRF-1. These results reveal, for the first time, a molecular mechanism by which the bone-marrow microenvironment supports NK-cell development.	Univ Tokyo, Grad Sch Med, Dept Immunol, Bunkyo Ku, Tokyo 113, Japan; Univ Tokyo, Fac Med, Bunkyo Ku, Tokyo 113, Japan; NCI, Metab Branch, NIH, Bethesda, MD 20892 USA	University of Tokyo; University of Tokyo; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Taki, S (corresponding author), Univ Tokyo, Grad Sch Med, Dept Immunol, Bunkyo Ku, Hongo 7-3-1, Tokyo 113, Japan.	shin-t@m.u-tokyo.ac.jp	Waldmann, Thomas/AAT-5972-2021; Ogasawara, Kouetsu/G-9892-2011	Waldmann, Thomas/0000-0003-4500-6660; Taki, Shinsuke/0000-0001-5143-3496				ANDERSON DM, 1995, GENOMICS, V25, P701, DOI 10.1016/0888-7543(95)80013-C; Bamford RN, 1996, P NATL ACAD SCI USA, V93, P2897, DOI 10.1073/pnas.93.7.2897; Bendelac A, 1997, ANNU REV IMMUNOL, V15, P535, DOI 10.1146/annurev.immunol.15.1.535; CARSON WE, 1994, J EXP MED, V180, P1395, DOI 10.1084/jem.180.4.1395; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; DiSanto JP, 1997, CURR BIOL, V7, pR424, DOI 10.1016/S0960-9822(06)00208-9; DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377; Duncan GS, 1996, J EXP MED, V184, P2043, DOI 10.1084/jem.184.5.2043; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; HACKETT J, 1985, J IMMUNOL, V134, P3731; HALLER O, 1977, J IMMUNOL, V118, P1503; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; KUMAR V, 1979, J IMMUNOL, V123, P1832; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; Mrozek E, 1996, BLOOD, V87, P2632, DOI 10.1182/blood.V87.7.2632.bloodjournal8772632; Ohbo K, 1996, BLOOD, V87, P956, DOI 10.1182/blood.V87.3.956.bloodjournal873956; Puzanov IJ, 1996, J IMMUNOL, V157, P4282; RODEWALD HR, 1992, CELL, V69, P139, DOI 10.1016/0092-8674(92)90125-V; Rolink A, 1996, J EXP MED, V183, P187, DOI 10.1084/jem.183.1.187; SCOTT P, 1995, CURR OPIN IMMUNOL, V7, P34, DOI 10.1016/0952-7915(95)80026-3; SEAMAN WE, 1979, J IMMUNOL, V122, P2541; Suzuki H, 1997, J EXP MED, V185, P499, DOI 10.1084/jem.185.3.499; Tagaya Y, 1996, IMMUNITY, V4, P329, DOI 10.1016/S1074-7613(00)80246-0; Taki S, 1997, IMMUNITY, V6, P673, DOI 10.1016/S1074-7613(00)80443-4; Tan RSP, 1996, CANCER RES, V56, P2417; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TANAKA T, 1993, J EXP MED, V178, P1103, DOI 10.1084/jem.178.3.1103; Taniguchi T, 1997, BBA-REV CANCER, V1333, pM9, DOI 10.1016/S0304-419X(97)00014-0; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1	30	282	285	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 12	1998	391	6668					700	703		10.1038/35636	http://dx.doi.org/10.1038/35636			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW872	9490414				2022-12-28	WOS:000071982500054
J	Bhugra, D				Bhugra, D			Promiscuity is acceptable only for men - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material									Inst Psychiat, London SE5 8AF, England	University of London; King's College London	Bhugra, D (corresponding author), Inst Psychiat, London SE5 8AF, England.							BANCROFT J, 1989, HUMAN SEXUALITY ITS; BEKKER MHJ, 1997, PSYCHOL INT, V8, P1; BROUDE G, 1980, CROSSCULTURAL SAMPLE; Daly M., 1978, SEX EVOLUTION BEHAV; Ford C.S., 1951, PATTERNSEXUAL BEHA	5	2	2	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 7	1998	316	7129					460	461		10.1136/bmj.316.7129.460a	http://dx.doi.org/10.1136/bmj.316.7129.460a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW874	9492679	Green Published			2022-12-28	WOS:000071982700044
J	Nyren, O; Yin, L; Josefsson, S; McLaughlin, JK; Blot, WJ; Engqvist, M; Hakelius, L; Boice, JD; Adami, HO				Nyren, O; Yin, L; Josefsson, S; McLaughlin, JK; Blot, WJ; Engqvist, M; Hakelius, L; Boice, JD; Adami, HO			Risk of connective tissue disease and related disorders among women with breast implants: a nation-wide retrospective cohort study in Sweden	BRITISH MEDICAL JOURNAL			English	Article							SILICONE; CONTROVERSY	Objective: To examine the relation between connective tissue disease and related conditions and breast implants. Design: Retrospective cohort study of all women in the Swedish national inpatient registry who underwent breast augmentation surgery with artificial implants during 1964-93, compared with women who underwent breast reduction surgery during the same period. Setting: Sweden. Subjects: 7442 women with implants for cosmetic reasons or for reconstruction after breast cancer surgery and 3353 women with breast reduction surgery. Main outcome measures: Subsequent hospitalisation for definite connective tissue diseases (rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, dermatomyositis, and Sjogren's syndrome) or related disorders. Results: 29 women with implants were hospitalised for definite connective tissue disease compared with 25.5 expected based on general population rates (standardised hospitalisation ratio 1.1 (95% confidence interval 0.8 to 1.6)). There were no diagnoses of systemic sclerosis, and no significant excess in risk for polymyalgia rheumatica, fibromyalgia, and several related disorders. Among women who underwent breast reduction surgery, 14 were hospitalised for definite connective tissue disease compared with 10.5 expected (standardised hospitalisation ratio 1.3 (0.7 to 2.2)). Compared with the breast reduction group, women with breast implants showed a slight reduction for all definite connective tissue disease (relative risk 0.8 (95% confidence interval 0.5 to 1.4)). Conclusions: This large nationwide cohort study shows no evidence of association between breast implants and connective tissue disease.	Karolinska Inst, Dept Med Epidemiol, S-17177 Stockholm, Sweden; Int Epidemiol Inst, Rockville, MD USA; Natl Board Hlth & Welf, Stockholm, Sweden; Univ Uppsala Hosp, Dept Plast & Hand Surg, Uppsala, Sweden; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	Karolinska Institutet; National Board of Health & Welfare; Uppsala University; Uppsala University Hospital; Harvard University; Harvard T.H. Chan School of Public Health	Nyren, O (corresponding author), Karolinska Inst, Dept Med Epidemiol, POB 281, S-17177 Stockholm, Sweden.	Olof.Nyren@mep.ki.se						BAILAR JC, 1964, BIOMETRICS, V20, P638; BERKSON J, 1946, BIOMETRICS BULL, V2, P47, DOI 10.2307/3002000; BRIDGES AJ, 1994, LANCET, V344, P1451, DOI 10.1016/S0140-6736(94)90284-4; Burns CJ, 1996, J RHEUMATOL, V23, P1904; Cronin TD., 1963, EXCERPTA MED, V66, P41; Hennekens CH, 1996, JAMA-J AM MED ASSOC, V275, P616, DOI 10.1001/jama.275.8.616; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Hochberg MC, 1996, CURR TOP MICROBIOL, V210, P411; Hochberg MC, 1996, ARTHRITIS RHEUM, V39, P1125, DOI 10.1002/art.1780390708; MARTIN L, 1995, J RHEUMATOL, V22, P198; McCullagh P., 1989, GEN LINEAR MODELS, V2nd; MIYOSHI K, 1964, IJISHIMPO, V2122, P9; Nilsson A C, 1994, Lakartidningen, V91, P603; Perkins LL, 1995, ANN PLAS SURG, V35, P561, DOI 10.1097/00000637-199512000-00001; Rothman K, 1986, MODERN EPIDEMIOLOGY; SANCHEZGUERRERO J, 1995, NEW ENGL J MED, V332, P1666, DOI 10.1056/NEJM199506223322502; *SOC EP CENTR, 1995, PAT 1992 93; SOLOMON G, 1994, SEMIN ARTHRITIS RHEU, V24, P29, DOI 10.1016/0049-0172(94)90107-4; Wong O, 1996, REGUL TOXICOL PHARM, V23, P74, DOI 10.1006/rtph.1996.0011	19	105	107	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 7	1998	316	7129					417	422		10.1136/bmj.316.7129.417	http://dx.doi.org/10.1136/bmj.316.7129.417			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW874	9492663	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000071982700021
J	Connolly, HC; Love, SG				Connolly, HC; Love, SG			The formation of chondrules: Petrologic tests of the shock wave model	SCIENCE			English	Article							PORPHYRITIC PYROXENE CHONDRULES; DYNAMIC CRYSTALLIZATION; FEO-RICH; ORDINARY CHONDRITES; OLIVINE CHONDRULES; SYSTEM; ORIGIN; MELTS	Chondrules are millimeter-sized rounded igneous rocks within chondritic meteorites, Their textures and fractionated mineral chemistries suggest that they formed by repeated, localized, brief (minutes to hours) melting of cold aggregates of mineral dust in the protoplanetary nebula, Astrophysical models of chondrule formation have been unable to explain the petrologically diverse nature of chondrites. However, a nebular shock wave model for chondrule formation agrees with many of the observed petrologic and geochemical properties of chondrules and shows how particles within the nebula are sorted by size and how rims around chondrules are formed. It also explains the volatile-rich nature of chondrule rims and the chondrite matrix.	CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA	California Institute of Technology; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Connolly, HC (corresponding author), CALTECH, Div Geol & Planetary Sci, Mail Code 100-23, Pasadena, CA 91125 USA.							ALEXANDER CMO, 1996, CHONDRULES PROTOPLAN, P233; ANDERS E, 1982, GEOCHIM COSMOCHIM AC, V46, P2363, DOI 10.1016/0016-7037(82)90208-3; Boss A. P., 1996, CHONDRULES PROTOPLAN, V27, P257; BOSS AP, 1993, ICARUS, V106, P168, DOI 10.1006/icar.1993.1164; Cassen P., 1996, CHONDRULES PROTOPLAN, P21; CONNOLLY HC, 1995, GEOCHIM COSMOCHIM AC, V59, P3231, DOI 10.1016/0016-7037(95)00207-G; CONNOLLY HC, 1994, NATURE, V371, P136, DOI 10.1038/371136a0; CONNOLLY HC, IN PRESS GEOCHIM COS; CUZZI JN, 1996, CHONDRULES PROTOPLAN, P35; DOHANYI JS, 1978, COSMIC DUST, P527; Ebel DS, 1997, METEORIT PLANET SCI, V32, pA37; EBEL DS, 1997, LUNAR PLANET SCI, V28, P317; Greenberg JS, 1996, P SOC PHOTO-OPT INS, V2813, P205, DOI 10.1117/12.256064; Grossman J.N., 1988, METEORITES EARLY SOL, P680; GROSSMAN L, 1974, REV GEOPHYS, V12, P71, DOI 10.1029/RG012i001p00071; Hanon P., 1996, METEORITICS, V31, pA57; HASHIMOTO A, 1990, NATURE, V347, P53, DOI 10.1038/347053a0; Hewins R. H., 1996, CHONDRULES PROTOPLAN, P197; HEWINS RH, 1990, METEORITICS, V25, P309, DOI 10.1111/j.1945-5100.1990.tb00715.x; Hewins RH, 1997, ANNU REV EARTH PL SC, V25, P61, DOI 10.1146/annurev.earth.25.1.61; HOOD LL, 1991, ICARUS, V93, P259, DOI 10.1016/0019-1035(91)90211-B; Hood LL, 1998, METEORIT PLANET SCI, V33, P97, DOI 10.1111/j.1945-5100.1998.tb01611.x; Huang SX, 1996, ICARUS, V122, P316, DOI 10.1006/icar.1996.0127; Jones R., 1989, P LUNAR PLANET SCI C, V19, P523; Jones R.H., 1996, CHONDRULES PROTOPLAN, P163; Jones RH, 1996, GEOCHIM COSMOCHIM AC, V60, P3115, DOI 10.1016/0016-7037(96)00152-4; JONES RH, 1993, METEORITICS, V28, P213, DOI 10.1111/j.1945-5100.1993.tb00759.x; JONES RH, 1990, GEOCHIM COSMOCHIM AC, V54, P1785, DOI 10.1016/0016-7037(90)90408-D; JONES RH, 1994, GEOCHIM COSMOCHIM AC, V58, P5325, DOI 10.1016/0016-7037(94)90316-6; Jones RH, 1997, METEORIT PLANET SCI, V32, P753, DOI 10.1111/j.1945-5100.1997.tb01565.x; King E. A., 1983, CHONDRULES THEIR ORI; Krot A.N., 1996, CHONDRULES PROTOPLAN, P181; KROT AN, 1995, GEOCHIM COSMOCHIM AC, V59, P4951, DOI 10.1016/0016-7037(95)00337-1; Liepmann H. W., 1957, ELEMENTS GASDYNAMICS; Liffman K., 1996, CHONDRULES PROTOPLAN, P285; LOFGREN G, 1986, GEOCHIM COSMOCHIM AC, V50, P1715, DOI 10.1016/0016-7037(86)90133-X; LOFGREN G, 1990, GEOCHIM COSMOCHIM AC, V54, P3537, DOI 10.1016/0016-7037(90)90303-3; LOFGREN G, 1989, GEOCHIM COSMOCHIM AC, V53, P461, DOI 10.1016/0016-7037(89)90397-9; LOFGREN GE, 1997, LUNAR PLANET SCI C, V28, P827; LOFGREN GE, 1986, CHONDRULES PROTOPLAN, P187; LOFGREN GE, 1997, 9702 LPI 1, P40; LOVE SG, 1993, ICARUS, V105, P216, DOI 10.1006/icar.1993.1119; LOVE SG, 1991, ICARUS, V89, P26, DOI 10.1016/0019-1035(91)90085-8; MORFILL G, 1993, PROTOSTARS PLANETS, V2, P939; NAGAHARA H, 1981, NATURE, V292, P135, DOI 10.1038/292135a0; NAGAHARA H, 1984, MEM NATL I POLAR RES, V30, P61; PAQUE JM, 1997, LUNAR PLANET SCI, V28, P1071; RADOMSKY PM, 1990, GEOCHIM COSMOCHIM AC, V54, P3475, DOI 10.1016/0016-7037(90)90299-Z; RAMBALDI ER, 1981, NATURE, V293, P558, DOI 10.1038/293558a0; RUZMAIKINA TV, 1994, ICARUS, V112, P430, DOI 10.1006/icar.1994.1196; RUZMAIKINA TV, 1996, CHONDRULES PROTOPLAN, P277; Sahagian D. L., 1992, LUNAR PLANET SCI, V23, P1197; Scott E. R. D., 1996, CHONDRULES PROTOPLAN, P87; Scott E. R. D., 1988, METEORITES EARLY SOL, P718; Scott E.R.D., 1996, CHONDRULES PROTOPLAN; Scott E.R.D., 1996, CHONDRULES PROTOPLAN, P265; SCOTT ERD, 1983, J GEOPHYS RES, V88, pB275, DOI 10.1029/JB088iS01p0B275; Sears D.W.G., 1988, METEORITES EARLY SOL, P3; SHU RH, 1997, SCIENCE, V271, P1545; Wasson J. T., 1985, METEORITES THEIR REC; Wasson J. T., 1996, CHONDRULES PROTOPLAN, P45; Weidenschilling SJ, 1998, SCIENCE, V279, P681, DOI 10.1126/science.279.5351.681; Weinbruch S, 1998, METEORIT PLANET SCI, V33, P65, DOI 10.1111/j.1945-5100.1998.tb01608.x; Weisberg M.K., 1996, CHONDRULES PROTOPLAN, P119; WOOD JA, 1993, GEOCHIM COSMOCHIM AC, V57, P2377, DOI 10.1016/0016-7037(93)90575-H; Wood JA, 1996, METORIT PLANET SCI, V31, P641, DOI 10.1111/j.1945-5100.1996.tb02037.x; WOOD JA, 1984, EARTH PLANET SC LETT, V70, P11, DOI 10.1016/0012-821X(84)90205-X; YU Y, 1997, LUNAR PLANET SCI C, V28, P613; Yu Y., 1996, CHONDRULES PROTOPLAN, P213; YU Y, IN PRESS GEOCHIM COS; ZANDA B, 1997, 9702 LPI 1, P68	71	118	118	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 3	1998	280	5360					62	67		10.1126/science.280.5360.62	http://dx.doi.org/10.1126/science.280.5360.62			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF314	9525858				2022-12-28	WOS:000072885100035
J	Grabowski, PJ				Grabowski, PJ			Splicing regulation in neurons: Tinkering with cell-specific central	CELL			English	Review							RNA		Univ Pittsburgh, Howard Hughes Med Inst, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA	Howard Hughes Medical Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Grabowski, PJ (corresponding author), Univ Pittsburgh, Howard Hughes Med Inst, Pittsburgh, PA 15260 USA.							Ashiya M, 1997, RNA, V3, P996; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; BLACK DL, 1992, CELL, V69, P795, DOI 10.1016/0092-8674(92)90291-J; BLACK DL, 1995, RNA, V1, P763; BUCK LB, 1987, CELL, V51, P127, DOI 10.1016/0092-8674(87)90017-1; Buckanovich RJ, 1997, MOL CELL BIOL, V17, P3194, DOI 10.1128/MCB.17.6.3194; Chan RCC, 1997, MOL CELL BIOL, V17, P4667, DOI 10.1128/MCB.17.8.4667; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; EHLERS MD, 1995, SCIENCE, V269, P1734, DOI 10.1126/science.7569904; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; FU XD, 1995, RNA, V1, P663; Lin CLG, 1998, NEURON, V20, P589, DOI 10.1016/S0896-6273(00)80997-6; Lin ZX, 1997, NEURON, V18, P153, DOI 10.1016/S0896-6273(01)80054-4; Lou H, 1996, GENE DEV, V10, P208, DOI 10.1101/gad.10.2.208; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; Min HS, 1997, GENE DEV, V11, P1023, DOI 10.1101/gad.11.8.1023; Okano HJ, 1997, J NEUROSCI, V17, P3024; Sakakibara S, 1997, J NEUROSCI, V17, P8300; Wang ZH, 1996, RNA, V2, P1241; Zhang L, 1996, RNA, V2, P682	20	107	108	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 20	1998	92	6					709	712		10.1016/S0092-8674(00)81399-9	http://dx.doi.org/10.1016/S0092-8674(00)81399-9			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZD198	9529247	Bronze			2022-12-28	WOS:000072661200004
J	Xu, JM; Qiu, YH; DeMayo, FJ; Tsai, SY; Tsai, MJ; O'Malley, BW				Xu, JM; Qiu, YH; DeMayo, FJ; Tsai, SY; Tsai, MJ; O'Malley, BW			Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene	SCIENCE			English	Article							NUCLEAR RECEPTORS; SUPERFAMILY; ACTIVATION; TRANSCRIPTION; PROTEIN	The in vivo biological function of a steroid receptor coactivator was assessed in mice in which the SRC-1 gene was inactivated by gene targeting. Although in both sexes the homozygous mutants were viable and fertile, target organs such as uterus, prostate, testis, and mammary gland exhibited decreased growth and development in response to steroid hormones. Expression of RNA encoding TIF2, a member of the SRC-1 family, was increased in the SRC-1 null mutant, perhaps compensating partially for the loss of SRC-1 function in target tissues, The results indicate that SRC-1 mediates steroid hormone responses in vivo and that loss of its coactivator function results in partial resistance to hormone.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	Baylor College of Medicine	O'Malley, BW (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.		DeMayo, Francesco/C-6255-2019	DeMayo, Francesco/0000-0002-9480-7336				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Korach KS, 1996, RECENT PROG HORM RES, V51, P159; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; ONATE SA, 1995, SCIENCE, V270, P1354; Qiu YH, 1997, GENE DEV, V11, P1925, DOI 10.1101/gad.11.15.1925; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; SPENCER TE, 1997, NATURE, V389, P197; SPENCER TE, UNPUB; Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wang Y, 1997, GENE THER, V4, P432, DOI 10.1038/sj.gt.3300402; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; WONG JM, 1995, GENE DEV, V9, P2696, DOI 10.1101/gad.9.21.2696; XU J, UNPUB	27	503	519	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 20	1998	279	5358					1922	1925		10.1126/science.279.5358.1922	http://dx.doi.org/10.1126/science.279.5358.1922			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506940				2022-12-28	WOS:000072613300043
J	Pereira, PJB; Bergner, A; Macedo-Ribeiro, S; Huber, R; Matschiner, G; Fritz, H; Sommerhoff, CP; Bode, W				Pereira, PJB; Bergner, A; Macedo-Ribeiro, S; Huber, R; Matschiner, G; Fritz, H; Sommerhoff, CP; Bode, W			Human beta-tryptase is a ring-like tetramer with active sites facing a central pore	NATURE			English	Article							MAST-CELL TRYPTASE; CRYSTAL-STRUCTURE; BENZAMIDINE DERIVATIVES; INHIBITORS; TRYPSIN; INACTIVATION; RESOLUTION; BINDING	Human tryptase, a mast-cell-specific serine proteinase that may be involved in causing asthma and other allergic and inflammatory disorders(1-3), is unique in two respects: it is enzymatically active only as a heparin-stabilized tetramer, and it is resistant to all known endogenous proteinase inhibitors. The 3-Angstrom crystal structure of human beta-tryptase in a complex with 4-amidinophenyl pyruvic acid shows four quasi-equivalent monomers arranged in a square flat ring of pseudo 222 symmetry, Each monomer contacts its neighbours at two different interfaces through six loop segments. These loops are located around the active site of beta-tryptase and differ considerably in length and conformation from loops of other trypsin-like proteinases. The four active centres of the tetramer are directed towards an oval central Fore, restricting access for macromolecular substrates and enzyme inhibitors. Heparin chains might stabilize the complex by binding to an elongated patch of positively charged residues spanning two adjacent monomers. The nature of this unique tetrameric architecture explains many of tryptase's biochemical properties and provides a basis for the rational design of monofunctional and bifunctional tryptase inhibitors.	Max Planck Inst Biochem, Abt Stukturforsch, D-85152 Martinsried, Germany; Univ Munich, Klinikum Innenstadt, Chirurg Klin & Poliklin, Klin Chem & Klin Biochem Abt, D-80336 Munich, Germany	Max Planck Society; University of Munich	Bode, W (corresponding author), Max Planck Inst Biochem, Abt Stukturforsch, Klopferspitz 18A, D-85152 Martinsried, Germany.	bode@biochem.mpg.de	Pereira, Pedro/F-8972-2011; Macedo-Ribeiro, Sandra/D-9258-2011	Pereira, Pedro/0000-0003-0969-5438; Macedo-Ribeiro, Sandra/0000-0002-7698-1170; Bergner, Andreas/0000-0002-5843-4325				Addington AK, 1996, BIOCHEMISTRY-US, V35, P13511, DOI 10.1021/bi960042t; ALTER SC, 1987, BIOCHEM J, V248, P821, DOI 10.1042/bj2480821; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BODE W, 1975, J MOL BIOL, V98, P693, DOI 10.1016/S0022-2836(75)80005-2; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; BRUNGER GJ, 1993, XPLOR VERSION 3 1 SY; Caughey G. H, 1995, MAST CELL PROTEASES; Caughey GH, 1997, AM J RESP CELL MOL, V16, P621, DOI 10.1165/ajrcmb.16.6.9191463; CAUGHEY GH, 1993, J PHARMACOL EXP THER, V264, P676; Clark James M., 1996, Drugs of the Future, V21, P811; EVANS R, 1990, VIA, V11, P134; Fiorucci L, 1997, FEBS LETT, V408, P85, DOI 10.1016/S0014-5793(97)00395-5; Fujinaga M, 1996, J MOL BIOL, V261, P267, DOI 10.1006/jmbi.1996.0458; JOHNSON DA, 1992, PROTEIN SCI, V1, P370; KAM CM, 1995, ARCH BIOCHEM BIOPHYS, V316, P808, DOI 10.1006/abbi.1995.1108; MATSUMOTO R, 1995, J BIOL CHEM, V270, P19524, DOI 10.1074/jbc.270.33.19524; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Otwinowski Z, 1993, DENZO FILM PROCESSIN; ROUSSEL A, 1989, TURBOFRODO SILICON G; Sakai K, 1996, J CLIN INVEST, V97, P988, DOI 10.1172/JCI118523; SCHECHTER NM, 1993, BIOCHEMISTRY-US, V32, P2617, DOI 10.1021/bi00061a020; Schwartz LB, 1995, J CLIN INVEST, V96, P2702, DOI 10.1172/JCI118337; SCHWARTZ LB, 1994, METHOD ENZYMOL, V244, P88; Seife C, 1997, SCIENCE, V277, P1602, DOI 10.1126/science.277.5332.1602; SOMMERHOFF CP, 1994, BIOL CHEM H-S, V375, P685, DOI 10.1515/bchm3.1994.375.10.685; Stubbs MT, 1997, J BIOL CHEM, V272, P19931, DOI 10.1074/jbc.272.32.19931; STURZEBECHER J, 1992, BIOL CHEM H-S, V373, P1025, DOI 10.1515/bchm3.1992.373.2.1025; WALTER J, 1983, H-S Z PHYSIOL CHEM, V364, P949, DOI 10.1515/bchm2.1983.364.2.949	30	270	281	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 19	1998	392	6673					306	311		10.1038/32703	http://dx.doi.org/10.1038/32703			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC739	9521329				2022-12-28	WOS:000072612300054
J	Horton, R				Horton, R			Why graduate medical schools make sense	LANCET			English	Editorial Material									Lancet, London WC1B 3SL, England		Horton, R (corresponding author), Lancet, 42 Bedford Sq, London WC1B 3SL, England.							Donnelly WJ, 1997, ANN INTERN MED, V127, P1045, DOI 10.7326/0003-4819-127-11-199712010-00035; Horton R, 1997, LANCET, V349, P872, DOI 10.1016/S0140-6736(97)02336-2; McLellan MF, 1996, LANCET, V348, P109, DOI 10.1016/S0140-6736(96)03521-0; McManus IC, 1998, LANCET, V351, P802, DOI 10.1016/S0140-6736(05)78929-7; NEUBERGER J, 1998, MED ED MILLENIUM, P54; Novack DH, 1997, JAMA-J AM MED ASSOC, V278, P502, DOI 10.1001/jama.278.6.502; Oakeshott M., 1991, RATIONALISM POLITICS, P184; PEIRCE CS, 1966, SELECTED WRITINGS, P331; Pfeiffer CA, 1997, ADVANCES IN MEDICAL EDUCATION, P695; *SEL COMM SCI TECH, 1998, CLIN AC CAR REP EV, P5; Sherwood T, 1998, J ROY COLL PHYS LOND, V32, P49; SMITH AG, 1972, IRVINGS ANAT MINEMON; STEINER G, 1997, ERRATA EXAMINED LIFE, P41; TERRY G, 1997, WELLCOME NEWS, P36; WILLIAMS PL, 1995, GRAYS ANAT, P889	15	20	20	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 14	1998	351	9105					826	828		10.1016/S0140-6736(98)02290-9	http://dx.doi.org/10.1016/S0140-6736(98)02290-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB916	9519976				2022-12-28	WOS:000072521200045
J	Wang, JS; Yoo, Y; Gao, C; Takeuchi, I; Sun, XD; Chang, HY; Xiang, XD; Schultz, PG				Wang, JS; Yoo, Y; Gao, C; Takeuchi, I; Sun, XD; Chang, HY; Xiang, XD; Schultz, PG			Identification of a blue photoluminescent composite material from a combinatorial library	SCIENCE			English	Article							SILICON	A quaternary combinatorial masking strategy was used in conjunction with photolithography to generate compositionally diverse thin-film phosphor libraries containing 1024 different compositions on substrates 2.5 centimeters square, A parallel imaging system and scanning spectrophotometer were used to identify and characterize compositions in the library with interesting luminescent behavior. Optimal compositions were identified with the use of gradient libraries, in which the stoichiometry of a material was varied continuously, This process led to the identification of an efficient blue photoluminescent composite material, Gd3Ga5O12/SiO2. Experimental evidence suggests that luminescence in this material may arise from interfacial effects between SiO2 and Gd3Ga5O12.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Howard Hughes Med Inst, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley	Xiang, XD (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, Berkeley, CA 94720 USA.	xdxiang@lbl.gov; PGSchultz@lbl.gov	Xiang, Xiaodong/A-5936-2017; Xiang, Xiaodong/A-9445-2012; Xiang, Xiaodong/Q-7727-2018	Xiang, X.-D./0000-0002-6155-7713				Blasse G., 1994, LUMINESCENT MAT, DOI [DOI 10.1007/978-3-642-79017-1_1, 10.1007/978-3-642-79017-1_1]; BRICENO G, 1995, SCIENCE, V270, P273, DOI 10.1126/science.270.5234.273; CHANG H, UNPUB; Collins RT, 1997, PHYS TODAY, V50, P24, DOI 10.1063/1.881650; Danielson E, 1997, NATURE, V389, P944, DOI 10.1038/40099; FISTER L, 1994, ADV SYN R S, V2, P155; ITO T, 1992, JPN J APPL PHYS 2, V31, pL1, DOI 10.1143/JJAP.31.L1; KOCH F, 1993, MATER RES SOC SYMP P, V298, P319, DOI 10.1557/PROC-298-319; Moates FC, 1996, IND ENG CHEM RES, V35, P4801, DOI 10.1021/ie960476k; NISHIKAWA H, 1992, PHYS REV B, V45, P586, DOI 10.1103/PhysRevB.45.586; Qin GG, 1997, PHYS REV B, V55, P12876, DOI 10.1103/PhysRevB.55.12876; STATHIS JH, 1987, PHYS REV B, V35, P2972, DOI 10.1103/PhysRevB.35.2972; Sun XD, 1997, ADV MATER, V9, P1046, DOI 10.1002/adma.19970091311; TOHMON R, 1989, PHYS REV LETT, V62, P1388, DOI 10.1103/PhysRevLett.62.1388; TSYBESKOV L, 1994, PHYS REV B, V49, P7821, DOI 10.1103/PhysRevB.49.7821; Wei T, 1996, APPL PHYS LETT, V68, P3506, DOI 10.1063/1.115773; XIANG XD, 1995, SCIENCE, V268, P1738, DOI 10.1126/science.268.5218.1738	17	282	315	2	110	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 13	1998	279	5357					1712	1714		10.1126/science.279.5357.1712	http://dx.doi.org/10.1126/science.279.5357.1712			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9497288				2022-12-28	WOS:000072490000053
J	Lucas, A				Lucas, A			WHO at country level	LANCET			English	Article							ELIMINATION; PROGRESS	WHO's activities at country level have earned the organisation both criticism and praise. The organisation's technical publications are esteemed as authoritative guidelines for disease control. Successful disease-control programmes and contributions to health research have heightened WHO's reputation, The organisation has also provided the focus for evolution of important ideas, such as primary health care and the relevance of equity and other ethical issues. But WHO has been criticised for not adapting rapidly and logically to changes in the health field. With increasing national capacity in the more advanced developing countries, and with the involvement of new participants in the health sphere, the organisation needs to reassess its role at country level. My recommendation is that WHO improves its analytical capacity so that its programmes take into consideration the health needs of the country, its national capacity, and the contributions from other external agencies.			Lucas, A (corresponding author), 17 Acacia Rd, London SW16 5PP, England.							ANDERSON J, 1996, 7 WELLC TRUST; Barnum H., 1993, PUBLIC HOSP DEV COUN; DEQUADROS CA, 1991, PEDIATR INFECT DIS J, V10, P222, DOI 10.1097/00006454-199103000-00011; GODLEE F, 1994, BRIT MED J, V309, P1424, DOI 10.1136/bmj.309.6966.1424; Jezek Z, 1988, HUMAN MONKEYPOX; Lucas A, 1997, COOPERATION HLTH DEV; NOORDEEN SK, 1995, B WORLD HEALTH ORGAN, V73, P1; RAYMOND SU, 1997, GLOBAL PUBLIC HLTH C; Samba E.M., 1994, ONCHOCERCIASIS CONTR; Schmunis GA, 1996, LANCET, V348, P1171, DOI 10.1016/S0140-6736(05)65305-6; STENSON B, 1994, HEALTH POLICY, V28, P235, DOI 10.1016/0168-8510(94)90063-9; *WHO, 1978, ALMA ATA PRIMARY HLT, V1; *WHO, 1996, URB GLOB HLTH CHALL; *WORLD BANK, 1997, SECT STRAT HLTH NUTR; World Bank, 1993, WORLD DEV REP INV HL	15	7	7	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 7	1998	351	9104					743	747		10.1016/S0140-6736(97)12451-5	http://dx.doi.org/10.1016/S0140-6736(97)12451-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB359	9504535				2022-12-28	WOS:000072463800042
J	Blaxter, ML; De Ley, P; Garey, JR; Liu, LX; Scheldeman, P; Vierstraete, A; Vanfleteren, JR; Mackey, LY; Dorris, M; Frisse, LM; Vida, JT; Thomas, WK				Blaxter, ML; De Ley, P; Garey, JR; Liu, LX; Scheldeman, P; Vierstraete, A; Vanfleteren, JR; Mackey, LY; Dorris, M; Frisse, LM; Vida, JT; Thomas, WK			A molecular evolutionary framework for the phylum Nematoda	NATURE			English	Article							CEPHALOBIDAE; RHABDITIDAE; GENES	Nematodes are important: parasitic nematodes threaten the health of plants, animals and humans on a global scale(1,2); interstitial nematodes pervade sediment and soil ecosystems in overwhelming numbers(3); and Caenorhabditis elegans is a favourite experimental model system(4). A lack of dearly homologous characters and the absence of an informative fossil record have prevented us from deriving a consistent evolutionary framework for the phylum. Here we present a phylogenetic analysis, using 53 small subunit ribosomal DNA sequences from a wide range of nematodes. With this analysis, we can compare animal-parasitic, plant-parasitic and free-living taxa using a common measurement. Our results indicate that convergent morphological evolution may be extensive and that present higher-level classification of the Nematoda will need revision. We identify five major clades within the phylum, all of which include parasitic species. We suggest that animal parasitism arose independently at least four times, and plant parasitism three times. We clarify the relationship of C. elegans to major parasitic groups; this will allow more effective exploitation of our genetic and biological knowledge of this model species.	Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland; Univ Ghent, Dept Morphol Systemat & Ecol, B-9000 Ghent, Belgium; Int Inst Parasitol, St Albans AL4 0XU, Herts, England; Univ S Florida, Dept Biol Sci, Tampa, FL 33620 USA; Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med,Dept Med, Harvard Thorndike Lab, Boston, MA 02215 USA; NemaPharm Inc, Cambridge, MA 02139 USA; Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA; Univ Missouri, Sch Biol Sci, Div Mol Biol & Biochem, Kansas City, MO 64110 USA	University of Edinburgh; Ghent University; State University System of Florida; University of South Florida; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Baylor College of Medicine; University of Missouri System; University of Missouri Kansas City	Blaxter, ML (corresponding author), Univ Edinburgh, Inst Cell Anim & Populat Biol, Kings Bldg, Edinburgh EH9 3JT, Midlothian, Scotland.	mark.blaxter@ed.ac.uk	Cote, Rick H/G-3363-2013; Blaxter, Mark L/B-4113-2010; Blaxter, Mark/O-2535-2019; Garey, James/J-1062-2017	Cote, Rick H/0000-0002-1573-6526; Blaxter, Mark L/0000-0003-2861-949X; Garey, James/0000-0001-8205-5563	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aguinaldo AMA, 1997, NATURE, V387, P489, DOI 10.1038/387489a0; Anderson RC, 1992, NEMATODE PARASITES V; BALDWIN JG, 1995, CAN J ZOOL, V73, P648, DOI 10.1139/z95-076; Baldwin JG, 1997, CAN J ZOOL, V75, P407, DOI 10.1139/z97-051; Baldwin JG, 1997, MOL PHYLOGENET EVOL, V8, P249, DOI 10.1006/mpev.1997.0433; Blaxter ML, 1996, MOL BIOCHEM PARASIT, V77, P77, DOI 10.1016/0166-6851(96)02571-6; DELEY P, 1995, NEMATOLOGICA, V41, P153, DOI 10.1163/003925995X00143; ELLIS RE, 1986, NUCLEIC ACIDS RES, V14, P2345, DOI 10.1093/nar/14.5.2345; ETZINGER A, 1997, SCIENCE, V278, P452; FELSENSTEIN J, 1978, SYST ZOOL, V27, P401, DOI 10.2307/2412923; FITCH DHA, 1995, MOL BIOL EVOL, V12, P346; Kumar S., 1993, MEGA MOL EVOLUTIONAR; LAMBSHEAD PJD, 1993, OCEANIS S D, V19, P5; Lorenzen S, 1994, PHYLOGENETIC SYSTEMA; Luc M, 1990, PLANT PARASITIC NEMA; MADDISON W, 1993, MACCLADE V3 0; Maggenti A.R., 1983, Systematics Association Special Volume Series, P25; Malakhov V. V., 1994, NEMATODES STRUCTURE; POINAR GO, 1993, FUND APPL NEMATOL, V16, P333; Poinar GO., 1983, NATURAL HIST NEMATOD; Riddle DL, 1997, C ELEGANS; Siddiqi M.R., 1983, Pakistan Journal of Nematology, V1, P79; Swofford D., 1998, PAUP PHYLOGENETIC AN; Swofford David L., 1996, P407; VanDePeer Y, 1996, P NATL ACAD SCI USA, V93, P7732, DOI 10.1073/pnas.93.15.7732; VANDEPEER Y, 1994, COMPUT APPL BIOSCI, V10, P569; WINNEPENNINCKX B, 1995, MOL BIOL EVOL, V12, P1132; Yang Z, 1996, PHYLOGENETIC ANAL MA; ZARLENGA DS, 1994, EXP PARASITOL, V78, P28, DOI 10.1006/expr.1994.1003	29	1456	1518	8	281	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAR 5	1998	392	6671					71	75		10.1038/32160	http://dx.doi.org/10.1038/32160			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA528	9510248				2022-12-28	WOS:000072373000051
J	Niederau, C; Niederau, CM; Lange, S; Littauer, A; Abdel-Jalil, N; Maurer, M; Haussinger, D; Strohmeyer, G				Niederau, C; Niederau, CM; Lange, S; Littauer, A; Abdel-Jalil, N; Maurer, M; Haussinger, D; Strohmeyer, G			Screening for hemochromatosis and iron deficiency in employees and primary care patients in western Germany	ANNALS OF INTERNAL MEDICINE			English	Article						hemochromatosis; iron overload; anemia, iron-deficiency; ferritin; transferrin	LONG-TERM SURVIVAL; COST-EFFECTIVENESS; HEREDITARY HEMOCHROMATOSIS; BLOOD-DONORS; GENETIC HEMOCHROMATOSIS; SERUM FERRITIN; PREVALENCE; HEMOGLOBIN; POPULATION; CHILDREN	Background: Many physicians still believe that iron overload (hemochromatosis) is an uncommon disorder. Objective: To estimate the frequency of iron overload and iron deficiency in a group of employees and a group of outpatients. Design: Prospective screening study. Setting: Western Germany. Participants: 3012 asymptomatic employees and 3027 outpatients of nine practitioners. Measurements: Serum ferritin levels and transferrin saturation were measured. Participants with repeatedly abnormal results had thorough clinical evaluations to identify the cause of iron deficiency or overload. Results: Gross iron overload (elevated transferrin saturation and ferritin levels) was proven by liver biopsy and phlebotomy treatment in 28 participants (0.4% of female outpatients, 0.7% of male outpatients, 0.2% bf female employees, and 0.4% of male employees) and in six siblings of these participants. Of the 34 participants with iron overload, 30 were precirrhotic. Because 60% of an unselected group of employees with elevated transferrin saturation but normal ferritin levels were assumed to have early hemochromatosis, the prevalence of hemochromatosis was estimated to be 1.8% among patients (1.9% in women and 1.6% in men) and 1.0% among employees (1.1% in women and 1.0% in men). Iron deficiency was found in 6.8% of female patients, 2.4% of male patients, 6.0% of female employees, and 0.5% of male employees. Conclusions: Iron deficiency was more common in women, and iron overload was more common in men. Among male employees, iron overload was almost as common as iron deficiency.	Univ Dusseldorf, Dept Med, Div Gatroenterol Hepatol & Infect Dis, D-40225 Dusseldorf, Germany; Mannesmann Rohrenwerke AG, Betriebsarztzentrum, D-40472 Dusseldorf, Germany; Univ Dusseldorf, Inst Clin Chem & Lab Diagnost, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf	Niederau, C (corresponding author), Univ Dusseldorf, Dept Med, Div Gatroenterol Hepatol & Infect Dis, Moorenstr 5, D-40225 Dusseldorf, Germany.							Adams PC, 1995, HEPATOLOGY, V22, P1720, DOI 10.1016/0270-9139(95)90197-3; ADAMS PC, 1995, GASTROENTEROLOGY, V109, P177, DOI 10.1016/0016-5085(95)90283-X; ADAMS PC, 1991, GASTROENTEROLOGY, V101, P368, DOI 10.1016/0016-5085(91)90013-B; BALAN V, 1994, GASTROENTEROLOGY, V107, P453, DOI 10.1016/0016-5085(94)90171-6; BUFFONE GJ, 1994, CLIN CHEM, V40, P1631; Bulaj ZJ, 1996, NEW ENGL J MED, V335, P1799, DOI 10.1056/NEJM199612123352403; COOK JD, 1986, BLOOD, V68, P726; DEUGNIER YM, 1993, GASTROENTEROLOGY, V104, P228, DOI 10.1016/0016-5085(93)90856-8; EDWARDS CQ, 1993, NEW ENGL J MED, V328, P1616; EDWARDS CQ, 1988, NEW ENGL J MED, V318, P1355, DOI 10.1056/NEJM198805263182103; FARGION S, 1992, HEPATOLOGY, V15, P655, DOI 10.1002/hep.1840150417; FISHER KD, 1985, AM J CLIN NUTR, V42, P1318; GORDEUK V, 1992, NEW ENGL J MED, V326, P95, DOI 10.1056/NEJM199201093260204; JONSSON JJ, 1991, J CLIN EPIDEMIOL, V44, P1289, DOI 10.1016/0895-4356(91)90090-V; KENT G, 1968, AM J MED, V44, P837, DOI 10.1016/0002-9343(68)90083-1; KUSHNER JP, 1992, CECIL TXB MED, P839; LOREAL O, 1992, J HEPATOL, V16, P122, DOI 10.1016/S0168-8278(05)80104-7; MerryweatherClarke AT, 1997, J MED GENET, V34, P275, DOI 10.1136/jmg.34.4.275; MILMAN N, 1984, TRANSFUSION, V24, P464, DOI 10.1046/j.1537-2995.1984.24685066801.x; NELSON M, 1993, BRIT J NUTR, V70, P147, DOI 10.1079/BJN19930112; Niederau C, 1996, GASTROENTEROLOGY, V110, P1107, DOI 10.1053/gast.1996.v110.pm8613000; NIEDERAU C, 1985, NEW ENGL J MED, V313, P1256, DOI 10.1056/NEJM198511143132004; NIEDERAU C, 1994, ADV EXP MED BIOL, V356, P293; OSKI FA, 1993, NEW ENGL J MED, V329, P190, DOI 10.1056/NEJM199307153290308; PHATAK PD, 1994, ARCH INTERN MED, V154, P769, DOI 10.1001/archinte.154.7.769; PI DW, 1994, TRANSFUSION, V34, P7, DOI 10.1046/j.1537-2995.1994.34194098609.x; SUMMERS KM, 1990, HEPATOLOGY, V12, P20, DOI 10.1002/hep.1840120105; VALBERG LS, 1976, CAN MED ASSOC J, V114, P417; WEINSTEIN MC, 1985, ANNU REV PUBL HEALTH, V6, P41; WELCH HG, 1989, NEW ENGL J MED, V321, P807, DOI 10.1056/NEJM198909213211207	30	85	85	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1998	128	5					337	+		10.7326/0003-4819-128-5-199803010-00001	http://dx.doi.org/10.7326/0003-4819-128-5-199803010-00001			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY519	9490593				2022-12-28	WOS:000072155600001
J	Chen, RT; DeStefano, F				Chen, RT; DeStefano, F			Vaccine adverse events: causal or coincidental?	LANCET			English	Editorial Material							CROHNS-DISEASE; ABSENCE		Ctr Dis Control & Prevent, Vaccine Safety & Dev Act Natl Immunizat Program, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Chen, RT (corresponding author), Ctr Dis Control & Prevent, Vaccine Safety & Dev Act Natl Immunizat Program, Atlanta, GA 30333 USA.		Chen, Robert T/AIA-8164-2022	Chen, Robert T/0000-0002-3094-8367				BEGG N, 1998, BRIT MED J, V316, P561, DOI DOI 10.1136/BMJ.316.7130.561; CHEN RT, 1994, VACCINE, V12, P542, DOI 10.1016/0264-410X(94)90315-8; CHEN RT, 1994, PHARMACOEPIDEM DR S, P581; FORSEY T, 1992, LANCET, V340, P980, DOI 10.1016/0140-6736(92)92873-E; Gangarosa EJ, 1998, LANCET, V351, P356, DOI 10.1016/S0140-6736(97)04334-1; Haga Y, 1996, GUT, V38, P211, DOI 10.1136/gut.38.2.211; HOWSON CP, 1991, I MED ADVERSE EFFECT; IIZUKA M, 1995, LANCET, V345, P199; KILROY AW, 1970, J AMER MED ASSOC, V214, P2287, DOI 10.1001/jama.214.13.2287; KULENKAMPFF M, 1974, ARCH DIS CHILD, V49, P46, DOI 10.1136/adc.49.1.46; Metcalf J, 1998, BRIT MED J, V316, P166; Stratton K.R., 1994, ADVERSE EVENTS ASS C	12	108	111	0	30	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 28	1998	351	9103					611	612		10.1016/S0140-6736(05)78423-3	http://dx.doi.org/10.1016/S0140-6736(05)78423-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA447	9500313				2022-12-28	WOS:000072364200003
J	Sirrenberg, C; Endres, M; Folsch, H; Stuart, RA; Neupert, W; Brunner, M				Sirrenberg, C; Endres, M; Folsch, H; Stuart, RA; Neupert, W; Brunner, M			Carrier protein import into mitochondria mediated by the intermembrane proteins Tim10/Mrs11 and Tim12/Mrs5	NATURE			English	Article							INNER MEMBRANE; SPLICING DEFECTS; YEAST; SUPPRESSORS; DISSECTION; MACHINERY; HSP70	Import of nuclear-encoded precursor proteins into mitochondria and their subsequent sorting into mitochondrial subcompartments is mediated by translocase enzymes in the mitochondrial outer and inner membranes(1-3). Precursor proteins carrying amino-terminal targeting signals are translocated into the matrix by the integral inner membrane proteins Tim23 and Tim17 in cooperation with Tim44 and mitochondrial Hsp70 (refs 4-7). We describe here the discovery of a new pathway for the transport of members of the mitochondrial carrier family and other inner membrane proteins that contain internal targeting signals. Two related proteins in the intermembrane space, Tim10/Mrs11 (ref. 8) and Tim12/Mrs5 (ref. 9), interact sequentially with these precursors and facilitate their translocation across the outer membrane, irrespective of the membrane potential. Tim10 and Tim12 are found in a complex with Tim22, which takes over the precursor and mediates its membrane-potential-dependent insertion into the inner membrane. This interaction of Tim10 and Tim12 with the precursors depends on the presence of divalent metal ions. Both proteins contain a zinc-finger-like motif with four cysteines and bind equimolar amounts of zinc ions.	Univ Munich, Inst Physiol Chem, D-80336 Munich, Germany	University of Munich	Neupert, W (corresponding author), Univ Munich, Inst Physiol Chem, Goethestr 33, D-80336 Munich, Germany.	neupert@bio.med.uni-muenchen.de		Brunner, Michael/0000-0001-9798-3047; Folsch, Heike/0000-0003-0897-0311				Bauer MF, 1996, CELL, V87, P33, DOI 10.1016/S0092-8674(00)81320-3; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; Brunner M, 1995, COLD SPRING HARB SYM, V60, P619, DOI 10.1101/SQB.1995.060.01.066; Dietmeier K, 1997, NATURE, V388, P195, DOI 10.1038/40663; Folsch H, 1996, EMBO J, V15, P479, DOI 10.1002/j.1460-2075.1996.tb00380.x; Jarosch E, 1996, J BIOL CHEM, V271, P17219, DOI 10.1074/jbc.271.29.17219; Jarosch E, 1997, MOL GEN GENET, V255, P157, DOI 10.1007/s004380050484; KRIZEK BA, 1993, INORG CHEM, V32, P937, DOI 10.1021/ic00058a030; KRONIDOU NG, 1994, P NATL ACAD SCI USA, V91, P12818, DOI 10.1073/pnas.91.26.12818; KUBRICH M, 1995, CURR GENET, V27, P393, DOI 10.1007/BF00311207; PALMIERI F, 1994, FEBS LETT, V346, P48, DOI 10.1016/0014-5793(94)00329-7; PFANNER N, 1987, J BIOL CHEM, V262, P7528; Pfanner N, 1996, TRENDS BIOCHEM SCI, V21, P51, DOI 10.1016/0968-0004(96)80864-4; RASSOW J, 1994, J CELL BIOL, V127, P1547, DOI 10.1083/jcb.127.6.1547; SARASTE M, 1982, FEBS LETT, V144, P250, DOI 10.1016/0014-5793(82)80648-0; SCHMIDT B, 1984, EUR J BIOCHEM, V144, P581, DOI 10.1111/j.1432-1033.1984.tb08505.x; Schneider HC, 1996, EMBO J, V15, P5796, DOI 10.1002/j.1460-2075.1996.tb00966.x; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; WALDHERR M, 1993, CURR GENET, V24, P301, DOI 10.1007/BF00336780; WIESENBERGER G, 1991, J MOL BIOL, V217, P23, DOI 10.1016/0022-2836(91)90608-9	21	247	250	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 26	1998	391	6670					912	915		10.1038/36136	http://dx.doi.org/10.1038/36136			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ206	9495346				2022-12-28	WOS:000072230900057
J	de Silva, R; Patterson, J; Hadley, D; Russell, A; Turner, M; Zeidler, M				de Silva, R; Patterson, J; Hadley, D; Russell, A; Turner, M; Zeidler, M			Single photon emission computed tomography in the identification of new variant Creutzfeldt-Jakob disease: case reports	BRITISH MEDICAL JOURNAL			English	Article									So Gen Hosp, Inst Neurosci, Dept Neurol, Glasgow G51 4TF, Lanark, Scotland; So Gen Hosp, Dept Neuroradiol, Glasgow G51 4TF, Lanark, Scotland; So Gen Hosp, Dept Electrophysiol, Glasgow G51 4TF, Lanark, Scotland; Woodilee Psychiat Hosp, Lenzie G66 3UG, Scotland; Western Gen Hosp, Natl CJD Surveillance Unit, Edinburgh EH4 2XU, Midlothian, Scotland	University of Glasgow; University of Glasgow; University of Glasgow; University of Edinburgh	de Silva, R (corresponding author), So Gen Hosp, Inst Neurosci, Dept Neurol, Glasgow G51 4TF, Lanark, Scotland.							Hill AF, 1997, LANCET, V349, P99, DOI 10.1016/S0140-6736(97)24002-X; KIRK A, 1994, CAN J NEUROL SCI, V21, P350, DOI 10.1017/S0317167100040944; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; Will RG, 1996, LANCET, V348, P955, DOI 10.1016/S0140-6736(96)24040-1; WILL RG, 1996, BRIT MED J, V318, P833	5	22	22	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 21	1998	316	7131					593	594		10.1136/bmj.316.7131.593	http://dx.doi.org/10.1136/bmj.316.7131.593			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ031	9518911	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000072213200029
J	Paassilta, M; Kervinen, K; Rantala, AO; Savolainen, MJ; Lilja, M; Reunanen, A; Kesaniemi, YA				Paassilta, M; Kervinen, K; Rantala, AO; Savolainen, MJ; Lilja, M; Reunanen, A; Kesaniemi, YA			Social alcohol consumption and low Lp(a) lipoprotein concentrations in middle aged Finnish men: population based study	BRITISH MEDICAL JOURNAL			English	Article							DISEASE; RISK		Univ Oulu, Dept Internal Med, FIN-90220 Oulu, Finland; Univ Oulu, Bioctr Oulu, FIN-90220 Oulu, Finland; Natl Publ Hlth Inst, FIN-00300 Helsinki, Finland	University of Oulu; University of Oulu; Finland National Institute for Health & Welfare	Kesaniemi, YA (corresponding author), Univ Oulu, Dept Internal Med, Kajaanintie 50, FIN-90220 Oulu, Finland.							Bostom AG, 1996, JAMA-J AM MED ASSOC, V276, P544, DOI 10.1001/jama.276.7.544; HASKELL WL, 1984, NEW ENGL J MED, V310, P805, DOI 10.1056/NEJM198403293101301; KERVINEN K, 1991, LIFE SCI, V48, P2183, DOI 10.1016/0024-3205(91)90152-2; NAGO N, 1995, AM J EPIDEMIOL, V141, P815, DOI 10.1093/oxfordjournals.aje.a117516; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W	5	38	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 21	1998	316	7131					594	595		10.1136/bmj.316.7131.594	http://dx.doi.org/10.1136/bmj.316.7131.594			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ031	9518912	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000072213200030
J	Finger, FP; Hughes, TE; Novick, P				Finger, FP; Hughes, TE; Novick, P			Sec3p is a spatial landmark for polarized secretion in budding yeast	CELL			English	Article							GREEN FLUORESCENT PROTEIN; BUD-SITE SELECTION; MYOSIN HEAVY-CHAIN; SACCHAROMYCES-CEREVISIAE; CELL POLARITY; PLASMA-MEMBRANE; ACTIN CYTOSKELETON; 19.5S PARTICLE; GENE; COMPONENTS	Exocytosis in yeast occurs at plasma membrane subdomains whose locations vary with the cell cycle, but the primary protein determinants of these sites are unknown. A functional fusion of Sec3 protein with green fluorescent protein (Sec3-GFP) localizes to the site of polarized exocytosis for each cell-cycle stage, where it colocalizes with Sec4p and Sec8p. Sec3-GFP localization is independent of secretory pathway function, of the actin and septin cytoskeletons, and of the polarity establishment proteins. We propose that Sec3p is a spatial landmark defining sites of exocytosis. Polarized secretion would result from the coupling of actin-dependent vesicle targeting with Sec3p-dependent establishment of the vesicle fusion site.	Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Ophthalmol & Visual Sci, New Haven, CT 06520 USA	Yale University; Yale University	Novick, P (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, 333 Cedar St, New Haven, CT 06520 USA.			Hughes, Thomas/0000-0002-8430-070X; Hughes, Thomas/0000-0001-5880-9951	NATIONAL EYE INSTITUTE [R01EY008362] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035370, R37GM035370] Funding Source: NIH RePORTER; NEI NIH HHS [EY08362] Funding Source: Medline; NIGMS NIH HHS [GM35370] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; Bi GQ, 1997, J CELL BIOL, V138, P999, DOI 10.1083/jcb.138.5.999; BOWSER R, 1992, J CELL BIOL, V118, P1041, DOI 10.1083/jcb.118.5.1041; BOWSER R, 1991, J CELL BIOL, V112, P1117, DOI 10.1083/jcb.112.6.1117; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; Byers B, 1981, MOL BIOL YEAST SACCH, P59; CHANT J, 1995, J CELL BIOL, V129, P751, DOI 10.1083/jcb.129.3.751; CHANT J, 1995, J CELL BIOL, V129, P767, DOI 10.1083/jcb.129.3.767; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; FARKAS V, 1974, J BACTERIOL, V117, P265; FIELD C, 1980, J CELL BIOL, V86, P123, DOI 10.1083/jcb.86.1.123; Finger FP, 1997, MOL BIOL CELL, V8, P647, DOI 10.1091/mbc.8.4.647; Goodson HV, 1996, J CELL BIOL, V133, P1277, DOI 10.1083/jcb.133.6.1277; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; Govindan B, 1995, J EXP ZOOL, V273, P401, DOI 10.1002/jez.1402730505; GOVINDAN B, 1995, J CELL BIOL, V128, P1055, DOI 10.1083/jcb.128.6.1055; Guo W, 1997, FEBS LETT, V404, P135, DOI 10.1016/S0014-5793(97)00109-9; GUTHRIE C, 1991, METH ENZYMOL, V194; HAARER BK, 1990, J CELL BIOL, V110, P105, DOI 10.1083/jcb.110.1.105; Haarer BK, 1996, GENETICS, V144, P495; HARTWELL LH, 1971, EXP CELL RES, V69, P265, DOI 10.1016/0014-4827(71)90223-0; Hazuka CD, 1997, GENE, V187, P67, DOI 10.1016/S0378-1119(96)00720-2; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; Hsu SC, 1996, NEURON, V17, P1209, DOI 10.1016/S0896-6273(00)80251-2; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; Kee Y, 1997, P NATL ACAD SCI USA, V94, P14438, DOI 10.1073/pnas.94.26.14438; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lew DJ, 1997, MOL CELLULAR BIOL YE, V3, P607; LI R, 1995, J CELL BIOL, V128, P599, DOI 10.1083/jcb.128.4.599; Longtine MS, 1996, CURR OPIN CELL BIOL, V8, P106, DOI 10.1016/S0955-0674(96)80054-8; Mondesert G, 1997, GENETICS, V147, P421; Mulholland J, 1997, MOL BIOL CELL, V8, P1481, DOI 10.1091/mbc.8.8.1481; NOVICK P, 1985, CELL, V40, P405, DOI 10.1016/0092-8674(85)90154-0; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Pringle JR, 1995, COLD SPRING HARB SYM, V60, P729, DOI 10.1101/SQB.1995.060.01.079; RODRIGUEZ JR, 1990, CELL MOTIL CYTOSKEL, V17, P301, DOI 10.1002/cm.970170405; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; Sanders SL, 1996, J CELL BIOL, V134, P413, DOI 10.1083/jcb.134.2.413; SIKORSKI RS, 1989, GENETICS, V122, P19; Simons K, 1993, Harvey Lect, V89, P125; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; TERBUSH DR, 1995, J CELL BIOL, V130, P299, DOI 10.1083/jcb.130.2.299; TING AE, 1995, P NATL ACAD SCI USA, V92, P9613, DOI 10.1073/pnas.92.21.9613; TKACZ JS, 1972, J GEN MICROBIOL, V72, P243, DOI 10.1099/00221287-72-2-243; TKACZ JS, 1973, J BACTERIOL, V113, P1073, DOI 10.1128/JB.113.2.1073-1075.1973; WalchSolimena C, 1997, J CELL BIOL, V137, P1495, DOI 10.1083/jcb.137.7.1495; WATTS FZ, 1985, NATURE, V316, P83, DOI 10.1038/316083a0	51	303	314	1	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 20	1998	92	4					559	571		10.1016/S0092-8674(00)80948-4	http://dx.doi.org/10.1016/S0092-8674(00)80948-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YZ409	9491896	hybrid			2022-12-28	WOS:000072251500015
J	Ruggenenti, P; Gaspari, F; Perna, A; Remuzzi, G				Ruggenenti, P; Gaspari, F; Perna, A; Remuzzi, G			Cross sectional longitudinal study of spot morning urine protein : creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes	BRITISH MEDICAL JOURNAL			English	Article							NEPHROPATHY; PROGRESSION; SAMPLES	Objective: To evaluate whether the protein:creatinine ratio in spot morning urine samples is a reliable indicator of 24 hour urinary protein excretion and predicts the rate of decline of glomerular filtration rate and progression to end stage renal failure in non-diabetic patients with chronic nephropathy. Design: Cross sectional correlation between the ratio and urinary protein excretion rate. Univariate and multivariate analysis of baseline predictors, including the ratio and 24 hour urinary protein, of decline in glomerular filtration rate and end stage renal failure in the long term. Setting: Research centre in Italy. Subjects: 177 non-diabetic outpatients with chronic renal disease screened for participation in the ramipril efficacy in nephropathy study. Main outcome measures: Rate of decline in filtration rate evaluated by repeated measurements of unlabelled iohexol plasma clearance and rate of progression to renal failure. Results: Protein:creatinine ratio was significantly correlated with absolute and log transformed 24 hour urinary protein values (P = 0.0001 and P < 0.0001, respectively.) Ratios also had high predictive value for rate of decline of the glomerular filtration rate (univariate P = 0.0003, multivariate P = 0.004) and end stage renal failure (P = 0.002 and P = 0.04). Baseline protein:creatinine ratios and rate of decline of the glomerular filtration rate were also significantly correlated (P < 0.0005), In the lowest third of the protein:creatinine ratio (< 1.7) there was 3% renal failure compared with 21.2% in the highest third (> 2.7) (P < 0.05). Conclusions: Protein:creatinine ratio in spot morning urine samples is a precise indicator of proteinuria and a reliable predictor of progression of disease in non-diabetic patients with chronic nephropathies and represents a simple and inexpensive procedure in establishing severity of renal disease and prognosis.	Mario Negri Inst Pharmacol Res, Clin Res Ctr Rare Dis, I-24125 Bergamo, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Ruggenenti, P (corresponding author), Mario Negri Inst Pharmacol Res, Clin Res Ctr Rare Dis, Via Gavazzeni 11, I-24125 Bergamo, Italy.	ruggenenti@irfmn.mnegri.it	Perna, Annalisa/AAC-1323-2020; Remuzzi, Giuseppe/V-9766-2017	Perna, Annalisa/0000-0002-9257-0283; Remuzzi, Giuseppe/0000-0002-6194-3446				BERTANI T, 1986, KIDNEY INT, V30, P488, DOI 10.1038/ki.1986.212; Draper N.R., 1998, APPL REGRESSION ANAL, P79; EDDY AA, 1991, AM J PATHOL, V138, P1111; GASPARI F, 1995, J AM SOC NEPHROL, V6, P257; GINSBERG JM, 1983, NEW ENGL J MED, V309, P1543, DOI 10.1056/NEJM198312223092503; GORDGE MP, 1991, NEPHROL DIAL TRANSPL, V6, P21, DOI 10.1093/ndt/6.1.21; *GRUPP IT STUD EP, 1991, J NEPHROL, V3, P193; KASSIRER JP, 1988, DISEASES KIDNEY, V1, P393; KENDALL KG, 1973, ADV THEORY STAT, V2, P323; LEMANN J, 1987, CLIN CHEM, V33, P297; McCullagh P., 1989, GEN LINEAR MODELS, V2nd; REMUZZI G, 1990, KIDNEY INT, V38, P384, DOI 10.1038/ki.1990.217; Remuzzi G, 1997, KIDNEY INT, V51, P2, DOI 10.1038/ki.1997.2; Remuzzi G, 1995, Curr Opin Nephrol Hypertens, V4, P339, DOI 10.1097/00041552-199507000-00009; Rodby RA, 1995, AM J KIDNEY DIS, V26, P904, DOI 10.1016/0272-6386(95)90054-3; ROSSING P, 1993, DIABETES, V42, P715, DOI 10.2337/diabetes.42.5.715; Ruggenenti P, 1997, LANCET, V349, P1857; *SAS I, 1989, SAS STAT US GUID VER, V1; SCHWAB SJ, 1987, ARCH INTERN MED, V147, P943, DOI 10.1001/archinte.147.5.943; SHIELD JPH, 1995, ARCH DIS CHILD, V72, P524, DOI 10.1136/adc.72.6.524; Warram JH, 1996, J AM SOC NEPHROL, V7, P930	21	193	196	1	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 14	1998	316	7130					504	509		10.1136/bmj.316.7130.504	http://dx.doi.org/10.1136/bmj.316.7130.504			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX955	9501711	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000072097400018
J	Lanier, LL; Corliss, BC; Wu, J; Leong, C; Phillips, JH				Lanier, LL; Corliss, BC; Wu, J; Leong, C; Phillips, JH			Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells	NATURE			English	Article							NATURAL-KILLER-CELLS; HLA-C; RECEPTOR; KINASES; PHOSPHATASES; SUPERFAMILY; RECOGNITION; FAMILY; CD94; TCR	Natural killer (NK) cells express cell-surface receptors of the immunoglobulin and C-type lectin superfamilies that recognize major histocompatibility complex (MHC) class I peptides and inhibit NK-cell-mediated cytotoxicity(1). These inhibitory receptors possess ITIM sequences (for immunoreceptor tyrosine-based inhibitory motifs) in their cytoplasmic domains that recruit SH2-domain-containing protein tyrosine phosphatases, resulting in inactivation of NK cells(2-4). Certain isoforms of these NK-cell receptors lack ITIM sequences and it has been proposed that these 'non-inhibitory' receptors may activate,rather than inhibit, NK cells(4-6). Here we show that DAP12, a disulphide-bonded homodimer containing an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain, non-covalently associates with membrane glycoproteins of the killer-cell inhibitory receptor (KIR) family without an ITIM in their cytoplasmic domain. Crosslinking of KIR-DAP12 complexes results in cellular activation, as demonstrated by tyrosine phosphorylation of cellular proteins and upregulation of early-activation antigens. Phosphorylated DAP12 peptides bind ZAP-70 and Syk protein tyrosine kinases, suggesting that the activation pathway is similar to that of the T- and B-cell antigen receptors.	DNAX Res Inst Mol & Cellular Biol Inc, Dept Immunobiol, Palo Alto, CA 94304 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Lanier, LL (corresponding author), DNAX Res Inst Mol & Cellular Biol Inc, Dept Immunobiol, 901 Calif Ave, Palo Alto, CA 94304 USA.		Lanier, Lewis L/E-2139-2014	Lanier, Lewis L/0000-0003-1308-3952				BAKER E, 1995, CHROMOSOME RES, V3, P511; Biassoni R, 1996, J EXP MED, V183, P645, DOI 10.1084/jem.183.2.645; Blery M, 1997, J BIOL CHEM, V272, P8989; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHAN AC, 1994, J IMMUNOL, V152, P4758; CHANG CW, 1995, EUR J IMMUNOL, V25, P2433, DOI 10.1002/eji.1830250904; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; COLONNA M, 1995, SCIENCE, V268, P405, DOI 10.1126/science.7716543; Hayami K, 1997, J BIOL CHEM, V272, P7320, DOI 10.1074/jbc.272.11.7320; Houchins JP, 1997, J IMMUNOL, V158, P3603; HOUCHINS JP, 1991, J EXP MED, V173, P1017, DOI 10.1084/jem.173.4.1017; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KESE L, 1997, J IMMUNOL, V158, P5083; Kubagawa H, 1997, P NATL ACAD SCI USA, V94, P5261, DOI 10.1073/pnas.94.10.5261; LANIER L L, 1991, Methods (Orlando), V2, P192, DOI 10.1016/S1046-2023(05)80061-1; Lanier LL, 1997, IMMUNITY, V6, P371, DOI 10.1016/S1074-7613(00)80280-0; LANIER LL, 1989, NATURE, V342, P803, DOI 10.1038/342803a0; Mason LH, 1996, J EXP MED, V184, P2119, DOI 10.1084/jem.184.6.2119; MEYAARD L, 1997, IMMUNITY, V7, P282; Olcese L, 1996, J IMMUNOL, V156, P4531; ONIHSI M, 1996, EXP HEMATOL, V24, P324; Phillips JH, 1996, IMMUNITY, V5, P163, DOI 10.1016/S1074-7613(00)80492-6; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; Samaridis J, 1997, EUR J IMMUNOL, V27, P660, DOI 10.1002/eji.1830270313; Takase K, 1997, J IMMUNOL, V159, P741; Wagtmann N, 1997, CURR BIOL, V7, P615, DOI 10.1016/S0960-9822(06)00263-6; WU J, 1995, MOL CELL BIOL, V15, P4337	28	742	779	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 12	1998	391	6668					703	707		10.1038/35642	http://dx.doi.org/10.1038/35642			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW872	9490415				2022-12-28	WOS:000071982500055
J	Webb, E				Webb, E			Cultural complexities should not be ignored - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Wales Coll Med, Dept Child Hlth, Cardiff CF4 4XN, S Glam, Wales	Cardiff University	Webb, E (corresponding author), Univ Wales Coll Med, Dept Child Hlth, Cardiff CF4 4XN, S Glam, Wales.								0	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 7	1998	316	7129					462	462		10.1136/bmj.316.7129.462	http://dx.doi.org/10.1136/bmj.316.7129.462			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW874	9492681	Green Published			2022-12-28	WOS:000071982700048
J	Palella, FJ; Delaney, KM; Moorman, AC; Loveless, MO; Fuhrer, J; Satten, GA; Aschman, DJ; Holmberg, SD				Palella, FJ; Delaney, KM; Moorman, AC; Loveless, MO; Fuhrer, J; Satten, GA; Aschman, DJ; Holmberg, SD		HIV Outpatient Study Investigators	Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DYNAMICS IN-VIVO; HIV-1 INFECTION; CLINICAL-PRACTICE; CUBIC MILLIMETER; THERAPY; ZIDOVUDINE; PLASMA; COUNTS; MARKERS; ADULTS	Background and Methods National surveillance data show recent, marked reductions in morbidity and mortality associated with the acquired immunodeficiency syndrome (AIDS). To evaluate these declines, we analyzed data on 1255 patients, each of whom had at least one CD4+ count below 100 cells per cubic millimeter, who were seen at nine clinics specializing in the treatment of human immunodeficiency virus (HIV) infection in eight U.S. cities from January 1994 through June 1997. Results Mortality among the patients declined from 29.4 per 100 person-years in 1995 to 8.8 per 100 person-years in the second quarter of 1997. There were reductions in mortality regardless of sex, race, age, and risk factors for transmission of HIV. The incidence of any of three major opportunistic infections (Pneumocystis carinii pneumonia, Mycobacterium avium complex disease, and cytomegalovirus retinitis) declined from 21.9 per 100 person-years in 1994 to 3.7 per 100 person-years by mid-1997. In a failure-rate model, increases in the intensity of antiretroviral therapy (classified as none, monotherapy, combination therapy without a protease inhibitor, and combination therapy with a protease inhibitor) were associated with stepwise reductions in morbidity and mortality. Combination antiretroviral therapy was associated with the most benefit; the inclusion of protease inhibitors in such regimens conferred additional benefit. Patients with private insurance were more often prescribed protease inhibitors and had lower mortality rates than those insured by Medicare or Medicaid. Conclusions The recent declines in morbidity and mortality due to AIDS are attributable to the use of more intensive antiretroviral therapies. (C) 1998, Massachusetts Medical Society.	Northwestern Univ, Sch Med, Chicago, IL 60611 USA; Hlth Res Network Apache Med Syst, Chicago, IL USA; Ctr Dis Control & Prevent, Atlanta, GA USA; Oregon Hlth & Sci Univ, Portland, OR 97201 USA; SUNY Stony Brook, Stony Brook, NY 11794 USA	Northwestern University; Centers for Disease Control & Prevention - USA; Oregon Health & Science University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Palella, FJ (corresponding author), Northwestern Univ, Sch Med, 303 E Super St,Passavant Pavil,Rm 828, Chicago, IL 60611 USA.			Satten, Glen/0000-0001-7275-5371; Moorman, Anne/0000-0003-2411-2798	PHS HHS [UC64/CCU5096889-03] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Aber V, 1996, LANCET, V348, P283, DOI 10.1016/S0140-6736(96)05387-1; Bartlett JA, 1996, ANN INTERN MED, V125, P161, DOI 10.7326/0003-4819-125-3-199608010-00001; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; CHAISSON MA, 1997, 4 C RETR OPP INF WAS, P133; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; DAquila RT, 1996, ANN INTERN MED, V124, P1019, DOI 10.7326/0003-4819-124-12-199606150-00001; GULICK R, 1996, 11 INT C AIDS VANC S, P19; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Ho DD, 1996, SCIENCE, V272, P1124, DOI 10.1126/science.272.5265.1124; Hogg RS, 1997, LANCET, V349, P1294, DOI 10.1016/S0140-6736(05)62505-6; Hughes MD, 1997, ANN INTERN MED, V126, P929, DOI 10.7326/0003-4819-126-12-199706150-00001; Katzenstein DA, 1996, NEW ENGL J MED, V335, P1091, DOI 10.1056/NEJM199610103351502; Kitahata MM, 1996, NEW ENGL J MED, V334, P701, DOI 10.1056/NEJM199603143341106; MARKSON LE, 1994, ARCH INTERN MED, V154, P1497, DOI 10.1001/archinte.154.13.1497; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; MOUTON Y, 1997, 4 C RETR OPP INF WAS; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; OBrien WA, 1997, ANN INTERN MED, V126, P939, DOI 10.7326/0003-4819-126-12-199706150-00002; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Saag MS, 1996, NAT MED, V2, P625, DOI 10.1038/nm0696-625; SELIGMANN M, 1994, LANCET, V343, P871; Torres RA, 1997, NEW ENGL J MED, V336, P1531, DOI 10.1056/NEJM199705223362118; 1997, MMWR MORB MORTAL WKL, V46, P165	27	7476	7704	10	785	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 26	1998	338	13					853	860		10.1056/NEJM199803263381301	http://dx.doi.org/10.1056/NEJM199803263381301			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD284	9516219				2022-12-28	WOS:000072669800001
J	Gardam, MA; Arthurs, BP; Miller, MA				Gardam, MA; Arthurs, BP; Miller, MA			An eye for horticulture	LANCET			English	Article							NOCARDIA-BRASILIENSIS		McGill Univ, Jewish Gen Hosp, SMBD, Dept Microbiol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Jewish Gen Hosp, SMBD, Div Infect Dis, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Ophthalmol, Montreal, PQ, Canada	McGill University; McGill University; McGill University	Miller, MA (corresponding author), McGill Univ, Jewish Gen Hosp, SMBD, Dept Microbiol, Montreal, PQ H3T 1E2, Canada.							CHIN GN, 1995, DUANES CLIN OPHTHALM, V4, P1; HUNTER LR, 1992, AM J OPHTHALMOL, V114, P373, DOI 10.1016/S0002-9394(14)71812-4; Parinaud H., 1889, ANN DOCULISTIQUE, V101, P252; SMEGO RA, 1984, REV INFECT DIS, V6, P164	4	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 21	1998	351	9106					876	876		10.1016/S0140-6736(97)11014-5	http://dx.doi.org/10.1016/S0140-6736(97)11014-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD047	9525366				2022-12-28	WOS:000072645500015
J	Sclavi, B; Sullivan, M; Chance, MR; Brenowitz, M; Woodson, SA				Sclavi, B; Sullivan, M; Chance, MR; Brenowitz, M; Woodson, SA			RNA folding at millisecond intervals by synchrotron hydroxyl radical footprinting	SCIENCE			English	Article							GROUP-I RIBOZYME; TETRAHYMENA RIBOZYME; TERTIARY STRUCTURE; RIBONUCLEIC-ACID; DOMAIN; KINETICS; MOLECULE; CLEAVAGE; PATHWAY	Radiolysis of water with a synchrotron x-ray beam permits the hydroxyl radical-accessible surface of an RNA to be mapped with nucleotide resolution in 10 milliseconds. Application of this method to folding of the Tetrahymena ribozyme revealed that the most stable domain of the tertiary structure, P4-P6, formed cooperatively within 3 seconds. Exterior helices became protected from hydroxyl radicals in 10 seconds, whereas the catalytic center required minutes to be completely folded. The results show that rapid collapse to a partially disordered state is followed by a slow search for the active structure.	Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Ctr Synchrotron Biosci, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Ctr Synchrotron Biosci, Bronx, NY 10461 USA; Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University System of Maryland; University of Maryland College Park	Chance, MR (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Ctr Synchrotron Biosci, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Sclavi, Bianca/AAT-4554-2021; sclavi, bianca/F-8536-2010	Sclavi, Bianca/0000-0002-3883-8592; Woodson, Sarah/0000-0003-0170-1987	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052348, R01GM039929, R29GM039929] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39929, GM52348, GM51506] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANERJEE AR, 1995, BIOCHEMISTRY-US, V34, P6504, DOI 10.1021/bi00019a031; BREHM SL, 1983, BIOCHEMISTRY-US, V22, P2390, DOI 10.1021/bi00279a014; Cate JH, 1997, NAT STRUCT BIOL, V4, P553, DOI 10.1038/nsb0797-553; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; CECH TR, 1994, NAT STRUCT BIOL, V1, P273, DOI 10.1038/nsb0594-273; CECH TR, 1996, NUCL ACIDS MOL BIOL, V10, P1; CELANDER DW, 1990, BIOCHEMISTRY-US, V29, P1355, DOI 10.1021/bi00458a001; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; Chance MR, 1997, STRUCTURE, V5, P865, DOI 10.1016/S0969-2126(97)00241-4; COLE PE, 1972, BIOCHEMISTRY-US, V11, P4358, DOI 10.1021/bi00773a024; CROTHERS DM, 1974, J MOL BIOL, V87, P63, DOI 10.1016/0022-2836(74)90560-9; Doherty EA, 1997, BIOCHEMISTRY-US, V36, P3159, DOI 10.1021/bi962428+; DOUDNA JA, 1995, RNA, V1, P31; Downs WD, 1996, RNA, V2, P718; Draper DE, 1996, NAT STRUCT BIOL, V3, P397, DOI 10.1038/nsb0596-397; EMERICK VL, 1994, P NATL ACAD SCI USA, V91, P9675, DOI 10.1073/pnas.91.21.9675; JAEGER L, 1996, NUCL ACIDS MOL BIOL, V10, P34; LAGGERBAUER B, 1994, EMBO J, V13, P2699; LATHAM JA, 1989, SCIENCE, V245, P276, DOI 10.1126/science.2501870; Lehnert V, 1996, CHEM BIOL, V3, P993, DOI 10.1016/S1074-5521(96)90166-0; MURPHY FL, 1993, BIOCHEMISTRY-US, V32, P5291, DOI 10.1021/bi00071a003; MURPHY FL, 1994, J MOL BIOL, V236, P49, DOI 10.1006/jmbi.1994.1117; Pan J, 1997, J MOL BIOL, V273, P7, DOI 10.1006/jmbi.1997.1311; PRICE MA, 1992, METHOD ENZYMOL, V212, P194; Sclavi B, 1997, J MOL BIOL, V266, P144, DOI 10.1006/jmbi.1996.0775; SCLAVI B, IN PRESS METHODS ENZ; Thirumalai D, 1996, ACCOUNTS CHEM RES, V29, P433, DOI 10.1021/ar9500933; Treiber DK, 1998, SCIENCE, V279, P1943, DOI 10.1126/science.279.5358.1943; TULIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469; Zarrinkar PP, 1996, RNA, V2, P564; Zarrinkar PP, 1996, NAT STRUCT BIOL, V3, P432, DOI 10.1038/nsb0596-432; ZARRINKAR PP, 1994, SCIENCE, V265, P918, DOI 10.1126/science.8052848; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008	33	328	335	2	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 20	1998	279	5358					1940	1943		10.1126/science.279.5358.1940	http://dx.doi.org/10.1126/science.279.5358.1940			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506944				2022-12-28	WOS:000072613300047
J	Yeh, WC; de la Pompa, JL; McCurrach, ME; Shu, HB; Elia, AJ; Shahinian, A; Ng, M; Wakeham, A; Khoo, W; Mitchell, K; El-Deiry, WS; Lowe, SW; Goeddel, DV; Mak, TW				Yeh, WC; de la Pompa, JL; McCurrach, ME; Shu, HB; Elia, AJ; Shahinian, A; Ng, M; Wakeham, A; Khoo, W; Mitchell, K; El-Deiry, WS; Lowe, SW; Goeddel, DV; Mak, TW			FADD: Essential for embryo development and signaling from some, but not all, inducers of apoptosis	SCIENCE			English	Article							DOMAIN-CONTAINING RECEPTOR; DEATH-DOMAIN; PROTEIN; CELLS; CD95; INTERACTS; GENES; MICE; FAS	FADD (also known as Mort-1) is a signal transducer downstream of cell death receptor CD95 (also called Fas), CD95, tumor necrosis factor receptor type 1 (TNFR-1), and death receptor 3 (DR3) did not induce apoptosis in FADD-deficient embryonic fibroblasts, whereas DR4, oncogenes E1A and c-myc, and chemotherapeutic agent adriamycin did. Mice with a deletion in the FADD gene did not survive beyond day 11.5 of embryogenesis; these mice showed signs of cardiac failure and abdominal hemorrhage. Chimeric embryos showing a high contribution of FADD null mutant cells to the heart reproduce the phenotype of FADD-deficient mutants. Thus, not only death receptors, but also receptors that couple to developmental programs, may use FADD for signaling.	Univ Toronto, Amgen Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 2C1, Canada; Ontario Canc Inst, Toronto, ON M5G 2C1, Canada; Cold Spring Harbor Labs, Cold Spring Harbor, NY 11724 USA; Tularik, S San Francisco, CA 94080 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Cold Spring Harbor Laboratory; Howard Hughes Medical Institute; University of Pennsylvania	Mak, TW (corresponding author), Univ Toronto, Amgen Inst, 610 Univ Ave, Toronto, ON M5G 2C1, Canada.		De La Pompa, José Luis/F-9719-2014; El-Deiry, Wafik/AAJ-6080-2020	De La Pompa, José Luis/0000-0001-6761-7265; El-Deiry, Wafik/0000-0002-9577-8266	NCI NIH HHS [CA13106] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI M, 1995, NAT GENET, V11, P294, DOI 10.1038/ng1195-294; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BOLDIN MP, 1995, CELL, V270, P803; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; Friesen C, 1997, LEUKEMIA, V11, P1833, DOI 10.1038/sj.leu.2400827; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; MCCURRACH ME, UNPUB; Mishina Y, 1995, GENE DEV, V9, P3027, DOI 10.1101/gad.9.24.3027; MOENS CB, 1993, DEVELOPMENT, V119, P485; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHMID I, 1994, CYTOMETRY, V15, P12, DOI 10.1002/cyto.990150104; WHITE E, 1987, J VIROL, V61, P426, DOI 10.1128/JVI.61.2.426-435.1987; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489; YEH WJ, UNPUB	29	778	805	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 20	1998	279	5358					1954	1958		10.1126/science.279.5358.1954	http://dx.doi.org/10.1126/science.279.5358.1954			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506948				2022-12-28	WOS:000072613300051
J	Krum, H; Viskoper, RJ; Lacourciere, Y; Budde, M; Charlon, V				Krum, H; Viskoper, RJ; Lacourciere, Y; Budde, M; Charlon, V		Bosentan Hypertension Investigators	The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC HEART-FAILURE; PLASMA ENDOTHELIN; ANGIOTENSIN-II; DISEASE; CLONING	Background Endothelin is a powerful vasoconstrictor peptide derived from the endothelium. We evaluated the contribution of endothelin to blood-pressure regulation in patients with essential hypertension by studying the effect of an endothelin-receptor antagonist, bosentan. Methods We studied 293 patients with mild-to-moderate essential hypertension. After a placebo run-in period of four to six weeks, patients were randomly assigned to receive one of four oral doses of bosentan (100, 500, or 1000 mg once daily or 1000 mg twice daily), placebo, or the angiotensin-converting-enzyme inhibitor enalapril (20 mg once daily) for four weeks. Blood pressure was measured before and after treatment. Results As compared with placebo, bosentan resulted in a significant reduction in diastolic pressure with a daily dose of 500 or 2000 mg (an absolute reduction of 5.7 mm Hg at each dose), which was similar to the reduction with enalapril (5.8 mm Hg), There were no significant changes in heart rate. Bosentan did not result in activation of the sympathetic nervous system (as determined by measurement of the plasma norepinephrine level) or the renin-angiotensin system (as determined by measurements of plasma renin activity and angiotensin II levels), Conclusions An endothelin-receptor antagonist, bosentan, significantly lowered blood pressure in patients with essential hypertension, suggesting that endothelin may contribute to elevated blood pressure in such patients. The favorable effect of treatment with bosentan on blood pressure occurred without reflexive neurohormonal activation, (C) 1998, Massachusetts Medical Society.	Monash Univ, Alfred Hosp, Clin Pharmacol Unit, Prahran, Vic 3181, Australia; Barzilai Med Ctr, Dept Med, Ashkelon, Israel; Ctr Hosp Univ Quebec, Hypertens Res Unit, St Foy, PQ, Canada; Hoffmann La Roche Inc, Basel, Switzerland	Florey Institute of Neuroscience & Mental Health; Monash University; Ben Gurion University; Barzilai Medical Center; Laval University; Roche Holding	Krum, H (corresponding author), Monash Univ, Alfred Hosp, Clin Pharmacol Unit, Prahran, Vic 3181, Australia.							ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BAUER P, 1991, STAT MED, V10, P871, DOI 10.1002/sim.4780100609; BOARDER MR, 1989, J CARDIOVASC PHARM, V13, pS223, DOI 10.1097/00005344-198900135-00066; CLOZEL M, 1994, J PHARMACOL EXP THER, V270, P228; CLOZEL M, 1993, NATURE, V365, P759, DOI 10.1038/365759a0; FURBERG CD, 1995, CIRCULATION, V92, P1326, DOI 10.1161/01.CIR.92.5.1326; HAYNES WG, 1993, CLIN SCI, V84, P485, DOI 10.1042/cs0840485; HAYNES WG, 1993, CLIN SCI, V84, P427, DOI 10.1042/cs0840427; KAPPELGAARD AM, 1976, CLIN CHIM ACTA, V67, P299; KAWAGUCHI H, 1990, J MOL CELL CARDIOL, V22, P839, DOI 10.1016/0022-2828(90)90115-I; KOHNO M, 1990, AM J MED, V88, P614, DOI 10.1016/0002-9343(90)90527-K; LEVINE TB, 1982, AM J CARDIOL, V49, P1659, DOI 10.1016/0002-9149(82)90243-0; Loeffler B., 1994, ENDOTHELIUM, V1, P273, DOI [10.3109/10623329409100966, DOI 10.3109/10623329409100966]; MCMURRAY JJ, 1992, CIRCULATION, V85, P1374, DOI 10.1161/01.CIR.85.4.1374; MILLER WL, 1989, J CLIN INVEST, V83, P317, DOI 10.1172/JCI113876; NISHIKIBE M, 1993, LIFE SCI, V52, P717, DOI 10.1016/0024-3205(93)90233-S; Ruzicka Marcel, 1995, P2815; SAITO Y, 1990, NEW ENGL J MED, V322, P205; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; Searle S.R., 1987, LINEAR MODELS UNBALA; SUETSCH G, 1997, CIRCULATION S1, V96, P93; SUMNER MJ, 1992, BRIT J PHARMACOL, V107, P858, DOI 10.1111/j.1476-5381.1992.tb14537.x; TEERLINK JR, 1994, CIRCULATION, V90, P2510, DOI 10.1161/01.CIR.90.5.2510; Weber C, 1996, CLIN PHARMACOL THER, V60, P124, DOI 10.1016/S0009-9236(96)90127-7	24	430	445	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 19	1998	338	12					784	790		10.1056/NEJM199803193381202	http://dx.doi.org/10.1056/NEJM199803193381202			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC163	9504938				2022-12-28	WOS:000072546800002
J	Nyquist, AC; Gonzales, R; Steiner, JF; Sande, MA				Nyquist, AC; Gonzales, R; Steiner, JF; Sande, MA			Antibiotic prescribing for children with colds, upper respiratory tract infections, and bronchitis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESISTANT STREPTOCOCCUS-PNEUMONIAE; YOUNG-CHILDREN; DAY-CARE; EXPECTATIONS; CARRIAGE	Context.-The spread of antibiotic-resistant bacteria is associated with antibiotic use. Children receive a significant proportion of the antibiotics prescribed each year and represent an important target group for efforts aimed at reducing unnecessary antibiotic use. Objective.-To evaluate antibiotic-prescribing practices for children younger than 18 years who had received a diagnosis of cold, upper respiratory tract infection (URI), or bronchitis in the United States. Design.-Representative national survey of practicing physicians participating in the National Ambulatory Medical Care Survey conducted in 1992 with a response rate of 73%. Setting.-Office-based physician practices. Participants.-Physicians completing patient record forms for patients younger than 18 years. Main Outcome Measures.-Principal diagnoses and antibiotic prescriptions. Results.-A total of 531 pediatric office visits were recorded that included a principal diagnosis of cold, URI, or bronchitis, Antibiotics were prescribed to 44% of patients with common colds, 46% with URIs, and 75% with bronchitis. Extrapolating to the United States, 6.5 million prescriptions (12% of all prescriptions for children) were written for children diagnosed as having a URI or nasopharyngitis (common cold), and 4.7 million (9% of all prescriptions for children) were written for children diagnosed as having bronchitis. After controlling for confounding factors, antibiotics were prescribed more often for children aged 5 to 11 years than for younger children (odds ratio [OR], 1.94; 95% confidence interval [CI], 1.13-3.33) and rates were lower for pediatricians than for nonpediatricians (OR, 0.57; 95% CI, 0.35-0.92), Children aged 0 to 4 years received 53% of all antibiotic prescriptions, and otitis media was the most frequent diagnosis for which antibiotics were prescribed (30% of all prescriptions). Conclusions.-Antibiotic prescribing for children diagnosed as having colds, URIs, and bronchitis, conditions that typically do not benefit from antibiotics, represents a substantial proportion of total antibiotic prescriptions to children in the United States each year.	Univ Colorado, Hlth Sci Ctr, Div Gen Internal Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Div Infect Dis, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, Denver, CO 80262 USA; Univ Utah, Dept Med, Salt Lake City, UT 84112 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Utah System of Higher Education; University of Utah	Gonzales, R (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Gen Internal Med, Box B-180,4200 E 9th Ave, Denver, CO 80262 USA.	Ralph.Gonzales@uchsc.edu			BHP HRSA HHS [5 T32 PE10006-04] Funding Source: Medline	BHP HRSA HHS		Arnold KE, 1996, J PEDIATR-US, V128, P757, DOI 10.1016/S0022-3476(96)70326-8; BAUCHNER H, 1997, AMBUL CHILD HLTH, V3, P171; CHERIAN T, 1994, JAMA-J AM MED ASSOC, V271, P695, DOI 10.1001/jama.271.9.695; GADOMSKI AM, 1993, PEDIATR INFECT DIS J, V12, P115, DOI 10.1097/00006454-199302000-00002; Gonzales R, 1997, JAMA-J AM MED ASSOC, V278, P901, DOI 10.1001/jama.278.11.901; GROB PR, 1992, SCAND J INFECT DIS, P7; Hamm R M, 1996, J Okla State Med Assoc, V89, P267; Hamm RM, 1996, J FAM PRACTICE, V43, P56; HENDERSON FW, 1988, J INFECT DIS, V157, P256, DOI 10.1093/infdis/157.2.256; Holmes Sandra J., 1997, Pediatric Research, V41, p122A; HOWIE JGR, 1983, SCAND J INFECT DIS, P68; Jernigan DB, 1996, JAMA-J AM MED ASSOC, V275, P206, DOI 10.1001/jama.275.3.206; Mainous AG, 1996, J FAM PRACTICE, V42, P357; Mainous AG, 1997, LANCET, V350, P1077, DOI 10.1016/S0140-6736(05)70457-8; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; REICHLER MR, 1992, J INFECT DIS, V166, P1346, DOI 10.1093/infdis/166.6.1346; SCHAPPERT SM, 1994, ADV DATA VITAL HLTH, V5253; Schwartz RH, 1997, PEDIATR INFECT DIS J, V16, P185, DOI 10.1097/00006454-199702000-00004; SOYKA LF, 1975, PEDIATRICS, V55, P552; *US DEP HHS, 1988, INT CLASS DIS 9 REV; VINSON DC, 1993, J FAM PRACTICE, V37, P23	21	511	536	2	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 18	1998	279	11					875	877		10.1001/jama.279.11.875	http://dx.doi.org/10.1001/jama.279.11.875			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA943	9516004				2022-12-28	WOS:000072417600036
J	McNamee, D				McNamee, D			Public's perception of RCTs	LANCET			English	Editorial Material									Lancet, London WC12 3SL, England		McNamee, D (corresponding author), Lancet, London WC12 3SL, England.								0	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 14	1998	351	9105					772	772		10.1016/S0140-6736(05)78927-3	http://dx.doi.org/10.1016/S0140-6736(05)78927-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB916	9519947				2022-12-28	WOS:000072521200008
J	Yeomans, ND; Tulassay, Z; Juhasz, L; Racz, I; Howard, JM; van Rensburg, CJ; Swannell, AJ; Hawkey, CJ				Yeomans, ND; Tulassay, Z; Juhasz, L; Racz, I; Howard, JM; van Rensburg, CJ; Swannell, AJ; Hawkey, CJ		ASTRONAUT Study Grp	A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLACEBO-CONTROLLED TRIAL; DUODENAL-ULCERS; ANTISECRETORY DRUGS; DYSPEPTIC SYMPTOMS; GASTRIC-ULCER; PEPTIC-ULCER; DOUBLE-BLIND; PREVENTION; DAMAGE; THERAPY	Background Suppressing acid secretion is thought to reduce the risk of ulcers associated with regular use of nonsteroidal antiinflammatory drugs (NSAIDs), but the best means of accomplishing this is uncertain. Methods We studied 541 patients who required continuous treatment with NSAIDs and who had ulcers or more than 10 erosions in either the stomach or duodenum. Patients were randomly assigned to double-blind treatment with omeprazole, 20 mg or 40 mg orally per day, or ranitidine, 150 mg orally twice a day, for four or eight weeks, depending on when treatment was successful (defined as the resolution of ulcer and the presence of fewer than five erosions in the stomach and fewer than five erosions in the duodenum, and not more than mild dyspepsia). We randomly assigned 432 patients in whom treatment was successful to maintenance treatment with either 20 mg of omeprazole per day or 150 mg of ranitidine twice a day for six months. Results At eight weeks, treatment was successful in 80 percent (140 of 174) of the patients in the group given 20 mg of omeprazole per day, 79 percent (148 of 187) of those given 40 mg of omeprazole per day, and 63 percent (110 of 174) of those given ranitidine (P<0.001 for the comparison with 20 mg of omeprazole and P=0.001 for the comparison with 40 mg of omeprazole). The rates of healing of all types of lesions were higher with omeprazole than with ranitidine. During maintenance therapy, the estimated proportion of patients in remission at the end of six months was 72 percent in the omeprazole group and 59 percent in the ranitidine group. The rates of adverse events were similar between groups during both phases. Both medications were well tolerated. Conclusions In patients who use NSAIDs regularly, omeprazole healed and prevented ulcers more effectively than did ranitidine. (C)1998, Massachusetts Medical Society.	Univ Melbourne, Western Hosp, Dept Med, Melbourne, Vic, Australia; Semmelweis Univ, Sch Med, Dept Internal Med 2, Budapest, Hungary; Borsod Cty Teaching Hosp, Dept Med 2, Miskolc, Hungary; Petz Aladar Teaching Cty Hosp, Dept Med 1, Gyor, Hungary; London Hlth Sci, Dept Med, London, ON, Canada; Tygerberg Hosp, Dept Gastroenterol, Tygerberg, South Africa; Univ Nottingham Hosp, Div Gastroenterol, Nottingham NG7 2UH, England	University of Melbourne; Western Hospital; Semmelweis University; London Health Sciences Centre; Tygerberg Hospital; University of Nottingham	Yeomans, ND (corresponding author), Univ Melbourne, Western Hosp, Dept Med, Footscray, Vic 3011, Australia.			Prof. Dr. Racz, Istvan/0000-0001-9740-6995; Yeomans, Neville/0000-0001-9870-832X				[Anonymous], 1990, Pharmacol Toxicol, V67, P361; CULLEN D, IN PRESS ALIMENT PHA; CULLEN DJE, 1994, GASTROENTEROLOGY, V106, pA66; Cullen DJE, 1997, GUT, V41, P459, DOI 10.1136/gut.41.4.459; DAJANI EZ, 1995, DIGEST DIS, V13, P48, DOI 10.1159/000171526; DANESHMEND TK, 1990, GUT, V31, P514, DOI 10.1136/gut.31.5.514; EHSANULLAH RSB, 1988, BRIT MED J, V297, P1017, DOI 10.1136/bmj.297.6655.1017; Ekstrom P, 1996, SCAND J GASTROENTERO, V31, P753, DOI 10.3109/00365529609010347; ELLIOTT SL, 1994, SCAND J RHEUMATOL, V23, P171, DOI 10.3109/03009749409103056; Elliott SL, 1996, CLIN EXP PHARMACOL P, V23, P432, DOI 10.1111/j.1440-1681.1996.tb02754.x; GIERCKSKY KE, 1989, SCAND J GASTROENTERO, V24, P3, DOI 10.3109/00365528909091168; GRAHAM DY, 1988, LANCET, V2, P1277; GRAHAM DY, 1991, GASTROENTEROLOGY, V100, P1653, DOI 10.1016/0016-5085(91)90665-8; Hawkey CJ, 1998, NEW ENGL J MED, V338, P727, DOI 10.1056/NEJM199803123381105; HOGBEN CAM, 1957, J PHARMACOL EXP THER, V120, P540; HUDSON N, 1993, GUT, V34, P748, DOI 10.1136/gut.34.6.748; Hudson N, 1997, GASTROENTEROLOGY, V112, P1817, DOI 10.1053/gast.1997.v112.pm9178671; IVEY K J, 1988, American Journal of Medicine, V84, P41, DOI 10.1016/0002-9343(88)90253-7; JONES DB, 1987, GUT, V28, P1120, DOI 10.1136/gut.28.9.1120; LANCASTERSMITH MJ, 1991, GUT, V32, P252, DOI 10.1136/gut.32.3.252; LANGMAN MJS, 1991, J GASTROEN HEPATOL, V6, P442, DOI 10.1111/j.1440-1746.1991.tb00885.x; LARKAI EN, 1987, AM J GASTROENTEROL, V82, P1153; LAURITSEN K, 1992, EUR J GASTROEN HEPAT, V4, P995; PAAKKARI I, 1994, PHARMACOL TOXICOL, V75, P56, DOI 10.1111/j.1600-0773.1994.tb01999.x; REYNOLDS JC, 1989, ANN INTERN MED, V111, P7, DOI 10.7326/0003-4819-111-1-7; ROBINSON MG, 1989, DIGEST DIS SCI, V34, P424, DOI 10.1007/BF01536266; ROTH SH, 1987, ARCH INTERN MED, V147, P1798, DOI 10.1001/archinte.147.10.1798; SCHEIMAN JM, 1994, DIGEST DIS SCI, V39, P97, DOI 10.1007/BF02090067; Singh G, 1996, ARCH INTERN MED, V156, P1530, DOI 10.1001/archinte.156.14.1530; Soll AH, 1996, JAMA-J AM MED ASSOC, V275, P622; Taha AS, 1996, NEW ENGL J MED, V334, P1435, DOI 10.1056/NEJM199605303342204; TAHA AS, 1991, AM J GASTROENTEROL, V86, P1588; WALAN A, 1989, NEW ENGL J MED, V320, P69, DOI 10.1056/NEJM198901123200201; WALT R, 1986, LANCET, V1, P489; YAMADA T, 1994, JAMA-J AM MED ASSOC, V272, P65, DOI 10.1001/jama.272.1.65	35	595	617	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 12	1998	338	11					719	726		10.1056/NEJM199803123381104	http://dx.doi.org/10.1056/NEJM199803123381104			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB546	9494148				2022-12-28	WOS:000072483400004
J	Millard, FJC				Millard, FJC			South Africa: a physician's view	LANCET			English	Article							DISEASE PATTERNS; TUBERCULOSIS; POPULATION		Jane Furse Mem Hosp, ZA-1085 N Province, South Africa		Millard, FJC (corresponding author), Jane Furse Mem Hosp, X429 Jane Furse, ZA-1085 N Province, South Africa.							Beyers N, 1996, S AFR MED J, V86, P40; Catanzaro A, 1996, LANCET, V347, P1500, DOI 10.1016/S0140-6736(96)90666-2; Chowdhury AMR, 1997, LANCET, V350, P169, DOI 10.1016/S0140-6736(96)11311-8; COWIE RL, 1994, AM J RESP CRIT CARE, V150, P1460, DOI 10.1164/ajrccm.150.5.7952577; *DEP HLTH, 1996, EP COMM, P23; EAST AFRICAN /BRITISH MEDICAL RESEARCH COUNCILS, 1973, Lancet, P1331; EDGINTON ME, 1972, S AFR MED J, V46, P968; MILLARD FJC, 1977, CLIN MED THERAPEUTIC, P117; MILLARD J, 1994, LANCET, V344, P260; REEVE PA, 1986, S AFR MED J, V69, P551; Wilkinson D, 1996, AM J PUBLIC HEALTH, V86, P1094, DOI 10.2105/AJPH.86.8_Pt_1.1094; Wilkinson D, 1996, S AFR MED J, V86, P64; 1995, COMMUNICABLE DIS REP, V5	13	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 7	1998	351	9104					748	749		10.1016/S0140-6736(97)10223-9	http://dx.doi.org/10.1016/S0140-6736(97)10223-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB359	9504536				2022-12-28	WOS:000072463800043
J	Nightingale, SL				Nightingale, SL			Teleconference on natural rubber/latex allergy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	22	25	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1998	279	9					645	645		10.1001/jama.279.9.645-b	http://dx.doi.org/10.1001/jama.279.9.645-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY849	9496968				2022-12-28	WOS:000072192800007
J	Whited, JD; Grichnik, JM				Whited, JD; Grichnik, JM			Does this patient have a mole or a melanoma?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CUTANEOUS MALIGNANT-MELANOMA; BENIGN PIGMENTED LESIONS; PRIMARY-CARE PHYSICIANS; 7-POINT CHECKLIST; SKIN-CANCER; GENERAL-PRACTITIONERS; MELANOCYTIC NEVI; DYSPLASTIC NEVI; HIGH-RISK; DIAGNOSIS	Lifetime risk for malignant melanoma has increased from 1 in 1500 in the United States in 1930 to 1 in 75 projected for the year 2000, Because the tumor's thickness at excision is the primary prognostic determinant, early detection through the history and physical examination can play an important role in the patient's clinical course, Two checklists have been developed as diagnostic aids, the ABCD (A indicates asymmetry; B, border irregularity; C, irregular color; and D, diameter >6 mm) and the revised 7-point checklists, These checklists should be interpreted with some discretion, but 2 studies have found the sensitivity for the ABCD checklist to be 92% (95% confidence interval [CI], 82%-96%) and 100% (95% CI, 54%-100%); 1 study found the specificity to be 98% (95% CI, 95%-99%), The revised 7-point checklist has been reported to have a sensitivity of 79% (95% CI, 70%-85%) to 100% (95% CI, 94%-100%) and specificity of 30% (95% CI, 21%-39%) to 37% (95% CI, 28%-46%), Physicians' global assessments for detecting the presence or absence of melanoma are estimated to have a specificity of 96% to 99%, while sensitivity ranges widely from 50% to 97%. Nondermatologists' examinations appear to be less sensitive than examinations performed by dermatologists.	Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC 27705 USA; Duke Univ, Med Ctr, Div Gen Internal Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Div Dermatol, Durham, NC 27710 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Duke University; Duke University	Whited, JD (corresponding author), Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, 152,508 Fulton St, Durham, NC 27705 USA.		Grichnik, James/R-3887-2019	Grichnik, James/0000-0002-9185-0056				*AM AC DERM, 1996, PROGR SCREEN GUID NA, P37; BARNHILL RL, 1992, J AM ACAD DERMATOL, V26, P185, DOI 10.1016/0190-9622(92)70023-9; BARNHILL RL, 1993, DERMATOLOGY GEN MED, P1078; CASSILETH BR, 1986, J AM ACAD DERMATOL, V14, P555, DOI 10.1016/S0190-9622(86)70068-6; CURLEY RK, 1989, BRIT MED J, V299, P16, DOI 10.1136/bmj.299.6690.16; DAY CL, 1982, CA-CANCER J CLIN, V32, P113, DOI 10.3322/canjclin.32.2.113; DECOSTE SD, 1993, ARCH DERMATOL, V129, P57, DOI 10.1001/archderm.129.1.57; DUVIVIER AWP, 1991, CLIN EXP DERMATOL, V16, P344, DOI 10.1111/j.1365-2230.1991.tb00397.x; Elwood JM, 1988, PIGMENT CELL RES, V9, P118; FITZPATRICK TB, 1988, PIGMENT CELL, V9, P110; FRIEDMAN RJ, 1985, CA-CANCER J CLIN, V35, P130, DOI 10.3322/canjclin.35.3.130; Gerbert B, 1996, ARCH DERMATOL, V132, P1030, DOI 10.1001/archderm.132.9.1030; GREENE MH, 1985, ANN INTERN MED, V102, P458, DOI 10.7326/0003-4819-102-4-458; GRIN CM, 1990, ARCH DERMATOL, V126, P763, DOI 10.1001/archderm.126.6.763; HALL WH, 1992, JAMA-J AM MED ASSOC, V268, P1314, DOI 10.1001/jama.1992.03490100112037; HEALSMITH MF, 1994, BRIT J DERMATOL, V130, P48, DOI 10.1111/j.1365-2133.1994.tb06881.x; HIGGINS EM, 1992, CLIN EXP DERMATOL, V17, P313, DOI 10.1111/j.1365-2230.1992.tb00218.x; HOLLEMAN DR, 1995, JAMA-J AM MED ASSOC, V273, P313, DOI 10.1001/jama.273.4.313; KEEFE M, 1990, CLIN EXP DERMATOL, V15, P167, DOI 10.1111/j.1365-2230.1990.tb02064.x; KOH HK, 1990, CANCER, V65, P375, DOI 10.1002/1097-0142(19900115)65:2<375::AID-CNCR2820650233>3.0.CO;2-Z; KOH HK, 1992, J AM ACAD DERMATOL, V26, P914, DOI 10.1016/0190-9622(92)70132-Y; Koh HK, 1996, J AM ACAD DERMATOL, V34, P971, DOI 10.1016/S0190-9622(96)90274-1; KOH HK, 1991, NEW ENGL J MED, V325, P171, DOI 10.1056/NEJM199107183250306; KROL S, 1991, ACTA DERM-VENEREOL, V71, P317; MACKIE RM, 1990, BRIT MED J, V301, P1005, DOI 10.1136/bmj.301.6759.1005; MASRI GD, 1990, J AM ACAD DERMATOL, V22, P1042, DOI 10.1016/0190-9622(90)70149-C; MCGEE R, 1994, NEW ZEAL MED J, V107, P287; MCGOVERN TW, 1992, J DERMATOL SURG ONC, V18, P22, DOI 10.1111/j.1524-4725.1992.tb03296.x; MCMULLAN FH, 1956, ARCH DERMATOL, V74, P618, DOI 10.1001/archderm.1956.01550120038009; Meyer LJ, 1996, J AM ACAD DERMATOL, V34, P618, DOI 10.1016/S0190-9622(96)80061-2; PAINE SL, 1994, MED J AUSTRALIA, V161, P188, DOI 10.5694/j.1326-5377.1994.tb127380.x; RAMSAY DL, 1981, ARCH DERMATOL, V117, P620, DOI 10.1001/archderm.117.10.620; RIES LA, 1991, CANC STAT REV 1973 1; Rigel DS, 1996, J AM ACAD DERMATOL, V34, P839, DOI 10.1016/S0190-9622(96)90041-9; RIGEL DS, 1989, CANCER, V63, P386, DOI 10.1002/1097-0142(19890115)63:2<386::AID-CNCR2820630231>3.0.CO;2-6; RIGEL DS, 1986, J AM ACAD DERMATOL, V14, P857, DOI 10.1016/S0190-9622(86)70100-X; SHAW HM, 1992, J AM ACAD DERMATOL, V27, P679, DOI 10.1016/0190-9622(92)70236-9; SWERDLOW AJ, 1986, BRIT MED J, V292, P1555, DOI 10.1136/bmj.292.6535.1555; TIERSTEN AD, 1991, J DERMATOL SURG ONC, V17, P44, DOI 10.1111/j.1524-4725.1991.tb01592.x; TITUSERNSTOFF L, 1989, CANCER DETECT PREV, V13, P317; Tucker MA, 1997, JAMA-J AM MED ASSOC, V277, P1439, DOI 10.1001/jama.277.18.1439; WICK MM, 1980, CANCER, V45, P2684, DOI 10.1002/1097-0142(19800515)45:10<2684::AID-CNCR2820451033>3.0.CO;2-2	42	73	77	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1998	279	9					696	701		10.1001/jama.279.9.696	http://dx.doi.org/10.1001/jama.279.9.696			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY849	9496989				2022-12-28	WOS:000072192800035
J	de Bruijn, SFTM; Stam, J; Koopman, MMW; Vandenbroucke, JP				de Bruijn, SFTM; Stam, J; Koopman, MMW; Vandenbroucke, JP		Cerebral Venous Sinus Thrombosis Study Grp	Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users who are carriers of hereditary prothrombotic conditions	BRITISH MEDICAL JOURNAL			English	Article							PROTEIN-C; VENOUS THROMBOSIS; FACTOR-V; COAGULATION; PREVALENCE; DEFICIENCY	Objective: To investigate whether users of oral contraceptives who are carriers of a hereditary prothrombotic condition (factor V Leiden mutation, protein C, S, or antithrombin deficiency) have an increased risk of cerebral sinus thrombosis. Design: Comparison of a prospective series of cases of cerebral sinus thrombosis with population data. Setting: Neurological teaching hospitals from different regions in the Netherlands (cases) and a representative sample of the non-institutionalised Dutch population (controls). Subjects: 40 women aged 18-54 years with cerebral sinus thrombosis (cases) and 2248 women aged 18-49 years (controls). Main outcome measure: Current use of oral contraceptives at the time of the thrombosis (cases) or at the time of the questionnaire (controls), Prevalences of a hereditary prothrombotic condition in patients and in the population with odds ratios. Results: 34 of 40 (85%) women with cerebral sinus thrombosis used oral contraceptives, versus 1007 of 2248 (45%) of the control women; the age adjusted odds ratio was 13 (95% confidence interval 5 to 37), Seven of 36 patients (19%) had a prothrombotic deficiency, versus 7% expected in the population; this corresponds to a threefold to fourfold increase in risk, Ln women who used oral contraceptives and also carried a prothrombotic defect, the odds ratio for cerebral sinus thrombosis was about 30 relative to women who had neither risk factor. Conclusion: The use of oral contraceptives and being a carrier of a hereditary prothrombotic condition increase the risk of and interact in a multiplicative way in the development of cerebral sinus thrombosis.	Univ Amsterdam, Acad Med Ctr, Dept Neurol, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands; Univ Leiden Hosp, Dept Clin Epidemiol, NL-2300 RC Leiden, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Leiden University; Leiden University Medical Center (LUMC)	Stam, J (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Neurol, POB 22700, NL-1100 DE Amsterdam, Netherlands.	j.stam@amc.uva.nl	Vandenbroucke, Jan/AAM-3928-2020	Vandenbroucke, Jan/0000-0001-5668-6716				BOUSSER MG, 1985, STROKE, V16, P199, DOI 10.1161/01.STR.16.2.199; BOYER C, 1984, THROMB RES, V36, P579, DOI 10.1016/0049-3848(84)90197-X; *CBS, 1996, CENTR BUR STAT STAT, P502; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; Deschiens MA, 1996, STROKE, V27, P1724, DOI 10.1161/01.STR.27.10.1724; DEUTZTERLOUW PP, 1989, CLIN CHIM ACTA, V186, P321; HACHWUNDERLE V, 1993, DEUT MED WOCHENSCHR, V118, P187, DOI 10.1055/s-2008-1059317; PETERS M, 1982, THROMB RES, V28, P773, DOI 10.1016/0049-3848(82)90103-7; POULTER NR, 1995, LANCET, V346, P1575; Ridker PM, 1997, JAMA-J AM MED ASSOC, V277, P1305, DOI 10.1001/jama.277.16.1305; Rothman K, 1986, MODERN EPIDEMIOLOGY; Statistics Netherlands, 1996, NETH HLTH INT SURV 1; TAIT RC, 1995, THROMB HAEMOSTASIS, V73, P87; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0; VOORBERG J, 1994, LANCET, V343, P1535, DOI 10.1016/S0140-6736(94)92939-4	15	198	206	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 21	1998	316	7131					589	592		10.1136/bmj.316.7131.589	http://dx.doi.org/10.1136/bmj.316.7131.589			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ031	9518910	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000072213200027
J	Jarvis, D; Burney, P				Jarvis, D; Burney, P			ABC of allergies - The epidemiology of allergic disease	BRITISH MEDICAL JOURNAL			English	Review									United Med & Dent Sch Guys & St Thomas Hosp, London SE1 9RT, England	University of London; King's College London	Jarvis, D (corresponding author), United Med & Dent Sch Guys & St Thomas Hosp, London SE1 9RT, England.		Jarvis, Deborah/E-6494-2011	Jarvis, Deborah/0000-0002-1753-3896; Burney, Peter/0000-0001-8635-5678				BARBEE RA, 1987, J ALLERGY CLIN IMMUN, V79, P16, DOI 10.1016/S0091-6749(87)80010-6; Burney P, 1996, EUR RESPIR J, V9, P687; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; BURR M, 1993, MONOGRAPHS ALLERGY, V31; *CENTR HLTH MON UN, 1995, ATHM EP OVERV	5	108	110	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 21	1998	316	7131					607	610		10.1136/bmj.316.7131.607	http://dx.doi.org/10.1136/bmj.316.7131.607			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ031	9518918	Green Published			2022-12-28	WOS:000072213200036
J	Masters, CL; Beyreuther, K				Masters, CL; Beyreuther, K			Science, medicine, and the future - Alzheimer's disease	BRITISH MEDICAL JOURNAL			English	Review									Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia; Univ Heidelberg, Ctr Mol Biol, D-69120 Heidelberg, Germany	University of Melbourne; Ruprecht Karls University Heidelberg	Masters, CL (corresponding author), Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia.							Cavallo MC, 1997, ALZ DIS ASSOC DIS, V11, P184; HHARDY J, 1997, TRENDS NEUROSCI, V20, P154; Kim TW, 1997, CURR OPIN NEUROBIOL, V7, P683, DOI 10.1016/S0959-4388(97)80089-X; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; STRUCHLERPIERRA.C, 1997, P NATL ACAD SCI USA, V94, P13287; Wimo A, 1997, ALZ DIS ASSOC DIS, V11, P191; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4	7	78	79	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 7	1998	316	7129					446	448		10.1136/bmj.316.7129.446	http://dx.doi.org/10.1136/bmj.316.7129.446			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW874	9492674	Green Published			2022-12-28	WOS:000071982700037
J	Brenner, M; Porcelli, S				Brenner, M; Porcelli, S			Antigen presentation: A balanced diet	SCIENCE			Unspecified	Editorial Material											Brenner, M (corresponding author), HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DIV RHEUMATOL ALLERGY & IMMUNOL, BOSTON, MA 02115 USA.							BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; Calabi F., 1991, Immunogenetics of the major histocompatibility complex., P215; PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0; PORCELLI SA, 1995, ADV IMMUNOL, V59, P1, DOI 10.1016/S0065-2776(08)60629-X; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; Zeng ZH, 1997, SCIENCE, V277, P339, DOI 10.1126/science.277.5324.339	6	23	24	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 18	1997	277	5324					332	332		10.1126/science.277.5324.332	http://dx.doi.org/10.1126/science.277.5324.332			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL358	9518365				2022-12-28	WOS:A1997XL35800035
J	Marais, R; Light, Y; Mason, C; Paterson, H; Olson, MF; Marshall, CJ				Marais, R; Light, Y; Mason, C; Paterson, H; Olson, MF; Marshall, CJ			Requirement of Ras-GTP-Raf complexes for activation of Raf-1 by protein kinase C	SCIENCE			English	Article							PLASMA-MEMBRANE; TYROSINE PHOSPHORYLATION; MAMMALIAN-CELLS; MAP KINASE; PATHWAY; GROWTH; HYDROLYSIS; MUTANT	Receptor tyrosine kinase-mediated activation of the Raf-1 protein kinase is coupled to the small guanosine triphosphate (GTP)-binding protein Ras, By contrast, protein kinase C (PKC)-mediated activation of Raf-1 is thought to be Ras independent, Nevertheless, stimulation of PKC in COS cells led to activation of Ras and formation of Ras-Raf-1 complexes containing active Raf-1, Raf-1 mutations that prevent its association with Ras blocked activation of Raf-1 by PKC, However, the activation of Raf-1 by PKC was not blocked by dominant negative Ras, indicating that PKC activates Ras by a mechanism distinct from that initiated by activation of receptor tyrosine kinases.	Inst Canc Res, CRC, Ctr Cell & Mol Biol, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Marshall, CJ (corresponding author), Inst Canc Res, CRC, Ctr Cell & Mol Biol, 237 Fulham Rd, London SW3 6JB, England.		Olson, Michael/ABA-4240-2021; Olson, Michael F/A-3240-2011	Olson, Michael/0000-0003-3428-3507; Marais, Richard/0000-0001-7484-4183; Mason, Clive/0000-0003-3179-6622				Blobe GC, 1996, CANCER SURV, V27, P213; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; Cox ME, 1997, J NEUROCHEM, V69, P1119; DAVIS PD, 1992, J MED CHEM, V35, P994, DOI 10.1021/jm00084a004; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Exton JH, 1997, EUR J BIOCHEM, V243, P10, DOI 10.1111/j.1432-1033.1997.t01-1-00010.x; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FINNEY R, 1995, METHOD ENZYMOL, V255, P310; GUPTA S, 1994, J BIOL CHEM, V269, P17349; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LOU Z, 1997, MOL CELL BIOL, V17, P46; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARAIS R, UNPUB; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; MEDEMA RH, 1991, J BIOL CHEM, V266, P21186; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NORI M, 1992, MOL CELL BIOL, V12, P936, DOI 10.1128/MCB.12.3.936; Racke FK, 1997, J BIOL CHEM, V272, P23366, DOI 10.1074/jbc.272.37.23366; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SMITS AMM, 1992, NATURE, V357, P602; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; Whelchel A, 1997, AM J RESP CELL MOL, V16, P589, DOI 10.1165/ajrcmb.16.5.9160841; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; Zou YZ, 1996, J BIOL CHEM, V271, P33592, DOI 10.1074/jbc.271.52.33592	45	384	386	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 3	1998	280	5360					109	112		10.1126/science.280.5360.109	http://dx.doi.org/10.1126/science.280.5360.109			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF314	9525855				2022-12-28	WOS:000072885100047
J	Lean, MEJ; Han, TS; Seidell, JC				Lean, MEJ; Han, TS; Seidell, JC			Impairment of health and quality of life in people with large waist circumference	LANCET			English	Article							WEIGHT-GAIN; UNITED-STATES; RISK; OBESITY; PERSPECTIVE; OVERWEIGHT; COST	Background Symptoms and secondary disorders associated with excess central fat distribution are being increasingly recognised. We aimed to define the symptoms and assess risks of chronic disorders in people with large waist circumferences, Methods We did a cross-sectional study of 5887 men and 7018 women aged 20-59 years from the general population of Maastricht, Amsterdam, and Doetinchem, Netherlands. We assessed in health centres respiratory insufficiency, low back pain, degree of physicical function, presence of noninsulin-dependent diabetes, and cardiovascular risk factors. We measured bodyweight, body-mass index, and waist circumference by action levels (men: less than action level 1<94.0 cm, action levels 1-2 94.0-101.9 cm, more than action level 2 greater than or equal to 102.0 cm; women: less than action level 1 <80.0 cm, action levels 1-2 80.0-87.9 cm) more than action level 2 greater than or equal to 88.0 cm). The reference group were people with waist circumferences lower than action level 1. Findings All symptoms and risks increased among participants higher than action level 2, after adjustment for age and lifestyle, by 3.1(95% CI 2.5-3.7) in men and 2.7 (2.3-3.1) in women for shortness of breath when walking upstairs; 4.5 (2.5-7.8) and 3.8 (1.9-7.3) for non-insulin-dependent diabetes; and 4.2 (3.6-5.0) and 2.8 (2.4-3.2) for at least one major cardiovascular risk factor. Above action level 2, compared with the reference group, men and women were at twice the risk of difficulties in everyday activities, women were 1.5 times more likely to have low back pain or symptoms of intervertebral disc herniation, with secondary problems including hindrance to daily activities. Interpretation People with large waist circumferences have excess burden of ill health. Waist action levels could be useful for health promotion to raise awareness of the need for weight management.	Univ Glasgow, Glasgow Royal Infirm, Dept Human Nutr, Glasgow G31 2ER, Lanark, Scotland; Natl Inst Publ Hlth & Environm, Dept Chron Dis & Environm Epidemiol, NL-3720 BA Bilthoven, Netherlands	University of Glasgow; Netherlands National Institute for Public Health & the Environment	Lean, MEJ (corresponding author), Univ Glasgow, Glasgow Royal Infirm, Dept Human Nutr, Glasgow G31 2ER, Lanark, Scotland.		seidell, jacob/AAF-5362-2019; seidell, jacob c/N-7427-2013	seidell, jacob/0000-0002-9262-9062; Han, Thang/0000-0003-2570-0938				[Anonymous], 1995, WHO TECH REP SER; Bennett N, 1995, HLTH SURVEY ENGLAND; CHAN JM, 1994, DIABETES CARE, V17, P961, DOI 10.2337/diacare.17.9.961; COLDITZ GA, 1995, ANN INTERN MED, V122, P481, DOI 10.7326/0003-4819-122-7-199504010-00001; GARFINKEL L, 1992, ANN INTERN MED, V103, P1032; Gregory J., 1990, DIETARY NUTR SURVEY; Han TS, 1997, INT J OBESITY, V21, P600, DOI 10.1038/sj.ijo.0800448; Han TS, 1997, INT J OBESITY, V21, P127, DOI 10.1038/sj.ijo.0800377; Han TS, 1997, INT J OBESITY, V21, P83, DOI 10.1038/sj.ijo.0800371; HAN TS, 1995, BRIT MED J, V311, P1041; KUCZMARSKI R J, 1992, American Journal of Clinical Nutrition, V55, p495S, DOI 10.1093/ajcn/55.2.495s; LEAN MEJ, 1995, BRIT MED J, V311, P158, DOI 10.1136/bmj.311.6998.158; LEE J, 1994, INT J EPIDEMIOL, V23, P201, DOI 10.1093/ije/23.1.201; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; Medical Outcome Trust, 1994, SCOR SF36 HLTH SURV SCOR SF36 HLTH SURV; RISSANEN A, 1990, BRIT MED J, V301, P835, DOI 10.1136/bmj.301.6756.835; SEGAL L, 1994, PHARMACOECONOMICS, V5, P45, DOI 10.2165/00019053-199400051-00009; SEIDELL JC, 1995, INT J OBESITY, V19, pS13; Seidell JC, 1997, J INTERN MED, V242, P401, DOI 10.1046/j.1365-2796.1997.00235.x; SEIDELL JC, 1995, INT J OBES S3, V19, P1; WOLF AM, 1994, PHARMACOECONOMICS, V5, P34, DOI 10.2165/00019053-199400051-00007	21	352	366	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 21	1998	351	9106					853	856		10.1016/S0140-6736(97)10004-6	http://dx.doi.org/10.1016/S0140-6736(97)10004-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD047	9525361				2022-12-28	WOS:000072645500010
J	Miller, KD; Jones, E; Yanovski, JA; Shankar, R; Feuerstein, I; Falloon, J				Miller, KD; Jones, E; Yanovski, JA; Shankar, R; Feuerstein, I; Falloon, J			Visceral abdominal-fat accumulation associated with use of indinavir	LANCET			English	Article							COMPUTED-TOMOGRAPHY; BODY-FAT; INFECTION; OBESITY	Background After the addition of the protease inhibitor indinavir to combination drug regimens for HIV-1 infection, some patients have experienced an increase in abdominal girth with symptoms of abdominal fullness, distension, or bloating. We aimed to find out whether this collection of symptoms was associated with changes in abdominal fat and whether such changes were associated with indinavir use. Methods Abdominal computed tomography was used in ten HIV-1-positive patients who had such abdominal symptoms to measure total adipose tissue (TAT) and visceral adipose tissue (VAT) at the umbilicus (L4 vertebral level). The VAT:TAT ratio in the ten cases was compared with that in ten HIV-1-infected patients who had been using indinavir without abdominal symptoms for at least 6 months and ten HIV-1-infected patients who were not using indinavir. Findings The mean VAT:TAT ratios for the three groups-non-users, symptom-free indinavir users, and symptomatic indinavir users-were 0.40 (SD 0.15), 0.59 (0.18), and 0.70 (0.20), respectively (p=0.004). The VAT:TAT ratio correlated with duration of indinavir use (r=0.47, p=0.01). The mean areas of VAT for the three groups were 106 cm(2) (SD 72), 141 cm(2) (65) and 202 cm(2) (93), respectively (p=0.03). The mean body-mass index of the groups was similar, and patients in the two indinavir groups did not gain a significant amount of weight after starting the drug. Serum triglyceride values increased after starting indinavir and correlated with VAT:TAT ratios. Interpretation Our data suggest that some HIV-1-infected patients on indinavir treatment accumulate intraabdominal fat that may cause abdominal symptoms. Recent evidence suggests that other HIV-1 protease inhibitors may be associated with changes in body-fat distribution. Larger studies of protease-inhibitor treatment are needed to investigate this association further and to investigate metabolic or endocrine mechanisms that may underlie this phenomenon.	NICHHD, Dept Crit Care Med, Warren Grant Magnuson Clin Ctr, NIH, Bethesda, MD 20892 USA; NICHHD, Dept Radiol, Warren Grant Magnuson Clin Ctr, NIH, Bethesda, MD 20892 USA; NICHHD, Dev Endocrinol Branch, NIH, Bethesda, MD 20892 USA; NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Miller, KD (corresponding author), NICHHD, Dept Crit Care Med, Warren Grant Magnuson Clin Ctr, NIH, Bldg 10,Room 8C410, Bethesda, MD 20892 USA.	kmiller@atlas.niaid.nih.gov		Yanovski, Jack/0000-0001-8542-1637				Bartlett JG, 1996, ANN INTERN MED, V124, P1086, DOI 10.7326/0003-4819-124-12-199606150-00011; BAUMGARTNER RN, 1988, AM J CLIN NUTR, V48, P936, DOI 10.1093/ajcn/48.4.936; BORKAN GA, 1982, AM J CLIN NUTR, V36, P172, DOI 10.1093/ajcn/36.1.172; CARR A, 1998, 5 C RETR OPP INF, P410; Corey L, 1996, NEW ENGL J MED, V335, P1142, DOI 10.1056/NEJM199610103351509; Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145; DIXON AK, 1983, CLIN RADIOL, V34, P189, DOI 10.1016/S0009-9260(83)80303-1; ENZI G, 1986, AM J CLIN NUTR, V44, P739, DOI 10.1093/ajcn/44.6.739; FUJIOKA S, 1987, METABOLISM, V36, P54, DOI 10.1016/0026-0495(87)90063-1; GRAUER WO, 1984, AM J CLIN NUTR, V39, P631, DOI 10.1093/ajcn/39.4.631; Hengel RL, 1997, LANCET, V350, P1596, DOI 10.1016/S0140-6736(05)64011-1; Herry I, 1997, CLIN INFECT DIS, V25, P937, DOI 10.1086/597649; JAMES JS, 1997, AIDS TREATMENT NEWS; LO JC, 1998, 5 C RETR OPP INF, P409; Macor C, 1997, METABOLISM, V46, P123, DOI 10.1016/S0026-0495(97)90288-2; MATSUZAWA Y, 1995, OBES RES, V3, P645; Matsuzawa Y., 1995, OBES RES S2, V3, p187S; PISUNYER FX, 1993, ANN INTERN MED, V119, P655, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00006; RUANE PJ, 1997, 37 INT C ANT AG CHEM, pI185; VANDERKOOY K, 1993, INT J OBESITY, V17, P187; VanLoan MD, 1996, AM J CLIN NUTR, V64, P787, DOI 10.1093/ajcn/64.5.787; Vehmas T, 1996, INT J OBESITY, V20, P570; WAJCHENBERG BL, 1995, J CLIN ENDOCR METAB, V80, P2791, DOI 10.1210/jc.80.9.2791; WEITS T, 1988, INT J OBESITY, V12, P217; 1997, MED LETT DRUGS THER, V39, P111	25	546	552	1	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 21	1998	351	9106					871	875		10.1016/S0140-6736(97)11518-5	http://dx.doi.org/10.1016/S0140-6736(97)11518-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD047	9525365				2022-12-28	WOS:000072645500014
J	Sobel, N; Prabhakaran, V; Desmond, JE; Glover, GH; Goode, RL; Sullivan, EV; Gabrieli, JDE				Sobel, N; Prabhakaran, V; Desmond, JE; Glover, GH; Goode, RL; Sullivan, EV; Gabrieli, JDE			Sniffing and smelling: separate subsystems in the human olfactory cortex	NATURE			English	Article							DISCRIMINATION; DEFICITS; DISEASE	The sensation and perception of smell (olfaction) are largely dependent on snifting, which is an active stage of stimulus transport and therefore an integral component of mammalian olfaction(1,2). Electrophysiological data obtained from study of the hedgehog, rat, rabbit, dog and monkey indicate that sniffing (whether or not an odorant is present) induces an oscillation of activity in the olfactory bulb, driving the piriform cortex in the temporal lobe, in other words, the piriform is driven by the olfactory bulb at the frequency of sniffing(1-4). Here we use functional magnetic resonance imaging (fMRI) that is dependent on the level of oxygen in the blood to determine whether sniffing can induce activation in the piriform of humans, and whether this activation can be differentiated from activation induced by an odorant, We find that sniffing, whether odorant is present or absent, induces activation primarily in the piriform cortex of the temporal lobe and in the medial and posterior orbito-frontal gyri of the frontal lobe. The source of the sniff-induced activation is the somatosensory stimulation that is induced by air flow through the nostrils. In contrast, a smell, regardless of snifting, induces activation mainly in the lateral and anterior orbito-frontal gyri of the frontal lobe. The dissociation between regions activated by olfactory exploration (sniffing) and regions activated by olfactory content (smell) shows a distinction in brain organization in terms of human olfaction.	Stanford Univ, Program Neurosci, Stanford, CA 94305 USA; Stanford Univ, Dept Psychol, Stanford, CA 94305 USA; Stanford Univ, Dept Radiol, Stanford, CA 94305 USA; Stanford Univ, Dept ENT Surg, Stanford, CA 94305 USA; Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA; Palo Alto VA Hosp, Palo Alto, CA 94305 USA	Stanford University; Stanford University; Stanford University; Stanford University; Stanford University	Sobel, N (corresponding author), Stanford Univ, Program Neurosci, Stanford, CA 94305 USA.	nsobel@leland.stanford.edu	Gabrieli, John/AAJ-2869-2020; Sullivan, Edith V/ABD-5684-2021	Sullivan, Edith V/0000-0001-6739-3716; prabhakaran, vivek/0000-0002-1974-3125; Sobel, Noam/0000-0002-3232-9391	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB015891] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Adrian ED, 1942, J PHYSIOL-LONDON, V100, P459, DOI 10.1113/jphysiol.1942.sp003955; ALLISON AC, 1954, J ANAT, V88, P481; BRESSLER SL, 1980, ELECTROEN CLIN NEURO, V50, P19, DOI 10.1016/0013-4694(80)90319-3; BRESSLER SL, 1987, BRAIN RES, V409, P294, DOI 10.1016/0006-8993(87)90714-1; Desmond JE, 1997, HUM BRAIN MAPP, V5, P58, DOI 10.1002/(SICI)1097-0193(1997)5:1<58::AID-HBM6>3.0.CO;2-M; Doty R L, 1991, Geriatrics, V46 Suppl 1, P47; DOTY RL, 1988, NEUROLOGY, V38, P1237, DOI 10.1212/WNL.38.8.1237; DOTY RL, 1984, PHYSIOL BEHAV, V32, P489, DOI 10.1016/0031-9384(84)90269-5; ELIAN M, 1991, J NEUROL NEUROSUR PS, V54, P927, DOI 10.1136/jnnp.54.10.927; Eslinger P J, 1982, Brain Cogn, V1, P259, DOI 10.1016/0278-2626(82)90028-8; Friston K.J., 1994, HUM BRAIN MAPP, V1, P153, DOI DOI 10.1002/HBM.460010207; GLOVER GH, 1998, MAGN RESON MED, V39; Henkin R I, 1977, Trans Am Neurol Assoc, V102, P146; JONES AS, 1989, CLIN OTOLARYNGOL, V14, P285, DOI 10.1111/j.1365-2273.1989.tb00375.x; JONES AS, 1986, ACTA OTO-LARYNGOL, V101, P328, DOI 10.3109/00016488609132846; JONESGOTMAN M, 1988, NEUROPSYCHOLOGIA, V26, P387, DOI 10.1016/0028-3932(88)90093-0; LAING DG, 1983, PERCEPTION, V12, P99, DOI 10.1068/p120099; Le Magnen J., 1945, ANN PSYCHOL, V45, P77; POTTER H, 1979, NEUROSCIENCE, V4, P361, DOI 10.1016/0306-4522(79)90099-X; POTTER H, 1980, NEUROPSYCHOLOGIA, V18, P621, DOI 10.1016/0028-3932(80)90101-3; PRICE JL, 1991, OLFACTION, P101; Price JL, 1990, HUMAN NERVOUS SYSTEM, P979; Sobel N, 1997, J NEUROSCI METH, V78, P115, DOI 10.1016/S0165-0270(97)00140-4; Talairach J., 1988, COPLANAR STEREOTAXIC; UEKI S, 1961, J NEUROPHYSIOL, V24, P12, DOI 10.1152/jn.1961.24.1.12; VONBONIN G, 1949, J COMP NEUROL, V92, P243; Wehr M, 1996, NATURE, V384, P162, DOI 10.1038/384162a0; ZATORRE RJ, 1990, PERCEPT PSYCHOPHYS, V47, P526, DOI 10.3758/BF03203105; ZATORRE RJ, 1991, BRAIN, V114, P71; ZATORRE RJ, 1992, NATURE, V360, P339, DOI 10.1038/360339a0	30	354	358	4	52	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1998	392	6673					282	286		10.1038/32654	http://dx.doi.org/10.1038/32654			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ZC739	9521322				2022-12-28	WOS:000072612300047
J	Crenner, CW				Crenner, CW			Introduction of the blood pressure cuff into US medical practice: Technology and skilled practice	ANNALS OF INTERNAL MEDICINE			English	Article								The history of the sphygmomanometer, or blood pressure cuff, raises;useful questions about the acceptance of new medical technologies. When the blood pressure cuff first appeared in U.S. medical practice in the first decade of the 1900s, it generated some concern and debate among physicians. Review of the medical literature, a systematic study of patient records from Massachusetts General Hospital, and consideration of events in Boston during this period suggest that physicians faced several important choices associated with the early acceptance of the cuff. The introduction of the blood pressure cuff presented physicians with several different, competing methods for assessing the force of a patient's blood flow. Physicians chose to use the cuff in a manner that preserved their exclusive use of the new tool and maintained a high level of skill for their individual practices. An early proposal to introduce the new blood pressure cuff as a simple tool for nursing use met with resistance. Many physicians initially favored a competing practice of assessing the force of blood flow by pulse palpation. Physicians eventually dropped the practice of subjectively palpating the force of blood flow and came to rely increasingly on the measurement of blood pressure using auscultation. Even after adopting the cuff into practice, however, they had little interest in completely standardizing the use of the blood pressure cuff across the practices of individual physicians.	Beth Israel Deaconess Med Ctr, Boston, MA USA; Manchester Vet Affairs Med Ctr, Manchester, NH USA	Harvard University; Beth Israel Deaconess Medical Center	Crenner, CW (corresponding author), Harvard Univ, Sch Med, Dept Social Med, 641 Huntington Ave, Boston, MA 02115 USA.							Archibald EW, 1917, ANN SURG, V66, P280, DOI 10.1097/00000658-191709000-00003; BRIGGS JB, 1903, MD MED J, V46, P1; *BUR STAND US DEP, 1927, US TEST SPHYGM TECHN, V21, P729; CABOT RC, 1913, PHYSICAL DIAGNOSIS, P111; CABOT RC, 1909, PHYSICAL DIAGNOSIS; *COMM SURG RES, 1904, B DIV SURG MED SCH H, V1, P35; Cook HW, 1903, J HOPKINS HOSP REP, V11, P451; CRENNER CW, 1993, THESIS HARVARD U CAM; CRILE GW, 1903, BLOOD PRESSURE SURG, P358; Cushing H, 1903, BOSTON MED SURG J, V148, P0250, DOI 10.1056/NEJM190303051481002; *DEP MED REC MASS, 1906, PATIENT RECORDS, V653, P111; *DEP MED REC MASS, 1903, PATIENT RECORDS, V581, P78; *DEP MED REC MASS, 1910, PATIENT RECORDS, V763, P178; *DEP MED REC MASS, 1915, PATIENT RECORDS, V988, P45; Department for Education and Child Development (SA), 2017, PATIENT RECORDS, P17; EHRET H, 1909, MUNCHEN MED WOCHEN, V56, P959; EVANS H, 1993, TECHNOL CULT, V34, P784, DOI 10.2307/3106415; FAULKNER WE, 1904, B DIVISION SURG MED, V1, P4; FRAUGHT FA, 1918, ESSENTIALS LAB DIAGN, P110; FULTON JF, 1946, HARVEY CUSHING BIOGR, P178; GIBSON CA, 1891, PHYSICAL DIAGNOSIS G, P94; Gittings JC, 1910, ARCH INTERN MED, V6, P196; Goodman EH, 1911, AM J MED SCI, V142, P334, DOI 10.1097/00000441-191109000-00003; GOODMAN EH, 1910, U PENN MED B, V23, P469; Howell JD, 1995, TECHNOLOGY HOSP TRAN; JACOBSON AC, 1915, MED TIMES        JAN, P24; Janeway TC, 1904, CLIN STUDY BLOOD PRE; Korotkoff NS, 1905, IZV IMP VOENNO MED A, VXI, P365, DOI DOI 10.1097/00004872-200501000-00001; LAYTON EN, 1906, JAMA-J AM MED ASSOC, V48, P274; Lewis W H, 1941, Bull N Y Acad Med, V17, P871; *METR LIF INS CO, 1917, INSTR MED EX; MURPHY FT, 1904, B DIVISION SURG MED, V1, P23; Reiser S., 1978, MED REIGN TECHNOLOGY; RIVAROCCI S, 1896, GAZZ MED TORINO, V47, P1001; RIVAROCCI S, 1896, GAZZ MED TORINO, V47, P981; Rosenberg Charles E., 1987, CARE STRANGERS RISE; SCHECHTER DC, 1969, DIS CHEST, VS 55, P535; SCHRUMPF P, 1909, MUNCHEN MED WOCHEN, V56, P704; SHULMAN M, 1917, JAMA-J AM MED ASSOC, V68, P1256; THULIN T, 1975, POSTGRAD MED J, V51, P390, DOI 10.1136/pgmj.51.596.390; Wailoo Keith., 1997, DRAWING BLOOD TECHNO, P46; Washburn F, 1939, MASSACHUSETTS GEN HO; 1909, JAMA, V52, P2121; 1909, JAMA, V52, P1729	44	29	29	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1998	128	6					488	493		10.7326/0003-4819-128-6-199803150-00010	http://dx.doi.org/10.7326/0003-4819-128-6-199803150-00010			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA914	9499333				2022-12-28	WOS:000072414700010
J	Nelson, EC; Splaine, ME; Batalden, PB; Plume, SK				Nelson, EC; Splaine, ME; Batalden, PB; Plume, SK			Building measurement and data collection into medical practice	ANNALS OF INTERNAL MEDICINE			English	Article							IMPROVING HEALTH-CARE; IMPROVEMENT; OUTCOMES	Clinicians can use data to improve daily clinical practice. This paper offers eight principles for using data to support improvement in busy clinical settings: 1) seek usefulness, not perfection, in the measurement; 2) use a balanced set of process, outcome, and cost measures; 3) keep measurement simple (think big, but start small); 4) use qualitative and quantitative data; 5) write down the operational definitions of measures; 6) measure small, representative samples; 7) build measurement into daily work; and 8) develop a measurement team. The following approaches to using data for improvement are recommended. First, begin with curiosity about outcomes or a need to improve results. Second, try to avoid knee-jerk, obstructive criticism of proposed measurements. Instead, propose solutions that are practical, goal-oriented, and good enough to start with. Third, gather baseline data on a small sample and check the findings. Fourth, try to change and improve the delivery process while gathering data. Fifth, plot results over time and analyze them by using a control charter other graphical method. Sixth, refine your understanding of variation in processes and outcomes by dividing patients into clinically homogeneous subgroups (stratification) and analyzing the results separately for each subgroup. Finally, make further changes while measuring key outcomes, over time. Measurement and improvement are intertwined; it is impossible to make improvements without measurement. Measuring and learning from each patient and using the information gleaned to test improvements can become part of daily medical practice in local settings.	Lahey Hitchcock Clin, Off President, Lebanon, NH 03756 USA; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Hanover, NH 03756 USA; Henry Ford Hlth Syst, Detroit, MI USA	Dartmouth College; Henry Ford Health System; Henry Ford Hospital	Nelson, EC (corresponding author), Lahey Hitchcock Clin, Off President, 1 Med Ctr, Lebanon, NH 03756 USA.							BATALDEN PB, 1994, JOINT COMM J QUAL IM, V20, P167, DOI 10.1016/S1070-3241(16)30059-1; Batalden PB, 1996, JOINT COMM J QUAL IM, V22, P651, DOI 10.1016/S1070-3241(16)30272-3; Berwick DM, 1998, ANN INTERN MED, V128, P289, DOI 10.7326/0003-4819-128-4-199802150-00008; BERWICK DM, 1991, MED CARE, V29, P1212, DOI 10.1097/00005650-199112000-00004; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; BLAND M, 1995, INTRO MED STAT; Chassin MR, 1996, NEW ENGL J MED, V335, P1060, DOI 10.1056/NEJM199610033351413; Clandinin DJ., 1994, HDB QUALITATIVE RES, P413; Deming EW., 1986, OUT CRISIS; Hennekens C.H., 1987, EPIDEMIOLOGY MED; *I CLIN SYST INT, 1996, HLTH CAR GUID, V1; Kish L, 1965, SURVEY SAMPLING; Kotter JohnP., 1996, LEADING CHANGE; MACMAHON B, 1970, EPIDEMIOLOGY PRINCIP, P23; NELSON EC, 1995, INT J QUAL HEALTH C, V7, P95, DOI 10.1093/intqhc/7.2.95; Nelson EC, 1996, JOINT COMM J QUAL IM, V22, P243, DOI 10.1016/S1070-3241(16)30228-0; NELSON EC, 1995, JOINT COMM J QUAL IM, V21, P155, DOI 10.1016/S1070-3241(16)30136-5; Nelson EC, 1996, JOINT COMM J QUAL IM, V22, P531, DOI 10.1016/S1070-3241(16)30254-1; NUGENT WC, 1994, J CLIN OUTCOMES MANA, V1, P57; STAMM WE, 1993, NEW ENGL J MED, V329, P1328, DOI 10.1056/NEJM199310283291808; WHEELER DJ, 1990, UNDERSTANDING IND EX, P54; WHEELER DJ, 1992, UNDERSTANDING STAT P, P48	23	88	88	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1998	128	6					460	466		10.7326/0003-4819-128-6-199803150-00007	http://dx.doi.org/10.7326/0003-4819-128-6-199803150-00007			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA914	9499330				2022-12-28	WOS:000072414700007
J	Kanabar, DJ; Agrawal, M; Saunders, A				Kanabar, DJ; Agrawal, M; Saunders, A			A period or not?	LANCET			English	Article									Guys Hosp, Dept Paediat, London SE1 9RT, England; Guys Hosp, Dept Radiol, London SE1 9RT, England	Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust	Kanabar, DJ (corresponding author), Guys Hosp, Dept Paediat, 10th Floor,Guys Tower,St Thomas St, London SE1 9RT, England.							RAIS AJH, 1984, BAILEY LOVES SHORT P; Steichen F M, 1967, Int Surg, V47, P260; Tanner JM, 1962, GROWTH ADOLESCENCE, V2nd	3	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 14	1998	351	9105					800	800		10.1016/S0140-6736(97)12225-5	http://dx.doi.org/10.1016/S0140-6736(97)12225-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB916	9519953				2022-12-28	WOS:000072521200014
J	Dillin, A; Rine, J				Dillin, A; Rine, J			Roles for ORC in M phase and S phase	SCIENCE			English	Article							ORIGIN RECOGNITION COMPLEX; YEAST SACCHAROMYCES-CEREVISIAE; CONTROLLING DNA-REPLICATION; BUDDING YEAST; CELL-CYCLE; XENOPUS; MITOSIS; ACTIVATION; PROTEIN; GENES	The origin recognition complex (ORC), a six-subunit protein, functions as the replication initiator in the yeast Saccharomyces cerevisiae. Initiation depends on the assembly of the prereplication complex in late M phase and activation in S phase. One subunit of ORC, Orc5p, was required at G(1)/S and in early M phase. Asynchronous cells with a temperature-sensitive orc5-1 allele arrested in early M phase. In contrast, cells that were first synchronized in M phase, shifted to the restrictive temperature, and then released from the block arrested at the G(1)/S boundary, The G(1)/S arrest phenotype could not be suppressed by introducing wild-type Orc5p during G(1). Although all orc2 and orc5 mutations were recessive in the conventional sense, this dominant phenotype was shared with other orc5 alleles and an orc2 allele, The dominant inhibition to cell-cycle progression exhibited by the ore mutants was restricted to the nucleus, suggesting that chromosomes with mutant ORC complexes were capable of sending a signal that blocked initiation on chromosomes containing functional origins.	Univ Calif Berkeley, Div Genet, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Rine, J (corresponding author), Univ Calif Berkeley, Div Genet, 401 Baker Hall, Berkeley, CA 94720 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031105, R01GM031105] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30ESO1896-12] Funding Source: Medline; NIGMS NIH HHS [GM-31105] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; CONDE J, 1976, P NATL ACAD SCI USA, V73, P3651, DOI 10.1073/pnas.73.10.3651; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Dillin A, 1997, GENETICS, V147, P1053; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; Landis G, 1997, P NATL ACAD SCI USA, V94, P3888, DOI 10.1073/pnas.94.8.3888; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MAINE GT, 1984, GENETICS, V106, P365; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Rose MD, 1996, ANNU REV CELL DEV BI, V12, P663, DOI 10.1146/annurev.cellbio.12.1.663; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Santocanale C, 1996, EMBO J, V15, P6671, DOI 10.1002/j.1460-2075.1996.tb01057.x; STUELAND CS, 1993, MOL CELL BIOL, V13, P3744, DOI 10.1128/MCB.13.6.3744; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652	24	50	51	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 13	1998	279	5357					1733	1737		10.1126/science.279.5357.1733	http://dx.doi.org/10.1126/science.279.5357.1733			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9497294				2022-12-28	WOS:000072490000059
J	Ofili, EO; Cohen, JD; St Vrain, JA; Pearson, A; Martin, TJ; Uy, ND; Castello, R; Labovitz, AJ				Ofili, EO; Cohen, JD; St Vrain, JA; Pearson, A; Martin, TJ; Uy, ND; Castello, R; Labovitz, AJ			Effect of treatment of isolated systolic hypertension on left ventricular mass	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANTIHYPERTENSIVE THERAPY; HYPERTROPHY; METAANALYSIS; REDUCTION; REVERSAL; DISEASE	Context.-Left ventricular (LV) hypertrophy is a common problem among elderly patients with isolated systolic hypertension (ISH), but the effect of treatment of ISH on LV mass is not known, Objective.-To assess the ability of antihypertensive drug treatment to reduce LV mass in ISH, Design.-Echocardiographic Substudy of the Systolic Hypertension in the Elderly Program (SHEP), Patients.-A total of 104 participants at the St Louis SHEP site who had interpretable baseline echocardiograms, 94 of whom had 3-year follow-up echocardiograms, Intervention.-The SHEP participants were randomized to placebo or active treatment with chlorthalidone (12.5-25 mg/d), with atenolol (25-50 mg/d) added if necessary to maintain goal blood pressure, Main Outcome Measure.-Change in LV mass assessed by echocardiography, Results.-Minimum follow-up was 3 years, In the active treatment group, 91% and 80% of subjects were receiving treatment with chlorthalidone alone by the end of years 1 and 3, respectively, The LV mass index was 93 g/m(2) in the active treatment group and 100 g/m(2) in the placebo group (P<.001), The LV mass index declined by 13% (95% confidence interval, -3% to -23%) in the active treatment group compared with a 6% increase (95% confidence interval, -3% to + 16%) in the placebo group over 3 years (P=.01). Conclusion.-Treatment of ISH with a diuretic-based regimen reduces LV mass.	Morehouse Sch Med, Dept Internal Med, Cardiol Sect, Atlanta, GA 30310 USA; St Louis Univ, Med Ctr, Dept Internal Med, Div Cardiol, St Louis, MO USA; Ohio State Univ, Coll Med, Div Cardiol, Columbus, OH 43210 USA	Morehouse School of Medicine; Saint Louis University; University System of Ohio; Ohio State University	Ofili, EO (corresponding author), Morehouse Sch Med, Dept Internal Med, Cardiol Sect, 720 Westview Dr SW, Atlanta, GA 30310 USA.				NHLBI NIH HHS [HL-02682] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1991, JAMA, V265, P3255; CRUICKSHANK JM, 1992, J HUM HYPERTENS, V6, P85; DAHLOF B, 1992, AM J HYPERTENS, V5, P95, DOI 10.1093/ajh/5.2.95; Gottdiener JS, 1997, CIRCULATION, V95, P2007, DOI 10.1161/01.CIR.95.8.2007; KOREN MJ, 1990, CIRCULATION, V82, P29; KOREN MJ, 1991, ANN INTERN MED, V114, P345, DOI 10.7326/0003-4819-114-5-345; Lavie CJ, 1996, CLIN GERIATR MED, V12, P57, DOI 10.1016/S0749-0690(18)30244-1; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LEVY D, 1989, ANN INTERN MED, V110, P101, DOI 10.7326/0003-4819-110-2-101; LIAO YL, 1995, JAMA-J AM MED ASSOC, V273, P1592, DOI 10.1001/jama.273.20.1592; LIEBSON PR, 1995, CIRCULATION, V91, P698, DOI 10.1161/01.CIR.91.3.698; MOSER M, 1991, EUR HEART J, V12, P1034, DOI 10.1093/eurheartj/12.9.1034; MUIESAN ML, 1995, J HYPERTENS, V13, P1091, DOI 10.1097/00004872-199510000-00003; OFILI EO, 1993, CIRCULATION, V88, P512; OFILI EO, 1991, CIRCULATION, V84, P137; PEARSON AC, 1991, J AM COLL CARDIOL, V17, P422, DOI 10.1016/S0735-1097(10)80109-3; PROBSTFIELD JL, 1988, J CLIN EPIDEMIOL, V41, P1197; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; Schmieder RE, 1996, JAMA-J AM MED ASSOC, V275, P1507, DOI 10.1001/jama.275.19.1507; SCHULMAN SP, 1990, NEW ENGL J MED, V322, P1350, DOI 10.1056/NEJM199005103221904	20	27	28	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 11	1998	279	10					778	780		10.1001/jama.279.10.778	http://dx.doi.org/10.1001/jama.279.10.778			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA474	9508155				2022-12-28	WOS:000072366900036
J	Cherfils, J; Menetrey, J; Mathieu, M; La Bras, G; Robineau, S; Beraud-Dufour, S; Antonny, B; Chardin, P				Cherfils, J; Menetrey, J; Mathieu, M; La Bras, G; Robineau, S; Beraud-Dufour, S; Antonny, B; Chardin, P			Structure of the Sec7 domain of the Arf exchange factor ARNO	NATURE			English	Article							NUCLEOTIDE EXCHANGE; GDP; PROTEIN; RESIDUES; BINDING	Small G proteins switch from a resting, GDP-bound state to an active, GTP-bound state. As spontaneous GDP release is slow, guanine-nucleotide-exchange factors (GEFs) are required to promote fast activation of small G proteins through replacement of GDP with GTP in vivo(1). Families of GEFs with no sequence similarity to other GEF families have now been assigned to most families of small G proteins. In the case of the small G protein Arf1, the exchange of bound GDP for GTP promotes the coating of secretory vesicles in Golgi traffic(2). An exchange factor for human Arf1, ARNO(3), and two closely related proteins, named cytohesin 1 (ref. 4) and GPS1 (ref. 5), have been identified. These three proteins are modular proteins with an amino-terminal coiled-coil, a Central Sec7-like domain and a carboxy-terminal pleckstrin homolog domain. The Sec7 domain contains the exchange-factor activity(3). It was first found in Sec7, a yeast protein and is present in several other proteins, including the yeast exchange factors for Arf, Gea1 and Gea2 (refs 7-9). Here we report the crystal structure of the Sec7 domain of human ARNO at 2 Angstrom resolution and the identification of the site of interaction of ARNO with Arf.	CNRS, UPR 9063, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France; CNRS, UPR 411, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Cherfils, J (corresponding author), CNRS, UPR 9063, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France.	cherfiles@lebs.cnrs-gif.fr	Ménétrey, Julie/AAM-6408-2021; Antonny, Bruno/ABH-7434-2020; BERAUD-DUFOUR, Sophie/M-4641-2016	Antonny, Bruno/0000-0002-9166-8668; BERAUD-DUFOUR, Sophie/0000-0002-0062-6842				AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; Antonny B, 1997, BIOCHEMISTRY-US, V36, P4675, DOI 10.1021/bi962252b; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Harrison CJ, 1997, SCIENCE, V276, P431, DOI 10.1126/science.276.5311.431; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; JACQUET E, 1995, BIOCHEMISTRY-US, V34, P12347, DOI 10.1021/bi00038a031; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; Keep NH, 1997, STRUCTURE, V5, P623, DOI 10.1016/S0969-2126(97)00218-9; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; MADEJ T, 1995, PROTEINS, V23, P356, DOI 10.1002/prot.340230309; Meacci E, 1997, P NATL ACAD SCI USA, V94, P1745, DOI 10.1073/pnas.94.5.1745; Morinaga N, 1997, P NATL ACAD SCI USA, V94, P12926, DOI 10.1073/pnas.94.24.12926; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; Renault L, 1998, NATURE, V392, P97, DOI 10.1038/32204; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Schalk I, 1996, NATURE, V381, P42, DOI 10.1038/381042a0; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schimmoller F, 1997, CURR BIOL, V7, pR235, DOI 10.1016/S0960-9822(06)00109-6; SEGAL M, 1993, P NATL ACAD SCI USA, V90, P5564, DOI 10.1073/pnas.90.12.5564; SHEVELL DE, 1994, CELL, V77, P1051, DOI 10.1016/0092-8674(94)90444-8; VERROTTI AC, 1992, EMBO J, V11, P2855, DOI 10.1002/j.1460-2075.1992.tb05353.x; Wang Y, 1997, NAT STRUCT BIOL, V4, P650, DOI 10.1038/nsb0897-650; YU HT, 1995, NATURE, V376, P788, DOI 10.1038/376788a0	30	145	150	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 5	1998	392	6671					101	105		10.1038/32210	http://dx.doi.org/10.1038/32210			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA528	9510256				2022-12-28	WOS:000072373000059
J	Reid, MC; Schoen, RT; Evans, J; Rosenberg, JC; Horwitz, RI				Reid, MC; Schoen, RT; Evans, J; Rosenberg, JC; Horwitz, RI			The consequences of overdiagnosis and overtreatment of Lyme disease: An observational study	ANNALS OF INTERNAL MEDICINE			English	Article						Lyme disease; health services misuse; health services needs and demands; antibiotics; depression	DIAGNOSIS; CHILDREN; FIBROMYALGIA; STRESS	Background: The adverse consequences associated with overdiagnosis and overtreatment of Lyme disease, although previously recognized, have received inadequate attention. Objective: To determine the use of health services and occurrence of treatment-related illness, disability, and distress among patients in whom Lyme disease is inappropriately diagnosed or treated. Design: Observational cohort study. Setting: University-based Lyme disease clinic. Participants: 209 patients with a presumptive diagnosis of Lyme disease previously assigned by referring physicians, the patients themselves, or both. Measurements: Self-reported data, review of medical records, and standardized instruments were used to determine 1) use of health services in terms of number of outpatient visits, number of physicians seen, types of serologic tests, and days of antibiotic treatment; 2) occurrence of antibiotic-related adverse events; and 3) levels of disability, depression, and stress. Results: Of the 209 patients, 44 (21%) met criteria for active Lyme disease, 40 (19%) had previous but not active Lyme disease, and 125 (60%) had no evidence of current or previous infection. In general, patients with active Lyme disease (who were not the focus of this study) had good outcomes. Patients with previous Lyme disease and patients with no evidence of Lyme disease used considerable health resources (median number of office visits, 11 and 7; median number of serologic tests, 4 and 4; and median days of antibiotic treatment, 75 and 42), had frequent minor adverse drug events (53% and 55%), reported significant disability (proportion of symptomatic days during which normal activities could not be performed, 16% and 18%), and had high rates of depression (38% and 42%) and stress (52% and 45%). Conclusions: Overdiagnosis and overtreatment of Lyme disease are associated with inappropriate use of health services, avoidable treatment-related illness, and substantial disability and distress.	Vet Affairs Connecticut Healthcare Syst, Sect Gen Med 111GIM, West Haven, CT 06516 USA; Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University	Reid, MC (corresponding author), Vet Affairs Connecticut Healthcare Syst, Sect Gen Med 111GIM, 950 Campbell Ave, West Haven, CT 06516 USA.			Reid, Cary/0000-0001-8117-662X	NIA NIH HHS [P30 AG022845] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG022845] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		*AM HOSP FORM SERV, 1996, DRUG INF; [Anonymous], 1995, MMWR MORB MORTAL WKL, V44, P590; [Anonymous], 1997, PHYS DESK REF, P1723; ASCH ES, 1994, J RHEUMATOL, V21, P454; BAKKEN LL, 1992, JAMA-J AM MED ASSOC, V268, P891, DOI 10.1001/jama.268.7.891; *CDCP, 1996, JAMA-J AM MED ASSOC, V275, P274; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; COHEN S, 1991, NEW ENGL J MED, V325, P606, DOI 10.1056/NEJM199108293250903; Cohen S., 1995, MEASURING STRESS GUI, P3; CRAFT JE, 1984, J INFECT DIS, V149, P789, DOI 10.1093/infdis/149.5.789; DATTWYLER RJ, 1990, LANCET, V336, P1404, DOI 10.1016/0140-6736(90)93103-V; DINERMAN H, 1992, ANN INTERN MED, V117, P281, DOI 10.7326/0003-4819-117-4-281; FEDER HM, 1995, JAMA-J AM MED ASSOC, V274, P66, DOI 10.1001/jama.274.1.66; HSU VM, 1993, ARTHRITIS RHEUM, V36, P1493, DOI 10.1002/art.1780361103; Johnson BJB, 1996, J INFECT DIS, V174, P346, DOI 10.1093/infdis/174.2.346; MIROWSKY J, 1992, J HEALTH SOC BEHAV, V33, P187, DOI 10.2307/2137349; RAHN DW, 1991, ANN INTERN MED, V114, P472, DOI 10.7326/0003-4819-114-6-472; ROSE CD, 1994, CLIN PEDIATR, V33, P663, DOI 10.1177/000992289403301105; SCHWARTZ BS, 1989, JAMA-J AM MED ASSOC, V262, P2431; Sigal LH, 1996, ARCH INTERN MED, V156, P1493, DOI 10.1001/archinte.156.14.1493; SIGAL LH, 1990, AM J MED, V88, P577, DOI 10.1016/0002-9343(90)90520-N; SIGAL LH, 1995, AM J MED, V98, pS74, DOI 10.1016/S0002-9343(99)80048-5; STEERE AC, 1993, JAMA-J AM MED ASSOC, V269, P1812, DOI 10.1001/jama.269.14.1812; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1983, ANN INTERN MED, V99, P22, DOI 10.7326/0003-4819-99-1-22; STEERE AC, 1977, ARTHRITIS RHEUM, V20, P7, DOI 10.1002/art.1780200102; *VIT HLTH STAT, 1993, DHHS PUBL	27	126	127	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1998	128	5					354	+		10.7326/0003-4819-128-5-199803010-00003	http://dx.doi.org/10.7326/0003-4819-128-5-199803010-00003			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY519	9490595				2022-12-28	WOS:000072155600003
J	Lauer, MS; Lytle, B; Pashkow, F; Snader, CE; Marwick, TH				Lauer, MS; Lytle, B; Pashkow, F; Snader, CE; Marwick, TH			Prediction of death and myocardial infarction by screening with exercise-thallium testing after coronary-artery-bypass grafting	LANCET			English	Article							EMISSION COMPUTED-TOMOGRAPHY; SURGERY; REVASCULARIZATION; DISEASE; PATENCY; PERFUSION	Background The role of myocardial-perfusion imaging in calculating risk in symptom-free patients who have had coronary-artery-bypass grafting (CABG) is unclear. Practice guidelines have argued against routine screening of these patients. We sought to find out the independent and incremental prognostic value of exercise thallium-201 single-photon-emission computed tomography (SPECT) for prediction of death and non-fatal myocardial infarction (MI) in these patients. Methods Analyses were based on 873 symptom-free patients undergoing symptom-limited exercise thallium-201 SPECT between September, 1990, and December, 1993. All had undergone CABG and none had recurrent angina or other major intercurrent coronary events. Exercise and thallium-perfusion Variables were analysed to determine their prognostic importance during 3 years of follow-up. Findings Myocardial-perfusion defects were noted in 508 (58%) patients, There were 57 deaths and 72 patients had major events (death or non-fatal MI), Patients with thallium-perfusion defects were more likely to die (9% vs 3%, p=0.0004) or suffer a major event (11% vs 4%, p=0.0002). Reversible defects were also predictive of death (12% vs 5%, p=0.002) and major events (13% vs 7%, p=0.004). The exercise variable with the strongest predictive power was an impaired (less than or equal to 6 METs [measure of oxygen consumption equal to 3.5 mL/kg/min]) exercise capacity; poor exercise capacity was predictive of death (18% vs 4%, p<0.0001) and death or non-fatal MI (19% vs 5%, p<0.0001). After adjusting for baseline clinical variables, surgical variables, time elapsed since CABG, and standard cardiovascular risk factors, thallium-perfusion defects remained predictive of death (adjusted relative risk 2.78, 95% CI 1.44-5.39) and major events (2.63, 1.49-4.66), Similarly, impaired exercise remained strongly predictive of death (4.16, 2.38-7.29) and major events (3.61, 2.22-5.87) after adjusting for confounders. Interpretation In this group of patients who were symptom-free after CABG, thallium-perfusion defects and impaired exercise capacity were strong and independent predictors of subsequent death or non-fatal MI. Recommendations against routine screening exercise myocardial-perfusion studies in this setting should be reconsidered.	Cleveland Clin Fdn, Dept Cardiol, Sect Heart Failure & Cardiac Transplant Med, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiothorac Surg, Cleveland, OH 44195 USA; Cleveland Clin Fdn, George M & Linda H Kaufman Ctr Heart Failure, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Lauer, MS (corresponding author), Cleveland Clin Fdn, Dept Cardiol, Sect Heart Failure & Cardiac Transplant Med, Desk F-25,9500 Euclid Ave, Cleveland, OH 44195 USA.	lauerm@cesmtp.ccf.org	Marwick, Thomas H/C-7261-2013; Lauer, Michael S/L-9656-2013	Marwick, Thomas H/0000-0001-9065-0899; Lauer, Michael S/0000-0002-9217-8177				Alazraki N P, 1996, Q J Nucl Med, V40, P85; *AM COLL SPORTS ME, 1985, GUID GRAD EX TEST EX; BRUCE RA, 1971, ANN CLIN RES, V3, P323; CAMPEAU L, 1984, NEW ENGL J MED, V311, P1329, DOI 10.1056/NEJM198411223112101; Campeau L, 1997, NEW ENGL J MED, V336, P153; COSGROVE DM, 1985, ANN SURG, V202, P480, DOI 10.1097/00000658-198510000-00008; COX DR, 1972, J R STAT SOC B, V34, P187; FIORETTI P, 1988, EUR HEART J, V9, P1332, DOI 10.1093/oxfordjournals.eurheartj.a062451; GIBSON RS, 1983, J AM COLL CARDIOL, V1, P804, DOI 10.1016/S0735-1097(83)80194-6; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GO RT, 1985, NUCL MED ANN, P171; Khoury AF, 1997, J AM COLL CARDIOL, V29, P1290, DOI 10.1016/S0735-1097(97)00045-4; LAKKIS NM, 1995, AM J CARDIOL, V76, P107, DOI 10.1016/S0002-9149(99)80039-3; Lauer MS, 1996, AM J CARDIOL, V78, P278, DOI 10.1016/S0002-9149(96)00277-9; NWASOKWA ON, 1995, ANN INTERN MED, V123, P528, DOI 10.7326/0003-4819-123-7-199510010-00009; PALMAS W, 1995, J AM COLL CARDIOL, V25, P403, DOI 10.1016/0735-1097(94)00380-9; Pilote L, 1998, AM J CARDIOL, V81, P219, DOI 10.1016/S0002-9149(97)00871-0; RASMUSSEN SL, 1984, EUR HEART J, V5, P494, DOI 10.1093/oxfordjournals.eurheartj.a061696; RITCHIE JL, 1995, J AM COLL CARDIOL, V25, P521, DOI 10.1016/0735-1097(95)90027-6; RITCHIE JL, 1977, CIRCULATION, V56, P830, DOI 10.1161/01.CIR.56.5.830; ROSE G, 1992, STRATEGY PREVENTIVE, P15; SINGH RN, 1983, J THORAC CARDIOV SUR, V86, P359	22	97	102	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 28	1998	351	9103					615	622		10.1016/S0140-6736(97)07062-1	http://dx.doi.org/10.1016/S0140-6736(97)07062-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA447	9500316				2022-12-28	WOS:000072364200006
J	Low-Beer, TS				Low-Beer, TS			How the colon begets gallstones	LANCET			English	Editorial Material							INTESTINAL TRANSIT; DEOXYCHOLIC-ACID; CHOLESTEROL SATURATION; BILE		Selly Oak Hosp, Birmingham B29 6RB, W Midlands, England		Low-Beer, TS (corresponding author), Selly Oak Hosp, Birmingham B29 6RB, W Midlands, England.							Berr F, 1996, GASTROENTEROLOGY, V111, P1611, DOI 10.1016/S0016-5085(96)70024-0; Carey MC, 1997, GUT, V41, P721, DOI 10.1136/gut.41.5.721; Dowling RH, 1997, CAN J GASTROENTEROL, V11, P57, DOI 10.1155/1997/532036; HEATON KW, 1993, LANCET, V341, P8, DOI 10.1016/0140-6736(93)92479-D; HOFFMANN AF, 1977, AM J CLIN NUTR, V30, P993; Hussaini SH, 1995, HEPATOLOGY, V22, P1735, DOI 10.1016/0270-9139(95)90199-X; LOWBEER TS, 1975, BRIT MED J, V1, P438, DOI 10.1136/bmj.1.5955.438; LOWBEER TS, 1978, LANCET, V2, P1063; MARCUS SN, 1986, GUT, V27, P550, DOI 10.1136/gut.27.5.550; POMARE EW, 1976, AM J DIG DIS, V21, P521, DOI 10.1007/BF01464757; POMARE EW, 1973, CLIN SCI MOL MED, V48, P315; SHODA J, 1995, HEPATOLOGY, V21, P1291, DOI 10.1016/0270-9139(95)90050-0; THORNTON JR, 1981, BRIT MED J, V282, P1018, DOI 10.1136/bmj.282.6269.1018; 1997, GUT, V3	14	3	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 28	1998	351	9103					612	613		10.1016/S0140-6736(05)78424-5	http://dx.doi.org/10.1016/S0140-6736(05)78424-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA447	9500314				2022-12-28	WOS:000072364200004
J	McCowan, C; Neville, RG; Thomas, GE; Crombie, IK; Clark, RA; Ricketts, IW; Cairns, AY; Warner, FC; Greene, SA; White, E				McCowan, C; Neville, RG; Thomas, GE; Crombie, IK; Clark, RA; Ricketts, IW; Cairns, AY; Warner, FC; Greene, SA; White, E			Effect of asthma and its treatment on growth: four year follow up of cohort of children from general practices in Tayside, Scotland	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PRIMARY SCHOOL-CHILDREN; CHILDHOOD ASTHMA; SOCIAL-FACTORS; HEIGHT; ENGLAND; RETARDATION; DIAGNOSIS; CHARTS; TRIAL	Objective: To investigate whether asthma or its treatment impairs children's growth, after allowing for socioeconomic group. Design: 4 year follow up of a cohort of children aged 1-15. Setting: 12 general practices in the Tayside region of Scotland. Subjects: 3347 children with asthma or features suggestive of asthma registered with the general practices. Main outcome measures: Height and weight standard deviation scores. Results: Children who lived in areas of social deprivation (assessed by postcode) had lower height and weight than their contemporaries (mean standard deviation score -0.26 (SD 1.02) and -0.18 (1.15) respectively, P < 0.001 for both). Children who were receiving greater than or equal to 400 mu g daily of inhaled steroids and who were attending both hospital and general practice for asthma care had lower height and weight than average, independent of the effect of deprivation (mean standard deviation score -0.62 (1.01), P = 0.002, for height and -0.58 (0.94), P = 0.005, for weight). Children receiving high doses of inhaled corticosteroids also showed lower growth rates (mean change in standard deviation score -0.19 (0.51), P = 0.003). However, no other children with asthma showed growth impairment. Conclusion: Most children with asthma were of normal height and weight and had normal growth rates. However, children receiving high doses of inhaled steroids and requiring both general practice and hospital services had a significant reduction in their stature. This effect was independent from but smaller than the effect of socioeconomic group on stature.	Univ Dundee, Tayside Ctr Gen Practice, Dundee DD2 4AD, Scotland	University of Dundee	McCowan, C (corresponding author), Univ Dundee, Tayside Ctr Gen Practice, Dundee DD2 4AD, Scotland.	c.mccowan@dundee.ac.uk		McCowan, Colin/0000-0002-9466-833X				AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; BALFOURLYNN L, 1986, ARCH DIS CHILD, V61, P1049, DOI 10.1136/adc.61.11.1049; *BRIT THOR SOC, 1993, THORAX, V48, pS1; BRYCE FP, 1995, BRIT MED J, V310, P838, DOI 10.1136/bmj.310.6983.838; COLE TJ, 1992, STAT MED, V11, P1305, DOI 10.1002/sim.4780111005; Cole TJ, 1997, ARCH DIS CHILD, V76, P47, DOI 10.1136/adc.76.1.47; COLE TJ, 1994, BMJ-BRIT MED J, V308, P641, DOI 10.1136/bmj.308.6929.641; *DEP ENV, 1995, 1991 DEPR IND REV AP; GULLIFORD MC, 1991, ARCH DIS CHILD, V66, P235, DOI 10.1136/adc.66.2.235; HALL DMB, 1995, BRIT MED J, V311, P583, DOI 10.1136/bmj.311.7005.583; HAUSPIE RC, 1979, HUM BIOL, V51, P507; LITTLEWOOD JM, 1988, LANCET, V1, P115; Mielck A, 1996, INT J EPIDEMIOL, V25, P388, DOI 10.1093/ije/25.2.388; MURRAY AB, 1976, LANCET, V2, P197; Neville RG, 1996, ANN HUM BIOL, V23, P323, DOI 10.1080/03014469600004552; NEVILLE RG, 1992, BRIT J GEN PRACT, V42, P501; NINAN TK, 1992, ARCH DIS CHILD, V67, P703, DOI 10.1136/adc.67.6.703; POWER C, 1995, ARCH DIS CHILD, V73, P298, DOI 10.1136/adc.73.4.298; RONA RJ, 1978, J EPIDEMIOL COMMUN H, V32, P147, DOI 10.1136/jech.32.3.147; RUSSELL G, 1994, RESP MED, V88, P31, DOI 10.1016/S0954-6111(05)80038-1; SMITH AM, 1980, ANN HUM BIOL, V7, P115, DOI 10.1080/03014468000004131; TANNER JM, 1966, ARCH DIS CHILD, V41, P613, DOI 10.1136/adc.41.220.613; VOSS L, 1989, ACTA PAEDIATR SCAND, P65; WALES JKH, 1991, LANCET, V338, P1535, DOI 10.1016/0140-6736(91)92362-6; White E, 1995, J Med Screen, V2, P140; WHITE EM, 1995, ARCH DIS CHILD, V72, P38, DOI 10.1136/adc.72.1.38; WOLTHERS OD, 1991, BMJ-BRIT MED J, V303, P163, DOI 10.1136/bmj.303.6795.163	27	35	40	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 28	1998	316	7132					668	672		10.1136/bmj.316.7132.668	http://dx.doi.org/10.1136/bmj.316.7132.668			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA282	9522793	Green Accepted, Green Published, Green Submitted, Bronze			2022-12-28	WOS:000072347900032
J	Podar, M; Chu, VT; Pyle, AM; Perlman, PS				Podar, M; Chu, VT; Pyle, AM; Perlman, PS			Group II intron splicing in vivo by first-step hydrolysis	NATURE			English	Article							MITOCHONDRIAL GENE-EXPRESSION; RNA; DNA; COMPONENT; SELECTION; PRODUCTS; DOMAIN-5; OXIDASE; MUTANTS; LARIAT	Group I, group II and spliceosomal introns splice by two sequential transesterification reactions(1). For both spliceosomal and group II introns, the first-step reaction occurs by nucleophilic attack on the 5' splice junction by the 2' hydroxyl of an internal adenosine, forming a 2'-5' phosphodiester branch in the intron. The second reaction joins the two exons with a 3'-5' phosphodiester bond and releases intron lariat. In vitro, group II introns can self-splice by an efficient alternative pathway in which the first-step reaction occurs by hydrolysis. The resulting linear splicing intermediate participates in normal second-step reactions, forming spliced exon and linear intron RNAs2,3. Here we show that the group II intron first-step hydrolysis reaction occurs in vivo in place of transesterification in the mitochondria of yeast strains containing branch-site mutations. As expected, the mutations block branching, but surprisingly still allow accurate splicing. This hydrolysis pathway may have been a step in the evolution of splicing mechanisms.	Univ Texas, SW Med Ctr, Dept Mol Biol & Oncol, Dallas, TX 75235 USA; Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10032 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Columbia University	Perlman, PS (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol & Oncol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	perlman@utsw.swmed.edu	Podar, Mircea/B-7299-2012	Podar, Mircea/0000-0003-2776-0205				ARNBERG AC, 1980, CELL, V19, P313, DOI 10.1016/0092-8674(80)90505-X; BONITZ SG, 1980, J BIOL CHEM, V255, P1927; BOULANGER SC, 1995, MOL CELL BIOL, V15, P4479; Boulanger SC, 1996, MOL CELL BIOL, V16, P5896; Butow R A, 1996, Methods Enzymol, V264, P265, DOI 10.1016/S0076-6879(96)64026-9; CECH TR, 1993, RNA WORLD, P239; CHANFREAU G, 1993, EMBO J, V12, P5173, DOI 10.1002/j.1460-2075.1993.tb06212.x; CHAPMAN KB, 1991, CELL, V65, P483, DOI 10.1016/0092-8674(91)90466-C; CONTRADWEBB H, 1990, NUCLEIC ACIDS RES, V18, P1369; COSTANZO MC, 1990, ANNU REV GENET, V24, P91; Daniels DL, 1996, J MOL BIOL, V256, P31, DOI 10.1006/jmbi.1996.0066; Eskes R, 1997, CELL, V88, P865, DOI 10.1016/S0092-8674(00)81932-7; GODA SK, 1995, NUCLEIC ACIDS RES, V23, P3357, DOI 10.1093/nar/23.16.3357; HENSGENS LAM, 1983, J MOL BIOL, V164, P35, DOI 10.1016/0022-2836(83)90086-4; JACQUIER A, 1991, J MOL BIOL, V219, P415, DOI 10.1016/0022-2836(91)90183-7; JARRELL KA, 1988, J BIOL CHEM, V263, P3432; Liu QL, 1997, J MOL BIOL, V267, P163, DOI 10.1006/jmbi.1996.0845; Margossian SP, 1996, TRENDS BIOCHEM SCI, V21, P392, DOI 10.1016/S0968-0004(96)90129-2; Margossian SP, 1996, CELL, V84, P199, DOI 10.1016/S0092-8674(00)80975-7; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MICHEL F, 1995, ANNU REV BIOCHEM, V64, P435, DOI 10.1146/annurev.bi.64.070195.002251; MORAN JV, 1994, NUCLEIC ACIDS RES, V22, P2057, DOI 10.1093/nar/22.11.2057; PEEBLES CL, 1986, CELL, V44, P213, DOI 10.1016/0092-8674(86)90755-5; PEEBLES CL, 1993, J BIOL CHEM, V268, P11929; PERLMAN P, 1995, METHOD ENZYMOL, V264, P66; PODAR M, 1995, RNA, V1, P828; ZIMMERLY S, 1995, CELL, V83, P529, DOI 10.1016/0092-8674(95)90092-6	27	81	82	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 26	1998	391	6670					915	918		10.1038/36142	http://dx.doi.org/10.1038/36142			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ206	9495347				2022-12-28	WOS:000072230900058
J	Coustan-Smith, E; Behm, FG; Sanchez, J; Boyett, JM; Hancock, ML; Raimondi, SC; Rubnitz, JE; Rivera, GK; Sandlund, JT; Pui, CH; Campana, D				Coustan-Smith, E; Behm, FG; Sanchez, J; Boyett, JM; Hancock, ML; Raimondi, SC; Rubnitz, JE; Rivera, GK; Sandlund, JT; Pui, CH; Campana, D			Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia	LANCET			English	Article							POLYMERASE CHAIN-REACTION; CELL RECEPTOR GENES; T-CELL; COMPLETE REMISSION; FOLLOW-UP; LEUKEMIA; RELAPSE; REARRANGEMENTS; PREDICTION; INDUCTION	Background The clinical significance of submicroscopic levels of leukaemic cells in bone-marrow aspirates from children with acute lymphoblastic leukaemia (ALL) remains controversial. We prospectively determined the frequency and prognostic importance of minimal residual disease detected by a rapid immunological assay in bone-marrow aspirates of children with ALL. Methods 1.58 children with newly diagnosed ALL received 6 weeks of remission-induction chemotherapy. Once complete clinical remission was attained the patients received 2 weeks of consolidation therapy followed by continuation therapy. Bone-marrow aspirates were collected after induction therapy and during weeks 14, 32, and 56 of continuation therapy, and then at 120 weeks (end of therapy). Cells with leukaemia-associated immuno-phenotypes were investigated by multiparameter flow-cytometry capable of detecting one leukaemic cell among 10 000 normal cells. Findings The proportion of patients with detectable leukaemic cells was 23% at remission induction and 17% at week 14 of continuation therapy, decreasing to 5% and 4% at weeks 32 and 56. None of the 65 samples examined at completion of therapy (week 120) showed evidence of Detectable residual disease at the end of induction correlated with adverse genetic abnormalities-the Philadelphia chromosome and MLL gene rearrangements-but not with other presenting features. Detectable leukaemia was associated with subsequent relapse regardless of the time at which bone-marrow samples were examined (p<0.002 for all comparisons). For example, 3-year cumulative incidence (SE) of relapse in patients with and without detectable leukaemia at remission induction was 32.5% (10.6) and 7.5% (4.0), respectively (p<0.001); for tests done at week 14, it was 42.1% (14.6) and 6.6% (3.5), p<0.001. These correlations remained significant after adjusting for adverse presenting features. A higher degree of marrow infiltration by leukaemic cells (greater than or equal to 0.1%) in week 14 samples identified a subset of patients with an especially poor prognosis. Interpretation Immunological detection of residual leukaemic cells at any point in the treatment course is a powerful predictor of relapse in children with ALL. Alternative treatment should be considered for cases with persistent disease beyond the first 3 months of continuation therapy.	St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Pathol & Lab Med, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biostat & Epidemiol, Memphis, TN 38105 USA; Univ Tennessee, Coll Med, Memphis, TN USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Campana, D (corresponding author), St Jude Childrens Res Hosp, Dept Hematol Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA.	dario.campana@stjude.org	Raimondi, Susana C/N-8166-2018; Rubnitz, Jeffrey E/N-2619-2018; Pui, Ching-Hon/N-8076-2018	Rubnitz, Jeffrey E/0000-0001-9885-3527; Pui, Ching-Hon/0000-0003-0303-5658	NATIONAL CANCER INSTITUTE [R01CA060419, P30CA021765, U01CA060419, P01CA020180] Funding Source: NIH RePORTER; NCI NIH HHS [CA60419, CA20180, CA21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Behm FG, 1996, BLOOD, V87, P1134, DOI 10.1182/blood.V87.3.1134.bloodjournal8731134; BEISHUIZEN A, 1994, BLOOD, V83, P2238, DOI 10.1182/blood.V83.8.2238.bloodjournal8382238; BIONDI A, 1992, LEUKEMIA, V6, P282; BRISCO MJ, 1994, LANCET, V343, P196, DOI 10.1016/S0140-6736(94)90988-1; CAMPANA D, 1995, BLOOD, V85, P1416, DOI 10.1182/blood.V85.6.1416.bloodjournal8561416; CAMPANA D, 1990, BLOOD, V76, P163, DOI 10.1182/blood.V76.1.163.163; CAVE H, 1994, BLOOD, V83, P1892; CoustanSmith E, 1996, BLOOD, V87, P1140, DOI 10.1182/blood.V87.3.1140.bloodjournal8731140; COUSTANSMITH E, 1993, LEUKEMIA, V7, P853; CROSS NCP, 1995, BRIT J HAEMATOL, V89, P693; ITO Y, 1993, J CLIN ONCOL, V11, P546, DOI 10.1200/JCO.1993.11.3.546; Jacquy C, 1997, BRIT J HAEMATOL, V98, P140, DOI 10.1046/j.1365-2141.1997.1792996.x; KITCHINGMAN GR, 1994, LEUKEMIA, V8, P395; MENSSEN HD, 1995, LEUKEMIA, V9, P1060; NEALE GAM, 1991, BLOOD, V78, P739, DOI 10.1182/blood.V78.3.739.bloodjournal783739; NIZET Y, 1993, BLOOD, V82, P1618; ORFAO A, 1994, LEUKEMIA LYMPHOMA, V13, P87, DOI 10.3109/10428199409052682; Pui CH, 1997, NEW ENGL J MED, V336, P1781, DOI 10.1056/NEJM199706193362503; PUI CH, 1997, ACUTE LEUKEMIA, V6, P629; Roberts WM, 1997, NEW ENGL J MED, V336, P317, DOI 10.1056/NEJM199701303360501; Sang BC, 1997, BLOOD, V89, P2909, DOI 10.1182/blood.V89.8.2909; SERIU T, 1995, LEUKEMIA, V9, P615; STEENBERGEN EJ, 1995, BLOOD, V86, P692, DOI 10.1182/blood.V86.2.692.bloodjournal862692; STEWARD CG, 1994, BLOOD, V83, P1355; Vervoordeldonk SF, 1996, BRIT J HAEMATOL, V92, P922, DOI 10.1046/j.1365-2141.1996.440979.x; WASSERMAN R, 1992, J CLIN ONCOL, V10, P1879, DOI 10.1200/JCO.1992.10.12.1879	26	346	357	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 21	1998	351	9102					550	554		10.1016/S0140-6736(97)10295-1	http://dx.doi.org/10.1016/S0140-6736(97)10295-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ216	9492773				2022-12-28	WOS:000072231900009
J	Donnelly, R; Millar-Craig, MW				Donnelly, R; Millar-Craig, MW			Cardiac troponins: IT upgrade for the heart	LANCET			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; PROGNOSTIC VALUE; MB MASS; RISK		Univ Nottingham, Derbyshire Royal Infirm, Dept Med & Surg Sci, Derby DE1 2QY, England	University of Nottingham	Donnelly, R (corresponding author), Univ Nottingham, Derbyshire Royal Infirm, Dept Med & Surg Sci, Derby DE1 2QY, England.							Antman EM, 1996, NEW ENGL J MED, V335, P1342, DOI 10.1056/NEJM199610313351802; Apple FS, 1996, AM J CLIN PATHOL, V105, P6; deWinter RJ, 1996, HEART, V75, P235, DOI 10.1136/hrt.75.3.235; Genser N, 1996, AM J CARDIOL, V78, P127, DOI 10.1016/S0002-9149(97)89225-9; Haft JI, 1997, NEW ENGL J MED, V336, P1257; Lindahl B, 1997, EUR HEART J, V18, P762; Lindahl B, 1997, J AM COLL CARDIOL, V29, P43, DOI 10.1016/S0735-1097(96)00447-0; LINDAHL B, 1996, CIRCULATION, V93, P151; Luscher MS, 1997, CIRCULATION, V96, P2578, DOI 10.1161/01.CIR.96.8.2578; Ohman EM, 1996, NEW ENGL J MED, V335, P1333, DOI 10.1056/NEJM199610313351801; Pettijohn TL, 1997, AM J CARDIOL, V80, P510, DOI 10.1016/S0002-9149(97)00405-0; RAVKILDE J, 1995, J AM COLL CARDIOL, V25, P574, DOI 10.1016/0735-1097(94)00430-X; Stubbs P, 1996, BRIT MED J, V313, P262, DOI 10.1136/bmj.313.7052.262; WU AHB, 1994, CLIN CHEM, V40, P900	14	37	42	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 21	1998	351	9102					537	539		10.1016/S0140-6736(05)78549-4	http://dx.doi.org/10.1016/S0140-6736(05)78549-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ216	9492767				2022-12-28	WOS:000072231900003
J	Wagner, G				Wagner, G			Complexity matters	SCIENCE			English	Article							MUTATION; EVOLUTION; SELECTION; BALANCE		Yale Univ, Dept Ecol & Evolutionary Biol, New Haven, CT 06520 USA	Yale University	Wagner, G (corresponding author), Yale Univ, Dept Ecol & Evolutionary Biol, New Haven, CT 06520 USA.	gpwag@peaplant.biology.yale.edu						BURGER R, 1988, MATH Z, V197, P259, DOI 10.1007/BF01215194; Burger R, 1996, ADV APPL PROBAB, V28, P227, DOI 10.2307/1427919; EIGEN M, 1989, ADV CHEM PHYS, V75, P149; Ghiselin M. T., 1997, METAPHYSICS ORIGIN S; KAUFFMAN S, 1987, J THEOR BIOL, V128, P11, DOI 10.1016/S0022-5193(87)80029-2; KAUFFMAN SA, 1993, ORIGINS ODER SELFORG; KINGMAN JFC, 1978, J APPL PROBAB, V15, P1, DOI 10.2307/3213231; LANDE R, 1975, GENET RES, V26, P221, DOI 10.1017/S0016672300016037; MULLER GB, 1991, ANNU REV ECOL SYST, V22, P229, DOI 10.1146/annurev.es.22.110191.001305; Provine, 1971, ORIGINS THEORETICAL; RIEDL R, 1977, Q REV BIOL, V52, P351, DOI 10.1086/410123; Riedl R., 1978, ORDER LIVING ORGANIS; STEARNS SC, 1993, ACTA PALAENTOL POL, V38, P1; TURELLI M, 1984, THEOR POPUL BIOL, V25, P138, DOI 10.1016/0040-5809(84)90017-0; Waddington C., 1957, STRATEGY GENES; WAGNER GP, 1984, BIOSYSTEMS, V17, P51, DOI 10.1016/0303-2647(84)90015-7; WAGNER GP, 1988, J EVOLUTION BIOL, V1, P45, DOI 10.1046/j.1420-9101.1988.1010045.x; WAGNER GP, 1986, PATTERNS PROCESSES H, P149; Waxman D, 1998, SCIENCE, V279, P1210, DOI 10.1126/science.279.5354.1210; Williams G. C., 1966, P307	20	15	15	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 20	1998	279	5354					1158	1159		10.1126/science.279.5354.1158	http://dx.doi.org/10.1126/science.279.5354.1158			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9508689				2022-12-28	WOS:000072115200029
J	van der Kuy, PHM; Hooymans, PM; Verkaaik, AJB				van der Kuy, PHM; Hooymans, PM; Verkaaik, AJB			Nortriptyline intoxication induced by terbinafine	BRITISH MEDICAL JOURNAL			English	Letter									Maasland Hosp, Sittard, Netherlands; Inst Ambulatory Psychiat Care, Sittard, Netherlands	Maasland Hospital	van der Kuy, PHM (corresponding author), Maasland Hosp, Sittard, Netherlands.		van der Kuy, hugo/AAU-1973-2020	van der Kuy, hugo/0000-0002-7128-8801					0	33	33	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 7	1998	316	7129					441	441						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW874	9492672				2022-12-28	WOS:000071982700032
J	Curhan, GC; Willett, WC; Speizer, FE; Stampfer, MJ				Curhan, GC; Willett, WC; Speizer, FE; Stampfer, MJ			Beverage use and risk for kidney stones in women	ANNALS OF INTERNAL MEDICINE			English	Article						kidney calculi; beverages; fluid intake; coffee; alcoholic beverages	FOOD FREQUENCY QUESTIONNAIRE; DIETARY CALCIUM; CONSUMPTION; REPRODUCIBILITY; VALIDITY; NEPHROLITHIASIS; UROLITHIASIS; PREVENTION; DISEASE; JUICE	Background: An increase in fluid intake is routinely recommended for patients who have had kidney stones to decrease the likelihood of recurrence. However, data on the effect of particular beverages on stone formation in women are limited. Objective: To examine the association between the intake of 17 beverages and risk for kidney stones in women. Design: Prospective cohort study with 8 years of follow-up. Setting: United States. Participants: 81093 women in the Nurses' Health Study who were 40 to 65 years of age in 1986 and had no history of kidney stones. Measurements: Beverage use and diet were assessed in 1986 and 1990 with a validated, self-administered food-frequency questionnaire. The main outcome measure was incident symptomatic kidney stones. Results: During 553081 person-years of follow-up over an 8-year period, 719 cases of kidney stones were documented. After risk factors other than fluid intake were controlled for, the relative risk for stone formation for women in the highest quintile of total fluid intake compared with women in the lowest quintile was 0.62 (95% CI, 0.48 to 0.80). Inclusion of consumption of specific beverages in the multivariate model significantly added to prediction of risk for kidney stones (P < 0.001). In a multivariate model that adjusted simultaneously for the 17 beverages and other possible risk factors, risk for stone formation decreased by the following amount for each 240-mL (8-oz) serving consumed daily: 10% (CI, 5% to 15%) for caffeinated coffee, 9% (CI, 2% to 15%) for decaffeinated coffee, 8% (CI, 1% to 15%) for tea, and 59% (CI, 32% to 75%) for wine. In contrast, a 44% (CI, 9% to 92%) increase in risk was seen for each 240-mL serving of grapefruit juice consumed daily. Conclusions: An increase in total fluid intake can reduce risk for kidney stones, and the choice of beverage may be meaningful.	Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Curhan, GC (corresponding author), Brigham & Womens Hosp, Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.				NCI NIH HHS [CA40356] Funding Source: Medline; NIDDK NIH HHS [DK45362] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045362] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAILEY DG, 1994, CLIN PHARMACOKINET, V26, P91, DOI 10.2165/00003088-199426020-00002; BRINKLEY LJ, 1990, J UROLOGY, V144, P94, DOI 10.1016/S0022-5347(17)39377-1; BROADUS AE, 1979, NEW ENGL J MED, V300, P839, DOI 10.1056/NEJM197904123001507; Colditz G A, 1995, J Am Med Womens Assoc (1972), V50, P40; Curhan GC, 1996, AM J EPIDEMIOL, V143, P240, DOI 10.1093/oxfordjournals.aje.a008734; Curhan GC, 1997, ANN INTERN MED, V126, P497, DOI 10.7326/0003-4819-126-7-199704010-00001; CURHAN GC, 1993, NEW ENGL J MED, V328, P833, DOI 10.1056/NEJM199303253281203; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E; HASLING C, 1992, J NUTR, V122, P1119, DOI 10.1093/jn/122.5.1119; KASIDAS GP, 1980, J HUM NUTR, V34, P255; Krieger JN, 1996, AM J KIDNEY DIS, V28, P195, DOI 10.1016/S0272-6386(96)90301-7; LJUNGHALL S, 1988, EUR UROL, V14, P381; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MCKAY DW, 1995, J AM DIET ASSOC, V95, P360, DOI 10.1016/S0002-8223(95)00093-3; PAK CYC, 1980, ANN INTERN MED, V93, P36, DOI 10.7326/0003-4819-93-1-36; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; ROBERTSON GL, 1992, KIDNEY PHYSL PATHOPH; ROTHMAN KJ, 1986, MOERN EPIDEMIOLOGY; SALVINI S, 1989, INT J EPIDEMIOL, V18, P858, DOI 10.1093/ije/18.4.858; SHUSTER J, 1992, J CLIN EPIDEMIOL, V45, P911, DOI 10.1016/0895-4356(92)90074-W; SHUSTER J, 1985, J CHRON DIS, V38, P907, DOI 10.1016/0021-9681(85)90126-2; SMITH LH, 1978, NEW ENGL J MED, V298, P87, DOI 10.1056/NEJM197801122980207; Soucie JM, 1996, AM J EPIDEMIOL, V143, P487; STRAUSS AL, 1982, AM J MED, V72, P17, DOI 10.1016/0002-9343(82)90566-6; VANDERHORST G, 1984, S AFR MED J, V66, P755; WABNER CL, 1993, J UROLOGY, V149, P1405, DOI 10.1016/S0022-5347(17)36401-7; WEISS GH, 1992, UROLOGY, V39, P331, DOI 10.1016/0090-4295(92)90208-E; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; Willett W., 1990, NUTR EPIDEMIOLOGY; WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086	32	186	189	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1998	128	7					534	+		10.7326/0003-4819-128-7-199804010-00003	http://dx.doi.org/10.7326/0003-4819-128-7-199804010-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE539	9518397				2022-12-28	WOS:000072803500003
J	Quill, TE; Meier, DE; Block, SD; Billings, JA				Quill, TE; Meier, DE; Block, SD; Billings, JA			The debate over physician-assisted suicide: Empirical data and convergent views	ANNALS OF INTERNAL MEDICINE			English	Article							LIFE-SUSTAINING TREATMENT; CRITICALLY ILL PATIENTS; CANCER PAIN MANAGEMENT; MEDICAL ILLNESS; TERMINALLY ILL; HOPELESSLY ILL; WASHINGTON-STATE; EUTHANASIA; DEPRESSION; ATTITUDES	The debate over physician-assisted suicide is a small part of the process of improving care for all dying patients and their families. Available data, although limited, can help clarify this narrow debate and can provide a useful context for articulation of the common ground. This paper reviews these data, which suggest that unnecessary end-of-life suffering can be considerably reduced by improving access to and delivery of palliative care and improving recognition and treatment of pain and depression in terminally ill persons. It also sets forth possible areas of common ground between the two sides in the debate. Even with the best of care, a small number of dying patients will still have suffering that cannot be satisfactorily relieved, and some of these patients will request assistance in hastening death. Terminal sedation and the voluntary cessation of eating and drinking may be legally acceptable alternatives to physician-assisted suicide for the few patients whose suffering cannot be made tolerable with standard palliative interventions. Physicians should not violate their fundamental values when faced with such patients but should make patients aware of the full range of available alternatives to prolonged, intolerable distress. Physicians have the responsibility to give comprehensive palliative care to terminally ill patients and their families throughout the dying process and to make every effort to explore, understand, and address suffering that persists despite their best efforts.	Harvard Univ, Sch Med, Boston, MA 02215 USA; Univ Rochester, Sch Med & Dent, Rochester, NY USA; Mt Sinai Sch Med, New York, NY USA	Harvard University; Harvard Medical School; University of Rochester; Icahn School of Medicine at Mount Sinai	Quill, TE (corresponding author), Genesee Hosp, Dept Med, 224 Alexander St, Rochester, NY 14607 USA.		Van den Block, Lieve/D-1247-2011	Van den Block, Lieve/0000-0002-7770-348X				ACKERMAN F, 1991, HASTINGS CENT REP, V21, P27, DOI 10.2307/3562998; Allen JP, 1996, JAMA-J AM MED ASSOC, V275, P474; ALPERS A, 1995, JAMA-J AM MED ASSOC, V274, P483, DOI 10.1001/jama.274.6.483; *AM COLL PHYS ETH, 1992, ANN INTERN MED, V117, P946; American Board of Internal Medicine, 1996, CAR DYING ID PROM PH; American Thoracic Society, 1991, Ann Intern Med, V115, P478; Angell M, 1996, NEW ENGL J MED, V335, P1676, DOI 10.1056/NEJM199611283352209; Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; BALLE WF, 1993, CANCER, V72, P2786; BERNAT JL, 1993, ARCH INTERN MED, V153, P2723, DOI 10.1001/archinte.153.24.2723; Billings J A, 1993, Hosp J, V9, P69, DOI 10.1300/J011v09n01_06; Billings JA, 1996, J PALLIAT CARE, V12, P21, DOI 10.1177/082585979601200404; Billings JA, 1997, JAMA-J AM MED ASSOC, V278, P733, DOI 10.1001/jama.278.9.733; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; BLOCH SD, 1994, ARCH INTERN MED, V154, P2039, DOI 10.1001/archinte.154.18.2039; Bookbinder M, 1996, J PAIN SYMPTOM MANAG, V12, P334, DOI 10.1016/S0885-3924(96)00204-7; Breitbart W, 1996, AM J PSYCHIAT, V153, P238; BREITBART W, 1990, P 2 INT C CANC PAIN, V16; Brody H, 1997, NEW ENGL J MED, V336, P652, DOI 10.1056/NEJM199702273360910; BRODY H, 1992, NEW ENGL J MED, V327, P1384, DOI 10.1056/NEJM199211053271912; BURNS MM, 1994, PSYCHOSOMATICS, V35, P80, DOI 10.1016/S0033-3182(94)71811-9; Burt RA, 1997, NEW ENGL J MED, V337, P1234, DOI 10.1056/NEJM199710233371712; BYOCK I, 1997, DYING WELL PROSPECTS; CARALIS PV, 1993, J CLIN ETHIC, V4, P155; CASSEL EJ, 1982, NEW ENGL J MED, V306, P639, DOI 10.1056/NEJM198203183061104; Cherny N I, 1994, J Palliat Care, V10, P31; CHOCHINOV HM, 1994, AM J PSYCHIAT, V151, P537; CHOCHINOV HM, 1995, AM J PSYCHIAT, V152, P1185; Christakis NA, 1996, NEW ENGL J MED, V335, P172, DOI 10.1056/NEJM199607183350306; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; COHEN LM, 1995, ARCH INTERN MED, V155, P42, DOI 10.1001/archinte.155.1.42; CONWELL Y, 1991, NEW ENGL J MED, V325, P1100, DOI 10.1056/NEJM199110103251511; Covinsky KE, 1996, ARCH INTERN MED, V156, P1737, DOI 10.1001/archinte.156.15.1737; Coyle N, 1990, J Pain Symptom Manage, V5, P83; CUMMINGS NB, 1993, NEPHROLOGY UROLOGY A; DUBERSEIN PR, 1995, J AM GERIATR SOC, V43, P395, DOI 10.1111/j.1532-5415.1995.tb05814.x; EMANUEL EJ, 1994, NEW ENGL J MED, V330, P540, DOI 10.1056/NEJM199402243300806; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; Field MJ, 1997, APPROACHING DEATH IM; FOLEY KM, 1995, PAIN FORUM, V4, P163; GANZINI L, 1994, AM J PSYCHIAT, V151, P1631; Glantz L H, 1987, Law Med Health Care, V15, P231; Graber MA, 1996, J GEN INTERN MED, V11, P71, DOI 10.1007/BF02599581; Hanson LC, 1996, ARCH INTERN MED, V156, P785, DOI 10.1001/archinte.156.7.785; HARRIS EC, 1994, MEDICINE, V73, P281, DOI 10.1097/00005792-199411000-00001; *HEML SOC, 1991, ROP POLL W COAST EUT; Hendin H, 1997, JAMA-J AM MED ASSOC, V277, P1720, DOI 10.1001/jama.277.21.1720; Ingham JM, 1996, HEMATOL ONCOL CLIN N, V10, P21, DOI 10.1016/S0889-8588(05)70325-7; JADAD AR, 1995, JAMA-J AM MED ASSOC, V274, P1870, DOI 10.1001/jama.274.23.1870; KASTING GA, 1993, PHYSICIAN ASSISTED D, P25; KATHOL RG, 1990, PSYCHOSOMATICS, V31, P434, DOI 10.1016/S0033-3182(90)72140-8; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; LEE MA, 1992, J AM GERIATR SOC, V40, P983, DOI 10.1111/j.1532-5415.1992.tb04473.x; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; Lynn J, 1996, NEW ENGL J MED, V335, P201, DOI 10.1056/NEJM199607183350311; MASAND P, 1991, PSYCHOSOMATICS, V32, P203, DOI 10.1016/S0033-3182(91)72093-8; MASSIE MJ, 1994, J PAIN SYMPTOM MANAG, V9, P325, DOI 10.1016/0885-3924(94)90192-9; MAX MB, 1995, JAMA-J AM MED ASSOC, V274, P1874, DOI 10.1001/jama.1995.03530230060032; McGough P M, 1993, Camb Q Healthc Ethics, V2, P63; McKinley ED, 1996, J GEN INTERN MED, V11, P651, DOI 10.1007/BF02600155; MEIER D, IN PRESS N ENGL J ME; MEIER DE, 1993, PHYSICIAN ASSISTED D; MEISEL A, 1991, ARCH INTERN MED, V151, P1497, DOI 10.1001/archinte.151.8.1497; MERMANN AC, 1991, ACAD MED, V66, P35, DOI 10.1097/00001888-199101000-00010; MILLER DK, 1992, J GEN INTERN MED, V7, P475, DOI 10.1007/BF02599446; MORRISON RS, 1994, GENERATIONS      WIN, P48; NEU S, 1986, NEW ENGL J MED, V314, P14, DOI 10.1056/NEJM198601023140103; Orentlicher D, 1997, NEW ENGL J MED, V337, P1236, DOI 10.1056/NEJM199710233371713; *PRES COMM STUD ET, 1983, DEC FOR LIF TREATM R; PRINTZ LA, 1992, ARCH INTERN MED, V152, P697, DOI 10.1001/archinte.152.4.697; Quill T, 1996, MIDWIFE DYING PROCES; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; Quill TE, 1997, JAMA-J AM MED ASSOC, V278, P2099, DOI 10.1001/jama.278.23.2099; QUILL TE, 1995, ANN INTERN MED, V122, P368, DOI 10.7326/0003-4819-122-5-199503010-00008; Quill TE, 1993, DEATH DIGNITY MAKING; RAPPAPORT W, 1993, SURGERY, V113, P163; RHYMES J, 1990, JAMA-J AM MED ASSOC, V264, P369, DOI 10.1001/jama.264.3.369; RIE MA, 1991, HASTINGS CENT REP, V21, P24, DOI 10.2307/3562997; SEALE CF, 1989, SOC SCI MED, V28, P551, DOI 10.1016/0277-9536(89)90249-9; SHAPIRO RS, 1994, ARCH INTERN MED, V154, P575, DOI 10.1001/archinte.154.5.575; Slome LR, 1997, NEW ENGL J MED, V336, P417, DOI 10.1056/NEJM199702063360606; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; SULLIVAN MD, 1994, AM J PSYCHIAT, V151, P971; Teno JM, 1997, J AM GERIATR SOC, V45, P939, DOI 10.1111/j.1532-5415.1997.tb02963.x; TRUOG RD, 1992, NEW ENGL J MED, V327, P1678, DOI 10.1056/NEJM199212033272311; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; VANDERMAAS PJ, 1992, EUTHANASIS OTHER MED; Ventafridda V, 1990, J Palliat Care, V6, P7; WALLSTON KA, 1988, MED CARE, V26, P177, DOI 10.1097/00005650-198802000-00008; WANZER SH, 1984, NEW ENGL J MED, V310, P955, DOI 10.1056/NEJM198404123101505; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; WEIR RF, 1990, JAMA-J AM MED ASSOC, V264, P1846, DOI 10.1001/jama.264.14.1846; WILSON WC, 1992, JAMA-J AM MED ASSOC, V267, P949; WOODS SW, 1986, J CLIN PSYCHIAT, V47, P12; 1992, JAMA, V276, P2229	97	50	50	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1998	128	7					552	558		10.7326/0003-4819-128-7-199804010-00006	http://dx.doi.org/10.7326/0003-4819-128-7-199804010-00006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZE539	9518400				2022-12-28	WOS:000072803500006
J	Hamuryudan, V; Mat, C; Saip, S; Ozyazgan, Y; Siva, A; Yurdakul, S; Zwingenberger, K; Yazici, H				Hamuryudan, V; Mat, C; Saip, S; Ozyazgan, Y; Siva, A; Yurdakul, S; Zwingenberger, K; Yazici, H			Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome - A randomized, double-blind, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article						thalidomide; Behcet's syndrome; oral ulcer; dose-response relationship, drug; genital diseases, male	BRITISH PATIENTS; DISEASE; NEUROPATHY; RECURRENT; TURKISH	Background: Recurrent oral and genital ulcers are the most frequent problem in the management of the Behcet syndrome. Uncontrolled experience suggests that thalidomide may help prevent recurrences of these ulcers. Objective: To determine the efficacy of two thalidomide dosages in the treatment of mucocutaneous lesions of the Behcet syndrome. Design: Randomized, double-blind, placebo-controlled trial. Setting: Specialist outpatient clinic for the Behcet syndrome in Turkey. Patients: 96 male patients with the Behcet syndrome who primarily had mucocutaneous lesions without major organ involvement. Intervention: Thalidomide, 100 mg/d or 300 mg/d, or placebo for 24 weeks. Measurements: Sustained absence of any oral and genital ulceration during treatment (complete response) and changes in the number of mucocutaneous lesions. An additional evaluation was done 4 weeks after treatment ended. Results: A complete response occurred in 2 of the 32 patients (6% [95% CI, 0.8% to 20.8%]) receiving thalidomide, 100 mg/d; in 5 of the 31 patients (16% [CI, 5.5% to 33.7%]) receiving thalidomide, 300 mg/d; and in none of the 32 patients (0% [CI, 0% to 10.9%]) receiving placebo (P = 0.031). The suppressive effect of thalidomide with either dosage was evident at 4 weeks for oral ulcers (P < 0.001) and at 8 weeks for genital ulcers (P < 0.001) and follicular lesions (P = 0.008). This effect persisted during treatment but diminished rapidly after treatment was discontinued. Both thalidomide dosages led to significant increases in the number of erythema nodosum lesions during the first 8 weeks of treatment (P = 0.03). Polyneuropathy developed in 4 patients (1 in the 100-mg/d group and 3 in the 300-mg/d group); in 3 of these patients, the condition was diagnosed after the trial had ended. Conclusions: Thalidomide is effective for treating the oral and genital ulcers and follicular lesions of the Behcet syndrome. A dosage of 100 mg/d is as effective as a dosage of 300 mg/day.	Istanbul Univ, Cerrahpasa Med Fac, Behcets Syndrome Res Ctr, Dept Internal Med,Div Rheumatol, TR-34303 Istanbul, Turkey; Istanbul Univ, Cerrahpasa Med Fac, Dept Dermatol, TR-34303 Istanbul, Turkey; Istanbul Univ, Cerrahpasa Med Fac, Dept Neurol, TR-34303 Istanbul, Turkey; Istanbul Univ, Cerrahpasa Med Fac, Dept Ophthalmol, TR-34303 Istanbul, Turkey; Grunenthal GMBH, Div Med Sci, D-52220 Stolberg, Germany	Istanbul University; Istanbul University - Cerrahpasa; Istanbul University; Istanbul University - Cerrahpasa; Istanbul University; Istanbul University - Cerrahpasa; Istanbul University; Istanbul University - Cerrahpasa; Grunenthal Group	Hamuryudan, V (corresponding author), 100 Yil Sitesi 1 Blok D 16, TR-81190 Istanbul, Turkey.		SAİP, SABAHATTİN/AAE-2410-2021; Hamuryudan, Vedat/AAA-1100-2020; Yurdakul, Sebahattin/M-6927-2013; Siva, Aksel/A-5132-2016; YURDAKUL, SEBAHATTİN/AAY-1069-2020	Hamuryudan, Vedat/0000-0001-6625-1652; Siva, Aksel/0000-0002-8340-6641; 				AKTULGA E, 1980, HAEMATOLOGICA, V65, P399; DENMAN AM, 1993, INT CONGR SER, V1037, P649; Ehrlich G E, 1997, Int Rev Immunol, V14, P81, DOI 10.3109/08830189709116846; FULLERTON PM, 1968, J NEUROL NEUROSUR PS, V31, P543, DOI 10.1136/jnnp.31.6.543; GARDNERMEDWIN JMM, 1994, ANN RHEUM DIS, V53, P828, DOI 10.1136/ard.53.12.828; Hamuryudan V, 1997, BAILLIERE CLIN RHEUM, V11, P335, DOI 10.1016/S0950-3579(97)80049-0; HAMZA MH, 1986, CLIN RHEUMATOL, V5, P365, DOI 10.1007/BF02054255; HESS CW, 1986, J NEUROL, V233, P83, DOI 10.1007/BF00313852; Jacobson JM, 1997, NEW ENGL J MED, V336, P1487, DOI 10.1056/NEJM199705223362103; JORIZZO JL, 1986, ARCH INTERN MED, V146, P878, DOI 10.1001/archinte.146.5.878; KANEKO F, 1985, BRIT J DERMATOL, V113, P303, DOI 10.1111/j.1365-2133.1985.tb02082.x; MASCARO JM, 1979, ARCH DERMATOL, V115, P636, DOI 10.1001/archderm.1979.04010050060027; OCHONISKY S, 1994, ARCH DERMATOL, V130, P66, DOI 10.1001/archderm.130.1.66; POWELL RJ, 1994, POSTGRAD MED J, V70, P901, DOI 10.1136/pgmj.70.830.901; REVUZ J, 1990, ARCH DERMATOL, V126, P923, DOI 10.1001/archderm.126.7.923; SAYLAN T, 1982, ARCH DERMATOL, V118, P536, DOI 10.1001/archderm.118.8.536; SILMAN AJ, 1990, LANCET, V335, P1078; Tseng S, 1996, J AM ACAD DERMATOL, V35, P969, DOI 10.1016/S0190-9622(96)90122-X; VIRABEN R, 1988, DERMATOLOGICA, V176, P107, DOI 10.1159/000248682; YAZICI H, 1984, ANN RHEUM DIS, V43, P783, DOI 10.1136/ard.43.6.783; YAZICI H, 1990, NEW ENGL J MED, V322, P281, DOI 10.1056/NEJM199002013220501; YAZICI H, 1980, ANN RHEUM DIS, V39, P344, DOI 10.1136/ard.39.4.344; YAZICI H, 1995, CLIN IMMUNOTHER, V3, P102, DOI 10.1007/BF03259272; YAZICI H, 1984, ANN RHEUM DIS, V43, P74, DOI 10.1136/ard.43.1.74; Yurdakul S, 1996, ANN RHEUM DIS, V55, P208, DOI 10.1136/ard.55.3.208	25	335	353	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1998	128	6					443	+		10.7326/0003-4819-128-6-199803150-00004	http://dx.doi.org/10.7326/0003-4819-128-6-199803150-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA914	9499327				2022-12-28	WOS:000072414700004
J	Lell, B; Luckner, D; Ndjave, M; Scott, T; Kremsner, PG				Lell, B; Luckner, D; Ndjave, M; Scott, T; Kremsner, PG			Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children	LANCET			English	Article							PLASMODIUM-FALCIPARUM MALARIA; CHLOROQUINE; THERAPY; 566C80; GABON	Background The combination of atovaquone and proguanil is highly effective and safe for the treatment of Plasmodium falciparum malaria. We aimed in this randomised, double-blind, placebo-controlled study to assess the efficacy and safety of this combination for malaria prophylaxis. Methods 320 children who lived in a hyperendemic area for P falciparum malaria were stratified by weight and randomly assigned atovaquone plus proguanil or placebo once daily for 12 weeks. All children received initial curative treatment with atovaquone and proguanil before the start of chemosuppression. We recorded adverse events daily and collected thick blood smears once a week. The primary endpoint was a positive blood smear. Findings 25 of 140 children in the placebo group and none of the 125 children in the atovaquone plus proguanil group had positive smears during chemosuppression (p<0.001). Adverse events during the chemosuppression phase did not differ between the groups. Interpretation The combination of atovaquone plus proguanil is a highly effective and well-tolerated chemosuppressive antimalarial in children. This drug combination could replace current regimens.	Univ Tubingen, Inst Trop Med, Dept Parasitol, D-72074 Tubingen, Germany; Albert Schweitzer Hosp, Res Unit, Lambarene, Gabon; Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA	Eberhard Karls University of Tubingen; GlaxoSmithKline	Kremsner, PG (corresponding author), Univ Tubingen, Inst Trop Med, Dept Parasitol, D-72074 Tubingen, Germany.							ALENCAR FEC, 1997, J INFECT DIS, V175, P1544; Bloland PB, 1997, LANCET, V350, P1624, DOI 10.1016/S0140-6736(97)06082-0; CANFIELD CJ, 1995, EXP PARASITOL, V80, P373, DOI 10.1006/expr.1995.1049; EDERER F, 1974, AM J EPIDEMIOL, V100, P165, DOI 10.1093/oxfordjournals.aje.a112024; FAIRLEY NH, 1946, T ROY SOC TROP MED H, V40, P105, DOI 10.1016/0035-9203(46)90052-1; FAWAZ G, 1951, AM J TROP MED, V31, P569; Foege WH, 1997, LANCET, V350, P1628, DOI 10.1016/S0140-6736(05)64045-7; FRY M, 1992, BIOCHEM PHARMACOL, V43, P1545, DOI 10.1016/0006-2952(92)90213-3; HUGHES W, 1993, NEW ENGL J MED, V328, P1521, DOI 10.1056/NEJM199305273282103; Hussein Z, 1997, CLIN PHARMACOL THER, V61, P518, DOI 10.1016/S0009-9236(97)90132-6; Hussein Z, 1996, BRIT J CLIN PHARMACO, V42, P589, DOI 10.1111/j.1365-2125.1996.tb00114.x; KREMSNER PG, 1988, J INFECT DIS, V158, P1368, DOI 10.1093/infdis/158.6.1368; KREMSNER PG, 1994, J INFECT DIS, V169, P467, DOI 10.1093/infdis/169.2.467; Looareesuwan S, 1996, AM J TROP MED HYG, V54, P62, DOI 10.4269/ajtmh.1996.54.62; Menendez C, 1997, LANCET, V350, P844, DOI 10.1016/S0140-6736(97)04229-3; Radloff PD, 1996, LANCET, V347, P1511, DOI 10.1016/S0140-6736(96)90671-6; Radloff PD, 1996, T ROY SOC TROP MED H, V90, P682, DOI 10.1016/S0035-9203(96)90435-6; Torres RA, 1997, CLIN INFECT DIS, V24, P422, DOI 10.1093/clinids/24.3.422; WILDLING E, 1995, TROP MED PARASITOL, V46, P77; Wolday D, 1995, T ROY SOC TROP MED H, V89, P654, DOI 10.1016/0035-9203(95)90431-X; World Health Organization, 1997, Weekly Epidemiological Record, V72, P269	21	102	102	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 7	1998	351	9104					709	713		10.1016/S0140-6736(97)09222-2	http://dx.doi.org/10.1016/S0140-6736(97)09222-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB359	9504515				2022-12-28	WOS:000072463800008
J	Hossain, S; Biswas, R; Kabir, I; Sarker, S; Dibley, M; Fuchs, G; Mahalanabis, D				Hossain, S; Biswas, R; Kabir, I; Sarker, S; Dibley, M; Fuchs, G; Mahalanabis, D			Single dose vitamin A treatment in acute shigellosis in Bangladeshi children: randomised double blind controlled trial	BRITISH MEDICAL JOURNAL			English	Article							A SUPPLEMENTATION; CHILDHOOD MORTALITY; NALIDIXIC-ACID; PROTEIN LOSS; DIARRHEA; INFECTION; MEASLES; DEFICIENCY; MORBIDITY; DYSENTERY	Objective: To evaluate the efficacy of a single large oral dose of vitamin A in treating acute shigellosis in children in Bangladesh. Design: Randomised double blind controlled clinical trial. Setting: Dhaka Hospital, International Centre for Diarrhoeal Disease Research, Bangladesh. Subjects: 83 children aged 1-7 years with bacteriologically proved shigellosis but no clinical signs of vitamin A deficiency; 42 were randomised to treatment with vitamin A and 41 formed a control group. Intervention: Children were given a single oral dose of 200 000 IU of vitamin A plus 25 IU vitamin E or a control preparation of 25 IU vitamin E. Main outcome measures: Clinical cure on study day 5 and bacteriological cure. Results: Baseline characteristics of the subjects in the two treatment groups were similar. Significantly more children in the vitamin A group than in the control group achieved clinical cure (19/42 (45%) v 8/14 (20%); chi(2)=5.14, 1 df, P=0.02; risk ratio=0.68 (95% confidence interval: 0.50 to 0.93)). When cure was determined bacteriologically, the groups had similar rates (16/42 (38%) v 16/41 (39%); chi(2)-0.02, 1 df, P=0.89; risk ratio=0.98 (0.70 to 1.39)). Conclusions: Vitamin a reduces the severity of acute shigellosis in children living in areas where vitamin A deficiency is a major public health problem.	Int Ctr Diarrhoeal Dis Res, Div Clin Sci, Dhaka 1000, Bangladesh; Univ Newcastle, Ctr Clin Epidemiol & Biostat, Newcastle, NSW 2300, Australia	International Centre for Diarrhoeal Disease Research (ICDDR); University of Newcastle	Hossain, S (corresponding author), Int Ctr Diarrhoeal Dis Res, Div Clin Sci, GPO Box 128, Dhaka 1000, Bangladesh.		Fuchs, George/GLV-1285-2022	Fuchs, George/0000-0002-8679-8265				ALAM AN, 1994, SCAND J GASTROENTERO, V29, P313, DOI 10.3109/00365529409094842; BARCLAY AJG, 1987, BMJ-BRIT MED J, V294, P294, DOI 10.1136/bmj.294.6567.294; BARKER BM, 1983, VITAMINS MED, V2, P211; BARRETO ML, 1994, LANCET, V344, P228, DOI 10.1016/S0140-6736(94)92998-X; BENNISH ML, 1990, J INFECT DIS, V162, P711, DOI 10.1093/infdis/162.3.711; BENNISH ML, 1991, REV INFECT DIS, V13, pS319; BENNISH ML, 1993, AM J GASTROENTEROL, V88, P53; BLACK RE, 1991, NUTR RES, V11, P1215, DOI 10.1016/S0271-5317(05)80540-8; BLACK RE, 1984, PEDIATRICS, V73, P799; CAMPOS FACS, 1987, AM J CLIN NUTR, V46, P91, DOI 10.1093/ajcn/46.1.91; Chandra R. K., 1981, Nutrient Research, V1, P181, DOI 10.1016/S0271-5317(81)80100-5; *COMM ISS PRIOR NE, 1986, NEW VACC DEV EST PRI, V2, P165; COUTSOUDIS A, 1991, AM J CLIN NUTR, V54, P890, DOI 10.1093/ajcn/54.5.890; COUTSOUDIS A, 1992, PEDIATR INFECT DIS J, V11, P203, DOI 10.1097/00006454-199203000-00006; DANTON H, 1988, HLTH POLICY PLANN, V3, P205; DAULAIRE NMP, 1992, BMJ-BRIT MED J, V304, P207, DOI 10.1136/bmj.304.6821.207; DELUCA L, 1969, J BIOL CHEM, V244, P701; DELUCA L, 1972, CANCER, V30, P1326, DOI 10.1002/1097-0142(197211)30:5<1326::AID-CNCR2820300527>3.0.CO;2-J; DUPONT WD, 1990, CONTROL CLIN TRIALS, V11, P116, DOI 10.1016/0197-2456(90)90005-M; Ghana VAST study Team, 1993, LANCET, V342, P7; GLAZIOU PP, 1993, BRIT MED J, V306, P366; HATCHIGIAN EA, 1989, P SOC EXP BIOL MED, V191, P47; HENNING B, 1992, EUR J CLIN NUTR, V46, P437; HENRY FJ, 1987, HUM NUTR-CLIN NUTR, V41C, P243; HUSSEY GD, 1990, NEW ENGL J MED, V323, P160, DOI 10.1056/NEJM199007193230304; KEUSCH GT, 1982, BACTERIAL INFECTIONS, P487; LEVINE MM, 1973, J INFECT DIS, V127, P261, DOI 10.1093/infdis/127.3.261; LEVINE MM, 1986, REV INFECT DIS, V8, pS207; MATHAN MM, 1986, AM J PATHOL, V123, P25; MILTON RC, 1987, AM J CLIN NUTR, V46, P827, DOI 10.1093/ajcn/46.5.827; MOLLA A, 1983, J PEDIATR-US, V103, P1000, DOI 10.1016/S0022-3476(83)80740-9; MUHILAL PD, 1988, AM J CLIN NUTR, V48, P1271; NAUSS KM, 1979, J NUTR, V109, P1815, DOI 10.1093/jn/109.10.1815; OLSON JA, 1972, ISRAEL J MED SCI, V8, P1170; RAHMAN MM, 1975, J INFECT DIS, V132, P15; RAHMATHULLAH L, 1990, NEW ENGL J MED, V323, P929, DOI 10.1056/NEJM199010043231401; REDDY V, 1986, B WORLD HEALTH ORGAN, V64, P721; SALAM MA, 1988, J PEDIATR-US, V113, P901, DOI 10.1016/S0022-3476(88)80029-5; SIVAKUMAR B, 1972, BRIT J NUTR, V27, P299, DOI 10.1079/BJN19720094; SOMMER A, 1986, LANCET, V1, P1169; SPEELMAN P, 1984, J INFECT DIS, V150, P899, DOI 10.1093/infdis/150.6.899; STEPHENSEN CB, 1994, AM J CLIN NUTR, V60, P388, DOI 10.1093/ajcn/60.3.388; WEST KP, 1991, LANCET, V338, P67, DOI 10.1016/0140-6736(91)90070-6; Wolbach SB, 1925, J EXP MED, V42, P753, DOI 10.1084/jem.42.6.753; World Health Organization, 1983, WHOCDD833; ZILE M, 1977, J NUTR, V107, P552, DOI 10.1093/jn/107.4.552	46	30	32	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 7	1998	316	7129					422	426		10.1136/bmj.316.7129.422	http://dx.doi.org/10.1136/bmj.316.7129.422			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW874	9492664	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000071982700022
J	Paterson-Brown, S				Paterson-Brown, S			Education about the hymen is needed - Commentary	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Queen Charlottes & Chelsea Hosp, London W6 0XG, England	Imperial College London	Paterson-Brown, S (corresponding author), Queen Charlottes & Chelsea Hosp, London W6 0XG, England.	s.paterson-brown@rpms.ac.uk						Adler MW, 1997, BRIT MED J, V314, P1743, DOI 10.1136/bmj.314.7096.1743; DeCock KM, 1997, BRIT MED J, V314, P1747, DOI 10.1136/bmj.314.7096.1747; EMANS SJ, 1994, J PEDIATR-US, V125, P153, DOI 10.1016/S0022-3476(94)70144-X; Fenton K, 1997, BRIT MED J, V314, P1703, DOI 10.1136/bmj.314.7096.1703; Kandela P, 1996, LANCET, V347, P1615, DOI 10.1016/S0140-6736(96)91096-X; Lacey CJN, 1997, BRIT MED J, V314, P1715, DOI 10.1136/bmj.314.7096.1715; Low N, 1997, BRIT MED J, V314, P1719, DOI 10.1136/bmj.314.7096.1719; UNDERHILL RA, 1978, LANCET, V1, P375, DOI 10.1016/S0140-6736(78)91094-2	8	18	17	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 7	1998	316	7129					461	461		10.1136/bmj.316.7129.461	http://dx.doi.org/10.1136/bmj.316.7129.461			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW874	9492680	Green Published			2022-12-28	WOS:000071982700046
J	Torrens, JK; McWhinney, PH				Torrens, JK; McWhinney, PH			Parotid swelling and terbinafine	BRITISH MEDICAL JOURNAL			English	Letter									Seacroft Hosp, Leeds LS14 6UH, W Yorkshire, England		Torrens, JK (corresponding author), Seacroft Hosp, Leeds LS14 6UH, W Yorkshire, England.			McWhinney, Paul/0000-0001-6232-2265				BALFOUR JA, 1992, DRUGS, V43, P259, DOI 10.2165/00003495-199243020-00010; BEUTLER M, 1993, BRIT MED J, V307, P26, DOI 10.1136/bmj.307.6895.26-b; Davies D., 1985, TXB ADVERSE DRUG REA, P18; LOWE G, 1993, BRIT MED J, V306, P248, DOI 10.1136/bmj.306.6872.248-a; MARTIN SD, 1993, BRIT J HOSP MED, V50, P426	5	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 7	1998	316	7129					440	441		10.1136/bmj.316.7129.440a	http://dx.doi.org/10.1136/bmj.316.7129.440a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW874	9492671	Green Published			2022-12-28	WOS:000071982700031
J	Hamman, BD; Hendershot, LM; Johnson, AE				Hamman, BD; Hendershot, LM; Johnson, AE			BiP maintains the permeability barrier of the ER membrane by sealing the lumenal end of the translocon pore before and early in translocation	CELL			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; PROTEIN DISULFIDE-ISOMERASE; SECRETORY PROTEINS; YEAST; COMPLEX; BINDING; TRANSPORT; CO	Secretory proteins are cotranslationally translocated across the mammalian ER membrane through an aqueous pore in the translocon while the permeability barrier is maintained by a tight ribosome-membrane junction. The lumenal end of the pore is also blocked early in translocation. Extraction of soluble lumenal proteins from microsomes and reconstitution with purified proteins demonstrate, by fluorescence collisional quenching, that BiP seals the lumenal end of this pore. BiP also seals translocons that are assembled but are not engaged in translocation. These ribosome-free translocons have smaller pores (9-15 Angstrom diameter versus 40-60 Angstrom in functioning translocons) and are generated when ribosomes dissociate from functioning translocons with large pores. BiP therefore maintains the permeability barrier by sealing both nontranslocating and newly targeted translocons.	Texas A&M Univ, Dept Med Biochem & Genet, College Stn, TX 77843 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38105 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; St Jude Children's Research Hospital	Johnson, AE (corresponding author), Texas A&M Univ, Dept Med Biochem & Genet, College Stn, TX 77843 USA.		Hendershot, Linda/N-8124-2018; Johnson, Arthur E/G-3457-2012	Hendershot, Linda/0000-0002-5473-0274; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026494, R01GM054068] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 26494, GM 54068] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; Bell CE, 1996, BIOCHEMISTRY-US, V35, P1137, DOI 10.1021/bi9520848; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; BRODSKY JL, 1995, P NATL ACAD SCI USA, V92, P9643, DOI 10.1073/pnas.92.21.9643; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; Corsi AK, 1997, J CELL BIOL, V137, P1483, DOI 10.1083/jcb.137.7.1483; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; CSERMELY P, 1995, J BIOL CHEM, V270, P6381, DOI 10.1074/jbc.270.11.6381; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Hamman BD, 1997, CELL, V89, P535, DOI 10.1016/S0092-8674(00)80235-4; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; Hendershot L, 1996, P NATL ACAD SCI USA, V93, P5269, DOI 10.1073/pnas.93.11.5269; Johnson AE, 1997, TRENDS CELL BIOL, V7, P90, DOI 10.1016/S0962-8924(97)01029-5; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; Liao SR, 1997, CELL, V90, P31, DOI 10.1016/S0092-8674(00)80311-6; Lyman SK, 1997, CELL, V88, P85, DOI 10.1016/S0092-8674(00)81861-9; MAYINGER P, 1995, J CELL BIOL, V131, P1377, DOI 10.1083/jcb.131.6.1377; NGUYEN TH, 1991, P NATL ACAD SCI USA, V88, P1565, DOI 10.1073/pnas.88.4.1565; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; PAVER JL, 1989, BIOCHEM J, V257, P657, DOI 10.1042/bj2570657; Powers T, 1996, CURR BIOL, V6, P331, DOI 10.1016/S0960-9822(02)00484-0; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; ROWLING PJE, 1994, PROTEIN EXPRES PURIF, V5, P331, DOI 10.1006/prep.1994.1049; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SIMONS JF, 1995, J CELL BIOL, V130, P41, DOI 10.1083/jcb.130.1.41; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WEI JY, 1995, J BIOL CHEM, V270, P26670, DOI 10.1074/jbc.270.44.26670	33	345	350	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 20	1998	92	6					747	758		10.1016/S0092-8674(00)81403-8	http://dx.doi.org/10.1016/S0092-8674(00)81403-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZD198	9529251	Bronze			2022-12-28	WOS:000072661200008
J	MacBeath, G; Kast, P; Hilvert, D				MacBeath, G; Kast, P; Hilvert, D			Redesigning enzyme topology by directed evolution	SCIENCE			English	Article							CHORISMATE MUTASE; PROTEIN; DOMAIN; SELECTION; MECHANISM; CREATION; SEQUENCE; MONOMER; SITE; ROP	Genetic selection was exploited in combination with structure-based design to transform an intimately entwined, dimeric chorismate mutase into a monomeric, four-helix-bundle protein with near native activity. Successful reengineering depended on choosing a thermostable starting protein, introducing point mutations that preferentially destabilize the wild-type dimer, and using directed evolution to optimize an inserted interhelical turn, Contrary to expectations based on studies of other four-helix-bundle proteins, only a small fraction of possible turn sequences (fewer than 0.05 percent) yielded well-behaved, monomeric, and highly active enzymes, Selection for catalytic function thus provides an efficient yet stringent method for rapidly assessing correctly folded polypeptides and may prove generally useful for protein design.	Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Hilvert, D (corresponding author), Swiss Fed Inst Technol ETH, Dept Chem, CH-8092 Zurich, Switzerland.							Albright RA, 1996, BIOCHEMISTRY-US, V35, P735, DOI 10.1021/bi951958n; BENNETT MJ, 1994, P NATL ACAD SCI USA, V91, P3127, DOI 10.1073/pnas.91.8.3127; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BORCHERT TV, 1994, P NATL ACAD SCI USA, V91, P1515, DOI 10.1073/pnas.91.4.1515; Braisted AC, 1996, P NATL ACAD SCI USA, V93, P5688, DOI 10.1073/pnas.93.12.5688; BRUNET AP, 1993, NATURE, V364, P355, DOI 10.1038/364355a0; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CASTAGNOLI L, 1994, J MOL BIOL, V237, P378, DOI 10.1006/jmbi.1994.1241; Dickason RR, 1996, NATURE, V379, P652, DOI 10.1038/379652a0; DIDONATO A, 1994, J BIOL CHEM, V269, P17394; FACBEATH G, UNPUB; Galopin CC, 1996, TETRAHEDRON LETT, V37, P8675, DOI 10.1016/S0040-4039(96)02007-2; Galopin CC, 1997, TETRAHEDRON LETT, V38, P1467; Gu W, 1997, Microb Comp Genomics, V2, P141, DOI 10.1089/omi.1.1997.2.141; Haslam E., 1993, SHIKIMIC ACID METABO; Kast P, 1996, P NATL ACAD SCI USA, V93, P5043, DOI 10.1073/pnas.93.10.5043; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LEE AY, 1995, J AM CHEM SOC, V117, P3627, DOI 10.1021/ja00117a038; MacBeath G, 1998, PROTEIN SCI, V7, P325; MOSSING MC, 1990, SCIENCE, V250, P1712, DOI 10.1126/science.2148648; NEET KE, 1994, PROTEIN SCI, V3, P2167, DOI 10.1002/pro.5560031202; Oakley MG, 1997, BIOCHEMISTRY-US, V36, P2544, DOI 10.1021/bi962391t; PICCOLI R, 1992, P NATL ACAD SCI USA, V89, P1870, DOI 10.1073/pnas.89.5.1870; PREDKI PF, 1995, BIOCHEMISTRY-US, V34, P9834, DOI 10.1021/bi00031a003; Schliebs W, 1997, BIOCHEMISTRY-US, V36, P9655, DOI 10.1021/bi963086a; TRINKL S, 1994, PROTEIN SCI, V3, P1392, DOI 10.1002/pro.5560030905	27	102	109	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 20	1998	279	5358					1958	1961		10.1126/science.279.5358.1958	http://dx.doi.org/10.1126/science.279.5358.1958			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506949				2022-12-28	WOS:000072613300052
J	Stipe, BC; Rezaei, MA; Ho, W				Stipe, BC; Rezaei, MA; Ho, W			Inducing and viewing the rotational motion of a single molecule	SCIENCE			English	Article							SCANNING TUNNELING MICROSCOPE; SURFACE; PT(111); MANIPULATION; OXYGEN	Tunneling electrons from the tip of a scanning tunneling microscope were used to induce and monitor the reversible rotation of single molecules of molecular oxygen among three equivalent orientations on the platinum(111) surface. Detailed studies of the rotation rates indicate a crossover from a single-electron process to a multielectron process below a threshold tunneling voltage. Values for the energy barrier to rotation and the vibrational relaxation rate of the molecule were obtained by comparing the experimental data with a theoretical model. The ability to induce the controlled motion of single molecules enhances our understanding of basic chemical processes on surfaces and may lead to useful single-molecule devices.	Cornell Univ, Atom & Solid State Phys Lab, Ithaca, NY 14853 USA; Cornell Univ, Ctr Mat Sci, Ithaca, NY 14853 USA	Cornell University; Cornell University	Ho, W (corresponding author), Cornell Univ, Atom & Solid State Phys Lab, Ithaca, NY 14853 USA.							AVOURIS P, 1995, ACCOUNTS CHEM RES, V28, P95, DOI 10.1021/ar00051a002; Bartels L, 1997, PHYS REV LETT, V79, P697, DOI 10.1103/PhysRevLett.79.697; CROMMIE MF, 1993, SCIENCE, V262, P218, DOI 10.1126/science.262.5131.218; Eichler A, 1997, PHYS REV LETT, V79, P4481, DOI 10.1103/PhysRevLett.79.4481; EIGLER DM, 1991, NATURE, V352, P600, DOI 10.1038/352600a0; EIGLER DM, 1990, NATURE, V344, P524, DOI 10.1038/344524a0; Gao SW, 1997, PHYS REV B, V55, P4825, DOI 10.1103/PhysRevB.55.4825; GLAND JL, 1980, SURF SCI, V95, P587, DOI 10.1016/0039-6028(80)90197-1; Jung TA, 1996, SCIENCE, V271, P181, DOI 10.1126/science.271.5246.181; MO YW, 1993, SCIENCE, V261, P886, DOI 10.1126/science.261.5123.886; PUGLIA C, 1995, SURF SCI, V342, P119, DOI 10.1016/0039-6028(95)00798-9; SALAM GP, 1994, PHYS REV B, V49, P10655, DOI 10.1103/PhysRevB.49.10655; STEININGER H, 1982, SURF SCI, V123, P1, DOI 10.1016/0039-6028(82)90124-8; Stipe BC, 1997, J CHEM PHYS, V107, P6443, DOI 10.1063/1.474304; Stipe BC, 1997, PHYS REV LETT, V78, P4410, DOI 10.1103/PhysRevLett.78.4410; Stipe BC, 1997, PHYS REV LETT, V79, P4397, DOI 10.1103/PhysRevLett.79.4397; STROSCIO JA, 1991, SCIENCE, V254, P1319, DOI 10.1126/science.254.5036.1319	17	346	352	8	88	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 20	1998	279	5358					1907	1909		10.1126/science.279.5358.1907	http://dx.doi.org/10.1126/science.279.5358.1907			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506935				2022-12-28	WOS:000072613300038
J	Wallin, JJ; Gackstetter, ER; Koshland, ME				Wallin, JJ; Gackstetter, ER; Koshland, ME			Dependence of BSAP repressor and activator functions on BSAP concentration	SCIENCE			English	Article							B-CELL DIFFERENTIATION; J-CHAIN GENE; TRANSCRIPTION FACTOR BSAP; IMMUNOGLOBULIN-J-CHAIN; 3'ALPHA ENHANCER; NF-HB; EXPRESSION; PROMOTER; INTERLEUKIN-2; BINDING	During a B cell immune response, the transcription factor BSAP maintains its activator functions but is relieved of its repressor functions. This selective targeting of BSAP activities was shown to be regulated by a concentration-dependent mechanism whereby activator motifs for BSAP had a 20-fold higher binding affinity than repressor motifs. An exchange of activator and repressor motifs, however, showed that the context of the motif, rather than the affinity, determined whether BSAP operated as an activator or repressor.	Univ Calif Berkeley, Dept Mol & Cell Biol, Div Immunol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Wallin, JJ (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Immunol, Berkeley, CA 94720 USA.			Wallin, Jeffrey/0000-0002-5952-3813	NCI NIH HHS [CA09179] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009179] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBERIS A, 1990, GENE DEV, V4, P849, DOI 10.1101/gad.4.5.849; BUSSLINGER M, 1995, CURR OPIN GENET DEV, V5, P595, DOI 10.1016/0959-437X(95)80028-X; COGNE M, 1994, CELL, V77, P737, DOI 10.1016/0092-8674(94)90057-4; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; DURAND DB, 1987, J EXP MED, V165, P395, DOI 10.1084/jem.165.2.395; Gaffen SL, 1996, CYTOKINE, V8, P513, DOI 10.1006/cyto.1996.0070; Gray S, 1996, CURR OPIN CELL BIOL, V8, P358; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; LAMSON G, 1984, J EXP MED, V160, P877, DOI 10.1084/jem.160.3.877; LANSFORD RD, 1992, P NATL ACAD SCI USA, V89, P5966, DOI 10.1073/pnas.89.13.5966; LLAO F, 1994, J IMMUNOL, V152, P2904; MCFADDEN HJ, 1991, P NATL ACAD SCI USA, V88, P11027, DOI 10.1073/pnas.88.24.11027; Michaelson JS, 1996, J IMMUNOL, V156, P2349; NEURATH MF, 1995, IMMUNOL TODAY, V16, P564, DOI 10.1016/0167-5699(95)80078-6; NEURATH MF, 1994, J IMMUNOL, V153, P730; NILES MJ, 1995, P NATL ACAD SCI USA, V92, P2884, DOI 10.1073/pnas.92.7.2884; Rinkenberger JL, 1996, IMMUNITY, V5, P377, DOI 10.1016/S1074-7613(00)80263-0; Sambrook J., 2002, MOL CLONING LAB MANU; Sato S, 1997, J IMMUNOL, V158, P4662; SINGH M, 1993, MOL CELL BIOL, V13, P3611, DOI 10.1128/MCB.13.6.3611; SMALL S, 1991, GENE DEV, V5, P827, DOI 10.1101/gad.5.5.827; Small S, 1991, CURR OPIN GENET DEV, V1, P255, DOI 10.1016/S0959-437X(05)80079-6; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; Usui T, 1997, J IMMUNOL, V158, P3197	25	48	52	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 20	1998	279	5358					1961	1964		10.1126/science.279.5358.1961	http://dx.doi.org/10.1126/science.279.5358.1961			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506950				2022-12-28	WOS:000072613300053
J	Zhang, YP; Xiong, Y; Yarbrough, WG				Zhang, YP; Xiong, Y; Yarbrough, WG			ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways	CELL			English	Article							CELL-CYCLE CONTROL; RETINOBLASTOMA PROTEIN; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; GENE-PRODUCT; CANCER; COMPLEX; UBIQUITINATION; AMPLIFICATION; EXPRESSION	The INK4a-ARF locus encodes two unrelated proteins that both function in tumor suppression. p16(INK4a) binds to and inhibits the activity of CDK4 and CDK6, and ARF arrests the cell cycle in a p53-dependent manner. We show here that ARF binds to MDM2 and promotes the rapid degradation of MDM2. This interaction is mediated by the exon 1 beta-encoded N-terminal domain of ARF and a C-terminal region of MDM2. ARF-promoted MDM2 degradation is associated with MDM2 modification and concurrent p53 stabilization and accumulation. The functional consequence of ARF-regulated p53 levels via MDM2 proteolysis is evidenced by the ability of ectopically expressed ARF to restore a; p53-imposed G1 cell cycle arrest that is otherwise abrogated by MDM2. Thus, deletion of the ARF-INK4a locus simultaneously impairs both the INK4a-cyclin D/CDK4-RB and the ARF-MDM2-p53 pathways.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Program Mol Biol & Biotechnol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Surg, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Xiong, Y (corresponding author), Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.		高, 雨莉/HGU-8187-2022		NATIONAL CANCER INSTITUTE [R01CA065572, K08CA072968] Funding Source: NIH RePORTER; NCI NIH HHS [KO8-CA72968, R01-CA65572] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BUTZ K, 1995, ONCOGENE, V10, P927; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; DURO D, 1995, ONCOGENE, V11, P21; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GOTTLIEB MT, 1996, BIOCHIM BIOPHYS ACTA, V1287, P77; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JENKINS CW, 1995, CELL CYCLE MAT METHO, P250; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KATO J, 1993, GENE DEV, V7, P331; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LEACH FS, 1993, CANCER RES, V53, P2231; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LUNA RMD, 1995, NATURE, V378, P203; Maki CG, 1996, CANCER RES, V56, P2649; MAO L, 1995, CANCER RES, V55, P2995; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; QUELLE DE, 1997, P NATL ACAD SCI USA, V94, P3436; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; STONE S, 1995, CANCER RES, V55, P2988; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XIONG Y, 1993, GENE DEV, V7, P1527; Yarbrough WG, 1996, J NATL CANCER I, V88, P1489, DOI 10.1093/jnci/88.20.1489	47	1331	1370	2	54	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 20	1998	92	6					725	734		10.1016/S0092-8674(00)81401-4	http://dx.doi.org/10.1016/S0092-8674(00)81401-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZD198	9529249	Bronze, Green Published			2022-12-28	WOS:000072661200006
J	Okuda-Ashitaka, E; Minami, T; Tachibana, S; Yoshihara, Y; Nishiuchi, Y; Kimura, T; Ito, S				Okuda-Ashitaka, E; Minami, T; Tachibana, S; Yoshihara, Y; Nishiuchi, Y; Kimura, T; Ito, S			Nocistatin, a peptide that blocks nociceptin action in pain transmission	NATURE			English	Article							OPIOID RECEPTOR FAMILY; ORPHANIN-FQ; TISSUE DISTRIBUTION; REGIONAL DISTRIBUTION; PROSTAGLANDIN E(2); MOLECULAR-CLONING; GENE; NEUROPEPTIDE; PRECURSOR; MEMBER	Prolonged tissue damage or injury often leads to chronic pain states such that noxious stimuli evoke hyperalgesia and innocuous tactile stimuli evoke pain (allodynia)(1,2), The neuropeptide nociceptin(3,4), also known as orphanin FQ (ref. 5), is an endogenous ligand for the orphan opioid-like receptor(6-8) which induces both hyperalgesia and allodynia when administered by injection through the theca of the spinal cord into the subarachnoid space (that is, intrathecally)(4,9). Here we show that the nociceptin precursor(3,10-13) contains another biologically active peptide which we call nocistatin, Nocistatin blocks nociceptin-induced allodynia and hyperalgesia, and attenuates pain evoked by prostaglandin E-2. It is the carboxy-terminal hexapeptide of nocistatin (Glu-Gln-Lys-Gln-Leu-Gin), which is conserved in bovine, human and murine species, that possesses allodynia-blocking activity, We have also isolated endogenous nocistatin from bovine brain, Furthermore, intrathecal pretreatment with anti-nocistatin antibody decreases the threshold for nociceptin-induced allodynia, Although nocistatin does not bind to the nociceptin receptor, it binds to the membrane of mouse brain and of spinal cord with high affinity, Our results show that nocistatin is a new biologically active peptide produced from the same precursor as nociceptin and indicate that these two peptides may play opposite roles in pain transmission.	Kansai Med Univ, Dept Med Chem, Moriguchi, Osaka 570, Japan; Osaka Med Coll, Dept Anesthesiol, Takatsuki, Osaka 569, Japan; Osaka Med Coll, Dept Biochem, Takatsuki, Osaka 569, Japan; Natl Univ Singapore, Sch Biol Sci, Singapore 119260, Singapore; Osaka Biosci Inst, Dept Neurosci, Suita, Osaka 565, Japan; Prot Res Fdn, Peptide Inst Inc, Minoh 562, Japan	Kansai Medical University; Osaka Medical College; Osaka Medical College; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; National University of Singapore	Ito, S (corresponding author), Kansai Med Univ, Dept Med Chem, Moriguchi, Osaka 570, Japan.		Yoshihara, Yoshihiro/N-6481-2015	Yoshihara, Yoshihiro/0000-0002-0319-7166				AMANO F, 1988, J CELL PHYSIOL, V135, P502, DOI 10.1002/jcp.1041350319; BUNZOW JR, 1994, FEBS LETT, V347, P284, DOI 10.1016/0014-5793(94)00561-3; DRAY A, 1994, TRENDS PHARMACOL SCI, V15, P190, DOI 10.1016/0165-6147(94)90147-3; Florin S, 1997, NEUROREPORT, V8, P705, DOI 10.1097/00001756-199702100-00025; FUKUDA K, 1994, FEBS LETT, V343, P42, DOI 10.1016/0014-5793(94)80603-9; Hara N, 1997, BRIT J PHARMACOL, V121, P401, DOI 10.1038/sj.bjp.0701146; Houtani T, 1996, BIOCHEM BIOPH RES CO, V219, P714, DOI 10.1006/bbrc.1996.0300; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; MINAMI T, 1994, BRIT J PHARMACOL, V112, P735, DOI 10.1111/j.1476-5381.1994.tb13139.x; MINAMI T, 1994, PAIN, V57, P217, DOI 10.1016/0304-3959(94)90226-7; MOLLEREAU C, 1994, FEBS LETT, V341, P33, DOI 10.1016/0014-5793(94)80235-1; Mollereau C, 1996, P NATL ACAD SCI USA, V93, P8666, DOI 10.1073/pnas.93.16.8666; Nothacker HP, 1996, P NATL ACAD SCI USA, V93, P8677, DOI 10.1073/pnas.93.16.8677; OkudaAshitaka E, 1996, J BIOL CHEM, V271, P31255, DOI 10.1074/jbc.271.49.31255; OkudaAshitaka E, 1996, MOL BRAIN RES, V43, P96, DOI 10.1016/S0169-328X(96)00165-9; Pan YX, 1996, BIOCHEM J, V315, P11, DOI 10.1042/bj3150011; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; Reinscheid RK, 1996, J BIOL CHEM, V271, P14163, DOI 10.1074/jbc.271.24.14163; Saito Y, 1996, J BIOL CHEM, V271, P15615, DOI 10.1074/jbc.271.26.15615; TAIWO YO, 1988, J NEUROSCI, V8, P1346; WOOLF CJ, 1994, TXB PAIN, P101	22	203	215	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1998	392	6673					286	289		10.1038/32660	http://dx.doi.org/10.1038/32660			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC739	9521323				2022-12-28	WOS:000072612300048
J	Ifudu, O; Mayers, JD; Matthew, JJ; Fowler, AM; Homel, P; Friedman, EA				Ifudu, O; Mayers, JD; Matthew, JJ; Fowler, AM; Homel, P; Friedman, EA			Standardized hemodialysis prescriptions promote inadequate treatment in patients with large body mass	ANNALS OF INTERNAL MEDICINE			English	Article							UNITED-STATES; MORTALITY; DIALYSIS; MORBIDITY; ADEQUACY; PAYMENT; WEIGHT	Background: Although a relation between the adequacy of hemodialysis and mortality has been established, hemodialysis prescription is rarely individualized precisely in adults with end-stage renal disease in the United States. Objective: To test whether persons who receive standardized hemodialysis prescriptions have an increased risk for inadequate hemodialysis with increasing body mass. Design: Cross-sectional study. Setting: Four ambulatory hemodialysis facilities in Brooklyn, New York. Patients: 214 patients receiving hemodialysis. Patients were sorted by body weight into quartiles (groups 1 through 4, in ascending order). Measurements: Urea reduction ratio (percentage reduction in blood urea nitrogen concentration after a hemodialysis session), prescribed length of hemodialysis, and body weight quartile at the start of the study. Urea reduction ratio was measured at the start of the study and at weeks 4, 8, and 12, and a mean value was calculated for each patient. Inadequate hemodialysis was defined by a urea reduction ratio of 65% or less. Results: Women had a higher mean urea reduction ratio (72% +/- 6%)than men (67.6% +/- 7%) (P < 0.001). The urea reduction ratio was inversely related to body weight (r = -0.47; P = 0.001). It was greater in group 1 (74% +/- 5.2%) than in group 2 (70% +/- 5.7%), group 3 (68% +/- 5.8%), or group 4 (66% +/- 8.4%) (P < 0.05). Logistic regression done with a urea reduction ratio of 65% or less as the outcome Variable showed that the odds of receiving inadequate hemodialysis were increased 3.5-fold in men(95% CI, 1.53-fold to 8-fold; P = 0.003), 10-fold in group 3 (CI, 2.1-fold to 50.3-fold; P = 0.003), and 13-fold in group 4 (CI, 2.6-fold to 61.6-fold; P = 0.001). Conclusions: Standardized hemodialysis prescriptions result in inadequate hemodialysis in many patients who weigh more than 68.2 kg.	SUNY Hlth Sci Ctr, Dept Med, Renal Dis Div, Brooklyn, NY 11203 USA; SUNY Hlth Sci Ctr, Dept Nursing, Brooklyn, NY 11203 USA; SUNY Hlth Sci Ctr, Sci Acad Comp Ctr, Brooklyn, NY 11203 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Ifudu, O (corresponding author), SUNY Hlth Sci Ctr, Dept Med, Renal Dis Div, 450 Clarkson Ave, Brooklyn, NY 11203 USA.							BARTH RH, 1994, DEV NEPHROL, V35, P143; Berwick DM, 1996, NEW ENGL J MED, V335, P1227, DOI 10.1056/NEJM199610173351611; CHARRA B, 1992, KIDNEY INT, V41, P1286, DOI 10.1038/ki.1992.191; HAKIM RM, 1994, AM J KIDNEY DIS, V23, P661, DOI 10.1016/S0272-6386(12)70276-7; HAKIM RM, 1993, AM J KIDNEY DIS, V21, P125, DOI 10.1016/S0272-6386(12)81083-3; HELD PJ, 1994, AM J KIDNEY DIS, V24, P974, DOI 10.1016/S0272-6386(12)81108-5; HELD PJ, 1992, KIDNEY INT, V42, pS16; Ifudu O, 1997, AM J KIDNEY DIS, V30, P28, DOI 10.1016/S0272-6386(97)90561-8; IFUDU O, 1994, AM J KIDNEY DIS, V23, P394, DOI 10.1016/S0272-6386(12)81002-X; Ifudu O, 1996, NEW ENGL J MED, V334, P420, DOI 10.1056/NEJM199602153340702; KESHAVIAH PR, 1994, J AM SOC NEPHROL, V4, P1475; KOPPLE JD, 1994, AM J KIDNEY DIS, V24, P968, DOI 10.1016/S0272-6386(12)81071-7; *NIH NAT I DIAB DI, 1996, US REN DAT SYST ANN; Norusis M.J., 1993, SPSS WINDOWS ADV STA, P1; NYENGAARD JR, 1992, ANAT REC, V232, P194, DOI 10.1002/ar.1092320205; OWEN WF, 1993, NEW ENGL J MED, V329, P1001, DOI 10.1056/NEJM199309303291404; Sherman R A, 1993, ASAIO J, V39, P933, DOI 10.1097/00002480-199310000-00020; Tabbush V, 1996, ARCH INTERN MED, V156, P357, DOI 10.1001/archinte.156.4.357; TISHER CC, 1994, ANN INTERN MED, V121, P62; Walter F, 1939, J EXP MED, V69, P467, DOI 10.1084/jem.69.3.467	20	29	29	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1998	128	6					451	454		10.7326/0003-4819-128-6-199803150-00005	http://dx.doi.org/10.7326/0003-4819-128-6-199803150-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA914	9499328				2022-12-28	WOS:000072414700005
J	Copeland, JRM				Copeland, JRM			Assessment of dementia	LANCET			English	Editorial Material							VASCULAR DEMENTIA; CRITERIA		Univ Liverpool, Royal Liverpool Hosp, Dept Psychiat, Liverpool L69 3BX, Merseyside, England	Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool	Copeland, JRM (corresponding author), Univ Liverpool, Royal Liverpool Hosp, Dept Psychiat, Liverpool L69 3BX, Merseyside, England.							Amar K, 1996, AGE AGEING, V25, P51, DOI 10.1093/ageing/25.1.51; Chui H, 1997, NEUROLOGY, V49, P925, DOI 10.1212/WNL.49.4.925; SKOOG I, 1993, NEW ENGL J MED, V328, P153, DOI 10.1056/NEJM199301213280301; Wetterling T, 1996, STROKE, V27, P30, DOI 10.1161/01.STR.27.1.30	4	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 14	1998	351	9105					769	770		10.1016/S0140-6736(05)78923-6	http://dx.doi.org/10.1016/S0140-6736(05)78923-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB916	9519943				2022-12-28	WOS:000072521200004
J	Martinez-Martinez, L; Pascual, A; Jacoby, GA				Martinez-Martinez, L; Pascual, A; Jacoby, GA			Quinolone resistance from a transferable plasmid	LANCET			English	Article							ESCHERICHIA-COLI; BETA-LACTAMASES; KLEBSIELLA-PNEUMONIAE; APPARENT ABSENCE	Background Bacteria can mutate to acquire quinolone resistance by target alterations or diminished drug accumulation. Plasmid-mediated resistance to quinolones in clinical isolates has been claimed but not confirmed. We investigated whether a multiresistance plasmid could transfer resistance to quinolones between bacteria. Methods We transferred resistance between strains by conjugation. The resistance plasmid was visualised in different hosts by agarose-gel electrophoresis. We determined the frequency of spontaneous mutations to ciprofloxacin or nalidixic-acid resistance in Escherichia coli strains, with or without the quinolone resistance plasmid. Findings A multiresistance plasmid (pMG252) from a clinical isolate of Klebsiella pneumoniae was found to increase quinolone resistance to minimum inhibitory concentrations (MICs) as high as 32 mu g/mL for ciprofloxacin when transferred to strains of K pneumoniae deficient in outer-membrane porins. Much lower resistance was seen when pMG252 was introduced into It pneumoniae or E coli strains with normal porins. The plasmid had a wide host range and expressed quinolone resistance in other enterobacteriaceae and in Pseudomonas aeruginosa. From a plasmid-containing E coli strain with ciprofloxacin MIC of 0.25 mu g/mL and nalidixic-acid MIC of 32 mu g/mL, quinolone-resistant mutants could be obtained at more than 100 times the frequency of a plasmid-free strain, reaching MICs for ciprofloxacin of 4 mu g/mL and for nalidixic acid of 256 mu g/mL. Interpretation Transferable resistance to fluoroquinines and nalidixic acid has been found in a clinical isolate of It pneumoniae on a broad host range plasmid. Although resistance was low in wild-type strains, higher levels of quinolone resistance arose readily by mutation. Such a plasmid can speed the development and spread of resistance to these valuable antimicrobial agents.	Lahey Hitchcock Clin, Burlington, MA 01805 USA; Univ Seville, Sch Med, Dept Clin Microbiol, Seville, Spain; Vet Adm Med Ctr, Burlington, MA USA	Lahey Hospital & Medical Center; University of Sevilla; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Jacoby, GA (corresponding author), Lahey Hitchcock Clin, 41 Mall Rd, Burlington, MA 01805 USA.		Jacoby, George A/G-2604-2011; Martínez, Luis Martínez/U-1801-2017; Pascual, Alvaro/Y-5854-2018	Martínez, Luis Martínez/0000-0002-6091-4045; Pascual, Alvaro/0000-0002-8672-5891				BURMAN LG, 1977, J ANTIMICROB CHEMOTH, V3, P509, DOI 10.1093/jac/3.5.509; COURVALIN P, 1990, ANTIMICROB AGENTS CH, V34, P681, DOI 10.1128/AAC.34.5.681; DILICA K, 1997, MICROBIOL MOL BIOL R, V61, P377; Goldman JD, 1996, ANTIMICROB AGENTS CH, V40, P1266, DOI 10.1128/AAC.40.5.1266; Goldstein F W, 1995, Drugs, V49 Suppl 2, P36; Hooper David C., 1993, P97; Jacoby GA, 1996, J CLIN MICROBIOL, V34, P908, DOI 10.1128/JCM.34.4.908-911.1996; JACOBY GA, 1974, ANTIMICROB AGENTS CH, V6, P239, DOI 10.1128/AAC.6.3.239; MACRINA FL, 1978, PLASMID, V1, P417, DOI 10.1016/0147-619X(78)90056-2; MartinezMartinez L, 1996, ANTIMICROB AGENTS CH, V40, P342, DOI 10.1128/AAC.40.2.342; MATTHEW M, 1975, J GEN MICROBIOL, V88, P169, DOI 10.1099/00221287-88-1-169; MEDEIROS AA, 1985, ANTIMICROB AGENTS CH, V27, P715, DOI 10.1128/AAC.27.5.715; MUNSHI MH, 1987, LANCET, V2, P4419; Murphy OM, 1997, LANCET, V349, P1028, DOI 10.1016/S0140-6736(05)62932-7; *NCCLS, 1997, M7A4 NCCLS, P1; PEARCE LE, 1968, J GEN MICROBIOL, V50, P173, DOI 10.1099/00221287-50-1-173; Threlfall EJ, 1997, LANCET, V349, P403, DOI 10.1016/S0140-6736(97)80024-4; TOMAS JM, 1986, INFECT IMMUN, V54, P85	18	816	920	1	87	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 14	1998	351	9105					797	799		10.1016/S0140-6736(97)07322-4	http://dx.doi.org/10.1016/S0140-6736(97)07322-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB916	9519952				2022-12-28	WOS:000072521200013
J	Smith, DE; Zuber, MT; Frey, HV; Garvin, JB; Head, JW; Muhleman, DO; Pettengill, GH; Phillips, RJ; Solomon, SC; Zwally, HJ; Banerdt, WB				Smith, DE; Zuber, MT; Frey, HV; Garvin, JB; Head, JW; Muhleman, DO; Pettengill, GH; Phillips, RJ; Solomon, SC; Zwally, HJ; Banerdt, WB			Topography of the northern hemisphere of Mars from the Mars orbiter laser altimeter	SCIENCE			English	Article							RADIO OCCULTATION MEASUREMENTS; MARINER-9; DICHOTOMY; VOLCANISM; IMPACT; ATMOSPHERE	The first 18 tracks of laser altimeter data across the northern hemisphere of Mars from the Mars Global Surveyor spacecraft show that the planet at latitudes north of 50 degrees is exceptionally flat; slopes and surface roughness increase toward the equator. The polar layered terrain appears to be a thick ice-rich formation with a non-equilibrium planform indicative of ablation near the periphery. Slope relations suggest that the northern Tharsis province was uplifted in the past. A profile across Ares Vallis channel suggests that the discharge through the chan nel was much greater than previously estimated. The martian atmosphere shows significant 1-micrometer atmospheric opacities, particularly in low-lying areas such as Valles Marineris.	NASA, Earth Sci Directorate, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; MIT, Cambridge, MA 02139 USA; Brown Univ, Providence, RI 02912 USA; CALTECH, Pasadena, CA 91125 USA; Washington Univ, St Louis, MO 63130 USA; Carnegie Inst Washington, Dept Terr Magnetism, Washington, DC 20015 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; NASA, Terr Phys Lab, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Massachusetts Institute of Technology (MIT); Brown University; California Institute of Technology; Washington University (WUSTL); Carnegie Institution for Science; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center	Smith, DE (corresponding author), NASA, Earth Sci Directorate, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA.		Banerdt, William/Q-7324-2019	Banerdt, William/0000-0003-3125-1542				Baker V.R., 1992, CHANNELS VALLEY NETW, P493; BAKER VR, 1991, NATURE, V352, P589, DOI 10.1038/352589a0; BANERDT WB, 1992, MARS, P249; BATSON RM, 1995, PHOTOGRAMM ENG REM S, V61, P1499; BLASIUS RK, 1982, ICARUS, V50, P140; BUDD WF, 1986, POLARFORSCHUNG, V56, P43; Carr M., 1981, SURFACE MARS; Carr M. H., 1977, Journal of Geophysical Research, V82, P4055, DOI 10.1029/JS082i028p04055; Carr M.H, 1996, WATER MARS; CARR MH, 1973, J GEOPHYS RES, V78, P4049, DOI 10.1029/JB078i020p04049; CONRATH B, 1973, J GEOPHYS RES, V78, P4267, DOI 10.1029/JB078i020p04267; CRR MH, 1972, ICARUS, V16, P17; DOWNS GS, 1982, J GEOPHYS RES, V87, P9747, DOI 10.1029/JB087iB12p09747; Folkner WM, 1997, SCIENCE, V278, P1749, DOI 10.1126/science.278.5344.1749; FRANCIS PW, 1983, J GEOPHYS RES, V88, P8333, DOI 10.1029/JB088iB10p08333; FREY H, 1988, GEOPHYS RES LETT, V15, P229, DOI 10.1029/GL015i003p00229; Granger RA., 1995, FLUID MECH-SOV RES; GREELEY R, 1987, SCIENCE, V236, P1653, DOI 10.1126/science.236.4809.1653; HORD CW, 1972, ICARUS, V17, P443, DOI 10.1016/0019-1035(72)90010-3; HOWARD AD, 1982, ICARUS, V50, P245, DOI 10.1016/0019-1035(82)90125-7; JANKOWSKI DG, 1992, ICARUS, V100, P26, DOI 10.1016/0019-1035(92)90015-Y; JORDAN JF, 1975, ICARUS, V25, P146, DOI 10.1016/0019-1035(75)90194-3; KLIORE AJ, 1972, ICARUS, V17, P484, DOI 10.1016/0019-1035(72)90014-0; Komatsu G, 1997, J GEOPHYS RES-PLANET, V102, P4151, DOI 10.1029/96JE02564; LINDAL GF, 1979, J GEOPHYS RES, V84, P8443, DOI 10.1029/JB084iB14p08443; Lingenfelter R. E., 1973, Moon, V7, P172, DOI 10.1007/BF00578814; LOPES RMC, 1980, MOON PLANETS, V22, P221, DOI 10.1007/BF00898433; Malin MC, 1998, SCIENCE, V279, P1681, DOI 10.1126/science.279.5357.1681; MALIN MC, 1986, GEOPHYS RES LETT, V13, P444, DOI 10.1029/GL013i005p00444; MORGAN JP, 1995, J GEOPHYS RES-SOL EA, V100, P8045, DOI 10.1029/94JB02887; Mouginis-Mark P.J., 1992, MARS PP, P424; PAIGE DA, 1994, J GEOPHYS RES, V99, P25595; PHILLIPS RJ, 1990, J GEOPHYS RES-SOLID, V95, P5089, DOI 10.1029/JB095iB04p05089; Schubert G., 1992, MARS, P147, DOI [10.2307/j.ctt207g59v.9, DOI 10.2307/J.CTT207G59V.9]; Smith DE, 1996, SCIENCE, V271, P184, DOI 10.1126/science.271.5246.184; SMITH DE, 1993, J GEOPHYS RES-PLANET, V98, P20871, DOI 10.1029/93JE01839; SODERBLOM L. A., 1992, MARS, P557; SOLOMON SC, 1982, J GEOPHYS RES, V87, P9755, DOI 10.1029/JB087iB12p09755; Tanaka K. L., 1992, MARS, P345; Thomas P., 1992, MARS, P767; WILHELMS DE, 1984, NATURE, V309, P138, DOI 10.1038/309138a0; WISE DU, 1979, ICARUS, V38, P456, DOI 10.1016/0019-1035(79)90200-8; Zuber MT, 1997, J GEOPHYS RES-PLANET, V102, P28673, DOI 10.1029/97JE02527; ZUBER MT, 1992, J GEOPHYS RES-PLANET, V97, P7781, DOI 10.1029/92JE00341; [No title captured]	45	185	188	2	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 13	1998	279	5357					1686	1692		10.1126/science.279.5357.1686	http://dx.doi.org/10.1126/science.279.5357.1686			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9497281				2022-12-28	WOS:000072490000046
J	Jorgensen, RA; Atkinson, RG; Forster, RLS; Lucas, WJ				Jorgensen, RA; Atkinson, RG; Forster, RLS; Lucas, WJ			Research: Botany - An RNA-based information superhighway in plants	SCIENCE			English	Article							TRANSGENIC PLANTS; GENE-EXPRESSION; VIRUS-RESISTANCE; COSUPPRESSION; PLASMODESMATA; SUPPRESSION; PATTERNS; DNA		Univ Arizona, Dept Plant Sci, Tucson, AZ 85721 USA; HortRes, Auckland, New Zealand; Univ Calif Davis, Plant Biol Sect, Davis, CA 95616 USA	University of Arizona; New Zealand Institute for Plant & Food Research Ltd; University of California System; University of California Davis	Jorgensen, RA (corresponding author), Univ Arizona, Dept Plant Sci, Tucson, AZ 85721 USA.		Atkinson, Ross G/A-4140-2008	Atkinson, Ross G/0000-0002-7062-6952; Jorgensen, Richard/0000-0002-0382-2371				ATKINSON RS, UNPUB; Baulcombe DC, 1996, CURR OPIN BIOTECH, V7, P173, DOI 10.1016/S0958-1669(96)80009-7; BOLLMANN J, 1991, PLANT CELL, V3, P1327, DOI 10.1105/tpc.3.12.1327; Covey SN, 1997, NATURE, V385, P781, DOI 10.1038/385781a0; DE CARVALHO-NIEBEL F, 1995, PLANT CELL, V7, P347, DOI 10.2307/3869856; DOUGHERTY WG, 1995, CURR OPIN CELL BIOL, V7, P399, DOI 10.1016/0955-0674(95)80096-4; Gilbertson RL, 1996, TRENDS PLANT SCI, V1, P260; Goodwin J, 1996, PLANT CELL, V8, P95, DOI 10.1105/tpc.8.1.95; Guo HS, 1997, MOL PLANT MICROBE IN, V10, P160, DOI 10.1094/MPMI.1997.10.2.160; JORGENSEN R, 1990, TRENDS BIOTECHNOL, V8, P340, DOI 10.1016/0167-7799(90)90220-R; JORGENSEN RA, 1995, SCIENCE, V268, P686, DOI 10.1126/science.268.5211.686; Jorgensen RA, 1996, PLANT MOL BIOL, V31, P957, DOI 10.1007/BF00040715; Kuhn C, 1997, SCIENCE, V275, P1298, DOI 10.1126/science.275.5304.1298; Kunz C, 1996, PLANT J, V10, P437, DOI 10.1046/j.1365-313X.1996.10030437.x; Lee KY, 1997, PLANT J, V12, P1127, DOI 10.1046/j.1365-313X.1997.12051127.x; LINDBO JA, 1993, PLANT CELL, V5, P1749, DOI 10.1105/tpc.5.12.1749; LUCAS WJ, 1995, SCIENCE, V270, P1980, DOI 10.1126/science.270.5244.1980; LUCAS WJ, 1993, NEW PHYTOL, V125, P435, DOI 10.1111/j.1469-8137.1993.tb03897.x; MATTHEWS REF, 1991, PLANT VIROLOGY, P445; Metzlaff M, 1997, CELL, V88, P845, DOI 10.1016/S0092-8674(00)81930-3; Mezitt LA, 1996, PLANT MOL BIOL, V32, P251, DOI 10.1007/BF00039385; MOORE CV, UNPUB; Palauqui JC, 1996, PLANT PHYSIOL, V112, P1447, DOI 10.1104/pp.112.4.1447; Palauqui JC, 1997, EMBO J, V16, P4738, DOI 10.1093/emboj/16.15.4738; Que QD, 1998, PLANT J, V13, P401, DOI 10.1046/j.1365-313X.1998.00038.x; Que QD, 1997, PLANT CELL, V9, P1357, DOI 10.1105/tpc.9.8.1357; Ratcliff F, 1997, SCIENCE, V276, P1558, DOI 10.1126/science.276.5318.1558; Ryals JA, 1996, PLANT CELL, V8, P1809, DOI 10.1105/tpc.8.10.1809; SMITH CJS, 1990, MOL GEN GENET, V224, P477, DOI 10.1007/BF00262443; Tanzer MM, 1997, PLANT CELL, V9, P1411, DOI 10.1105/tpc.9.8.1411; Vaucheret H, 1997, PLANT CELL, V9, P1495, DOI 10.1105/tpc.9.8.1495; Voinnet O, 1997, NATURE, V389, P553, DOI 10.1038/39215	32	184	203	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 6	1998	279	5356					1486	1487		10.1126/science.279.5356.1486	http://dx.doi.org/10.1126/science.279.5356.1486			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA527	9508725				2022-12-28	WOS:000072372900051
J	Albert, ML; Sauter, B; Bhardwaj, N				Albert, ML; Sauter, B; Bhardwaj, N			Dendritic cells acquire antigen from apoptotic cells and induce class I restricted CTLs	NATURE			English	Article							TOXIC LYMPHOCYTES-T; INFLUENZA-VIRUS; MATRIX PROTEIN; HUMAN BLOOD; GENERATION; RESPONSES; HLA-A2; VIVO	CD8(+) cytotoxic T lymphocytes (CTLs) mediate resistance to infectious agents and tumours. Classically, CTLs recognize antigens that are localized in the cytoplasm of target cells, processed and presented as peptide complexes with class I molecules of the major histocompatibility complex (MHC)(1). However, there is evidence for an exogenous pathway whereby antigens that are not expected to gain access to the cytoplasm are presented on MHC class I molecules(2-6). The most dramatic example is the in vivo phenomenon of cross-priming(7): antigens from donor cells are acquired by bone-marrow-derived host antigen-presenting cells (APCs) and presented on MHC class I molecules. Two unanswered questions concern the identity of this bone-marrow-derived cell and how such antigens are acquired. Here we show that human dendritic cells, but not macrophages, efficiently present antigen derived from apoptotic cells, stimulating class I-restricted CD8(+) CTLs, Our findings suggest a mechanism by which potent APCs acquire antigens from tumours, transplants, infected cells, or even self-tissue, for stimulation or tolerization of CTLs.	Rockefeller Univ, Cellular Physiol & Immunol Lab, New York, NY 10021 USA	Rockefeller University	Bhardwaj, N (corresponding author), Rockefeller Univ, Cellular Physiol & Immunol Lab, 1230 York Ave, New York, NY 10021 USA.	bhardwn@rockvax.rockefeller.edu	Albert, Matthew L/C-9782-2009					BACHMANN MF, 1996, EUR J IMMUNOL, V26, P1; Badley AD, 1997, J EXP MED, V185, P55, DOI 10.1084/jem.185.1.55; BENDER A, 1995, J EXP MED, V182, P1663, DOI 10.1084/jem.182.6.1663; Bender A, 1996, J IMMUNOL METHODS, V196, P121, DOI 10.1016/0022-1759(96)00079-8; BENDER A, IN PRESS IMMUNOBIOLO; BEVAN MJ, 1977, J IMMUNOL, V118, P1370; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; BHARDWAJ N, 1994, J CLIN INVEST, V94, P797, DOI 10.1172/JCI117399; CASCIOLAROSEN LA, 1994, J EXP MED, V179, P1317, DOI 10.1084/jem.179.4.1317; DEPANFILIS G, 1986, J INVEST DERMATOL, V87, P510, DOI 10.1111/1523-1747.ep12455586; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FESQ H, 1994, IMMUNOBIOLOGY, V190, P175, DOI 10.1016/S0171-2985(11)80292-5; FOSSUM S, 1986, EUR J IMMUNOL, V16, P440, DOI 10.1002/eji.1830160422; GOTCH F, 1988, J EXP MED, V168, P2045, DOI 10.1084/jem.168.6.2045; GOTCH F, 1987, NATURE, V326, P881, DOI 10.1038/326881a0; HEEMELS MT, 1995, ANNU REV BIOCHEM, V64, P463, DOI 10.1146/annurev.bi.64.070195.002335; Hofmann P, 1997, J LEUKOCYTE BIOL, V61, P408, DOI 10.1002/jlb.61.4.408; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; KOVACSOVICSBANKOWSKI M, 1995, SCIENCE, V267, P243, DOI 10.1126/science.7809629; Kurts C, 1997, J EXP MED, V186, P239, DOI 10.1084/jem.186.2.239; Kurts C, 1996, J EXP MED, V184, P923, DOI 10.1084/jem.184.3.923; NOTBURY CC, 1997, EUR J IMMUNOL, V27, P280; Paglia P, 1996, J EXP MED, V183, P317, DOI 10.1084/jem.183.1.317; PFEIFER JD, 1993, NATURE, V361, P359, DOI 10.1038/361359a0; Romani N, 1996, J IMMUNOL METHODS, V196, P137, DOI 10.1016/0022-1759(96)00078-6; Rubartelli A, 1997, EUR J IMMUNOL, V27, P1893, DOI 10.1002/eji.1830270812; Shen ZH, 1997, J IMMUNOL, V158, P2723; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; Watts C, 1997, ANNU REV IMMUNOL, V15, P821, DOI 10.1146/annurev.immunol.15.1.821	29	1924	2032	1	82	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 5	1998	392	6671					86	89		10.1038/32183	http://dx.doi.org/10.1038/32183			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA528	9510252				2022-12-28	WOS:000072373000055
J	Wagner, L; Yang, OO; Garcia-Zepeda, EA; Ge, YM; Kalams, SA; Walker, BD; Pasternack, MS; Luster, AD				Wagner, L; Yang, OO; Garcia-Zepeda, EA; Ge, YM; Kalams, SA; Walker, BD; Pasternack, MS; Luster, AD			beta-chemokines are released from HIV-1-specific cytolytic T-cell granules complexed to proteoglycans	NATURE			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; HEPARAN-SULFATE; VIRUS-REPLICATION; SERINE ESTERASE; LYMPHOCYTES-T; RECEPTOR; HIV-1; IDENTIFICATION; LOCALIZATION; MIP-1-BETA	CD8(+) lymphocytes are believed to be important in host defence against the human immunodeficiency virus (HIV)-1, inhibiting HIV-1 replication through both cytolytic and non-cytolytic pathways(1-13). The cytolytic pathway involves calcium-dependent exocytosis of perforin and granzyme proteases, as well as Fas-mediated programmed cell death(4), whereas the noncytolytic pathway involves the release of chemokines that prevent viral entry(5). Using-granzyme A as a marker of cytolytic granule proteins, and macrophage inflammatory protein (MIP)-1 alpha and RANTES as markers of HIV-1 inhibitory chemokines, we show that these two very different mediators of viral inhibition are both localized in the cytolytic granules of HIV-1-specific CD8(+) cytotoxic T lymphocytes (CTL). Following antigen-specific activation, these mediators are secreted together facilitating both lysis of virion-producing cells and the inhibition of free virus. In addition, RANTES, MIP-1 alpha and MIP-1 beta are secreted by CTL as a macromolecular complex containing sulphated proteoglycans. This association appears to have a functional significance, because heparan sulphate facilitates RANTES inhibition of HIV-1 infection of monocytes.	Massachusetts Gen Hosp, Partners AIDS Res Ctr, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Infect Dis Unit, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Infect Dis Unit, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Massachusetts General Hospital	Luster, AD (corresponding author), Massachusetts Gen Hosp, Partners AIDS Res Ctr, Charlestown, MA 02129 USA.	luster@helix.mgh.harvard.edu	Luster, Andrew/ABE-6504-2020	Luster, Andrew/0000-0001-9679-7912				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; BERKE G, 1995, CELL, V81, P9, DOI 10.1016/0092-8674(95)90365-8; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; KALAMS SA, 1994, J EXP MED, V179, P1261, DOI 10.1084/jem.179.4.1261; KAPLAN KL, 1979, BLOOD, V53, P604; LEVINE SP, 1990, BLOOD, V75, P902; LUSTER AD, 1995, J EXP MED, V182, P219, DOI 10.1084/jem.182.1.219; MACDERMOTT RP, 1985, J EXP MED, V162, P1771, DOI 10.1084/jem.162.6.1771; Moriuchi H, 1996, P NATL ACAD SCI USA, V93, P15341, DOI 10.1073/pnas.93.26.15341; Oravecz T, 1997, J IMMUNOL, V159, P4587; PASTERNACK MS, 1986, NATURE, V322, P740, DOI 10.1038/322740a0; PASTERNACK MS, 1985, NATURE, V314, P743, DOI 10.1038/314743a0; PATEL M, 1993, AIDS RES HUM RETROV, V9, P167, DOI 10.1089/aid.1993.9.167; Schmidtmayerova H, 1996, NATURE, V382, P767, DOI 10.1038/382767a0; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; STEVENS RL, 1987, J IMMUNOL, V139, P863; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TSCHOPP J, 1987, MOL IMMUNOL, V24, P907, DOI 10.1016/0161-5890(87)90002-2; TSUBOTA H, 1989, J EXP MED, V169, P1421, DOI 10.1084/jem.169.4.1421; UHLINHANSEN L, 1989, J BIOL CHEM, V264, P14916; Verani A, 1997, J EXP MED, V185, P805, DOI 10.1084/jem.185.5.805; WALKER BD, 1989, P NATL ACAD SCI USA, V86, P9514, DOI 10.1073/pnas.86.23.9514; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9; Yang OO, 1997, J VIROL, V71, P3120, DOI 10.1128/JVI.71.4.3120-3128.1997; YEAMAN C, 1993, J CELL PHYSIOL, V157, P413, DOI 10.1002/jcp.1041570226	28	291	298	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 26	1998	391	6670					908	911		10.1038/36129	http://dx.doi.org/10.1038/36129			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ206	9495345				2022-12-28	WOS:000072230900056
J	Kostrikis, LG; Tyagi, S; Mhlanga, MM; Ho, DD; Kramer, FR				Kostrikis, LG; Tyagi, S; Mhlanga, MM; Ho, DD; Kramer, FR			Molecular beacons - Spectral genotyping of human alleles	SCIENCE			English	Article							HIV-1 INFECTION; HYBRIDIZATION; INDIVIDUALS; PROGRESSION; RESISTANCE; PROBES; GENE; DNA		Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA; Publ Hlth Res Inst, Dept Mol Genet, New York, NY 10016 USA	Rockefeller University	Kostrikis, LG (corresponding author), Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA.		Mhlanga, Musa/D-1283-2011; Tyagi, Sanjay/F-1109-2010; KOSTRIKIS, LEONDIOS G/A-5330-2016	Mhlanga, Musa/0000-0003-1381-3409; KOSTRIKIS, LEONDIOS G/0000-0002-5340-7109; Tyagi, Sanjay/0000-0001-7303-5827	NHLBI NIH HHS [HL-43521] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043521] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BONNET GV, UNPUB; Cantor CR, 1996, NAT BIOTECHNOL, V14, P264, DOI 10.1038/nbt0396-264; COTTON R, 1997, MUTAT DETECTION; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Ehricht R, 1997, NUCLEIC ACIDS RES, V25, P4697, DOI 10.1093/nar/25.22.4697; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; KEEN J, 1991, TRENDS GENET, V7, P5; KOSTRIKIS L, IN PRESS NAT MED; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; MATSUO T, IN PRESS BIOCH BIOPH; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; Rappaport J, 1997, LANCET, V349, P922, DOI 10.1016/S0140-6736(05)62697-9; SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; Tyagi S, 1996, NAT BIOTECHNOL, V14, P303, DOI 10.1038/nbt0396-303; Tyagi S, 1998, NAT BIOTECHNOL, V16, P49, DOI 10.1038/nbt0198-49	18	256	324	1	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	1998	279	5354					1228	1229		10.1126/science.279.5354.1228	http://dx.doi.org/10.1126/science.279.5354.1228			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9508692				2022-12-28	WOS:000072115200049
J	Ekbom, A; Lundegardh, G; McLaughlin, JK; Nyren, O				Ekbom, A; Lundegardh, G; McLaughlin, JK; Nyren, O			Relation of vagotomy to subsequent risk of lung cancer: population based cohort study	BRITISH MEDICAL JOURNAL			English	Article							DUODENAL-ULCER; SMOKING; TRIAL		Karolinska Inst, Dept Med Epidemiol, S-17177 Stockholm, Sweden	Karolinska Institutet	Ekbom, A (corresponding author), Karolinska Inst, Dept Med Epidemiol, POB 281, S-17177 Stockholm, Sweden.							DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; HOFFMANN J, 1989, ANN SURG, V209, P40, DOI 10.1097/00000658-198901000-00006; KATSCHINSKI BD, 1991, EUR J GASTROEN HEPAT, V3, P443; LAURITSEN K, 1985, NEW ENGL J MED, V312, P958, DOI 10.1056/NEJM198504113121505; MACINTYRE IMC, 1994, GUT, V35, P451, DOI 10.1136/gut.35.4.451	5	22	23	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 14	1998	316	7130					518	519		10.1136/bmj.316.7130.518	http://dx.doi.org/10.1136/bmj.316.7130.518			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX955	9501714	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000072097400021
J	Kay, AB				Kay, AB			Good allergy practice	BRITISH MEDICAL JOURNAL			English	Article									Imperial Coll, Sch Med, Natl Heart & Lung Inst, London, England	Imperial College London	Kay, AB (corresponding author), Imperial Coll, Sch Med, Natl Heart & Lung Inst, London, England.							KAY AB, CLIN EXPT ALLERGY	1	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 14	1998	316	7130					535	537		10.1136/bmj.316.7130.535	http://dx.doi.org/10.1136/bmj.316.7130.535			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX955	9501719	Green Published			2022-12-28	WOS:000072097400029
J	Moynihan, C; Bliss, JM; Davidson, J; Burchell, L; Horwich, A				Moynihan, C; Bliss, JM; Davidson, J; Burchell, L; Horwich, A			Evaluation of adjuvant psychological therapy in patients with testicular cancer: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective: To determine the efficacy of adjuvant psychological therapy in patients with testicular cancer and to compare the characteristics and psychosocial outcomes of men who agreed to participate with those who declined to participate in a randomised trial of psychological intervention. Design: Newly diagnosed patients were asked to participate in a randomised trial of psychological support compared with standard medical care. Participants and non-participants completed self assessment questionnaires at baseline and at 2, 4 and 12 months. Setting: Testicular Tumour Unit of the Royal Marsden Hospital. Subjects: 73 of 184 (40%) eligible patients agreed to enter the randomised trial (participants) and 81 (44%) declined to participate but agreed to complete further assessments (non-participants). 30 patients wanted no further contact with the researchers. Outcome measures: Hospital anxiety and depression scale, psychosocial adjustment to illness scale, Rotterdam symptom checklist, mental adjustment to cancer scale, Only scores on the hospital anxiety and depression scale are reported for evaluating treatment efficacy. Results: 111 of 184 (60%) eligible men declined to participate in the trial. Patients with stage I disease were most Likely to refuse to participate. A patient was less likely to participate if he had low volume disease and was receiving no further treatment Likelihood of participation was associated with stage of disease and with type of primary treatment (P<0.001 for heterogeneity). Patients with early stage disease (P<0.001) and fewer physical symptoms (P<0.001) were less likely to participate. Psychosocial factors associated with participation included anxious preoccupation regarding disease (P = 0.01). There were no differences in outcome between participants and non-participants during follow up. Patients seemed to gain little benefit from adjuvant psychological therapy. At 2 months change from baseline favoured the treated group in the anxiety subscale (mean difference between groups -1.41 (95% confidence interval -2.86 to 0.03)). This was not sustained when adjusted for factors related to the disease. By 12 months change from baseline seemed to favour the control group (mean difference between groups 1.66 (-0.18 to 3.50)). Conclusions: Patients with testicular cancer seem to have considerable coping abilities. Those who declined to participate in the trial differed from those who participated. Those who agreed to participate may comprise the clinical group who perceive a need for psychological support No evidence was found to indicate a need for routinely offering adjuvant psychological therapy.	Royal Marsden NHS Trust, Acad Dept Radiotherapy & Oncol, Surrey SM2 5PT, England; Inst Canc Res, Epidemiol Sect, Clin Trials & Stat Unit, Surrey SM2 5NG, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Moynihan, C (corresponding author), Royal Marsden NHS Trust, Acad Dept Radiotherapy & Oncol, Surrey SM2 5PT, England.	clare@icr.ac.uk		Bliss, Judith/0000-0001-7957-7424				[Anonymous], COUNSELLING COMMUNIC; Bauman Laurie J., 1992, Journal of Psychosocial Oncology, V10, P1; Bloom J R, 1978, Patient Couns Health Educ, V1, P50; Brannon R., 1984, PSYCH DOC, V14, P30; DEHAES JCJM, 1990, BRIT J CANCER, V62, P1034, DOI 10.1038/bjc.1990.434; Derogatis LR, 1983, PSYCHOSOCIAL ADJUSTM; FAHY T, 1993, BRIT MED J, V307, P576, DOI 10.1136/bmj.307.6904.576; FAWZY FI, 1990, ARCH GEN PSYCHIAT, V47, P720; GOLONKA LM, 1977, DISS ABSTR INT, V37, P6362; GREER S, 1987, CANCER SURV, V6, P439; GREER S, 1992, BRIT MED J, V304, P675, DOI 10.1136/bmj.304.6828.675; Moorey S, 1994, PSYCHO-ONCOLOGY, V3, P39, DOI DOI 10.1002/PON.2960030108; Moorey S., 1989, PSYCHOL THERAPY PATI; MOYNIHAN C, 1987, CANCER SURV, V6, P477; MOYNIHAN C, 1996, TESTICULAR CANC INVE; RIEKER PP, 1989, CANCER, V64, P2399, DOI 10.1002/1097-0142(19891201)64:11<2399::AID-CNCR2820641134>3.0.CO;2-P; SPIEGEL D, 1981, ARCH GEN PSYCHIAT, V38, P527; VINGERHOETS AJJM, 1990, PSYCHOL MED, V20, P125, DOI 10.1017/S0033291700013301; Wing JK, 1980, MEASUREMENT CLASSIFI; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	21	69	69	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 7	1998	316	7129					429	435		10.1136/bmj.316.7129.429	http://dx.doi.org/10.1136/bmj.316.7129.429			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YW874	9492666	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000071982700024
J	Ren, D				Ren, D			Flower-associated Brachycera flies as fossil evidence for Jurassic angiosperm origins	SCIENCE			English	Article								Pollinating insects played a decisive role in the origin and early evolution of the angiosperms. Pollinating orthorrhaphous Brachycera fossils (short-horned flies) collected from Late Jurassic rocks in Liaoning Province of northeast China provide evidence for a pre-Cretaceous origin of angiosperms. Functional morphology and comparison with modern confamilial taxa show that the orthorrhaphous Brachycera were some of the most ancient pollinators, These data thus imply that angiosperms originated during the Late Jurassic and were represented by at least two floral types.	Natl Geol Museum China, Beijing 100034, Peoples R China		Ren, D (corresponding author), Natl Geol Museum China, Beijing 100034, Peoples R China.			Ren, Dong/0000-0001-8660-0901				Brenner Gilbert J., 1996, P91, DOI 10.1007/978-0-585-23095-5_5; Colless D.H., 1991, P717; CRANE PR, 1995, NATURE, V374, P27, DOI 10.1038/374027a0; Crepet W.L., 1987, P181; Crepet William L., 1996, P25; Crowson Roy A., 1991, P13; Duan SY, 1998, SCI CHINA SER D, V41, P14, DOI 10.1007/BF02932415; ENDRESS PK, 1986, PLANT SYST EVOL, V152, P1, DOI 10.1007/BF00985348; EVENHUIS NL, 1994, CATALOGUE FOSSILS WO; Faegri K., 1979, PRINCIPLES POLLINATI; Grimaldi D., 1990, B AM MUS NAT HIST, V195, P164; HUGHES NF, 1994, ENIGMA ANGIOSPERM OR; Kovalev V. G., 1985, Systematics of Diptera (Insecta). Ecological and morphological principles, P56; Kozlov M.V., 1989, PALEONTOL J+, V23, P34; Labandeira CC, 1997, ANNU REV ECOL SYST, V28, P153, DOI 10.1146/annurev.ecolsys.28.1.153; LABANDEIRA CC, 1994, P NATL ACAD SCI USA, V91, P12278, DOI 10.1073/pnas.91.25.12278; Labandeira Conrad C., 1994, Milwaukee Public Museum Contributions in Biology and Geology, V88, P1; MACKERRAS IM, 1954, AUST J ZOOL, V2, P431, DOI 10.1071/ZO9540431; Manning JC, 1996, ANN MO BOT GARD, V83, P67, DOI 10.2307/2399969; Mostovski M.B., 1997, Paleontologicheskii Zhurnal, V1, P72; Proctor M., 1996, NATURAL HIST POLLINA; Ren D., 1997, GEOLOGICAL REV, V43, P449; Ren D., 1995, FAUNAE STRATIGRAPHY; Ren Dong, 1998, Acta Zootaxonomica Sinica, V23, P65; Ren Dong, 1996, Acta Geoscientia Sinica, V17, P148; Rohdendorf B.B., 1968, P180; RUSSELL DA, 1993, CAN J EARTH SCI, V30, P2002, DOI 10.1139/e93-176; Stuckenberg B.R., 1996, Annals of the Natal Museum, V37, P239; SUN G, 1997, ACTA PALAEONTOL SIN, V36, P135; Takhtajan A, 1997, DIVERSITY CLASSIFICA; Taylor David Winship, 1996, P1, DOI 10.1007/978-0-585-23095-5_1; Tetley H., 1918, Bulletin of Entomological Research London, V8; Thorne Robert F., 1996, P286, DOI 10.1007/978-0-585-23095-5_11; Zhang Jun-feng, 1993, Acta Palaeontologica Sinica, V32, P662	34	134	169	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 3	1998	280	5360					85	88		10.1126/science.280.5360.85	http://dx.doi.org/10.1126/science.280.5360.85			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF314	9525862				2022-12-28	WOS:000072885100039
J	Ando, A; Camm, J; Polasky, S; Solow, A				Ando, A; Camm, J; Polasky, S; Solow, A			Species distributions, land values, and efficient conservation	SCIENCE			English	Article							RESERVE SELECTION	Efforts at species conservation in the United States have tended to be opportunistic and uncoordinated. Recently, however, ecologists and economists have begun to develop more systematic approaches. Here, the problem of efficiently allocating scarce conservation resources in the selection of sites for biological reserves is addressed. With the use of county-level data on land prices and the incidence of endangered species, it is shown that accounting for heterogeneity in land prices results in a substantial increase in efficiency in terms of either the cost of achieving a fixed coverage of species or the coverage attained from a fixed budget.	Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA; Resources Future Inc, Washington, DC 20036 USA; Univ Cincinnati, Dept Quantitat Anal & Operat Management, Cincinnati, OH 45221 USA; Oregon State Univ, Dept Agr & Resource Econ, Corvallis, OR 97331 USA	Woods Hole Oceanographic Institution; Resources for the Future; University System of Ohio; University of Cincinnati; Oregon State University	Solow, A (corresponding author), Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA.	asolow@whoi.edu	Polasky, Stephen/AAC-5341-2019					Camm JD, 1996, BIOL CONSERV, V78, P353, DOI 10.1016/0006-3207(95)00132-8; Church RL, 1996, BIOL CONSERV, V76, P105, DOI 10.1016/0006-3207(95)00102-6; Csuti B, 1997, BIOL CONSERV, V80, P83, DOI 10.1016/S0006-3207(96)00068-7; Dobson AP, 1997, SCIENCE, V275, P550, DOI 10.1126/science.275.5299.550; Downs BT, 1996, NAV RES LOG, V43, P435, DOI 10.1002/(SICI)1520-6750(199604)43:3<435::AID-NAV8>3.0.CO;2-A; FISHER ML, 1990, MANAGE SCI, V36, P674, DOI 10.1287/mnsc.36.6.674; Fourer R., 1993, AMPL MODELLING LANGU; Meffe G. K., 1994, PRINCIPLES CONSERVAT; SHAFER ML, 1990, NATURE RESERVES ISLA; SOULE ME, 1986, BIOL CONSERV, V35, P19, DOI 10.1016/0006-3207(86)90025-X; UNDERHILL LG, 1994, BIOL CONSERV, V70, P85, DOI 10.1016/0006-3207(94)90302-6; *US EPA, 1995, END SPEC COUNT DAT; *USDA, 1995, AV VAL ACR FARM REAL	13	525	547	1	93	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 27	1998	279	5359					2126	2128		10.1126/science.279.5359.2126	http://dx.doi.org/10.1126/science.279.5359.2126			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZE274	9516117				2022-12-28	WOS:000072775600053
J	Gupta, VK; Skaife, JJ; Dubrovsky, TB; Abbott, NL				Gupta, VK; Skaife, JJ; Dubrovsky, TB; Abbott, NL			Optical amplification of ligand-receptor binding using liquid crystals	SCIENCE			English	Article							SELF-ASSEMBLED MONOLAYERS; MOLECULAR RECOGNITION; ANTIBODIES; BIOTIN; DRUGS	Liquid crystals (LCs) were used to amplify and transduce receptor-mediated binding of proteins at surfaces into optical outputs, Spontaneously organized surfaces were designed so that protein molecules, upon binding to ligands hosted on these surfaces, triggered changes in the orientations of 1- to 20-micrometer-thick films of supported LCs, thus corresponding to a reorientation of similar to 10(5) to 10(6) mesogens per protein. Binding-induced changes in the intensity of light transmitted through the LC were easily seen with the naked eye and could be further amplified by using surfaces designed so that protein-ligand recognition causes twisted nematic LCs to untwist. This approach to the detection of ligand-receptor binding does not require labeling of the analyte, does not require the use of electroanalytical apparatus, provides a spatial resolution of micrometers, and is sufficiently simple that it may find use in biochemical assays and imaging of spatially resolved chemical libraries.	Univ Calif Davis, Dept Chem Engn & Mat Sci, Davis, CA 95616 USA	University of California System; University of California Davis	Gupta, VK (corresponding author), Univ Calif Davis, Dept Chem Engn & Mat Sci, Davis, CA 95616 USA.	nlabbott@ucdavis.edu						BAGCI H, 1993, FEBS LETT, V322, P47, DOI 10.1016/0014-5793(93)81108-C; Bahadur B., 1990, LIQUID CRYSTALS APPL; Chandrasekhar S., 1992, LIQ CRYST, DOI 10.1017/CBO9780511622496; Charych D, 1996, CHEM BIOL, V3, P113, DOI 10.1016/S1074-5521(96)90287-2; CHARYCH DH, 1993, SCIENCE, V261, P585, DOI 10.1126/science.8342021; Cornell BA, 1997, NATURE, V387, P580, DOI 10.1038/42432; Crews H. M., 1995, BIOMARKERS FOOD CHEM; DEGENNES PG, 1993, PHYSICS LIQUID CRYST; GAMALEYA NB, 1993, FORENSIC SCI INT, V63, P285, DOI 10.1016/0379-0738(93)90282-F; Gupta VK, 1996, LANGMUIR, V12, P2587, DOI 10.1021/la960003i; Gupta VK, 1997, SCIENCE, V276, P1533, DOI 10.1126/science.276.5318.1533; Gupta VK, 1996, PHYS REV E, V54, pR4540, DOI 10.1103/PhysRevE.54.R4540; KUMAR A, 1995, ACCOUNTS CHEM RES, V28, P219, DOI 10.1021/ar00053a003; Lin VSY, 1997, SCIENCE, V278, P840, DOI 10.1126/science.278.5339.840; Pan JJ, 1997, LANGMUIR, V13, P1365, DOI 10.1021/la9602675; Price C.P., 1991, PRINCIPLES PRACTICE; PRIME KL, 1993, J AM CHEM SOC, V115, P10714, DOI 10.1021/ja00076a032; SKAIFE JJ, UNPUB; SOLANS A, 1995, J ANAL TOXICOL, V19, P104, DOI 10.1093/jat/19.2.104; SPINKE J, 1993, J CHEM PHYS, V99, P7012, DOI 10.1063/1.465447; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722; Wild D., 2013, IMMUNOASSAY HDB	22	403	446	9	110	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 27	1998	279	5359					2077	2080		10.1126/science.279.5359.2077	http://dx.doi.org/10.1126/science.279.5359.2077			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZE274	9516101				2022-12-28	WOS:000072775600037
J	Ogg, GS; Jin, X; Bonhoeffer, S; Dunbar, PR; Nowak, MA; Monard, S; Segal, JP; Cao, YZ; Rowland-Jones, SL; Cerundolo, V; Hurley, A; Markowitz, M; Ho, DD; Nixon, DF; McMichael, AJ				Ogg, GS; Jin, X; Bonhoeffer, S; Dunbar, PR; Nowak, MA; Monard, S; Segal, JP; Cao, YZ; Rowland-Jones, SL; Cerundolo, V; Hurley, A; Markowitz, M; Ho, DD; Nixon, DF; McMichael, AJ			Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA	SCIENCE			English	Article							VIRUS TYPE-1 INFECTION; HIV-1 INFECTION; DISEASE PROGRESSION; IMMUNE-RESPONSES; HIGH-FREQUENCY; CELLS; IDENTIFICATION; VIREMIA; MEMORY; AIDS	Although cytotoxic T lymphocytes (CTLs) are thought to be involved in the control of human immunodeficiency virus-type 1 (HIV-1) infection, it has not been possible to demonstrate a direct relation between CTL activity and plasma RNA viral load. Human leukocyte antigen-peptide tetrameric complexes offer a specific means to directly quantitate circulating CTLs ex vivo. With the use of the tetrameric complexes, a significant inverse correlation was observed between HIV-specific CTL frequency and plasma RNA viral load. In contrast, no significant association was detected between the clearance rate of productively infected cells and frequency of HIV-specific CTLs. These data are consistent with a significant role for HIV-specific CTLs in the control of HIV infection and suggest a considerable cytopathic effect of the virus in vivo.	Nuffield Dept Med, Inst Mol Med, Oxford OX3 9DS, England; Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA; Univ Oxford, Dept Zool, Oxford OX1 3PS, England	University of Oxford; University of Oxford	McMichael, AJ (corresponding author), Nuffield Dept Med, Inst Mol Med, Oxford OX3 9DS, England.		Dunbar, Rod/C-2570-2012; Bonhoeffer, Sebastian/A-2735-2008; Nixon, Douglas/AAU-5734-2020; Nowak, Martin A/A-6977-2008	Dunbar, Rod/0000-0001-9626-2600; Bonhoeffer, Sebastian/0000-0001-8052-3925; Nixon, Douglas/0000-0002-2801-1786; Cerundolo, Vincenzo/0000-0003-0040-3793; Ogg, Graham/0000-0002-3097-045X	NCRR NIH HHS [MO1-RR00102] Funding Source: Medline; NIAID NIH HHS [U01AI41534] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI041534] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; ARIYOSHI K, 1995, AIDS, V9, P555, DOI 10.1097/00002030-199506000-00004; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Bonhoeffer S, 1997, P NATL ACAD SCI USA, V94, P6971, DOI 10.1073/pnas.94.13.6971; Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CARMICHAEL A, 1993, J EXP MED, V177, P249, DOI 10.1084/jem.177.2.249; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; DUNBAR PR, UNPUB; GOTCH FM, 1990, INT IMMUNOL, V2, P707, DOI 10.1093/intimm/2.8.707; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; Goulder PJR, 1997, J EXP MED, V185, P1423, DOI 10.1084/jem.185.8.1423; GRANT MD, 1992, AIDS, V6, P1085, DOI 10.1097/00002030-199210000-00004; Greenough TC, 1997, J INFECT DIS, V176, P118, DOI 10.1086/514013; Harrer T, 1996, J IMMUNOL, V156, P2616; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365; Klenerman P, 1996, P NATL ACAD SCI USA, V93, P15323, DOI 10.1073/pnas.93.26.15323; KOENIG S, 1995, NAT MED, V1, P330, DOI 10.1038/nm0495-330; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; MOSS PAH, 1995, P NATL ACAD SCI USA, V92, P5773, DOI 10.1073/pnas.92.13.5773; Musey L, 1997, NEW ENGL J MED, V337, P1267, DOI 10.1056/NEJM199710303371803; Nowak MA, 1996, SCIENCE, V272, P74, DOI 10.1126/science.272.5258.74; OBrien TR, 1996, JAMA-J AM MED ASSOC, V276, P105, DOI 10.1001/jama.276.2.105; OGG GS, UNPUB; PARKER KC, 1992, J IMMUNOL, V149, P3580; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; Price DA, 1997, P NATL ACAD SCI USA, V94, P1890, DOI 10.1073/pnas.94.5.1890; RINALDO C, 1995, J VIROL, V69, P5838, DOI 10.1128/JVI.69.9.5838-5842.1995; RINALDO CR, 1995, AIDS RES HUM RETROV, V11, P481, DOI 10.1089/aid.1995.11.481; Shiga H, 1996, AIDS, V10, P1075, DOI 10.1097/00002030-199609000-00004; Steven NM, 1997, J EXP MED, V185, P1605, DOI 10.1084/jem.185.9.1605; TSOMIDES TJ, 1991, P NATL ACAD SCI USA, V88, P11276, DOI 10.1073/pnas.88.24.11276; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	40	1208	1280	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 27	1998	279	5359					2103	2106		10.1126/science.279.5359.2103	http://dx.doi.org/10.1126/science.279.5359.2103			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZE274	9516110				2022-12-28	WOS:000072775600046
J	van Jaarsveld, AS; Freitag, S; Chown, SL; Muller, C; Koch, S; Hull, H; Bellamy, C; Kruger, M; Endrody-Younga, S; Mansell, MW; Scholtz, CH				van Jaarsveld, AS; Freitag, S; Chown, SL; Muller, C; Koch, S; Hull, H; Bellamy, C; Kruger, M; Endrody-Younga, S; Mansell, MW; Scholtz, CH			Biodiversity assessment and conservation strategies	SCIENCE			English	Article							RESERVE SELECTION; DIVERSITY; HOTSPOTS	The efficient representation of all species in conservation planning is problematic. Often, species distribution is assessed by dividing the land into a grid; complementary sets of grids, in which each taxon is represented at least once, are then sought. To determine if this approach provides useful surrogate information, species and higher taxon data for South African plants and animals were analyzed. Complementary species sets did not coincide and overlapped little with higher taxon sets. Survey extent and taxonomic knowledge did not affect this overlap. Thus, the assumptions of surrogacy, on which so much conservation planning is based, are not supported.	Univ Pretoria, Dept Zool & Entomol, ZA-0002 Pretoria, South Africa; Transvaal Museum, ZA-0001 Pretoria, South Africa; Agr Res Council, Plant Protect Res Inst, ZA-0001 Pretoria, South Africa	University of Pretoria; Agricultural Research Council of South Africa	van Jaarsveld, AS (corresponding author), Univ Pretoria, Dept Zool & Entomol, ZA-0002 Pretoria, South Africa.	albert@scientia.up.ac.za	Chown, Steven/ABD-7646-2021; van Jaarsveld, Albert/H-5368-2013; Scholtz, Clarke/E-7121-2010; Chown, Steven L/H-3347-2011	Chown, Steven L/0000-0001-6069-5105; Freitag, Stef/0000-0001-7466-6778				Cowling RM, 1994, STRELITZIA, P31; CURNUTT J, 1994, NATURE, V367, P326, DOI 10.1038/367326a0; Dobson AP, 1997, SCIENCE, V275, P550, DOI 10.1126/science.275.5299.550; Faith DP, 1996, BIODIVERS CONSERV, V5, P399, DOI 10.1007/BF00056387; Gaston KJ, 1996, PROG PHYS GEOG, V20, P105, DOI 10.1177/030913339602000108; GASTON KJ, 1992, FUNCT ECOL, V6, P243, DOI 10.2307/2389513; GASTON KJ, 1991, OIKOS, V61, P434, DOI 10.2307/3545251; GASTON KJ, 1996, PROGR PHYS GEOGR, V20, P77; Haila Y, 1996, ECOGRAPHY, V19, P323, DOI 10.1111/j.1600-0587.1996.tb00243.x; Harrison JA, 1997, ATLAS SO AFRICAN BIR; *INT COUNC BIRD PR, 1992, PUTT BIOD MAP PRIOR; *IUCN WORLD CONS U, 1987, CTR PLANT DIV GUID S; LANDRES PB, 1988, CONSERV BIOL, V2, P316, DOI 10.1111/j.1523-1739.1988.tb00195.x; Lawton JH, 1998, NATURE, V391, P72, DOI 10.1038/34166; Lombard AT, 1995, S AFR J ZOOL, V30, P145; Margules C. R., 1994, V50, P327; Muller C, 1997, AFR ENTOMOL, V5, P261; NICHOLLS AO, 1993, BIOL CONSERV, V64, P165, DOI 10.1016/0006-3207(93)90654-J; NOSS RF, 1990, CONSERV BIOL, V4, P355, DOI 10.1111/j.1523-1739.1990.tb00309.x; PEARSON DL, 1994, PHILOS T ROY SOC B, V345, P75, DOI 10.1098/rstb.1994.0088; Prendergast JR, 1997, ECOGRAPHY, V20, P210, DOI 10.1111/j.1600-0587.1997.tb00363.x; PRENDERGAST JR, 1993, NATURE, V365, P335, DOI 10.1038/365335a0; PRESSEY RL, 1993, TRENDS ECOL EVOL, V8, P124, DOI 10.1016/0169-5347(93)90023-I; Rebelo A.G., 1994, STRELITZIA, P231; SCHOLTZ CH, 1995, S AFR J SCI, V91, P124; SCHOLTZ CH, 1995, INSECTS SO AFRICA; SCOTT JM, 1993, WILDLIFE MONOGR, V123, P41; VANJAARSVELD AS, 1996, AFR J SCI, V92, P459; Williams Paul H., 1996, P54; WILLIAMS PH, 1994, BIOL CONSERV, V67, P211, DOI 10.1016/0006-3207(94)90612-2	30	271	276	0	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 27	1998	279	5359					2106	2108		10.1126/science.279.5359.2106	http://dx.doi.org/10.1126/science.279.5359.2106			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZE274	9516111				2022-12-28	WOS:000072775600047
J	Levinsky, NG				Levinsky, NG			Sounding board - Truth or consequences	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HEALTH-CARE; BEDSIDE		Boston Univ, Med Ctr, Boston, MA 02118 USA	Boston University	Levinsky, NG (corresponding author), Boston Univ, Med Ctr, 80 E Concord St, Boston, MA 02118 USA.							ABRAMS FR, 1986, JAMA-J AM MED ASSOC, V256, P1784; HALL MA, 1994, NEW YORK U LAW REV, V69, P693; HIATT HH, 1975, NEW ENGL J MED, V293, P235, DOI 10.1056/NEJM197507312930506; Lee R G, 1990, Law Med Health Care, V18, P69; LEVINSKY NG, 1984, NEW ENGL J MED, V311, P1573, DOI 10.1056/NEJM198412133112412; MORREIM EH, 1989, ARCH INTERN MED, V149, P1012, DOI 10.1001/archinte.149.5.1012; UBEL PA, 1995, ARCH INTERN MED, V155, P1837, DOI 10.1001/archinte.155.17.1837; WELCH HG, 1991, ANN INTERN MED, V115, P223, DOI 10.7326/0003-4819-115-3-223	8	14	14	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 26	1998	338	13					913	915		10.1056/NEJM199803263381313	http://dx.doi.org/10.1056/NEJM199803263381313			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD284	9516231				2022-12-28	WOS:000072669800013
J	Lisberger, SG				Lisberger, SG			Cerebellar LTD: A molecular mechanism of behavioral learning?	CELL			English	Review							LONG-TERM DEPRESSION; VESTIBULOOCULAR REFLEX; MUTANT MICE		Univ Calif San Francisco, Howard Hughes Med Inst, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, WM Keck Fdn Ctr Integrat Neurosci, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Lisberger, SG (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Dept Physiol, San Francisco, CA 94143 USA.							AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; DEZEEUW CI, 1998, IN PRESS NEURON; ITO M, 1972, BRAIN RES, V40, P80; Kim JJ, 1997, TRENDS NEUROSCI, V20, P177, DOI 10.1016/S0166-2236(96)10081-3; Koekkoek Sebastiaan K. E., 1997, Genes and Function, V1, P175; LevRam V, 1997, NEURON, V18, P1025, DOI 10.1016/S0896-6273(00)80340-2; LINDEN DJ, 1995, ANNU REV NEUROSCI, V18, P319, DOI 10.1146/annurev.ne.18.030195.001535; LISBERGER SG, 1994, J NEUROPHYSIOL, V72, P974, DOI 10.1152/jn.1994.72.2.974; Mauk MD, 1997, NEURON, V18, P343, DOI 10.1016/S0896-6273(00)81235-0; MILES FA, 1980, J NEUROPHYSIOL, V43, P1437, DOI 10.1152/jn.1980.43.5.1437; Raymond JL, 1996, SCIENCE, V272, P1126, DOI 10.1126/science.272.5265.1126; Raymond JL, 1997, LEARN MEMORY, V3, P503, DOI 10.1101/lm.3.6.503; SAKURAI M, 1987, J PHYSIOL-LONDON, V394, P463, DOI 10.1113/jphysiol.1987.sp016881; Shibuki K, 1996, NEURON, V16, P587, DOI 10.1016/S0896-6273(00)80078-1	14	56	56	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 20	1998	92	6					701	704		10.1016/S0092-8674(00)81397-5	http://dx.doi.org/10.1016/S0092-8674(00)81397-5			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZD198	9529245	Bronze			2022-12-28	WOS:000072661200002
J	Polyak, VJ; McIntosh, WC; Guven, N; Provencio, P				Polyak, VJ; McIntosh, WC; Guven, N; Provencio, P			Age and origin of Carlsbad cavern and related caves from 40Ar/39Ar of alunite	SCIENCE			English	Article							POTASSIUM-ARGON; NORTH-AMERICA; KENYA RIFT; NEVADA; GEOCHRONOLOGY	40Ar/39Ar dating of fine-grained alunite that formed during cave genesis provides ages of formation for the Big Room level of Carlsbad Cavern [4.0 to 3.9 million years ago (Ma)], the upper level of Lechuguilla Cave (6.0 to 5.7 Ma), and three other hypogene caves (11.3 to 6.0 Ma) in the Guadalupe Mountains of New Mexico. Alunite ages increase and are strongly correlative with cave elevations, which indicates an 1100-meter decline in the water table, apparently related to tectonic uplift and tilting, from 11.3 Ma to the present. 40Ar/39Ar dating studies of the hypogene caves have the potential to help resolve late Cenozoic climatic, speleologic, and tectonic questions.	Texas Tech Univ, Dept Geosci, Lubbock, TX 79409 USA; New Mexico Inst Min & Technol, New Mexico Geochronol Res Lab, Socorro, NM 87801 USA; Sandia Natl Labs, Albuquerque, NM 87185 USA	Texas Tech University System; Texas Tech University; New Mexico Institute of Mining Technology; United States Department of Energy (DOE); Sandia National Laboratories	Polyak, VJ (corresponding author), Texas Tech Univ, Dept Geosci, Lubbock, TX 79409 USA.	aqvjp@ttuvm1.ttu.edu; mcintosh@nmt.edu						AREHART GB, 1992, ECON GEOL BULL SOC, V87, P263, DOI 10.2113/gsecongeo.87.2.263; ASHLEY RP, 1976, ECON GEOL, V71, P904, DOI 10.2113/gsecongeo.71.5.904; BARKER DS, 1977, GEOL SOC AM BULL, V88, P1421, DOI 10.1130/0016-7606(1977)88<1421:NTMPIA>2.0.CO;2; BIRD MI, 1990, CHEM GEOL, V80, P133, DOI 10.1016/0168-9622(90)90022-5; BRETZ JH, 1949, J GEOL, V57, P447, DOI 10.1086/625660; Cabezas P., 1991, NEW MEXICO GEOLOGY, V13, P25; Chapin C.E., 1994, GEOL SOC AM SPEC PAP, V291, P5, DOI DOI 10.1130/SPE291-P5; COMPTON JS, 1990, GEOLOGY, V18, P1227, DOI 10.1130/0091-7613(1990)018<1227:PAWOSS>2.3.CO;2; DAVIS DG, 1980, NATIONAL SPELEOLOGIC, V42, P42; DEINO A, 1990, J GEOPHYS RES-SOLID, V95, P8453, DOI 10.1029/JB095iB06p08453; DUCHENE HR, 1989, SEPM CORE WORKSHOP, V13, P475; Eaton G. P., 1987, CONTINENTAL EXTENSIO, V28, P355, DOI [10.1144/GSL.SP.1987.028.01.22, DOI 10.1144/GSL.SP.1987.028.01.22]; Egemeier S.J., 1981, NATL SPELEOLOGICAL S, V43, P31; ELSTON WE, 1984, TECTONICS, V3, P229, DOI 10.1029/TC003i002p00229; Filippelli GM, 1997, GEOLOGY, V25, P27, DOI 10.1130/0091-7613(1997)025<0027:IOTAMA>2.3.CO;2; FLOWER BP, 1994, PALAEOGEOGR PALAEOCL, V108, P537, DOI 10.1016/0031-0182(94)90251-8; FORD DC, 1992, KARST GEOMORPHOLOGY; FORD DC, 1989, ISOCHRON W, V54, P3; Gardner JH, 1935, BULL GEOL SOC AM, V46, P1255; HAYES PT, 1964, US GEOL SURV PROF PA, V446; HENDRICKSON GE, 1952, 3 NEW MEX BUR MIN MI; Hill C.A., 1987, N M BUR MINES BULL, V117; HILL CA, 1990, AAPG BULL, V74, P1685; HILL CA, 1996, SEPM PUBL, V9639; HISS WL, 1980, NEW MEXICO GEOLOGICA, V31, P289; Itaya T, 1996, GEOCHIM COSMOCHIM AC, V60, P4525, DOI 10.1016/S0016-7037(97)82784-6; Izett G. L., 1975, GEOLOGICAL SOC AM ME, V144, P179, DOI DOI 10.1130/MEM144-P179; JAGNOW DH, 1989, SUBSURFACE OUTCROP E, V13, P459; KING PB, 1948, US GEOL SURV PROF PA, V215; Latorre C, 1997, EARTH PLANET SC LETT, V146, P83, DOI 10.1016/S0012-821X(96)00231-2; MOTTS WS, 1968, GEOL SOC AM BULL, V79, P283, DOI 10.1130/0016-7606(1968)79[283:TCOGOB]2.0.CO;2; ONSTOTT TC, 1995, GEOCHIM COSMOCHIM AC, V59, P1821, DOI 10.1016/0016-7037(95)00085-E; PALMER AN, 1991, GEOL SOC AM BULL, V103, P1, DOI 10.1130/0016-7606(1991)103<0001:OAMOLC>2.3.CO;2; Polyak VJ, 1996, CLAY CLAY MINER, V44, P843, DOI 10.1346/CCMN.1996.0440616; POLYAK VJ, IN PRESS J CAVES KAR; SAMSON SD, 1987, CHEM GEOL, V66, P27, DOI 10.1016/0168-9622(87)90025-X; STEIGER RH, 1977, EARTH PLANET SC LETT, V36, P359, DOI 10.1016/0012-821X(77)90060-7; STOFFREGEN RE, 1994, GEOCHIM COSMOCHIM AC, V58, P917, DOI 10.1016/0016-7037(94)90515-0; VASCONCELOS PM, 1994, GEOCHIM COSMOCHIM AC, V58, P401, DOI 10.1016/0016-7037(94)90473-1; VIKRE PG, 1985, ECON GEOL, V80, P360, DOI 10.2113/gsecongeo.80.2.360; WHITE WB, 1992, GEOMORPHOLOGY HYDROL; WOLFE JA, 1994, PALAEOGEOGR PALAEOCL, V108, P195, DOI 10.1016/0031-0182(94)90233-X; YORK D, 1994, US GEOL SURV CIRC, V1107, P360	43	95	96	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 20	1998	279	5358					1919	1922		10.1126/science.279.5358.1919	http://dx.doi.org/10.1126/science.279.5358.1919			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506939				2022-12-28	WOS:000072613300042
J	Nuki, G				Nuki, G			Ankylosing spondylitis, HLA B27, and beyond	LANCET			English	Editorial Material							HLA-B27 TRANSGENIC RATS; INFLAMMATORY DISEASE; ARTHRITIS; MODEL		Univ Edinburgh, Western Gen Hosp, Rheumat Dis Unit, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Nuki, G (corresponding author), Univ Edinburgh, Western Gen Hosp, Rheumat Dis Unit, Edinburgh EH4 2XU, Midlothian, Scotland.							Breban M, 1996, J IMMUNOL, V156, P794; BREWERTON DA, 1973, LANCET, V1, P904; Brown MA, 1997, ANN RHEUM DIS, V56, P68, DOI 10.1136/ard.56.1.68; Brown MA, 1997, ARTHRITIS RHEUM, V40, P1823, DOI 10.1002/art.1780401015; BROWN MA, 1997, BR J RHEUMATOL S1, V36; Brown Matthew, 1997, Current Opinion in Rheumatology, V9, P308; HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092-8674(90)90512-D; HILL AVS, 1991, LANCET, V337, P640, DOI 10.1016/0140-6736(91)92452-8; KHAN M, 1997, J RHEUMATOL S3, V4, P39; KHARE SD, 1995, J EXP MED, V182, P1153, DOI 10.1084/jem.182.4.1153; LOPEZLARREA C, 1995, TISSUE ANTIGENS, V45, P169, DOI 10.1111/j.1399-0039.1995.tb02436.x; Nasution AR, 1997, J RHEUMATOL, V24, P1111; Rath HC, 1996, J CLIN INVEST, V98, P945, DOI 10.1172/JCI118878; Smith GW, 1997, BRIT J RHEUMATOL, V36, P778; TAUROG JD, 1994, J EXP MED, V180, P2359, DOI 10.1084/jem.180.6.2359; WRIGHT V, 1976, SERONEGATIVE POLYART, P1	16	8	8	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 14	1998	351	9105					767	769		10.1016/S0140-6736(05)78922-4	http://dx.doi.org/10.1016/S0140-6736(05)78922-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB916	9519942				2022-12-28	WOS:000072521200003
J	Demple, B				Demple, B			Signal transduction - A bridge to control	SCIENCE			English	Article							TRANSCRIPTIONAL REGULATOR; ACTIVATION; OXIDATION		Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Div Toxicol, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Demple, B (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Div Toxicol, 665 Huntington Ave, Boston, MA 02115 USA.							AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Ding HG, 1997, P NATL ACAD SCI USA, V94, P8445, DOI 10.1073/pnas.94.16.8445; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Gaudu P, 1997, J BIOL CHEM, V272, P5082, DOI 10.1074/jbc.272.8.5082; Hidalgo E, 1997, CELL, V88, P121, DOI 10.1016/S0092-8674(00)81864-4; Hidalgo Elena, 1996, P435; Kim JM, 1997, SCIENCE, V278, P1954, DOI 10.1126/science.278.5345.1954; KULLIK I, 1995, J BACTERIOL, V177, P1275, DOI 10.1128/jb.177.5.1275-1284.1995; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	12	58	59	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 13	1998	279	5357					1655	1656		10.1126/science.279.5357.1655	http://dx.doi.org/10.1126/science.279.5357.1655			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9518377				2022-12-28	WOS:000072490000038
J	Keating, GM; Bougher, SW; Zurek, RW; Tolson, RH; Cancro, GJ; Noll, SN; Parker, JS; Schellenberg, TJ; Shane, RW; Wilkerson, BL; Murphy, JR; Hollingsworth, JL; Haberle, RM; Joshi, M; Pearl, JC; Conrath, BJ; Smith, MD; Clancy, RT; Blanchard, RC; Wilmoth, RG; Rault, DF; Martin, TZ; Lyons, DT; Esposito, PB; Johnston, MD; Whetzel, CW; Justus, CG; Babicke, JM				Keating, GM; Bougher, SW; Zurek, RW; Tolson, RH; Cancro, GJ; Noll, SN; Parker, JS; Schellenberg, TJ; Shane, RW; Wilkerson, BL; Murphy, JR; Hollingsworth, JL; Haberle, RM; Joshi, M; Pearl, JC; Conrath, BJ; Smith, MD; Clancy, RT; Blanchard, RC; Wilmoth, RG; Rault, DF; Martin, TZ; Lyons, DT; Esposito, PB; Johnston, MD; Whetzel, CW; Justus, CG; Babicke, JM			The structure of the upper atmosphere of Mars: In situ accelerometer measurements from Mars global surveyor	SCIENCE			English	Article							GENERAL-CIRCULATION; THERMOSPHERES; POLAR; VENUS; MODEL	The Mars Global Surveyor (MGS) z-axis accelerometer has obtained over 200 vertical structures of thermospheric density, temperature, and pressure, ranging from 110 to 170 kilometers, compared to only three previous such vertical structures. In November 1997 a regional dust storm in the Southern Hemisphere triggered an unexpectedly large thermospheric response at mid-northern latitudes, increasing the altitude of thermospheric pressure surfaces there by as much as 8 kilometers and indicating a strong global thermospheric response to a regional dust storm. Throughout the MGS mission, thermospheric density bulges have been detected on opposite sides of the planet near 90 degrees E and 90 degrees W, in the vicinity of maximum terrain heights. This wave 2 pattern may be caused by topographically-forced planetary waves propagating up from the lower atmosphere.	George Washington Univ, NASA, Langley Res Ctr, Hampton, VA 23681 USA; Univ Arizona, Tucson, AZ 85721 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; NASA, Ames Res Ctr, Moffett Field, CA 94035 USA; NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; Space Sci Inst, Boulder, CO 80309 USA; Comp Sci Corp, Huntsville, AL 35824 USA	George Washington University; National Aeronautics & Space Administration (NASA); NASA Langley Research Center; University of Arizona; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); National Aeronautics & Space Administration (NASA); NASA Ames Research Center; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center	Keating, GM (corresponding author), George Washington Univ, NASA, Langley Res Ctr, MS 269, Hampton, VA 23681 USA.		Bougher, Stephen/C-1913-2013; Joshi, Manoj/C-1795-2008; Smith, Michael/C-8875-2012	Bougher, Stephen/0000-0002-4178-2729; Joshi, Manoj/0000-0002-2948-2811; Cancro, George/0000-0002-9362-1011				Albee AL, 1998, SCIENCE, V279, P1671, DOI 10.1126/science.279.5357.1671; BALMINO G, 1982, J GEOPHYS RES, V87, P9735, DOI 10.1029/JB087iB12p09735; Barnes JR, 1996, J GEOPHYS RES-PLANET, V101, P12753, DOI 10.1029/96JE00179; BARTH CA, 1992, MARS, P1054; BLANCHARD RC, 1980, 1793 NASA; BOUGHER SW, 1995, ADV SPACE RES, V15, P21, DOI 10.1016/0273-1177(94)00062-6; BOUGHER SW, 1990, J GEOPHYS RES-SOLID, V95, P14811, DOI 10.1029/JB095iB09p14811; Bougher SW, 1997, ADV SPACE RES, V19, P1255, DOI 10.1016/S0273-1177(97)00278-0; BOUGHER SW, 1993, J GEOPHYS RES-PLANET, V98, P3281, DOI 10.1029/92JE02727; BOUGHER SW, 1994, J GEOPHYS RES-PLANET, V99, P14609, DOI 10.1029/94JE01088; Christensen PR, 1998, SCIENCE, V279, P1692, DOI 10.1126/science.279.5357.1692; Clancy R, COMMUNICATION; CLANCY RT, 1990, J GEOPHYS RES-SOLID, V95, P14543, DOI 10.1029/JB095iB09p14543; Clancy RT, 1996, ICARUS, V122, P36, DOI 10.1006/icar.1996.0108; Hollingsworth JL, 1996, J ATMOS SCI, V53, P428, DOI 10.1175/1520-0469(1996)053<0428:FSPWIM>2.0.CO;2; JAMES PB, 1994, ICARUS, V109, P79, DOI 10.1006/icar.1994.1078; JAMES PB, COMMUNICATION; Kahn R. A., 1992, MARS, P1017; KEATING GM, 1992, J GEOPHYS RES-SPACE, V97, P4189, DOI 10.1029/91JA02444; KEATING GM, 1987, ADV SPACE RES, V7, P57, DOI DOI 10.1016/0273-1177(87)90202-X; KEATING GM, 1997, EOS, V78, P48; KEATING GM, 1995, MGS ACCELEROMETER PR; KEATING GM, 1997, EOS, V78, pF401; KLIORE AJ, 1973, J GEOPHYS RES, V78, P4331, DOI 10.1029/JB078i020p04331; Malin MC, 1998, SCIENCE, V279, P1681, DOI 10.1126/science.279.5357.1681; MARTIN LJ, 1993, J GEOPHYS RES-PLANET, V98, P3221, DOI 10.1029/92JE02937; Murphy JR, 1995, J GEOPHYS RES-PLANET, V100, P26357, DOI 10.1029/95JE02984; Nier A. O., 1977, Journal of Geophysical Research, V82, P4341, DOI 10.1126/science.194.4271.1298; POLLACK JB, 1990, J GEOPHYS RES-SOLID, V95, P1447, DOI 10.1029/JB095iB02p01447; Schofield JT, 1997, SCIENCE, V278, P1752, DOI 10.1126/science.278.5344.1752; Seiff A., 1977, Journal of Geophysical Research, V82, P4364, DOI 10.1029/JS082i028p04364; SHANE RW, 1997, AM I AERONAUTICS AST, V97, P2509; Smith DE, 1996, SCIENCE, V271, P184, DOI 10.1126/science.271.5246.184; Smith PH, 1997, SCIENCE, V278, P1758, DOI 10.1126/science.278.5344.1758; Stewart A.J., 1982, ADV SPACE RES, V2, P87, DOI [10.1016/0273-1177(82)90109-0, DOI 10.1016/0273-1177(82)90109-0]; STEWART AIF, NQ802429 LASP JPL; Zurek R.W., 1992, MARS, P835	37	214	217	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 13	1998	279	5357					1672	1676		10.1126/science.279.5357.1672	http://dx.doi.org/10.1126/science.279.5357.1672			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9497278				2022-12-28	WOS:000072490000043
J	Notzon, FC; Komarov, YM; Ermakov, SP; Sempos, CT; Marks, JS; Sempos, EV				Notzon, FC; Komarov, YM; Ermakov, SP; Sempos, CT; Marks, JS; Sempos, EV			Causes of declining life expectancy in Russia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FORMER SOVIET-UNION; NORTH-KARELIA; MORTALITY; DISEASE; DEPRESSION; SUICIDES; FINLAND; RISK	Context.-Russian life expectancy has fallen sharply in the 1990s, but the impact of the major causes of death on that decline has not been measured. Objective.-To assess the contribution of selected causes of death to the dramatic decline in life expectancy in Russia in the years following the breakup of the Soviet Union, Design.-Mortality and natality data from the vital statistics systems of Russia and the United States, Setting.-Russia, 1990-1994, Population.-Entire population of Russia, Main Outcome Variables.-Mortality rates, life expectancy, and contribution to change in life expectancy, Methods.-Application of standard life-table methods to calculate life expectancy by year, and a partitioning method to assess the contribution of specific causes of death and age groups to the overall decline in life expectancy, United States data presented for comparative purposes, Results.-Age-adjusted mortality in Russia rose by almost 33% between 1990 and 1994, During that period, life expectancy for Russian men and women declined dramatically from 63.8 and 74.4 years to 57.7 and 71.2 years, respectively, while in the United States, life expectancy increased for both men and women from 71.8 and 78.8 years to 72.4 and 79.0 years, respectively, More than 75% of the decline in life expectancy was due to increased mortality rates for ages 25 to 64 years. Overall, cardiovascular diseases (heart disease and stroke) and injuries accounted for 65% of the decline in life expectancy while infectious diseases, including pneumonia and influenza, accounted for 5.8%, chronic liver diseases and cirrhosis for 2.4%, other alcohol-related causes for 9.6%, and cancer for 0.7%. Increases in cardiovascular mortality accounted for 41.6% of the decline in life expectancy for women and 33.4% for men, while increases in mortality from injuries leg, falls, occupational injuries, motor vehicle crashes, suicides, and homicides) accounted for 32.8% of the decline in life expectancy for men and 21.8% for women. Conclusion.-The striking rise in Russian mortality is beyond the peacetime experience of industrialized countries, with a 5-year decline in life expectancy in 4 years' time, Many factors appear to be operating simultaneously, including economic and social instability, high rates of tobacco and alcohol consumption, poor nutrition, depression, and deterioration of the health care system, Problems in data quality and reporting appear unable to account for these findings, These results clearly demonstrate that major declines in health and life expectancy can take place rapidly.	Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, US Dept HHS, Hyattsville, MD 20782 USA; Minist Publ Hlth Russia, Moscow, Russia; MedSocEconomInorm, Moscow, Russia; Univ Illinois, Dept Internal Med, Urbana, IL 61801 USA; Univ Illinois, Div Nutr Sci, Urbana, IL 61801 USA; Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, US Dept HHS, Atlanta, GA USA; Midatlantic Kaiser Permanente Med Grp, Gaithersburg, MD USA	Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Centers for Disease Control & Prevention - USA; Kaiser Permanente	Notzon, FC (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, US Dept HHS, 6525 Belcrest Rd,Room 701, Hyattsville, MD 20782 USA.		Ermakov, Sergey/G-1709-2016	Ermakov, Sergey/0000-0003-1072-1162				ANDERSON BA, 1986, POPUL DEV REV, V12, P705, DOI 10.2307/1973432; ANDERTON CH, 1993, DEFENC ECON, V4, P285, DOI 10.1080/10430719308404767; ANDREEV E, 1997, DEMOGRAPHIC REPORTS, V19; Arriaga E. E., 1989, DIFFERENTIAL MORTALI, P105; ARRIAGA EE, 1984, DEMOGRAPHY, V21, P83, DOI 10.2307/2061029; Barefoot JC, 1996, CIRCULATION, V93, P1976, DOI 10.1161/01.CIR.93.11.1976; BERKELMAN RL, 1990, INT J EPIDEMIOL, V19, P628, DOI 10.1093/ije/19.3.628; CARNEY RM, 1995, AM J CARDIOL, V76, P562, DOI 10.1016/S0002-9149(99)80155-6; *CDCP, 1996, MMWR-MORBID MORTAL W, V1, P1; Chen LC, 1996, POPUL DEV REV, V22, P517, DOI 10.2307/2137719; CHERNIACK MG, 1996, CURR ISSUES PUBLIC H, V2, P78; CHIANG CL, 1984, LIFE TABLE ITS APPLI; COOPER R, 1982, AM J PUBLIC HEALTH, V72, P431, DOI 10.2105/AJPH.72.5.431; DEEV AD, 1989, INT J EPIDEMIOL, V18, pS137; *GOSK RUSS, 1996, DEM YB RUSS STAT HDB; *GOSK RUSS, 1995, DEM YB RUSS STAT HDB; GRAITCER PL, 1994, WORKSH AD HLTH PRIOR; HAUB C, 1994, POPULATION CHANGE FO, V49; HJERMANN I, 1981, LANCET, V2, P130; Jonas BS, 1997, ARCH FAM MED, V6, P43, DOI 10.1001/archfami.6.1.43; KAWACHI I, 1994, CIRCULATION, V89, P1992, DOI 10.1161/01.CIR.89.5.1992; KLUGMAN J, 1995, WORKSH EC TRANSF HOU; Leon DA, 1997, LANCET, V350, P383, DOI 10.1016/S0140-6736(97)03360-6; LIGHT DW, 1992, LANCET, V339, P236; LOPEZ AD, 1997, PREMATURE DEATH NEW, P262; MATILAINEN TKM, 1994, INT J BEHAV MED, V1, P285, DOI 10.1207/s15327558ijbm0104_1; MESLE F, 1995, DOSSIERS RECHERCHES, V50; Mitchell F., 1997, PREMATURE DEATH NEW, P220; MURRAY CJL, 1994, PREMATURE DEATH NEW, P18; *NAT CTR HLTH STAT, 1995, VIT HLTH STAT, V5, P1; POPKIN B, 1997, PREMATURE DEATH NEW, P314; Popkin BM, 1996, AM J PUBLIC HEALTH, V86, P355, DOI 10.2105/AJPH.86.3.355; Pratt LA, 1996, CIRCULATION, V94, P3123, DOI 10.1161/01.CIR.94.12.3123; PROKHOROV AV, 1997, PREMATURE DEATH NEW, P275; PUSKA P, 1993, INT J EPIDEMIOL, V22, P1048, DOI 10.1093/ije/22.6.1048; ROGOT E, 1980, PUBLIC HEALTH REP, V95, P213; Rush D, 1996, AM J PUBLIC HEALTH, V86, P361, DOI 10.2105/AJPH.86.3.361; Shryock HS, 1973, METHODS MAT DEMOGRAP; SKOLNIKOV V, 1997, PREMATURE DEATH NEW, P239; SKOLNIKOV V, 1997, PREMATURE DEATH NEW, P34; Tulchinsky TH, 1996, AM J PUBLIC HEALTH, V86, P313, DOI 10.2105/AJPH.86.3.313; *US DEP HHS, 1988, INT CLASS DIS 9 REV; VARNIK A, 1992, ACTA PSYCHIAT SCAND, V86, P76, DOI 10.1111/j.1600-0447.1992.tb03230.x; WASSERMAN D, 1994, ACTA PSYCHIAT SCAND, V89, P306, DOI 10.1111/j.1600-0447.1994.tb01520.x; *WHO, 1986, WORLD HLTH STAT ANN; *WHO, 1994, WORLD HLTH STAT ANN	46	188	198	0	18	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 11	1998	279	10					793	800		10.1001/jama.279.10.793	http://dx.doi.org/10.1001/jama.279.10.793			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZA474	9508159				2022-12-28	WOS:000072366900040
J	Takaku, K; Oshima, M; Miyoshi, H; Matsui, M; Seldin, MF; Taketo, MM				Takaku, K; Oshima, M; Miyoshi, H; Matsui, M; Seldin, MF; Taketo, MM			Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes	CELL			English	Article							GROWTH-FACTOR-BETA; FAMILIAL ADENOMATOUS POLYPOSIS; TUMOR-SUPPRESSOR GENE; TARGETED DISRUPTION; PANCREATIC-CANCER; COLORECTAL-CANCER; NEOPLASIA MIN; MOUSE; CARCINOMA; RECEPTOR	The DPC4 (SMAD4) gene plays a key role in the TGF beta signaling pathway. We inactivated its mouse homolog Dpc4 (Smad4). The homozygous mutants were embryonic lethal, whereas the heterozygotes showed no abnormality. We then introduced the Dpc4 mutation into the Apc(Delta 716) knockout mice, a model for human familiar adenomatous polyposis. Because both Ape and Dpc4 are located on chromosome 18, we constructed compound heterozygotes carrying both mutations on the same chromosome by meiotic recombination. In such mice, intestinal polyps developed into more malignant tumors than those in the simple Apc(Delta 716) heterozygotes, showing an extensive stromal cell proliferation, submucosal invasion, cell type heterogeneity, and in vivo transplantability. These results indicate that mutations in DPC4 (SMAD4) play a significant role in the malignant progression of colorectal tumors.	Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Biomed Genet, Tokyo 1130033, Japan; Banyu Tsukuba Res Inst Merck, Tsukuba, Ibaraki 3002611, Japan; Univ Calif Davis, Dept Biol Chem, Rowe Program Genet, Davis, CA 95616 USA	University of Tokyo; Merck & Company; University of California System; University of California Davis	Taketo, MM (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Biomed Genet, Tokyo 1130033, Japan.		Oshima, Masanobu/F-9958-2014	Oshima, Masanobu/0000-0002-3304-0004; Miyoshi, Hiroyuki/0000-0001-7400-0714	NHGRI NIH HHS [HG00734] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000734] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Anna CH, 1997, MAMM GENOME, V8, P443, DOI 10.1007/s003359900465; BECKWITH PS, 1991, ARCH SURG-CHICAGO, V126, P825; CAVENEE WK, 1986, COLD SPRING HARB SYM, V51, P829, DOI 10.1101/SQB.1986.051.01.096; COFFEY RJ, 1987, J CLIN INVEST, V80, P750, DOI 10.1172/JCI113130; Derynck R, 1996, CELL, V87, P173, DOI 10.1016/S0092-8674(00)81335-5; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; Fenoglio-Preiser CM, 1990, TUMORS INTESTINES; FILMUS J, 1992, ONCOGENE, V7, P521; Filmus Jorge, 1993, Current Opinion in Oncology, V5, P123; FRIESS H, 1993, GASTROENTEROLOGY, V105, P1846, DOI 10.1016/0016-5085(93)91084-U; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; GARIBOLDI M, 1995, MAMM GENOME, V6, P581, DOI 10.1007/BF00352361; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hahn SA, 1996, CANCER RES, V56, P490; HORII A, 1992, CANCER RES, V52, P6696; INAZAWA J, 1992, JPN J CANCER RES, V83, P1248, DOI 10.1111/j.1349-7006.1992.tb02753.x; JAGELMAN DG, 1988, LANCET, V1, P1149; JENNINGS MT, 1991, INT J CANCER, V49, P129, DOI 10.1002/ijc.2910490124; Johnson KR, 1997, MAMM GENOME, V7, pS295, DOI 10.1007/s003359900330; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kloppel G., 1993, PANCREAS, P871; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LU SL, 1995, BIOCHEM BIOPH RES CO, V216, P452, DOI 10.1006/bbrc.1995.2644; LUONGO C, 1993, GENOMICS, V15, P3, DOI 10.1006/geno.1993.1002; LUONGO C, 1994, CANCER RES, V54, P5947; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MARKOWITZ SD, 1994, J CLIN INVEST, V93, P1005, DOI 10.1172/JCI117048; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Mishina Y, 1995, GENE DEV, V9, P3027, DOI 10.1101/gad.9.24.3027; Moskaluk CA, 1996, BBA-REV CANCER, V1288, pM31, DOI 10.1016/S0304-419X(96)00033-9; MULDER KM, 1988, CANCER RES, V48, P7120; OAKEY RJ, 1991, GENOMICS, V10, P338, DOI 10.1016/0888-7543(91)90317-8; Oshima H, 1997, CANCER RES, V57, P1644; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Polyak K, 1996, BBA-REV CANCER, V1242, P185, DOI 10.1016/0304-419X(95)00009-5; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Sanabria JR, 1996, AM J SURG, V171, P136, DOI 10.1016/S0002-9610(99)80088-9; SELDIN MF, 1988, J EXP MED, V167, P688, DOI 10.1084/jem.167.2.688; SHOEMAKER AR, 1995, CANCER RES, V55, P4479; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Smits R, 1997, CARCINOGENESIS, V18, P321, DOI 10.1093/carcin/18.2.321; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUGIHARA K, 1982, DIS COLON RECTUM, V25, P766, DOI 10.1007/BF02553308; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	51	480	500	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 6	1998	92	5					645	656		10.1016/S0092-8674(00)81132-0	http://dx.doi.org/10.1016/S0092-8674(00)81132-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZA827	9506519	Bronze			2022-12-28	WOS:000072406000010
J	Schlechte, JA; Kreisberg, R				Schlechte, JA; Kreisberg, R			Update in endocrinology	ANNALS OF INTERNAL MEDICINE			English	Article							POLYCYSTIC-OVARY-SYNDROME; PLACEBO-CONTROLLED TRIAL; GROWTH-HORMONE; ALENDRONATE; BONE; TROGLITAZONE; FRACTURES; DENSITY; DISEASE; NIDDM		Univ Iowa, MRF, Clin Res Ctr, Iowa City, IA 52242 USA; Baptist Hlth Syst, Dept Internal Med, Birmingham, AL 35213 USA	University of Iowa	Schlechte, JA (corresponding author), Univ Iowa, MRF, Clin Res Ctr, Room 157, Iowa City, IA 52242 USA.			Schlechte, Janet/0000-0002-4089-0445				*AM DIAB ASS, 1996, DIABETES CARE S1, V19, pS54; [Anonymous], 1997, Diabetes Care, V20 Suppl 1, pS1; [Anonymous], 1992, Consens Statement, V10, P1; BakkerArkema RG, 1996, JAMA-J AM MED ASSOC, V275, P128, DOI 10.1001/jama.275.2.128; Baum HBA, 1996, ANN INTERN MED, V125, P883, DOI 10.7326/0003-4819-125-11-199612010-00003; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; Colwell JA, 1996, ANN INTERN MED, V124, P131, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00010; deGroen PC, 1996, NEW ENGL J MED, V335, P1016, DOI 10.1056/NEJM199610033351403; Dunaif A, 1996, J CLIN ENDOCR METAB, V81, P3299, DOI 10.1210/jc.81.9.3299; FRANKS S, 1995, NEW ENGL J MED, V333, P853, DOI 10.1056/NEJM199509283331307; Gavin JR, 1997, DIABETES CARE, V20, P1183; Greenberger NJ, 1997, ANN INTERN MED, V127, P827, DOI 10.7326/0003-4819-127-9-199711010-00009; KritzSilverstein D, 1996, JAMA-J AM MED ASSOC, V275, P46; Kumar S, 1996, DIABETOLOGIA, V39, P701; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; NAWROCKI JW, 1995, ARTERIOSCL THROM VAS, V15, P678, DOI 10.1161/01.ATV.15.5.678; PEDERSEN TR, 1994, LANCET, V344, P1383; Schambelan M, 1996, ANN INTERN MED, V125, P873, DOI 10.7326/0003-4819-125-11-199612010-00002; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Shorr RI, 1996, J AM GERIATR SOC, V44, P751, DOI 10.1111/j.1532-5415.1996.tb03729.x; Siris E, 1996, J CLIN ENDOCR METAB, V81, P961, DOI 10.1210/jc.81.3.961	22	2	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1998	128	5					378	385		10.7326/0003-4819-128-5-199803010-00007	http://dx.doi.org/10.7326/0003-4819-128-5-199803010-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY519	9490599				2022-12-28	WOS:000072155600007
J	Schwartz, TB				Schwartz, TB			On first looking into Cabot's Differential Diagnosis	ANNALS OF INTERNAL MEDICINE			English	Article									Rush Med Coll, Chicago, IL 60612 USA	Rush University	Schwartz, TB (corresponding author), 200 Lee St, Evanston, IL 60202 USA.							ANDERS JM, 1906, TXB PRACTICE MED; CABOT RC, 1915, DIFFERENTIAL DIAGNOS, V2, P587; CABOT RC, 1915, DIFFERNTIAL DIAGNOSI, V2, P697; CABOT RC, 1915, DIFFERENTIAL DIAGNOS, V1, P17; CABOT RC, 1917, SOCIAL SCI ART HEALI, P4; CABOT RC, 1915, DIFFERENTIAL DIAGNOS, V1; CABOT RC, 1915, DIFFERENTIAL DIAGNOS, V1, P737; CABOT RC, 1915, DIFFERENTIAL DIAGNOS, V2, P175; CABOT RC, 1915, DIFFERENTIAL DIAGNOS, V1, P698; CABOT RC, 1915, DIFFERENTIAL DIAGNOS, V1, P32; CABOT RC, 1915, DIFFERENTIAL DIAGNOS, V2; CABOT RC, 1915, DIFFERENTIAL DIAGNOS, V1, P226; CABOT RC, 1915, DIFFERENTIAL DIAGNOS, V2, P541; CABOT RC, 1915, DIFFERENTIAL DIAGNOS, V1, P422; CABOT RC, 1915, DIFFERENTIAL DIAGNOS, V1, P128; Carlson KJ, 1996, NEW ENGL J MED, V335, P198, DOI 10.1056/NEJM199607183350309; DODDS TA, 1993, ANN INTERN MED, V119, P417, DOI 10.7326/0003-4819-119-5-199309010-00011; FRENCH H, 1918, INDEX DIFFERENTIAL D; HARE HA, 1907, TXB PRACTICAL THERAP; HERLITZ J, 1995, AM J EMERG MED, V13, P127, DOI 10.1016/0735-6757(95)90077-2; MORSE JL, 1913, CASE HIST PEDIAT COL; MUMFORD JG, 1911, 100 SURG PROBLEMS EX; OSLER W, 1916, PRINCIPOLES PRACTICE; SAJOUS CED, 1907, INTERNAL SECRETIONS, V2; SAJOUS CED, 1903, INTERNAL SECRETIONS, V1; TAYLOR EW, 1911, CASE HIST NEUROLOGY; Vallerand A H, 1995, Image J Nurs Sch, V27, P235; [No title captured]	28	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1998	128	5					411	414		10.7326/0003-4819-128-5-199803010-00018	http://dx.doi.org/10.7326/0003-4819-128-5-199803010-00018			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY519	9490608				2022-12-28	WOS:000072155600017
J	Dantal, J; Hourmant, M; Cantarovich, D; Giral, M; Blancho, G; Dreno, B; Soulillou, JP				Dantal, J; Hourmant, M; Cantarovich, D; Giral, M; Blancho, G; Dreno, B; Soulillou, JP			Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens	LANCET			English	Article							RENAL-TRANSPLANT PATIENTS; MONOCLONAL-ANTIBODY; REJECTION; THERAPY; PROPHYLAXIS; RECEPTOR; TRIAL; RISK	Background Long-term administration of cyclosporin carries a risk of renal toxicity, and immunosuppressants are associated with an increased rate of malignant disorders. We undertook an open randomised study of the risks and benefits of two long-term maintenance regimens of cyclosporin in kidney-allograft recipients. The primary endpoint was graft function; secondary endpoints were survival and occurrence of cancer and rejection. Methods 231 recipients of a first allograft with at most one previous rejection episode were randomised 1 year after transplantation. Most were receiving cyclosporin and azathioprine. One group received cyclosporin doses adjusted to yield trough blood concentrations of 75-125 ng/mL (low-dose group); the second received doses that yielded trough concentrations of 150-250 ng/mL (normal-dose group). Analysis was by intention to treat. Findings At 66 months' follow-up, the low-dose and normal-dose groups were similar in mean serum creatinine (182 [SD 160] vs 184 [157] mu mol/L; p=0.9) and mean creatinine clearance (47.5 [25.1] vs 45.3 (22.5] mL/min; p=0.6). Nine of 116 patients in the low-dose group and one of 115 in the normal-dose group had symptoms of rejection (p<0.02). There was no difference between the low-dose and normal-dose groups in survival (95 vs 92%; p=0.7) or graft survival (89 vs 82%; p=0.17) at 6 years. 60 patients developed cancers, 37 in the normal-dose group and 23 in the row-dose group (p<0.034); 66% were skin cancers (26 vs 17; p<0.05). Interpretation We found no evidence that halving of trough blood cyclosporin concentrations significantly changes graft function or graft survival. The low-dose regimen was associated with fewer malignant disorders but more frequent rejection. The design of long-term maintenance protocols for transplant recipients based on powerful immunosuppressant combinations should take these potential risks into account.	CHU Hotel Dieu, INSERM, U437, ITERT, F-44093 Nantes, France; CHU Hotel Dieu, Serv Dermatol, F-44093 Nantes, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes	Soulillou, JP (corresponding author), CHU Hotel Dieu, INSERM, U437, ITERT, F-44093 Nantes, France.	jps@nantes.inserm.fr						Bennett WM, 1996, KIDNEY INT, V50, P1089, DOI 10.1038/ki.1996.415; BLOHME I, 1984, TRANSPLANTATION, V37, P165, DOI 10.1097/00007890-198402000-00010; Buccianti G, 1996, LANCET, V347, P59, DOI 10.1016/S0140-6736(96)91591-3; BURKE JF, 1994, NEW ENGL J MED, V331, P358, DOI 10.1056/NEJM199408113310604; Canadian Multicentre Transplant Study Group, 1986, N Engl J Med, V314, P1219; CECKA JM, 1992, TRANSPLANTATION, V53, P59, DOI 10.1097/00007890-199201000-00011; Confavreux C, 1996, NEUROLOGY, V46, P1607, DOI 10.1212/WNL.46.6.1607; Dantal J, 1996, TRANSPLANTATION, V62, P1502, DOI 10.1097/00007890-199611270-00020; DILLING MB, 1994, CANCER RES, V54, P903; *EUR MULT TRIAL GR, 1983, JAMA-J AM MED ASSOC, V2, P986; HOURMANT M, 1989, TRANSPLANT INT, V2, P113; HOURMANT M, 1994, TRANSPLANTATION, V58, P377, DOI 10.1097/00007890-199408150-00023; KAHAN BD, 1997, TRANSPL P, V29, P36; Keown P, 1996, TRANSPLANTATION, V61, P1029; KOVARIK JM, 1994, TRANSPLANTATION, V58, P658; LINDHOLM A, 1993, TRANSPLANTATION, V56, P307, DOI 10.1097/00007890-199308000-00010; LONDON NJ, 1995, LANCET, V346, P403, DOI 10.1016/S0140-6736(95)92780-8; MORRIS JDH, 1995, LANCET, V346, P754, DOI 10.1016/S0140-6736(95)91510-9; Morris RE, 1996, LANCET, V348, pSII26; OPELZ G, 1993, LANCET, V342, P1514, DOI 10.1016/S0140-6736(05)80084-4; OPELZ G, 1994, TRANSPLANTATION, V58, P443, DOI 10.1097/00007890-199408270-00009; Penn I, 1994, Clin Transpl, P99; SHEIL AGR, 1993, TRANSPLANT P, V25, P1383; SOLEZ K, 1993, KIDNEY INT, V44, P411, DOI 10.1038/ki.1993.259; SOULILLOU JP, 1990, NEW ENGL J MED, V322, P1175, DOI 10.1056/NEJM199004263221702; STEWART T, 1995, LANCET, V346, P796, DOI 10.1016/S0140-6736(95)91618-0; TRESSLER RJ, 1994, INT J CANCER, V57, P568, DOI 10.1002/ijc.2910570421; Vincenti F, 1996, TRANSPLANTATION, V61, P1576, DOI 10.1097/00007890-199606150-00005; West M, 1996, TRANSPLANTATION, V62, P1029, DOI 10.1097/00007890-199610150-00025	29	554	586	0	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 28	1998	351	9103					623	628		10.1016/S0140-6736(97)08496-1	http://dx.doi.org/10.1016/S0140-6736(97)08496-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA447	9500317				2022-12-28	WOS:000072364200007
J	Wagner, G; de Tejada, IS				Wagner, G; de Tejada, IS			Fortnightly review - Update on male erectile dysfunction	BMJ-BRITISH MEDICAL JOURNAL			English	Review							NITRIC-OXIDE; CORPUS CAVERNOSUM; SMOOTH-MUSCLE; IMPOTENCE; PHYSIOLOGY; PENIS		Univ Copenhagen, Panum Inst, DK-2200 Copenhagen N, Denmark; Hosp Ruber Int, Androl Unit, Urol Serv, Madrid, Spain	University of Copenhagen	Wagner, G (corresponding author), Univ Copenhagen, Panum Inst, DK-2200 Copenhagen N, Denmark.	gorm@mfi.ku.dk						ANDERSSON KE, 1995, PHYSIOL REV, V75, P191, DOI 10.1152/physrev.1995.75.1.191; [Anonymous], AUTONOMIC NERVOUS SY; BALON R, 1993, J CLIN PSYCHIAT, V54, P209; Boolell M, 1996, BRIT J UROL, V78, P257, DOI 10.1046/j.1464-410X.1996.10220.x; Boolell M, 1996, Int J Impot Res, V8, P47; BOOLELL M, 1996, INT J IMPOT RES, V8, P186; BUFFUM J, 1986, J PSYCHOACTIVE DRUGS, V18, P97; BURNETT AL, 1995, BIOL REPROD, V52, P485, DOI 10.1095/biolreprod52.3.485; BURNETT AL, 1993, J UROLOGY, V150, P73, DOI 10.1016/S0022-5347(17)35401-0; Buvat Jacque, 1997, Journal of Urology, V157, P204; CARRIER S, 1994, ENDOCRIN METAB CLIN, V23, P773, DOI 10.1016/S0889-8529(18)30066-5; CHRIST GJ, 1995, UROL CLIN N AM, V22, P727; DERRY F, 1997, NEUROLOGY S2, V48, P215; Derry Fadel, 1997, Journal of Urology, V157, P181; DETEJADA IS, 1988, AM J PHYSIOL, V254, pH459, DOI 10.1152/ajpheart.1988.254.3.H459; EARDLEY I, 1996, EUR UROL S2, V30, P355; FELDMAN HA, 1994, J UROLOGY, V151, P54, DOI 10.1016/S0022-5347(17)34871-1; GINGELL C, 1996, EUR UROL S2, V30, P353; GREENSTEIN A, 1995, J UROLOGY, V153, P650, DOI 10.1016/S0022-5347(01)67675-4; GUAY AT, 1995, POSTGRAD MED, V97, P127, DOI 10.1080/00325481.1995.11945985; HEATON JPW, 1995, UROLOGY, V45, P200, DOI 10.1016/0090-4295(95)80005-0; IGNARRO LJ, 1990, BIOCHEM BIOPH RES CO, V170, P843, DOI 10.1016/0006-291X(90)92168-Y; KIRBY RS, 1994, BRIT MED J, V308, P957, DOI 10.1136/bmj.308.6934.957; KORENMAN SG, 1995, J CLIN ENDOCR METAB, V80, P1985, DOI 10.1210/jc.80.7.1985; KRANE RJ, 1989, NEW ENGL J MED, V321, P1648, DOI 10.1056/NEJM198912143212406; KURT U, 1994, J UROLOGY, V152, P407, DOI 10.1016/S0022-5347(17)32750-7; Lewis R W, 1994, Acta Chir Hung, V34, P231; Li M. K., 1995, Annals Academy of Medicine Singapore, V24, P741; LUE TF, 1990, WORLD J UROL, V8, P67, DOI 10.1007/BF01576350; Lue Tom F., 1997, Journal of Urology, V157, P181; MEINHARDT W, 1996, INT J IMPOT RES, V8, P116; MORALES A, 1995, UROL CLIN N AM, V165, P60; OKEEFE M, 1995, MED CLIN N AM, V79, P415, DOI 10.1016/S0025-7125(16)30076-1; PadmaNathan H, 1997, NEW ENGL J MED, V336, P1, DOI 10.1056/NEJM199701023360101; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; REID K, 1987, LANCET, V2, P421; RUBIN A, 1958, JAMA-J AM MED ASSOC, V168, P498, DOI 10.1001/jama.1958.03000050010003; *TOMHS RES GROUP, 1996, EUR UROL S2, V30, P38; WAGNER G, 1994, INT J IMPOT RES S1, V6, pD78; Wagner G, 1981, IMPOTENCE PHYSL PSYC; ZEMEL P, 1988, AM J CARDIOL, V61, pH27, DOI 10.1016/0002-9149(88)91102-2	41	71	74	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 28	1998	316	7132					678	682		10.1136/bmj.316.7132.678	http://dx.doi.org/10.1136/bmj.316.7132.678			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA282	9522795	Green Published			2022-12-28	WOS:000072347900035
J	Howson, CP; Fineberg, HV; Bloom, BR				Howson, CP; Fineberg, HV; Bloom, BR			The pursuit of global health: the relevance of engagement for developed countries	LANCET			English	Article								The globalisation of the world economy and the consequent increase in commerce, travel, and communication have brought benefits to virtually every country. But these changes also bring risks that cannot be addressed adequately within traditional national borders. These risks include emerging infectious diseases, resulting in part from increased prevalence of drug-resistant pathogens; exposure to dangerous substances, such as contaminated foodstuffs, and banned and toxic substances; and violence, including chemical and bioterrorist attack. By investing in global health, industrliased countries will not only benefit populations in desperate and immediate need of assistance, but also themselves-through protecting their people, improving their economies, and advancing their international interests. This paper describes the rationale for involvement of industrialised countries in global health, and suggests a means for its coordination.	Natl Acad Sci, Inst Med, Board Int Hlth, Washington, DC 20418 USA; Harvard Univ, Boston, MA 02115 USA; Albert Einstein Coll Med, Howard Hughes Med Inst, Dept Microbiol, Bronx, NY 10460 USA	National Academies of Sciences, Engineering & Medicine; Harvard University; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine	Howson, CP (corresponding author), Natl Acad Sci, Inst Med, Board Int Hlth, 2101 Constitut Ave NW, Washington, DC 20418 USA.							BALLANCE R, 1992, UN IND DEV ORG UNIDO; *COMM INT SCI ENG, GLOB MICR THREATS 19; Garrett L., 1996, FOREIGN AFF, V75, P66, DOI 10.2307/20047468; *I MED, 1979, PHARM INN NEEDS DEV; Kaplan David E., 1996, CULT END WORLD; LINDEN E, 1996, FOREIGN AFF      JAN, P52; *UN DEV PROGR, 1991, HUM DEV REP; *WORLD BANK, 1993, WORLD DEV REP 1993 I	8	34	34	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 21	1998	351	9102					586	590		10.1016/S0140-6736(97)11452-0	http://dx.doi.org/10.1016/S0140-6736(97)11452-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ216	9492799				2022-12-28	WOS:000072231900044
J	Elledge, SJ				Elledge, SJ			Mitotic arrest: Mad2 prevents sleepy from waking up the APC	SCIENCE			English	Article							CELL-CYCLE; MITOSIS; YEAST		Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Dept Biochem, Houston, TX 77030 USA	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine	Elledge, SJ (corresponding author), Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM044664, R01GM044664] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44664] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amon A, 1997, EMBO J, V16, P2693, DOI 10.1093/emboj/16.10.2693; AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Geiser JR, 1997, MOL BIOL CELL, V8, P1035, DOI 10.1091/mbc.8.6.1035; He XW, 1997, P NATL ACAD SCI USA, V94, P7965, DOI 10.1073/pnas.94.15.7965; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; HUNT T, 1992, J CELL BIOL, V116, P707, DOI 10.1083/jcb.116.3.707; Hwang LH, 1998, SCIENCE, V279, P1041, DOI 10.1126/science.279.5353.1041; Kim SH, 1998, SCIENCE, V279, P1045, DOI 10.1126/science.279.5353.1045; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460	19	55	57	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 13	1998	279	5353					999	1000		10.1126/science.279.5353.999	http://dx.doi.org/10.1126/science.279.5353.999			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX100	9490488				2022-12-28	WOS:000072006400034
J	Bowers, TR; O'Neill, WW; Grines, C; Pica, MC; Safian, RD; Goldstein, JA				Bowers, TR; O'Neill, WW; Grines, C; Pica, MC; Safian, RD; Goldstein, JA			Effect of reperfusion on biventricular function and survival after right ventricular infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INFERIOR MYOCARDIAL-INFARCTION; RIGHT CORONARY-ARTERY; THROMBOLYTIC THERAPY; EJECTION FRACTION; PROGNOSTIC-SIGNIFICANCE; HEMODYNAMIC COMPROMISE; DYSFUNCTION; STREPTOKINASE; INVOLVEMENT; PERFORMANCE	Background Although the salutary effects of reperfusion in patients with left ventricular infarction are well documented, the benefits in patients with acute right ventricular infarction are less clear. Methods To determine whether primary angioplasty improves right ventricular function and the clinical outcome in patients with right ventricular infarction, we performed echocardiographic studies before and after angioplasty in 53 patients with acute right ventricular infarction. Results Complete reperfusion, defined as normal flow in the right main coronary artery and its major right ventricular branches, was achieved in 41 patients (77 percent), leading to prompt and striking recovery of right ventricular function (mean [+/-SE] score for free-wall motion, 3.0+/-0.4 at base line and 1.4+/-0.1 at three days; P<0.001). Twelve patients (23 percent) had unsuccessful reperfusion, defined as the failure to restore right ventricular branch flow, with or without patency of the right main coronary artery. Unsuccessful reperfusion was associated with lack of recovery of right ventricular function (score for free-wall motion, 3.2+/-0.6 at base line and 3.0+/-0.9 at three days; P=0.55), as well as persistent hypotension and low cardiac output (in 83 percent of the patients, vs. 12 percent of those with successful reperfusion; P=0.002) and a high mortality rate (58 percent, vs. 2 percent for those with successful reperfusion P=0.001). Conclusions In patients with right ventricular infarction, complete reperfusion of the right coronary artery by angioplasty results in the dramatic recovery of right ventricular performance and an excellent clinical outcome. In contrast, unsuccessful reperfusion is associated with impaired recovery of right ventricular function, persistent hemodynamic compromise, and a high mortality rate. (C) 1998, Massachusetts Medical Society.	William Beaumont Hosp, Div Cardiol, Royal Oak, MI 48073 USA	Beaumont Health	Goldstein, JA (corresponding author), William Beaumont Hosp, Div Cardiol, 3601 W 13th Mile Rd, Royal Oak, MI 48073 USA.							[Anonymous], 1986, LANCET, V1, P397; BATES ER, 1989, J AM COLL CARDIOL, V13, P12, DOI 10.1016/0735-1097(89)90542-1; BERGER PB, 1993, AM J CARDIOL, V71, P1148, DOI 10.1016/0002-9149(93)90637-R; Bier J. D., 1997, Journal of the American College of Cardiology, V29, p460A; BRAAT SH, 1987, AM HEART J, V113, P257, DOI 10.1016/0002-8703(87)90262-6; BRAAT SH, 1984, AM HEART J, V107, P1183, DOI 10.1016/0002-8703(84)90275-8; BRODER MI, 1972, CIRCULATION, V46, P731, DOI 10.1161/01.CIR.46.4.731; Bueno H, 1997, CIRCULATION, V96, P436; COHN JN, 1974, AM J CARDIOL, V33, P209, DOI 10.1016/0002-9149(74)90276-8; DELLITALIA LJ, 1984, J AM COLL CARDIOL, V4, P931, DOI 10.1016/S0735-1097(84)80053-4; DELLITALIA LJ, 1987, CIRCULATION, V75, P996, DOI 10.1161/01.CIR.75.5.996; GOLDSTEIN JA, 1982, CIRCULATION, V65, P513, DOI 10.1161/01.CIR.65.3.513; GOLDSTEIN JA, 1992, J AM COLL CARDIOL, V19, P704, DOI 10.1016/S0735-1097(10)80296-7; GOLDSTEIN JA, 1990, CIRCULATION, V82, P359, DOI 10.1161/01.CIR.82.2.359; GOLDSTEIN JA, 1991, J AM COLL CARDIOL, V18, P1564, DOI 10.1016/0735-1097(91)90691-2; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; ISNER JM, 1978, AM J CARDIOL, V42, P885, DOI 10.1016/0002-9149(78)90672-0; KINCH JW, 1994, NEW ENGL J MED, V330, P1211, DOI 10.1056/NEJM199404283301707; KINN JW, 1995, J AM COLL CARDIOL, V26, P1230, DOI 10.1016/0735-1097(95)00311-8; KUSACHI S, 1982, AM J PHYSIOL, V243, pH761, DOI 10.1152/ajpheart.1982.243.5.H761; LASTER SB, 1994, CIRCULATION, V90, P1398, DOI 10.1161/01.CIR.90.3.1398; LASTER SB, 1993, CIRCULATION, V88, P696, DOI 10.1161/01.CIR.88.2.696; LORELL B, 1979, AM J CARDIOL, V43, P465, DOI 10.1016/0002-9149(79)90001-8; MAVRIC Z, 1990, AM HEART J, V119, P823; OHNISHI Y, 1995, CIRCULATION, V92, P500, DOI 10.1161/01.CIR.92.3.500; OHZONO K, 1986, CIRC RES, V59, P63, DOI 10.1161/01.RES.59.1.63; ONEILL W, 1986, NEW ENGL J MED, V314, P812, DOI 10.1056/NEJM198603273141303; PFISTERER M, 1986, EUR HEART J, V7, P289, DOI 10.1093/oxfordjournals.eurheartj.a062066; REDUTO LA, 1978, ANN INTERN MED, V89, P441, DOI 10.7326/0003-4819-89-4-441; ROTH A, 1990, CARDIOLOGY, V77, P40, DOI 10.1159/000174578; SCHELBERT HR, 1976, AM J CARDIOL, V38, P407, DOI 10.1016/0002-9149(76)90455-0; SCHULER G, 1984, AM J CARDIOL, V54, P951, DOI 10.1016/S0002-9149(84)80124-1; SHAH PK, 1985, J AM COLL CARDIOL, V6, P1264, DOI 10.1016/S0735-1097(85)80212-6; SHEEHAN FH, 1987, CIRCULATION, V75, P817, DOI 10.1161/01.CIR.75.4.817; STEELE P, 1977, BRIT HEART J, V39, P1319; VERANI MS, 1985, J AM COLL CARDIOL, V5, P1029, DOI 10.1016/S0735-1097(85)80002-4; WHITE HD, 1987, NEW ENGL J MED, V317, P850, DOI 10.1056/NEJM198710013171402; YASUDA T, 1990, AM HEART J, V119, P816, DOI 10.1016/S0002-8703(05)80317-5; ZEHENDER M, 1994, J AM COLL CARDIOL, V24, P362, DOI 10.1016/0735-1097(94)90289-5; ZEHENDER M, 1993, NEW ENGL J MED, V328, P981, DOI 10.1056/NEJM199304083281401	40	189	205	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 2	1998	338	14					933	940		10.1056/NEJM199804023381401	http://dx.doi.org/10.1056/NEJM199804023381401			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE776	9521980				2022-12-28	WOS:000072829800001
J	Hollander, GA; Zuklys, S; Morel, C; Mizoguchi, E; Mobisson, K; Simpson, S; Terhorst, C; Wishart, W; Golan, DE; Bhan, AK; Burakoff, SJ				Hollander, GA; Zuklys, S; Morel, C; Mizoguchi, E; Mobisson, K; Simpson, S; Terhorst, C; Wishart, W; Golan, DE; Bhan, AK; Burakoff, SJ			Monoallelic expression of the interleukin-2 locus	SCIENCE			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; VERSUS-HOST DISEASE; CELL GROWTH-FACTOR; T-CELLS; CD28 RECEPTOR; RECOMBINANT INTERLEUKIN-2; SIGNAL-TRANSDUCTION; AUTOIMMUNE-DISEASE; PROTEIN-TYROSINE; ANTIGEN RECEPTOR	The lymphokine interleukin-2 (IL-2) is responsible for autocrine cell cycle progression and regulation of immune responses. Uncontrolled secretion of IL-2 results in adverse reactions ranging from anergy, to aberrant T cell activation, to autoimmunity. With the use of fluorescent in situ hybridization and single-cell polymerase chain reaction in cells with different IL-2 alleles; IL-2 expression in mature thymocytes and T cells was found to be tightly controlled by monoallelic expression. Because IL-2 is encoded at a nonimprinted autosomal locus, this result represents an unusual regulatory mode for controlling the precise expression of a single gene.	Univ Basel, Sch Med, Dept Res, CH-4031 Basel, Switzerland; Univ Basel, Sch Med, Childrens Hosp, CH-4031 Basel, Switzerland; Harvard Univ, Sch Med, Dept Pediat, Dana Farber Canc Inst,Div Pediat Oncol, Boston, MA 02115 USA; Novartis Pharmaceut, Preclin Res, CH-4002 Basel, Switzerland; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Beth Israel Hosp, Div Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Hematol Oncol, Boston, MA 02115 USA	University of Basel; University of Basel; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Novartis; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Burakoff, SJ (corresponding author), Univ Basel, Sch Med, Dept Res, CH-4031 Basel, Switzerland.			Hollander, Georg/0000-0002-8790-0874	NATIONAL CANCER INSTITUTE [P01CA039542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017258] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047677] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA39542-09] Funding Source: Medline; NIAID NIH HHS [R01 AI17258-18] Funding Source: Medline; NIDDK NIH HHS [R01 DK47677] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREUSANCHEZ JL, 1991, J EXP MED, V173, P1323, DOI 10.1084/jem.173.6.1323; Beechey C. V., 1994, Mouse Genome, V92, P108; BOGEN SA, 1993, J IMMUNOL, V150, P4197; CERFBENSUSSAN N, 1984, J IMMUNOL, V132, P2244; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHATILA T, 1989, NEW ENGL J MED, V320, P696, DOI 10.1056/NEJM198903163201104; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; COLLINS TL, 1994, CURR OPIN IMMUNOL, V6, P385, DOI 10.1016/0952-7915(94)90117-1; DAVIS MM, 1990, ANNU REV BIOCHEM, V59, P475, DOI 10.1146/annurev.biochem.59.1.475; DESILVA DR, 1991, J IMMUNOL, V147, P3261; DISANTO JP, 1990, J EXP MED, V171, P1697, DOI 10.1084/jem.171.5.1697; ESSERY G, 1988, IMMUNOLOGY, V64, P413; FIORENTINO L, 1989, GENOMICS, V5, P651, DOI 10.1016/0888-7543(89)90039-6; FUSE A, 1984, NUCLEIC ACIDS RES, V12, P9323, DOI 10.1093/nar/12.24.9323; GARRITY PA, 1994, MOL CELL BIOL, V14, P2159, DOI 10.1128/MCB.14.3.2159; GUTIERREZRAMOS JC, 1992, EUR J IMMUNOL, V22, P2867, DOI 10.1002/eji.1830221117; HOLBROOK NJ, 1984, P NATL ACAD SCI-BIOL, V81, P1634, DOI 10.1073/pnas.81.6.1634; HOLLANDER GA, UNPUB; HOLMQUIST GP, 1987, AM J HUM GENET, V40, P151; JENKINS MK, 1994, IMMUNITY, V1, P443, DOI 10.1016/1074-7613(94)90086-8; JUNE CH, 1990, IMMUNOL TODAY, V11, P211, DOI 10.1016/0167-5699(90)90085-N; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; KITSBERG D, 1993, NATURE, V364, P459, DOI 10.1038/364459a0; KNOLL JHM, 1994, NAT GENET, V6, P41, DOI 10.1038/ng0194-41; KRAMER S, 1994, EUR J IMMUNOL, V24, P2317, DOI 10.1002/eji.1830241009; Kroemer G, 1992, Semin Immunol, V4, P167; LAWRENCE JB, 1988, CELL, V52, P51; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; LOPEZBOTET M, 1982, J IMMUNOL, V128, P679; MALKOVSKY M, 1985, P NATL ACAD SCI USA, V82, P536, DOI 10.1073/pnas.82.2.536; MATESANZ F, 1993, IMMUNOGENETICS, V38, P300, DOI 10.1007/BF00188809; Matesanz F, 1996, EUR J IMMUNOL, V26, P1675, DOI 10.1002/eji.1830260802; MOMBAERTS P, 1993, CELL, V75, P275, DOI 10.1016/0092-8674(93)80069-Q; NIEDERKORN JY, 1987, TRANSPLANTATION, V43, P523, DOI 10.1097/00007890-198704000-00014; OHNO T, 1987, CLIN IMMUNOL IMMUNOP, V45, P471, DOI 10.1016/0090-1229(87)90098-5; PAGANELLI R, 1983, CLIN EXP IMMUNOL, V51, P338; PAHWA R, 1989, P NATL ACAD SCI USA, V86, P5069, DOI 10.1073/pnas.86.13.5069; PFEIFER K, 1987, GENE DEV, V8, P1867; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; ROCHA B, 1988, SCAND J IMMUNOL, V27, P47, DOI 10.1111/j.1365-3083.1988.tb02322.x; RUDD CE, 1994, IMMUNOL TODAY, V15, P225, DOI 10.1016/0167-5699(94)90248-8; RUMP JA, 1992, CLIN EXP IMMUNOL, V89, P204; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; SAKAMOTO H, 1991, P NATL ACAD SCI USA, V88, P10890, DOI 10.1073/pnas.88.23.10890; SCHATZ DG, 1992, ANNU REV IMMUNOL, V10, P359, DOI 10.1146/annurev.iy.10.040192.002043; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; SORENSEN RU, 1992, J PEDIATR-US, V121, P873, DOI 10.1016/S0022-3476(05)80331-2; SYKES M, 1994, BLOOD, V83, P2560; TANIGUCHI T, 1986, IMMUNOL REV, V92, P121, DOI 10.1111/j.1600-065X.1986.tb01497.x; TAYLOR JH, 1960, J BIOPHYS BIOCHEM CY, V7, P455, DOI 10.1083/jcb.7.3.455; TIGGES MA, 1989, SCIENCE, V243, P781, DOI 10.1126/science.2492678; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; WEBB GC, 1990, CYTOGENET CELL GENET, V54, P164, DOI 10.1159/000132985; WEINBERG K, 1990, NEW ENGL J MED, V322, P1718, DOI 10.1056/NEJM199006143222406	55	201	204	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 27	1998	279	5359					2118	2121		10.1126/science.279.5359.2118	http://dx.doi.org/10.1126/science.279.5359.2118			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZE274	9516115				2022-12-28	WOS:000072775600051
J	Romesberg, FE; Spiller, B; Schultz, PG; Stevens, RC				Romesberg, FE; Spiller, B; Schultz, PG; Stevens, RC			Immunological origins of binding and catalysis in a Diels-Alderase antibody	SCIENCE			English	Article							TOXIN PEPTIDE COMPLEX; CHORISMATE MUTASE; CRYSTAL-STRUCTURE; MOLECULAR REPLACEMENT; ACTIVE-SITE; RESOLUTION; DIVERSITY; PROTEINS; FAMILY; GENES	The three-dimensional structure of an antibody (39-A11) that catalyzes a Diels-Alder reaction has been determined, The structure suggests that the antibody catalyzes this pericyclic reaction through a combination of packing and hydrogen-bonding interactions that control the relative geometries of the bound substrates and electronic distribution in the dienophile. A single somatic mutation, serine-91 of the light chain to valine, is largely responsible for the increase in affinity and catalytic activity of the affinity-matured antibody. Structural and functional studies of the germ-line precursor suggest that 39-A11 and related antibodies derive from a family of germ-line genes that have been selected throughout evolution for the ability of the encoded proteins to form a polyspecific combining site. Germ line-encoded antibodies of this type, which can rapidly evolve into high-affinity receptors for a broad range of structures, may help to expand the binding potential associated with the structural diversity of the primary antibody repertoire.	Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Schultz, PG (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA.		Stevens, Raymond/K-7272-2015; Romesberg, Floyd/M-2821-2017	Stevens, Raymond/0000-0002-4522-8725; Romesberg, Floyd/0000-0001-6317-1315				AVEVALO JH, 1993, NATURE, V365, P859; AVEVALO JH, 1994, J MOL BIOL, V241, P663; AVEVALO JH, 1993, J MOL BIOL, V231, P103; BRAISTED AC, 1990, J AM CHEM SOC, V112, P7430, DOI 10.1021/ja00176a073; BRUICE TC, 1960, J AM CHEM SOC, V82, P5858, DOI 10.1021/ja01507a023; BRUNGER AT, 1992, XPLOR VERSION 3 851; Charbonnier JB, 1997, SCIENCE, V275, P1140, DOI 10.1126/science.275.5303.1140; CHOOK YM, 1993, P NATL ACAD SCI USA, V90, P8600, DOI 10.1073/pnas.90.18.8600; DEVERSON E, 1987, EUR J IMMUNOL, V17, P9, DOI 10.1002/eji.1830170103; FLEMING I, 1976, FRONTIER ORBITALS OR; GOUVERNEUR VE, 1993, SCIENCE, V262, P204, DOI 10.1126/science.8211138; GU H, 1991, CELL, V65, P47, DOI 10.1016/0092-8674(91)90406-O; HAYNES M, 1996, ISRAEL J CHEM, V136, P151; HAYNES MR, 1994, SCIENCE, V263, P646, DOI 10.1126/science.8303271; HILVERT D, 1989, J AM CHEM SOC, V111, P9261, DOI 10.1021/ja00208a037; HsiehWilson LC, 1996, P NATL ACAD SCI USA, V93, P5363, DOI 10.1073/pnas.93.11.5363; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kabat EA, 1991, SEQUENCES PROTEINS I; KIM HNG, 1989, J IMMUNOL, V143, P638; LEVY R, 1989, BIOCHEMISTRY-US, V28, P7168, DOI 10.1021/bi00444a006; Liu DR, 1996, J AM CHEM SOC, V118, P1789, DOI 10.1021/ja953151o; Mesecar AD, 1997, SCIENCE, V277, P202, DOI 10.1126/science.277.5323.202; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; PAGE MI, 1971, P NATL ACAD SCI USA, V68, P1678, DOI 10.1073/pnas.68.8.1678; Patten PA, 1996, SCIENCE, V271, P1086, DOI 10.1126/science.271.5252.1086; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; ROTHBARD JB, 1991, ANNU REV IMMUNOL, V9, P527, DOI 10.1146/annurev.iy.09.040191.002523; SCHERF T, 1992, BIOCHEMISTRY-US, V31, P6884, DOI 10.1021/bi00145a004; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; SHOHAM M, 1993, J MOL BIOL, V232, P1169, DOI 10.1006/jmbi.1993.1469; SHOHAM M, 1991, PROTEINS, V11, P218, DOI 10.1002/prot.340110306; SIMS MJ, 1992, J IMMUNOL, V149, P1642; STORM DR, 1970, P NATL ACAD SCI USA, V66, P445, DOI 10.1073/pnas.66.2.445; TAIRA K, 1988, J MED CHEM, V31, P129, DOI 10.1021/jm00396a019; ULRICH HD, 1995, P NATL ACAD SCI USA, V92, P11907, DOI 10.1073/pnas.92.25.11907; Ulrich HD, 1997, NATURE, V389, P271, DOI 10.1038/38470; Wedemayer GJ, 1997, SCIENCE, V276, P1665, DOI 10.1126/science.276.5319.1665; XUE YF, 1995, P NATL ACAD SCI USA, V92, P10595, DOI 10.1073/pnas.92.23.10595; XUE YF, 1994, P NATL ACAD SCI USA, V91, P10814, DOI 10.1073/pnas.91.23.10814; ZHOU GW, 1994, SCIENCE, V265, P1059, DOI 10.1126/science.8066444	41	142	141	1	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 20	1998	279	5358					1929	1933		10.1126/science.279.5358.1929	http://dx.doi.org/10.1126/science.279.5358.1929			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506942				2022-12-28	WOS:000072613300045
J	Munin, MC; Rudy, TE; Glynn, NW; Crossett, LS; Rubash, HE				Munin, MC; Rudy, TE; Glynn, NW; Crossett, LS; Rubash, HE			Early inpatient rehabilitation after elective hip and knee arthroplasty	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH SURVEY SF-36; COST-EFFECTIVENESS; RELIABILITY; VALIDITY; TESTS	Context.-Inpatient rehabilitation after elective hip and knee arthroplasty is often necessary for patients who cannot function at home soon after surgery, but how soon after surgery inpatient rehabilitation can be initiated has not been studied. Objective.-To test the hypothesis that high-risk patients undergoing elective hip and knee arthroplasty would incur less total cost and experience more rapid functional improvement if inpatient rehabilitation began on postoperative day 3 rather than day 7, without adverse consequences to the patients. Design.-Randomized controlled trial conducted from 1994 to 1996. Setting.-Tertiary care center. Participants.-A total of 86 patients undergoing elective hip or knee arthroplasty and who met the following criteria for being high risk: 70 years of age or older and living alone, 70 years of age or older with 2 or more comorbid conditions, or any age with 3 or more comorbid conditions. Of the 86 patients, 71 completed the study. Interventions.-Random assignment to begin inpatient rehabilitation on postoperative day 3 vs postoperative day 7. Main Outcome Measures.-Total length of stay and cost from orthopedic and rehabilitation hospital admissions, functional performance in hospitals using a subset of the functional independence measure, and 4-month follow-up assessment using the RAND 36-item health survey I and the functional status index. Results.-Patients who completed the study and began inpatient rehabilitation on postoperative day 3 exhibited shorter mean (+/-SD) total length of stay (11.7+/-2.3 days vs 14.5+/-1.9, P<.001), lower mean (+/-SD) total cost ($25 891+/-$3648 vs $27 762+/-$3626, P<.03), more rapid attainment of short-term functional milestones between days 6 and 10 (36.2+/-14.4 m ambulated vs 21.4+/-13.3 m, P<.001; 4.8+/-0.8 mean transfer functional independence measure score vs 4.3+/-0.7, P<.01), and equivalent functional outcome at 4-month follow-up. Conclusion.-These data showed that high-risk individuals were able to tolerate early intensive rehabilitation, and this intervention yielded faster attainment of short-term functional milestones in fewer days using less total cost.	Univ Pittsburgh, Div Phys Med & Rehabil, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Orthopaed Surg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Anesthesiol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Munin, MC (corresponding author), Univ Pittsburgh, Div Phys Med & Rehabil, Suite 901,Kaufmann Bldg,3471 5th Ave, Pittsburgh, PA 15213 USA.	muninmc@msx.upmc.edu		Glynn, Nancy/0000-0003-2265-0162				BARBER TC, 1993, J BONE JOINT SURG AM, V75A, P321, DOI 10.2106/00004623-199303000-00002; Baron JA, 1996, AM J PUBLIC HEALTH, V86, P70, DOI 10.2105/AJPH.86.1.70; BAYLEY KB, 1995, MED CARE, V33, pAS226; CAMERON ID, 1994, J CLIN EPIDEMIOL, V47, P1307, DOI 10.1016/0895-4356(94)90136-8; Chang RW, 1996, JAMA-J AM MED ASSOC, V275, P858, DOI 10.1001/jama.275.11.858; Hamilton B. B., 1987, REHABILITATION OUTCO, P137; HEALY WL, 1994, J BONE JOINT SURG AM, V76A, P801, DOI 10.2106/00004623-199406000-00002; *INF PROC MAN, 1991, MED ARCH SYST DAT PI; JETTE AM, 1987, J RHEUMATOL, V14, P15; KATZ JN, 1990, MED CARE, V28, P632; KIM PR, 1996, ANN M AM AC ORTH SUR; Kwoh CK, 1997, ARTHRIT CARE RES, V10, P128, DOI 10.1002/art.1790100208; LIANG MH, 1986, ARTHRITIS RHEUM, V29, P937, DOI 10.1002/art.1780290801; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MEHTA C, 1991, STATXACT STAT SOFTWA; Mosteller F., 1968, HDB SOC PSYCHOL, V2, P80; MUNIN MC, 1995, AM J PHYS MED REHAB, V74, P294, DOI 10.1097/00002060-199507000-00006; Shwartz M, 1995, INQUIRY-J HEALTH CAR, V32, P476; Stineman MG, 1996, ARCH PHYS MED REHAB, V77, P1101, DOI 10.1016/S0003-9993(96)90130-6; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WEINGARTEN S, 1994, AM J MED, V97, P208, DOI 10.1016/0002-9343(94)90002-7	21	220	237	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 18	1998	279	11					847	852		10.1001/jama.279.11.847	http://dx.doi.org/10.1001/jama.279.11.847			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA943	9515999	Bronze			2022-12-28	WOS:000072417600031
J	Chamberlain, MA				Chamberlain, MA			Changing attitudes to disability in hospitals	LANCET			English	Editorial Material									Univ Leeds, Sch Med, Rehabil Div, Rheumatol & Rehabil Res Unit, Leeds LS2 9NZ, W Yorkshire, England	University of Leeds	Chamberlain, MA (corresponding author), Univ Leeds, Sch Med, Rehabil Div, Rheumatol & Rehabil Res Unit, Leeds LS2 9NZ, W Yorkshire, England.							Doyle B., 1996, DISABILITY DISCRIMIN; GOODING GC, 1996, BLACKSTONES GUIDE DI; HORDON LD, 1994, BRIT J RHEUMATOL, V33, P203; MARTIN J, 1988, 1 OPCS; *NHS EX, 1996, EMPL DIS PEOPL NHS G; *ROYAL COLL PHYS, 1992, CHARG DIS PEOPL US H; *ROYAL COLL PHYS, 1998, DIS PEOPL US HOSP CH	7	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 14	1998	351	9105					771	772		10.1016/S0140-6736(05)78926-1	http://dx.doi.org/10.1016/S0140-6736(05)78926-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB916	9519946				2022-12-28	WOS:000072521200007
J	Nguyen, QT; Parsadanian, AS; Snider, WD; Lichtman, JW				Nguyen, QT; Parsadanian, AS; Snider, WD; Lichtman, JW			Hyperinnervation of neuromuscular junctions caused by GDNF overexpression in muscle	SCIENCE			English	Article							CILIARY NEUROTROPHIC FACTOR; FACIAL MOTOR-NEURONS; SKELETAL-MUSCLE; IN-VIVO; POLYNEURONAL INNERVATION; SYNAPSE ELIMINATION; LIMB BUD; MOTONEURONS; EXPRESSION; SURVIVAL	Overexpression of glial cell line-derived neurotrophic factor (GDNF) by muscle greatly increased the number of motor axons innervating neuromuscular junctions in neonatal mice. The extent of hyperinnervation correlated with the amount of GDNF expressed in four transgenic lines. Overexpression of GDNF by glia and overexpression of neurotrophin-3 and neurotrophin-4 in muscle did not cause hyperinnervation. Thus, increased amounts of GDNF in postsynaptic target cells can regulate the number of innervating axons.	Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Lichtman, JW (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA.							BETZ WJ, 1979, J PHYSIOL-LONDON, V297, P463, DOI 10.1113/jphysiol.1979.sp013051; BLONDET B, 1989, DEV BIOL, V132, P153, DOI 10.1016/0012-1606(89)90213-3; BRENNER M, 1994, J NEUROSCI, V14, P1030, DOI 10.1523/JNEUROSCI.14-03-01030.1994; BROWN MC, 1976, J PHYSIOL-LONDON, V261, P387, DOI 10.1113/jphysiol.1976.sp011565; CABELLI RJ, 1995, SCIENCE, V267, P1662, DOI 10.1126/science.7886458; CARONI P, 1990, J CELL BIOL, V110, P1307, DOI 10.1083/jcb.110.4.1307; CARONI P, 1992, J NEUROSCI, V12, P3849; Causing CG, 1997, NEURON, V18, P257, DOI 10.1016/S0896-6273(00)80266-4; CHENG TC, 1992, J CELL BIOL, V119, P1649, DOI 10.1083/jcb.119.6.1649; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; COHENCORY S, 1995, NATURE, V378, P192, DOI 10.1038/378192a0; ENGLISH AW, 1995, DEV BIOL, V169, P57, DOI 10.1006/dbio.1995.1126; FLADBY T, 1987, ACTA PHYSIOL SCAND, V129, P229, DOI 10.1111/j.1748-1716.1987.tb08063.x; FUNAKOSHI H, 1995, SCIENCE, V268, P1495, DOI 10.1126/science.7770776; HENDERSON CE, 1993, NATURE, V363, P266, DOI 10.1038/363266a0; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; Houenou LJ, 1996, CELL TISSUE RES, V286, P219, DOI 10.1007/s004410050690; Jordan CL, 1996, DEV NEUROSCI-BASEL, V18, P185, DOI 10.1159/000111407; Keller-Peck C. R., 1997, Society for Neuroscience Abstracts, V23, P620; KOLIATSOS VE, 1994, P NATL ACAD SCI USA, V91, P3304, DOI 10.1073/pnas.91.8.3304; KWON YW, 1995, J NEUROBIOL, V28, P35, DOI 10.1002/neu.480280105; MERLIE JP, 1994, J BIOL CHEM, V269, P2461; Molliver DC, 1997, NEURON, V19, P849, DOI 10.1016/S0896-6273(00)80966-6; Nguyen QT, 1996, CURR OPIN NEUROBIOL, V6, P104, DOI 10.1016/S0959-4388(96)80015-8; Oppenheim RW, 1996, NEURON, V17, P195, DOI 10.1016/S0896-6273(00)80151-8; PRANZATELLI MR, 1990, CLIN NEUROPHARMACOL, V13, P329, DOI 10.1097/00002826-199008000-00008; REDFERN PA, 1970, J PHYSIOL-LONDON, V209, P701, DOI 10.1113/jphysiol.1970.sp009187; ROSMAN NP, 1984, J DEV BEHAV PEDIATR, V54, P263; ROTTOPERCELAY DM, 1992, BRAIN RES, V574, P291, DOI 10.1016/0006-8993(92)90829-X; SCHMUED LC, 1982, J HISTOCHEM CYTOCHEM, V30, P123, DOI 10.1177/30.2.6174560; Snider WD, 1996, MOL CELL NEUROSCI, V7, P433, DOI 10.1006/mcne.1996.0031; TSUZUKI T, 1995, ONCOGENE, V10, P191; Wright DE, 1997, NEURON, V19, P503, DOI 10.1016/S0896-6273(00)80367-0; Wright DE, 1996, CELL TISSUE RES, V286, P209, DOI 10.1007/s004410050689; Yamamoto M, 1996, NEUROCHEM RES, V21, P929, DOI 10.1007/BF02532343; YAN Q, 1995, NATURE, V373, P341, DOI 10.1038/373341a0; YAN Q, 1993, J NEUROBIOL, V24, P1555, DOI 10.1002/neu.480241202	37	216	223	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 13	1998	279	5357					1725	1729		10.1126/science.279.5357.1725	http://dx.doi.org/10.1126/science.279.5357.1725			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9497292				2022-12-28	WOS:000072490000057
J	Zheng, M; Aslund, F; Storz, G				Zheng, M; Aslund, F; Storz, G			Activation of the OxyR transcription factor by reversible disulfide bond formation	SCIENCE			English	Article							ESCHERICHIA-COLI; NEGATIVE MUTANTS; DNA-BINDING; GLUTATHIONE; STABILIZATION; REACTIVITY; REGULATOR; CHEMISTRY; PROTEINS; STRESS	The OxyR transcription factor is sensitive to oxidation and activates the expression of antioxidant genes in response to hydrogen peroxide in Escherichia coli. Genetic and biochemical studies revealed that OxyR is activated through the formation of a disulfide bond and is deactivated by enzymatic reduction with glutaredoxin 1 (Grx1). The gene encoding Grx1 is regulated by OxyR, th us providing a mechanism for autoregulation. The redox potential of OxyR was determined to be -185 millivolts, ensuring that OxyR is reduced in the absence of stress. These results represent an example of redox signaling through disulfide bond formation and reduction.	NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Harvard University; Harvard Medical School	Storz, G (corresponding author), NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA.	storz@helix.nih.gov		Storz, Gisela/0000-0001-6698-1241				Altuvia S, 1997, CELL, V90, P43, DOI 10.1016/S0092-8674(00)80312-8; Aslund F, 1997, J BIOL CHEM, V272, P30780, DOI 10.1074/jbc.272.49.30780; BLOCK E, 1974, J AM CHEM SOC, V96, P3929, DOI 10.1021/ja00819a034; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; CLAIBORNE A, 1993, FASEB J, V7, P1483, DOI 10.1096/fasebj.7.15.8262333; DAVIS FA, 1986, J ORG CHEM, V51, P1033, DOI 10.1021/jo00357a017; DAVIS FA, 1981, J AM CHEM SOC, V103, P7016, DOI 10.1021/ja00413a064; DAVIS NK, 1982, J GEN MICROBIOL, V128, P1631; DERMAN AI, 1993, SCIENCE, V262, P1744, DOI 10.1126/science.8259521; Ding HG, 1996, J BIOL CHEM, V271, P33173, DOI 10.1074/jbc.271.52.33173; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P13349, DOI 10.1021/bi9713658; Gaudu P, 1996, P NATL ACAD SCI USA, V93, P10094, DOI 10.1073/pnas.93.19.10094; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GONZALEZFLECHA B, REACTIVE OXYGEN SPEC; GREENBERG JT, 1986, J BACTERIOL, V168, P1026, DOI 10.1128/jb.168.2.1026-1029.1986; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; Hidalgo E, 1997, CELL, V88, P121, DOI 10.1016/S0092-8674(00)81864-4; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Jamieson D. J., 1997, OXIDATIVE STRESS MOL, P91; KICE JL, 1980, ADV PHYS ORG CHEM, V17, P65; KULLIK I, 1995, J BACTERIOL, V177, P1285, DOI 10.1128/jb.177.5.1285-1291.1995; LULLIK I, 1995, J BACTERIOL, V177, P1275; Prinz WA, 1997, J BIOL CHEM, V272, P15661, DOI 10.1074/jbc.272.25.15661; PRIVALLE CT, 1990, J BIOL CHEM, V265, P21966; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; RUSSEL M, 1988, P NATL ACAD SCI USA, V85, P990, DOI 10.1073/pnas.85.4.990; RUSSEL M, 1986, THIOREDOXIN GLUTARED, P331; SCHULTZ GE, 1979, PRINCIPLES PROTEIN S; STAMLER JS, 1992, ANAL CHEM, V64, P779, DOI 10.1021/ac00031a014; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; Tao K, 1997, J BACTERIOL, V179, P5967, DOI 10.1128/jb.179.18.5967-5970.1997; THANNHAUSER TW, 1984, ANAL BIOCHEM, V138, P181, DOI 10.1016/0003-2697(84)90786-3; THORNTON JM, 1981, J MOL BIOL, V151, P261, DOI 10.1016/0022-2836(81)90515-5; TOLEDANO MB, 1994, CELL, V78, P897, DOI 10.1016/S0092-8674(94)90702-1	35	943	971	0	83	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 13	1998	279	5357					1718	1721		10.1126/science.279.5357.1718	http://dx.doi.org/10.1126/science.279.5357.1718			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9497290				2022-12-28	WOS:000072490000055
J	Hawkey, CJ; Karrasch, JA; Szczepanski, L; Walker, DG; Barkun, A; Swannell, AJ; Yeomans, ND				Hawkey, CJ; Karrasch, JA; Szczepanski, L; Walker, DG; Barkun, A; Swannell, AJ; Yeomans, ND		Omeprazole versus Misoprostol NSAID Induced Ma	Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTI-INFLAMMATORY DRUGS; PLACEBO-CONTROLLED TRIAL; SERIOUS GASTROINTESTINAL COMPLICATIONS; GASTRODUODENAL MUCOSAL DAMAGE; PEPTIC-ULCER; HELICOBACTER-PYLORI; DUODENAL-ULCER; RHEUMATOID-ARTHRITIS; DYSPEPTIC SYMPTOMS; GASTRIC-ULCER	Background Misoprostol is effective for ulcers associated with the use of nonsteroidal antiinflammatory drugs (NSAIDs) but is often poorly tolerated because of diarrhea and abdominal pain. We compared the efficacy of omeprazole and misoprostol in healing and preventing ulcers associated with NSAIDs. Methods In a double-blind study, we randomly assigned 935 patients who required continuous NSAID therapy and who had ulcers or more than 10 erosions in the stomach or duodenum (or both) to receive 20 mg or 40 mg of omeprazole orally in the morning or 200 mu g of misoprostol orally four times daily. Patients were treated for four weeks or, in the absence of healing, eight weeks. Treatment success was defined as the absence of ulcers and the presence of fewer than five erosions at each site and not more than mild dyspepsia. We then randomly reassigned 732 patients in whom treatment was successful to maintenance therapy with 20 mg of omeprazole daily, 200 mu g of misoprostol twice daily, or placebo for six months. Results At eight weeks, treatment was successful in 76 percent of the patients given 20 mg of omeprazole (233 of 308), 75 percent of those given 40 mg of omeprazole (237 of 315), and 71 percent of those given misoprostol (212 of 298). The rates of gastric-ulcer healing were significantly higher with 20 mg of omeprazole (but not 40 mg of omeprazole) than with misoprostol. Healing rates among patients with duodenal ulcers were higher with either dose of omeprazole than with misoprostol, whereas healing rates among patients with erosions alone were higher with misoprostol. More patients remained in remission during maintenance treatment with omeprazole (61 percent) than with misoprostol (48 percent, P=0.001) and with either drug than with placebo (27 percent, P<0.001). There were more adverse events during the healing phase in the misoprostol group than in the groups given 20 mg and 40 mg of omeprazole (59 percent, 48 percent, and 46 percent, respectively). Conclusions The overall rates of successful treatment of ulcers, erosions, and symptoms associated with NSAIDs were similar for the two doses of omeprazole and misoprostol. Maintenance therapy with omeprazole was associated with a lower rate of relapse than misoprostol. Omeprazole was better tolerated than misoprostol. (C)1998, Massachusetts Medical Society.	Univ Nottingham Hosp, Div Gastroenterol, Nottingham NG7 2UH, England; Univ Med Sch, Dept Rheumatol, Lublin, Poland; Sunshine Coast Day Surg, Maroochydore, Qld, Australia; Montreal Gen Hosp, Div Gastroenterol, Montreal, PQ H3G 1A4, Canada; City Hosp Nottingham, Rheumatol Unit, Nottingham, England; Univ Melbourne, Western Hosp, Dept Med, Melbourne, Vic, Australia	University of Nottingham; McGill University; Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Melbourne; Western Hospital	Hawkey, CJ (corresponding author), Univ Nottingham Hosp, Div Gastroenterol, Nottingham NG7 2UH, England.			Yeomans, Neville/0000-0001-9870-832X				BARDHAN KD, 1993, BRIT J RHEUMATOL, V32, P990; BROOKS PM, 1991, NEW ENGL J MED, V324, P1716; BROOKS PM, 1991, NEW ENGL J MED, V325, P747; CHVASTA TE, 1972, J LAB CLIN MED, V79, P302; CULLEN D, IN PRESS ALIMENT PHA; CULLEN DJE, 1994, GASTROENTEROLOGY, V106, pA66; Cullen DJE, 1997, GUT, V41, P459, DOI 10.1136/gut.41.4.459; DANESHMEND TK, 1990, GUT, V31, P514, DOI 10.1136/gut.31.5.514; DAVENPORT HW, 1964, GASTROENTEROLOGY, V46, P245; DIMENAS E, 1995, SCAND J GASTROENTERO, V30, P1046, DOI 10.3109/00365529509101605; Dupuy H.J., 1984, ASSESSMENT QUALITY L, P170; *ECC, 1990, PHARMACOL TOXICOL, V67, P361; EHSANULLAH RSB, 1988, BRIT MED J, V297, P1017, DOI 10.1136/bmj.297.6655.1017; Ekstrom P, 1996, SCAND J GASTROENTERO, V31, P753, DOI 10.3109/00365529609010347; ELLIOTT SL, 1994, SCAND J RHEUMATOL, V23, P171, DOI 10.3109/03009749409103056; FRIES JF, 1991, J RHEUMATOL S, V28, P6; GABRIEL SE, 1991, ANN INTERN MED, V115, P787, DOI 10.7326/0003-4819-115-10-787; GRAHAM DY, 1988, LANCET, V2, P1277; Graham DY, 1996, AM J GASTROENTEROL, V91, P2080; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; HAWKEY C, 1990, BRIT MED J, V300, P764; HAWKEY CJ, 1990, BMJ-BRIT MED J, V300, P278, DOI 10.1136/bmj.300.6720.278; Hazleman B L, 1989, Scand J Rheumatol Suppl, V78, P1; Henry D, 1996, BRIT MED J, V312, P1563, DOI 10.1136/bmj.312.7046.1563; Huang J., 1996, Inflammopharmacology, V4, P17, DOI 10.1007/BF02735556; HUDSON N, 1993, GUT, V34, P748, DOI 10.1136/gut.34.6.748; Hudson N, 1997, GASTROENTEROLOGY, V112, P1817, DOI 10.1053/gast.1997.v112.pm9178671; HUNT SM, 1981, J EPIDEMIOL COMMUN H, V35, P297, DOI 10.1136/jech.35.4.297; JENSEN DM, 1994, NEW ENGL J MED, V330, P382, DOI 10.1056/NEJM199402103300602; Labenz J, 1997, AM J GASTROENTEROL, V92, P576; LANGMAN MJS, 1994, LANCET, V343, P1075, DOI 10.1016/S0140-6736(94)90185-6; MCCARTHY DM, 1989, GASTROENTEROLOGY, V96, P662, DOI 10.1016/S0016-5085(89)80063-0; MCCORMACK K, 1987, ARCH TOXICOL, V60, P261, DOI 10.1007/BF01234664; PAAKKARI I, 1994, PHARMACOL TOXICOL, V75, P56, DOI 10.1111/j.1600-0773.1994.tb01999.x; PENSTON JG, 1992, ALIMENT PHARM THERAP, V6, P629; ROBINSON MG, 1989, DIGEST DIS SCI, V34, P424, DOI 10.1007/BF01536266; RODRIGUEZ LAG, 1994, LANCET, V343, P769, DOI 10.1016/S0140-6736(94)91843-0; SCHEIMAN JM, 1994, DIGEST DIS SCI, V39, P97, DOI 10.1007/BF02090067; SCHEIMAN JM, 1992, SEMIN ARTHRITIS RHEU, V21, P201, DOI 10.1016/0049-0172(92)90050-N; SCHOEN RT, 1989, AM J MED, V86, P449, DOI 10.1016/0002-9343(89)90344-6; SHALLCROSS TM, 1990, BRIT MED J, V300, P368, DOI 10.1136/bmj.300.6721.368; SILVERSTEIN FE, 1995, ANN INTERN MED, V123, P241, DOI 10.7326/0003-4819-123-4-199508150-00001; VERDU EF, 1995, GUT, V37, P743, DOI 10.1136/gut.37.6.743; WALAN A, 1989, NEW ENGL J MED, V320, P69, DOI 10.1056/NEJM198901123200201; WALT RP, 1992, NEW ENGL J MED, V327, P1575; WOLFE F, 1986, ARTHRITIS RHEUM, V29, P614, DOI 10.1002/art.1780290505	46	662	690	0	18	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 12	1998	338	11					727	734		10.1056/NEJM199803123381105	http://dx.doi.org/10.1056/NEJM199803123381105			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB546	9494149	Green Published			2022-12-28	WOS:000072483400005
J	Donovan, JP; Schafer, DF; Shaw, BW; Sorrell, MF				Donovan, JP; Schafer, DF; Shaw, BW; Sorrell, MF			Cerebral oedema and increased intracranial pressure in chronic liver disease	LANCET			English	Article							FULMINANT HEPATIC-FAILURE	Background Cerebral oedema is a cause of morbidity and mortality in fulminant hepatic failure but has not been well documented as a complication of chronic liver diseases. We report here the development of cerebral oedema and increased intracranial pressure in 12 patients with chronic liver disease. Methods Between July 1, 1987, and Dec 31, 1993, we studied 12 patients aged 29-67 years with end-stage chronic liver disease. All the patients had cirrhosis. portal hypertension, hypoprothrombinaemia, hepatic encephalopathy, and decreased serum concentrations of albumin (<25 g/L). During the study, the patients developed signs of increased intracranial pressure and had documented intracranial hypertension, cerebral oedema, or both. Intracranial hypertension was suspected on physical examination and confirmed by epidural catheters. We detected cerebral oedema by computed axial tomography of the head and necropsy of the brain when possible. Findings All the patients had intracranial hypertension and cerebral oedema. Two patients had successful treatment of cerebral hypertension with improvement of intracranial pressure such that orthotopic liver transplantation was undertaken. Both patients became neurologically normal after transplantation. Eight patients had only a transient reponse to treatment and died of cerebral oedema before a transplant could be done. Interpretation Cerebral oedema and increased intracranial pressure can occur in chronic liver disease and presents as neurological deterioration. Treatment guided by monitoring of intracranial pressure can lead to the reversal of intracranial hypertension, but in most patients cerebral oedema contributes to death or places them at too high a risk for liver transplantation.	Univ Nebraska, Med Ctr, Dept Internal Med, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Surg, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Donovan, JP (corresponding author), Univ Nebraska, Med Ctr, Dept Internal Med, Omaha, NE 68198 USA.							CANALESE J, 1982, GUT, V23, P625, DOI 10.1136/gut.23.7.625; CONOMY JP, 1968, NEW ENGL J MED, V278, P876, DOI 10.1056/NEJM196804182781603; JABBOUR N, 1994, J OKLA STATE MED ASS, V84, P501; LIDOFSKY SD, 1992, HEPATOLOGY, V16, P1, DOI 10.1002/hep.1840160102; Plum F, 1980, DIAGNOSIS STUPOR COM, P177; Schafer DF, 1990, HEPATOLOGY, P447; SCHAFER DF, 1990, CURRENT THERAPY GAST, P451; WENDON JA, 1992, HEPATOLOGY, V15, P1067, DOI 10.1002/hep.1840150616; Yundt KD, 1997, CRIT CARE CLIN, V13, P163, DOI 10.1016/S0749-0704(05)70300-6	9	123	131	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 7	1998	351	9104					719	721		10.1016/S0140-6736(97)07373-X	http://dx.doi.org/10.1016/S0140-6736(97)07373-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB359	9504517				2022-12-28	WOS:000072463800010
J	Pahor, M; Psaty, BM; Furberg, CD				Pahor, M; Psaty, BM; Furberg, CD			Treatment of hypertensive patients with diabetes	LANCET			English	Editorial Material									Univ Tennessee, Dept Prevent Med, Memphis, TN 38105 USA; Univ Washington, Dept Med, Seattle, WA USA; Univ Washington, Dept Epidemiol, Seattle, WA USA; Univ Washington, Dept Hlth Serv, Seattle, WA USA; Wake Forest Univ, Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27109 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Wake Forest University	Pahor, M (corresponding author), Univ Tennessee, Dept Prevent Med, Memphis, TN 38105 USA.							Alderman M, 1998, LANCET, V351, P216, DOI 10.1016/S0140-6736(05)78175-7; Byington RP, 1997, LANCET, V350, P1075, DOI 10.1016/S0140-6736(05)70455-4; Curb JD, 1996, JAMA-J AM MED ASSOC, V276, P1886, DOI 10.1001/jama.276.23.1886; DiPasquale P, 1997, J CARDIOVASC PHARM, V29, P202; Estacio RO, 1998, NEW ENGL J MED, V338, P645, DOI 10.1056/NEJM199803053381003; Packer M, 1996, NEW ENGL J MED, V335, P1107, DOI 10.1056/NEJM199610103351504; Pahor M, 1998, DIABETES CARE, V21, P193, DOI 10.2337/diacare.21.1.193; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; TATTI P, 1997, CIRCULATION S1, V96, P764; TATTI P, IN PRESS DIABETES CA; Vaughan DE, 1997, CIRCULATION, V96, P442	11	62	63	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 7	1998	351	9104					689	690		10.1016/S0140-6736(05)78489-0	http://dx.doi.org/10.1016/S0140-6736(05)78489-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB359	9504510				2022-12-28	WOS:000072463800003
J	George, SE; Simokat, K; Hardin, J; Chisholm, AD				George, SE; Simokat, K; Hardin, J; Chisholm, AD			The VAB-1 Eph receptor tyrosine kinase functions in neural and epithelial morphogenesis in C-elegans	CELL			English	Article							CAENORHABDITIS-ELEGANS; DROSOPHILA GASTRULATION; MOLECULAR-CLONING; COMMISSURAL AXONS; IN-VITRO; GENE; PROTEIN; ENCODES; FAMILY; IDENTIFICATION	Mutations in the C. elegans vab-1 gene disrupt the coordinated movements of cells during two periods of embryogenesis. vab-1 mutants are defective in the movement of neuroblasts during closure of the ventral gastrulation cleft and in the movements of epidermal cells during ventral enclosure of the embryo by the epidermis. We show that vab-1 encodes a receptor tyrosine kinase of the Eph family. Disruption of the kinase domain of VAB-1 causes weak mutant phenotypes, indicating that VAB-1 may have both kinase-dependent and kinase-independent activities. VAB-1 is expressed in neurons during epidermal enclosure and is required in these cells for normal epidermal morphogenesis, demonstrating that cell-cell interactions are required between neurons and epidermal cells for epidermal morphogenesis.	Univ Calif Santa Cruz, Dept Biol, Sinsheimer Labs, Santa Cruz, CA 95064 USA; Univ Wisconsin, Dept Zool, Program Cellular & Mol Biol, Madison, WI 53706 USA	University of California System; University of California Santa Cruz; University of Wisconsin System; University of Wisconsin Madison	Chisholm, AD (corresponding author), Univ Calif Santa Cruz, Dept Biol, Sinsheimer Labs, Santa Cruz, CA 95064 USA.			Chisholm, Andrew/0000-0001-5091-0537	NIGMS NIH HHS [GM54657] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054657] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AROIAN RV, 1994, EMBO J, V13, P360, DOI 10.1002/j.1460-2075.1994.tb06269.x; BARD JB, 1992, MORPHOGENESIS; BRANDLI AW, 1995, DEV DYNAM, V203, P119; BRENNER S, 1974, GENETICS, V77, P71; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; Chen J, 1996, ONCOGENE, V12, P979; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; CHISHOLM AD, 1995, NATURE, V377, P52, DOI 10.1038/377052a0; CLARK SG, 1993, CELL, V74, P43, DOI 10.1016/0092-8674(93)90293-Y; CLARK SG, 1994, GENETICS, V137, P987; Connor RJ, 1995, ONCOGENE, V11, P2429; COSTA M, 1994, CELL, V76, P1075, DOI 10.1016/0092-8674(94)90384-0; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; Flanagan JG, 1997, CELL, V90, P403; FOX GM, 1995, ONCOGENE, V10, P897; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Gao PP, 1996, P NATL ACAD SCI USA, V93, P11161, DOI 10.1073/pnas.93.20.11161; GLISE B, 1995, CELL, V83, P451, DOI 10.1016/0092-8674(95)90123-X; HEDGECOCK EM, 1995, GENETICS, V141, P989; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; HERMAN RK, 1995, CAENORHABDITIS ELEGA, P123; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; Hodgkin J, 1997, C ELEGANS, P881; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Knust E, 1997, CURR BIOL, V7, pR558, DOI 10.1016/S0960-9822(06)00281-8; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; Labrador JP, 1997, EMBO J, V16, P3889, DOI 10.1093/emboj/16.13.3889; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Miller LM, 1996, GENETICS, V143, P1181; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; Orioli D, 1996, EMBO J, V15, P6035, DOI 10.1002/j.1460-2075.1996.tb00992.x; Orioli D, 1997, TRENDS GENET, V13, P354, DOI 10.1016/S0168-9525(97)01220-1; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PRIESS JR, 1986, DEV BIOL, V117, P156, DOI 10.1016/0012-1606(86)90358-1; RiesgoEscovar JR, 1996, GENE DEV, V10, P2759, DOI 10.1101/gad.10.21.2759; RUIZ JC, 1994, MECH DEVELOP, V46, P87; RUIZ JC, 1994, MECH DEVELOP, V48, P153, DOI 10.1016/0925-4773(94)90056-6; SCHEDL T, 1988, GENETICS, V119, P43; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WilliamsMasson EM, 1997, DEVELOPMENT, V124, P2889; Winning RS, 1996, DEV BIOL, V179, P309, DOI 10.1006/dbio.1996.0262; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; Xu QL, 1995, DEVELOPMENT, V121, P4005; YACIUK P, 1986, MOL CELL BIOL, V6, P2807, DOI 10.1128/MCB.6.8.2807	50	186	192	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 6	1998	92	5					633	643		10.1016/S0092-8674(00)81131-9	http://dx.doi.org/10.1016/S0092-8674(00)81131-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZA827	9506518	Bronze			2022-12-28	WOS:000072406000009
J	Hylek, EM; Heiman, H; Skates, SJ; Sheehan, MA; Singer, DE				Hylek, EM; Heiman, H; Skates, SJ; Sheehan, MA; Singer, DE			Acetaminophen and other risk factors for excessive warfarin anticoagulation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANTI-COAGULANT THERAPY; VITAMIN-K; BLEEDING COMPLICATIONS; POTENTIATION; OUTPATIENTS; DRUGS; WINE	Context.-Warfarin is highly effective in preventing thromboembolism, but increases the risk of hemorrhage, particularly at an international normalized ratio (INR) greater than 4.0. Identifying causes of excessive anticoagulation in clinical practice could help target patients at risk for elevated INRs. Objective.-To determine causes of INRs greater than 6.0 in a clinical practice setting. Design.-Case-control study. Setting.-Outpatient anticoagulant therapy unit, Patients.-Outpatients followed up prospectively from April 1995 to March 1996 who had been taking warfarin for more than 1 month, had a target INR of 2.0 to 3.0, and were able to be interviewed within 24 hours of their reported INR. Case patients had INRs greater than 6.0; controls were randomly selected from patients having INRs between 1.7 and 3.3. Main Outcome Measures.-Factors associated with INRs greater than 6.0, including medication use, recent diet, illness, alcohol consumption, and actual warfarin use. Results.-A total of 93 cases and 196 controls were interviewed; they did not differ in age, indication for warfarin, length of therapy, warfarin dose, number of prescription medications, or previous INR or long-term INR variability. Acetaminophen ingestion was independently associated in a dose-dependent manner with having an INR greater than 6.0 (P for trend <.001). For the highest-dose category of acetaminophen intake, 9100 mg/wk or more, the odds of having an INR greater than 6.0 were increased 10-fold (95% confidence interval [CI], 2.6-37.9). Other factors independently associated with an INR greater than 6.0 were new medication known to potentiate warfarin (odds ratio [OR], 8.5; 95% CI, 2.9-24.7), advanced malignancy (OR, 16.4; 95% CI, 2.4-111.0), recent diarrheal illness (OR, 3.5; 95% CI, 1.4-8.6), decreased oral intake (OR, 3.6; 95% CI, 1.3-9.7), and taking more warfarin than prescribed (OR, 8.1; 95% CI, 2.2-30.0). Higher vitamin K intake (OR, 0.7; 95% CI, 0.5-0.9) and habitual alcohol consumption of from 1 drink every other day to 2 drinks a day (OR, 0.2; 95% CI, 0.1-0.7) were associated with decreased risk. Conclusions.-These data suggest that acetaminophen is an underrecognized cause of overanticoagulation in the outpatient setting. Several other clinically important risk factors were identified. Increased monitoring of INR values when such risk factors are present or modification of the risk factors themselves should reduce the frequency of dangerously high levels of anticoagulation.	Massachusetts Gen Hosp, Med Practices Evaluat Ctr, Div Med Genet, Clin Epidemiol Unit,Dept Med, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Hylek, EM (corresponding author), Massachusetts Gen Hosp, Med Practices Evaluat Ctr, Div Med Genet, Clin Epidemiol Unit,Dept Med, S50-9, Boston, MA 02114 USA.			Hylek, Elaine/0000-0001-8263-8304	NIA NIH HHS [AG15478] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG015478] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AHLBOM A, 1990, INTRO MODERN EPIDEMI, P47; ANTLITZ AM, 1969, CURR THER RES CLIN E, V11, P360; ANTLITZ AM, 1968, CURR THER RES CLIN E, V10, P501; BARTLE WR, 1991, JAMA-J AM MED ASSOC, V265, P1260, DOI 10.1001/jama.265.10.1260; BENNETT DR, 1995, DRUG EVALUATIONS ANN, P773; BLACK JA, 1994, LANCET, V344, P1373, DOI 10.1016/S0140-6736(94)90737-4; BOEIJINGA JJ, 1982, LANCET, V1, P506; Booth Sarah L., 1993, Journal of Food Composition and Analysis, V6, P109, DOI 10.1006/jfca.1993.1014; CANNEGIETER SC, 1995, NEW ENGL J MED, V333, P11, DOI 10.1056/NEJM199507063330103; CARON J, 1992, MEYLERS SIDE EFFECTS, P900; CHOW WH, 1990, POSTGRAD MED J, V66, P855, DOI 10.1136/pgmj.66.780.855; COLE P, 1971, BRIT J PREV SOC MED, V25, P242; DALE J, 1980, AM HEART J, V99, P746, DOI 10.1016/0002-8703(80)90625-0; DEGROOT MH, 1986, PROBABILITY STAT, P552; FIHN SD, 1993, ANN INTERN MED, V118, P511, DOI 10.7326/0003-4819-118-7-199304010-00005; HENNEKENS CH, 1987, EPIDEMIOLOGY MED, P148; HIRSH J, 1995, CHEST, V108, pS231, DOI 10.1378/chest.108.4_Supplement.231S; HYLEK EM, 1994, ANN INTERN MED, V120, P897, DOI 10.7326/0003-4819-120-11-199406010-00001; JONES RH, 1993, LONGITUDINAL DATA SE, P171; KARLSON B, 1986, ACTA MED SCAND, V220, P347; KATER RMH, 1969, AM J MED SCI, V258, P35, DOI 10.1097/00000441-196907000-00005; KEMPIN SJ, 1983, NEW ENGL J MED, V308, P1229; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P299; LALIBERTE R, 1977, J PHARMACOL EXP THER, V200, P44; LALIBERTE R, 1976, J PHARMACOL EXP THER, V196, P194; LANDEFELD CS, 1989, AM J MED, V87, P144; MAJERUS PW, 1996, GOODMAN GILMANS PHAR, P1346; *MED EC DAT PROD C, 1995, PHYS DESK REF; MEHTA CR, 1985, J AM STAT ASSOC, V80, P969, DOI 10.2307/2288562; OREILLY RA, 1981, ARCH INTERN MED, V141, P458, DOI 10.1001/archinte.141.4.458; Palareti G, 1996, LANCET, V348, P423, DOI 10.1016/S0140-6736(96)01109-9; PEDERSEN FM, 1991, J INTERN MED, V229, P517, DOI 10.1111/j.1365-2796.1991.tb00388.x; PORTER RS, 1986, APPL PHARMACOKINETIC; ROGERS AS, 1991, PHARMACOEPIDEM DR S, P64; RUBIN RN, 1984, CLIN RES, V32, pA698; Schlesselman JJ, 1982, CASE CONTROL STUDIES, P144; SCHULMAN S, 1989, BR J RHEUMATOL, V38, P46; SHORR RI, 1993, ARCH INTERN MED, V153, P1665, DOI 10.1001/archinte.153.14.1665; SNEDECOR GW, 1980, STATISTICAL METHODS, P206; Stafford RS, 1996, ARCH INTERN MED, V156, P2537, DOI 10.1001/archinte.156.22.2537; STOCKLEY IH, 1991, DRUG INTERACTIONS SO, P196; *US PHARM CONV INC, 1997, US PHARM DISP INF DR, P232; VANDERMEER FJM, 1993, ARCH INTERN MED, V153, P1557, DOI 10.1001/archinte.153.13.1557; WELLS PS, 1994, ANN INTERN MED, V121, P676, DOI 10.7326/0003-4819-121-9-199411010-00009	44	265	272	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1998	279	9					657	662		10.1001/jama.279.9.657	http://dx.doi.org/10.1001/jama.279.9.657			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY849	9496982	Bronze			2022-12-28	WOS:000072192800028
J	Belchetz, PE				Belchetz, PE			Hypoadrenalism should also be considered in cases of persistent hyponatraemia - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material							HYPOPITUITARISM		Gen Infirm, Dept Endocrinol, Leeds LS1 3EX, W Yorkshire, England	Leeds General Infirmary	Belchetz, PE (corresponding author), Gen Infirm, Dept Endocrinol, Leeds LS1 3EX, W Yorkshire, England.							AUBRY RH, 1965, J CLIN ENDOCR METAB, V25, P1481, DOI 10.1210/jcem-25-11-1481; BELCHETZ PE, 1985, BRIT MED J, V291, P247, DOI 10.1136/bmj.291.6490.247; BELCHETZ PE, 1987, GERIATRIC MED TODAY, V6, P27; CUNEO RC, 1992, CLIN ENDOCRINOL, V37, P387, DOI 10.1111/j.1365-2265.1992.tb02347.x; ROSEN T, 1990, LANCET, V336, P285, DOI 10.1016/0140-6736(90)91812-O; Sheehan H. L., 1982, POSTPARTUM HYPOPITUI; SMITH PL, 1993, CARDIAC SURG BRAIN; TAYLOR KM, 1978, J THORAC CARDIOV SUR, V75, P579; TAYLOR KM, 1978, J THORAC CARDIOV SUR, V75, P574	9	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 28	1998	316	7132					685	685						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA282	9522797				2022-12-28	WOS:000072347900037
J	Withers, DJ; Gutierrez, JS; Towery, H; Burks, DJ; Ren, JM; Previs, S; Zhang, YT; Bernal, D; Pons, S; Shulman, GI; Bonner-Weir, S; White, MF				Withers, DJ; Gutierrez, JS; Towery, H; Burks, DJ; Ren, JM; Previs, S; Zhang, YT; Bernal, D; Pons, S; Shulman, GI; Bonner-Weir, S; White, MF			Disruption of IRS-2 causes type 2 diabetes in mice	NATURE			English	Article							INSULIN-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; KINASE; PATHOGENESIS; STIMULATION; ACTIVATION; ADIPOCYTES; WORTMANNIN; PATHWAY; PROTEIN	Human type 2 diabetes is characterized by defects in both insulin action and insulin secretion, It has been difficult to identify a single molecular abnormality underlying these features, Insulin-receptor substrates (IRS proteins) may be involved in type 2 diabetes: they mediate pleiotropic signals initiated by receptors for insulin and other cytokines(1). Disruption of IRS-1 hl mice retards growth, but diabetes does not develop because insulin secretion increases to compensate for the mild resistance to insulin(2,3). Here we show that disruption of IRS-2 impairs both peripheral insulin signalling-and pancreatic beta-cell function. IRS-2-deficient mice show progressive deterioration of glucose homeostasis because of insulin resistance in the liver and skeletal muscle and a lack of beta-cell compensation for this insulin resistance, Our results indicate that dysfunction of IRS-2 may contribute to the pathophysiology of human type 2 diabetes.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Joslin Diabet Ctr,Dept Med, Boston, MA 02215 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Med, New Haven, CT 06520 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Howard Hughes Medical Institute; Howard Hughes Medical Institute; Yale University	White, MF (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Joslin Diabet Ctr,Dept Med, Boston, MA 02215 USA.	Whitemor@joslab.harvard.edu	Pons, Sebastian/K-7794-2014; Withers, Dominic J/D-7671-2014; Shulman, Gerald I./P-7176-2019; Bernal, Dolores/K-7769-2014	Pons, Sebastian/0000-0003-1027-0621; Withers, Dominic J/0000-0002-8009-7521; Shulman, Gerald I./0000-0003-1529-5668; Bernal, Dolores/0000-0003-4627-8393	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040936] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK040936] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BonnerWeir S, 1995, INT CONGR SER, V1100, P179; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; Gabbay RA, 1996, J BIOL CHEM, V271, P1890, DOI 10.1074/jbc.271.4.1890; KLOPPEL G, 1985, SURV SYN PATHOL RES, V4, P110; MONTANA E, 1994, J CLIN INVEST, V93, P1577, DOI 10.1172/JCI117137; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; OKADA T, 1994, J BIOL CHEM, V269, P3568; Papaioannou V., 1993, Gene targeting: a practical approach., P107; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; PONS S, 1995, MOL CELL BIOL, V15, P4453; REN JM, 1995, J CLIN INVEST, V95, P429, DOI 10.1172/JCI117673; Scaglia L, 1997, ENDOCRINOLOGY, V138, P1736, DOI 10.1210/en.138.4.1736; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; Sun XJ, 1997, MOL ENDOCRINOL, V11, P251, DOI 10.1210/me.11.2.251; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Warram J.H., 1994, JOSLINS DIABETES MEL, P201	22	1250	1312	0	73	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 26	1998	391	6670					900	904		10.1038/36116	http://dx.doi.org/10.1038/36116			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ206	9495343				2022-12-28	WOS:000072230900054
J	Thomson, R; McElroy, H; Sudlow, M				Thomson, R; McElroy, H; Sudlow, M			Guidelines on anticoagulant treatment in atrial fibrillation in Great Britain: variation in content and implications for treatment	BRITISH MEDICAL JOURNAL			English	Article								Objective: To describe the content of guidelines on the use of anticoagulant treatment in patients with atrial fibrillation and the impact of variations in guidelines on treatment. Design: Postal survey of guidelines, semistructured interview with lead developers of guidelines, and application of guidelines to patient sample. Subjects: 15 lead developers of the 20 guidelines identified in the postal survey were interviewed. 100 patients over 65 with atrial fibrillation to whom the guidelines were applied. Main outcome measures: Evaluation of guidelines and the methods of dissemination, implementation, review and evaluation; proportion of patients recommended for anticoagulant treatment by each guideline; and level of agreement between guidelines. Results: There was considerable variation in whether anticoagulant treatment was recommended for subjects (range 13% to 100%, kappa = 0.12). Guidelines varied greatly in advice on treatment by age, the use of echocardiography, and the target value or range of the international normalised ratio (8 of the 20 guidelines included values unlikely to be effective). Development was unsystematic; evidence based approaches were rarely used, 9 of the 15 lead developers had developed the guidelines themselves, and the 6 guidelines developed by groups relied on informal consensus, Methods to support effective dissemination, implementation, and evaluation were limited. Conclusion: The widespread non-systematic production of guidelines has led to considerable variation with implications for the quality of care and clinical decision making, There is a need for a central, well funded programme of guideline development to ensure that valid guidelines are produced and disseminated.	Univ Newcastle Upon Tyne, Sch Med, Dept Epidemiol & Publ Hlth, Sch Hlth Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Newcastle Upon Tyne, Sch Med, Dept Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK	Thomson, R (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Dept Epidemiol & Publ Hlth, Sch Hlth Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	Richard.Thomson@newcastle.ac.uk						BATH PMW, 1993, BRIT MED J, V307, P1045, DOI 10.1136/bmj.307.6911.1045; CHANG HJ, 1990, ARCH INTERN MED, V150, P83, DOI 10.1001/archinte.150.1.83; CLUZEAU F, 1995, J INTERPROF CARE, V9, P227; Eccles M, 1996, QUAL HEALTH CARE, V5, P44, DOI 10.1136/qshc.5.1.44; Fahey TP, 1996, BMJ-BRIT MED J, V313, P93, DOI 10.1136/bmj.313.7049.93; Glaser B.G., 1965, AWARENESS DYING; Grimshaw J, 1993, Qual Health Care, V2, P243, DOI 10.1136/qshc.2.4.243; Grimshaw J, 1995, J Eval Clin Pract, V1, P37, DOI 10.1111/j.1365-2753.1995.tb00006.x; Grimshaw J M, 1994, Qual Health Care, V3, P45, DOI 10.1136/qshc.3.1.45; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; HENDRY A, 1994, SCOT MED J, V39, P110, DOI 10.1177/003693309403900404; KOUDSTAAL PJ, 1993, LANCET, V342, P1255; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Lawson F, 1996, J AM GERIATR SOC, V44, P708, DOI 10.1111/j.1532-5415.1996.tb01837.x; LIP GYH, 1994, BRIT HEART J, V71, P92; LOK N, 1997, INT J CARDIOL, V48, P271; NHS Executive, 1996, CLIN GUID US CLIN GU; OConnell JE, 1996, AGE AGEING, V25, P307, DOI 10.1093/ageing/25.4.307; Sudlow M, 1997, BRIT MED J, V314, P1529, DOI 10.1136/bmj.314.7093.1529; Sudlow M, 1997, QUAL HEALTH CARE, V6, P60, DOI 10.1136/qshc.6.2.60; THOMSON R, 1995, BMJ-BRIT MED J, V311, P237, DOI 10.1136/bmj.311.6999.237; Varonen H, 1997, QUAL HEALTH CARE, V6, P75, DOI 10.1136/qshc.6.2.75; WOOLF SH, 1992, ARCH INTERN MED, V152, P946, DOI 10.1001/archinte.152.5.946; 1994, EFFECTIVE HLTH CARE, V8	24	95	100	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 14	1998	316	7130					509	513		10.1136/bmj.316.7130.509	http://dx.doi.org/10.1136/bmj.316.7130.509			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX955	9501712	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000072097400019
J	Sheldon, F				Sheldon, F			ABC of palliative care - Bereavement	BRITISH MEDICAL JOURNAL			English	Review									Univ Southampton, Southampton SO9 5NH, Hants, England	University of Southampton	Sheldon, F (corresponding author), Univ Southampton, Southampton SO9 5NH, Hants, England.							Couldrick A., 1991, YOUR MUM DAD HAS CAN; HEEGARD M, 1988, SOMEONE VERY SPECIAL; HEEGARD M, 1991, SOMEONE HAS SERIOUS; Stickney D, 1982, WATER BUGS DRAGONFLI; Varley S., 1982, BADGERS PARTING GIFT; WILLIAMS G, 1983, PEOPLE DIE; [No title captured]	7	18	19	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 7	1998	316	7129					456	458		10.1136/bmj.316.7129.456	http://dx.doi.org/10.1136/bmj.316.7129.456			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW874	9492677	Green Published			2022-12-28	WOS:000071982700041
J	Crane, BR; Arvai, AS; Ghosh, DK; Wu, CQ; Getzoff, ED; Stuehr, DJ; Tainer, JA				Crane, BR; Arvai, AS; Ghosh, DK; Wu, CQ; Getzoff, ED; Stuehr, DJ; Tainer, JA			Structure of nitric oxide synthase oxygenase dimer with pterin and substrate	SCIENCE			English	Article							L-ARGININE; TETRAHYDROBIOPTERIN; NO; MECHANISM; BINDING; ENZYME; SITE	Crystal structures of the murine cytokine-inducible nitric oxide synthase oxygenase dimer with active-center water molecules, the substrate L-arginine (L-Arg), or product analog thiocitrulline reveal how dimerization, cofactor tetrahydrobiopterin, and L-Arg binding complete the catalytic center for synthesis of the essential biological signal and cytotoxin nitric oxide. Pterin binding refolds the central interface region, recruits new structural elements, creates a 30 angstrom deep active-center channel, and causes a 35 degrees helical tilt to expose a heme edge and the adjacent residue tryptophan-366 for likely reductase domain interactions and caveolin inhibition. Heme propionate interactions with pterin and L-Arg suggest that pterin has electronic influences on heme-bound oxygen. L-Arginine binds to glutamic acid-371 and stacks with heme in an otherwise hydrophobic pocket to aid activation of heme-bound oxygen by direct proton donation and thereby differentiate the two chemical steps of nitric oxide synthesis.	Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Cleveland Clinic Foundation; Scripps Research Institute; Scripps Research Institute	Tainer, JA (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Tainer, John/GWQ-4878-2022	Tainer, John/0000-0003-1659-2429	NHLBI NIH HHS [HL58883] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058883] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; AbuSoud HM, 1997, BIOCHEMISTRY-US, V36, P10811, DOI 10.1021/bi971414g; ABUSOUD HM, IN PRESS BIOCHEMISTR; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Chabin RM, 1996, BIOCHEMISTRY-US, V35, P9567, DOI 10.1021/bi960476o; Chen PF, 1997, J BIOL CHEM, V272, P6114, DOI 10.1074/jbc.272.10.6114; CHO HJ, 1995, P NATL ACAD SCI USA, V92, P11514, DOI 10.1073/pnas.92.25.11514; Christopherson KS, 1997, J CLIN INVEST, V100, P2424, DOI 10.1172/JCI119783; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Crane BR, 1997, SCIENCE, V278, P425, DOI 10.1126/science.278.5337.425; Cubberley RR, 1997, BIOCHEM J, V323, P141, DOI 10.1042/bj3230141; DIX TA, 1988, ACCOUNTS CHEM RES, V21, P101, DOI 10.1021/ar00147a002; Erlandsen H, 1997, NAT STRUCT BIOL, V4, P995, DOI 10.1038/nsb1297-995; GACHHUI R, 1997, IN PRESS BIOCHEMISTR, V36, P5097; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; Genick UK, 1997, SCIENCE, V275, P1471, DOI 10.1126/science.275.5305.1471; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; GIOVANELLI J, 1991, P NATL ACAD SCI USA, V88, P7091, DOI 10.1073/pnas.88.16.7091; Goodwill KE, 1997, NAT STRUCT BIOL, V4, P578, DOI 10.1038/nsb0797-578; Gorren ACF, 1996, BIOCHEMISTRY-US, V35, P16735, DOI 10.1021/bi961931j; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; KAUFMAN S, 1993, ADV ENZYMOL RAMB, V67, P77; KLATT P, 1994, J BIOL CHEM, V269, P13861; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; Masters BSS, 1996, FASEB J, V10, P552, DOI 10.1096/fasebj.10.5.8621055; MASTERS BSS, 1998, OXIDANTS ANTIOXIDANT; MAYER B, 1995, N-S ARCH PHARMACOL, V351, P453; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Nathan C, 1997, J CLIN INVEST, V100, P2417, DOI 10.1172/JCI119782; NAVAZA L, 1993, ACTA CRYSTALLOGR D, V49, P127; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pfeiffer S, 1997, BIOCHEM J, V328, P349, DOI 10.1042/bj3280349; Presta A, 1998, BIOCHEMISTRY-US, V37, P298, DOI 10.1021/bi971944c; PRESTA A, IN PRESS J AM CHEM S; RodriguezCrespo I, 1997, BIOCHEMISTRY-US, V36, P8530, DOI 10.1021/bi970192j; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Sennequier N, 1996, BIOCHEMISTRY-US, V35, P5883, DOI 10.1021/bi952844e; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; STUEHR D, 1997, ANN REV PHARM TOXICO, V18, P707; UPSON C, 1989, IEEE COMPUT GRAPH, V9, P30, DOI 10.1109/38.31462; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; WHITEVEEN KE, 1996, J BIOL CHEM, V271, P4143	48	600	610	1	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 27	1998	279	5359					2121	2126		10.1126/science.279.5359.2121	http://dx.doi.org/10.1126/science.279.5359.2121			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZE274	9516116				2022-12-28	WOS:000072775600052
J	Gerlach, M; Koutsilieri, E; Riederer, P				Gerlach, M; Koutsilieri, E; Riederer, P			N-methyl-(R)-salsolinol and its relevance to Parkinson's disease	LANCET			English	Editorial Material							DOPAMINERGIC NEUROTOXIN		Univ Wurzburg, Dept Psychiat, Div Clin Neurochem, D-97060 Wurzburg, Germany	University of Wurzburg	Gerlach, M (corresponding author), Univ Wurzburg, Dept Psychiat, Div Clin Neurochem, Fuchsleinstr 15, D-97060 Wurzburg, Germany.							Gerlach M, 1996, J NEURAL TRANSM, V103, P987, DOI 10.1007/BF01291788; Jellinger KA, 1988, HDB EXPT PHARM, V88, P47, DOI DOI 10.1007/978-3-642-73899-9_2; Maruyama W, 1996, ANN NEUROL, V40, P119, DOI 10.1002/ana.410400120; Naoi M, 1997, NEUROSCI LETT, V235, P81, DOI 10.1016/S0304-3940(97)00723-4; NAOI M, 1995, LIFE SCI, V57, P1061, DOI 10.1016/0024-3205(95)02051-J; Naoi M, 1998, ANN NEUROL, V43, P212, DOI 10.1002/ana.410430211; Naoi M, 1997, J NEURAL TRANSM-SUPP, P89; ROMMELSPACHER H, 1995, ALCOHOL, V12, P309, DOI 10.1016/0741-8329(95)00004-B; TAKAHASHI T, 1994, J NEURAL TRANSM-GEN, V98, P107, DOI 10.1007/BF01277014	9	19	20	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 21	1998	351	9106					850	851		10.1016/S0140-6736(05)70284-1	http://dx.doi.org/10.1016/S0140-6736(05)70284-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD047	9525358				2022-12-28	WOS:000072645500006
J	Lee, K				Lee, K			Shaping the future of global health cooperation: where can we go from here?	LANCET			English	Article								A review of recent studies and initiatives on global health cooperation groups their findings into ten key reform issues. In addressing these issues, policy makers need to improve their understanding of what is meant by the shift from International to global health. Attention must also be paid to the fundamental question of what we want from a system of global health cooperation. Three main views currently exist on what priority activities such a system should pursue-traditionalist, essentialist, and social justice. Reconciliation of these views can then be followed by consideration of the structural features of a global health organisation for the 21st century. Achievement of the above will require a reform process that is more broadly participatory, well-informed, and coherent in purpose and direction.	Univ London London Sch Hyg & Trop Med, Hlth Policy Unit, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Lee, K (corresponding author), Univ London London Sch Hyg & Trop Med, Hlth Policy Unit, Keppel St, London WC1E 7HT, England.							Bell D., 1973, COMING POST-IND SOC; Buse K, 1996, HEALTH POLICY, V38, P173, DOI 10.1016/0168-8510(96)00855-X; *DAG HAMM FDN, 1996, GLOB HLTH COOP 21 CE, P6; FRENK J, 1997, BRIT MED J, V314, P1303; Gill S., 1988, GLOBAL POLITICAL EC; *GOV AUSTR, 1996, MOD WHO AUSTR AG CHA; Institute of Medicine, 1997, AM VIT INT GLOB HLTH; LEE K, 1997, REFORM WHO WHERE CAN; Lucas A, 1997, COOPERATION HLTH DEV; Modelski G., 1972, MULTINATIONAL CORPOR; PEABODY JW, 1995, SOC SCI MED, V40, P731, DOI 10.1016/0277-9536(94)00300-I; *S CTR, 1996, STRONG DEM UN S PERS, pR15; *SIDA, LIST 17 STUD IN SIDA	13	11	11	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 21	1998	351	9106					899	902		10.1016/S0140-6736(97)11455-6	http://dx.doi.org/10.1016/S0140-6736(97)11455-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD047	9525388				2022-12-28	WOS:000072645500046
J	Mathey-Prevot, B; Perrimon, N				Mathey-Prevot, B; Perrimon, N			Mammalian and Drosophila blood: JAK of all trades?	CELL			English	Review							SYSTEM		Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Mathey-Prevot, B (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.			Perrimon, Norbert/0000-0001-7542-472X				BOMAN HG, 1972, NATURE, V237, P232, DOI 10.1038/237232a0; Daga A, 1996, GENE DEV, V10, P1194, DOI 10.1101/gad.10.10.1194; Gateff E., 1978, GENETICS BIOL DROS B, V2b, P181; Hou XS, 1997, TRENDS GENET, V13, P105, DOI 10.1016/S0168-9525(97)01006-8; IP YT, 1994, CURR OPIN GENET DEV, V4, P672, DOI 10.1016/0959-437X(94)90133-N; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Luo H, 1997, MOL CELL BIOL, V17, P1562, DOI 10.1128/MCB.17.3.1562; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Meister M, 1997, BIOESSAYS, V19, P1019, DOI 10.1002/bies.950191112; Ohmori Y, 1997, J BIOL CHEM, V272, P14899, DOI 10.1074/jbc.272.23.14899; Orkin SH, 1996, CURR OPIN GENET DEV, V6, P597, DOI 10.1016/S0959-437X(96)80089-X; QUI P, 1998, IN PRESS DEVELOPMENT; Rehorn KP, 1996, DEVELOPMENT, V122, P4023; RIZKI TM, 1981, GENETICS, V97, P90; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Williams MJ, 1997, EMBO J, V16, P6120, DOI 10.1093/emboj/16.20.6120; WU LP, 1998, IN PRESS NATURE; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369	21	44	45	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 20	1998	92	6					697	700		10.1016/S0092-8674(00)81396-3	http://dx.doi.org/10.1016/S0092-8674(00)81396-3			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZD198	9529244	Bronze			2022-12-28	WOS:000072661200001
J	Meier, R; Owen, TC; Jewitt, DC; Matthews, HE; Senay, M; Biver, N; Bockelee-Morvan, D; Crovisier, J; Gautier, D				Meier, R; Owen, TC; Jewitt, DC; Matthews, HE; Senay, M; Biver, N; Bockelee-Morvan, D; Crovisier, J; Gautier, D			Deuterium in comet C 1995 O1 (Hale-Bopp): Detection of DCN	SCIENCE			English	Article							DENSE INTERSTELLAR CLOUDS; SOLAR NEBULA; WATER; CHEMISTRY; TAURUS; HCN	Deuterated hydrogen cyanide (DCN) was detected in a comet, C/1995 O1 (Hale-Bopp), with the use of the James Clerk Maxwell Telescope on Mauna Kea, Hawaii. The inferred deuterium/hydrogen (D/H) ratio in hydrogen cyanide (HCN) is (D/H)(HCN) = (2.3 +/- 0.4) x 10(-3). This ratio is higher than the D/H ratio found in cometary water and supports the interstellar origin of cometary ices. The observed values of D/H in water and HCN imply a kinetic temperature greater than or equal to 30 +/- 10 K in the fragment of interstellar cloud that formed the solar system.	Univ Hawaii, Inst Astron, Honolulu, HI 96822 USA; Natl Res Council Canada, Herzberg Inst Astrophys, Victoria, BC V8X 4M6, Canada; Joint Astron Ctr, Hilo, HI 96720 USA; Univ Massachusetts, Five Coll Radio Astron Observ, Amherst, MA 01003 USA; Observ Paris, F-92195 Meudon, France	University of Hawaii System; National Research Council Canada; University of Massachusetts System; University of Massachusetts Amherst; UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris	Meier, R (corresponding author), Univ Hawaii, Inst Astron, 2680 Woodlawn Dr, Honolulu, HI 96822 USA.	meier@uhifa.ifa.hawall.edu						ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; BALSIGER H, 1995, J GEOPHYS RES, V100, P5287; Bates D. R., 1988, RATE COEFFICIENTS AS, P41; BIVER N, 1997, B AM ASTRON SOC, V29, P1047; BOCKELEEMORVAN D, 1994, PLANET SPACE SCI, V42, P655, DOI 10.1016/0032-0633(94)90043-4; BOCKELEEMORVAN D, 1997, B AM ASTRON SOC, V29, P1047; BOSS AP, 1989, ORIGIN EVOLUTION PLA, P35; BROWN PD, 1989, MON NOT R ASTRON SOC, V237, P661, DOI 10.1093/mnras/237.3.661; CROVISIER J, 1987, ASTRON ASTROPHYS SUP, V68, P223; DUBRULLE B, 1993, ICARUS, V106, P59, DOI 10.1006/icar.1993.1158; EBERHARDT P, 1995, ASTRON ASTROPHYS, V302, P301; Fegley B.J., 1989, FORMATION EVOLUTION, P171; Gautier D, 1995, SPACE SCI S, P547; Gautier D, 1997, ASTRON ASTROPHYS, V323, pL9; Geiss J., 1993, ORIGIN EVOLUTION ELE, V89; Greenfield J.C., 1981, COMETS ORIGIN LIFE, P111; Irvine WM, 1989, ORIGIN EVOLUTION PLA, P3; JACQ T, 1990, ASTRON ASTROPHYS, V228, P447; Jewitt DC, 1997, SCIENCE, V278, P90, DOI 10.1126/science.278.5335.90; JONES AP, 1984, MON NOT R ASTRON SOC, V209, P955, DOI 10.1093/mnras/209.4.955; KIM K, 1979, J CHEM PHYS, V71, P1967, DOI 10.1063/1.438510; Krasnopolsky VA, 1997, SCIENCE, V277, P1488, DOI 10.1126/science.277.5331.1488; KRASNOPOLSKY VA, 1997, 6625 IAU; LECLUSE C, 1994, GEOCHIM COSMOCHIM AC, V58, P2927, DOI 10.1016/0016-7037(94)90126-0; LUNINE JI, 1991, ICARUS, V94, P333, DOI 10.1016/0019-1035(91)90232-I; Meier R, 1998, SCIENCE, V279, P842, DOI 10.1126/science.279.5352.842; MEIER RR, UNPUB; MILLAR TJ, 1989, ASTROPHYS J, V340, P906, DOI 10.1086/167444; Niemann HB, 1996, SCIENCE, V272, P846, DOI 10.1126/science.272.5263.846; OWEN T, 1995, ICARUS, V116, P215, DOI 10.1006/icar.1995.1122; OWEN T, 1995, AIP C P, V341, P123; POINTER RL, 1985, APPL OPTICS, V24, P2235; THANH NV, 1993, J MOL SPECTROSC, V157, P68, DOI 10.1006/jmsp.1993.1006; UNGERECHTS H, 1987, ASTROPHYS J SUPPL S, V63, P645, DOI 10.1086/191176; van Dishoeck E. F., 1993, PROTOSTARS PLANETS, P163; WATSON WD, 1976, REV MOD PHYS, V48, P513, DOI 10.1103/RevModPhys.48.513; Williams TL, 1996, MON NOT R ASTRON SOC, V282, P413, DOI 10.1093/mnras/282.2.413; Wootten A., 1987, IAU S, V120, P311	38	141	143	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 13	1998	279	5357					1707	1710		10.1126/science.279.5357.1707	http://dx.doi.org/10.1126/science.279.5357.1707			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9497286				2022-12-28	WOS:000072490000051
J	Hegde, RS; Voigt, S; Rapoport, TA; Lingappa, VR				Hegde, RS; Voigt, S; Rapoport, TA; Lingappa, VR			TRAM regulates the exposure of nascent secretory proteins to the cytosol during translocation into the endoplasmic reticulum	CELL			English	Article							APOLIPOPROTEIN-B; SIGNAL SEQUENCE; ER MEMBRANE; PROTEOLIPOSOMES; LIPOPROTEINS; MICROSOMES; TRANSPORT; BINDING	Translocational pausing is a mechanism used by certain specialized secretory proteins whereby discrete domains of a nascent chain destined for the endoplasmic reticulum lumen are transiently exposed to the cytosol. Proteoliposomes reconstituted from total endoplasmic reticulum proteins properly assemble translocationally paused intermediates. The capacity of the translocon to correctly pause the nascent chain is dependent on a glycoprotein fraction whose active component is TRAM. In the absence of TRAM, the normally sealed ribosome-membrane junction still opens in response to a pause transfer sequence. However, nascent chain domains that are not exposed to the cytosol in the presence of TRAM are so exposed in its absence. Thus, TRAM regulates which domains of the nascent chain are visible to the cytosol during a translocational pause.	Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Harvard University; Harvard Medical School	Lingappa, VR (corresponding author), Univ Calif San Francisco, Dept Physiol, Box 0444, San Francisco, CA 94143 USA.			Hegde, Ramanujan/0000-0001-8338-852X; Lingappa, Vishwanath R./0000-0003-0962-6571	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045480] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG002132] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 45480] Funding Source: Medline; NIA NIH HHS [AG 02132] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Andrews DW, 1996, TRENDS BIOCHEM SCI, V21, P365; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BRODSKY JL, 1995, P NATL ACAD SCI USA, V92, P9643, DOI 10.1073/pnas.92.21.9643; BULLEID NJ, 1993, ADV PROTEIN CHEM, V44, P125, DOI 10.1016/S0065-3233(08)60566-5; CHEN W, 1995, P NATL ACAD SCI USA, V92, P6229, DOI 10.1073/pnas.92.14.6229; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; DIXON JL, 1993, J LIPID RES, V34, P167; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; Du EZ, 1996, J LIPID RES, V37, P1309; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; Hegde RS, 1996, CELL, V85, P217, DOI 10.1016/S0092-8674(00)81098-3; HIGH S, 1993, J BIOL CHEM, V268, P26745; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; Kivlen MH, 1997, J LIPID RES, V38, P1149; Liao SR, 1997, CELL, V90, P31, DOI 10.1016/S0092-8674(00)80311-6; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NICCHITTA CV, 1990, CELL, V60, P259, DOI 10.1016/0092-8674(90)90741-V; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; OLIVER J, 1995, FEBS LETT, V362, P126, DOI 10.1016/0014-5793(95)00223-V; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; RUSINOL AE, 1993, J BIOL CHEM, V268, P25168; Silberstein S, 1996, FASEB J, V10, P849, DOI 10.1096/fasebj.10.8.8666161; Voigt S, 1996, J CELL BIOL, V134, P25, DOI 10.1083/jcb.134.1.25; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; YAO ZM, 1994, BBA-LIPID LIPID MET, V1212, P152, DOI 10.1016/0005-2760(94)90249-6; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777	34	75	75	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 6	1998	92	5					621	631		10.1016/S0092-8674(00)81130-7	http://dx.doi.org/10.1016/S0092-8674(00)81130-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZA827	9506517	Bronze			2022-12-28	WOS:000072406000008
J	Wiholm, BE; Kelly, JP; Kaufman, D; Issaragrisil, S; Levy, M; Anderson, T; Shapiro, S				Wiholm, BE; Kelly, JP; Kaufman, D; Issaragrisil, S; Levy, M; Anderson, T; Shapiro, S			Relation of aplastic anaemia to use of chloramphenicol eye drops in two international case-control studies	BRITISH MEDICAL JOURNAL			English	Article									Huddinge Univ Hosp, Karolinska Inst, Dept Clin Pharmacol, Med Pharmacoepidemiol Unit, S-14186 Huddinge, Sweden; Boston Univ, Sch Med, Slone Epidemiol Unit, Brookline, MA 02146 USA; Mahidol Univ, Bangkok 10700, Thailand; Hadassah Univ Hosp, IL-91120 Jerusalem, Israel	Karolinska Institutet; Boston University; Mahidol University; Hebrew University of Jerusalem	Wiholm, BE (corresponding author), Med Prod Agcy, POB 26, S-75103 Uppsala, Sweden.			Issaragrisil, Surapol/0000-0002-8924-0646; Kaufman, David/0000-0002-2150-5070	NHLBI NIH HHS [R01-HL35068] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035068] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		DOONA M, 1995, BRIT MED J, V310, P1217, DOI 10.1136/bmj.310.6989.1217; Issaragrisil S, 1997, BLOOD, V89, P4034; Kaufman DW, 1991, DRUG ETIOLOGY AGRANU; THOMAS DG, 1971, APPLIED STATISTICS, V20, P105, DOI DOI 10.2307/2346643	4	28	29	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 28	1998	316	7132					666	666		10.1136/bmj.316.7132.666	http://dx.doi.org/10.1136/bmj.316.7132.666			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA282	9522791	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000072347900030
J	Welsh, K				Welsh, K			Scleroderma: chimerism, the blind man, and the scientist	LANCET			English	Editorial Material							AUTOIMMUNE		Churchill Hosp, Nuffield Dept Surg, Oxford OX3 7LI, England		Welsh, K (corresponding author), Churchill Hosp, Nuffield Dept Surg, Oxford OX3 7LI, England.							Artlett CM, 1997, IMMUNOGENETICS, V47, P17, DOI 10.1007/s002510050321; CAILLATZUCMAN S, 1994, HUM IMMUNOL, V41, P91, DOI 10.1016/0198-8859(94)90091-4; DELAHERA M, 1992, INT IMMUNOL, V4, P67, DOI 10.1093/intimm/4.1.67; PAULUS HE, 1996, SYSTEMIC SCLEROSIS; Rapanotti MC, 1997, BONE MARROW TRANSPL, V19, P703, DOI 10.1038/sj.bmt.1700723; SCHURMANS S, 1991, AUTOIMMUNITY, V9, P283, DOI 10.3109/08916939108997130; Sivasai KSR, 1997, TRANSPLANTATION, V64, P427, DOI 10.1097/00007890-199708150-00010	7	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 21	1998	351	9102					540	541		10.1016/S0140-6736(05)78551-2	http://dx.doi.org/10.1016/S0140-6736(05)78551-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ216	9492769				2022-12-28	WOS:000072231900005
J	Oakley, MJ; Wheelwright, EF; James, PJ				Oakley, MJ; Wheelwright, EF; James, PJ			Lesson of the week - Pneumatic compression boots for prophylaxis against deep vein thrombosis: beware occult arterial disease	BRITISH MEDICAL JOURNAL			English	Review							TOTAL HIP-REPLACEMENT		Glasgow Royal Infirm, Orthopaed Directorate, Glasgow G4 0SF, Lanark, Scotland; Stobhill Hosp NHS Trust, Orthopaed Directorate, Glasgow G21 3UW, Lanark, Scotland	University of Glasgow	James, PJ (corresponding author), Glasgow Royal Infirm, Orthopaed Directorate, Glasgow G4 0SF, Lanark, Scotland.							BERNSTEIN MJ, 1986, JAMA-J AM MED ASSOC, V256, P744; EVARTS CM, 1967, MED CLIN N AM, V51, P1285, DOI 10.1016/S0025-7125(16)32995-9; EVARTS CM, 1987, CLIN ORTHOP RELAT R, P98; FORDYCE MJF, 1992, J BONE JOINT SURG BR, V74, P775; Gardner A M, 1983, Bristol Med Chir J, V98, P109; HULL RD, 1990, JAMA-J AM MED ASSOC, V263, P2313, DOI 10.1001/jama.263.17.2313; IMPERIALE TF, 1994, JAMA-J AM MED ASSOC, V271, P1780, DOI 10.1001/jama.271.22.1780; KILLEWICH LA, 1995, J VASC SURG, V22, P598, DOI 10.1016/S0741-5214(95)70046-3; LOTKE PA, 1984, J BONE JOINT SURG AM, V66A, P202, DOI 10.2106/00004623-198466020-00006; LYNCH JA, 1990, CLIN ORTHOP RELAT R, P24; Murray DW, 1996, J BONE JOINT SURG BR, V78B, P863, DOI 10.1302/0301-620X78B6.6714; SALZMAN EW, 1983, NEW ENGL J MED, V16, P980; STRANKS GL, 1996, J BONE JOINT SURG BR, V74, P775; STULBERG BN, 1984, J BONE JOINT SURG AM, V66A, P194, DOI 10.2106/00004623-198466020-00005; WILSON NV, 1992, J BONE JOINT SURG BR, V74, P50, DOI 10.1302/0301-620X.74B1.1732265	15	7	7	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 7	1998	316	7129					454	455		10.1136/bmj.316.7129.454	http://dx.doi.org/10.1136/bmj.316.7129.454			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW874	9492676	Green Published			2022-12-28	WOS:000071982700040
J	Clark, RE; Squire, LR				Clark, RE; Squire, LR			Classical conditioning and brain systems: The role of awareness	SCIENCE			English	Article							SHORT-TERM-MEMORY; AMNESIC PATIENTS; EYE-BLINK; MAMMALIAN BRAIN; HIPPOCAMPUS; LESIONS; ACQUISITION; RABBITS; NEUROPSYCHOLOGY; DISSOCIATION	Classical conditioning of the eye-blink response, perhaps the best studied example of associative learning in vertebrates, is relatively automatic and reflexive, and with the standard procedure (simple delay conditioning), it is intact in animals with hippocampal lesions. In delay conditioning, a tone [the conditioned stimulus (CS)] is presented just before an air puff to the eye [the unconditioned stimulus (US)]. The US is then presented, and the two stimuli coterminate. In trace conditioning, a variant of the standard paradigm, a short interval (500 to 1000 ms) is interposed between the offset of the CS and the onset of the US. Animals with hippocampal lesions fail to acquire trace conditioning. Amnesic patients with damage to the hippocampal formation and normal volunteers were tested on two versions of delay conditioning and two versions of trace conditioning and then assessed for the extent to which they became aware of the temporal relationship between the CS and the US. Amnesic patients acquired delay conditioning at a normal rate but failed to acquire trace conditioning. For normal volunteers, awareness was unrelated to successful delay conditioning but was a prerequisite for successful trace conditioning, Trace conditioning is hippocampus dependent because, as in other tasks of declarative memory, conscious knowledge must be acquired across the training session. Trace conditioning may provide a means for studying awareness in nonhuman animals, in the context of current ideas about multiple memory systems and the function of the hippocampus.	Vet Affairs Med Ctr, San Diego, CA 92161 USA; Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Diego; University of California System; University of California San Diego	Squire, LR (corresponding author), Vet Affairs Med Ctr, San Diego, CA 92161 USA.				PHS HHS [24600] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BADDELEY AD, 1970, J VERB LEARN VERB BE, V9, P176, DOI 10.1016/S0022-5371(70)80048-2; BAKIN JS, 1990, BRAIN RES, V536, P271, DOI 10.1016/0006-8993(90)90035-A; BERGER TW, 1976, SCIENCE, V192, P483, DOI 10.1126/science.1257783; CAREW TJ, 1986, ANNU REV NEUROSCI, V9, P435, DOI 10.1146/annurev.ne.09.030186.002251; CARILLO MC, 1996, SOC NEUR ABSTR, V22, P1866; CAVE CB, 1992, HIPPOCAMPUS, V2, P151, DOI 10.1002/hipo.450020207; CLARK GA, 1984, BRAIN RES, V291, P125, DOI 10.1016/0006-8993(84)90658-9; Cohen N. J., 1984, NEUROPSYCHOLOGY MEMO, P83; DAUM I, 1994, INT J NEUROSCI, V75, P153, DOI 10.3109/00207459408986299; DAUM I, 1989, J NEUROL NEUROSUR PS, V52, P47, DOI 10.1136/jnnp.52.1.47; DAUM I, 1993, BEHAV NEUROSCI, V107, P748, DOI 10.1037/0735-7044.107.5.748; DAWSON ME, 1973, J EXP PSYCHOL, V98, P308, DOI 10.1037/h0034372; DRACHMAN DA, 1966, ARCH NEUROL-CHICAGO, V15, P52, DOI 10.1001/archneur.1966.00470130056005; Eichenbaum H, 1997, ANNU REV PSYCHOL, V48, P547, DOI 10.1146/annurev.psych.48.1.547; FINKBINER RG, 1991, PSYCHOL AGING, V6, P109, DOI 10.1037/0882-7974.6.1.109; FREKA A, 1983, PAVLOVIAN J BIOL SCI, V18, P69; GABRIELI JDE, 1995, BEHAV NEUROSCI, V109, P819, DOI 10.1037/0735-7044.109.5.819; GORMEZANO I, 1962, SCIENCE, V138, P33, DOI 10.1126/science.138.3536.33; Gormezano I., 1987, CLASSICAL CONDITIONI; GRANT DA, 1973, PSYCHOPHYSIOLOGY, V10, P75, DOI 10.1111/j.1469-8986.1973.tb01086.x; Hamann SB, 1997, BEHAV NEUROSCI, V111, P850, DOI 10.1037/0735-7044.111.4.850; Hamann SB, 1995, BEHAV NEUROSCI, V109, P1027, DOI 10.1037/0735-7044.109.6.1027; Hilgard ER, 1938, J GEN PSYCHOL, V19, P111, DOI 10.1080/00221309.1938.9711190; KANDEL ER, 1995, NEUROSCIENCE MEMORY, P45; KIM JJ, 1995, BEHAV NEUROSCI, V109, P195, DOI 10.1037/0735-7044.109.2.195; KRONFORSTCOLLIN.MA, IN PRESS NEUROBIOL L; LAVOND DG, 1993, ANNU REV PSYCHOL, V44, P317, DOI 10.1146/annurev.ps.44.020193.001533; MAUK MD, 1987, BRAIN RES, V244, P347; MCDONALD RJ, 1993, BEHAV NEUROSCI, V107, P3, DOI 10.1037/0735-7044.107.1.3; McGlincheyBerroth R, 1997, BEHAV NEUROSCI, V111, P873, DOI 10.1037/0735-7044.111.5.873; Milner B., 1966, AMNESIA, P109; Moyer JR, 1996, J NEUROSCI, V16, P5536; MOYER JR, 1990, BEHAV NEUROSCI, V104, P243, DOI 10.1037/0735-7044.104.2.243; NORMAN RJ, 1977, SCIENCE, V196, P551, DOI 10.1126/science.850800; Papka M, 1997, PSYCHOL SCI, V8, P404, DOI 10.1111/j.1467-9280.1997.tb00434.x; Pavlov I.P., 1927, CONDITIONED REFLEXES; Petri HL, 1984, NEUROPSYCHOLOGY MEMO, P287; POLICH J, 1993, ELECTROEN CLIN NEURO, V86, P408, DOI 10.1016/0013-4694(93)90136-J; Schacter D. L., 1994, MEMORY SYSTEMS 1994; SCHACTER DL, 1993, ANNU REV NEUROSCI, V16, P159, DOI 10.1146/annurev.ne.16.030193.001111; SCHACTER DL, 1990, J CLIN EXP NEUROPSYC, V12, P155, DOI 10.1080/01688639008400962; SCHMALTZ LW, 1972, J COMP PHYSIOL PSYCH, V79, P328, DOI 10.1037/h0032531; SEARS LL, 1990, BEHAV NEUROSCI, V104, P681, DOI 10.1037/0735-7044.104.5.681; SEARS LL, 1994, J AUTISM DEV DISORD, V24, P737, DOI 10.1007/BF02172283; SOLOMON PR, 1986, BEHAV NEUROSCI, V100, P729, DOI 10.1037/0735-7044.100.5.729; SPENCE KW, 1959, J EXP PSYCHOL, V58, P376, DOI 10.1037/h0045837; SPENCE KW, 1951, J EXP PSYCHOL, V42, P183, DOI 10.1037/h0061580; SPENCE KW, 1951, J EXP PSYCHOL, V29, P30; SQUIRE LR, 1982, ANNU REV NEUROSCI, V5, P241, DOI 10.1146/annurev.ne.05.030182.001325; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Squire LR, 1995, P NATL ACAD SCI USA, V92, P12470, DOI 10.1073/pnas.92.26.12470; SQUIRE LR, 1988, BEHAV NEUROSCI, V102, P210, DOI 10.1037/0735-7044.102.2.210; SQUIRE LR, 1990, J NEUROSCI, V10, P3106; SQUIRE LR, 1994, COGNITIVE NEUROSCIEN, P825; THOMPSON RF, 1994, ANNU REV NEUROSCI, V17, P519, DOI 10.1146/annurev.neuro.17.1.519; WEINBERGER NM, IN PRESS NEUROBIOL L; WEISKRANTZ L, 1979, NEUROPSYCHOLOGIA, V17, P187, DOI 10.1016/0028-3932(79)90009-5; WOODRUFFPAK DS, 1985, BRAIN RES, V348, P249, DOI 10.1016/0006-8993(85)90443-3; WOODRUFFPAK DS, 1993, BEHAV NEUROSCI, V107, P911	59	636	645	0	79	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 3	1998	280	5360					77	81		10.1126/science.280.5360.77	http://dx.doi.org/10.1126/science.280.5360.77			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ZF314	9525860				2022-12-28	WOS:000072885100037
J	von Mutius, E; Weiland, SK; Fritzsch, C; Duhme, H; Keil, U				von Mutius, E; Weiland, SK; Fritzsch, C; Duhme, H; Keil, U			Increasing prevalence of hay fever and atopy among children in Leipzig, East Germany	LANCET			English	Article							RESPIRATORY SYMPTOMS; WEST-GERMANY; ASTHMA; SENSITIZATION; RESPONSIVENESS; REACTIVITY; BAVARIA; ADULTS; HEALTH; LIFE	Background Several surveys in children and adults have shown significantly lower prevalences of asthma and allergic diseases in eastern Europe than in western countries. In the former East Germany tremendous changes towards western lifestyle have occurred since unification. The aim of this survey was to investigate time trends in the prevalence of asthma and allergic diseases among children living in the eastern part of Germany. Methods In 1995-96, 2334 (87.5%) schoolchildren in Leipzig participated in a cross-sectional study that used the same methods as a previous survey done shortly after the fall of communism in 1991-92. A self-administered questionnaire was distributed to the parents. Children underwent cold-air challenge and allergy skinprick tests to SIX common aeroallergens. Findings The prevalence of hay fever (2.3% [34/1454] vs 5.1% [115/2252], p<0.0001) and atopic sensitisation (19.3% [252/1303] vs 26.7% [434/1624], p<0.0001) increased significantly between 1991-92 and 1995-96. However, there was no significant change in the prevalence of asthma, asthma-related symptoms, or bronchial hyper-responsiveness. Interpretation These findings suggest important differences in the development of atopic disorders. The children were born about 3 years before unification and were therefore exposed to western living conditions only after the third birthday: Thus, factors operating very early in life may be particularly important for the acquisition of childhood asthma, whereas the development of atopic sensitisation and hay fever may also be affected by environmental factors occurring beyond infancy.	Univ Munich, Childrens Hosp, D-8000 Munich, Germany; Univ Munster, Inst Epidemiol & Social Med, D-4400 Munster, Germany; Univ Leipzig, Childrens Hosp, D-7010 Leipzig, Germany	University of Munich; University of Munster; Leipzig University	von Mutius, E (corresponding author), Univ Munich, Kinderklin, Lindwurmstr 4, D-80337 Munich, Germany.							BERBIG B, 1991, ALLERGOLOGIE, V14, P51; Black PN, 1997, EUR RESPIR J, V10, P6, DOI 10.1183/09031936.97.10010006; BRABACK L, 1994, CLIN EXP ALLERGY, V24, P826, DOI 10.1111/j.1365-2222.1994.tb01805.x; EMANUEL MB, 1988, CLIN ALLERGY, V18, P295, DOI 10.1111/j.1365-2222.1988.tb02872.x; Jaross W., 1996, Reviews on Environmental Health, V11, P27; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; Livingstone AE, 1996, BRIT MED J, V312, P676; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MICHELS K, 1995, NEW ENGL J MED, V333, P130; NICOLAI T, 1993, AM REV RESPIR DIS, V147, P565, DOI 10.1164/ajrccm/147.3.565; Nowak D, 1996, EUR RESPIR J, V9, P2541, DOI 10.1183/09031936.96.09122541; PICCINNI MP, 1993, INT ARCH ALLERGY IMM, V102, P301, DOI 10.1159/000236541; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358, DOI 10.1164/ajrccm.149.2.8306030; vonMutius E, 1996, BRIT MED J, V312, P1448, DOI 10.1136/bmj.312.7044.1448; VONMUTIUS E, 1992, BMJ-BRIT MED J, V305, P1395, DOI 10.1136/bmj.305.6866.1395; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692; WARE JH, 1986, AM REV RESPIR DIS, V133, P834; Warner JA, 1996, ALLERGY, V51, P447, DOI 10.1111/j.1398-9995.1996.tb04650.x; WINKLER G, 1992, ANN NUTR METAB, V36, P219, DOI 10.1159/000177721; WJST M, 1993, BRIT MED J, V307, P596, DOI 10.1136/bmj.307.6904.596; 1997, SACHSISCHES LANDESAM; 1997, STAT LANDESAMT SACHS	24	430	441	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 21	1998	351	9106					862	866		10.1016/S0140-6736(97)10100-3	http://dx.doi.org/10.1016/S0140-6736(97)10100-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD047	9525363				2022-12-28	WOS:000072645500012
J	Cahill, DP; Lengauer, C; Yu, J; Riggins, GJ; Willson, JKV; Markowitz, SD; Kinzler, KW; Vogelstein, B				Cahill, DP; Lengauer, C; Yu, J; Riggins, GJ; Willson, JKV; Markowitz, SD; Kinzler, KW; Vogelstein, B			Mutations of mitotic checkpoint genes in human cancers	NATURE			English	Article							SPINDLE ASSEMBLY CHECKPOINT; BUDDING YEAST; COLORECTAL-CANCER; MISMATCH REPAIR; MICROSATELLITE INSTABILITY; PROTEIN-KINASE; CELL-CYCLE; IDENTIFICATION; DEFECTS; MITOSIS	Genetic instability was one of the first characteristics to be postulated to underlie neoplasia(1-3). Such genetic instability occurs in two different forms. In a small fraction of colorectal and some other cancers, defective repair of mismatched bases results in an increased mutation rate at the nucleotide level and consequent widespread microsatellite instability(4-7). In most colorectal cancers, and probably in many other cancer types, a chromosomal instability (GIN) leading to an abnormal chromosome number (aneuploidy) is observed(8). The physiological and molecular bases of this pervasive abnormality are unknown. Here we show that CIN is consistently associated with the loss of function of a mitotic checkpoint, Moreover, in some cancers displaying CIN the loss of this checkpoint was associated with the mutational inactivation of a human homologue of the yeast BUB1 gene; BUB1 controls mitotic checkpoints and chromosome segregation in yeast, The normal mitotic checkpoints of cells displaying microsatellite instability become defective upon transfer of mutant hBUB1 alleles from either of two CIN cancers.	Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Program Human Genet, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21231 USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ireland Canc Ctr, Cleveland, OH 44106 USA; Howard Hughes Med Inst, Cleveland, OH 44106 USA	Johns Hopkins University; Johns Hopkins Medicine; Howard Hughes Medical Institute; Johns Hopkins University; Case Western Reserve University; Case Western Reserve University; Howard Hughes Medical Institute	Lengauer, C (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Program Human Genet, 424 N Bond St, Baltimore, MD 21231 USA.	lengauer@welchlink.welch.jhu.edu	Yu, Jian/A-8301-2009	Yu, Jian/0000-0002-4021-1000; Cahill, Daniel/0000-0003-2552-6546				Boveri T, 1914, FRAGE ENTSTEHUNG MAL, V1; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Hardwick KG, 1996, SCIENCE, V273, P953, DOI 10.1126/science.273.5277.953; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; LENGAUER C, 1994, GENET ANAL-BIOMOL E, V11, P140, DOI 10.1016/1050-3862(94)90034-5; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LOEB LA, 1991, CANCER RES, V51, P3075; Modrich P, 1997, J BIOL CHEM, V272, P24727, DOI 10.1074/jbc.272.40.24727; MURRAY AW, 1995, CURR OPIN GENET DEV, V5, P5, DOI 10.1016/S0959-437X(95)90046-2; Nasmyth K, 1996, TRENDS GENET, V12, P405, DOI 10.1016/0168-9525(96)10041-X; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; Pangilinan F, 1997, GENOMICS, V46, P379, DOI 10.1006/geno.1997.5068; Pangilinan F, 1996, MOL BIOL CELL, V7, P1195, DOI 10.1091/mbc.7.8.1195; PARSONS R, 1995, CANCER RES, V55, P5548; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Perucho M, 1996, BIOL CHEM, V377, P675; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Riggins GJ, 1997, CANCER RES, V57, P2578; ROBERTS BT, 1994, MOL CELL BIOL, V14, P8282, DOI 10.1128/MCB.14.12.8282; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0	29	1272	1329	3	61	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 19	1998	392	6673					300	303		10.1038/32688	http://dx.doi.org/10.1038/32688			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC739	9521327				2022-12-28	WOS:000072612300052
J	Mizunuma, M; Hirata, D; Miyahara, K; Tsuchiya, E; Miyakawa, T				Mizunuma, M; Hirata, D; Miyahara, K; Tsuchiya, E; Miyakawa, T			Role of calcineurin and Mpk1 in regulating the onset of mitosis in budding yeast	NATURE			English	Article							MAP KINASE PATHWAY; SACCHAROMYCES-CEREVISIAE; HYPOTONIC SHOCK; CELL INTEGRITY; GENE; CALMODULIN; CALCIUM; PHOSPHATASE; ADAPTATION; EXPRESSION	Signalling via calcium is probably involved in regulating eukaryotic cell proliferation, but details of its mechanism of action are unknown(1,2). In Schizosaccharomyces pombe, the onset of mitosis is determined by activation of a complex of the p36(cdc2) protein kinase and a cyclin protein that is specific to the G2 phase of the cell cycle. This activation requires dephosphorylation of p34(cdc2) (ref. 3). Wee1, a tyrosine kinase that inhibits p34(cdc2) by phosphorylating it, is needed to determine the length of G2 phase, Here we show that calcium-activated pathways in Saccharomyces cerevisiae control the onset of mitosis by regulating Swe1, a Wee1 homologue. Zds1 (also known as Oss1 and Hst1) (refs 4-7) is important in repressing the transcription of SWE1 in G2 phase. In the presence of high calcium levels, cells lacking Zds1 are delayed in entering mitosis. Calcineurin(8-11) and Mpk1 (refs 12, 13) regulate Swe1 activation at the transcriptional and posttranslational levels, respectively, and both are required for the calcium-induced delay in G2 phase. These cellular pathways also induce a G2-phase delay In response to hypotonic shock.	Hiroshima Univ, Grad Sch Engn, Dept Mol Biotechnol, Higashihiroshima 739, Japan	Hiroshima University	Miyakawa, T (corresponding author), Hiroshima Univ, Grad Sch Engn, Dept Mol Biotechnol, Higashihiroshima 739, Japan.		Mizunuma, Masaki/V-2941-2017	Mizunuma, Masaki/0000-0002-1531-1763				Batiza AF, 1996, J BIOL CHEM, V271, P23357, DOI 10.1074/jbc.271.38.23357; Bi EF, 1996, MOL CELL BIOL, V16, P5264; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; DAVENPORT KR, 1995, J BIOL CHEM, V270, P30157; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; FOOR F, 1992, NATURE, V360, P682; Igual JC, 1996, EMBO J, V15, P5001, DOI 10.1002/j.1460-2075.1996.tb00880.x; KAMADA Y, 1995, GENE DEV, V9, P1559, DOI 10.1101/gad.9.13.1559; KUNO T, 1991, BIOCHEM BIOPH RES CO, V180, P1159, DOI 10.1016/S0006-291X(05)81188-X; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; LIU Y, 1991, MOL GEN GENET, V227, P52, DOI 10.1007/BF00260706; Ma XJ, 1996, GENE DEV, V10, P1327, DOI 10.1101/gad.10.11.1327; MARTINAC B, 1990, NATURE, V348, P261, DOI 10.1038/348261a0; MAZUR P, 1995, MOL CELL BIOL, V15, P5671; MEANS AR, 1994, FEBS LETT, V347, P1, DOI 10.1016/0014-5793(94)00492-7; NAKAMURA T, 1993, EMBO J, V12, P4063, DOI 10.1002/j.1460-2075.1993.tb06090.x; Nakamura T, 1996, MOL GEN GENET, V251, P211; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Tanaka S, 1996, GENES CELLS, V1, P905, DOI 10.1046/j.1365-2443.1996.d01-213.x; Tsuchiya E, 1996, GENE, V176, P35, DOI 10.1016/0378-1119(96)00204-1; Yu YX, 1996, MOL CELL BIOL, V16, P5254; ZARZOV P, 1996, EMBO J, V15, P81	25	115	116	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1998	392	6673					303	306		10.1038/32695	http://dx.doi.org/10.1038/32695			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC739	9521328				2022-12-28	WOS:000072612300053
J	Zucca, E; Bertoni, F; Roggero, E; Bosshard, G; Cazzaniga, G; Pedrinis, E; Biondi, A; Cavalli, F				Zucca, E; Bertoni, F; Roggero, E; Bosshard, G; Cazzaniga, G; Pedrinis, E; Biondi, A; Cavalli, F			Molecular analysis of the progression from Helicobacter pylori-associated chronic gastritis to mucosa-associated lymphoid-tissue lymphoma of the stomach	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							B-CELL LYMPHOMA; POLYMERASE CHAIN-REACTION; MALT LYMPHOMA; GENE REARRANGEMENTS; ERADICATION; INFECTION; REGRESSION; DIAGNOSIS; WORKSHOP		Osped San Giovanni Bellinzona, Serv Oncol Cantonale, CH-6500 Bellinzona, Switzerland; Univ Milan, Osped San Gerardo, Pediat Clin, Monza, Italy; Ist Cantonale Patol, Locarno, Switzerland	Regional Hospital of Bellinzona & Valleys, San Giovanni; San Gerardo Hospital; University of Milan	Cavalli, F (corresponding author), Osped San Giovanni Bellinzona, Serv Oncol Cantonale, CH-6500 Bellinzona, Switzerland.		Bertoni, Francesco/G-6922-2014; Biondi, Andrea/AAX-1865-2020; Biondi, Andrea/K-9997-2016; Cazzaniga, Giovanni/K-6338-2016	Bertoni, Francesco/0000-0001-5637-8983; Biondi, Andrea/0000-0002-6757-6173; Zucca, Emanuele/0000-0002-5522-6109; Cazzaniga, Giovanni/0000-0003-2955-4528				Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BAYERDORFFER E, 1995, LANCET, V345, P1591, DOI 10.1016/S0140-6736(95)90113-2; Bertoni F, 1997, BRIT J HAEMATOL, V97, P830, DOI 10.1046/j.1365-2141.1997.1392954.x; BOTTARO M, 1994, BLOOD, V83, P3271, DOI 10.1182/blood.V83.11.3271.bloodjournal83113271; Bower H, 1997, BRIT MED J, V315, P383, DOI 10.1136/bmj.315.7105.383; CABANILLAS F, 1991, ANN ONCOL, V2, P31, DOI 10.1093/annonc/2.suppl_1.31; Carlson SJ, 1996, JAMA-J AM MED ASSOC, V275, P937; Cover TL, 1996, ADV INTERNAL MED, V41, P85; DISS TC, 1993, J PATHOL, V169, P291, DOI 10.1002/path.1711690303; DOGLIONI C, 1992, LANCET, V339, P834, DOI 10.1016/0140-6736(92)90280-G; Du M, 1996, LEUKEMIA, V10, P1190; GOULDEN N, 1996, METH MOLEC MED, P3; HUSSELL T, 1993, LANCET, V342, P571, DOI 10.1016/0140-6736(93)91408-E; ISAACSON PG, 1995, ANN ONCOL, V6, P319, DOI 10.1093/oxfordjournals.annonc.a059177; Isaacson PG, 1994, EXTRANODAL LYMPHOMAS, P15; LEVINE AM, 1994, ANN ONCOL, V5, pS29, DOI 10.1093/annonc/5.suppl_2.S29; LUDWIG CU, 1993, ANN ONCOL, V4, P825, DOI 10.1093/oxfordjournals.annonc.a058387; Magrath IT, 1997, NONHODGKINS LYMPHOMA, P3; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; POTTERS HVPJ, 1987, HISTOPATHOLOGY, V11, P1223, DOI 10.1111/j.1365-2559.1987.tb01863.x; QIN YF, 1995, BLOOD, V86, P3528, DOI 10.1182/blood.V86.9.3528.bloodjournal8693528; Rabeneck L, 1997, ANN INTERN MED, V126, P315, DOI 10.7326/0003-4819-126-4-199702150-00008; ROGGERO E, 1995, ANN INTERN MED, V122, P767, DOI 10.7326/0003-4819-122-10-199505150-00006; Roggero E, 1997, JNCI-J NATL CANCER I, V89, P1328, DOI 10.1093/jnci/89.18.1328; ROHATINER A, 1994, ANN ONCOL, V5, P397, DOI 10.1093/oxfordjournals.annonc.a058869; Rudolph B, 1997, J CLIN ONCOL, V15, P1104, DOI 10.1200/JCO.1997.15.3.1104; Savio A, 1996, BLOOD, V87, P1255, DOI 10.1182/blood.V87.4.1255.bloodjournal8741255; SCHWARTZ RS, 1995, NEW ENGL J MED, V333, P42, DOI 10.1056/NEJM199507063330108; SKLAR J, 1984, NEW ENGL J MED, V311, P20, DOI 10.1056/NEJM198407053110104; WEBER DM, 1994, GASTROENTEROLOGY, V107, P1835, DOI 10.1016/0016-5085(94)90828-1; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F; WOTHERSPOON AC, 1991, LANCET, V338, P1175, DOI 10.1016/0140-6736(91)92035-Z; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153; YAMADA T, 1994, JAMA-J AM MED ASSOC, V272, P65, DOI 10.1001/jama.272.1.65; ZAKI M, 1995, GASTROENTEROLOGY, V108, pA265; Zucca E, 1996, ANN ONCOL, V7, P787; Zucca E, 1996, BAILLIERE CLIN HAEM, V9, P727, DOI 10.1016/S0950-3536(96)80051-5; ZUCCA E, 1993, P AN M AM SOC CLIN, V12, P369	39	176	180	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 19	1998	338	12					804	810		10.1056/NEJM199803193381205	http://dx.doi.org/10.1056/NEJM199803193381205			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC163	9504941				2022-12-28	WOS:000072546800005
J	Golomb, BA				Golomb, BA			Cholesterol and violence: Is there a connection?	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							CORONARY HEART-DISEASE; LOW SERUM-CHOLESTEROL; MIDDLE-AGED MEN; AGGRESSIVE-BEHAVIOR; PRIMARY-PREVENTION; BLOOD CHOLESTEROL; SOCIAL-BEHAVIOR; TERM MORTALITY; LOWERING DRUGS; ARTERY DISEASE	Purpose: To determine whether the seeming relation between low or lowered cholesterol levels and violence is consistent with causality according to Hill's criteria and whether construct validity is supported by convergence of findings across different types of studies. Data Sources: Search of the MEDLINE database for English-language articles published between 1965 and 1995 was supplemented by searches of the PsyclNFO and Current Contents databases and bibliographies of relevant articles. Study Selection: Peer-reviewed observational and experimental articles and meta-analyses that presented original research; related cholesterol levels to behaviorally defined violence; and, if experimental, had single-factor (lipid-only) intervention. Data Extraction: Studies were grouped according to type. Data on the relation of violence to cholesterol levels from each study were recorded. Data Synthesis: Observational studies (including cohort, case-control, and cross-sectional studies) consistently showed increased violent death and violent behaviors in persons with low cholesterol levels. Some meta-analyses of randomized trials found excess violent deaths in men without heart disease who were randomly assigned to receive cholesterol-lowering therapy. Experimental studies showed increased violent behaviors in monkeys assigned to low-cholesterol diets. Human and animal research indicates that low or lowered cholesterol levels may reduce central serotonin activity, which in turn is causally linked to violent behaviors. Many trials support a significant relation between low or lowered cholesterol levels and violence (P < 0.001). Conclusions: A significant association between low or lowered cholesterol levels and violence is found across many types of studies. Data on this association conform to Hill's criteria for a causal association. Concerns about increased risk for violent outcomes should figure in risk-benefit analyses for cholesterol screening and treatment.	Univ Calif Los Angeles, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles	Golomb, BA (corresponding author), Univ Calif San Diego, San Diego Vet Affairs Med Ctr, Dept Med, 3350 La Jolla Village Dr 111N-1, La Jolla, CA 92161 USA.							ALPERT EJ, 1995, ANN INTERN MED, V123, P774, DOI 10.7326/0003-4819-123-10-199511150-00006; ANDERSON IM, 1990, PSYCHOL MED, V20, P785, DOI 10.1017/S0033291700036473; Asberg M., 1994, CRIM BEHAV MENT HEAL, V4, P303; BERZSENYI P, 1983, AGGRESSIVE BEHAV, V9, P333, DOI 10.1002/1098-2337(1983)9:4<333::AID-AB2480090408>3.0.CO;2-R; BIOULAC B, 1978, NEUROPSYCHOBIOLOGY, V4, P366, DOI 10.1159/000117653; BIOULAC B, 1980, BIOL PSYCHIAT, V15, P917; BLANCHARD DC, 1988, PHARMACOL BIOCHEM BE, V31, P269; BRAMBLETT C A, 1981, Primates, V22, P96, DOI 10.1007/BF02382560; BROWN GL, 1990, J CLIN PSYCHIAT, V51, P31; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; COCCARO EF, 1989, BRIT J PSYCHIAT, V155, P52, DOI 10.1192/S0007125000291769; Corsini A, 1996, CARDIOLOGY, V87, P458, DOI 10.1159/000177139; CUMMINGS P, 1994, ANN INTERN MED, V120, P848, DOI 10.7326/0003-4819-120-10-199405150-00006; DAYTON S, 1969, CIRCULATION       S2, V40, P1; Delva NJ, 1996, BIOL PSYCHIAT, V39, P100, DOI 10.1016/0006-3223(95)00140-9; DROSSMAN DA, 1995, ANN INTERN MED, V123, P782, DOI 10.7326/0003-4819-123-10-199511150-00007; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; Ericsson CG, 1996, LANCET, V347, P849, DOI 10.1016/S0140-6736(96)91343-4; FARCHI G, 1987, AM J EPIDEMIOL, V126, P400, DOI 10.1093/oxfordjournals.aje.a114671; FLITCRAFT A, 1995, ANN INTERN MED, V123, P800, DOI 10.7326/0003-4819-123-10-199511150-00009; FLITCRAFT AH, 1992, JAMA-J AM MED ASSOC, V267, P3194, DOI 10.1001/jama.267.23.3194; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; GALLERANI M, 1995, BMJ-BRIT MED J, V310, P1632, DOI 10.1136/bmj.310.6995.1632; Garber AM, 1996, ANN INTERN MED, V124, P518, DOI 10.7326/0003-4819-124-5-199603010-00013; Gaziano JM, 1996, ANN INTERN MED, V124, P914, DOI 10.7326/0003-4819-124-10-199605150-00009; GEDYE A, 1991, BIOL PSYCHIAT, V30, P88, DOI 10.1016/0006-3223(91)90074-V; GIBBONS JL, 1979, BRAIN RES, V169, P139, DOI 10.1016/0006-8993(79)90380-9; GIBBONS JL, 1978, PHARMACOL BIOCHEM BE, V9, P91, DOI 10.1016/0091-3057(78)90017-5; GLUECK CJ, 1994, PEDIATR RES, V35, P602, DOI 10.1203/00006450-199405000-00013; GOLIER JA, 1995, AM J PSYCHIAT, V152, P419; GORDON T, 1986, ARCH INTERN MED, V146, P262, DOI 10.1001/archinte.146.2.262; GRANT L D, 1973, Pharmacology Biochemistry and Behavior, V1, P77, DOI 10.1016/0091-3057(73)90059-2; GRAY RF, 1993, NEUROREPORT, V4, P754, DOI 10.1097/00001756-199306000-00039; Harper CM, 1997, CIRCULATION, V96, P977; Hebert PR, 1997, JAMA-J AM MED ASSOC, V278, P313, DOI 10.1001/jama.278.4.313; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; HILLBRAND M, 1993, PSYCHOL REP, V72, P270, DOI 10.2466/pr0.1993.72.1.270; HILLBRAND M, 1995, J BEHAV MED, V18, P33, DOI 10.1007/BF01857703; HOLINGER PC, 1982, SOC SCI MED, V16, P1929, DOI 10.1016/0277-9536(82)90392-6; IRIBARREN C, 1995, ARCH INTERN MED, V155, P695, DOI 10.1001/archinte.155.7.695; JACOBS D, 1992, CIRCULATION, V86, P1046, DOI 10.1161/01.CIR.86.3.1046; KANTAK KM, 1980, PHARMACOL BIOCHEM BE, V12, P675, DOI 10.1016/0091-3057(80)90147-1; KAPLAN JR, 1991, PSYCHOSOM MED, V53, P634, DOI 10.1097/00006842-199111000-00005; KAPLAN JR, 1994, PSYCHOSOM MED, V56, P479, DOI 10.1097/00006842-199411000-00001; KOOP CE, 1992, JAMA-J AM MED ASSOC, V267, P3075, DOI 10.1001/jama.267.22.3075; Lareau SC, 1996, HEART LUNG, V25, P212, DOI 10.1016/S0147-9563(96)80032-X; LaRosa JC, 1996, ANN INTERN MED, V124, P505, DOI 10.7326/0003-4819-124-5-199603010-00008; LAUFS U, 1997, CIRCULATION, V96, P1677; LAW MR, 1994, BRIT MED J, V308, P373, DOI 10.1136/bmj.308.6925.373; LEIKER M, 1988, BEHAV MED, V14, P129, DOI 10.1080/08964289.1988.9935136; LINDBERG G, 1992, BRIT MED J, V305, P277, DOI 10.1136/bmj.305.6848.277; MANN JJ, 1989, PSYCHOPHARMACOL BULL, V25, P407; MARTINEZ R, 1994, JAMA-J AM MED ASSOC, V272, P1541; Massy ZA, 1996, LANCET, V347, P102, DOI 10.1016/S0140-6736(96)90217-2; MCCAULEY J, 1995, ANN INTERN MED, V123, P737, DOI 10.7326/0003-4819-123-10-199511150-00001; MICZEK KA, 1994, NEUROSCI BIOBEHAV R, V18, P97, DOI 10.1016/0149-7634(94)90040-X; MODAI I, 1994, J CLIN PSYCHIAT, V55, P252; MORAND C, 1983, BIOL PSYCHIAT, V18, P575; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; MULDOON MF, 1993, METABOLISM, V42, P45, DOI 10.1016/0026-0495(93)90259-Q; MULDOON MF, 1992, BIOL PSYCHIAT, V31, P739, DOI 10.1016/0006-3223(92)90285-8; Muldoon MF, 1997, BRIT MED J, V315, P1554, DOI 10.1136/bmj.315.7122.1554; NEATON JD, 1992, ARCH INTERN MED, V152, P1490, DOI 10.1001/archinte.152.7.1490; OLIVER M F, 1978, British Heart Journal, V40, P1069, DOI 10.1136/hrt.40.10.1069; PAXINOS G, 1977, AGGRESSIVE BEHAV, V3, P107, DOI 10.1002/1098-2337(1977)3:2<107::AID-AB2480030202>3.0.CO;2-5; PEDERSEN TR, 1994, LANCET, V344, P1383; PEKKANEN J, 1989, ARCH INTERN MED, V149, P1589, DOI 10.1001/archinte.149.7.1589; PFEFFER MA, 1995, AM J CARDIOL, V76, pC98, DOI 10.1016/S0002-9149(99)80478-0; RATEY J, 1991, J CLIN PSYCHIAT, V52, P159; RAVNSKOV U, 1992, BMJ-BRIT MED J, V305, P15, DOI 10.1136/bmj.305.6844.15; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; RINGO DL, 1994, BIOL PSYCHIAT, V35, P957, DOI 10.1016/0006-3223(94)91242-4; ROCHET T, 1992, BIOL PSYCHIAT, V32, P922, DOI 10.1016/0006-3223(92)90181-X; RYAN M, 1995, BRIT MED J, V311, P807, DOI 10.1136/bmj.311.7008.807b; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SAUDOU F, 1994, SCIENCE, V265, P1875, DOI 10.1126/science.8091214; SCHUIT AJ, 1993, LANCET, V341, P827, DOI 10.1016/0140-6736(93)90600-L; SHEARD MH, 1976, EUR J PHARMACOL, V40, P295, DOI 10.1016/0014-2999(76)90066-2; SHEARD MH, 1976, AM J PSYCHIAT, V133, P1409; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SIGUEL EN, 1994, METABOLISM, V43, P982, DOI 10.1016/0026-0495(94)90178-3; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367; SMITH GD, 1992, BMJ-BRIT MED J, V304, P431, DOI 10.1136/bmj.304.6824.431; SPITZ RT, 1994, PSYCHOL REP, V74, P622, DOI 10.2466/pr0.1994.74.2.622; Steegmans PHA, 1996, BRIT MED J, V312, P221, DOI 10.1136/bmj.312.7025.221; STRANDBERG TE, 1991, JAMA-J AM MED ASSOC, V266, P1225, DOI 10.1001/jama.266.9.1225; SUH I, 1992, ANN INTERN MED, V116, P881, DOI 10.7326/0003-4819-116-11-881; SULLIVAN PF, 1994, BIOL PSYCHIAT, V36, P472, DOI 10.1016/0006-3223(94)90643-2; TAKEI N, 1994, BRIT J PSYCHIAT, V164, P702, DOI 10.1192/S0007125000034632; VARTIAINEN E, 1994, BRIT MED J, V309, P445, DOI 10.1136/bmj.309.6952.445; VIRKKUNEN M, 1979, NEUROPSYCHOBIOLOGY, V5, P27, DOI 10.1159/000117660; VIRKKUNEN M, 1984, BIOL PSYCHIAT, V19, P435; Walker KW, 1997, CIRCULATION, V96, P2560; WANNAMETHEE G, 1992, J EPIDEMIOL COMMUN H, V46, P197, DOI 10.1136/jech.46.3.197; YAMAMOTO T, 1977, PHYSIOL BEHAV, V19, P105, DOI 10.1016/0031-9384(77)90166-4; Zureik M, 1996, BMJ-BRIT MED J, V313, P649, DOI 10.1136/bmj.313.7058.649	96	160	165	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1998	128	6					478	487		10.7326/0003-4819-128-6-199803150-00009	http://dx.doi.org/10.7326/0003-4819-128-6-199803150-00009			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZA914	9499332				2022-12-28	WOS:000072414700009
J	Cascinelli, N; Morabito, A; Santinami, M; MacKie, RM; Belli, F				Cascinelli, N; Morabito, A; Santinami, M; MacKie, RM; Belli, F		WHO Melanoma Programme	Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial	LANCET			English	Article							MANAGEMENT; EFFICACY	Background The use of elective regional node dissection in patients with cutaneous melanoma without any clinical evidence of metastatic spread is still debated. Our aim was to evaluate the efficacy of immediate node dissection in patients with melanoma of the trunk and without clinical evidence of regional node and distant metastases. Methods An international multicentre randomised trial was carried out by the WHO Melanoma Programme from 1982 to 1989. The trial included only patients with a trunk melanoma 1.5 mm or more in thickness. After wide excision of primary melanoma, patients were randomised to either immediate regiona node dissection or a regional node dissection delayed until appearance of regional-node metastases. Findings Of the 252 patients entered, 240 (95%) were eligible and evaluable for analysis. 122 of these were randomised to immediate node dissection. 5-year survival observed in patients who had delayed node dissection was 51.3% (95% CI 41.7-60.1) compared with 61.7% (52.0-70.1) of patients who had immediate node dissection (p=0.09). 5-year survival rate in patients with occult regional node metastases was 48.2% (28.0-65.8) and 26.6% (13.4-41.8, p=0.04) in patients in whom the regional node dissection was delayed until the time of appearance of regional node metastases. Multivariate analysis showed that routine use of immediate node dissection had no impact on survival (hazard ratio 0.72, 95% CI 0.5-1.02), whilst the status of regional nodes affected survival significantly (p=0.007). The patients with regional nodes that became clinically and histologically positive during follow-up had the poorest prognosis. Interpretation Node dissection offers increased survival in patients with node metastases only. Sentinel node biopsy may become a tool to identify patients with occult node metastases, who could then undergo node dissection.	Casa Cura S Pio X, Dept Gen Surg, Milan, Italy; Univ Milan, Inst Med Stat & Biometry, Milan, Italy; Univ Glasgow, Dept Dermatol, Glasgow G12 8QQ, Lanark, Scotland; Natl Canc Inst, Dept Gen Surg B, I-20133 Milan, Italy	University of Milan; University of Glasgow; Fondazione IRCCS Istituto Nazionale Tumori Milan	Cascinelli, N (corresponding author), Natl Canc Inst, Dept Gen Surg B, Via G Venezian 1, I-20133 Milan, Italy.	n.cascinelli@who-melanoma.org	Santinami, Mario/I-3795-2017; Belli, Filiberto/AAA-6209-2020	Santinami, Mario/0000-0001-8436-4757; Belli, Filiberto/0000-0003-3973-4979				Balch CM, 1996, ANN SURG, V224, P255, DOI 10.1097/00000658-199609000-00002; BALCH CM, 1992, CUTANEOUS MELANOMA, P345; Cascinelli N, 1996, EUR J SURG ONCOL, V22, P123, DOI 10.1016/S0748-7983(96)90463-1; GERSHENWALD J, 1996, 49 ANN CANC S SOC SU, P20; Kapteijn BAE, 1997, ANN SURG ONCOL, V4, P156, DOI 10.1007/BF02303799; Mackie R. M., 1997, Melanoma Research, V7, pS102, DOI 10.1097/00008390-199706001-00357; MORTON DL, 1992, ARCH SURG-CHICAGO, V127, P392; REINTGEN D, 1994, ANN SURG, V220, P756; Ross MI, 1996, SEMIN SURG ONCOL, V12, P394, DOI 10.1002/(SICI)1098-2388(199611/12)12:6<394::AID-SSU4>3.0.CO;2-5; SIM FH, 1978, CANCER-AM CANCER SOC, V41, P948, DOI 10.1002/1097-0142(197803)41:3<948::AID-CNCR2820410324>3.0.CO;2-Z; THOMPSON JF, 1995, MELANOMA RES, V5, P255, DOI 10.1097/00008390-199508000-00008; VERONESI U, 1982, CANCER-AM CANCER SOC, V49, P2420, DOI 10.1002/1097-0142(19820601)49:11<2420::AID-CNCR2820491133>3.0.CO;2-2; VERONESI U, 1977, NEW ENGL J MED, V297, P627, DOI 10.1056/NEJM197709222971202	13	467	474	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 14	1998	351	9105					793	796		10.1016/S0140-6736(97)08260-3	http://dx.doi.org/10.1016/S0140-6736(97)08260-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB916	9519951				2022-12-28	WOS:000072521200012
J	Irifune, T; Nishiyama, N; Kuroda, K; Inoue, T; Isshiki, M; Utsumi, W; Funakoshi, K; Urakawa, S; Uchida, T; Katsura, T; Ohtaka, O				Irifune, T; Nishiyama, N; Kuroda, K; Inoue, T; Isshiki, M; Utsumi, W; Funakoshi, K; Urakawa, S; Uchida, T; Katsura, T; Ohtaka, O			The postspinel phase boundary in Mg2SiO4 determined by in situ x-ray diffraction	SCIENCE			English	Article							SYSTEM MG2SIO4-FE2SIO4; MGSIO3 PEROVSKITE; SPINEL TRANSITIONS; LOWER MANTLE; OLIVINE; DISCONTINUITY; EQUATION; STATE	The phase boundary between spinel (gamma phase) and MgSiO3 perovskite + MgO periclase in Mg2SiO4 was determined by in situ x-ray measurements by a combination of the synchrotron radiation source (SPring-8) and a large multianvil high-pressure apparatus. The boundary was determined at temperatures between 1400 degrees to 1800 degrees C, demonstrating that the postspinel phase boundary has a negative Clapeyron slope as estimated by quench experiments and thermodynamic analyses. The boundary was located at 21.1 (+/-0.2) gigapascals, al 1600 degrees C, which is similar to 2 gigapascals lower than earlier estimates based on other high-pressure studies.	Ehime Univ, Dept Earth Sci, Matsuyama, Ehime 790, Japan; Japan Atom Energy Res Inst, Kamigori, Hyogo 67812, Japan; Japan Synchrotron Radiat Res Inst, Kamigori, Hyogo 67812, Japan; Okayama Univ, Dept Earth Sci, Okayama 700, Japan; Univ Tokyo, Inst Solid State Phys, Tokyo 106, Japan; Okayama Univ, Inst Study Earths Interior, Tottori 68201, Japan; Osaka Univ, Dept Earth & Space Sci, Toyonaka, Osaka 560, Japan	Ehime University; Japan Atomic Energy Agency; Japan Synchrotron Radiation Research Institute; Okayama University; University of Tokyo; Okayama University; Osaka University	Irifune, T (corresponding author), Ehime Univ, Dept Earth Sci, Matsuyama, Ehime 790, Japan.		Nishiyama, Norimasa/A-7627-2016; URAKAWA, Satoru/B-1494-2011; Katsura, Tomoo/A-7483-2010; Nishiyama, Norimasa/U-8670-2018; Katsura, Tomoo/ABC-1899-2021	URAKAWA, Satoru/0000-0002-1292-8573; Katsura, Tomoo/0000-0001-7857-5101; Nishiyama, Norimasa/0000-0001-6214-0875; Katsura, Tomoo/0000-0001-7857-5101; Nishibori, Maiko/0000-0002-6743-786X				AKAOGI M, 1989, J GEOPHYS RES-SOLID, V94, P15671, DOI 10.1029/JB094iB11p15671; AKIMOTO SI, 1968, J GEOPHYS RES, V73, P1467, DOI 10.1029/JB073i004p01467; ANDERSON OL, 1989, J APPL PHYS, V65, P1534, DOI 10.1063/1.342969; BINA CR, 1987, J GEOPHYS RES-SOLID, V92, P4853, DOI 10.1029/JB092iB06p04853; BROWN JM, 1981, GEOPHYS J ROY ASTR S, V66, P579, DOI 10.1111/j.1365-246X.1981.tb04891.x; DECKER DL, 1971, J APPL PHYS, V42, P3239, DOI 10.1063/1.1660714; Funamori N, 1996, J GEOPHYS RES-SOL EA, V101, P8257, DOI 10.1029/95JB03732; ITO E, 1990, SCIENCE, V249, P1275, DOI 10.1126/science.249.4974.1275; ITO E, 1989, GEOPHYS RES LETT, V16, P425, DOI 10.1029/GL016i005p00425; ITO E, 1991, NATURE, V351, P140, DOI 10.1038/351140a0; ITO E, 1989, J GEOPHYS RES-SOLID, V94, P10637, DOI 10.1029/JB094iB08p10637; KATO T, 1995, J GEOPHYS RES-SOL EA, V100, P20475, DOI 10.1029/95JB01688; KATO T, 1997, REV HIGH PRESS SCI T, V6, P718; KATSURA T, 1989, J GEOPHYS RES-SOLID, V94, P15663, DOI 10.1029/JB094iB11p15663; KAWAI N, 1970, PHYS EARTH PLANET IN, V3, P182; LIEBERMANN RC, 1997, REV HIGH PRESS SCI T, V6, P61; LIU LG, 1976, NATURE, V262, P770, DOI 10.1038/262770a0; Major A., 1966, EARTH PLANET SC LETT, V1, P241, DOI [10.1016/0012-821X(66)90077-X, DOI 10.1016/0012-821X(66)90077-X]; MARTINEZ I, 1997, J GEOPHYS RES, V102, P5256; MORISHIMA H, 1994, SCIENCE, V265, P1202, DOI 10.1126/science.265.5176.1202; NISHIYAMA N, UNPUB; SHEARER PM, 1992, NATURE, V355, P791, DOI 10.1038/355791a0; SUITO K, 1972, J PHYS EARTH, V20, P225; UTSUMI W, 1997, REV HIGH PRESS SCI T, V6, P512; Wang YB, 1997, SCIENCE, V275, P510, DOI 10.1126/science.275.5299.510; Weidner D.J., 1992, HIGH PRESSURE RES AP, V67, P13; Yamazaki D, 1996, SCIENCE, V274, P2052, DOI 10.1126/science.274.5295.2052; Zhang J, 1996, PHYS CHEM MINER, V23, P1, DOI 10.1007/BF00202987	28	200	215	1	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 13	1998	279	5357					1698	1700		10.1126/science.279.5357.1698	http://dx.doi.org/10.1126/science.279.5357.1698			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9497283				2022-12-28	WOS:000072490000048
J	Auwerx, J; Staels, B				Auwerx, J; Staels, B			Leptin	LANCET			English	Review							OB GENE-EXPRESSION; ACTIVATED RECEPTOR-GAMMA; WHITE ADIPOSE-TISSUE; MOUSE OBESE GENE; NEUROPEPTIDE-Y; BODY-WEIGHT; FOOD-INTAKE; OB/OB MICE; DB/DB MICE; TRANSCRIPTION FACTOR	Leptin (from the Greek leptos=thin) was identified only 3 years ago. It has attracted huge attention both scentifically, with more than 600 publications, and in the media, where this protein has been portrayed as the way to a cure for obesity. Indeed, leptin was first described as an adipocyte-derived signalling factor, which, after interaction with its receptors, induced a complex response including control of bodyweight and energy expenditure. Leptin seems in addition to its role in metabolic control to have important roles In reproduction and neuroendocrine signalling. Human obesity is a complex disorder, with many factors playing a part; the pathophysiology of leptin is not as simple as it seems to be in rodent models of obesity.	Inst Pasteur, INSERM, Dept Atherosclerose, Lab Biol Regulat Eucaryotes, F-59019 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Auwerx, J (corresponding author), Inst Pasteur, INSERM, Dept Atherosclerose, Lab Biol Regulat Eucaryotes, 1 Rue Calmette, F-59019 Lille, France.	johan.auwerx@pasteur-lille.fr	Guerre-Millo, Michele/G-7253-2017; Wong, Ma-Li/D-7903-2011; Alemany, Marià/H-5224-2011; Auwerx, Johan/ABE-9307-2021; Licinio, Julio/L-4244-2013; Jansen, Heiko T./A-5770-2008; Staels, Bart/N-9497-2016; Ahima, Rexford/W-1394-2019	Wong, Ma-Li/0000-0003-1512-3073; Alemany, Marià/0000-0002-9783-8293; Licinio, Julio/0000-0001-6905-5884; Jansen, Heiko T./0000-0003-0178-396X; Staels, Bart/0000-0002-3784-1503; Auwerx, Johan/0000-0002-5065-5393				Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; ARASE K, 1988, AM J PHYSIOL, V255, pE255, DOI 10.1152/ajpendo.1988.255.3.E255; Auwerx J, 1996, J MOL MED, V74, P347, DOI 10.1007/BF00210629; Bai YL, 1996, J BIOL CHEM, V271, P13939, DOI 10.1074/jbc.271.24.13939; Banks WA, 1996, PEPTIDES, V17, P305, DOI 10.1016/0196-9781(96)00025-3; Barash IA, 1996, ENDOCRINOLOGY, V137, P3144, DOI 10.1210/en.137.7.3144; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; Boden G, 1996, J CLIN ENDOCR METAB, V81, P3419, DOI 10.1210/jc.81.9.3419; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Campfield LA, 1996, HORM METAB RES, V28, P619, DOI 10.1055/s-2007-979867; Caro JF, 1996, DIABETES, V45, P1455, DOI 10.2337/diab.45.11.1455; Caro JF, 1996, LANCET, V348, P159, DOI 10.1016/S0140-6736(96)03173-X; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; Chehab FF, 1997, SCIENCE, V275, P88, DOI 10.1126/science.275.5296.88; Chen GX, 1996, P NATL ACAD SCI USA, V93, P14795, DOI 10.1073/pnas.93.25.14795; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Cheung CC, 1997, ENDOCRINOLOGY, V138, P855, DOI 10.1210/en.138.2.855; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; Clement K, 1996, DIABETES, V45, P687, DOI 10.2337/diabetes.45.5.687; Cohen B, 1996, SCIENCE, V274, P1185, DOI 10.1126/science.274.5290.1185; Comuzzie AG, 1997, NAT GENET, V15, P273, DOI 10.1038/ng0397-273; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; CONSIDINE RV, 1995, J CLIN INVEST, V95, P2986, DOI 10.1172/JCI118007; Cumin F, 1996, INT J OBESITY, V20, P1120; DALLONGEVILLE J, 1997, UNPUB DIABETES; Darnell JE, 1996, P NATL ACAD SCI USA, V93, P6221, DOI 10.1073/pnas.93.13.6221; DeVos P, 1996, J CLIN INVEST, V98, P1004, DOI 10.1172/JCI118860; DEVOS P, 1995, J BIOL CHEM, V270, P15958, DOI 10.1074/jbc.270.27.15958; Erickson JC, 1996, SCIENCE, V274, P1704, DOI 10.1126/science.274.5293.1704; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; Flier JS, 1997, P NATL ACAD SCI USA, V94, P4242, DOI 10.1073/pnas.94.9.4242; FREDERICH RC, 1995, J CLIN INVEST, V96, P1658, DOI 10.1172/JCI118206; Gainsford T, 1996, P NATL ACAD SCI USA, V93, P14564, DOI 10.1073/pnas.93.25.14564; Ghilardi N, 1997, MOL ENDOCRINOL, V11, P393, DOI 10.1210/me.11.4.393; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; Golden PL, 1997, J CLIN INVEST, V99, P14, DOI 10.1172/JCI119125; Grunfeld C, 1996, J CLIN INVEST, V97, P2152, DOI 10.1172/JCI118653; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HAMILTON BS, 1995, NAT MED, V1, P953, DOI 10.1038/nm0995-953; HE YF, 1995, J BIOL CHEM, V270, P28887, DOI 10.1074/jbc.270.48.28887; Hollenberg AN, 1997, J BIOL CHEM, V272, P5283, DOI 10.1074/jbc.272.8.5283; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Iida M, 1996, BIOCHEM BIOPH RES CO, V222, P19, DOI 10.1006/bbrc.1996.0691; Kallen CB, 1996, P NATL ACAD SCI USA, V93, P5793, DOI 10.1073/pnas.93.12.5793; Kamohara S, 1997, NATURE, V389, P374, DOI 10.1038/38717; Kolaczynski JW, 1996, DIABETES, V45, P1511, DOI 10.2337/diabetes.45.11.1511; Kolaczynski JW, 1996, J CLIN ENDOCR METAB, V81, P4162, DOI 10.1210/jc.81.11.4162; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Leroy P, 1996, J BIOL CHEM, V271, P2365, DOI 10.1074/jbc.271.5.2365; LONNQVIST F, 1995, NAT MED, V1, P950, DOI 10.1038/nm0995-950; MACDOUGALD OA, 1995, P NATL ACAD SCI USA, V92, P9034, DOI 10.1073/pnas.92.20.9034; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; Maffei M, 1996, DIABETES, V45, P679, DOI 10.2337/diabetes.45.5.679; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; Malmstrom R, 1996, DIABETOLOGIA, V39, P993; Masuzaki H, 1997, NAT MED, V3, P1029, DOI 10.1038/nm0997-1029; Merabet E, 1997, J CLIN ENDOCR METAB, V82, P847, DOI 10.1210/jc.82.3.847; Miller SG, 1996, P NATL ACAD SCI USA, V93, P5507, DOI 10.1073/pnas.93.11.5507; MOINAT M, 1995, FEBS LETT, V373, P131, DOI 10.1016/0014-5793(95)01030-I; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; MUGLIA L, 1995, NATURE, V373, P427, DOI 10.1038/373427a0; Muller G, 1997, J BIOL CHEM, V272, P10585, DOI 10.1074/jbc.272.16.10585; Muzzin P, 1996, P NATL ACAD SCI USA, V93, P14804, DOI 10.1073/pnas.93.25.14804; Nolan JJ, 1996, DIABETES, V45, P1276, DOI 10.2337/diabetes.45.9.1276; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Phillips MS, 1996, NAT GENET, V13, P18, DOI 10.1038/ng0596-18; Qu DQ, 1996, NATURE, V380, P243, DOI 10.1038/380243a0; Ravussin E, 1997, NAT MED, V3, P238, DOI 10.1038/nm0297-238; Reed DR, 1996, DIABETES, V45, P691, DOI 10.2337/diabetes.45.5.691; Saladin R, 1996, HORM METAB RES, V28, P638, DOI 10.1055/s-2007-979869; SALADIN R, 1995, NATURE, V377, P527, DOI 10.1038/377527a0; Schwartz MW, 1996, NAT MED, V2, P589, DOI 10.1038/nm0596-589; Schwartz MW, 1996, J CLIN INVEST, V98, P1101, DOI 10.1172/JCI118891; Sharma K, 1997, KIDNEY INT, V51, P1980, DOI 10.1038/ki.1997.269; Shimabukuro M, 1997, P NATL ACAD SCI USA, V94, P4637, DOI 10.1073/pnas.94.9.4637; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Spina M, 1996, SCIENCE, V273, P1561, DOI 10.1126/science.273.5281.1561; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; STIRLING B, 1995, DIABETES, V44, P999, DOI 10.2337/diabetes.44.8.999; Takaya K, 1996, BIOCHEM BIOPH RES CO, V225, P75, DOI 10.1006/bbrc.1996.1133; Takaya K, 1996, NAT GENET, V14, P130, DOI 10.1038/ng1096-130; Tartaglia LA, 1997, J BIOL CHEM, V272, P6093, DOI 10.1074/jbc.272.10.6093; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TRAYHURN P, 1995, FEBS LETT, V368, P488, DOI 10.1016/0014-5793(95)00719-P; Turton MD, 1996, NATURE, V379, P69, DOI 10.1038/379069a0; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; Vidal H, 1996, J CLIN INVEST, V98, P251, DOI 10.1172/JCI118786; Wabitsch M, 1996, DIABETES, V45, P1435, DOI 10.2337/diabetes.45.10.1435; WEIGLE DS, 1995, J CLIN INVEST, V96, P2065, DOI 10.1172/JCI118254; Widjaja A, 1997, J CLIN ENDOCR METAB, V82, P654, DOI 10.1210/jc.82.2.654; Zhang B, 1996, MOL ENDOCRINOL, V10, P1457, DOI 10.1210/me.10.11.1457; Zhang B, 1996, J BIOL CHEM, V271, P9455, DOI 10.1074/jbc.271.16.9455; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	96	456	485	0	18	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 7	1998	351	9104					737	742		10.1016/S0140-6736(97)06348-4	http://dx.doi.org/10.1016/S0140-6736(97)06348-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB359	9504534				2022-12-28	WOS:000072463800041
J	Untoro, J; Schultink, CE; Gross, R; West, CE; Hautvast, JGAJ				Untoro, J; Schultink, CE; Gross, R; West, CE; Hautvast, JGAJ			Efficacy of different types of iodised oil	LANCET			English	Letter									Wageningen Univ Agr, Div Nutr & Epidemiol, NL-6700 EV Wageningen, Netherlands; SEAMEO TROPMED Reg Ctr Community Nutr, Jakarta, Indonesia; Deutsch Gessell Tech Zusammenarbeit GmbH, Eschborn, Germany	Wageningen University & Research	West, CE (corresponding author), Wageningen Univ Agr, Div Nutr & Epidemiol, POB 8129, NL-6700 EV Wageningen, Netherlands.			Untoro, Juliawati/0000-0003-1287-0217				Ingenbleek Y, 1997, LANCET, V350, P1542, DOI 10.1016/S0140-6736(97)02427-6; Van der Heide D, 1989, ANN ENDOCRINOL, V50	2	5	5	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 7	1998	351	9104					752	753		10.1016/S0140-6736(05)78525-1	http://dx.doi.org/10.1016/S0140-6736(05)78525-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB359	9504541				2022-12-28	WOS:000072463800050
J	Mayer-Davis, EJ; D'Agostino, R; Karter, AJ; Haffner, SM; Rewers, MJ; Saad, M; Bergman, RN				Mayer-Davis, EJ; D'Agostino, R; Karter, AJ; Haffner, SM; Rewers, MJ; Saad, M; Bergman, RN		IRAS Invest	Intensity and amount of physical activity in relation to insulin sensitivity - The Insulin Resistance Atherosclerosis Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEPENDENT DIABETES-MELLITUS; IMPAIRED GLUCOSE-TOLERANCE; NATIONAL-HEALTH; MINIMAL MODEL; YOUNG-ADULTS; EXERCISE; MUSCLE; OBESE; MEN; METABOLISM	Context.-Exercise training is associated with improved insulin sensitivity (S-I), but the potential impact of habitual, nonvigorous activity is uncertain. Objective.-To determine whether habitual, nonvigorous physical activity, as well as vigorous and overall activity, is associated with better S-I. Design.-A multicultural epidemiologic study. Setting.-The Insulin Resistance Atherosclerosis Study, conducted in Oakland, Calif; Los Angeles, Calif; the San Luis Valley, Cole; and San Antonio, Tex. Participants.-A total of 1467 men and women of African American, Hispanic, and non-Hispanic white ethnicity, aged 40 to 69 years, with glucose tolerance ranging from normal to mild non-insulin-dependent diabetes mellitus. Main Outcome Measure.-Insulin sensitivity as measured by an intravenous glucose tolerance test. Results.-The mean S-I for individuals who participated in vigorous activity 5 or more times per week was 1.59 min(-1).mu U-1.mL(-1).10(-4) (95% confidence interval [CI], 1.39-1.79) compared with 0.90 (95% CI, 0.83-0.97) for those who rarely or never participated in vigorous activity, after adjusting for potential confounders (P<.001). When habitual physical activity (estimated energy expenditure [EEE]) was assessed by 1-year recall of activities, the correlation coefficient between S-I and total EEE was 0.14 (P<.001), After adjustment for confounders, vigorous and nonvigorous levels of EEE (metabolic equivalent levels greater than or equal to 6.0 and <6.0, respectively) were each positively and independently associated with S-I (P less than or equal to.01 for each), The association was attenuated after adjustment for the potential mediators, body mass index (a measure of weight in kilograms divided by the square of the height in meters), and waist-to-hip ratio. Results were similar for subgroups of sex, ethnicity, and diabetes. Conclusions.-Increased participation in nonvigorous as well as overall and vigorous physical activity was associated with significantly higher S-I. These findings lend further support to current public health recommendations for increased moderate-intensity physical activity on most days.	Univ S Carolina, Sch Publ Hlth, Dept Epidemiol & Biostat, Columbia, SC 29208 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27103 USA; Kaiser Permanente, So Calif Permanente Med Grp, Div Res, Oakland, CA USA; Univ Texas, Hlth Sci Ctr, Dept Med, Div Clin Epidemiol, San Antonio, TX 78284 USA; Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, Denver, CO 80262 USA; Univ So Calif, Med Ctr, Dept Med, Los Angeles, CA USA; Univ So Calif, Med Ctr, Dept Physiol & Biophys, Los Angeles, CA USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Wake Forest University; Wake Forest Baptist Medical Center; Kaiser Permanente; Southern California Permanente Medical Group (SCPMG); Permanente Medical Groups; University of Texas System; University of Texas Health San Antonio; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of Southern California; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of Southern California	Mayer-Davis, EJ (corresponding author), Univ S Carolina, Sch Publ Hlth, Dept Epidemiol & Biostat, Columbia, SC 29208 USA.	ejmayerd@sph.sc.edu	Dagostino, Ralph/C-4060-2017	Dagostino, Ralph/0000-0002-3550-8395; Bergman, Richard/0000-0003-1539-4471	NHLBI NIH HHS [UO1-HL47890, UO1-HL47887, UO1-HL47889] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL047887, U01HL047890, U01HL047889] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; [Anonymous], 1996, JAMA, V276, P241; BERGMAN RN, 1985, ENDOCR REV, V6, P45, DOI 10.1210/edrv-6-1-45; BLOCK G, 1986, AM J EPIDEMIOL, V124, P453, DOI 10.1093/oxfordjournals.aje.a114416; BLOCK G, 1990, J CLIN EPIDEMIOL, V43, P1327, DOI 10.1016/0895-4356(90)90099-B; Boyko EJ, 1997, AM J EPIDEMIOL, V145, P18; BROZINICK JT, 1992, J APPL PHYSIOL, V73, P382, DOI 10.1152/jappl.1992.73.1.382; BURSTEIN R, 1990, J APPL PHYSIOL, V69, P299, DOI 10.1152/jappl.1990.69.1.299; Crespo CJ, 1996, ARCH INTERN MED, V156, P93, DOI 10.1001/archinte.156.1.93; Folsom AR, 1996, AM J EPIDEMIOL, V144, P235, DOI 10.1093/oxfordjournals.aje.a008918; FORD ES, 1995, DIABETES CARE, V18, P27, DOI 10.2337/diacare.18.1.27; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; HERBERT V, 1965, J CLIN ENDOCR METAB, V25, P1375, DOI 10.1210/jcem-25-10-1375; HOLLOSZY JO, 1986, ACTA MED SCAND, P55; HUGHES VA, 1993, AM J PHYSIOL, V264, pE855, DOI 10.1152/ajpendo.1993.264.6.E855; Kang J, 1996, DIABETES CARE, V19, P341, DOI 10.2337/diacare.19.4.341; KELLEY DE, 1995, INT J OBESITY, V19, pS14; KING DS, 1987, J APPL PHYSIOL, V63, P2247, DOI 10.1152/jappl.1987.63.6.2247; LAAKSO M, 1993, AM J EPIDEMIOL, V137, P959, DOI 10.1093/oxfordjournals.aje.a116768; LEBLANC J, 1981, METABOLISM, V30, P1119, DOI 10.1016/0026-0495(81)90057-3; Lynch J, 1996, ARCH INTERN MED, V156, P1307, DOI 10.1001/archinte.156.12.1307; MANSON JE, 1992, JAMA-J AM MED ASSOC, V268, P62; *NUTR COORD CTR, 1990, MINN NUTR DAT SYST C; PACINI G, 1986, COMPUT METH PROG BIO, V23, P113, DOI 10.1016/0169-2607(86)90106-9; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; Perseghin G, 1996, NEW ENGL J MED, V335, P1357, DOI 10.1056/NEJM199610313351804; REGENSTEINER JG, 1991, DIABETES CARE, V14, P1066, DOI 10.2337/diacare.14.11.1066; REGENSTEINER JG, 1995, DIABETES CARE, V18, P490, DOI 10.2337/diacare.18.4.490; ROMIJN JA, 1993, AM J PHYSIOL, V265, pE380, DOI 10.1152/ajpendo.1993.265.3.E380; SAAD MF, 1994, DIABETES, V43, P1114, DOI 10.2337/diabetes.43.9.1114; *SAS I, 1989, SAS STAT US GUID VER, V2; SEGAL KR, 1991, J APPL PHYSIOL, V71, P2402, DOI 10.1152/jappl.1991.71.6.2402; SIDNEY S, 1991, AM J EPIDEMIOL, V133, P1231, DOI 10.1093/oxfordjournals.aje.a115835; SIEGEL PZ, 1995, AM J PUBLIC HEALTH, V85, P706, DOI 10.2105/AJPH.85.5.706; STEIL GM, 1993, DIABETES, V42, P250, DOI 10.2337/diabetes.42.2.250; Wagenknecht Lynne E., 1995, Annals of Epidemiology, V5, P464, DOI 10.1016/1047-2797(95)00062-3; WELCH S, 1990, J CLIN ENDOCR METAB, V71, P1508, DOI 10.1210/jcem-71-6-1508; Wolf A., 1992, American Journal of Epidemiology, V136, P992; World Health Organization, 1985, WHO TECHN REP SER, V727; YAMANOUCHI K, 1995, DIABETES CARE, V18, P775, DOI 10.2337/diacare.18.6.775	40	455	469	0	46	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1998	279	9					669	674		10.1001/jama.279.9.669	http://dx.doi.org/10.1001/jama.279.9.669			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY849	9496984	Bronze			2022-12-28	WOS:000072192800030
J	Spinozzi, F; Fizzotti, M; Agea, E; Piattoni, S; Droetto, S; Russano, A; Forenza, N; Bassotti, G; Grignani, F; Bertotto, A				Spinozzi, F; Fizzotti, M; Agea, E; Piattoni, S; Droetto, S; Russano, A; Forenza, N; Bassotti, G; Grignani, F; Bertotto, A			Defective expression of Fas messenger RNA and Fas receptor on pulmonary T cells from patients with asthma	ANNALS OF INTERNAL MEDICINE			English	Article						T-lymphocytes; asthma; I gene expression; DNA fragmentation; I receptors, Fas	BRONCHOALVEOLAR LAVAGE; INDUCED APOPTOSIS; ATOPIC ASTHMA; LYMPHOCYTES; DEATH; ACTIVATION; ENGAGEMENT; EXPANSION; ETIOLOGY; DISEASE	Background: Inflammation at sites of target organs seems to be the pathologic hallmark of respiratory allergic diseases, but why this response cannot be turned off in atopic persons is not known. Programmed cell death (apoptosis) mediated by Fas/APO-1 (CD95), a 45-kD surface protein belonging to the tumor necrosis factor receptor family, is important in the resolution of all inflammatory immune responses. Objective: To test whether the expression of Fas receptor is defective in allergen-specific pulmonary T lymphocytes from persons with asthma. Design: 12-month prospective study. Setting: University allergy and immunology clinic. Patients: 12 untreated persons with newly diagnosed allergic asthma who underwent bronchoalveolar lavage. Ten normal persons served as controls. Measurements: Fas receptor expression was studied by using surface double-color cytofluorometry on pulmonary and circulating T lymphocytes. Fas messenger RNA (mRNA) was searched for in bronchoalveolar lavage cells from patients and controls by reverse transcription polymerase chain reaction (PCR). In vitro induction of DNA fragmentation, as an expression of cell death induced by an IgM anti-fas monoclonal antibody, was assessed by propidium iodide staining and agarose gel electrophoresis. In vitro modulation of surface Fas receptor was studied on pulmonary T lymphocytes stimulated with anti-CD3 monoclonal antibody and interleukin-2 or interleukin-4. Results: Pulmonary T lymphocytes from patients as opposed to controls did not undergo DNA fragmentation after in vitro exposure to IgM anti-Fas. Other activation markers (CD25, HLA-DR, and CD45R0) were displayed, but surface Fas expression was always negative. A remarkable proportion of T cells from controls showed a clear double-staining pattern. Reverse transcription PCR for Fas mRNA yielded the same results. Circulating T lymphocytes from patients and controls included similar percentages of CD3(+) Fast cells. Pulmonary T cells from both patients and controls showed upregulation of Fas receptor expression after in vitro anti-CD3 stimulation; co-culturing with interleukin-4 downmodulated surface Fas receptor expression on T cells from patients; it was less effective in controls. Conclusions: Hypoexpression of Fas mRNA and surface Fas receptor on pulmonary CD3(+) T lymphocytes may explain the persistence of inflammatory cellular infiltrates in allergic bronchial asthma.	Univ Perugia, Sez Med Interna & Sci Oncol, Dipartimento Med Clin & Sperimentale, Monteluce Policlin, I-06122 Perugia, Italy; Univ Perugia, Monteluce Policlin, Ist Clin Pediat, I-06122 Perugia, Italy	University of Perugia; University of Perugia	Spinozzi, F (corresponding author), Univ Perugia, Sez Med Interna & Sci Oncol, Dipartimento Med Clin & Sperimentale, Monteluce Policlin, I-06122 Perugia, Italy.							Abbas AK, 1996, CELL, V84, P655, DOI 10.1016/S0092-8674(00)81042-9; BARNES PJ, 1995, MOL MED TODAY, V1, P149, DOI 10.1016/S1357-4310(95)80093-X; BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; BELLAMY COC, 1995, SEMIN CANCER BIOL, V6, P3, DOI 10.1006/scbi.1995.0002; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Chauhan AJ, 1996, MOL MED TODAY, V2, P192, DOI 10.1016/1357-4310(96)88771-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; CORRIS PA, 1993, LANCET, V341, P1369, DOI 10.1016/0140-6736(93)90941-9; Critchfield Jeffrey M., 1995, P55; DELPRETE G, 1992, ALLERGY, V47, P450; DeMaria R, 1996, J CLIN INVEST, V97, P316, DOI 10.1172/JCI118418; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; DORWARD AJ, 1988, THORAX, V43, P98, DOI 10.1136/thx.43.2.98; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KALINER MA, 1996, CLIN IMMUNOLOGY, P909; Keegan AD, 1996, IMMUNOLOGIST, V4, P194; Lenardo M J, 1995, Int Rev Immunol, V13, P115, DOI 10.3109/08830189509061742; LYNCH DH, 1995, IMMUNOL TODAY, V16, P569, DOI 10.1016/0167-5699(95)80079-4; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MIGLIORATI G, 1993, BLOOD, V81, P1352; Milik AM, 1997, J CLIN INVEST, V99, P1082, DOI 10.1172/JCI119236; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; OWENSCHAUB LB, 1992, CELL IMMUNOL, V140, P197, DOI 10.1016/0008-8749(92)90187-T; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; Rovere P, 1996, J IMMUNOL, V156, P4631; Sandford A, 1996, AM J RESP CRIT CARE, V153, P1749, DOI 10.1164/ajrccm.153.6.8665031; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; Simon HU, 1996, J EXP MED, V183, P1071, DOI 10.1084/jem.183.3.1071; SPINOZZI F, 1992, ARCH INTERN MED, V152, P99, DOI 10.1001/archinte.152.1.99; SPINOZZI F, 1995, MOL MED, V1, P821, DOI 10.1007/BF03401896; SPINOZZI F, 1995, SCAND J IMMUNOL, V41, P504, DOI 10.1111/j.1365-3083.1995.tb03599.x; SPINOZZI F, 1993, GASTROENTEROLOGY, V105, P1490, DOI 10.1016/0016-5085(93)90156-7; Spinozzi F, 1996, ANN INTERN MED, V124, P223, DOI 10.7326/0003-4819-124-2-199601150-00005; Spinozzi F, 1998, IMMUNOL TODAY, V19, P22, DOI 10.1016/S0167-5699(97)01182-1; SPINOZZI F, 1995, IMMUNOLOGY, V86, P379; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62	40	31	41	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1998	128	5					363	+		10.7326/0003-4819-128-5-199803010-00004	http://dx.doi.org/10.7326/0003-4819-128-5-199803010-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY519	9490596				2022-12-28	WOS:000072155600004
J	Coiera, E; Tombs, V				Coiera, E; Tombs, V			Communication behaviours in a hospital setting: an observational study	BRITISH MEDICAL JOURNAL			English	Article							INFORMATION; CARE	Objective: An exploratory study to identify patterns of communication behaviour among hospital based healthcare workers. Design: Non-participatory, qualitative observational study. Setting: British district general hospital. Subjects: Eight doctors and two nurses. Results: Communication behaviours resulted in an interruptive workplace, which seemed to contribute to inefficiency in work practice. Medical staff generated twice as many interruptions via telephone and paging systems as they received. Hypothesised causes for this level of interruption include a bias by staff to interruptive communication methods, a tendency to seek information from colleagues in preference to printed materials, and poor provision of information in support of contacting individuals in specific roles. Staff were observed to infer the intention of messages based on insufficient information, and clinical teams demonstrated complex communication patterns, which could lead to inefficiency. Conclusion: The results suggest a number of improvements to processes or technologies. Staff may need instruction in appropriate use of communication facilities. Further, excessive emphasis on information technology may be misguided since much may be gained by supporting information exchange through communication technology. Voicemail and email with acknowledgment, mobile communication, improved support for role based contact, and message screening may be beneficial in the hospital environment.	Hewlett Packard Labs, Bristol BS12 6QZ, Avon, England	Hewlett-Packard	Coiera, E (corresponding author), Univ New S Wales, Sch Comp Sci & Engn, Sydney, NSW 2052, Australia.			Coiera, Enrico/0000-0002-6444-6584				Baddeley A.D., 1986, WORKING MEMORY THOUG; BARTON CF, 1989, NEW ENGL J MED, V320, P1150; BEEBE SA, 1995, ARCH PEDIAT ADOL MED, V149, P187, DOI 10.1001/archpedi.1995.02170140069011; BLUM NJ, 1992, AM J DIS CHILD, V146, P806, DOI 10.1001/archpedi.1992.02160190038016; COIERA E, 1995, BRIT MED J, V310, P1381, DOI 10.1136/bmj.310.6991.1381; Coiera E, 1996, Proc AMIA Annu Fall Symp, P17; COIERA E, 1997, GUIDE MED INFORMATIC; COVELL DG, 1985, ANN INTERN MED, V103, P596, DOI 10.7326/0003-4819-103-4-596; DRAPER SW, 1984, INTERACT 84; FACHAMPS D, 1991, P ANN S COMP APPL ME, P788; FITZPATRICK K, 1993, PHYSICIAN ASSISS JUN, P87; KATZ MH, 1988, NEW ENGL J MED, V319, P1585, DOI 10.1056/NEJM198812153192406; Little AD., 1992, TELECOMMUNICATIONS C; Mays N, 1996, QUALITATIVE RES HLTH; PIDGEON NF, 1991, INT J MAN MACH STUD, V35, P151, DOI 10.1016/S0020-7373(05)80146-4; Reason J., 1991, HUMAN ERROR, DOI 10.1017/cbo9781139062367; REITMAN JS, 1974, J VERB LEARN VERB BE, V13, P365, DOI 10.1016/S0022-5371(74)80015-0; SCHARER LL, 1983, DATAMATION, V2, P175; WITHERS CB, 1988, COMPUT HEALTHCARE, P28; 1995, BMJ, V310, P1487	20	309	311	2	36	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 28	1998	316	7132					673	676		10.1136/bmj.316.7132.673	http://dx.doi.org/10.1136/bmj.316.7132.673			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA282	9522794	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000072347900034
J	Caine, N; Schofield, PM; Wallwork, J; Sharples, LD				Caine, N; Schofield, PM; Wallwork, J; Sharples, LD			British trial of transmyocardial revascularisation is continuing	BRITISH MEDICAL JOURNAL			English	Letter									Papworth Hosp NHS Trus, Cambridge CB3 8RE, England; Univ Cambridge, Inst Publ Hlth, MRC, Biostat Unit, Cambridge CB2 2SR, England	Papworth Hospital; MRC Biostatistics Unit; University of Cambridge	Caine, N (corresponding author), Papworth Hosp NHS Trus, Cambridge CB3 8RE, England.			Sharples, Linda/0000-0003-0894-966X				Ault A, 1997, LANCET, V350, P420, DOI 10.1016/S0140-6736(05)64152-9; Josefson D, 1997, BRIT MED J, V315, P328	2	2	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 7	1998	316	7129					474	475						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW874	9492701				2022-12-28	WOS:000071982700067
J	Mallipeddi, R; Mathias, CJ				Mallipeddi, R; Mathias, CJ			Raynaud's phenomenon after sympathetic denervation in patients with primary autonomic failure: questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article									Univ London, Natl Hosp Neurol & Neurosurg, Dept Clin Neurol, Auton Unit, London WC1N 3BG, England; UCL, Inst Neurol, London WC1N 3BG, England; St Marys Hosp, Imperial Coll Sch Med, Div Neurosci & Psychol Med, Neurovasc Med Unit, London W2 1NY, England	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London; Imperial College London	Mathias, CJ (corresponding author), Univ London, Natl Hosp Neurol & Neurosurg, Dept Clin Neurol, Auton Unit, Queen Sq, London WC1N 3BG, England.	c.mathias@ic.ac.uk						BLACK C, 1994, BRIT J HOSP MED, V52, P555; DOWD PM, 1995, LANCET, V346, P286; JAMIESON GG, 1971, CIRCULATION, V44, P254, DOI 10.1161/01.CIR.44.2.254; MATHIAS CJ, 1996, NEUROLOGY CLIN PRACT, V2, P1953; POLINSKY RJ, 1992, AUTONOMIC FAILURE TX, P234	5	7	7	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 7	1998	316	7129					438	439		10.1136/bmj.316.7129.438	http://dx.doi.org/10.1136/bmj.316.7129.438			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW874	9492669	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000071982700028
J	Oka, T				Oka, T			Water on the sun: Molecules everywhere	SCIENCE			English	Editorial Material									UNIV CHICAGO, DEPT ASTRON & ASTROPHYS, CHICAGO, IL 60637 USA	University of Chicago	Oka, T (corresponding author), UNIV CHICAGO, DEPT CHEM, 5735 S ELLIS AVE, CHICAGO, IL 60637 USA.							BRAULT J, 1983, ASTROPHYS J, V269, pL61, DOI 10.1086/184056; CHEUNG AC, 1969, NATURE, V221, P626, DOI 10.1038/221626a0; FLAUD JM, 1976, MOL PHYS, V32, P499, DOI 10.1080/00268977600103251; Genzel R, 1992, GALACTIC INTERSTELLA, P275; HALL DNB, 1970, THESIS HARVARD U; Nozette S, 1996, SCIENCE, V274, P1495, DOI 10.1126/science.274.5292.1495; PARTRIDGE DW, 1997, J CHEM PHYS, V106, P4618; Polyansky OL, 1997, SCIENCE, V277, P346, DOI 10.1126/science.277.5324.346; TENNYSON J, 1995, REP PROG PHYS, V58, P421, DOI 10.1088/0034-4885/58/4/002; The Infrared Space Observatory (ISO), 1996, ASTRON ASTROPHYS, V315; TSUJI T, 1986, ANNU REV ASTRON ASTR, V24, P89, DOI 10.1146/annurev.aa.24.090186.000513; WALLACE L, 1995, SCIENCE, V268, P1155, DOI 10.1126/science.7761830; Wallace L, 1996, ASTROPHYS J SUPPL S, V106, P165, DOI 10.1086/192333	13	8	8	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 18	1997	277	5324					328	329		10.1126/science.277.5324.328	http://dx.doi.org/10.1126/science.277.5324.328			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL358	9518362				2022-12-28	WOS:A1997XL35800032
J	Bennett, CL; Weinberg, PD; Rozenberg-Ben-Dror, K; Yarnold, PR; Kwaan, HC; Green, D				Bennett, CL; Weinberg, PD; Rozenberg-Ben-Dror, K; Yarnold, PR; Kwaan, HC; Green, D			Thrombotic thrombocytopenic purpura associated with ticlopidine - A review of 60 cases	ANNALS OF INTERNAL MEDICINE			English	Review							BINDING; ADP; RAT	Background: Thrombotic thrombocytopenic purpura, a life-threatening multisystem disease, has been infrequently associated with use of ticlopidine, a platelet antiaggregating agent. Purpose: To review 60 cases of ticlopidine-associated thrombotic thrombocytopenic purpura. Data Sources: Medical records, published case reports, and case reports submitted to the U.S. Food and Drug Administration. Study Selection: Instances of ticlopidine-associated thrombotic thrombocytopenic purpura were identified. Data Synthesis: Ticlopidine had been prescribed for less than 1 month in 80% of the patients, and normal platelet counts had been found within 2 weeks of the onset of thrombotic thrombocytopenic purpura in most patients. Mortality rates were higher among patients who were not treated with plasmapheresis than amog those who underwent plasmapheresis (50% compared with 24%; P<0.05). Conclusions: Ticlopidine use may be associated with the development of thrombotic thrombocytopenic purpura, usually within 1 month of initiation of therapy. The onset of ticlopidine-associated thrombotic thrombocytopenic purpura is difficult to predict, despite close monitoring of platelet counts.	Chicago Vet Affairs Healthcare Syst, Lakeside Div, Chicago, IL 60611 USA; Northwestern Univ, Chicago, IL 60611 USA	Northwestern University	Bennett, CL (corresponding author), Vet Affairs Med Sci Bldg,205,400 E Ontario, Chicago, IL 60611 USA.		Bennett, Charles L/C-2050-2008	Yarnold, Paul/0000-0002-1648-739X				Ariyoshi K, 1997, AM J HEMATOL, V54, P175; BELL WR, 1991, NEW ENGL J MED, V325, P398, DOI 10.1056/NEJM199108083250605; CAPRA R, 1992, ACTA NEUROL BELG, V92, P83; DEFREYN G, 1989, SEMIN THROMB HEMOST, V15, P159, DOI 10.1055/s-2007-1002699; deMaat MPM, 1996, THROMB HAEMOSTASIS, V76, P166; ELLIE E, 1992, STROKE, V23, P922, DOI 10.1161/01.STR.23.6.922; GACHET C, 1990, BIOCHEM PHARMACOL, V40, P229, DOI 10.1016/0006-2952(90)90683-C; Gordon LI, 1997, SEMIN HEMATOL, V34, P140; HASS WK, 1989, NEW ENGL J MED, V321, P501, DOI 10.1056/NEJM198908243210804; Kodama K, 1996, Rinsho Ketsueki, V37, P1334; KOVACS MJ, 1993, ANN PHARMACOTHER, V27, P1060, DOI 10.1177/106002809302700910; Kupfer Y, 1997, NEW ENGL J MED, V337, P1245, DOI 10.1056/NEJM199710233371717; PAGE Y, 1991, LANCET, V337, P774, DOI 10.1016/0140-6736(91)91383-6; PIOVELLA F, 1985, BLOOD, V66, P311; ROCK GA, 1991, NEW ENGL J MED, V325, P393, DOI 10.1056/NEJM199108083250604; ROSE M, 1993, BLOOD REV, V7, P94, DOI 10.1016/S0268-960X(05)80019-0; ROSE M, 1987, AM J MED, V83, P437, DOI 10.1016/0002-9343(87)90753-4; SAVI P, 1994, J PHARMACOL EXP THER, V269, P772; TOROK TJ, 1995, AM J HEMATOL, V50, P84, DOI 10.1002/ajh.2830500203; Wysowksi DK, 1996, JAMA-J AM MED ASSOC, V276, P952, DOI 10.1001/jama.1996.03540120030022	20	297	301	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1998	128	7					541	544		10.7326/0003-4819-128-7-199804010-00004	http://dx.doi.org/10.7326/0003-4819-128-7-199804010-00004			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE539	9518398				2022-12-28	WOS:000072803500004
J	Gai, F; Hasson, KC; McDonald, JC; Anfinrud, PA				Gai, F; Hasson, KC; McDonald, JC; Anfinrud, PA			Chemical dynamics in proteins: The photoisomerization of retinal in bacteriorhodopsin	SCIENCE			English	Article							RESONANCE RAMAN-SPECTROSCOPY; EXCITED-STATE DYNAMICS; DARK-ADAPTED BACTERIORHODOPSIN; PURPLE MEMBRANE; SCHIFF-BASE; HALOBACTERIUM-HALOBIUM; K-INTERMEDIATE; FEMTOSECOND; PICOSECOND; ISOMERIZATION	Chemical dynamics in proteins are discussed, with bacteriorhodopsin serving as a model system. Ultrafast time-resolved methods used to probe the chemical dynamics of retinal photoisomerization in bacteriorhodopsin are discussed, along with future prospects for ultrafast time-resolved crystallography, The photoisomerization of retinal in bacteriorhodopsin is far more selective and efficient than in solution, the origins of which are discussed in the context of a three-state model for the photoisomerization reaction coordinate. The chemical dynamics are complex, with the excited-state relaxation exhibiting a multiexponential decay with well-defined rate constants, Possible origins for the two major components are also discussed.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA	Harvard University	Anfinrud, PA (corresponding author), Harvard Univ, Dept Chem & Biol Chem, 12 Oxford St, Cambridge, MA 02138 USA.	anfinrud@chemistry.harvard.edu			NIDDK NIH HHS [DK45306] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045306, R29DK045306] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALFANO RR, 1976, BIOPHYS J, V16, P541, DOI 10.1016/S0006-3495(76)85709-8; Althaus T, 1995, ISRAEL J CHEM, V35, P227; ARLT T, 1995, CHEM PHYS LETT, V241, P559, DOI 10.1016/0009-2614(95)00664-P; ATKINSON GH, 1989, CHEM PHYS, V131, P1, DOI 10.1016/0301-0104(89)87077-6; BEECE D, 1980, BIOCHEMISTRY-US, V19, P5147, DOI 10.1021/bi00564a001; BIRGE RR, 1991, J AM CHEM SOC, V113, P4327, DOI 10.1021/ja00011a043; BIRGE RR, 1995, SCI AM, V272, P90, DOI 10.1038/scientificamerican0395-90; BRACK TL, 1991, J PHYS CHEM-US, V95, P2351, DOI 10.1021/j100159a043; BRAIMAN M, 1982, P NATL ACAD SCI-BIOL, V79, P403, DOI 10.1073/pnas.79.2.403; BRAIMAN MS, 1988, BIOCHEMISTRY-US, V27, P8516, DOI 10.1021/bi00423a002; DELANEY JK, 1993, J PHYS CHEM-US, V97, P12416, DOI 10.1021/j100149a050; DELANEY JK, 1995, P NATL ACAD SCI USA, V92, P2101, DOI 10.1073/pnas.92.6.2101; DEXHEIMER SL, 1992, CHEM PHYS LETT, V188, P61, DOI 10.1016/0009-2614(92)85089-S; DOBLER J, 1988, CHEM PHYS LETT, V144, P215, DOI 10.1016/0009-2614(88)87120-3; DOIG SJ, 1991, J PHYS CHEM-US, V95, P6372, DOI 10.1021/j100169a054; DU M, 1993, BIOPHYS CHEM, V48, P101, DOI 10.1016/0301-4622(93)85002-Y; ElSayed MA, 1997, PURE APPL CHEM, V69, P749, DOI 10.1351/pac199769040749; Freed K. F., 1976, Radiationless processes in molecules and condensed phases, P23; Gai F, 1997, J AM CHEM SOC, V119, P6201, DOI 10.1021/ja9703685; GAI F, 1996, SPRINGER SER CHEM PH, V62, P353; GAI F, UNPUB; GERWERT K, 1989, P NATL ACAD SCI USA, V86, P4943, DOI 10.1073/pnas.86.13.4943; GOVINDJEE R, 1990, BIOPHYS J, V58, P597, DOI 10.1016/S0006-3495(90)82403-6; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; GULL SF, 1978, NATURE, V272, P686, DOI 10.1038/272686a0; HAMAGUCHI H, 1994, ANNU REV PHYS CHEM, V45, P593, DOI 10.1146/annurev.physchem.45.1.593; Haran G, 1996, CHEM PHYS LETT, V261, P389, DOI 10.1016/0009-2614(96)01017-2; HARBISON GS, 1984, P NATL ACAD SCI-BIOL, V81, P1706, DOI 10.1073/pnas.81.6.1706; Hasson KC, 1996, P NATL ACAD SCI USA, V93, P15124, DOI 10.1073/pnas.93.26.15124; Humphrey W, 1997, BIOPHYS J, V72, P1347, DOI 10.1016/S0006-3495(97)78781-2; KANDORI H, 1993, CHEM PHYS LETT, V211, P385, DOI 10.1016/0009-2614(93)87078-H; KATRE NV, 1981, P NATL ACAD SCI-BIOL, V78, P4068, DOI 10.1073/pnas.78.7.4068; KAUFMANN KJ, 1976, BIOCHEM BIOPH RES CO, V68, P1109, DOI 10.1016/0006-291X(76)90310-7; Kimura Y, 1997, NATURE, V389, P206, DOI 10.1038/38323; Kobayashi T, 1998, J PHYS CHEM B, V102, P272, DOI 10.1021/jp970705w; Kochendoerfer GG, 1995, ISRAEL J CHEM, V35, P211; KOYAMA Y, 1991, PHOTOCHEM PHOTOBIOL, V54, P433, DOI 10.1111/j.1751-1097.1991.tb02038.x; Landau L., 1932, PHYZ SOWJETUNION, V2, P46, DOI DOI 10.1098/RSPA.1932.0165; Lanyi JK, 1997, J BIOL CHEM, V272, P31209, DOI 10.1074/jbc.272.50.31209; LEWIS A, 1974, P NATL ACAD SCI USA, V71, P4462, DOI 10.1073/pnas.71.11.4462; Logunov SL, 1996, J PHYS CHEM-US, V100, P18586, DOI 10.1021/jp962046d; Logunov SL, 1997, J PHYS CHEM B, V101, P6629, DOI 10.1021/jp970955c; Logunov SL, 1996, J PHYS CHEM-US, V100, P2391, DOI 10.1021/jp9515242; Logunov SL, 1996, BIOPHYS J, V70, P2875, DOI 10.1016/S0006-3495(96)79857-0; MATHIES RA, 1988, SCIENCE, V240, P777, DOI 10.1126/science.3363359; MOTTO MG, 1980, J AM CHEM SOC, V102, P7947, DOI 10.1021/ja00547a029; NAKANISHI K, 1980, J AM CHEM SOC, V102, P7945, DOI 10.1021/ja00547a028; OESTERHELT D, 1971, NATURE-NEW BIOL, V233, P149, DOI 10.1038/newbio233149a0; PebayPeyroula E, 1997, SCIENCE, V277, P1676, DOI 10.1126/science.277.5332.1676; Perman B, 1998, SCIENCE, V279, P1946, DOI 10.1126/science.279.5358.1946; PETRICH JW, 1987, CHEM PHYS LETT, V137, P369, DOI 10.1016/0009-2614(87)80902-8; PETTEI MJ, 1977, BIOCHEMISTRY-US, V16, P1955, DOI 10.1021/bi00628a031; RACKER E, 1974, J BIOL CHEM, V249, P662; Rischel C, 1997, NATURE, V390, P490, DOI 10.1038/37317; ROHR M, 1992, J PHYS CHEM-US, V96, P6055, DOI 10.1021/j100193a074; Schoenlein RW, 1996, SCIENCE, V274, P236, DOI 10.1126/science.274.5285.236; SCHOENLEIN RW, 1991, SCIENCE, V254, P412, DOI 10.1126/science.1925597; Schulten K, 1995, ISRAEL J CHEM, V35, P447; SHAPIRO SL, 1978, BIOPHYS J, V23, P383, DOI 10.1016/S0006-3495(78)85457-5; SMITH SO, 1986, P NATL ACAD SCI USA, V83, P967, DOI 10.1073/pnas.83.4.967; SMITH SO, 1985, J MEMBRANE BIOL, V85, P95, DOI 10.1007/BF01871263; Song L, 1996, J PHYS CHEM-US, V100, P10479, DOI 10.1021/jp960734r; SONG L, 1993, SCIENCE, V261, P891, DOI 10.1126/science.261.5123.891; Srajer V, 1996, SCIENCE, V274, P1726, DOI 10.1126/science.274.5293.1726; STEINBACH PJ, 1992, BIOPHYS J, V61, P235, DOI 10.1016/S0006-3495(92)81830-1; TALLENT JR, UNPUB; VARO G, 1991, BIOCHEMISTRY-US, V30, P7165, DOI 10.1021/bi00243a018; Zener C, 1932, P R SOC LOND A-CONTA, V137, P696, DOI 10.1098/rspa.1932.0165; Zhong Q, 1996, J AM CHEM SOC, V118, P12828, DOI 10.1021/ja961058+	69	225	230	7	69	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 20	1998	279	5358					1886	1891		10.1126/science.279.5358.1886	http://dx.doi.org/10.1126/science.279.5358.1886			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506931				2022-12-28	WOS:000072613300034
J	Lanier, LL				Lanier, LL			Follow the leader: NK cell receptors for classical and nonclassical MHC class I	CELL			English	Review							NATURAL-KILLER-CELLS; SELF		DNAX Res Inst Mol & Cellular Biol Inc, Dept Immunobiol, Palo Alto, CA 94304 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Lanier, LL (corresponding author), DNAX Res Inst Mol & Cellular Biol Inc, Dept Immunobiol, 901 Calif Ave, Palo Alto, CA 94304 USA.		Lanier, Lewis L/E-2139-2014	Lanier, Lewis L/0000-0003-1308-3952				ALDRICH CJ, 1994, CELL, V79, P649, DOI 10.1016/0092-8674(94)90550-9; BORREGO F, 1998, IN PRESS J EXP MED, V187; Braud V, 1997, EUR J IMMUNOL, V27, P1164, DOI 10.1002/eji.1830270517; Braud VM, 1998, CURR BIOL, V8, P1, DOI 10.1016/S0960-9822(98)70014-4; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; Fan QR, 1997, NATURE, V389, P96, DOI 10.1038/38028; Lanier LL, 1997, IMMUNITY, V6, P371, DOI 10.1016/S1074-7613(00)80280-0; Lanier LL, 1998, NATURE, V391, P703, DOI 10.1038/35642; LEE N, 1998, IN PRESS J IMMUNOL, V160; LEE N, 1998, IN PRESS P NATL ACAD; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; OCALLAGHAN CA, 1998, IN PRESS MOL CELL, V1; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1; YOKOYAMA WM, 1993, ANNU REV IMMUNOL, V11, P613, DOI 10.1146/annurev.iy.11.040193.003145	15	139	143	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 20	1998	92	6					705	707		10.1016/S0092-8674(00)81398-7	http://dx.doi.org/10.1016/S0092-8674(00)81398-7			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZD198	9529246	Bronze			2022-12-28	WOS:000072661200003
J	Lee, A				Lee, A			The Helicobacter pylori genome - New insights into pathogenesis and therapeutics	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ New S Wales, Sydney, NSW 2052, Australia	University of New South Wales Sydney	Lee, A (corresponding author), Univ New S Wales, Sydney, NSW 2052, Australia.							Cohen J, 1997, SCIENCE, V275, P767, DOI 10.1126/science.275.5301.767; Deitsch KW, 1997, MICROBIOL MOL BIOL R, V61, P281, DOI 10.1128/.61.3.281-293.1997; Lee A, 1996, ALIMENT PHARM THER, V10, P129, DOI 10.1046/j.1365-2036.1996.22164013.x; Smith DR, 1996, TRENDS BIOTECHNOL, V14, P290, DOI 10.1016/0167-7799(96)10038-X; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483	5	15	15	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 19	1998	338	12					832	833		10.1056/NEJM199803193381211	http://dx.doi.org/10.1056/NEJM199803193381211			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC163	9504947				2022-12-28	WOS:000072546800011
J	Acuna, MH; Connerney, JEP; Wasilewski, P; Lin, RP; Anderson, KA; Carlson, CW; McFadden, J; Curtis, DW; Mitchell, D; Reme, H; Mazelle, C; Sauvaud, JA; d'Uston, C; Cros, A; Medale, JL; Bauer, SJ; Cloutier, P; Mayhew, M; Winterhalter, D; Ness, NF				Acuna, MH; Connerney, JEP; Wasilewski, P; Lin, RP; Anderson, KA; Carlson, CW; McFadden, J; Curtis, DW; Mitchell, D; Reme, H; Mazelle, C; Sauvaud, JA; d'Uston, C; Cros, A; Medale, JL; Bauer, SJ; Cloutier, P; Mayhew, M; Winterhalter, D; Ness, NF			Magnetic field and plasma observations at Mars: Initial results of the Mars global surveyor mission	SCIENCE			English	Article							SOLAR-WIND INTERACTION; SPECTROMETER MEASUREMENTS; MARTIAN MAGNETOSPHERE; BOW SHOCK; ELECTRON; VENUS; IONOSPHERE; BOUNDARY; PLANETS; DAYSIDE	The magnetometer and electron reflectometer investigation (MAG/ER) on the Mars Global Surveyor spacecraft has obtained magnetic field and plasma observations throughout the near-Mars environment, from beyond the influence of Mars to just above the surface (at an altitude of similar to 100 kilometers). The solar wind interaction with Mars is in many ways similar to that at Venus and at an active comet, that is, primarily an ionospheric-atmospheric interaction. No significant planetary magnetic field of global scale has been detected to date (<2 X 10(21) Gauss-cubic centimeter), but here the discovery of multiple magnetic anomalies of small spatial scale in the crust of Mars is reported.	NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; Univ Calif Berkeley, Space Sci Lab, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Ctr Etud Spatiale Rayonnements, F-31209 Toulouse, France; Graz Univ, A-8010 Graz, Austria; Austrian Acad Sci, Space Res Inst, A-8010 Graz, Austria; Rice Univ, Dept Space Phys & Astron, Houston, TX 77005 USA; Natl Sci Fdn, Arlington, VA 22230 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Univ Delaware, Bartol Res Inst, Newark, DE 19716 USA	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of Graz; Austrian Academy of Sciences; Rice University; National Science Foundation (NSF); California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Delaware	Acuna, MH (corresponding author), NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA.		connerney, john/I-5127-2013	Bauer, Siegfried/0000-0003-4213-2047				ACUNA MH, 1992, J GEOPHYS RES-PLANET, V97, P7799, DOI 10.1029/92JE00344; ANDERSON KA, 1975, P 6 LUN SCI C, V3, P2971; AXFORD WI, 1991, PLANET SPACE SCI, V39, P167, DOI 10.1016/0032-0633(91)90139-2; BEHANNON KW, 1977, SPACE SCI REV, V21, P235, DOI 10.1007/BF00211541; BRACE LH, 1982, PLANET SPACE SCI, V30, P29, DOI 10.1016/0032-0633(82)90069-1; Brecht SH, 1997, J GEOPHYS RES-SPACE, V102, P4743, DOI 10.1029/96JA03205; BREUS TK, 1991, J GEOPHYS RES-SPACE, V96, P11165, DOI 10.1029/91JA01131; BREUS TK, 1992, MONOGRAPH AM GEOPHYS, V66, P387; CISOWSKI SM, 1986, GEOCHIM COSMOCHIM AC, V50, P1043, DOI 10.1016/0016-7037(86)90386-8; CLOUTIER PA, 1974, PLANET SPACE SCI, V22, P967, DOI 10.1016/0032-0633(74)90166-4; Collinson DW, 1997, METEORIT PLANET SCI, V32, P803, DOI 10.1111/j.1945-5100.1997.tb01571.x; CONNERNEY JEP, 1993, J GEOPHYS RES-PLANET, V98, P18659, DOI 10.1029/93JE00980; CURTIS SA, 1988, GEOPHYS RES LETT, V15, P737, DOI 10.1029/GL015i008p00737; DETEJADA HP, 1991, J GEOPHYS RES, V96, P11155; DOLGINOV SS, 1978, GEOPHYS RES LETT, V5, P93, DOI 10.1029/GL005i001p00093; DOLGINOV SS, 1978, GEOPHYS RES LETT, V5, P89, DOI 10.1029/GL005i001p00089; Dubinin E, 1996, J GEOPHYS RES-SPACE, V101, P27061, DOI 10.1029/96JA02021; Folkner WM, 1997, SCIENCE, V278, P1749, DOI 10.1126/science.278.5344.1749; HANSON WB, 1988, J GEOPHYS RES, V93, P7538, DOI 10.1029/JA093iA07p07538; Hood LL, 1997, GEOPHYS RES LETT, V24, P727, DOI 10.1029/97GL00497; INTRILIGATOR DS, 1989, GEOPHYS RES LETT, V16, P167, DOI 10.1029/GL016i002p00167; INTRILIGATOR DS, 1979, J GEOPHYS RES, V84, P8427, DOI 10.1029/JB084iB14p08427; KLIORE A, 1992, MONOGRAPH AM GEOPHYS, V66, P387; LANGEL RA, 1982, GEOPHYS RES LETT, V9, P269, DOI 10.1029/GL009i004p00269; LIN RP, 1976, P 7 LUN SCI C, V3, P2691; MAZELLE C, 1989, GEOPHYS RES LETT, V16, P1035, DOI 10.1029/GL016i009p01035; MOHLMANN D, 1991, PLANET SPACE SCI, V39, P83, DOI 10.1016/0032-0633(91)90130-3; NESS NF, 1994, PHILOS T R SOC A, V349, P249, DOI 10.1098/rsta.1994.0129; OGALLAGHER JJ, 1965, SCIENCE, V149, P1233, DOI 10.1126/science.149.3689.1233; REME H, 1993, J GEOPHYS RES-SPACE, V98, P20965, DOI 10.1029/93JA02536; RIEDLER W, 1989, NATURE, V341, P604, DOI 10.1038/341604a0; RIEDLER W, 1991, PLANET SPACE SCI, V39, P75, DOI 10.1016/0032-0633(91)90129-X; RUSSELL CT, 1995, PLANET SPACE SCI, V43, P875, DOI 10.1016/0032-0633(94)00217-F; RUSSELL CT, 1993, J GEOPHYS RES-PLANET, V98, P18681, DOI 10.1029/93JE00981; RUSSELL CT, 1978, GEOPHYS RES LETT, V5, P85, DOI 10.1029/GL005i001p00085; Schubert G., 1992, MARS, P147, DOI [10.2307/j.ctt207g59v.9, DOI 10.2307/J.CTT207G59V.9]; SCHWINGENSCHUH K, 1992, ADV SPACE RES-SERIES, V12, P213, DOI 10.1016/0273-1177(92)90333-S; SHINAGAWA H, 1989, J GEOPHYS RES, V94, P6506, DOI 10.1029/JA094iA06p06506; SHINAGAWA H, 1992, J GEOPHYS RES-PLANET, V97, P1027, DOI 10.1029/91JE02720; SHUTTE NM, 1989, NATURE, V341, P614, DOI 10.1038/341614a0; SLAVIN JA, 1991, J GEOPHYS RES-SPACE, V96, P11235, DOI 10.1029/91JA00439; SMITH EJ, 1965, SCIENCE, V149, P1241, DOI 10.1126/science.149.3689.1241; VANALLEN JA, 1965, SCIENCE, V149, P1228, DOI 10.1126/science.149.3689.1228; VERIGIN MI, 1993, J GEOPHYS RES-SPACE, V98, P1303, DOI 10.1029/92JA01666; VERIGIN MI, 1991, J GEOPHYS RES-SPACE, V96, P19307, DOI 10.1029/91JA00924; Warner RD, 1997, J GEOPHYS RES-SOL EA, V102, P20225, DOI 10.1029/97JB01517; ZHANG MHG, 1990, J GEOPHYS RES-SPACE, V95, P17095, DOI 10.1029/JA095iA10p17095	47	561	576	4	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 13	1998	279	5357					1676	1680		10.1126/science.279.5357.1676	http://dx.doi.org/10.1126/science.279.5357.1676			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9497279				2022-12-28	WOS:000072490000044
J	Franklyn, JA; Maisonneuve, P; Sheppard, MC; Betteridge, J; Boyle, P				Franklyn, JA; Maisonneuve, P; Sheppard, MC; Betteridge, J; Boyle, P			Mortality after the treatment of hyperthyroidism with radioactive iodine	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ATRIAL-FIBRILLATION; OLDER PERSONS; FOLLOW-UP; THERAPY; THYROTOXICOSIS; DISEASE; CANCER; WOMEN; I-131; RISK	Background Hyperthyroidism affects many organ systems, but the effects are usually considered reversible. The long-term effects of hyperthyroidism on mortality are not known. Methods We conducted a population-based study of mortality in a cohort of 7209 subjects with hyper thyroidism who were treated with radioactive iodine in Birmingham, United Kingdom, between 1950 and 1989. The vital status of the subjects was determined on March 1, 1996, and causes of death were ascertained for those who had died. The data on the causes of death were compared with data on age-specific mortality in England and Wales. The standardized mortality ratio was used as a measure of relative risk, and the effect of covariates on mortality was assessed by regression analysis. Results During 105,028 person-years of follow-up, 3611 subjects died; the expected number of deaths was 3186 (standardized mortality ratio, 1.1; 95 percent confidence interval, 1.1 to 1.2; P<0.001). The risk was increased for deaths due to thyroid disease (106 excess deaths; standardized mortality ratio, 24.8; 95 percent confidence interval, 20.4 to 29.9), cardiovascular disease (240 excess deaths; standardized mortality ratio, 1.2; 95 percent confidence interval, 1.2 to 1.3), and cerebrovascular disease (159 excess deaths; standardized mortality ratio, 1.4; 95 percent confidence interval, 1.2 to 1.5), as well as fracture of the femur (26 excess deaths; standardized mortality ratio, 2.9; 95 percent confidence interval, 2.0 to 3.9). The excess mortality was most evident in the first year after radioiodine therapy and declined thereafter. Conclusions Among patients with hyperthyroidism treated with radioiodine, mortality from all causes and mortality due to cardiovascular and cerebrovascular disease and fracture are increased. (C)1998, Massachusetts Medical Society.	Univ Birmingham, Queen Elizabeth Hosp, Dept Med, Birmingham B15 2TH, W Midlands, England; European Inst Oncol, Div Epidemiol & Biostat, Milan, Italy	University of Birmingham; IRCCS European Institute of Oncology (IEO)	Franklyn, JA (corresponding author), Univ Birmingham, Queen Elizabeth Hosp, Dept Med, Birmingham B15 2TH, W Midlands, England.		Maisonneuve, Patrick/U-9789-2018; Boyle, Peter/A-4380-2014	Maisonneuve, Patrick/0000-0002-5309-4704; Boyle, Peter/0000-0001-6251-0610				AUWERX J, 1986, Q J MED, V60, P737; BARBER SG, 1977, LANCET, V2, P967; BAUER DC, 1992, J BONE MINER RES, V7, pS121; BIONDI B, 1993, J CLIN ENDOCR METAB, V77, P334, DOI 10.1210/jc.77.2.334; BRESLOW NE, 1987, IARC SCI PUBL, V82; Ching GW, 1996, HEART, V75, P363, DOI 10.1136/hrt.75.4.363; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; FORFAR JC, 1982, NEW ENGL J MED, V307, P1165, DOI 10.1056/NEJM198211043071901; FRANKLYN J, 1994, CLIN ENDOCRINOL, V41, P425, DOI 10.1111/j.1365-2265.1994.tb02572.x; FRANKLYN JA, 1991, CLIN ENDOCRINOL, V34, P71, DOI 10.1111/j.1365-2265.1991.tb01738.x; FRANKLYN JA, 1995, QJM-MON J ASSOC PHYS, V88, P175; Gammage M, 1997, HEART, V77, P189, DOI 10.1136/hrt.77.3.189; GARDNER MJ, 1989, STAT CONFIDENCE CONF; GOLDMAN MB, 1990, CANCER RES, V50, P2283; GOLDMAN MB, 1988, AM J EPIDEMIOL, V127, P969, DOI 10.1093/oxfordjournals.aje.a114900; HALL P, 1993, ACTA ENDOCRINOL-COP, V128, P230, DOI 10.1530/acta.0.1280230; HALL P, 1992, LANCET, V340, P1; HOFFMAN DA, 1982, AM J EPIDEMIOL, V115, P243, DOI 10.1093/oxfordjournals.aje.a113296; HOLM LE, 1991, JNCI-J NATL CANCER I, V83, P1072, DOI 10.1093/jnci/83.15.1072; IWASAKI T, 1989, CARDIOLOGY, V76, P10, DOI 10.1159/000174467; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KLEIN I, 1992, J CLIN ENDOCR METAB, V75, P339, DOI 10.1210/jc.75.2.339; KUTTY KM, 1978, J CLIN ENDOCR METAB, V46, P55, DOI 10.1210/jcem-46-1-55; PARLE JV, 1991, LANCET, V337, P171, DOI 10.1016/0140-6736(91)90831-9; PRESTI CF, 1989, AM HEART J, V117, P976, DOI 10.1016/0002-8703(89)90642-X; *SAS I, 1991, SAS STAT SOFTW REL 6; SAWIN CT, 1989, JAMA-J AM MED ASSOC, V261, P2653, DOI 10.1001/jama.261.18.2653; SAWIN CT, 1994, NEW ENGL J MED, V331, P1249, DOI 10.1056/NEJM199411103311901; SMITH RN, 1967, BRIT MED J, V1, P129, DOI 10.1136/bmj.1.5533.129; TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL, V7, P481, DOI 10.1111/j.1365-2265.1977.tb01340.x; WOEBER KA, 1992, NEW ENGL J MED, V327, P94; *WORLD HLTH ORG, 1975, INT CLASS DIS MAN IN, V1	32	204	218	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 12	1998	338	11					712	718		10.1056/NEJM199803123381103	http://dx.doi.org/10.1056/NEJM199803123381103			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB546	9494147				2022-12-28	WOS:000072483400003
J	Conte, D; Manachino, D; Colli, A; Guala, A; Aimo, G; Andreoletti, M; Corsetti, M; Fraquelli, M				Conte, D; Manachino, D; Colli, A; Guala, A; Aimo, G; Andreoletti, M; Corsetti, M; Fraquelli, M			Prevalence of genetic hemochromatosis in a cohort of Italian patients with diabetes mellitus	ANNALS OF INTERNAL MEDICINE			English	Article							LONG-TERM SURVIVAL; HEREDITARY HEMOCHROMATOSIS; EXPRESSION	Background: Few data exist on the prevalence of genetic hemochromatosis among diabetic patients. Objective: To compare the prevalence of genetic hemochromatosis in diabetic patients and a matched control group and to evaluate the accuracy of iron-related indexes in detecting hemochromatosis. Design: Cross-sectional study. Setting: Diabetes clinics of four hospitals in northern Italy. Patients: 894 diabetic patients (117 with type 1 diabetes and 777 with type 2 diabetes) and 467 matched controls. Measurements: Transferrin saturation and serum ferritin levels were measured in all study participants. After secondary iron overload was excluded as the cause of persistently elevated transferrin saturation and serum ferritin levels, liver biopsy was performed and siderosis was estimated semiquantitatively and quantitatively. A hepatic iron index greater than 1.9 was considered diagnostic for hemochromatosis. Results: Hemochromatosis was diagnosed in 12 patients with type Z diabetes (prevalence, 1.34% [95% CI, 0.7% to 2.3%]) and 1 control (prevalence, 0.2% [CI, 0.1% to 1.4%]; P = 0.032). The odds ratio of hemochromatosis in association with diabetes was 6.3 (CI, 1.1 to 37.7). Measurement of transferrin saturation was the most sensitive test for hemochromatosis. Conclusions: Genetic hemochromatosis is frequently not diagnosed in patients with diabetes, although it is a hallmark of the disease. Screening for hemochromatosis could be beneficial for patients with diabetes.	Univ Milan, Osped Maggiore, IRCCS, Ist Sci Med,Cattedra Gastroenterol, I-20122 Milan, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan	Conte, D (corresponding author), Univ Milan, Osped Maggiore, IRCCS, Ist Sci Med,Cattedra Gastroenterol, Padiglione Granelli 3 Piano,Via F Sforza 35, I-20122 Milan, Italy.			Corsetti, Maura/0000-0003-2957-4684				ADAMS PC, 1995, GASTROENTEROLOGY, V109, P177, DOI 10.1016/0016-5085(95)90283-X; ADAMS PC, 1991, GASTROENTEROLOGY, V101, P368, DOI 10.1016/0016-5085(91)90013-B; BARRY M, 1971, LANCET, V1, P100; BASSETT ML, 1984, GASTROENTEROLOGY, V87, P628; BASSETT ML, 1986, HEPATOLOGY, V6, P24, DOI 10.1002/hep.1840060106; Carella M, 1997, AM J HUM GENET, V60, P828; DADONE MM, 1982, AM J CLIN PATHOL, V78, P196, DOI 10.1093/ajcp/78.2.196; FARGION S, 1992, HEPATOLOGY, V15, P655, DOI 10.1002/hep.1840150417; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; LEGGETT BA, 1990, BRIT J HAEMATOL, V74, P525, DOI 10.1111/j.1365-2141.1990.tb06345.x; Niederau C, 1996, GASTROENTEROLOGY, V110, P1107, DOI 10.1053/gast.1996.v110.pm8613000; NIEDERAU C, 1985, NEW ENGL J MED, V313, P1256, DOI 10.1056/NEJM198511143132004; OBRIEN T, 1990, DIABETES CARE, V13, P532, DOI 10.2337/diacare.13.5.532; PHELPS G, 1989, LANCET, V2, P233; Piperno A, 1996, HEPATOLOGY, V24, P43, DOI 10.1002/hep.510240109; SCHEUER PJ, 1962, J PATHOL BACTERIOL, V84, P53, DOI 10.1002/path.1700840107; SIMON M, 1988, J HEPATOL, V6, P116, DOI 10.1016/S0168-8278(88)80471-9; SINGH BM, 1992, DIABETIC MED, V9, P730, DOI 10.1111/j.1464-5491.1992.tb01881.x; SUMMERS KM, 1990, HEPATOLOGY, V12, P20, DOI 10.1002/hep.1840120105	19	64	65	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1998	128	5					370	373		10.7326/0003-4819-128-5-199803010-00005	http://dx.doi.org/10.7326/0003-4819-128-5-199803010-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY519	9490597				2022-12-28	WOS:000072155600005
J	Holm, HA				Holm, HA			Continuing medical education - Quality issues in continuing medical education	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RECERTIFICATION		Norwegian Med Assoc, N-0107 Oslo, Norway		Holm, HA (corresponding author), Norwegian Med Assoc, POB 1152 Sentrum, N-0107 Oslo, Norway.	hans.asbjoern.holm@legeforeningen.no						Bashook PG, 1998, BRIT MED J, V316, P545, DOI 10.1136/bmj.316.7130.545; BENNETT NL, 1995, J CONT ED HLTH PROF, V15, P70; BERWICK DM, 1992, BRIT MED J, V304, P304, DOI 10.1136/bmj.304.6822.304; Brigley S, 1997, MED EDUC, V31, P67, DOI 10.1111/j.1365-2923.1997.tb00046.x; Candy PC., 1991, SELF DIRECTION LIFEL; CATTLFORD PG, 1993, ACAD MED S, V270, P16; Challis M, 1997, MED EDUC, V31, P22, DOI 10.1111/j.1365-2923.1997.tb00038.x; Coles, 1996, J CONTIN EDUC HEALTH, V16, P152, DOI DOI 10.1002/chp.4750160305; DAVIS DA, 1994, PHYSICIANS LEARNER L; *EUR UN GEN PRACT, 1995, EUR UN GEN PRACT REF; *EUR UN SPEC, 1994, CHART CONT MED ED ME; Fox RD., 1989, CHANGING LEARNING LI; Grol R., 1997, EUR J GEN PRACT, V3, P65; Hammond M., 1991, SELF DIRECTED LEARNI; JENNET PA, 1994, J CONTIN EDUC HEALTH, V14, P69; Knowles M.S., 1975, SELF DIRECTED LEARNI; LANAAS S, 1996, TIDSSKR NAT LOEGEFOR, V116, P63; MANNING PR, 1987, ANN INTERN MED, V107, P909, DOI 10.7326/0003-4819-107-6-909; MANNING PR, 1987, JAMA-J AM MED ASSOC, V258, P3542, DOI 10.1001/jama.258.24.3542; MANNING PR, 1987, MED PRESERVING PASSI; MAST T, 1994, PHYSICIAN LEARNER LI; NORMAN GR, 1993, JAMA-J AM MED ASSOC, V270, P1046; Nowlen PM., 1988, NEW APPROACH CONTINU; PARBOOSINGH J, 1996, J CONTIN EDUC HEALTH, V16, P75; PIETRONI R, 1993, PORTFOLIO BASED LEAR; Sacket DL, 1997, EVIDENCE BASED MED P; Schon D.A., 1987, ED REFLECTIVE PRACTI; Schon D.A, 2017, REFLECTIVE PRACTITIO; Slotnick HB, 1996, ACAD MED, V71, P28, DOI 10.1097/00001888-199601000-00014; SOUTHGATE L, IN PRESS BMJ; *STAND COMM EUR DO, 1993, DECL DUBL CONT MED E	31	60	60	1	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 21	1998	316	7131					621	624		10.1136/bmj.316.7131.621	http://dx.doi.org/10.1136/bmj.316.7131.621			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ031	9518922	Green Published			2022-12-28	WOS:000072213200041
J	Kemeny, M; Peakman, M				Kemeny, M; Peakman, M			Recent advances - Immunology	BRITISH MEDICAL JOURNAL			English	Review							T-CELL-RECEPTOR; LYMPHOPROLIFERATIVE SYNDROME; INTERLEUKIN (IL)-4; CYTOKINE PROFILES; HIV-1 INFECTION; LIGAND; ANTIGEN; TYPE-1; DIFFERENTIATION; AUTOIMMUNITY		Univ London Kings Coll, Sch Med & Dent, Dept Immunol, London SE5 9PJ, England	University of London; King's College London	Kemeny, M (corresponding author), Univ London Kings Coll, Sch Med & Dent, Dept Immunol, London SE5 9PJ, England.	m.kemeny@kcl.ac.uk						Birkhofer A, 1996, EUR J IMMUNOL, V26, P957, DOI 10.1002/eji.1830260437; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; COYLE AJ, 1995, J EXP MED, V181, P1229, DOI 10.1084/jem.181.3.1229; CROFT M, 1994, J EXP MED, V180, P1715, DOI 10.1084/jem.180.5.1715; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; ERARD F, 1993, SCIENCE, V260, P1802, DOI 10.1126/science.8511588; FISCHER P, 1991, Zeitschrift fuer Erkrankungen der Atmungsorgane, V177, P88; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; Giordano C, 1997, SCIENCE, V275, P960, DOI 10.1126/science.275.5302.960; Holt PG, 1996, TOXICOL LETT, V86, P205, DOI 10.1016/0378-4274(96)03692-2; LANG DM, 1994, NEW ENGL J MED, V331, P1542, DOI 10.1056/NEJM199412083312302; Lau HT, 1996, SCIENCE, V273, P109, DOI 10.1126/science.273.5271.109; Lehner T, 1996, NAT MED, V2, P767, DOI 10.1038/nm0796-767; MAGGI E, 1994, J EXP MED, V180, P489, DOI 10.1084/jem.180.2.489; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; NICHOLSON LB, 1995, IMMUNITY, V3, P397, DOI 10.1016/1074-7613(95)90169-8; NOBLE A, 1995, J IMMUNOL, V155, P2928; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; SAD S, 1995, J EXP MED, V182, P1505, DOI 10.1084/jem.182.5.1505; SAD S, 1995, IMMUNITY, V2, P271, DOI 10.1016/1074-7613(95)90051-9; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; SLOANLANCASTER J, 1993, NATURE, V363, P156, DOI 10.1038/363156a0; STEIN BS, 1987, CELL, V49, P659, DOI 10.1016/0092-8674(87)90542-3; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; vanParijs L, 1996, CURR OPIN IMMUNOL, V8, P355, DOI 10.1016/S0952-7915(96)80125-7; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358, DOI 10.1164/ajrccm.149.2.8306030; Wassenaar A, 1996, IMMUNOLOGY, V87, P113; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; Zanussi S, 1996, CLIN EXP IMMUNOL, V105, P220, DOI 10.1046/j.1365-2249.1996.d01-746.x	36	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 21	1998	316	7131					600	603		10.1136/bmj.316.7131.600	http://dx.doi.org/10.1136/bmj.316.7131.600			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ031	9518915	Green Published			2022-12-28	WOS:000072213200033
J	Alberts, AS; Geneste, O; Treisman, R				Alberts, AS; Geneste, O; Treisman, R			Activation of SRF-regulated chromosomal templates by Rho-family GTPases requires a signal that also induces H4 hyperacetylation	CELL			English	Article							CORE HISTONE HYPERACETYLATION; PROTEIN-SYNTHESIS INHIBITORS; SERUM RESPONSE ELEMENT; TUMOR VIRUS PROMOTER; C-FOS PROMOTER; TERNARY COMPLEX; TRANSCRIPTIONAL ACTIVATION; NUCLEOSOME STRUCTURE; CHROMATIN STRUCTURE; GENE-EXPRESSION	Constitutively active forms of the small GTPases RhoA (RhoA.V14) and Cdc42 (Cdc42.V12) induce expression of extrachromosomal SRF reporter genes in microinjection experiments, but only Cdc42.V12 can efficiently activate a chromosomal template. Both SAPK/JNK-dependent or -independent signals can cooperate with RhoA.V14 to activate chromosomal SRF reporters, and it is SAPK/JNK activation by Cdc42.V12 that allows it to activate chromosomal templates. Cooperating signals can be bypassed by deacetylase inhibitors. Three findings show that histone H4 hyperacetylation is one target for cooperating signals, although it alone is not sufficient: (1) Cdc42.V12, but not RhoA.V14, induces H4 hyperacetylation; (2) cooperating signals use the same SAPK/JNK-dependent or -independent pathways to induce H4 hyperacetylation; (3) growth factor and stress stimuli induce substantial H4 hyperacetylation, detectable in reporter gene chromatin. These data establish a link between signal-regulated acetylation events and gene transcription.	Imperial Canc Res Fund, Transcript Lab, London WC2A 3PX, England	Cancer Research UK	Treisman, R (corresponding author), Imperial Canc Res Fund, Transcript Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.			Treisman, Richard/0000-0002-9658-0067				ALBERTS AS, 1993, DNA CELL BIOL, V12, P935, DOI 10.1089/dna.1993.12.935; ALBERTS AS, 1994, MOL CELL BIOL, V14, P4398, DOI 10.1128/MCB.14.7.4398; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ALLEGRA P, 1987, J MOL BIOL, V196, P379, DOI 10.1016/0022-2836(87)90698-X; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; ARCHER TK, 1992, SCIENCE, V256, P161; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BARRATT MJ, 1994, P NATL ACAD SCI USA, V91, P4781, DOI 10.1073/pnas.91.11.4781; BARRATT MJ, 1994, EMBO J, V13, P4524, DOI 10.1002/j.1460-2075.1994.tb06774.x; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; BRESNICK EH, 1990, P NATL ACAD SCI USA, V87, P3977, DOI 10.1073/pnas.87.10.3977; CEREGHINI S, 1984, EMBO J, V3, P1243, DOI 10.1002/j.1460-2075.1984.tb01959.x; CHEN TA, 1990, J MOL BIOL, V212, P481, DOI 10.1016/0022-2836(90)90327-I; CHEN TA, 1987, P NATL ACAD SCI USA, V84, P5252, DOI 10.1073/pnas.84.15.5252; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HEBBES TR, 1989, MOL IMMUNOL, V26, P865, DOI 10.1016/0161-5890(89)90143-0; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; INNIS JW, 1983, MOL CELL BIOL, V3, P2203, DOI 10.1128/MCB.3.12.2203; Janknecht R, 1996, ONCOGENE, V12, P1961; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; JEONG S, 1994, J BIOL CHEM, V269, P2197; JEONG SW, 1994, NUCLEIC ACIDS RES, V22, P370, DOI 10.1093/nar/22.3.370; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LIN R, 1989, J CELL BIOL, V108, P1577, DOI 10.1083/jcb.108.5.1577; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MEISTRICH ML, 1992, MOL REPROD DEV, V31, P170, DOI 10.1002/mrd.1080310303; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; NICOLAS RH, 1990, GEL ELECTROPHORESIS, P249; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONEILL LP, 1995, EMBO J, V14, P3946, DOI 10.1002/j.1460-2075.1995.tb00066.x; PALMER RH, 1994, FEBS LETT, V356, P5, DOI 10.1016/0014-5793(94)01202-4; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; PENNIE WD, 1995, MOL CELL BIOL, V15, P2125; PERRY CA, 1993, BIOCHEMISTRY-US, V32, P13605, DOI 10.1021/bi00212a028; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; SCHLAKE T, 1994, BIOCHEMISTRY-US, V33, P4197, DOI 10.1021/bi00180a012; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VanLint C, 1996, EMBO J, V15, P1112, DOI 10.1002/j.1460-2075.1996.tb00449.x; YAN MH, 1994, NATURE, V372, P798; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510	57	193	197	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 20	1998	92	4					475	487		10.1016/S0092-8674(00)80941-1	http://dx.doi.org/10.1016/S0092-8674(00)80941-1			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YZ409	9491889	Bronze			2022-12-28	WOS:000072251500008
J	Frankel, S; Gunnell, DJ; Peters, TJ; Maynard, M; Smith, GD				Frankel, S; Gunnell, DJ; Peters, TJ; Maynard, M; Smith, GD			Childhood energy intake and adult mortality from cancer: the Boyd Orr cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BREAST-CANCER; CALORIC RESTRICTION; COLORECTAL-CANCER; RISK-FACTORS; BODY HEIGHT; EARLY-LIFE; DISEASE; WOMEN; DIET; LONGEVITY	Objective: To examine the relation between energy intake in childhood and adult mortality from cancer. Study design: Cohort study. Setting: 16 rural and urban centres in England and Scotland. Subjects: 3834 people who took part in Lord Boyd Orr's Carnegie survey of family diet and health in prewar Britain between 1937 and 1939 who were followed up with the NHS central register. Standardised methods were used to measure household dietary intake during a one week period. Main outcome measures: Cancer mortality. Results: Significant associations between childhood energy intake and cancer mortality were seen when the confounding effects of social variables were taken into account in proportional hazards models (relative hazard for all cancer mortality 1.15 (95% confidence interval 1.06 to 1.24), P = 0.001, for every MJ increase in adult equivalent daily intake in fully adjusted models). This effect was essentially limited to cancers not related to smoking (relative hazard 1.20; 1.07 to 1.34; P = 0.001), with similar effects seen in men and women. Conclusion: This positive association between childhood energy intake and later cancer is consistent with animal evidence linking energy restriction with reduced incidence of cancer and the association between height and human cancer, implying that higher levels of energy intake in childhood increase the risk of later development of cancer. This evidence for long term effects of early diet confirm the importance of optimal nutrition in childhood and suggest that the unfavourable trends seen in die incidence of some cancers may have their origins in early life.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England	University of Bristol	Frankel, S (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.	stephen.frankel.@bristol.ac.uk	Davey Smith, George/A-7407-2013; Gunnell, David/ABE-6653-2020	Davey Smith, George/0000-0002-1407-8314; Gunnell, David/0000-0002-0829-6470; Peters, Tim/0000-0003-2881-4180				ALBANES D, 1988, CANCER RES, V48, P1658; ALBANES D, 1990, NUTR CANCER, V14, P69, DOI 10.1080/01635589009514078; ANDERSSON SO, 1995, CANCER EPIDEM BIOMAR, V4, P187; [Anonymous], 1992, DIET REF VAL FOOD EN; BARKER DJP, 1990, ANN HUM BIOL, V17, P1, DOI 10.1080/03014469000000732; BERG BN, 1960, J NUTR, V71, P255; Blane D, 1996, BMJ-BRIT MED J, V313, P1434, DOI 10.1136/bmj.313.7070.1434; *BRIT MED ASS, 1933, REP COMM NUTR; CHUTE CG, 1991, CANCER CAUSE CONTROL, V2, P117, DOI 10.1007/BF00053131; GUNNELL D, 1996, J EPIDEMIOL COMMUNIT, V50, P580; Gunnell DJ, 1996, PUBLIC HEALTH, V110, P85, DOI 10.1016/S0033-3506(96)80052-7; GUNNELL DJ, 1937, IN PRESS PAEDIAT PER; HISLOP TG, 1986, CANCER DETECT PREV, V9, P47; KAGAWA Y, 1978, PREV MED, V7, P205, DOI 10.1016/0091-7435(78)90246-3; KRISTAL BS, 1994, MODULATION AGING PRO, P1; KRITCHEVSKY D, 1995, EUR J CANCER PREV, V4, P445, DOI 10.1097/00008469-199512000-00002; KUNE GA, 1990, NUTR CANCER, V13, P9, DOI 10.1080/01635589009514041; LEON DA, 1995, J EPIDEMIOL COMMUN H, V49, P5, DOI 10.1136/jech.49.1.5; McCay CM, 1935, J NUTR, V10, P63, DOI 10.1093/jn/10.1.63; PALMER JR, 1995, AM J EPIDEMIOL, V141, P845, DOI 10.1093/oxfordjournals.aje.a117520; PHILLIMORE P, 1994, BRIT MED J, V308, P1125, DOI 10.1136/bmj.308.6937.1125; PHILLIPS AN, 1991, J CLIN EPIDEMIOL, V44, P1223, DOI 10.1016/0895-4356(91)90155-3; PRENTICE AM, 1995, BRIT MED J, V311, P437, DOI 10.1136/bmj.311.7002.437; PRYOR M, 1989, CANCER RES, V49, P2161; ROSS MH, 1971, J NATL CANCER I, V47, P1095; Rous P, 1914, J EXP MED, V20, P433, DOI 10.1084/jem.20.5.433; SHIMOKAWA I, 1991, J GERONTOL, V46, pB228, DOI 10.1093/geronj/46.6.B228; SHIMOKAWA I, 1994, MODULATION AGING PRO, P247; STAT, 1996, STAT SOFTW REL 5 0; Tannenbaum A, 1940, ARCH PATHOL, V30, P509; TANNER JM, 1982, ANN HUM BIOL, V9, P411, DOI 10.1080/03014468200005951; Thorling EB, 1996, NUTR RES, V16, P315, DOI 10.1016/0271-5317(96)00015-2; Tretli S, 1996, CANCER CAUSE CONTROL, V7, P507, DOI 10.1007/BF00051882; VALLEJO EA, 1956, REV CLIN ESP, V63, P25; VATTEN LJ, 1990, BRIT J CANCER, V61, P881, DOI 10.1038/bjc.1990.197; Vatten LJ, 1996, BREAST, V5, P5, DOI 10.1016/S0960-9776(96)90042-9; WEINDRUCH R, 1992, EXP GERONTOL, V27, P575, DOI 10.1016/0531-5565(92)90012-O; YU BP, 1982, J GERONTOL, V37, P130, DOI 10.1093/geronj/37.2.130	38	134	136	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 14	1998	316	7130					499	504		10.1136/bmj.316.7130.499	http://dx.doi.org/10.1136/bmj.316.7130.499			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX955	9501710	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000072097400017
J	Todd, A; Newlands, E; Palazzo, M				Todd, A; Newlands, E; Palazzo, M			Lesson of the week - Unusual case of choriocarcinoma occurring 12 months after delivery	BRITISH MEDICAL JOURNAL			English	Article								Choriocarcinoma is a malignant tumour that arises from trophoblastic epithelium; it has an incidence of 0.05 to 0.23 per 1000 live births.(1) The most important risk factor, a history of hydatidiform mole, is present in only half of cases, and many cases occur after a normal full term pregnancy.(2) We report the case of a young woman with choriocarcinoma who presented with an intraperitoneal haemorrhage from splenic metastases. She also developed multiple pulmonary tumour emboli and haemorrhage from tumour infiltration. She is the first patient in the United Kingdom, so far as we are aware, to survive ventilation for this disease.	Ipswich Gen Hosp, Dept Haematol, Ipswich IP1 5PD, Suffolk, England; Sunderland Gen Hosp, Dept Gastroenterol, Sunderland SR4 7TP, Tyne & Wear, England; Charing Cross Hosp, Dept Med Oncol, London W6 8RF, England; Charing Cross Hosp, Intens Care Unit, London, England	Imperial College London; Imperial College London	Todd, A (corresponding author), Ipswich Gen Hosp, Dept Haematol, Ipswich IP1 5PD, Suffolk, England.								0	3	3	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 14	1998	316	7130					532	534		10.1136/bmj.316.7130.532	http://dx.doi.org/10.1136/bmj.316.7130.532			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX955	9501718	Green Published			2022-12-28	WOS:000072097400027
J	Bunge, HP; Richards, MA; Lithgow-Bertelloni, C; Baumgardner, JR; Grand, SP; Romanowicz, BA				Bunge, HP; Richards, MA; Lithgow-Bertelloni, C; Baumgardner, JR; Grand, SP; Romanowicz, BA			Time scales and heterogeneous structure in geodynamic earth models	SCIENCE			English	Article							MANTLE CONVECTION; DYNAMIC EARTH; SUBDUCTION; VISCOSITY; VELOCITY; DEPTH	Computer models of mantle convection constrained by the history of Cenozoic and Mesozoic plate motions explain some deep-mantle structural heterogeneity imaged by seismic tomography, especially those related to subduction. They also reveal a 150-million-year time scale for generating thermal heterogeneity in the mantle, comparable to the record of plate motion reconstructions, so that the problem of unknown initial conditions can be overcome. The pattern of lowermost mantle structure at the core-mantle boundary is controlled by subduction history, although seismic tomography reveals intense large-scale hot (low-velocity) upwelling features not explicitly predicted by the models.	Inst Phys Globe, Sismol Lab, F-75252 Paris 05, France; Univ Calif Berkeley, Dept Geol & Geophys, Berkeley, CA 94720 USA; Univ Michigan, Dept Geol Sci, Ann Arbor, MI 48109 USA; Los Alamos Natl Lab, Div Theoret, Los Alamos, NM 87544 USA; Univ Texas, Dept Geol Sci, Austin, TX 78713 USA; Univ Calif Berkeley, Berkeley Seismol Lab, Berkeley, CA 94720 USA	UDICE-French Research Universities; Universite Paris Cite; University of California System; University of California Berkeley; University of Michigan System; University of Michigan; United States Department of Energy (DOE); Los Alamos National Laboratory; University of Texas System; University of Texas Austin; University of California System; University of California Berkeley	Bunge, HP (corresponding author), Inst Phys Globe, Sismol Lab, 4 Pl Jussieu, F-75252 Paris 05, France.	bunge@ipgp.jussieu.ir	Lithgow-Bertelloni, Carolina/P-3952-2019; Lithgow-Bertelloni, Carolina/C-4827-2011; Grand, Stephen/B-4238-2011; bunge, hans-peter/AAA-1860-2021; Romanowicz, barbara A/H-6726-2017	Lithgow-Bertelloni, Carolina/0000-0003-0924-6587; Lithgow-Bertelloni, Carolina/0000-0003-0924-6587; Romanowicz, barbara A/0000-0002-6208-6044				Bunge H.-P., 1995, Computers in Physics, V9, P207, DOI 10.1063/1.168525; Bunge HP, 1996, GEOPHYS RES LETT, V23, P2987, DOI 10.1029/96GL02522; Bunge HP, 1996, NATURE, V379, P436, DOI 10.1038/379436a0; Bunge HP, 1997, J GEOPHYS RES-SOL EA, V102, P11991, DOI 10.1029/96JB03806; BUNGE HP, UNPUB; DAVIES GF, 1992, J GEOL, V100, P151, DOI 10.1086/629582; DZIEWONSKI AM, 1984, J GEOPHYS RES, V89, P5929, DOI 10.1029/JB089iB07p05929; GORDON RG, 1986, J GEOPHYS RES-SOLID, V91, P2389, DOI 10.1029/JB091iB12p12389; GRAND SP, 1994, J GEOPHYS RES-SOL EA, V99, P11591, DOI 10.1029/94JB00042; Grand SP., 1997, GSA TODAY, V7, P1; GURNIS M, 1990, NATURE, V344, P754, DOI 10.1038/344754a0; HAGER BH, 1989, PHILOS T R SOC A, V328, P309, DOI 10.1098/rsta.1989.0038; HAGER BH, 1979, J GEOPHYS RES, V84, P1031, DOI 10.1029/JB084iB03p01031; HAGER BH, 1989, MANTLE CONVECTION PL, V4, pCH9; Li XD, 1996, J GEOPHYS RES-SOL EA, V101, P22245, DOI 10.1029/96JB01306; Lithgow-Bertelloni C, 1998, REV GEOPHYS, V36, P27, DOI 10.1029/97RG02282; LITHGOWBERTELLONI C, 1995, GEOPHYS RES LETT, V22, P1317, DOI 10.1029/95GL01325; Masters G, 1996, PHILOS T R SOC A, V354, P1385, DOI 10.1098/rsta.1996.0054; MITROVICA JX, 1989, TECTONICS, V8, P1079, DOI 10.1029/TC008i005p01079; Mitrovica JX, 1996, J GEOPHYS RES-SOL EA, V101, P555, DOI 10.1029/95JB03208; RICARD Y, 1993, J GEOPHYS RES-SOL EA, V98, P21895, DOI 10.1029/93JB02216; RICARD Y, 1993, GEOPHYS J INT, V113, P284, DOI 10.1111/j.1365-246X.1993.tb00888.x; RICARD Y, 1984, ANN GEOPHYS, V2, P267; RICHARDS MA, 1984, J GEOPHYS RES, V89, P5987, DOI 10.1029/JB089iB07p05987; RICHARDS MA, 1992, NATURE, V355, P437, DOI 10.1038/355437a0; SU WJ, 1994, J GEOPHYS RES-SOL EA, V99, P6945, DOI 10.1029/93JB03408; TACKLEY PJ, 1993, NATURE, V361, P699, DOI 10.1038/361699a0; vanderHilst RD, 1997, NATURE, V386, P578, DOI 10.1038/386578a0; WASSERBURG GJ, 1964, SCIENCE, V143, P465, DOI 10.1126/science.143.3605.465; WOODHOUSE JH, 1984, J GEOPHYS RES, V89, P5953, DOI 10.1029/JB089iB07p05953	30	180	181	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 3	1998	280	5360					91	95		10.1126/science.280.5360.91	http://dx.doi.org/10.1126/science.280.5360.91			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF314	9525864				2022-12-28	WOS:000072885100041
J	Billker, O; Lindo, V; Panico, M; Etienne, AE; Paxton, T; Dell, A; Rogers, M; Sinden, RE; Morris, HR				Billker, O; Lindo, V; Panico, M; Etienne, AE; Paxton, T; Dell, A; Rogers, M; Sinden, RE; Morris, HR			Identification of xanthurenic acid as the putative inducer of malaria development in the mosquito	NATURE			English	Article							PLASMODIUM; VECTOR	Malaria is transmitted from vertebrate host to mosquito vector by mature sexual blood-living stages called gametocytes(1,2). Within seconds of ingestion into the mosquito bloodmeal, gametocytes undergo gametogenesis. Induction requires the simultaneous exposure to at least two stimuli in vitro: a drop in bloodmeal temperature to 5 degrees C below that of the vertebrate host(1-3), and a rise in pH from 7.4 to 8.0-8.2 (refs 1, 4). In vivo the mosquito bloodmeal has a pH of between 7.5 and 7.6 (refs 5, 6). It is thought that in vivo the second inducer is an unknown mosquito-derived gametocyte-activating factor(5,7,8). Here we show that this factor is xanthurenic acid. We also show that low concentrations of xanthurenic acid can act together with pH to induce gametogenesis in vitro. Structurally related compounds are at least ninefold less effective at inducing gametogenesis in vitro. In Drosophila mutants with lesions in the kynurenine pathway of tryptophan metabolism (of which xanthurenic acid is a side product), no alternative active compound was detected in crude insect homogenates. These data could form the basis of the rational development of new methods of interrupting the transmission of malaria using-drugs or new refractory mosquito genotypes to block parasite gametogenesis.	Univ London Imperial Coll Sci Technol & Med, Dept Biol, London SW7 2BB, England; Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AZ, England; M Scan Inc, W Chester, PA 19380 USA	Imperial College London; Imperial College London	Sinden, RE (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol, London SW7 2BB, England.		Ranford-Cartwright, Lisa C/H-4701-2013	Ranford-Cartwright, Lisa C/0000-0003-1992-3940; Billker, Oliver/0000-0003-1716-168X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BATTERSBY A R, 1977, Tetrahedron Letters, V25, P2213; BEARD CB, 1995, J HERED, V86, P375, DOI 10.1093/oxfordjournals.jhered.a111606; BILLKER O, 1997, PARASITOLOGY, V14, P1; BISHOP A, 1956, PARASITOLOGY, V46, P192, DOI 10.1017/S0031182000026433; CARTER R, 1988, MALARIA PRINCIPLES P, P273; Cochran D.G., 1985, P467; Garcia GE, 1997, MOL BIOCHEM PARASIT, V88, P127, DOI 10.1016/S0166-6851(97)00086-8; HUNT E, 1973, BIOCHEM J, V135, P833, DOI 10.1042/bj1350833; KAYSER H, 1985, COMP INSECT PHYSL BI, V10, P368; MICKS DW, 1948, AM J HYG, V48, P182, DOI 10.1093/oxfordjournals.aje.a119234; MORRIS A, 1998, MASS SPECTROMETRY BI, V2, P53; MORRIS HR, 1980, NATURE, V285, P104, DOI 10.1038/285104a0; Morris HR, 1996, RAPID COMMUN MASS SP, V10, P889, DOI 10.1002/(SICI)1097-0231(19960610)10:8<889::AID-RCM615>3.0.CO;2-F; Morris HR, 1997, J PROTEIN CHEM, V16, P469, DOI 10.1023/A:1026309410737; MORRIS HR, 1987, NATURE, V328, P811, DOI 10.1038/328811a0; MORRIS HR, 1980, J NEUROCHEM, V34, P574, DOI 10.1111/j.1471-4159.1980.tb11183.x; NIJHOUT MM, 1978, PARASITOLOGY, V76, P39, DOI 10.1017/S0031182000047375; NIJHOUT MM, 1979, EXP PARASITOL, V48, P75, DOI 10.1016/0014-4894(79)90056-0; PHILLIPS JP, 1980, GENETICS BIOL DROS B, V2, P542; SINDEN RE, 1983, ADV PARASIT, V22, P153, DOI 10.1016/S0065-308X(08)60462-5; Sinden RE, 1996, ADV PARASIT, V38, P53, DOI 10.1016/S0065-308X(08)60033-0; SULLIVAN DT, 1979, BIOCHEM GENET, V17, P565, DOI 10.1007/BF00498891; SULLIVAN DT, 1975, BIOCHEM GENET, V13, P603, DOI 10.1007/BF00484918; TRUSCOTT RJW, 1995, CLIN SCI, V89, P591, DOI 10.1042/cs0890591; WESSING A, 1968, Z NATURFORSCH PT B, VB 23, P376; WILLIAMS SA, 1984, AM J CLIN NUTR, V40, P159, DOI 10.1093/ajcn/40.1.159	26	452	461	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1998	392	6673					289	292		10.1038/32667	http://dx.doi.org/10.1038/32667			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC739	9521324				2022-12-28	WOS:000072612300049
J	Alderman, MH; Cohen, H; Madhavan, S				Alderman, MH; Cohen, H; Madhavan, S			Dietary sodium intake and mortality: the national health and nutrition examination survey (NHANES I)	LANCET			English	Article							LOWER BLOOD-PRESSURE; MYOCARDIAL-INFARCTION; OBSERVATIONAL DATA; UNITED-STATES; SALT; RISK; POPULATIONS; MEN	Background Population-wide restriction of dietary sodium has been recommended. However, little evidence directly links sodium intake to morbidity and mortality. The aim of this study was to assess the relation of sodium intake to subsequent all-cause and cardiovascular-disease (CVD) mortality in a general population. Methods The first National Health and Nutrition Examination Survey established baseline information during 1971-75 in a representative sample of 20 729 US adults (aged 25-75). 11 348 underwent medical examination and nutritional examination based on 24 h recall. Two had no data on sodium intake available. Vital status at June 30, 1992, was obtained for the 11 346 participants through interview, tracing, and searches of the national death index. Mortality was examined in sex-specific quartiles of sodium intake. calorie intake, and sodium/calorie ratio. Multiple regression analyses were done to assess the relations with mortality. Findings There were 3923 deaths, of which 1970 were due to CVD. All-cause mortality (per 1000 person-years; adjusted for age and sex) was inversely associated viith sex-specific quartiles of sodium intake (lowest to highest quartile 23.18 to 19.01, p<0.0001) and total calorie intake (25.03 to 18.40, p<0.0001) and showed a weak positive association with quartiles of sodium/calorie ratio (20.27 to 21.71, p=0.14). The pattern for CVD mortality was similar (sodium 11.80 to 9.60, p<0.0019; calories 12.80 to 8.94, p<0.0002; sodium/calorie ratio 9.73 to 11.35, p=0.017). In Cox multiple regression analysis, sodium intake was inversely associated with all-cause (p=0.0069) and CVD mortality (p=0.086) and sodium/calorie ratio was directly associated with all-cause (p=0.0004) and CVD mortality (p=0.0056). By contrast, calorie intake in the presence of the two measures of sodium intake was not independently associated with mortality (all-cause p=0.86; CVD p=0.74). Analysis restricted to participants with no history of CVD at baseline gave similar results. Interpretation This observational study does not justify any particular dietary recommendation. Specifically, these results do not support current recommendations for routine reduction of sodium consumption, nor do they justify advice to increase salt intake or to decrease its concentration in the diet.	Yeshiva Univ Albert Einstein Coll Med, Dept Epidemiol & Social Med, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Alderman, MH (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Epidemiol & Social Med, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	alderman@aecom.yu.edu		Cohen, Hillel/0000-0002-4524-0898				Alaimo K, 1994, Adv Data, P1; ALDERMAN MH, 1995, HYPERTENSION, V25, P1144, DOI 10.1161/01.HYP.25.6.1144; ALDERMAN MH, 1991, NEW ENGL J MED, V324, P1098, DOI 10.1056/NEJM199104183241605; BEEVERS DG, 1989, J HUM HYPERTENS, V3, P279; COX CS, 1992, VITAL HLTH STAT, V1, P1; CUTLER JA, 1991, HYPERTENSION, V17, pI27, DOI 10.1161/01.HYP.17.1_Suppl.I27; DAHL LK, 1954, ARCH INTERN MED, V94, P525, DOI 10.1001/archinte.1954.00250040017003; DESIMONE G, 1990, CIRCULATION, V81, P107, DOI 10.1161/01.CIR.81.1.107; DWYER JT, 1994, AM J PUBLIC HEALTH, V84, P1299, DOI 10.2105/AJPH.84.8.1299; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; ELLIOTT P, 1991, HYPERTENSION, V17, pI3, DOI 10.1161/01.HYP.17.1_Suppl.I3; ENGSTROM AM, 1983, ANN INTERN MED, V98, P870, DOI 10.7326/0003-4819-98-5-870; FOLKOW B, 1989, ACTA PHYSIOL SCAND, V136, P89; FROST CD, 1991, BRIT MED J, V302, P815, DOI 10.1136/bmj.302.6780.815; GLEIBERMANN L., 1973, Ecology of Food and Nutrition, V2, P143, DOI 10.1080/03670244.1973.9990329; GRACIA G, 1997, HYPERTENSION, V29, P802; Hollenberg NK, 1997, HYPERTENSION, V29, P171, DOI 10.1161/01.HYP.29.1.171; Huijbregts P, 1997, BRIT MED J, V315, P13, DOI 10.1136/bmj.315.7099.13; JACKSON FLC, 1991, HYPERTENSION S1, V17, P129; JAMES GD, 1993, AM J HYPERTENS, V6, pA86; JENSEN OM, 1984, AM J EPIDEMIOL, V120, P281, DOI 10.1093/oxfordjournals.aje.a113891; KANT AK, 1995, AM J CLIN NUTR, V61, P11, DOI 10.1093/ajcn/61.1.11; KIM I, 1993, AM J PUBLIC HEALTH, V83, P546, DOI 10.2105/AJPH.83.4.546; LAW MR, 1991, BMJ-BRIT MED J, V302, P811, DOI 10.1136/bmj.302.6780.811; LUFT FC, 1979, CIRCULATION, V60, P697, DOI 10.1161/01.CIR.60.3.697; MacGregor GA, 1996, BRIT MED J, V312, P1287, DOI 10.1136/bmj.312.7041.1287; MCCARRON DA, 1984, SCIENCE, V224, P1392, DOI 10.1126/science.6729459; Midgley JP, 1996, JAMA-J AM MED ASSOC, V275, P1590, DOI 10.1001/jama.275.20.1590; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; *US DEP HHS, 1996, PUBL US TAP DOC NHAN; *USDA, 1995, DIET GUID ADV COMM R; Wassertheilsmoller S, 1991, ANN INTERN MED, V114, P613, DOI 10.7326/0003-4819-114-8-613	32	251	253	0	20	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 14	1998	351	9105					781	785		10.1016/S0140-6736(97)09092-2	http://dx.doi.org/10.1016/S0140-6736(97)09092-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB916	9519949				2022-12-28	WOS:000072521200010
J	Burnett, AK; Goldstone, AH; Stevens, RMF; Hann, IM; Rees, JKH; Gray, RG; Wheatley, K				Burnett, AK; Goldstone, AH; Stevens, RMF; Hann, IM; Rees, JKH; Gray, RG; Wheatley, K		UK Med Res Council Adult Childrens Leukaemia W	Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial	LANCET			English	Article							ACUTE MYELOGENOUS LEUKEMIA; ACUTE NONLYMPHOCYTIC LEUKEMIA; NON-LYMPHOBLASTIC LEUKEMIA; 1ST REMISSION; POSTREMISSION CHEMOTHERAPY; CONSOLIDATION; INDUCTION; CHILDHOOD	Background Three strategies are used to prevent relapse in patients with acute myeloid leukaemia in first remission. Most of those with suitable donors are offered allogeneic haemopoietic-stem-cell transplant. Other patients may receive intensive chemotherapy or autologous transplantation; we undertook this randomised prospective trial to assess which is the better option. Methods After three courses of intensive chemotherapy, bone marrow was harvested from patients (<56 years of age) in remission who lacked an HLA-matched sibling donor. These patients were then randomised to receive, after one more course of chemotherapy, no further treatment (n=191) or an autologous bone-marrow transplant (BMT) after preparation with cyclophosphamide and total-body irradiation (n=190). Outcome comparisons were by intention to treat with adjustment for the most important risk factors for relapse. Findings 381 patients were randomised (38% of those eligible). Of the 190 patients allocated autologous BMT. 126 received it. On intention-to-treat analysis the number of relapses was substantially lower in the autologous BMT group than in the group assigned no further treatment (64/190 [37%] vs 101/191 [58%], p=0.0007), resulting in superior disease-free survival at 7 years (53 vs 40%; p=0.04). These benefits were observed in all risk groups and age-groups. There were more deaths in remission in the autologous BMT group than in the no further treatment group (22 [12%] vs 7 [4%], p=0.008). In children (<15 years) and patients with good-risk disease, survival from relapse in the no further treatment group was 35% and 38% at 2 years. There was an overall survival advantage in the autologous BMT group at 7 years (57 vs 45%, p=0.2). Interpretation The addition of autologous BMT to four courses of intensive chemotherapy substantially reduces the risk of relapse in ail risk groups, leading to improvement in long-term survival. The good chance of salvage for children or patients with good-risk disease who relapse from chemotherapy, and the mortality, morbidity, late effects, and expense of autologous BMT, suggest that delay of autograft until second remission in these two groups may be appropriate.	Cardiff Univ, Dept Haematol, Cardiff CF4 4XN, S Glam, Wales; UCL Hosp, London, England; Royal Manchester Childrens Hosp, Manchester M27 1HA, Lancs, England; Great Ormond St Hosp Sick Children, London WC1N 3JH, England; MRC Ctr, Dept Haematol, Cambridge, England; Radcliffe Infirm, Clin Trial Serv Unit, Oxford OX2 6HE, England	Cardiff University; University College London Hospitals NHS Foundation Trust; University of London; University College London; Royal Manchester Children's Hospital; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; MRC Laboratory Molecular Biology; Radcliffe Infirmary; University of Oxford	Burnett, AK (corresponding author), Cardiff Univ, Dept Haematol, Heath Pk, Cardiff CF4 4XN, S Glam, Wales.			Gray, Richard/0000-0003-4440-574X				AMADORI S, 1993, J CLIN ONCOL, V11, P1046, DOI 10.1200/JCO.1993.11.6.1046; APPELBAUM FR, 1988, BLOOD, V72, P179; Bishop JF, 1996, BLOOD, V87, P1710, DOI 10.1182/blood.V87.5.1710.bloodjournal8751710; BUCHNER T, 1985, J CLIN ONCOL, V3, P1583; BURNETT AK, 1984, LANCET, V2, P1068; CARELLA AM, 1988, BONE MARROW TRANSPL, V3, P537; CLIFT RA, 1987, BONE MARROW TRANSPL, V2, P243; DEMIRER T, 1995, BONE MARROW TRANSPL, V15, P915; Goldstone AH, 1995, BLOOD, V86, P359; GOLDSTONE AH, 1986, BRIT J HAEMATOL, V64, P529, DOI 10.1111/j.1365-2141.1986.tb02209.x; GORIN NC, 1990, BLOOD, V75, P1606; GRAY R, 1991, BONE MARROW TRANSPL, V7, P9; Hann IM, 1997, BLOOD, V89, P2311, DOI 10.1182/blood.V89.7.2311; HAROUSSEAU JL, 1994, BLOOD, V84, pA251; LOWENBERG B, 1990, J CLIN ONCOL, V8, P287; MAYER RJ, 1994, NEW ENGL J MED, V331, P896, DOI 10.1056/NEJM199410063311402; PENDRY K, 1993, BRIT J HAEMATOL, V83, P45, DOI 10.1111/j.1365-2141.1993.tb04629.x; Ravindranath Y, 1996, NEW ENGL J MED, V334, P1428, DOI 10.1056/NEJM199605303342203; Rees JKH, 1996, BRIT J HAEMATOL, V94, P89, DOI 10.1046/j.1365-2141.1996.d01-1769.x; REIFFERS J, 1989, BRIT J HAEMATOL, V72, P57, DOI 10.1111/j.1365-2141.1989.tb07652.x; ROWLINGS PA, 1994, EXP HEMATOL, V22, P762; SANTOS GW, 1983, NEW ENGL J MED, V309, P1347, DOI 10.1056/NEJM198312013092202; STEWART P, 1985, EXP HEMATOL, V13, P267; WOODS WG, 1994, BLOOD, V84, pA232; ZITTOUN RA, 1995, NEW ENGL J MED, V332, P217, DOI 10.1056/NEJM199501263320403	25	439	450	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 7	1998	351	9104					700	708		10.1016/S0140-6736(97)09214-3	http://dx.doi.org/10.1016/S0140-6736(97)09214-3			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB359	9504514				2022-12-28	WOS:000072463800007
J	Patel, SK; Indig, FE; Olivieri, N; Levine, ND; Latterich, M				Patel, SK; Indig, FE; Olivieri, N; Levine, ND; Latterich, M			Organelle membrane fusion: A novel function for the syntaxin homolog Ufe1p in ER membrane fusion	CELL			English	Article							ENDOPLASMIC-RETICULUM; TRANSPORT VESICLES; CELL-CYCLE; PROTEIN; GENE; DOCKING; REQUIRES; COMPLEX; PATHWAY; ENCODES	The fusion of endoplasmic reticulum (ER) membranes in yeast does not require Sec18p/NSF and Sec17p, two proteins needed for docking of vesicles with their target membrane. Instead, ER membranes require a NSF-related ATPase, Cdc48p. Since both vesicular and organelle fusion events use related ATPases, we investigated whether both fusion events are also SNARE mediated. We present evidence that the fusion of ER membranes requires Ufe1p, a t-SNARE that localizes to the ER, but no known v-SNAREs. We propose that the Ufe1 protein acts in the dual capacity of an organelle membrane fusion-associated SNARE by undergoing direct t-t-SNARE and Cdc48p interactions during organelle membrane fusion as well as a t-SNARE for vesicular traffic.	Salk Inst, La Jolla, CA 92037 USA	Salk Institute	Latterich, M (corresponding author), Salk Inst, La Jolla, CA 92037 USA.							ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; Darsow T, 1997, J CELL BIOL, V138, P517, DOI 10.1083/jcb.138.3.517; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; Hay JC, 1997, CURR OPIN CELL BIOL, V9, P505, DOI 10.1016/S0955-0674(97)80026-9; Indig FE, 1997, BIOCHEM J, V327, P291, DOI 10.1042/bj3270291; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; KURIHARA LJ, 1994, J CELL BIOL, V126, P911, DOI 10.1083/jcb.126.4.911; LATTERICH M, 1994, CELL, V78, P87, DOI 10.1016/0092-8674(94)90575-4; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; Lewis MJ, 1997, EMBO J, V16, P3017, DOI 10.1093/emboj/16.11.3017; Lewis MJ, 1996, CELL, V85, P205, DOI 10.1016/S0092-8674(00)81097-1; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; Madeo F, 1998, MOL BIOL CELL, V9, P131, DOI 10.1091/mbc.9.1.131; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; McNew JA, 1997, J BIOL CHEM, V272, P17776, DOI 10.1074/jbc.272.28.17776; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; Pevsner J, 1996, J NEUROSCI RES, V45, P89, DOI 10.1002/(SICI)1097-4547(19960715)45:2<89::AID-JNR1>3.3.CO;2-K; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; Rabouille C, 1998, CELL, V92, P603, DOI 10.1016/S0092-8674(00)81128-9; REXACH MF, 1994, J CELL BIOL, V126, P1133, DOI 10.1083/jcb.126.5.1133; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SWEET DJ, 1993, EMBO J, V12, P2831, DOI 10.1002/j.1460-2075.1993.tb05944.x; SWEET DJ, 1992, EMBO J, V11, P423, DOI 10.1002/j.1460-2075.1992.tb05071.x; WEIDMAN PJ, 1989, J CELL BIOL, V108, P1589, DOI 10.1083/jcb.108.5.1589; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; Xu ZY, 1997, J CELL BIOL, V136, P299, DOI 10.1083/jcb.136.2.299	33	135	138	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 6	1998	92	5					611	620		10.1016/S0092-8674(00)81129-0	http://dx.doi.org/10.1016/S0092-8674(00)81129-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZA827	9506516	Bronze			2022-12-28	WOS:000072406000007
J	Wu, LP; Anderson, KV				Wu, LP; Anderson, KV			Regulated nuclear import of Rel proteins in the Drosophila immune response	NATURE			English	Article							KAPPA-B-ALPHA; INDUCED PHOSPHORYLATION; DORSOVENTRAL PATTERN; DORSAL; CACTUS; GENE; DEGRADATION; EMBRYO; DISSOCIATION; EXPRESSION	The Drosophila immune response uses many of the same components as the mammalian innate immune response, including signalling pathways that activate transcription factors of the Rel/NK-kappa B family(1-4). In response to infection, two Rel proteins, Dif and Dorsal, translocate from the cytoplasm to the nuclei of larval fat-body cells(1,2,5). The Toll signalling pathway, which controls dorsal-ventral patterning during Drosophila embryogenesis(6), regulates the nuclear import of Dorsal in the immune response(2,7), but here we show that the Toll pathway is not required for nuclear import of Dif. Cytoplasmic retention of both Dorsal and Dif depends on Cactus protein; nuclear import of Dorsal and Dif is accompanied by degradation of Cactus. Therefore the two signalling pathways that target Cactus for degradation must discriminate between Cactus-Dorsal and Cactus-Dif complexes. We identified new genes that are required for normal induction of transcription of an antibacterial peptide during the immune response. Mutations in three of these genes prevent nuclear import of Dif in response to infection, and define new components of signalling pathways involving Rel. Mutations in three other genes cause constitutive nuclear localization of Dif; these mutations may block Rel protein activity by a novel mechanism.	Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, Sloan Kettering Div, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center	Anderson, KV (corresponding author), Mem Sloan Kettering Canc Ctr, Program Mol Biol, 1275 York Ave, New York, NY 10021 USA.			Wu, Louisa/0000-0001-8609-3081				ANDERSON KV, 1984, NATURE, V311, P223, DOI 10.1038/311223a0; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BELVIN MP, 1995, GENE DEV, V9, P783, DOI 10.1101/gad.9.7.783; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Bergmann A, 1996, MECH DEVELOP, V60, P109, DOI 10.1016/S0925-4773(96)00607-7; Corbo JC, 1996, MECH DEVELOP, V55, P211, DOI 10.1016/0925-4773(96)00506-0; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; Dushay MS, 1996, P NATL ACAD SCI USA, V93, P10343, DOI 10.1073/pnas.93.19.10343; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; HOFFMANN JA, 1993, FEBS LETT, V325, P63, DOI 10.1016/0014-5793(93)81414-U; Hoffmann JA, 1997, TRENDS CELL BIOL, V7, P309, DOI 10.1016/S0962-8924(97)01087-8; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; Kadalayil L, 1997, NUCLEIC ACIDS RES, V25, P1233, DOI 10.1093/nar/25.6.1233; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; Klement JF, 1996, MOL CELL BIOL, V16, P2341; LEMAITRE B, 1995, EMBO J, V14, P536, DOI 10.1002/j.1460-2075.1995.tb07029.x; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; LEMAITRE B, 1995, P NATL ACAD SCI USA, V92, P9465, DOI 10.1073/pnas.92.21.9465; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; Reach M, 1996, DEV BIOL, V180, P353, DOI 10.1006/dbio.1996.0308; REICHHART JM, 1992, EMBO J, V11, P1469, DOI 10.1002/j.1460-2075.1992.tb05191.x; REICHHART JM, 1993, CR ACAD SCI III-VIE, V316, P1218; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Williams MJ, 1997, EMBO J, V16, P6120, DOI 10.1093/emboj/16.20.6120	28	141	144	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 5	1998	392	6671					93	97		10.1038/32195	http://dx.doi.org/10.1038/32195			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA528	9510254				2022-12-28	WOS:000072373000057
J	Torgerson, DJ; Roland, M				Torgerson, DJ; Roland, M			Understanding controlled trials - What is Zelen's design?	BRITISH MEDICAL JOURNAL			English	Review							COLORECTAL-CANCER; CLINICAL-TRIALS		Univ York, Ctr Hlth Econ, Natl Primary Care Res & Dev Ctr, York YO1 5DD, N Yorkshire, England; Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England	University of York - UK; University of Manchester	Torgerson, DJ (corresponding author), Univ York, Ctr Hlth Econ, Natl Primary Care Res & Dev Ctr, York YO1 5DD, N Yorkshire, England.		Torgerson, David/L-4566-2019	Torgerson, David/0000-0002-1667-4275				Altman DG, 1995, EUR J CANCER, V31A, P1934, DOI 10.1016/0959-8049(95)00470-X; Kronborg O, 1996, LANCET, V348, P1467, DOI 10.1016/S0140-6736(96)03430-7; OROURKE PP, 1989, PEDIATRICS, V84, P957; Smith R, 1997, BRIT MED J, V314, P1059, DOI 10.1136/bmj.314.7087.1059; Torgerson DJ, 1998, BRIT MED J, V316, P360, DOI 10.1136/bmj.316.7128.360; Torgerson DJ, 1997, ARCH INTERN MED, V157, P2121, DOI 10.1001/archinte.157.18.2121; ZELEN M, 1979, NEW ENGL J MED, V300, P1242, DOI 10.1056/NEJM197905313002203; ZELEN M, 1990, STAT MED, V9, P645, DOI 10.1002/sim.4780090611	9	77	80	1	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 21	1998	316	7131					606	606		10.1136/bmj.316.7131.606	http://dx.doi.org/10.1136/bmj.316.7131.606			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ031	9518917	Green Published			2022-12-28	WOS:000072213200035
J	Shannon, M; Weigert, M				Shannon, M; Weigert, M			Fixing mismatches	SCIENCE			English	Article							V(D)J RECOMBINATION; SCID MUTATION; RAG2 PROTEINS; DNA-REPAIR; GENE; ANTIBODY; DEFECT		Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Shannon, M (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.							BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; Cascalho M, 1998, SCIENCE, V279, P1207, DOI 10.1126/science.279.5354.1207; CLARKE SH, 1985, J EXP MED, V161, P687, DOI 10.1084/jem.161.4.687; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GORSKI J, 1983, SCIENCE, V220, P1179, DOI 10.1126/science.6857243; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; MCKEAN DJ, 1985, J EXP MED, V161, P687; SCHATZ DG, 1988, CELL, V53, P107, DOI 10.1016/0092-8674(88)90492-8; vanGent DC, 1996, CELL, V85, P107, DOI 10.1016/S0092-8674(00)81086-7; WEIGERT MG, 1970, NATURE, V228, P1045, DOI 10.1038/2281045a0	11	7	7	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	1998	279	5354					1159	1160		10.1126/science.279.5354.1159	http://dx.doi.org/10.1126/science.279.5354.1159			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9508690				2022-12-28	WOS:000072115200030
J	Ross, LF				Ross, LF			Surgery is not what it seems - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Chicago, MacLean Ctr Clin Med Eth, Chicago, IL 60637 USA	University of Chicago	Ross, LF (corresponding author), Univ Chicago, MacLean Ctr Clin Med Eth, Chicago, IL 60637 USA.								0	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 7	1998	316	7129					462	462		10.1136/bmj.316.7129.462a	http://dx.doi.org/10.1136/bmj.316.7129.462a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW874	9492682	Green Published			2022-12-28	WOS:000071982700047
J	Doyle, DA; Cabral, JM; Pfuetzner, RA; Kuo, AL; Gulbis, JM; Cohen, SL; Chait, BT; MacKinnon, R				Doyle, DA; Cabral, JM; Pfuetzner, RA; Kuo, AL; Gulbis, JM; Cohen, SL; Chait, BT; MacKinnon, R			The structure of the potassium channel: Molecular basis of K+ conduction and selectivity	SCIENCE			English	Article							PEPTIDE INHIBITOR; CALCIUM CHANNELS; ION PERMEATION; TEA BLOCKADE; ALPHA-HELIX; PORE; CHARYBDOTOXIN; MUTATIONS; RECEPTOR; RESOLUTION	The potassium channel from Streptomyces lividans is an integral membrane protein with sequence similarity to all known K+ channels, particularly in the pore region. X-ray analysis with data to 3.2 angstroms reveals that four identical subunits create an inverted teepee, or cone, cradling the selectivity filter of the pore in its outer end, The narrow selectivity filter is only 12 angstroms long, whereas the remainder of the pore is wider and lined with hydrophobic amino acids, A large water-filled cavity and helix dipoles are positioned so as to overcome electrostatic destabilization of an ion in the pore at the center of the bilayer. Main chain carbonyl oxygen atoms from the K+ channel signature sequence line the selectivity filter, which is held open by structural constraints to coordinate K+ ions but not smaller Na+ ions. The selectivity filter contains two K+ ions about 7.5 angstroms apart. This configuration promotes ion conduction by exploiting electrostatic repulsive forces to overcome attractive forces between K+ ions and the selectivity filler. The architecture of the pore establishes the physical principles underlying selective K+ conduction.	Rockefeller Univ, Lab Mol Neurobiol & Biophys, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; Rockefeller Univ, Lab Mass Spectrometry & Gaseous Ion Chem, New York, NY 10021 USA	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; Rockefeller University	MacKinnon, R (corresponding author), Rockefeller Univ, Lab Mol Neurobiol & Biophys, 1230 York Ave, New York, NY 10021 USA.	mackinn@rockvax.rockefeller.edu	Oka, Yoshitaka/C-9670-2010; Morais-Cabral, Joao H/J-4914-2013	Oka, Yoshitaka/0000-0002-3482-3051; Morais-Cabral, Joao H/0000-0002-4461-9716				AIYAR J, 1995, NEURON, V15, P1169, DOI 10.1016/0896-6273(95)90104-3; ALMERS W, 1984, J PHYSIOL-LONDON, V353, P585, DOI 10.1113/jphysiol.1984.sp015352; AQVIST J, 1991, P NATL ACAD SCI USA, V88, P2026, DOI 10.1073/pnas.88.5.2026; ARMSTRON.CM, 1969, J GEN PHYSIOL, V54, P553, DOI 10.1085/jgp.54.5.553; ARMSTRONG CM, 1965, J GEN PHYSIOL, V48, P859, DOI 10.1085/jgp.48.5.859; ARMSTRONG CM, 1966, J GEN PHYSIOL, V50, P491, DOI 10.1085/jgp.50.2.491; ARMSTRONG CM, 1971, J GEN PHYSIOL, V58, P413, DOI 10.1085/jgp.58.4.413; ARMSTRONG CM, 1972, J GEN PHYSIOL, V59, P388, DOI 10.1085/jgp.59.4.388; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEZANILLA F, 1972, J GEN PHYSIOL, V60, P588, DOI 10.1085/jgp.60.5.588; BRUNGER AT, XPLOR VERSION 3 851; Cortes DM, 1997, BIOCHEMISTRY-US, V36, P10343, DOI 10.1021/bi971018y; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; GAMBLIN SJ, 1996, P CCP4 STUD WEEK DAR, P163; GOLDSTEIN SAN, 1994, NEURON, V12, P1377, DOI 10.1016/0896-6273(94)90452-9; Gross A, 1996, NEURON, V16, P399, DOI 10.1016/S0896-6273(00)80057-4; HAGIWARA S, 1977, J GEN PHYSIOL, V70, P269, DOI 10.1085/jgp.70.3.269; Heginbotham L, 1997, BIOCHEMISTRY-US, V36, P10335, DOI 10.1021/bi970988i; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; HILLE B, 1973, J GEN PHYSIOL, V61, P669, DOI 10.1085/jgp.61.6.669; HILLE B, 1978, J GEN PHYSIOL, V72, P409, DOI 10.1085/jgp.72.4.409; Hille B., 1992, IONIC CHANNELS EXCIT; HODGKIN AL, 1955, J PHYSIOL-LONDON, V128, P61, DOI 10.1113/jphysiol.1955.sp005291; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KETCHUM KA, 1995, NATURE, V376, P690, DOI 10.1038/376690a0; Kleywegt GJ, 1997, STRUCTURE, V5, P1557, DOI 10.1016/S0969-2126(97)00305-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KREUSCH A, 1994, J MOL BIOL, V243, P891, DOI 10.1006/jmbi.1994.1690; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; LOCKHART DJ, 1992, SCIENCE, V257, P947, DOI 10.1126/science.1502559; LOCKHART DJ, 1993, SCIENCE, V260, P198, DOI 10.1126/science.8469972; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1990, NEURON, V5, P767, DOI 10.1016/0896-6273(90)90335-D; MacKinnon R, 1998, SCIENCE, V280, P106, DOI 10.1126/science.280.5360.106; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; Naranjo D, 1996, NEURON, V16, P123, DOI 10.1016/S0896-6273(00)80029-X; NEYTON J, 1988, J GEN PHYSIOL, V92, P569, DOI 10.1085/jgp.92.5.569; NEYTON J, 1988, J GEN PHYSIOL, V92, P549, DOI 10.1085/jgp.92.5.549; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PARSEGIAN VA, 1975, ANN NY ACAD SCI, V264, P161, DOI 10.1111/j.1749-6632.1975.tb31481.x; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; SALI D, 1988, NATURE, V335, P740, DOI 10.1038/335740a0; SCHEMPF H, 1995, EMBO J, V14, P5170; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; Smart OS, 1996, J MOL GRAPH MODEL, V14, P354, DOI 10.1016/S0263-7855(97)00009-X; STOCKER M, 1994, P NATL ACAD SCI USA, V91, P9509, DOI 10.1073/pnas.91.20.9509; TATE MW, 1995, J APPL CRYSTALLOGR, V28, P196, DOI 10.1107/S0021889894007867; THIEL DJ, 1996, REV SCI INSTRUM, V67, P1; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158	55	5420	5573	96	1220	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 3	1998	280	5360					69	77		10.1126/science.280.5360.69	http://dx.doi.org/10.1126/science.280.5360.69			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF314	9525859	Green Submitted			2022-12-28	WOS:000072885100036
J	Steven, R; Kubiseski, TJ; Zheng, H; Kulkarni, S; Mancillas, J; Morales, AR; Hogue, CWV; Pawson, T; Culotti, J				Steven, R; Kubiseski, TJ; Zheng, H; Kulkarni, S; Mancillas, J; Morales, AR; Hogue, CWV; Pawson, T; Culotti, J			UNC-73 activates the Rac GTPase and is required for cell and growth cone migrations in C-elegans	CELL			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; TRANSMEMBRANE TYROSINE PHOSPHATASE; CAENORHABDITIS-ELEGANS; BINDING PROTEIN; AXON MIGRATIONS; SH3 DOMAINS; GENE; DROSOPHILA; NEURONS; KINASE	unc-73 is required for cell migrations and axon guidance in C. elegans and encodes overlapping isoforms of 283 and 189 kDa that are closely related to the vertebrate Trio and Kalirin proteins, respectively. UNC-73A contains, in order, eight spectrin-like repeats, a Dbl/Pleckstrin homology (DH/PH) element, an SH3-like domain, a second DH/PH element, an immunoglobulin domain, and a fibronectin type ill domain. UNC-73B terminates just downstream of the SH3-like domain. The first DR/PH element specifically activates the Rac GTPase in vitro and stimulates actin polymerization when expressed in Rat2 cells. Both functions are eliminated by introducing the S1216F mutation of unc-73(rh40) into this DH domain. Our results suggest that UNC-73 acts cell autonomously in a protein complex to regulate actin dynamics during cell and growth cone migrations.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Univ Calif Los Angeles, Dept Anat & Cell Biol, Los Angeles, CA 90024 USA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of California System; University of California Los Angeles	Culotti, J (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.		Hogue, Christopher/B-6726-2008; Culotti, Joseph/G-6467-2013; Pawson, Tony J/E-4578-2013; Hogue, Christopher W V/AAZ-3934-2020	Hogue, Christopher W V/0000-0002-3107-5246; Culotti, Joseph/0000-0001-6325-4612; Kubiseski, Terrance/0000-0001-9388-8608				Alam MR, 1997, J BIOL CHEM, V272, P12667, DOI 10.1074/jbc.272.19.12667; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BARSAGI D, 1995, METHOD ENZYMOL, V255, P436; Bower MJ, 1997, J MOL BIOL, V267, P1268, DOI 10.1006/jmbi.1997.0926; Bryant SH, 1996, PROTEINS, V26, P172; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; Chen EB, 1997, DEV BIOL, V182, P88, DOI 10.1006/dbio.1996.8473; Chen WN, 1996, J BIOL CHEM, V271, P26362, DOI 10.1074/jbc.271.42.26362; Chen WN, 1996, GENE, V180, P217, DOI 10.1016/S0378-1119(96)00414-3; CHEN WN, 1994, J BIOL CHEM, V269, P32394; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; Forrester WC, 1997, DEVELOPMENT, V124, P1831; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GARRIGA G, 1993, DEVELOPMENT, V117, P1071; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HAMELIN M, 1992, EMBO J, V11, P2885, DOI 10.1002/j.1460-2075.1992.tb05357.x; HART MJ, 1994, J BIOL CHEM, V269, P62; HEDGECOCK EM, 1987, DEVELOPMENT, V100, P365; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; Krueger NX, 1996, CELL, V84, P611, DOI 10.1016/S0092-8674(00)81036-3; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Lin Chi-Hung, 1994, Current Opinion in Neurobiology, V4, P640, DOI 10.1016/0959-4388(94)90004-3; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; MANSER J, 1990, DEV GENET, V11, P49, DOI 10.1002/dvg.1020110107; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MCINTIRE SL, 1992, NEURON, V8, P307, DOI 10.1016/0896-6273(92)90297-Q; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MORI I, 1988, GENETICS, V120, P397; Murphy AM, 1996, J CELL BIOL, V133, P617, DOI 10.1083/jcb.133.3.617; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rost B, 1996, METHOD ENZYMOL, V266, P525; Run JQ, 1996, GENETICS, V143, P225; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; SIDDIQUI SS, 1990, NEUROSCI RES, pS171, DOI 10.1016/0921-8696(90)90047-7; SIDDIQUI SS, 1991, J NEUROGENET, V7, P193, DOI 10.3109/01677069109167433; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; WAY JC, 1992, DEV DYNAM, V194, P289, DOI 10.1002/aja.1001940405; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Wightman B, 1997, DEVELOPMENT, V124, P2571; Xie GF, 1995, GENET ANAL-BIOMOL E, V12, P95, DOI 10.1016/1050-3862(95)00112-3; ZHENG Y, 1994, J BIOL CHEM, V269, P2369; Zipkin ID, 1997, CELL, V90, P883, DOI 10.1016/S0092-8674(00)80353-0	56	261	266	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 20	1998	92	6					785	795		10.1016/S0092-8674(00)81406-3	http://dx.doi.org/10.1016/S0092-8674(00)81406-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZD198	9529254	Bronze			2022-12-28	WOS:000072661200011
J	Passaro, DJ; Werner, SB; McGee, J; Mac Kenzie, WR; Vugia, DJ				Passaro, DJ; Werner, SB; McGee, J; Mac Kenzie, WR; Vugia, DJ			Wound botulism associated with black tar heroin among injecting drug users	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							22-YEAR FOLLOW-UP; INFECTIONS; ADDICTS; ABUSERS; CARE	Context.-Wound botulism (WB) is a potentially lethal, descending, flaccid, paralysis that results when spores of Clostridium botulinum germinate in a wound and elaborate neurotoxin. Since 1988, California has experienced a dramatic increase in WB associated with injecting "black tar" heroin (BTH), a dark, tarry form of the drug. Objective.-To identify risk factors for WB among injecting drug users (IDUs). Design.-Case-control study based on data from in-person and telephone interviews. Participants.-Case patients (n=26) were IDUs who developed WB from January 1994 through February 1996. Controls (n=110) were IDUs newly enrolled in methadone detoxification programs in 4 counties. Main Outcome Measures.-Factors associated with the development of WB. Results.-Among the 26 patients, the median age was 41.5 years, 15 (58%) were women, 14 (54%) were non-Hispanic white, 11 (42%) were Hispanic, and none were positive for the human immunodeficiency virus. Nearly all participants (96% of patients and 97% of controls) injected BTH, and the mean cumulative dose of BTH used per month was similar for patients and controls (27 g and 31 g, respectively; P=.6). Patients were more likely than controls to inject drugs subcutaneously or intramuscularly (92% vs 44%, P<.001) and used this route of drug administration more times per month (mean, 67 vs 24, P<.001), with a greater cumulative monthly dose of BTH (22.3 g vs 6.3 g, P<.001). A dose-response relationship was observed between the monthly cumulative dose of BTH injected subcutaneously or intramuscularly and the development of WB (chi(2) for linear trend, 26.5; P<.001). In the final regression model, subcutaneous or intramuscular injection of BTH was the only behavior associated with WB among IDUs (odds ratio, 13.7; 95% confidence interval, 3.0-63.0). The risk for development of WB was not affected by cleaning the skin, cleaning injection paraphernalia, or sharing needles. Conclusions.-Injection of BTH intramuscularly or subcutaneously is the primary risk factor for the development of WB. Physicians in the western United States, where BTH is widely used, should be aware of the potential for WB to occur among IDUs.	Calif Dept Hlth Serv, Div Communicable Dis, Berkeley, CA 94704 USA; Stanford Univ, Sch Med, Div Infect Dis & Geog Med, Stanford, CA 94305 USA; Ctr Dis Control & Prevent, Epidemiol Program Off, Div Field Epidemiol, Atlanta, GA USA	California Department of Health Care Services; Stanford University; Centers for Disease Control & Prevention - USA	Passaro, DJ (corresponding author), Calif Dept Hlth Serv, Div Communicable Dis, Berkeley, CA 94704 USA.	dpass@ix.netcom.com	Kenzie, William R Mac/F-1528-2013	Kenzie, William R Mac/0000-0001-7723-0339				BALDWIN WA, 1993, CHEST, V103, P21, DOI 10.1378/chest.103.1.21; *CAL DEP HLTHS ERV, 1986, CALIFORNIA MORB, V26, P1; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P889; GILL DM, 1982, MICROBIOL REV, V46, P86, DOI 10.1128/MMBR.46.1.86-94.1982; Goldstein A, 1995, DRUG ALCOHOL DEPEN, V40, P139, DOI 10.1016/0376-8716(95)01205-2; GRONBLADH L, 1990, ACTA PSYCHIAT SCAND, V82, P223, DOI 10.1111/j.1600-0447.1990.tb03057.x; HAVERKOS HW, 1990, J INFECT DIS, V161, P894, DOI 10.1093/infdis/161.5.894; MACDONALD KL, 1985, ANN INTERN MED, V102, P616, DOI 10.7326/0003-4819-102-5-616; MARX A, 1994, INT J ADDICT, V29, P837, DOI 10.3109/10826089409047914; OPPENHEIMER E, 1994, ADDICTION, V89, P1299, DOI 10.1111/j.1360-0443.1994.tb03309.x; STEIN MD, 1990, J GEN INTERN MED, V5, P249, DOI 10.1007/BF02600544; *US DEP HHS, 1995, FIN REP 1994 HOUS SU; *US DRUG ENF ADM, 1994, DOM MON PROGR 1993 A; VLAHOV D, 1992, PUBLIC HEALTH REP, V107, P595; WEBER JT, 1993, CLIN INFECT DIS, V16, P635, DOI 10.1093/clind/16.5.635; WERNER SB, 1996, 36 ANN INT C ANT AG; WYSKOWSKI DK, 1993, PUBLIC HLTH REP, V108, P565; ZOOK CJ, 1980, NEW ENGL J MED, V302, P996, DOI 10.1056/NEJM198005013021804	18	148	152	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 18	1998	279	11					859	863		10.1001/jama.279.11.859	http://dx.doi.org/10.1001/jama.279.11.859			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZA943	9516001	Bronze			2022-12-28	WOS:000072417600033
J	Craven, DE; Duncan, RA; Stram, JR; O'Hara, CJ; Steger, KA; Jhamb, K; Hirschhorn, LR				Craven, DE; Duncan, RA; Stram, JR; O'Hara, CJ; Steger, KA; Jhamb, K; Hirschhorn, LR			Response of lymphoepithelial parotid cysts to antiretroviral treatment in HIV-infected adults	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	35th Annual Meeting of the Infectious-Diseases-Society-of-America	SEP 07-16, 1997	SAN FRANCISCO, CA	Infect Dis Soc Amer			ACQUIRED-IMMUNODEFICIENCY-SYNDROME; SALIVARY-GLANDS; VIRUS-INFECTION; LESIONS; AIDS	Background: Surgical resection has been the usual therapy for HIV-infected patients with lymphoepithelial parotid cysts. Objective: To study antiretroviral therapy for lymphoepithelial parotid cysts. Design: Case series. Setting: HIV outpatient clinics. Patients: HIV-infected patients with lymphoepithelial parotid cysts. Intervention: Antiretroviral therapy. Measurements: Change in size of the parotid cyst, CD4 lymphocyte count, and HIV viral load. Results: Nine HIV-infected adults presented with chronic, large parotid cysts, eight of which were bilateral. in at least seven patients, the cysts were the initial sign of HIV infection. In six patients, the cysts resolved completely with combination antiretroviral therapy. Four of these patients also received prednisone. Three patients who did not comply with antiretroviral therapy had partial responses followed by relapses. Conclusions: Parotid cysts are an unrecognized sign of early HIV infection. These cysts respond to combination antiretroviral therapy, with or without corticosteroids. Surgical resection should be reserved for patients in whom medical therapy has failed or those who refuse or are poorly compliant with medical therapy.	Boston Univ, Med Ctr, Sch Med, Dept Otolaryngol, Boston, MA 02118 USA; Lahey Hitchcock Clin, Infect Dis Sect, Burlington, MA 01805 USA; Boston Med Ctr, Dept Pathol, Boston, MA 02118 USA; Boston Med Ctr, Dept Gen Internal Med, Boston, MA 02118 USA; Dimock Community Hlth Ctr, Roxbury, MA 02119 USA	Boston University; Lahey Hospital & Medical Center; Boston Medical Center; Boston Medical Center	Craven, DE (corresponding author), Boston Univ, Med Ctr, Sch Med, Dept Otolaryngol, Dowling 3 N,1 Boston Med Ctr, Boston, MA 02118 USA.			Stram, John/0000-0003-3526-157X; O'Hara, Carl/0000-0001-7404-3597				BEITLER JJ, 1995, HEAD NECK-J SCI SPEC, V17, P31, DOI 10.1002/hed.2880170107; BERNIER JL, 1958, CANCER, V11, P1156, DOI 10.1002/1097-0142(195811/12)11:6<1156::AID-CNCR2820110611>3.0.CO;2-2; ELLIOTT JN, 1990, AM J CLIN PATHOL, V93, P39, DOI 10.1093/ajcp/93.1.39; FINFER MD, 1988, ARCH OTOLARYNGOL, V114, P1290; IOACHIM HL, 1988, ARCH PATHOL LAB MED, V112, P1224; ITESCU S, 1990, ANN INTERN MED, V112, P3, DOI 10.7326/0003-4819-112-1-3; LEE KC, 1992, OTOLARYNG CLIN N AM, V25, P1287; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; SCHIODT M, 1992, ORAL SURG ORAL MED O, V74, P326, DOI 10.1016/0030-4220(92)90069-3; SHAHA AR, 1993, AM J SURG, V166, P403, DOI 10.1016/S0002-9610(05)80342-3; SHUGAR JMA, 1988, LARYNGOSCOPE, V98, P772; Smith F B, 1990, Prog AIDS Pathol, V2, P61; SPERLING NM, 1990, HEAD NECK-J SCI SPEC, V12, P337, DOI 10.1002/hed.2880120411; TERRY JH, 1991, AM J SURG, V162, P324, DOI 10.1016/0002-9610(91)90141-Y; TUNKEL DE, 1989, LARYNGOSCOPE, V99, P590; Wagner RP, 1996, CLIN INFECT DIS, V22, P369, DOI 10.1093/clinids/22.2.369; WEIDNER N, 1986, AM J CLIN PATHOL, V85, P395, DOI 10.1093/ajcp/85.4.395; IN PRESS MMWR MORB M	19	29	30	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1998	128	6					455	459		10.7326/0003-4819-128-6-199803150-00006	http://dx.doi.org/10.7326/0003-4819-128-6-199803150-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	ZA914	9499329				2022-12-28	WOS:000072414700006
J	Sumkin, J				Sumkin, J			The coding audit	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Sumkin, J (corresponding author), 210 Wisconsin Ave, Fond Du Lac, WI 54935 USA.								0	4	4	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1998	128	6					502	502		10.7326/0003-4819-128-6-199803150-00014	http://dx.doi.org/10.7326/0003-4819-128-6-199803150-00014			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA914	9499337				2022-12-28	WOS:000072414700014
J	Jareg, P; Kaseje, DCO				Jareg, P; Kaseje, DCO			Growth of civil society in developing countries: implications for health	LANCET			English	Article								Owing to changes in political systems, the number of non-governmental organisations worldwide has increased substantially since 1980. The influence of civil society on health and health care depends on the recognition of its role as a partner in primary health care, on its success in the scaling up of activities, ton its cooperation with the State and business sector, and on networking. In the event of health-sector reforms, civil society should focus on equity and justice, and advocate health as a public responsibility. The impact on health would increase if medical personnel joined forces with civil society and if medical schools added public speaking, networking, and lobbying to their agenda. The trend is that an increasing number of agents are getting involved in the promotion of health.	Diakonhjemmets Int Senter, N-0319 Oslo, Norway; CISS Int, Nairobi, Kenya	Diakonhjemmet Hospital	Jareg, P (corresponding author), Diakonhjemmets Int Senter, POB 23 Vindern, N-0319 Oslo, Norway.							ALLAIN A, 1989, DEV DIALOGUE, V2, P4; Clayton A., 1993, GOVERNANCE DEMOCRACY; Cohen Jean L., 1994, CIVIL SOC POLITICAL, pix; Edwards M., 1992, MAKING DIFFERENCE NG, P13; Edwards M., 1995, NONGOVERNMENTAL ORG, P3; ELHADI AA, 1996, LANCET, V349, P129; HOWES M, 1992, MAKING DIFFERENCE NG, P99; Hulme D., 1997, NGOS STATES DONORS T; MOGEDAL S, 1997, CONTACT, V158, P3; NYANGGORO JE, 1993, CIVIL SOC STATE AFRI; OSHAUG A, 1991, MILK WAR; Ramsay S, 1997, LANCET, V349, P110, DOI 10.1016/S0140-6736(05)60900-2; SMITH D, 1997, LANCET, V345, P312; TANDON R, 1992, DEV J SID, V3, P38; UNICEF & WHO, 1978, DECL ALM AT INT C PR; Weston J., 1997, QUESTIONING SOLUTION	16	19	21	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 14	1998	351	9105					819	822		10.1016/S0140-6736(97)11454-4	http://dx.doi.org/10.1016/S0140-6736(97)11454-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB916	9519974				2022-12-28	WOS:000072521200043
J	Kobayashi, T; Stang, E; Fang, KS; de Moerloose, P; Parton, RG; Gruenberg, J				Kobayashi, T; Stang, E; Fang, KS; de Moerloose, P; Parton, RG; Gruenberg, J			A lipid associated with the antiphospholipid syndrome regulates endosome structure and function	NATURE			English	Article							MONOCLONAL-ANTIBODIES; 6-PHOSPHATE RECEPTOR; FUSION INVITRO; BHK-CELLS; BINDING; STEREOCONFIGURATION; RECOGNITION; TRANSPORT; LYSOSOMES; GROWTH	Little is known about the structure and function of membrane domains in the vacuolar apparatus of animal cells. A unique feature of late endosomes, which are part of the pathway that leads to lysosomes, is that they contain a complex system of poorly characterized internal membranes in their lumen. These endosomes are therefore known as multivesicular or multilamellar organelles(1,2). Some proteins distribute preferentially within these internal membranes, whereas others are exclusively localized to the organelle's limiting membrane(3). The composition and function of this membrane system are poorly understood. Here we show that these internal membranes contain large amounts of a unique lipid, and thus form specialized domains within endosomes, These specialized domains are involved in sorting the multifunctional receptor(4) for insulin-like growth factor 2 and ligands bearing mannose-6-phosphate, in particular lysosomal enzymes, We also show that this unique lipid is a specific antigen for human antibodies associated with the antiphospholipid syndrome(5,6). These antibodies may act intracellularly by altering the protein-sorting functions of endosomes.	Univ Geneva, Dept Biochem, CH-1211 Geneva 4, Switzerland; Univ Queensland, Ctr Microscopy & Microanal, Dept Physiol & Pharmacol, St Lucia, Qld 4072, Australia; Univ Queensland, Ctr Mol & Cellular Biol, St Lucia, Qld 4072, Australia; Univ Hosp Geneva, Div Angiol & Haemostasis, CH-1211 Geneva 14, Switzerland	University of Geneva; University of Queensland; University of Queensland; University of Geneva	Gruenberg, J (corresponding author), Univ Geneva, Dept Biochem, 30 Quai E Ansermet, CH-1211 Geneva 4, Switzerland.	jean.gruenberg@biochemunige.ch	Parton, Robert G/C-5673-2009; KOBAYASHI, TOSHIHIDE/S-8313-2019; Kobayashi, Toshihide/B-6298-2015	Parton, Robert G/0000-0002-7494-5248; KOBAYASHI, TOSHIHIDE/0000-0002-4811-7270; Kobayashi, Toshihide/0000-0002-4811-7270				ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; AlarconSegovia D, 1996, J RHEUMATOL, V23, P1319; ANIENTO F, 1993, J CELL BIOL, V123, P1373, DOI 10.1083/jcb.123.6.1373; ASHERSON RA, 1996, ANTIPHOSPHOLIPID SYN, P1; BROTHERUS J, 1974, CHEM PHYS LIPIDS, V13, P178, DOI 10.1016/0009-3084(74)90034-6; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; Cosson P, 1997, CURR OPIN CELL BIOL, V9, P484, DOI 10.1016/S0955-0674(97)80023-3; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GRIFFITHS G, 1984, J ULTRA MOL STRUCT R, V89, P65, DOI 10.1016/S0022-5320(84)80024-6; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; Groskopf JC, 1997, ENDOCRINOLOGY, V138, P2835, DOI 10.1210/en.138.7.2835; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; Gu F, 1997, J CELL BIOL, V139, P1183, DOI 10.1083/jcb.139.5.1183; Horkko S, 1996, J CLIN INVEST, V98, P815, DOI 10.1172/JCI118854; JOUTTI A, 1979, BIOCHIM BIOPHYS ACTA, V575, P10, DOI 10.1016/0005-2760(79)90125-5; KARASAWA K, 1991, LIPIDS, V26, P1122, DOI 10.1007/BF02536514; Khamashta Munther A., 1996, Lupus, V5, P343; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LUDWIG T, 1995, TRENDS CELL BIOL, V5, P202, DOI 10.1016/S0962-8924(00)89000-5; MCNEIL HP, 1991, ADV IMMUNOL, V49, P193; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; REAVES B, 1993, MOL BIOL CELL, V4, P93, DOI 10.1091/mbc.4.1.93; REBER G, 1990, THROMB RES, V57, P215, DOI 10.1016/0049-3848(90)90321-3; SOMERHARJU P, 1979, BIOCHIM BIOPHYS ACTA, V573, P83, DOI 10.1016/0005-2760(79)90175-9; UMEDA M, 1989, J IMMUNOL, V143, P2273; Volpert O, 1996, ENDOCRINOLOGY, V137, P3871, DOI 10.1210/en.137.9.3871; WANG ZQ, 1994, NATURE, V372, P464, DOI 10.1038/372464a0; WHERRETT JR, 1972, J BIOL CHEM, V247, P4114	30	634	643	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 12	1998	392	6672					193	197		10.1038/32440	http://dx.doi.org/10.1038/32440			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB349	9515966				2022-12-28	WOS:000072462700066
J	Mattingley, JB; Husain, M; Rorden, C; Kennard, C; Driver, J				Mattingley, JB; Husain, M; Rorden, C; Kennard, C; Driver, J			Motor role of human inferior parietal lobe revealed in unilateral neglect patients	NATURE			English	Article							DIRECTIONAL HYPOKINESIA; ATTENTION; REPRESENTATION; CORTEX	The exact role of the parietal lobe in spatial cognition is controversial. One influential hypothesis proposes that it subserves spatial perception(1), whereas other accounts suggest that its primary role is to direct spatial movement(2,3). For humans, it has been suggested that these functions may be divided between inferior and superior parietal lobes, respectively(2,4). In apparent support of a purely perceptual function for the inferior parietal lobe (IPL), patients with lesions to this structure, particularly in the right hemisphere, exhibit unilateral spatial neglect (deficient awareness for the side of space opposite to that of their lesion)(5). Here we show that patients with right IPL lesions also have a specific difficulty in initiating leftward movements towards visual targets on the left side of space, This motor impairment was not found in neglect patients,vith frontal lesions, contrary to precious proposals that motor aspects of neglect are particularly associated with anterior damage(6-9). Our results suggest that the human IPL operates as a sensorimotor interface, rather than subserving only perceptual functions.	Charing Cross Hosp, Imperial Coll Sch Med, Div Neurosci & Psychol Med, London W6 8RF, England; UCL, Inst Cognit Neurosci, Dept Psychol, London WC1E 6BT, England; Univ Cambridge, Dept Expt Psychol, Cambridge CB2 3EB, England	Imperial College London; University of London; University College London; University of Cambridge	Husain, M (corresponding author), Charing Cross Hosp, Imperial Coll Sch Med, Div Neurosci & Psychol Med, London W6 8RF, England.	m.husain@cxwms.ac.uk	Husain, Masud/C-2074-2008; Mattingley, Jason/J-1537-2014; Driver, Jon/A-4779-2010	Husain, Masud/0000-0002-6850-9255; Mattingley, Jason/0000-0003-0929-9216; Rorden, Chris/0000-0002-7554-6142	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Andersen RA, 1997, ANNU REV NEUROSCI, V20, P303, DOI 10.1146/annurev.neuro.20.1.303; BISIACH E, 1993, Q J EXP PSYCHOL-A, V46, P435, DOI 10.1080/14640749308401056; BISIACH E, 1990, NEUROLOGY, V40, P1278, DOI 10.1212/WNL.40.8.1278; BUSHNELL MC, 1981, J NEUROPHYSIOL, V46, P755, DOI 10.1152/jn.1981.46.4.755; Damasio H, 1989, LESION ANAL NEUROPSY; DUHAMEL JR, 1992, SCIENCE, V255, P90, DOI 10.1126/science.1553535; Duncan John, 1995, P721; Graziano Michael S. A., 1996, Society for Neuroscience Abstracts, V22, P398; Heilman K.M., 1985, INT J CLIN NEUROPSYC, V2nd, P243; Husain M, 1996, J NEUROL, V243, P652, DOI 10.1007/BF00878662; HUSAIN M, 1997, NATURE, V385, P184; HUSAIN M, 1991, VISION VISUAL DYSFUN, V13, P12; Kinsbourne M, 1970, Trans Am Neurol Assoc, V95, P143; MATTINGLEY JB, 1992, BRAIN, V115, P1849, DOI 10.1093/brain/115.6.1849; MATTINGLEY JB, 1997, PARIETAL LOBE CONTRI, P309, DOI DOI 10.1007/978-3-642-60661-8_18; Mesulam M-M, 1985, PRINCIPLES BEHAV NEU; MESULAM MM, 1981, ANN NEUROL, V10, P309, DOI 10.1002/ana.410100402; Milner A. D., 1995, VISUAL BRAIN ACTION; Milner AD., 1997, PARIETAL LOBE CONTRI, P3; PERENIN MT, 1988, BRAIN, V111, P643, DOI 10.1093/brain/111.3.643; POSNER MI, 1984, J NEUROSCI, V4, P1863; RIDDOCH MJ, 1983, NEUROPSYCHOLOGIA, V21, P589, DOI 10.1016/0028-3932(83)90056-8; ROBERTSON IH, 1993, UNILATERAL NEGLECT C; Snyder LH, 1997, NATURE, V386, P167, DOI 10.1038/386167a0; TEGNER R, 1991, BRAIN, V114, P1943, DOI 10.1093/brain/114.4.1943; Ungerleider L.G., 1982, ANAL VISUAL BEHAV, P549	26	223	224	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 12	1998	392	6672					179	182		10.1038/32413	http://dx.doi.org/10.1038/32413			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB349	9515962				2022-12-28	WOS:000072462700062
J	Kroop-Martin, E				Kroop-Martin, E			Paths	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 11	1998	279	10					734	734		10.1001/jama.279.10.734-a	http://dx.doi.org/10.1001/jama.279.10.734-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA474	9508133				2022-12-28	WOS:000072366900001
J	Martin, W; Muller, M				Martin, W; Muller, M			The hydrogen hypothesis for the first eukaryote	NATURE			English	Article							TRICHOMONAS-VAGINALIS; AMITOCHONDRIATE EUKARYOTE; MITOCHONDRIA; PROTIST; ORIGIN; GENE; ENDOSYMBIONT; METABOLISM; EVOLUTION; ARCHAEA	A new hypothesis for the origin of eukaryotic cells is proposed, based on the comparative biochemistry of energy metabolism. Eukaryotes are suggested to have arisen through symbiotic association of an anaerobic, strictly hydrogen-dependent, strictly autotrophic archaebacterium (the host) with a eubacterium (the symbiont) that was able to respire, but generated molecular hydrogen as a waste product of anaerobic heterotrophic metabolism. The host's dependence upon molecular hydrogen produced by the symbiont is put forward as the selective principle that forged the common ancestor of eukaryotic cells.	Tech Univ Carolo Wilhelmina Braunschweig, Inst Genet, D-38023 Braunschweig, Germany; Rockefeller Univ, New York, NY 10021 USA	Braunschweig University of Technology; Rockefeller University	Muller, M (corresponding author), Tech Univ Carolo Wilhelmina Braunschweig, Inst Genet, Spielmannstr 7, D-38023 Braunschweig, Germany.	w.martin@tu-bs.de; mmuller@rockvax.rockefeller.edu	Martin, William/C-5680-2008; Martin, William F./O-5446-2015	Martin, William F./0000-0003-1478-6449				Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Brinkmann H, 1996, PLANT MOL BIOL, V30, P65, DOI 10.1007/BF00017803; BROERS CAM, 1990, EUR J PROTISTOL, V25, P369, DOI 10.1016/S0932-4739(11)80130-6; BRYANT MP, 1967, ARCH MIKROBIOL, V59, P20, DOI 10.1007/BF00406313; Bui ETN, 1996, P NATL ACAD SCI USA, V93, P9651, DOI 10.1073/pnas.93.18.9651; CAVALIER-SMITH T, 1987, ANN NY ACAD SCI, V503, P7; CavalierSmith T, 1996, J MOL EVOL, V43, P551, DOI 10.1007/BF02202103; CAVALIERSMITH T, 1987, NATURE, V326, P332, DOI 10.1038/326332a0; CLARK CG, 1995, P NATL ACAD SCI USA, V92, P6518, DOI 10.1073/pnas.92.14.6518; Conrad R, 1996, MICROBIOL REV, V60, P609, DOI 10.1128/MMBR.60.4.609-640.1996; Coombs Graham H., 1995, P33, DOI 10.1016/B978-012473345-9/50004-0; de Duve C, 1991, BLUEPRINT CELL NATUR; DOOLITTLE WF, 1996, S SOC GEN MICROBIOL, V54, P1; EMBLEY TM, 1995, P ROY SOC B-BIOL SCI, V262, P87, DOI 10.1098/rspb.1995.0180; Fenchel T., 1995, ECOLOGY EVOLUTION AN; FINLAY BJ, 1993, J GEN MICROBIOL, V139, P371, DOI 10.1099/00221287-139-2-371; Germot A, 1996, P NATL ACAD SCI USA, V93, P14614, DOI 10.1073/pnas.93.25.14614; Gibson JL, 1996, ARCH MICROBIOL, V166, P141, DOI 10.1007/s002030050369; GRAY MW, 1982, MICROBIOL REV, V46, P1; Gupta RS, 1996, TRENDS BIOCHEM SCI, V21, P166, DOI 10.1016/0968-0004(96)20013-1; HENZE K, 1995, P NATL ACAD SCI USA, V92, P9122, DOI 10.1073/pnas.92.20.9122; Horner DS, 1996, P ROY SOC B-BIOL SCI, V263, P1053, DOI 10.1098/rspb.1996.0155; HRDY I, 1995, J MOL EVOL, V41, P388, DOI 10.1007/BF01215186; IWABE N, 1989, P NATL ACAD SCI USA, V86, P9355, DOI 10.1073/pnas.86.23.9355; Kaneko T, 1996, DNA Res, V3, P109; KASTING JF, 1993, SCIENCE, V259, P920, DOI 10.1126/science.11536547; Keeling PJ, 1997, P NATL ACAD SCI USA, V94, P1270, DOI 10.1073/pnas.94.4.1270; LAKE JA, 1994, P NATL ACAD SCI USA, V91, P2880, DOI 10.1073/pnas.91.8.2880; LANGER D, 1995, P NATL ACAD SCI USA, V92, P5768, DOI 10.1073/pnas.92.13.5768; MARKOS A, 1993, J MOL EVOL, V37, P631, DOI 10.1007/BF00182749; Martin W, 1997, CURR GENET, V32, P1, DOI 10.1007/s002940050241; MULLER M, 1988, ANNU REV MICROBIOL, V42, P465, DOI 10.1146/annurev.mi.42.100188.002341; Muller M, 1998, SYST ASSOC SPEC VOL, V56, P109; MULLER M, 1993, J GEN MICROBIOL, V139, P2879, DOI 10.1099/00221287-139-12-2879; MULLER M, 1996, CG EHRENBERGFESTSCHR, P63; MURRELL JC, 1992, FEMS MICROBIOL LETT, V88, P233, DOI 10.1016/0378-1097(92)90805-X; Poole AM, 1998, J MOL EVOL, V46, P1, DOI 10.1007/PL00006275; Roger AJ, 1996, P NATL ACAD SCI USA, V93, P14618, DOI 10.1073/pnas.93.25.14618; Rosenthal B, 1997, J BACTERIOL, V179, P3736, DOI 10.1128/jb.179.11.3736-3745.1997; ROSPERT S, 1991, ARCH MICROBIOL, V156, P49, DOI 10.1007/BF00418187; Sanchez LB, 1996, FEBS LETT, V378, P240, DOI 10.1016/0014-5793(95)01463-2; SCHONHEIT P, 1995, WORLD J MICROB BIOT, V11, P26, DOI 10.1007/BF00339135; Searcy Dennis G., 1992, P47; SOGIN ML, 1996, S SOC GEN MICROBIOL, V54, P167; STEVENS TO, 1995, SCIENCE, V270, P450, DOI 10.1126/science.270.5235.450; Thauer Rudolf K., 1993, P209; WHATLEY JM, 1979, PROC R SOC SER B-BIO, V204, P165, DOI 10.1098/rspb.1979.0020; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; Yamamoto A, 1997, J MOL EVOL, V44, P98, DOI 10.1007/PL00006127; ZILLIG W, 1989, ENDOCYT CELL RES, V6, P1	50	858	888	14	179	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 5	1998	392	6671					37	41		10.1038/32096	http://dx.doi.org/10.1038/32096			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA528	9510246				2022-12-28	WOS:000072373000041
J	Finkelstein, BS; Silvers, JB; Marrero, U; Neuhauser, D; Cuttler, L				Finkelstein, BS; Silvers, JB; Marrero, U; Neuhauser, D; Cuttler, L			Insurance coverage, physician recommendations, and access to emerging treatments - Growth hormone therapy for childhood short stature	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Meeting of the Association-of-Health-Services-Research	JUN 15-17, 1997	CHICAGO, ILLINOIS	Assoc Hlth Serv Res			HEALTH-INSURANCE; CHILDREN; CARE; DEFICIENCY; COMPANIES; DIAGNOSIS; DRUG	Context.-There is concern in both the medical community and the general public about mechanisms of medical decision making and the interplay of physician and insurer decisions in determining access to care. Objective.-To examine the medical process influencing access to growth hormone (GH) therapy for childhood short stature by comparing coverage policies of US insurers with the treatment recommendations of US physicians. Design and Participants.-Independent national representative surveys were mailed to insurers (private, Blue Cross/Blue Shield, health maintenance organizations, programs for Children with Special Health Care Needs, and Medicaid programs, n=113), primary care physicians (n=1504), and pediatric endocrinologists (n=534) with response rates of 75%, 60%, and 81%, respectively, Each survey included identical case scenarios. Primary care physicians were asked decisions about referrals to pediatric endocrinologists, Endocrinologists were asked GH treatment recommendations. Insurers were asked coverage decisions for GH therapy. Main Outcome Measures.-Insurer coverage decisions for GH in specific case scenarios were compared with the recommendations of primary care physicians and pediatric endocrinologists. Results.-Physician recommendations and insurance coverage decisions differed strikingly, For example, while 96% of pediatric endocrinologists recommended GH therapy for children with Turner syndrome, insurer policies covered GH therapy for only 52% of these children, Overall, referral and treatment decisions by physicians resulted in recommendations for GH therapy in 78% of children with GH deficiency, Turner syndrome, or renal failure; of those recommended for treatment, 28% were denied coverage by insurers. Similarly, GH therapy would be recommended by physicians for only 9% of children with idiopathic short stature, but insurers would not cover GH for the vast majority of these children. Furthermore, the data indicated considerable variation among insurers regarding coverage policies for GH (P<.01). Conclusions.-Access to GH therapy differs depending on the type of insurance coverage. The deep discord between physician recommendations and insurance coverage decisions, exemplified by these findings, represents a major challenge to mechanisms of health care decision making, access, and costs.	Case Western Reserve Univ, Sch Med, Dept Pediat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Weatherhead Sch Management, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Cuttler, L (corresponding author), Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Dept Pediat, 11000 Euclid Ave, Cleveland, OH 44106 USA.				AHRQ HHS [T32 HS00059-03] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ABRAMOWICZ M, 1994, MED LETT DRUGS THER, V36, P77; ADAY LA, 1993, MED CARE, V31, P1013, DOI 10.1097/00005650-199311000-00004; *AM MED ASS DEP DA, 1995, PHYS CHAR DISTR US 1; Berlin CM, 1997, PEDIATRICS, V99, P122; BUCHANAN RJ, 1994, ANN PHARMACOTHER, V28, P528, DOI 10.1177/106002809402800418; *C RES SERV, 1993, MED SOURC BOOK BACKG; Cuttler L, 1996, JAMA-J AM MED ASSOC, V276, P531, DOI 10.1001/jama.276.7.531; FURLANETTO RW, 1995, J PEDIATR-US, V127, P857; *GROUP HLTH ASS AM, 1993, 1993 HMO NAT DIR; HADLEY J, 1991, JAMA-J AM MED ASSOC, V265, P374, DOI 10.1001/jama.265.3.374; HALL MA, 1992, U PENN LAW REV, V140, P1637, DOI 10.2307/3312428; LANTOS J, 1989, JAMA-J AM MED ASSOC, V261, P1020, DOI 10.1001/jama.261.7.1020; Lewit EM, 1995, FUTURE CHILD, V5, P192, DOI 10.2307/1602375; LIGHT DW, 1994, NEW ENGL J MED, V330, P498, DOI 10.1056/NEJM199402173300711; LIPPE BM, 1993, RECENT PROG HORM RES, V48, P179; MILHOLLAND AV, 1973, NEW ENGL J MED, V288, P1272, DOI 10.1056/NEJM197306142882405; Moore K G, 1992, Womens Health Issues, V2, P40, DOI 10.1016/S1049-3867(05)80136-7; MOORE KC, 1993, J PEDIATR-US, V122, P687, DOI 10.1016/S0022-3476(06)80005-3; NEWACHECK PW, 1988, PEDIATRICS, V81, P385; NEWACHECK PW, 1995, HEALTH AFFAIR, V14, P244, DOI 10.1377/hlthaff.14.1.244; *NIH CAR MAN AG HL, 1995, MED NEC S POL ISS IM; OCONNER M, 1995, CHICAGO TRIBUNE 0722, P5; PETERS WP, 1994, NEW ENGL J MED, V330, P473, DOI 10.1056/NEJM199402173300707; ROSENFELD RG, 1994, ENDOCRINOLOGIST, V4, P351, DOI 10.1097/00019616-199409000-00006; ROSENFELD RG, 1995, J CLIN ENDOCR METAB, V80, P1532, DOI 10.1210/jc.80.5.1532; ROSENFIELD RL, 1995, ENDOCRINOLOGY, P2549; ROSENTHAL E, 1996, NY TIMES        0524, pA1; ROSENTHAL E, 1996, NY TIMES        0715, pA7; SALMON JW, 1995, INT J HEALTH SERV, V25, P11, DOI 10.2190/YLBF-L031-6MN8-JE01; SINGH J, IN PRESS MED CARE; Steiner CA, 1996, J GEN INTERN MED, V11, P294, DOI 10.1007/BF02598272; TANNER JM, 1985, J PEDIATR-US, V107, P317, DOI 10.1016/S0022-3476(85)80501-1; UNDERWOOD LE, 1992, HOSP PRACT, V27, P192; *US BUR CENS, 1995, STAT ABSTR US 1993, P118; *US REN DAT SYST, 1995, USRDS 1995 ANN DATA, pB11; VIMPANI GV, 1977, BMJ-BRIT MED J, V2, P427, DOI 10.1136/bmj.2.6084.427; WIT JM, 1997, ENDOCR NEWS, V22, P1; WYATT DT, 1995, J CLIN ENDOCR METAB, V80, P3292, DOI 10.1210/jc.80.11.3292	38	41	41	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1998	279	9					663	668		10.1001/jama.279.9.663	http://dx.doi.org/10.1001/jama.279.9.663			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YY849	9496983				2022-12-28	WOS:000072192800029
J	Rouillard, SS; Bass, NM; Roberts, JP; Doherty, CA; Gee, L; Bacchetti, P; Somberg, KA				Rouillard, SS; Bass, NM; Roberts, JP; Doherty, CA; Gee, L; Bacchetti, P; Somberg, KA			Severe hyperbilirubinemia after creation of transjugular intrahepatic portosystemic shunts: Natural history and predictors of outcome	ANNALS OF INTERNAL MEDICINE			English	Article							THERAPEUTIC PORTACAVAL-SHUNT; ENCEPHALOPATHY; SURVIVAL	Background: Hyperbilirubinemia after creation of transjugular intrahepatic portosystemic shunts (TIPS) has been attributed to hemolysis and portal diversion, but the causes and natural history of this condition remain unknown. Objective: To determine clinical outcomes and predictors of severe hyperbilirubinemia after TIPS creation. Design: Retrospective analysis of all patients who underwent TIPS creation from June 1990 to September 1996. Setting: Academic medical center. Patients: 19 adults who developed severe hyperbilirubinemia (bilirubin level > 171.0 mu mol/L) within 1 month after TIPS creation were compared with 213 adults who did not develop hyperbilirubinemia after TIPS creation. Intervention: TIPS creation. Measurements: Laboratory measures and clinical outcomes. Results: According to laboratory indices, hemolysis was unlikely to have occurred. By 90 days, 95% of patients with hyperbilirubinemia had died or had undergone liver transplantation compared with 17% of controls (P < 0.001). Predictors of hyperbilirubinemia included nonalcoholic causes of liver disease (P = 0.01) and a pre-TIPS prothrombin time of 17 seconds or more (P = 0.016). Conclusions: Severe hyperbilirubinemia after TIPS creation heralds a high risk for death or need for liver transplantation. Reduced hepatic reserve predicts the development of hyperbilirubinemia.	Univ Calif San Francisco, Div Gastroenterol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Div Transplant Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Knowledge Management, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Somberg, KA (corresponding author), Univ Calif San Francisco, Div Gastroenterol, S-357,513 Parnassus Ave,Box 0538, San Francisco, CA 94143 USA.				NIDDK NIH HHS [T32DK07007, 5 P30 DK26743-17] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007007, P30DK026743] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BURCHELL AR, 1976, ANN SURG, V184, P289, DOI 10.1097/00000658-197609000-00006; CONN HO, 1974, GASTROENTEROLOGY, V67, P1065; CRIPPIN JS, 1995, J VASC INTERV RADIOL, V6, P461, DOI 10.1016/S1051-0443(95)72842-1; DAWSONSAUNDERS B, 1994, BASIC CLIN BIOSTATIS, P222; FREEDMAN AM, 1993, RADIOGRAPHICS, V13, P1185, DOI 10.1148/radiographics.13.6.8290720; GIMSON AES, 1986, HEPATOLOGY, V6, P288, DOI 10.1002/hep.1840060222; JACKSON FC, 1971, ANN SURG, V174, P672, DOI 10.1097/00000658-197110000-00012; LABERGE JM, 1993, RADIOLOGY, V187, P413, DOI 10.1148/radiology.187.2.8475283; NOELDGE G, 1992, CARDIOVASC INTER RAD, V15, P342, DOI 10.1007/BF02733960; RESNICK RH, 1974, GASTROENTEROLOGY, V67, P843; RING EJ, 1992, ANN INTERN MED, V116, P304, DOI 10.7326/0003-4819-116-4-304; RUEFF B, 1976, LANCET, V1, P655; RYPINS EB, 1988, AM J SURG, V155, P152, DOI 10.1016/S0002-9610(88)80273-3; Sanyal AJ, 1996, HEPATOLOGY, V23, P32, DOI 10.1002/hep.510230105; SANYAL AJ, 1992, ANN INTERN MED, V117, P443, DOI 10.7326/0003-4819-117-5-443; SOMBERG KA, 1995, HEPATOLOGY, V21, P709, DOI 10.1016/0270-9139(95)90522-7; SOMBERG KA, 1995, AM J GASTROENTEROL, V90, P549	17	25	25	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1998	128	5					374	377		10.7326/0003-4819-128-5-199803010-00006	http://dx.doi.org/10.7326/0003-4819-128-5-199803010-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY519	9490598				2022-12-28	WOS:000072155600006
J	Perez-Reyes, E; Cribbs, LL; Daud, A; Lacerda, AE; Barclay, J; Williamson, MP; Fox, M; Rees, M; Lee, JH				Perez-Reyes, E; Cribbs, LL; Daud, A; Lacerda, AE; Barclay, J; Williamson, MP; Fox, M; Rees, M; Lee, JH			Molecular characterization of a neuronal low-voltage-activated T-type calcium channel	NATURE			English	Article							ABSENCE EPILEPSY; CA2+ CHANNELS; CELLS; INACTIVATION; CONDUCTANCE; PERMEATION; MOTIF; MOUSE	The molecular diversity of voltage-activated calcium channels was established by studies showing that channels could be distinguished by their voltage-dependence, deactivation and single-channel conductance(1-3). Low-voltage-activated channels are called 'T' type because their currents are both transient (owing. to fast inactivation) and tiny (owing to small conductance)(2). T-type channels are thought to be involved in pacemaker activity, low-threshold calcium spikes, neuronal oscillations and resonance, and rebound burst firing(4). Here we report the identification of a neuronal T-type channel. Our cloning strategy began with an analysis of Genbank sequences defined as sharing homology with calcium channels. We sequenced an expressed sequence tag (EST), then used it to done a full-length complementary DNA from rat brain. Northern blot analysis indicated that this gene is expressed predominantly in brain, in particular the amygdala, cerebellum and thalamus. We mapped the human gene to chromosome 17q22, and the mouse gene to chromosome 11. Functional expression of the channel was measured in Xenopus oocytes. Based on the channel's distinctive voltage dependence, slow deactivation kinetics, and 7.5-pS single-channel conductance, we conclude that this channel is a low-voltage-activated T-type calcium channel.	Loyola Univ, Med Ctr, Dept Physiol, Maywood, IL 60153 USA; Loyola Univ, Med Ctr, Cardiovasc Inst, Maywood, IL 60153 USA; Metrohlth Med Ctr, Rammelkamp Ctr Res & Educ, Cleveland, OH 44109 USA; Univ London Univ Coll, Sch Med, Rayne Inst, Dept Paediat, London WC1E 6JJ, England; Galton Lab, MRC, Human Biochem Genet Unit, London NW1 2HE, England	Loyola University Chicago; Loyola University Chicago; MetroHealth System; University of London; King's College London; University College London; UCL Medical School; University of London; University College London	Perez-Reyes, E (corresponding author), Loyola Univ, Med Ctr, Dept Physiol, Maywood, IL 60153 USA.	eperez@luc.edu		Williamson, Magali/0000-0002-7183-7495				Banfi S, 1996, NAT GENET, V13, P167, DOI 10.1038/ng0696-167; Bernal J, 1997, J PHARMACOL EXP THER, V282, P172; Bourinet E, 1996, J NEUROSCI, V16, P4983; BREEN M, 1994, HUM MOL GENET, V3, P621, DOI 10.1093/hmg/3.4.621; CARBONE E, 1984, NATURE, V310, P501, DOI 10.1038/310501a0; DELEON M, 1995, SCIENCE, V270, P1502, DOI 10.1126/science.270.5241.1502; DROOGMANS G, 1989, J PHYSIOL-LONDON, V419, P627, DOI 10.1113/jphysiol.1989.sp017890; Fletcher CF, 1996, CELL, V87, P607, DOI 10.1016/S0092-8674(00)81381-1; Huguenard JR, 1996, ANNU REV PHYSIOL, V58, P329, DOI 10.1146/annurev.physiol.58.1.329; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; LACERDA AE, 1994, BIOPHYS J, V66, P1833, DOI 10.1016/S0006-3495(94)80977-4; Lambert RC, 1997, J NEUROSCI, V17, P6621; MATTESON DR, 1986, J GEN PHYSIOL, V87, P161, DOI 10.1085/jgp.87.1.161; MEIER H, 1967, ARCH NEUROL-CHICAGO, V16, P59, DOI 10.1001/archneur.1967.00470190063008; Montgomery JC, 1997, MAMM GENOME, V7, pS190, DOI 10.1007/s003359900323; NILIUS B, 1985, NATURE, V316, P443, DOI 10.1038/316443a0; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; PEREZREYES E, 1995, KIDNEY INT, V48, P1111, DOI 10.1038/ki.1995.395; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Randall AD, 1997, NEUROPHARMACOLOGY, V36, P879, DOI 10.1016/S0028-3908(97)00086-5; SCHNEIDER T, 1994, RECEPTOR CHANNEL, V2, P255; SHUBA YM, 1991, J PHYSIOL-LONDON, V443, P25, DOI 10.1113/jphysiol.1991.sp018820; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TSAKIRIDOU E, 1995, J NEUROSCI, V15, P3110, DOI 10.1523/jneurosci.15-04-03110.1995; VanDongen AMJ, 1996, BIOPHYS J, V70, P1303, DOI 10.1016/S0006-3495(96)79687-X; WAKAMORI M, 1994, RECEPTOR CHANNEL, V2, P303; WILLIAMS ME, 1994, J BIOL CHEM, V269, P22347; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0	30	612	641	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 26	1998	391	6670					896	900		10.1038/36110	http://dx.doi.org/10.1038/36110			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ206	9495342				2022-12-28	WOS:000072230900053
J	Leyland, AH; Boddy, FA				Leyland, AH; Boddy, FA			League tables and acute myocardial infarction	LANCET			English	Article							PERFORMANCE; HOSPITALS	Background Comparison of the outcomes of care provided by hospitals is a growing trend. Outcomes need to be distinguished into those attributable to the practice of hospitals and those that arise from differences in the characteristics of patients and the underlying morbidity of the populations for whom hospitals provide care. We explored these issues for deaths in hospital or within 30 days of discharge after acute myocardial infarction in Scotland, UK. Methods We used records from December, 1992, to November, 1993, for 14 359 episodes of acute myocardial infarction, the death records of those who died, and 9391 death records for individuals who died after acute myocardial infarction but who had not been in hospital in the 30 days before death. Hospital discharge records were taken from the Scottish Morbidity Records. The outcomes we investigated were all-cause mortality within 30 Flays of discharge from hospital, and death from acute myocardial infarction at any time during the study period. We estimated separately effects attributable to patients' characteristics, hospitals, and areas of residence with multilevel modelling. Findings We found significant differences between hospitals by age, sex, and medical history. The odds ratios for death ranged from 0.62 (95% CI 0.50-0.80) to 1.28 (1.07-1.59), relative to the average performance for Scotland as a whole. Analysis including area of residence, deaths occurring out of hospital, and more detailed information about patients showed no significant differences between hospitals for patients aged 70 years. By postcode area, there was a strong association between out-of-hospital deaths and deaths in hospital or shortly after discharge. Interpretation Hospital outcomes may vary from one subgroup of patients to another and should be assessed independently of patients' areas of residence. Measures of performance that do not provide valid comparisons could diminish public confidence in hospital services.	Univ Glasgow, Publ Hlth Res Inst, Glasgow G12 8RZ, Lanark, Scotland	University of Glasgow	Leyland, AH (corresponding author), Univ Glasgow, Publ Hlth Res Inst, Glasgow G12 8RZ, Lanark, Scotland.	a.leyland@udcf.gla.ac.uk	Leyland, Alastair/C-6069-2011	Leyland, Alastair/0000-0003-3741-7099				Blumberg M S, 1986, Med Care Rev, V43, P351, DOI 10.1177/107755878604300205; Carstairs V., 1991, DEPRIVATION HLTH SCO; CHRISTIE B, 1996, SCOTSMAN        0217; DILLNER L, 1994, BRIT MED J, V309, P1599, DOI 10.1136/bmj.309.6969.1599a; EPSTEIN A, 1995, NEW ENGL J MED, V333, P57, DOI 10.1056/NEJM199507063330114; Goldstein H, 1996, J ROY STAT SOC A STA, V159, P385, DOI 10.2307/2983325; Goldstein H, 1995, MULTILEVEL STAT MODE, DOI 10.1002/9780470973394; GOLDSTEIN H, 1996, RES INTELLIGENCE, V57, P12; GREEN J, 1995, NEW ENGL J MED, V332, P1229, DOI 10.1056/NEJM199505043321812; Kendrick Stephen, 1993, Health Bulletin (Edinburgh), V51, P72; Leyland AH, 1997, EUR J PUBLIC HEALTH, V7, P136, DOI 10.1093/eurpub/7.2.136; Leyland AH, 1995, IMA J MATH APPL MED, V12, P175; LOVE D, 1995, HEALTH SERV RES, V29, P629; LOWRY S, 1988, BRIT MED J, V296, P992, DOI 10.1136/bmj.296.6627.992; McKee M, 1997, BRIT MED J, V315, P142, DOI 10.1136/bmj.315.7101.142; McKee M, 1995, Qual Health Care, V4, P5, DOI 10.1136/qshc.4.1.5; Morrison C, 1997, BMJ-BRIT MED J, V314, P541, DOI 10.1136/bmj.314.7080.541; Naylor CD, 1997, BRIT MED J, V315, P1462, DOI 10.1136/bmj.315.7120.1462; Normand SLT, 1997, J AM STAT ASSOC, V92, P803, DOI 10.2307/2965545; ORCHARD C, 1994, BRIT MED J, V308, P1493, DOI 10.1136/bmj.308.6942.1493; Orchard C, 1996, J Eval Clin Pract, V2, P111, DOI 10.1111/j.1365-2753.1996.tb00035.x; Rasbash J., 1995, MLN COMMAND REFERENC; Rasbash J., 1994, J EDUC BEHAV STAT, V19, P337, DOI 10.2307/1165397.; Rice N, 1996, J Health Serv Res Policy, V1, P154; *SCOTT OFF, 1994, CLIN OUTC IND; *SCOTT OFF, 1995, CLIN OUTC IND; SMITH P, 1990, J ROY STAT SOC A STA, V153, P53, DOI 10.2307/2983096; Smith P., 1995, INT J PUBLIC ADMIN, V18, P277, DOI DOI 10.1080/01900699508525011; Wise J, 1997, BRIT MED J, V315, P76; YATES JM, 1984, BRIT MED J, V288, P1935, DOI 10.1136/bmj.288.6434.1935	30	69	69	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 21	1998	351	9102					555	558		10.1016/S0140-6736(97)09362-8	http://dx.doi.org/10.1016/S0140-6736(97)09362-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ216	9492774				2022-12-28	WOS:000072231900010
J	Nelson, JL; Furst, DE; Maloney, S; Gooley, T; Evans, PC; Smith, A; Bean, MA; Ober, C; Bianchi, DW				Nelson, JL; Furst, DE; Maloney, S; Gooley, T; Evans, PC; Smith, A; Bean, MA; Ober, C; Bianchi, DW			Microchimerism and HLA-compatible relationships of pregnancy in scleroderma	LANCET			English	Article							MATERNAL BLOOD; CELLS; SEQUENCE; DISEASE; HYBRIDIZATION; ALLOANTIGENS; WOMEN; DNA	Background Fetal cells can be found in the maternal circulation in most pregnancies. Fetal progenitor cells have been found to persist in the circulation of women many years after childbirth. We tested the hypothesis that microchimerism is involved in the pathogenesis of scleroderma. Scleroderma is of interest because of a strong female predilection, an increased incidence in the years after childbearing, and clinical similarities between scleroderma and chronic graft-versus-host disease after allogeneic bone-marrow transplantation. We also investigated whether HLA-compatibility of a child was associated with later development of scleroderma in the mother. Methods We enrolled 40 women who had previously given birth to at least one son-16 healthy controls, 17 scleroderma and seven healthy sisters of quantitative PCR to Y-chromosome-specific sequence in blood from these women. Also 32 children, and 21 scleroderma patients with 47 children were HLA genotyped. Findings The mean number of male cell DNA equivalents among controls was 0.38 cells per 16 mL whole blood (median 0 [range 0-2]) and 11.1 (6.0 [0-61]) among scleroderma patients (p=0.0007). Controls' youngest sons were born a mean of 15.4 years previously, and scleroderma patients' sons 18.5 years previously. Some scleroderma patients had concentrations of male DNA higher than those found in most pregnant women, HLA-class II compatibility of a child from the mother's perspective was more common among scleroderma patients than among controls, but was not essential for persistence of male DNA in maternal peripheral blood. Interpretation Low concentrations of male DNA can be detected in healthy women decades after the birth of a son. Microchimerism in scleroderma patients could be secondary to the underlying disease. However, the finding that HLA class II compatibility of a child was more common for scleroderma patients than for controls, supports the possibility that microchimerism may be involved in the pathogenesis of scleroderma.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Univ Washington, Seattle, WA 98195 USA; Virginia Mason Res Ctr, Seattle, WA 98101 USA; Pacific NW Res Fdn, Seattle, WA 98122 USA; Univ Chicago, Med Ctr, Ctr Med Genet, Chicago, IL 60637 USA; Tufts Univ New England Med Ctr, Boston, MA 02111 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Virginia Mason Medical Center; University of Chicago; University of Chicago Medical Center; Tufts Medical Center	Nelson, JL (corresponding author), Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.			Evans, Paul/0000-0001-7975-681X	NIAID NIH HHS [AI 41721, AI 38583] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038583, R01AI041721] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1980, ARTHRITIS RHEUM, V23, P581, DOI 10.1002/art.1780230510; Bianchi DW, 1996, P NATL ACAD SCI USA, V93, P705, DOI 10.1073/pnas.93.2.705; BIANCHI DW, 1995, J PEDIATR-US, V127, P847, DOI 10.1016/S0022-3476(95)70018-8; Bianchi DW, 1997, AM J HUM GENET, V61, P822, DOI 10.1086/514885; Bodmer JG, 1997, TISSUE ANTIGENS, V49, P297, DOI 10.1111/j.1399-0039.1997.tb02759.x; Bonney EA, 1997, J IMMUNOL, V158, P40; Claman HN, 1993, IMMUNOLOGY HUMAN PRE; DEMOOR G, 1988, ACTA CLIN BELG, V43, P231; ENGLERT H, 1992, J RHEUMATOL, V19, P1575; FINK PJ, 1988, ANNU REV IMMUNOL, V6, P115; FURST DE, 1979, ARTHRITIS RHEUM, V22, P904, DOI 10.1002/art.1780220815; HALL JM, 1995, BLOOD, V86, P2829; HUTCHINSON DL, 1971, AM J OBSTET GYNECOL, V109, P281, DOI 10.1016/0002-9378(71)90876-3; LAWLEY TJ, 1977, ANN INTERN MED, V87, P707, DOI 10.7326/0003-4819-87-6-707; LEE TH, 1997, J ALLERGY CLIN IMMUN, V99, P468; Lo YMD, 1996, BLOOD, V88, P4390; LUCOTTE G, 1991, MOL CELL PROBE, V5, P359, DOI 10.1016/S0890-8508(06)80007-1; McMilin Kenneth D., 1993, Transfusion Medicine Reviews, V7, P37, DOI 10.1016/S0887-7963(93)70031-0; MICKELSON E, 1993, TISSUE ANTIGENS, V41, P86, DOI 10.1111/j.1399-0039.1993.tb01984.x; Nelson JL, 1996, ARTHRITIS RHEUM, V39, P191, DOI 10.1002/art.1780390203; NELSON JL, 1993, NEW ENGL J MED, V329, P466, DOI 10.1056/NEJM199308123290704; Piotrowski P, 1996, BIOL REPROD, V54, P1103, DOI 10.1095/biolreprod54.5.1103; POLLACK MS, 1982, NEW ENGL J MED, V307, P662, DOI 10.1056/NEJM198209093071106; Silman A., 1993, EPIDEMIOLOGY RHEUMAT, P192; Smith AG, 1996, TISSUE ANTIGENS, V48, P118, DOI 10.1111/j.1399-0039.1996.tb02616.x; TAFURI A, 1995, SCIENCE, V270, P630, DOI 10.1126/science.270.5236.630; THOMAS MR, 1994, LANCET, V343, P413, DOI 10.1016/S0140-6736(94)91248-3	27	456	469	1	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 21	1998	351	9102					559	562		10.1016/S0140-6736(97)08357-8	http://dx.doi.org/10.1016/S0140-6736(97)08357-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ216	9492775				2022-12-28	WOS:000072231900011
J	Hof, P; Pluskey, S; Dhe-Paganon, S; Eck, MJ; Shoelson, SE				Hof, P; Pluskey, S; Dhe-Paganon, S; Eck, MJ; Shoelson, SE			Crystal structure of the tyrosine phosphatase SHP-2	CELL			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; INSULIN-RECEPTOR SUBSTRATE-1; CAVITY-CREATING MUTATIONS; SH2 DOMAINS; PHOSPHATIDYLINOSITOL 3'-KINASE; CHYMOTRYPSIN INHIBITOR-2; HYDROPHOBIC CORE; PROTEIN; SH-PTP2; ACTIVATION	The structure of the SHP-2 tyrosine phosphatase, determined at 2.0 Angstrom resolution, shows how its catalytic activity is regulated by its two SH2 domains. In the absence of a tyrosine-phosphorylated binding partner, the N-terminal SH2 domain binds the phosphatase domain and directly blocks its active site. This interaction alters the structure of the N-SH2 domain, disrupting its phosphopeptide-binding cleft. Conversely, interaction of the N-SH2 domain with phosphopeptide disrupts its phosphatase recognition surface. Thus, the N-SHP domain is a conformational switch; it either binds and inhibits the phosphatase, or it binds phosphoproteins and activates the enzyme. Recognition of bisphosphorylated ligands by the tandem SH2 domains is an integral element of this switch; the C-terminal SH2 domain contributes binding energy and specificity, but it does not have a direct role in activation.	Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	Eck, MJ (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA.							Allard JD, 1996, DEVELOPMENT, V122, P1137; Arrandale JM, 1996, J BIOL CHEM, V271, P21353, DOI 10.1074/jbc.271.35.21353; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baldwin E, 1996, J MOL BIOL, V259, P542, DOI 10.1006/jmbi.1996.0338; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DECHERT U, 1994, J BIOL CHEM, V269, P5602; Eck MJ, 1996, NATURE, V379, P277, DOI 10.1038/379277a0; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Hoffmann KMV, 1997, J BIOL CHEM, V272, P27505, DOI 10.1074/jbc.272.44.27505; Jackson DE, 1997, J BIOL CHEM, V272, P24868, DOI 10.1074/jbc.272.40.24868; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P11270, DOI 10.1021/bi00093a002; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P11259, DOI 10.1021/bi00093a001; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; JONES TA, 1989, CRYSTALLOGRAPHIC COM; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; NAVAZA J, 1992, MOL REPLACEMENT, P87; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; O'Reilly AM, 1998, MOL CELL BIOL, V18, P161, DOI 10.1128/MCB.18.1.161; Ottinger EA, 1998, J BIOL CHEM, V273, P729, DOI 10.1074/jbc.273.2.729; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pei DH, 1996, P NATL ACAD SCI USA, V93, P1141, DOI 10.1073/pnas.93.3.1141; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; RICHARDS FM, 1988, PROTEINS, V3, P71, DOI 10.1002/prot.340030202; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; SHIUE L, 1995, J BIOL CHEM, V270, P10498, DOI 10.1074/jbc.270.18.10498; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUGIMOTO S, 1993, J BIOL CHEM, V268, P22771; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; Tonks N K, 1996, Adv Pharmacol, V36, P91, DOI 10.1016/S1054-3589(08)60578-5; TOWNLEY R, 1993, BIOCHEMISTRY-US, V32, P13414, DOI 10.1021/bi00212a006; TURK D, 1996, P 1996 M INT UN CRYS; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	59	707	733	1	33	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 20	1998	92	4					441	450		10.1016/S0092-8674(00)80938-1	http://dx.doi.org/10.1016/S0092-8674(00)80938-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YZ409	9491886	Bronze			2022-12-28	WOS:000072251500005
J	Audetat, A; Gunther, D; Heinrich, CA				Audetat, A; Gunther, D; Heinrich, CA			Formation of a magmatic-hydrothermal ore deposit: Insights with LA-ICP-MS analysis of fluid inclusions	SCIENCE			English	Article							NEW-SOUTH-WALES; PIXE MICROANALYSIS; ELEMENTAL ANALYSIS; VAPOR; MINERALIZATION; GRANITE; QUARTZ; COPPER; PHASE	The physical and chemical mechanism of ore precipitation in the Yankee Lode tin deposit (Mole Granite, Australia) was quantified by direct trace-element microanalysis of fluid inclusions. Laser ablation-inductively coupled plasma-mass spectrometry (LA-ICP-MS) was used to measure element concentrations in a series of fluid inclusions representing the fluid before, during, and after the deposition of cassiterite (SnO2). Tin precipitation was driven by mixing of hot magmatic brine with cooler meteoric water. At the same time, a separate magmatic vapor phase selectively transported copper and boron into the liquid mixture.	ETH Zentrum, Inst Isotope Geol & Mineral Resources, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Audetat, A (corresponding author), ETH Zentrum, Inst Isotope Geol & Mineral Resources, CH-8092 Zurich, Switzerland.		Heinrich, Christoph A/D-3921-2014	Heinrich, Christoph A/0000-0001-5838-4607; Audetat, Andreas/0000-0002-6176-4122				BISCHOFF JL, 1989, AM J SCI, V289, P217, DOI 10.2475/ajs.289.3.217; Bodnar R.J., 1994, FLUID INCLUSIONS MIN, P117; BODNAR RJ, 1985, GEOCHIM COSMOCHIM AC, V49, P1861, DOI 10.1016/0016-7037(85)90081-X; BOIRON MC, 1991, GEOCHIM COSMOCHIM AC, V55, P917, DOI 10.1016/0016-7037(91)90352-6; Candela PA, 1995, MINERALOGICAL ASS CA, V23, P101; CLINE JS, 1991, J GEOPHYS RES-SOLID, V96, P8113, DOI 10.1029/91JB00053; Damman AH, 1996, EUR J MINERAL, V8, P1081; DUBESSY J, 1989, EUR J MINERAL, V1, P517; EADINGTON PJ, 1983, ECON GEOL, V78, P1204, DOI 10.2113/gsecongeo.78.6.1204; Gunther D, 1997, J ANAL ATOM SPECTROM, V12, P939, DOI 10.1039/a701423f; GUNTHER D, IN PRESS J ANAL ATOM; HEDENQUIST JW, 1994, NATURE, V370, P519, DOI 10.1038/370519a0; HEINRICH CA, 1990, ECON GEOL BULL SOC, V85, P457, DOI 10.2113/gsecongeo.85.3.457; HEINRICH CA, 1992, ECON GEOL BULL SOC, V87, P1566, DOI 10.2113/gsecongeo.87.6.1566; HEINRICH CA, 1992, WATER-ROCK INTERACTION, VOLS 1 AND 2, P1583; Kesler SE., 1994, MINERAL RESOURCES EC; KLEEMAN JD, 1982, NEW ENGLAND GEOLOGY, P327; LOUCKS RR, 1996, GEOL SOC AUST ABSTR, V41, P258; LOWENSTERN JB, 1991, SCIENCE, V252, P1405, DOI 10.1126/science.252.5011.1405; MAVROGENES JA, 1995, GEOCHIM COSMOCHIM AC, V59, P3987, DOI 10.1016/0016-7037(95)00261-W; MULHOLLAND CSJ, 1953, GEOLOGY AUSTR ORE DE, V1, P944; Roedder E., 1997, GEOCHEMISTRY HYDROTH, Vthird, P657; RYAN CG, 1991, NUCL INSTRUM METH B, V54, P292, DOI 10.1016/0168-583X(91)95528-L; Seward T.M., 1997, GEOCHEMISTRY HYDROTH, P435; SHEPHERD TJ, 1995, GEOCHIM COSMOCHIM AC, V59, P3997, DOI 10.1016/0016-7037(95)00294-A; SUN SS, 1987, ECON GEOL, V82, P43, DOI 10.2113/gsecongeo.82.1.43	26	304	353	5	152	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 27	1998	279	5359					2091	2094		10.1126/science.279.5359.2091	http://dx.doi.org/10.1126/science.279.5359.2091			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZE274	9516106				2022-12-28	WOS:000072775600042
J	Penn, AA; Riquelme, PA; Feller, MB; Shatz, CJ				Penn, AA; Riquelme, PA; Feller, MB; Shatz, CJ			Competition in retinogeniculate patterning driven by spontaneous activity	SCIENCE			English	Article							LATERAL GENICULATE-NUCLEUS; NICOTINIC ACETYLCHOLINE-RECEPTORS; PRENATAL DEVELOPMENT; MAMMALIAN RETINA; NEUROMUSCULAR-JUNCTION; GANGLION-CELLS; CONNECTIONS; NEURONS; SEGREGATION; TETRODOTOXIN	When contacts are first forming in the developing nervous system, many neurons generate spontaneous activity that has been hypothesized to shape appropriately patterned connections. In Mustela putorius furo, monocular intraocular blockade of spontaneous retinal waves of action potentials by cholinergic agents altered the subsequent eye-specific lamination pattern of the lateral geniculate nucleus (LGN). The projection from the active retina was greatly expanded into territory normally belonging to the other eye, and the projection from the inactive retina was substantially reduced. Thus, interocular competition driven by endogenous retinal activity determines the pattern of eye-specific connections from retina to LGN, demonstrating that spontaneous activity can produce highly stereotyped patterns of connections before the onset of visual experience.	Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Penn, AA (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, 221 Life Sci Addit, Berkeley, CA 94720 USA.				NIMH NIH HHS [MH 98108] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BADIO B, 1994, MOL PHARMACOL, V45, P563; Baldridge WH, 1996, J NEUROSCI, V16, P5060; Cartier GE, 1996, J BIOL CHEM, V271, P7522, DOI 10.1074/jbc.271.13.7522; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; Cramer KS, 1997, DEV BRAIN RES, V98, P287, DOI 10.1016/S0165-3806(96)00188-5; Dan Y, 1995, PROG BRAIN RES, V105, P211; Drescher U, 1997, CURR OPIN NEUROBIOL, V7, P75, DOI 10.1016/S0959-4388(97)80123-7; DUBIN MW, 1986, J NEUROSCI, V6, P1021; Feller MB, 1996, SCIENCE, V272, P1182, DOI 10.1126/science.272.5265.1182; Fiordalisi JJ, 1996, TOXICON, V34, P213, DOI 10.1016/0041-0101(95)00135-2; GARRAGHTY PE, 1988, VISUAL NEUROSCI, V1, P93, DOI 10.1017/S0952523800001048; GHOSH A, 1990, NATURE, V347, P179, DOI 10.1038/347179a0; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; HAHM JO, 1991, NATURE, V351, P568, DOI 10.1038/351568a0; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; JEFFERY G, 1990, EXP BRAIN RES, V82, P408; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Kittila CA, 1997, J NEUROPHYSIOL, V77, P675, DOI 10.1152/jn.1997.77.2.675; Kulak JM, 1997, J NEUROSCI, V17, P5263; LINDEN DC, 1981, J COMP NEUROL, V203, P189, DOI 10.1002/cne.902030204; Marks MJ, 1996, J PHARMACOL EXP THER, V277, P1383; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; MEISTER M, 1991, SCIENCE, V252, P939, DOI 10.1126/science.2035024; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; Mooney R, 1996, NEURON, V17, P863, DOI 10.1016/S0896-6273(00)80218-4; Nguyen QT, 1996, CURR OPIN NEUROBIOL, V6, P104, DOI 10.1016/S0959-4388(96)80015-8; OLIVERA T, COMMUNICATION; PRUSKY GT, 1988, VISUAL NEUROSCI, V1, P245, DOI 10.1017/S0952523800001504; RAKIC P, 1976, NATURE, V261, P467, DOI 10.1038/261467a0; RAMOA AS, 1989, P NATL ACAD SCI USA, V86, P2061, DOI 10.1073/pnas.86.6.2061; RIDDLE DR, 1995, NATURE, V378, P189, DOI 10.1038/378189a0; Sernagor E, 1996, CURR BIOL, V6, P1503, DOI 10.1016/S0960-9822(96)00755-5; SHATZ CJ, 1983, J NEUROSCI, V3, P482; SHATZ CJ, 1988, SCIENCE, V242, P87, DOI 10.1126/science.3175636; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SRETAVAN DW, 1986, J NEUROSCI, V6, P234; SRETAVAN DW, 1986, J NEUROSCI, V6, P990; SRETAVAN DW, 1988, NATURE, V336, P468, DOI 10.1038/336468a0; STEIN BE, 1985, J COMP NEUROL, V239, P402, DOI 10.1002/cne.902390406; WONG ROL, 1993, NEURON, V11, P923, DOI 10.1016/0896-6273(93)90122-8; XIE Y, 1993, J PHARMACOL EXP THER, V264, P689; Xie Y, 1996, J PHARMACOL EXP THER, V276, P169; Yuste R, 1997, SEMIN CELL DEV BIOL, V8, P1, DOI 10.1006/scdb.1996.0114; ZOLL M, 1995, J NEUROSCI, V15, P1912	44	399	405	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 27	1998	279	5359					2108	2112		10.1126/science.279.5359.2108	http://dx.doi.org/10.1126/science.279.5359.2108			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZE274	9516112				2022-12-28	WOS:000072775600048
J	Wernicke, B; Davis, JL; Bennett, RA; Elosegui, P; Abolins, MJ; Brady, RJ; House, MA; Niemi, NA; Snow, JK				Wernicke, B; Davis, JL; Bennett, RA; Elosegui, P; Abolins, MJ; Brady, RJ; House, MA; Niemi, NA; Snow, JK			Anomalous strain accumulation in the Yucca Mountain Area, Nevada	SCIENCE			English	Article							LITTLE-SKULL-MOUNTAIN; GREAT-BASIN PROVINCE; SOUTHERN NEVADA; SLIP RATES; CONSTRAINTS; EARTHQUAKE; VOLCANISM; COMPLEX; GEODESY; REGION	Global Positioning System (GPS) surveys from 1991 to 1997 near Yucca Mountain, Nevada, indicate west-northwest crustal elongation at a rate of 1.7 +/- 0.3 millimeters per year (1 sigma) over 34 kilometers, or 50 +/- 9 nanostrain per year. Global Positioning System and trilateration surveys from 1983 to 1997 on a 14-kilometer baseline across the proposed repository site for high-level radioactive waste indicate that the crust extended by 0.7 to 0.9 +/- 0.2 millimeter per year (50 to 64 +/- 14 nanostrain per year), depending on the coseismic effect of the M-s 5.4 1992 Little Skull Mountain earthquake. These strain rates are at least an order of magnitude higher than would be predicted from the Quaternary volcanic and tectonic history of the area.	CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA; Harvard Smithsonian Ctr Astrophys, Cambridge, MA 02138 USA	California Institute of Technology; Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution	Wernicke, B (corresponding author), CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA.		Niemi, Nathan A/A-9996-2011; Davis, James/D-8766-2013	Davis, James/0000-0003-3057-477X; Niemi, Nathan Alan/0000-0002-3380-3024				Anderson LW, 1997, GEOLOGY, V25, P189, DOI 10.1130/0091-7613(1997)025<0189:QSHOTB>2.3.CO;2; Bennett RA, 1997, GEOPHYS RES LETT, V24, P3073, DOI 10.1029/97GL02951; Bennett RA, 1998, GEOPHYS RES LETT, V25, P563, DOI 10.1029/98GL00128; Bennett RA, 1996, J GEOPHYS RES-SOL EA, V101, P21943, DOI 10.1029/96JB02488; CONNOR CB, 1995, J GEOPHYS RES-SOL EA, V100, P10107, DOI 10.1029/95JB01055; COPPERSMITH KJ, 1990, NP7057 EL POW RES I; DAVIS JL, 1985, RADIO SCI, V20, P1593, DOI 10.1029/RS020i006p01593; Delaney PT, 1997, GEOL SOC AM BULL, V109, P1177, DOI 10.1130/0016-7606(1997)109<1177:PPOSMD>2.3.CO;2; DIXON TH, 1995, TECTONICS, V14, P755, DOI 10.1029/95TC00931; EVANS JR, 1995, MAJOR RESULTS GEOPHY, P135; Ferrill DA, 1996, GEOLOGY, V24, P559, DOI 10.1130/0091-7613(1996)024<0559:QSHOTB>2.3.CO;2; Fleck RJ, 1996, J GEOPHYS RES-SOL EA, V101, P8205, DOI 10.1029/95JB03123; HARMSEN SC, 1994, B SEISMOL SOC AM, V84, P1484; HERRING TA, 1995, GLOBK GLOBAL KALMAN; KING RW, 1995, DOCUMENTATION MIT GP; Machette M. N., 1992, ANN TECTONICAE, V6, P5; MCGUIRE R, 1992, GROUND WATER YUCCA M; MEREMONTE M, 1995, B SEISMOL SOC AM, V85, P1039; PARSONS T, 1991, SCIENCE, V253, P1399, DOI 10.1126/science.253.5026.1399; REHEIS MC, 1988, US GEOL SURV B, V1790, P103; SAVAGE JC, 1994, J GEOPHYS RES-SOL EA, V99, P18103, DOI 10.1029/94JB01551; SAVAGE JC, 1996, J GEOPHYS RES, V191, P547; SCHOLZ CH, 1990, MECH EARTHQUAKE FAUL, pCH4; SCOTT RB, 1990, GEOLOGICAL SOC AM ME, V176, P251; SMITH EI, 1990, HIGH LEVEL RADIOACTI, V1, P81; SMITH KD, IN PRESS B SEISMOL S; SNYDER DB, 1984, J GEOPHYS RES, V89, P193, DOI 10.1029/JB089iB12p10193; STEIN RS, 1985, J GEOPHYS RES-SOLID, V90, P1355, DOI 10.1029/JB090iB13p11355; STOCK JM, 1988, US GEOL SURV B, V1790, P87; THATCHER W, 1990, US GEOL SURV PROF PA, V1515, P189; WALLACE RE, 1984, J GEOPHYS RES, V89, P5763, DOI 10.1029/JB089iB07p05763; WALLACE RE, 1987, B SEISMOL SOC AM, V77, P868; WELLS SG, 1990, GEOLOGY, V18, P549, DOI 10.1130/0091-7613(1990)018<0549:GAOLQV>2.3.CO;2; WHITNEY JW, 1984, GEOL SOC AM ABSTR, V16, P787; ZREDA MG, 1993, GEOLOGY, V21, P57, DOI 10.1130/0091-7613(1993)021<0057:CCDOAY>2.3.CO;2	35	21	21	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 27	1998	279	5359					2096	2100		10.1126/science.279.5359.2096	http://dx.doi.org/10.1126/science.279.5359.2096			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZE274	9516108				2022-12-28	WOS:000072775600044
J	Besenbacher, F; Chorkendorff, I; Clausen, BS; Hammer, B; Molenbroek, AM; Norskov, JK; Stensgaard, I				Besenbacher, F; Chorkendorff, I; Clausen, BS; Hammer, B; Molenbroek, AM; Norskov, JK; Stensgaard, I			Design of a surface alloy catalyst for steam reforming	SCIENCE			English	Article							SINGLE-CRYSTAL; DISSOCIATIVE CHEMISORPTION; MOLECULAR-BEAM; METHANE; NICKEL; CH4; KINETICS; NI(111); CO; DYNAMICS	Detailed studies of elementary chemical processes on well-characterized single crystal surfaces have contributed substantially to the understanding of heterogeneous catalysis. insight into the structure of surface alloys combined with an understanding of the relation between the surface composition and reactivity is shown to lead directly to new ideas for catalyst design, The feasibility of such an approach is illustrated by the synthesis, characterization, and tests of a high-surface area gold-nickel catalyst for steam reforming.	Tech Univ Denmark, Dept Phys, Ctr Atom Scale Mat Phys, DK-2800 Lyngby, Denmark; Aarhus Univ, Inst Phys & Astron, Ctr Atom Scale Mat Phys, DK-8000 Aarhus C, Denmark; Haldor Topsoe Res Labs, DK-2800 Lyngby, Denmark; Univ Aalborg, Inst Phys, DK-9220 Aalborg Ost, Denmark	Technical University of Denmark; Aarhus University; Haldor Topsoe; Aalborg University	Norskov, JK (corresponding author), Tech Univ Denmark, Dept Phys, Ctr Atom Scale Mat Phys, DK-2800 Lyngby, Denmark.	norskov@fysik.dtu.dk	Norskov, Jens K/D-2539-2017; Chorkendorff, Ib/C-7282-2008; Besenbacher, Flemming/A-9623-2010; Hammer, Bjørk/C-3701-2013	Norskov, Jens K/0000-0002-4427-7728; Chorkendorff, Ib/0000-0003-2738-0325; Hammer, Bjørk/0000-0002-7849-6347				ANDERSEN NT, 1987, J CATAL, V104, P454, DOI 10.1016/0021-9517(87)90377-0; ATTARD GA, 1987, SURF SCI, V188, P589, DOI 10.1016/S0039-6028(87)80207-8; BEEBE TP, 1987, J CHEM PHYS, V87, P2305, DOI 10.1063/1.453162; BESENBACHER F, 1997, CHEM PHYS SOLID SURF, V8, pCH10; BRADLEY JM, 1995, J PHYS CHEM-US, V99, P17032, DOI 10.1021/j100046a032; BURGHGRAEF H, 1994, J CHEM PHYS, V101, P11012, DOI 10.1063/1.467852; Ertl G., 1991, CATALYTIC AMMONIA SY, P109, DOI DOI 10.1007/978-1-4757-9592-9; GOODMAN DW, 1980, J CATAL, V63, P226, DOI 10.1016/0021-9517(80)90075-5; HAMMER B, 1995, NATURE, V376, P238, DOI 10.1038/376238a0; Holmblad PM, 1996, CATAL LETT, V40, P131, DOI 10.1007/BF00815272; Holmblad PM, 1996, J CHEM PHYS, V104, P7289, DOI 10.1063/1.471395; HOLMBLAD PM, 1995, J CHEM PHYS, V102, P8255, DOI 10.1063/1.468955; King DA, 1997, STUD SURF SCI CATAL, V109, P79; Kratzer P, 1996, J CHEM PHYS, V105, P5595, DOI 10.1063/1.472399; LEE MB, 1987, J CHEM PHYS, V87, P2724, DOI 10.1063/1.453060; NIELSEN LP, 1993, PHYS REV LETT, V71, P754, DOI 10.1103/PhysRevLett.71.754; OH SH, 1986, J CATAL, V100, P360, DOI 10.1016/0021-9517(86)90103-X; PAPAPOLYMEROU GA, 1985, LANGMUIR, V1, P488, DOI 10.1021/la00064a015; PERDEW JP, 1992, PHYS REV B, V46, P6671, DOI 10.1103/PhysRevB.46.6671; PONEC V, 1983, ADV CATAL, V32, P149, DOI 10.1016/S0360-0564(08)60440-X; Rostrup-Nielsen J.R., 1984, CATAL SCI TECHNOL, V5, P1, DOI [10.1007/978-3-642-93247-2_1, DOI 10.1007/978-3-642-93247-2_1, DOI 10.1007/978-3-642-93247-2_]; ROSTRUPNIELSEN JR, 1984, J CATAL, V85, P31, DOI 10.1016/0021-9517(84)90107-6; Sinfelt J. H., 1983, BIMETALLIC CATALYSTS; STRONGIN DR, CATALYTIC AMMONIA SY, V1, P91; SWANG O, 1991, CHEM PHYS, V156, P379, DOI 10.1016/0301-0104(91)89006-V; YANG H, 1992, J CHEM PHYS, V96, P5529, DOI 10.1063/1.462690; Yoshihara J, 1996, J CATAL, V161, P776, DOI 10.1006/jcat.1996.0240; ZHDANOV VP, 1994, SURF SCI REP, V20, P111, DOI 10.1016/0167-5729(94)90009-4	28	862	876	11	612	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 20	1998	279	5358					1913	1915		10.1126/science.279.5358.1913	http://dx.doi.org/10.1126/science.279.5358.1913			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506937				2022-12-28	WOS:000072613300040
J	Forster, CA; Sampson, SD; Chiappe, LM; Krause, DW				Forster, CA; Sampson, SD; Chiappe, LM; Krause, DW			The theropod ancestry of birds: New evidence from the Late Cretaceous of Madagascar	SCIENCE			English	Article							EVOLUTION	A partial skeleton of a primitive bird, Rahona ostromi, gen. et sp. nov., has been discovered from the Late Cretaceous of Madagascar. This specimen, although exhibiting avian features such as a reversed hallux and ulnar papillae, retains characteristics that indicate a theropod ancestry, including a pubic foot and hyposphene-hypantra vertebral articulations. Rahona has a robust, hyperextendible second digit on the hind foot that terminates in a sicklelike claw, a unique characteristic of the theropod groups Troodontidae and Dromaeosauridae. A phylogenetic analysis places Rahona with Archaeopteryx, making Rahona one of the most primitive birds yet discovered.	SUNY Stony Brook, Dept Anat Sci, Stony Brook, NY 11794 USA; New York Coll Osteopath Med, Dept Anat, Old Westbury, NY 11568 USA; Amer Museum Nat Hist, Dept Ornithol, New York, NY 10024 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; New York Institute Technology; American Museum of Natural History (AMNH)	Forster, CA (corresponding author), SUNY Stony Brook, Dept Anat Sci, Stony Brook, NY 11794 USA.	cforster@mail.som.sunysb.edu		Chiappe, Luis/0000-0001-9661-0601				[Anonymous], 1966, VERTEBRATE PALEONTOL; BONDE N, 1996, CONTINENTAL JURASSIC, P193; Brodkorb P., 1971, P19; Burke AC, 1997, SCIENCE, V278, P666, DOI 10.1126/science.278.5338.666; CHIAPPE LM, 1995, NATURE, V378, P349, DOI 10.1038/378349a0; Chiappe Luis M., 1996, Memoirs of the Queensland Museum, V39, P533; Cope E. D., 1867, Proceedings of the Academy of Natural Sciences of Philadelphia, P235; Currie P.J., 1987, Journal of Vertebrate Paleontology, V7, P72; CURRIE PJ, 1993, CAN J EARTH SCI, V30, P2231, DOI 10.1139/e93-194; FEDUCCIA A, 1993, NATURWISSENSCHAFTEN, V80, P564, DOI 10.1007/BF01149272; Feduccia Alan, 1996, Museum of Northern Arizona Bulletin, V60, P185; Forster CA, 1996, NATURE, V382, P532, DOI 10.1038/382532a0; GAUTHIER JA, 1986, MEM CALIF ACAD SCI, V8, P1; Heilman G, 1927, ORIGIN BIRDS; HOLTZ TR, 1994, J PALEONTOL, V68, P1100, DOI 10.1017/S0022336000026706; Hou LH, 1996, SCIENCE, V274, P1164, DOI 10.1126/science.274.5290.1164; Huxley TH, 1868, GEOLOGY MAGAZINE, V5, P357, DOI [10.1017/S0016756800207784, DOI 10.1017/S0016756800207784]; JENKINS FA, 1993, AM J SCI, V293A, P253, DOI 10.2475/ajs.293.A.253; Martin L.D., 1991, P485; Novas FE, 1997, NATURE, V387, P390, DOI 10.1038/387390a0; Novas Fernando E., 1996, Memoirs of the Queensland Museum, V39, P675; Ostrom J. H., 1969, Bulletin of the Peabody Museum of Natural History, VNo. 30, P1; OSTROM JH, 1976, BIOL J LINN SOC, V8, P91, DOI 10.1111/j.1095-8312.1976.tb00244.x; OSTROM JH, 1984, BEGINNINGS BIRDS, P161; PAUL G, 1996, SOC AV PAL EV WASH D, P15; Poore SO, 1997, NATURE, V387, P799, DOI 10.1038/42930; Rietschel S., 1984, BEGINNINGS BIRDS, P251; Ruben JA, 1997, SCIENCE, V278, P1267, DOI 10.1126/science.278.5341.1267; SERENO PC, 1992, SCIENCE, V255, P845, DOI 10.1126/science.255.5046.845; STEPHAN B, 1974, URVOGEL ARCHAEOPTERY; Tarsitano S., 1991, P541; WILLISTON SW, 1879, KANSAS CITY REV SCI, V3, P457; Witmer L.M., 1991, P427	33	250	262	2	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 20	1998	279	5358					1915	1919		10.1126/science.279.5358.1915	http://dx.doi.org/10.1126/science.279.5358.1915			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506938				2022-12-28	WOS:000072613300041
J	Jenekhe, SA; Chen, XL				Jenekhe, SA; Chen, XL			Self-assembled aggregates of rod-coil block copolymers and their solubilization and encapsulation of fullerenes	SCIENCE			English	Article							POLYMERS; C-60; POLYQUINOLINES; MICELLES; POLYANTHRAZOLINES; NANOSTRUCTURES; MORPHOLOGY; BEHAVIOR; SOLVENTS; C-70	Amphiphilic poly(phenylquinoline)-block-polystyrene rod-coil diblock copolymers were observed to self-organize into robust, micrometer-scale, spherical, vesicular, cylindrical, and lamellar aggregates from solution. These diverse aggregate morphologies were seen at each composition, but their size scale decreased with a decreasing fraction of the rigid-rod block. Compared to coil-coil block copolymer micelles, the present aggregates are larger by about two orders of magnitude and have aggregation numbers of over 10(8). The spherical and cylindrical aggregates have large hollow cavities. Only spherical aggregates with aggregation numbers in excess of 10(9) were formed in the presence of fullerenes (C(60), C(70)) in solution, resulting in the solubilization and encapsulation of over 10(10) fullerene molecules per aggregate.	Univ Rochester, Dept Chem Engn, Rochester, NY 14627 USA; Univ Rochester, Dept Chem, Rochester, NY 14627 USA	University of Rochester; University of Rochester	Jenekhe, SA (corresponding author), Univ Rochester, Dept Chem Engn, Rochester, NY 14627 USA.	jenekhe@che.rochester.edu	Jenekhe, Samson/AAC-4212-2022					Agrawal AK, 1996, CHEM MATER, V8, P579, DOI 10.1021/cm9504753; AGRAWAL AK, 1993, MACROMOLECULES, V26, P895, DOI 10.1021/ma00057a003; ANDERSSON T, 1992, J CHEM SOC CHEM COMM, P604, DOI 10.1039/c39920000604; ATWOOD JL, 1994, NATURE, V368, P229, DOI 10.1038/368229a0; BATES FS, 1991, SCIENCE, V251, P898, DOI 10.1126/science.251.4996.898; Chen JT, 1996, SCIENCE, V273, P343, DOI 10.1126/science.273.5273.343; CHEN JT, 1995, MACROMOLECULES, V28, P1688, DOI 10.1021/ma00109a048; Chen XL, 1997, APPL PHYS LETT, V70, P487, DOI 10.1063/1.118189; Chen XL, 1996, MACROMOLECULES, V29, P6189, DOI 10.1021/ma9605715; Chen ZR, 1997, SCIENCE, V277, P1248, DOI 10.1126/science.277.5330.1248; Dresselhaus M.S., 1996, SCI FULLERENES CARBO; ERMER O, 1993, J AM CHEM SOC, V115, P10077, DOI 10.1021/ja00075a024; Fredrickson GH, 1996, ANNU REV MATER SCI, V26, P501, DOI 10.1146/annurev.ms.26.080196.002441; Gast AP, 1996, NATO ADV SCI INST SE, V327, P259; HALPERIN A, 1992, ADV POLYM SCI, V100, P31; HALPERIN A, 1990, MACROMOLECULES, V23, P2724, DOI 10.1021/ma00212a023; HALPERIN A, 1989, EUROPHYS LETT, V10, P549, DOI 10.1209/0295-5075/10/6/008; JENEKHE SA, 1994, SCIENCE, V265, P765, DOI 10.1126/science.265.5173.765; Jenekhe SA, 1997, CHEM MATER, V9, P409, DOI 10.1021/cm960474q; JENEKHE SA, 1997, PHOTONIC OPTOELECTRO; Lehn J.-M., 1995, SUPRAMOLECULAR CHEM; MILNER ST, 1991, SCIENCE, V251, P905, DOI 10.1126/science.251.4996.905; Muthukumar M, 1997, SCIENCE, V277, P1225, DOI 10.1126/science.277.5330.1225; Nagarajan R, 1996, NATO ADV SCI INST SE, V327, P121; NAGARAJAN R, 1986, LANGMUIR, V2, P210, DOI 10.1021/la00068a017; Noshay A., 1977, BLOCK COPOLYMERS OVE; OSAHENI JA, 1994, J PHYS CHEM-US, V98, P12727, DOI 10.1021/j100099a042; OSAHENI JA, 1995, J AM CHEM SOC, V117, P7389, DOI 10.1021/ja00133a012; PAI DM, 1993, REV MOD PHYS, V65, P163, DOI 10.1103/RevModPhys.65.163; Park M, 1997, SCIENCE, V276, P1401, DOI 10.1126/science.276.5317.1401; RADZILOWSKI LH, 1993, MACROMOLECULES, V26, P879, DOI 10.1021/ma00056a053; RADZILOWSKI LH, 1994, MACROMOLECULES, V27, P7747, DOI 10.1021/ma00104a033; RAPHAEL E, 1992, MAKROMOL CHEM-M SYMP, V62, P1, DOI 10.1002/masy.19920620104; RUOFF RS, 1993, J PHYS CHEM-US, V97, P3379, DOI 10.1021/j100115a049; SEMENOV AN, 1991, MOL CRYST LIQ CRYST, V209, P191, DOI 10.1080/00268949108036194; SEMENOV AN, 1986, ZH EKSP TEOR FIZ, V63, P70; SHETTY AS, UNPUB; SIVARAMAN N, 1992, J ORG CHEM, V57, P6077, DOI 10.1021/jo00048a056; SYBERT PD, 1981, MACROMOLECULES, V14, P493, DOI 10.1021/ma50004a006; Thies C., 1996, MICROENCAPSULATION M, P1; Tirrell M, 1996, NATO ADV SCI INST SE, V327, P281; TUZAR Z, 1993, SURF COLLOID SCI, V15, P1; VAGBERG LJM, 1991, MACROMOLECULES, V24, P1670, DOI 10.1021/ma00007a033; VERNINO D, 1994, POLYM MAT SCI ENG, V71, P496; WEBER SE, 1996, SOLVENTS SELF ORG PO; WHITESIDES GM, 1991, SCIENCE, V254, P1312, DOI 10.1126/science.1962191; WIDAWSKI G, 1994, NATURE, V369, P387, DOI 10.1038/369387a0; WILCOX DL, 1995, MRS P, V372; WILLIAMS DRM, 1992, MACROMOLECULES, V25, P3561, DOI 10.1021/ma00039a040; ZHANG LF, 1995, SCIENCE, V268, P1728, DOI 10.1126/science.268.5218.1728; Zhang LF, 1996, SCIENCE, V272, P1777, DOI 10.1126/science.272.5269.1777; Zhang LF, 1996, J AM CHEM SOC, V118, P3168, DOI 10.1021/ja953709s	52	808	853	7	224	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 20	1998	279	5358					1903	1907		10.1126/science.279.5358.1903	http://dx.doi.org/10.1126/science.279.5358.1903			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506934				2022-12-28	WOS:000072613300037
J	Thomas, MK; Lloyd-Jones, DM; Thadhani, RI; Shaw, AC; Deraska, DJ; Kitch, BT; VAmvakas, EC; Dick, IM; Prince, RL; Finkelstein, JS				Thomas, MK; Lloyd-Jones, DM; Thadhani, RI; Shaw, AC; Deraska, DJ; Kitch, BT; VAmvakas, EC; Dick, IM; Prince, RL; Finkelstein, JS			Hypovitaminosis D in medical inpatients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VITAMIN-D DEFICIENCY; POSTMENOPAUSAL WOMEN; D SUPPLEMENTATION; HIP-FRACTURES; ELDERLY PERSONS; BONE LOSS; POPULATION; EXPOSURE; SUNLIGHT; CALCIUM	Background: Vitamin D deficiency is a major risk factor for bone loss and fracture. Although hypovitaminosis D has been detected frequently in elderly and housebound people, the prevalence of vitamin D deficiency among patients hospitalized on a general medical service is unknown. Methods We assessed vitamin D intake, ultraviolet-light exposure, and risk factors for hypovitaminosis D and measured serum 25-hydroxyvitamin D, parathyroid hormone, and ionized calcium in 290 consecutive patients on a general medical ward. Results A total of 164 patients (57 percent)were considered vitamin D-deficient (serum concentration of 25-hydroxyvitamin D, less than or equal to 15 ng per milliliter), of whom 65 (22 percent) were considered severely vitamin D-deficient (serum concentration of 25-hydroxyvitamin D, <8 ng.per milliliter). Serum 25-hydroxyvitamin D concentrations were related inversely to parathyroid hormone concentrations. Lower vitamin D intake, less exposure to ultraviolet light, anticonvulsant-drug therapy, renal dialysis, nephrotic syndrome, hypertension, diabetes mellitus, winter season, higher serum concentrations of parathyroid hormone and alkaline phosphatase, and lower serum concentrations of ionized calcium and albumin were significant univariate predictors of hypovitaminosis D. Sixty-six percent of the patients who consumed less than the recommended daily amount of vitamin D and 37 percent of the patients with intakes above the recommended daily amount were vitamin D-deficient. inadequate vitamin D intake, winter season, and housebound status were independent predictors of hypovitaminosis D in a multivariate model. In a subgroup of 77 patients less than 65 years of age without known risk factors for hypovitaminosis D, the prevalence of vitamin D deficiency was 42 percent. Conclusions Hypovitaminosis D is common in general medical inpatients, including those with vitamin D intakes exceeding the recommended daily amount and those without apparent risk factors for vitamin D deficiency. (C) 1998, Massachusetts Medical Society.	Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Western Australia, Dept Med, Perth, WA 6009, Australia; Sir Charles Gairdner Hosp, Dept Endocrinol & Diabet, Nedlands, WA 6009, Australia	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Western Australia; University of Western Australia	Finkelstein, JS (corresponding author), Massachusetts Gen Hosp, Endocrine Unit, 55 Fruit St,Bulfinch 327, Boston, MA 02114 USA.		Finkelstein, Joel/M-6463-2019; Lloyd-Jones, Donald M/C-5899-2009; Shaw, Albert/AAD-2567-2021	Shaw, Albert/0000-0003-4970-7640; Lloyd-Jones, Donald/0000-0003-0847-6110	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043341, T32DK007028] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-1066] Funding Source: Medline; NIDDK NIH HHS [R29-DK43341, DK07028] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Afifi A.A., 1984, COMPUTER AIDED MULTI; BAKER MR, 1979, BRIT MED J, V1, P589, DOI 10.1136/bmj.1.6163.589; Boonen S, 1996, J ENDOCRINOL, V149, P13, DOI 10.1677/joe.0.1490013; BOUILLON RA, 1987, AM J CLIN NUTR, V45, P755, DOI 10.1093/ajcn/45.4.755; CHAPUY MC, 1994, BRIT MED J, V308, P1081, DOI 10.1136/bmj.308.6936.1081; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; COOKE NE, 1989, ENDOCR REV, V10, P294, DOI 10.1210/edrv-10-3-294; DAWSONHUGHES B, 1991, ANN INTERN MED, V115, P505, DOI 10.7326/0003-4819-115-7-505; DAWSONHUGHES B, 1995, AM J CLIN NUTR, V61, P1140, DOI 10.1093/ajcn/61.5.1140; DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003; [Food and Nutrition Board Institute of Medicine Standing Committee on the Scientific Evaluation of Dietary Reference Intakes], 1997, DIET REF INT CALC PH, DOI 10.17226/5776; GAVISON R, 1989, J IMMUNOL, V143, P3686; GLOTH FM, 1995, J AM GERIATR SOC, V43, P822, DOI 10.1111/j.1532-5415.1995.tb07059.x; GLOTH FM, 1995, JAMA-J AM MED ASSOC, V274, P1683, DOI 10.1001/jama.274.21.1683; GOLDRAY D, 1989, J AM GERIATR SOC, V37, P589, DOI 10.1111/j.1532-5415.1989.tb01247.x; HOLICK MF, 1992, NEW ENGL J MED, V326, P1178, DOI 10.1056/NEJM199204303261802; HOLICK MF, 1990, J NUTR, V120, P1464, DOI 10.1093/jn/120.suppl_11.1464; KRALL EA, 1989, NEW ENGL J MED, V321, P1777, DOI 10.1056/NEJM198912283212602; LACHENBR.PA, 1968, TECHNOMETRICS, V10, P1, DOI 10.2307/1266219; LIPS P, 1988, J CLIN ENDOCR METAB, V67, P644, DOI 10.1210/jcem-67-4-644; Lips P, 1996, ANN INTERN MED, V124, P400, DOI 10.7326/0003-4819-124-4-199602150-00003; McAlindon TE, 1996, ANN INTERN MED, V125, P353, DOI 10.7326/0003-4819-125-5-199609010-00001; MCKENNA MJ, 1992, AM J MED, V93, P69, DOI 10.1016/0002-9343(92)90682-2; MEUNIER PJ, 1993, AM J MED, V95, pS75, DOI 10.1016/0002-9343(93)90387-5; NUSSBAUM SR, 1987, CLIN CHEM, V33, P1364; OMDAHL JL, 1982, AM J CLIN NUTR, V36, P1225, DOI 10.1093/ajcn/36.6.1225; Parfitt A. M., 1998, METABOLIC BONE DIS C, P327, DOI [10.1016/B978-012068700-8/50012-8, DOI 10.1016/B978-012068700-8/50012-8]; PEACOCK M, 1985, VITAMIN D CHEM BIOCH, P569; PENNINGTON JAT, 1994, BOWES CHURCHS FOOD V, P411; SALAMONE LM, 1993, AM J CLIN NUTR, V58, P80; SHERMAN SS, 1990, J CLIN ENDOCR METAB, V71, P405, DOI 10.1210/jcem-71-2-405; VILLAREAL DT, 1991, J CLIN ENDOCR METAB, V72, P628, DOI 10.1210/jcem-72-3-628; WEBB AR, 1988, J CLIN ENDOCR METAB, V67, P373, DOI 10.1210/jcem-67-2-373; WEBB AR, 1990, AM J CLIN NUTR, V51, P1075, DOI 10.1093/ajcn/51.6.1075; WILSON SG, 1990, CLIN ENDOCRINOL, V32, P613, DOI 10.1111/j.1365-2265.1990.tb00905.x	35	1086	1132	0	29	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 19	1998	338	12					777	783		10.1056/NEJM199803193381201	http://dx.doi.org/10.1056/NEJM199803193381201			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC163	9504937				2022-12-28	WOS:000072546800001
J	Vashi, P				Vashi, P			Briskly bleeding gastric ulcer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Midwestern Reg Med Ctr, Zion, IL 60099 USA		Vashi, P (corresponding author), Midwestern Reg Med Ctr, Zion, IL 60099 USA.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 19	1998	338	12					811	811		10.1056/NEJM199803193381206	http://dx.doi.org/10.1056/NEJM199803193381206			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC163	9504942				2022-12-28	WOS:000072546800006
J	Cook, D; De Jonghe, B; Brochard, L; Brun-Buisson, C				Cook, D; De Jonghe, B; Brochard, L; Brun-Buisson, C			Influence of airway management on ventilator-associated pneumonia - Evidence from randomized trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CRITICALLY ILL PATIENTS; INTENSIVE-CARE-UNIT; NOSOCOMIAL MAXILLARY SINUSITIS; RESPIRATORY-TRACT INFECTIONS; STRESS-ULCER PROPHYLAXIS; IMMUNE-ENHANCING DIET; MECHANICAL VENTILATION; MOISTURE EXCHANGERS; DIGESTIVE-TRACT; CIRCUIT CHANGES	Objective.-Ventilator-associated pneumonia (VAP) is a serious complication of critical illness, conferring increased morbidity and mortality. Many interventions have been studied to reduce the risk of VAP. We systematically reviewed the influence of airway management on VAP in critically ill patients. Data Sources.-Studies were identified through searching MEDLINE and EMBASE from 1980 through July 1997 and by searching SCISEARCH, the Cochrane Library, bibliographies of primary and review articles, personal files, and contact with authors of the randomized trials. Study Selection.-We selected randomized trials evaluating ventilator circuit and secretion management strategies on the rate of VAP. Data Extraction.-Two investigators independently abstracted key data on design features, the population, intervention, and outcome of the studies. Data Synthesis.-The frequency of ventilator circuit changes and the type of endotracheal suction system do not appear to influence VAP rates (3 trials, none with significant difference; range of relative risks [RRs], 0.84-0.91). However, lower VAP rates may be associated with avoidance of heated humidifiers and use of heat and moisture exchangers (5 trials, only 1 showing a significant difference; range of RRs, 0.34-0.86), use of oral vs nasal intubation (1 trial; RR, 0.52; 95% confidence interval, 0.24-1.13), subglottic secretion drainage vs standard endotracheal tubes (2 trials, 1 showing a significant difference; range of RRs, 0.46-0.57), and kinetic vs conventional beds (5 trials, only 1 showing a significant difference; range of RRs, 0.35-0.78). Conclusions.-Some ventilator circuit and secretion management strategies may influence VAP rates in critically ill patients. Whether these strategies are adopted in practice depends on several factors such as the magnitude and precision of estimates of benefit and harm, as well as access, availability, and costs.	St Josephs Hosp, Dept Med, Hamilton, ON L8N 4A6, Canada; McMaster Univ, Hamilton, ON, Canada; Hop Poissy, Serv Reanimat Med, Poissy, France; Univ Paris 12, Hop Henri Mondor, Serv Reanimat Med, F-94010 Creteil, France	McGill University; McMaster University; McMaster University; Hospital Chi of Poissy Saint Germain; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP	Cook, D (corresponding author), St Josephs Hosp, Dept Med, 50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.	debcook@fhs.csu.mcmaster.ca						AERDTS SJA, 1993, BRIT MED J, V307, P525; *AM THOR SOC, 1995, AM J RESP CRIT CARE, V153, P1711; Bonten MJM, 1996, AM J RESP CRIT CARE, V154, P394, DOI 10.1164/ajrccm.154.2.8756812; BORZOTTA AP, 1994, J TRAUMA, V37, P459, DOI 10.1097/00005373-199409000-00022; CHASTRE J, 1994, AM J RESP CRIT CARE, V150, P570, DOI 10.1164/ajrccm.150.2.8049850; CHIARANDA M, 1993, INTENS CARE MED, V19, P462, DOI 10.1007/BF01711088; CONTI G, 1990, INTENS CARE MED, V16, P441, DOI 10.1007/BF01711222; Cook, 1997, Crit Care, V1, P3, DOI 10.1186/cc1; Cook DJ, 1996, JAMA-J AM MED ASSOC, V275, P308, DOI 10.1001/jama.275.4.308; Cook DJ, 1997, ANN INTERN MED, V126, P376, DOI 10.7326/0003-4819-126-5-199703010-00006; CRAVEN DE, 1982, NEW ENGL J MED, V306, P1505, DOI 10.1056/NEJM198206243062501; DEBOISBLANC BP, 1993, CHEST, V103, P1543, DOI 10.1378/chest.103.5.1543; DEPPE SA, 1990, CRIT CARE MED, V18, P1389, DOI 10.1097/00003246-199012000-00016; DOTSON RG, 1993, CHEST, V103, P541, DOI 10.1378/chest.103.2.541; DREYFUSS D, 1995, AM J RESP CRIT CARE, V151, P986; DREYFUSS D, 1991, AM REV RESPIR DIS, V143, P738, DOI 10.1164/ajrccm/143.4_Pt_1.738; EYER SD, 1993, J TRAUMA, V34, P639, DOI 10.1097/00005373-199305000-00005; FAGON JY, 1996, JAMA-J AM MED ASSOC, V275, P868; FINK MP, 1990, CHEST, V97, P132, DOI 10.1378/chest.97.1.132; GENTILELLO L, 1988, CRIT CARE MED, V16, P783, DOI 10.1097/00003246-198808000-00010; GIROU E, 1995, AM J RESP CRIT CARE, V151, pA720; GOTTSCHLICH MM, 1990, JPEN-PARENTER ENTER, V14, P225, DOI 10.1177/0148607190014003225; HESS D, 1995, ANESTHESIOLOGY, V82, P903, DOI 10.1097/00000542-199504000-00013; HEYLAND DK, 1994, CHEST, V105, P1221, DOI 10.1378/chest.105.4.1221; Heyland DK, 1996, CRIT CARE MED, V24, P1591, DOI 10.1097/00003246-199609000-00025; HOLZAPFEL L, 1993, CRIT CARE MED, V21, P1132, DOI 10.1097/00003246-199308000-00010; HURLEY JC, 1995, ANTIMICROB AGENTS CH, V39, P941, DOI 10.1128/AAC.39.4.941; Hurni JM, 1997, CHEST, V111, P686, DOI 10.1378/chest.111.3.686; IBANEZ J, 1992, JPEN-PARENTER ENTER, V16, P419, DOI 10.1177/0148607192016005419; JOHNSON KL, 1994, CRIT CARE MED, V22, P658, DOI 10.1097/00003246-199404000-00023; Kirton OC, 1997, CHEST, V112, P1055, DOI 10.1378/chest.112.4.1055; Kollef MH, 1997, AM J RESP CRIT CARE, V156, P1040, DOI 10.1164/ajrccm.156.4.9701046; KOLLEF MH, 1994, CHEST, V105, P1101, DOI 10.1378/chest.105.4.1101; KOLLEF MH, 1993, JAMA-J AM MED ASSOC, V270, P1965, DOI 10.1001/jama.270.16.1965; KOLLEF MH, 1995, ANN INTERN MED, V123, P168, DOI 10.7326/0003-4819-123-3-199508010-00002; KOLLEF MH, 1997, CHEST, V112, pS86; KUDSK KA, 1992, ANN SURG, V215, P503, DOI 10.1097/00000658-199205000-00013; Kudsk KA, 1996, ANN SURG, V224, P531, DOI 10.1097/00000658-199610000-00011; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; LeBourdelles G, 1996, CHEST, V110, P1294, DOI 10.1378/chest.110.5.1294; LODE H, 1992, Intensive Care Medicine, V18, pS24, DOI 10.1007/BF01752973; Long MN, 1996, INFECT CONT HOSP EP, V17, P14; MAHUL P, 1992, INTENS CARE MED, V18, P20, DOI 10.1007/BF01706421; MARTIN C, 1990, CHEST, V97, P144, DOI 10.1378/chest.97.1.144; MISSET B, 1991, CHEST, V100, P160, DOI 10.1378/chest.100.1.160; MONTECALVO MA, 1992, CRIT CARE MED, V20, P1377, DOI 10.1097/00003246-199210000-00004; MOORE FA, 1989, J TRAUMA, V29, P916, DOI 10.1097/00005373-198907000-00003; MOORE FA, 1994, J TRAUMA, V37, P607, DOI 10.1097/00005373-199410000-00014; NIEDERMAN MS, 1994, AM J RESP CRIT CARE, V150, P565, DOI 10.1164/ajrccm.150.2.8049849; OROZCOLEVI M, 1995, AM J RESP CRIT CARE, V152, P1387, DOI 10.1164/ajrccm.152.4.7551400; PLOYSONGSANG Y, 1988, AM REV RESPIR DIS, V138, P675, DOI 10.1164/ajrccm/138.3.675; RENZ C, 1997, AM J RESP CRIT CARE, V155, pA19; ROUBY JJ, 1994, AM J RESP CRIT CARE, V150, P776, DOI 10.1164/ajrccm.150.3.8087352; ROUBY JJ, 1994, INTENS CARE MED, V20, P187, DOI 10.1007/BF01704698; ROUSTAN JP, 1992, INTENS CARE MED, V18, P97, DOI 10.1007/BF01705040; SUMMER WR, 1989, J CRIT CARE, V4, P45, DOI 10.1016/0883-9441(89)90091-9; TABLAN OC, 1994, AM J INFECT CONTROL, V22, P247; TIMSIT JF, 1995, CHEST, V108, P1036, DOI 10.1378/chest.108.4.1036; TORRES A, 1992, ANN INTERN MED, V116, P540, DOI 10.7326/0003-4819-116-7-540; VALLES J, 1995, ANN INTERN MED, V122, P179, DOI 10.7326/0003-4819-122-3-199502010-00004; VANDENBROUCKEGRAULS CMJE, 1991, LANCET, V338, P859, DOI 10.1016/0140-6736(91)91510-2; Villafane MC, 1996, ANESTHESIOLOGY, V85, P1341, DOI 10.1097/00000542-199612000-00015; VINCENT JL, 1995, JAMA-J AM MED ASSOC, V274, P639, DOI 10.1001/jama.274.8.639; Whiteman K, 1995, Am J Crit Care, V4, P133; YOUNG B, 1987, J NEUROSURG, V67, P668, DOI 10.3171/jns.1987.67.5.0668	65	132	141	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 11	1998	279	10					781	787		10.1001/jama.279.10.781	http://dx.doi.org/10.1001/jama.279.10.781			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA474	9508156				2022-12-28	WOS:000072366900037
J	Rogers, J; Wood, J; McCandlish, R; Ayers, S; Truesdale, A; Elbourne, D				Rogers, J; Wood, J; McCandlish, R; Ayers, S; Truesdale, A; Elbourne, D			Active versus expectant management of third stage of labour: the Hinchingbrooke randomised controlled trial	LANCET			English	Article							POSTPARTUM HEMORRHAGE; 3RD STAGE	Background This study tested the hypotheses that active management of the third stage of labour lowers the rates of primary postpartum haemorrhage (PPH) and longer-term consequences compared with expectant management, in a setting where both managements are commonly practised, and that this effect is not mediated by maternal posture. Background 1512 women judged to be at low risk of PPH (blood loss >500 mL) were randomly assigned active management of the third stage (prophylactic oxytocic within 2 min of baby's birth, immediate cutting and clamping of the cord, delivery of placenta by controlled cord traction or maternal effort) or expectant management (no prophylactic oxytocic, no cord clamping until pulsation ceased, delivery of placenta by maternal effort). Women were also randomly assigned upright or supine posture. Analyses were by intention to treat. Findings The rate of PPH was significantly lower with active than with expectant management (51 [6.8%] of 748 vs 126 [16.5%] of 764; relative risk 2.42 [95% CI 1.78-3.30], p<0.0001). Posture had no effect on this risk (upright 92 [12%] of 755 vs supine 85 [11%] of 757). Objective measures of blood loss confirmed the results. There was more vomiting in the active group but no other important differences were detected. Interpretation Active management of the third stage reduces the risk of PPH, whatever the woman's posture, even when midwives are familiar with both approaches. We recommend that clinical guidelines in hospital settings advocate active management (with oxytocin alone). However, decisions about individual care should take into account the weights placed by pregnant women and their caregivers on blood loss compared with an intervention-free third stage.	Univ London London Sch Hyg & Trop Med, Med Stat Unit, London WC1E 7HT, England; Radcliffe Infirm, Natl Perinatal Epidemiol Unit, Oxford OX2 6HE, England; Hinchingbrooke Healthcare NHS Trust, Huntingdon, England	University of London; London School of Hygiene & Tropical Medicine; Radcliffe Infirmary; University of Oxford	Elbourne, D (corresponding author), Univ London London Sch Hyg & Trop Med, Med Stat Unit, Keppel St, London WC1E 7HT, England.							Audit Commission, 1997, 1 CLASS DEL IMPR MAT; Begley C M, 1990, Midwifery, V6, P3, DOI 10.1016/S0266-6138(05)80091-9; BULLOUGH CHW, 1989, LANCET, V2, P522; COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782; Elbourne D, 1998, BRIT MED J, V316, P145; Garcia J, 1989, Midwifery, V5, P155, DOI 10.1016/S0266-6138(89)80002-6; Gyte G, 1992, MIDIRS MIDWIFERY DIG, V2, P88; HARDING JE, 1989, BIRTH-ISS PERINAT C, V16, P1, DOI 10.1111/j.1523-536X.1989.tb00846.x; INCH S, 1989, BIRTHRIGHTS; Levy V, 1985, Nurs Times, V81, P47; MCDONALD S, 1997, COCHRANE LIB CDROM O; PISCANE A, 1996, BMJ-BRIT MED J, V312, P136; PRENDIVILLE W, 1997, COCHRANE LIB CDROM O; PRENDIVILLE WJ, 1988, BMJ-BRIT MED J, V297, P1295, DOI 10.1136/bmj.297.6659.1295; SPENCER P M, 1962, Br Med J, V1, P1728; SPIBY H, 1991, OXFORDS DATABASE PER; THILAGANATHAN B, 1993, EUR J OBSTET GYN R B, V48, P19, DOI 10.1016/0028-2243(93)90048-H	17	143	148	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 7	1998	351	9104					693	699		10.1016/S0140-6736(97)09409-9	http://dx.doi.org/10.1016/S0140-6736(97)09409-9			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZB359	9504513				2022-12-28	WOS:000072463800006
J	Zhou, P; Sun, LJ; Dotsch, V; Wagner, G; Verdine, GL				Zhou, P; Sun, LJ; Dotsch, V; Wagner, G; Verdine, GL			Solution structure of the core NFATC1/DNA complex	CELL			English	Article							ACTIVATED T-CELLS; TRANSCRIPTION FACTOR NFAT1; CRYSTAL-STRUCTURE; NUCLEAR FACTOR; DNA-BINDING; TATA-ELEMENT; NF-ATP; PROTEINS; DOMAIN; RECOGNITION	The nuclear factor of the activated T cell (NFAT) family of transcription factors regulates cytokine gene expression by binding to the promoter/enhancer regions of antigen-responsive genes, usually in cooperation with heterologous DNA-binding partners. Here we report the solution structure of the binary complex formed between the core DNA-binding domain of human NFATC1 and the ARRE2 DNA site from the interleukin-2 promoter. The structure reveals that DNA binding induces the folding of key structural elements that are required for both sequence-specific recognition and the establishment of cooperative protein-protein contacts. The orientation of the NFAT DNA-binding domain observed in the binary NFATC1-DBD*/DNA complex is distinct from that seen in the ternary NFATC2/AP-1/DNA complex, suggesting that the domain reorients upon formation of a cooperative transcriptional complex.	Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard University; Harvard Medical School	Verdine, GL (corresponding author), Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA.		Doetsch, Volker/D-5697-2011; Zhou, Pei/O-6704-2019	Zhou, Pei/0000-0002-7823-3416; Dotsch, Volker/0000-0001-5720-212X	NIGMS NIH HHS [P01GM47467, P01 GM047467] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM047467] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altmann S, 1995, NUCLEIC ACIDS RES, V23, P4827, DOI 10.1093/nar/23.23.4827; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; BRUNGER AT, 1992, XPLOR 3 1 MANUAL; CHEN L, 1995, CURR BIOL, V5, P882, DOI 10.1016/S0960-9822(95)00178-3; CHEN L, 1998, IN PRESS NATURE; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FISHER DE, 1993, CELL, V72, P467, DOI 10.1016/0092-8674(93)90122-7; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1995, J BIOL CHEM, V270, P4138, DOI 10.1074/jbc.270.8.4138; JAIN JN, 1993, J IMMUNOL, V151, P837; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LIU J, 1991, CELL, V66, P1; Luo C, 1996, P NATL ACAD SCI USA, V93, P8907, DOI 10.1073/pnas.93.17.8907; MULLER CW, 1995, NATURE, V373, P301; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; Peterson BR, 1996, P NATL ACAD SCI USA, V93, P13671, DOI 10.1073/pnas.93.24.13671; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Saenger W., 1984, PRINCIPLES NUCL ACID; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SHORTLE D, 1994, J MAGN RESON SER B, V105, P88, DOI 10.1006/jmrb.1994.1106; Shuker SB, 1996, SCIENCE, V274, P1531, DOI 10.1126/science.274.5292.1531; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Sun LJ, 1997, P NATL ACAD SCI USA, V94, P4919, DOI 10.1073/pnas.94.10.4919; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; Wolfe SA, 1997, NATURE, V385, P172, DOI 10.1038/385172a0; WOLFE SA, 1996, THESIS HARVARD U CAM; WOODROW MA, 1993, J IMMUNOL, V150, P3853; Xanthoudakis S, 1996, SCIENCE, V272, P892, DOI 10.1126/science.272.5263.892	43	93	100	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 6	1998	92	5					687	696		10.1016/S0092-8674(00)81136-8	http://dx.doi.org/10.1016/S0092-8674(00)81136-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZA827	9506523	Bronze			2022-12-28	WOS:000072406000014
J	Davies, JS; Scanlon, MF				Davies, JS; Scanlon, MF			Lesson of the week - Hypopituitarism after coronary artery bypass grafting	BRITISH MEDICAL JOURNAL			English	Article							PITUITARY APOPLEXY; CARDIAC-SURGERY		Univ Wales, Coll Med, Dept Med, Cardiff CF4 4XN, S Glam, Wales	Cardiff University	Davies, JS (corresponding author), Univ Wales, Coll Med, Dept Med, Cardiff CF4 4XN, S Glam, Wales.							ABSALOM M, 1993, ANESTH ANALG, V76, P648; COOPER DM, 1986, ANN THORAC SURG, V41, P547, DOI 10.1016/S0003-4975(10)63039-1; HARRISON MJG, 1995, ANN THORAC SURG, V59, P1356, DOI 10.1016/0003-4975(95)00056-Q; KHARDORI R, 1987, POSTGRAD MED J, V63, P489, DOI 10.1136/pgmj.63.740.489; KOVACS K, 1975, Z KARDIOL, V64, P52; PECK V, 1980, NEW YORK STATE J MED, V80, P641; ROLIH CA, 1993, ENDOCRIN METAB CLIN, V22, P291, DOI 10.1016/S0889-8529(18)30167-1; SAVAGE EB, 1994, EUR J CARDIO-THORAC, V8, P333, DOI 10.1016/S1010-7940(05)80095-8; SHAPIRO LM, 1990, J SURG ONCOL, V44, P66, DOI 10.1002/jso.2930440115; Sheehan HL, 1939, Q J MED, V8, P277; SLAVIN ML, 1984, AM J OPHTHALMOL, V98, P291, DOI 10.1016/0002-9394(84)90318-0	11	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 28	1998	316	7132					682	684		10.1136/bmj.316.7132.682	http://dx.doi.org/10.1136/bmj.316.7132.682			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA282	9522796	Green Published			2022-12-28	WOS:000072347900036
J	Clandinin, TR; DeModena, JA; Sternberg, PW				Clandinin, TR; DeModena, JA; Sternberg, PW			Inositol trisphosphate mediates a RAS-independent response to LET-23 receptor tyrosine kinase activation in C-elegans	CELL			English	Article							EPIDERMAL GROWTH-FACTOR; LIGAND-BINDING SITE; CAENORHABDITIS-ELEGANS; PHOSPHOLIPASE-C; 1,4,5-TRISPHOSPHATE 3-KINASE; VULVAR INDUCTION; SMOOTH-MUSCLE; EGF RECEPTOR; NEURONAL DIFFERENTIATION; POINT MUTATION	Activity of LET-23, the C. elegans homolog of the epidermal growth factor receptor, is required in multiple tissues. RAS activation is necessary and sufficient for certain LET-23 functions. We show that an inositol trisphosphate receptor can act as a PAS-independent, tissue-specific positive effector of LET-23. Moreover, an inositol trisphosphate kinase negatively regulates this transduction pathway. Signals transduced by LET-23 control ovulation through changes in spermathecal dilation, possibly dependent upon calcium release regulated by both IP3 and IP4. Our results demonstrate that one mechanism by which receptor tyrosine kinases can evoke tissue-specific responses is through activation of distinct signal transduction cascades in different tissues.	CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology	Sternberg, PW (corresponding author), CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA.							AROIAN RV, 1991, GENETICS, V128, P251; AROIAN RV, 1994, EMBO J, V13, P360, DOI 10.1002/j.1460-2075.1994.tb06269.x; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; Beitel GJ, 1995, GENE DEV, V9, P3149, DOI 10.1101/gad.9.24.3149; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BRENNER S, 1974, GENETICS, V77, P71; CHAMBERLIN HM, 1994, DEVELOPMENT, V120, P2713; Chen P, 1996, MOL BIOL CELL, V7, P871, DOI 10.1091/mbc.7.6.871; CHOI KY, 1990, SCIENCE, V248, P64, DOI 10.1126/science.2157285; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CLARK SG, 1992, COLD SPRING HARB SYM, V57, P363, DOI 10.1101/SQB.1992.057.01.041; COMMUNI D, 1993, BIOCHEM J, V291, P811, DOI 10.1042/bj2910811; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; Dufour JF, 1997, J BIOL CHEM, V272, P2675, DOI 10.1074/jbc.272.5.2675; ERNEUX C, 1993, EUR J BIOCHEM, V214, P497, DOI 10.1111/j.1432-1033.1993.tb17947.x; FERGUSON EL, 1985, GENETICS, V110, P17; Fleming JT, 1996, PARASITOLOGY, V113, pS175, DOI 10.1017/S0031182000077969; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Hajnal A, 1997, GENE DEV, V11, P2715, DOI 10.1101/gad.11.20.2715; HAN M, 1990, GENETICS, V126, P899; HEPLER JR, 1987, J BIOL CHEM, V262, P2951; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; HOLLENBERG MD, 1994, TRENDS PHARMACOL SCI, V15, P108, DOI 10.1016/0165-6147(94)90046-9; IRVINE RF, 1991, BIOESSAYS, V13, P419, DOI 10.1002/bies.950130810; JONGEWARD GD, 1995, GENETICS, V139, P1553; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; Kornfeld K, 1997, TRENDS GENET, V13, P55, DOI 10.1016/S0168-9525(97)01005-6; Lesa GM, 1997, MOL BIOL CELL, V8, P779, DOI 10.1091/mbc.8.5.779; LoomisHusselbee JW, 1996, BIOCHEM J, V314, P811, DOI 10.1042/bj3140811; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McCarter J, 1997, DEV BIOL, V181, P121, DOI 10.1006/dbio.1996.8429; Mello C, 1995, CAENORHABDITIS ELEGA, P451; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MOOLENAAR WH, 1986, J BIOL CHEM, V261, P279; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; Obermeier A, 1996, EMBO J, V15, P73, DOI 10.1002/j.1460-2075.1996.tb00335.x; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; Sambrook J., 2002, MOL CLONING LAB MANU; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; STEHNOBITTEL L, 1995, NEURON, V14, P163, DOI 10.1016/0896-6273(95)90250-3; TAKAZAWA K, 1990, BIOCHEM J, V272, P107, DOI 10.1042/bj2720107; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; Yoshikawa F, 1996, J BIOL CHEM, V271, P18277, DOI 10.1074/jbc.271.30.18277	57	160	172	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 20	1998	92	4					523	533		10.1016/S0092-8674(00)80945-9	http://dx.doi.org/10.1016/S0092-8674(00)80945-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YZ409	9491893	Bronze			2022-12-28	WOS:000072251500012
J	Luo, RX; Postigo, AA; Dean, DC				Luo, RX; Postigo, AA; Dean, DC			Rb interacts with histone deacetylase to repress transcription	CELL			English	Article							CELL-CYCLE ARREST; RETINOBLASTOMA PROTEIN; BINDING PROTEIN; E2F; NUCLEOSOME; COMPLEX; DOMAIN; FAMILY; YEAST; REGULATOR	Previously, we found that Rb can actively repress transcription of cell cycle genes by binding and inactivating transcription factors at the promoter. Here, we demonstrate that Rb can also repress transcription of endogenous cell cycle genes containing E2F sites through recruitment of histone deacetylase, which deacetylates histones on the promoter, thereby promoting formation of nucleosomes that inhibit transcription. These two mechanisms of repression by Rb are selective-some promoters and transcription factors are blocked by this recruitment of histone deacetylase, whereas others are resistant to histone deacetylase activity and are repressed directly by inhibition of transcription factors.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Dean, DC (corresponding author), Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.			Postigo, Antonio/0000-0003-4605-2634				Adams PD, 1996, CURR TOP MICROBIOL, V208, P79; Alevizopoulos A, 1995, GENE DEV, V9, P3051, DOI 10.1101/gad.9.24.3051; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, GENE DEV, V7, P211; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; BRAUNSTEIN M, 1993, GENE DEV, V7, P4592; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; Candau R, 1996, J STEROID BIOCHEM, V57, P19, DOI 10.1016/0960-0760(96)00262-2; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chow KNB, 1996, MOL CELL BIOL, V16, P4862; Chow KNB, 1996, MOL CELL BIOL, V16, P7173; DEDON PC, 1991, ANAL BIOCHEM, V197, P83, DOI 10.1016/0003-2697(91)90359-2; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; Hartzog GA, 1997, CURR OPIN GENET DEV, V7, P192, DOI 10.1016/S0959-437X(97)80128-1; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; JEONG SW, 1994, NUCLEIC ACIDS RES, V22, P370, DOI 10.1093/nar/22.3.370; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KODOSH D, 1997, CELL, V89, P365; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; NEVINS JR, 1992, SCIENCE, V258, P424; NGY L, 1997, CELL, V89, P373; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; POSTIGO AP, 1997, EMBO J, V16, P3835; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SHAO ZH, 1995, P NATL ACAD SCI USA, V92, P3115, DOI 10.1073/pnas.92.8.3115; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; Starostik P, 1996, MOL CELL BIOL, V16, P3606; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439; Tyler JK, 1996, MOL CELL BIOL, V16, P6149; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	58	809	823	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 20	1998	92	4					463	473		10.1016/S0092-8674(00)80940-X	http://dx.doi.org/10.1016/S0092-8674(00)80940-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YZ409	9491888	Bronze			2022-12-28	WOS:000072251500007
J	Hanck, D				Hanck, D			Update: Muscle contraction - Heartthrobs	SCIENCE			English	Article									Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Pharmacol & Physiol Sci, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Hanck, D (corresponding author), Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA.							Santana LF, 1998, SCIENCE, V279, P1027, DOI 10.1126/science.279.5353.1027	1	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 13	1998	279	5353					1004	1004		10.1126/science.279.5353.1004	http://dx.doi.org/10.1126/science.279.5353.1004			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX100	9490476				2022-12-28	WOS:000072006400038
J	Mann, C; Guly, H				Mann, C; Guly, H			Is the emergency (999) service being misused? Retrospective analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Derriford Hosp, Dept Accid & Emergency Med, Plymouth PL6 8DH, Devon, England	Derriford Hospital	Mann, C (corresponding author), Derriford Hosp, Dept Accid & Emergency Med, Plymouth PL6 8DH, Devon, England.	iain.grant@phnt.swest.nhs.uk						ANTHONY P, 1995, CASEMIX MEASURES ACC; BROWN E, 1993, ANN EMERG MED, V22, P646, DOI 10.1016/S0196-0644(05)81841-4; EDWARDS E, 1994, HLTH SERV J, V8, P30; LEY R, 1995, INSPECTION EMERGENCY; *NAT ASS HLTH AUTH, 1996, EM ADM MAN CHALL	5	13	13	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 7	1998	316	7129					437	438		10.1136/bmj.316.7129.437	http://dx.doi.org/10.1136/bmj.316.7129.437			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW874	9492668	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000071982700027
J	Sauter, C; Jacky, E				Sauter, C; Jacky, E			Chloroma in acute myelogenous leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Zurich Hosp, CH-8091 Zurich, Switzerland	University of Zurich; University Zurich Hospital	Sauter, C (corresponding author), Univ Zurich Hosp, CH-8091 Zurich, Switzerland.								0	11	11	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 2	1998	338	14					969	969		10.1056/NEJM199804023381406	http://dx.doi.org/10.1056/NEJM199804023381406			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE776	9521985				2022-12-28	WOS:000072829800006
J	Monzon, J; Liu, L; Brill, H; Goldstein, AM; Tucker, MA; From, L; McLaughlin, J; Hogg, D; Lassam, NJ				Monzon, J; Liu, L; Brill, H; Goldstein, AM; Tucker, MA; From, L; McLaughlin, J; Hogg, D; Lassam, NJ			CDKN2A mutations in multiple primary melanomas	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FAMILIAL MELANOMA; MALIGNANT-MELANOMA; GERMLINE MUTATIONS; CANCER; KINDREDS; RISK; RETINOBLASTOMA; GENE	Background Germ-line mutations in the CDKN2A tumor-suppressor gene (also known as p16, p16(INK4a), and MTS1) have been linked to the development of melanoma in some families with inherited melanoma. Whether mutations in CDKN2A confer a predisposition to sporadic (nonfamilial) melanoma is not known. In some patients with sporadic melanoma, one or more additional primary lesions develop, suggesting that some of these patients have an un derlying genetic susceptibility to the cancer. We hypothesized that this predisposition might be due to germ-line CDKN2A mutations. Methods We used the polymerase chain reaction, single-strand conformation polymorphism analysis, and direct DNA sequencing to identify germ-line mutations in the CDKN2A gene in patients with multiple primary melanomas who did not have family histories of the disease. A quantitative yeast two-hybrid assay was used to evaluate the functional importance of the CDKN2A variants. Results Of 33 patients with multiple primary melanomas, 5 (15 percent; 95 percent confidence interval, 4 percent to 27 percent) had germ-line CDKN2A mutations. These included a 24-bp insertion at the 5' end of the coding sequence, three missense mutations (Arg24Pro, Met53lle, and Ser56lle), and a 2-bp deletion at position 307 to 308 (resulting in a truncated CDKN2A protein). In three families, CDKN2A mutations identical to those in the probands were found in other family members. In two families with mutations, we uncovered previously unknown evidence of family histories of melanoma. Conclusions Some patients with multiple primary melanomas but without family histories of the disease have germ-line mutations of the CDKN2A gene. The presence of multiple primary melanomas may signal a genetic susceptibility to melanoma not only in the index patient but also in family members, who may benefit from melanoma-surveillance programs. (C) 1998, Massachusetts Medical Society.	Toronto Sunnybrook Reg Canc Ctr, Div Med Oncol, Toronto, ON M4N 3M5, Canada; Univ Toronto, Inst Med Sci, Toronto, ON, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; Univ Toronto, Dept Dermatol, Toronto, ON, Canada; Univ Toronto, Dept Prevent Med & Biostat, Toronto, ON, Canada; NCI, Genet Epidemiol Branch, Bethesda, MD 20892 USA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; University of Toronto; University of Toronto; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lassam, NJ (corresponding author), Toronto Sunnybrook Reg Canc Ctr, Div Med Oncol, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.		Tucker, Margaret A/B-4297-2015; McLaughlin, John R/E-4577-2013					BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; BATAILLE V, 1995, BRIT J DERMATOL, V132, P134, DOI 10.1111/j.1365-2133.1995.tb08639.x; BIRCH JM, 1987, BIOL CARCINOGENESIS, P165; Brobeil A, 1997, ANN SURG ONCOL, V4, P19, DOI 10.1007/BF02316806; Carey TE, 1996, ANN MED, V28, P183, DOI 10.3109/07853899609033118; DRAPER GJ, 1986, BRIT J CANCER, V53, P661, DOI 10.1038/bjc.1986.110; ENG C, 1993, JNCI-J NATL CANCER I, V85, P1121, DOI 10.1093/jnci/85.14.1121; FRANK W, 1993, J DERMATOL SURG ONC, V19, P427, DOI 10.1111/j.1524-4725.1993.tb00369.x; GILES G, 1995, MELANOMA RES, V5, P433, DOI 10.1097/00008390-199512000-00007; GOLDSTEIN AM, 1995, DERMATOL CLIN, V13, P605, DOI 10.1016/S0733-8635(18)30066-4; Goldstein AM, 1997, J NATL CANCER I, V89, P676, DOI 10.1093/jnci/89.10.676; GOLDSTEIN AM, 1995, NEW ENGL J MED, V333, P970, DOI 10.1056/NEJM199510123331504; GREENE MH, 1985, ANN INTERN MED, V102, P458, DOI 10.7326/0003-4819-102-4-458; GUPTA BK, 1991, CANCER-AM CANCER SOC, V67, P1984, DOI 10.1002/1097-0142(19910401)67:7<1984::AID-CNCR2820670727>3.0.CO;2-H; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; Holland EA, 1995, ONCOGENE, V11, P2289; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KANG S, 1992, CANCER, V70, P1911, DOI 10.1002/1097-0142(19921001)70:7<1911::AID-CNCR2820700718>3.0.CO;2-Q; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Lilischkis R, 1996, INT J CANCER, V66, P249, DOI 10.1002/(SICI)1097-0215(19960410)66:2<249::AID-IJC19>3.0.CO;2-7; LIU L, 1995, ONCOGENE, V11, P405; LYNCH HT, 1995, CANCER DETECT PREV, V19, P219; MOSELEY HS, 1979, CANCER, V43, P939, DOI 10.1002/1097-0142(197903)43:3<939::AID-CNCR2820430323>3.0.CO;2-N; Parry D, 1996, MOL CELL BIOL, V16, P3844; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; REIMER RR, 1978, JAMA-J AM MED ASSOC, V239, P744, DOI 10.1001/jama.239.8.744; Rigel DS, 1996, J AM ACAD DERMATOL, V34, P839, DOI 10.1016/S0190-9622(96)90041-9; Rigel DS, 1997, MAYO CLIN PROC, V72, P367, DOI 10.4065/72.4.367; Schottenfeld D, 1996, CANC EPIDEMIOLOGY PR, P1370; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SLINGLUFF CL, 1993, SURGERY, V113, P330; SmithSorensen B, 1996, HUM MUTAT, V7, P294, DOI 10.1002/(SICI)1098-1004(1996)7:4<294::AID-HUMU2>3.0.CO;2-9; TRABOULSI EI, 1988, ARCH OPHTHALMOL-CHIC, V106, P1059; WALKER GJ, 1995, HUM MOL GENET, V4, P1845, DOI 10.1093/hmg/4.10.1845; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	36	201	211	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 26	1998	338	13					879	887		10.1056/NEJM199803263381305	http://dx.doi.org/10.1056/NEJM199803263381305			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD284	9516223				2022-12-28	WOS:000072669800005
J	Jeffcoate, W				Jeffcoate, W			Obesity is a disease: food for thought	LANCET			English	Article							WEIGHT-LOSS; MORTALITY; WOMEN		City Hosp, Dept Endocrinol, Nottingham NG5 1PB, England	University of Nottingham	Jeffcoate, W (corresponding author), City Hosp, Dept Endocrinol, Nottingham NG5 1PB, England.							DIETZ WH, 1986, PEDIATR CLIN N AM, V33, P823; LEE IM, 1992, JAMA-J AM MED ASSOC, V268, P2045, DOI 10.1001/jama.268.15.2045; MULS E, 1995, INT J OBESITY, V19, pS46; PAMUK ER, 1992, AM J EPIDEMIOL, V136, P686, DOI 10.1093/oxfordjournals.aje.a116548; SOBAL J, 1989, PSYCHOL BULL, V105, P260, DOI 10.1037/0033-2909.105.2.260; STAMPFER MJ, 1992, AM J CLIN NUTR, V55, P652, DOI 10.1093/ajcn/55.3.652; Wilding J, 1997, BRIT MED BULL, V53, P286, DOI 10.1093/oxfordjournals.bmb.a011614; WILLIAMSON DF, 1995, AM J EPIDEMIOL, V141, P1128, DOI 10.1093/oxfordjournals.aje.a117386; WOODFORDE J, 1788, DIARY COUNTRY PARSON	9	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 21	1998	351	9106					903	904		10.1016/S0140-6736(97)11326-5	http://dx.doi.org/10.1016/S0140-6736(97)11326-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD047	9525389				2022-12-28	WOS:000072645500047
J	Lin, Y; Nielsen, R; Murray, D; Hubbell, WL; Mailer, C; Robinson, BH; Gelb, MH				Lin, Y; Nielsen, R; Murray, D; Hubbell, WL; Mailer, C; Robinson, BH; Gelb, MH			Docking phospholipase A(2) on membranes using electrostatic potential-modulated spin relaxation magnetic resonance	SCIENCE			English	Article							BEE-VENOM PHOSPHOLIPASE-A2; PARAMAGNETIC RESONANCE; INTERFACIAL CATALYSIS; CRYSTAL-STRUCTURE; BACTERIORHODOPSIN MUTANTS; SUBSTRATE; COMPLEX; MECHANISM; BINDING; STATE	A method involving electron paramagnetic resonance spectroscopy of a site-selectively spin-labeled peripheral membrane protein in the presence and absence of membranes and of a water-soluble spin relaxant (chromium oxalate) has been developed to determine how bee venom phospholipase A(2) sits on the membrane. Theory based on the Poisson-Boltzmann equation shows that the rate of spin relaxation of a protein-bound nitroxide by a membrane-impermeant spin relaxant depends on the distance (up to tens of angstroms) from the spin probe to the membrane. The measurements define the interfacial binding surface of this secreted phospholipase A(2).	Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; SUNY Stony Brook, Hlth Sci Ctr, Dept Physiol, Stony Brook, NY 11794 USA; Univ Calif Los Angeles, Jules Stein Eye Inst, Dept Chem & Biochem, Los Angeles, CA 90024 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of California System; University of California Los Angeles	Robinson, BH (corresponding author), Univ Washington, Dept Chem, Box 351700, Seattle, WA 98195 USA.	robinson@chem.washington.edu; gelb@chem.washington.edu		gelb, michael/0000-0001-7000-5219	NATIONAL CANCER INSTITUTE [R01CA052874] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL036235, R01HL036235, R23HL036235] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007033] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM032681] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA052874] Funding Source: Medline; NHLBI NIH HHS [R37 HL036235, HL36235, R01 HL036235] Funding Source: Medline; NIEHS NIH HHS [P30 ES07033, P30 ES007033] Funding Source: Medline; NIGMS NIH HHS [P01 GM032681, GM32681] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHARI A, 1987, COLD SPRING HARB SYM, V52, P441, DOI 10.1101/SQB.1987.052.01.051; ALTENBACH C, 1989, BIOPHYS J, V56, P1183, DOI 10.1016/S0006-3495(89)82765-1; ALTENBACH C, 1994, P NATL ACAD SCI USA, V91, P1667, DOI 10.1073/pnas.91.5.1667; ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; ALTENBACH C, 1989, BIOCHEMISTRY-US, V28, P7806, DOI 10.1021/bi00445a042; Annand RR, 1996, BIOCHEMISTRY-US, V35, P4591, DOI 10.1021/bi9528412; BAYBURT T, 1995, ANAL BIOCHEM, V232, P7, DOI 10.1006/abio.1995.9967; BenTal N, 1996, BIOPHYS J, V71, P561, DOI 10.1016/S0006-3495(96)79280-9; CASTLE JD, 1976, BIOCHEMISTRY-US, V15, P4818, DOI 10.1021/bi00667a011; DEREWENDA ZS, 1994, ADV PROTEIN CHEM, V45, P1; DIJKSTRA BW, 1983, J MOL BIOL, V168, P163, DOI 10.1016/S0022-2836(83)80328-3; DIN N, 1994, MOL MICROBIOL, V11, P747, DOI 10.1111/j.1365-2958.1994.tb00352.x; DUDLER T, 1992, BIOCHIM BIOPHYS ACTA, V1165, P201, DOI 10.1016/0005-2760(92)90188-2; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; GHOMASCHCHI F, IN PRESS BIOCHEMISTR; GHOMASHCHI F, 1991, BIOCHEMISTRY-US, V30, P9559, DOI 10.1021/bi00104a001; HAAS DA, 1993, BIOPHYS J, V64, P594, DOI 10.1016/S0006-3495(93)81418-8; HEINZ DW, 1995, EMBO J, V14, P3855, DOI 10.1002/j.1460-2075.1995.tb00057.x; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; HUBBELL WL, UNPUB; HYDE JS, 1979, SPIN LABELING, V2, P71; JAIN MK, 1991, BIOCHEMISTRY-US, V30, P7306, DOI 10.1021/bi00243a036; JAIN MK, 1991, METHOD ENZYMOL, V197, P112; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lakshminarayanaiah N., 1984, EQUATIONS MEMBRANE B; LANGEN R, UNPUB; MAILER C, 1985, REV SCI INSTRUM, V56, P1917, DOI 10.1063/1.1138445; MAILER C, 1991, J MAGN RESON, V91, P475, DOI 10.1016/0022-2364(91)90375-4; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Molin Y. N., 1980, SPRINGER SERIES CHEM, V8; Press W. H., 1987, NUMERICAL RECIPES; ROBINSON BH, 1994, SCIENCE, V263, P490, DOI 10.1126/science.8290958; SCOTT DL, 1994, ADV PROTEIN CHEM, V45, P53; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SCOTT DL, 1990, SCIENCE, V250, P1563, DOI 10.1126/science.2274788; SHIN YK, 1992, BIOPHYS J, V61, P1443, DOI 10.1016/S0006-3495(92)81950-1; THUNNISSEN MMGM, 1990, NATURE, V347, P689, DOI 10.1038/347689a0; THUREN T, 1984, BIOCHEMISTRY-US, V23, P5129, DOI 10.1021/bi00317a008; VANTILBEURGH H, 1992, NATURE, V359, P159, DOI 10.1038/359159a0; Yu BZ, 1997, BIOCHEMISTRY-US, V36, P3870, DOI 10.1021/bi961541x	40	112	112	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 20	1998	279	5358					1925	1929		10.1126/science.279.5358.1925	http://dx.doi.org/10.1126/science.279.5358.1925			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506941	Green Accepted			2022-12-28	WOS:000072613300044
J	Banchereau, J; Steinman, RM				Banchereau, J; Steinman, RM			Dendritic cells and the control of immunity	NATURE			English	Review							COLONY-STIMULATING FACTOR; TUMOR-NECROSIS-FACTOR; ANTIGENS IN-VIVO; C-KIT-LIGAND; CD4 T-CELLS; CLASS-II; HUMAN BLOOD; LANGERHANS CELLS; GERMINAL-CENTERS; INFLUENZA-VIRUS	B and T lymphocytes are the mediators of Immunity, but their function is under the control of dendritic cells. Dendritic cells in the periphery capture and process antigens, express lymphocyte co-stimulatory molecules, migrate to lymphoid organs and secrete cytokines to initiate immune responses, They not only activate lymphocytes, they also tolerize T cells to antigens that are Innate to the body (self-antigens), thereby minimizing autoimmune reactions. Once a neglected cell type, dendritic cells can now be readily obtained in sufficient quantities to allow molecular and cell biological analysis, With knowledge comes the realization that these cells are a powerful tool for manipulating the immune system.	Baylor Res Inst, Baylor Inst Immunol, Dallas, TX 75246 USA; Rockefeller Univ, Cellular Physiol & Immunol Lab, New York, NY 10021 USA	Baylor Scott & White Health; Baylor University Medical Center; Rockefeller University	Banchereau, J (corresponding author), Baylor Res Inst, Baylor Inst Immunol, 3409 Worth St, Dallas, TX 75246 USA.		Steinman, Ralph/F-7729-2012					Adema GJ, 1997, NATURE, V387, P713, DOI 10.1038/42716; Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; ARDAVIN C, 1993, NATURE, V362, P761, DOI 10.1038/362761a0; BENDER A, 1995, J EXP MED, V182, P1663, DOI 10.1084/jem.182.6.1663; BHARDWAJ N, 1994, J CLIN INVEST, V94, P797, DOI 10.1172/JCI117399; BHARDWAJ N, 1993, J EXP MED, V178, P633, DOI 10.1084/jem.178.2.633; Borkowski TA, 1996, J EXP MED, V184, P2417, DOI 10.1084/jem.184.6.2417; Brocker T, 1997, J EXP MED, V185, P541, DOI 10.1084/jem.185.3.541; Brocker T, 1997, J EXP MED, V186, P1223, DOI 10.1084/jem.186.8.1223; Brown KA, 1997, CLIN EXP IMMUNOL, V107, P601, DOI 10.1046/j.1365-2249.1997.d01-951.x; Buelens C, 1997, EUR J IMMUNOL, V27, P1848, DOI 10.1002/eji.1830270805; CAMERON PU, 1992, SCIENCE, V257, P383, DOI 10.1126/science.1352913; Casares S, 1997, J EXP MED, V186, P1481, DOI 10.1084/jem.186.9.1481; CAUX C, 1994, J EXP MED, V180, P1263, DOI 10.1084/jem.180.4.1263; CAUX C, 1994, J EXP MED, V180, P1841, DOI 10.1084/jem.180.5.1841; Caux C, 1997, BLOOD, V90, P1458, DOI 10.1182/blood.V90.4.1458.1458_1458_1470; Caux C, 1996, J EXP MED, V184, P695, DOI 10.1084/jem.184.2.695; CAUX C, 1992, NATURE, V360, P258, DOI 10.1038/360258a0; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; Cella M, 1997, NATURE, V388, P782, DOI 10.1038/42030; Chaux P, 1996, LAB INVEST, V74, P975; Colonna M, 1997, J EXP MED, V186, P1809, DOI 10.1084/jem.186.11.1809; Condon C, 1996, NAT MED, V2, P1122, DOI 10.1038/nm1096-1122; DeSmedt T, 1996, J EXP MED, V184, P1413, DOI 10.1084/jem.184.4.1413; Dubois B, 1997, J EXP MED, V185, P941, DOI 10.1084/jem.185.5.941; Fayette J, 1997, J EXP MED, V185, P1909, DOI 10.1084/jem.185.11.1909; FloresRomo L, 1997, J EXP MED, V185, P341, DOI 10.1084/jem.185.2.341; Forster I, 1996, EUR J IMMUNOL, V26, P3194, DOI 10.1002/eji.1830261253; FRAKEL SS, 1997, AM J PATHOL, V151, P89; Frankel SS, 1996, SCIENCE, V272, P115, DOI 10.1126/science.272.5258.115; FugierVivier I, 1997, J EXP MED, V186, P813, DOI 10.1084/jem.186.6.813; GRANELLIPIPERNO A, 1995, P NATL ACAD SCI USA, V92, P10944, DOI 10.1073/pnas.92.24.10944; Greaves DR, 1997, J EXP MED, V186, P837, DOI 10.1084/jem.186.6.837; Grosjean I, 1997, J EXP MED, V186, P801, DOI 10.1084/jem.186.6.801; Grouard G, 1997, J EXP MED, V185, P1101, DOI 10.1084/jem.185.6.1101; Grouard G, 1996, NATURE, V384, P364, DOI 10.1038/384364a0; HOSOI J, 1993, NATURE, V363, P159, DOI 10.1038/363159a0; Hsu FJ, 1996, NAT MED, V2, P52, DOI 10.1038/nm0196-52; INABA K, 1994, J EXP MED, V180, P1849, DOI 10.1084/jem.180.5.1849; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Inaba K, 1997, J EXP MED, V186, P665, DOI 10.1084/jem.186.5.665; INABA K, 1993, J EXP MED, V178, P479, DOI 10.1084/jem.178.2.479; Ingulli E, 1997, J EXP MED, V185, P2133, DOI 10.1084/jem.185.12.2133; JIANG WP, 1995, NATURE, V375, P151, DOI 10.1038/375151a0; Josien R, 1997, J EXP MED, V186, P467, DOI 10.1084/jem.186.3.467; Kelsall BL, 1996, J EXP MED, V183, P237, DOI 10.1084/jem.183.1.237; Kitajima T, 1996, J CLIN INVEST, V98, P142, DOI 10.1172/JCI118759; Koch F, 1996, J EXP MED, V184, P741, DOI 10.1084/jem.184.2.741; Kudo S, 1997, J EXP MED, V185, P777, DOI 10.1084/jem.185.4.777; Kurts C, 1997, J EXP MED, V186, P239, DOI 10.1084/jem.186.2.239; Kurts C, 1996, J EXP MED, V184, P923, DOI 10.1084/jem.184.3.923; Laufer TM, 1996, NATURE, V383, P81, DOI 10.1038/383081a0; Lieberman PH, 1996, AM J SURG PATHOL, V20, P519, DOI 10.1097/00000478-199605000-00001; Liu YJ, 1996, INT REV CYTOL, V166, P139, DOI 10.1016/S0074-7696(08)62508-5; Liu YJ, 1997, J EXP MED, V185, P165, DOI 10.1084/jem.185.1.165; Lukas M, 1996, J INVEST DERMATOL, V106, P1293, DOI 10.1111/1523-1747.ep12349010; Luther SA, 1997, J EXP MED, V185, P551, DOI 10.1084/jem.185.3.551; MACPHERSON GG, 1995, J IMMUNOL, V154, P1317; Maraskovsky E, 1996, J EXP MED, V184, P1953, DOI 10.1084/jem.184.5.1953; Matsumoto M, 1997, J EXP MED, V186, P1997, DOI 10.1084/jem.186.12.1997; Matsuno K, 1996, J EXP MED, V183, P1865, DOI 10.1084/jem.183.4.1865; MAYORDOMO JI, 1995, NAT MED, V1, P1297, DOI 10.1038/nm1295-1297; McWilliam AS, 1996, J EXP MED, V184, P2429, DOI 10.1084/jem.184.6.2429; MOLL H, 1993, EUR J IMMUNOL, V23, P1595, DOI 10.1002/eji.1830230730; Mueller CGF, 1997, J EXP MED, V186, P655, DOI 10.1084/jem.186.5.655; NIJMAN HW, 1995, J EXP MED, V182, P163, DOI 10.1084/jem.182.1.163; ODOHERTY U, 1994, IMMUNOLOGY, V82, P487; Paglia P, 1996, J EXP MED, V183, P317, DOI 10.1084/jem.183.1.317; Pierre P, 1997, NATURE, V388, P787, DOI 10.1038/42039; PINCHUK LM, 1994, IMMUNITY, V1, P317, DOI 10.1016/1074-7613(94)90083-3; Pope M, 1997, AIDS RES HUM RETROV, V13, P819, DOI 10.1089/aid.1997.13.819; POPE M, 1994, CELL, V78, P389, DOI 10.1016/0092-8674(94)90418-9; Reddy A, 1997, BLOOD, V90, P3640, DOI 10.1182/blood.V90.9.3640; Rettig MB, 1997, SCIENCE, V276, P1851, DOI 10.1126/science.276.5320.1851; ROAKE JA, 1995, J EXP MED, V181, P2237, DOI 10.1084/jem.181.6.2237; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; Romani N, 1996, J IMMUNOL METHODS, V196, P137, DOI 10.1016/0022-1759(96)00078-6; Sallusto F, 1996, J EXP MED, V184, P2411, DOI 10.1084/jem.184.6.2411; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Saunders D, 1996, J EXP MED, V184, P2185, DOI 10.1084/jem.184.6.2185; Schnorr JJ, 1997, P NATL ACAD SCI USA, V94, P5326, DOI 10.1073/pnas.94.10.5326; Schuler G, 1997, J EXP MED, V186, P1183, DOI 10.1084/jem.186.8.1183; SoderbergNaucler C, 1997, CELL, V91, P119, DOI 10.1016/S0092-8674(01)80014-3; Song W, 1997, J EXP MED, V186, P1247, DOI 10.1084/jem.186.8.1247; SOUSA CRE, 1993, J EXP MED, V178, P509, DOI 10.1084/jem.178.2.509; Sousa CRE, 1997, J EXP MED, V186, P1819, DOI 10.1084/jem.186.11.1819; SOZZANI S, 1995, J IMMUNOL, V155, P3292; Specht JM, 1997, J EXP MED, V186, P1213, DOI 10.1084/jem.186.8.1213; STEINMAN RM, IN PRESS FUNDAMENTAL; Strunk D, 1997, J EXP MED, V185, P1131, DOI 10.1084/jem.185.6.1131; Suss G, 1996, J EXP MED, V183, P1789, DOI 10.1084/jem.183.4.1789; Svensson M, 1997, J IMMUNOL, V158, P4229; Szabolcs P, 1996, BLOOD, V87, P4520, DOI 10.1182/blood.V87.11.4520.bloodjournal87114520; SZABOLCS P, 1995, J IMMUNOL, V154, P5851; Vicari AP, 1997, IMMUNITY, V7, P291, DOI 10.1016/S1074-7613(00)80531-2; Weissman D, 1996, J EXP MED, V183, P687, DOI 10.1084/jem.183.2.687; Winzler C, 1997, J EXP MED, V185, P317, DOI 10.1084/jem.185.2.317; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; YOUNG JW, 1995, J EXP MED, V182, P1111, DOI 10.1084/jem.182.4.1111; ZAL T, 1994, J EXP MED, V180, P2089, DOI 10.1084/jem.180.6.2089; Zitvogel L, 1996, J EXP MED, V183, P87, DOI 10.1084/jem.183.1.87	103	11489	12293	36	1597	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 19	1998	392	6673					245	252		10.1038/32588	http://dx.doi.org/10.1038/32588			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC739	9521319				2022-12-28	WOS:000072612300037
J	Downie, RS; Macnaughton, RJ				Downie, RS; Macnaughton, RJ			Images of health	LANCET			English	Article									Woodside Hlth Ctr, Dept Gen Practice, Glasgow G20 7LR, Lanark, Scotland		Downie, RS (corresponding author), Woodside Hlth Ctr, Dept Gen Practice, Barr St, Glasgow G20 7LR, Lanark, Scotland.							[Anonymous], 1946, CONST; ARISTOTLE, 1953, NICOMACHEAN ETHICS, pCH3; BETJEMAN S, 1958, COLLECTED POEMS; BLAKE W, 1951, SELECTED POEMS W BLA; DONNE J, 1970, NORTON ANTHOLOGY POE; DOWNIE RS, 1994, HEALING ARTS OXFORD, P186; DRYDEN J, 1956, COLLECTED WORKS; GOLDSMITH O, 1869, DESERTED VILLAG; HERBERT G, 1972, NEW OXFORD BOOK ENGL; NIETZSCHE FW, 1967, JOYFUL SCI; PINES S, 1963, MAIMONIDES GUIDE PER; Plato, 1970, REPUBLIC; PLATO, 1951, PHAEDO, P118; PORTER P, 1972, MARTIAL; SHAKESPEARE W, 1993, OXFORD SHAKESPEARE; THURBER J, 1939, NEW YORKER      0429; TOLSTOY L, 1922, WAR PEACE; WAGNER R, 1965, MUSICIANS WORLD LETT, pP290	18	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 14	1998	351	9105					823	825		10.1016/S0140-6736(97)10282-3	http://dx.doi.org/10.1016/S0140-6736(97)10282-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB916	9519975				2022-12-28	WOS:000072521200044
J	Halsey, NA; Coberly, JS; Desormeaux, J; Losikoff, P; Atkinson, J; Moulton, LH; Contave, M; Johnson, M; Davis, H; Geiter, L; Johnson, E; Huebner, R; Boulos, R; Chaisson, RE				Halsey, NA; Coberly, JS; Desormeaux, J; Losikoff, P; Atkinson, J; Moulton, LH; Contave, M; Johnson, M; Davis, H; Geiter, L; Johnson, E; Huebner, R; Boulos, R; Chaisson, RE			Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; THERAPY; RISK	Background Tuberculosis is a common complication of HIV-1 infection, especially in developing countries. Practical and effective chemoprophylaxis regimens for HIV-1-related tuberculosis are needed, Our aim was to test the efficacy of isoniazid versus rifampicin with pyrazinamide for prevention of tuberculosis in HIV-1-positive individuals. Methods We compared the efficacy of 6 months of isoniazid with 2 months of rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1-seropositive individuals. Eligible participants were aged 16-77 years, HIV-1 seropositive, had a positive purified-protein derivative (PPD) skin test reaction of at least 5 mm, and had a normal chest radiograph. Participants were randomly assigned partially supervised twice weekly isoniazid for 24 weeks or twice weekly rifampicin and pyrazinamide for 8 weeks. Participants were followed up for up to 4 years for the development of tuberculosis and survival. Findings Tuberculosis developed in 14 (3.8%) of 370 participants assigned isoniazid and 19 (5.0%) of 380 participants assigned rifampicin and pyrazinamide (Cox model rate ratio 1.3 [95% CI 0.7-2.7]). The Kaplan-Meier estimate of the risk of tuberculosis during the first 10 months after entry was 3.7% among participants who received rifampicin and pyrazinamide compared with 1.0% (p=0.03) among participants who received isoniazid, and 5.4% versus 5.1%, respectively (p=0.9) at 36 months after entry. Higher rates of tuberculosis were observed in people with baseline CD4 percentages (of total lymphocytes) of less than 20 (rate ratio 4.0 [95% CI 1.8-9.0]). There were no significant differences in total mortality at any time. Interpretation Twice-weekly isoniazid preventive therapy for 6 months or rifampicin and pyrazinamide for 2 months provided similar overall protection against tuberculosis in HIV-1-infected, PPD-positive adults, The better protection among recipients of isoniazid during the first 10 months was most likely secondary to the longer duration of chemoprophylaxis. Preventive therapy for HIV-1-seropositive, PPD-positive individuals could be practical in developing countries with a once weekly clinic visit, but optimum duration of chemoprophylaxis has not been determined.	Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Int Hlth, Baltimore, MD USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Biostat, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Ctr Dev Sante, Port Au Prince, Haiti; Ctr Dis Control & Prevent, Div TB Eliminat, Ctr Prevent Serv, Atlanta, GA USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Centers for Disease Control & Prevention - USA	Halsey, NA (corresponding author), Johns Hopkins Univ, Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA.			Moulton, Lawrence/0000-0001-7041-7387	PHS HHS [U52/CCU 301871] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLEN S, 1992, AM REV RESPIR DIS, V146, P1439, DOI 10.1164/ajrccm/146.6.1439; BLOCH AB, 1994, JAMA-J AM MED ASSOC, V271, P665, DOI 10.1001/jama.271.9.665; Blower SM, 1996, SCIENCE, V273, P497, DOI 10.1126/science.273.5274.497; Chaisson RE, 1996, AM J RESP CRIT CARE, V154, P1034, DOI 10.1164/ajrccm.154.4.8887603; Chaulet P, 1995, TUBERCLE LUNG DIS, V76, P487, DOI 10.1016/0962-8479(95)90523-5; COHN DL, 1990, ANN INTERN MED, V112, P407, DOI 10.7326/0003-4819-76-3-112-6-407; COMSTOCK GW, 1974, AM REV RESPIR DIS, V110, P195; COMSTOCK GW, 1970, AM REV RESPIR DIS, V101, P780; DECOCK KM, 1992, JAMA-J AM MED ASSOC, V268, P1581, DOI 10.1001/jama.1992.03490120095035; Desormeaux J, 1996, Bull Pan Am Health Organ, V30, P1; ELDRED LJ, 1997, IN PRESS J AIDS; FEREBEE SH, 1970, ADV TUBERC RES, V17, P28; Girling D. J., 1991, American Review of Respiratory Disease, V143, P700; Graham NMH, 1996, ARCH INTERN MED, V156, P889, DOI 10.1001/archinte.156.8.889; GREENBERG AE, 1995, AIDS, V9, P1251, DOI 10.1097/00002030-199511000-00006; GUELAR A, 1993, AIDS, V7, P1345, DOI 10.1097/00002030-199310000-00007; JI BH, 1993, AM REV RESPIR DIS, V148, P1541, DOI 10.1164/ajrccm/148.6_Pt_1.1541; JOHNSON MP, 1992, J INFECT DIS, V166, P194, DOI 10.1093/infdis/166.1.194; Kent PT, 1985, GUIDE LEVEL 3 LAB; LECOEUR HF, 1989, AM REV RESPIR DIS, V140, P1189, DOI 10.1164/ajrccm/140.5.1189; Markowitz N, 1997, ANN INTERN MED, V126, P123, DOI 10.7326/0003-4819-126-2-199701150-00005; Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6; PAPE JW, 1993, LANCET, V342, P268, DOI 10.1016/0140-6736(93)91817-6; RAVIGLIONE MC, 1992, B WORLD HEALTH ORGAN, V70, P515; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601; SNIDER DE, 1992, AM REV RESPIR DIS, V145, P494, DOI 10.1164/ajrccm/145.2_Pt_1.494; THOMPSON NJ, 1982, B WORLD HEALTH ORGAN, V60, P555; WALLIS RS, 1993, J INFECT DIS, V167, P43, DOI 10.1093/infdis/167.1.43; Whalen CC, 1997, NEW ENGL J MED, V337, P801, DOI 10.1056/NEJM199709183371201; *WHO, 1993, WKLY EPIDEMIOL REC, V68, P361	31	234	238	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 14	1998	351	9105					786	792		10.1016/S0140-6736(97)06532-X	http://dx.doi.org/10.1016/S0140-6736(97)06532-X			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB916	9519950	hybrid			2022-12-28	WOS:000072521200011
J	Witkowski, FX; Leon, LJ; Penkoske, PA; Giles, WR; Spano, ML; Ditto, WL; Winfree, AT				Witkowski, FX; Leon, LJ; Penkoske, PA; Giles, WR; Spano, ML; Ditto, WL; Winfree, AT			Spatiotemporal evolution of ventricular fibrillation	NATURE			English	Article							MECHANISMS; MUSCLE	Sudden cardiac death is the leading cause of death in the industrialized world, with the majority of such tragedies being due to ventricular fibrillation(1). Ventricular fibrillation is a frenzied and irregular disturbance of the heart rhythm that quickly renders the heart incapable of sustaining life. Rotors, electrophysiological structures that emit rotating spiral waves, occur in several systems that all share with the heart the functional properties of excitability and refractoriness, These re-entrant waves, seen in numerical solutions of simplified models of cardiac tissue(2), may occur during ventricular tachycardias(3,4). It has been difficult to detect such forms of re-entry in fibrillating mammalian ventricles(5-8). Here we show that, in isolated perfused dog hearts, high spatial and temporal resolution mapping of optical transmembrane potentials can easily detect transiently erupting rotors during the early phase of ventricular fibrillation, This activity is characterized by a relatively high spatiotemporal cross-correlation. During this early fibrillatory interval, frequent wavefront collisions and wavebreak generation(9) are also dominant features. Interestingly, this spatiotemporal pattern undergoes an evolution to a less highly spatially correlated mechanism that lacks the epicardial manifestations of rotors despite continued myocardial perfusion.	Univ Alberta, Dept Med, Edmonton, AB T6G 2R7, Canada; Univ Alberta, Dept Surg, Edmonton, AB T6G 2R7, Canada; Ecole Polytech, Montreal, PQ H3C 3J7, Canada; Univ Calgary, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada; USN, Ctr Surface Warfare, Bethesda, MD 20817 USA; Georgia Inst Technol, Sch Phys, Appl Chaos Lab, Atlanta, GA 30332 USA; Univ Arizona, Dept Ecol & Evolut Biol, Tucson, AZ 85721 USA	University of Alberta; University of Alberta; Universite de Montreal; Polytechnique Montreal; University of Calgary; United States Department of Defense; United States Navy; University System of Georgia; Georgia Institute of Technology; University of Arizona	Witkowski, FX (corresponding author), Univ Alberta, Dept Med, Edmonton, AB T6G 2R7, Canada.	fwitkows@gpu.srv.ualberta.ca	Ditto, William/AAK-9827-2020; Spano, Mark L/B-6883-2011	Ditto, William/0000-0002-7416-8012; 				Castellanos A., 1990, CARDIAC ELECTROPHYSI, P666; CHEN PS, 1988, CIRC RES, V62, P1191, DOI 10.1161/01.RES.62.6.1191; GRAY RA, 1995, SCIENCE, V270, P1222, DOI 10.1126/science.270.5239.1222; GRAY RA, 1996, CIRCULATION, V94, P1; Holden A, 1997, COMPUTATIONAL BIOL H; Holden AV, 1997, NATURE, V387, P655, DOI 10.1038/42597; Lee JJ, 1996, CIRC RES, V78, P660, DOI 10.1161/01.RES.78.4.660; PERTSOV AM, 1993, CIRC RES, V72, P631, DOI 10.1161/01.RES.72.3.631; ROGERS JM, 1996, CIRCULATION, V94, P1; RUSS JC, 1994, IMAGE PROCESSING HDB, P157; Wiggers CJ, 1930, AM HEART J, V5, P351, DOI 10.1016/S0002-8703(30)90334-1; WINFREE AT, 1994, SCIENCE, V266, P1003, DOI 10.1126/science.7973648; WINFREE AT, 1987, TIME BREAKS DOWN, V40, P292; WITKOWSKI FX, 1994, CIRC RES, V74, P507, DOI 10.1161/01.RES.74.3.507; Witkowski FX, 1998, CHAOS, V8, P94, DOI 10.1063/1.166290	15	399	420	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 5	1998	392	6671					78	82		10.1038/32170	http://dx.doi.org/10.1038/32170			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA528	9510250				2022-12-28	WOS:000072373000053
J	Bindman, AB; Grumbach, K; Vranizan, K; Jaffe, D; Osmond, D				Bindman, AB; Grumbach, K; Vranizan, K; Jaffe, D; Osmond, D			Selection and exclusion of primary care physicians by managed care organizations	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-Little is known about the problems physicians may be encountering in gaining access to managed care networks and whether the process used by managed care plans to select physicians is discriminatory. Objective.-To investigate the incidence and predictors of denials or terminations of physicians' managed care contracts and the impact these denials and terminations had on primary care physicians' involvement with managed care. Design.-Cross-sectional mail survey of a probability sample of primary care physicians. Setting.-A total of 13 large urban counties in California. Participants.-Primary care physicians (family practice, internal medicine, obstetrics and gynecology, or pediatrics) who work in office-based practice. Main Outcome Measures.-Denial or termination from a contract with an independent practice association (IPA) or health maintenance organization (HMO) and managed care contracts. Results.-Of the 947 respondents (response rate, 71%), 520 were involved in office-based primary care. After adjusting for sampling and response rate, 22% of primary care physicians had been denied or terminated from a contract with an IPA or HMO, but 87% of office-based primary care physicians had at least 1 IPA or di rect HMO contract, Solo practice was the strongest predictor of having experienced a denial or termination and of having neither an IPA nor a direct HMO contract, Physician age, sex, and race did not predict the level of involvement with managed care, However, physicians' patient demographics were associated with managed care participation; physicians in managed care had significantly lower percentages of uninsured and nonwhite patients in their practices, Physicians experiencing a denial or termination had fewer capitated patients in their practice. Conclusions.-Denials and terminations, although relatively common, do not preclude most primary care physicians from participating in managed care, Managed care selective contracting does not appear to be systematically discriminatory based on physician characteristics, but it may be biased against physicians who provide greater amounts of care to the underserved.	San Francisco Gen Hosp, Primary Care Res Ctr, San Francisco, CA 94110 USA; San Francisco Gen Hosp, Div Gen Internal Med, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA USA; Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA USA; Univ Calif San Francisco, Ctr Hlth Profess, San Francisco, CA USA	San Francisco General Hospital Medical Center; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bindman, AB (corresponding author), San Francisco Gen Hosp, Primary Care Res Ctr, Bldg 90,Ward 95,1001 Potrero Ave, San Francisco, CA 94110 USA.		Grumbach, Kevin/L-9222-2016					Blum JD, 1996, AM J LAW MED, V22, P173; Bodenheimer T, 1996, NEW ENGL J MED, V335, P1601, DOI 10.1056/NEJM199611213352112; BODENHEIMER T, 1995, JAMA-J AM MED ASSOC, V274, P85, DOI 10.1001/jama.274.1.85; Hellinger FJ, 1995, HEALTH AFFAIR, V14, P297, DOI 10.1377/hlthaff.14.4.297; Kassirer JP, 1997, NEW ENGL J MED, V337, P43, DOI 10.1056/NEJM199707033370108; Kletke PR, 1996, JAMA-J AM MED ASSOC, V276, P555, DOI 10.1001/jama.276.7.555; LavizzoMourey R, 1996, J NATL MED ASSOC, V88, P210; Miller RS, 1997, JAMA-J AM MED ASSOC, V277, P1699, DOI 10.1001/jama.277.21.1699; *PHYS PAYM REV COM, 1995, ANN REP C, P221; ROBINSON JC, 1995, NEW ENGL J MED, V333, P1684, DOI 10.1056/NEJM199512213332506; ROSENTHAL E, 1977, NY TIMES        0126; Seifer SD, 1996, JAMA-J AM MED ASSOC, V276, P695, DOI 10.1001/jama.276.9.695	12	41	41	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1998	279	9					675	679		10.1001/jama.279.9.675	http://dx.doi.org/10.1001/jama.279.9.675			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY849	9496985	Bronze			2022-12-28	WOS:000072192800031
J	Ben-Chetrit, E; Levy, M				Ben-Chetrit, E; Levy, M			Familial Mediterranean fever	LANCET			English	Article							RECURRENT HEREDITARY POLYSEROSITIS; TUMOR-NECROSIS-FACTOR; HIGH GENE-FREQUENCY; COLCHICINE DISPOSITION; DIAGNOSTIC-TEST; CHILDREN; AUTOANTIBODIES; AMYLOIDOSIS; ARMENIANS; PROTEIN		Hadassah Univ Hosp, Dept Med, Familial Mediterranean Fever Clin, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Ben-Chetrit, E (corresponding author), Hadassah Univ Hosp, Dept Med, Familial Mediterranean Fever Clin, POB 12000, IL-91120 Jerusalem, Israel.		Grieshaber-Bouyer, Ricardo/R-7512-2016; Bhatt, Harshil/AAY-5781-2020	Grieshaber-Bouyer, Ricardo/0000-0002-2873-5135; Bhatt, Harshil/0000-0001-9447-9443				AKSENTIEVITZ I, 1997, P 1 INT C FMF JER, P246; Aksentijevich I, 1997, CELL, V90, P797; AYESH SK, 1995, BLOOD, V85, P3503, DOI 10.1182/blood.V85.12.3503.bloodjournal85123503; Balow JE, 1997, GENOMICS, V44, P280, DOI 10.1006/geno.1997.4860; BARAKAT MH, 1984, LANCET, V1, P656; BARAKAT MH, 1986, Q J MED, V60, P837; BARAKAT MH, 1988, LANCET, V2, P1280; BARELI M, 1981, AM J MED SCI, V281, P15, DOI 10.1097/00000441-198101000-00002; BENCHETRIT E, 1991, SEMIN ARTHRITIS RHEU, V20, P241, DOI 10.1016/0049-0172(91)90019-V; BENCHETRIT E, 1990, LANCET, V335, P176, DOI 10.1016/0140-6736(90)90055-A; BENCHETRIT E, 1988, J EXP MED, V167, P1560, DOI 10.1084/jem.167.5.1560; BENCHETRIT E, 1994, J RHEUMATOL, V21, P710; BENCHETRIT E, 1990, BRIT J RHEUMATOL, V29, P459; BENCHETRIT E, IN PRESS MED HYPOTH; BENCHETRIT E, IN PRESS SEM ARTHRIT; Bernot A, 1997, NAT GENET, V17, P25; BITAR E, 1976, REV RHUM, V43, P267; BRENNERULLMAN A, 1994, AM J MED GENET, V53, P172, DOI 10.1002/ajmg.1320530210; BUADES J, 1995, ISRAEL J MED SCI, V31, P497; CATTAN R, 1954, Bull Mem Soc Med Hop Paris, V70, P43; CHAPPEY ON, 1993, CLIN PHARMACOL THER, V54, P360, DOI 10.1038/clpt.1993.161; Cook GC, 1996, LANCET, V347, P1779, DOI 10.1016/S0140-6736(96)91611-6; COURILLONMALLET A, 1992, ISRAEL J MED SCI, V28, P427; DAGAN T, 1997, P 1 INT C FMF JER, P109; DANIELS M, 1995, AM J MED GENET, V55, P311, DOI 10.1002/ajmg.1320550313; DEWALL M, IN PRESS EUR J HUM G; DRENTH JPH, 1994, MEDICINE, V73, P133, DOI 10.1097/00005792-199405000-00002; ELIAKIM M, 1981, RECURRENT POLYSEROSI; Erken E, 1996, ANN RHEUM DIS, V55, P852, DOI 10.1136/ard.55.11.852; ESHEL G, 1994, BRIT J SURG, V81, P894, DOI 10.1002/bjs.1800810633; GARCIAGONZALEZ A, 1992, SEMIN ARTHRITIS RHEU, V22, P139, DOI 10.1016/0049-0172(92)90014-5; GEDALIA A, 1992, J RHEUMATOL, V19, P1; GEDALIA A, 1993, PEDIATR NEUROL, V9, P301, DOI 10.1016/0887-8994(93)90068-N; GOLDFINGER SE, 1972, NEW ENGL J MED, V287, P1302; Henry J, 1997, BIOCHEM BIOPH RES CO, V235, P162, DOI 10.1006/bbrc.1997.6751; JACK LJW, 1990, J BIOL CHEM, V265, P14481; KASTNER DL, 1991, CYTOGENET CELL GENET, V58, P2115; Kees S, 1997, QJM-MON J ASSOC PHYS, V90, P643; KLIMECKI WT, 1994, BLOOD, V83, P2451; KNOCKAERT DC, 1993, MEDICINE, V72, P184; LANGEVITZ P, 1994, J RHEUMATOL, V21, P1708; Langevitz P., 1994, Arthritis and Rheumatism, V37, pS203; LIVNEH A, 1994, ARTHRITIS RHEUM-US, V37, P1804, DOI 10.1002/art.1780371215; Livneh A, 1996, SEMIN ARTHRITIS RHEU, V26, P612, DOI 10.1016/S0049-0172(96)80012-6; MAJEED HA, 1990, Q J MED, V75, P607; MAJEED HA, 1990, J PEDIATR-US, V116, P997, DOI 10.1016/S0022-3476(05)80667-5; MAMOU H, 1954, Bull Mem Soc Med Hop Paris, V70, P520; MATZNER Y, 1990, ARCH INTERN MED, V150, P1289, DOI 10.1001/archinte.150.6.1289; McDermott EM, 1996, LANCET, V348, P554, DOI 10.1016/S0140-6736(05)64720-4; MEGE JL, 1993, J RHEUMATOL, V20, P1544; MERY JP, 1993, RENAL FAILURE, V15, P379, DOI 10.3109/08860229309054948; OZDEMIR A I, 1969, American Journal of Gastroenterology, V51, P311; Ozdogan H, 1997, J RHEUMATOL, V24, P323; OZEN S, 1992, SCAND J RHEUMATOL, V21, P312, DOI 10.3109/03009749209099250; OZYILKAN E, 1992, AM J MED, V92, P579; PATARCA R, 1988, P NATL ACAD SCI USA, V85, P2733, DOI 10.1073/pnas.85.8.2733; PETERS RS, 1997, 1 INT C FMF JER, P8; Pras E, 1998, AM J MED GENET, V75, P216, DOI 10.1002/(SICI)1096-8628(19980113)75:2<216::AID-AJMG20>3.0.CO;2-R; PRAS E, 1992, NEW ENGL J MED, V326, P1509, DOI 10.1056/NEJM199206043262301; PRAS E, 1997, P 1 INT C FMF, P260; PRAS M, 1982, JOHNS HOPKINS MED J, V150, P22; Rawashdeh MO, 1996, EUR J PEDIATR, V155, P540, DOI 10.1007/s004310050438; REIMANN HA, 1948, JAMA-J AM MED ASSOC, V136, P238; REISSMAN P, 1994, WORLD J SURG, V18, P139, DOI 10.1007/BF00348205; ROGERS DB, 1989, AM J MED GENET, V34, P168, DOI 10.1002/ajmg.1320340206; ROZENBAUM M, 1992, J RHEUMATOL, V19, P416; Saatci U, 1997, EUR J PEDIATR, V156, P619, DOI 10.1007/s004310050677; Schattner A, 1996, QJM-MON J ASSOC PHYS, V89, P205; SCHWABE AD, 1974, MEDICINE, V53, P453, DOI 10.1097/00005792-197411000-00005; SCHWABE AD, 1997, W J MED, V127, P15; SHOHAT M, 1990, GENOMICS, V8, P83, DOI 10.1016/0888-7543(90)90228-M; SIEGAL S, 1945, ANN INTERN MED, V23, P1, DOI 10.7326/0003-4819-23-1-1; SOHAR E, 1967, AM J MED, V43, P227, DOI 10.1016/0002-9343(67)90167-2; SOHAR E, 1997, P 1 INT C FMF JER; SUNGUR C, 1993, KIDNEY INT, V44, P834, DOI 10.1038/ki.1993.318; SWISSA M, 1991, J RHEUMATOL, V18, P606; Yazici H, 1997, P 1 INT C FMF JER 19, P66; ZEMER D, 1992, ANN INTERN MED, V116, P426, DOI 10.7326/0003-4819-116-5-426_1; Zemer D, 1993, Contrib Nephrol, V102, P187	79	600	608	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 28	1998	351	9103					659	664		10.1016/S0140-6736(97)09408-7	http://dx.doi.org/10.1016/S0140-6736(97)09408-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA447	9500348				2022-12-28	WOS:000072364200041
J	Turrigiano, GG; Leslie, KR; Desai, NS; Rutherford, LC; Nelson, SB				Turrigiano, GG; Leslie, KR; Desai, NS; Rutherford, LC; Nelson, SB			Activity-dependent scaling of quantal amplitude in neocortical neurons	NATURE			English	Article							CULTURED HIPPOCAMPAL-NEURONS; MINIATURE SYNAPTIC CURRENTS; LONG-TERM POTENTIATION; VISUAL-CORTEX; GLUTAMATE; SYNAPSES; COMPETITION; PLASTICITY; ACTIVATION; MATURATION	Information is stored in neural circuits through long-lasting changes in synaptic strengths(1,2). Most studies of information storage have focused on mechanisms such as long-term potentiation and depression (LTP and LTD), in which synaptic strengths change in a synapse-specific manner(3,4). In contrast, little attention has been paid to mechanisms that regulate the total synaptic strength of a neuron, Here we describe a new form of synaptic plasticity that increases or decreases the strength of all of a neuron's synaptic inputs as a function of activity, Chronic blockade of cortical culture activity increased the amplitude of miniature excitatory postsynaptic currents (mEPSCs) without changing their kinetics. Conversely, blocking GABA (gamma-aminobutyric acid)-mediated inhibition initially raised firing rates, but over a 48-hour period mESPC amplitudes decreased and firing rates returned to close to control values. These changes were at least partly due to postsynaptic alterations in the response tb glutamate, and apparently affected each synapse in proportion to its initial strength. Such 'synaptic scaling' may help to ensure that firing rates do not become saturated during developmental changes in the number and strength of synaptic inputs(5), as well as stabilizing synaptic strengths during Hebbian modification(6,7) and facilitating competition between synapses(7-9).	Brandeis Univ, Dept Biol, Waltham, MA 02254 USA; Brandeis Univ, Ctr Complex Syst, Waltham, MA 02254 USA	Brandeis University; Brandeis University	Turrigiano, GG (corresponding author), Brandeis Univ, Dept Biol, Waltham, MA 02254 USA.	turrigiano@binah.cc.brandeis.edu		Nelson, Sacha/0000-0002-0108-8599				AXELSSON J, 1957, J PHYSIOL-LONDON, V149, P178; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BEKKERS JM, 1990, P NATL ACAD SCI USA, V87, P5359, DOI 10.1073/pnas.87.14.5359; Benson DL, 1996, J NEUROSCI, V16, P6424; BERG DK, 1975, J PHYSIOL-LONDON, V244, P659, DOI 10.1113/jphysiol.1975.sp010818; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; BLUE ME, 1983, J NEUROCYTOL, V12, P697, DOI 10.1007/BF01181531; Colman H, 1997, SCIENCE, V275, P356, DOI 10.1126/science.275.5298.356; GERFINMOSER A, 1995, NEUROSCIENCE, V67, P849, DOI 10.1016/0306-4522(95)00130-B; Hebb D. O., 1949, ORG BEHAV NEUROPHYSI; HESTRIN S, 1992, NEURON, V9, P991, DOI 10.1016/0896-6273(92)90250-H; KIRKWOOD A, 1994, J NEUROSCI, V14, P1634, DOI 10.1523/JNEUROSCI.14-03-01634.1994; Liang FY, 1997, J NEUROSCI, V17, P2168; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; LINDEN DJ, 1995, ANNU REV NEUROSCI, V18, P319, DOI 10.1146/annurev.ne.18.030195.001535; LIU GS, 1995, NATURE, V375, P404, DOI 10.1038/375404a0; LO YJ, 1991, SCIENCE, V254, P1019, DOI 10.1126/science.1658939; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; MICHEVA KD, 1995, P NATL ACAD SCI USA, V92, P11834, DOI 10.1073/pnas.92.25.11834; Miller KD, 1996, NEURON, V17, P371, DOI 10.1016/S0896-6273(00)80169-5; MILLER KD, 1994, NEURAL COMPUT, V6, P100, DOI 10.1162/neco.1994.6.1.100; RAMAKERS GJA, 1990, EXP BRAIN RES, V79, P157; Rutherford LC, 1997, J NEUROSCI, V17, P4527; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; Wu GY, 1996, SCIENCE, V274, P972, DOI 10.1126/science.274.5289.972; WYLLIE DJA, 1994, NEURON, V12, P127, DOI 10.1016/0896-6273(94)90158-9	30	1565	1582	2	73	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 26	1998	391	6670					892	896		10.1038/36103	http://dx.doi.org/10.1038/36103			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ206	9495341				2022-12-28	WOS:000072230900052
J	Beaglehole, R; Bonita, R				Beaglehole, R; Bonita, R			Public health at the crossroads: which way forward?	LANCET			English	Article							EPIDEMIOLOGY	Public health represents society's organised and publicly supported efforts to improve the health status of the entire population; its focus is on the reduction of health inequalities by optimising the underlying determinants of health and preventing disease. But public health is under threat and needs to be strengthened so that it is at the centre of human endeavour-locally, nationally, and worldwide.	Univ Auckland, Fac Med & Hlth Sci, Dept Community Med, Auckland 1, New Zealand; Univ Auckland, Fac Med & Hlth Sci, Dept Med, Auckland 1, New Zealand	University of Auckland; University of Auckland	Beaglehole, R (corresponding author), Univ Auckland, Fac Med & Hlth Sci, Dept Community Med, Private Bag 92 019, Auckland 1, New Zealand.							Beaglehole R, 1997, PUBLIC HLTH CROSSROA; BHOPAL RS, 1993, BRIT MED J, V306, P381, DOI 10.1136/bmj.306.6874.381; CATFORD J, 1995, HEALTH PROMOT INT, V10, P41, DOI 10.1093/heapro/10.1.41; Committee for the Study of the Future of Public Health, 1988, FUT PUBL HLTH; DURHAM G, 1997, WHO HLTH PROM STREET; Gepkens A., 1996, European Journal of Public Health, V6, P218, DOI 10.1093/eurpub/6.3.218; GODLEE F, 1993, BRIT MED J, V307, P1369, DOI 10.1136/bmj.307.6916.1369; Godlee F, 1997, BRIT MED J, V314, P1359; Haines A, 1997, BRIT MED J, V314, P529, DOI 10.1136/bmj.314.7080.529; Halstead S, 1985, GOOD HLTH LOW COST; Kickbusch I, 1997, J PUBLIC HEALTH MED, V19, P171, DOI 10.1093/oxfordjournals.pubmed.a024605; Leon DA, 1997, LANCET, V350, P383, DOI 10.1016/S0140-6736(97)03360-6; McMichael A J, 1993, PLANETARY OVERLOAD G; MCMICHAEL AJ, 1994, AM J EPIDEMIOL, V140, P1; McMichael AJ, 1997, AUST NZ J PUBL HEAL, V21, P425, DOI 10.1111/j.1467-842X.1997.tb01727.x; MILIO N, 1990, NUTRITION POLICY FOO; MURRAY CJL, 1996, GLOBAL BURDEN DIS, V1; Olsen N, 1997, BRIT MED J, V314, P1498, DOI 10.1136/bmj.314.7093.1498; RAEBURN J, 1997, PEOPLE CTR HLTH PROM; Ratner PA, 1997, J PUBLIC HEALTH POL, V18, P67, DOI 10.2307/3343358; Schoenbach Victor J., 1994, Annals of Epidemiology, V4, P259; SCUTCHFIELD FD, 1995, J PUBLIC HEALTH POL, V16, P304, DOI 10.2307/3342861; Scutchfield FD, 1997, J PUBLIC HEALTH POL, V18, P13, DOI 10.2307/3343355; Susser M, 1996, AM J PUBLIC HEALTH, V86, P674, DOI 10.2105/AJPH.86.5.674; SUSSER M, 1994, AM J PUBLIC HEALTH, V84, P825, DOI 10.2105/AJPH.84.5.825; United Nations Development Programme, 1997, HUM DEV REP; Warden J, 1997, BRIT MED J, V315, P75; WHO, 1997, HLTH ENV SUST DEV; Wilkinson R., 1996, UNHEALTHY SOC AFFLIC; World Bank, 1997, WORLD DEV REP 1997; 1997, LANCET, V350, P229	32	41	42	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 21	1998	351	9102					590	592		10.1016/S0140-6736(97)09494-4	http://dx.doi.org/10.1016/S0140-6736(97)09494-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YZ216	9492800				2022-12-28	WOS:000072231900045
J	Hurwitz, B				Hurwitz, B			Dead notes: a meditation and an investigation in general practice	LANCET			English	Article									St Marys Hosp, Imperial Coll Sch Med, Dept Gen Practice, London W2 1PG, England	Imperial College London	Hurwitz, B (corresponding author), St Marys Hosp, Imperial Coll Sch Med, Dept Gen Practice, Norfolk Pl, London W2 1PG, England.								0	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 21	1998	351	9102					593	594		10.1016/S0140-6736(97)08382-7	http://dx.doi.org/10.1016/S0140-6736(97)08382-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ216	9492801				2022-12-28	WOS:000072231900046
J	Bashook, PG; Parboosingh, J				Bashook, PG; Parboosingh, J			Continuing medical education - Recertification and the maintenance of competence	BRITISH MEDICAL JOURNAL			English	Article							PHYSICIANS		Royal Coll Phys & Surg Canada, Ottawa, ON K1S 5N8, Canada; Amer Board Med Specialties, Evanston, IL 60201 USA		Bashook, PG (corresponding author), Amer Board Med Specialties, Evanston, IL 60201 USA.							*AM BOARD MED SPEC, 1997, OFF ABMS DIR BOARD C; *AM BOARD MED SPEC, 1996, 1996 ANN REP REF HDB; *AM MED ASS, 1997, AM MED ACCR PROGR AM; BASHOOK PG, 1994, RECERTIFICATION: NEW EVALUATION METHODS AND STRATEGIES, P15; Campbell CM, 1996, ACAD MED, V71, pS49, DOI 10.1097/00001888-199610000-00042; *COLL FAM PHYS CAN, 1995, MAINPROTM MAINT PROF; DAVIS DA, 1995, PHYSICIAN LEARNER RE; FOX RD, 1989, CHANGING LEARNING LI; HALADYNA TM, 1994, DEV VALIDATING MULTI, P87; HARTMANN WH, 1996, COMPUTER BASED EXAMI, P91; KARLE H, 1993, MED EDUC, V27, P299, DOI 10.1111/j.1365-2923.1993.tb00274.x; Kassirer JP, 1997, NEW ENGL J MED, V337, P43, DOI 10.1056/NEJM199707033370108; KETTLEKAMP DB, 1994, RECERTIFICATION: NEW EVALUATION METHODS AND STRATEGIES, P53; LEIGH TM, 1987, RECERTIFICATION MED, P103; MANNING PR, 1987, PRESERVING PASSION; MCGAGHIE WC, 1993, ED PROFESSIONALS RES, P229; MERRILL JA, 1987, RECERTIFICATION MED, P97; NEALE HW, 1994, RECERTIFICATION: NEW EVALUATION METHODS AND STRATEGIES, P57; NEWBLE D, 1991, CERTIFICATION RECERT, P13; Page G, 1995, ASSESSING CLIN REASO, P9; PARBOOSINGH J, 1996, J CONTIN EDUC HEALTH, V16, P75; Ramsey PG, 1996, ACAD MED, V71, P364, DOI 10.1097/00001888-199604000-00014; ROSEN GA, 1996, COMPUTER BASED EXAMI, P41; SATAVA RM, 1996, COMPUTER BASED EXAMI, P121; Seifer SD, 1996, JAMA-J AM MED ASSOC, V276, P695, DOI 10.1001/jama.276.9.695; SMITH FG, 1994, RECERTIFICATION: NEW EVALUATION METHODS AND STRATEGIES, P33; TAGGART WR, 1995, ASSESSING CLIN REASO, P175; Violato C, 1997, ACAD MED, V72, pS82, DOI 10.1097/00001888-199710001-00028; YOUNG PR, 1994, RECERTIFICATION: NEW EVALUATION METHODS AND STRATEGIES, P63	29	42	43	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 14	1998	316	7130					545	548		10.1136/bmj.316.7130.545	http://dx.doi.org/10.1136/bmj.316.7130.545			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX955	9501722	Green Published			2022-12-28	WOS:000072097400033
J	Kamm, MA				Kamm, MA			Fortnightly review - Faecal incontinence	BRITISH MEDICAL JOURNAL			English	Review							FECAL INCONTINENCE; ANAL ENDOSONOGRAPHY; BOWEL DYSFUNCTION; SPINA-BIFIDA; PREVALENCE; CONSTIPATION; SYMPTOMS; SPHINCTEROTOMY; ABNORMALITIES; CONTINENCE		St Marks Hosp, Harrow HA1 3UJ, Middx, England	Imperial College London	Kamm, MA (corresponding author), St Marks Hosp, Harrow HA1 3UJ, Middx, England.							BAETEN CGMI, 1995, NEW ENGL J MED, V332, P1600, DOI 10.1056/NEJM199506153322403; BURNETT SJD, 1991, BRIT J RADIOL, V64, P225, DOI 10.1259/0007-1285-64-759-225; CATTOSMITH AG, 1995, J PEDIATR-US, V127, P954, DOI 10.1016/S0022-3476(95)70036-6; Cavina E, 1996, DIS COLON RECTUM, V39, P182, DOI 10.1007/BF02068073; DENIS P, 1992, GASTROEN CLIN BIOL, V16, P344; ENCK P, 1993, DIGEST DIS SCI, V38, P1953, DOI 10.1007/BF01297069; ENGEL AF, 1995, INT J COLORECTAL DIS, V10, P152, DOI 10.1007/BF00298538; ENGEL AF, 1994, GUT, V35, P857, DOI 10.1136/gut.35.6.857; ENGEL AF, 1994, BRIT J SURG, V81, P1231, DOI 10.1002/bjs.1800810853; ENGEL AF, 1995, EUR J GASTROEN HEPAT, V7, P65; Gattuso JM, 1997, GUT, V41, P93, DOI 10.1136/gut.41.1.93; Glickman S, 1996, LANCET, V347, P1651, DOI 10.1016/S0140-6736(96)91487-7; GRIFFITHS DM, 1995, J PEDIATR SURG, V30, P68, DOI 10.1016/0022-3468(95)90613-4; Hassink EA, 1996, DIS COLON RECTUM, V39, P695, DOI 10.1007/BF02056953; HINDS JP, 1990, GASTROENTEROLOGY, V98, P1538, DOI 10.1016/0016-5085(90)91087-M; HUGHES SF, 1995, BRIT J SURG, V82, P1318, DOI 10.1002/bjs.1800821008; Johanson JF, 1996, AM J GASTROENTEROL, V91, P33; KAMM MA, 1994, LANCET, V344, P730, DOI 10.1016/S0140-6736(94)92213-6; KHUBCHANDANI IT, 1989, BRIT J SURG, V76, P431, DOI 10.1002/bjs.1800760504; KING JC, 1994, ARCH PHYS MED REHAB, V75, P243, DOI 10.1016/0003-9993(94)90022-1; LAHR C J, 1988, Practical Gastroenterology, V12, P27; LODER PB, 1994, BRIT J SURG, V81, P1386, DOI 10.1002/bjs.1800810949; LOENINGBAUCKE V, 1991, DIGEST DIS SCI, V36, P153, DOI 10.1007/BF01300749; LUDMAN L, 1994, ARCH DIS CHILD, V71, P194, DOI 10.1136/adc.71.3.194; Lund JN, 1997, LANCET, V349, P11, DOI 10.1016/S0140-6736(96)06090-4; MADDEN MV, 1992, DIS COLON RECTUM, V35, P48, DOI 10.1007/BF02053338; MALONE PS, 1994, ARCH DIS CHILD, V70, P107, DOI 10.1136/adc.70.2.107; MATZEL KE, 1995, LANCET, V346, P1124, DOI 10.1016/S0140-6736(95)91799-3; MULDER W, 1995, EUR J PEDIATR SURG, V5, P170, DOI 10.1055/s-2008-1066197; NELSON R, 1995, JAMA-J AM MED ASSOC, V274, P559, DOI 10.1001/jama.274.7.559; SMITH LJ, 1994, DEV MED CHILD NEUROL, V36, P41; SULTAN AH, 1993, NEW ENGL J MED, V329, P1905, DOI 10.1056/NEJM199312233292601; SULTAN AH, 1994, BRIT J SURG, V81, P463, DOI 10.1002/bjs.1800810349; SULTAN AH, 1994, BRIT MED J, V308, P887, DOI 10.1136/bmj.308.6933.887; TALLEY NJ, 1992, GASTROENTEROLOGY, V102, P895, DOI 10.1016/0016-5085(92)90175-X; Vaizey CJ, 1997, LANCET, V349, P612, DOI 10.1016/S0140-6736(96)09188-X; vanderPlas RN, 1996, LANCET, V348, P776, DOI 10.1016/S0140-6736(96)03206-0; Wexner SD, 1996, DIS COLON RECTUM, V39, P957, DOI 10.1007/BF02054681	38	77	80	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 14	1998	316	7130					528	532		10.1136/bmj.316.7130.528	http://dx.doi.org/10.1136/bmj.316.7130.528			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX955	9501717	Green Published			2022-12-28	WOS:000072097400026
J	Jaglo-Ottosen, KR; Gilmour, SJ; Zarka, DG; Schabenberger, O; Thomashow, MF				Jaglo-Ottosen, KR; Gilmour, SJ; Zarka, DG; Schabenberger, O; Thomashow, MF			Arabidopsis CBF1 overexpression induces COR genes and enhances freezing tolerance	SCIENCE			English	Article							CIS-ACTING ELEMENT; LOW-TEMPERATURE; MOLECULAR-CLONING; COLD-ACCLIMATION; THALIANA COR15A; EXPRESSION; DROUGHT; STRESS; ABA	Many plants, including Arabidopsis, show increased resistance to freezing after they have been exposed to low nonfreezing temperatures. This response, termed cold acclimation, is associated with the induction of COR (cold-regulated) genes mediated by the C-repeat/drought-responsive element (CRT/DRE) DNA regulatory element, Increased expression of Arabidopsis CBF1, a transcriptional activator that binds to the CRT/DRE sequence, induced COR gene expression and increased the freezing tolerance of nonacclimated Arabidopsis plants, We conclude that CBF1 is a likely regulator of the cold acclimation response, controlling the level of COR gene expression, which in turn promotes tolerance to freezing.	Michigan State Univ, Dept Crop & Soil Sci, E Lansing, MI 48824 USA	Michigan State University	Thomashow, MF (corresponding author), Michigan State Univ, Dept Crop & Soil Sci, Plant & Soil Sci Bldg, E Lansing, MI 48824 USA.							Artus NN, 1996, P NATL ACAD SCI USA, V93, P13404, DOI 10.1073/pnas.93.23.13404; BAKER SS, 1994, PLANT MOL BIOL, V24, P701, DOI 10.1007/BF00029852; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; Crosatti C, 1996, THEOR APPL GENET, V93, P975, DOI 10.1007/BF00224101; GILMOUR SJ, 1988, PLANT PHYSIOL, V87, P735; GILMOUR SJ, UNPUB; GUY CL, 1990, ANNU REV PLANT PHYS, V41, P187, DOI 10.1146/annurev.pp.41.060190.001155; HAJELA RK, 1990, PLANT PHYSIOL, V93, P1246, DOI 10.1104/pp.93.3.1246; HOUDE M, 1992, MOL GEN GENET, V234, P43, DOI 10.1007/BF00272343; Hughes MA, 1996, J EXP BOT, V47, P291, DOI 10.1093/jxb/47.3.291; Jiang C, 1996, PLANT MOL BIOL, V30, P679, DOI 10.1007/BF00049344; Larcher W., 1981, Physiological processes limiting plant productivity [Johnson, C.B. (Editor)]., P253; Larcher W., 1981, PHYSIOLOGICAL PLANT, P403; METZ AM, 1992, GENE, V120, P313, DOI 10.1016/0378-1119(92)90112-3; MOHAPATRA SS, 1989, PLANT PHYSIOL, V89, P375, DOI 10.1104/pp.89.1.375; NORDIN K, 1993, PLANT MOL BIOL, V21, P641, DOI 10.1007/BF00014547; ROTHSTEIN SJ, 1987, GENE, V53, P153, DOI 10.1016/0378-1119(87)90003-5; Sambrook J., 2002, MOL CLONING LAB MANU; *SAS I, 1989, SAS STAT US GUID VER; Stockinger EJ, 1997, P NATL ACAD SCI USA, V94, P1035, DOI 10.1073/pnas.94.3.1035; SUKUMARAN N P, 1972, Hortscience, V7, P467; Thomashow M. F., 1990, Advances in Genetics, V28, P99; THOMASHOW MF, 1994, ARABIDOPSIS, P807, DOI DOI 10.1101/0.807-834; vanHoof A, 1996, PLANT J, V10, P415, DOI 10.1046/j.1365-313x.1996.10030415.x; WANG H, 1995, PLANT MOL BIOL, V28, P605, DOI 10.1007/BF00021187; YAMAGUCHISHINOZAKI K, 1994, PLANT CELL, V6, P251, DOI 10.1105/tpc.6.2.251	26	1249	1491	7	300	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 3	1998	280	5360					104	106		10.1126/science.280.5360.104	http://dx.doi.org/10.1126/science.280.5360.104			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF314	9525853				2022-12-28	WOS:000072885100045
J	Heine, A; Stura, EA; Yli-Kauhaluoma, JT; Gao, CS; Deng, QL; Beno, BR; Houk, KN; Janda, KD; Wilson, IA				Heine, A; Stura, EA; Yli-Kauhaluoma, JT; Gao, CS; Deng, QL; Beno, BR; Houk, KN; Janda, KD; Wilson, IA			An antibody exo Diels-Alderase inhibitor complex at 1.95 angstrom resolution	SCIENCE			English	Article							CATALYTIC ANTIBODIES; 3-DIMENSIONAL STRUCTURE; REACTIVE IMMUNIZATION; COMPUTER-SIMULATIONS; ANTIGEN INTERACTIONS; STEPWISE MECHANISMS; AUTOMATED DOCKING; CRYSTAL-STRUCTURE; TRANSITION-STATE; ACCELERATION	A highly specific Diels-Alder protein catalyst was made by manipulating the antibody repertoire of the immune system, The catalytic antibody 13G5 catalyzes a disfavored exo Diels-Alder transformation in a reaction for which there is no natural enzyme counterpart and that yields a single regioisomer in high enantiomeric excess. The crystal structure of the antibody Fab in complex with a ferrocenyl inhibitor containing the essential haptenic core that elicited 13G5 was determined at 1.95 angstrom resolution, Three key antibody residues appear to be responsible for the observed catalysis and product control, Tyrosine-L36 acts as a Lewis acid activating the dienophile for nucleophilic attack, and asparagine-L91 and aspartic acid-H50 form hydrogen bonds to the carboxylate side chain that substitutes for the carbamate diene substrate, This hydrogen-bonding scheme leads to rate acceleration and also pronounced stereoselectivity, Docking experiments with the four possible ortho transition states of the reaction explain the specific exo effect and suggest that the (3R, 4R)-exo stereoisomer is the preferred product.	Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA	Scripps Research Institute; University of California System; University of California Los Angeles; Scripps Research Institute; Scripps Research Institute	Heine, A (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Stura, Enrico A./A-2793-2010	Stura, Enrico A./0000-0001-6718-2118; Yli-Kauhaluoma, Jari/0000-0003-0370-7653	NATIONAL CANCER INSTITUTE [P01CA027489] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM043858, R01GM043858] Funding Source: NIH RePORTER; NCI NIH HHS [CA27489, P01 CA27489] Funding Source: Medline; NIGMS NIH HHS [GM-43858] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AREVALO JH, 1993, J MOL BIOL, V231, P103, DOI 10.1006/jmbi.1993.1260; Barone V, 1997, J CHEM PHYS, V106, P8727, DOI 10.1063/1.473933; BECKE AD, 1993, J CHEM PHYS, V98, P5648, DOI 10.1063/1.464913; Beno BR, 1996, J AM CHEM SOC, V118, P9984, DOI 10.1021/ja9615278; Bjornestedt R, 1996, J AM CHEM SOC, V118, P11720, DOI 10.1021/ja9620797; BLAKE JF, 1991, J AM CHEM SOC, V113, P7430, DOI 10.1021/ja00019a055; BLAKE JF, 1994, J ORG CHEM, V59, P803, DOI 10.1021/jo00083a021; BRAISTED AC, 1990, J AM CHEM SOC, V112, P7430, DOI 10.1021/ja00176a073; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CANNIZZARO C, COMMUNICATION; Charbonnier JB, 1997, SCIENCE, V275, P1140, DOI 10.1126/science.275.5303.1140; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P439; CRAVATT BF, 1994, J AM CHEM SOC, V116, P6013, DOI 10.1021/ja00092a080; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FREMONT DH, COMMUNICATION; Goldstein E, 1996, J AM CHEM SOC, V118, P6036, DOI 10.1021/ja9601494; GOLINELLIPIMPANEAU B, 1994, STRUCTURE, V2, P175, DOI 10.1016/S0969-2126(00)00019-8; Goodsell DS, 1996, J MOL RECOGNIT, V9, P1, DOI 10.1002/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO;2-6; GOODSELL DS, 1990, PROTEINS, V8, P195, DOI 10.1002/prot.340080302; GOUVERNEUR VE, 1993, SCIENCE, V262, P204, DOI 10.1126/science.8211138; GRIECO PA, 1983, TETRAHEDRON LETT, V24, P1897, DOI 10.1016/S0040-4039(00)81800-6; GUO JC, 1995, P NATL ACAD SCI USA, V92, P1694, DOI 10.1073/pnas.92.5.1694; Haynes MR, 1996, ISR J CHEM, V36, P133; HAYNES MR, 1994, SCIENCE, V263, P646, DOI 10.1126/science.8303271; Hehre W. J., 1986, AB INITIO MOL ORBITA, P76; HEINE A, UNPUB; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; HILVERT D, 1989, J AM CHEM SOC, V111, P9261, DOI 10.1021/ja00208a037; JANDA KD, 1989, SCIENCE, V244, P437, DOI 10.1126/science.2717936; JANDA KD, 1993, SCIENCE, V259, P490, DOI 10.1126/science.8424171; JANDA KD, 1996, COMPREHENSIVE SUPRAM, P43; Jencks W. P., 1969, CATALYSIS CHEM ENZYM; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORGENSEN WL, 1994, J CHEM SOC FARADAY T, V90, P1727, DOI 10.1039/ft9949001727; Kabat EA, 1991, SEQUENCES PROTEINS I; KEINAN E, 1996, ISR J CHEM, V36, P133; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lavey BJ, 1995, ACS SYM SER, V604, P123, DOI 10.1021/bk-1995-0604.ch010; LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PhysRevB.37.785; LI Y, 1993, J AM CHEM SOC, V115, P7478, DOI 10.1021/ja00069a055; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OIKAWA H, 1995, J CHEM SOC CHEM COMM, P1321, DOI 10.1039/c39950001321; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PALENIK GJ, 1969, INORG CHEM, V8, P2744, DOI 10.1021/ic50082a041; Patten PA, 1996, SCIENCE, V271, P1086, DOI 10.1126/science.271.5252.1086; PURVIS GD, 1986, J MOL GRAPH, V4; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RIDEOUT DC, 1980, J AM CHEM SOC, V102, P7816, DOI 10.1021/ja00546a048; ROSSMANN MG, 1975, J BIOL CHEM, V250, P7525; SAUER J, 1980, ANGEW CHEM INT EDIT, V19, P779, DOI 10.1002/anie.198007791; Schlegel HB., 2009, GAUSSIAN 09 REVISION; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; SHELDRICK GM, 1996, SHELXL 96 PROGRAM CR; SHERIFF S, 1993, IMMUNOMETHODS, V3, P191; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; Streitwieser A.J., 1981, INTRO ORGANIC CHEM; Stura E. A., 1993, IMMUNOMETHODS, V3, P164; TAKUSAGAWA F, 1979, ACTA CRYSTALLOGR B, V35, P2888, DOI 10.1107/S0567740879010906; TRAMONTANO A, 1986, SCIENCE, V234, P1566, DOI 10.1126/science.3787261; UPSON C, 1989, IEEE COMPUT GRAPH, V9, P30, DOI 10.1109/38.31462; WAGNER J, 1995, SCIENCE, V270, P1797, DOI 10.1126/science.270.5243.1797; WILSON IA, 1993, CURR OPIN STRUC BIOL, V3, P113, DOI 10.1016/0959-440X(93)90210-C; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4; WIRSCHING P, 1995, SCIENCE, V270, P1775, DOI 10.1126/science.270.5243.1775; YLIKAUHALUOMA JT, 1995, J AM CHEM SOC, V117, P7041, DOI 10.1021/ja00132a001; ZHOU GW, 1994, SCIENCE, V265, P1059, DOI 10.1126/science.8066444	68	117	119	2	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 20	1998	279	5358					1934	1940		10.1126/science.279.5358.1934	http://dx.doi.org/10.1126/science.279.5358.1934			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506943	Green Submitted			2022-12-28	WOS:000072613300046
J	Soker, S; Takashima, S; Miao, HQ; Neufeld, G; Klagsbrun, M				Soker, S; Takashima, S; Miao, HQ; Neufeld, G; Klagsbrun, M			Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor	CELL			English	Article							HEPARIN-LIKE MOLECULES; TYROSINE KINASE; FACTOR VEGF; PERMEABILITY FACTOR; ANGIOGENESIS FACTOR; MEMBRANE-PROTEIN; NERVOUS-SYSTEM; BINDING; DIFFERENTIATION; GENE	Vascular endothelial growth factor (VEGF), a major regulator of angiogenesis, binds to two receptor tyrosine kinases, KDR/Flk-1 and Flt-1. We now describe the purification and the expression cloning from tumor cells of a third VEGF receptor, one that binds VEGF(165) but not VEGF(121). This isoform-specific VEGF receptor (VEGF(165)R) is identical to human neuropilin-1, a receptor for the collapsin/semaphorin family that mediates neuronal cell guidance. When coexpressed in cells with KDR, neuropilin-1 enhances the binding of VEGF(165) to KDR and VEGF(165)-mediated chemotaxis. Conversely, inhibition of VEGF(165) binding to neuropilin-1 inhibits its binding to KDR and its mitogenic activity for endothelial cells. We propose that neuropilin-1 is a novel VEGF receptor that modulates VEGF binding to KDR and subsequent bioactivity and therefore may regulate VEGF-induced angiogenesis.	Harvard Univ, Childrens Hosp, Sch Med, Dept Surg, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA; Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Technion Israel Institute of Technology	Klagsbrun, M (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Dept Surg, Boston, MA 02115 USA.		Neufeld, Gera/F-1524-2019		NCI NIH HHS [CA37392, CA45548] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA037392, P01CA045548, R01CA037392] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; BREIER G, 1992, DEVELOPMENT, V114, P521; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; Cohen T, 1992, GROWTH FACTORS, V7, P131, DOI 10.3109/08977199209046402; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DVORAK HF, 1995, AM J PATHOL, V146, P1029; DVORAK HF, 1991, J EXP MED, V174, P1275, DOI 10.1084/jem.174.5.1275; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; ENOMOTO T, 1994, BIOCHEM BIOPH RES CO, V202, P1716, DOI 10.1006/bbrc.1994.2133; Feiner L, 1997, NEURON, V19, P539, DOI 10.1016/S0896-6273(00)80370-0; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FLAMME I, 1995, DEV BIOL, V169, P699, DOI 10.1006/dbio.1995.1180; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fujisawa H, 1995, DEV NEUROSCI-BASEL, V17, P343, DOI 10.1159/000111304; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; Joukov V, 1996, EMBO J, V15, P1751; KAWAKAMI A, 1995, J NEUROBIOL, V29, P1; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kitsukawa T, 1997, NEURON, V19, P995, DOI 10.1016/S0896-6273(00)80392-X; Kitsukawa T, 1995, DEVELOPMENT, V121, P4309; KLAGSBRUN M, 1993, CURR BIOL, V3, P699, DOI 10.1016/0960-9822(93)90073-W; Klagsbrun Michael, 1996, Cytokine and Growth Factor Reviews, V7, P259, DOI 10.1016/S1359-6101(96)00027-5; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MIDY V, 1994, BIOCHEM BIOPH RES CO, V199, P380, DOI 10.1006/bbrc.1994.1240; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Omura T, 1997, J BIOL CHEM, V272, P23317, DOI 10.1074/jbc.272.37.23317; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHWEIKI D, 1993, J CLIN INVEST, V91, P2235, DOI 10.1172/JCI116450; Soker S, 1997, J BIOL CHEM, V272, P31582, DOI 10.1074/jbc.272.50.31582; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; TAKAGI S, 1987, DEV BIOL, V122, P90, DOI 10.1016/0012-1606(87)90335-6; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; TAKAGI S, 1995, DEV BIOL, V170, P207, DOI 10.1006/dbio.1995.1208; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0; TISCHER E, 1991, J BIOL CHEM, V266, P11947; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WILCHEK M, 1982, BIOCHEM INT, V4, P629; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Yoshida A, 1996, GROWTH FACTORS, V13, P57, DOI 10.3109/08977199609034566	60	1935	2082	3	100	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 20	1998	92	6					735	745		10.1016/S0092-8674(00)81402-6	http://dx.doi.org/10.1016/S0092-8674(00)81402-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZD198	9529250	Bronze			2022-12-28	WOS:000072661200007
J	Chen, QY; Kirsch, GE; Zhang, DM; Brugada, R; Brugada, J; Brugada, P; Potenza, D; Moya, A; Borggrefe, M; Breithardt, G; Ortiz-Lopez, R; Wang, Z; Antzelevitch, C; O'Brien, RE; Schulze-Bahr, E; Keating, MT; Towbin, JA; Wang, Q				Chen, QY; Kirsch, GE; Zhang, DM; Brugada, R; Brugada, J; Brugada, P; Potenza, D; Moya, A; Borggrefe, M; Breithardt, G; Ortiz-Lopez, R; Wang, Z; Antzelevitch, C; O'Brien, RE; Schulze-Bahr, E; Keating, MT; Towbin, JA; Wang, Q			Genetic basis and molecular mechanism for idiopathic: ventricular fibrillation	NATURE			English	Article							INHERITED CARDIAC-ARRHYTHMIA; ST SEGMENT ELEVATION; LONG-QT SYNDROME; BUNDLE-BRANCH BLOCK; SODIUM-CHANNEL; HEART-DISEASE; J-WAVE; DEATH; MUTATIONS	Ventricular fibrillation causes more than 300,000 sudden deaths each year in the USA alone(1,2). In approximately 5-12% of these cases, there are no demonstrable cardiac or non-cardiac causes to account for the episode, which is therefore classified as idiopathic ventricular fibrillation (IVF)(3-6). A distinct group of IVF patients has been found to present with a characteristic electrocardiographic pattern(7-15). Because of the small size of most pedigrees and the high incidence of sudden death, however, molecular genetic studies of NF have not yet been done. Because IVF causes cardiac rhythm disturbance, we investigated whether malfunction of ion channels could cause the disorder by studying mutations in the cardiac sodium channel gene SCN5A. We have now identified a missense mutation, a splice-donor mutation, and a frameshift mutation in the coding region of SCN5A in three IVF families. We show that sodium channels with the missense mutation recover from inactivation more rapidly than normal and that the frameshift mutation causes the sodium channel to be non-functional. Our results indicate that mutations in cardiac ion-channel genes contribute to the risk of developing IVF.	Baylor Coll Med, Dept Pediat Cardiol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med Cardiol, Houston, TX 77030 USA; Baylor Coll Med, Dept Cardiovasc Sci, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Case Western Reserve Univ, Rammelkamp Ctr Res, Cleveland, OH 44109 USA; Univ Barcelona, Hosp Clin, Cardiovasc Inst, Arrhythmia Unit, E-08036 Barcelona, Spain; OLV Hosp, Ctr Cardiovasc, B-9300 Aalst, Belgium; IRCCS, Dept Cardiol, S Giovanni Rotondo, Italy; Hosp Gen Valle Hebron, Dept Cardiol, Barcelona 08020, Spain; Hosp Univ Munster, Inst Arteriosclerosis Res, Dept Cardiol & Angiol, D-48129 Munster, Germany; Masonic Med Res Lab, Utica, NY 13504 USA; Univ Utah, Howard Hughes Med Inst, Dept Human Genet & Med, Salt Lake City, UT 84112 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Case Western Reserve University; MetroHealth System; University of Barcelona; Hospital Clinic de Barcelona; Cardiovascular Center Aalst; Hospital Universitari Vall d'Hebron; University of Munster; Masonic Medical Research Laboratory; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah	Wang, Q (corresponding author), Baylor Coll Med, Dept Pediat Cardiol, Houston, TX 77030 USA.	qwang@bcm.tmc.edu	Towbin, Jeffrey A./J-5595-2019; Ortiz-Lopez, Rocio/F-7020-2014	Towbin, Jeffrey A./0000-0002-6585-714X; Ortiz-Lopez, Rocio/0000-0002-7783-026X; Antzelevitch, Charles/0000-0001-5215-4667; Antzelevitch, Charles/0000-0001-7349-1582; BRUGADA, JOSEP/0000-0002-5662-8302				AIZAWA Y, 1993, AM HEART J, V126, P1473, DOI 10.1016/0002-8703(93)90550-S; BENNETT PB, 1995, NATURE, V376, P683, DOI 10.1038/376683a0; BJERREGAARD P, 1994, AM HEART J, V127, P1426, DOI 10.1016/0002-8703(94)90070-1; Brugada J, 1997, J CARDIOVASC ELECTR, V8, P325, DOI 10.1111/j.1540-8167.1997.tb00796.x; BRUGADA J, 1996, PACE, V19, P599; BRUGADA J, 1997, CIRCULATION, V96, P1151; BRUGADA P, 1992, J AM COLL CARDIOL, V20, P1391, DOI 10.1016/0735-1097(92)90253-J; COBB LA, 1994, HURSTS HEART, P947; Dumaine R, 1996, CIRC RES, V78, P916, DOI 10.1161/01.RES.78.5.916; HOFFMAN EP, 1995, CELL, V80, P681, DOI 10.1016/0092-8674(95)90345-3; KANNEL WB, 1987, AM HEART J, V113, P799, DOI 10.1016/0002-8703(87)90722-8; KRISHNAN SC, 1993, CIRCULATION, V87, P562, DOI 10.1161/01.CIR.87.2.562; KRISHNAN SC, 1991, CIRC RES, V69, P277, DOI 10.1161/01.RES.69.2.277; MARTINI B, 1989, AM HEART J, V118, P1203, DOI 10.1016/0002-8703(89)90011-2; Miyanuma H, 1993, Kokyu To Junkan, V41, P287; Miyazaki T, 1996, J AM COLL CARDIOL, V27, P1061, DOI 10.1016/0735-1097(95)00613-3; Rogers JC, 1996, J BIOL CHEM, V271, P15950, DOI 10.1074/jbc.271.27.15950; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; SUMIYOSHI M, 1993, JPN HEART J, V34, P661; TRAPPE HJ, 1988, J AM COLL CARDIOL, V12, P166, DOI 10.1016/0735-1097(88)90370-1; TUNG RT, 1994, PACE, V17, P1405, DOI 10.1111/j.1540-8159.1994.tb02460.x; VISKIN S, 1990, AM HEART J, V120, P661, DOI 10.1016/0002-8703(90)90025-S; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; WANG Q, 1995, HUM MOL GENET, V4, P1603, DOI 10.1093/hmg/4.9.1603; Wang Q, 1996, GENOMICS, V34, P9, DOI 10.1006/geno.1996.0236; WICHTER T, 1995, CARDIAC ARRHYTHMIA M, P1219; WILLICH SN, 1987, AM J CARDIOL, V60, P801, DOI 10.1016/0002-9149(87)91027-7; Yan GX, 1996, CIRCULATION, V93, P372, DOI 10.1161/01.CIR.93.2.372; YANG NB, 1995, NEURON, V15, P213, DOI 10.1016/0896-6273(95)90078-0	30	1268	1335	0	50	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1998	392	6673					293	296		10.1038/32675	http://dx.doi.org/10.1038/32675			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC739	9521325				2022-12-28	WOS:000072612300050
J	Hanzlick, R; Combs, D				Hanzlick, R; Combs, D			Medical examiner and coroner systems - History and trends	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Meeting of the National-Association-of-Medical-Examiners	SEP   17, 1997	BALTIMORE, MARYLAND	Natl Assoc Med Examiners				Context.-Medical legal investigations in the United States (primarily unnatural or suspected unnatural deaths) are carried out by medical examiner or coroner systems, Medical examiners-usually physicians and generally with training in pathology, medicolegal death investigation, and performance of forensic autopsies-generally have greater expertise in unnatural death investigations than do coroners. Objective.-To document the locations and implementation year for states and counties that have medical examiner systems that have replaced coroner systems or that are defined in statute and assist coroners in their investigations. Design.-Review of published information and national survey in 1997. Setting.-United States. Participants.-County medical examiners and state medical examiners or their administrators. Main Outcome Measures.-The location of states and counties with medical examiner systems, the implementation year for each system, and the proportion of counties and population served by medical examiner systems. Results.-A total of 79 of 91 county medical examiners responded. A total of 36 states have at least 1 medical examiner system at the county, district, or state level in which there is no coroner involved in the death investigation process. Only 22 states have medical examiner death investigation systems in place and have no coroners in the state. Among 13 states in which some counties have coroner systems and some have medical examiner systems, medical examiner systems exist in 8% of counties and serve 43% of the population, Medical examiner systems that operate without coroner involvement serve about 48% of the population nationwide. Few state or county medical examiner systems have been implemented since 1990. Conclusions.-In this century, medical examiner systems have gradually replaced coroner systems, but such change has slowed in recent years, with medical examiner systems now serving about 48% of the national population.	Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA; Emory Univ, Sch Med, Dept Forens Pathol, Atlanta, GA USA	Centers for Disease Control & Prevention - USA; Emory University	Hanzlick, R (corresponding author), 916 Cumberland Rd NE, Atlanta, GA 30306 USA.							COMBS DL, 1995, DEATH INVESTIGATION; HANSLICK R, 1996, JAMA-J AM MED ASSOC, V276, P1775; Hanzlick R, 1996, ARCH PATHOL LAB MED, V120, P329; Spitz W. U., 1982, MEDICOLEGAL INVESTIG	4	56	57	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 18	1998	279	11					870	874		10.1001/jama.279.11.870	http://dx.doi.org/10.1001/jama.279.11.870			5	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA943	9516003				2022-12-28	WOS:000072417600035
J	Juliano, SL				Juliano, SL			Neurobiology - Mapping the sensory mosaic	SCIENCE			English	Article							PRIMARY SOMATOSENSORY CORTEX; LONG-TERM ENHANCEMENT; ADULT FLYING-FOX; RECEPTIVE-FIELDS; CEREBRAL-CORTEX; STRIATE CORTEX; CAT; REORGANIZATION; ACETYLCHOLINE; THALAMUS		Uniformed Serv Univ Hlth Sci, Dept Anat & Cell Biol, Bethesda, MD 20814 USA	Uniformed Services University of the Health Sciences - USA	Juliano, SL (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat & Cell Biol, Bethesda, MD 20814 USA.	sjuliano@mx3.usuhs.mil	Juliano, Sharon/AAO-1030-2020					Bakin JS, 1996, P NATL ACAD SCI USA, V93, P11219, DOI 10.1073/pnas.93.20.11219; CALFORD MB, 1988, NATURE, V332, P446, DOI 10.1038/332446a0; CALFORD MB, 1991, J NEUROPHYSIOL, V65, P178, DOI 10.1152/jn.1991.65.2.178; DARIANSMITH C, 1995, J NEUROSCI, V15, P1631, DOI 10.1523/JNEUROSCI.15-03-01631.1995; DARIANSMITH C, 1994, NATURE, V368, P737, DOI 10.1038/368737a0; Dykes RW, 1997, CAN J PHYSIOL PHARM, V75, P535, DOI 10.1139/cjpp-75-5-535; Faggin BM, 1997, P NATL ACAD SCI USA, V94, P9428, DOI 10.1073/pnas.94.17.9428; Gil Z, 1997, NEURON, V19, P679, DOI 10.1016/S0896-6273(00)80380-3; HOHMANN CF, IN PRESS PERSPECTIVE; Huntley GW, 1997, CEREB CORTEX, V7, P143, DOI 10.1093/cercor/7.2.143; JULIANO SL, 1990, J COMP NEUROL, V297, P106, DOI 10.1002/cne.902970108; JULIANO SL, 1991, P NATL ACAD SCI USA, V88, P780, DOI 10.1073/pnas.88.3.780; Kawaguchi Y, 1997, J NEUROPHYSIOL, V78, P1743, DOI 10.1152/jn.1997.78.3.1743; Kilgard MP, 1998, SCIENCE, V279, P1714, DOI 10.1126/science.279.5357.1714; KOSSUT M, UNPUB; Malenka RC, 1997, NEURON, V19, P473, DOI 10.1016/S0896-6273(00)80362-1; MCCORMICK DA, 1985, P NATL ACAD SCI USA, V82, P6344, DOI 10.1073/pnas.82.18.6344; MCCORMICK DA, 1992, PROG NEUROBIOL, V39, P337, DOI 10.1016/0301-0082(92)90012-4; MCCORMICK DA, 1993, PROG BRAIN RES, V98, P303; METHERATE R, 1987, NEUROSCIENCE, V22, P75, DOI 10.1016/0306-4522(87)90198-9; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; RASMUSSON DD, 1988, EXP BRAIN RES, V70, P276; Richardson R.T, 1991, ACTIVATION ACQUISITI; Tang AC, 1997, CEREB CORTEX, V7, P502, DOI 10.1093/cercor/7.6.502; WALL PD, 1977, PHILOS T R SOC B, V278, P361, DOI 10.1098/rstb.1977.0048; Weinberger N M, 1993, Curr Opin Neurobiol, V3, P570, DOI 10.1016/0959-4388(93)90058-7; WEINBERGER NM, 1995, ANNU REV NEUROSCI, V18, P129	27	19	21	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 13	1998	279	5357					1653	1654		10.1126/science.279.5357.1653	http://dx.doi.org/10.1126/science.279.5357.1653			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9518376				2022-12-28	WOS:000072490000037
J	Hall, MA; Berenson, RA				Hall, MA; Berenson, RA			Ethical practice in managed care: A dose of realism	ANNALS OF INTERNAL MEDICINE			English	Article							UNIVERSAL HEALTH-INSURANCE; CAPITATED PAYMENT; COST-CONTAINMENT; PROMOTE QUALITY; MEDICAL-ETHICS; PHYSICIAN; CHOICE; 1990S; ORGANIZATIONS; COMPETITION	This article examines the ethics of medical practice under managed care from a pragmatic perspective that gives physicians more useful guidance than do existing ethical statements. The article begins with a framework for constructing a realistic set of ethical principles, namely, that medical ethics derives from physicians' role as healers; that ethical statements are primarily aspirational, not regulatory; and that preserving patient trust is the primary objective. The following concrete ethical guidelines are presented: Financial incentives should influence physicians to maximize the health of the group of patients under their care; physicians should not enter into incentive arrangements that they are embarrassed to describe accurately to their patients; physicians should treat each patient impartially without regard to source of payment, consistent with the physician's own treatment style; if physicians depart from this ideal, they should inform their patients honestly; and it is desirable, although not mandatory, to differentiate medical treatment recommendations from insurance coverage decisions by clearly assigning authority over these different roles and by physicians advocating for recommended treatment that is not covered.	Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth, Winston Salem, NC 27157 USA; Georgetown Univ, Sch Med, Washington, DC USA	Wake Forest University; Wake Forest Baptist Medical Center; Georgetown University	Hall, MA (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth, Med Ctr Blvd, Winston Salem, NC 27157 USA.							Angell M, 1993, Kennedy Inst Ethics J, V3, P279; Berenson R A, 1986, Health Aff (Millwood), V5, P141, DOI 10.1377/hlthaff.5.1.141; Berenson RA, 1997, HEALTH AFFAIR, V16, P171, DOI 10.1377/hlthaff.16.2.171; Berwick DM, 1996, NEW ENGL J MED, V335, P1227, DOI 10.1056/NEJM199610173351611; BRENNAN TA, 1991, JUST DOCTORING MED E; BRETT AS, 1992, NEW ENGL J MED, V326, P1353, DOI 10.1056/NEJM199205143262010; Brody H, 1987, Theor Med, V8, P5, DOI 10.1007/BF00539762; Brody H., 1987, STORIES SICKNESS; BRODY H, 1982, HEALERS POWER; CHRISTENSEN KT, 1995, J LAW MED ETHICS, V23, P223, DOI 10.1111/j.1748-720X.1995.tb01358.x; DANIELS N, 1986, NEW ENGL J MED, V314, P1380, DOI 10.1056/NEJM198605223142109; Daniels N, 1987, Theor Med, V8, P69, DOI 10.1007/BF00539767; EDDY DM, 1993, JAMA-J AM MED ASSOC, V270, P520; EDDY DM, 1994, JAMA-J AM MED ASSOC, V271, P1792, DOI 10.1001/jama.271.22.1792; Elkowitz A, 1986, J Med Humanit Bioeth, V7, P122, DOI 10.1007/BF01117903; Emanuel EJ, 1995, J CLIN ETHIC, V6, P335; EMANUEL EJ, 1993, NEW ENGL J MED, V329, P879, DOI 10.1056/NEJM199309163291213; EMANUEL EJ, 1995, JAMA-J AM MED ASSOC, V273, P323, DOI 10.1001/jama.273.4.323; Emmet Dorothy, 1994, ROLE UNREALISABLE ST; ENGLEHARDT HT, 1996, FDN BIOETHICS; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P94, DOI 10.1056/NEJM198901123200205; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P29, DOI 10.1056/NEJM198901053200106; ENTHOVEN AC, 1995, HEALTH AFFAIR, V14, P105, DOI 10.1377/hlthaff.14.1.105; FIGA SF, 1990, SETON HALL LEGIS J, V14, P151; GLASSON J, 1995, JAMA-J AM MED ASSOC, V273, P330, DOI 10.1001/jama.1995.03520280076044; GOLD MR, 1995, NEW ENGL J MED, V333, P1678, DOI 10.1056/NEJM199512213332505; Good D., 1988, TRUST MAKING BREAKIN; GOOLD SD, 1995, HLTH CARE CRISIS SEA, P141; *GOV COMM, 1995, GREAT GOOD REC AM PH; Gray BH, 1997, HEALTH AFFAIR, V16, P34, DOI 10.1377/hlthaff.16.1.34; Green GD, 1996, WOMEN THER, V18, P1, DOI 10.1300/J015v18n02_04; Hall M A, 1997, Georgia Law Rev, V31, P511; HALL MA, 1994, NEW YORK U LAW REV, V69, P693; HALL MA, 1996, MAKING MED SPENDING; Harris JM, 1996, ANN INTERN MED, V124, P838, DOI 10.7326/0003-4819-124-9-199605010-00009; HAVIGHURST CC, 1995, HLTH CARE CHOICES PR; HIRSH D, 1990, MOL BIOL REP, V14, P115, DOI 10.1007/BF00360438; JECKER NS, 1994, CLIN GERIATR MED, V10, P527, DOI 10.1016/S0749-0690(18)30338-0; JOHNSON SH, 1995, J LAW MED ETHICS, V23, P266, DOI 10.1111/j.1748-720X.1995.tb01362.x; Jones S.B., 1996, IMPROVING MED MARKET IMPROVING MED MARKET; KASSIRER JP, 1995, NEW ENGL J MED, V333, P50, DOI 10.1056/NEJM199507063330110; KERR EA, 1995, ANN INTERN MED, V123, P500, DOI 10.7326/0003-4819-123-7-199510010-00004; KOLLER M, 1988, BASIC APPL SOC PSYCH, V9, P265, DOI 10.1207/s15324834basp0904_2; Langan, 1991, ETHICS TRUST PROFESS; LEVINSKY NG, 1984, NEW ENGL J MED, V311, P1573, DOI 10.1056/NEJM198412133112412; LEVINSON DF, 1987, NEW ENGL J MED, V317, P1729, DOI 10.1056/NEJM198712313172708; LINDSEY PA, 1990, J HEALTH POLIT POLIC, V15, P543, DOI 10.1215/03616878-15-3-543; Luban D., 1988, LAWYERS JUSTICE ETHI; MARINER WK, 1995, J LAW MED ETHICS, V23, P236, DOI 10.1111/j.1748-720X.1995.tb01360.x; Mechanic D, 1996, JAMA-J AM MED ASSOC, V275, P1693, DOI 10.1001/jama.275.21.1693; MENZEL PT, 1990, STRONG MED ETHICAL R; Morreim E. H., 1991, BALANCING ACT NEW ME; Newcomer LN, 1997, HEALTH AFFAIR, V16, P50, DOI 10.1377/hlthaff.16.1.50; Orentlicher David, 1996, Univ Richmond Law Rev, V30, P155; PEAR R, 1995, NY TIMES        0527, P1; Pellegrino Edmund D., 1993, VIRTUES MED PRACTICE; RELMAN AS, 1993, NEW ENGL J MED, V329, P1574, DOI 10.1056/NEJM199311183292113; RELMAN AS, 1988, NEW ENGL J MED, V319, P784, DOI 10.1056/NEJM198809223191209; ROBINSON JC, 1995, NEW ENGL J MED, V333, P1684, DOI 10.1056/NEJM199512213332506; Rodwin M. A., 1993, MED MONEY MORALS PHY; ROSENTHAL E, 1996, NY TIMES        1125; SABIN JE, 1994, HOSP COMMUNITY PSYCH, V45, P859; Selker HP, 1996, ANN INTERN MED, V124, P449, DOI 10.7326/0003-4819-124-4-199602150-00010; SHAPIRO MH, 1994, U PITT LAW REV, V55, P681; Swartz K, 1996, ANN INTERN MED, V124, P442, DOI 10.7326/0003-4819-124-4-199602150-00009; TOMSHO R, 1996, WALL STREET J A 0312, P1; UBEL PA, 1995, ARCH INTERN MED, V155, P1837, DOI 10.1001/archinte.155.17.1837; Ubel PA, 1997, ANN INTERN MED, V126, P74, DOI 10.7326/0003-4819-126-1-199701010-00010; *US DEP HHS, 1990, REP C INC ARR OFF HL; WOLF SM, 1994, HASTINGS CENT REP, V24, P28, DOI 10.2307/3562181; Zaner R.M., 1991, ETHICS TRUST PROFESS	71	77	77	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1998	128	5					395	402		10.7326/0003-4819-128-5-199803010-00009	http://dx.doi.org/10.7326/0003-4819-128-5-199803010-00009			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YY519	9490601				2022-12-28	WOS:000072155600009
J	Dubowitz, G				Dubowitz, G			Effect of temazepam on oxygen saturation and sleep quality at high altitude: randomised placebo controlled crossover trial	BRITISH MEDICAL JOURNAL			English	Article								Objective: To determine the effects of temazepam on the quality of sleep and on oxygen saturation during sleep in subjects at high altitude. Design: Randomised, blinded, crossover, placebo controlled trial. Setting: Base camp at Mount Everest (altitude 5300 m). Subjects: 11 members of British Mount Everest Medical Expedition recently arrived at base camp. Intervention: Participants were randomly allocated to receive either temazepam 10 mg or placebo on their first night at base camp and the other treatment on the second night. Main outcome measures: Quality of sleep (assessed subjectively), mean arterial oxygen saturation value, and changes in saturation values (as measure of periodic breathing) while participants taking temazepam or placebo. Results: All participants noted subjective improvements in sleep. Mean saturation value remained unchanged when temazepam was compared with placebo (74.65% v 75.70%, P = 0.5437). There were fewer changes in oxygen saturation when participants took temazepam and when measured as decreases > 4% below the mean value of saturation each hour (P = 0.0036, paired Student's t test (two tailed)). Conclusions: Participants taking temazepam at 5300 m showed no significant drop in mean oxygen saturation values during sleep. Both the number and severity of changes in saturation during sleep decreased and the quality of sleep improved. This may be a result of a reduction in the number of awakenings and might lead to greater respiratory stability and fever episodes of periodic breathing. This has the effect of improving the quality of sleep and reducing the number of periods of desaturation during sleep.	British Mt Everest Med Expedit, Montgomery, Powys, Wales		Dubowitz, G (corresponding author), 25 Middleton Rd, London NW11 7NR, England.							ANHOLM JD, 1992, AM REV RESPIR DIS, V145, P817, DOI 10.1164/ajrccm/145.4_Pt_1.817; BARCROFT J, 1925, LESSONS HIGH ALTITUD; BAVENHILL T. H., 1913, Journal of Tropical Medicine and Hygiene, V16, P313; BONNET MH, 1986, PHYSIOL BEHAV, V37, P915, DOI 10.1016/S0031-9384(86)80012-9; BONNET MH, 1990, SLEEP, V13, P31, DOI 10.1093/sleep/13.1.31; GOLDENBERG F, 1992, INT J SPORTS MED, V13, pS34, DOI 10.1055/s-2007-1024586; GOLDENBERG F, 1988, PRESSE MED, V17, P471; LASERRE E, 1979, NOUV PRESSE MED, V8, P2577; NICHOLSON AN, 1988, SLEEP, V11, P354, DOI 10.1093/sleep/11.4.354; POWLES SCP, 1983, SEMIN RESPIR MED, V5, P175; REITE M, 1975, ELECTROEN CLIN NEURO, V38, P463, DOI 10.1016/0013-4694(75)90188-1; SUTTON JR, 1983, HIGH ALTITUDE MAN; WEIL JV, 1985, CLIN CHEST MED, V6, P615; WEST JB, 1986, J APPL PHYSIOL, V61, P280, DOI 10.1152/jappl.1986.61.1.280	14	27	27	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 21	1998	316	7131					587	589		10.1136/bmj.316.7131.587	http://dx.doi.org/10.1136/bmj.316.7131.587			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ031	9518909	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000072213200026
J	Lennox, A; Petersen, S				Lennox, A; Petersen, S			Development and evaluation of a community based, multiagency course for medical students: descriptive survey	BRITISH MEDICAL JOURNAL			English	Article								Objective: To develop and evaluate an effective, community based, multiagency; course (involving doctors, nurses, non-health statutory workers, and voluntary organisations) for all Leicester medical students, in response to the General Medical Council's recommendation of preparing the doctors of tomorrow to handle society's medical problems. Design: Survey evaluating a task oriented, problem solving course, designed by medical students in partnership with the University of Leicester and the local community. The students, staff, and participating agencies and patients all helped in the evaluation of the first course, The students' performance on the course nas also individually assessed. Setting: Inner city housing estate with Jarman index 64.1 in Leicester. Subjects: All third year medical students at Leicester University. Main outcome measures: Results of the student assignments and students' responses to a questionnaire. Results of feedback questionnaires distributed to the patients and agency representatives. Results: In a two month period, 168 students completed the first course. 163 students passed the criterion referenced assignment, 50 of whom achieved an "excellent" grade. 166 completed the questionnaire, with 159 wishing to see the course continue in the present format and 149 saying that the course linked theoretical teaching with the practical experiences gained in the community. Conclusions: The University of Leicester has a viable mechanism for providing a community based, multiagency course for all its medical students. Many of the principles applied in the development and implementation of the course could be transferred to other medical schools.	Univ Leicester, Fac Med, Div Med Educ, Leicester LE1 9HN, Leics, England	University of Leicester	Lennox, A (corresponding author), Univ Leicester, Fac Med, Div Med Educ, POB 138, Leicester LE1 9HN, Leics, England.							Barrows H., 1980, PROBLEM BASED LEARNI; Department of Health, 1992, HLTH NAT SUMM STRAT; *GEN MED COUNC, 1993, TOM DOCT REP ED COMM; Habbick BF, 1996, MED EDUC, V30, P163, DOI 10.1111/j.1365-2923.1996.tb00738.x; LORENZ RA, 1986, MED EDUC, V20, P195, DOI 10.1111/j.1365-2923.1986.tb01167.x; *NHS EX, 1995, SIFT FUT REP ADV GRO; *SECR STAT HLTH, 1996, PRIM CAR DEL FUT; *SECR STAT HLTH, 1996, NAT HLTH SERV SERV A; WALTON HJ, 1989, MED EDUC, V23, P542, DOI 10.1111/j.1365-2923.1989.tb01581.x; *WHO, 1988, WHO TECH REP SER, P769; *WORLD FED MED ED, 1994, MED ED S1, V28	11	27	28	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 21	1998	316	7131					596	599		10.1136/bmj.316.7131.596	http://dx.doi.org/10.1136/bmj.316.7131.596			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ031	9518914	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000072213200032
J	Lyon, CC; Telfer, NR; Croall, J; Griffiths, CEM				Lyon, CC; Telfer, NR; Croall, J; Griffiths, CEM			A painful spot on the nose	LANCET			English	Article							INFECTION		Univ Manchester, Sch Med, Dermatol Ctr, Manchester M13 9PL, Lancs, England; Hope Hosp, Dept Microbiol, Salford M6 8HD, Lancs, England	University of Manchester	Lyon, CC (corresponding author), Univ Manchester, Sch Med, Dermatol Ctr, Manchester M13 9PL, Lancs, England.		Griffiths, Christopher E.M./P-5448-2014	Griffiths, Christopher E.M./0000-0001-5371-4427; lyon, calum/0000-0001-5971-9739				BROOK I, 1991, REV INFECT DIS, V13, P819; ESTEBAN J, 1994, EUR J CLIN MICROBIOL, V13, P1084, DOI 10.1007/BF02111835; GIMENEZ JJ, 1994, PRESSE MED, V23, P1539; MAIBACH HI, 1967, ARCH DERMATOL, V96, P453, DOI 10.1001/archderm.96.4.453; Ramon Quiles L, 1990, Ann Dermatol Venereol, V117, P467	5	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 21	1998	351	9102					566	566		10.1016/S0140-6736(97)11183-7	http://dx.doi.org/10.1016/S0140-6736(97)11183-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ216	9492777				2022-12-28	WOS:000072231900013
J	Sundar, S; Reed, SG; Singh, VP; Kumar, PCK; Murray, HW				Sundar, S; Reed, SG; Singh, VP; Kumar, PCK; Murray, HW			Rapid accurate field diagnosis of Indian visceral leishmaniasis	LANCET			English	Article							KALA-AZAR; RECOMBINANT ANTIGEN; INTERFERON-GAMMA; INFECTION; IMMUNOCHEMOTHERAPY; SPECTRUM; KINESIN; FOCUS	Background A firm diagnosis of visceral leishmaniasis (kalaazar) requires demonstration of the parasite in organ aspirates or tissue biopsy samples. The aim of this prospective study was to assess the diagnostic usefulness of non-invasive testing for antibody to the leishmanial antigen K39 by means of antigen-impregnated nitrocellulose paper strips adapted for use under field conditions. Methods One drop of peripheral blood is applied to the nitrocellulose strip. Three drops of test buffer (phosphate-buffered saline plus bovine serum albumin) are added to the dried blood. The development of two visible bands indicates presence of IgG anti-K39. 323 consecutive patients with suspected kala-azar referred to two specialist units in India, and 25 healthy controls, provided fingerstick blood samples for the test. Spleen aspirates were taken from 250 patients. Findings Kala-azar was confirmed by microscopy of spleen-aspirate smears in 127 patients. The K39 strip test was positive in all 127; the estimated sensitivity was therefore 100% (95% CI 98-100). Four patients had positive strip tests but negative aspirate smears; all four responded to treatment for leishmaniasis. 217 individuals, including the 25 healthy controls, 73 patients with malaria or tuberculosis, and 119 spleen-aspirate-negative patients who had presumed malaria or cirrhosis (79) or no final diagnosis (40), had negative strip-test results. None of the 119 aspirate-negative patients developed evidence of kala-azar during 3-6 months of follow-up. The estimated specificity of the strip test was 98% (95-100; 217/221). Interpretation Detection of anti-K39 by immunochromatographic strip testing is a rapid and non-invasive method of diagnosing kala-azar, which has good sensitivity and specificity and is well suited for use in field conditions.	Banaras Hindu Univ, Inst Med Sci, Kala Azar Med Res Ctr, Varanasi 221005, Uttar Pradesh, India; Corixa Corp, Seattle, WA USA; Cornell Univ, Coll Med, Dept Med, New York, NY USA	Banaras Hindu University (BHU); Corixa; Cornell University	Murray, HW (corresponding author), Box 130,525 E 68th St, New York, NY 10021 USA.		Murray, Heather/GQY-8016-2022					ACHORD D, 1991, PRINCIPLES PRACTICE, P584; ASHFORD RW, 1992, PARASITOL TODAY, V8, P104, DOI 10.1016/0169-4758(92)90249-2; BADARO R, 1986, J INFECT DIS, V154, P1003, DOI 10.1093/infdis/154.6.1003; BARDARO R, 1996, J INFECT DIS, V173, P758; BURNS JM, 1993, P NATL ACAD SCI USA, V90, P775, DOI 10.1073/pnas.90.2.775; GALVIN JP, 1987, RAPID METHODS AUTOMA, P558; HO M, 1982, T ROY SOC TROP MED H, V76, P741, DOI 10.1016/0035-9203(82)90095-5; MARTY P, 1994, T ROY SOC TROP MED H, V88, P658, DOI 10.1016/0035-9203(94)90214-3; NUZUM E, 1995, J INFECT DIS, V171, P751, DOI 10.1093/infdis/171.3.751; Pearson RD, 1996, CLIN INFECT DIS, V22, P1, DOI 10.1093/clinids/22.1.1; PETERS BS, 1990, Q J MED, V77, P1101, DOI 10.1093/qjmed/77.2.1101; PIARROUX R, 1994, J CLIN MICROBIOL, V32, P746, DOI 10.1128/JCM.32.3.746-749.1994; QU JQ, 1994, T ROY SOC TROP MED H, V88, P543, DOI 10.1016/0035-9203(94)90154-6; SACKS DL, 1987, J IMMUNOL, V138, P908; Saran R., 1992, Journal of Communicable Diseases, V24, P242; SCOTT JM, 1991, AM J TROP MED HYG, V44, P272, DOI 10.4269/ajtmh.1991.44.272; Singh S, 1995, J PARASITOL, V81, P1000, DOI 10.2307/3284056; SINHA R, 1994, J TROP MED HYG, V97, P333; SQUIRES KE, 1993, AM J TROP MED HYG, V48, P666, DOI 10.4269/ajtmh.1993.48.666; SUNDAR S, 1995, J INFECT DIS, V171, P992, DOI 10.1093/infdis/171.4.992; Sundar S, 1997, ANN INTERN MED, V127, P133, DOI 10.7326/0003-4819-127-2-199707150-00007; ZIJLSTRA EE, 1992, T ROY SOC TROP MED H, V86, P505, DOI 10.1016/0035-9203(92)90086-R	22	196	201	0	12	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 21	1998	351	9102					563	565		10.1016/S0140-6736(97)04350-X	http://dx.doi.org/10.1016/S0140-6736(97)04350-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ216	9492776	hybrid			2022-12-28	WOS:000072231900012
